Naloxone	B-Chemical	NOUN	B
reverses	O	VERB	B
the	O	DET	O
antihypertensive	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
clonidine	B-Chemical	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
unanesthetized	O	ADJ	B
,	O	PUNCT	O
spontaneously	O	ADV	B
hypertensive	B-Disease	ADJ	I
rats	O	NOUN	B
the	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
blood	O	NOUN	B
pressure	O	NOUN	I
and	O	CCONJ	O
heart	O	NOUN	B
rate	O	NOUN	I
produced	O	VERB	O
by	O	ADP	O
intravenous	O	ADJ	B
clonidine	B-Chemical	NOUN	B
,	O	PUNCT	O
5	O	NUM	O
to	O	PART	O
20	O	NUM	O
micrograms	O	NOUN	B
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
inhibited	O	VERB	B
or	O	CCONJ	O
reversed	O	VERB	O
by	O	ADP	O
nalozone	B-Chemical	NOUN	B
,	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
to	O	PART	O
2	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
hypotensive	B-Disease	ADJ	B
effect	O	NOUN	O
of	O	ADP	O
100	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
kg	O	NOUN	B
alpha-methyldopa	B-Chemical	NOUN	B
was	O	AUX	O
also	O	ADV	O
partially	O	ADV	O
reversed	O	VERB	O
by	O	ADP	O
naloxone	B-Chemical	NOUN	B
.	O	PUNCT	O


Naloxone	B-Chemical	NOUN	B
alone	O	ADV	O
did	O	AUX	O
not	O	PART	O
affect	O	VERB	O
either	O	CCONJ	O
blood	O	NOUN	B
pressure	O	NOUN	I
or	O	CCONJ	O
heart	O	NOUN	B
rate	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
brain	O	NOUN	B
membranes	O	NOUN	I
from	O	ADP	O
spontaneously	O	ADV	B
hypertensive	B-Disease	ADJ	O
rats	O	NOUN	B
clonidine	B-Chemical	NOUN	B
,	O	PUNCT	O
10	O	NUM	O
(-	O	PUNCT	O
8	O	NUM	O
)	O	PUNCT	O
to	O	PART	O
10	O	NUM	O
(-	O	PUNCT	O
5	O	NUM	O
)	O	PUNCT	O
M	O	NOUN	B
,	O	PUNCT	O
did	O	AUX	O
not	O	PART	O
influence	O	VERB	B
stereoselective	O	ADJ	B
binding	O	NOUN	I
of	O	ADP	O
[3H]-naloxone	B-Chemical	X	B
(	O	PUNCT	O
8	O	NUM	O
nM	O	NOUN	O
),	O	PUNCT	O
and	O	CCONJ	O
naloxone	B-Chemical	NOUN	B
,	O	PUNCT	O
10	O	NUM	O
(-	O	PUNCT	O
8	O	NUM	O
)	O	PUNCT	O
to	O	PART	O
10	O	NUM	O
(-	O	PUNCT	O
4	O	NUM	O
)	O	PUNCT	O
M	O	NOUN	B
,	O	PUNCT	O
did	O	AUX	O
not	O	PART	O
influence	O	VERB	B
clonidine	B-Chemical	NOUN	B
-	O	PUNCT	O
suppressible	O	ADJ	B
binding	O	NOUN	B
of	O	ADP	O
[3H]-dihydroergocryptine	B-Chemical	X	B
(	O	PUNCT	O
1	O	NUM	O
nM	O	NOUN	O
).	O	PUNCT	O
These	O	DET	O
findings	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
in	O	ADP	O
spontaneously	O	ADV	B
hypertensive	B-Disease	ADJ	I
rats	O	NOUN	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
central	O	ADJ	B
alpha	O	NOUN	I
-	O	PUNCT	O
adrenoceptor	O	NOUN	B
stimulation	O	NOUN	B
involve	O	VERB	O
activation	O	NOUN	B
of	O	ADP	O
opiate	O	ADJ	B
receptors	O	NOUN	I
.	O	PUNCT	O


As	O	ADP	O
naloxone	B-Chemical	NOUN	B
and	O	CCONJ	O
clonidine	B-Chemical	NOUN	B
do	O	AUX	O
not	O	PART	O
appear	O	VERB	O
to	O	PART	O
interact	O	VERB	B
with	O	ADP	O
the	O	DET	O
same	O	ADJ	O
receptor	O	NOUN	B
site	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
observed	O	VERB	O
functional	O	ADJ	B
antagonism	O	NOUN	B
suggests	O	VERB	O
the	O	DET	O
release	O	NOUN	B
of	O	ADP	O
an	O	DET	O
endogenous	O	ADJ	B
opiate	O	NOUN	B
by	O	ADP	O
clonidine	B-Chemical	NOUN	B
or	O	CCONJ	O
alpha-methyldopa	B-Chemical	NOUN	B


Lidocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cardiac	B-Disease	ADJ	B
asystole	I-Disease	NOUN	I
.	O	PUNCT	O


Intravenous	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
a	O	DET	O
single	O	ADJ	O
50	O	NUM	O
-	O	PUNCT	O
mg	O	NOUN	O
bolus	O	NOUN	B
of	O	ADP	O
lidocaine	B-Chemical	NOUN	B
in	O	ADP	O
a	O	DET	O
67	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
man	O	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
profound	O	ADJ	O
depression	B-Disease	NOUN	B
of	O	ADP	O
the	O	DET	O
activity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
sinoatrial	O	ADJ	B
and	O	CCONJ	O
atrioventricular	O	ADJ	B
nodal	O	ADJ	I
pacemakers	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
had	O	AUX	O
no	O	DET	O
apparent	O	ADJ	O
associated	O	VERB	O
conditions	O	NOUN	O
which	O	DET	O
might	O	AUX	O
have	O	AUX	O
predisposed	O	VERB	B
him	O	PRON	O
to	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
bradyarrhythmias	B-Disease	NOUN	B
;	O	PUNCT	O
and	O	CCONJ	O
,	O	PUNCT	O
thus	O	ADV	O
,	O	PUNCT	O
this	O	DET	O
probably	O	ADV	O
represented	O	VERB	O
a	O	DET	O
true	O	ADJ	O
idiosyncrasy	O	NOUN	O
to	O	PART	O
lidocaine	B-Chemical	VERB	B


Suxamethonium	B-Chemical	NOUN	B
infusion	O	NOUN	B
rate	O	NOUN	B
and	O	CCONJ	O
observed	O	VERB	O
fasciculations	B-Disease	NOUN	B
.	O	PUNCT	O


A	O	DET	O
dose	O	NOUN	B
-	O	PUNCT	O
response	O	NOUN	B
study	O	NOUN	I
.	O	PUNCT	O


Suxamethonium	B-Chemical	NOUN	B
chloride	I-Chemical	NOUN	I
(	O	PUNCT	O
Sch	B-Chemical	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
administered	O	VERB	B
i	O	PRON	O
.	O	PUNCT	O


v	O	NOUN	O
.	O	PUNCT	O


to	O	PART	O
36	O	NUM	O
adult	O	ADJ	B
males	O	NOUN	B
at	O	ADP	O
six	O	NUM	O
rates	O	NOUN	B
:	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


25	O	NUM	O
mg	O	NOUN	O
s	O	NOUN	O
-	O	PUNCT	O
1	O	NUM	O
to	O	PART	O
20	O	NUM	O
mg	O	NOUN	O
s	O	NOUN	O
-	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
infusion	O	NOUN	B
was	O	AUX	O
discontinued	O	VERB	B
either	O	CCONJ	O
when	O	SCONJ	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	O
muscular	O	ADJ	B
response	O	NOUN	I
to	O	PART	O
tetanic	B-Disease	ADJ	B
stimulation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
ulnar	O	ADJ	B
nerve	O	NOUN	I
or	O	CCONJ	O
when	O	SCONJ	O
Sch	B-Chemical	NOUN	B
120	O	NUM	O
mg	O	NOUN	O
was	O	AUX	O
exceeded	O	VERB	O
.	O	PUNCT	O


Six	O	NUM	O
additional	O	ADJ	O
patients	O	NOUN	B
received	O	VERB	O
a	O	DET	O
30	O	NUM	O
-	O	PUNCT	O
mg	O	NOUN	O
i	O	NUM	O
.	O	PUNCT	O


v	O	NOUN	O
.	O	PUNCT	O


bolus	O	NOUN	B
dose	O	NOUN	I
.	O	PUNCT	O


Fasciculations	B-Disease	NOUN	B
in	O	ADP	O
six	O	NUM	O
areas	O	NOUN	O
of	O	ADP	O
the	O	DET	O
body	O	NOUN	B
were	O	AUX	O
scored	O	VERB	B
from	O	ADP	O
0	O	NUM	O
to	O	PART	O
3	O	NUM	O
and	O	CCONJ	O
summated	O	VERB	B
as	O	ADP	O
a	O	DET	O
total	O	ADJ	O
fasciculation	B-Disease	NOUN	B
score	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
times	O	NOUN	O
to	O	PART	O
first	O	ADJ	O
fasciculation	B-Disease	NOUN	B
,	O	PUNCT	O
twitch	B-Disease	NOUN	B
suppression	O	NOUN	B
and	O	CCONJ	O
tetanus	B-Disease	NOUN	B
suppression	O	NOUN	B
were	O	AUX	O
inversely	O	ADV	O
related	O	ADJ	O
to	O	PART	O
the	O	DET	O
infusion	O	NOUN	B
rates	O	NOUN	B
.	O	PUNCT	O


Fasciculations	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
six	O	NUM	O
areas	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
total	O	ADJ	O
fasciculation	B-Disease	NOUN	B
score	O	NOUN	B
were	O	AUX	O
related	O	VERB	O
directly	O	ADV	O
to	O	ADP	O
the	O	DET	O
rate	O	NOUN	B
of	O	ADP	O
infusion	O	NOUN	B
.	O	PUNCT	O


Total	O	ADJ	O
fasciculation	B-Disease	NOUN	B


Galanthamine	B-Chemical	NOUN	B
hydrobromide	I-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
longer	O	ADV	O
acting	O	NOUN	O
anticholinesterase	O	NOUN	B
drug	O	NOUN	O
,	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
the	O	DET	O
central	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
scopolamine	B-Chemical	NOUN	B
(	O	PUNCT	O
Hyoscine	B-Chemical	ADJ	B
).	O	PUNCT	O
Galanthamine	B-Chemical	NOUN	B
hydrobromide	I-Chemical	NOUN	I
,	O	PUNCT	O
an	O	DET	O
anticholinesterase	O	NOUN	B
drug	O	NOUN	I
capable	O	ADJ	O
of	O	ADP	O
penetrating	O	VERB	B
the	O	DET	O
blood	O	NOUN	B
-	O	PUNCT	O
brain	O	NOUN	B
barrier	O	NOUN	O
,	O	PUNCT	O
was	O	AUX	O
used	O	VERB	O
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
demonstrating	O	VERB	O
central	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
scopolamine	B-Chemical	NOUN	B
(	O	PUNCT	O
hyoscine	B-Chemical	NOUN	B
)	O	PUNCT	O
overdosage	B-Disease	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
longer	O	ADV	O
acting	O	VERB	O
than	O	ADP	O
physostigmine	B-Chemical	NOUN	B
and	O	CCONJ	O
is	O	AUX	O
used	O	VERB	O
in	O	ADP	O
anaesthesia	O	NOUN	B
to	O	PART	O
reverse	O	VERB	B
the	O	DET	O
non	O	ADV	B
-	O	PUNCT	O
depolarizing	O	VERB	B
neuromuscular	O	ADJ	B
block	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
studies	O	NOUN	B
into	O	ADP	O
the	O	DET	O
dose	O	NOUN	B
necessary	O	ADJ	O
to	O	PART	O
combating	O	VERB	O
scopolamine	B-Chemical	NOUN	B


Effects	O	NOUN	B
of	O	ADP	I
uninephrectomy	O	NOUN	B
and	O	CCONJ	O
high	O	ADJ	O
protein	O	NOUN	B
feeding	O	NOUN	B
on	O	ADP	O
lithium	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
chronic	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
failure	I-Disease	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


Rats	O	NOUN	B
with	O	ADP	O
lithium	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
nephropathy	B-Disease	NOUN	B
were	O	AUX	O
subjected	O	VERB	O
to	O	PART	O
high	O	ADJ	B
protein	O	NOUN	I
(	O	PUNCT	O
HP	O	NOUN	B
)	O	PUNCT	O
feeding	O	NOUN	B
,	O	PUNCT	O
uninephrectomy	O	NOUN	B
(	O	PUNCT	O
NX	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
a	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
these	O	DET	O
,	O	PUNCT	O
in	O	ADP	O
an	O	DET	O
attempt	O	NOUN	O
to	O	PART	O
induce	O	VERB	B
glomerular	O	ADJ	B
hyperfiltration	O	NOUN	B
and	O	CCONJ	O
further	O	ADJ	O
progression	O	NOUN	B
of	O	ADP	O
renal	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
.	O	PUNCT	O


Newborn	O	ADJ	B
female	O	NOUN	B
Wistar	O	PROPN	B
rats	O	NOUN	I
were	O	AUX	O
fed	O	VERB	O
a	O	DET	O
lithium	B-Chemical	NOUN	B
-	O	PUNCT	O
containing	O	VERB	B
diet	O	NOUN	B
(	O	PUNCT	O
50	O	NUM	O
mmol	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
for	O	ADP	O
8	O	NUM	O
weeks	O	NOUN	B
and	O	CCONJ	O
then	O	ADV	O
randomized	O	VERB	B
to	O	PART	O
normal	O	ADJ	B
diet	O	NOUN	I
,	O	PUNCT	O
HP	O	NOUN	B
diet	O	NOUN	O
(	O	PUNCT	O
40	O	NUM	O
vs	O	CCONJ	O
.	O	PUNCT	O


19	O	NUM	O
%),	O	ADJ	O
NX	O	NOUN	B
or	O	CCONJ	O
HP	O	NOUN	B
+	O	CCONJ	O
NX	O	NOUN	B
for	O	ADP	O
another	O	DET	O
8	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


Corresponding	O	ADJ	O
non	O	ADJ	B
-	O	PUNCT	O
lithium	B-Chemical	NOUN	B
pretreated	O	ADJ	B
groups	O	NOUN	B
were	O	AUX	O
generated	O	VERB	O
.	O	PUNCT	O


When	O	SCONJ	O
comparing	O	VERB	B
all	O	DET	O
lithium	B-Chemical	NOUN	B
treated	O	VERB	B
versus	O	CCONJ	O
non	O	ADJ	B
-	O	PUNCT	O
lithium	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
groups	O	NOUN	B
,	O	PUNCT	O
lithium	B-Chemical	NOUN	B
caused	O	VERB	O
a	O	DET	O
reduction	O	NOUN	B
in	O	ADP	O
glomerular	O	ADJ	B
filtration	O	NOUN	I
rate	O	NOUN	I
(	O	PUNCT	O
GFR	O	NOUN	B
)	O	PUNCT	O
without	O	ADP	O
significant	O	ADJ	B
changes	O	NOUN	B
in	O	ADP	O
effective	O	ADJ	B
renal	O	ADJ	B
plasma	O	NOUN	I
flow	O	NOUN	I
(	O	PUNCT	O
as	O	ADP	O
determined	O	VERB	O
by	O	ADP	O
a	O	DET	O
marker	O	NOUN	B
secreted	O	VERB	B
into	O	ADP	O
the	O	DET	O
proximal	O	ADJ	B
tubules	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
lithium	B-Chemical	NOUN	B
clearance	O	NOUN	B
.	O	PUNCT	O


Consequently	O	ADV	O
,	O	PUNCT	O
lithium	B-Chemical	NOUN	B
pretreatment	O	NOUN	B
caused	O	VERB	O
a	O	DET	O
fall	O	NOUN	B
in	O	ADP	O
filtration	O	NOUN	B
fraction	O	NOUN	I
and	O	CCONJ	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
fractional	O	ADJ	B
Li	B-Chemical	PROPN	B
excretion	O	NOUN	B
.	O	PUNCT	O


Lithium	B-Chemical	NOUN	B
also	O	ADV	O
caused	O	VERB	O
proteinuria	B-Disease	NOUN	B
and	O	CCONJ	O
systolic	O	NOUN	B
hypertension	B-Disease	NOUN	I
in	O	ADP	O
absence	O	NOUN	B
of	O	ADP	O
glomerulosclerosis	B-Disease	NOUN	B
.	O	PUNCT	O


HP	O	NOUN	B
failed	O	VERB	B
to	O	PART	O
accentuante	O	VERB	B
progression	O	NOUN	B
of	O	ADP	O
renal	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
and	O	CCONJ	O
in	O	ADP	O
fact	O	NOUN	O
tended	O	VERB	O
to	O	PART	O
increase	O	VERB	B
GFR	O	NOUN	B
and	O	CCONJ	O
decrease	O	VERB	B
plasma	O	NOUN	B
creatinine	B-Chemical	NOUN	O
levels	O	NOUN	O
in	O	ADP	O
lithium	B-Chemical	NOUN	B
pretreated	O	ADJ	O
rats	O	NOUN	B
.	O	PUNCT	O


NX	O	NOUN	B
caused	O	VERB	O
an	O	DET	O
additive	O	ADJ	B
deterioration	O	NOUN	I
in	O	ADP	O
GFR	O	NOUN	B
which	O	DET	O
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
was	O	AUX	O
ameliorated	O	VERB	B
by	O	ADP	O
HP	O	NOUN	B
.	O	PUNCT	O


NX	O	NOUN	B
+	O	CCONJ	O
HP	O	NOUN	B
caused	O	VERB	O
a	O	DET	O
further	O	ADJ	O
rise	O	NOUN	O
in	O	ADP	O
blood	O	NOUN	B
pressure	O	NOUN	I
in	O	ADP	O
Li	B-Chemical	PROPN	B
-	O	PUNCT	O
pretreated	O	VERB	B
rats	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
Li	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
nephropathy	B-Disease	NOUN	B
,	O	PUNCT	O
even	O	ADV	O
when	O	SCONJ	O
the	O	DET	O
GFR	O	NOUN	B
is	O	AUX	O
only	O	ADV	O
modestly	O	ADV	O
reduced	O	VERB	B
,	O	PUNCT	O
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
proteinuria	B-Disease	NOUN	B
and	O	CCONJ	O
arterial	O	ADJ	B
systolic	O	NOUN	I
hypertension	B-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
model	O	NOUN	B
of	O	ADP	O
chronic	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
failure	I-Disease	NOUN	I


Treatment	O	NOUN	B
of	O	ADP	O
Crohn's	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
with	O	ADP	O
fusidic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
:	O	PUNCT	O
an	O	DET	O
antibiotic	O	NOUN	B
with	O	ADP	O
immunosuppressive	O	ADJ	B
properties	O	NOUN	B
similar	O	ADJ	O
to	O	PART	O
cyclosporin	B-Chemical	NOUN	B
.	O	PUNCT	O


Fusidic	O	ADJ	B
acid	O	NOUN	I
is	O	AUX	O
an	O	DET	O
antibiotic	O	NOUN	B
with	O	ADP	O
T	O	NOUN	B
-	O	PUNCT	O
cell	O	NOUN	B
specific	O	ADJ	O
immunosuppressive	O	ADJ	B
effects	O	NOUN	O
similar	O	ADJ	O
to	O	PART	O
those	O	DET	O
of	O	ADP	O
cyclosporin	B-Chemical	NOUN	B
.	O	PUNCT	O


Because	O	SCONJ	O
of	O	ADP	O
the	O	DET	O
need	O	NOUN	O
for	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
new	O	ADJ	O
treatments	O	NOUN	B
for	O	ADP	O
Crohn's	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
,	O	PUNCT	O
a	O	DET	O
pilot	O	NOUN	B
study	O	NOUN	I
was	O	AUX	O
undertaken	O	VERB	O
to	O	PART	O
estimate	O	VERB	B
the	O	DET	O
pharmacodynamics	O	NOUN	B
and	O	CCONJ	O
tolerability	O	NOUN	B
of	O	ADP	O
fusidic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
treatment	O	NOUN	B
in	O	ADP	O
chronic	O	ADJ	B
active	O	ADJ	I
,	O	PUNCT	O
therapy	O	NOUN	B
-	O	PUNCT	O
resistant	O	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O


Eight	O	NUM	O
Crohn's	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
patients	O	NOUN	B
were	O	AUX	O
included	O	VERB	O
.	O	PUNCT	O


Fusidic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
was	O	AUX	O
administered	O	VERB	B
orally	O	ADV	B
in	O	ADP	O
a	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
500	O	NUM	O
mg	O	NOUN	O
t	O	NOUN	O
.	O	PUNCT	O


d	O	X	O
.	O	PUNCT	O


s	O	NOUN	O
.	O	PUNCT	O


and	O	CCONJ	O
the	O	DET	O
treatment	O	NOUN	B
was	O	AUX	O
planned	O	VERB	B
to	O	PART	O
last	O	ADJ	O
8	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
disease	O	NOUN	B
activity	O	NOUN	I
was	O	AUX	O
primarily	O	ADV	O
measured	O	VERB	B
by	O	ADP	O
a	O	DET	O
modified	O	VERB	B
individual	O	ADJ	O
grading	O	NOUN	B
score	O	NOUN	I
.	O	PUNCT	O


Five	O	NUM	O
of	O	ADP	O
8	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
63	O	NUM	O
%)	O	NOUN	O
improved	O	VERB	B
during	O	ADP	O
fusidic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
treatment	O	NOUN	B
:	O	PUNCT	O
3	O	NUM	O
at	O	ADP	O
two	O	NUM	O
weeks	O	NOUN	B
and	O	CCONJ	O
2	O	NUM	O
after	O	ADP	O
four	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
serious	O	ADJ	O
clinical	O	ADJ	B
side	O	NOUN	B
effects	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
dose	O	NOUN	B
reduction	O	NOUN	B
was	O	AUX	O
required	O	VERB	O
in	O	ADP	O
two	O	NUM	O
patients	O	NOUN	B
because	O	SCONJ	O
of	O	ADP	O
nausea	B-Disease	NOUN	B
.	O	PUNCT	O


Biochemically	O	ADV	B
,	O	PUNCT	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
alkaline	O	NOUN	B
phosphatases	O	NOUN	I
was	O	AUX	O
noted	O	VERB	O
in	O	ADP	O
5	O	NUM	O
of	O	ADP	O
8	O	NUM	O
cases	O	NOUN	B
(	O	PUNCT	O
63	O	NUM	O
%),	O	NOUN	O
and	O	CCONJ	O
the	O	DET	O
greatest	O	ADJ	O
increases	O	NOUN	B
were	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
those	O	DET	O
who	O	PRON	O
had	O	AUX	O
elevated	O	ADJ	B
levels	O	NOUN	B
prior	O	ADJ	O
to	O	PART	O
treatment	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
reversed	O	VERB	O
to	O	ADP	O
pre	O	NOUN	B
-	O	PUNCT	O
treatment	O	NOUN	B
levels	O	NOUN	B
after	O	ADP	O
cessation	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
of	O	ADP	O
this	O	DET	O
pilot	O	NOUN	B
study	O	NOUN	I
suggest	O	VERB	O
that	O	SCONJ	O
fusidic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
may	O	AUX	O
be	O	AUX	O
of	O	ADP	O
benefit	O	NOUN	B
in	O	ADP	O
selected	O	VERB	O
chronic	O	ADJ	B
active	O	ADJ	O
Crohn's	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
patients	O	NOUN	B
in	O	ADP	O
whom	O	PRON	O
conventional	O	ADJ	B
treatment	O	NOUN	B
is	O	AUX	O
ineffective	O	ADJ	B
.	O	PUNCT	O


Because	O	SCONJ	O
there	O	PRON	O
seems	O	VERB	O
to	O	PART	O
exist	O	VERB	O
a	O	DET	O
scientific	O	ADJ	B
rationale	O	NOUN	I
for	O	ADP	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
fusidic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
at	O	ADP	O
the	O	DET	O
cytokine	O	NOUN	B
level	O	NOUN	B
in	O	ADP	O
inflammatory	B-Disease	ADJ	B
bowel	I-Disease	NOUN	I
disease	I-Disease	NOUN	I


Electrocardiographic	O	ADJ	B
evidence	O	NOUN	B
of	O	ADP	O
myocardial	B-Disease	ADJ	B
injury	I-Disease	NOUN	I
in	O	ADP	O
psychiatrically	O	ADV	B
hospitalized	O	VERB	I
cocaine	B-Chemical	NOUN	B
abusers	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
electrocardiograms	O	NOUN	B
(	O	PUNCT	I
ECG	O	PROPN	B
)	O	PUNCT	O
of	O	ADP	O
99	O	NUM	O
cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
abusing	O	VERB	B
patients	O	NOUN	B
were	O	AUX	O
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
ECGs	O	NOUN	B
of	O	ADP	O
50	O	NUM	O
schizophrenic	B-Disease	ADJ	B
controls	O	NOUN	I
.	O	PUNCT	O


Eleven	O	NOUN	O
of	O	ADP	O
the	O	DET	O
cocaine	B-Chemical	NOUN	B
abusers	O	NOUN	I
and	O	CCONJ	O
none	O	NOUN	O
of	O	ADP	O
the	O	DET	O
controls	O	NOUN	B
had	O	AUX	O
ECG	O	PROPN	B
evidence	O	NOUN	B
of	O	ADP	O
significant	O	ADJ	O
myocardial	B-Disease	ADJ	B
injury	I-Disease	NOUN	I
defined	O	VERB	O
as	O	ADP	O
myocardial	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
,	O	PUNCT	O
ischemia	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
bundle	B-Disease	VERB	B
branch	I-Disease	NOUN	I
block	I-Disease	NOUN	I


Sulpiride	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
tardive	B-Disease	NOUN	B
dystonia	I-Disease	NOUN	B
.	O	PUNCT	O


Sulpiride	B-Chemical	NOUN	B
is	O	AUX	O
a	O	DET	O
selective	O	ADJ	O
D2	O	NOUN	B
-	O	PUNCT	O
receptor	O	NOUN	B
antagonist	O	NOUN	B
with	O	ADP	O
antipsychotic	O	ADJ	B
and	O	CCONJ	O
antidepressant	B-Chemical	ADJ	B
properties	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
initially	O	ADV	O
thought	O	VERB	O
to	O	PART	O
be	O	AUX	O
free	O	ADJ	B
of	O	ADP	O
extrapyramidal	O	ADJ	B
side	O	NOUN	I
effects	O	NOUN	I
,	O	PUNCT	O
sulpiride	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
tardive	B-Disease	NOUN	B
dyskinesia	I-Disease	NOUN	O
and	O	CCONJ	O
parkinsonism	B-Disease	NOUN	B
have	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
occasionally	O	ADV	O
.	O	PUNCT	O


We	O	PRON	O
studied	O	VERB	O
a	O	DET	O
37	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
man	O	NOUN	B
who	O	PRON	O
developed	O	VERB	O
persistent	O	ADJ	B
segmental	O	ADJ	B
dystonia	B-Disease	NOUN	I
within	O	ADP	O
2	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
starting	O	VERB	O
sulpiride	B-Chemical	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
could	O	AUX	O
not	O	PART	O
find	O	VERB	O
any	O	DET	O
previous	O	ADJ	O
reports	O	NOUN	B
of	O	ADP	O
sulpiride	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
tardive	B-Disease	NOUN	B
dystonia	I-Disease	NOUN	B


Ocular	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
auditory	I-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
in	O	ADP	O
hemodialyzed	O	ADJ	B
patients	O	NOUN	I
receiving	O	VERB	O
desferrioxamine	B-Chemical	NOUN	B
.	O	PUNCT	O


During	O	ADP	O
an	O	DET	O
18	O	NUM	O
-	O	PUNCT	O
month	O	NOUN	B
period	O	NOUN	B
of	O	ADP	O
study	O	NOUN	B
41	O	NUM	O
hemodialyzed	O	ADJ	B
patients	O	NOUN	B
receiving	O	VERB	O
desferrioxamine	B-Chemical	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
-	O	SYM	O
40	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
BW	O	NOUN	B
/	O	SYM	O
3	O	NUM	O
times	O	NOUN	O
weekly	O	ADJ	B
)	O	PUNCT	O
for	O	ADP	O
the	O	DET	O
first	O	ADJ	O
time	O	NOUN	O
were	O	AUX	O
monitored	O	VERB	B
for	O	ADP	O
detection	O	NOUN	B
of	O	ADP	O
audiovisual	B-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
.	O	PUNCT	O


6	O	NUM	O
patients	O	NOUN	B
presented	O	VERB	O
clinical	O	ADJ	B
symptoms	O	NOUN	I
of	O	ADP	O
visual	B-Disease	ADJ	B
or	I-Disease	CCONJ	O
auditory	I-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
.	O	PUNCT	O


Moreover	O	ADV	O
,	O	PUNCT	O
detailed	O	ADJ	O
ophthalmologic	O	ADJ	B
and	O	CCONJ	O
audiologic	O	ADJ	B
studies	O	NOUN	I
disclosed	O	VERB	O
abnormalities	O	NOUN	B
in	O	ADP	O
7	O	NUM	O
more	O	ADV	O
asymptomatic	O	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O


Visual	B-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
was	O	AUX	O
of	O	ADP	O
retinal	O	ADJ	B
origin	O	NOUN	B
and	O	CCONJ	O
was	O	AUX	O
characterized	O	VERB	B
by	O	ADP	O
a	O	DET	O
tritan	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
dyschromatopsy	B-Disease	NOUN	B
,	O	PUNCT	O
sometimes	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
a	B-Disease	DET	O
loss	I-Disease	NOUN	B
of	I-Disease	ADP	O
visual	I-Disease	ADJ	B
acuity	I-Disease	NOUN	I
and	O	CCONJ	O
pigmentary	B-Disease	ADJ	B
retinal	I-Disease	ADJ	I
deposits	I-Disease	NOUN	I
.	O	PUNCT	O


Auditory	B-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
was	O	AUX	O
characterized	O	VERB	B
by	O	ADP	O
a	O	DET	O
mid	O	ADJ	B
-	O	PUNCT	O
to	O	PART	O
high	O	ADJ	B
-	O	PUNCT	O
frequency	O	NOUN	B
neurosensorial	B-Disease	ADJ	B
hearing	I-Disease	NOUN	I
loss	I-Disease	NOUN	I
and	O	CCONJ	O
the	O	DET	O
lesion	O	NOUN	B
was	O	AUX	O
of	O	ADP	O
the	O	DET	O
cochlear	O	ADJ	B
type	O	NOUN	I
.	O	PUNCT	O


Desferrioxamine	B-Chemical	NOUN	B
withdrawal	O	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
a	O	DET	O
complete	O	ADJ	O
recovery	O	NOUN	B
of	O	ADP	O
visual	O	ADJ	B
function	O	NOUN	I
in	O	ADP	O
1	O	NUM	O
patient	O	NOUN	B
and	O	CCONJ	O
partial	O	ADJ	B
recovery	O	NOUN	B
in	O	ADP	O
3	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
complete	O	ADJ	O
reversal	O	NOUN	B
of	O	ADP	O
hearing	B-Disease	VERB	B
loss	I-Disease	NOUN	I
in	O	ADP	O
3	O	NUM	O
patients	O	NOUN	B
and	O	CCONJ	O
partial	O	ADJ	B
recovery	O	NOUN	B
in	O	ADP	O
3	O	NUM	O
.	O	PUNCT	O


This	O	DET	O
toxicity	B-Disease	NOUN	B
appeared	O	VERB	O
in	O	ADP	O
patients	O	NOUN	B
receiving	O	VERB	O
the	O	DET	O
higher	O	ADJ	B
doses	O	NOUN	B
of	O	ADP	O
desferrioxamine	B-Chemical	NOUN	B
or	O	CCONJ	O
coincided	O	VERB	O
with	O	ADP	O
the	O	DET	O
normalization	O	NOUN	B
of	O	ADP	O
ferritin	O	NOUN	B
or	O	CCONJ	O
aluminium	B-Chemical	NOUN	B
serum	O	NOUN	O
levels	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
data	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
audiovisual	B-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
is	O	AUX	O
not	O	PART	O
an	O	DET	O
infrequent	O	ADJ	B
complication	O	NOUN	B
in	O	ADP	O
hemodialyzed	O	ADJ	B
patients	O	NOUN	I
receiving	O	VERB	O
desferrioxamine	B-Chemical	NOUN	B


Myasthenia	B-Disease	ADJ	B
gravis	I-Disease	NOUN	I
presenting	O	VERB	O
as	O	ADP	O
weakness	O	NOUN	B
after	O	ADP	O
magnesium	B-Chemical	NOUN	B
administration	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
studied	O	VERB	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
no	O	DET	O
prior	O	ADJ	O
history	O	NOUN	B
of	O	ADP	O
neuromuscular	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
who	O	PRON	O
became	O	VERB	O
virtually	O	ADV	O
quadriplegic	B-Disease	ADJ	B
after	O	ADP	O
parenteral	O	ADJ	B
magnesium	B-Chemical	NOUN	O
administration	O	NOUN	O
for	O	ADP	O
preeclampsia	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
serum	O	NOUN	B
magnesium	B-Chemical	NOUN	B
concentration	O	NOUN	I
was	O	AUX	O
3	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
mEq	O	NOUN	B
/	O	SYM	O
L	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
usually	O	ADV	O
well	O	ADV	O
tolerated	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
magnesium	B-Chemical	NOUN	B
was	O	AUX	O
stopped	O	VERB	B
and	O	CCONJ	O
she	O	PRON	O
recovered	O	VERB	B
over	O	ADP	O
a	O	DET	O
few	O	ADJ	O
days	O	NOUN	B
.	O	PUNCT	O


While	O	SCONJ	O
she	O	PRON	O
was	O	AUX	O
weak	O	ADJ	B
,	O	PUNCT	O
2	O	NUM	O
-	O	PUNCT	O
Hz	O	NOUN	O
repetitive	O	ADJ	B
stimulation	O	NOUN	I
revealed	O	VERB	O
a	O	DET	O
decrement	O	NOUN	B
without	O	ADP	O
significant	O	ADJ	B
facilitation	O	NOUN	B
at	O	ADP	O
rapid	O	ADJ	O
rates	O	NOUN	B
or	O	CCONJ	O
after	O	ADP	O
exercise	O	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
postsynaptic	B-Disease	ADJ	B
neuromuscular	I-Disease	ADJ	I
blockade	I-Disease	NOUN	I
.	O	PUNCT	O


After	O	ADP	O
her	O	PRON	O
strength	O	NOUN	B
returned	O	VERB	O
,	O	PUNCT	O
repetitive	O	ADJ	B
stimulation	O	NOUN	I
was	O	AUX	O
normal	O	ADJ	B
,	O	PUNCT	O
but	O	CCONJ	O
single	O	ADJ	O
fiber	O	NOUN	B
EMG	O	NOUN	B
revealed	O	VERB	O
increased	O	VERB	B
jitter	O	NOUN	B
and	O	CCONJ	O
blocking	O	NOUN	B
.	O	PUNCT	O


Her	O	PRON	O
acetylcholine	B-Chemical	NOUN	B
receptor	O	NOUN	I
antibody	O	NOUN	I
level	O	NOUN	B
was	O	AUX	O
markedly	O	ADV	O
elevated	O	ADJ	B
.	O	PUNCT	O


Although	O	SCONJ	O
paralysis	B-Disease	NOUN	B
after	O	ADP	O
magnesium	B-Chemical	NOUN	B
administration	O	NOUN	I
has	O	AUX	O
been	O	AUX	O
described	O	VERB	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
known	O	ADJ	O
myasthenia	B-Disease	NOUN	B
gravis	I-Disease	NOUN	I
,	O	PUNCT	O
it	O	PRON	O
has	O	AUX	O
not	O	PART	O
previously	O	ADV	O
been	O	AUX	O
reported	O	VERB	O
to	O	PART	O
be	O	AUX	O
the	O	DET	O
initial	O	ADJ	B
or	O	CCONJ	O
only	O	ADJ	O
manifestation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
.	O	PUNCT	O


Patients	O	NOUN	B
who	O	PRON	O
are	O	AUX	O
unusually	O	ADV	O
sensitive	O	ADJ	B
to	O	PART	O
the	O	DET	O
neuromuscular	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
magnesium	B-Chemical	NOUN	B
should	O	AUX	O
be	O	AUX	O
suspected	O	VERB	B
of	O	ADP	O
having	O	VERB	O
an	O	DET	O
underlying	O	ADJ	O
disorder	B-Disease	NOUN	B
of	I-Disease	ADP	O
neuromuscular	I-Disease	ADJ	B
transmission	I-Disease	NOUN	I


Chloroacetaldehyde	B-Chemical	NOUN	B
and	O	CCONJ	O
its	O	PRON	O
contribution	O	NOUN	O
to	O	PART	O
urotoxicity	O	NOUN	B
during	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
cyclophosphamide	B-Chemical	NOUN	B
or	O	CCONJ	O
ifosfamide	B-Chemical	NOUN	B
.	O	PUNCT	O


An	O	DET	O
experimental	O	ADJ	B
study	O	NOUN	I
/	O	SYM	O
short	O	ADJ	B
communication	O	NOUN	I
.	O	PUNCT	O


Based	O	VERB	O
on	O	ADP	O
clinical	O	ADJ	B
data	O	NOUN	I
,	O	PUNCT	O
indicating	O	VERB	O
that	O	SCONJ	O
chloroacetaldehyde	B-Chemical	NOUN	B
(	O	PUNCT	O
CAA	B-Chemical	PROPN	B
)	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
important	O	ADJ	O
metabolite	O	NOUN	B
of	O	ADP	O
oxazaphosphorine	O	ADJ	B
cytostatics	O	NOUN	I
,	O	PUNCT	O
an	O	DET	O
experimental	O	ADJ	B
study	O	NOUN	I
was	O	AUX	O
carried	O	VERB	O
out	O	ADP	O
in	O	ADP	O
order	O	NOUN	O
to	O	PART	O
elucidate	O	VERB	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
CAA	B-Chemical	PROPN	B
in	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
hemorrhagic	B-Disease	ADJ	B
cystitis	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
data	O	NOUN	B
demonstrate	O	VERB	O
that	O	SCONJ	O
CAA	B-Chemical	PROPN	B
after	O	ADP	O
i	O	PRON	O
.	O	PUNCT	O


v	O	NOUN	O
.	O	PUNCT	O


administration	O	NOUN	B
does	O	AUX	O
not	O	PART	O
contribute	O	VERB	O
to	O	ADP	O
bladder	B-Disease	NOUN	B
damage	I-Disease	NOUN	B
.	O	PUNCT	O


When	O	SCONJ	O
instilled	O	VERB	B
directly	O	ADV	O
into	O	ADP	O
the	O	DET	O
bladder	O	NOUN	B
,	O	PUNCT	O
CAA	B-Chemical	PROPN	B
exerts	O	VERB	O
urotoxic	O	ADJ	B
effects	O	NOUN	O
,	O	PUNCT	O
it	O	PRON	O
is	O	AUX	O
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
susceptible	O	ADJ	B
to	O	PART	O
detoxification	O	NOUN	B
with	O	ADP	O
mesna	B-Chemical	NOUN	B


Source	O	NOUN	B
of	O	ADP	I
pain	B-Disease	NOUN	I
and	O	CCONJ	O
primitive	O	ADJ	B
dysfunction	O	NOUN	I
in	O	ADP	O
migraine	B-Disease	NOUN	B
:	O	PUNCT	O
an	O	DET	O
identical	O	ADJ	B
site	O	NOUN	B
?	O	PUNCT	O
Twenty	O	NUM	O
common	O	ADJ	O
migraine	B-Disease	NOUN	B
patients	O	NOUN	B
received	O	VERB	O
a	O	DET	O
one	O	NUM	O
sided	O	ADJ	O
frontotemporal	O	ADJ	B
application	O	NOUN	O
of	O	ADP	O
nitroglycerin	B-Chemical	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
patients	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
placebo	O	NOUN	B
ointment	O	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
patients	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
double	O	ADJ	O
blind	O	ADJ	O
study	O	NOUN	O
.	O	PUNCT	O


Early	O	ADJ	B
onset	O	NOUN	O
migraine	B-Disease	NOUN	B
attacks	O	NOUN	B
were	O	AUX	O
induced	O	VERB	B
by	O	ADP	O
nitroglycerin	B-Chemical	NOUN	B
in	O	ADP	O
seven	O	NUM	O
out	O	ADP	O
of	O	ADP	O
10	O	NUM	O
patients	O	NOUN	B
versus	O	CCONJ	O
no	O	DET	O
patient	O	NOUN	B
in	O	ADP	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	B
.	O	PUNCT	O


Subsequently	O	ADV	O
20	O	NUM	O
migraine	B-Disease	NOUN	B
patients	O	NOUN	B
,	O	PUNCT	O
who	O	PRON	O
developed	O	VERB	O
an	O	DET	O
early	O	ADJ	B
onset	O	NOUN	B
attack	O	NOUN	I
with	O	ADP	O
frontotemporal	O	ADJ	B
nitroglycerin	B-Chemical	NOUN	I
,	O	PUNCT	O
received	O	VERB	O
the	O	DET	O
drug	O	NOUN	B
in	O	ADP	O
a	O	DET	O
second	O	ADJ	O
induction	O	NOUN	B
test	O	NOUN	I
at	O	ADP	O
other	O	ADJ	O
body	O	NOUN	B
areas	O	NOUN	I
.	O	PUNCT	O


No	O	DET	B
early	O	ADJ	I
onset	O	NOUN	O
migraine	B-Disease	NOUN	B
was	O	AUX	O
observed	O	VERB	B
.	O	PUNCT	O


Thus	O	ADV	O
the	O	DET	O
migraine	B-Disease	NOUN	B
-	O	PUNCT	O
inducing	O	VERB	B
effect	O	NOUN	B
of	O	ADP	O
nitroglycerin	B-Chemical	NOUN	B
seems	O	VERB	O
to	O	PART	O
depend	O	VERB	O
on	O	ADP	O
direct	O	ADJ	O
stimulation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
habitual	O	ADJ	B
site	O	NOUN	I
of	O	ADP	O
pain	B-Disease	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
frontotemporal	O	ADJ	B
region	O	NOUN	I
is	O	AUX	O
of	O	ADP	O
crucial	O	ADJ	O
importance	O	NOUN	O
in	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
a	O	DET	O
migraine	B-Disease	NOUN	B
crisis	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
is	O	AUX	O
not	O	PART	O
consistent	O	ADJ	B
with	O	ADP	I
a	O	DET	O
CNS	O	NOUN	B
origin	O	NOUN	B
of	O	ADP	O
migraine	B-Disease	NOUN	B


Clotiazepam	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
acute	O	ADJ	B
hepatitis	B-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
the	O	DET	O
case	O	NOUN	B
of	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
who	O	PRON	O
developed	O	VERB	O
acute	O	ADJ	B
hepatitis	B-Disease	NOUN	I
with	O	ADP	O
extensive	B-Disease	ADJ	O
hepatocellular	I-Disease	NOUN	B
necrosis	I-Disease	NOUN	I
,	O	PUNCT	O
7	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
the	O	DET	O
onset	O	NOUN	B
of	O	ADP	I
administration	O	NOUN	B
of	O	ADP	O
clotiazepam	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
thienodiazepine	B-Chemical	NOUN	B
derivative	O	NOUN	O
.	O	PUNCT	O


Clotiazepam	B-Chemical	PROPN	B
withdrawal	O	NOUN	B
was	O	AUX	O
followed	O	VERB	O
by	O	ADP	O
prompt	O	ADJ	O
recovery	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
several	O	ADJ	O
benzodiazepines	B-Chemical	NOUN	B
,	O	PUNCT	O
chemically	O	ADV	B
related	O	ADJ	O
to	O	ADP	O
clotiazepam	B-Chemical	NOUN	B
,	O	PUNCT	O
did	O	AUX	O
not	O	PART	O
interfere	O	VERB	B
with	O	ADP	I
recovery	O	NOUN	B
and	O	CCONJ	O
did	O	AUX	O
not	O	PART	O
induce	O	VERB	B
any	O	DET	O
relapse	O	NOUN	B
of	O	ADP	O
hepatitis	B-Disease	NOUN	B
.	O	PUNCT	O


This	O	DET	O
observation	O	NOUN	B
shows	O	VERB	O
that	O	SCONJ	O
clotiazepam	B-Chemical	NOUN	B
can	O	AUX	O
induce	O	VERB	B
acute	O	ADJ	B
hepatitis	B-Disease	NOUN	I
and	O	CCONJ	O
suggests	O	VERB	O
that	O	SCONJ	O
there	O	PRON	O
is	O	AUX	O
no	O	DET	O
cross	O	NOUN	B
hepatotoxicity	B-Disease	NOUN	I
between	O	ADP	O
clotiazepam	B-Chemical	NOUN	B
and	O	CCONJ	O
several	O	ADJ	O
benzodiazepines	B-Chemical	NOUN	B


Arterial	O	ADJ	B
hypertension	B-Disease	NOUN	I
as	O	ADP	O
a	O	DET	O
complication	O	NOUN	B
of	O	ADP	O
prolonged	O	ADJ	B
ketoconazole	B-Chemical	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


Two	O	NUM	O
of	O	ADP	O
14	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
Cushing's	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
treated	O	VERB	B
on	O	ADP	O
a	O	DET	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
basis	O	NOUN	O
with	O	ADP	O
ketoconazole	B-Chemical	NOUN	B
developed	O	VERB	O
sustained	O	ADJ	B
hypertension	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
both	O	DET	O
cases	O	NOUN	B
normal	O	ADJ	O
plasma	O	NOUN	B
and	O	CCONJ	O
urinary	O	ADJ	B
free	O	ADJ	I
cortisol	B-Chemical	NOUN	I
levels	O	NOUN	O
had	O	AUX	O
been	O	AUX	O
achieved	O	VERB	O
following	O	VERB	O
ketoconazole	B-Chemical	NOUN	B
therapy	O	NOUN	I
,	O	PUNCT	O
yet	O	CCONJ	O
continuous	O	ADJ	B
blood	O	NOUN	I
pressure	O	NOUN	I
monitoring	O	NOUN	B
demonstrated	O	VERB	O
hypertension	B-Disease	NOUN	B
31	O	NUM	O
(	O	PUNCT	O
patient	O	NOUN	B
1	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
52	O	NUM	O
weeks	O	NOUN	B
(	O	PUNCT	O
patient	O	NOUN	B
2	O	NUM	O
)	O	PUNCT	O
after	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
patient	O	NOUN	B
1	O	NUM	O
,	O	PUNCT	O
plasma	O	NOUN	B
levels	O	NOUN	B
of	O	ADP	O
deoxycorticosterone	B-Chemical	NOUN	B
and	O	CCONJ	O
11-deoxycortisol	B-Chemical	NOUN	B
were	O	AUX	O
elevated	O	ADJ	B
.	O	PUNCT	O


In	O	ADP	O
patient	O	NOUN	B
2	O	NUM	I
,	O	PUNCT	O
in	O	ADP	O
addition	O	NOUN	O
to	O	PART	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
both	O	CCONJ	O
deoxycorticosterone	B-Chemical	NOUN	B
and	O	CCONJ	O
11-deoxycortisol	B-Chemical	NOUN	B
levels	O	NOUN	B
,	O	PUNCT	O
plasma	O	NOUN	B
aldosterone	B-Chemical	NOUN	O
values	O	NOUN	O
were	O	AUX	O
raised	O	VERB	B
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
concomitant	O	ADJ	B
suppression	O	NOUN	B
of	O	ADP	O
renin	O	NOUN	B
levels	O	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
findings	O	NOUN	B
show	O	VERB	O
that	O	SCONJ	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
treatment	O	NOUN	B
with	O	ADP	O
high	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
ketoconazole	B-Chemical	NOUN	B
may	O	AUX	O
induce	O	VERB	B
enzyme	O	NOUN	B
blockade	O	NOUN	I
leading	O	VERB	O
to	O	PART	O
mineralocorticoid	O	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
hypertension	B-Disease	NOUN	B


Effects	O	NOUN	B
of	O	ADP	I
an	O	DET	O
inhibitor	O	NOUN	B
of	O	ADP	O
angiotensin	B-Chemical	NOUN	B
converting	O	NOUN	I
enzyme	O	NOUN	I
(	O	PUNCT	O
Captopril	B-Chemical	NOUN	B
)	O	PUNCT	O
on	O	ADP	O
pulmonary	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
renal	I-Disease	ADJ	B
insufficiency	I-Disease	NOUN	I
due	O	ADP	O
to	O	PART	O
intravascular	B-Disease	ADJ	B
coagulation	I-Disease	NOUN	I
in	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
.	O	PUNCT	O


Induction	O	NOUN	B
of	O	ADP	O
intravascular	B-Disease	ADJ	B
coagulation	I-Disease	NOUN	I
and	O	CCONJ	O
inhibition	O	NOUN	B
of	O	ADP	O
fibrinolysis	O	NOUN	B
by	O	ADP	O
injection	O	NOUN	B
of	O	ADP	O
thrombin	O	NOUN	B
and	O	CCONJ	O
tranexamic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
(	O	PUNCT	O
AMCA	B-Chemical	PROPN	B
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
gives	O	VERB	O
rise	O	NOUN	O
to	O	PART	O
pulmonary	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
renal	I-Disease	ADJ	B
insufficiency	I-Disease	NOUN	I
resembling	O	VERB	O
that	O	DET	O
occurring	O	VERB	O
after	O	ADP	O
trauma	B-Disease	NOUN	B
or	O	CCONJ	O
sepsis	B-Disease	NOUN	B
in	O	ADP	O
man	O	NOUN	B
.	O	PUNCT	O


Injection	O	NOUN	B
of	O	ADP	O
Captopril	B-Chemical	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
),	O	PUNCT	O
an	O	DET	O
inhibitor	O	NOUN	B
of	O	ADP	O
angiotensin	B-Chemical	NOUN	B
converting	O	NOUN	I
enzyme	O	NOUN	I
(	O	PUNCT	O
ACE	O	NOUN	B
),	O	PUNCT	O
reduced	O	VERB	B
both	O	CCONJ	O
pulmonary	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
renal	I-Disease	ADJ	B
insufficiency	I-Disease	NOUN	I
in	O	ADP	O
this	O	DET	O
rat	O	NOUN	B
model	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
lung	O	NOUN	B
weights	O	NOUN	I
were	O	AUX	O
lower	O	ADJ	B
and	O	CCONJ	O
PaO2	O	NOUN	B
was	O	AUX	O
improved	O	VERB	B
in	O	ADP	O
rats	O	NOUN	B
given	O	VERB	O
this	O	DET	O
enzyme	O	NOUN	B
-	O	PUNCT	O
blocking	O	VERB	B
agent	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
contents	O	NOUN	B
of	O	ADP	O
albumin	O	NOUN	B
in	O	ADP	O
the	O	DET	O
lungs	O	NOUN	B
were	O	AUX	O
not	O	PART	O
changed	O	VERB	O
,	O	PUNCT	O
indicating	O	VERB	O
that	O	SCONJ	O
Captopril	B-Chemical	NOUN	B
did	O	AUX	O
not	O	PART	O
influence	O	VERB	B
the	O	DET	O
extravasation	O	NOUN	B
of	O	ADP	O
protein	O	NOUN	B
.	O	PUNCT	O


Renal	B-Disease	ADJ	B
damage	I-Disease	NOUN	I
as	O	ADP	O
reflected	O	VERB	O
by	O	ADP	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
serum	O	NOUN	B
urea	B-Chemical	NOUN	I
and	O	CCONJ	O
in	O	ADP	O
kidney	O	NOUN	B
weight	O	NOUN	I
was	O	AUX	O
prevented	O	VERB	B
by	O	ADP	O
Captopril	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
amount	O	NOUN	B
of	O	ADP	O
fibrin	O	NOUN	B
in	O	ADP	O
the	O	DET	O
kidneys	O	NOUN	B
was	O	AUX	O
also	O	ADV	O
considerably	O	ADV	O
lower	O	ADJ	O
than	O	ADP	O
in	O	ADP	O
animals	O	NOUN	B
which	O	DET	O
received	O	VERB	O
thrombin	O	NOUN	B
and	O	CCONJ	O
AMCA	B-Chemical	PROPN	B
alone	O	ADV	O
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
suggested	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
Captopril	B-Chemical	NOUN	B
on	O	ADP	O
the	O	DET	O
lungs	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
attributable	O	ADJ	O
to	O	PART	O
a	O	DET	O
vasodilatory	O	ADJ	B
effect	O	NOUN	I
due	O	ADJ	O
to	O	PART	O
a	O	DET	O
reduction	O	NOUN	B
in	O	ADP	O
the	O	DET	O
circulating	O	VERB	B
level	O	NOUN	B
of	O	ADP	O
Angiotension	B-Chemical	NOUN	B
II	I-Chemical	NUM	I
and	O	CCONJ	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
prostacyclin	B-Chemical	NOUN	B
(	O	PUNCT	O
secondary	O	ADJ	B
to	O	PART	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
bradykinin	B-Chemical	NOUN	B
).	O	PUNCT	O
Captopril	B-Chemical	NOUN	B
may	O	AUX	O
,	O	PUNCT	O
by	O	ADP	O
the	O	DET	O
same	O	ADJ	O
mechanism	O	NOUN	B
,	O	PUNCT	O
reduce	O	VERB	B
the	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
glomerular	O	ADJ	B
filtration	O	NOUN	I
that	O	PRON	O
is	O	AUX	O
known	O	VERB	O
to	O	PART	O
occur	O	VERB	O
after	O	ADP	O
an	O	DET	O
injection	O	NOUN	B
of	O	ADP	O
thrombin	O	NOUN	B
,	O	PUNCT	O
thereby	O	ADV	O
diminishing	O	VERB	O
the	O	DET	O
aggregation	O	NOUN	B
of	O	ADP	O
fibrin	O	NOUN	B
monomers	O	NOUN	I
in	O	ADP	O
the	O	DET	O
glomeruli	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
the	O	DET	O
result	O	NOUN	O
that	O	SCONJ	O
less	O	ADJ	O
fibrin	O	NOUN	B
will	O	AUX	O
be	O	AUX	O
deposited	O	VERB	B
and	O	CCONJ	O
thus	O	ADV	O
less	O	ADJ	O
kidney	B-Disease	NOUN	B
damage	I-Disease	NOUN	O


A	O	DET	O
randomized	O	ADJ	B
comparison	O	NOUN	B
of	O	ADP	O
labetalol	B-Chemical	NOUN	B
and	O	CCONJ	O
nitroprusside	B-Chemical	NOUN	B
for	O	ADP	O
induced	O	VERB	B
hypotension	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
study	O	NOUN	I
,	O	PUNCT	O
labetalol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypotension	B-Disease	NOUN	B
and	O	CCONJ	O
nitroprusside	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypotension	B-Disease	NOUN	B
were	O	AUX	O
compared	O	VERB	B
in	O	ADP	O
20	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
in	O	ADP	O
each	O	DET	O
group	O	NOUN	B
)	O	PUNCT	O
scheduled	O	VERB	B
for	O	ADP	O
major	O	ADJ	O
orthopedic	O	ADJ	B
procedures	O	NOUN	I
.	O	PUNCT	O


Each	O	DET	O
patient	O	NOUN	B
was	O	AUX	O
subjected	O	VERB	O
to	O	PART	O
an	O	DET	O
identical	O	ADJ	B
anesthetic	O	ADJ	B
protocol	O	NOUN	I
and	O	CCONJ	O
similar	O	ADJ	O
drug	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
reductions	B-Disease	NOUN	B
in	I-Disease	ADP	O
mean	I-Disease	ADJ	O
arterial	I-Disease	ADJ	B
blood	I-Disease	NOUN	I
pressure	I-Disease	NOUN	I
(	O	PUNCT	O
BP	O	NOUN	B
)(	O	NOUN	O
50	O	NUM	O
to	O	PART	O
55	O	NUM	O
mmHg	O	NOUN	B
).	O	PUNCT	O
Nitroprusside	O	NOUN	B
infusion	O	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
significant	O	ADJ	B
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
)	O	PUNCT	O
increase	B-Disease	NOUN	B
in	I-Disease	ADP	O
heart	I-Disease	NOUN	B
rate	I-Disease	NOUN	I
and	I-Disease	CCONJ	O
cardiac	I-Disease	ADJ	B
output	I-Disease	NOUN	I
;	O	PUNCT	O
rebound	O	ADJ	B
hypertension	B-Disease	NOUN	B
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
three	O	NUM	O
patients	O	NOUN	B
after	O	ADP	O
discontinuation	O	NOUN	B
of	O	ADP	O
nitroprusside	B-Chemical	NOUN	B
.	O	PUNCT	O


Labetalol	B-Chemical	NOUN	B
administration	O	NOUN	B
was	O	AUX	O
not	O	PART	O
associated	O	VERB	B
with	O	ADP	I
any	O	DET	O
of	O	ADP	O
these	O	DET	O
findings	O	NOUN	B
.	O	PUNCT	O


Arterial	O	ADJ	B
PO2	B-Chemical	NOUN	B
decreased	O	VERB	B
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
was	O	AUX	O
concluded	O	VERB	O
that	O	SCONJ	O
labetalol	B-Chemical	NOUN	B
offers	O	VERB	O
advantages	O	NOUN	O
over	O	ADP	O
nitroprusside	B-Chemical	NOUN	B


Chronic	O	ADJ	B
carbamazepine	B-Chemical	NOUN	I
treatment	O	NOUN	B
in	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
:	O	PUNCT	O
efficacy	O	NOUN	B
,	O	PUNCT	O
toxicity	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
effect	O	NOUN	B
on	O	ADP	O
plasma	O	NOUN	B
and	O	CCONJ	O
tissue	O	NOUN	B
folate	B-Chemical	NOUN	B
concentrations	O	NOUN	B
.	O	PUNCT	O


Folate	B-Chemical	NOUN	B
depletion	O	NOUN	B
has	O	AUX	O
often	O	ADV	O
been	O	AUX	O
a	O	DET	O
problem	O	NOUN	B
in	O	ADP	O
chronic	O	ADJ	B
antiepileptic	O	ADJ	I
drug	O	NOUN	I
(	O	PUNCT	O
AED	O	NOUN	B
)	O	PUNCT	O
therapy	O	NOUN	B
.	O	PUNCT	O


Carbamazepine	B-Chemical	NOUN	B
(	O	PUNCT	O
CBZ	B-Chemical	NOUN	B
),	O	PUNCT	O
a	O	DET	O
commonly	O	ADV	O
used	O	VERB	O
AED	O	PROPN	B
,	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
implicated	O	VERB	O
in	O	ADP	O
some	O	DET	O
clinical	O	ADJ	B
studies	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
rat	O	NOUN	B
model	O	NOUN	B
was	O	AUX	O
developed	O	VERB	O
to	O	PART	O
examine	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
chronic	O	ADJ	B
CBZ	B-Chemical	NOUN	B
treatment	O	NOUN	B
on	O	ADP	O
folate	B-Chemical	NOUN	B
concentrations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
course	O	NOUN	B
of	O	ADP	O
developing	O	VERB	O
this	O	DET	O
model	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
common	O	ADJ	O
vehicle	O	NOUN	B
,	O	PUNCT	O
propylene	B-Chemical	NOUN	B
glycol	I-Chemical	NOUN	I
,	O	PUNCT	O
by	O	ADP	O
itself	O	PRON	O
in	O	ADP	O
high	O	ADJ	B
doses	O	NOUN	I
,	O	PUNCT	O
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
exhibit	O	VERB	O
protective	O	ADJ	O
properties	O	NOUN	O
against	O	ADP	O
induced	O	VERB	B
seizures	B-Disease	NOUN	B
and	O	CCONJ	O
inhibited	O	VERB	B
weight	B-Disease	NOUN	B
gain	I-Disease	NOUN	I
.	O	PUNCT	O


Seizures	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
hexafluorodiethyl	B-Chemical	NOUN	B
ether	I-Chemical	NOUN	I
(	O	PUNCT	O
HFDE	B-Chemical	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
also	O	ADV	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
a	O	DET	O
more	O	ADV	O
sensitive	O	ADJ	B
measure	O	NOUN	B
of	O	ADP	O
protection	O	NOUN	B
by	O	ADP	O
CBZ	B-Chemical	NOUN	B
than	O	ADP	O
seizures	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
maximal	O	ADJ	B
electroshock	O	NOUN	I
(	O	PUNCT	O
MES	O	PROPN	B
).	O	PUNCT	O
Oral	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
CBZ	B-Chemical	NOUN	B
as	O	ADP	O
an	O	DET	O
aqueous	O	ADJ	B
suspension	O	NOUN	B
every	O	DET	O
8	O	NUM	O
h	O	NOUN	O
at	O	ADP	O
a	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
250	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
kg	O	NOUN	B
was	O	AUX	O
continuously	O	ADV	O
protective	O	ADJ	O
against	O	ADP	O
HFDE	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
seizures	B-Disease	NOUN	B
and	O	CCONJ	O
was	O	AUX	O
minimally	O	ADV	B
toxic	O	ADJ	I
as	O	ADP	O
measured	O	VERB	B
by	O	ADP	O
weight	B-Disease	NOUN	B
gain	I-Disease	NOUN	I
over	O	ADP	O
8	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
CBZ	B-Chemical	NOUN	B
levels	O	NOUN	B
measured	O	VERB	B
in	O	ADP	O
plasma	O	NOUN	B
and	O	CCONJ	O
brain	O	NOUN	B
of	O	ADP	O
these	O	DET	O
animals	O	NOUN	B
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
were	O	AUX	O
below	O	ADP	O
those	O	DET	O
normally	O	ADV	O
considered	O	VERB	O
protective	O	ADJ	B
.	O	PUNCT	O


This	O	DET	O
treatment	O	NOUN	B
with	O	ADP	O
CBZ	B-Chemical	NOUN	B
had	O	AUX	O
no	O	DET	O
apparent	O	ADJ	B
adverse	O	ADJ	B
effect	O	NOUN	I
on	O	ADP	O
folate	B-Chemical	NOUN	B
concentrations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
,	O	PUNCT	O
indeed	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
folate	B-Chemical	NOUN	B


Inhibition	O	NOUN	B
of	O	ADP	O
sympathoadrenal	O	ADJ	B
activity	O	NOUN	I
by	O	ADP	O
atrial	O	ADJ	B
natriuretic	O	ADJ	I
factor	O	NOUN	I
in	O	ADP	O
dogs	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
six	O	NUM	O
conscious	O	ADJ	B
,	O	PUNCT	O
trained	O	VERB	B
dogs	O	NOUN	B
,	O	PUNCT	O
maintained	O	VERB	B
on	O	ADP	O
a	O	DET	O
normal	O	ADJ	O
sodium	B-Chemical	NOUN	B
intake	O	NOUN	I
of	O	ADP	O
2	O	NUM	O
to	O	PART	O
4	O	NUM	O
mEq	O	NOUN	B
/	O	SYM	O
kg	O	NOUN	B
/	O	PUNCT	O
day	O	NOUN	B
,	O	PUNCT	O
sympathetic	O	ADJ	B
activity	O	NOUN	I
was	O	AUX	O
assessed	O	VERB	B
as	O	ADP	O
the	O	DET	O
release	O	NOUN	B
rate	O	NOUN	B
of	O	ADP	O
norepinephrine	B-Chemical	NOUN	B
and	O	CCONJ	O
epinephrine	B-Chemical	NOUN	B
during	O	ADP	O
15	O	NUM	O
-	O	PUNCT	O
minute	O	NOUN	B
i	O	NUM	O
.	O	PUNCT	O


v	O	NOUN	O
.	O	PUNCT	O


infusions	O	NOUN	B
of	O	ADP	O
human	O	ADJ	B
alpha	O	NOUN	I
-	O	PUNCT	O
atrial	O	ADJ	B
natriuretic	O	ADJ	I
factor	O	NOUN	I
.	O	PUNCT	O


Mean	O	VERB	O
arterial	O	ADJ	O
pressure	O	NOUN	O
(	O	PUNCT	O
as	O	ADP	O
a	O	DET	O
percentage	O	NOUN	B
of	O	ADP	O
control	O	NOUN	B
+/-	O	CCONJ	O
SEM	O	NOUN	B
)	O	PUNCT	O
during	O	ADP	O
randomized	O	ADJ	B
infusions	O	NOUN	B
of	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


03	O	NUM	O
,	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
,	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
,	O	PUNCT	O
or	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
microgram	O	NOUN	B
/	O	SYM	O
kg	O	NOUN	B
/	O	SYM	O
min	O	NOUN	B
was	O	AUX	O
99	O	NUM	O
+/-	O	CCONJ	O
1	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
+/-	O	CCONJ	O
1	O	NUM	O
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
),	O	PUNCT	O
93	O	NUM	O
+/-	O	CCONJ	O
1	O	NUM	O
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
),	O	PUNCT	O
or	O	CCONJ	O
79	O	NUM	O
+/-	O	CCONJ	O
6	O	NUM	O
%(	O	NOUN	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
),	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
but	O	CCONJ	O
no	O	DET	O
tachycardia	B-Disease	NOUN	B
and	O	CCONJ	O
no	O	DET	O
augmentation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
norepinephrine	B-Chemical	NOUN	B
release	O	NOUN	I
rate	O	NOUN	B
(	O	PUNCT	O
up	O	ADV	O
to	O	PART	O
0	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
microgram	O	NOUN	B
/	O	SYM	O
kg	O	NOUN	B
/	O	PUNCT	O
min	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
observed	O	VERB	B
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
in	O	ADP	O
contrast	O	NOUN	O
to	O	PART	O
comparable	O	ADJ	O
hypotension	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
hydralazine	B-Chemical	NOUN	B
or	O	CCONJ	O
nitroglycerin	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
release	O	NOUN	B
rate	O	NOUN	B
of	O	ADP	O
epinephrine	B-Chemical	NOUN	B


Death	B-Disease	NOUN	B
from	O	ADP	O
chemotherapy	O	NOUN	B
in	O	ADP	O
gestational	B-Disease	ADJ	B
trophoblastic	I-Disease	ADJ	I
disease	I-Disease	NOUN	I
.	O	PUNCT	O


Multiple	O	ADJ	B
cytotoxic	O	ADJ	B
drug	O	NOUN	B
administration	O	NOUN	I
is	O	AUX	O
the	O	DET	O
generally	O	ADV	O
accepted	O	VERB	B
treatment	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
a	O	DET	O
high	O	ADJ	B
-	O	PUNCT	O
risk	O	NOUN	B
stage	O	NOUN	I
of	O	ADP	O
choriocarcinoma	B-Disease	NOUN	B
.	O	PUNCT	O


Based	O	VERB	O
on	O	ADP	O
this	O	DET	O
principle	O	NOUN	O
a	O	DET	O
27	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
old	O	ADJ	O
woman	O	NOUN	B
,	O	PUNCT	O
classified	O	VERB	O
as	O	ADP	O
being	O	AUX	O
in	O	ADP	O
the	O	DET	O
high	O	ADJ	B
-	O	PUNCT	O
risk	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
Goldstein	O	PROPN	B
and	O	CCONJ	O
Berkowitz	O	PROPN	B
score	O	NOUN	I
:	O	PUNCT	O
11	O	NUM	O
),	O	PUNCT	O
was	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
multiple	O	ADJ	O
cytotoxic	O	ADJ	B
drugs	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
multiple	O	ADJ	B
drug	O	NOUN	B
schema	O	NOUN	I
consisted	O	VERB	O
of	O	ADP	O
:	O	PUNCT	O
Etoposide	B-Chemical	NOUN	B
16	O	NUM	O
.	O	PUNCT	O


213	O	NUM	O
,	O	PUNCT	O
Methotrexate	B-Chemical	NOUN	B
,	O	PUNCT	O
Cyclophosphamide	B-Chemical	NOUN	B
,	O	PUNCT	O
Actomycin-D	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
Cisplatin	B-Chemical	PROPN	B
.	O	PUNCT	O


On	O	ADP	O
the	O	DET	O
first	O	ADJ	O
day	O	NOUN	B
of	O	ADP	O
the	O	DET	O
schedule	O	NOUN	B
,	O	PUNCT	O
moderate	O	ADJ	B
high	O	ADJ	O
doses	O	NOUN	B
of	O	ADP	O
Methotrexate	B-Chemical	NOUN	B
,	O	PUNCT	O
Etoposide	B-Chemical	NOUN	B
and	O	CCONJ	O
Cyclophosphamide	B-Chemical	NOUN	B
were	O	AUX	O
administered	O	VERB	B
.	O	PUNCT	O


Within	O	ADP	O
8	O	NUM	O
hours	O	NOUN	O
after	O	ADP	O
initiation	O	NOUN	B
of	O	ADP	O
therapy	O	NOUN	B
the	O	DET	O
patient	O	NOUN	B
died	O	VERB	B
with	O	ADP	O
a	O	DET	O
clinical	O	ADJ	B
picture	O	NOUN	I
resembling	O	VERB	O
massive	O	ADJ	O
pulmonary	B-Disease	ADJ	B
obstruction	I-Disease	NOUN	I
due	O	ADJ	O
to	O	PART	O
choriocarcinomic	O	ADJ	B
tissue	O	NOUN	B
plugs	O	NOUN	B
,	O	PUNCT	O
probably	O	ADV	O
originating	O	VERB	O
from	O	ADP	O
the	O	DET	O
uterus	O	NOUN	B
.	O	PUNCT	O


Formation	O	NOUN	B
of	O	ADP	O
these	O	DET	O
plugs	O	NOUN	B
was	O	AUX	O
probably	O	ADV	O
due	O	ADJ	O
to	O	PART	O
extensive	O	ADJ	B
tumor	B-Disease	NOUN	B
necrosis	B-Disease	NOUN	I
at	O	ADP	O
the	O	DET	O
level	O	NOUN	B
of	O	ADP	O
the	O	DET	O
walls	O	NOUN	B
of	O	ADP	O
the	O	DET	O
major	O	ADJ	O
uterine	O	NOUN	B
veins	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
resulted	O	VERB	O
in	O	ADP	O
an	O	DET	O
open	O	ADJ	O
exchange	O	NOUN	O
of	O	ADP	O
tumor	B-Disease	NOUN	B
plugs	O	NOUN	I
to	O	PART	O
the	O	DET	O
vascular	O	ADJ	B
spaces	O	NOUN	I
;	O	PUNCT	O
decrease	O	NOUN	B
in	O	ADP	O
tumor	B-Disease	NOUN	B
tissue	O	NOUN	I
coherence	O	NOUN	I
secondary	O	ADJ	B
to	O	PART	I
chemotherapy	O	NOUN	B
may	O	AUX	O
have	O	AUX	O
further	O	ADV	O
contributed	O	VERB	O
to	O	PART	O
the	O	DET	O
formation	O	NOUN	B
of	O	ADP	O
tumor	B-Disease	NOUN	B
emboli	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
view	O	NOUN	O
of	O	ADP	O
the	O	DET	O
close	O	ADJ	O
time	O	NOUN	O
association	O	NOUN	B
between	O	ADP	O
the	O	DET	O
start	O	NOUN	O
of	O	ADP	O
chemotherapy	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
acute	O	ADJ	B
onset	O	NOUN	O
of	O	ADP	O
massive	O	ADJ	B
embolism	B-Disease	NOUN	B
other	O	ADJ	O
explanations	O	NOUN	B
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
spontaneous	O	ADJ	B
necrosis	B-Disease	NOUN	B
,	O	PUNCT	O
must	O	AUX	O
be	O	AUX	O
considered	O	VERB	O
less	O	ADV	O
likely	O	ADJ	O
.	O	PUNCT	O


Patients	O	NOUN	B
with	O	ADP	O
large	O	ADJ	O
pelvic	B-Disease	ADJ	B
tumor	I-Disease	NOUN	I


Sexual	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
among	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
arthritis	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
relationship	O	NOUN	B
of	O	ADP	O
arthritis	B-Disease	NOUN	B
and	O	CCONJ	O
sexual	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
was	O	AUX	O
investigated	O	VERB	B
among	O	ADP	O
169	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
rheumatoid	B-Disease	ADJ	B
arthritis	I-Disease	NOUN	I
,	O	PUNCT	O
osteoarthritis	B-Disease	NOUN	B
and	O	CCONJ	O
spondyloarthropathy	B-Disease	NOUN	B
,	O	PUNCT	O
130	O	NUM	O
of	O	ADP	O
whom	O	PRON	O
were	O	AUX	O
pair	O	NOUN	B
-	O	PUNCT	O
matched	O	VERB	B
to	O	PART	O
controls	O	NOUN	B
.	O	PUNCT	O


Assessments	O	NOUN	B
of	O	ADP	O
marital	O	ADJ	B
happiness	O	NOUN	I
and	O	CCONJ	O
depressed	B-Disease	ADJ	B
mood	I-Disease	NOUN	I
were	O	AUX	O
also	O	ADV	O
made	O	VERB	O
using	O	VERB	O
the	O	DET	O
CES	O	PROPN	B
-	O	PUNCT	O
D	O	PROPN	B
and	O	CCONJ	O
the	O	DET	O
Azrin	O	PROPN	B
Marital	O	PROPN	I
Happiness	O	PROPN	I
Scale	O	NOUN	I
(	O	PUNCT	O
AMHS	O	NOUN	B
).	O	PUNCT	O
Sexual	B-Disease	ADJ	B
dysfunctions	I-Disease	NOUN	I
were	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
common	O	ADJ	O
among	O	ADP	O
patients	O	NOUN	B
and	O	CCONJ	O
controls	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
majority	O	NOUN	O
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
reporting	O	VERB	B
one	O	NUM	O
or	O	CCONJ	O
more	O	ADJ	O
dysfunctions	O	NOUN	B
.	O	PUNCT	O


Impotence	B-Disease	NOUN	B
was	O	AUX	O
more	O	ADV	O
common	O	ADJ	O
among	O	ADP	O
male	O	NOUN	B
patients	O	NOUN	B
than	O	ADP	O
controls	O	NOUN	B
and	O	CCONJ	O
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
co	O	ADJ	B
-	O	PUNCT	O
morbidity	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
taking	O	NOUN	O
of	O	ADP	O
methotrexate	B-Chemical	NOUN	B
.	O	PUNCT	O


Depressed	B-Disease	ADJ	B
mood	I-Disease	NOUN	I
was	O	AUX	O
more	O	ADV	O
common	O	ADJ	O
among	O	ADP	O
patients	O	NOUN	B
and	O	CCONJ	O
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
certain	O	ADJ	O
sexual	O	ADJ	B
difficulties	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
with	O	ADP	O
impotence	B-Disease	NOUN	B
.	O	PUNCT	O


Marital	O	ADJ	B
unhappiness	O	NOUN	O
,	O	PUNCT	O
as	O	ADP	O
indicated	O	VERB	O
by	O	ADP	O
AMHS	O	NOUN	B
scores	O	NOUN	O
,	O	PUNCT	O
was	O	AUX	O
not	O	PART	O
associated	O	VERB	B
with	O	ADP	I
arthritis	B-Disease	NOUN	B
but	O	CCONJ	O
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
sexual	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I


Does	O	AUX	O
paracetamol	B-Chemical	NOUN	B
cause	O	VERB	O
urothelial	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
or	O	CCONJ	O
renal	B-Disease	ADJ	B
papillary	I-Disease	ADJ	I
necrosis	I-Disease	NOUN	I
?	O	PUNCT	O
The	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
developing	O	VERB	O
renal	B-Disease	ADJ	B
papillary	I-Disease	ADJ	I
necrosis	I-Disease	NOUN	I
or	O	CCONJ	O
cancer	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
renal	I-Disease	ADJ	B
pelvis,	I-Disease	NOUN	I
ureter	I-Disease	NOUN	I
or	I-Disease	CCONJ	O
bladder	I-Disease	NOUN	B
associated	O	VERB	B
with	O	ADP	I
consumption	O	NOUN	B
of	O	ADP	O
either	O	CCONJ	O
phenacetin	B-Chemical	NOUN	B
or	O	CCONJ	O
paracetamol	B-Chemical	NOUN	B
was	O	AUX	O
calculated	O	VERB	O
from	O	ADP	O
data	O	NOUN	B
acquired	O	VERB	O
by	O	ADP	O
questionnaire	O	NOUN	B
from	O	ADP	O
381	O	NUM	O
cases	O	NOUN	B
and	O	CCONJ	O
808	O	NUM	O
controls	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
renal	B-Disease	ADJ	B
papillary	I-Disease	ADJ	I
necrosis	I-Disease	NOUN	I
was	O	AUX	O
increased	O	VERB	B
nearly	O	ADV	O
20	O	NUM	O
-	O	PUNCT	O
fold	O	NOUN	B
by	O	ADP	O
consumption	O	NOUN	B
of	O	ADP	O
phenacetin	B-Chemical	NOUN	B
,	O	PUNCT	O
which	O	DET	O
also	O	ADV	O
increased	O	VERB	B
the	O	DET	O
risk	O	NOUN	B
for	O	ADP	O
cancer	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
renal	I-Disease	ADJ	B
pelvis	I-Disease	NOUN	I
and	I-Disease	CCONJ	O
bladder	I-Disease	NOUN	B
but	O	CCONJ	O
not	O	PART	O
for	O	ADP	O
ureteric	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


By	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
we	O	PRON	O
were	O	AUX	O
unable	O	ADJ	O
to	O	PART	O
substantiate	O	VERB	O
an	O	DET	O
increased	O	VERB	B
risk	O	NOUN	B
from	O	ADP	O
paracetamol	B-Chemical	NOUN	B
consumption	O	NOUN	I
for	O	ADP	O
renal	B-Disease	ADJ	B
papillary	I-Disease	ADJ	I
necrosis	I-Disease	NOUN	I
or	O	CCONJ	O
any	O	DET	O
of	O	ADP	O
these	O	DET	O
cancers	B-Disease	NOUN	B
although	O	SCONJ	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
suggestion	O	NOUN	O
of	O	ADP	O
an	O	DET	O
association	O	NOUN	B
with	O	ADP	I
cancer	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
ureter	I-Disease	NOUN	B


Dapsone	B-Chemical	PROPN	B
-	O	PUNCT	O
associated	O	VERB	B
Heinz	O	NOUN	B
body	O	NOUN	O
hemolytic	B-Disease	ADJ	O
anemia	I-Disease	NOUN	B
in	O	ADP	O
a	O	DET	O
Cambodian	O	ADJ	B
woman	O	NOUN	B
with	O	ADP	O
hemoglobin	O	NOUN	B
E	O	NOUN	I
trait	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
Cambodian	O	ADJ	B
woman	O	NOUN	B
with	O	ADP	O
hemoglobin	O	NOUN	B
E	O	NOUN	I
trait	O	NOUN	I
(	O	PUNCT	O
AE	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
leprosy	B-Disease	NOUN	B
developed	O	VERB	O
a	O	DET	O
Heinz	O	NOUN	B
body	O	NOUN	I
hemolytic	B-Disease	ADJ	I
anemia	I-Disease	NOUN	B
while	O	SCONJ	O
taking	O	VERB	O
a	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
dapsone	B-Chemical	NOUN	B
(	O	PUNCT	O
50	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
day	O	NOUN	B
)	O	PUNCT	O
not	O	PART	O
usually	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
clinical	O	ADJ	B
hemolysis	B-Disease	NOUN	I
.	O	PUNCT	O


Her	O	PRON	O
red	O	ADJ	B
blood	O	NOUN	I
cells	O	NOUN	I
(	O	PUNCT	O
RBCs	O	NOUN	B
)	O	PUNCT	O
had	O	AUX	O
increased	O	VERB	B
incubated	O	VERB	B
Heinz	O	NOUN	B
body	O	NOUN	I
formation	O	NOUN	I
,	O	PUNCT	O
decreased	O	VERB	B
reduced	O	VERB	O
glutathione	B-Chemical	NOUN	B
(	O	PUNCT	O
GSH	B-Chemical	NOUN	B
),	O	PUNCT	O
and	O	CCONJ	O
decreased	O	VERB	B
GSH	B-Chemical	NOUN	B
stability	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
pentose	B-Chemical	NOUN	B
phosphate	I-Chemical	NOUN	I
shunt	O	NOUN	I
activity	O	NOUN	O
of	O	ADP	O
the	O	DET	O
dapsone	B-Chemical	NOUN	B
-	O	PUNCT	O
exposed	O	VERB	B
AE	O	NOUN	B
RBCs	O	NOUN	B
was	O	AUX	O
increased	O	VERB	B
compared	O	VERB	O
to	O	PART	O
normal	O	ADJ	O
RBCs	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
the	O	DET	O
AE	O	NOUN	B
RBCs	O	NOUN	B
from	O	ADP	O
an	O	DET	O
individual	O	NOUN	B
not	O	PART	O
taking	O	VERB	O
dapsone	B-Chemical	NOUN	B
had	O	AUX	O
increased	O	VERB	B
incubated	O	VERB	B
Heinz	O	NOUN	B
body	O	NOUN	I
formation	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
GSH	B-Chemical	NOUN	B
content	O	NOUN	B
and	O	CCONJ	O
GSH	B-Chemical	NOUN	B
stability	O	NOUN	B
were	O	AUX	O
normal	O	ADJ	O
.	O	PUNCT	O


The	O	DET	O
pentose	B-Chemical	NOUN	B
phosphate	I-Chemical	NOUN	I
shunt	O	NOUN	I
activity	O	NOUN	O
of	O	ADP	O
the	O	DET	O
non	O	ADJ	B
-	O	PUNCT	O
dapsone	B-Chemical	NOUN	B
-	O	PUNCT	O
exposed	O	VERB	B
AE	O	NOUN	B
RBCs	O	NOUN	B
was	O	AUX	O
decreased	O	VERB	B
compared	O	VERB	O
to	O	PART	O
normal	O	ADJ	O
RBCs	O	NOUN	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
AE	O	NOUN	B
RBCs	O	NOUN	B
appear	O	VERB	O
to	O	PART	O
have	O	AUX	O
an	O	DET	O
increased	O	VERB	B
sensitivity	O	NOUN	B
to	O	PART	O
oxidant	O	ADJ	B
stress	O	NOUN	I
both	O	CCONJ	O
in	O	X	B
vitro	O	X	I
and	O	CCONJ	O
in	O	X	B
vivo	O	X	I
,	O	PUNCT	O
since	O	SCONJ	O
dapsone	B-Chemical	NOUN	B
does	O	AUX	O
not	O	PART	O
cause	O	VERB	O
hemolytic	B-Disease	ADJ	B
anemia	I-Disease	NOUN	B
at	O	ADP	O
this	O	DET	O
dose	O	NOUN	B
in	O	ADP	O
hematologically	O	ADV	B
normal	O	ADJ	O
individuals	O	NOUN	B
.	O	PUNCT	O


Given	O	VERB	O
the	O	DET	O
influx	O	NOUN	B
of	O	ADP	O
Southeast	O	PROPN	B
Asians	O	PROPN	B
into	O	ADP	O
the	O	DET	O
United	O	PROPN	B
States	O	PROPN	I
,	O	PUNCT	O
oxidant	O	ADJ	B
medications	O	NOUN	I
should	O	AUX	O
be	O	AUX	O
used	O	VERB	O
with	O	ADP	O
caution	O	NOUN	B
,	O	PUNCT	O
especially	O	ADV	O
if	O	SCONJ	O
an	O	DET	O
infection	B-Disease	NOUN	B


Severe	O	ADJ	B
complications	O	NOUN	B
of	O	ADP	O
antianginal	O	ADJ	B
drug	O	NOUN	B
therapy	O	NOUN	I
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
identified	O	VERB	B
as	O	ADP	O
a	O	DET	O
poor	O	ADJ	O
metabolizer	O	NOUN	B
of	O	ADP	O
metoprolol	B-Chemical	NOUN	B
,	O	PUNCT	O
propafenone	B-Chemical	NOUN	B
,	O	PUNCT	O
diltiazem	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
sparteine	B-Chemical	NOUN	B
.	O	PUNCT	O


A	O	DET	O
47	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
patient	O	NOUN	B
suffering	O	VERB	O
from	O	ADP	O
coronary	B-Disease	ADJ	B
artery	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
was	O	AUX	O
admitted	O	VERB	B
to	O	ADP	O
the	O	DET	O
CCU	O	PROPN	B
in	O	ADP	O
shock	B-Disease	NOUN	B
with	O	ADP	I
III	O	NUM	B
.	O	PUNCT	O


AV	B-Disease	NOUN	B
block	I-Disease	NOUN	I
,	O	PUNCT	O
severe	O	ADJ	B
hypotension	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
impairment	B-Disease	NOUN	B
of	I-Disease	ADP	O
ventricular	I-Disease	ADJ	B
function	I-Disease	NOUN	I
.	O	PUNCT	O


One	O	NUM	O
week	O	NOUN	B
prior	O	ADV	O
to	O	PART	O
admission	O	NOUN	B
a	O	DET	O
therapy	O	NOUN	B
with	O	ADP	O
standard	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
metoprolol	B-Chemical	NOUN	B
(	O	PUNCT	O
100	O	NUM	O
mg	O	NOUN	O
t	O	NOUN	O
.	O	PUNCT	O


i	O	X	O
.	O	PUNCT	O


d	O	X	O
.	O	PUNCT	O


and	O	CCONJ	O
then	O	ADV	O
100	O	NUM	O
mg	O	NOUN	O
b	O	NOUN	O
.	O	PUNCT	O


i	O	X	O
.	O	PUNCT	O


d	O	X	O
.)	O	NOUN	O
had	O	AUX	O
been	O	AUX	O
initiated	O	VERB	O
.	O	PUNCT	O


Two	O	NUM	O
days	O	NOUN	B
before	O	ADP	O
admission	O	NOUN	B
diltiazem	B-Chemical	NOUN	B
(	O	PUNCT	O
60	O	NUM	O
mg	O	NOUN	O
b	O	NOUN	O
.	O	PUNCT	O


i	O	X	O
.	O	PUNCT	O


d	O	X	O
.)	O	NOUN	O
was	O	AUX	O
prescribed	O	VERB	B
in	O	ADP	O
addition	O	NOUN	O
.	O	PUNCT	O


Analyses	O	NOUN	B
of	O	ADP	O
a	O	DET	O
blood	O	NOUN	B
sample	O	NOUN	I
revealed	O	VERB	O
unusually	O	ADV	O
high	O	ADJ	O
plasma	O	NOUN	B
concentrations	O	NOUN	B
of	O	ADP	O
metoprolol	B-Chemical	NOUN	B
(	O	PUNCT	O
greater	O	ADJ	O
than	O	ADP	O
3000	O	NUM	O
ng	O	NOUN	O
/	O	PUNCT	O
ml	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
diltiazem	B-Chemical	NOUN	B
(	O	PUNCT	O
526	O	NUM	O
ng	O	NOUN	O
/	O	PUNCT	O
ml	O	NOUN	O
).	O	PUNCT	O
The	O	DET	O
patient	O	NOUN	B
recovered	O	VERB	B
within	O	ADP	O
1	O	NUM	O
week	O	NOUN	B
following	O	VERB	O
discontinuation	O	NOUN	B
of	O	ADP	O
antianginal	O	ADJ	B
therapy	O	NOUN	I
.	O	PUNCT	O


Three	O	NUM	O
months	O	NOUN	B
later	O	ADV	O
the	O	DET	O
patient	O	NOUN	B
was	O	AUX	O
exposed	O	VERB	O
to	O	PART	O
a	O	DET	O
single	O	ADJ	O
dose	O	NOUN	B
of	O	ADP	O
metoprolol	B-Chemical	NOUN	B
,	O	PUNCT	O
diltiazem	B-Chemical	NOUN	B
,	O	PUNCT	O
propafenone	B-Chemical	NOUN	B
(	O	PUNCT	O
since	O	SCONJ	O
he	O	PRON	O
had	O	AUX	O
received	O	VERB	O
this	O	DET	O
drug	O	NOUN	B
in	O	ADP	O
the	O	DET	O
past	O	NOUN	O
),	O	PUNCT	O
and	O	CCONJ	O
sparteine	B-Chemical	NOUN	B
(	O	PUNCT	O
as	O	ADP	O
a	O	DET	O
probe	O	NOUN	B
for	O	ADP	O
the	O	DET	O
debrisoquine	B-Chemical	NOUN	B
/	O	SYM	O
sparteine	B-Chemical	NOUN	B
type	O	NOUN	O
polymorphism	O	NOUN	B
of	O	ADP	O
oxidative	O	ADJ	B
drug	O	NOUN	I
metabolism	O	NOUN	I
).	O	PUNCT	O
It	O	PRON	O
was	O	AUX	O
found	O	VERB	O
that	O	SCONJ	O
he	O	PRON	O
was	O	AUX	O
a	O	DET	O
poor	O	ADJ	B
metabolizer	O	NOUN	B
of	O	ADP	O
all	O	DET	O
four	O	NUM	O
drugs	O	NOUN	B
,	O	PUNCT	O
indicating	O	VERB	O
that	O	SCONJ	O
their	O	PRON	O
metabolism	O	NOUN	B
is	O	AUX	O
under	O	ADP	O
the	O	DET	O
same	O	ADJ	O
genetic	O	ADJ	B
control	O	NOUN	I
.	O	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
patients	O	NOUN	B
belonging	O	VERB	O
to	O	ADP	O
the	O	DET	O
poor	O	ADJ	B
-	O	PUNCT	O
metabolizer	O	NOUN	B
phenotype	O	NOUN	B
of	O	ADP	O
sparteine	B-Chemical	NOUN	B
/	O	SYM	O
debrisoquine	B-Chemical	NOUN	B
polymorphism	O	NOUN	B
in	O	ADP	O
drug	O	NOUN	B
metabolism	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
constitutes	O	VERB	O
6	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
German	O	ADJ	B
population	O	NOUN	I
,	O	PUNCT	O
may	O	AUX	O
experience	O	VERB	O
adverse	B-Disease	ADJ	B
drug	I-Disease	NOUN	I
reactions	I-Disease	NOUN	I


Triazolam	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
brief	O	ADJ	B
episodes	O	NOUN	I
of	O	ADP	O
secondary	O	ADJ	B
mania	B-Disease	NOUN	B
in	O	ADP	O
a	O	DET	O
depressed	B-Disease	ADJ	B
patient	O	NOUN	I
.	O	PUNCT	O


Large	O	ADJ	O
doses	O	NOUN	B
of	O	ADP	O
triazolam	B-Chemical	NOUN	B
repeatedly	O	ADV	O
induced	O	VERB	B
brief	O	ADJ	O
episodes	O	NOUN	B
of	O	ADP	O
mania	B-Disease	NOUN	B
in	O	ADP	O
a	O	DET	O
depressed	B-Disease	ADJ	B
elderly	O	ADJ	I
woman	O	NOUN	O
.	O	PUNCT	O


Features	O	NOUN	B
of	O	ADP	O
organic	B-Disease	ADJ	B
mental	I-Disease	ADJ	I
disorder	I-Disease	NOUN	I
(	O	PUNCT	O
delirium	B-Disease	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
not	O	PART	O
present	O	ADJ	O
.	O	PUNCT	O


Manic	B-Disease	ADJ	B
excitement	O	NOUN	B
was	O	AUX	O
coincident	O	ADJ	O
with	O	ADP	O
the	O	DET	O
duration	O	NOUN	B
of	O	ADP	O
action	O	NOUN	B
of	O	ADP	O
triazolam	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
possible	O	ADJ	O
contribution	O	NOUN	B
of	O	ADP	O
the	O	DET	O
triazolo	B-Chemical	NOUN	B


On	O	ADP	O
the	O	DET	O
mechanisms	O	NOUN	B
of	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
tolerance	O	NOUN	B
to	O	PART	O
the	O	DET	O
muscular	B-Disease	ADJ	B
rigidity	I-Disease	NOUN	I
produced	O	VERB	O
by	O	ADP	O
morphine	B-Chemical	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
development	O	NOUN	B
of	O	ADP	O
tolerance	O	NOUN	B
to	O	PART	O
the	O	DET	O
muscular	B-Disease	ADJ	B
rigidity	I-Disease	NOUN	I
produced	O	VERB	O
by	O	ADP	O
morphine	B-Chemical	NOUN	B
was	O	AUX	O
studied	O	VERB	O
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


Saline	O	NOUN	B
-	O	PUNCT	O
pretreated	O	VERB	B
controls	O	NOUN	B
given	O	VERB	O
a	O	DET	O
test	O	NOUN	B
dose	O	NOUN	I
of	O	ADP	O
morphine	B-Chemical	NOUN	B
(	O	PUNCT	O
20	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
i	O	X	O
.	O	PUNCT	O


p	O	NOUN	O
.)	O	PUNCT	O
showed	O	VERB	O
a	O	DET	O
pronounced	O	ADJ	O
rigidity	B-Disease	NOUN	B
recorded	O	VERB	O
as	O	ADP	O
tonic	O	ADJ	B
activity	O	NOUN	I
in	O	ADP	O
the	O	DET	O
electromyogram	O	NOUN	B
.	O	PUNCT	O


Rats	O	NOUN	B
treated	O	VERB	B
for	O	ADP	O
11	O	NUM	O
days	O	NOUN	B
with	O	ADP	O
morphine	B-Chemical	NOUN	B
and	O	CCONJ	O
withdrawn	O	VERB	O
for	O	ADP	O
36	O	NUM	O
-	O	PUNCT	O
40	O	NUM	O
h	O	NOUN	O
showed	O	VERB	O
differences	O	NOUN	O
in	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
tolerance	O	NOUN	B
:	O	PUNCT	O
about	O	ADV	O
half	O	NOUN	O
of	O	ADP	O
the	O	DET	O
animals	O	NOUN	B
showed	O	VERB	O
a	O	DET	O
rigidity	B-Disease	NOUN	B
after	O	ADP	O
the	O	DET	O
test	O	NOUN	B
dose	O	NOUN	I
of	O	ADP	O
morphine	B-Chemical	NOUN	B
that	O	PRON	O
was	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
less	O	ADJ	O
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
controls	O	NOUN	B
and	O	CCONJ	O
were	O	AUX	O
akinetic	B-Disease	ADJ	B
(	O	PUNCT	O
A	O	DET	O
group	O	NOUN	B
).	O	PUNCT	O
The	O	DET	O
other	O	ADJ	O
rats	O	NOUN	B
showed	O	VERB	O
a	O	DET	O
strong	O	ADJ	O
decrease	O	NOUN	B
in	O	ADP	O
the	O	DET	O
rigidity	B-Disease	NOUN	B
and	O	CCONJ	O
the	O	DET	O
occurrence	O	NOUN	B
of	O	ADP	O
stereotyped	O	ADJ	B
(	O	PUNCT	I
S	O	NOUN	I
)	O	PUNCT	I
licking	O	NOUN	B
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
gnawing	O	NOUN	B
in	O	ADP	O
presence	O	NOUN	B
of	O	ADP	O
akinetic	B-Disease	ADJ	B
or	O	CCONJ	O
hyperkinetic	B-Disease	ADJ	O
(	O	PUNCT	O
K	O	NOUN	O
)	O	PUNCT	O
behaviour	O	NOUN	O
(	O	PUNCT	O
AS	O	ADJ	B
/	O	SYM	O
KS	O	NOUN	B
group	O	NOUN	B
),	O	PUNCT	O
suggesting	O	VERB	O
signs	O	NOUN	O
of	O	ADP	O
dopaminergic	O	ADJ	B
activation	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
rigidity	B-Disease	NOUN	B
was	O	AUX	O
considerably	O	ADV	O
decreased	O	VERB	B
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
after	O	ADP	O
20	O	NUM	O
days	O	NOUN	B
'	O	PART	O
treatment	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
further	O	ADJ	O
series	O	NOUN	O
of	O	ADP	O
experiments	O	NOUN	B
,	O	PUNCT	O
haloperidol	B-Chemical	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
i	O	X	O
.	O	PUNCT	O


p	O	NOUN	O
.)	O	PUNCT	O
was	O	AUX	O
used	O	VERB	O
in	O	ADP	O
order	O	NOUN	O
to	O	PART	O
block	O	VERB	B
the	O	DET	O
dopaminergic	O	ADJ	B
activation	O	NOUN	O
and	O	CCONJ	O
to	O	PART	O
estimate	O	VERB	B
the	O	DET	O
real	O	ADJ	O
degree	O	NOUN	B
of	O	ADP	O
the	O	DET	O
tolerance	O	NOUN	B
to	O	PART	O
the	O	DET	O
rigidity	B-Disease	NOUN	B
without	O	ADP	O
any	O	DET	O
dopaminergic	O	ADJ	B
interference	O	NOUN	B
.	O	PUNCT	O


Haloperidol	B-Chemical	NOUN	B
enhanced	O	VERB	B
the	O	DET	O
rigidity	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
A	O	NOUN	O
group	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
level	O	NOUN	B
in	O	ADP	O
the	O	DET	O
AS	O	ADJ	B
/	O	SYM	O
KS	O	NOUN	B
group	O	NOUN	B
remained	O	VERB	O
considerably	O	ADV	O
lower	O	ADJ	O
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
A	O	NOUN	O
group	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
rigidity	B-Disease	NOUN	B
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
assumed	O	VERB	O
to	O	PART	O
be	O	AUX	O
due	O	ADJ	O
to	O	PART	O
an	O	DET	O
action	O	NOUN	B
of	O	ADP	O
morphine	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
striatum	O	NOUN	B
,	O	PUNCT	O
can	O	AUX	O
be	O	AUX	O
antagonized	O	VERB	B
by	O	ADP	O
another	O	DET	O
process	O	NOUN	B
leading	O	VERB	O
to	O	PART	O
dopaminergic	O	ADJ	B
activation	O	NOUN	I
in	O	ADP	O
the	O	DET	O
striatum	O	NOUN	B
.	O	PUNCT	O


Nevertheless	O	ADV	O
,	O	PUNCT	O
there	O	PRON	O
occurs	O	VERB	O
some	O	DET	O
real	O	ADJ	O
tolerance	O	NOUN	B
to	O	PART	O
this	O	DET	O
effect	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
rapid	O	ADJ	O
alternations	O	NOUN	B
of	O	ADP	O
rigidity	B-Disease	NOUN	B


Compression	B-Disease	NOUN	B
neuropathy	I-Disease	NOUN	I
of	I-Disease	ADP	O
the	I-Disease	DET	O
radial	I-Disease	ADJ	B
nerve	I-Disease	NOUN	I
due	O	ADP	O
to	O	PART	O
pentazocine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
fibrous	B-Disease	ADJ	B
myopathy	I-Disease	NOUN	I
.	O	PUNCT	O


Fibrous	B-Disease	ADJ	B
myopathy	I-Disease	NOUN	I
is	O	AUX	O
a	O	DET	O
common	O	ADJ	O
,	O	PUNCT	O
well	O	ADV	O
-	O	PUNCT	O
known	O	VERB	B
side	O	NOUN	B
effect	O	NOUN	I
of	O	ADP	O
repeated	O	VERB	O
pentazocine	B-Chemical	NOUN	B
injection	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
compression	B-Disease	NOUN	B
neuropathy	I-Disease	NOUN	I
due	O	ADJ	O
to	O	PART	O
fibrotic	O	ADJ	B
muscle	O	NOUN	I
affected	O	VERB	B
by	O	ADP	O
pentazocine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
myopathy	B-Disease	NOUN	B
has	O	AUX	O
not	O	PART	O
previously	O	ADV	O
been	O	AUX	O
reported	O	VERB	O
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
37	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
woman	O	NOUN	B
with	O	ADP	O
documented	O	VERB	B
pentazocine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
fibrous	B-Disease	ADJ	B
myopathy	I-Disease	NOUN	I
of	O	ADP	O
triceps	O	NOUN	B
and	O	CCONJ	O
deltoid	O	ADJ	B
muscles	O	NOUN	I
bilaterally	O	ADV	B
and	O	CCONJ	O
a	O	DET	O
three	O	NUM	B
-	O	PUNCT	O
week	O	NOUN	B
history	O	NOUN	B
of	O	ADP	O
right	O	ADJ	B
wrist	O	ADJ	I
drop	O	NOUN	I
,	O	PUNCT	O
electrodiagnostic	O	ADJ	B
examination	O	NOUN	I
showed	O	VERB	O
a	O	DET	O
severe	O	ADJ	B
but	O	CCONJ	O
partial	O	ADJ	B
lesion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
right	O	ADJ	B
radial	O	ADJ	I
nerve	O	NOUN	I
distal	O	ADJ	I
to	O	ADP	O
the	O	DET	O
branches	O	NOUN	B
to	O	ADP	O
the	O	DET	O
triceps	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
addition	O	NOUN	O
to	O	PART	O
the	O	DET	O
fibrous	B-Disease	ADJ	B
myopathy	I-Disease	NOUN	I


Recurrent	O	ADJ	B
reversible	O	ADJ	O
acute	B-Disease	ADJ	O
renal	I-Disease	ADJ	O
failure	I-Disease	NOUN	O
from	O	ADP	O
amphotericin	B-Chemical	NOUN	B
.	O	PUNCT	O


A	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
cryptogenic	O	ADJ	B
cirrhosis	B-Disease	NOUN	I
and	O	CCONJ	O
disseminated	O	ADJ	B
sporotrichosis	B-Disease	NOUN	B
developed	O	VERB	O
acute	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
failure	I-Disease	NOUN	I
immediately	O	ADV	O
following	O	VERB	O
the	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
amphotericin	B-Chemical	NOUN	B
B	I-Chemical	NOUN	O
on	O	ADP	O
four	O	NUM	O
separate	O	ADJ	B
occasions	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
abruptness	O	NOUN	B
of	O	ADP	O
the	O	DET	O
renal	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
and	O	CCONJ	O
its	O	PRON	O
reversibility	O	NOUN	B
within	O	ADP	O
days	O	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
functional	O	ADJ	B
component	O	NOUN	O
to	O	PART	O
the	O	DET	O
renal	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
propose	O	VERB	O
that	O	SCONJ	O
amphotericin	B-Chemical	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
setting	O	NOUN	O
of	O	ADP	O
reduced	O	VERB	B
effective	O	ADJ	B
arterial	O	ADJ	B
volume	O	NOUN	I
,	O	PUNCT	O
may	O	AUX	O
activate	O	VERB	B
tubuloglomerular	O	NOUN	B
feedback	O	NOUN	I
,	O	PUNCT	O
thereby	O	ADV	O
contributing	O	VERB	O
to	O	PART	O
acute	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
failure	I-Disease	NOUN	I


Pneumonitis	O	NOUN	B
with	O	ADP	O
pleural	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
pericardial	I-Disease	ADJ	B
effusion	I-Disease	NOUN	I
and	O	CCONJ	O
neuropathy	B-Disease	NOUN	B
during	O	ADP	O
amiodarone	B-Chemical	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
sinuatrial	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
and	O	CCONJ	O
implanted	O	VERB	B
pacemaker	O	NOUN	I
was	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
amiodarone	B-Chemical	NOUN	B
(	O	PUNCT	O
maximum	O	ADJ	B
dose	O	NOUN	I
1000	O	NUM	O
mg	O	NOUN	O
,	O	PUNCT	O
maintenance	O	NOUN	B
dose	O	NOUN	B
800	O	NUM	O
mg	O	NOUN	O
daily	O	ADV	B
)	O	PUNCT	O
for	O	ADP	O
10	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
for	O	ADP	O
control	O	NOUN	B
of	O	ADP	O
supraventricular	B-Disease	ADJ	B
tachyarrhythmias	I-Disease	NOUN	I
.	O	PUNCT	O


He	O	PRON	O
developed	O	VERB	O
pneumonitis	B-Disease	NOUN	B
,	O	PUNCT	O
pleural	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
pericardial	I-Disease	ADJ	B
effusions	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
predominantly	O	ADV	O
proximal	B-Disease	ADJ	B
motor	I-Disease	NOUN	B
neuropathy	I-Disease	NOUN	I
.	O	PUNCT	O


Immediate	O	ADJ	B
but	O	CCONJ	O
gradual	O	ADJ	O
improvement	O	NOUN	B
followed	O	VERB	O
withdrawal	O	NOUN	B
of	O	ADP	I
amiodarone	B-Chemical	NOUN	B
and	O	CCONJ	O
treatment	O	NOUN	B
with	O	ADP	O
prednisolone	B-Chemical	NOUN	B
.	O	PUNCT	O


Review	O	NOUN	B
of	O	ADP	O
this	O	DET	O
and	O	CCONJ	O
previously	O	ADV	O
reported	O	VERB	O
cases	O	NOUN	B
indicates	O	VERB	O
the	O	DET	O
need	O	NOUN	O
for	O	ADP	O
early	O	ADJ	B
diagnosis	O	NOUN	I
of	O	ADP	O
amiodarone	B-Chemical	NOUN	B
pneumonitis	B-Disease	NOUN	I
,	O	PUNCT	O
immediate	O	ADJ	O
withdrawal	O	NOUN	B
of	O	ADP	I
amiodarone	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
prompt	O	ADJ	B
but	O	CCONJ	O
continued	O	VERB	O
steroid	B-Chemical	NOUN	B


Indomethacin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
renal	B-Disease	ADJ	B
insufficiency	I-Disease	NOUN	I
:	O	PUNCT	O
recurrence	O	NOUN	B
on	O	ADP	O
rechallenge	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
reported	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
acute	O	ADJ	B
oliguric	O	ADJ	I
renal	B-Disease	ADJ	I
failure	I-Disease	NOUN	I
with	O	ADP	O
hyperkalemia	B-Disease	NOUN	B
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
cirrhosis	B-Disease	NOUN	B
,	O	PUNCT	O
ascites	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
cor	B-Disease	NOUN	B
pulmonale	I-Disease	NOUN	I
after	O	ADP	O
indomethacin	B-Chemical	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


Prompt	O	ADJ	B
restoration	O	NOUN	B
of	O	ADP	O
renal	O	ADJ	B
function	O	NOUN	I
followed	O	VERB	O
drug	O	NOUN	B
withdrawal	O	NOUN	I
,	O	PUNCT	O
while	O	SCONJ	O
re	O	ADP	B
-	O	PUNCT	O
exposure	O	NOUN	B
to	O	PART	O
a	O	DET	O
single	O	ADJ	O
dose	O	NOUN	B
of	O	ADP	O
indomethacin	B-Chemical	NOUN	B
caused	O	VERB	O
recurrence	O	NOUN	B
of	O	ADP	O
acute	O	ADJ	B
reversible	O	ADJ	O
oliguria	B-Disease	NOUN	O
.	O	PUNCT	O


Our	O	PRON	O
case	O	NOUN	B
supports	O	VERB	O
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
endogenous	O	ADJ	B
renal	O	ADJ	B
prostaglandins	B-Chemical	NOUN	I
play	O	VERB	O
a	O	DET	O
role	O	NOUN	O
in	O	ADP	O
the	O	DET	O
maintenance	O	NOUN	B
of	O	ADP	O
renal	O	ADJ	B
blood	O	NOUN	I
flow	O	NOUN	I
when	O	SCONJ	O
circulating	O	VERB	B
plasma	O	NOUN	B
volume	O	NOUN	I
is	O	AUX	O
diminished	O	VERB	B
.	O	PUNCT	O


Since	O	SCONJ	O
nonsteroidal	O	ADJ	B
anti	O	ADJ	I
-	O	PUNCT	O
inflammatory	O	ADJ	B
agents	O	NOUN	I
interfere	O	VERB	B
with	O	ADP	I
this	O	DET	O
compensatory	O	ADJ	B
mechanism	O	NOUN	B
and	O	CCONJ	O
may	O	AUX	O
cause	O	VERB	O
acute	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
failure	I-Disease	NOUN	I


Comparison	O	NOUN	B
of	O	ADP	O
the	O	DET	O
subjective	O	ADJ	B
effects	O	NOUN	I
and	O	CCONJ	O
plasma	O	NOUN	B
concentrations	O	NOUN	B
following	O	VERB	O
oral	O	ADJ	B
and	O	CCONJ	O
i	O	PRON	O
.	O	PUNCT	O


m	O	NOUN	O
.	O	PUNCT	O


administration	O	NOUN	B
of	O	ADP	O
flunitrazepam	B-Chemical	NOUN	B
in	O	ADP	O
volunteers	O	NOUN	B
.	O	PUNCT	O


Flunitrazepam	B-Chemical	NOUN	B
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
,	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
or	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
mg	O	NOUN	O
was	O	AUX	O
given	O	VERB	O
by	O	ADP	O
the	O	DET	O
oral	O	ADJ	B
or	O	CCONJ	O
i	O	PRON	O
.	O	PUNCT	O


m	O	NOUN	O
.	O	PUNCT	O


routes	O	NOUN	B
to	O	ADP	O
groups	O	NOUN	B
of	O	ADP	O
volunteers	O	NOUN	B
and	O	CCONJ	O
its	O	PRON	O
effects	O	NOUN	B
compared	O	VERB	O
.	O	PUNCT	O


Plasma	O	NOUN	B
concentrations	O	NOUN	B
of	O	ADP	O
the	O	DET	O
drug	O	NOUN	B
were	O	AUX	O
estimated	O	VERB	O
by	O	ADP	O
gas	O	NOUN	B
-	O	PUNCT	O
liquid	O	ADJ	B
chromatography	O	NOUN	I
,	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
smaller	O	ADJ	O
number	O	NOUN	O
of	O	ADP	O
the	O	DET	O
subjects	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
most	O	ADV	O
striking	O	ADJ	O
effect	O	NOUN	B
was	O	AUX	O
sedation	O	NOUN	B
which	O	DET	O
increased	O	VERB	B
with	O	ADP	O
the	O	DET	O
dose	O	NOUN	B
,	O	PUNCT	O
2	O	NUM	O
mg	O	NOUN	O
producing	O	VERB	O
deep	O	ADJ	B
sleep	O	NOUN	I
although	O	SCONJ	O
the	O	DET	O
subjects	O	NOUN	B
could	O	AUX	O
still	O	ADV	O
be	O	AUX	O
aroused	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
i	O	PRON	O
.	O	PUNCT	O


m	O	NOUN	O
.	O	PUNCT	O


administration	O	NOUN	B
were	O	AUX	O
apparent	O	ADJ	B
earlier	O	ADV	O
and	O	CCONJ	O
sometimes	O	ADV	O
lasted	O	VERB	O
longer	O	ADV	O
than	O	ADP	O
those	O	DET	O
following	O	VERB	O
oral	O	ADJ	B
administration	O	NOUN	I
.	O	PUNCT	O


Dizziness	B-Disease	NOUN	B
was	O	AUX	O
less	O	ADV	O
marked	O	ADJ	O
than	O	ADP	O
sedation	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
increased	O	VERB	B
with	O	ADP	O
the	O	DET	O
dose	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
pain	B-Disease	NOUN	B
on	O	ADP	O
i	O	PRON	O
.	O	PUNCT	O


m	O	NOUN	O
.	O	PUNCT	O


injection	O	NOUN	B
of	O	ADP	O
flunitrazepam	B-Chemical	NOUN	B


Changes	O	NOUN	B
in	O	ADP	O
heart	O	NOUN	B
size	O	NOUN	I
during	O	ADP	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
timolol	B-Chemical	NOUN	B
treatment	O	NOUN	B
after	O	ADP	O
myocardial	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
timolol	B-Chemical	NOUN	B
treatment	O	NOUN	B
on	O	ADP	O
heart	O	NOUN	B
size	O	NOUN	I
after	O	ADP	O
myocardial	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
was	O	AUX	O
evaluated	O	VERB	B
by	O	ADP	O
X	O	NOUN	B
-	O	PUNCT	O
ray	O	NOUN	B
in	O	ADP	O
a	O	DET	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	NOUN	B
study	O	NOUN	B
including	O	VERB	O
241	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
placebo	O	NOUN	B
126	O	NUM	O
,	O	PUNCT	O
timolol	B-Chemical	NOUN	B
115	O	NUM	O
).	O	PUNCT	O
The	O	DET	O
follow	O	NOUN	B
-	O	PUNCT	O
up	O	ADP	O
period	O	NOUN	B
was	O	AUX	O
12	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
timolol	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
patients	O	NOUN	B
showed	O	VERB	O
a	O	DET	O
small	O	ADJ	B
but	O	CCONJ	O
significant	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
heart	O	NOUN	B
size	O	NOUN	I
from	O	ADP	O
baseline	O	NOUN	B
in	O	ADP	O
contrast	O	NOUN	O
to	O	PART	O
a	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
differences	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
timolol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
bradycardia	B-Disease	NOUN	B
and	O	CCONJ	O
a	O	DET	O
compensatory	O	ADJ	B
increase	O	NOUN	B
in	O	ADP	O
end	O	NOUN	B
-	O	PUNCT	O
diastolic	O	ADJ	B
volume	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
timolol	B-Chemical	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
increase	O	NOUN	B
in	O	ADP	O
heart	O	NOUN	B
size	O	NOUN	I
was	O	AUX	O
observed	O	VERB	O
only	O	ADV	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
normal	O	ADJ	B
and	O	CCONJ	O
borderline	O	NOUN	B
heart	O	NOUN	I
size	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
cardiomegaly	B-Disease	NOUN	B
,	O	PUNCT	O
the	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
heart	O	NOUN	B
size	O	NOUN	I
was	O	AUX	O
similar	O	ADJ	O
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
re	O	ADP	B
-	O	PUNCT	O
infarction	B-Disease	NOUN	B
,	O	PUNCT	O
heart	O	NOUN	B
size	O	NOUN	I
increased	O	VERB	B
in	O	ADP	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	O
and	O	CCONJ	O
remained	O	VERB	O
unchanged	O	ADJ	B
in	O	ADP	O
the	O	DET	O
timolol	B-Chemical	NOUN	B


Vitamin	B-Chemical	NOUN	B
D3	I-Chemical	NOUN	I
toxicity	B-Disease	NOUN	B
in	O	ADP	O
dairy	O	ADJ	B
cows	O	NOUN	I
.	O	PUNCT	O


Large	O	ADJ	O
parenteral	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
vitamin	B-Chemical	NOUN	B
D3	I-Chemical	NOUN	I
(	O	PUNCT	O
15	O	NUM	O
to	O	PART	O
17	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
x	O	CCONJ	O
10	O	NUM	O
(	O	PUNCT	O
6	O	NUM	O
)	O	PUNCT	O
IU	O	NOUN	B
vitamin	B-Chemical	NOUN	B
D3	I-Chemical	NOUN	I
)	O	PUNCT	O
were	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
prolonged	O	ADJ	B
hypercalcemia	B-Disease	NOUN	B
,	O	PUNCT	O
hyperphosphatemia	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
large	O	ADJ	O
increases	O	NOUN	B
of	O	ADP	O
vitamin	B-Chemical	NOUN	B
D3	I-Chemical	NOUN	I
and	O	CCONJ	O
its	O	PRON	O
metabolites	O	NOUN	B
in	O	ADP	O
the	O	DET	O
blood	O	NOUN	B
plasma	O	NOUN	I
of	O	ADP	O
nonlactating	O	VERB	B
nonpregnant	O	ADJ	B
and	O	CCONJ	O
pregnant	O	ADJ	B
Jersey	O	PROPN	I
cows	O	NOUN	B
.	O	PUNCT	O


Calcium	B-Chemical	NOUN	B
concentrations	O	NOUN	O
1	O	NUM	O
day	O	NOUN	B
postpartum	O	NOUN	B
were	O	AUX	O
higher	O	ADJ	O
in	O	ADP	O
cows	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
vitamin	B-Chemical	NOUN	B
D3	I-Chemical	NOUN	I
about	O	ADP	O
32	O	NUM	O
days	O	NOUN	B
prepartum	O	NOUN	B
(	O	PUNCT	O
8	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
100	O	NUM	O
ml	O	NOUN	O
)	O	PUNCT	O
than	O	ADP	O
in	O	ADP	O
control	O	ADJ	B
cows	O	NOUN	I
(	O	PUNCT	O
5	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
100	O	NUM	O
ml	O	NOUN	O
).	O	PUNCT	O
of	O	ADP	O
the	O	DET	O
cows	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
vitamin	B-Chemical	NOUN	B
D3	I-Chemical	NOUN	I
showed	O	VERB	O
signs	O	NOUN	O
of	O	ADP	O
milk	B-Disease	NOUN	B
fever	I-Disease	NOUN	I
during	O	ADP	O
the	O	DET	O
peripartal	O	ADJ	B
period	O	NOUN	B
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
22	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
control	O	NOUN	B
cows	O	NOUN	B
developed	O	VERB	O
clinical	O	ADJ	B
signs	O	NOUN	O
of	O	ADP	O
milk	B-Disease	NOUN	B
fever	I-Disease	NOUN	I
during	O	ADP	O
this	O	DET	O
period	O	NOUN	B
.	O	PUNCT	O


Signs	O	NOUN	B
of	O	ADP	I
vitamin	B-Chemical	NOUN	B
D3	I-Chemical	NOUN	I
toxicity	B-Disease	NOUN	B
were	O	AUX	O
not	O	PART	O
observed	O	VERB	O
in	O	ADP	O
nonlactating	O	VERB	B
nonpregnant	O	ADJ	B
cows	O	NOUN	B
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
pregnant	O	ADJ	B
cows	O	NOUN	I
commonly	O	ADV	O
developed	O	VERB	O
severe	O	ADJ	B
signs	O	NOUN	O
of	O	ADP	O
vitamin	B-Chemical	NOUN	B
D3	I-Chemical	NOUN	I
toxicity	B-Disease	NOUN	B
and	O	CCONJ	O
10	O	NUM	O
of	O	ADP	O
17	O	NUM	O
cows	O	NOUN	B
died	O	VERB	B
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
widespread	O	ADJ	O
metastatic	O	ADJ	B
calcification	O	NOUN	I
in	O	ADP	O
the	O	DET	O
cows	O	NOUN	B
that	O	PRON	O
died	O	VERB	B
.	O	PUNCT	O


Because	O	SCONJ	O
of	O	ADP	O
the	O	DET	O
extreme	O	ADJ	O
toxicity	B-Disease	NOUN	B
of	O	ADP	O
vitamin	B-Chemical	NOUN	B
D3	I-Chemical	NOUN	I
in	O	ADP	O
pregnant	O	ADJ	B
Jersey	O	PROPN	I
cows	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
low	O	ADJ	B
margin	O	NOUN	B
of	O	ADP	O
safety	O	NOUN	B
between	O	ADP	O
doses	O	NOUN	B
of	O	ADP	O
vitamin	B-Chemical	NOUN	B
D3	I-Chemical	NOUN	I
that	O	PRON	O
prevent	O	VERB	B
milk	B-Disease	NOUN	B
fever	I-Disease	NOUN	I
and	O	CCONJ	O
doses	O	NOUN	B
that	O	PRON	O
induce	O	VERB	B
milk	B-Disease	NOUN	B
fever	I-Disease	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
concluded	O	VERB	O
that	O	SCONJ	O
vitamin	B-Chemical	NOUN	B
D3	I-Chemical	NOUN	I
cannot	O	NOUN	O
be	O	AUX	O
used	O	VERB	O
practically	O	ADV	O
to	O	PART	O
prevent	O	VERB	B
milk	B-Disease	NOUN	B
fever	I-Disease	NOUN	I


Diseases	B-Disease	NOUN	B
of	I-Disease	ADP	O
peripheral	I-Disease	ADJ	B
nerves	I-Disease	NOUN	I
as	O	ADP	O
seen	O	VERB	O
in	O	ADP	O
the	O	DET	O
Nigerian	O	ADJ	B
African	O	PROPN	B
.	O	PUNCT	O


The	O	DET	O
anatomical	O	ADJ	B
and	O	CCONJ	O
aetiological	O	ADJ	B
diagnoses	O	NOUN	I
of	O	ADP	O
peripheral	B-Disease	ADJ	B
nerve	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
excluding	O	VERB	O
its	O	PRON	O
primary	O	ADJ	B
benign	O	ADJ	I
and	O	CCONJ	O
malignant	O	ADJ	B
disorders	O	NOUN	I
,	O	PUNCT	O
as	O	ADP	O
seen	O	VERB	O
in	O	ADP	O
358	O	NUM	O
Nigerians	O	PROPN	B
are	O	AUX	O
presented	O	VERB	O
.	O	PUNCT	O


There	O	PRON	O
is	O	AUX	O
a	O	DET	O
male	O	NOUN	B
preponderance	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
peak	O	NOUN	B
incidence	O	NOUN	I
is	O	AUX	O
in	O	ADP	O
the	O	DET	O
fourth	O	ADJ	O
decade	O	NOUN	B
.	O	PUNCT	O


Sensori-motor	B-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I
was	O	AUX	O
the	O	DET	O
commonest	O	ADJ	O
presentation	O	NOUN	B
(	O	PUNCT	O
50	O	NUM	O
%).	O	ADJ	O
Guillain-Barr	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
was	O	AUX	O
the	O	DET	O
commonest	O	ADJ	O
identifiable	O	ADJ	B
cause	O	NOUN	B
(	O	PUNCT	O
15	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
%),	O	ADJ	O
accounting	O	VERB	O
for	O	ADP	O
half	O	NOUN	O
of	O	ADP	O
the	O	DET	O
cases	O	NOUN	B
with	O	ADP	O
motor	B-Disease	NOUN	B
neuropathy	I-Disease	NOUN	I
.	O	PUNCT	O


Peripheral	B-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I
due	O	ADJ	O
to	O	PART	O
nutritional	B-Disease	ADJ	B
deficiency	I-Disease	NOUN	I
of	O	ADP	O
thiamine	B-Chemical	NOUN	B
and	O	CCONJ	O
riboflavin	B-Chemical	NOUN	B
was	O	AUX	O
common	O	ADJ	O
(	O	PUNCT	O
10	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
%)	O	NOUN	O
and	O	CCONJ	O
presented	O	VERB	O
mainly	O	ADV	O
as	O	ADP	O
sensory	O	ADJ	B
and	O	CCONJ	O
sensori-motor	B-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I
.	O	PUNCT	O


Diabetes	B-Disease	NOUN	B
mellitus	I-Disease	NOUN	I
was	O	AUX	O
the	O	DET	O
major	O	ADJ	O
cause	O	NOUN	O
of	O	ADP	O
autonomic	B-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I
.	O	PUNCT	O


Isoniazid	B-Chemical	NOUN	B
was	O	AUX	O
the	O	DET	O
most	O	ADV	O
frequent	O	ADJ	B
agent	O	NOUN	B
in	O	ADP	O
drug	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
neuropathy	B-Disease	NOUN	B
.	O	PUNCT	O


Migraine	B-Disease	NOUN	B
(	O	PUNCT	O
20	O	NUM	O
%)	O	NOUN	O
was	O	AUX	O
not	O	PART	O
an	O	DET	O
uncommon	O	ADJ	O
cause	O	NOUN	O
of	O	ADP	O
cranial	B-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I
although	O	SCONJ	O
malignancies	B-Disease	NOUN	B
arising	O	VERB	O
from	O	ADP	O
the	O	DET	O
reticuloendothelial	O	ADJ	B
system	O	NOUN	I
or	O	CCONJ	O
related	O	ADJ	O
structures	O	NOUN	B
of	O	ADP	O
the	O	DET	O
head	O	NOUN	B
and	O	CCONJ	I
neck	O	NOUN	B
were	O	AUX	O
more	O	ADV	O
frequent	O	ADJ	B
(	O	PUNCT	O
26	O	NUM	O
%).	O	NOUN	B
In	O	ADP	O
26	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
all	O	DET	O
the	O	DET	O
cases	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
aetiology	O	NOUN	B
of	O	ADP	O
the	O	DET	O
neuropathy	B-Disease	NOUN	B
was	O	AUX	O
undetermined	O	ADJ	O
.	O	PUNCT	O


Heredofamilial	O	ADJ	B
and	O	CCONJ	O
connective	B-Disease	ADJ	B
tissue	I-Disease	NOUN	I
disorders	I-Disease	NOUN	I
were	O	AUX	O
rare	O	ADJ	B
.	O	PUNCT	O


Some	O	DET	O
of	O	ADP	O
the	O	DET	O
factors	O	NOUN	B
related	O	ADJ	O
to	O	PART	O
the	O	DET	O
clinical	O	ADJ	B
presentation	O	NOUN	I
and	O	CCONJ	O
pathogenesis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
neuropathies	B-Disease	NOUN	B


A	O	DET	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	ADJ	B
study	O	NOUN	B
of	O	ADP	O
the	O	DET	O
efficacy	O	NOUN	B
and	O	CCONJ	O
safety	O	NOUN	B
of	O	ADP	O
dothiepin	B-Chemical	NOUN	B
hydrochloride	I-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
major	O	ADJ	O
depressive	B-Disease	ADJ	B
disorder	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
6	O	NUM	O
-	O	PUNCT	O
week	O	NOUN	B
double	O	ADJ	B
-	O	PUNCT	O
blind	O	ADJ	B
parallel	O	NOUN	B
treatment	O	NOUN	I
study	O	NOUN	I
,	O	PUNCT	O
dothiepin	B-Chemical	NOUN	B
and	O	CCONJ	O
amitriptyline	B-Chemical	NOUN	B
were	O	AUX	O
compared	O	VERB	O
to	O	PART	O
placebo	O	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
33	O	NUM	O
depressed	B-Disease	ADJ	B
outpatients	O	NOUN	I
.	O	PUNCT	O


Dothiepin	B-Chemical	NOUN	B
and	O	CCONJ	O
amitriptyline	B-Chemical	NOUN	B
were	O	AUX	O
equally	O	ADV	O
effective	O	ADJ	B
in	O	ADP	O
alleviating	O	VERB	O
the	O	DET	O
symptoms	O	NOUN	B
of	O	ADP	O
depressive	B-Disease	ADJ	B
illness	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
both	O	DET	O
were	O	AUX	O
significantly	O	ADV	O
superior	O	ADJ	O
to	O	PART	O
placebo	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
overall	O	ADJ	O
incidence	O	NOUN	B
of	O	ADP	O
side	O	NOUN	B
effects	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
frequency	O	NOUN	B
and	O	CCONJ	O
severity	O	NOUN	B
of	O	ADP	O
blurred	B-Disease	ADJ	B
vision	I-Disease	NOUN	I
,	O	PUNCT	O
dry	B-Disease	ADJ	B
mouth	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
drowsiness	O	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
less	O	ADJ	O
with	O	ADP	O
dothiepin	B-Chemical	NOUN	B
than	O	ADP	O
with	O	ADP	O
amitriptyline	B-Chemical	NOUN	B
.	O	PUNCT	O


Dothiepin	B-Chemical	PROPN	B
also	O	ADV	O
produced	O	VERB	O
fewer	O	ADJ	O
CNS	O	NOUN	B
and	O	CCONJ	O
cardiovascular	O	ADJ	B
effects	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
clinically	O	ADV	O
important	O	ADJ	O
changes	O	NOUN	B
in	O	ADP	O
laboratory	O	ADJ	B
parameters	O	NOUN	I
.	O	PUNCT	O


Dothiepin	B-Chemical	PROPN	B
thus	O	ADV	O
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
an	O	DET	O
effective	O	ADJ	B
antidepressant	B-Chemical	ADJ	B
drug	O	NOUN	O
associated	O	VERB	B
with	O	ADP	I
fewer	O	ADJ	O
side	O	NOUN	B
effects	O	NOUN	I
than	O	ADP	O
amitriptyline	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
depressed	B-Disease	ADJ	B


Behavioral	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
diazepam	B-Chemical	NOUN	B
and	O	CCONJ	O
propranolol	B-Chemical	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
panic	B-Disease	NOUN	B
disorder	I-Disease	NOUN	I
and	O	CCONJ	O
agoraphobia	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
oral	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
diazepam	B-Chemical	NOUN	B
(	O	PUNCT	O
single	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
10	O	NUM	O
mg	O	NOUN	O
and	O	CCONJ	O
a	O	DET	O
median	O	ADJ	B
dose	O	NOUN	B
of	O	ADP	O
30	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
day	O	NOUN	B
for	O	ADP	O
2	O	NUM	O
weeks	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
propranolol	B-Chemical	NOUN	B
(	O	PUNCT	O
single	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
80	O	NUM	O
mg	O	NOUN	O
and	O	CCONJ	O
a	O	DET	O
median	O	ADJ	B
dose	O	NOUN	B
of	O	ADP	O
240	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
day	O	NOUN	B
for	O	ADP	O
2	O	NUM	O
weeks	O	NOUN	B
)	O	PUNCT	O
on	O	ADP	O
psychological	O	ADJ	B
performance	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
panic	B-Disease	NOUN	B
disorders	I-Disease	NOUN	I
and	O	CCONJ	O
agoraphobia	B-Disease	NOUN	B
were	O	AUX	O
investigated	O	VERB	B
in	O	ADP	O
a	O	DET	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	NOUN	B
,	O	PUNCT	O
randomized	O	ADJ	B
and	O	CCONJ	O
crossover	O	NOUN	B
design	O	NOUN	I
.	O	PUNCT	O


Both	O	DET	O
drugs	O	NOUN	B
impaired	B-Disease	VERB	B
immediate	I-Disease	ADJ	O
free	I-Disease	ADJ	O
recall	I-Disease	NOUN	O
but	O	CCONJ	O
the	O	DET	O
decrease	O	NOUN	B
was	O	AUX	O
greater	O	ADJ	O
for	O	ADP	O
diazepam	B-Chemical	NOUN	B
than	O	ADP	O
propranolol	B-Chemical	NOUN	B
.	O	PUNCT	O


Delayed	B-Disease	VERB	B
free	I-Disease	ADJ	I
recall	I-Disease	NOUN	I
was	I-Disease	AUX	O
also	I-Disease	ADV	O
impaired	I-Disease	ADJ	B
but	O	CCONJ	O
the	O	DET	O
two	O	NUM	O
drugs	O	NOUN	B
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
.	O	PUNCT	O


Patients	O	NOUN	B
tapped	O	VERB	O
faster	O	ADV	O
after	O	ADP	O
propranolol	B-Chemical	NOUN	B
than	O	ADP	O
diazepam	B-Chemical	NOUN	B
and	O	CCONJ	O
they	O	PRON	O
were	O	AUX	O
more	O	ADV	O
sedated	O	ADJ	B
after	O	ADP	O
diazepam	B-Chemical	NOUN	B
than	O	ADP	O
propranolol	B-Chemical	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
2	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
,	O	PUNCT	O
patients	O	NOUN	B
tested	O	VERB	B
5	O	NUM	O
-	O	SYM	O
8	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
the	O	DET	O
last	O	ADJ	O
dose	O	NOUN	B
of	O	ADP	O
medication	O	NOUN	B
did	O	AUX	O
not	O	PART	O
show	O	VERB	O
any	O	DET	O
decrement	O	NOUN	B
of	O	ADP	O
performance	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
are	O	AUX	O
similar	O	ADJ	O
to	O	PART	O
those	O	DET	O
previously	O	ADV	O
found	O	VERB	O
in	O	ADP	O
healthy	O	ADJ	B
subjects	O	NOUN	I
.	O	PUNCT	O


Accumulation	O	NOUN	B
of	O	ADP	O
drugs	O	NOUN	B
was	O	AUX	O
not	O	PART	O
reflected	O	VERB	O
in	O	ADP	O
prolonged	O	ADJ	B
behavioral	B-Disease	ADJ	B
impairment	I-Disease	NOUN	O


Effect	O	NOUN	B
of	O	ADP	O
aspirin	B-Chemical	NOUN	B
on	O	ADP	O
N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide	B-Chemical	ADJ	B
-	O	PUNCT	O
induced	O	VERB	B
epithelial	O	ADJ	B
proliferation	O	NOUN	I
in	O	ADP	O
the	O	DET	O
urinary	O	ADJ	B
bladder	O	NOUN	I
and	O	CCONJ	O
forestomach	O	NOUN	B
of	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
co	O	ADJ	B
-	O	PUNCT	O
administration	O	NOUN	B
of	O	ADP	O
aspirin	B-Chemical	NOUN	B
with	O	ADP	O
N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide	B-Chemical	NOUN	B
(	O	PUNCT	O
FANFT	B-Chemical	NOUN	B
)	O	PUNCT	O
to	O	PART	O
rats	O	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
a	O	DET	O
reduced	O	VERB	B
incidence	O	NOUN	B
of	O	ADP	O
FANFT	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
bladder	B-Disease	NOUN	B
carcinomas	I-Disease	NOUN	I
but	O	CCONJ	O
a	O	DET	O
concomitant	O	ADJ	B
induction	O	NOUN	B
of	O	ADP	O
forestomach	B-Disease	ADJ	B
tumors	I-Disease	NOUN	I
.	O	PUNCT	O


An	O	DET	O
autoradiographic	O	ADJ	B
study	O	NOUN	I
was	O	AUX	O
performed	O	VERB	O
on	O	ADP	O
male	O	ADJ	B
F	O	PROPN	B
-	O	PUNCT	O
344	O	NUM	O
rats	O	NOUN	B
fed	O	VERB	O
diet	O	NOUN	B
containing	O	VERB	O
FANFT	B-Chemical	NOUN	B
at	O	ADP	O
a	O	DET	O
level	O	NOUN	B
of	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
aspirin	B-Chemical	NOUN	B
at	O	ADP	O
a	O	DET	O
level	O	NOUN	B
of	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
%	O	NOUN	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
aspirin	B-Chemical	NOUN	B
on	O	ADP	O
the	O	DET	O
increased	O	VERB	B
cell	O	NOUN	B
proliferation	O	NOUN	I
induced	O	VERB	B
by	O	ADP	O
FANFT	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
forestomach	O	NOUN	B
and	O	CCONJ	O
bladder	O	NOUN	B
.	O	PUNCT	O


FANFT	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cell	O	NOUN	B
proliferation	O	NOUN	I
in	O	ADP	O
the	O	DET	O
bladder	O	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
suppressed	O	VERB	B
by	O	ADP	O
aspirin	B-Chemical	NOUN	B
co	O	X	B
-	O	PUNCT	O
administration	O	NOUN	B
after	O	ADP	O
4	O	NUM	O
weeks	O	NOUN	B
but	O	CCONJ	O
not	O	PART	O
after	O	ADP	O
12	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
forestomach	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
also	O	ADV	O
in	O	ADP	O
the	O	DET	O
liver	O	NOUN	B
,	O	PUNCT	O
aspirin	B-Chemical	NOUN	B
did	O	AUX	O
not	O	PART	O
affect	O	VERB	O
the	O	DET	O
FANFT	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
increase	O	NOUN	B
in	O	ADP	O
labeling	O	NOUN	B
index	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
results	O	NOUN	B
are	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
the	O	DET	O
carcinogenicity	O	NOUN	B
experiment	O	NOUN	B
suggesting	O	VERB	O
that	O	SCONJ	O
different	O	ADJ	O
mechanisms	O	NOUN	B
are	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
FANFT	B-Chemical	NOUN	B
carcinogenesis	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
bladder	O	NOUN	B
and	O	CCONJ	O
forestomach	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
that	O	SCONJ	O
aspirin	B-Chemical	NOUN	B
'	O	PART	O
s	O	NOUN	O
effect	O	NOUN	B
on	O	ADP	O
FANFT	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
forestomach	O	NOUN	B
is	O	AUX	O
not	O	PART	O
due	O	ADJ	O
to	O	PART	O
an	O	DET	O
irritant	O	ADJ	B
effect	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
increased	O	VERB	B
cell	O	NOUN	B
proliferation	O	NOUN	I
.	O	PUNCT	O


Also	O	ADV	O
,	O	PUNCT	O
there	O	PRON	O
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
an	O	DET	O
adaptation	O	NOUN	B
by	O	ADP	O
the	O	DET	O
rats	O	NOUN	B
to	O	PART	O
the	O	DET	O
chronic	O	ADJ	B
ingestion	O	NOUN	I
of	O	ADP	O
aspirin	B-Chemical	NOUN	B


Provocation	O	NOUN	B
of	O	ADP	O
postural	O	ADJ	B
hypotension	B-Disease	NOUN	I
by	O	ADP	O
nitroglycerin	B-Chemical	NOUN	B
in	O	ADP	O
diabetic	B-Disease	ADJ	B
autonomic	I-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I
?	O	PUNCT	O
The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
nitroglycerin	B-Chemical	NOUN	B
on	O	ADP	O
heart	O	NOUN	B
rate	O	NOUN	I
and	O	CCONJ	O
systolic	O	ADJ	B
blood	O	NOUN	I
pressure	O	NOUN	I
was	O	AUX	O
compared	O	VERB	B
in	O	ADP	O
5	O	NUM	O
normal	O	ADJ	B
subjects	O	NOUN	I
,	O	PUNCT	O
12	O	NUM	O
diabetic	B-Disease	ADJ	B
subjects	O	NOUN	B
without	O	ADP	O
autonomic	B-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
5	O	NUM	O
diabetic	B-Disease	ADJ	B
subjects	O	NOUN	B
with	O	ADP	O
autonomic	B-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
magnitude	O	NOUN	B
and	O	CCONJ	O
time	O	NOUN	B
course	O	NOUN	I
of	O	ADP	O
the	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
heart	O	NOUN	B
rate	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
systolic	O	ADJ	B
blood	O	NOUN	I
pressure	O	NOUN	I
after	O	ADP	O
nitroglycerin	B-Chemical	NOUN	B
were	O	AUX	O
similar	O	ADJ	O
in	O	ADP	O
the	O	DET	O
normal	O	ADJ	B
and	O	CCONJ	O
diabetic	B-Disease	ADJ	B
subjects	O	NOUN	B
without	O	ADP	O
autonomic	B-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I
,	O	PUNCT	O
whereas	O	SCONJ	O
a	O	DET	O
lesser	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
heart	O	NOUN	B
rate	O	NOUN	I
and	O	CCONJ	O
a	O	DET	O
greater	O	ADJ	O
decrease	O	NOUN	B
in	O	ADP	O
systolic	O	ADJ	B
blood	O	NOUN	I
pressure	O	NOUN	I
occurred	O	VERB	O
in	O	ADP	O
the	O	DET	O
diabetic	B-Disease	ADJ	B
subjects	O	NOUN	B
with	O	ADP	O
autonomic	B-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
therefore	O	ADV	O
suggested	O	VERB	O
that	O	SCONJ	O
caution	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
exercised	O	VERB	O
when	O	SCONJ	O
prescribing	O	VERB	B
vasodilator	O	NOUN	B
drugs	O	NOUN	I
in	O	ADP	O
diabetic	B-Disease	ADJ	B
patients	O	NOUN	B
,	O	PUNCT	O
particularly	O	ADV	O
those	O	DET	O
with	O	ADP	O
autonomic	B-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I


Characterization	O	NOUN	B
of	O	ADP	O
estrogen	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
adenohypophyseal	B-Disease	ADJ	B
tumors	I-Disease	NOUN	I
in	O	ADP	O
the	O	DET	O
Fischer	O	NOUN	B
344	O	NUM	O
rat	O	NOUN	B
.	O	PUNCT	O


Pituitary	B-Disease	ADJ	B
tumors	I-Disease	NOUN	I
were	O	AUX	O
induced	O	VERB	B
in	O	ADP	O
F344	O	NOUN	B
female	O	NOUN	O
rats	O	NOUN	B
by	O	ADP	O
chronic	O	ADJ	B
treatment	O	NOUN	I
with	O	ADP	O
diethylstilbestrol	B-Chemical	NOUN	B
(	O	PUNCT	O
DES	B-Chemical	NOUN	B
,	O	PUNCT	O
8	O	NUM	O
-	O	SYM	O
10	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
implanted	O	VERB	B
subcutaneously	O	ADV	B
in	O	ADP	O
silastic	O	ADJ	B
capsules	O	NOUN	I
.	O	PUNCT	O


Over	O	ADP	O
a	O	DET	O
range	O	NOUN	O
of	O	ADP	O
1	O	NUM	O
-	O	PUNCT	O
150	O	NUM	O
days	O	NOUN	B
of	O	ADP	O
DES	B-Chemical	NOUN	B
treatment	O	NOUN	B
,	O	PUNCT	O
pairs	O	NOUN	B
of	O	ADP	O
control	O	NOUN	B
and	O	CCONJ	O
DES	B-Chemical	PROPN	B
-	O	PUNCT	O
treated	O	VERB	B
rats	O	NOUN	B
were	O	AUX	O
sacrificed	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
their	O	PRON	O
pituitaries	O	NOUN	B
dissociated	O	VERB	O
enzymatically	O	ADV	B
into	O	ADP	O
single	O	ADJ	B
-	O	PUNCT	O
cell	O	NOUN	B
preparations	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
cell	O	NOUN	B
populations	O	NOUN	I
were	O	AUX	O
examined	O	VERB	O
regarding	O	VERB	O
total	O	ADJ	B
cell	O	NOUN	I
recovery	O	NOUN	B
correlated	O	VERB	B
with	O	ADP	O
gland	O	NOUN	B
weight	O	NOUN	I
,	O	PUNCT	O
intracellular	O	ADJ	B
prolactin	O	NOUN	O
(	O	PUNCT	O
PRL	O	NOUN	B
)	O	PUNCT	O
content	O	NOUN	B
and	O	CCONJ	O
subsequent	O	ADJ	O
release	O	NOUN	B
in	O	ADP	O
primary	O	ADJ	B
culture	O	NOUN	I
,	O	PUNCT	O
immunocytochemical	O	ADJ	B
PRL	O	NOUN	B
staining	O	NOUN	B
,	O	PUNCT	O
density	O	NOUN	B
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
size	O	NOUN	B
alterations	O	NOUN	B
via	O	ADP	O
separation	O	NOUN	B
on	O	ADP	O
Ficoll	O	NOUN	B
-	O	PUNCT	O
Hypaque	O	NOUN	B
and	O	CCONJ	O
by	O	ADP	O
unit	O	NOUN	O
gravity	O	NOUN	B
sedimentation	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
cell	O	NOUN	B
cycle	O	NOUN	I
analysis	O	NOUN	I
,	O	PUNCT	O
after	O	ADP	O
acriflavine	B-Chemical	NOUN	B
DNA	O	NOUN	B
staining	O	NOUN	I
,	O	PUNCT	O
by	O	ADP	O
laser	O	NOUN	B
flow	O	NOUN	I
cytometry	O	NOUN	I
.	O	PUNCT	O


Total	O	ADJ	B
cell	O	NOUN	I
yields	O	NOUN	O
from	O	ADP	O
DES	B-Chemical	PROPN	B
-	O	PUNCT	O
treated	O	VERB	B
pituitaries	O	NOUN	B
increased	O	VERB	B
from	O	ADP	O
1	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
times	O	NOUN	O
control	O	VERB	B
yields	O	NOUN	O
at	O	ADP	O
8	O	NUM	O
days	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
to	O	PART	O
58	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
times	O	NOUN	O
control	O	NOUN	B
values	O	NOUN	I
by	O	ADP	O
day	O	NOUN	B
150	O	NUM	O
.	O	PUNCT	O


Intracellular	O	ADJ	B
PRL	O	NOUN	B
content	O	NOUN	B
ranged	O	VERB	O
from	O	ADP	O
1	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
to	O	PART	O
9	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
times	O	NOUN	O
control	O	NOUN	O
levels	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
PRL	O	NOUN	B
release	O	NOUN	B
in	O	X	B
vitro	O	X	I
was	O	AUX	O
significantly	O	ADV	B
and	O	CCONJ	O
consistently	O	ADV	O
higher	O	ADJ	O
than	O	ADP	O
controls	O	NOUN	B
,	O	PUNCT	O
after	O	ADP	O
at	O	ADP	O
least	O	ADJ	O
8	O	NUM	O
days	O	NOUN	B
of	O	ADP	O
DES	B-Chemical	NOUN	B
exposure	O	NOUN	B
.	O	PUNCT	O


Beyond	O	NOUN	O
8	O	NUM	O
days	O	NOUN	B
of	O	ADP	O
DES	B-Chemical	NOUN	B
exposure	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
immunochemically	O	ADV	B
PRL	O	NOUN	B
-	O	PUNCT	O
positive	O	ADJ	B
proportion	O	NOUN	B
of	O	ADP	O
cells	O	NOUN	B
increased	O	VERB	B
to	O	PART	O
over	O	ADP	O
50	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
total	O	ADJ	B
population	O	NOUN	I
.	O	PUNCT	O


Increased	O	VERB	B
density	O	NOUN	B
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
size	O	NOUN	B
and	O	CCONJ	O
PRL	O	NOUN	B
content	O	NOUN	B
were	O	AUX	O
indicated	O	VERB	O
for	O	ADP	O
the	O	DET	O
majority	O	NOUN	O
of	O	ADP	O
the	O	DET	O
PRL	O	NOUN	B
cell	O	NOUN	B
population	O	NOUN	I
in	O	ADP	O
both	O	DET	O
types	O	NOUN	O
of	O	ADP	O
separation	O	NOUN	B
protocols	O	NOUN	I
.	O	PUNCT	O


All	O	DET	O
these	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
DES	B-Chemical	NOUN	B
were	O	AUX	O
more	O	ADV	O
pronounced	O	ADJ	O
among	O	ADP	O
previously	O	ADV	O
ovariectomized	O	VERB	B
animals	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
data	O	NOUN	B
extend	O	VERB	O
the	O	DET	O
findings	O	NOUN	B
of	O	ADP	O
other	O	ADJ	O
investigators	O	NOUN	B
,	O	PUNCT	O
further	O	ADV	O
establishing	O	VERB	O
the	O	DET	O
DES	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
tumor	B-Disease	NOUN	B


Triamterene	B-Chemical	NOUN	B
nephrolithiasis	B-Disease	NOUN	I
complicating	O	VERB	O
dyazide	B-Chemical	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
case	O	NOUN	B
of	O	ADP	O
triamterene	B-Chemical	NOUN	B
nephrolithiasis	B-Disease	NOUN	B
is	O	AUX	O
reported	O	VERB	O
in	O	ADP	O
a	O	DET	O
man	O	NOUN	B
after	O	ADP	O
4	O	NUM	O
years	O	NOUN	B
of	O	ADP	O
hydrochlorothiazide-triamterene	B-Chemical	ADJ	B
therapy	O	NOUN	I
for	O	ADP	O
hypertension	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
stone	O	NOUN	B
passed	O	VERB	O
spontaneously	O	ADV	B
and	O	CCONJ	O
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
contain	O	VERB	O
a	O	DET	O
triamterene	B-Chemical	NOUN	B
metabolite	O	NOUN	B
admixed	O	ADJ	B
with	O	ADP	O
uric	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
salts	I-Chemical	NOUN	I
.	O	PUNCT	O


Factors	O	NOUN	B
affecting	O	VERB	O
triamterene	B-Chemical	NOUN	B
nephrolithiasis	B-Disease	NOUN	B


Metabolic	O	ADJ	B
involvement	O	NOUN	B
in	O	ADP	O
adriamycin	B-Chemical	NOUN	B
cardiotoxicity	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
cardiotoxic	B-Disease	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
adriamycin	B-Chemical	NOUN	B
were	O	AUX	O
studied	O	VERB	O
in	O	ADP	O
mammalian	O	ADJ	B
myocardial	O	ADJ	B
cells	O	NOUN	I
in	O	ADP	O
culture	O	NOUN	B
as	O	ADP	O
a	O	DET	O
model	O	NOUN	B
system	O	NOUN	I
.	O	PUNCT	O


Adriamycin	B-Chemical	NOUN	B
inhibited	O	VERB	B
cell	O	NOUN	B
growth	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
rhythmic	O	ADJ	B
contractions	O	NOUN	B
characteristic	O	ADJ	B
of	O	ADP	O
myocardial	O	ADJ	B
cells	O	NOUN	I
in	O	ADP	O
culture	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
possible	O	ADJ	O
involvement	O	NOUN	B
of	O	ADP	O
energy	O	NOUN	B
metabolism	O	NOUN	I
was	O	AUX	O
suggested	O	VERB	O
previously	O	ADV	O
,	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
this	O	DET	O
study	O	NOUN	B
the	O	DET	O
adenylate	O	ADJ	B
energy	O	NOUN	I
charge	O	NOUN	I
and	O	CCONJ	O
phosphorylcreatine	B-Chemical	ADJ	B
mole	O	NOUN	I
fraction	O	NOUN	O
were	O	AUX	O
determined	O	VERB	O
in	O	ADP	O
the	O	DET	O
adriamycin	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
cells	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
adenylate	O	ADJ	B
energy	O	NOUN	I
charge	O	NOUN	I
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
significantly	O	ADV	O
decreased	O	VERB	B
,	O	PUNCT	O
while	O	SCONJ	O
the	O	DET	O
phophorylcreatine	B-Chemical	NOUN	B
mole	O	NOUN	B
fraction	O	NOUN	O
was	O	AUX	O
unchanged	O	ADJ	B
.	O	PUNCT	O


Such	O	ADJ	O
disparity	O	NOUN	B
suggests	O	VERB	O
an	O	DET	O
inhibition	O	NOUN	B
of	O	ADP	O
creatine	B-Chemical	NOUN	B
phosphokinase	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
addition	O	NOUN	O
of	O	ADP	O
1	O	NUM	O
mM	O	NOUN	O
adenosine	B-Chemical	NOUN	B
to	O	PART	O
the	O	DET	O
myocardial	O	ADJ	B
cell	O	NOUN	I
cultures	O	NOUN	I
markedly	O	ADV	O
increases	O	VERB	B
the	O	DET	O
ATP	B-Chemical	NOUN	B
concentration	O	NOUN	B
through	O	ADP	O
a	O	DET	O
pathway	O	NOUN	B
reportedly	O	ADV	O
leading	O	VERB	O
to	O	PART	O
a	O	DET	O
compartmentalized	O	ADJ	B
ATP	B-Chemical	NOUN	B
pool	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
adriamycin	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
cells	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
addition	O	NOUN	O
of	O	ADP	O
adenosine	B-Chemical	NOUN	B


Age	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
sensitivity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
to	O	PART	O
neurotoxic	B-Disease	ADJ	B
effects	O	NOUN	O
of	O	ADP	O
streptomycin	B-Chemical	NOUN	B
.	O	PUNCT	O


Streptomycin	B-Chemical	NOUN	B
sulfate	O	NOUN	I
(	O	PUNCT	O
300	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
s	O	NOUN	O
.	O	PUNCT	O


c	O	X	O
.)	O	NOUN	O
was	O	AUX	O
injected	O	VERB	B
for	O	ADP	O
various	O	ADJ	O
periods	O	NOUN	B
into	O	ADP	O
preweanling	O	NOUN	B
rats	O	NOUN	B
and	O	CCONJ	O
for	O	ADP	O
3	O	NUM	O
weeks	O	NOUN	B
into	O	ADP	O
weanling	O	VERB	B
rats	O	NOUN	B
.	O	PUNCT	O


Beginning	O	VERB	B
at	O	ADP	O
8	O	NUM	O
days	O	NOUN	B
of	O	ADP	O
age	O	NOUN	B
,	O	PUNCT	O
body	O	NOUN	B
movement	O	NOUN	I
and	O	CCONJ	O
hearing	O	NOUN	B
were	O	AUX	O
examined	O	VERB	O
for	O	ADP	O
6	O	NUM	O
and	O	CCONJ	O
up	O	ADP	O
to	O	PART	O
17	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Abnormal	B-Disease	ADJ	B
movements	I-Disease	NOUN	B
and	O	CCONJ	O
deafness	B-Disease	NOUN	B
occurred	O	VERB	O
only	O	ADV	O
in	O	ADP	O
rats	O	NOUN	B
treated	O	VERB	B
during	O	ADP	O
the	O	DET	O
preweaning	O	NOUN	B
period	O	NOUN	B
;	O	PUNCT	O
within	O	ADP	O
this	O	DET	O
period	O	NOUN	B
the	O	DET	O
greatest	O	ADJ	O
sensitivities	O	NOUN	B
for	O	ADP	O
these	O	DET	O
abnormalities	O	NOUN	B
occurred	O	VERB	O
from	O	ADP	O
2	O	NUM	O
to	O	PART	O
11	O	NUM	O
-	O	SYM	O
17	O	NUM	O
and	O	CCONJ	O
5	O	NUM	O
to	O	PART	O
11	O	NUM	O
days	O	NOUN	B
of	O	ADP	O
age	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
indicating	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
cochlea	O	NOUN	B
is	O	AUX	O
more	O	ADV	O
sensitive	O	ADJ	B
to	O	PART	O
streptomycin	B-Chemical	NOUN	B
than	O	ADP	O
the	O	DET	O
site	O	NOUN	B
(	O	PUNCT	O
vestibular	O	ADJ	B
or	O	CCONJ	O
central	O	ADJ	B
)	O	PUNCT	O
responsible	O	ADJ	O
for	O	ADP	O
the	O	DET	O
dyskinesias	B-Disease	NOUN	B


Crescentic	O	ADJ	B
fibrillary	O	ADJ	I
glomerulonephritis	B-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
intermittent	O	ADJ	B
rifampin	B-Chemical	NOUN	O
therapy	O	NOUN	O
for	O	ADP	O
pulmonary	B-Disease	ADJ	B
tuberculosis	I-Disease	NOUN	I
.	O	PUNCT	O


This	O	DET	O
case	O	NOUN	B
study	O	NOUN	I
reveals	O	VERB	O
an	O	DET	O
unusual	O	ADJ	O
finding	O	NOUN	B
of	O	ADP	O
rapidly	O	ADV	B
proliferative	O	ADJ	B
crescentic	O	ADJ	O
glomerulonephritis	B-Disease	NOUN	O
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
rifampin	B-Chemical	NOUN	B
who	O	PRON	O
had	O	AUX	O
no	O	DET	O
other	O	ADJ	O
identifiable	O	ADJ	O
causes	O	NOUN	O
for	O	ADP	O
developing	O	VERB	O
this	O	DET	O
disease	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
patient	O	NOUN	B
underwent	O	VERB	O
a	O	DET	O
10	O	NUM	O
-	O	PUNCT	O
month	O	NOUN	B
regimen	O	NOUN	B
of	O	ADP	O
rifampin	B-Chemical	NOUN	B
and	O	CCONJ	O
isoniazid	B-Chemical	NOUN	B
for	O	ADP	O
pulmonary	B-Disease	ADJ	B
tuberculosis	I-Disease	NOUN	I
and	O	CCONJ	O
was	O	AUX	O
discovered	O	VERB	O
to	O	PART	O
have	O	AUX	O
developed	O	VERB	O
signs	O	NOUN	O
of	O	ADP	O
severe	O	ADJ	B
renal	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
five	O	NUM	O
weeks	O	NOUN	B
after	O	ADP	O
completion	O	NOUN	B
of	O	ADP	O
therapy	O	NOUN	B
.	O	PUNCT	O


Renal	O	ADJ	B
biopsy	O	NOUN	I
revealed	O	VERB	O
severe	O	ADJ	B
glomerulonephritis	B-Disease	NOUN	B
with	O	ADP	O
crescents	O	NOUN	B
,	O	PUNCT	O
electron	O	NOUN	B
dense	O	ADJ	I
fibrillar	O	ADJ	I
deposits	O	NOUN	I
and	O	CCONJ	O
moderate	O	ADJ	B
lymphocytic	O	ADJ	B
interstitial	O	ADJ	I
infiltrate	O	NOUN	I
.	O	PUNCT	O


Other	O	ADJ	O
possible	O	ADJ	O
causes	O	NOUN	O
of	O	ADP	O
rapidly	O	ADV	O
progressive	O	ADJ	B
glomerulonephritis	B-Disease	NOUN	B
were	O	AUX	O
investigated	O	VERB	B
and	O	CCONJ	O
ruled	O	VERB	O
out	O	ADP	O
.	O	PUNCT	O


This	O	DET	O
report	O	NOUN	B
documents	O	VERB	I
the	O	DET	O
unusual	O	ADJ	B
occurrence	O	NOUN	B
of	O	ADP	O
rapidly	O	ADV	O
progressive	O	ADJ	B
glomerulonephritis	B-Disease	NOUN	B
with	O	ADP	O
crescents	O	NOUN	B
and	O	CCONJ	O
fibrillar	O	ADJ	B
glomerulonephritis	B-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
rifampin	B-Chemical	NOUN	B


Time	O	NOUN	B
course	O	NOUN	I
of	O	ADP	O
lipid	O	NOUN	B
peroxidation	O	NOUN	I
in	O	ADP	O
puromycin	B-Chemical	NOUN	B
aminonucleoside	I-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
nephropathy	B-Disease	NOUN	B
.	O	PUNCT	O


Reactive	O	ADJ	B
oxygen	B-Chemical	NOUN	I
species	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
implicated	O	VERB	O
in	O	ADP	O
the	O	DET	O
pathogenesis	O	NOUN	B
of	O	ADP	O
acute	O	ADJ	B
puromycin	B-Chemical	NOUN	I
aminonucleoside	I-Chemical	NOUN	I
(	O	PUNCT	O
PAN	B-Chemical	NOUN	B
)-	O	ADJ	O
induced	O	VERB	B
nephropathy	B-Disease	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
antioxidants	O	NOUN	B
significantly	O	ADV	O
reducing	O	VERB	B
the	O	DET	O
proteinuria	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
temporal	O	ADJ	B
relationship	O	NOUN	B
between	O	ADP	O
lipid	O	NOUN	B
peroxidation	O	NOUN	I
in	O	ADP	O
the	O	DET	O
kidney	O	NOUN	B
and	O	CCONJ	O
proteinuria	B-Disease	NOUN	B
was	O	AUX	O
examined	O	VERB	O
in	O	ADP	O
this	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


Rats	O	NOUN	B
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
a	O	DET	O
single	O	ADJ	B
IV	O	NUM	I
injection	O	NOUN	B
of	O	ADP	O
puromycin	B-Chemical	NOUN	B
aminonucleoside	I-Chemical	NOUN	B
,(	O	PUNCT	O
PAN	B-Chemical	NOUN	B
,	O	PUNCT	O
7	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
24	O	NUM	O
hour	O	NOUN	B
urine	O	NOUN	B
samples	O	NOUN	I
were	O	AUX	O
obtained	O	VERB	O
prior	O	ADJ	O
to	O	PART	O
sacrifice	O	VERB	B
on	O	ADP	O
days	O	NOUN	B
3	O	NUM	O
,	O	PUNCT	O
5	O	NUM	O
,	O	PUNCT	O
7	O	NUM	O
,	O	PUNCT	O
10	O	NUM	O
,	O	PUNCT	O
17	O	NUM	O
,	O	PUNCT	O
27	O	NUM	O
,	O	PUNCT	O
41	O	NUM	O
(	O	PUNCT	O
N	O	NOUN	O
=	O	ADJ	O
5	O	NUM	O
-	O	SYM	O
10	O	NUM	O
per	O	ADP	O
group	O	NOUN	B
).	O	VERB	B
The	O	DET	O
kidneys	O	NOUN	B
were	O	AUX	O
removed	O	VERB	B
,	O	PUNCT	O
flushed	O	VERB	O
with	O	ADP	O
ice	O	NOUN	B
cold	O	ADJ	I
TRIS	O	NOUN	O
buffer	O	NOUN	B
.	O	PUNCT	O


Kidney	O	NOUN	B
cortices	O	NOUN	I
from	O	ADP	O
each	O	DET	O
animal	O	NOUN	B
were	O	AUX	O
used	O	VERB	O
to	O	PART	O
prepare	O	VERB	O
homogenates	O	NOUN	B
.	O	PUNCT	O


Tissue	O	NOUN	B
lipid	O	NOUN	B
peroxidation	O	NOUN	I
was	O	AUX	O
measured	O	VERB	B
in	O	ADP	O
whole	O	ADJ	O
homogenates	O	NOUN	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
in	O	ADP	O
lipid	O	NOUN	B
extracts	O	NOUN	I
from	O	ADP	O
homogenates	O	NOUN	B
as	O	ADP	O
thiobarbituric	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
reactive	O	ADJ	B
substances	O	NOUN	I
.	O	PUNCT	O


Proteinuria	B-Disease	NOUN	B
was	O	AUX	O
evident	O	ADJ	O
at	O	ADP	O
day	O	NOUN	B
5	O	NUM	O
,	O	PUNCT	O
peaked	O	VERB	O
at	O	ADP	O
day	O	NOUN	B
7	O	NUM	O
and	O	CCONJ	O
persisted	O	VERB	O
to	O	ADP	O
day	O	NOUN	B
27	O	NUM	O
.	O	PUNCT	O


Lipid	O	NOUN	B
peroxidation	O	NOUN	I
in	O	ADP	O
homogenates	O	NOUN	B
was	O	AUX	O
maximal	O	ADJ	B
at	O	ADP	O
day	O	NOUN	B
3	O	NUM	O
and	O	CCONJ	O
declined	O	VERB	B
rapidly	O	ADV	O
to	O	PART	O
control	O	NOUN	B
levels	O	NOUN	O
by	O	ADP	O
day	O	NOUN	B
17	O	NUM	O
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
supports	O	VERB	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
lipid	O	NOUN	B
peroxidation	O	NOUN	I
in	O	ADP	O
mediating	O	VERB	O
the	O	DET	O
proteinuric	B-Disease	ADJ	B
injury	I-Disease	NOUN	I
in	O	ADP	O
PAN	B-Chemical	NOUN	B
nephropathy	B-Disease	NOUN	I


Clomipramine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
sleep	B-Disease	NOUN	B
disturbance	I-Disease	NOUN	I
does	O	AUX	O
not	O	PART	O
impair	O	VERB	O
its	O	PRON	O
prolactin	O	NOUN	B
-	O	PUNCT	O
releasing	O	VERB	B
action	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
was	O	AUX	O
undertaken	O	VERB	O
to	O	PART	O
examine	O	VERB	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
sleep	B-Disease	NOUN	B
disturbance	I-Disease	NOUN	I
,	O	PUNCT	O
induced	O	VERB	B
by	O	ADP	O
clomipramine	B-Chemical	NOUN	B
administration	O	NOUN	B
,	O	PUNCT	O
on	O	ADP	O
the	O	DET	O
secretory	O	ADJ	B
rate	O	NOUN	O
of	O	ADP	O
prolactin	O	NOUN	B
(	O	PUNCT	O
PRL	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
addition	O	NOUN	O
to	O	PART	O
the	O	DET	O
direct	O	ADJ	O
drug	O	NOUN	B
effect	O	NOUN	I
.	O	PUNCT	O


Two	O	NUM	O
groups	O	NOUN	B
of	O	ADP	O
supine	O	ADJ	B
subjects	O	NOUN	I
were	O	AUX	O
studied	O	VERB	O
under	O	ADP	O
placebo	O	NOUN	B
-	O	PUNCT	O
controlled	O	VERB	B
conditions	O	NOUN	B
,	O	PUNCT	O
one	O	NUM	O
during	O	ADP	O
the	O	DET	O
night	O	NOUN	B
,	O	PUNCT	O
when	O	SCONJ	O
sleeping	O	VERB	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
7	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
other	O	ADJ	O
at	O	ADP	O
daytime	O	NOUN	B
,	O	PUNCT	O
when	O	SCONJ	O
awake	O	ADJ	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
6	O	NUM	O
).	O	PUNCT	O
Each	O	DET	O
subject	O	NOUN	B
received	O	VERB	O
a	O	DET	O
single	O	ADJ	O
50	O	NUM	O
mg	O	NOUN	O
dose	O	NOUN	B
of	O	ADP	O
clomipramine	B-Chemical	NOUN	B
given	O	VERB	O
orally	O	ADV	B
2	O	NUM	I
hours	O	NOUN	B
before	O	ADP	O
blood	O	NOUN	B
collection	O	NOUN	I
.	O	PUNCT	O


Plasma	O	NOUN	B
PRL	O	NOUN	B
concentrations	O	NOUN	B
were	O	AUX	O
analysed	O	VERB	B
at	O	ADP	O
10	O	NUM	O
min	O	NOUN	O
intervals	O	NOUN	B
and	O	CCONJ	O
underlying	O	VERB	O
secretory	O	ADJ	B
rates	O	NOUN	I
calculated	O	VERB	B
by	O	ADP	O
a	O	DET	O
deconvolution	O	NOUN	B
procedure	O	NOUN	I
.	O	PUNCT	O


For	O	ADP	O
both	O	DET	O
experiments	O	NOUN	B
the	O	DET	O
drug	O	NOUN	B
intake	O	NOUN	I
led	O	VERB	O
to	O	PART	O
significant	O	ADJ	O
increases	O	NOUN	B
in	O	ADP	O
PRL	O	NOUN	B
secretion	O	NOUN	B
,	O	PUNCT	O
acting	O	VERB	O
preferentially	O	ADV	O
on	O	ADP	O
tonic	O	ADJ	B
secretion	O	NOUN	I
as	O	ADP	O
pulse	O	NOUN	B
amplitude	O	NOUN	I
and	O	CCONJ	O
frequency	O	NOUN	B
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
significantly	O	ADV	O
from	O	ADP	O
corresponding	O	VERB	O
control	O	NOUN	B
values	O	NOUN	I
.	O	PUNCT	O


During	O	ADP	O
the	O	DET	O
night	O	NOUN	B
clomipramine	B-Chemical	NOUN	B
ingestion	O	NOUN	B
altered	O	VERB	O
the	O	DET	O
complete	O	ADJ	B
sleep	O	NOUN	B
architecture	O	NOUN	O
in	O	ADP	O
that	O	SCONJ	O
it	O	PRON	O
suppressed	O	VERB	B
REM	O	NOUN	B
sleep	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
sleep	O	NOUN	B
cycles	O	NOUN	I
and	O	CCONJ	O
induced	O	VERB	B
increased	O	VERB	B
wakefulness	O	NOUN	B
.	O	PUNCT	O


As	O	ADP	O
the	O	DET	O
relative	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
PRL	O	NOUN	B
secretion	O	NOUN	B
expressed	O	VERB	B
as	O	ADP	O
a	O	DET	O
percentage	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mean	O	NOUN	O
did	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
differ	O	VERB	O
between	O	ADP	O
the	O	DET	O
night	O	NOUN	B
and	O	CCONJ	O
day	O	NOUN	B
time	O	NOUN	O
studies	O	NOUN	O
(	O	PUNCT	O
46	O	NUM	O
+/-	O	CCONJ	O
19	O	NUM	O
%	O	NOUN	O
vs	O	CCONJ	O
34	O	NUM	O
+/-	O	CCONJ	O
10	O	NUM	O
%),	O	ADJ	O
it	O	PRON	O
can	O	AUX	O
be	O	AUX	O
concluded	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
observed	O	VERB	B
sleep	B-Disease	NOUN	B
disturbance	I-Disease	NOUN	I
did	O	AUX	O
not	O	PART	O
interfere	O	VERB	B
with	O	ADP	I
the	O	DET	O
drug	O	NOUN	B
action	O	NOUN	I
per	O	X	O
se	O	X	O
.	O	PUNCT	O


The	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
REM	O	PROPN	B
sleep	O	NOUN	I
was	O	AUX	O
shown	O	VERB	O
not	O	PART	O
to	O	PART	O
be	O	AUX	O
a	O	DET	O
determining	O	VERB	O
factor	O	NOUN	B
either	O	CCONJ	O
for	O	ADP	O
secretory	O	ADJ	B
pulse	O	NOUN	B
amplitude	O	NOUN	I
and	O	CCONJ	O
frequency	O	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
,	O	PUNCT	O
for	O	ADP	O
both	O	DET	O
,	O	PUNCT	O
mean	O	ADJ	O
nocturnal	O	ADJ	B
values	O	NOUN	O
were	O	AUX	O
similar	O	ADJ	O
with	O	ADP	O
and	O	CCONJ	O
without	O	ADP	O
prior	O	ADJ	O
clomipramine	B-Chemical	NOUN	B


Angioedema	B-Disease	NOUN	B
following	O	VERB	O
the	O	DET	O
intravenous	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
metoprolol	B-Chemical	NOUN	B
.	O	PUNCT	O


A	O	DET	O
72	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
woman	O	NOUN	B
was	O	AUX	O
admitted	O	VERB	B
to	O	ADP	O
the	O	DET	O
hospital	O	NOUN	B
with	O	ADP	O
"	O	PUNCT	O
flash	O	NOUN	B
"	O	PUNCT	O
pulmonary	B-Disease	ADJ	O
edema	I-Disease	NOUN	O
,	O	PUNCT	O
preceded	O	VERB	O
by	O	ADP	O
chest	B-Disease	ADJ	B
pain	I-Disease	NOUN	I
,	O	PUNCT	O
requiring	O	VERB	O
intubation	O	NOUN	B
.	O	PUNCT	O


Her	O	PRON	O
medical	O	ADJ	B
history	O	NOUN	I
included	O	VERB	O
coronary	B-Disease	ADJ	B
artery	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
with	O	ADP	O
previous	O	ADJ	O
myocardial	B-Disease	ADJ	B
infarctions	I-Disease	NOUN	I
,	O	PUNCT	O
hypertension	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
diabetes	B-Disease	NOUN	B
mellitus	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
history	O	NOUN	B
of	O	ADP	O
angioedema	B-Disease	NOUN	B
secondary	O	ADJ	B
to	O	PART	I
lisinopril	B-Chemical	NOUN	B
therapy	O	NOUN	I
was	O	AUX	O
elicited	O	VERB	O
.	O	PUNCT	O


Current	O	ADJ	B
medications	O	NOUN	B
did	O	AUX	O
not	O	PART	O
include	O	VERB	O
angiotensin	B-Chemical	NOUN	B
-	O	PUNCT	O
converting	O	VERB	B
enzyme	O	NOUN	B
inhibitors	O	NOUN	I
or	O	CCONJ	O
beta	O	NOUN	B
-	O	PUNCT	O
blockers	O	NOUN	B
.	O	PUNCT	O


She	O	PRON	O
had	O	AUX	O
no	O	DET	O
previous	O	ADJ	O
beta	O	NOUN	B
-	O	PUNCT	O
blocking	O	VERB	B
drug	O	NOUN	B
exposure	O	NOUN	I
.	O	PUNCT	O


During	O	ADP	O
the	O	DET	O
first	O	ADJ	O
day	O	NOUN	B
of	O	ADP	O
hospitalization	O	NOUN	B
(	O	PUNCT	O
while	O	SCONJ	O
intubated	O	VERB	B
),	O	PUNCT	O
intravenous	O	ADJ	B
metoprolol	B-Chemical	NOUN	B
was	O	AUX	O
given	O	VERB	O
,	O	PUNCT	O
resulting	O	VERB	O
in	O	ADP	O
severe	O	ADJ	B
angioedema	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
angioedema	B-Disease	NOUN	B
resolved	O	VERB	B
after	O	ADP	O
therapy	O	NOUN	B
with	O	ADP	O
intravenous	O	ADJ	B
steroids	B-Chemical	NOUN	I
and	O	CCONJ	O
diphenhydramine	B-Chemical	NOUN	B


Effect	O	NOUN	B
of	O	ADP	O
coniine	B-Chemical	NOUN	B
on	O	ADP	O
the	O	DET	O
developing	O	VERB	O
chick	O	NOUN	B
embryo	O	NOUN	B
.	O	PUNCT	O


Coniine	B-Chemical	PROPN	B
,	O	PUNCT	O
an	O	DET	O
alkaloid	O	NOUN	B
from	O	ADP	O
Conium	O	PROPN	B
maculatum	O	X	I
(	O	PUNCT	O
poison	O	NOUN	B
hemlock	O	NOUN	I
),	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
be	O	AUX	O
teratogenic	O	ADJ	B
in	O	ADP	O
livestock	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
major	O	ADJ	O
teratogenic	O	ADJ	B
outcome	O	NOUN	O
is	O	AUX	O
arthrogryposis	B-Disease	NOUN	B
,	O	PUNCT	O
presumably	O	ADV	O
due	O	ADJ	O
to	O	PART	O
nicotinic	O	ADJ	B
receptor	O	NOUN	I
blockade	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
coniine	B-Chemical	NOUN	B
has	O	AUX	O
failed	O	VERB	B
to	O	PART	O
produce	O	VERB	O
arthrogryposis	B-Disease	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
or	O	CCONJ	O
mice	O	NOUN	B
and	O	CCONJ	O
is	O	AUX	O
only	O	ADV	O
weakly	O	ADJ	O
teratogenic	O	ADJ	B
in	O	ADP	O
rabbits	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
evaluate	O	VERB	B
and	O	CCONJ	O
compare	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
coniine	B-Chemical	NOUN	B
and	O	CCONJ	O
nicotine	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
developing	O	VERB	O
chick	O	NOUN	B
.	O	PUNCT	O


Concentrations	O	NOUN	B
of	O	ADP	O
coniine	B-Chemical	NOUN	B
and	O	CCONJ	O
nicotine	B-Chemical	NOUN	B
sulfate	O	NOUN	B
were	O	AUX	O
0	O	NUM	O
.	O	PUNCT	O


015	O	NUM	O
%,	O	ADV	O
0	O	NUM	O
.	O	PUNCT	O


03	O	NUM	O
%,	O	ADV	O
0	O	NUM	O
.	O	PUNCT	O


075	O	NUM	O
%,	O	INTJ	O
0	O	NUM	O
.	O	PUNCT	O


15	O	NUM	O
%,	O	ADV	O
0	O	NUM	O
.	O	PUNCT	O


75	O	NUM	O
%,	O	NOUN	O
1	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
%,	O	NOUN	O
3	O	NUM	O
%,	O	ADJ	B
and	O	CCONJ	O
6	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
1	O	NUM	O
%,	O	NOUN	O
5	O	NUM	O
%,	O	ADJ	B
and	O	CCONJ	O
10	O	NUM	O
%,	O	NOUN	O
respectively	O	ADV	O
.	O	PUNCT	O


Both	O	DET	O
compounds	O	NOUN	B
caused	O	VERB	O
deformations	B-Disease	NOUN	B
and	O	CCONJ	O
lethality	O	NOUN	B
in	O	ADP	O
a	O	DET	O
dose	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
manner	O	NOUN	O
.	O	PUNCT	O


All	O	DET	O
concentrations	O	NOUN	B
of	O	ADP	O
nicotine	B-Chemical	NOUN	B
sulfate	O	NOUN	B
caused	O	VERB	O
some	O	DET	O
lethality	O	NOUN	B
but	O	CCONJ	O
a	O	DET	O
no	O	DET	O
effect	O	NOUN	O
level	O	NOUN	B
for	O	ADP	O
coniine	B-Chemical	NOUN	B
lethality	O	NOUN	B
was	O	AUX	O
0	O	NUM	O
.	O	PUNCT	O


75	O	NUM	O
%.	O	NOUN	O
The	O	DET	O
deformations	B-Disease	NOUN	B
caused	O	VERB	O
by	O	ADP	O
both	O	CCONJ	O
coniine	B-Chemical	NOUN	B
and	O	CCONJ	O
nicotine	B-Chemical	NOUN	B
sulfate	O	NOUN	B
were	O	AUX	O
excessive	B-Disease	ADJ	B
flexion	I-Disease	NOUN	B
or	I-Disease	CCONJ	O
extension	I-Disease	NOUN	B
of	I-Disease	ADP	O
one	I-Disease	NUM	O
or	I-Disease	CCONJ	O
more	I-Disease	ADJ	O
toes	I-Disease	NOUN	B
.	O	PUNCT	O


No	O	DET	O
histopathological	O	ADJ	B
alterations	O	NOUN	B
or	O	CCONJ	O
differences	O	NOUN	B
in	O	ADP	O
bone	O	NOUN	B
formation	O	NOUN	I
were	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
the	O	DET	O
limbs	O	NOUN	B
or	O	CCONJ	O
toes	O	NOUN	B
of	O	ADP	O
any	O	DET	O
chicks	O	NOUN	B
from	O	ADP	O
any	O	DET	O
group	O	NOUN	B
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
extensive	O	ADJ	O
cranial	B-Disease	ADJ	B
hemorrhage	I-Disease	NOUN	I
occurred	O	VERB	O
in	O	ADP	O
all	O	DET	O
nicotine	B-Chemical	NOUN	B
sulfate	O	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
chicks	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
a	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
or	O	CCONJ	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
)	O	PUNCT	O
decrease	O	NOUN	B
in	O	ADP	O
movement	O	NOUN	B
in	O	ADP	O
coniine	B-Chemical	NOUN	B
and	O	CCONJ	O
nicotine	B-Chemical	NOUN	B
sulfate	O	NOUN	B
treated	O	ADJ	B
chicks	O	NOUN	B
as	O	ADP	O
determined	O	VERB	O
by	O	ADP	O
ultrasound	O	NOUN	B
.	O	PUNCT	O


Control	O	ADJ	B
chicks	O	NOUN	I
were	O	AUX	O
in	O	ADP	O
motion	O	NOUN	B
an	O	DET	O
average	O	NOUN	B
of	O	ADP	O
33	O	NUM	O
.	O	PUNCT	O


67	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
time	O	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
coniine	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
chicks	O	NOUN	B
were	O	AUX	O
only	O	ADV	O
moving	O	VERB	B
8	O	NUM	O
.	O	PUNCT	O


95	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
a	O	DET	O
5	O	NUM	O
-	O	PUNCT	O
min	O	NOUN	B
interval	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
no	O	DET	O
movement	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
for	O	ADP	O
nicotine	B-Chemical	NOUN	B
sulfate	O	NOUN	B
treated	O	ADJ	B
chicks	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
summary	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
chick	O	NOUN	B
embryo	O	NOUN	B
provides	O	VERB	O
a	O	DET	O
reliable	O	ADJ	B
and	O	CCONJ	O
simple	O	ADJ	O
experimental	O	ADJ	B
animal	O	NOUN	O
model	O	NOUN	O
of	O	ADP	O
coniine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
arthrogryposis	B-Disease	NOUN	B


Epidural	O	ADJ	B
blood	O	NOUN	I
flow	O	NOUN	I
during	O	ADP	O
prostaglandin	B-Chemical	NOUN	B
E1	I-Chemical	NOUN	I
or	O	CCONJ	O
trimethaphan	B-Chemical	NOUN	B
induced	O	VERB	B
hypotension	B-Disease	NOUN	B
.	O	PUNCT	O


To	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
prostaglandin	B-Chemical	NOUN	B
E1	I-Chemical	NOUN	I
(	O	PUNCT	O
PGE1	B-Chemical	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
trimethaphan	B-Chemical	NOUN	B
(	O	PUNCT	O
TMP	B-Chemical	NOUN	B
)	O	PUNCT	O
induced	O	VERB	B
hypotension	B-Disease	NOUN	B
on	O	ADP	O
epidural	O	ADJ	B
blood	O	NOUN	I
flow	O	NOUN	I
(	O	PUNCT	O
EBF	O	NOUN	B
)	O	PUNCT	O
during	O	ADP	O
spinal	O	ADJ	B
surgery	O	NOUN	I
,	O	PUNCT	O
EBF	O	NOUN	B
was	O	AUX	O
measured	O	VERB	B
using	O	VERB	O
the	O	DET	O
heat	O	NOUN	B
clearance	O	NOUN	I
method	O	NOUN	I
in	O	ADP	O
30	O	NUM	O
patients	O	NOUN	B
who	O	PRON	O
underwent	O	VERB	O
postero	O	NOUN	B
-	O	PUNCT	O
lateral	O	ADJ	B
interbody	O	NOUN	B
fusion	O	NOUN	I
under	O	ADP	O
isoflurane	B-Chemical	NOUN	B
anaesthesia	O	NOUN	I
.	O	PUNCT	O


An	O	DET	O
initial	O	ADJ	B
dose	O	NOUN	B
of	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
microgram	O	NOUN	B
.	O	PUNCT	O


kg	O	NOUN	O
-	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


min	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	O
of	O	ADP	O
PGE1	B-Chemical	NOUN	B
(	O	PUNCT	O
15	O	NUM	O
patients	O	NOUN	B
),	O	PUNCT	O
or	O	CCONJ	O
10	O	NUM	O
micrograms	O	NOUN	B
.	O	PUNCT	O


kg	O	NOUN	O
-	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


min	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	O
of	O	ADP	O
TMP	B-Chemical	PROPN	B
(	O	PUNCT	O
15	O	NUM	O
patients	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
administered	O	VERB	B
intravenously	O	ADV	B
after	O	ADP	O
the	O	DET	O
dural	O	ADJ	B
opening	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
dose	O	NOUN	B
was	O	AUX	O
adjusted	O	VERB	O
to	O	PART	O
maintain	O	VERB	O
the	O	DET	O
mean	O	ADJ	O
arterial	O	ADJ	B
blood	O	NOUN	I
pressure	O	NOUN	I
(	O	PUNCT	O
MAP	O	NOUN	B
)	O	PUNCT	O
at	O	ADP	O
about	O	ADV	O
60	O	NUM	O
mmHg	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
hypotensive	B-Disease	ADJ	B
drug	O	NOUN	I
was	O	AUX	O
discontinued	O	VERB	B
at	O	ADP	O
the	O	DET	O
completion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
operative	O	ADJ	B
procedure	O	NOUN	I
.	O	PUNCT	O


After	O	ADP	O
starting	O	VERB	O
PGE1	B-Chemical	NOUN	B
or	O	CCONJ	O
TMP	B-Chemical	NOUN	B
,	O	PUNCT	O
MAP	O	NOUN	B
and	O	CCONJ	O
rate	O	NOUN	B
pressure	O	NOUN	I
product	O	NOUN	I
(	O	PUNCT	O
RPP	O	NOUN	B
)	O	PUNCT	O
decreased	O	VERB	B
significantly	O	ADV	O
compared	O	VERB	O
with	O	ADP	O
preinfusion	O	NOUN	B
values	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
),	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
degree	O	NOUN	B
of	O	ADP	O
hypotension	B-Disease	NOUN	B
due	O	ADJ	O
to	O	PART	O
PGE1	B-Chemical	NOUN	B
remained	O	VERB	O
constant	O	ADJ	B
until	O	ADP	O
60	O	NUM	O
min	O	NOUN	O
after	O	ADP	O
its	O	PRON	O
discontinuation	O	NOUN	B
.	O	PUNCT	O


Heart	O	NOUN	B
rate	O	NOUN	I
(	O	PUNCT	O
HR	O	NOUN	B
)	O	PUNCT	O
did	O	AUX	O
not	O	PART	O
change	O	VERB	O
in	O	ADP	O
either	O	DET	O
group	O	NOUN	B
.	O	PUNCT	O


EBFF	O	NOUN	B
did	O	AUX	O
not	O	PART	O
change	O	VERB	O
during	O	ADP	O
PGE1	B-Chemical	NOUN	B
infusion	O	NOUN	B
whereas	O	SCONJ	O
in	O	ADP	O
the	O	DET	O
TMP	B-Chemical	PROPN	B
group	O	NOUN	B
,	O	PUNCT	O
EBF	O	NOUN	B
decreased	O	VERB	B
significantly	O	ADV	O
at	O	ADP	O
30	O	NUM	O
and	O	CCONJ	O
60	O	NUM	O
min	O	NOUN	O
after	O	ADP	O
the	O	DET	O
start	O	NOUN	O
of	O	ADP	O
TMP	B-Chemical	NOUN	B
(	O	PUNCT	O
preinfusion	O	NOUN	B
:	O	PUNCT	O
45	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
+/-	O	CCONJ	O
13	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
ml	O	NOUN	O
/	O	SYM	O
100g	O	NOUN	B
/	O	PUNCT	O
min	O	NOUN	B
.	O	PUNCT	O


30	O	NUM	O
min	O	NOUN	O
:	O	PUNCT	O
32	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
+/-	O	CCONJ	O
9	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
ml	O	NOUN	O
/	O	SYM	O
100	O	NUM	O
g	O	NOUN	B
/	O	PUNCT	O
min	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
).	O	PUNCT	O
60	O	NUM	O
min	O	NOUN	O
:	O	PUNCT	O
30	O	NUM	O
+/-	O	CCONJ	O
7	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
ml	O	NOUN	O
/	O	SYM	O
100	O	NUM	O
g	O	NOUN	B
/	O	PUNCT	O
min	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
)).	O	NOUN	O
These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
PGE1	B-Chemical	NOUN	B
may	O	AUX	O
be	O	AUX	O
preferable	O	ADJ	O
to	O	PART	O
TMP	B-Chemical	PROPN	B
for	O	ADP	O
hypotensive	B-Disease	ADJ	B
anaesthesia	O	NOUN	I
in	O	ADP	O
spinal	O	ADJ	B
surgery	O	NOUN	I
because	O	SCONJ	O
TMP	B-Chemical	PROPN	B


Immunohistochemical	O	ADJ	B
studies	O	NOUN	I
with	O	ADP	O
antibodies	O	NOUN	B
to	O	PART	O
neurofilament	O	ADJ	B
proteins	O	NOUN	I
on	O	ADP	O
axonal	B-Disease	ADJ	B
damage	I-Disease	NOUN	I
in	O	ADP	O
experimental	O	ADJ	B
focal	O	ADJ	I
lesions	O	NOUN	I
in	O	ADP	O
rat	O	NOUN	B
.	O	PUNCT	O


Immunohistochemistry	O	NOUN	B
with	O	ADP	O
monoclonal	O	ADJ	B
antibodies	O	NOUN	I
against	O	ADP	O
neurofilament	O	NOUN	B
(	O	PUNCT	O
NF	O	NOUN	B
)	O	PUNCT	O
proteins	O	NOUN	B
of	O	ADP	O
middle	O	NOUN	B
and	O	CCONJ	O
high	O	ADJ	O
molecular	O	ADJ	O
weight	O	NOUN	O
class	O	NOUN	O
,	O	PUNCT	O
NF	O	NOUN	B
-	O	PUNCT	O
M	O	NOUN	B
and	O	CCONJ	O
NF	O	NOUN	B
-	O	PUNCT	O
H	O	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
study	O	VERB	B
axonal	B-Disease	ADJ	B
injury	I-Disease	NOUN	I
in	O	ADP	O
the	O	DET	O
borderzone	O	NOUN	B
of	O	ADP	O
focal	O	ADJ	B
lesions	O	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


Focal	O	ADJ	B
injury	B-Disease	NOUN	I
in	I-Disease	ADP	O
the	I-Disease	DET	O
cortex	I-Disease	NOUN	B
was	O	AUX	O
produced	O	VERB	O
by	O	ADP	O
infusion	O	NOUN	B
of	O	ADP	O
lactate	B-Chemical	NOUN	B
at	O	ADP	O
acid	O	NOUN	B
pH	O	NOUN	I
or	O	CCONJ	O
by	O	ADP	O
stab	O	NOUN	B
caused	O	VERB	O
by	O	ADP	O
needle	O	NOUN	B
insertion	O	NOUN	B
.	O	PUNCT	O


Infarcts	B-Disease	NOUN	B
in	I-Disease	ADP	O
substantia	I-Disease	NOUN	B
nigra	I-Disease	NOUN	I
pars	I-Disease	X	I
reticulata	I-Disease	NOUN	I
were	O	AUX	O
evoked	O	VERB	O
by	O	ADP	O
prolonged	O	ADJ	B
pilocarpine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
status	B-Disease	NOUN	B
epilepticus	I-Disease	NOUN	I
.	O	PUNCT	O


Immunohistochemical	O	ADJ	B
staining	O	NOUN	I
for	O	ADP	O
NFs	O	NOUN	B
showed	O	VERB	O
characteristic	O	ADJ	O
terminal	O	ADJ	B
clubs	O	NOUN	B
of	O	ADP	O
axons	O	NOUN	B
in	O	ADP	O
the	O	DET	O
borderzone	O	NOUN	B
of	O	ADP	O
lesions	O	NOUN	B
.	O	PUNCT	O


Differences	O	NOUN	B
in	O	ADP	O
the	O	DET	O
labelling	O	NOUN	B
pattern	O	NOUN	B
occurred	O	VERB	O
with	O	ADP	O
different	O	ADJ	O
antibodies	O	NOUN	B
which	O	DET	O
apparently	O	ADV	O
depended	O	VERB	O
on	O	ADP	O
molecular	O	ADJ	B
weight	O	NOUN	I
class	O	NOUN	O
of	O	ADP	O
NFs	O	NOUN	B
and	O	CCONJ	O
phosphorylation	O	NOUN	B
state	O	NOUN	O
.	O	PUNCT	O


These	O	DET	O
immunohistochemical	O	ADJ	B
changes	O	NOUN	B
of	O	ADP	O
NFs	O	NOUN	B
can	O	AUX	O
serve	O	VERB	O
as	O	ADP	O
a	O	DET	O
marker	O	NOUN	B
for	O	ADP	O
axonal	B-Disease	ADJ	B
damage	I-Disease	NOUN	O
in	O	ADP	O
various	O	ADJ	O
experimental	O	ADJ	B
traumatic	B-Disease	ADJ	B


Increase	O	NOUN	B
of	O	ADP	O
Parkinson	B-Disease	PROPN	B
disability	I-Disease	NOUN	I
after	O	ADP	O
fluoxetine	B-Chemical	NOUN	B
medication	O	NOUN	B
.	O	PUNCT	O


Depression	B-Disease	NOUN	B
is	O	AUX	O
a	O	DET	O
major	O	ADJ	O
clinical	O	ADJ	B
feature	O	NOUN	I
of	O	ADP	O
Parkinson's	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
the	O	DET	O
increased	O	VERB	B
amount	O	NOUN	B
of	O	ADP	O
motor	B-Disease	NOUN	B
disability	I-Disease	NOUN	I
in	O	ADP	O
four	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
idiopathic	B-Disease	ADJ	B
Parkinson's	I-Disease	ADJ	I
disease	I-Disease	NOUN	I
after	O	ADP	O
exposure	O	NOUN	B
to	O	PART	I
the	O	DET	O
antidepressant	B-Chemical	ADJ	B
fluoxetine	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
possibility	O	NOUN	O
of	O	ADP	O
a	O	DET	O
clinically	O	ADV	B
relevant	O	ADJ	O
dopamine	B-Chemical	NOUN	B
-	O	PUNCT	O
antagonistic	O	ADJ	B
capacity	O	NOUN	B
of	O	ADP	O
fluoxetine	B-Chemical	NOUN	B
in	O	ADP	O
Parkinson's	B-Disease	ADJ	O
disease	I-Disease	NOUN	B


Acetaminophen	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypotension	B-Disease	NOUN	B
.	O	PUNCT	O


Through	O	ADP	O
30	O	NUM	O
years	O	NOUN	B
of	O	ADP	O
widespread	O	ADJ	B
use	O	NOUN	O
,	O	PUNCT	O
acetaminophen	B-Chemical	NOUN	B
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
be	O	AUX	O
a	O	DET	O
remarkably	O	ADV	O
safe	O	ADJ	O
medication	O	NOUN	B
in	O	ADP	O
therapeutic	O	ADJ	B
dosages	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
potential	O	NOUN	B
for	O	ADP	O
acetaminophen	B-Chemical	NOUN	B
to	O	PART	O
produce	O	VERB	O
cardiovascular	B-Disease	ADJ	B
toxicities	I-Disease	NOUN	B
is	O	AUX	O
very	O	ADV	O
low	O	ADJ	O
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
acetaminophen	B-Chemical	NOUN	B
has	O	AUX	O
been	O	AUX	O
demonstrated	O	VERB	O
to	O	PART	O
produce	O	VERB	O
symptoms	O	NOUN	B
of	O	ADP	O
anaphylaxis	B-Disease	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
hypotension	B-Disease	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
sensitive	O	ADJ	B
individuals	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
article	O	NOUN	B
describes	O	VERB	O
two	O	NUM	O
critically	B-Disease	ADV	B
ill	I-Disease	ADJ	I
patients	O	NOUN	B
in	O	ADP	O
whom	O	PRON	O
transient	O	ADJ	B
episodes	O	NOUN	I
of	O	ADP	O
hypotension	B-Disease	NOUN	B
reproducibly	O	ADV	B
developed	O	VERB	O
after	O	ADP	O
administration	O	NOUN	B
of	O	ADP	O
acetaminophen	B-Chemical	NOUN	B
.	O	PUNCT	O


Other	O	ADJ	O
symptoms	O	NOUN	B
of	O	ADP	O
allergic	B-Disease	ADJ	B
reactions	I-Disease	NOUN	I
were	O	AUX	O
not	O	PART	O
clinically	O	ADV	O
detectable	O	ADJ	B
.	O	PUNCT	O


The	O	DET	O
hypotensive	B-Disease	ADJ	B
episodes	O	NOUN	I
were	O	AUX	O
severe	O	ADJ	B
enough	O	ADV	O
to	O	PART	O
require	O	VERB	O
vasopressor	O	ADJ	B
administration	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
reports	O	NOUN	B
illustrate	O	VERB	O
the	O	DET	O
need	O	NOUN	O
for	O	ADP	O
clinicians	O	NOUN	B
to	O	PART	O
consider	O	VERB	O
acetaminophen	B-Chemical	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
hypotension	B-Disease	NOUN	B


Acute	O	ADJ	B
hepatitis	B-Disease	NOUN	I
,	O	PUNCT	O
autoimmune	B-Disease	ADJ	B
hemolytic	I-Disease	ADJ	I
anemia	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
erythroblastocytopenia	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
ceftriaxone	B-Chemical	NOUN	B
.	O	PUNCT	O


An	O	DET	O
80	O	NUM	O
-	O	PUNCT	O
yr	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
man	O	NOUN	B
developed	O	VERB	O
acute	O	ADJ	B
hepatitis	B-Disease	NOUN	I
shortly	O	ADV	O
after	O	ADP	O
ingesting	O	VERB	B
oral	O	ADJ	B
ceftriaxone	B-Chemical	NOUN	I
.	O	PUNCT	O


Although	O	SCONJ	O
the	O	DET	O
transaminases	O	NOUN	B
gradually	O	ADV	O
returned	O	VERB	O
to	O	PART	O
baseline	O	NOUN	B
after	O	ADP	O
withholding	O	VERB	B
the	O	DET	O
beta	B-Chemical	NOUN	B
lactam	I-Chemical	NOUN	I
antibiotic	O	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
gradual	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
serum	O	NOUN	B
bilirubin	B-Chemical	NOUN	B
and	O	CCONJ	O
a	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
hemoglobin	O	NOUN	B
concentration	O	NOUN	I
caused	O	VERB	O
by	O	ADP	O
an	O	DET	O
autoimmune	B-Disease	ADJ	B
hemolytic	I-Disease	ADJ	I
anemia	I-Disease	NOUN	I
and	O	CCONJ	O
erythroblastocytopenia	B-Disease	NOUN	B
.	O	PUNCT	O


These	O	DET	O
responded	O	VERB	O
to	O	PART	O
systemic	O	ADJ	B
steroids	B-Chemical	NOUN	I
and	O	CCONJ	O
immunoglobulins	O	NOUN	B
.	O	PUNCT	O


Despite	O	SCONJ	O
the	O	DET	O
widespread	O	ADJ	B
use	O	NOUN	O
of	O	ADP	O
these	O	DET	O
agents	O	NOUN	B
this	O	DET	O
triad	O	NOUN	O
of	O	ADP	O
side	O	NOUN	B
effects	O	NOUN	I
has	O	AUX	O
not	O	PART	O
previously	O	ADV	O
been	O	AUX	O
reported	O	VERB	O
in	O	ADP	O
connection	O	NOUN	B
with	O	ADP	O
beta	B-Chemical	NOUN	B
lactam	I-Chemical	NOUN	I


Adverse	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
the	O	DET	O
atypical	O	ADJ	B
antipsychotics	O	NOUN	B
.	O	PUNCT	O


Collaborative	O	PROPN	B
Working	O	PROPN	B
Group	O	PROPN	I
on	O	ADP	O
Clinical	O	PROPN	B
Trial	O	PROPN	I
Evaluations	O	PROPN	B
.	O	PUNCT	O


Adverse	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
antipsychotics	O	NOUN	B
often	O	ADV	O
lead	O	VERB	O
to	O	PART	O
noncompliance	O	NOUN	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
clinicians	O	NOUN	B
should	O	AUX	O
address	O	VERB	O
patients	O	NOUN	B
'	O	PART	O
concerns	O	NOUN	B
about	O	ADP	O
adverse	O	ADJ	B
effects	O	NOUN	I
and	O	CCONJ	O
attempt	O	VERB	B
to	O	PART	O
choose	O	VERB	O
medications	O	NOUN	B
that	O	PRON	O
will	O	AUX	O
improve	O	VERB	O
their	O	PRON	O
patients	O	NOUN	B
'	O	PART	O
quality	O	NOUN	B
of	O	ADP	I
life	O	NOUN	I
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
overall	O	ADJ	B
health	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
side	O	NOUN	B
effect	O	NOUN	I
profiles	O	NOUN	B
of	O	ADP	O
the	O	DET	O
atypical	O	ADJ	B
antipsychotics	O	NOUN	B
are	O	AUX	O
more	O	ADV	O
advantageous	O	ADJ	O
than	O	ADP	O
those	O	DET	O
of	O	ADP	O
the	O	DET	O
conventional	O	ADJ	B
neuroleptics	O	NOUN	B
.	O	PUNCT	O


Conventional	O	ADJ	B
agents	O	NOUN	I
are	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
unwanted	O	ADJ	O
central	O	ADJ	B
nervous	O	ADJ	I
system	O	NOUN	I
effects	O	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
extrapyramidal	B-Disease	ADJ	B
symptoms	I-Disease	NOUN	I
(	O	PUNCT	O
EPS	B-Disease	NOUN	B
),	O	PUNCT	O
tardive	B-Disease	NOUN	B
dyskinesia	I-Disease	NOUN	I
,	O	PUNCT	O
sedation	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
possible	O	ADJ	O
impairment	O	NOUN	B
of	O	ADP	O
some	O	DET	O
cognitive	O	ADJ	B
measures	O	NOUN	I
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
cardiac	O	ADJ	B
effects	O	NOUN	I
,	O	PUNCT	O
orthostatic	B-Disease	ADJ	B
hypotension	I-Disease	NOUN	B
,	O	PUNCT	O
hepatic	O	ADJ	B
changes	O	NOUN	I
,	O	PUNCT	O
anticholinergic	O	ADJ	B
side	O	NOUN	B
effects	O	NOUN	I
,	O	PUNCT	O
sexual	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
weight	B-Disease	NOUN	B
gain	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
newer	O	ADJ	O
atypical	O	ADJ	B
agents	O	NOUN	I
have	O	AUX	O
a	O	DET	O
lower	O	ADJ	O
risk	O	NOUN	B
of	O	ADP	O
EPS	B-Disease	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
are	O	AUX	O
associated	O	VERB	O
in	O	ADP	O
varying	O	VERB	O
degrees	O	NOUN	B
with	O	ADP	O
sedation	O	NOUN	B
,	O	PUNCT	O
cardiovascular	O	ADJ	B
effects	O	NOUN	I
,	O	PUNCT	O
anticholinergic	O	ADJ	B
effects	O	NOUN	I
,	O	PUNCT	O
weight	B-Disease	NOUN	B
gain	I-Disease	NOUN	I
,	O	PUNCT	O
sexual	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
,	O	PUNCT	O
hepatic	O	ADJ	B
effects	O	NOUN	I
,	O	PUNCT	O
lowered	O	VERB	B
seizure	B-Disease	ADJ	O
threshold	O	NOUN	B
(	O	PUNCT	O
primarily	O	ADV	O
clozapine	B-Chemical	NOUN	B
),	O	PUNCT	O
and	O	CCONJ	O
agranulocytosis	B-Disease	NOUN	B
(	O	PUNCT	O
clozapine	B-Chemical	NOUN	B


Effects	O	NOUN	B
of	O	ADP	O
tetrandrine	B-Chemical	NOUN	B
and	O	CCONJ	O
fangchinoline	B-Chemical	NOUN	B
on	O	ADP	O
experimental	O	ADJ	B
thrombosis	B-Disease	NOUN	I
in	O	ADP	O
mice	O	NOUN	B
and	O	CCONJ	O
human	O	ADJ	B
platelet	B-Disease	NOUN	O
aggregation	I-Disease	NOUN	O
.	O	PUNCT	O


Tetrandrine	B-Chemical	NOUN	B
(	O	PUNCT	O
TET	B-Chemical	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
fangchinoline	B-Chemical	NOUN	B
(	O	PUNCT	O
FAN	B-Chemical	NOUN	B
)	O	PUNCT	O
are	O	AUX	O
two	O	NUM	O
naturally	O	ADV	O
occurring	O	VERB	O
analogues	O	NOUN	B
with	O	ADP	O
a	O	DET	O
bisbenzylisoquinoline	B-Chemical	NOUN	B
structure	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
was	O	AUX	O
undertaken	O	VERB	O
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
TET	B-Chemical	NOUN	B
and	O	CCONJ	O
FAN	B-Chemical	NOUN	B
on	O	ADP	O
the	O	DET	O
experimental	O	ADJ	B
thrombosis	B-Disease	NOUN	I
induced	O	VERB	B
by	O	ADP	O
collagen	O	NOUN	B
plus	O	CCONJ	O
epinephrine	B-Chemical	NOUN	B
(	O	PUNCT	O
EP	B-Chemical	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
mice	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
platelet	B-Disease	NOUN	B
aggregation	I-Disease	NOUN	I
and	O	CCONJ	O
blood	B-Disease	NOUN	B
coagulation	I-Disease	NOUN	I
in	O	X	B
vitro	O	X	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
in	O	X	B
vivo	O	X	I
study	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
administration	O	NOUN	B
(	O	PUNCT	O
50	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


p	O	NOUN	O
.)	O	NUM	O
of	O	ADP	O
TET	B-Chemical	NOUN	B
and	O	CCONJ	O
FAN	B-Chemical	NOUN	B
in	O	ADP	O
mice	O	NOUN	B
showed	O	VERB	O
the	O	DET	O
inhibition	O	NOUN	B
of	O	ADP	O
thrombosis	B-Disease	NOUN	B
by	O	ADP	O
55	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
35	O	NUM	O
%,	O	ADJ	O
respectively	O	ADV	O
,	O	PUNCT	O
while	O	SCONJ	O
acetylsalicylic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
(	O	PUNCT	O
ASA	B-Chemical	NOUN	B
,	O	PUNCT	O
50	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


p	O	NOUN	O
.),	O	PUNCT	O
a	O	DET	O
positive	O	ADJ	B
control	O	NOUN	I
,	O	PUNCT	O
showed	O	VERB	O
only	O	ADV	O
30	O	NUM	O
%	O	NOUN	O
inhibition	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
vitro	O	X	O
human	O	ADJ	B
platelet	B-Disease	NOUN	B
aggregations	I-Disease	NOUN	I
induced	O	VERB	B
by	O	ADP	O
the	O	DET	O
agonists	O	NOUN	B
used	O	VERB	O
in	O	ADP	O
tests	O	NOUN	B
,	O	PUNCT	O
TET	B-Chemical	NOUN	B
and	O	CCONJ	O
FAN	B-Chemical	PROPN	B
showed	O	VERB	O
the	O	DET	O
inhibitions	O	NOUN	B
dose	O	NOUN	B
dependently	O	ADV	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
neither	O	CCONJ	O
TET	B-Chemical	NOUN	B
nor	O	CCONJ	O
FAN	B-Chemical	PROPN	B
showed	O	VERB	O
any	O	DET	O
anticoagulation	O	NOUN	B
activities	O	NOUN	I
in	O	ADP	O
the	O	DET	O
measurement	O	NOUN	B
of	O	ADP	O
the	O	DET	O
activated	O	VERB	B
partial	O	ADJ	I
thromboplastin	O	NOUN	I
time	O	NOUN	I
(	O	PUNCT	O
APTT	O	NOUN	B
),	O	PUNCT	O
prothrombin	O	NOUN	B
time	O	NOUN	I
(	O	PUNCT	O
PT	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
thrombin	O	NOUN	B
time	O	NOUN	I
(	O	PUNCT	O
TT	O	NOUN	B
)	O	PUNCT	O
using	O	VERB	O
human	O	ADJ	B
-	O	PUNCT	O
citrated	O	VERB	B
plasma	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
antithrombosis	O	NOUN	B
of	O	ADP	O
TET	B-Chemical	NOUN	B
and	O	CCONJ	O
FAN	B-Chemical	NOUN	B


Gemcitabine	B-Chemical	NOUN	B
plus	O	CCONJ	O
vinorelbine	B-Chemical	NOUN	B
in	O	ADP	O
nonsmall	B-Disease	NOUN	B
cell	I-Disease	NOUN	I
lung	I-Disease	NOUN	I
carcinoma	I-Disease	NOUN	I
patients	O	NOUN	B
age	O	NOUN	B
70	O	NUM	O
years	O	NOUN	B
or	O	CCONJ	O
older	O	ADJ	B
or	O	CCONJ	O
patients	O	NOUN	B
who	O	PRON	O
cannot	O	VERB	O
receive	O	VERB	O
cisplatin	B-Chemical	NOUN	B
.	O	PUNCT	O


Oncopaz	O	PROPN	B
Cooperative	O	PROPN	I
Group	O	PROPN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Although	O	SCONJ	O
the	O	DET	O
prevalence	O	NOUN	B
of	O	ADP	O
nonsmall	B-Disease	NOUN	B
cell	I-Disease	NOUN	I
lung	I-Disease	NOUN	I
carcinoma	I-Disease	NOUN	I
(	O	PUNCT	O
NSCLC	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
high	O	ADJ	O
among	O	ADP	O
elderly	O	ADJ	B
patients	O	NOUN	B
,	O	PUNCT	O
few	O	ADJ	O
data	O	NOUN	B
are	O	AUX	O
available	O	ADJ	O
regarding	O	VERB	O
the	O	DET	O
efficacy	O	NOUN	B
and	O	CCONJ	O
toxicity	B-Disease	NOUN	B
of	O	ADP	O
chemotherapy	O	NOUN	B
in	O	ADP	O
this	O	DET	O
group	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
.	O	PUNCT	O


Recent	O	ADJ	O
reports	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
single	O	ADJ	B
agent	O	NOUN	I
therapy	O	NOUN	I
with	O	ADP	O
vinorelbine	B-Chemical	NOUN	B
(	O	PUNCT	O
VNB	B-Chemical	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
gemcitabine	B-Chemical	NOUN	B
(	O	PUNCT	O
GEM	B-Chemical	NOUN	B
)	O	PUNCT	O
may	O	AUX	O
obtain	O	VERB	O
a	O	DET	O
response	O	NOUN	B
rate	O	NOUN	I
of	O	ADP	O
20	O	NUM	O
-	O	SYM	O
30	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
elderly	O	ADJ	B
patients	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
acceptable	O	ADJ	O
toxicity	B-Disease	NOUN	B
and	O	CCONJ	O
improvement	O	NOUN	B
in	O	ADP	O
symptoms	O	NOUN	B
and	O	CCONJ	O
quality	O	NOUN	B
of	O	ADP	I
life	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
current	O	ADJ	O
study	O	NOUN	B
the	O	DET	O
efficacy	O	NOUN	B
and	O	CCONJ	O
toxicity	B-Disease	NOUN	B
of	O	ADP	O
the	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
GEM	B-Chemical	NOUN	B
and	O	CCONJ	O
VNB	B-Chemical	NOUN	B
in	O	ADP	O
elderly	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
advanced	O	ADJ	B
NSCLC	B-Disease	NOUN	B
or	O	CCONJ	O
those	O	DET	O
with	O	ADP	O
some	O	DET	O
contraindication	O	NOUN	B
to	O	ADP	O
receiving	O	VERB	O
cisplatin	B-Chemical	NOUN	B
were	O	AUX	O
assessed	O	VERB	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
Forty	O	NUM	B
-	O	PUNCT	O
nine	O	NUM	B
patients	O	NOUN	B
with	O	ADP	O
advanced	O	ADJ	B
NSCLC	B-Disease	NOUN	B
were	O	AUX	O
included	O	VERB	O
,	O	PUNCT	O
38	O	NUM	O
of	O	ADP	O
whom	O	PRON	O
were	O	AUX	O
age	O	NOUN	B
>/=	O	NOUN	O
70	O	NUM	O
years	O	NOUN	B
and	O	CCONJ	O
11	O	NUM	O
were	O	AUX	O
age	O	NOUN	B
<	O	ADP	O
70	O	NUM	O
years	O	NOUN	B
but	O	CCONJ	O
who	O	PRON	O
had	O	AUX	O
some	O	DET	O
contraindication	O	NOUN	B
to	O	ADP	O
receiving	O	VERB	O
cisplatin	B-Chemical	NOUN	B
.	O	PUNCT	O


All	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
evaluable	O	ADJ	O
for	O	ADP	O
response	O	NOUN	B
and	O	CCONJ	O
toxicity	B-Disease	NOUN	B
.	O	PUNCT	O


Treatment	O	NOUN	B
was	O	AUX	O
comprised	O	VERB	O
of	O	ADP	O
VNB	B-Chemical	NOUN	B
,	O	PUNCT	O
25	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
),	O	PUNCT	O
plus	O	CCONJ	O
GEM	B-Chemical	NOUN	B
,	O	PUNCT	O
1000	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
),	O	PUNCT	O
both	O	DET	O
on	O	ADP	O
Days	O	NOUN	O
1	O	NUM	O
,	O	PUNCT	O
8	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
15	O	NUM	O
every	O	DET	O
28	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


Patients	O	NOUN	B
received	O	VERB	O
a	O	DET	O
minimum	O	NOUN	B
of	O	ADP	O
three	O	NUM	O
courses	O	NOUN	B
unless	O	SCONJ	O
progressive	O	ADJ	B
disease	O	NOUN	O
was	O	AUX	O
detected	O	VERB	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
One	O	NUM	O
hundred	O	NUM	O
sixty	O	NUM	B
-	O	PUNCT	O
five	O	NUM	O
courses	O	NOUN	B
were	O	AUX	O
administered	O	VERB	B
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
median	O	NOUN	B
of	O	ADP	O
3	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
courses	O	NOUN	B
per	O	ADP	O
patient	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
overall	O	ADJ	O
response	O	NOUN	B
rate	O	NOUN	I
was	O	AUX	O
26	O	NUM	O
%(	O	NOUN	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
15	O	NUM	O
-	O	SYM	O
41	O	NUM	O
%).	O	NOUN	O
Two	O	NUM	O
patients	O	NOUN	B
attained	O	VERB	O
a	O	DET	O
complete	O	ADJ	B
response	O	NOUN	I
(	O	PUNCT	O
4	O	NUM	O
%)	O	NOUN	O
and	O	CCONJ	O
11	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
22	O	NUM	O
%)	O	NOUN	O
achieved	O	VERB	O
a	O	DET	O
partial	O	ADJ	B
response	O	NOUN	I
.	O	PUNCT	O


Eastern	O	PROPN	B
Cooperative	O	PROPN	I
Oncology	O	PROPN	I
Group	O	PROPN	I
performance	O	NOUN	I
status	O	NOUN	O
improved	O	VERB	B
in	O	ADP	O
35	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
those	O	DET	O
patients	O	NOUN	B
with	O	ADP	O
an	O	DET	O
initial	O	ADJ	O
value	O	NOUN	O
>	O	NOUN	O
0	O	NUM	O
,	O	PUNCT	O
whereas	O	SCONJ	O
relief	O	NOUN	B
of	O	ADP	O
at	O	ADP	O
least	O	ADJ	O
1	O	NUM	O
symptom	O	NOUN	B
without	O	ADP	O
worsening	O	NOUN	B
of	O	ADP	O
other	O	ADJ	O
symptoms	O	NOUN	B
was	O	AUX	O
noted	O	VERB	O
in	O	ADP	O
27	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
55	O	NUM	O
%).	O	NOUN	O
The	O	DET	O
median	O	ADJ	B
time	O	NOUN	O
to	O	PART	O
progression	O	NOUN	B
was	O	AUX	O
16	O	NUM	O
weeks	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
1	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
survival	O	NOUN	B
rate	O	NOUN	I
was	O	AUX	O
33	O	NUM	O
%.	O	NOUN	B
Toxicity	B-Disease	NOUN	B
was	O	AUX	O
mild	O	ADJ	B
.	O	PUNCT	O


Six	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
12	O	NUM	O
%)	O	NOUN	O
had	O	AUX	O
World	O	PROPN	B
Health	O	PROPN	I
Organization	O	PROPN	I
Grade	O	PROPN	I
3	O	NUM	I
-	O	SYM	O
4	O	NUM	O
neutropenia	B-Disease	NOUN	B
,	O	PUNCT	O
2	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
4	O	NUM	O
%)	O	NOUN	O
had	O	AUX	O
Grade	O	PROPN	B
3	O	NUM	I
-	O	SYM	O
4	O	NUM	O
thrombocytopenia	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
2	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
4	O	NUM	O
%)	O	NOUN	O
had	O	AUX	O
Grade	O	PROPN	B
3	O	NUM	I
neurotoxicity	B-Disease	NOUN	B
.	O	PUNCT	O


Three	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
severe	O	ADJ	B
neutropenia	B-Disease	NOUN	B
(	O	PUNCT	O
6	O	NUM	O
%)	O	NOUN	O
died	O	VERB	B
of	O	ADP	O
sepsis	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
median	O	ADJ	B
age	O	NOUN	B
of	O	ADP	O
those	O	DET	O
patients	O	NOUN	B
developing	O	VERB	O
Grade	O	NOUN	B
3	O	NUM	I
-	O	SYM	O
4	O	NUM	O
neutropenia	B-Disease	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
than	O	ADP	O
that	O	DET	O
of	O	ADP	O
the	O	DET	O
remaining	O	VERB	O
patients	O	NOUN	B
(	O	PUNCT	O
75	O	NUM	O
years	O	NOUN	B
vs	O	ADV	O
.	O	PUNCT	O


72	O	NUM	O
years	O	NOUN	B
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


047	O	NUM	O
).	O	PUNCT	O
CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
GEM	B-Chemical	NOUN	B
and	O	CCONJ	O
VNB	B-Chemical	NOUN	B
is	O	AUX	O
moderately	O	ADV	O
active	O	ADJ	B
and	O	CCONJ	O
well	O	ADV	O
tolerated	O	VERB	B
except	O	SCONJ	O
in	O	ADP	O
patients	O	NOUN	B
age	O	NOUN	B
>/=	O	NOUN	O
75	O	NUM	O
years	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
age	O	NOUN	B
group	O	NOUN	I
had	O	AUX	O
an	O	DET	O
increased	O	VERB	B
risk	O	NOUN	B
of	O	ADP	O
myelosuppression	B-Disease	NOUN	B
.	O	PUNCT	O


Therefore	O	ADV	O
the	O	DET	O
prophylactic	O	ADJ	B
use	O	NOUN	O
of	O	ADP	O
granulocyte	O	NOUN	B
-	O	PUNCT	O
colony	O	NOUN	B
stimulating	O	NOUN	B
factor	O	NOUN	I
should	O	AUX	O
be	O	AUX	O
considered	O	VERB	O
with	O	ADP	O
this	O	DET	O
treatment	O	NOUN	B
.	O	PUNCT	O


New	O	ADJ	B
chemotherapy	O	NOUN	I
combinations	O	NOUN	B
with	O	ADP	O
higher	O	ADJ	O
activity	O	NOUN	B
and	O	CCONJ	O
lower	O	ADJ	B
toxicity	B-Disease	NOUN	B
are	O	AUX	O
needed	O	VERB	O
for	O	ADP	O
elderly	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
advanced	O	ADJ	B
NSCLC	B-Disease	NOUN	B


Warfarin	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
artery	B-Disease	NOUN	B
calcification	I-Disease	NOUN	I
is	O	AUX	O
accelerated	O	VERB	B
by	O	ADP	O
growth	O	NOUN	B
and	O	CCONJ	O
vitamin	B-Chemical	NOUN	B
D	I-Chemical	NOUN	I
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
studies	O	NOUN	B
demonstrate	O	VERB	O
that	O	SCONJ	O
growth	O	NOUN	B
and	O	CCONJ	O
vitamin	B-Chemical	NOUN	B
D	I-Chemical	NOUN	I
treatment	O	NOUN	B
enhance	O	VERB	B
the	O	DET	O
extent	O	NOUN	B
of	O	ADP	O
artery	B-Disease	NOUN	B
calcification	I-Disease	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
given	O	VERB	O
sufficient	O	ADJ	O
doses	O	NOUN	B
of	O	ADP	O
Warfarin	B-Chemical	NOUN	B
to	O	PART	O
inhibit	O	VERB	B
gamma	O	NOUN	B
-	O	PUNCT	O
carboxylation	O	NOUN	B
of	O	ADP	O
matrix	O	NOUN	B
Gla	O	NOUN	I
protein	O	NOUN	I
,	O	PUNCT	O
a	O	DET	O
calcification	B-Disease	NOUN	B
inhibitor	O	NOUN	B
known	O	VERB	O
to	O	PART	O
be	O	AUX	O
expressed	O	VERB	B
by	O	ADP	O
smooth	O	ADJ	B
muscle	O	NOUN	I
cells	O	NOUN	I
and	O	CCONJ	O
macrophages	O	NOUN	B
in	O	ADP	O
the	O	DET	O
artery	O	NOUN	B
wall	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
first	O	ADJ	O
series	O	NOUN	O
of	O	ADP	O
experiments	O	NOUN	B
examined	O	VERB	B
the	O	DET	O
influence	O	NOUN	B
of	O	ADP	O
age	O	NOUN	B
and	O	CCONJ	O
growth	O	NOUN	B
status	O	NOUN	I
on	O	ADP	O
artery	B-Disease	NOUN	B
calcification	I-Disease	NOUN	I
in	O	ADP	O
Warfarin	B-Chemical	PROPN	B
-	O	PUNCT	O
treated	O	VERB	B
rats	O	NOUN	B
.	O	PUNCT	O


Treatment	O	NOUN	B
for	O	ADP	O
2	O	NUM	O
weeks	O	NOUN	B
with	O	ADP	O
Warfarin	B-Chemical	NOUN	B
caused	O	VERB	O
massive	O	ADJ	B
focal	O	ADJ	B
calcification	B-Disease	NOUN	I
of	I-Disease	ADP	O
the	I-Disease	DET	O
artery	I-Disease	NOUN	B
media	O	NOUN	I
in	O	ADP	O
20	O	NUM	O
-	O	PUNCT	O
day	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
rats	O	NOUN	B
and	O	CCONJ	O
less	O	ADV	O
extensive	O	ADJ	O
focal	O	ADJ	B
calcification	B-Disease	NOUN	I
in	O	ADP	O
42	O	NUM	O
-	O	PUNCT	O
day	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
rats	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
no	O	DET	O
artery	B-Disease	NOUN	B
calcification	I-Disease	NOUN	I
could	O	AUX	O
be	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
10	O	NUM	O
-	O	PUNCT	O
month	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
adult	O	ADJ	B
rats	O	NOUN	B
even	O	ADV	O
after	O	ADP	O
4	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
Warfarin	B-Chemical	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
directly	O	ADV	O
examine	O	VERB	O
the	O	DET	O
importance	O	NOUN	O
of	O	ADP	O
growth	O	NOUN	B
to	O	ADP	O
Warfarin	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
artery	B-Disease	NOUN	B
calcification	I-Disease	NOUN	I
in	O	ADP	O
animals	O	NOUN	B
of	O	ADP	O
the	O	DET	O
same	O	ADJ	O
age	O	NOUN	B
,	O	PUNCT	O
20	O	NUM	O
-	O	PUNCT	O
day	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
rats	O	NOUN	B
were	O	AUX	O
fed	O	VERB	B
for	O	ADP	O
2	O	NUM	O
weeks	O	NOUN	B
either	O	CCONJ	O
an	O	DET	O
ad	O	NOUN	B
libitum	O	NOUN	I
diet	O	NOUN	I
or	O	CCONJ	O
a	O	DET	O
6	O	NUM	O
-	O	PUNCT	O
g	O	NOUN	B
/	O	SYM	O
d	O	NOUN	B
restricted	O	ADJ	B
diet	O	NOUN	B
that	O	PRON	O
maintains	O	VERB	B
weight	O	NOUN	B
but	O	CCONJ	O
prevents	O	VERB	B
growth	O	NOUN	B
.	O	PUNCT	O


Concurrent	O	ADJ	B
treatment	O	NOUN	B
of	O	ADP	O
both	O	CCONJ	O
dietary	O	ADJ	B
groups	O	NOUN	I
with	O	ADP	O
Warfarin	B-Chemical	NOUN	B
produced	O	VERB	O
massive	O	ADJ	B
focal	O	ADJ	B
calcification	B-Disease	NOUN	I
of	I-Disease	ADP	O
the	I-Disease	DET	O
artery	I-Disease	NOUN	B
media	O	NOUN	I
in	O	ADP	O
the	O	DET	O
ad	O	NOUN	B
libitum	O	NOUN	I
-	O	PUNCT	O
fed	O	VERB	B
rats	O	NOUN	B
but	O	CCONJ	O
no	O	DET	O
detectable	O	ADJ	O
artery	B-Disease	NOUN	B
calcification	I-Disease	NOUN	I
in	O	ADP	O
the	O	DET	O
restricted	O	ADJ	B
-	O	PUNCT	O
diet	O	NOUN	B
,	O	PUNCT	O
growth	O	NOUN	B
-	O	PUNCT	O
inhibited	O	VERB	B
group	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
the	O	DET	O
explanation	O	NOUN	B
for	O	ADP	O
the	O	DET	O
association	O	NOUN	B
between	O	ADP	O
artery	B-Disease	NOUN	B
calcification	I-Disease	NOUN	I
and	O	CCONJ	O
growth	O	NOUN	B
status	O	NOUN	I
cannot	O	NOUN	O
be	O	AUX	O
determined	O	VERB	O
from	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
relationship	O	NOUN	B
between	O	ADP	O
higher	O	ADJ	B
serum	O	NOUN	B
phosphate	B-Chemical	NOUN	I
and	O	CCONJ	O
susceptibility	O	NOUN	B
to	O	PART	O
artery	B-Disease	NOUN	B
calcification	I-Disease	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
30	O	NUM	O
%	O	NOUN	O
higher	O	ADJ	O
levels	O	NOUN	B
of	O	ADP	O
serum	O	NOUN	B
phosphate	B-Chemical	NOUN	I
in	O	ADP	O
young	O	ADJ	B
,	O	PUNCT	O
ad	O	NOUN	B
libitum	O	NOUN	I
-	O	PUNCT	O
fed	O	VERB	B
rats	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
either	O	DET	O
of	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
that	O	PRON	O
was	O	AUX	O
resistant	O	ADJ	B
to	O	ADP	O
Warfarin	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
artery	B-Disease	NOUN	B
calcification	I-Disease	NOUN	I
,	O	PUNCT	O
ie	O	X	O
,	O	PUNCT	O
the	O	DET	O
10	O	NUM	O
-	O	PUNCT	O
month	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
rats	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
restricted	O	ADJ	B
-	O	PUNCT	O
diet	O	NOUN	B
,	O	PUNCT	O
growth	O	NOUN	B
-	O	PUNCT	O
inhibited	O	VERB	B
young	O	ADJ	B
rats	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
observation	O	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
increased	O	VERB	B
susceptibility	O	NOUN	B
to	O	ADP	O
Warfarin	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
artery	B-Disease	NOUN	B
calcification	I-Disease	NOUN	I
could	O	AUX	O
be	O	AUX	O
related	O	ADJ	O
to	O	PART	O
higher	O	ADJ	O
serum	O	NOUN	B
phosphate	B-Chemical	NOUN	I
levels	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
second	O	ADJ	O
set	O	NOUN	O
of	O	ADP	O
experiments	O	NOUN	B
examined	O	VERB	B
the	O	DET	O
possible	O	ADJ	O
synergy	O	NOUN	B
between	O	ADP	O
vitamin	B-Chemical	NOUN	B
D	I-Chemical	NOUN	I
and	O	CCONJ	O
Warfarin	B-Chemical	NOUN	B
in	O	ADP	O
artery	B-Disease	NOUN	B
calcification	I-Disease	NOUN	I
.	O	PUNCT	O


High	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
vitamin	B-Chemical	NOUN	B
D	I-Chemical	NOUN	I
are	O	AUX	O
known	O	VERB	O
to	O	PART	O
cause	O	VERB	O
calcification	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
artery	I-Disease	NOUN	B
media	O	NOUN	I
in	O	ADP	O
as	O	ADV	O
little	O	ADJ	O
as	O	ADP	O
3	O	NUM	O
to	O	PART	O
4	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


High	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
the	O	DET	O
vitamin	B-Chemical	NOUN	B
K	I-Chemical	NOUN	I
antagonist	O	NOUN	I
Warfarin	B-Chemical	PROPN	B
are	O	AUX	O
also	O	ADV	O
known	O	VERB	O
to	O	PART	O
cause	O	VERB	O
calcification	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
artery	I-Disease	NOUN	B
media	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
at	O	ADP	O
treatment	O	NOUN	B
times	O	NOUN	O
of	O	ADP	O
2	O	NUM	O
weeks	O	NOUN	B
or	O	CCONJ	O
longer	O	ADV	O
yet	O	ADV	O
not	O	PART	O
at	O	ADP	O
1	O	NUM	O
week	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
current	O	ADJ	O
study	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
investigated	O	VERB	B
the	O	DET	O
synergy	O	NOUN	B
between	O	ADP	O
these	O	DET	O
2	O	NUM	O
treatments	O	NOUN	B
and	O	CCONJ	O
found	O	VERB	O
that	O	SCONJ	O
concurrent	O	ADJ	B
Warfarin	B-Chemical	PROPN	B
administration	O	NOUN	O
dramatically	O	ADV	O
increased	O	VERB	B
the	O	DET	O
extent	O	NOUN	O
of	O	ADP	O
calcification	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
media	O	NOUN	B
of	O	ADP	O
vitamin	B-Chemical	NOUN	B
D	I-Chemical	NOUN	I
-	O	PUNCT	O
treated	O	VERB	B
rats	O	NOUN	B
at	O	ADP	O
3	O	NUM	O
and	O	CCONJ	O
4	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
a	O	DET	O
close	O	ADJ	O
parallel	O	NOUN	O
between	O	ADP	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
vitamin	B-Chemical	NOUN	B
D	I-Chemical	NOUN	I
dose	O	NOUN	B
on	O	ADP	O
artery	B-Disease	NOUN	B
calcification	I-Disease	NOUN	I
and	O	CCONJ	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
vitamin	B-Chemical	NOUN	B
D	I-Chemical	NOUN	I
dose	O	NOUN	B
on	O	ADP	O
the	O	DET	O
elevation	O	NOUN	B
of	O	ADP	O
serum	O	NOUN	B
calcium	B-Chemical	NOUN	I
,	O	PUNCT	O
which	O	DET	O
suggests	O	VERB	O
that	O	SCONJ	O
vitamin	B-Chemical	NOUN	B
D	I-Chemical	NOUN	I
may	O	AUX	O
induce	O	VERB	B
artery	B-Disease	NOUN	B
calcification	I-Disease	NOUN	I
through	O	ADP	O
its	O	PRON	O
effect	O	NOUN	B
on	O	ADP	O
serum	O	NOUN	B
calcium	B-Chemical	NOUN	I
.	O	PUNCT	O


Because	O	SCONJ	O
Warfarin	B-Chemical	NOUN	B
treatment	O	NOUN	B
had	O	AUX	O
no	O	DET	B
effect	O	NOUN	I
on	O	ADP	O
the	O	DET	O
elevation	O	NOUN	B
in	O	ADP	O
serum	O	NOUN	B
calcium	B-Chemical	NOUN	I
produced	O	VERB	O
by	O	ADP	O
vitamin	B-Chemical	NOUN	B
D	I-Chemical	NOUN	I
,	O	PUNCT	O
the	O	DET	O
synergy	O	NOUN	B
between	O	ADP	O
Warfarin	B-Chemical	NOUN	B
and	O	CCONJ	O
vitamin	B-Chemical	NOUN	B
D	I-Chemical	NOUN	I
is	O	AUX	O
probably	O	ADV	O
best	O	ADV	O
explained	O	VERB	O
by	O	ADP	O
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
Warfarin	B-Chemical	NOUN	B
inhibits	O	VERB	B
the	O	DET	O
activity	O	NOUN	B
of	O	ADP	O
matrix	O	NOUN	B
Gla	O	NOUN	I
protein	O	NOUN	I
as	O	ADP	O
a	O	DET	O
calcification	B-Disease	NOUN	B
inhibitor	O	NOUN	B
.	O	PUNCT	O


High	O	ADJ	O
levels	O	NOUN	B
of	O	ADP	O
matrix	O	NOUN	B
Gla	O	NOUN	I
protein	O	NOUN	I
are	O	AUX	O
found	O	VERB	O
at	O	ADP	O
sites	O	NOUN	B
of	O	ADP	O
artery	B-Disease	NOUN	B
calcification	I-Disease	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
vitamin	B-Chemical	NOUN	B
D	I-Chemical	NOUN	I
plus	O	CCONJ	O
Warfarin	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
chemical	O	NOUN	B
analysis	O	NOUN	I
showed	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
protein	O	NOUN	B
that	O	PRON	O
accumulated	O	VERB	O
was	O	AUX	O
indeed	O	ADV	O
not	O	PART	O
gamma-carboxylated	B-Chemical	VERB	B
.	O	PUNCT	O


These	O	DET	O
observations	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
although	O	SCONJ	O
the	O	DET	O
gamma-carboxyglutamate	B-Chemical	ADJ	B
residues	O	NOUN	I
of	O	ADP	O
matrix	O	NOUN	B
Gla	O	NOUN	I
protein	O	NOUN	I
are	O	AUX	O
apparently	O	ADV	O
required	O	VERB	O
for	O	ADP	O
its	O	PRON	O
function	O	NOUN	B
as	O	ADP	O
a	O	DET	O
calcification	B-Disease	NOUN	B
inhibitor	O	NOUN	B
,	O	PUNCT	O
they	O	PRON	O
are	O	AUX	O
not	O	PART	O
required	O	VERB	O
for	O	ADP	O
its	O	PRON	O
accumulation	O	NOUN	B
at	O	ADP	O
calcification	B-Disease	NOUN	B


Antidepressant	B-Chemical	ADJ	B
-	O	PUNCT	O
induced	O	VERB	B
mania	B-Disease	NOUN	B
in	O	ADP	O
bipolar	B-Disease	ADJ	B
patients	O	NOUN	B
:	O	PUNCT	O
identification	O	NOUN	B
of	O	ADP	O
risk	O	NOUN	B
factors	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Concerns	O	NOUN	B
about	O	ADP	O
possible	O	ADJ	O
risks	O	NOUN	B
of	O	ADP	O
switching	O	NOUN	B
to	O	PART	O
mania	B-Disease	NOUN	B
associated	O	VERB	B
with	O	ADP	I
antidepressants	B-Chemical	NOUN	B
continue	O	VERB	O
to	O	PART	O
interfere	O	VERB	B
with	O	ADP	I
the	O	DET	O
establishment	O	NOUN	O
of	O	ADP	O
an	O	DET	O
optimal	O	ADJ	B
treatment	O	NOUN	B
paradigm	O	NOUN	B
for	O	ADP	O
bipolar	B-Disease	ADJ	B
depression	I-Disease	NOUN	I
.	O	PUNCT	O


METHOD	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
response	O	NOUN	B
of	O	ADP	O
44	O	NUM	O
patients	O	NOUN	B
meeting	O	VERB	O
DSM	O	PROPN	B
-	O	PUNCT	O
IV	O	NUM	B
criteria	O	NOUN	B
for	O	ADP	O
bipolar	B-Disease	ADJ	B
disorder	I-Disease	NOUN	I
to	O	PART	O
naturalistic	O	ADJ	B
treatment	O	NOUN	I
was	O	AUX	O
assessed	O	VERB	B
for	O	ADP	O
at	O	ADP	O
least	O	ADJ	O
6	O	NUM	O
weeks	O	NOUN	B
using	O	VERB	O
the	O	DET	O
Montgomery	O	PROPN	B
-	O	PUNCT	O
Asberg	O	PROPN	B
Depression	O	PROPN	I
Rating	O	PROPN	I
Scale	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
Bech	O	PROPN	B
-	O	PUNCT	O
Rafaelson	O	PROPN	B
Mania	O	PROPN	O
Rating	O	PROPN	O
Scale	O	NOUN	O
.	O	PUNCT	O


Patients	O	NOUN	B
who	O	PRON	O
experienced	O	VERB	O
a	O	DET	O
manic	B-Disease	ADJ	B
or	O	CCONJ	O
hypomanic	B-Disease	ADJ	B
switch	O	NOUN	B
were	O	AUX	O
compared	O	VERB	B
with	O	ADP	O
those	O	DET	O
who	O	PRON	O
did	O	AUX	O
not	O	PART	O
on	O	ADP	O
several	O	ADJ	O
variables	O	NOUN	B
including	O	VERB	O
age	O	NOUN	B
,	O	PUNCT	O
sex	O	NOUN	B
,	O	PUNCT	O
diagnosis	O	NOUN	B
(	O	PUNCT	O
DSM-IV	B-Disease	NOUN	B
bipolar	I-Disease	NOUN	I
I	I-Disease	NUM	I
vs	O	ADV	O
.	O	PUNCT	O


bipolar	B-Disease	NOUN	B
II	I-Disease	NUM	I
),	O	PUNCT	O
number	O	NOUN	O
of	O	ADP	O
previous	O	ADJ	O
manic	B-Disease	ADJ	B
episodes	O	NOUN	I
,	O	PUNCT	O
type	O	NOUN	O
of	O	ADP	O
antidepressant	B-Chemical	ADJ	B
therapy	O	NOUN	I
used	O	VERB	O
(	O	PUNCT	O
electroconvulsive	O	ADJ	B
therapy	O	NOUN	I
vs	O	CCONJ	O
.	O	PUNCT	O


antidepressant	B-Chemical	ADJ	B
drugs	O	NOUN	B
and	O	CCONJ	O
,	O	PUNCT	O
more	O	ADV	O
particularly	O	ADV	O
,	O	PUNCT	O
selective	O	ADJ	O
serotonin	B-Chemical	NOUN	B
reuptake	I-Chemical	NOUN	I
inhibitors	I-Chemical	NOUN	I
[	O	PUNCT	O
SSRIs	B-Chemical	PROPN	B
]),	O	ADJ	O
use	O	NOUN	O
and	O	CCONJ	O
type	O	NOUN	O
of	O	ADP	O
mood	O	NOUN	B
stabilizers	O	NOUN	I
(	O	PUNCT	O
lithium	B-Chemical	NOUN	B
vs	O	CCONJ	O
.	O	PUNCT	O


anticonvulsants	O	NOUN	B
),	O	PUNCT	O
and	O	CCONJ	O
temperament	O	NOUN	B
of	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
,	O	PUNCT	O
assessed	O	VERB	B
during	O	ADP	O
a	O	DET	O
normothymic	O	ADJ	B
period	O	NOUN	B
using	O	VERB	O
the	O	DET	O
hyperthymia	O	NOUN	B
component	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Semi	O	PROPN	B
-	O	PUNCT	O
structured	O	ADJ	B
Affective	O	ADJ	O
Temperament	O	PROPN	O
Interview	O	PROPN	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Switches	O	NOUN	B
to	O	PART	O
hypomania	B-Disease	NOUN	B
or	O	CCONJ	O
mania	B-Disease	NOUN	B
occurred	O	VERB	O
in	O	ADP	O
27	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
all	O	DET	O
patients	O	NOUN	B
(	O	PUNCT	O
N	O	NOUN	O
=	O	ADJ	O
12	O	NUM	O
)(	O	NOUN	O
and	O	CCONJ	O
in	O	ADP	O
24	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
subgroup	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
SSRIs	B-Chemical	NOUN	B
[	O	PUNCT	O
8	O	NUM	O
/	O	SYM	O
33	O	NUM	O
]);	O	NOUN	O
16	O	NUM	O
%(	O	NOUN	O
N	O	NOUN	O
=	O	ADJ	O
7	O	NUM	O
)	O	PUNCT	O
experienced	O	VERB	O
manic	B-Disease	ADJ	B
episodes	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
11	O	NUM	O
%(	O	NOUN	O
N	O	NOUN	O
=	O	ADJ	O
5	O	NUM	O
)	O	PUNCT	O
experienced	O	VERB	O
hypomanic	B-Disease	ADJ	B
episodes	O	NOUN	O
.	O	PUNCT	O


Sex	O	NOUN	B
,	O	PUNCT	O
age	O	NOUN	B
,	O	PUNCT	O
diagnosis	O	NOUN	B
(	O	PUNCT	O
bipolar	B-Disease	NOUN	B
I	I-Disease	NUM	I
vs	O	ADV	O
.	O	PUNCT	O


bipolar	B-Disease	NOUN	B
II	I-Disease	NUM	I
),	O	PUNCT	O
and	O	CCONJ	O
additional	O	ADJ	B
treatment	O	NOUN	B
did	O	AUX	O
not	O	PART	O
affect	O	VERB	O
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
switching	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
mood	O	NOUN	B
switches	O	NOUN	I
seemed	O	VERB	O
not	O	PART	O
to	O	PART	O
differ	O	VERB	O
between	O	ADP	O
patients	O	NOUN	B
receiving	O	VERB	O
an	O	DET	O
anticonvulsant	O	NOUN	B
and	O	CCONJ	O
those	O	DET	O
receiving	O	VERB	O
no	O	DET	O
mood	O	NOUN	B
stabilizer	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
mood	O	NOUN	B
switches	O	NOUN	I
were	O	AUX	O
less	O	ADV	O
frequent	O	ADJ	B
in	O	ADP	O
patients	O	NOUN	B
receiving	O	VERB	O
lithium	B-Chemical	NOUN	B
(	O	PUNCT	O
15	O	NUM	O
%,	O	NOUN	O
4	O	NUM	O
/	O	SYM	O
26	O	NUM	O
)	O	PUNCT	O
than	O	ADP	O
in	O	ADP	O
patients	O	NOUN	B
not	O	PART	O
treated	O	VERB	B
with	O	ADP	I
lithium	B-Chemical	NOUN	B
(	O	PUNCT	O
44	O	NUM	O
%,	O	NOUN	O
8	O	NUM	O
/	O	SYM	O
18	O	NUM	O
;	O	PUNCT	O
p	O	NOUN	O
=.	O	NOUN	O
04	O	NUM	O
).	O	PUNCT	O
The	O	DET	O
number	O	NOUN	O
of	O	ADP	O
previous	O	ADJ	O
manic	B-Disease	ADJ	B
episodes	O	NOUN	I
did	O	AUX	O
not	O	PART	O
affect	O	VERB	O
the	O	DET	O
probability	O	NOUN	B
of	O	ADP	O
switching	O	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
a	O	DET	O
high	O	ADJ	B
score	O	NOUN	I
on	O	ADP	O
the	O	DET	O
hyperthymia	O	NOUN	B
component	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Semistructured	O	ADJ	B
Affective	O	ADJ	I
Temperament	O	PROPN	I
Interview	O	PROPN	I
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
greater	O	ADJ	O
risk	O	NOUN	B
of	O	ADP	O
switching	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=.	O	NOUN	O
008	O	NUM	O
).	O	NOUN	O
CONCLUSION	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
frequency	O	NOUN	B
of	O	ADP	O
mood	O	NOUN	B
switching	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
acute	O	ADJ	B
antidepressant	B-Chemical	ADJ	I
therapy	O	NOUN	I
may	O	AUX	O
be	O	AUX	O
reduced	O	VERB	B
by	O	ADP	O
lithium	B-Chemical	NOUN	B


Caffeine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cardiac	B-Disease	ADJ	B
arrhythmia	I-Disease	NOUN	I
:	O	PUNCT	O
an	O	DET	O
unrecognised	O	ADJ	B
danger	O	NOUN	B
of	O	ADP	O
healthfood	O	NOUN	B
products	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
describe	O	VERB	O
a	O	DET	O
25	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
woman	O	NOUN	B
with	O	ADP	O
pre	O	NOUN	B
-	O	PUNCT	O
existing	O	VERB	B
mitral	B-Disease	ADJ	B
valve	I-Disease	NOUN	I
prolapse	I-Disease	NOUN	I
who	O	PRON	O
developed	O	VERB	O
intractable	O	ADJ	B
ventricular	B-Disease	ADJ	B
fibrillation	I-Disease	NOUN	I
after	O	ADP	O
consuming	O	VERB	O
a	O	DET	O
"	O	PUNCT	O
natural	O	ADJ	B
energy	O	NOUN	I
"	O	PUNCT	O
guarana	O	NOUN	B
health	O	NOUN	B
drink	O	NOUN	I
containing	O	VERB	O
a	O	DET	O
high	O	ADJ	O
concentration	O	NOUN	B
of	O	ADP	O
caffeine	B-Chemical	NOUN	B


Bladder	O	ADJ	B
retention	B-Disease	NOUN	B
of	I-Disease	ADP	O
urine	I-Disease	NOUN	B
as	O	ADP	O
a	O	DET	O
result	O	NOUN	O
of	O	ADP	O
continuous	O	ADJ	B
intravenous	O	ADJ	B
infusion	O	NOUN	B
of	O	ADP	O
fentanyl	B-Chemical	NOUN	B
:	O	PUNCT	O
2	O	NUM	O
case	O	NOUN	B
reports	O	NOUN	I
.	O	PUNCT	O


Sedation	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
commonly	O	ADV	O
used	O	VERB	O
in	O	ADP	O
the	O	DET	O
neonate	O	NOUN	B
to	O	PART	O
decrease	O	VERB	B
the	O	DET	O
stress	O	NOUN	B
and	O	CCONJ	O
pain	B-Disease	NOUN	B
from	O	ADP	O
the	O	DET	O
noxious	O	ADJ	B
stimuli	O	NOUN	I
and	O	CCONJ	O
invasive	O	ADJ	B
procedures	O	NOUN	I
in	O	ADP	O
the	O	DET	O
neonatal	O	ADJ	B
intensive	O	ADJ	B
care	O	NOUN	I
unit	O	NOUN	I
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
to	O	PART	O
facilitate	O	VERB	O
synchrony	O	NOUN	B
between	O	ADP	O
ventilator	O	NOUN	B
and	O	CCONJ	O
spontaneous	O	ADJ	B
breaths	O	NOUN	O
.	O	PUNCT	O


Fentanyl	B-Chemical	NOUN	B
,	O	PUNCT	O
an	O	DET	O
opioid	O	NOUN	B
analgesic	O	NOUN	I
,	O	PUNCT	O
is	O	AUX	O
frequently	O	ADV	O
used	O	VERB	O
in	O	ADP	O
the	O	DET	O
neonatal	O	ADJ	B
intensive	O	ADJ	B
care	O	NOUN	I
unit	O	NOUN	I
setting	O	VERB	O
for	O	ADP	O
these	O	DET	O
very	O	ADJ	O
purposes	O	NOUN	O
.	O	PUNCT	O


Various	O	ADJ	O
reported	O	ADJ	O
side	O	NOUN	B
effects	O	NOUN	I
of	O	ADP	O
fentanyl	B-Chemical	NOUN	B
administration	O	NOUN	I
include	O	VERB	O
chest	B-Disease	ADJ	B
wall	I-Disease	NOUN	I
rigidity	I-Disease	NOUN	B
,	O	PUNCT	O
hypotension	B-Disease	NOUN	B
,	O	PUNCT	O
respiratory	B-Disease	ADJ	B
depression	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
bradycardia	B-Disease	NOUN	B
.	O	PUNCT	O


Here	O	ADV	O
,	O	PUNCT	O
2	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
urinary	B-Disease	ADJ	B
bladder	I-Disease	NOUN	I
retention	I-Disease	NOUN	B
leading	O	VERB	O
to	O	PART	O
renal	O	ADJ	B
pelvocalyceal	O	ADJ	O
dilatation	O	NOUN	O
mimicking	O	VERB	O
hydronephrosis	B-Disease	NOUN	B
as	O	ADP	O
a	O	DET	O
result	O	NOUN	O
of	O	ADP	O
continuous	O	ADJ	B
infusion	O	NOUN	B
of	O	ADP	O
fentanyl	B-Chemical	NOUN	B


Combined	O	ADJ	B
antiretroviral	O	ADJ	B
therapy	O	NOUN	I
causes	O	VERB	O
cardiomyopathy	B-Disease	NOUN	B
and	O	CCONJ	O
elevates	O	VERB	B
plasma	O	NOUN	B
lactate	B-Chemical	NOUN	I
in	O	ADP	O
transgenic	O	ADJ	B
AIDS	B-Disease	NOUN	I
mice	O	NOUN	I
.	O	PUNCT	O


Highly	O	ADV	O
active	O	ADJ	O
antiretroviral	O	ADJ	B
therapy	O	NOUN	I
(	O	PUNCT	O
HAART	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
implicated	O	VERB	O
in	O	ADP	O
cardiomyopathy	B-Disease	NOUN	B
(	O	PUNCT	O
CM	B-Disease	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
elevated	O	ADJ	B
plasma	O	NOUN	O
lactate	B-Chemical	NOUN	O
(	O	PUNCT	O
LA	B-Chemical	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
AIDS	B-Disease	NOUN	B
through	O	ADP	O
mechanisms	O	NOUN	B
of	O	ADP	O
mitochondrial	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
.	O	PUNCT	O


To	O	PART	O
determine	O	VERB	O
mitochondrial	O	ADJ	B
events	O	NOUN	I
from	O	ADP	O
HAART	O	NOUN	B
in	O	X	B
vivo	O	X	I
,	O	PUNCT	O
8	O	NUM	O
-	O	PUNCT	O
week	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
hemizygous	O	ADJ	B
transgenic	O	ADJ	I
AIDS	B-Disease	NOUN	I
mice	O	NOUN	I
(	O	PUNCT	O
NL4	O	NOUN	B
-	O	PUNCT	O
3Delta	O	NOUN	O
gag	O	NOUN	B
/	O	SYM	O
pol	O	NOUN	B
;	O	PUNCT	O
TG	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
FVB	O	PROPN	B
/	O	PUNCT	O
n	O	NOUN	B
littermates	O	NOUN	B
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
the	O	DET	O
HAART	O	NOUN	B
combination	O	NOUN	B
of	O	ADP	O
zidovudine	B-Chemical	NOUN	B
,	O	PUNCT	O
lamivudine	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
indinavir	B-Chemical	NOUN	B
or	O	CCONJ	O
vehicle	O	NOUN	B
control	O	NOUN	I
for	O	ADP	O
10	O	NUM	O
days	O	NOUN	B
or	O	CCONJ	O
35	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


At	O	ADP	O
termination	O	NOUN	B
of	O	ADP	O
the	O	DET	O
experiments	O	NOUN	B
,	O	PUNCT	O
mice	O	NOUN	B
underwent	O	VERB	O
echocardiography	O	NOUN	B
,	O	PUNCT	O
quantitation	O	NOUN	B
of	O	ADP	O
abundance	O	NOUN	B
of	O	ADP	O
molecular	O	ADJ	B
markers	O	NOUN	I
of	O	ADP	O
CM	B-Disease	NOUN	B
(	O	PUNCT	O
ventricular	O	ADJ	B
mRNA	O	NOUN	I
encoding	O	VERB	O
atrial	O	ADJ	B
natriuretic	O	ADJ	I
factor	O	NOUN	I
[	O	PUNCT	O
ANF	O	NOUN	B
]	O	PUNCT	O
and	O	CCONJ	O
sarcoplasmic	O	ADJ	B
calcium	B-Chemical	NOUN	I
ATPase	O	NOUN	I
[	O	PUNCT	O
SERCA2	O	NOUN	B
]),	O	NOUN	O
and	O	CCONJ	O
determination	O	NOUN	B
of	O	ADP	O
plasma	O	NOUN	B
LA	B-Chemical	NOUN	B
.	O	PUNCT	O


Myocardial	O	ADJ	B
histologic	O	ADJ	O
features	O	NOUN	B
were	O	AUX	O
analyzed	O	VERB	B
semiquantitatively	O	ADV	B
and	O	CCONJ	O
results	O	NOUN	B
were	O	AUX	O
confirmed	O	VERB	O
by	O	ADP	O
transmission	O	NOUN	B
electron	O	NOUN	I
microscopy	O	NOUN	I
.	O	PUNCT	O


After	O	ADP	O
35	O	NUM	O
days	O	NOUN	B
in	O	ADP	O
the	O	DET	O
TG	O	NOUN	B
+	O	CCONJ	O
HAART	O	NOUN	B
cohort	O	NOUN	B
,	O	PUNCT	O
left	O	VERB	B
ventricular	O	ADJ	I
mass	O	NOUN	I
increased	O	VERB	B
160	O	NUM	O
%	O	NOUN	O
by	O	ADP	O
echocardiography	O	NOUN	B
.	O	PUNCT	O


Molecularly	O	NOUN	B
,	O	PUNCT	O
ANF	O	NOUN	B
mRNA	O	NOUN	B
increased	O	VERB	B
250	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
SERCA2	O	NOUN	B
mRNA	O	NOUN	B
decreased	O	VERB	B
57	O	NUM	O
%.	O	NOUN	B
Biochemically	O	ADV	B
,	O	PUNCT	O
LA	B-Chemical	PROPN	B
was	O	AUX	O
elevated	O	ADJ	B
(	O	PUNCT	O
8	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
+/-	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
mM	O	NOUN	O
).	O	PUNCT	O
Pathologically	O	ADV	B
,	O	PUNCT	O
granular	O	ADJ	B
cytoplasmic	O	ADJ	B
changes	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
cardiac	O	ADJ	B
myocytes	O	NOUN	I
,	O	PUNCT	O
indicating	O	VERB	O
enlarged	O	ADJ	B
,	O	PUNCT	O
damaged	O	ADJ	B
mitochondria	O	NOUN	B
.	O	PUNCT	O


Findings	O	NOUN	B
were	O	AUX	O
confirmed	O	VERB	O
ultrastructurally	O	ADV	B
.	O	PUNCT	O


No	O	DET	O
changes	O	NOUN	O
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
other	O	ADJ	O
cohorts	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
10	O	NUM	O
days	O	NOUN	B
,	O	PUNCT	O
only	O	ADV	O
ANF	O	NOUN	B
was	O	AUX	O
elevated	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
only	O	ADV	O
in	O	ADP	O
the	O	DET	O
TG	O	NOUN	B
+	O	CCONJ	O
HAART	O	NOUN	B
cohort	O	NOUN	B
.	O	PUNCT	O


Results	O	NOUN	B
show	O	VERB	O
that	O	SCONJ	O
cumulative	O	ADJ	B
HAART	O	NOUN	B
caused	O	VERB	O
mitochondrial	O	ADJ	B
CM	B-Disease	NOUN	B
with	O	ADP	O
elevated	O	ADJ	B
LA	B-Chemical	NOUN	B
in	O	ADP	O
AIDS	B-Disease	NOUN	B


Oral	B-Chemical	ADJ	B
contraceptives	I-Chemical	NOUN	I
and	O	CCONJ	O
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
myocardial	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
An	O	DET	O
association	O	NOUN	B
between	O	ADP	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
oral	B-Chemical	ADJ	B
contraceptives	I-Chemical	NOUN	I
and	O	CCONJ	O
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
myocardial	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
has	O	AUX	O
been	O	AUX	O
found	O	VERB	O
in	O	ADP	O
some	O	DET	O
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
all	O	DET	O
,	O	PUNCT	O
studies	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
investigated	O	VERB	B
this	O	DET	O
association	O	NOUN	B
,	O	PUNCT	O
according	O	VERB	O
to	O	PART	O
the	O	DET	O
type	O	NOUN	O
of	O	ADP	O
progestagen	B-Chemical	NOUN	B
included	O	VERB	O
in	O	ADP	O
third	O	ADJ	B
-	O	PUNCT	O
generation	O	NOUN	B
(	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


e	O	X	O
.,	O	NOUN	O
desogestrel	B-Chemical	NOUN	B
or	O	CCONJ	O
gestodene	B-Chemical	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
second	O	ADJ	B
-	O	PUNCT	O
generation	O	NOUN	B
(	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


e	O	X	O
.,	O	NOUN	O
levonorgestrel	B-Chemical	NOUN	B
)	O	PUNCT	O
oral	B-Chemical	ADJ	B
contraceptives	I-Chemical	NOUN	I
,	O	PUNCT	O
the	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
estrogen	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
presence	O	NOUN	B
or	O	CCONJ	O
absence	O	NOUN	B
of	O	ADP	O
prothrombotic	O	ADJ	B
mutations	O	NOUN	I
METHODS	O	NOUN	O
:	O	PUNCT	O
In	O	ADP	O
a	O	DET	O
nationwide	O	NOUN	B
,	O	PUNCT	O
population	O	NOUN	B
-	O	PUNCT	O
based	O	VERB	B
,	O	PUNCT	O
case	O	NOUN	B
-	O	PUNCT	O
control	O	NOUN	B
study	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
identified	O	VERB	B
and	O	CCONJ	O
enrolled	O	VERB	O
248	O	NUM	O
women	O	NOUN	B
18	O	NUM	O
through	O	ADP	O
49	O	NUM	O
years	O	NOUN	B
of	O	ADP	O
age	O	NOUN	B
who	O	PRON	O
had	O	AUX	O
had	O	AUX	O
a	O	DET	O
first	O	ADJ	O
myocardial	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
between	O	ADP	O
1990	O	NUM	O
and	O	CCONJ	O
1995	O	NUM	O
and	O	CCONJ	O
925	O	NUM	O
control	O	NOUN	B
women	O	NOUN	B
who	O	PRON	O
had	O	AUX	O
not	O	PART	O
had	O	AUX	O
a	O	DET	O
myocardial	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
and	O	CCONJ	O
who	O	PRON	O
were	O	AUX	O
matched	O	VERB	B
for	O	ADP	O
age	O	NOUN	B
,	O	PUNCT	O
calendar	O	NOUN	B
year	O	NOUN	I
of	O	ADP	O
the	O	DET	O
index	O	NOUN	O
event	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
area	O	NOUN	B
of	O	ADP	O
residence	O	NOUN	B
.	O	PUNCT	O


Subjects	O	NOUN	B
supplied	O	VERB	O
information	O	NOUN	B
on	O	ADP	O
oral-contraceptive	B-Chemical	ADJ	B
use	O	NOUN	I
and	O	CCONJ	O
major	O	ADJ	O
cardiovascular	O	ADJ	B
risk	O	NOUN	I
factors	O	NOUN	I
.	O	PUNCT	O


An	O	DET	O
analysis	O	NOUN	B
for	O	ADP	O
factor	O	NOUN	B
V	O	PROPN	I
Leiden	O	PROPN	I
and	O	CCONJ	O
the	O	DET	O
G20210A	O	NOUN	B
mutation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
prothrombin	O	NOUN	B
gene	O	NOUN	I
was	O	AUX	O
conducted	O	VERB	O
in	O	ADP	O
217	O	NUM	O
patients	O	NOUN	B
and	O	CCONJ	O
763	O	NUM	O
controls	O	NOUN	B
RESULTS	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
odds	O	NOUN	B
ratio	O	NOUN	I
for	O	ADP	O
myocardial	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
among	O	ADP	O
women	O	NOUN	B
who	O	PRON	O
used	O	VERB	O
any	O	DET	O
type	O	NOUN	O
of	O	ADP	O
combined	O	ADJ	O
oral	B-Chemical	ADJ	O
contraceptive	I-Chemical	NOUN	O
,	O	PUNCT	O
as	O	ADP	O
compared	O	VERB	B
with	O	ADP	O
nonusers	O	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
2	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
percent	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
to	O	PART	O
2	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
).	O	PUNCT	O
The	O	DET	O
adjusted	O	ADJ	O
odds	O	NOUN	B
ratio	O	NOUN	I
was	O	AUX	O
2	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
percent	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
to	O	PART	O
4	O	NUM	O
.	O	PUNCT	O


1	O	X	O
)	O	PUNCT	O
among	O	ADP	O
women	O	NOUN	B
who	O	PRON	O
used	O	VERB	O
second	O	ADJ	B
-	O	PUNCT	O
generation	O	NOUN	B
oral	B-Chemical	ADJ	B
contraceptives	I-Chemical	NOUN	I
and	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
percent	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
to	O	PART	O
2	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
)	O	PUNCT	O
among	O	ADP	O
those	O	DET	O
who	O	PRON	O
used	O	VERB	O
third	O	ADJ	B
-	O	PUNCT	O
generation	O	NOUN	B
oral	B-Chemical	ADJ	B
contraceptives	I-Chemical	NOUN	I
.	O	PUNCT	O


Among	O	ADP	O
women	O	NOUN	B
who	O	PRON	O
used	O	VERB	O
oral	B-Chemical	ADJ	B
contraceptives	I-Chemical	NOUN	I
,	O	PUNCT	O
the	O	DET	O
odds	O	NOUN	B
ratio	O	NOUN	I
was	O	AUX	O
2	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
percent	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
to	O	PART	O
3	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
)	O	PUNCT	O
for	O	ADP	O
those	O	DET	O
without	O	ADP	O
a	O	DET	O
prothrombotic	O	ADJ	B
mutation	O	NOUN	O
and	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
percent	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
to	O	PART	O
5	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
)	O	PUNCT	O
for	O	ADP	O
those	O	DET	O
with	O	ADP	O
a	O	DET	O
mutation	O	NOUN	B
CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
myocardial	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
was	O	AUX	O
increased	O	VERB	B
among	O	ADP	O
women	O	NOUN	B
who	O	PRON	O
used	O	VERB	O
second	O	ADJ	B
-	O	PUNCT	O
generation	O	NOUN	B
oral	B-Chemical	ADJ	B
contraceptives	I-Chemical	NOUN	I
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
with	O	ADP	O
respect	O	NOUN	O
to	O	PART	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
third	O	ADJ	B
-	O	PUNCT	O
generation	O	NOUN	B
oral	B-Chemical	ADJ	B
contraceptives	I-Chemical	NOUN	I
were	O	AUX	O
inconclusive	O	ADJ	B
but	O	CCONJ	O
suggested	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
risk	O	NOUN	B
was	O	AUX	O
lower	O	ADJ	O
than	O	ADP	O
the	O	DET	O
risk	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
second	O	ADJ	B
-	O	PUNCT	O
generation	O	NOUN	B
oral	B-Chemical	ADJ	B
contraceptives	I-Chemical	NOUN	I
.	O	PUNCT	O


The	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
myocardial	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
was	O	AUX	O
similar	O	ADJ	O
among	O	ADP	O
women	O	NOUN	B
who	O	PRON	O
used	O	VERB	O
oral	B-Chemical	ADJ	B
contraceptives	I-Chemical	NOUN	B


Effects	O	NOUN	B
of	O	ADP	I
5	O	NUM	O
-	O	PUNCT	O
HT1B	O	NOUN	B
receptor	O	NOUN	I
ligands	O	NOUN	B
microinjected	O	VERB	B
into	O	ADP	O
the	O	DET	O
accumbal	O	NOUN	B
shell	O	NOUN	I
or	O	CCONJ	O
core	O	NOUN	B
on	O	ADP	O
the	O	DET	O
cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
locomotor	B-Disease	NOUN	B
hyperactivity	I-Disease	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
was	O	AUX	O
designed	O	VERB	O
to	O	PART	O
examine	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
5	O	NUM	O
-	O	PUNCT	O
HT1B	O	NOUN	B
receptor	O	NOUN	I
ligands	O	NOUN	B
microinjected	O	VERB	B
into	O	ADP	O
the	O	DET	O
subregions	O	NOUN	B
of	O	ADP	O
the	O	DET	O
nucleus	O	NOUN	B
accumbens	O	NOUN	I
(	O	PUNCT	O
the	O	DET	O
shell	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
core	O	NOUN	B
)	O	PUNCT	O
on	O	ADP	O
the	O	DET	O
locomotor	B-Disease	NOUN	B
hyperactivity	I-Disease	NOUN	I
induced	O	VERB	B
by	O	ADP	O
cocaine	B-Chemical	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


Male	O	NOUN	B
Wistar	O	PROPN	B
rats	O	NOUN	I
were	O	AUX	O
implanted	O	VERB	B
bilaterally	O	ADV	O
with	O	ADP	O
cannulae	O	NOUN	B
into	O	ADP	O
the	O	DET	O
accumbens	O	NOUN	B
shell	O	NOUN	B
or	O	CCONJ	O
core	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
then	O	ADV	O
were	O	AUX	O
locally	O	ADV	B
injected	O	VERB	I
with	O	ADP	O
GR	B-Chemical	NOUN	B
55562	I-Chemical	NUM	O
(	O	PUNCT	O
an	O	DET	O
antagonist	O	NOUN	B
of	O	ADP	O
5	O	NUM	O
-	O	PUNCT	O
HT1B	O	NOUN	B
receptors	O	NOUN	I
)	O	PUNCT	O
or	O	CCONJ	O
CP	B-Chemical	NOUN	B
93129	I-Chemical	NUM	O
(	O	PUNCT	O
an	O	DET	O
agonist	O	NOUN	B
of	O	ADP	O
5	O	NUM	O
-	O	PUNCT	O
HT1B	O	NOUN	B
receptors	O	NOUN	I
).	O	PUNCT	B
Given	O	VERB	O
alone	O	ADV	O
to	O	PART	O
any	O	DET	O
accumbal	O	NOUN	B
subregion	O	NOUN	B
,	O	PUNCT	O
GR	B-Chemical	NOUN	B
55562	I-Chemical	NUM	O
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
-	O	SYM	O
10	O	NUM	O
microg	O	NOUN	B
/	O	SYM	O
side	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
CP	B-Chemical	NOUN	B
93129	I-Chemical	NUM	O
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
-	O	SYM	O
10	O	NUM	O
microg	O	NOUN	B
/	O	SYM	O
side	O	NOUN	B
)	O	PUNCT	O
did	O	AUX	O
not	O	PART	O
change	O	VERB	O
basal	O	ADJ	B
locomotor	O	NOUN	O
activity	O	NOUN	O
.	O	PUNCT	O


Systemic	O	ADJ	B
cocaine	B-Chemical	NOUN	I
(	O	PUNCT	O
10	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
significantly	O	ADV	O
increased	O	VERB	B
the	O	DET	O
locomotor	O	NOUN	B
activity	O	NOUN	I
of	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


GR	B-Chemical	NOUN	B
55562	I-Chemical	NUM	O
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
-	O	SYM	O
10	O	NUM	O
microg	O	NOUN	B
/	O	SYM	O
side	O	NOUN	B
),	O	PUNCT	O
administered	O	VERB	B
intra	O	ADJ	B
-	O	PUNCT	O
accumbens	O	NOUN	B
shell	O	NOUN	B
prior	O	ADV	O
to	O	PART	O
cocaine	B-Chemical	NOUN	B
,	O	PUNCT	O
dose	O	NOUN	B
-	O	PUNCT	O
dependently	O	ADV	B
attenuated	O	VERB	B
the	O	DET	O
psychostimulant	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
locomotor	B-Disease	NOUN	B
hyperactivity	I-Disease	NOUN	I
.	O	PUNCT	O


Such	O	ADJ	O
attenuation	O	NOUN	B
was	O	AUX	O
not	O	PART	O
found	O	VERB	O
in	O	ADP	O
animals	O	NOUN	B
which	O	DET	O
had	O	AUX	O
been	O	AUX	O
injected	O	VERB	B
with	O	ADP	O
GR	B-Chemical	NOUN	B
55562	I-Chemical	NUM	O
into	O	ADP	O
the	O	DET	O
accumbens	O	NOUN	B
core	O	NOUN	B
.	O	PUNCT	O


When	O	SCONJ	O
injected	O	VERB	B
into	O	ADP	O
the	O	DET	O
accumbens	O	NOUN	B
shell	O	NOUN	B
(	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
the	O	DET	O
core	O	NOUN	B
)	O	PUNCT	O
before	O	ADP	O
cocaine	B-Chemical	NOUN	B
,	O	PUNCT	O
CP	B-Chemical	NOUN	B
93129	I-Chemical	NUM	O
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
-	O	SYM	O
10	O	NUM	O
microg	O	NOUN	B
/	O	SYM	O
side	O	NOUN	B
)	O	PUNCT	O
enhanced	O	VERB	B
the	O	DET	O
locomotor	O	NOUN	B
response	O	NOUN	I
to	O	PART	O
cocaine	B-Chemical	NOUN	B
;	O	PUNCT	O
the	O	DET	O
maximum	O	ADJ	B
effect	O	NOUN	B
being	O	AUX	O
observed	O	VERB	B
after	O	ADP	O
10	O	NUM	O
microg	O	NOUN	B
/	O	SYM	O
side	O	NOUN	B
of	O	ADP	O
the	O	DET	O
agonist	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
later	O	ADJ	O
enhancement	O	NOUN	B
was	O	AUX	O
attenuated	O	VERB	B
after	O	ADP	O
intra	O	ADJ	B
-	O	PUNCT	O
accumbens	O	NOUN	B
shell	O	NOUN	B
treatment	O	NOUN	B
with	O	ADP	O
GR	B-Chemical	NOUN	B
55562	I-Chemical	NUM	O
(	O	PUNCT	O
1	O	NUM	O
microg	O	NOUN	B
/	O	SYM	O
side	O	NOUN	B
).	O	PUNCT	O
Our	O	PRON	O
findings	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
cocaine	B-Chemical	NOUN	B
induced	O	VERB	B
hyperlocomotion	B-Disease	NOUN	B
is	O	AUX	O
modified	O	VERB	B
by	O	ADP	O
5	O	NUM	O
-	O	PUNCT	O
HT1B	O	NOUN	B
receptor	O	NOUN	I
ligands	O	NOUN	B
microinjected	O	VERB	B
into	O	ADP	O
the	O	DET	O
accumbens	O	NOUN	B
shell	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
core	O	NOUN	O
,	O	PUNCT	O
this	O	DET	O
modification	O	NOUN	B
consisting	O	VERB	O
in	O	ADP	O
inhibitory	O	ADJ	B
and	O	CCONJ	O
facilitatory	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
the	O	DET	O
5	O	NUM	O
-	O	PUNCT	O
HT1B	O	NOUN	B
receptor	O	NOUN	I
antagonist	O	NOUN	I
(	O	PUNCT	O
GR	B-Chemical	NOUN	B
55562	I-Chemical	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
agonist	O	NOUN	B
(	O	PUNCT	O
CP	B-Chemical	NOUN	B
93129	I-Chemical	NUM	O


Ticlopidine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cholestatic	B-Disease	ADJ	B
hepatitis	I-Disease	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
:	O	PUNCT	O
To	O	PART	O
report	O	VERB	O
2	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
ticlopidine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cholestatic	B-Disease	ADJ	B
hepatitis	I-Disease	NOUN	I
,	O	PUNCT	O
investigate	O	VERB	B
its	O	PRON	O
mechanism	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
compare	O	VERB	B
the	O	DET	O
observed	O	VERB	O
main	O	ADJ	O
characteristics	O	NOUN	B
with	O	ADP	O
those	O	DET	O
of	O	ADP	O
the	O	DET	O
published	O	VERB	B
cases	O	NOUN	I
.	O	PUNCT	O


CASE	O	ADJ	B
SUMMARIES	O	NOUN	I
:	O	PUNCT	O
Two	O	NUM	O
patients	O	NOUN	B
developed	O	VERB	O
prolonged	O	ADJ	B
cholestatic	B-Disease	ADJ	B
hepatitis	I-Disease	NOUN	I
after	O	ADP	O
receiving	O	VERB	O
ticlopidine	B-Chemical	NOUN	B
following	O	VERB	O
percutaneous	O	ADJ	B
coronary	O	ADJ	I
angioplasty	O	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
complete	O	ADJ	O
remission	O	NOUN	B
during	O	ADP	O
the	O	DET	O
follow	O	NOUN	B
-	O	PUNCT	O
up	O	ADP	O
period	O	NOUN	B
.	O	PUNCT	O


T	O	NOUN	B
-	O	PUNCT	O
cell	O	NOUN	B
stimulation	O	NOUN	B
by	O	ADP	O
therapeutic	O	ADJ	B
concentration	O	NOUN	B
of	O	ADP	O
ticlopidine	B-Chemical	NOUN	B
was	O	AUX	O
demonstrated	O	VERB	O
in	O	X	B
vitro	O	X	I
in	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
in	O	ADP	O
healthy	O	ADJ	B
controls	O	NOUN	I
.	O	PUNCT	O


DISCUSSION	O	NOUN	O
:	O	PUNCT	O
Cholestatic	B-Disease	ADJ	B
hepatitis	I-Disease	NOUN	I
is	O	AUX	O
a	O	DET	O
rare	O	ADJ	O
complication	O	NOUN	B
of	O	ADP	O
the	O	DET	O
antiplatelet	O	NOUN	B
agent	O	NOUN	I
ticlopidine	B-Chemical	NOUN	B
;	O	PUNCT	O
several	O	ADJ	O
cases	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
but	O	CCONJ	O
few	O	ADJ	O
in	O	ADP	O
the	O	DET	O
English	O	ADJ	B
literature	O	NOUN	I
.	O	PUNCT	O


Our	O	PRON	O
patients	O	NOUN	B
developed	O	VERB	O
jaundice	B-Disease	NOUN	B
following	O	VERB	O
treatment	O	NOUN	B
with	O	ADP	O
ticlopidine	B-Chemical	NOUN	B
and	O	CCONJ	O
showed	O	VERB	O
the	O	DET	O
clinical	O	ADJ	B
and	O	CCONJ	O
laboratory	O	ADJ	B
characteristics	O	NOUN	I
of	O	ADP	O
cholestatic	B-Disease	ADJ	B
hepatitis	I-Disease	NOUN	I
,	O	PUNCT	O
which	O	DET	O
resolved	O	VERB	B
after	O	ADP	O
discontinuation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
drug	O	NOUN	B
.	O	PUNCT	O


Hepatitis	B-Disease	NOUN	B
may	O	AUX	O
develop	O	VERB	O
weeks	O	NOUN	B
after	O	ADP	O
discontinuation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
drug	O	NOUN	B
and	O	CCONJ	O
may	O	AUX	O
run	O	VERB	O
a	O	DET	O
prolonged	O	ADJ	B
course	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
complete	O	ADJ	O
remission	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
all	O	DET	O
reported	O	VERB	O
cases	O	NOUN	B
.	O	PUNCT	O


An	O	DET	O
objective	O	ADJ	O
causality	O	NOUN	B
assessment	O	NOUN	O
revealed	O	VERB	B
that	O	SCONJ	O
the	O	DET	O
adverse	O	ADJ	B
drug	O	NOUN	I
event	O	NOUN	I
was	O	AUX	O
probably	O	ADV	O
related	O	ADJ	O
to	O	PART	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
ticlopidine	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
mechanisms	O	NOUN	B
of	O	ADP	O
this	O	DET	O
ticlopidine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cholestasis	B-Disease	NOUN	B
are	O	AUX	O
unclear	O	ADJ	B
.	O	PUNCT	O


Immune	O	ADJ	B
mechanisms	O	NOUN	I
may	O	AUX	O
be	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
the	O	DET	O
drug	O	NOUN	B
'	O	PART	O
s	O	NOUN	O
hepatotoxicity	B-Disease	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
suggested	O	VERB	O
by	O	ADP	O
the	O	DET	O
T	O	NOUN	B
-	O	PUNCT	O
cell	O	NOUN	B
stimulation	O	NOUN	I
study	O	NOUN	B
reported	O	VERB	O
here	O	ADV	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
Cholestatic	B-Disease	ADJ	B
hepatitis	I-Disease	NOUN	I
is	O	AUX	O
a	O	DET	O
rare	O	ADJ	B
adverse	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
ticlopidine	B-Chemical	NOUN	B
that	O	PRON	O
may	O	AUX	O
be	O	AUX	O
immune	O	ADJ	B
mediated	O	VERB	I
.	O	PUNCT	O


Patients	O	NOUN	B
receiving	O	VERB	O
the	O	DET	O
drug	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
monitored	O	VERB	B
with	O	ADP	O
liver	O	NOUN	B
function	O	NOUN	I
tests	O	NOUN	I
along	O	ADP	O
with	O	ADP	O
complete	O	ADJ	O
blood	O	NOUN	B
cell	O	NOUN	I
counts	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
complication	O	NOUN	B
will	O	AUX	O
be	O	AUX	O
observed	O	VERB	B
even	O	ADV	O
less	O	ADV	O
often	O	ADV	O
in	O	ADP	O
the	O	DET	O
future	O	NOUN	O
as	O	ADP	O
ticlopidine	B-Chemical	NOUN	B
is	O	AUX	O
being	O	AUX	O
replaced	O	VERB	O
by	O	ADP	O
the	O	DET	O
newer	O	ADJ	O
antiplatelet	O	NOUN	B
agent	O	NOUN	I
clopidogrel	B-Chemical	NOUN	B


Epithelial	O	ADJ	B
sodium	B-Chemical	NOUN	I
channel	O	NOUN	I
(	O	PUNCT	O
ENaC	O	NOUN	O
)	O	PUNCT	O
subunit	O	NOUN	B
mRNA	O	NOUN	B
and	O	CCONJ	O
protein	O	NOUN	B
expression	O	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
with	O	ADP	O
puromycin	B-Chemical	NOUN	B
aminonucleoside	I-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
nephrotic	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
experimental	O	ADJ	B
nephrotic	B-Disease	ADJ	I
syndrome	I-Disease	NOUN	I
,	O	PUNCT	O
urinary	O	ADJ	B
sodium	B-Chemical	NOUN	I
excretion	O	NOUN	B
is	O	AUX	O
decreased	O	VERB	B
during	O	ADP	O
the	O	DET	O
early	O	ADJ	B
phase	O	NOUN	B
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
molecular	O	ADJ	B
mechanism	O	NOUN	I
(	O	PUNCT	O
s	O	NOUN	O
)	O	PUNCT	O
leading	O	VERB	O
to	O	PART	O
salt	O	NOUN	B
retention	O	NOUN	I
has	O	AUX	O
not	O	PART	O
been	O	AUX	O
completely	O	ADV	O
elucidated	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
rate	O	NOUN	B
-	O	PUNCT	O
limiting	O	VERB	B
constituent	O	NOUN	B
of	O	ADP	O
collecting	O	VERB	O
duct	O	NOUN	B
sodium	B-Chemical	NOUN	I
transport	O	NOUN	I
is	O	AUX	O
the	O	DET	O
epithelial	O	ADJ	B
sodium	B-Chemical	NOUN	I
channel	O	NOUN	I
(	O	PUNCT	O
ENaC	O	NOUN	B
).	O	PUNCT	O
We	O	PRON	O
examined	O	VERB	O
the	O	DET	O
abundance	O	NOUN	B
of	O	ADP	O
ENaC	O	NOUN	B
subunit	O	NOUN	I
mRNAs	O	NOUN	B
and	O	CCONJ	O
proteins	O	NOUN	B
in	O	ADP	O
puromycin	B-Chemical	NOUN	B
aminonucleoside	I-Chemical	NOUN	B
(	O	PUNCT	O
PAN	B-Chemical	NOUN	B
)-	O	ADJ	O
induced	O	VERB	B
nephrotic	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
time	O	NOUN	B
courses	O	NOUN	I
of	O	ADP	O
urinary	O	ADJ	B
sodium	B-Chemical	NOUN	I
excretion	O	NOUN	B
,	O	PUNCT	O
plasma	O	NOUN	B
aldosterone	B-Chemical	NOUN	B
concentration	O	NOUN	B
and	O	CCONJ	O
proteinuria	B-Disease	NOUN	B
were	O	AUX	O
studied	O	VERB	O
in	O	ADP	O
male	O	NOUN	B
Sprague	O	PROPN	B
-	O	PUNCT	O
Dawley	O	NOUN	B
rats	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
a	O	DET	O
single	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
either	O	CCONJ	O
PAN	B-Chemical	NOUN	B
or	O	CCONJ	O
vehicle	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
relative	O	ADJ	O
amounts	O	NOUN	O
of	O	ADP	O
alphaENaC	O	NOUN	B
,	O	PUNCT	O
betaENaC	O	NOUN	B
and	O	CCONJ	O
gammaENaC	O	NOUN	B
mRNAs	O	NOUN	B
were	O	AUX	O
determined	O	VERB	O
in	O	ADP	O
kidneys	O	NOUN	B
from	O	ADP	O
these	O	DET	O
rats	O	NOUN	B
by	O	ADP	O
real	O	ADJ	B
-	O	PUNCT	O
time	O	NOUN	B
quantitative	O	ADJ	O
TaqMan	O	NOUN	O
PCR	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
amounts	O	NOUN	B
of	O	ADP	O
proteins	O	NOUN	B
by	O	ADP	O
Western	O	NOUN	B
blot	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
kinetics	O	NOUN	B
of	O	ADP	O
urinary	O	ADJ	B
sodium	B-Chemical	NOUN	I
excretion	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
appearance	O	NOUN	B
of	O	ADP	O
proteinuria	B-Disease	NOUN	B
were	O	AUX	O
comparable	O	ADJ	O
with	O	ADP	O
those	O	DET	O
reported	O	VERB	O
previously	O	ADV	O
.	O	PUNCT	O


Sodium	B-Chemical	NOUN	B
retention	O	NOUN	I
occurred	O	VERB	O
on	O	ADP	O
days	O	NOUN	B
2	O	NUM	O
,	O	PUNCT	O
3	O	NUM	O
and	O	CCONJ	O
6	O	NUM	O
after	O	ADP	O
PAN	B-Chemical	NOUN	B
injection	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
significant	O	ADJ	O
up	O	ADV	B
-	O	PUNCT	O
regulation	O	NOUN	B
of	O	ADP	O
alphaENaC	O	NOUN	B
and	O	CCONJ	O
betaENaC	O	NOUN	B
mRNA	O	NOUN	B
abundance	O	NOUN	B
on	O	ADP	O
days	O	NOUN	B
1	O	NUM	O
and	O	CCONJ	O
2	O	NUM	O
preceded	O	VERB	O
sodium	B-Chemical	NOUN	B
retention	O	NOUN	I
on	O	ADP	O
days	O	NOUN	B
2	O	NUM	O
and	O	CCONJ	O
3	O	NUM	O
.	O	PUNCT	O


Conversely	O	ADV	O
,	O	PUNCT	O
down	O	ADV	B
-	O	PUNCT	O
regulation	O	NOUN	B
of	O	ADP	O
alphaENaC	O	NOUN	B
,	O	PUNCT	O
betaENaC	O	NOUN	B
and	O	CCONJ	O
gammaENaC	O	NOUN	B
mRNA	O	NOUN	B
expression	O	NOUN	I
on	O	ADP	O
day	O	NOUN	B
3	O	NUM	O
occurred	O	VERB	O
in	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
high	O	ADJ	B
aldosterone	B-Chemical	NOUN	B
concentrations	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
was	O	AUX	O
followed	O	VERB	O
by	O	ADP	O
a	O	DET	O
return	O	NOUN	B
of	O	ADP	I
sodium	B-Chemical	NOUN	B
excretion	O	NOUN	B
to	O	PART	O
control	O	NOUN	B
values	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
amounts	O	NOUN	O
of	O	ADP	O
alphaENaC	O	NOUN	B
,	O	PUNCT	O
betaENaC	O	NOUN	B
and	O	CCONJ	O
gammaENaC	O	NOUN	B
proteins	O	NOUN	I
were	O	AUX	O
not	O	PART	O
increased	O	VERB	B
during	O	ADP	O
PAN	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
sodium	B-Chemical	NOUN	B
retention	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
ENaC	O	NOUN	B
mRNA	O	NOUN	B
expression	O	NOUN	B
,	O	PUNCT	O
especially	O	ADV	O
alphaENaC	O	NOUN	B
,	O	PUNCT	O
is	O	AUX	O
increased	O	VERB	B
in	O	ADP	O
the	O	DET	O
very	O	ADV	O
early	O	ADJ	B
phase	O	NOUN	B
of	O	ADP	O
the	O	DET	O
experimental	O	ADJ	B
model	O	NOUN	I
of	O	ADP	O
PAN	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
nephrotic	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
appears	O	VERB	O
to	O	PART	O
escape	O	VERB	O
from	O	ADP	O
the	O	DET	O
regulation	O	NOUN	B
by	O	ADP	O
aldosterone	B-Chemical	NOUN	B


NO	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
migraine	B-Disease	NOUN	B
attack	O	NOUN	B
:	O	PUNCT	O
strong	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
plasma	O	NOUN	B
calcitonin	B-Chemical	NOUN	O
gene-related	I-Chemical	ADJ	O
peptide	I-Chemical	NOUN	O
(	O	PUNCT	O
CGRP	B-Chemical	NOUN	B
)	O	PUNCT	O
concentration	O	NOUN	B
and	O	CCONJ	O
negative	O	ADJ	B
correlation	O	NOUN	B
with	O	ADP	O
platelet	O	NOUN	B
serotonin	B-Chemical	NOUN	I
release	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
investigate	O	VERB	B
changes	O	NOUN	B
in	O	ADP	O
the	O	DET	O
plasma	O	NOUN	B
calcitonin	B-Chemical	NOUN	I
gene-related	I-Chemical	ADJ	I
peptide	I-Chemical	NOUN	I
(	O	PUNCT	O
CGRP	B-Chemical	NOUN	B
)	O	PUNCT	O
concentration	O	NOUN	B
and	O	CCONJ	O
platelet	O	NOUN	B
serotonin	B-Chemical	NOUN	I
(	O	PUNCT	O
5-hydroxytriptamine	B-Chemical	NOUN	B
,	O	PUNCT	O
5-HT	B-Chemical	NOUN	B
)	O	PUNCT	O
content	O	NOUN	B
during	O	ADP	O
the	O	DET	O
immediate	O	ADJ	B
headache	B-Disease	NOUN	B
and	O	CCONJ	O
the	O	DET	O
delayed	O	VERB	B
genuine	O	ADJ	O
migraine	B-Disease	NOUN	B
attack	O	NOUN	B
provoked	O	VERB	O
by	O	ADP	O
nitroglycerin	B-Chemical	NOUN	B
.	O	PUNCT	O


Fifteen	O	NUM	O
female	O	ADJ	B
migraineurs	B-Disease	NOUN	I
(without	I-Disease	ADP	O
aura)	I-Disease	ADJ	B
and	O	CCONJ	O
eight	O	NUM	O
controls	O	NOUN	B
participated	O	VERB	O
in	O	ADP	O
the	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


Sublingual	O	ADJ	B
nitroglycerin	B-Chemical	NOUN	I
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
was	O	AUX	O
administered	O	VERB	B
.	O	PUNCT	O


Blood	O	NOUN	B
was	O	AUX	O
collected	O	VERB	O
from	O	ADP	O
the	O	DET	O
antecubital	O	ADJ	B
vein	O	NOUN	I
four	O	NUM	O
times	O	NOUN	O
:	O	PUNCT	O
60	O	NUM	O
min	O	NOUN	O
before	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
the	O	DET	O
nitroglycerin	B-Chemical	NOUN	B
application	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
60	O	NUM	O
and	O	CCONJ	O
120	O	NUM	O
min	O	NOUN	O
after	O	ADP	O
the	O	DET	O
beginning	O	NOUN	O
of	O	ADP	O
the	O	DET	O
migraine	B-Disease	NOUN	B
attack	O	NOUN	B
(	O	PUNCT	O
mean	O	NOUN	O
344	O	NUM	O
and	O	CCONJ	O
404	O	NUM	O
min	O	NOUN	O
;	O	PUNCT	O
12	O	NUM	O
subjects	O	NOUN	B
).	O	PUNCT	B
In	O	ADP	O
those	O	DET	O
subjects	O	NOUN	B
who	O	PRON	O
had	O	AUX	O
no	O	DET	O
migraine	B-Disease	NOUN	B
attack	O	NOUN	B
(	O	PUNCT	O
11	O	NUM	O
subjects	O	NOUN	B
)	O	PUNCT	O
a	O	DET	O
similar	O	ADJ	O
time	O	NOUN	B
schedule	O	NOUN	I
was	O	AUX	O
used	O	VERB	O
.	O	PUNCT	O


Plasma	O	NOUN	B
CGRP	B-Chemical	NOUN	B
concentration	O	NOUN	B
increased	O	VERB	B
significantly	O	ADV	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
)	O	PUNCT	O
during	O	ADP	O
the	O	DET	O
migraine	B-Disease	NOUN	B
attack	O	NOUN	B
and	O	CCONJ	O
returned	O	VERB	O
to	O	PART	O
baseline	O	NOUN	B
after	O	ADP	O
the	O	DET	O
cessation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
migraine	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
both	O	DET	O
change	O	NOUN	B
and	O	CCONJ	O
peak	O	NOUN	B
,	O	PUNCT	O
showed	O	VERB	O
significant	O	ADJ	O
positive	O	ADJ	B
correlations	O	NOUN	B
with	O	ADP	O
migraine	B-Disease	NOUN	B
headache	B-Disease	NOUN	I
intensity	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
).	O	PUNCT	O
However	O	ADV	O
,	O	PUNCT	O
plasma	O	NOUN	B
CGRP	B-Chemical	NOUN	B
concentrations	O	NOUN	B
failed	O	VERB	B
to	O	PART	O
change	O	VERB	O
during	O	ADP	O
immediate	O	ADJ	B
headache	B-Disease	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
the	O	DET	O
subjects	O	NOUN	B
with	O	ADP	O
no	O	DET	O
migraine	B-Disease	NOUN	B
attack	O	NOUN	B
.	O	PUNCT	O


Basal	O	ADJ	B
CGRP	B-Chemical	NOUN	B
concentration	O	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
and	O	CCONJ	O
platelet	O	NOUN	B
5-HT	B-Chemical	NOUN	I
content	O	NOUN	B
tended	O	VERB	O
to	O	PART	O
be	O	AUX	O
lower	O	ADJ	O
in	O	ADP	O
subjects	O	NOUN	B
who	O	PRON	O
experienced	O	VERB	O
a	O	DET	O
migraine	B-Disease	NOUN	B
attack	O	NOUN	B
.	O	PUNCT	O


Platelet	O	NOUN	B
serotonin	B-Chemical	NOUN	B
content	O	NOUN	B
decreased	O	VERB	B
significantly	O	ADV	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
)	O	PUNCT	O
after	O	ADP	O
nitroglycerin	B-Chemical	NOUN	B
in	O	ADP	O
subjects	O	NOUN	B
with	O	ADP	O
no	O	DET	O
migraine	B-Disease	NOUN	B
attack	O	NOUN	B
but	O	CCONJ	O
no	O	DET	O
consistent	O	ADJ	O
change	O	NOUN	O
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
migraine	B-Disease	NOUN	B
attack	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
fact	O	NOUN	O
that	O	SCONJ	O
plasma	O	NOUN	B
CGRP	B-Chemical	NOUN	B
concentration	O	NOUN	B
correlates	O	VERB	B
with	O	ADP	O
the	O	DET	O
timing	O	NOUN	B
and	O	CCONJ	O
severity	O	NOUN	B
of	O	ADP	O
a	O	DET	O
migraine	B-Disease	NOUN	B
headache	B-Disease	NOUN	I
suggests	O	VERB	O
a	O	DET	O
direct	O	ADJ	O
relationship	O	NOUN	B
between	O	ADP	O
CGRP	B-Chemical	NOUN	B
and	O	CCONJ	O
migraine	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
serotonin	B-Chemical	NOUN	B
release	O	NOUN	B
from	O	ADP	O
platelets	O	NOUN	B
does	O	AUX	O
not	O	PART	O
provoke	O	VERB	O
migraine	B-Disease	NOUN	B
,	O	PUNCT	O
it	O	PRON	O
may	O	AUX	O
even	O	ADV	O
counteract	O	VERB	O
the	O	DET	O
headache	B-Disease	NOUN	B
and	O	CCONJ	O
the	O	DET	O
concomitant	O	ADJ	B
CGRP	B-Chemical	NOUN	B


Coronary	B-Disease	ADJ	B
aneurysm	I-Disease	NOUN	I
after	O	ADP	O
implantation	O	NOUN	B
of	O	ADP	O
a	O	DET	O
paclitaxel	B-Chemical	NOUN	B
-	O	PUNCT	O
eluting	O	VERB	B
stent	O	NOUN	B
.	O	PUNCT	O


Formation	O	NOUN	B
of	O	ADP	O
coronary	B-Disease	ADJ	B
aneurysm	I-Disease	NOUN	I
is	O	AUX	O
a	O	DET	O
rare	O	ADJ	O
complication	O	NOUN	B
of	O	ADP	O
stenting	O	VERB	B
with	O	ADP	O
bare	O	ADJ	B
metal	O	NOUN	B
stents	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
based	O	VERB	O
on	O	ADP	O
experimental	O	ADJ	B
studies	O	NOUN	I
drug	O	NOUN	B
-	O	PUNCT	O
eluting	O	VERB	B
stents	O	NOUN	B
may	O	AUX	O
induce	O	VERB	B
toxic	O	ADJ	B
effects	O	NOUN	I
on	O	ADP	O
the	O	DET	O
vessel	O	NOUN	B
wall	O	NOUN	I
with	O	ADP	O
incomplete	O	ADJ	O
stent	O	NOUN	B
apposition	O	NOUN	I
,	O	PUNCT	O
aneurysm	B-Disease	NOUN	B
formation	O	NOUN	I
and	O	CCONJ	O
with	O	ADP	O
the	O	DET	O
potential	O	NOUN	B
of	O	ADP	O
stent	O	ADJ	B
thrombosis	B-Disease	NOUN	I
or	O	CCONJ	O
vessel	B-Disease	NOUN	B
rupture	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
present	O	VERB	O
a	O	DET	O
43	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
man	O	NOUN	B
who	O	PRON	O
developed	O	VERB	O
a	O	DET	O
coronary	B-Disease	ADJ	B
aneurysm	I-Disease	NOUN	I
in	O	ADP	O
the	O	DET	O
right	O	ADJ	B
coronary	O	ADJ	I
artery	O	NOUN	I
6	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
receiving	O	VERB	O
a	O	DET	O
paclitaxel	B-Chemical	NOUN	B
-	O	PUNCT	O
eluting	O	VERB	B
stent	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
was	O	AUX	O
asymptomatic	O	ADJ	B
and	O	CCONJ	O
the	O	DET	O
aneurysm	B-Disease	NOUN	B
was	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
a	O	DET	O
routine	O	ADJ	O
control	O	NOUN	B
.	O	PUNCT	O


Angiography	O	NOUN	B
and	O	CCONJ	O
intracoronary	O	ADJ	B
ultrasound	O	NOUN	I
demonstrated	O	VERB	O
lack	O	NOUN	O
of	O	ADP	O
contact	O	NOUN	B
between	O	ADP	O
stent	O	NOUN	B
and	O	CCONJ	O
vessel	O	NOUN	B
wall	O	NOUN	I
in	O	ADP	O
a	O	DET	O
15	O	NUM	O
-	O	PUNCT	O
mm	O	PROPN	O
long	O	ADJ	B
segment	O	NOUN	I
with	O	ADP	O
maximal	O	ADJ	B
aneurysm	B-Disease	NOUN	B


Behavioral	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
urotensin-II	B-Chemical	NOUN	B
centrally	O	ADV	O
administered	O	VERB	B
in	O	ADP	O
mice	O	NOUN	B
.	O	PUNCT	O


Urotensin-II	B-Chemical	NOUN	B
(	O	PUNCT	O
U-II	B-Chemical	NOUN	B
)	O	PUNCT	O
receptors	O	NOUN	O
are	O	AUX	O
widely	O	ADV	O
distributed	O	VERB	B
in	O	ADP	O
the	O	DET	O
central	O	ADJ	B
nervous	O	ADJ	I
system	O	NOUN	I
.	O	PUNCT	O


Intracerebroventricular	O	NOUN	B
(	O	PUNCT	O
i	O	NOUN	O
.	O	PUNCT	O


c	O	X	O
.	O	PUNCT	O


v	O	DET	O
.)	O	ADJ	O
injection	O	NOUN	B
of	O	ADP	O
U-II	B-Chemical	NOUN	B
causes	O	VERB	O
hypertension	B-Disease	NOUN	B
and	O	CCONJ	O
bradycardia	B-Disease	NOUN	B
and	O	CCONJ	O
stimulates	O	VERB	B
prolactin	O	NOUN	B
and	O	CCONJ	O
thyrotropin	O	NOUN	B
secretion	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
behavioral	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
centrally	O	ADV	B
administered	O	VERB	I
U-II	B-Chemical	NOUN	B
have	O	AUX	O
received	O	VERB	O
little	O	ADJ	O
attention	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
tested	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
i	O	PRON	O
.	O	PUNCT	O


c	O	X	O
.	O	PUNCT	O


v	O	NOUN	O
.	O	PUNCT	O


injections	O	NOUN	B
of	O	ADP	O
U-II	B-Chemical	NOUN	B
on	O	ADP	O
behavioral	O	ADJ	B
,	O	PUNCT	O
metabolic	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
endocrine	O	ADJ	B
responses	O	NOUN	I
in	O	ADP	O
mice	O	NOUN	B
.	O	PUNCT	O


Administration	O	NOUN	B
of	O	ADP	O
graded	O	VERB	B
doses	O	NOUN	I
of	O	ADP	O
U-II	B-Chemical	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
-	O	SYM	O
10	O	NUM	O
,	O	PUNCT	O
000	O	NUM	O
ng	O	NOUN	O
/	O	SYM	O
mouse	O	NOUN	B
)	O	PUNCT	O
provoked	O	VERB	O
:(	O	PUNCT	O
1	O	X	O
)	O	PUNCT	O
a	O	DET	O
dose	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
reduction	O	NOUN	B
in	O	ADP	O
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
head	O	NOUN	B
dips	O	NOUN	I
in	O	ADP	O
the	O	DET	O
hole	O	NOUN	B
-	O	PUNCT	O
board	O	NOUN	B
test	O	NOUN	I
;(	O	ADV	O
2	O	X	O
)	O	PUNCT	O
a	O	DET	O
dose	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
reduction	O	NOUN	B
in	O	ADP	O
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
entries	O	NOUN	B
in	O	ADP	O
the	O	DET	O
white	O	ADJ	B
chamber	O	NOUN	I
in	O	ADP	O
the	O	DET	O
black	O	ADJ	B
-	O	PUNCT	O
and	O	CCONJ	O
-	O	PUNCT	O
white	O	ADJ	B
compartment	O	NOUN	O
test	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
entries	O	NOUN	B
in	O	ADP	O
the	O	DET	O
central	O	ADJ	B
platform	O	NOUN	I
and	O	CCONJ	O
open	O	ADJ	O
arms	O	NOUN	O
in	O	ADP	O
the	O	DET	O
plus	O	CCONJ	B
-	O	PUNCT	O
maze	O	NOUN	B
test	O	NOUN	O
;	O	PUNCT	O
and	O	CCONJ	O
(	O	PUNCT	O
3	O	X	O
)	O	PUNCT	O
a	O	DET	O
dose	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
increase	O	NOUN	B
in	O	ADP	O
the	O	DET	O
duration	O	NOUN	B
of	O	ADP	O
immobility	O	NOUN	B
in	O	ADP	O
the	O	DET	O
forced	O	VERB	B
-	O	PUNCT	O
swimming	O	NOUN	B
test	O	NOUN	B
and	O	CCONJ	O
tail	O	NOUN	B
suspension	O	NOUN	I
test	O	NOUN	I
.	O	PUNCT	O


Intracerebroventricular	O	NOUN	B
injection	O	NOUN	B
of	O	ADP	O
U-II	B-Chemical	NOUN	B
also	O	ADV	O
caused	O	VERB	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
:	O	PUNCT	O
food	O	NOUN	B
intake	O	NOUN	I
at	O	ADP	O
doses	O	NOUN	B
of	O	ADP	O
100	O	NUM	O
and	O	CCONJ	O
1	O	NUM	O
,	O	PUNCT	O
000	O	NUM	O
ng	O	NOUN	O
/	O	SYM	O
mouse	O	NOUN	B
,	O	PUNCT	O
water	O	NOUN	B
intake	O	NOUN	I
at	O	ADP	O
doses	O	NOUN	B
of	O	ADP	O
100	O	NUM	O
-	O	SYM	O
10	O	NUM	O
,	O	PUNCT	O
000	O	NUM	O
ng	O	NOUN	O
/	O	SYM	O
mouse	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
horizontal	O	ADJ	B
locomotion	O	NOUN	B
activity	O	NOUN	I
at	O	ADP	O
a	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
10	O	NUM	O
,	O	PUNCT	O
000	O	NUM	O
ng	O	NOUN	O
/	O	SYM	O
mouse	O	NOUN	B
.	O	PUNCT	O


Whatever	O	DET	O
was	O	AUX	O
the	O	DET	O
dose	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
central	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
U-II	B-Chemical	NOUN	B
had	O	AUX	O
no	O	DET	B
effect	O	NOUN	I
on	O	ADP	O
body	O	NOUN	B
temperature	O	NOUN	I
,	O	PUNCT	O
nociception	O	NOUN	B
,	O	PUNCT	O
apomorphine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
penile	B-Disease	ADJ	B
erection	I-Disease	NOUN	I
and	O	CCONJ	O
climbing	O	NOUN	B
behavior	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
stress	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
plasma	O	NOUN	B
corticosterone	B-Chemical	NOUN	B
level	O	NOUN	B
.	O	PUNCT	O


Taken	O	VERB	O
together	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
demonstrates	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
central	O	ADJ	B
injection	O	NOUN	I
of	O	ADP	O
U-II	B-Chemical	NOUN	B
at	O	ADP	O
doses	O	NOUN	B
of	O	ADP	O
1	O	NUM	O
-	O	SYM	O
10	O	NUM	O
,	O	PUNCT	O
000	O	NUM	O
ng	O	NOUN	O
/	O	SYM	O
mouse	O	NOUN	B
induces	O	VERB	O
anxiogenic	O	ADJ	B
-	O	PUNCT	O
and	O	CCONJ	O
depressant	O	ADJ	B
-	O	PUNCT	O
like	O	ADJ	B
effects	O	NOUN	B
in	O	ADP	O
mouse	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
U-II	B-Chemical	NOUN	B
may	O	AUX	O
be	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
some	O	DET	O
aspects	O	NOUN	O
of	O	ADP	O
psychiatric	B-Disease	ADJ	B
disorders	I-Disease	NOUN	I


Recurrent	O	ADJ	B
dysphonia	B-Disease	NOUN	I
and	O	CCONJ	O
acitretin	B-Chemical	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
the	O	DET	O
case	O	NOUN	B
of	O	ADP	O
a	O	DET	O
woman	O	NOUN	B
complaining	O	NOUN	O
of	O	ADP	O
dysphonia	B-Disease	NOUN	B
while	O	SCONJ	O
she	O	PRON	O
was	O	AUX	O
treated	O	VERB	B
by	O	ADP	O
acitretin	B-Chemical	NOUN	B
.	O	PUNCT	O


Her	O	PRON	O
symptoms	O	NOUN	B
totally	O	ADV	O
regressed	O	VERB	O
after	O	ADP	O
drug	O	NOUN	B
withdrawal	O	NOUN	I
and	O	CCONJ	O
reappeared	O	VERB	O
when	O	SCONJ	O
acitretin	B-Chemical	NOUN	B
was	O	AUX	O
reintroduced	O	VERB	O
.	O	PUNCT	O


To	O	ADP	O
our	O	PRON	O
knowledge	O	NOUN	B
,	O	PUNCT	O
this	O	DET	O
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
case	O	NOUN	B
of	O	ADP	O
acitretin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
dysphonia	B-Disease	NOUN	B


Pharmacological	O	ADJ	B
modulation	O	NOUN	O
of	O	ADP	O
pain	B-Disease	NOUN	B
-	O	PUNCT	O
related	O	ADJ	B
brain	O	NOUN	B
activity	O	NOUN	I
during	O	ADP	O
normal	O	ADJ	B
and	O	CCONJ	O
central	O	ADJ	B
sensitization	O	NOUN	I
states	O	NOUN	I
in	O	ADP	O
humans	O	NOUN	B
.	O	PUNCT	O


Abnormal	O	ADJ	B
processing	O	NOUN	B
of	O	ADP	O
somatosensory	O	ADJ	B
inputs	O	NOUN	B
in	O	ADP	O
the	O	DET	O
central	O	ADJ	B
nervous	O	ADJ	I
system	O	NOUN	I
(	O	PUNCT	O
central	O	ADJ	B
sensitization	O	NOUN	I
)	O	PUNCT	O
is	O	AUX	O
the	O	DET	O
mechanism	O	NOUN	B
accounting	O	VERB	O
for	O	ADP	O
the	O	DET	O
enhanced	O	VERB	B
pain	B-Disease	NOUN	B
sensitivity	O	NOUN	I
in	O	ADP	O
the	O	DET	O
skin	O	NOUN	B
surrounding	O	VERB	O
tissue	B-Disease	NOUN	B
injury	I-Disease	NOUN	I
(	O	PUNCT	O
secondary	B-Disease	ADJ	B
hyperalgesia	I-Disease	NOUN	I
).	O	PUNCT	O
Secondary	B-Disease	ADJ	B
hyperalgesia	I-Disease	NOUN	I
shares	O	VERB	O
clinical	O	ADJ	B
characteristics	O	NOUN	I
with	O	ADP	O
neurogenic	B-Disease	ADJ	B
hyperalgesia	I-Disease	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
neuropathic	B-Disease	ADJ	B
pain	I-Disease	NOUN	I
.	O	PUNCT	O


Abnormal	O	ADJ	B
brain	O	NOUN	B
responses	O	NOUN	I
to	O	PART	O
somatosensory	O	ADJ	B
stimuli	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
found	O	VERB	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
hyperalgesia	B-Disease	NOUN	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
in	O	ADP	O
normal	O	ADJ	B
subjects	O	NOUN	I
during	O	ADP	O
experimental	O	ADJ	B
central	O	ADJ	I
sensitization	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
gabapentin	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
drug	O	NOUN	B
effective	O	ADJ	B
in	O	ADP	O
neuropathic	B-Disease	ADJ	B
pain	I-Disease	NOUN	I
patients	O	NOUN	B
,	O	PUNCT	O
on	O	ADP	O
brain	O	NOUN	B
processing	O	NOUN	I
of	O	ADP	O
nociceptive	O	ADJ	B
information	O	NOUN	B
in	O	ADP	O
normal	O	ADJ	B
and	O	CCONJ	O
central	O	ADJ	B
sensitization	O	NOUN	I
states	O	NOUN	I
.	O	PUNCT	O


Using	O	VERB	O
functional	O	ADJ	B
magnetic	O	ADJ	B
resonance	O	NOUN	I
imaging	O	NOUN	I
(	O	PUNCT	O
fMRI	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
normal	O	ADJ	B
volunteers	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
studied	O	VERB	O
the	O	DET	O
gabapentin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
modulation	O	NOUN	B
of	O	ADP	O
brain	O	NOUN	B
activity	O	NOUN	I
in	O	ADP	O
response	O	NOUN	B
to	O	PART	O
nociceptive	O	ADJ	B
mechanical	O	ADJ	B
stimulation	O	NOUN	I
of	O	ADP	O
normal	O	ADJ	B
skin	O	NOUN	I
and	O	CCONJ	O
capsaicin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
secondary	B-Disease	ADJ	B
hyperalgesia	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
gabapentin	B-Chemical	NOUN	B
was	O	AUX	O
1	O	NUM	O
,	O	PUNCT	O
800	O	NUM	O
mg	O	NOUN	O
per	O	ADP	O
os	O	NOUN	O
,	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
single	O	ADJ	O
administration	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
found	O	VERB	O
that	O	SCONJ	O
(	O	PUNCT	O
i	O	X	O
)	O	PUNCT	O
gabapentin	B-Chemical	NOUN	B
reduced	O	VERB	B
the	O	DET	O
activations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
bilateral	O	ADJ	B
operculoinsular	O	ADJ	B
cortex	O	NOUN	I
,	O	PUNCT	O
independently	O	ADV	O
of	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
central	O	ADJ	B
sensitization	O	NOUN	I
;(	O	PUNCT	O
ii	O	X	O
)	O	PUNCT	O
gabapentin	B-Chemical	NOUN	B
reduced	O	VERB	B
the	O	DET	O
activation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
brainstem	O	NOUN	B
,	O	PUNCT	O
only	O	ADV	O
during	O	ADP	O
central	O	ADJ	B
sensitization	O	NOUN	I
;(	O	PUNCT	O
iii	O	X	O
)	O	PUNCT	O
gabapentin	B-Chemical	NOUN	B
suppressed	O	VERB	B
stimulus	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
deactivations	O	NOUN	B
,	O	PUNCT	O
only	O	ADV	O
during	O	ADP	O
central	O	ADJ	B
sensitization	O	NOUN	I
;	O	PUNCT	O
this	O	DET	O
effect	O	NOUN	B
was	O	AUX	O
more	O	ADV	O
robust	O	ADJ	B
than	O	ADP	O
the	O	DET	O
effect	O	NOUN	B
on	O	ADP	O
brain	O	NOUN	B
activation	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
observed	O	VERB	B
drug	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
effects	O	NOUN	B
were	O	AUX	O
not	O	PART	O
due	O	ADJ	O
to	O	PART	O
changes	O	NOUN	B
in	O	ADP	O
the	O	DET	O
baseline	O	NOUN	B
fMRI	O	NOUN	B
signal	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
gabapentin	B-Chemical	NOUN	B
has	O	AUX	O
a	O	DET	O
measurable	O	ADJ	O
antinociceptive	O	ADJ	B
effect	O	NOUN	O
and	O	CCONJ	O
a	O	DET	O
stronger	O	ADJ	O
antihyperalgesic	O	ADJ	B
effect	O	NOUN	I
most	O	ADV	O
evident	O	ADJ	O
in	O	ADP	O
the	O	DET	O
brain	O	NOUN	B
areas	O	NOUN	I
undergoing	O	VERB	O
deactivation	O	NOUN	B
,	O	PUNCT	O
thus	O	ADV	O
supporting	O	VERB	O
the	O	DET	O
concept	O	NOUN	B
that	O	SCONJ	O
gabapentin	B-Chemical	NOUN	B


MDMA	B-Chemical	NOUN	B
polydrug	O	NOUN	O
users	O	NOUN	O
show	O	VERB	O
process	O	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
central	O	ADJ	B
executive	O	ADJ	I
impairments	O	NOUN	I
coupled	O	VERB	O
with	O	ADP	O
impaired	B-Disease	ADJ	B
social	I-Disease	ADJ	B
and	I-Disease	CCONJ	O
emotional	I-Disease	ADJ	B
judgement	I-Disease	NOUN	B
processes	I-Disease	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
recent	O	ADJ	O
years	O	NOUN	B
working	O	VERB	B
memory	B-Disease	NOUN	I
deficits	I-Disease	NOUN	O
have	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
in	O	ADP	O
users	O	NOUN	B
of	O	ADP	O
MDMA	B-Chemical	NOUN	B
(	O	PUNCT	O
3,4-methylenedioxymethamphetamine	B-Chemical	NOUN	B
,	O	PUNCT	O
ecstasy	B-Chemical	NOUN	B
).	O	PUNCT	O
The	O	DET	O
current	O	ADJ	O
study	O	NOUN	B
aimed	O	VERB	O
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
impact	O	NOUN	B
of	O	ADP	O
MDMA	B-Chemical	NOUN	B
use	O	NOUN	O
on	O	ADP	O
three	O	NUM	O
separate	O	ADJ	O
central	O	ADJ	B
executive	O	NOUN	I
processes	O	NOUN	I
(	O	PUNCT	O
set	O	VERB	O
shifting	O	VERB	O
,	O	PUNCT	O
inhibition	O	NOUN	B
and	O	CCONJ	O
memory	O	NOUN	B
updating	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
also	O	ADV	O
on	O	ADP	O
"	O	PUNCT	O
prefrontal	O	ADJ	B
"	O	PUNCT	O
mediated	O	VERB	B
social	O	ADJ	B
and	O	CCONJ	O
emotional	O	ADJ	B
judgement	O	NOUN	B
processes	O	NOUN	O
.	O	PUNCT	O


Fifteen	O	NUM	O
polydrug	O	NOUN	B
ecstasy	B-Chemical	NOUN	O
users	O	NOUN	B
and	O	CCONJ	O
15	O	NUM	O
polydrug	O	NOUN	B
non	O	NOUN	B
-	O	PUNCT	O
ecstasy	B-Chemical	NOUN	B
user	O	NOUN	B
controls	O	NOUN	I
completed	O	VERB	O
a	O	DET	O
general	O	ADJ	B
drug	O	NOUN	I
use	O	NOUN	I
questionnaire	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
Brixton	O	PROPN	B
Spatial	O	PROPN	I
Anticipation	O	PROPN	I
task	O	NOUN	I
(	O	PUNCT	O
set	O	VERB	O
shifting	O	VERB	O
),	O	PUNCT	O
Backward	O	PROPN	B
Digit	O	PROPN	I
Span	O	PROPN	I
procedure	O	NOUN	I
(	O	PUNCT	O
memory	O	NOUN	B
updating	O	VERB	O
),	O	PUNCT	O
Inhibition	O	NOUN	B
of	O	ADP	O
Return	O	NOUN	B
(	O	PUNCT	O
inhibition	O	NOUN	B
),	O	PUNCT	O
an	O	DET	O
emotional	O	ADJ	B
intelligence	O	NOUN	I
scale	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
Tromso	O	PROPN	B
Social	O	PROPN	I
Intelligence	O	PROPN	I
Scale	O	PROPN	I
and	O	CCONJ	O
the	O	DET	O
Dysexecutive	O	PROPN	B
Questionnaire	O	PROPN	I
(	O	PUNCT	O
DEX	O	NOUN	B
).	O	PUNCT	O
Compared	O	VERB	O
with	O	ADP	O
MDMA	B-Chemical	NOUN	B
-	O	PUNCT	O
free	O	ADJ	B
polydrug	O	NOUN	B
controls	O	NOUN	I
,	O	PUNCT	O
MDMA	B-Chemical	NOUN	B
polydrug	O	NOUN	I
users	O	NOUN	I
showed	O	VERB	O
impairments	O	NOUN	B
in	O	ADP	O
set	O	VERB	O
shifting	O	VERB	O
and	O	CCONJ	O
memory	O	NOUN	B
updating	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
also	O	ADV	O
in	O	ADP	O
social	O	ADJ	B
and	O	CCONJ	O
emotional	O	ADJ	B
judgement	O	NOUN	B
processes	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
latter	O	ADJ	O
two	O	NUM	O
deficits	O	NOUN	B
remained	O	VERB	O
significant	O	ADJ	O
after	O	ADP	O
controlling	O	VERB	B
for	O	ADP	O
other	O	ADJ	O
drug	O	NOUN	B
use	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
lend	O	VERB	O
further	O	ADJ	O
support	O	NOUN	O
to	O	ADP	O
the	O	DET	O
proposal	O	NOUN	B
that	O	SCONJ	O
cognitive	O	ADJ	B
processes	O	NOUN	I
mediated	O	VERB	O
by	O	ADP	O
the	O	DET	O
prefrontal	O	ADJ	B
cortex	O	NOUN	I
may	O	AUX	O
be	O	AUX	O
impaired	O	VERB	B
by	O	ADP	O
recreational	O	ADJ	B
ecstasy	B-Chemical	NOUN	B


Severe	O	ADJ	B
citrate	B-Chemical	NOUN	B
toxicity	B-Disease	NOUN	B
complicating	O	VERB	O
volunteer	O	NOUN	B
apheresis	O	NOUN	B
platelet	O	NOUN	B
donation	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
severe	O	ADJ	B
citrate	B-Chemical	NOUN	B
toxicity	B-Disease	NOUN	B
during	O	ADP	O
volunteer	O	NOUN	B
donor	O	NOUN	B
apheresis	O	NOUN	I
platelet	O	NOUN	B
collection	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
donor	O	NOUN	B
was	O	AUX	O
a	O	DET	O
40	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
female	O	NOUN	B
,	O	PUNCT	O
first	O	ADJ	B
-	O	PUNCT	O
time	O	NOUN	B
apheresis	O	NOUN	B
platelet	O	NOUN	B
donor	O	NOUN	I
.	O	PUNCT	O


Past	O	ADJ	B
medical	O	ADJ	B
history	O	NOUN	I
was	O	AUX	O
remarkable	O	ADJ	O
for	O	ADP	O
hypertension	B-Disease	NOUN	B
,	O	PUNCT	O
hyperlipidemia	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
depression	B-Disease	NOUN	B
.	O	PUNCT	O


Reported	O	ADJ	O
medications	O	NOUN	B
included	O	VERB	O
bumetanide	B-Chemical	NOUN	B
,	O	PUNCT	O
pravastatin	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
paroxetine	B-Chemical	NOUN	B
.	O	PUNCT	O


Thirty	O	NUM	O
minutes	O	NOUN	O
from	O	ADP	O
the	O	DET	O
start	O	NOUN	O
of	O	ADP	O
the	O	DET	O
procedure	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
donor	O	NOUN	B
noted	O	VERB	O
tingling	O	VERB	B
around	O	ADP	O
the	O	DET	O
mouth	O	NOUN	B
,	O	PUNCT	O
hands	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
feet	O	NOUN	B
.	O	PUNCT	O


She	O	PRON	O
then	O	ADV	O
very	O	ADV	O
rapidly	O	ADV	O
developed	O	VERB	O
acute	O	ADJ	B
onset	O	NOUN	O
of	O	ADP	O
severe	O	ADJ	B
facial	O	ADJ	B
and	O	CCONJ	O
extremity	O	NOUN	B
tetany	B-Disease	NOUN	I
.	O	PUNCT	O


Empirical	O	ADJ	B
treatment	O	NOUN	I
with	O	ADP	O
intravenous	O	ADJ	B
calcium	B-Chemical	NOUN	O
gluconate	I-Chemical	NOUN	O
was	O	AUX	O
initiated	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
muscle	B-Disease	NOUN	B
contractions	I-Disease	NOUN	I
slowly	O	ADV	O
subsided	O	VERB	O
over	O	ADP	O
approximately	O	ADV	O
10	O	NUM	O
to	O	PART	O
15	O	NUM	O
minutes	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
events	O	NOUN	B
are	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
a	O	DET	O
severe	O	ADJ	B
reaction	O	NOUN	B
to	O	PART	O
calcium	B-Chemical	NOUN	B
chelation	O	NOUN	I
by	O	ADP	O
sodium	B-Chemical	NOUN	B
citrate	I-Chemical	NOUN	I
anticoagulant	O	NOUN	I
resulting	O	VERB	O
in	O	ADP	O
symptomatic	O	ADJ	B
systemic	O	ADJ	B
hypocalcemia	B-Disease	NOUN	I
.	O	PUNCT	O


Upon	O	SCONJ	O
additional	O	ADJ	O
retrospective	O	ADJ	B
analysis	O	NOUN	I
,	O	PUNCT	O
it	O	PRON	O
was	O	AUX	O
noted	O	VERB	O
that	O	SCONJ	O
bumetanide	B-Chemical	NOUN	B
is	O	AUX	O
a	O	DET	O
loop	B-Chemical	NOUN	B
diuretic	I-Chemical	ADJ	B
that	O	PRON	O
may	O	AUX	O
cause	O	VERB	O
significant	O	ADJ	O
hypocalcemia	B-Disease	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
careful	O	ADJ	O
screening	O	NOUN	B
for	O	ADP	O
medications	O	NOUN	B
and	O	CCONJ	O
underlying	O	VERB	O
conditions	O	NOUN	B
predisposing	O	VERB	B
to	O	PART	O
hypocalcemia	B-Disease	NOUN	B
is	O	AUX	O
recommended	O	VERB	O
to	O	PART	O
help	O	VERB	O
prevent	O	VERB	B
severe	O	ADJ	B
reactions	O	NOUN	O
due	O	ADJ	O
to	O	PART	O
citrate	B-Chemical	NOUN	B
toxicity	B-Disease	NOUN	B
.	O	PUNCT	O


Laboratory	O	ADJ	B
measurement	O	NOUN	I
of	O	ADP	O
pre	O	ADJ	B
-	O	PUNCT	O
procedure	O	NOUN	B
serum	O	NOUN	B
calcium	B-Chemical	NOUN	I


Proteinuria	B-Disease	NOUN	B
after	O	ADP	O
conversion	O	NOUN	B
to	O	PART	O
sirolimus	B-Chemical	NOUN	B
in	O	ADP	O
renal	O	ADJ	B
transplant	O	NOUN	I
recipients	O	NOUN	B
.	O	PUNCT	O


Sirolimus	B-Chemical	NOUN	B
(	O	PUNCT	O
SRL	B-Chemical	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
new	O	ADJ	O
,	O	PUNCT	O
potent	O	ADJ	O
immunosuppressive	O	ADJ	B
agent	O	NOUN	I
.	O	PUNCT	O


More	O	ADV	O
recently	O	ADV	O
,	O	PUNCT	O
proteinuria	B-Disease	NOUN	B
has	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
as	O	ADP	O
a	O	DET	O
consequence	O	NOUN	B
of	O	ADP	I
sirolimus	B-Chemical	NOUN	B
therapy	O	NOUN	I
,	O	PUNCT	O
although	O	SCONJ	O
the	O	DET	O
mechanism	O	NOUN	B
has	O	AUX	O
remained	O	VERB	O
unclear	O	ADJ	B
.	O	PUNCT	O


We	O	PRON	O
retrospectively	O	ADV	B
examined	O	VERB	O
the	O	DET	O
records	O	NOUN	B
of	O	ADP	O
25	O	NUM	O
renal	O	ADJ	B
transplant	O	NOUN	I
patients	O	NOUN	B
,	O	PUNCT	O
who	O	PRON	O
developed	O	VERB	O
or	O	CCONJ	O
displayed	O	VERB	O
increased	O	VERB	B
proteinuria	B-Disease	NOUN	B
after	O	ADP	O
SRL	B-Chemical	NOUN	B
conversion	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
cohort	O	NOUN	I
(	O	PUNCT	O
14	O	NUM	O
men	O	NOUN	B
,	O	PUNCT	O
11	O	NUM	O
women	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
SRL	B-Chemical	NOUN	B
as	O	ADP	O
conversion	O	NOUN	B
therapy	O	NOUN	I
,	O	PUNCT	O
due	O	ADP	O
to	O	PART	O
chronic	B-Disease	ADJ	B
allograft	I-Disease	NOUN	I
nephropathy	I-Disease	NOUN	I
(	O	PUNCT	O
CAN	B-Disease	NOUN	B
)(	O	NOUN	O
n	O	NOUN	O
=	O	ADJ	O
15	O	NUM	O
)	O	PUNCT	O
neoplasia	B-Disease	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
8	O	NUM	O
);	O	ADJ	B
Kaposi's	B-Disease	NOUN	B
sarcoma	I-Disease	NOUN	I
,	O	PUNCT	O
Four	O	NUM	O
skin	B-Disease	NOUN	B
cancers	I-Disease	NOUN	I
,	O	PUNCT	O
One	O	NUM	O
intestinal	B-Disease	ADJ	B
tumors	I-Disease	NOUN	I
,	O	PUNCT	O
One	O	NUM	O
renal	B-Disease	ADJ	B
cell	I-Disease	NOUN	I
carsinom	I-Disease	NOUN	I
)	O	PUNCT	O
or	O	CCONJ	O
BK	O	NOUN	B
virus	O	NOUN	I
nephropathy	B-Disease	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
2	O	NUM	O
).	O	PUNCT	O
SRL	B-Chemical	PROPN	B
was	O	AUX	O
started	O	VERB	O
at	O	ADP	O
a	O	DET	O
mean	O	NOUN	O
of	O	ADP	O
78	O	NUM	O
+/-	O	CCONJ	O
42	O	NUM	O
(	O	PUNCT	O
15	O	NUM	O
to	O	PART	O
163	O	NUM	O
)	O	PUNCT	O
months	O	NOUN	B
after	O	ADP	O
transplantation	O	NOUN	B
.	O	PUNCT	O


Mean	O	VERB	O
follow	O	NOUN	B
-	O	PUNCT	O
up	O	NOUN	O
on	O	ADP	O
SRL	B-Chemical	NOUN	B
therapy	O	NOUN	B
was	O	AUX	O
20	O	NUM	O
+/-	O	CCONJ	O
12	O	NUM	O
(	O	PUNCT	O
6	O	NUM	O
to	O	PART	O
43	O	NUM	O
)	O	PUNCT	O
months	O	NOUN	B
.	O	PUNCT	O


Proteinuria	B-Disease	NOUN	B
increased	O	VERB	B
from	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


445	O	NUM	O
(	O	PUNCT	O
0	O	NUM	O
to	O	PART	O
1	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
)	O	PUNCT	O
g	O	NOUN	B
/	O	SYM	O
d	O	NOUN	O
before	O	ADP	O
conversion	O	NOUN	B
to	O	PART	O
3	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
g	O	NOUN	B
/	O	SYM	O
dL	O	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
to	O	PART	O
12	O	NUM	O
)	O	PUNCT	O
after	O	ADP	O
conversion	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
).	O	PUNCT	O
Before	O	ADP	O
conversion	O	NOUN	B
8	O	NUM	O
(	O	PUNCT	O
32	O	NUM	O
%)	O	NOUN	O
patients	O	NOUN	B
had	O	AUX	O
no	O	DET	O
proteinuria	B-Disease	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
afterwards	O	ADV	O
all	O	DET	O
patients	O	NOUN	B
had	O	AUX	O
proteinuria	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
28	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
proteinuria	B-Disease	NOUN	B
remained	O	VERB	O
unchanged	O	ADJ	B
,	O	PUNCT	O
whereas	O	SCONJ	O
it	O	PRON	O
increased	O	VERB	B
in	O	ADP	O
68	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
40	O	NUM	O
%	O	NOUN	O
it	O	PRON	O
increased	O	VERB	B
by	O	ADP	O
more	O	ADJ	O
than	O	ADP	O
100	O	NUM	O
%.	O	NOUN	O
Twenty	O	NUM	B
-	O	PUNCT	O
eight	O	NUM	O
percent	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
showed	O	VERB	O
increased	O	VERB	B
proteinuria	B-Disease	NOUN	B
to	O	PART	O
the	O	DET	O
nephrotic	B-Disease	ADJ	B
range	O	NOUN	O
.	O	PUNCT	O


Biopsies	O	NOUN	B
performed	O	VERB	B
in	O	ADP	O
five	O	NUM	O
patients	O	NOUN	B
revealed	O	VERB	O
new	O	ADJ	O
pathological	O	ADJ	B
changes	O	NOUN	B
:	O	PUNCT	O
One	O	NUM	O
membranoproliferative	B-Disease	NOUN	B
glomerulopathy	I-Disease	NOUN	I
and	O	CCONJ	O
interstitial	B-Disease	ADJ	B
nephritis	I-Disease	NOUN	I
.	O	PUNCT	O


These	O	DET	O
patients	O	NOUN	B
showed	O	VERB	O
persistently	O	ADV	B
good	O	ADJ	O
graft	O	NOUN	B
function	O	NOUN	I
.	O	PUNCT	O


Serum	O	NOUN	B
creatinine	B-Chemical	NOUN	I
values	O	NOUN	I
did	O	AUX	O
not	O	PART	O
change	O	VERB	O
significantly	O	ADV	B
:	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


98	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
dL	O	NOUN	B
before	O	ADP	O
SRL	B-Chemical	NOUN	B
therapy	O	NOUN	B
and	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O


53	O	NUM	O
+/-	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
dL	O	NOUN	B
at	O	ADP	O
last	O	ADJ	O
follow	O	NOUN	B
-	O	PUNCT	O
up	O	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
=.	O	NOUN	O
14	O	NUM	O
).	O	PUNCT	O
Five	O	NUM	O
grafts	O	NOUN	B
were	O	AUX	O
lost	O	VERB	B
and	O	CCONJ	O
the	O	DET	O
patients	O	NOUN	B
returned	O	VERB	O
to	O	ADP	O
dialysis	O	NOUN	B
.	O	PUNCT	O


Five	O	NUM	O
patients	O	NOUN	B
displayed	O	VERB	O
CAN	B-Disease	NOUN	B
and	O	CCONJ	O
Kaposi's	B-Disease	NOUN	B
sarcoma	I-Disease	NOUN	I
.	O	PUNCT	O


Mean	O	VERB	B
urinary	O	ADJ	I
protein	O	NOUN	I
of	O	ADP	O
patients	O	NOUN	B
who	O	PRON	O
returned	O	VERB	O
to	O	ADP	O
dialysis	O	NOUN	B
was	O	AUX	O
1	O	NUM	O
.	O	PUNCT	O


26	O	NUM	O
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
to	O	PART	O
3	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
)	O	PUNCT	O
g	O	NOUN	B
/	O	SYM	O
d	O	NOUN	O
before	O	ADP	B
and	O	CCONJ	O
4	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
(	O	PUNCT	O
3	O	NUM	O
to	O	PART	O
12	O	NUM	O
)	O	PUNCT	O
g	O	NOUN	B
/	O	SYM	O
d	O	X	O
after	O	ADP	O
conversion	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=.	O	NOUN	O
01	O	NUM	O
).	O	PUNCT	O
Mean	O	ADJ	O
serum	O	NOUN	O
creatinine	B-Chemical	NOUN	O
level	O	NOUN	O
before	O	ADP	O
conversion	O	NOUN	B
was	O	AUX	O
2	O	NUM	O
.	O	PUNCT	O


21	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
dL	O	NOUN	B
and	O	CCONJ	O
thereafter	O	ADV	O
,	O	PUNCT	O
4	O	NUM	O
.	O	PUNCT	O


93	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
dL	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=.	O	NOUN	O
02	O	NUM	O
).	O	PUNCT	O
Heavy	O	ADJ	B
proteinuria	B-Disease	NOUN	I
was	O	AUX	O
common	O	ADJ	O
after	O	ADP	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
SRL	B-Chemical	PROPN	B
as	O	ADP	O
rescue	O	NOUN	B
therapy	O	NOUN	I
for	O	ADP	O
renal	O	ADJ	B
transplantation	O	NOUN	I
.	O	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
conversion	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
considered	O	VERB	O
for	O	ADP	O
patients	O	NOUN	B
who	O	PRON	O
have	O	AUX	O
not	O	PART	O
developed	O	VERB	O
advanced	O	ADJ	B
CAN	B-Disease	NOUN	B
and	O	CCONJ	O
proteinuria	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
possibility	O	NOUN	O
of	O	ADP	O
de	O	X	O
novo	O	X	O
glomerular	O	ADJ	B
pathology	O	NOUN	B
under	O	ADP	O
SRL	B-Chemical	PROPN	B


In	O	X	B
vitro	O	X	I
characterization	O	NOUN	B
of	O	ADP	O
parasympathetic	O	ADJ	B
and	O	CCONJ	O
sympathetic	O	ADJ	B
responses	O	NOUN	I
in	O	ADP	O
cyclophosphamide	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cystitis	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
cyclophosphamide	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cystitis	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
,	O	PUNCT	O
detrusor	O	NOUN	B
function	O	NOUN	I
is	O	AUX	O
impaired	O	ADJ	B
and	O	CCONJ	O
the	O	DET	O
expression	O	NOUN	B
and	O	CCONJ	O
effects	O	NOUN	B
of	O	ADP	O
muscarinic	O	ADJ	B
receptors	O	NOUN	I
altered	O	VERB	O
.	O	PUNCT	O


Whether	O	SCONJ	O
or	O	CCONJ	O
not	O	PART	O
the	O	DET	O
neuronal	O	ADJ	B
transmission	O	NOUN	O
may	O	AUX	O
be	O	AUX	O
affected	O	VERB	B
by	O	ADP	O
cystitis	B-Disease	NOUN	B
was	O	AUX	O
presently	O	ADV	O
investigated	O	VERB	B
.	O	PUNCT	O


Responses	O	NOUN	B
of	O	ADP	O
urinary	O	ADJ	B
strip	O	NOUN	I
preparations	O	NOUN	O
from	O	ADP	O
control	O	NOUN	B
and	O	CCONJ	O
cyclophosphamide	B-Chemical	NOUN	B
-	O	PUNCT	O
pretreated	O	VERB	B
rats	O	NOUN	B
to	O	PART	O
electrical	O	ADJ	B
field	O	NOUN	I
stimulation	O	NOUN	I
and	O	CCONJ	O
to	O	PART	O
agonists	O	NOUN	B
were	O	AUX	O
assessed	O	VERB	B
in	O	ADP	O
the	O	DET	O
absence	O	NOUN	B
and	O	CCONJ	O
presence	O	NOUN	B
of	O	ADP	O
muscarinic	O	ADJ	B
,	O	PUNCT	O
adrenergic	O	ADJ	B
and	O	CCONJ	O
purinergic	O	ADJ	B
receptor	O	NOUN	I
antagonists	O	NOUN	I
.	O	PUNCT	O


Generally	O	ADV	O
,	O	PUNCT	O
atropine	B-Chemical	NOUN	B
reduced	O	VERB	B
contractions	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
in	O	ADP	O
contrast	O	NOUN	O
to	O	PART	O
controls	O	NOUN	B
,	O	PUNCT	O
it	O	PRON	O
also	O	ADV	O
reduced	O	VERB	B
responses	O	NOUN	B
to	O	PART	O
low	O	ADJ	B
electrical	O	ADJ	B
field	O	NOUN	I
stimulation	O	NOUN	I
intensity	O	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
-	O	PUNCT	O
5	O	NUM	O
Hz	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
inflamed	O	ADJ	B
preparations	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
both	O	DET	O
types	O	NOUN	O
,	O	PUNCT	O
purinoceptor	O	NOUN	B
desensitization	O	NOUN	I
with	O	ADP	O
alpha,beta-methylene	B-Chemical	NOUN	B
adenosine-5'-triphosphate	I-Chemical	NOUN	I
(	O	PUNCT	O
alpha,beta-meATP	B-Chemical	NOUN	B
)	O	PUNCT	O
caused	O	VERB	O
further	O	ADJ	O
reductions	O	NOUN	B
at	O	ADP	O
low	O	ADJ	B
frequencies	O	NOUN	B
(<	O	NOUN	O
10	O	NUM	O
Hz	O	NOUN	O
).	O	PUNCT	O
The	O	DET	O
muscarinic	O	ADJ	B
receptor	O	NOUN	I
antagonists	O	NOUN	I
atropine	B-Chemical	NOUN	B
,	O	PUNCT	O
4-diphenylacetoxy-N-methylpiperidine	B-Chemical	NOUN	B
(	O	PUNCT	O
4-DAMP	B-Chemical	NOUN	B
)('	O	PUNCT	O
M	O	NOUN	O
(	O	PUNCT	O
1	O	NUM	O
)/	O	PROPN	B
M	O	NOUN	I
(	O	PUNCT	O
3	O	NUM	O
)/	O	NUM	B
M	O	NOUN	I
(	O	PUNCT	O
5	O	NUM	O
)-	O	ADJ	O
selective	O	ADJ	O
'),	O	NOUN	O
methoctramine	B-Chemical	NOUN	O
('	O	PUNCT	O
M	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)-	O	ADJ	O
selective	O	ADJ	O
')	O	NOUN	B
and	O	CCONJ	O
pirenzepine	B-Chemical	NOUN	B
('	O	PROPN	O
M	O	NOUN	O
(	O	PUNCT	O
1	O	NUM	O
)-	O	ADJ	O
selective	O	ADJ	O
')	O	NOUN	O
antagonized	O	VERB	B
the	O	DET	O
tonic	O	ADJ	B
component	O	NOUN	B
of	O	ADP	O
the	O	DET	O
electrical	O	ADJ	B
field	O	NOUN	I
stimulation	O	NOUN	I
-	O	PUNCT	O
evoked	O	VERB	B
contractile	O	ADJ	B
response	O	NOUN	I
more	O	ADV	O
potently	O	ADV	O
than	O	ADP	O
the	O	DET	O
phasic	O	ADJ	B
component	O	NOUN	B
.	O	PUNCT	O


4-DAMP	B-Chemical	NOUN	B
inhibited	O	VERB	B
the	O	DET	O
tonic	O	ADJ	B
contractions	O	NOUN	B
in	O	ADP	O
controls	O	NOUN	B
more	O	ADV	O
potently	O	ADV	O
than	O	ADP	O
methoctramine	B-Chemical	NOUN	B
and	O	CCONJ	O
pirenzepine	B-Chemical	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
inflamed	O	ADJ	B
preparations	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
muscarinic	O	NOUN	B
receptor	O	NOUN	I
antagonism	O	NOUN	B
on	O	ADP	O
the	O	DET	O
phasic	O	ADJ	B
component	O	NOUN	B
of	O	ADP	O
the	O	DET	O
electrical	O	ADJ	B
field	O	NOUN	I
stimulation	O	NOUN	I
-	O	PUNCT	O
evoked	O	VERB	B
contraction	O	NOUN	B
was	O	AUX	O
decreased	O	VERB	B
and	O	CCONJ	O
the	O	DET	O
pirenzepine	B-Chemical	NOUN	B
and	O	CCONJ	O
4-DAMP	B-Chemical	NOUN	B
antagonism	O	NOUN	B
on	O	ADP	O
the	O	DET	O
tonic	O	ADJ	B
component	O	NOUN	I
was	O	AUX	O
much	O	ADV	O
less	O	ADV	O
efficient	O	ADJ	B
than	O	ADP	O
in	O	ADP	O
controls	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
to	O	PART	O
controls	O	NOUN	B
,	O	PUNCT	O
methoctramine	B-Chemical	NOUN	B
increased	O	VERB	B
--	O	PUNCT	O
instead	O	ADV	O
of	O	ADP	O
decreased	O	VERB	B
--	O	PUNCT	O
the	O	DET	O
tonic	O	ADJ	B
responses	O	NOUN	I
at	O	ADP	O
high	O	ADJ	O
frequencies	O	NOUN	B
.	O	PUNCT	O


While	O	SCONJ	O
contractions	O	NOUN	B
to	O	PART	O
carbachol	B-Chemical	NOUN	B
and	O	CCONJ	O
ATP	B-Chemical	NOUN	B
were	O	AUX	O
the	O	DET	O
same	O	ADJ	O
in	O	ADP	O
inflamed	O	ADJ	B
and	O	CCONJ	O
in	O	ADP	O
control	O	NOUN	B
strips	O	NOUN	I
when	O	SCONJ	O
related	O	VERB	O
to	O	PART	O
a	O	DET	O
reference	O	NOUN	O
potassium	B-Chemical	NOUN	B
response	O	NOUN	I
,	O	PUNCT	O
isoprenaline	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
relaxations	O	NOUN	B
were	O	AUX	O
smaller	O	ADJ	O
in	O	ADP	O
inflamed	O	ADJ	B
strips	O	NOUN	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
in	O	ADP	O
cystitis	B-Disease	NOUN	B


Associations	O	NOUN	B
between	O	ADP	O
use	O	NOUN	O
of	O	ADP	O
benzodiazepines	B-Chemical	NOUN	B
or	O	CCONJ	O
related	O	ADJ	O
drugs	O	NOUN	B
and	O	CCONJ	O
health	O	NOUN	B
,	O	PUNCT	O
physical	O	ADJ	B
abilities	O	NOUN	I
and	O	CCONJ	O
cognitive	O	ADJ	B
function	O	NOUN	I
:	O	PUNCT	O
a	O	DET	O
non	O	ADV	B
-	O	PUNCT	O
randomised	O	VERB	B
clinical	O	ADJ	B
study	O	NOUN	I
in	O	ADP	O
the	O	DET	O
elderly	O	ADJ	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	B
:	O	PUNCT	O
To	O	PART	O
describe	O	VERB	O
associations	O	NOUN	B
between	O	ADP	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
benzodiazepines	B-Chemical	NOUN	B
or	O	CCONJ	O
related	O	ADJ	O
drugs	O	NOUN	B
(	O	PUNCT	O
BZDs	B-Chemical	NOUN	B
/	O	SYM	O
RDs	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
health	O	NOUN	B
,	O	PUNCT	O
functional	O	ADJ	B
abilities	O	NOUN	I
and	O	CCONJ	O
cognitive	O	ADJ	B
function	O	NOUN	I
in	O	ADP	O
the	O	DET	O
elderly	O	ADJ	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
A	O	DET	O
non	O	ADV	B
-	O	PUNCT	O
randomised	O	VERB	B
clinical	O	ADJ	B
study	O	NOUN	I
of	O	ADP	O
patients	O	NOUN	B
aged	O	ADJ	B
>	O	X	O
or	O	CCONJ	O
=	O	ADJ	O
65	O	NUM	O
years	O	NOUN	B
admitted	O	VERB	B
to	O	ADP	I
acute	O	ADJ	B
hospital	O	NOUN	I
wards	O	NOUN	I
during	O	ADP	O
1	O	NUM	O
month	O	NOUN	B
.	O	PUNCT	O


164	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
mean	O	ADJ	O
age	O	NOUN	B
+/-	O	CCONJ	O
standard	O	ADJ	B
deviation	O	NOUN	I
[	O	PUNCT	O
SD	O	NOUN	B
]	O	PUNCT	O
81	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
+/-	O	CCONJ	O
6	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
years	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
admitted	O	VERB	B
.	O	PUNCT	O


Of	O	ADP	O
these	O	DET	O
,	O	PUNCT	O
nearly	O	ADV	O
half	O	NOUN	O
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
78	O	NUM	O
)	O	PUNCT	O
had	O	AUX	O
used	O	VERB	O
BZDs	B-Chemical	PROPN	B
/	O	SYM	O
RDs	O	NOUN	B
before	O	ADP	O
admission	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
remainder	O	NOUN	O
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
86	O	NUM	O
)	O	PUNCT	O
were	O	AUX	O
non	O	ADJ	B
-	O	PUNCT	O
users	O	NOUN	B
.	O	PUNCT	O


Cognitive	O	ADJ	B
ability	O	NOUN	I
was	O	AUX	O
assessed	O	VERB	B
by	O	ADP	O
the	O	DET	O
Mini	O	PROPN	B
-	O	PUNCT	O
Mental	O	PROPN	B
State	O	PROPN	I
Examination	O	PROPN	I
(	O	PUNCT	O
MMSE	O	PROPN	B
).	O	PUNCT	O
Patients	O	NOUN	B
scoring	O	VERB	I
>	O	X	O
or	O	CCONJ	O
=	O	ADJ	O
20	O	NUM	O
MMSE	O	NOUN	B
sum	O	NOUN	O
points	O	NOUN	O
were	O	AUX	O
interviewed	O	VERB	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
79	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
questioned	O	VERB	O
regarding	O	VERB	O
symptoms	O	NOUN	B
and	O	CCONJ	O
functional	O	ADJ	B
abilities	O	NOUN	O
during	O	ADP	O
the	O	DET	O
week	O	NOUN	B
prior	O	ADV	O
to	O	ADP	O
admission	O	NOUN	B
.	O	PUNCT	O


Data	O	NOUN	B
on	O	ADP	O
use	O	NOUN	O
of	O	ADP	O
BZDs	B-Chemical	NOUN	B
/	O	SYM	O
RDs	O	NOUN	B
before	O	ADP	O
admission	O	NOUN	B
,	O	PUNCT	O
current	O	ADJ	O
medications	O	NOUN	B
and	O	CCONJ	O
discharge	O	NOUN	B
diagnoses	O	NOUN	I
were	O	AUX	O
collected	O	VERB	O
from	O	ADP	O
medical	O	ADJ	B
records	O	NOUN	I
.	O	PUNCT	O


Health	O	PROPN	B
,	O	PUNCT	O
physical	O	ADJ	B
abilities	O	NOUN	I
and	O	CCONJ	O
cognitive	O	ADJ	B
function	O	NOUN	I
were	O	AUX	O
compared	O	VERB	O
between	O	ADP	O
BZD	O	PROPN	B
/	O	SYM	O
RD	O	PROPN	B
users	O	NOUN	B
and	O	CCONJ	O
non	O	ADJ	B
-	O	PUNCT	O
users	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
adjustments	O	NOUN	B
were	O	AUX	O
made	O	VERB	O
for	O	ADP	O
confounding	O	NOUN	B
variables	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
residual	O	ADJ	B
serum	O	NOUN	B
concentrations	O	NOUN	B
of	O	ADP	O
oxazepam	B-Chemical	NOUN	B
,	O	PUNCT	O
temazepam	B-Chemical	NOUN	B
and	O	CCONJ	O
zopiclone	B-Chemical	NOUN	B
were	O	AUX	O
analysed	O	VERB	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
mean	O	NOUN	O
+/-	O	CCONJ	O
SD	O	NOUN	B
duration	O	NOUN	B
of	O	ADP	O
BZD	O	PROPN	B
/	O	SYM	O
RD	O	PROPN	B
use	O	NOUN	O
was	O	AUX	O
7	O	NUM	O
+/-	O	CCONJ	O
7	O	NUM	O
years	O	NOUN	B
(	O	PUNCT	O
range	O	NOUN	O
1	O	NUM	O
-	O	SYM	O
31	O	NUM	O
).	O	PUNCT	O
Two	O	NUM	O
or	O	CCONJ	O
three	O	NUM	O
BZDs	B-Chemical	NOUN	B
/	O	SYM	O
RDs	O	NOUN	B
were	O	AUX	O
concomitantly	O	ADV	O
taken	O	VERB	O
by	O	ADP	O
26	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
users	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
20	O	NUM	O
).	O	PUNCT	O
Long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
use	O	NOUN	O
of	O	ADP	O
these	O	DET	O
drugs	O	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
female	O	ADJ	B
sex	O	NOUN	B
and	O	CCONJ	O
use	O	NOUN	O
of	O	ADP	O
a	O	DET	O
higher	O	ADJ	O
number	O	NOUN	O
of	O	ADP	O
drugs	O	NOUN	B
with	O	ADP	O
effects	O	NOUN	B
on	O	ADP	O
the	O	DET	O
CNS	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
tended	O	VERB	O
to	O	PART	O
be	O	AUX	O
related	O	ADJ	O
to	O	PART	O
diagnosed	O	VERB	B
dementia	B-Disease	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
adjustment	O	NOUN	B
for	O	ADP	O
these	O	DET	O
variables	O	NOUN	B
as	O	ADP	O
confounders	O	NOUN	B
,	O	PUNCT	O
use	O	NOUN	O
of	O	ADP	O
BZDs	B-Chemical	NOUN	B
/	O	SYM	O
RDs	O	NOUN	B
was	O	AUX	O
not	O	PART	O
associated	O	VERB	B
with	O	ADP	I
cognitive	O	ADJ	B
function	O	NOUN	I
as	O	ADP	O
measured	O	VERB	B
by	O	ADP	O
the	O	DET	O
MMSE	O	PROPN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
use	O	NOUN	O
of	O	ADP	O
BZDs	B-Chemical	NOUN	B
/	O	SYM	O
RDs	O	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
dizziness	B-Disease	NOUN	B
,	O	PUNCT	O
inability	B-Disease	NOUN	O
to	I-Disease	PART	O
sleep	I-Disease	VERB	B
after	O	ADP	O
awaking	O	VERB	B
at	O	ADP	O
night	O	NOUN	B
and	O	CCONJ	O
tiredness	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
mornings	O	NOUN	B
during	O	ADP	O
the	O	DET	O
week	O	NOUN	B
prior	O	ADV	O
to	O	ADP	O
admission	O	NOUN	B
and	O	CCONJ	O
with	O	ADP	O
stronger	O	ADJ	B
depressive	B-Disease	ADJ	B
symptoms	I-Disease	NOUN	I
measured	O	VERB	B
at	O	ADP	O
the	O	DET	O
beginning	O	NOUN	O
of	O	ADP	O
the	O	DET	O
hospital	O	NOUN	B
stay	O	NOUN	I
.	O	PUNCT	O


Use	O	PROPN	O
of	O	ADP	O
BZDs	B-Chemical	PROPN	B
/	O	PUNCT	O
RDs	O	NOUN	B
tended	O	VERB	O
to	O	PART	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
reduced	O	VERB	B
ability	O	NOUN	O
to	O	PART	O
walk	O	VERB	B
and	O	CCONJ	O
shorter	O	ADJ	B
night	O	NOUN	B
-	O	PUNCT	O
time	O	NOUN	B
sleep	O	NOUN	O
during	O	ADP	O
the	O	DET	O
week	O	NOUN	B
prior	O	ADV	O
to	O	ADP	O
admission	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
higher	O	ADJ	O
residual	O	ADJ	B
serum	O	NOUN	B
concentration	O	NOUN	B
of	O	ADP	O
temazepam	B-Chemical	NOUN	B


Acute	O	ADJ	B
vocal	B-Disease	ADJ	O
fold	I-Disease	ADJ	O
palsy	I-Disease	NOUN	B
after	O	ADP	O
acute	O	ADJ	B
disulfiram	B-Chemical	NOUN	B
intoxication	O	NOUN	B
.	O	PUNCT	O


Acute	O	ADJ	B
peripheral	B-Disease	ADJ	I
neuropathy	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
a	O	DET	O
disulfiram	B-Chemical	NOUN	B
overdose	B-Disease	NOUN	B
is	O	AUX	O
very	O	ADV	O
rare	O	ADJ	B
and	O	CCONJ	O
there	O	PRON	O
is	O	AUX	O
no	O	DET	O
report	O	NOUN	O
of	O	ADP	O
it	O	PRON	O
leading	O	VERB	O
to	O	PART	O
vocal	B-Disease	ADJ	B
fold	I-Disease	ADJ	I
palsy	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
49	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
woman	O	NOUN	B
was	O	AUX	O
transferred	O	VERB	B
to	O	ADP	O
our	O	PRON	O
department	O	NOUN	B
because	O	SCONJ	O
of	O	ADP	O
quadriparesis	B-Disease	NOUN	B
,	O	PUNCT	O
lancinating	O	VERB	B
pain	B-Disease	NOUN	I
,	O	PUNCT	O
sensory	B-Disease	ADJ	B
loss	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
paresthesia	B-Disease	NOUN	B
of	O	ADP	O
the	O	DET	O
distal	O	ADJ	B
limbs	O	NOUN	I
.	O	PUNCT	O


One	O	NUM	O
month	O	NOUN	B
previously	O	ADV	O
,	O	PUNCT	O
she	O	PRON	O
had	O	AUX	O
taken	O	VERB	O
a	O	DET	O
single	O	ADJ	O
high	O	ADJ	O
dose	O	NOUN	B
of	O	ADP	O
disulfiram	B-Chemical	NOUN	B
(	O	PUNCT	O
130	O	NUM	O
tablets	O	NOUN	B
of	O	ADP	O
ALCOHOL	B-Chemical	NOUN	B
STOP	O	NOUN	I
TAB	O	NOUN	I
,	O	PUNCT	O
Shin	O	PROPN	B
-	O	PUNCT	O
Poong	O	PROPN	B
Pharm	O	PROPN	I
.	O	PUNCT	O


Co	O	PROPN	B
.,	O	PROPN	O
Ansan	O	PROPN	B
,	O	PUNCT	O
Korea	O	PROPN	B
)	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
suicide	O	NOUN	B
attempt	O	NOUN	I
.	O	PUNCT	O


She	O	PRON	O
was	O	AUX	O
not	O	PART	O
an	O	DET	O
alcoholic	O	ADJ	B
.	O	PUNCT	O


For	O	ADP	O
the	O	DET	O
first	O	ADJ	O
few	O	ADJ	O
days	O	NOUN	B
after	O	ADP	O
ingestion	O	NOUN	B
,	O	PUNCT	O
she	O	PRON	O
was	O	AUX	O
in	O	ADP	O
a	O	DET	O
confused	O	ADJ	O
state	O	NOUN	B
and	O	CCONJ	O
had	O	AUX	O
mild	O	ADJ	B
to	O	PART	O
moderate	O	ADJ	B
ataxia	B-Disease	NOUN	B
and	O	CCONJ	O
giddiness	B-Disease	NOUN	B
.	O	PUNCT	O


She	O	PRON	O
noticed	O	VERB	O
hoarseness	B-Disease	ADJ	B
and	O	CCONJ	O
distally	O	ADV	B
accentuated	O	ADJ	I
motor	O	NOUN	B
and	O	CCONJ	O
sensory	O	ADJ	B
dysfunction	O	NOUN	I
after	O	ADP	O
she	O	PRON	O
had	O	AUX	O
recovered	O	VERB	O
from	O	ADP	O
this	O	DET	O
state	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
nerve	O	NOUN	B
conduction	O	NOUN	I
study	O	NOUN	I
was	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
severe	O	ADJ	B
sensorimotor	O	NOUN	B
axonal	O	ADJ	I
polyneuropathy	B-Disease	NOUN	I
.	O	PUNCT	O


Laryngeal	O	ADJ	B
electromyography	O	NOUN	I
(	O	PUNCT	O
thyroarytenoid	O	ADJ	B
muscle	O	NOUN	I
)	O	PUNCT	O
showed	O	VERB	O
ample	O	ADJ	O
denervation	O	NOUN	B
potentials	O	NOUN	B
.	O	PUNCT	O


Laryngoscopy	O	NOUN	B
revealed	O	VERB	O
asymmetric	O	ADJ	B
vocal	O	ADJ	O
fold	O	ADJ	O
movements	O	NOUN	B
during	O	ADP	O
phonation	O	NOUN	B
.	O	PUNCT	O


Her	O	PRON	O
vocal	O	ADJ	B
change	O	NOUN	I
and	O	CCONJ	O
weakness	O	NOUN	B
began	O	VERB	O
to	O	PART	O
improve	O	VERB	B
spontaneously	O	ADV	B
about	O	ADV	O
3	O	NUM	O
weeks	O	NOUN	B
after	O	ADP	O
transfer	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
was	O	AUX	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
acute	O	ADJ	B
palsy	B-Disease	NOUN	I
of	O	ADP	O
the	O	DET	O
recurrent	O	ADJ	B
laryngeal	O	ADJ	B
nerve	O	NOUN	I
and	O	CCONJ	O
superimposed	O	VERB	B
severe	O	ADJ	I
acute	O	ADJ	B
sensorimotor	O	NOUN	O
axonal	O	ADJ	O
polyneuropathy	B-Disease	NOUN	O
caused	O	VERB	O
by	O	ADP	O
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
disulfiram	B-Chemical	NOUN	B


Higher	O	ADJ	B
optical	O	ADJ	B
density	O	NOUN	I
of	O	ADP	O
an	O	DET	O
antigen	O	NOUN	B
assay	O	NOUN	I
predicts	O	VERB	O
thrombosis	B-Disease	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
heparin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
thrombocytopenia	B-Disease	NOUN	B
.	O	PUNCT	O


OBJECTIVES	O	NOUN	O
:	O	PUNCT	O
To	O	PART	O
correlate	O	VERB	O
optical	O	ADJ	B
density	O	NOUN	I
and	O	CCONJ	O
percent	O	NOUN	O
inhibition	O	NOUN	B
of	O	ADP	O
a	O	DET	O
two	O	NUM	O
-	O	PUNCT	O
step	O	NOUN	B
heparin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
thrombocytopenia	B-Disease	NOUN	B
(	O	PUNCT	O
HIT	B-Disease	NOUN	B
)	O	PUNCT	O
antigen	O	NOUN	O
assay	O	NOUN	O
with	O	ADP	O
thrombosis	B-Disease	NOUN	B
;	O	PUNCT	O
the	O	DET	O
assay	O	NOUN	B
utilizes	O	VERB	O
reaction	O	NOUN	B
inhibition	O	NOUN	B
characteristics	O	NOUN	B
of	O	ADP	O
a	O	DET	O
high	O	ADJ	O
heparin	B-Chemical	NOUN	B
concentration	O	NOUN	B
.	O	PUNCT	O


PATIENTS	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
:	O	PUNCT	O
Patients	O	NOUN	B
with	O	ADP	O
more	O	ADJ	O
than	O	ADP	O
50	O	NUM	O
%	O	NOUN	O
decrease	O	NOUN	B
in	O	ADP	O
platelet	O	NOUN	B
count	O	NOUN	I
or	O	CCONJ	O
thrombocytopenia	B-Disease	NOUN	B
(<	O	NOUN	O
150	O	NUM	O
x	O	CCONJ	O
10	O	NUM	O
(	O	PUNCT	O
9	O	NUM	O
)/	O	PROPN	B
L	O	NOUN	I
)	O	PUNCT	O
after	O	ADP	O
exposure	O	NOUN	B
to	O	PART	I
heparin	B-Chemical	NOUN	B
,	O	PUNCT	O
who	O	PRON	O
had	O	AUX	O
a	O	DET	O
positive	O	ADJ	B
two	O	NUM	O
-	O	PUNCT	O
step	O	NOUN	B
antigen	O	NOUN	O
assay	O	NOUN	O
[	O	PUNCT	O
optical	O	ADJ	B
density	O	NOUN	I
(	O	PUNCT	O
OD	O	NOUN	B
)>	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
and	O	CCONJ	O
>	O	X	O
50	O	NUM	O
inhibition	O	NOUN	B
with	O	ADP	O
high	O	ADJ	O
concentration	O	NOUN	B
of	O	ADP	O
heparin	B-Chemical	NOUN	B
]	O	PUNCT	O
were	O	AUX	O
included	O	VERB	O
in	O	ADP	O
the	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Forty	O	NUM	O
of	O	ADP	O
94	O	NUM	O
HIT	B-Disease	NOUN	B
patients	O	NOUN	B
had	O	AUX	O
thrombosis	B-Disease	NOUN	B
at	O	ADP	O
diagnosis	O	NOUN	B
;	O	PUNCT	O
54	O	NUM	O
/	O	SYM	O
94	O	NUM	O
had	O	AUX	O
isolated	O	VERB	B
-	O	PUNCT	O
HIT	B-Disease	NOUN	B
without	O	ADP	O
thrombosis	B-Disease	NOUN	B
.	O	PUNCT	O


Eight	O	NUM	O
of	O	ADP	O
the	O	DET	O
isolated	O	VERB	B
-	O	PUNCT	O
HIT	B-Disease	NOUN	B
patients	O	NOUN	B
developed	O	VERB	O
thrombosis	B-Disease	NOUN	B
within	O	ADP	O
the	O	DET	O
next	O	ADJ	O
30	O	NUM	O
d	O	NOUN	O
;	O	PUNCT	O
thus	O	ADV	O
,	O	PUNCT	O
a	O	DET	O
total	O	NOUN	O
of	O	ADP	O
48	O	NUM	O
patients	O	NOUN	B
had	O	AUX	O
thrombosis	B-Disease	NOUN	B
at	O	ADP	O
day	O	NOUN	B
30	O	NUM	O
.	O	PUNCT	O


At	O	ADP	O
diagnosis	O	NOUN	B
there	O	PRON	O
was	O	AUX	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
in	O	ADP	O
OD	O	NOUN	B
between	O	ADP	O
HIT	B-Disease	NOUN	B
patients	O	NOUN	B
with	O	ADP	O
thrombosis	B-Disease	NOUN	B
and	O	CCONJ	O
those	O	DET	O
with	O	ADP	O
isolated	O	VERB	B
-	O	PUNCT	O
HIT	B-Disease	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
OD	O	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
in	O	ADP	O
all	O	DET	O
patients	O	NOUN	B
with	O	ADP	O
thrombosis	B-Disease	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
48	O	NUM	O
,	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


34	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


89	O	NUM	O
),	O	PUNCT	O
including	O	VERB	O
isolated	O	VERB	B
-	O	PUNCT	O
HIT	B-Disease	NOUN	B
patients	O	NOUN	B
who	O	PRON	O
later	O	ADV	O
developed	O	VERB	O
thrombosis	B-Disease	NOUN	B
within	O	ADP	O
30	O	NUM	O
d	O	NOUN	O
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
8	O	NUM	O
,	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


84	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


64	O	X	O
)	O	PUNCT	O
as	O	ADP	O
compared	O	VERB	B
to	O	PART	O
isolated	O	VERB	B
-	O	PUNCT	O
HIT	B-Disease	NOUN	B
patients	O	NOUN	B
who	O	PRON	O
did	O	AUX	O
not	O	PART	O
develop	O	VERB	O
thrombosis	B-Disease	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


96	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


75	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


011	O	NUM	O
and	O	CCONJ	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


008	O	NUM	O
).	O	PUNCT	O
The	O	DET	O
Receiver	O	ADJ	B
Operative	O	ADJ	I
Characteristic	O	PROPN	I
Curve	O	NOUN	I
showed	O	VERB	O
that	O	SCONJ	O
OD	O	NOUN	B
>	O	X	O
1	O	NUM	O
.	O	PUNCT	O


27	O	NUM	O
in	O	ADP	O
the	O	DET	O
isolated	O	VERB	B
-	O	PUNCT	O
HIT	B-Disease	NOUN	B
group	O	NOUN	B
had	O	AUX	O
a	O	DET	O
significantly	O	ADV	O
higher	O	ADJ	O
chance	O	NOUN	B
of	O	ADP	O
developing	O	VERB	O
thrombosis	B-Disease	NOUN	B
by	O	ADP	O
day	O	NOUN	B
30	O	NUM	O
.	O	PUNCT	O


of	O	ADP	O
these	O	DET	O
groups	O	NOUN	B
showed	O	VERB	O
significant	O	ADJ	O
difference	O	NOUN	O
in	O	ADP	O
percent	O	NOUN	O
inhibition	O	NOUN	B
.	O	PUNCT	O


Multivariate	O	ADJ	B
analysis	O	NOUN	I
showed	O	VERB	O
a	O	DET	O
2	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
-	O	PUNCT	O
fold	O	NOUN	B
increased	O	VERB	B
risk	O	NOUN	B
of	O	ADP	O
thrombosis	B-Disease	NOUN	B
in	O	ADP	O
females	O	NOUN	B
.	O	PUNCT	O


Similarly	O	ADV	O
,	O	PUNCT	O
thrombotic	B-Disease	ADJ	B
risk	O	NOUN	I
increased	O	VERB	B
with	O	ADP	O
age	O	NOUN	B
and	O	CCONJ	O
OD	O	NOUN	B
values	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
Higher	O	ADJ	B
OD	O	NOUN	B
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
significant	O	ADJ	B
risk	O	NOUN	B
of	O	ADP	O
subsequent	O	ADJ	O
thrombosis	B-Disease	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
isolated	O	VERB	B
-	O	PUNCT	O
HIT	B-Disease	NOUN	B


Central	O	ADJ	B
retinal	B-Disease	ADJ	I
vein	I-Disease	NOUN	I
occlusion	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
clomiphene	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
ovulation	O	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
:	O	PUNCT	O
To	O	PART	O
report	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
central	O	ADJ	B
retinal	B-Disease	ADJ	I
vein	I-Disease	NOUN	I
occlusion	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
clomiphene	B-Chemical	NOUN	B
citrate	I-Chemical	NOUN	I
(	O	PUNCT	O
CC	B-Chemical	NOUN	B
).	O	PUNCT	O
DESIGN	O	NOUN	O
:	O	PUNCT	O
Case	O	NOUN	B
study	O	NOUN	I
.	O	PUNCT	O


SETTING	O	NOUN	B
:	O	PUNCT	O
Ophthalmology	O	NOUN	B
clinic	O	NOUN	I
of	O	ADP	O
an	O	DET	O
academic	O	ADJ	B
hospital	O	NOUN	I
.	O	PUNCT	O


PATIENT	O	NOUN	B
(	O	PUNCT	O
S	O	PROPN	B
):	O	PUNCT	O
A	O	PROPN	O
36	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
woman	O	NOUN	B
referred	O	VERB	O
from	O	ADP	O
the	O	DET	O
infertility	B-Disease	NOUN	B
clinic	O	NOUN	B
for	O	ADP	O
blurred	B-Disease	ADJ	B
vision	I-Disease	NOUN	I
.	O	PUNCT	O


INTERVENTION	O	NOUN	B
(	O	PUNCT	O
S	O	PROPN	B
):	O	PUNCT	O
Ophthalmic	O	ADJ	B
examination	O	NOUN	I
after	O	ADP	O
CC	B-Chemical	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


MAIN	O	NOUN	O
OUTCOME	O	NOUN	O
MEASURE	O	NOUN	O
(	O	PUNCT	O
S	O	PROPN	B
):	O	PUNCT	O
Central	O	ADJ	B
retinal	B-Disease	ADJ	I
vein	I-Disease	NOUN	I
occlusion	I-Disease	NOUN	I
after	O	ADP	O
ovulation	O	NOUN	B
induction	O	NOUN	B
with	O	ADP	O
CC	B-Chemical	NOUN	B
.	O	PUNCT	O


RESULT	O	NOUN	B
(	O	PUNCT	O
S	O	NOUN	B
):	O	PUNCT	O
A	O	PROPN	O
36	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
Chinese	O	ADJ	B
woman	O	NOUN	B
developed	O	VERB	O
central	O	ADJ	B
retinal	B-Disease	ADJ	I
vein	I-Disease	NOUN	I
occlusion	I-Disease	NOUN	I
after	O	ADP	O
eight	O	NUM	O
courses	O	NOUN	B
of	O	ADP	O
CC	B-Chemical	NOUN	B
.	O	PUNCT	O


A	O	DET	O
search	O	NOUN	B
of	O	ADP	O
the	O	DET	O
literature	O	NOUN	B
on	O	ADP	O
the	O	DET	O
thromboembolic	B-Disease	ADJ	B
complications	O	NOUN	B
of	O	ADP	O
CC	B-Chemical	NOUN	B
does	O	AUX	O
not	O	PART	O
include	O	VERB	O
this	O	DET	O
severe	O	ADJ	B
ophthalmic	O	ADJ	B
complication	O	NOUN	I
,	O	PUNCT	O
although	O	SCONJ	O
mild	O	ADJ	B
visual	B-Disease	ADJ	B
disturbance	I-Disease	NOUN	I
after	O	ADP	O
CC	B-Chemical	NOUN	B
intake	O	NOUN	O
is	O	AUX	O
not	O	PART	O
uncommon	O	ADJ	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
(	O	PUNCT	O
S	O	NOUN	B
):	O	PUNCT	O
This	O	DET	O
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
reported	O	VERB	O
case	O	NOUN	B
of	O	ADP	O
central	O	ADJ	B
retinal	B-Disease	ADJ	I
vein	I-Disease	NOUN	I
occlusion	I-Disease	NOUN	I
after	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
CC	B-Chemical	NOUN	B
.	O	PUNCT	O


Extra	O	NOUN	B
caution	O	NOUN	I
is	O	AUX	O
warranted	O	VERB	O
in	O	ADP	O
treating	O	VERB	B
infertility	B-Disease	NOUN	B
patients	O	NOUN	B
with	O	ADP	O
CC	B-Chemical	NOUN	B


Nicotine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
nystagmus	B-Disease	NOUN	B
correlates	O	VERB	O
with	O	ADP	O
midpontine	O	ADJ	B
activation	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
pathomechanism	O	NOUN	B
of	O	ADP	O
nicotine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
nystagmus	B-Disease	NOUN	B
(	O	PUNCT	O
NIN	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
unknown	O	ADJ	O
.	O	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
delineate	O	VERB	O
brain	O	NOUN	B
structures	O	NOUN	I
that	O	PRON	O
are	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
NIN	B-Disease	NOUN	B
generation	O	NOUN	B
.	O	PUNCT	O


Eight	O	NUM	O
healthy	O	ADJ	B
volunteers	O	NOUN	I
inhaled	O	VERB	B
nicotine	B-Chemical	NOUN	B
in	O	ADP	O
darkness	O	NOUN	B
during	O	ADP	O
a	O	DET	O
functional	O	ADJ	B
magnetic	O	ADJ	B
resonance	O	NOUN	I
imaging	O	NOUN	I
(	O	PUNCT	O
fMRI	O	NOUN	B
)	O	PUNCT	O
experiment	O	NOUN	B
;	O	PUNCT	O
eye	O	NOUN	B
movements	O	NOUN	I
were	O	AUX	O
registered	O	VERB	O
using	O	VERB	O
video	O	NOUN	B
-	O	PUNCT	O
oculography	O	NOUN	B
.	O	PUNCT	O


NIN	B-Disease	NOUN	B
correlated	O	VERB	B
with	O	ADP	O
blood	O	NOUN	B
oxygen	B-Chemical	NOUN	I
level	O	NOUN	I
-	O	PUNCT	O
dependent	O	ADJ	B
(	O	PUNCT	O
BOLD	O	NOUN	B
)	O	PUNCT	O
activity	O	NOUN	B
levels	O	NOUN	O
in	O	ADP	O
a	O	DET	O
midpontine	O	ADJ	B
site	O	NOUN	B
in	O	ADP	O
the	O	DET	O
posterior	O	ADJ	B
basis	O	NOUN	O
pontis	O	NOUN	B
.	O	PUNCT	O


NIN	B-Disease	NOUN	B


Protective	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
verapamil	B-Chemical	NOUN	B
on	O	ADP	O
gastric	B-Disease	ADJ	B
hemorrhagic	I-Disease	ADJ	I
ulcers	B-Disease	NOUN	I
in	O	ADP	O
severe	O	ADJ	B
atherosclerotic	B-Disease	ADJ	B
rats	O	NOUN	B
.	O	PUNCT	O


Studies	O	NOUN	B
concerning	O	VERB	O
with	O	ADP	O
pathogenesis	O	NOUN	B
of	O	ADP	O
gastric	B-Disease	ADJ	B
hemorrhage	I-Disease	NOUN	I
and	O	CCONJ	O
mucosal	O	ADJ	B
ulceration	O	NOUN	I
produced	O	VERB	O
in	O	ADP	O
atherosclerotic	B-Disease	ADJ	B
rats	O	NOUN	B
are	O	AUX	O
lacking	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
is	O	AUX	O
to	O	PART	O
examine	O	VERB	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
gastric	O	ADJ	B
acid	O	NOUN	I
back	O	NOUN	I
-	O	PUNCT	O
diffusion	O	NOUN	B
,	O	PUNCT	O
mast	O	NOUN	B
cell	O	NOUN	I
histamine	B-Chemical	NOUN	B
release	O	NOUN	B
,	O	PUNCT	O
lipid	O	NOUN	B
peroxide	O	NOUN	I
(	O	PUNCT	O
LPO	O	NOUN	B
)	O	PUNCT	O
generation	O	NOUN	B
and	O	CCONJ	O
mucosal	O	ADJ	B
microvascular	O	ADJ	O
permeability	O	NOUN	O
in	O	ADP	O
modulating	O	VERB	B
gastric	B-Disease	ADJ	B
hemorrhage	I-Disease	NOUN	I
and	O	CCONJ	O
ulcer	B-Disease	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
with	O	ADP	O
atherosclerosis	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
coadministration	O	NOUN	B
of	O	ADP	O
vitamin	B-Chemical	NOUN	B
D2	I-Chemical	NOUN	I
and	O	CCONJ	O
cholesterol	B-Chemical	NOUN	B
.	O	PUNCT	O


Additionally	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
protective	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
verapamil	B-Chemical	NOUN	B
on	O	ADP	O
this	O	DET	O
ulcer	B-Disease	NOUN	B
model	O	NOUN	I
was	O	AUX	O
evaluated	O	VERB	B
.	O	PUNCT	O


Male	O	NOUN	B
Wistar	O	PROPN	B
rats	O	NOUN	I
were	O	AUX	O
challenged	O	VERB	O
intragastrically	O	ADV	B
once	O	ADV	O
daily	O	ADV	O
for	O	ADP	O
9	O	NUM	O
days	O	NOUN	B
with	O	ADP	O
1	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
ml	O	NOUN	O
/	O	PUNCT	O
kg	O	NOUN	B
of	O	ADP	O
corn	O	NOUN	B
oil	O	NOUN	I
containing	O	VERB	O
vitamin	B-Chemical	NOUN	B
D2	I-Chemical	NOUN	I
and	O	CCONJ	O
cholesterol	B-Chemical	NOUN	B
to	O	PART	O
induce	O	VERB	B
atherosclerosis	B-Disease	NOUN	B
.	O	PUNCT	O


Control	O	ADJ	B
rats	O	NOUN	B
received	O	VERB	O
corn	O	NOUN	B
oil	O	NOUN	I
only	O	ADV	O
.	O	PUNCT	O


After	O	ADP	O
gastric	O	ADJ	B
surgery	O	NOUN	I
,	O	PUNCT	O
rat	O	NOUN	B
stomachs	O	NOUN	B
were	O	AUX	O
irrigated	O	VERB	B
for	O	ADP	O
3	O	NUM	O
h	O	NOUN	O
with	O	ADP	O
either	O	CCONJ	O
simulated	O	ADJ	B
gastric	O	ADJ	B
juice	O	NOUN	I
or	O	CCONJ	O
normal	O	ADJ	B
saline	O	NOUN	I
.	O	PUNCT	O


Gastric	O	ADJ	B
acid	O	NOUN	I
back	O	NOUN	I
-	O	PUNCT	O
diffusion	O	NOUN	B
,	O	PUNCT	O
mucosal	O	ADJ	B
LPO	O	NOUN	B
generation	O	NOUN	B
,	O	PUNCT	O
histamine	B-Chemical	NOUN	B
concentration	O	NOUN	B
,	O	PUNCT	O
microvascular	O	ADJ	B
permeability	O	NOUN	I
,	O	PUNCT	O
luminal	B-Chemical	ADJ	B
hemoglobin	O	NOUN	I
content	O	NOUN	O
and	O	CCONJ	O
ulcer	B-Disease	NOUN	B
areas	O	NOUN	I
were	O	AUX	O
determined	O	VERB	O
.	O	PUNCT	O


Elevated	O	ADJ	B
atherosclerotic	B-Disease	ADJ	B
parameters	O	NOUN	B
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
serum	O	NOUN	B
calcium	B-Chemical	NOUN	I
,	O	PUNCT	O
total	O	ADJ	B
cholesterol	B-Chemical	NOUN	I
and	O	CCONJ	O
low	O	ADJ	B
-	O	PUNCT	O
density	O	NOUN	B
lipoprotein	O	NOUN	O
concentration	O	NOUN	O
were	O	AUX	O
obtained	O	VERB	O
in	O	ADP	O
atherosclerotic	B-Disease	ADJ	B
rats	O	NOUN	B
.	O	PUNCT	O


Severe	O	ADJ	B
gastric	O	ADJ	B
ulcers	B-Disease	NOUN	I
accompanied	O	VERB	O
with	O	ADP	O
increased	O	VERB	B
ulcerogenic	O	ADJ	B
factors	O	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
gastric	O	ADJ	B
acid	O	NOUN	I
back	O	NOUN	I
-	O	PUNCT	O
diffusion	O	NOUN	B
,	O	PUNCT	O
histamine	B-Chemical	NOUN	B
release	O	NOUN	B
,	O	PUNCT	O
LPO	O	NOUN	B
generation	O	NOUN	B
and	O	CCONJ	O
luminal	B-Chemical	ADJ	B
hemoglobin	O	NOUN	I
content	O	NOUN	O
were	O	AUX	O
also	O	ADV	O
observed	O	VERB	O
in	O	ADP	O
these	O	DET	O
rats	O	NOUN	B
.	O	PUNCT	O


Moreover	O	ADV	O
,	O	PUNCT	O
a	O	DET	O
positive	O	ADJ	B
correlation	O	NOUN	B
of	O	ADP	O
histamine	B-Chemical	NOUN	B
to	O	PART	O
gastric	B-Disease	ADJ	B
hemorrhage	I-Disease	NOUN	I
and	O	CCONJ	O
to	O	PART	O
ulcer	B-Disease	NOUN	B
was	O	AUX	O
found	O	VERB	O
in	O	ADP	O
those	O	DET	O
atherosclerotic	B-Disease	ADJ	B
rats	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
hemorrhagic	B-Disease	ADJ	B
ulcer	B-Disease	NOUN	I
and	O	CCONJ	O
various	O	ADJ	O
ulcerogenic	O	ADJ	B
parameters	O	NOUN	B
were	O	AUX	O
dose	O	NOUN	B
-	O	PUNCT	O
dependently	O	ADV	B
ameliorated	O	VERB	B
by	O	ADP	O
daily	O	ADJ	O
intragastric	O	ADJ	B
verapamil	B-Chemical	NOUN	B
.	O	PUNCT	O


Atherosclerosis	B-Disease	NOUN	B
could	O	AUX	O
produce	O	VERB	O
gastric	B-Disease	ADJ	B
hemorrhagic	I-Disease	ADJ	I
ulcer	B-Disease	NOUN	I
via	O	ADP	O
aggravation	O	NOUN	B
of	O	ADP	O
gastric	O	ADJ	B
acid	O	NOUN	I
back	O	NOUN	I
-	O	PUNCT	O
diffusion	O	NOUN	B
,	O	PUNCT	O
LPO	O	NOUN	B
generation	O	NOUN	B
,	O	PUNCT	O
histamine	B-Chemical	NOUN	B
release	O	NOUN	B
and	O	CCONJ	O
microvascular	O	ADJ	B
permeability	O	NOUN	I
that	O	PRON	O
could	O	AUX	O
be	O	AUX	O
ameliorated	O	VERB	B
by	O	ADP	O
verapamil	B-Chemical	NOUN	B


Adriamycin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
autophagic	O	ADJ	B
cardiomyocyte	O	NOUN	O
death	B-Disease	NOUN	B
plays	O	VERB	O
a	O	DET	O
pathogenic	O	ADJ	B
role	O	NOUN	O
in	O	ADP	O
a	O	DET	O
rat	O	NOUN	B
model	O	NOUN	B
of	O	ADP	O
heart	B-Disease	NOUN	B
failure	I-Disease	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
mechanisms	O	NOUN	B
underlying	O	VERB	O
heart	B-Disease	NOUN	B
failure	I-Disease	NOUN	I
induced	O	VERB	B
by	O	ADP	O
adriamycin	B-Chemical	NOUN	B
are	O	AUX	O
very	O	ADV	O
complicated	O	ADJ	B
and	O	CCONJ	O
still	O	ADV	O
unclear	O	ADJ	B
.	O	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
investigate	O	VERB	B
whether	O	SCONJ	O
autophagy	O	NOUN	B
was	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
the	O	DET	O
progression	O	NOUN	B
of	O	ADP	O
heart	B-Disease	NOUN	B
failure	I-Disease	NOUN	I
induced	O	VERB	B
by	O	ADP	O
adriamycin	B-Chemical	NOUN	B
,	O	PUNCT	O
so	O	SCONJ	O
that	O	SCONJ	O
we	O	PRON	O
can	O	AUX	O
develop	O	VERB	O
a	O	DET	O
novel	O	ADJ	B
treatment	O	NOUN	B
strategy	O	NOUN	O
for	O	ADP	O
heart	B-Disease	NOUN	B
failure	I-Disease	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
3-methyladenine	B-Chemical	NOUN	B
(	O	PUNCT	O
3MA	B-Chemical	NOUN	B
),	O	PUNCT	O
a	O	DET	O
specific	O	ADJ	O
inhibitor	O	NOUN	B
on	O	ADP	O
autophagy	O	NOUN	B
was	O	AUX	O
used	O	VERB	O
in	O	ADP	O
a	O	DET	O
heart	B-Disease	NOUN	B
failure	I-Disease	NOUN	I
model	O	NOUN	B
of	O	ADP	O
rats	O	NOUN	B
induced	O	VERB	B
by	O	ADP	O
adriamycin	B-Chemical	NOUN	B
.	O	PUNCT	O


Neonatal	O	ADJ	B
cardiomyocytes	O	NOUN	B
were	O	AUX	O
isolated	O	VERB	B
from	O	ADP	O
Sprague	O	PROPN	B
-	O	PUNCT	O
Dawley	O	PROPN	B
rat	O	NOUN	B
hearts	O	NOUN	B
and	O	CCONJ	O
randomly	O	ADV	O
divided	O	VERB	O
into	O	ADP	O
controls	O	NOUN	B
,	O	PUNCT	O
an	O	DET	O
adriamycin	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
group	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
3MA	B-Chemical	NOUN	B
plus	O	CCONJ	O
adriamycin	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
group	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
then	O	ADV	O
examined	O	VERB	O
the	O	DET	O
morphology	O	NOUN	B
,	O	PUNCT	O
expression	O	NOUN	B
of	O	ADP	O
beclin	O	NOUN	B
1	O	NUM	I
gene	O	NOUN	I
,	O	PUNCT	O
mitochondrial	O	ADJ	B
permeability	O	NOUN	I
transition	O	NOUN	I
(	O	PUNCT	O
MPT	O	NOUN	B
),	O	PUNCT	O
and	O	CCONJ	O
Na	O	NOUN	B
+-	O	NUM	O
K	B-Chemical	NOUN	O
+	O	CCONJ	O
ATPase	O	NOUN	B
activity	O	NOUN	B
in	O	X	B
vivo	O	X	I
.	O	PUNCT	O


We	O	PRON	O
also	O	ADV	O
assessed	O	VERB	B
cell	O	NOUN	B
viability	O	NOUN	I
,	O	PUNCT	O
mitochondrial	O	ADJ	B
membrane	O	NOUN	I
potential	O	ADJ	B
changes	O	NOUN	B
and	O	CCONJ	O
counted	O	VERB	O
autophagic	O	ADJ	B
vacuoles	O	NOUN	I
in	O	ADP	O
cultured	O	VERB	B
cardiomyocytes	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
we	O	PRON	O
analyzed	O	VERB	B
the	O	DET	O
expression	O	NOUN	B
of	O	ADP	O
autophagy	O	ADJ	B
associated	O	VERB	O
gene	O	NOUN	O
,	O	PUNCT	O
beclin	O	NOUN	B
1	O	NUM	O
using	O	VERB	O
RT	O	NOUN	B
-	O	PUNCT	O
PCR	O	NOUN	B
and	O	CCONJ	O
Western	O	NOUN	B
blotting	O	NOUN	I
in	O	ADP	O
an	O	DET	O
animal	O	NOUN	B
model	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
3MA	B-Chemical	NOUN	B
significantly	O	ADV	O
improved	O	VERB	O
cardiac	O	ADJ	B
function	O	NOUN	I
and	O	CCONJ	O
reduced	O	VERB	B
mitochondrial	O	ADJ	B
injury	O	NOUN	I
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
adriamycin	B-Chemical	NOUN	B
induced	O	VERB	B
the	O	DET	O
formation	O	NOUN	B
of	O	ADP	O
autophagic	O	ADJ	B
vacuoles	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
3MA	B-Chemical	NOUN	B
strongly	O	ADV	O
downregulated	O	VERB	B
the	O	DET	O
expression	O	NOUN	B
of	O	ADP	O
beclin	O	NOUN	B
1	O	NUM	O
in	O	ADP	O
adriamycin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
failing	O	ADJ	B
heart	O	NOUN	B
and	O	CCONJ	O
inhibited	O	VERB	B
the	O	DET	O
formation	O	NOUN	B
of	O	ADP	O
autophagic	O	ADJ	B
vacuoles	O	NOUN	I
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
Autophagic	O	NOUN	B
cardiomyocyte	O	NOUN	B
death	B-Disease	NOUN	B
plays	O	VERB	O
an	O	DET	O
important	O	ADJ	O
role	O	NOUN	O
in	O	ADP	O
the	O	DET	O
pathogenesis	O	NOUN	B
of	O	ADP	O
heart	B-Disease	NOUN	B
failure	I-Disease	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
induced	O	VERB	B
by	O	ADP	O
adriamycin	B-Chemical	NOUN	B
.	O	PUNCT	O


Mitochondrial	O	ADJ	B
injury	O	NOUN	I
may	O	AUX	O
be	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
the	O	DET	O
progression	O	NOUN	B
of	O	ADP	O
heart	B-Disease	NOUN	B
failure	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
adriamycin	B-Chemical	NOUN	B


Confusion	B-Disease	NOUN	B
,	O	PUNCT	O
a	O	DET	O
rather	O	ADV	O
serious	O	ADJ	O
adverse	O	ADJ	B
drug	O	NOUN	I
reaction	O	NOUN	I
with	O	ADP	O
valproic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
:	O	PUNCT	O
a	O	DET	O
review	O	NOUN	B
of	O	ADP	O
the	O	DET	O
French	O	PROPN	B
Pharmacovigilance	O	PROPN	I
database	O	NOUN	I
.	O	PUNCT	O


INTRODUCTION	O	NOUN	O
:	O	PUNCT	O
Confusion	B-Disease	NOUN	B
is	O	AUX	O
an	O	DET	O
adverse	O	ADJ	B
drug	O	NOUN	I
reaction	O	NOUN	I
frequently	O	ADV	O
observed	O	VERB	O
with	O	ADP	O
valproic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
.	O	PUNCT	O


Some	O	DET	O
case	O	NOUN	B
reports	O	NOUN	I
are	O	AUX	O
published	O	VERB	B
in	O	ADP	O
the	O	DET	O
literature	O	NOUN	B
but	O	CCONJ	O
no	O	DET	O
systematic	O	ADJ	B
study	O	NOUN	I
from	O	ADP	O
a	O	DET	O
sample	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
published	O	VERB	B
.	O	PUNCT	O


We	O	PRON	O
performed	O	VERB	O
this	O	DET	O
study	O	NOUN	B
in	O	ADP	O
order	O	NOUN	O
to	O	PART	O
describe	O	VERB	O
the	O	DET	O
main	O	ADJ	O
characteristics	O	NOUN	B
of	O	ADP	O
this	O	DET	O
adverse	O	ADJ	B
drug	O	NOUN	I
reaction	O	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
Using	O	VERB	O
the	O	DET	O
French	O	PROPN	B
Pharmacovigilance	O	PROPN	I
database	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
selected	O	VERB	O
the	O	DET	O
cases	O	NOUN	B
of	O	ADP	O
confusion	B-Disease	NOUN	B
reported	O	VERB	B
since	O	SCONJ	O
1985	O	NUM	O
with	O	ADP	O
valproic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
272	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
confusion	B-Disease	NOUN	B
were	O	AUX	O
reported	O	VERB	O
with	O	ADP	O
valproic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
:	O	PUNCT	O
153	O	NUM	O
women	O	NOUN	B
and	O	CCONJ	O
119	O	NUM	O
men	O	NOUN	B
.	O	PUNCT	O


Confusion	B-Disease	NOUN	B
mostly	O	ADV	O
occurred	O	VERB	O
during	O	ADP	O
the	O	DET	O
two	O	NUM	O
first	O	ADJ	O
weeks	O	NOUN	B
following	O	VERB	O
valproic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
exposure	O	NOUN	I
(	O	PUNCT	O
39	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
%).	O	NOUN	O
It	O	PRON	O
was	O	AUX	O
"	O	PUNCT	O
serious	O	ADJ	B
"	O	PUNCT	O
for	O	ADP	O
almost	O	ADV	O
2	O	NUM	O
/	O	SYM	O
3	O	NUM	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
(	O	PUNCT	O
62	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
%)	O	INTJ	O
and	O	CCONJ	O
its	O	PRON	O
outcome	O	NOUN	B
favourable	O	ADJ	O
in	O	ADP	O
most	O	ADJ	O
of	O	ADP	O
the	O	DET	O
cases	O	NOUN	B
(	O	PUNCT	O
82	O	NUM	O
%).	O	NOUN	O
The	O	DET	O
occurrence	O	NOUN	B
of	O	ADP	O
this	O	DET	O
ADR	O	NOUN	B
was	O	AUX	O
more	O	ADV	O
frequent	O	ADJ	B
in	O	ADP	O
patients	O	NOUN	B
aged	O	ADJ	B
between	O	ADP	O
61	O	NUM	O
and	O	CCONJ	O
80	O	NUM	O
years	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	B
:	O	PUNCT	O
This	O	DET	O
work	O	NOUN	O
shows	O	VERB	O
that	O	SCONJ	O
confusion	B-Disease	NOUN	B
with	O	ADP	O
valproic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I


Learning	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
memory	I-Disease	NOUN	B
deficits	I-Disease	NOUN	I
in	O	ADP	O
ecstasy	B-Chemical	NOUN	B
users	O	NOUN	I
and	O	CCONJ	O
their	O	PRON	O
neural	O	ADJ	B
correlates	O	VERB	B
during	O	ADP	O
a	O	DET	O
face	O	NOUN	B
-	O	PUNCT	O
learning	O	NOUN	B
task	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
has	O	AUX	O
been	O	AUX	O
consistently	O	ADV	O
shown	O	VERB	O
that	O	SCONJ	O
ecstasy	B-Chemical	NOUN	B
users	O	NOUN	B
display	O	VERB	O
impairments	B-Disease	NOUN	B
in	I-Disease	ADP	O
learning	I-Disease	NOUN	B
and	I-Disease	CCONJ	O
memory	I-Disease	NOUN	B
performance	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
working	O	VERB	B
memory	O	NOUN	I
processing	O	NOUN	O
in	O	ADP	O
ecstasy	B-Chemical	NOUN	B
users	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
neural	O	ADJ	B
alterations	O	NOUN	B
in	O	ADP	O
hippocampal	O	NOUN	B
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
cortical	O	ADJ	B
regions	O	NOUN	I
as	O	ADP	O
measured	O	VERB	B
by	O	ADP	O
functional	O	ADJ	B
magnetic	O	ADJ	B
resonance	O	NOUN	I
imaging	O	NOUN	I
(	O	PUNCT	O
fMRI	O	NOUN	B
).	O	ADJ	O
Using	O	VERB	O
functional	O	ADJ	B
imaging	O	NOUN	I
and	O	CCONJ	O
a	O	DET	O
face	O	NOUN	B
-	O	PUNCT	O
learning	O	NOUN	B
task	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
investigated	O	VERB	B
neural	O	ADJ	B
correlates	O	NOUN	B
of	O	ADP	O
encoding	O	VERB	B
and	O	CCONJ	O
recalling	O	VERB	B
face	O	NOUN	B
-	O	PUNCT	O
name	O	NOUN	B
associations	O	NOUN	B
in	O	ADP	O
20	O	NUM	O
recreational	O	ADJ	B
drug	O	NOUN	O
users	O	NOUN	O
whose	O	DET	O
predominant	O	ADJ	B
drug	O	NOUN	B
use	O	NOUN	I
was	O	AUX	O
ecstasy	B-Chemical	ADJ	B
and	O	CCONJ	O
20	O	NUM	O
controls	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
address	O	VERB	O
the	O	DET	O
potential	O	ADJ	B
confounding	O	NOUN	B
effects	O	NOUN	O
of	O	ADP	O
the	O	DET	O
cannabis	B-Chemical	NOUN	B
use	O	NOUN	O
of	O	ADP	O
the	O	DET	O
ecstasy	B-Chemical	NOUN	B
using	O	VERB	O
group	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
second	O	ADJ	O
analysis	O	NOUN	B
included	O	VERB	O
14	O	NUM	O
previously	O	ADV	O
tested	O	VERB	B
cannabis	B-Chemical	NOUN	B
users	O	NOUN	I
(	O	PUNCT	O
Nestor	O	PROPN	B
,	O	PUNCT	O
L	O	PROPN	B
.,	O	NOUN	O
Roberts	O	PROPN	B
,	O	PUNCT	O
G	O	PROPN	O
.,	O	NOUN	O
Garavan	O	PROPN	O
,	O	PUNCT	O
H	O	PROPN	O
.,	O	NOUN	O
Hester	O	PROPN	O
,	O	PUNCT	O
R	O	PROPN	O
.,	O	NOUN	O
2008	O	NUM	O
.	O	PUNCT	O


Deficits	B-Disease	NOUN	B
in	I-Disease	ADP	O
learning	I-Disease	NOUN	B
and	I-Disease	CCONJ	O
memory	I-Disease	NOUN	B
:	O	PUNCT	O
parahippocampal	O	ADJ	B
hyperactivity	B-Disease	NOUN	I
and	O	CCONJ	O
frontocortical	O	ADJ	B
hypoactivity	O	NOUN	O
in	O	ADP	O
cannabis	B-Chemical	NOUN	B
users	O	NOUN	I
.	O	PUNCT	O


Neuroimage	O	NOUN	B
40	O	NUM	O
,	O	PUNCT	O
1328	O	NUM	O
-	O	SYM	O
1339	O	NUM	O
).	O	PROPN	O
Ecstasy	B-Chemical	PROPN	B
users	O	NOUN	I
performed	O	VERB	O
significantly	O	ADV	O
worse	O	ADJ	O
in	O	ADP	O
learning	O	NOUN	B
and	O	CCONJ	O
memory	O	NOUN	B
compared	O	VERB	B
to	O	PART	O
controls	O	NOUN	B
and	O	CCONJ	O
cannabis	B-Chemical	NOUN	B
users	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
conjunction	O	NOUN	B
analysis	O	NOUN	I
of	O	ADP	O
the	O	DET	O
encode	O	NOUN	B
and	O	CCONJ	O
recall	O	VERB	B
phases	O	NOUN	B
of	O	ADP	O
the	O	DET	O
task	O	NOUN	B
revealed	O	VERB	O
ecstasy	B-Chemical	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
hyperactivity	B-Disease	NOUN	B
in	O	ADP	O
bilateral	O	ADJ	B
frontal	O	ADJ	O
regions	O	NOUN	O
,	O	PUNCT	O
left	O	VERB	B
temporal	O	ADJ	I
,	O	PUNCT	O
right	O	ADV	B
parietal	O	ADJ	I
,	O	PUNCT	O
bilateral	O	ADJ	B
temporal	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
bilateral	O	ADJ	B
occipital	O	ADJ	B
brain	O	NOUN	I
regions	O	NOUN	I
.	O	PUNCT	O


Ecstasy	B-Chemical	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
hypoactivity	O	NOUN	B
was	O	AUX	O
evident	O	ADJ	O
in	O	ADP	O
the	O	DET	O
right	O	ADJ	B
dorsal	O	ADJ	I
anterior	O	ADJ	I
cingulated	O	ADJ	I
cortex	O	NOUN	I
(	O	PUNCT	O
ACC	O	PROPN	B
)	O	PUNCT	O
and	O	CCONJ	O
left	O	VERB	B
posterior	O	ADJ	I
cingulated	O	ADJ	I
cortex	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
both	O	DET	O
ecstasy	B-Chemical	NOUN	B
and	O	CCONJ	O
cannabis	B-Chemical	NOUN	B
groups	O	NOUN	I
brain	O	NOUN	B
activation	O	NOUN	I
was	O	AUX	O
decreased	O	VERB	B
in	O	ADP	O
the	O	DET	O
right	O	ADJ	B
medial	O	ADJ	I
frontal	O	ADJ	I
gyrus	O	NOUN	I
,	O	PUNCT	O
left	O	VERB	B
parahippocampal	O	ADJ	I
gyrus	O	NOUN	I
,	O	PUNCT	O
left	O	VERB	B
dorsal	O	ADJ	I
cingulate	O	NOUN	I
gyrus	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
left	O	VERB	B
caudate	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	O
elucidated	O	VERB	O
ecstasy	B-Chemical	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
deficits	O	NOUN	B
,	O	PUNCT	O
only	O	ADV	O
some	O	DET	O
of	O	ADP	O
which	O	DET	O
might	O	AUX	O
be	O	AUX	O
attributed	O	VERB	O
to	O	PART	O
cannabis	B-Chemical	NOUN	B
use	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
ecstasy	B-Chemical	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
effects	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
related	O	ADJ	O
to	O	PART	O
the	O	DET	O
vulnerability	O	NOUN	B
of	O	ADP	O
isocortical	O	ADJ	B
and	O	CCONJ	O
allocortical	O	ADJ	B
regions	O	NOUN	I
to	O	PART	O
the	O	DET	O
neurotoxic	B-Disease	ADJ	B
effects	O	NOUN	O
of	O	ADP	O
ecstasy	B-Chemical	NOUN	B


Prolonged	O	ADJ	B
elevation	O	NOUN	B
of	O	ADP	O
plasma	O	NOUN	B
argatroban	B-Chemical	NOUN	B
in	O	ADP	O
a	O	DET	O
cardiac	O	ADJ	B
transplant	O	NOUN	I
patient	O	NOUN	B
with	O	ADP	O
a	O	DET	O
suspected	O	VERB	B
history	O	NOUN	B
of	O	ADP	O
heparin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
thrombocytopenia	B-Disease	NOUN	B
with	O	ADP	O
thrombosis	B-Disease	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Direct	O	ADJ	B
thrombin	O	NOUN	I
inhibitors	O	NOUN	I
(	O	PUNCT	O
DTIs	O	NOUN	B
)	O	PUNCT	O
provide	O	VERB	O
an	O	DET	O
alternative	O	ADJ	B
method	O	NOUN	B
of	O	ADP	O
anticoagulation	O	NOUN	B
for	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
a	O	DET	O
history	O	NOUN	B
of	O	ADP	O
heparin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
thrombocytopenia	B-Disease	NOUN	B
(	O	PUNCT	O
HIT	B-Disease	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
HIT	B-Disease	NOUN	B
with	O	ADP	O
thrombosis	B-Disease	NOUN	B
(	O	PUNCT	O
HITT	B-Disease	NOUN	B
)	O	PUNCT	O
undergoing	O	VERB	O
cardiopulmonary	O	ADJ	B
bypass	O	NOUN	I
(	O	PUNCT	O
CPB	O	PROPN	B
).	O	PUNCT	B
In	O	ADP	O
the	O	DET	O
following	O	VERB	O
report	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
65	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
critically	B-Disease	ADV	B
ill	I-Disease	ADJ	I
patient	O	NOUN	B
with	O	ADP	O
a	O	DET	O
suspected	O	VERB	B
history	O	NOUN	B
of	O	ADP	O
HITT	B-Disease	NOUN	B
was	O	AUX	O
administered	O	VERB	B
argatroban	B-Chemical	NOUN	B
for	O	ADP	O
anticoagulation	O	NOUN	B
on	O	ADP	O
bypass	O	NOUN	B
during	O	ADP	O
heart	O	NOUN	B
transplantation	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
required	O	VERB	O
massive	O	ADJ	B
transfusion	O	NOUN	B
support	O	NOUN	O
(	O	PUNCT	O
55	O	NUM	O
units	O	NOUN	O
of	O	ADP	O
red	O	ADJ	B
blood	O	NOUN	I
cells	O	NOUN	I
,	O	PUNCT	O
42	O	NUM	O
units	O	NOUN	B
of	O	ADP	O
fresh	O	ADJ	B
-	O	PUNCT	O
frozen	O	VERB	B
plasma	O	NOUN	B
,	O	PUNCT	O
40	O	NUM	O
units	O	NOUN	O
of	O	ADP	O
cryoprecipitate	O	NOUN	B
,	O	PUNCT	O
40	O	NUM	O
units	O	NOUN	O
of	O	ADP	O
platelets	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
three	O	NUM	O
doses	O	NOUN	B
of	O	ADP	O
recombinant	O	ADJ	B
Factor	O	NOUN	I
VIIa	O	NOUN	I
)	O	PUNCT	O
for	O	ADP	O
severe	O	ADJ	B
intraoperative	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
postoperative	I-Disease	ADJ	B
bleeding	I-Disease	NOUN	I
.	O	PUNCT	O


STUDY	O	NOUN	O
DESIGN	O	NOUN	O
AND	O	CCONJ	O
METHODS	O	NOUN	O
:	O	PUNCT	O
Plasma	O	NOUN	B
samples	O	NOUN	B
from	O	ADP	O
before	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
CPB	O	NOUN	B
were	O	AUX	O
analyzed	O	VERB	B
postoperatively	O	ADV	B
for	O	ADP	O
argatroban	B-Chemical	ADJ	B
concentration	O	NOUN	B
using	O	VERB	O
a	O	DET	O
modified	O	VERB	B
ecarin	O	NOUN	O
clotting	O	NOUN	O
time	O	NOUN	O
(	O	PUNCT	O
ECT	O	NOUN	B
)	O	PUNCT	O
assay	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Unexpectedly	O	ADV	O
high	O	ADJ	O
concentrations	O	NOUN	B
of	O	ADP	O
argatroban	B-Chemical	NOUN	B
were	O	AUX	O
measured	O	VERB	B
in	O	ADP	O
these	O	DET	O
samples	O	NOUN	B
(	O	PUNCT	O
range	O	NOUN	B
,	O	PUNCT	O
0	O	NUM	O
-	O	SYM	O
32	O	NUM	O
microg	O	NOUN	B
/	O	PUNCT	O
mL	O	NOUN	B
),	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
prolonged	O	ADJ	B
plasma	O	NOUN	B
argatroban	B-Chemical	NOUN	B
half	O	NOUN	O
life	O	NOUN	O
(	O	PUNCT	O
t	O	NOUN	O
(	O	PUNCT	O
1	O	NUM	O
/	O	SYM	O
2	O	NUM	O
))	O	PUNCT	O
of	O	ADP	O
514	O	NUM	O
minutes	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
(	O	PUNCT	O
published	O	VERB	B
elimination	O	NOUN	I
t	O	NOUN	O
(	O	PUNCT	O
1	O	NUM	O
/	O	SYM	O
2	O	NUM	B
)	O	PUNCT	O
is	O	AUX	O
39	O	NUM	O
-	O	SYM	O
51	O	NUM	O
minutes	O	NOUN	B
[<	O	X	B
or	O	CCONJ	O
=	O	ADJ	O
181	O	NUM	O
minutes	O	NOUN	O
with	O	ADP	O
hepatic	B-Disease	ADJ	B
impairment	I-Disease	NOUN	I
]).	O	PUNCT	O
CONCLUSIONS	O	NOUN	B
:	O	PUNCT	O
Correlation	O	NOUN	B
of	O	ADP	O
plasma	O	NOUN	B
argatroban	B-Chemical	ADJ	B
concentration	O	NOUN	B
versus	O	CCONJ	O
the	O	DET	O
patient	O	NOUN	B
'	O	PART	O
s	O	NOUN	O
coagulation	O	NOUN	B
variables	O	NOUN	B
and	O	CCONJ	O
clinical	O	ADJ	B
course	O	NOUN	I
suggest	O	VERB	O
that	O	SCONJ	O
prolonged	O	ADJ	B
elevated	O	ADJ	B
levels	O	NOUN	B
of	O	ADP	O
plasma	O	NOUN	B
argatroban	B-Chemical	NOUN	B
may	O	AUX	O
have	O	AUX	O
contributed	O	VERB	O
to	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
'	O	PART	O
s	O	NOUN	O
extended	O	VERB	O
coagulopathy	B-Disease	NOUN	B
.	O	PUNCT	O


Because	O	SCONJ	O
DTIs	O	NOUN	B
do	O	AUX	O
not	O	PART	O
have	O	AUX	O
reversal	O	ADJ	B
agents	O	NOUN	I
,	O	PUNCT	O
surgical	O	ADJ	B
teams	O	NOUN	I
and	O	CCONJ	O
transfusion	O	NOUN	B
services	O	NOUN	I
should	O	AUX	O
remain	O	VERB	O
aware	O	ADJ	O
of	O	ADP	O
the	O	DET	O
possibility	O	NOUN	O
of	O	ADP	O
massive	O	ADJ	B
transfusion	O	NOUN	B
events	O	NOUN	O
during	O	ADP	O
anticoagulation	O	NOUN	B
with	O	ADP	O
these	O	DET	O
agents	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
report	O	NOUN	O
to	O	PART	O
measure	O	VERB	B
plasma	O	NOUN	B
argatroban	B-Chemical	ADJ	B
concentration	O	NOUN	B
in	O	ADP	O
the	O	DET	O
context	O	NOUN	B
of	O	ADP	O
CPB	O	NOUN	B
and	O	CCONJ	O
extended	O	VERB	O
coagulopathy	B-Disease	ADJ	B


Antituberculosis	B-Chemical	NOUN	B
therapy	O	NOUN	I
-	O	PUNCT	O
induced	O	VERB	B
acute	B-Disease	ADJ	B
liver	I-Disease	NOUN	O
failure	I-Disease	NOUN	O
:	O	PUNCT	O
magnitude	O	NOUN	B
,	O	PUNCT	O
profile	O	NOUN	B
,	O	PUNCT	O
prognosis	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
predictors	O	NOUN	B
of	O	ADP	O
outcome	O	NOUN	B
.	O	PUNCT	O


Antituberculosis	B-Chemical	NOUN	B
therapy	O	NOUN	I
(	O	PUNCT	O
ATT	O	NOUN	B
)-	O	ADJ	O
associated	O	VERB	O
acute	B-Disease	ADJ	B
liver	I-Disease	NOUN	I
failure	I-Disease	NOUN	I
(	O	PUNCT	O
ATT	O	NOUN	B
-	O	PUNCT	O
ALF	B-Disease	PROPN	B
)	O	PUNCT	O
is	O	AUX	O
the	O	DET	O
commonest	O	ADJ	O
drug	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
ALF	B-Disease	NOUN	B
in	O	ADP	O
South	O	PROPN	B
Asia	O	PROPN	I
.	O	PUNCT	O


Prospective	O	ADJ	B
studies	O	NOUN	I
on	O	ADP	O
ATT	O	NOUN	B
-	O	PUNCT	O
ALF	B-Disease	PROPN	B
are	O	AUX	O
lacking	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
current	O	ADJ	O
study	O	NOUN	B
prospectively	O	ADV	O
evaluated	O	VERB	B
the	O	DET	O
magnitude	O	NOUN	B
,	O	PUNCT	O
clinical	O	ADJ	B
course	O	NOUN	I
,	O	PUNCT	O
outcome	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
prognostic	O	ADJ	B
factors	O	NOUN	I
in	O	ADP	O
ATT	O	NOUN	B
-	O	PUNCT	O
ALF	B-Disease	PROPN	B
.	O	PUNCT	O


From	O	ADP	O
January	O	PROPN	O
1986	O	NUM	O
to	O	ADP	O
January	O	PROPN	O
2009	O	NUM	O
,	O	PUNCT	O
1223	O	NUM	O
consecutive	O	ADJ	B
ALF	B-Disease	NOUN	B
patients	O	NOUN	B
were	O	AUX	O
evaluated	O	VERB	B
:	O	PUNCT	O
ATT	O	NOUN	B
alone	O	ADV	O
was	O	AUX	O
the	O	DET	O
cause	O	NOUN	O
in	O	ADP	O
70	O	NUM	O
(	O	PUNCT	O
5	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
%)	O	NOUN	O
patients	O	NOUN	B
.	O	PUNCT	O


Another	O	DET	O
15	O	NUM	O
(	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
%)	O	NOUN	O
had	O	AUX	O
ATT	O	PROPN	B
and	O	CCONJ	O
simultaneous	O	ADJ	B
hepatitis	B-Disease	NOUN	B
virus	I-Disease	NOUN	I
infection	I-Disease	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
44	O	NUM	O
(	O	PUNCT	O
62	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
%)	O	NOUN	O
patients	O	NOUN	B
,	O	PUNCT	O
ATT	O	NOUN	B
was	O	AUX	O
prescribed	O	VERB	B
empirically	O	ADV	O
without	O	ADP	O
definitive	O	ADJ	B
evidence	O	NOUN	B
of	O	ADP	O
tuberculosis	B-Disease	NOUN	B
.	O	PUNCT	O


ATT	O	PROPN	B
-	O	PUNCT	O
ALF	B-Disease	NOUN	B
patients	O	NOUN	B
were	O	AUX	O
younger	O	ADJ	B
(	O	PUNCT	O
32	O	NUM	O
.	O	PUNCT	O


87	O	NUM	O
[+/-	O	X	O
15	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
]	O	PUNCT	O
years	O	NOUN	B
),	O	PUNCT	O
and	O	CCONJ	O
49	O	NUM	O
(	O	PUNCT	O
70	O	NUM	O
%)	O	NOUN	O
of	O	ADP	O
them	O	PRON	O
were	O	AUX	O
women	O	NOUN	B
.	O	PUNCT	O


Most	O	ADV	O
had	O	AUX	O
hyperacute	O	ADJ	B
presentation	O	NOUN	B
;	O	PUNCT	O
the	O	DET	O
median	O	ADJ	B
icterus	B-Disease	NOUN	B
encephalopathy	B-Disease	NOUN	I
interval	O	NOUN	B
was	O	AUX	O
4	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
(	O	PUNCT	O
0	O	NUM	O
-	O	SYM	O
30	O	NUM	O
)	O	PUNCT	O
days	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
median	O	ADJ	B
duration	O	NOUN	B
of	O	ADP	O
ATT	O	NOUN	B
before	O	ADP	O
ALF	B-Disease	NOUN	B
was	O	AUX	O
30	O	NUM	O
(	O	PUNCT	O
7	O	NUM	O
-	O	PUNCT	O
350	O	NUM	O
)	O	PUNCT	O
days	O	NOUN	B
.	O	PUNCT	O


At	O	ADP	O
presentation	O	NOUN	B
,	O	PUNCT	O
advanced	O	ADJ	B
encephalopathy	B-Disease	NOUN	I
and	O	CCONJ	O
cerebral	B-Disease	ADJ	B
edema	I-Disease	NOUN	I
were	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
51	O	NUM	O
(	O	PUNCT	O
76	O	NUM	O
%)	O	NOUN	O
and	O	CCONJ	O
29	O	NUM	O
(	O	PUNCT	O
41	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
%)	O	NOUN	O
patients	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Gastrointestinal	B-Disease	ADJ	B
bleed	I-Disease	NOUN	I
,	O	PUNCT	O
seizures	B-Disease	NOUN	B
,	O	PUNCT	O
infection	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
acute	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
failure	I-Disease	NOUN	I
were	O	AUX	O
documented	O	VERB	B
in	O	ADP	O
seven	O	NUM	O
(	O	PUNCT	O
10	O	NUM	O
%),	O	ADJ	O
five	O	NUM	O
(	O	PUNCT	O
7	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
%),	O	VERB	O
26	O	NUM	O
(	O	PUNCT	O
37	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
%),	O	NOUN	O
and	O	CCONJ	O
seven	O	NUM	O
(	O	PUNCT	O
10	O	NUM	O
%)	O	NOUN	O
patients	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Compared	O	VERB	B
with	O	ADP	O
hepatitis	B-Disease	NOUN	B
E	I-Disease	NOUN	I
virus	O	NOUN	I
(	O	PUNCT	O
HEV	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
non	O	ADJ	B
-	O	PUNCT	O
A	O	NOUN	B
non	O	ADJ	B
-	O	PUNCT	O
E	O	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
ALF	B-Disease	NOUN	B
,	O	PUNCT	O
ATT	O	NOUN	B
-	O	PUNCT	O
ALF	B-Disease	NOUN	B
patients	O	NOUN	B
had	O	AUX	O
nearly	O	ADV	O
similar	O	ADJ	O
presentations	O	NOUN	B
except	O	SCONJ	O
for	O	ADP	O
older	O	ADJ	B
age	O	NOUN	I
and	O	CCONJ	O
less	O	ADJ	O
elevation	O	NOUN	B
of	O	ADP	O
liver	O	NOUN	B
enzymes	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
mortality	O	NOUN	B
rate	O	NOUN	I
among	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
ATT	O	NOUN	B
-	O	PUNCT	O
ALF	B-Disease	PROPN	B
was	O	AUX	O
high	O	ADJ	O
(	O	PUNCT	O
67	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
%,	O	NOUN	O
n	O	NOUN	O
=	O	ADJ	O
47	O	NUM	O
),	O	PUNCT	O
and	O	CCONJ	O
only	O	ADV	O
23	O	NUM	O
(	O	PUNCT	O
32	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
%)	O	NOUN	O
patients	O	NOUN	B
recovered	O	VERB	B
with	O	ADP	O
medical	O	ADJ	B
treatment	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
multivariate	O	ADJ	B
analysis	O	NOUN	I
,	O	PUNCT	O
three	O	NUM	O
factors	O	NOUN	B
independently	O	ADV	O
predicted	O	VERB	B
mortality	O	NOUN	B
:	O	PUNCT	O
serum	O	NOUN	B
bilirubin	B-Chemical	NOUN	O
(>	O	NOUN	O
or	O	CCONJ	O
=	O	ADJ	O
10	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
dL	O	NOUN	B
),	O	PUNCT	O
prothrombin	O	NOUN	B
time	O	NOUN	I
(	O	PUNCT	O
PT	O	NOUN	B
)	O	PUNCT	O
prolongation	O	NOUN	B
(>	O	NOUN	B
or	O	CCONJ	O
=	O	ADJ	O
26	O	NUM	O
seconds	O	NOUN	O
),	O	PUNCT	O
and	O	CCONJ	O
grade	O	NOUN	B
III	O	NUM	I
/	O	SYM	O
IV	O	NUM	B
encephalopathy	B-Disease	NOUN	B
at	O	ADP	O
presentation	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
ATT	O	PROPN	B
-	O	PUNCT	O
ALF	B-Disease	PROPN	B
constituted	O	VERB	O
5	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
ALF	B-Disease	NOUN	B


Central	B-Disease	ADJ	B
nervous	I-Disease	ADJ	I
system	I-Disease	NOUN	I
complications	I-Disease	NOUN	B
during	O	ADP	O
treatment	O	NOUN	B
of	O	ADP	O
acute	B-Disease	ADJ	B
lymphoblastic	I-Disease	ADJ	I
leukemia	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
single	O	ADJ	O
pediatric	O	ADJ	B
institution	O	NOUN	B
.	O	PUNCT	O


Central	B-Disease	ADJ	B
nervous	I-Disease	ADJ	I
system	I-Disease	NOUN	I
(CNS)	I-Disease	ADJ	O
complications	I-Disease	NOUN	B
during	O	ADP	O
treatment	O	NOUN	B
of	O	ADP	O
childhood	O	NOUN	B
acute	B-Disease	ADJ	I
lymphoblastic	I-Disease	ADJ	I
leukemia	I-Disease	NOUN	I
(	O	PUNCT	O
ALL	B-Disease	NOUN	B
)	O	PUNCT	O
remain	O	VERB	O
a	O	DET	O
challenging	O	ADJ	O
clinical	O	ADJ	B
problem	O	NOUN	I
.	O	PUNCT	O


Outcome	O	NOUN	B
improvement	O	NOUN	I
with	O	ADP	O
more	O	ADV	O
intensive	O	ADJ	B
chemotherapy	O	NOUN	I
has	O	AUX	O
significantly	O	ADV	O
increased	O	VERB	B
the	O	DET	O
incidence	O	NOUN	B
and	O	CCONJ	O
severity	O	NOUN	B
of	O	ADP	O
adverse	O	ADJ	B
events	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
analyzed	O	VERB	B
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
neurological	B-Disease	ADJ	B
complications	I-Disease	NOUN	I
during	O	ADP	O
ALL	B-Disease	NOUN	B
treatment	O	NOUN	B
in	O	ADP	O
a	O	DET	O
single	O	ADJ	O
pediatric	O	ADJ	B
institution	O	NOUN	B
,	O	PUNCT	O
focusing	O	VERB	O
on	O	ADP	O
clinical	O	ADJ	B
,	O	PUNCT	O
radiological	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
electrophysiological	O	ADJ	B
findings	O	NOUN	I
.	O	PUNCT	O


Exclusion	O	NOUN	B
criteria	O	NOUN	I
included	O	VERB	O
CNS	O	NOUN	B
leukemic	B-Disease	ADJ	B
infiltration	I-Disease	NOUN	B
at	O	ADP	O
diagnosis	O	NOUN	B
,	O	PUNCT	O
therapy	O	NOUN	B
-	O	PUNCT	O
related	O	ADJ	B
peripheral	B-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I
,	O	PUNCT	O
late	O	ADJ	B
-	O	PUNCT	O
onset	O	NOUN	B
encephalopathy	B-Disease	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
neurocognitive	B-Disease	ADJ	B
defects	I-Disease	NOUN	I
.	O	PUNCT	O


During	O	ADP	O
a	O	DET	O
9	O	NUM	B
-	O	PUNCT	O
year	O	NOUN	B
period	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
retrospectively	O	ADV	B
collected	O	VERB	O
27	O	NUM	O
neurological	O	ADJ	B
events	O	NOUN	I
(	O	PUNCT	O
11	O	NUM	O
%)	O	NOUN	O
in	O	ADP	O
as	O	ADV	O
many	O	ADJ	O
patients	O	NOUN	B
,	O	PUNCT	O
from	O	ADP	O
253	O	NUM	O
children	O	NOUN	B
enrolled	O	VERB	O
in	O	ADP	O
the	O	DET	O
ALL	B-Disease	NOUN	B
front	O	NOUN	B
-	O	PUNCT	O
line	O	NOUN	B
protocol	O	NOUN	B
.	O	PUNCT	O


CNS	O	NOUN	B
complications	O	NOUN	B
included	O	VERB	O
posterior	O	ADJ	B
reversible	O	ADJ	O
leukoencephalopathy	B-Disease	NOUN	O
syndrome	O	NOUN	O
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
10	O	NUM	O
),	O	PUNCT	O
stroke	B-Disease	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
5	O	NUM	O
),	O	PUNCT	O
temporal	B-Disease	ADJ	B
lobe	I-Disease	NOUN	I
epilepsy	I-Disease	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
2	O	NUM	O
),	O	PUNCT	O
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
methotrexate	B-Chemical	NOUN	B
toxicity	B-Disease	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
2	O	NUM	O
),	O	PUNCT	O
syndrome	O	NOUN	B
of	O	ADP	O
inappropriate	B-Disease	ADJ	O
antidiuretic	I-Disease	ADJ	B
hormone	I-Disease	NOUN	I
secretion	I-Disease	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
1	O	NUM	O
),	O	PUNCT	O
and	O	CCONJ	O
other	O	ADJ	O
unclassified	O	ADJ	O
events	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
7	O	NUM	O
).	O	PUNCT	O
In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
CNS	O	NOUN	B
complications	O	NOUN	B
are	O	AUX	O
frequent	O	ADJ	B
events	O	NOUN	B
during	O	ADP	O
ALL	B-Disease	NOUN	B


Safety	O	NOUN	B
of	O	ADP	O
capecitabine	B-Chemical	NOUN	B
:	O	PUNCT	O
a	O	DET	O
review	O	NOUN	B
.	O	PUNCT	O


IMPORTANCE	O	NOUN	B
OF	O	ADP	O
THE	O	DET	O
FIELD	O	PROPN	B
:	O	PUNCT	O
Fluoropyrimidines	B-Chemical	PROPN	B
,	O	PUNCT	O
in	O	ADP	O
particular	O	ADJ	O
5-fluorouracil	B-Chemical	NOUN	B
(	O	PUNCT	O
5-FU	B-Chemical	NOUN	B
),	O	PUNCT	O
have	O	AUX	O
been	O	AUX	O
the	O	DET	O
mainstay	O	ADJ	O
of	O	ADP	O
treatment	O	NOUN	B
for	O	ADP	O
several	O	ADJ	O
solid	O	ADJ	B
tumors	B-Disease	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
colorectal,	B-Disease	NOUN	B
breast	I-Disease	NOUN	B
and	I-Disease	CCONJ	O
head	I-Disease	NOUN	B
and	I-Disease	CCONJ	O
neck	I-Disease	NOUN	O
cancers	I-Disease	NOUN	O
,	O	PUNCT	O
for	O	ADP	O
>	O	SYM	O
40	O	NUM	O
years	O	NOUN	B
.	O	PUNCT	O


AREAS	O	NOUN	B
COVERED	O	VERB	B
IN	O	ADP	O
THIS	O	DET	O
REVIEW	O	NOUN	B
:	O	PUNCT	O
This	O	DET	O
article	O	NOUN	O
reviews	O	VERB	B
the	O	DET	O
pharmacology	O	NOUN	B
and	O	CCONJ	O
efficacy	O	NOUN	B
of	O	ADP	O
capecitabine	B-Chemical	NOUN	B
with	O	ADP	O
a	O	DET	O
special	O	ADJ	O
emphasis	O	NOUN	O
on	O	ADP	O
its	O	PRON	O
safety	O	NOUN	B
.	O	PUNCT	O


WHAT	O	PRON	O
THE	O	DET	O
READER	O	PROPN	O
WILL	O	PROPN	O
GAIN	O	PROPN	O
:	O	PUNCT	O
The	O	DET	O
reader	O	NOUN	O
will	O	AUX	O
gain	O	VERB	O
better	O	ADJ	O
insight	O	NOUN	O
into	O	ADP	O
the	O	DET	O
safety	O	NOUN	B
of	O	ADP	O
capecitabine	B-Chemical	NOUN	B
in	O	ADP	O
special	O	ADJ	O
populations	O	NOUN	B
such	O	ADJ	O
as	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
advanced	O	ADJ	B
age	O	NOUN	I
,	O	PUNCT	O
renal	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
kidney	I-Disease	NOUN	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
also	O	ADV	O
explore	O	VERB	O
different	O	ADJ	O
dosing	O	NOUN	B
and	O	CCONJ	O
schedules	O	NOUN	B
of	O	ADP	O
capecitabine	B-Chemical	NOUN	B
administration	O	NOUN	B
.	O	PUNCT	O


TAKE	O	PROPN	B
HOME	O	PROPN	B
MESSAGE	O	PROPN	I
:	O	PUNCT	O
Capecitabine	B-Chemical	NOUN	B
is	O	AUX	O
an	O	DET	O
oral	O	ADJ	B
prodrug	O	NOUN	B
of	O	ADP	O
5-FU	B-Chemical	NOUN	B
and	O	CCONJ	O
was	O	AUX	O
developed	O	VERB	O
to	O	PART	O
fulfill	O	VERB	O
the	O	DET	O
need	O	NOUN	O
for	O	ADP	O
a	O	DET	O
more	O	ADV	O
convenient	O	ADJ	O
therapy	O	NOUN	B
and	O	CCONJ	O
provide	O	VERB	O
an	O	DET	O
improved	O	VERB	O
safety	O	NOUN	B
/	O	SYM	O
efficacy	O	NOUN	B
profile	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
has	O	AUX	O
shown	O	VERB	O
promising	O	ADJ	O
results	O	NOUN	B
alone	O	ADV	O
or	O	CCONJ	O
in	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
other	O	ADJ	O
chemotherapeutic	O	ADJ	B
agents	O	NOUN	I
in	O	ADP	O
colorectal,	B-Disease	NOUN	B
breast,	I-Disease	NOUN	B
pancreaticobiliary,	I-Disease	VERB	O
gastric,	I-Disease	ADJ	B
renal	I-Disease	ADJ	I
cell	I-Disease	NOUN	I
and	I-Disease	CCONJ	O
head	I-Disease	NOUN	B
and	I-Disease	CCONJ	O
neck	I-Disease	NOUN	O
cancers	I-Disease	NOUN	O
.	O	PUNCT	O


The	O	DET	O
most	O	ADV	O
commonly	O	ADV	O
reported	O	VERB	O
toxic	O	ADJ	B
effects	O	NOUN	O
of	O	ADP	O
capecitabine	B-Chemical	NOUN	B
are	O	AUX	O
diarrhea	B-Disease	NOUN	B
,	O	PUNCT	O
nausea	B-Disease	NOUN	B
,	O	PUNCT	O
vomiting	B-Disease	NOUN	B
,	O	PUNCT	O
stomatitis	B-Disease	NOUN	B
and	O	CCONJ	O
hand-foot	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


Capecitabine	B-Chemical	NOUN	B
has	O	AUX	O
a	O	DET	O
well	O	ADV	O
-	O	PUNCT	O
established	O	VERB	B
safety	O	NOUN	B
profile	O	NOUN	I
and	O	CCONJ	O
can	O	AUX	O
be	O	AUX	O
given	O	VERB	O
safely	O	ADV	O
to	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
advanced	O	ADJ	B
age	O	NOUN	I
,	O	PUNCT	O
hepatic	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
renal	I-Disease	ADJ	B
dysfunctions	I-Disease	NOUN	I


Effects	O	NOUN	B
of	O	ADP	I
pallidal	O	ADJ	B
neurotensin	B-Chemical	NOUN	I
on	O	ADP	O
haloperidol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
parkinsonian	B-Disease	ADJ	B
catalepsy	I-Disease	NOUN	B
:	O	PUNCT	O
behavioral	O	ADJ	B
and	O	CCONJ	O
electrophysiological	O	ADJ	B
studies	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
globus	O	ADJ	B
pallidus	O	NOUN	I
plays	O	VERB	O
a	O	DET	O
critical	O	ADJ	O
role	O	NOUN	O
in	O	ADP	O
movement	O	NOUN	B
regulation	O	NOUN	B
.	O	PUNCT	O


Previous	O	ADJ	O
studies	O	NOUN	B
have	O	AUX	O
indicated	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
globus	O	NOUN	B
pallidus	O	NOUN	I
receives	O	VERB	O
neurotensinergic	O	ADJ	B
innervation	O	NOUN	I
from	O	ADP	O
the	O	DET	O
striatum	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
systemic	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
a	O	DET	O
neurotensin	B-Chemical	NOUN	B
analog	O	NOUN	I
could	O	AUX	O
produce	O	VERB	O
antiparkinsonian	O	ADJ	B
effects	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
aimed	O	VERB	O
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
pallidal	O	ADJ	B
neurotensin	B-Chemical	NOUN	I
on	O	ADP	O
haloperidol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
parkinsonian	B-Disease	ADJ	B
symptoms	I-Disease	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
Behavioral	O	ADJ	B
experiments	O	NOUN	I
and	O	CCONJ	O
electrophysiological	O	ADJ	B
recordings	O	NOUN	I
were	O	AUX	O
performed	O	VERB	O
in	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Bilateral	O	ADJ	B
infusions	O	NOUN	B
of	O	ADP	O
neurotensin	B-Chemical	NOUN	B
into	O	ADP	O
the	O	DET	O
globus	O	NOUN	B
pallidus	O	NOUN	I
reversed	O	VERB	O
haloperidol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
parkinsonian	B-Disease	ADJ	B
catalepsy	I-Disease	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


Electrophysiological	O	ADJ	B
recordings	O	NOUN	I
showed	O	VERB	O
that	O	SCONJ	O
microinjection	O	NOUN	B
of	O	ADP	O
neurotensin	B-Chemical	NOUN	B
induced	O	ADJ	B
excitation	O	NOUN	B
of	O	ADP	O
pallidal	O	ADJ	B
neurons	O	NOUN	B
in	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
systemic	O	ADJ	B
haloperidol	B-Chemical	NOUN	B
administration	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
neurotensin	B-Chemical	NOUN	B
type-1	I-Chemical	NOUN	I
receptor	I-Chemical	NOUN	I
antagonist	I-Chemical	NOUN	I
SR48692	B-Chemical	NOUN	B
blocked	O	VERB	B
both	O	CCONJ	O
the	O	DET	O
behavioral	O	ADJ	B
and	O	CCONJ	O
the	O	DET	O
electrophysiological	O	ADJ	B
effects	O	NOUN	I
induced	O	VERB	B
by	O	ADP	O
neurotensin	B-Chemical	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
Activation	O	NOUN	B
of	O	ADP	O
pallidal	O	ADJ	B
neurotensin	B-Chemical	NOUN	I
receptors	O	NOUN	I
may	O	AUX	O
be	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
neurotensin	B-Chemical	NOUN	B


Antihypertensive	O	ADJ	B
drugs	O	NOUN	I
and	O	CCONJ	O
depression	B-Disease	NOUN	B
:	O	PUNCT	O
a	O	DET	O
reappraisal	O	NOUN	B
.	O	PUNCT	O


Eighty	O	NUM	B
-	O	PUNCT	O
nine	O	NUM	O
new	O	ADJ	O
referral	O	NOUN	B
hypertensive	B-Disease	NOUN	I
out	O	ADP	I
-	O	PUNCT	O
patients	O	NOUN	B
and	O	CCONJ	O
46	O	NUM	O
new	O	ADJ	O
referral	O	NOUN	B
non	O	NOUN	B
-	O	PUNCT	O
hypertensive	B-Disease	ADJ	B
chronically	O	ADV	B
physically	O	ADV	B
ill	O	ADJ	I
out	O	ADP	O
-	O	PUNCT	O
patients	O	NOUN	B
completed	O	VERB	O
a	O	DET	O
mood	O	NOUN	B
rating	O	NOUN	I
scale	O	NOUN	I
at	O	ADP	O
regular	O	ADJ	O
intervals	O	NOUN	B
for	O	ADP	O
one	O	NUM	O
year	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
showed	O	VERB	O
a	O	DET	O
high	O	ADJ	O
prevalence	O	NOUN	B
of	O	ADP	O
depression	B-Disease	NOUN	B
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
no	O	DET	O
preponderance	O	NOUN	O
in	O	ADP	O
the	O	DET	O
hypertensive	B-Disease	ADJ	B
group	O	NOUN	B
.	O	PUNCT	O


Hypertensive	B-Disease	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
psychiatric	B-Disease	ADJ	B
histories	O	NOUN	I
had	O	AUX	O
a	O	DET	O
higher	O	ADJ	O
prevalence	O	NOUN	B
of	O	ADP	O
depression	B-Disease	NOUN	B
than	O	ADP	O
the	O	DET	O
comparison	O	NOUN	B
patients	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
was	O	AUX	O
accounted	O	VERB	O
for	O	ADP	O
by	O	ADP	O
a	O	DET	O
significant	O	ADJ	O
number	O	NOUN	O
of	O	ADP	O
depressions	B-Disease	NOUN	B
occurring	O	VERB	O
in	O	ADP	O
methyl	B-Chemical	NOUN	B
dopa	I-Chemical	NOUN	I
treated	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
psychiatric	B-Disease	ADJ	B


Pulmonary	O	ADJ	B
shunt	O	NOUN	I
and	O	CCONJ	O
cardiovascular	O	ADJ	B
responses	O	NOUN	I
to	O	PART	O
CPAP	O	NOUN	B
during	O	ADP	O
nitroprusside	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypotension	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
continuous	O	ADJ	B
positive	O	ADJ	O
airway	O	NOUN	O
pressure	O	NOUN	O
(	O	PUNCT	O
CPAP	O	NOUN	B
)	O	PUNCT	O
on	O	ADP	O
cardiovascular	O	ADJ	B
dynamics	O	NOUN	B
and	O	CCONJ	O
pulmonary	O	ADJ	B
shunt	O	NOUN	I
(	O	PUNCT	O
QS	O	PROPN	B
/	O	SYM	O
QT	O	PROPN	B
)	O	PUNCT	O
were	O	AUX	O
investigated	O	VERB	B
in	O	ADP	O
12	O	NUM	O
dogs	O	NOUN	B
before	O	ADP	O
and	O	CCONJ	O
during	O	ADP	O
sodium	B-Chemical	NOUN	B
nitroprusside	I-Chemical	NOUN	I
infusion	O	NOUN	B
that	O	PRON	O
decreased	O	VERB	B
mean	O	ADJ	O
arterial	O	ADJ	B
blood	O	NOUN	I
pressure	O	NOUN	I
40	O	NUM	O
-	O	SYM	O
50	O	NUM	O
per	O	ADP	O
cent	O	NOUN	O
.	O	PUNCT	O


Before	O	ADP	O
nitroprusside	B-Chemical	NOUN	B
infusion	O	NOUN	B
,	O	PUNCT	O
5	O	NUM	O
cm	O	NOUN	O
H2O	B-Chemical	NOUN	B
CPAP	O	NOUN	B
significantly	O	ADV	O
,	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
.	O	PUNCT	O


05	O	NUM	O
,	O	PUNCT	O
decreased	O	VERB	B
arterial	O	ADJ	B
blood	O	NOUN	I
pressure	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
did	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
alter	O	VERB	O
heart	O	NOUN	B
rate	O	NOUN	I
,	O	PUNCT	O
cardiac	O	ADJ	B
output	O	NOUN	I
,	O	PUNCT	O
systemic	O	ADJ	B
vascular	O	ADJ	B
resistance	O	NOUN	I
,	O	PUNCT	O
or	O	CCONJ	O
QS	O	PROPN	B
/	O	SYM	O
QT	O	PROPN	B
.	O	PUNCT	O


Ten	O	NUM	O
cm	O	NOUN	O
H2O	B-Chemical	NOUN	O
CPAP	O	NOUN	O
before	O	ADP	O
nitroprusside	B-Chemical	NOUN	B
infusion	O	NOUN	B
produced	O	VERB	O
a	O	DET	O
further	O	ADJ	O
decrease	B-Disease	NOUN	B
in	I-Disease	ADP	O
arterial	I-Disease	ADJ	B
blood	I-Disease	NOUN	I
pressure	I-Disease	NOUN	I
and	O	CCONJ	O
significantly	O	ADV	O
increased	O	VERB	B
heart	O	NOUN	B
rate	O	NOUN	I
and	O	CCONJ	O
decreased	B-Disease	VERB	B
cardiac	I-Disease	ADJ	B
output	I-Disease	NOUN	I
and	O	CCONJ	O
QS	O	PROPN	B
/	O	SYM	O
QT	O	PROPN	B
.	O	PUNCT	O


Nitroprusside	B-Chemical	NOUN	B
caused	O	VERB	O
significant	O	ADJ	O
decreases	B-Disease	NOUN	B
in	I-Disease	ADP	O
arterial	I-Disease	ADJ	B
blood	I-Disease	NOUN	I
pressure	I-Disease	NOUN	I
and	O	CCONJ	O
systemic	O	ADJ	B
vascular	O	ADJ	B
resistance	O	NOUN	I
and	O	CCONJ	O
increases	O	VERB	B
in	O	ADP	O
heart	O	NOUN	B
rate	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
did	O	AUX	O
not	O	PART	O
change	O	VERB	O
cardiac	O	ADJ	B
output	O	NOUN	I
or	O	CCONJ	O
QS	O	PROPN	B
/	O	SYM	O
QT	O	PROPN	B
.	O	PUNCT	O


Five	O	NUM	O
cm	O	NOUN	O
H2O	B-Chemical	NOUN	B
CPAP	O	NOUN	I
during	O	ADP	O
nitroprusside	B-Chemical	NOUN	B
did	O	AUX	O
not	O	PART	O
further	O	ADV	O
alter	O	VERB	O
any	O	DET	O
of	O	ADP	O
the	O	DET	O
above	O	ADJ	B
-	O	PUNCT	O
mentioned	O	VERB	B
variables	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
10	O	NUM	O
cm	O	NOUN	O
H2O	B-Chemical	NOUN	B
CPAP	O	NOUN	I
decreased	O	VERB	B
arterial	O	ADJ	B
blood	O	NOUN	I
pressure	O	NOUN	I
,	O	PUNCT	O
cardiac	O	ADJ	B
output	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
QS	O	PROPN	B
/	O	SYM	O
QT	O	PROPN	B
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
nitroprusside	B-Chemical	NOUN	B
infusion	O	NOUN	B
rates	O	NOUN	B
that	O	PRON	O
decrease	O	VERB	B
mean	O	ADJ	O
arterial	O	ADJ	B
blood	O	NOUN	I
pressure	O	NOUN	I
by	O	ADP	O
40	O	NUM	O
-	O	SYM	O
50	O	NUM	O
per	O	ADP	O
cent	O	NOUN	O
do	O	AUX	O
not	O	PART	O
change	O	VERB	O
cardiac	O	ADJ	B
output	O	NOUN	I
or	O	CCONJ	O
QS	O	PROPN	B
/	O	SYM	O
QT	O	PROPN	B
.	O	PUNCT	O


During	O	ADP	O
nitroprusside	B-Chemical	NOUN	B
infusion	O	NOUN	B
low	O	ADJ	O
levels	O	NOUN	B
of	O	ADP	O
CPAP	O	NOUN	B
do	O	AUX	O
not	O	PART	O
markedly	O	ADV	O
alter	O	VERB	O
cardiovascular	O	ADJ	B
dynamics	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
high	O	ADJ	O
levels	O	NOUN	B
of	O	ADP	O
CPAP	O	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
cm	O	NOUN	O
H2O	B-Chemical	NOUN	B
),	O	PUNCT	O
while	O	SCONJ	O
decreasing	O	VERB	B
QS	O	PROPN	B
/	O	SYM	O
QT	O	PROPN	B
,	O	PUNCT	O
produce	O	VERB	O
marked	O	ADJ	O
decreases	B-Disease	NOUN	B
in	I-Disease	ADP	O
arterial	I-Disease	ADJ	B
blood	I-Disease	NOUN	I
pressure	I-Disease	NOUN	I
and	I-Disease	CCONJ	O
cardiac	I-Disease	ADJ	B
output	I-Disease	NOUN	I


Mediation	O	NOUN	B
of	O	ADP	O
enhanced	O	VERB	B
reflex	O	ADJ	B
vagal	O	ADJ	B
bradycardia	B-Disease	NOUN	I
by	O	ADP	O
L-dopa	B-Chemical	NOUN	B
via	O	ADP	O
central	O	ADJ	O
dopamine	B-Chemical	NOUN	O
formation	O	NOUN	O
in	O	ADP	O
dogs	O	NOUN	B
.	O	PUNCT	O


L-Dopa	B-Chemical	NOUN	B
(	O	PUNCT	O
5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
i	O	X	O
.	O	PUNCT	O


v	O	ADP	O
.)	O	NOUN	O
decreased	O	VERB	B
blood	O	NOUN	B
pressure	O	NOUN	I
and	O	CCONJ	O
heart	O	NOUN	B
rate	O	NOUN	I
after	O	ADP	O
extracerebral	O	ADJ	B
decarboxylase	O	NOUN	I
inhibition	O	NOUN	B
with	O	ADP	O
MK-486	B-Chemical	NOUN	B
(	O	PUNCT	O
25	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
i	O	X	O
.	O	PUNCT	O


v	O	ADP	O
.)	O	NOUN	O
in	O	ADP	O
anesthetize	O	ADJ	B
MAO	B-Chemical	NOUN	B
-	O	PUNCT	O
inhibited	O	VERB	B
dogs	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
reflex	O	ADJ	B
bradycardia	B-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
injected	O	VERB	B
norepinephrine	B-Chemical	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
enhanced	O	VERB	B
by	O	ADP	O
L-dopa	B-Chemical	NOUN	B
,	O	PUNCT	O
DL-Threo-dihydroxyphenylserine	B-Chemical	NOUN	B
had	O	AUX	O
no	O	DET	B
effect	O	NOUN	I
on	O	ADP	O
blood	O	NOUN	B
pressure	O	NOUN	I
,	O	PUNCT	O
heart	O	NOUN	B
rate	O	NOUN	I
or	O	CCONJ	O
reflex	O	ADJ	B
responses	O	NOUN	I
to	O	PART	O
norepinephrine	B-Chemical	NOUN	B
.	O	PUNCT	O


FLA-63	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
dopamine	B-Chemical	NOUN	B
-	O	PUNCT	O
beta	O	NOUN	B
-	O	PUNCT	O
oxidase	O	NOUN	B
inhibitor	O	NOUN	B
,	O	PUNCT	O
did	O	AUX	O
not	O	PART	O
have	O	AUX	O
any	O	DET	O
effect	O	NOUN	B
on	O	ADP	O
the	O	DET	O
hypotension	B-Disease	NOUN	B
,	O	PUNCT	O
bradycardia	B-Disease	NOUN	B
or	O	CCONJ	O
reflex	O	ADJ	B
-	O	PUNCT	O
enhancing	O	VERB	B
effect	O	NOUN	B
of	O	ADP	O
L-dopa	B-Chemical	NOUN	B
.	O	PUNCT	O


Pimozide	B-Chemical	NOUN	B
did	O	AUX	O
not	O	PART	O
affect	O	VERB	O
the	O	DET	O
actions	O	NOUN	B
of	O	ADP	O
L-dopa	B-Chemical	NOUN	B
on	O	ADP	O
blood	O	NOUN	B
pressure	O	NOUN	I
and	O	CCONJ	O
heart	O	NOUN	B
rate	O	NOUN	I
but	O	CCONJ	O
completely	O	ADV	O
blocked	O	VERB	B
the	O	DET	O
enhancement	O	NOUN	B
of	O	ADP	O
reflexes	O	NOUN	B
.	O	PUNCT	O


Removal	O	NOUN	B
of	O	ADP	O
the	O	DET	O
carotid	O	NOUN	B
sinuses	O	NOUN	I
caused	O	VERB	O
an	O	DET	O
elevation	O	NOUN	B
blood	O	NOUN	I
pressure	O	NOUN	I
and	O	CCONJ	O
heart	O	NOUN	B
rate	O	NOUN	I
and	O	CCONJ	O
abolished	O	VERB	B
the	O	DET	O
negative	O	ADJ	B
chronotropic	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
norepinephrine	B-Chemical	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
L-dopa	B-Chemical	NOUN	B
restored	O	VERB	B
the	O	DET	O
bradycardia	B-Disease	NOUN	B
caused	O	VERB	O
by	O	ADP	O
norepinephrine	B-Chemical	NOUN	B
in	O	ADP	O
addition	O	NOUN	O
to	O	PART	O
decreasing	O	VERB	B
blood	O	NOUN	B
pressure	O	NOUN	I
and	O	CCONJ	O
heart	O	NOUN	B
rate	O	NOUN	I
.	O	PUNCT	O


5-HTP	B-Chemical	NOUN	B
(	O	PUNCT	O
5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
i	O	X	O
.	O	PUNCT	O


v	O	ADP	O
.)	O	NOUN	O
decreased	O	VERB	B
blood	O	NOUN	B
pressure	O	NOUN	I
and	O	CCONJ	O
heart	O	NOUN	B
rate	O	NOUN	I
and	O	CCONJ	O
decreased	O	VERB	B
the	O	DET	O
reflex	O	ADJ	B
bradycardia	B-Disease	NOUN	B
to	O	PART	O
norepinephrine	B-Chemical	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
concluded	O	VERB	O
that	O	SCONJ	O
L-dopa	B-Chemical	NOUN	B
enhances	O	VERB	O
reflex	O	ADJ	B
bradycardia	B-Disease	NOUN	I
through	O	ADP	O
central	O	ADJ	B
alpha	O	NOUN	I
-	O	PUNCT	O
receptor	O	NOUN	B
stimulation	O	NOUN	B
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
effects	O	NOUN	B
are	O	AUX	O
mediated	O	VERB	O
through	O	ADP	O
dopamine	B-Chemical	NOUN	B
rather	O	ADV	O
than	O	ADP	O
norepinephrine	B-Chemical	NOUN	B


Cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
myocardial	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
:	O	PUNCT	O
clinical	O	ADJ	B
observations	O	NOUN	I
and	O	CCONJ	O
pathogenetic	O	ADJ	B
considerations	O	NOUN	B
.	O	PUNCT	O


Clinical	O	ADJ	B
and	O	CCONJ	O
experimental	O	ADJ	B
data	O	NOUN	O
published	O	VERB	O
to	O	PART	O
date	O	NOUN	O
suggest	O	VERB	O
several	O	ADJ	O
possible	O	ADJ	O
mechanisms	O	NOUN	B
by	O	ADP	O
which	O	DET	O
cocaine	B-Chemical	NOUN	B
may	O	AUX	O
result	O	VERB	O
in	O	ADP	O
acute	B-Disease	ADJ	B
myocardial	I-Disease	ADJ	I
infarction	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
individuals	O	NOUN	B
with	O	ADP	O
preexisting	O	VERB	B
,	O	PUNCT	O
high	O	ADJ	B
-	O	PUNCT	O
grade	O	NOUN	B
coronary	O	ADJ	B
arterial	O	ADJ	I
narrowing	O	NOUN	I
,	O	PUNCT	O
acute	B-Disease	ADJ	B
myocardial	I-Disease	ADJ	I
infarction	I-Disease	NOUN	I
may	O	AUX	O
result	O	VERB	O
from	O	ADP	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
myocardial	O	ADJ	B
oxygen	B-Chemical	NOUN	I
demand	O	NOUN	O
associated	O	VERB	B
with	O	ADP	I
cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
increase	O	NOUN	B
in	O	ADP	O
rate	O	NOUN	B
-	O	PUNCT	O
pressure	O	NOUN	B
product	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
other	O	ADJ	O
individuals	O	NOUN	B
with	O	ADP	O
no	O	DET	O
underlying	O	ADJ	O
atherosclerotic	B-Disease	ADJ	B
obstruction	I-Disease	NOUN	I
,	O	PUNCT	O
coronary	B-Disease	ADJ	B
occlusion	I-Disease	NOUN	I
may	O	AUX	O
be	O	AUX	O
due	O	ADJ	O
to	O	ADP	O
spasm	B-Disease	NOUN	B
,	O	PUNCT	O
thrombus	B-Disease	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
both	O	DET	O
.	O	PUNCT	O


With	O	ADP	O
regard	O	NOUN	O
to	O	ADP	O
spasm	B-Disease	NOUN	B
,	O	PUNCT	O
the	O	DET	O
clinical	O	ADJ	B
findings	O	NOUN	I
are	O	AUX	O
largely	O	ADV	O
circumstantial	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
locus	O	NOUN	B
of	O	ADP	O
cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
vasoconstriction	O	NOUN	B
remains	O	VERB	O
speculative	O	ADJ	O
.	O	PUNCT	O


Although	O	SCONJ	O
certain	O	ADJ	O
clinical	O	ADJ	B
and	O	CCONJ	O
experimental	O	ADJ	B
findings	O	NOUN	I
support	O	VERB	O
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
spasm	B-Disease	NOUN	B
involves	O	VERB	O
the	O	DET	O
epicardial	O	ADJ	B
,	O	PUNCT	O
medium	O	ADJ	B
-	O	PUNCT	O
size	O	NOUN	B
vessels	O	NOUN	B
,	O	PUNCT	O
other	O	ADJ	O
data	O	NOUN	B
suggest	O	VERB	O
intramural	O	ADJ	B
vasoconstriction	O	NOUN	B
.	O	PUNCT	O


Diffuse	O	ADJ	B
intramural	O	ADJ	I
vasoconstriction	O	NOUN	I
is	O	AUX	O
not	O	PART	O
consistent	O	ADJ	B
with	O	ADP	I
reports	O	NOUN	B
of	O	ADP	O
segmental	O	ADJ	B
,	O	PUNCT	O
discrete	O	ADJ	B
infarction	B-Disease	NOUN	I
.	O	PUNCT	O


Whereas	O	SCONJ	O
certain	O	ADJ	O
in	O	X	B
vivo	O	X	I
data	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
these	O	DET	O
effects	O	NOUN	B
are	O	AUX	O
alpha	O	NOUN	B
-	O	PUNCT	O
mediated	O	VERB	B
,	O	PUNCT	O
other	O	ADJ	O
in	O	X	B
vitro	O	X	I
data	O	NOUN	B
suggest	O	VERB	O
the	O	DET	O
opposite	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
finding	O	NOUN	B
of	O	ADP	O
cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
vasoconstriction	O	NOUN	B
in	O	ADP	O
segments	O	NOUN	B
of	O	ADP	O
(	O	PUNCT	O
noninnervated	O	ADJ	B
)	O	PUNCT	O
human	O	ADJ	O
umbilical	O	ADJ	O
artery	O	NOUN	O
suggests	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
presence	O	NOUN	B
or	O	CCONJ	O
absence	O	NOUN	B
of	O	ADP	O
intact	O	ADJ	B
innervation	O	NOUN	B
is	O	AUX	O
not	O	PART	O
sufficient	O	ADJ	O
to	O	PART	O
explain	O	VERB	O
the	O	DET	O
discrepant	O	ADJ	O
data	O	NOUN	B
involving	O	VERB	O
the	O	DET	O
possibility	O	NOUN	O
of	O	ADP	O
alpha	O	NOUN	B
-	O	PUNCT	O
mediated	O	VERB	B
effects	O	NOUN	B
.	O	PUNCT	O


Finally	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
contribution	O	NOUN	B
of	O	ADP	O
a	O	DET	O
primary	O	ADJ	B
,	O	PUNCT	O
thrombotic	B-Disease	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
cocaine	B-Chemical	NOUN	B


Rabbit	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
,	O	PUNCT	O
antidepressant	B-Chemical	ADJ	B
use	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
cerebral	O	ADJ	B
perfusion	O	NOUN	I
SPECT	O	NOUN	I
scan	O	NOUN	I
findings	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
rabbit	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
is	O	AUX	O
an	O	DET	O
extrapyramidal	O	ADJ	B
side	O	NOUN	I
effect	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
chronic	O	ADJ	B
neuroleptic	O	ADJ	I
therapy	O	NOUN	I
.	O	PUNCT	O


Its	O	PRON	O
occurrence	O	NOUN	B
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
being	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
imipramine	B-Chemical	NOUN	B
is	O	AUX	O
described	O	VERB	O
,	O	PUNCT	O
representing	O	VERB	O
the	O	DET	O
first	O	ADJ	O
reported	O	VERB	O
case	O	NOUN	B
of	O	ADP	O
this	O	DET	O
syndrome	O	NOUN	B
in	O	ADP	O
conjunction	O	NOUN	B
with	O	ADP	O
antidepressants	B-Chemical	NOUN	B
.	O	PUNCT	O


Repeated	O	VERB	B
cerebral	O	ADJ	B
perfusion	O	NOUN	I
SPECT	O	NOUN	O
scans	O	NOUN	O
revealed	O	VERB	O
decreased	B-Disease	VERB	B
basal	I-Disease	ADJ	B
ganglia	I-Disease	NOUN	I
perfusion	I-Disease	NOUN	B
while	O	SCONJ	O
the	O	DET	O
movement	B-Disease	NOUN	B
disorder	I-Disease	NOUN	I
was	O	AUX	O
present	O	ADJ	O
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
return	O	NOUN	B
to	O	ADP	I
normal	O	ADJ	I
perfusion	O	NOUN	I
when	O	SCONJ	O
the	O	DET	O
rabbit	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I


Acute	O	ADJ	B
bronchodilating	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
ipratropium	B-Chemical	NOUN	B
bromide	I-Chemical	NOUN	I
and	O	CCONJ	O
theophylline	B-Chemical	NOUN	B
in	O	ADP	O
chronic	B-Disease	ADJ	B
obstructive	I-Disease	ADJ	I
pulmonary	I-Disease	ADJ	I
disease	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
bronchodilator	O	NOUN	B
effects	O	NOUN	B
of	O	ADP	O
a	O	DET	O
single	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
ipratropium	B-Chemical	NOUN	B
bromide	I-Chemical	NOUN	I
aerosol	O	NOUN	B
(	O	PUNCT	O
36	O	NUM	O
micrograms	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
short	O	ADJ	B
-	O	PUNCT	O
acting	O	VERB	B
theophylline	B-Chemical	NOUN	B
tablets	O	NOUN	B
(	O	PUNCT	O
dose	O	NOUN	B
titrated	O	VERB	B
to	O	PART	O
produce	O	VERB	O
serum	O	NOUN	B
levels	O	NOUN	B
of	O	ADP	O
10	O	NUM	O
-	O	SYM	O
20	O	NUM	O
micrograms	O	NOUN	B
/	O	PUNCT	O
mL	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
compared	O	VERB	B
in	O	ADP	O
a	O	DET	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	ADJ	B
,	O	PUNCT	O
placebo	O	NOUN	B
-	O	PUNCT	O
controlled	O	VERB	B
crossover	O	NOUN	B
study	O	NOUN	I
in	O	ADP	O
21	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
stable	O	ADJ	B
,	O	PUNCT	O
chronic	B-Disease	ADJ	B
obstructive	I-Disease	ADJ	I
pulmonary	I-Disease	ADJ	I
disease	I-Disease	NOUN	I
.	O	PUNCT	O


Mean	O	VERB	O
peak	O	NOUN	B
forced	O	ADJ	I
expiratory	O	ADJ	I
volume	O	NOUN	I
in	O	ADP	O
1	O	NUM	O
second	O	NOUN	O
(	O	PUNCT	O
FEV1	O	NOUN	B
)	O	PUNCT	O
increases	O	VERB	B
over	O	ADP	O
baseline	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
proportion	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
attaining	O	VERB	O
at	O	ADP	O
least	O	ADJ	O
a	O	DET	O
15	O	NUM	O
%	O	NOUN	O
increase	O	NOUN	B
in	O	ADP	O
the	O	DET	O
FEV1	O	NOUN	B
(	O	PUNCT	O
responders	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
31	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
90	O	NUM	O
%,	O	NOUN	B
respectively	O	ADV	O
,	O	PUNCT	O
for	O	ADP	O
ipratropium	B-Chemical	NOUN	B
and	O	CCONJ	O
17	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
50	O	NUM	O
%,	O	ADJ	B
respectively	O	ADV	O
,	O	PUNCT	O
for	O	ADP	O
theophylline	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
average	O	ADJ	B
FEV1	O	NOUN	B
increases	O	NOUN	B
during	O	ADP	O
the	O	DET	O
6	O	NUM	O
-	O	PUNCT	O
hour	O	NOUN	B
observation	O	NOUN	B
period	O	NOUN	O
were	O	AUX	O
18	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
ipratropium	B-Chemical	NOUN	B
and	O	CCONJ	O
8	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
theophylline	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
mean	O	ADJ	O
duration	O	NOUN	B
of	O	ADP	I
action	O	NOUN	B
was	O	AUX	O
3	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
hours	O	NOUN	O
with	O	ADP	O
ipratropium	B-Chemical	NOUN	B
and	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
hours	O	NOUN	O
with	O	ADP	O
theophylline	B-Chemical	NOUN	B
.	O	PUNCT	O


While	O	SCONJ	O
side	O	NOUN	B
effects	O	NOUN	I
were	O	AUX	O
rare	O	ADJ	B
,	O	PUNCT	O
those	O	DET	O
experienced	O	VERB	O
after	O	ADP	O
theophylline	B-Chemical	NOUN	B
use	O	NOUN	B
did	O	AUX	O
involve	O	VERB	O
the	O	DET	O
cardiovascular	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
gastrointestinal	I-Disease	ADJ	B
systems	I-Disease	NOUN	I
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
show	O	VERB	O
that	O	SCONJ	O
ipratropium	B-Chemical	NOUN	B
is	O	AUX	O
a	O	DET	O
more	O	ADV	O
potent	O	ADJ	O
bronchodilator	O	NOUN	B
than	O	ADP	O
oral	O	ADJ	B
theophylline	B-Chemical	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
chronic	B-Disease	ADJ	B
airflow	I-Disease	NOUN	I
obstruction	I-Disease	NOUN	I


Irreversible	O	ADJ	B
damage	O	NOUN	B
to	O	ADP	O
the	O	DET	O
medullary	O	ADJ	B
interstitium	O	NOUN	B
in	O	ADP	O
experimental	O	ADJ	B
analgesic	O	NOUN	I
nephropathy	B-Disease	NOUN	I
in	O	ADP	O
F344	O	NOUN	B
rats	O	NOUN	B
.	O	PUNCT	O


Renal	B-Disease	ADJ	B
papillary	I-Disease	ADJ	I
necrosis	I-Disease	NOUN	I
(	O	PUNCT	O
RPN	B-Disease	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
decreased	O	VERB	B
urinary	O	ADJ	B
concentrating	O	ADJ	O
ability	O	NOUN	O
developed	O	VERB	O
during	O	ADP	O
continuous	O	ADJ	B
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
treatment	O	NOUN	B
with	O	ADP	O
aspirin	B-Chemical	NOUN	B
and	O	CCONJ	O
paracetamol	B-Chemical	NOUN	B
in	O	ADP	O
female	O	ADJ	B
Fischer	O	NOUN	O
344	O	NUM	O
rats	O	NOUN	B
.	O	PUNCT	O


Renal	O	ADJ	B
structure	O	NOUN	I
and	O	CCONJ	O
concentrating	O	VERB	B
ability	O	NOUN	B
were	O	AUX	O
examined	O	VERB	O
after	O	ADP	O
a	O	DET	O
recovery	O	NOUN	B
period	O	NOUN	B
of	O	ADP	O
up	O	ADV	O
to	O	PART	O
18	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
when	O	SCONJ	O
no	O	DET	O
analgesics	O	NOUN	B
were	O	AUX	O
given	O	VERB	O
,	O	PUNCT	O
to	O	PART	O
investigate	O	VERB	B
whether	O	SCONJ	O
the	O	DET	O
analgesic	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
changes	O	NOUN	B
were	O	AUX	O
reversible	O	ADJ	B
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
evidence	O	NOUN	O
of	O	ADP	O
repair	O	NOUN	B
to	O	PART	O
the	O	DET	O
damaged	O	ADJ	B
medullary	O	ADJ	B
interstitial	O	ADJ	I
matrix	O	NOUN	I
,	O	PUNCT	O
or	O	CCONJ	O
proliferation	O	NOUN	B
of	O	ADP	O
remaining	O	VERB	O
undamaged	O	ADJ	B
type	O	NOUN	I
1	O	NUM	I
medullary	O	ADJ	I
interstitial	O	ADJ	I
cells	O	NOUN	I
after	O	ADP	O
the	O	DET	O
recovery	O	NOUN	B
period	O	NOUN	B
following	O	VERB	O
analgesic	O	ADJ	B
treatment	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
recovery	O	NOUN	B
of	O	ADP	O
urinary	O	ADJ	B
concentrating	O	ADJ	O
ability	O	NOUN	B
was	O	AUX	O
related	O	ADJ	O
to	O	PART	O
the	O	DET	O
length	O	NOUN	B
of	O	ADP	O
analgesic	O	NOUN	B
treatment	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
extent	O	NOUN	O
of	O	ADP	O
the	O	DET	O
resulting	O	VERB	O
inner	O	ADJ	B
medullary	O	ADJ	I
structural	O	ADJ	I
damage	O	NOUN	I
.	O	PUNCT	O


During	O	ADP	O
the	O	DET	O
early	O	ADJ	B
stages	O	NOUN	I
of	O	ADP	O
analgesic	O	NOUN	B
treatment	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
changes	O	NOUN	B
in	O	ADP	O
urinary	O	ADJ	B
concentrating	O	ADJ	O
ability	O	NOUN	O
were	O	AUX	O
reversible	O	ADJ	B
,	O	PUNCT	O
but	O	CCONJ	O
after	O	ADP	O
prolonged	O	ADJ	B
analgesic	O	NOUN	B
treatment	O	NOUN	I
,	O	PUNCT	O
maximum	O	ADJ	B
urinary	O	ADJ	B
concentrating	O	ADJ	O
ability	O	NOUN	O
failed	O	VERB	B
to	O	PART	O
recover	O	VERB	B
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
shows	O	VERB	O
that	O	SCONJ	O
prolonged	O	ADJ	B
analgesic	O	NOUN	B
treatment	O	NOUN	I
in	O	ADP	O
Fischer	O	NOUN	O
344	O	NUM	O
rats	O	NOUN	B
causes	O	VERB	O
progressive	O	ADJ	B
and	O	CCONJ	O
irreversible	O	ADJ	B
damage	O	NOUN	B
to	O	PART	O
the	O	DET	O
interstitial	O	ADJ	B
matrix	O	NOUN	I
and	O	CCONJ	O
type	O	NOUN	O
1	O	NUM	O
interstitial	O	ADJ	B
cells	O	NOUN	I
leading	O	VERB	O
to	O	PART	O
RPN	B-Disease	NOUN	B


Less	O	ADV	O
frequent	O	ADJ	B
lithium	B-Chemical	NOUN	B
administration	O	NOUN	O
and	O	CCONJ	O
lower	O	ADJ	B
urine	O	NOUN	B
volume	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
:	O	PUNCT	O
This	O	DET	O
study	O	NOUN	B
was	O	AUX	O
designed	O	VERB	O
to	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
patients	O	NOUN	B
maintained	O	VERB	B
on	O	ADP	O
a	O	DET	O
regimen	O	NOUN	B
of	O	ADP	O
lithium	B-Chemical	NOUN	B
on	O	ADP	O
a	O	DET	O
once	O	ADV	B
-	O	PUNCT	O
per	O	ADP	B
-	O	PUNCT	O
day	O	NOUN	B
schedule	O	NOUN	B
have	O	AUX	O
lower	O	ADJ	O
urine	O	NOUN	B
volumes	O	NOUN	O
than	O	ADP	O
do	O	AUX	O
patients	O	NOUN	B
receiving	O	VERB	O
multiple	O	ADJ	B
doses	O	NOUN	I
per	O	ADP	O
day	O	NOUN	B
.	O	PUNCT	O


METHOD	O	NOUN	B
:	O	PUNCT	O
This	O	DET	O
was	O	AUX	O
a	O	DET	O
cross	O	NOUN	B
-	O	PUNCT	O
sectional	O	ADJ	B
study	O	NOUN	I
of	O	ADP	O
85	O	NUM	O
patients	O	NOUN	B
from	O	ADP	O
a	O	DET	O
lithium	B-Chemical	NOUN	B
clinic	O	NOUN	I
who	O	PRON	O
received	O	VERB	O
different	O	ADJ	O
dose	O	NOUN	B
schedules	O	NOUN	O
.	O	PUNCT	O


Patients	O	NOUN	B
were	O	AUX	O
admitted	O	VERB	B
to	O	ADP	O
the	O	DET	O
hospital	O	NOUN	B
for	O	ADP	O
measurement	O	NOUN	B
of	O	ADP	O
lithium	B-Chemical	NOUN	B
level	O	NOUN	B
,	O	PUNCT	O
creatinine	B-Chemical	NOUN	B
clearance	O	NOUN	B
,	O	PUNCT	O
urine	O	NOUN	B
volume	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
maximum	O	ADJ	B
osmolality	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Multiple	O	ADJ	B
daily	O	ADJ	O
doses	O	NOUN	B
of	O	ADP	O
lithium	B-Chemical	NOUN	B
were	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
higher	O	ADJ	O
urine	O	NOUN	B
volumes	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
dosing	O	NOUN	B
schedule	O	NOUN	B
,	O	PUNCT	O
duration	O	NOUN	B
of	O	ADP	O
lithium	B-Chemical	NOUN	B
treatment	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
daily	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
lithium	B-Chemical	NOUN	B
did	O	AUX	O
not	O	PART	O
affect	O	VERB	O
maximum	O	ADJ	B
osmolality	O	NOUN	B
or	O	CCONJ	O
creatinine	B-Chemical	NOUN	B
clearance	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
Urine	O	NOUN	B
volume	O	NOUN	I
can	O	AUX	O
be	O	AUX	O
reduced	O	VERB	B
by	O	ADP	O
giving	O	VERB	O
lithium	B-Chemical	NOUN	B
once	O	SCONJ	B
daily	O	ADV	I
and	O	CCONJ	O
/	O	PUNCT	O
or	O	CCONJ	O
by	O	ADP	O
lowering	O	VERB	B
the	O	DET	O
total	O	ADJ	O
daily	O	ADJ	O
dose	O	NOUN	O
.	O	PUNCT	O


Lithium	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
polyuria	B-Disease	NOUN	B


Effect	O	NOUN	B
of	O	ADP	O
adriamycin	B-Chemical	NOUN	B
combined	O	VERB	O
with	O	ADP	O
whole	O	ADJ	B
body	O	NOUN	I
hyperthermia	B-Disease	NOUN	I
on	O	ADP	O
tumor	B-Disease	NOUN	B
and	O	CCONJ	O
normal	O	ADJ	B
tissues	O	NOUN	I
.	O	PUNCT	O


Thermal	O	ADJ	B
enhancement	O	NOUN	O
of	O	ADP	O
Adriamycin	B-Chemical	NOUN	B
-	O	PUNCT	O
mediated	O	VERB	B
antitumor	O	NOUN	B
activity	O	NOUN	O
and	O	CCONJ	O
normal	O	ADJ	O
tissue	O	NOUN	B
toxicities	B-Disease	NOUN	B
by	O	ADP	O
whole	O	ADJ	B
body	O	NOUN	I
hyperthermia	B-Disease	NOUN	I
were	O	AUX	O
compared	O	VERB	O
using	O	VERB	O
a	O	DET	O
F344	O	NOUN	B
rat	O	NOUN	I
model	O	NOUN	B
.	O	PUNCT	O


Antitumor	O	NOUN	B
activity	O	NOUN	I
was	O	AUX	O
studied	O	VERB	O
using	O	VERB	O
a	O	DET	O
tumor	B-Disease	NOUN	B
growth	O	NOUN	I
delay	O	NOUN	I
assay	O	NOUN	I
.	O	PUNCT	O


Acute	O	ADJ	B
normal	O	ADJ	I
tissue	O	NOUN	I
toxicities	B-Disease	NOUN	B
(	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


e	O	X	O
.,	O	NOUN	O
leukopenia	B-Disease	NOUN	B
and	O	CCONJ	O
thrombocytopenia	B-Disease	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
late	O	ADJ	O
normal	O	ADJ	O
tissue	O	NOUN	O
toxicities	B-Disease	NOUN	B
(	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


e	O	X	O
.,	O	PUNCT	O
myocardial	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
kidney	I-Disease	NOUN	B
injury	I-Disease	NOUN	I
)	O	PUNCT	O
were	O	AUX	O
evaluated	O	VERB	B
by	O	ADP	O
functional	O	ADJ	B
/	O	PUNCT	O
physiological	O	ADJ	B
assays	O	NOUN	I
and	O	CCONJ	O
by	O	ADP	O
morphological	O	ADJ	B
techniques	O	NOUN	B
.	O	PUNCT	O


Whole	O	ADJ	B
body	O	NOUN	I
hyperthermia	B-Disease	NOUN	I
(	O	PUNCT	O
120	O	NUM	O
min	O	NOUN	O
at	O	ADP	O
41	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
degrees	O	NOUN	B
C	O	NOUN	O
)	O	PUNCT	O
enhanced	O	VERB	O
both	O	CCONJ	O
Adriamycin	B-Chemical	NOUN	B
-	O	PUNCT	O
mediated	O	VERB	B
antitumor	O	NOUN	B
activity	O	NOUN	O
and	O	CCONJ	O
toxic	O	ADJ	B
side	O	NOUN	B
effects	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
thermal	O	ADJ	B
enhancement	O	NOUN	I
ratio	O	NOUN	B
calculated	O	VERB	O
for	O	ADP	O
antitumor	O	NOUN	B
activity	O	NOUN	I
was	O	AUX	O
1	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
.	O	PUNCT	O


Thermal	O	ADJ	B
enhancement	O	NOUN	I
ratios	O	NOUN	I
estimated	O	VERB	B
for	O	ADP	O
"	O	PUNCT	O
acute	O	ADJ	B
"	O	PUNCT	O
hematological	O	ADJ	B
changes	O	NOUN	B
were	O	AUX	O
1	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
,	O	PUNCT	O
whereas	O	SCONJ	O
those	O	DET	O
estimated	O	VERB	B
for	O	ADP	O
"	O	PUNCT	O
late	O	ADJ	B
"	O	PUNCT	O
damage	O	NOUN	B
(	O	PUNCT	O
based	O	VERB	O
on	O	ADP	O
morphological	O	ADJ	B
cardiac	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
renal	I-Disease	ADJ	B
lesions	I-Disease	NOUN	I
)	O	PUNCT	O
varied	O	VERB	O
between	O	ADP	O
2	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
and	O	CCONJ	O
4	O	NUM	O
.	O	PUNCT	O


3	O	X	O
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
while	O	SCONJ	O
whole	O	ADJ	B
body	O	NOUN	I
hyperthermia	B-Disease	NOUN	I
enhances	O	VERB	O
Adriamycin	B-Chemical	NOUN	B
-	O	PUNCT	O
mediated	O	VERB	B
antitumor	O	NOUN	B
effect	O	NOUN	O
,	O	PUNCT	O
normal	O	ADJ	O
tissue	O	NOUN	B
toxicity	B-Disease	NOUN	B


Prazosin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
stress	B-Disease	NOUN	B
incontinence	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
case	O	NOUN	B
of	O	ADP	O
genuine	O	ADJ	O
stress	B-Disease	NOUN	B
incontinence	I-Disease	NOUN	I
due	O	ADP	O
to	O	PART	O
prazosin	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
common	O	ADJ	O
antihypertensive	O	ADJ	B
drug	O	NOUN	I
,	O	PUNCT	O
is	O	AUX	O
presented	O	VERB	O
.	O	PUNCT	O


Prazosin	B-Chemical	NOUN	B
exerts	O	VERB	O
its	O	PRON	O
antihypertensive	O	ADJ	B
effects	O	NOUN	I
through	O	ADP	O
vasodilatation	O	NOUN	B
caused	O	VERB	O
by	O	ADP	O
selective	O	ADJ	O
blockade	O	NOUN	B
of	O	ADP	O
postsynaptic	O	ADJ	B
alpha	O	NOUN	I
-	O	PUNCT	O
1	O	NUM	O
adrenergic	O	ADJ	B
receptors	O	NOUN	I
.	O	PUNCT	O


As	O	ADP	O
an	O	DET	O
alpha	O	NOUN	B
-	O	PUNCT	O
blocker	O	NOUN	B
,	O	PUNCT	O
it	O	PRON	O
also	O	ADV	O
exerts	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
relaxant	O	ADJ	B
effect	O	NOUN	O
on	O	ADP	O
the	O	DET	O
bladder	O	NOUN	B
neck	O	NOUN	B
and	O	CCONJ	O
urethra	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
'	O	PART	O
s	O	NOUN	O
clinical	O	ADJ	B
course	O	NOUN	I
is	O	AUX	O
described	O	VERB	O
and	O	CCONJ	O
correlated	O	VERB	B
with	O	ADP	O
initial	O	ADJ	O
urodynamic	O	ADJ	B
studies	O	NOUN	I
while	O	SCONJ	O
on	O	ADP	O
prazosin	B-Chemical	NOUN	B
and	O	CCONJ	O
subsequent	O	ADJ	O
studies	O	NOUN	B
while	O	SCONJ	O
taking	O	VERB	O
verapamil	B-Chemical	NOUN	B
.	O	PUNCT	O


Her	O	PRON	O
incontinence	B-Disease	NOUN	B
resolved	O	VERB	B
with	O	ADP	O
the	O	DET	O
change	O	NOUN	B
of	O	ADP	O
medication	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
restoration	O	NOUN	B
of	O	ADP	O
continence	O	NOUN	B
was	O	AUX	O
accompanied	O	VERB	O
by	O	ADP	O
a	O	DET	O
substantial	O	ADJ	O
rise	O	NOUN	O
in	O	ADP	O
maximum	O	ADJ	B
urethral	O	ADJ	B
pressure	O	NOUN	I
,	O	PUNCT	O
maximum	O	ADJ	B
urethral	O	ADJ	B
closure	O	NOUN	I
pressure	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
functional	O	ADJ	B
urethral	O	ADJ	O
length	O	NOUN	O
.	O	PUNCT	O


Patients	O	NOUN	B
who	O	PRON	O
present	O	VERB	O
with	O	ADP	O
stress	B-Disease	NOUN	B
incontinence	I-Disease	NOUN	I
while	O	SCONJ	O
taking	O	VERB	O
prazosin	B-Chemical	NOUN	B
should	O	AUX	O
change	O	VERB	O
their	O	PRON	O
antihypertensive	O	ADJ	B
medication	O	NOUN	I
before	O	ADP	O
considering	O	VERB	O
surgery	O	NOUN	B
,	O	PUNCT	O
because	O	SCONJ	O
their	O	PRON	O
incontinence	B-Disease	NOUN	B


Myocardial	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
following	O	VERB	O
sublingual	O	ADJ	B
administration	O	NOUN	B
of	O	ADP	O
isosorbide	B-Chemical	NOUN	B
dinitrate	I-Chemical	NOUN	B
.	O	PUNCT	O


A	O	DET	O
78	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
with	O	ADP	O
healed	O	VERB	B
septal	O	ADJ	B
necrosis	B-Disease	NOUN	I
suffered	O	VERB	O
a	O	DET	O
recurrent	O	ADJ	O
myocardial	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
of	O	ADP	O
the	O	DET	O
anterior	O	ADJ	B
wall	O	NOUN	O
following	O	VERB	O
the	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
isosorbide	B-Chemical	NOUN	B
dinitrate	I-Chemical	NOUN	O
5	O	NUM	O
mg	O	NOUN	O
sublingually	O	ADV	B
.	O	PUNCT	O


After	O	ADP	O
detailing	O	VERB	O
the	O	DET	O
course	O	NOUN	B
of	O	ADP	O
events	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
discuss	O	VERB	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
paradoxical	O	ADJ	B
coronary	O	ADJ	B
spasm	B-Disease	NOUN	I
and	O	CCONJ	O
hypotension	B-Disease	NOUN	B
-	O	PUNCT	O
mediated	O	VERB	B
myocardial	B-Disease	ADJ	B
ischemia	I-Disease	NOUN	I
occurring	O	VERB	O
downstream	O	ADJ	B
to	O	PART	O
significant	O	ADJ	O
coronary	B-Disease	ADJ	B
arterial	I-Disease	ADJ	I
stenosis	I-Disease	NOUN	I
in	O	ADP	O
the	O	DET	O
pathophysiology	O	NOUN	B
of	O	ADP	O
acute	B-Disease	ADJ	B
coronary	I-Disease	ADJ	I
insufficiency	I-Disease	NOUN	I


Fluoxetine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
akathisia	B-Disease	NOUN	B
:	O	PUNCT	O
clinical	O	ADJ	B
and	O	CCONJ	O
theoretical	O	ADJ	B
implications	O	NOUN	B
.	O	PUNCT	O


Five	O	NUM	O
patients	O	NOUN	B
receiving	O	VERB	O
fluoxetine	B-Chemical	NOUN	B
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
obsessive	B-Disease	ADJ	B
compulsive	I-Disease	ADJ	I
disorder	I-Disease	NOUN	I
or	O	CCONJ	O
major	B-Disease	ADJ	O
depression	I-Disease	NOUN	B
developed	O	VERB	O
akathisia	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
typical	O	ADJ	O
fluoxetine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
symptoms	O	NOUN	B
of	O	ADP	O
restlessness	O	NOUN	B
,	O	PUNCT	O
constant	O	ADJ	B
pacing	O	NOUN	B
,	O	PUNCT	O
purposeless	O	NOUN	B
movements	O	NOUN	B
of	O	ADP	O
the	O	DET	O
feet	O	NOUN	B
and	O	CCONJ	O
legs	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
marked	O	ADJ	O
anxiety	B-Disease	NOUN	B
were	O	AUX	O
indistinguishable	O	ADJ	B
from	O	ADP	O
those	O	DET	O
of	O	ADP	O
neuroleptic	O	ADJ	B
-	O	PUNCT	O
induced	O	VERB	B
akathisia	B-Disease	NOUN	B
.	O	PUNCT	O


Three	O	NUM	O
patients	O	NOUN	B
who	O	PRON	O
had	O	AUX	O
experienced	O	VERB	O
neuroleptic	O	ADJ	B
-	O	PUNCT	O
induced	O	VERB	B
akathisia	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
past	O	NOUN	O
reported	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
symptoms	O	NOUN	B
of	O	ADP	O
fluoxetine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
akathisia	B-Disease	NOUN	B
were	O	AUX	O
identical	O	ADJ	B
,	O	PUNCT	O
although	O	SCONJ	O
somewhat	O	ADV	O
milder	O	ADJ	B
.	O	PUNCT	O


Akathisia	B-Disease	PROPN	B
appeared	O	VERB	O
to	O	PART	O
be	O	AUX	O
a	O	DET	O
common	O	ADJ	O
side	O	NOUN	B
effect	O	NOUN	I
of	O	ADP	O
fluoxetine	B-Chemical	NOUN	B
and	O	CCONJ	O
generally	O	ADV	O
responded	O	VERB	O
well	O	ADV	O
to	O	PART	O
treatment	O	NOUN	B
with	O	ADP	O
the	O	DET	O
beta	O	NOUN	B
-	O	PUNCT	O
adrenergic	O	ADJ	B
antagonist	O	NOUN	B
propranolol	B-Chemical	NOUN	B
,	O	PUNCT	O
dose	O	NOUN	B
reduction	O	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
both	O	DET	O
.	O	PUNCT	O


The	O	DET	O
authors	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
fluoxetine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
akathisia	B-Disease	NOUN	B
may	O	AUX	O
be	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
serotonergically	O	ADV	B
mediated	O	VERB	O
inhibition	O	NOUN	B
of	O	ADP	O
dopaminergic	O	ADJ	B
neurotransmission	O	NOUN	I
and	O	CCONJ	O
that	O	SCONJ	O
the	O	DET	O
pathophysiology	O	NOUN	B
of	O	ADP	O
fluoxetine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
akathisia	B-Disease	NOUN	B
and	O	CCONJ	O
tricyclic	O	ADJ	B
antidepressant	B-Chemical	NOUN	I


Chronic	B-Disease	ADJ	B
active	I-Disease	ADJ	I
hepatitis	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
diclofenac	B-Chemical	ADJ	B
sodium	I-Chemical	NOUN	I
therapy	O	NOUN	I
.	O	PUNCT	O


Diclofenac	B-Chemical	ADJ	B
sodium	I-Chemical	NOUN	I
(	O	PUNCT	O
Voltarol	B-Chemical	PROPN	B
,	O	PUNCT	O
Geigy	O	PROPN	B
Pharmaceuticals	O	PROPN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
non	O	ADJ	B
-	O	PUNCT	O
steroidal	O	ADJ	B
anti	O	ADJ	B
-	O	PUNCT	O
inflammatory	O	ADJ	B
derivative	O	NOUN	B
of	O	ADP	O
phenylacetic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
.	O	PUNCT	O


Although	O	SCONJ	O
generally	O	ADV	O
well	O	ADV	B
-	O	PUNCT	O
tolerated	O	VERB	B
,	O	PUNCT	O
asymptomatic	O	ADJ	B
abnormalities	B-Disease	NOUN	B
of	I-Disease	ADP	O
liver	I-Disease	NOUN	B
function	I-Disease	NOUN	I
have	O	AUX	O
been	O	AUX	O
recorded	O	VERB	O
and	O	CCONJ	O
,	O	PUNCT	O
less	O	ADV	O
commonly	O	ADV	O
,	O	PUNCT	O
severe	O	ADJ	B
hepatitis	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
diclofenac	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
described	O	VERB	O
developed	O	VERB	O
chronic	B-Disease	ADJ	B
active	I-Disease	ADJ	O
hepatitis	I-Disease	NOUN	O
after	O	ADP	O
six	O	NUM	O
months	O	NOUN	B
therapy	O	NOUN	B
with	O	ADP	O
diclofenac	B-Chemical	ADJ	B
sodium	I-Chemical	NOUN	I


Stroke	B-Disease	NOUN	B
associated	O	VERB	B
with	O	ADP	I
cocaine	B-Chemical	NOUN	B
use	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
describe	O	VERB	O
eight	O	NUM	O
patients	O	NOUN	B
in	O	ADP	O
whom	O	PRON	O
cocaine	B-Chemical	NOUN	B
use	O	NOUN	I
was	O	AUX	O
related	O	ADJ	O
to	O	PART	O
stroke	B-Disease	NOUN	B
and	O	CCONJ	O
review	O	VERB	B
39	O	NUM	O
cases	O	NOUN	B
from	O	ADP	O
the	O	DET	O
literature	O	NOUN	B
.	O	PUNCT	O


Among	O	ADP	O
these	O	DET	O
47	O	NUM	O
patients	O	NOUN	B
the	O	DET	O
mean	O	NOUN	O
(+/-	O	PUNCT	O
SD	O	NOUN	B
)	O	PUNCT	O
age	O	NOUN	B
was	O	AUX	O
32	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
+/-	O	CCONJ	O
12	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
years	O	NOUN	B
;	O	PUNCT	O
76	O	NUM	O
%(	O	NOUN	O
34	O	NUM	O
/	O	SYM	O
45	O	NUM	O
)	O	PUNCT	O
were	O	AUX	O
men	O	NOUN	B
.	O	PUNCT	O


Stroke	B-Disease	NOUN	B
followed	O	VERB	O
cocaine	B-Chemical	NOUN	B
use	O	NOUN	O
by	O	ADP	O
inhalation	O	NOUN	B
,	O	PUNCT	O
intranasal	O	ADJ	B
,	O	PUNCT	O
intravenous	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
intramuscular	O	ADJ	B
routes	O	NOUN	B
.	O	PUNCT	O


Intracranial	B-Disease	ADJ	B
aneurysms	I-Disease	NOUN	I
or	O	CCONJ	O
arteriovenous	B-Disease	ADJ	B
malformations	I-Disease	NOUN	I
were	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
17	O	NUM	O
of	O	ADP	O
32	O	NUM	O
patients	O	NOUN	B
studied	O	VERB	O
angiographically	O	ADV	B
or	O	CCONJ	O
at	O	ADP	O
autopsy	O	NOUN	B
;	O	PUNCT	O
cerebral	B-Disease	ADJ	B
vasculitis	I-Disease	NOUN	I
was	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
two	O	NUM	O
patients	O	NOUN	B
.	O	PUNCT	O


Cerebral	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
occurred	O	VERB	O
in	O	ADP	O
10	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
22	O	NUM	O
%),	O	ADJ	O
intracerebral	B-Disease	ADJ	B
hemorrhage	I-Disease	NOUN	I
in	O	ADP	O
22	O	NUM	O
(	O	PUNCT	O
49	O	NUM	O
%),	O	NOUN	O
and	O	CCONJ	O
subarachnoid	B-Disease	ADJ	B
hemorrhage	I-Disease	NOUN	O
in	O	ADP	O
13	O	NUM	O
(	O	PUNCT	O
29	O	NUM	O
%).	O	NOUN	O
These	O	DET	O
data	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
(	O	PUNCT	O
1	O	X	O
)	O	PUNCT	O
the	O	DET	O
apparent	O	ADJ	B
incidence	O	NOUN	B
of	O	ADP	O
stroke	B-Disease	NOUN	B
related	O	ADJ	O
to	O	PART	O
cocaine	B-Chemical	NOUN	B
use	O	NOUN	I
is	O	AUX	O
increasing	O	VERB	B
;(	O	PUNCT	O
2	O	X	O
)	O	PUNCT	O
cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
stroke	B-Disease	NOUN	B
occurs	O	VERB	B
primarily	O	ADV	O
in	O	ADP	O
young	O	ADJ	B
adults	O	NOUN	I
;(	O	PUNCT	O
3	O	X	O
)	O	PUNCT	O
stroke	B-Disease	NOUN	B
may	O	AUX	O
follow	O	VERB	O
any	O	DET	O
route	O	NOUN	O
of	O	ADP	O
cocaine	B-Chemical	NOUN	B
administration	O	NOUN	I
;(	O	PUNCT	O
4	O	X	O
)	O	PUNCT	O
stroke	B-Disease	NOUN	B
after	O	ADP	O
cocaine	B-Chemical	NOUN	B
use	O	NOUN	O
is	O	AUX	O
frequently	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
intracranial	B-Disease	ADJ	B
aneurysms	I-Disease	NOUN	I
and	O	CCONJ	O
arteriovenous	B-Disease	ADJ	B
malformations	I-Disease	NOUN	I
;	O	PUNCT	O
and	O	CCONJ	O
(	O	PUNCT	O
5	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
stroke	B-Disease	NOUN	B
,	O	PUNCT	O
the	O	DET	O
frequency	O	NOUN	B
of	O	ADP	O
intracranial	B-Disease	ADJ	B
hemorrhage	I-Disease	NOUN	I
exceeds	O	VERB	O
that	O	DET	O
of	O	ADP	O
cerebral	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I


Glyburide	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hepatitis	B-Disease	NOUN	B
.	O	PUNCT	O


Drug	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hepatotoxicity	B-Disease	NOUN	B
,	O	PUNCT	O
although	O	SCONJ	O
common	O	ADJ	O
,	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
only	O	ADV	O
infrequently	O	ADV	O
with	O	ADP	O
sulfonylureas	B-Chemical	NOUN	B
.	O	PUNCT	O


For	O	ADP	O
glyburide	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
second	O	ADV	B
-	O	PUNCT	O
generation	O	NOUN	B
sulfonylurea	B-Chemical	NOUN	B
,	O	PUNCT	O
only	O	ADV	O
two	O	NUM	O
brief	O	ADJ	O
reports	O	NOUN	B
of	O	ADP	O
hepatotoxicity	B-Disease	NOUN	B
exist	O	VERB	O
.	O	PUNCT	O


Two	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
type	B-Disease	NOUN	B
II	I-Disease	NUM	I
diabetes	I-Disease	NOUN	I
mellitus	I-Disease	NOUN	I
developed	O	VERB	O
an	O	DET	O
acute	B-Disease	ADJ	B
hepatitis-like	I-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
soon	O	ADV	O
after	O	ADP	O
initiation	O	NOUN	B
of	O	ADP	O
glyburide	B-Chemical	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
serologic	O	ADJ	B
evidence	O	NOUN	B
of	O	ADP	O
viral	B-Disease	ADJ	B
infection	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
liver	O	NOUN	B
biopsy	O	NOUN	I
sample	O	NOUN	O
showed	O	VERB	O
a	O	DET	O
histologic	O	ADJ	B
pattern	O	NOUN	O
consistent	O	ADJ	B
with	O	ADP	I
drug-induced	B-Disease	ADJ	B
hepatitis	I-Disease	NOUN	I
.	O	PUNCT	O


Both	O	DET	O
patients	O	NOUN	B
recovered	O	VERB	B
quickly	O	ADV	O
after	O	ADP	O
stopping	O	VERB	B
glyburide	B-Chemical	NOUN	B
therapy	O	NOUN	I
and	O	CCONJ	O
have	O	AUX	O
remained	O	VERB	O
well	O	ADV	O
for	O	ADP	O
a	O	DET	O
follow	O	NOUN	B
-	O	PUNCT	O
up	O	ADP	O
period	O	NOUN	B
of	O	ADP	O
1	O	NUM	O
year	O	NOUN	B
.	O	PUNCT	O


Glyburide	B-Chemical	NOUN	B
can	O	AUX	O
produce	O	VERB	O
an	O	DET	O
acute	B-Disease	ADJ	B
hepatitis-like	I-Disease	ADJ	O
illness	I-Disease	NOUN	O


Systolic	O	NOUN	B
pressure	O	NOUN	I
variation	O	NOUN	B
is	O	AUX	O
greater	O	ADJ	O
during	O	ADP	O
hemorrhage	B-Disease	NOUN	B
than	O	ADP	O
during	O	ADP	O
sodium	B-Chemical	NOUN	B
nitroprusside	I-Chemical	NOUN	I
-	O	PUNCT	O
induced	O	VERB	B
hypotension	B-Disease	NOUN	B
in	O	ADP	O
ventilated	O	VERB	B
dogs	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
systolic	O	ADJ	B
pressure	O	NOUN	I
variation	O	NOUN	I
(	O	PUNCT	O
SPV	O	NOUN	B
),	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
the	O	DET	O
difference	O	NOUN	O
between	O	ADP	O
the	O	DET	O
maximal	O	ADJ	B
and	O	CCONJ	O
minimal	O	ADJ	B
values	O	NOUN	B
of	O	ADP	O
the	O	DET	O
systolic	O	NOUN	B
blood	O	NOUN	I
pressure	O	NOUN	I
(	O	PUNCT	O
SBP	O	NOUN	B
)	O	PUNCT	O
after	O	ADP	O
one	O	NUM	O
positive	O	ADJ	B
-	O	PUNCT	O
pressure	O	NOUN	B
breath	O	NOUN	O
,	O	PUNCT	O
was	O	AUX	O
studied	O	VERB	O
in	O	ADP	O
ventilated	O	VERB	B
dogs	O	NOUN	B
subjected	O	VERB	O
to	O	PART	O
hypotension	B-Disease	NOUN	B
.	O	PUNCT	O


Mean	O	VERB	O
arterial	O	ADJ	B
pressure	O	NOUN	I
was	O	AUX	O
decreased	O	VERB	B
to	O	ADP	O
50	O	NUM	O
mm	O	X	B
Hg	O	NOUN	I
for	O	ADP	O
30	O	NUM	O
minutes	O	NOUN	B
either	O	CCONJ	O
by	O	ADP	O
hemorrhage	B-Disease	NOUN	B
(	O	PUNCT	O
HEM	B-Disease	NOUN	B
,	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
7	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
by	O	ADP	O
continuous	O	ADJ	B
infusion	O	NOUN	B
of	O	ADP	O
sodium	B-Chemical	NOUN	B
nitroprusside	I-Chemical	NOUN	I
(	O	PUNCT	O
SNP	B-Chemical	NOUN	B
,	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
7	O	NUM	O
).	O	PUNCT	O
During	O	ADP	O
HEM	B-Disease	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypotension	B-Disease	NOUN	B
the	O	DET	O
cardiac	O	ADJ	B
output	O	NOUN	I
was	O	AUX	O
significantly	O	ADV	O
lower	O	ADJ	O
and	O	CCONJ	O
systemic	O	ADJ	B
vascular	O	ADJ	B
resistance	O	NOUN	I
higher	O	ADV	O
compared	O	VERB	B
with	O	ADP	O
that	O	DET	O
in	O	ADP	O
the	O	DET	O
SNP	B-Chemical	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
systemic	O	ADJ	B
,	O	PUNCT	O
central	O	ADJ	B
venous	O	ADJ	I
,	O	PUNCT	O
pulmonary	O	ADJ	B
capillary	O	ADJ	I
wedge	O	NOUN	I
pressures	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
heart	O	NOUN	B
rates	O	NOUN	I
,	O	PUNCT	O
were	O	AUX	O
similar	O	ADJ	O
in	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


Analysis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
respiratory	O	ADJ	B
changes	O	NOUN	I
in	O	ADP	O
the	O	DET	O
arterial	O	ADJ	B
pressure	O	NOUN	I
waveform	O	NOUN	I
enabled	O	VERB	O
differentiation	O	NOUN	B
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
SPV	O	NOUN	B
during	O	ADP	O
hypotension	B-Disease	NOUN	B
was	O	AUX	O
15	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
+/-	O	CCONJ	O
6	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
mm	O	NOUN	B
Hg	O	NOUN	I
in	O	ADP	O
the	O	DET	O
HEM	B-Disease	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
9	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
+/-	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
mm	O	X	B
Hg	O	NOUN	I
in	O	ADP	O
the	O	DET	O
SNP	B-Chemical	NOUN	B
group	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


02	O	NUM	O
).	O	PUNCT	O
The	O	DET	O
delta	O	NOUN	B
down	O	ADV	I
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
the	O	DET	O
measure	O	NOUN	B
of	O	ADP	O
decrease	O	NOUN	B
of	O	ADP	O
SBP	O	NOUN	B
after	O	ADP	O
a	O	DET	O
mechanical	O	ADJ	B
breath	O	NOUN	I
,	O	PUNCT	O
was	O	AUX	O
20	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
+/-	O	CCONJ	O
8	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
and	O	CCONJ	O
10	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
+/-	O	CCONJ	O
3	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
mm	O	NOUN	B
Hg	O	NOUN	I
in	O	ADP	O
the	O	DET	O
HEM	B-Disease	NOUN	B
and	O	CCONJ	O
SNP	B-Chemical	NOUN	B
groups	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
during	O	ADP	O
hypotension	B-Disease	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


02	O	NUM	O
).	O	PUNCT	O
It	O	PRON	O
is	O	AUX	O
concluded	O	VERB	O
that	O	SCONJ	O
increases	O	VERB	B
in	O	ADP	O
the	O	DET	O
SPV	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
delta	O	NOUN	B
down	O	ADP	I
are	O	AUX	O
characteristic	O	ADJ	O
of	O	ADP	O
a	O	DET	O
hypotensive	B-Disease	ADJ	B
state	O	NOUN	I
due	O	ADP	O
to	O	ADP	O
a	O	DET	O
predominant	O	ADJ	O
decrease	O	NOUN	B
in	O	ADP	O
preload	O	NOUN	B
.	O	PUNCT	O


They	O	PRON	O
are	O	AUX	O
thus	O	ADV	O
more	O	ADV	O
important	O	ADJ	O
during	O	ADP	O
absolute	O	ADJ	B
hypovolemia	B-Disease	NOUN	B
than	O	ADP	O
during	O	ADP	O
deliberate	O	ADJ	B
hypotension	B-Disease	NOUN	B


Drug	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
arterial	O	ADJ	B
spasm	B-Disease	NOUN	I
relieved	O	VERB	O
by	O	ADP	O
lidocaine	B-Chemical	NOUN	B
.	O	PUNCT	O


Case	O	NOUN	B
report	O	NOUN	I
.	O	PUNCT	O


Following	O	VERB	O
major	O	ADJ	O
intracranial	O	ADJ	B
surgery	O	NOUN	I
in	O	ADP	O
a	O	DET	O
35	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
man	O	NOUN	B
,	O	PUNCT	O
sodium	B-Chemical	NOUN	B
pentothal	I-Chemical	NOUN	I
was	O	AUX	O
intravenously	O	ADV	B
infused	O	VERB	B
to	O	PART	O
minimize	O	VERB	O
cerebral	B-Disease	ADJ	B
ischaemia	I-Disease	NOUN	I
.	O	PUNCT	O


Intense	O	ADJ	B
vasospasm	B-Disease	NOUN	B
with	O	ADP	O
threatened	O	ADJ	B
gangrene	B-Disease	NOUN	B
arose	O	VERB	O
in	O	ADP	O
the	O	DET	O
arm	O	NOUN	B
used	O	VERB	O
for	O	ADP	O
the	O	DET	O
infusion	O	NOUN	B
.	O	PUNCT	O


Since	O	SCONJ	O
the	O	DET	O
cranial	O	ADJ	B
condition	O	NOUN	I
precluded	O	VERB	O
use	O	NOUN	O
of	O	ADP	O
more	O	ADV	O
usual	O	ADJ	O
methods	O	NOUN	B
,	O	PUNCT	O
lidocaine	B-Chemical	NOUN	B
was	O	AUX	O
given	O	VERB	O
intra	O	ADJ	B
-	O	PUNCT	O
arterially	O	ADJ	B
,	O	PUNCT	O
with	O	ADP	O
careful	O	ADJ	O
cardiovascular	O	ADJ	B
monitoring	O	NOUN	B
,	O	PUNCT	O
to	O	PART	O
counteract	O	VERB	O
the	O	DET	O
vasospasm	B-Disease	NOUN	B


Cerebral	O	ADJ	B
blood	O	NOUN	I
flow	O	NOUN	I
and	O	CCONJ	O
metabolism	O	NOUN	B
during	O	ADP	O
isoflurane	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypotension	B-Disease	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
subjected	O	VERB	O
to	O	ADP	O
surgery	O	NOUN	B
for	O	ADP	O
cerebral	B-Disease	ADJ	B
aneurysms	I-Disease	NOUN	I
.	O	PUNCT	O


Cerebral	O	ADJ	B
blood	O	NOUN	I
flow	O	NOUN	I
and	O	CCONJ	O
cerebral	O	ADJ	B
metabolic	O	ADJ	O
rate	O	NOUN	O
for	O	ADP	O
oxygen	B-Chemical	NOUN	B
were	O	AUX	O
measured	O	VERB	O
during	O	ADP	O
isoflurane	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypotension	B-Disease	NOUN	B
in	O	ADP	O
10	O	NUM	O
patients	O	NOUN	B
subjected	O	VERB	O
to	O	ADP	O
craniotomy	O	NOUN	B
for	O	ADP	O
clipping	O	VERB	B
of	O	ADP	O
a	O	DET	O
cerebral	B-Disease	ADJ	B
aneurysm	I-Disease	NOUN	I
.	O	PUNCT	O


Flow	O	NOUN	B
and	O	CCONJ	O
metabolism	O	NOUN	B
were	O	AUX	O
measured	O	VERB	B
5	O	NUM	O
-	O	SYM	O
13	O	NUM	O
days	O	NOUN	B
after	O	ADP	O
the	O	DET	O
subarachnoid	B-Disease	ADJ	B
haemorrhage	I-Disease	NOUN	B
by	O	ADP	O
a	O	DET	O
modification	O	NOUN	B
of	O	ADP	O
the	O	DET	O
classical	O	ADJ	O
Kety	O	PROPN	B
-	O	PUNCT	O
Schmidt	O	PROPN	B
technique	O	NOUN	I
using	O	VERB	O
xenon	B-Chemical	NOUN	B
-	O	SYM	O
133	O	NUM	O
i	O	NUM	O
.	O	PUNCT	O


v	O	NOUN	O
.	O	PUNCT	O


Anaesthesia	O	NOUN	B
was	O	AUX	O
maintained	O	VERB	B
with	O	ADP	O
an	O	DET	O
inspired	O	ADJ	B
isoflurane	B-Chemical	NOUN	I
concentration	O	NOUN	B
of	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


75	O	NUM	O
%(	O	NOUN	O
plus	O	CCONJ	O
67	O	NUM	O
%	O	NOUN	O
nitrous	B-Chemical	ADJ	B
oxide	I-Chemical	NOUN	I
in	O	ADP	O
oxygen	B-Chemical	NOUN	B
),	O	PUNCT	O
during	O	ADP	O
which	O	DET	O
CBF	O	NOUN	B
and	O	CCONJ	O
CMRO2	O	NOUN	B
were	O	AUX	O
34	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
+/-	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
ml	O	NOUN	O
/	O	SYM	O
100	O	NUM	O
g	O	NOUN	O
min	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	O
and	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O


32	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


16	O	NUM	O
ml	O	NOUN	O
/	O	SYM	O
100	O	NUM	O
g	O	NOUN	O
min	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	O
at	O	ADP	O
PaCO2	O	NOUN	B
4	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
kPa	O	NOUN	B
(	O	PUNCT	O
mean	O	NOUN	O
+/-	O	CCONJ	O
SEM	O	NOUN	B
).	O	PUNCT	O
Controlled	O	ADJ	B
hypotension	B-Disease	NOUN	I
to	O	PART	O
an	O	DET	O
average	O	ADJ	B
MAP	O	NOUN	B
of	O	ADP	O
50	O	NUM	O
-	O	SYM	O
55	O	NUM	O
mm	O	X	B
Hg	B-Chemical	NOUN	I
was	O	AUX	O
induced	O	VERB	B
by	O	ADP	O
increasing	O	VERB	B
the	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
isoflurane	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
maintained	O	VERB	B
at	O	ADP	O
an	O	DET	O
inspired	O	ADJ	B
concentration	O	NOUN	I
of	O	ADP	O
2	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
%.	O	NOUN	B
This	O	DET	O
resulted	O	VERB	O
in	O	ADP	O
a	O	DET	O
significant	O	ADJ	O
decrease	O	NOUN	B
in	O	ADP	O
CMRO2	O	NOUN	B
(	O	PUNCT	O
to	O	PART	O
1	O	NUM	O
.	O	PUNCT	O


73	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


16	O	NUM	O
ml	O	NOUN	O
/	O	SYM	O
100	O	NUM	O
g	O	NOUN	O
min	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	O
),	O	PUNCT	O
while	O	SCONJ	O
CBF	O	NOUN	B
was	O	AUX	O
unchanged	O	ADJ	B
.	O	PUNCT	O


After	O	ADP	O
the	O	DET	O
clipping	O	NOUN	B
of	O	ADP	O
the	O	DET	O
aneurysm	B-Disease	NOUN	B
the	O	DET	O
isoflurane	B-Chemical	NOUN	B
concentration	O	NOUN	B
was	O	AUX	O
reduced	O	VERB	B
to	O	PART	O
0	O	NUM	O
.	O	PUNCT	O


75	O	NUM	O
%.	O	NOUN	B
There	O	PRON	O
was	O	AUX	O
a	O	DET	O
significant	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
CBF	O	NOUN	B
,	O	PUNCT	O
although	O	SCONJ	O
CMRO2	O	NOUN	B
was	O	AUX	O
unchanged	O	ADJ	B
,	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
pre	O	ADJ	B
-	O	PUNCT	O
hypotensive	B-Disease	ADJ	B
values	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
changes	O	NOUN	B
might	O	AUX	O
offer	O	VERB	O
protection	O	NOUN	B
to	O	PART	O
brain	O	NOUN	B
tissue	O	NOUN	I
during	O	ADP	O
periods	O	NOUN	B
of	O	ADP	O
induced	O	VERB	B
hypotension	B-Disease	NOUN	B


Allergic	B-Disease	ADJ	B
reaction	I-Disease	NOUN	I
to	O	PART	O
5-fluorouracil	B-Chemical	NOUN	B
infusion	O	NOUN	B
.	O	PUNCT	O


An	O	DET	O
allergic	B-Disease	ADJ	B
reaction	I-Disease	NOUN	I
consisting	O	VERB	O
of	O	ADP	O
angioneurotic	B-Disease	ADJ	B
edema	I-Disease	NOUN	I
secondary	O	ADJ	B
to	O	PART	I
continuous	O	ADJ	B
infusion	O	NOUN	B
5-fluorouracil	B-Chemical	NOUN	B
occurred	O	VERB	O
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
recurrent	O	ADJ	B
carcinoma	B-Disease	NOUN	I
of	I-Disease	ADP	O
the	I-Disease	DET	O
oral	I-Disease	ADJ	B
cavity	I-Disease	NOUN	I
,	O	PUNCT	O
cirrhosis	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
cisplatin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
impaired	B-Disease	ADJ	B
renal	I-Disease	ADJ	O
function	I-Disease	NOUN	O
.	O	PUNCT	O


This	O	DET	O
reaction	O	NOUN	B
occurred	O	VERB	O
during	O	ADP	O
the	O	DET	O
sixth	O	ADJ	B
and	O	CCONJ	O
seventh	O	ADJ	O
courses	O	NOUN	B
of	O	ADP	O
infusional	O	ADJ	B
chemotherapy	O	NOUN	I
.	O	PUNCT	O


Oral	O	ADJ	B
diphenhydramine	B-Chemical	NOUN	I
and	O	CCONJ	O
prednisone	B-Chemical	NOUN	B
were	O	AUX	O
ineffective	O	ADJ	B
in	O	ADP	O
preventing	O	VERB	B
the	O	DET	O
recurrence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
allergic	B-Disease	ADJ	B
reaction	I-Disease	NOUN	I


Amiodarone	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
sinoatrial	B-Disease	ADJ	B
block	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
observed	O	VERB	O
sinoatrial	B-Disease	ADJ	B
block	I-Disease	NOUN	I
due	O	ADJ	O
to	O	PART	O
chronic	O	ADJ	B
amiodarone	B-Chemical	NOUN	O
administration	O	NOUN	B
in	O	ADP	O
a	O	DET	O
5	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
boy	O	NOUN	B
with	O	ADP	O
primary	B-Disease	ADJ	B
cardiomyopathy	I-Disease	NOUN	I
,	O	PUNCT	O
Wolff-Parkinson-White	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
and	O	CCONJ	O
supraventricular	B-Disease	ADJ	B
tachycardia	I-Disease	NOUN	I
.	O	PUNCT	O


Reduction	O	NOUN	B
in	O	ADP	O
the	O	DET	O
dosage	O	NOUN	B
of	O	ADP	O
amiodarone	B-Chemical	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
the	O	DET	O
disappearance	O	NOUN	B
of	O	ADP	O
the	O	DET	O
sinoatrial	B-Disease	ADJ	B
block	I-Disease	NOUN	I
and	O	CCONJ	O
the	O	DET	O
persistence	O	NOUN	B
of	O	ADP	O
asymptomatic	O	ADJ	B
sinus	B-Disease	NOUN	B
bradycardia	I-Disease	NOUN	O


Possible	O	ADJ	O
teratogenicity	O	NOUN	B
of	O	ADP	O
sulphasalazine	B-Chemical	NOUN	B
.	O	PUNCT	O


Three	O	NUM	O
infants	O	NOUN	B
,	O	PUNCT	O
born	O	VERB	B
of	O	ADP	O
two	O	NUM	O
mothers	O	NOUN	B
with	O	ADP	O
inflammatory	B-Disease	ADJ	B
bowel	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
who	O	PRON	O
received	O	VERB	O
treatment	O	NOUN	B
with	O	ADP	O
sulphasalazine	B-Chemical	NOUN	B
throughout	O	ADP	O
pregnancy	O	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
found	O	VERB	O
to	O	PART	O
have	O	AUX	O
major	O	ADJ	O
congenital	B-Disease	ADJ	B
anomalies	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
singleton	O	ADJ	B
pregnancy	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
mother	O	NOUN	B
had	O	AUX	O
ulcerative	B-Disease	ADJ	B
colitis	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
infant	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
male	O	NOUN	B
,	O	PUNCT	O
had	O	AUX	O
coarctation	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
aorta	I-Disease	NOUN	B
and	O	CCONJ	O
a	O	DET	O
ventricular	B-Disease	ADJ	B
septal	I-Disease	ADJ	I
defect	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
twin	O	NOUN	B
pregnancy	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
mother	O	NOUN	B
had	O	AUX	O
Crohn's	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
first	O	ADJ	O
twin	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
female	O	NOUN	B
,	O	PUNCT	O
had	O	AUX	O
a	O	DET	O
left	O	ADJ	O
Potter-type	B-Disease	ADJ	B
IIa	I-Disease	NOUN	I
polycystic	I-Disease	ADJ	I
kidney	I-Disease	NOUN	I
and	O	CCONJ	O
a	O	DET	O
rudimentary	B-Disease	ADJ	B
left	I-Disease	ADJ	O
uterine	I-Disease	ADJ	O
cornu	I-Disease	NOUN	O
.	O	PUNCT	O


The	O	DET	O
second	O	ADJ	O
twin	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
male	O	NOUN	B
,	O	PUNCT	O
had	O	AUX	O
some	O	DET	O
features	O	NOUN	B
of	O	ADP	O
Potter's	B-Disease	NOUN	B
facies	I-Disease	NOUN	B
,	O	PUNCT	O
hypoplastic	B-Disease	ADJ	B
lungs	I-Disease	NOUN	I
,	O	PUNCT	O
absent	B-Disease	ADJ	B
kidneys	I-Disease	NOUN	B
and	I-Disease	CCONJ	O
ureters	I-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
talipes	B-Disease	NOUN	B
equinovarus	I-Disease	NOUN	I
.	O	PUNCT	O


Despite	O	SCONJ	O
reports	O	NOUN	B
to	O	ADP	O
the	O	DET	O
contrary	O	NOUN	O
,	O	PUNCT	O
it	O	PRON	O
is	O	AUX	O
suggested	O	VERB	O
that	O	SCONJ	O
sulphasalazine	B-Chemical	NOUN	B


Veno-occlusive	B-Disease	ADJ	B
liver	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
after	O	ADP	O
dacarbazine	B-Chemical	NOUN	B
therapy	O	NOUN	I
(	O	PUNCT	O
DTIC	B-Chemical	NOUN	B
)	O	PUNCT	O
for	O	ADP	O
melanoma	B-Disease	NOUN	B
.	O	PUNCT	O


A	O	DET	O
case	O	NOUN	B
of	O	ADP	O
veno-occlusive	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
of	I-Disease	ADP	O
the	I-Disease	DET	O
liver	I-Disease	NOUN	B
with	O	ADP	O
fatal	O	ADJ	B
outcome	O	NOUN	B
after	O	ADP	O
dacarbazine	B-Chemical	NOUN	B
(	O	PUNCT	O
DTIC	B-Chemical	NOUN	B
)	O	PUNCT	O
therapy	O	NOUN	B
for	O	ADP	O
melanoma	B-Disease	NOUN	B
is	O	AUX	O
reported	O	VERB	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
a	O	DET	O
fulminant	O	ADJ	B
clinical	O	ADJ	B
course	O	NOUN	I
from	O	ADP	O
start	O	NOUN	O
of	O	ADP	O
symptoms	O	NOUN	B
until	O	ADP	O
death	B-Disease	NOUN	B
.	O	PUNCT	O


At	O	ADP	O
autopsy	O	NOUN	B
the	O	DET	O
liver	O	NOUN	B
was	O	AUX	O
enlarged	O	ADJ	B
and	O	CCONJ	O
firm	O	NOUN	O
with	O	ADP	O
signs	O	NOUN	O
of	O	ADP	O
venous	B-Disease	ADJ	B
congestion	I-Disease	NOUN	I
.	O	PUNCT	O


Small	O	ADJ	B
-	O	PUNCT	O
and	O	CCONJ	O
medium	O	NOUN	B
-	O	PUNCT	O
sized	O	ADJ	B
hepatic	O	ADJ	B
veins	O	NOUN	I
were	O	AUX	O
blocked	O	VERB	B
by	O	ADP	O
thrombosis	B-Disease	NOUN	B


A	O	DET	O
case	O	NOUN	B
of	O	ADP	O
tardive	B-Disease	ADJ	B
dyskinesia	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
metoclopramide	B-Chemical	NOUN	B
.	O	PUNCT	O


Abnormal	B-Disease	ADJ	B
involuntary	I-Disease	ADJ	B
movements	I-Disease	NOUN	B
appeared	O	VERB	O
in	O	ADP	O
the	O	DET	O
mouth	O	NOUN	B
,	O	PUNCT	O
tongue	O	NOUN	B
,	O	PUNCT	O
neck	O	NOUN	B
and	O	CCONJ	O
abdomen	O	NOUN	B
of	O	ADP	O
a	O	DET	O
64	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
male	O	NOUN	B
patient	O	NOUN	B
after	O	ADP	O
he	O	PRON	O
took	O	VERB	O
metoclopramide	B-Chemical	NOUN	B
for	O	ADP	O
gastrointestinal	B-Disease	ADJ	B
disorder	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
regimen	O	NOUN	B
of	O	ADP	O
30	O	NUM	O
mg	O	NOUN	O
per	O	ADP	O
day	O	NOUN	B
for	O	ADP	O
a	O	DET	O
total	O	NOUN	O
of	O	ADP	O
about	O	ADV	O
260	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
symptoms	O	NOUN	B
exacerbated	O	VERB	B
to	O	PART	O
a	O	DET	O
maximum	O	NOUN	B
in	O	ADP	O
a	O	DET	O
month	O	NOUN	B
.	O	PUNCT	O


When	O	SCONJ	O
the	O	DET	O
metoclopramide	B-Chemical	NOUN	B
administration	O	NOUN	B
was	O	AUX	O
discontinued	O	VERB	B
,	O	PUNCT	O
the	O	DET	O
abnormal	B-Disease	ADJ	B
movements	I-Disease	NOUN	B
gradually	O	ADV	O
improved	O	VERB	B
to	O	ADP	O
a	O	DET	O
considerable	O	ADJ	O
extent	O	NOUN	O
.	O	PUNCT	O


Attention	O	NOUN	B
to	O	ADP	O
the	O	DET	O
possible	O	ADJ	O
induction	O	NOUN	B
of	O	ADP	O
specific	O	ADJ	O
tardive	B-Disease	ADJ	B
dyskinesia	I-Disease	NOUN	B


Further	O	ADJ	O
observations	O	NOUN	B
on	O	ADP	O
the	O	DET	O
electrophysiologic	O	ADJ	B
effects	O	NOUN	O
of	O	ADP	O
oral	O	ADJ	B
amiodarone	B-Chemical	NOUN	I
therapy	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
case	O	NOUN	B
is	O	AUX	O
presented	O	VERB	O
of	O	ADP	O
a	O	DET	O
reversible	O	ADJ	B
intra-Hisian	B-Disease	ADJ	B
block	I-Disease	NOUN	I
occurring	O	VERB	O
under	O	ADP	O
amiodarone	B-Chemical	NOUN	B
treatment	O	NOUN	B
for	O	ADP	O
atrial	B-Disease	ADJ	B
tachycardia	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
without	O	ADP	O
clear	O	ADJ	O
intraventricular	B-Disease	ADJ	B
conduction	I-Disease	NOUN	O
abnormalities	I-Disease	NOUN	O
.	O	PUNCT	O


His	O	PRON	O
bundle	O	NOUN	B
recordings	O	NOUN	I
showed	O	VERB	O
an	O	DET	O
atrial	B-Disease	ADJ	B
tachycardia	I-Disease	NOUN	I
with	O	ADP	O
intermittent	O	ADJ	B
exit	O	NOUN	I
block	O	NOUN	I
and	O	CCONJ	O
greatly	O	ADV	O
prolonged	O	ADJ	B
BH	O	NOUN	B
and	O	CCONJ	O
HV	O	NOUN	B
intervals	O	NOUN	B
(	O	PUNCT	O
40	O	NUM	O
and	O	CCONJ	O
100	O	NUM	O
msec	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
).	O	SYM	O
Thirty	O	NUM	O
days	O	NOUN	B
after	O	ADP	O
amiodarone	B-Chemical	NOUN	B
discontinuation	O	NOUN	B
,	O	PUNCT	O
His	O	PRON	O
bundle	O	NOUN	B
electrograms	O	NOUN	I
showed	O	VERB	O
atrial	B-Disease	ADJ	B
flutter	I-Disease	NOUN	I
without	O	ADP	O
intra	O	ADJ	B
-	O	PUNCT	O
Hisian	O	PROPN	B
or	O	CCONJ	O
infra	O	X	B
-	O	PUNCT	O
Hisian	O	ADJ	B
delay	O	NOUN	I
.	O	PUNCT	O


Amiodarone	B-Chemical	NOUN	B


Busulfan	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
hemorrhagic	B-Disease	ADJ	B
cystitis	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
case	O	NOUN	B
of	O	ADP	O
a	O	DET	O
busulfan	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hemorrhage	B-Disease	NOUN	B
cystitis	I-Disease	NOUN	O
is	O	AUX	O
reported	O	VERB	O
.	O	PUNCT	O


Spontaneous	O	ADJ	B
resolution	O	NOUN	B
occurred	O	VERB	O
following	O	VERB	O
cessation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
drug	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
similarity	O	NOUN	B
between	O	ADP	O
the	O	DET	O
histologic	O	ADJ	B
appearances	O	NOUN	B
of	O	ADP	O
busulfan	B-Chemical	NOUN	B
cystitis	B-Disease	NOUN	B
and	O	CCONJ	O
both	O	CCONJ	O
radiation	O	NOUN	B
and	O	CCONJ	O
cyclophosphamide	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cystitis	B-Disease	NOUN	B
is	O	AUX	O
discussed	O	VERB	O
and	O	CCONJ	O
the	O	DET	O
world	O	NOUN	B
literature	O	NOUN	I
reviewed	O	VERB	B
.	O	PUNCT	O


In	O	ADP	O
view	O	NOUN	O
of	O	ADP	O
the	O	DET	O
known	O	ADJ	O
tendency	O	NOUN	O
of	O	ADP	O
busulfan	B-Chemical	NOUN	B
to	O	PART	O
induce	O	VERB	B
cellular	O	ADJ	B
atypia	O	NOUN	I
and	O	CCONJ	O
carcinoma	B-Disease	NOUN	B


Rebound	O	ADJ	B
hypertensive	B-Disease	NOUN	I
after	O	ADP	O
sodium	B-Chemical	NOUN	B
nitroprusside	I-Chemical	NOUN	I
prevented	O	VERB	B
by	O	ADP	O
saralasin	B-Chemical	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
role	O	NOUN	O
of	O	ADP	O
the	O	DET	O
renin	O	NOUN	B
--	O	PUNCT	O
angiotensin	B-Chemical	NOUN	B
system	O	NOUN	I
in	O	ADP	O
the	O	DET	O
maintenance	O	NOUN	B
of	O	ADP	O
blood	O	NOUN	B
pressure	O	NOUN	I
during	O	ADP	O
halothane	B-Chemical	NOUN	B
anesthesia	O	NOUN	I
and	O	CCONJ	O
sodium	B-Chemical	NOUN	B
nitroprusside	I-Chemical	NOUN	I
(	O	PUNCT	O
SNP	B-Chemical	NOUN	B
)-	O	ADJ	O
induced	O	VERB	B
hypotension	B-Disease	NOUN	B
was	O	AUX	O
evaluated	O	VERB	B
.	O	PUNCT	O


Control	O	ADJ	B
rats	O	NOUN	B
received	O	VERB	O
halothane	B-Chemical	NOUN	B
anesthesia	O	NOUN	I
(	O	PUNCT	O
1	O	NUM	O
MAC	O	NOUN	B
)	O	PUNCT	O
for	O	ADP	O
one	O	NUM	O
hour	O	NOUN	B
,	O	PUNCT	O
followed	O	VERB	O
by	O	ADP	O
SNP	B-Chemical	NOUN	B
infusion	O	NOUN	B
,	O	PUNCT	O
40	O	NUM	O
microgram	O	NOUN	B
/	O	SYM	O
kg	O	NOUN	B
/	O	PUNCT	O
min	O	NOUN	B
,	O	PUNCT	O
for	O	ADP	O
30	O	NUM	O
min	O	NOUN	O
,	O	PUNCT	O
followed	O	VERB	O
by	O	ADP	O
a	O	DET	O
30	O	NUM	O
-	O	PUNCT	O
min	O	NOUN	B
recovery	O	NOUN	B
period	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
second	O	ADJ	O
group	O	NOUN	B
of	O	ADP	O
rats	O	NOUN	B
was	O	AUX	O
treated	O	VERB	B
identically	O	ADV	O
and	O	CCONJ	O
,	O	PUNCT	O
in	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
received	O	VERB	O
an	O	DET	O
infusion	O	NOUN	B
of	O	ADP	O
saralasin	B-Chemical	NOUN	B
(	O	PUNCT	O
a	O	DET	O
competitive	O	ADJ	B
inhibitor	O	NOUN	B
of	O	ADP	O
angiotensin	B-Chemical	NOUN	B
II	I-Chemical	NUM	I
)	O	PUNCT	O
throughout	O	ADP	O
the	O	DET	O
experimental	O	ADJ	B
period	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
each	O	DET	O
group	O	NOUN	B
,	O	PUNCT	O
SNP	B-Chemical	NOUN	B
infusion	O	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
an	O	DET	O
initial	O	ADJ	O
decrease	O	NOUN	B
in	O	ADP	O
blood	O	NOUN	B
pressure	O	NOUN	I
from	O	ADP	O
86	O	NUM	O
torr	O	NOUN	B
and	O	CCONJ	O
83	O	NUM	O
torr	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
to	O	PART	O
48	O	NUM	O
torr	O	NOUN	B
.	O	PUNCT	O


During	O	ADP	O
the	O	DET	O
SNP	B-Chemical	NOUN	B
infusion	O	NOUN	B
the	O	DET	O
control	O	NOUN	B
animals	O	NOUN	I
demonstrated	O	VERB	O
a	O	DET	O
progressive	O	ADJ	B
increase	B-Disease	NOUN	B
in	I-Disease	ADP	O
blood	I-Disease	NOUN	B
pressure	I-Disease	NOUN	I
to	O	PART	O
61	O	NUM	O
torr	O	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
the	O	DET	O
saralasin	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
animals	O	NOUN	B
showed	O	VERB	O
no	O	DET	O
change	O	NOUN	O
.	O	PUNCT	O


Following	O	VERB	O
discontinuation	O	NOUN	B
of	O	ADP	O
SNP	B-Chemical	NOUN	B
,	O	PUNCT	O
blood	O	NOUN	B
pressure	O	NOUN	I
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
animals	O	NOUN	I
rebounded	O	VERB	O
to	O	PART	O
94	O	NUM	O
torr	O	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
compared	O	VERB	B
with	O	ADP	O
78	O	NUM	O
torr	O	NOUN	B
in	O	ADP	O
the	O	DET	O
saralasin	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
rats	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
indicates	O	VERB	O
that	O	SCONJ	O
with	O	ADP	O
stable	O	ADJ	B
halothane	B-Chemical	NOUN	B
anesthesia	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
partial	O	ADJ	B
recovery	O	NOUN	B
of	O	ADP	O
blood	O	NOUN	B
pressure	O	NOUN	I
during	O	ADP	O
SNP	B-Chemical	NOUN	B
infusion	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
post	O	NOUN	B
-	O	PUNCT	O
SNP	B-Chemical	PROPN	B
rebound	O	NOUN	B
of	O	ADP	O
blood	O	NOUN	B
pressure	O	NOUN	I
can	O	AUX	O
be	O	AUX	O
completely	O	ADV	O
blocked	O	VERB	B
by	O	ADP	O
saralasin	B-Chemical	NOUN	B
.	O	PUNCT	O


This	O	DET	O
demonstrates	O	VERB	O
the	O	DET	O
participation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
renin	O	NOUN	B
--	O	PUNCT	O
angiotensin	B-Chemical	ADJ	B
system	O	NOUN	I
in	O	ADP	O
antagonizing	O	VERB	B
the	O	DET	O
combined	O	ADJ	B
hypotensive	B-Disease	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
halothane	B-Chemical	NOUN	B
and	O	CCONJ	O
SNP	B-Chemical	NOUN	B


Toxic	B-Disease	NOUN	B
hepatitis	I-Disease	NOUN	I
induced	O	VERB	B
by	O	ADP	O
antithyroid	O	ADJ	B
drugs	O	NOUN	I
:	O	PUNCT	O
four	O	NUM	O
cases	O	NOUN	B
including	O	VERB	O
one	O	NUM	O
with	O	ADP	O
cross	O	NOUN	B
-	O	PUNCT	O
reactivity	O	NOUN	B
between	O	ADP	O
carbimazole	B-Chemical	NOUN	B
and	O	CCONJ	O
benzylthiouracil	B-Chemical	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
:	O	PUNCT	O
This	O	DET	O
study	O	NOUN	B
was	O	AUX	O
conducted	O	VERB	O
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
occurrence	O	NOUN	B
of	O	ADP	O
hepatic	B-Disease	ADJ	B
adverse	I-Disease	ADJ	O
effects	I-Disease	NOUN	O
encountered	O	VERB	O
with	O	ADP	O
antithyroid	O	ADJ	B
drugs	O	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
Retrospective	O	ADJ	B
review	O	NOUN	I
of	O	ADP	O
medical	O	ADJ	B
records	O	NOUN	I
of	O	ADP	O
236	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
hyperthyroidism	B-Disease	NOUN	B
admitted	O	VERB	B
in	O	ADP	O
our	O	PRON	O
department	O	NOUN	B
(	O	PUNCT	O
in	O	ADP	O
-	O	PUNCT	O
or	O	CCONJ	O
out	O	ADJ	B
-	O	PUNCT	O
patients	O	NOUN	B
)	O	PUNCT	O
from	O	ADP	O
1986	O	NUM	O
to	O	ADP	O
1992	O	NUM	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Four	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
%)	O	NOUN	O
were	O	AUX	O
identified	O	VERB	B
with	O	ADP	O
toxic	B-Disease	ADJ	B
hepatitis	I-Disease	NOUN	O
which	O	DET	O
could	O	AUX	O
reasonably	O	ADV	O
be	O	AUX	O
attributed	O	VERB	O
to	O	PART	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
antithyroid	O	ADJ	B
agent	O	NOUN	I
.	O	PUNCT	O


Two	O	NUM	O
patients	O	NOUN	B
had	O	AUX	O
a	O	DET	O
cholestatic	B-Disease	ADJ	B
hepatitis	I-Disease	NOUN	I
induced	O	VERB	B
by	O	ADP	O
carbimazole	B-Chemical	NOUN	B
(	O	PUNCT	O
N	B-Chemical	NOUN	B
omercazole	I-Chemical	NOUN	I
).	O	PUNCT	O
Two	O	NUM	O
others	O	NOUN	O
had	O	AUX	O
a	O	DET	O
mixed	O	ADJ	O
(	O	PUNCT	O
cholestatic	B-Disease	ADJ	B
and	O	CCONJ	O
cytolytic	O	ADJ	B
)	O	PUNCT	O
hepatitis	B-Disease	NOUN	O
following	O	VERB	O
carbimazole	B-Chemical	NOUN	B
.	O	PUNCT	O


One	O	NUM	O
of	O	ADP	O
the	O	DET	O
latter	O	ADJ	O
two	O	NUM	O
patients	O	NOUN	B
further	O	ADV	O
experienced	O	VERB	O
a	O	DET	O
cytolytic	O	ADJ	B
hepatitis	B-Disease	NOUN	I
which	O	DET	O
appeared	O	VERB	O
after	O	ADP	O
Benzylthiouracil	B-Chemical	NOUN	B
(	O	PUNCT	O
Basd	B-Chemical	PROPN	B
ne	I-Chemical	X	O
)	O	PUNCT	O
had	O	AUX	O
replaced	O	VERB	O
carbimazole	B-Chemical	NOUN	B
.	O	PUNCT	O


Biological	O	ADJ	B
features	O	NOUN	B
of	O	ADP	O
hepatitis	B-Disease	NOUN	B
disappeared	O	VERB	O
in	O	ADP	O
all	O	DET	O
cases	O	NOUN	B
after	O	ADP	O
cessation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
incriminated	O	VERB	B
drug	O	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
biliary	O	ADJ	B
,	O	PUNCT	O
viral	O	ADJ	B
and	O	CCONJ	O
immunological	O	ADJ	B
searches	O	NOUN	O
were	O	AUX	O
negative	O	ADJ	B
.	O	PUNCT	O


Only	O	ADV	O
2	O	NUM	O
patients	O	NOUN	B
of	O	ADP	O
our	O	PRON	O
retrospective	O	ADJ	B
study	O	NOUN	I
experienced	O	VERB	O
a	O	DET	O
mild	O	ADJ	B
or	O	CCONJ	O
severe	O	ADJ	B
neutropenia	B-Disease	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
Toxic	B-Disease	NOUN	B
hepatitis	I-Disease	NOUN	I
is	O	AUX	O
a	O	DET	O
potential	O	ADJ	B
adverse	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
antithyroid	O	ADJ	B
drugs	O	NOUN	I
which	O	DET	O
warrants	O	VERB	O
,	O	PUNCT	O
as	O	ADP	O
for	O	ADP	O
haematological	O	ADJ	B
disturbances	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
pre	O	ADJ	B
-	O	PUNCT	O
therapeutic	O	ADJ	B
determination	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
careful	O	ADJ	O
follow	O	NOUN	B
-	O	PUNCT	O
up	O	NOUN	O
of	O	ADP	O
relevant	O	ADJ	B
biological	O	ADJ	B
markers	O	NOUN	B
.	O	PUNCT	O


Moreover	O	ADV	O
,	O	PUNCT	O
hepatotoxicity	B-Disease	NOUN	B


Study	O	NOUN	B
of	O	ADP	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
vitamin	B-Chemical	NOUN	B
B12	I-Chemical	NOUN	I
and	O	CCONJ	O
folinic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
supplementation	O	NOUN	B
in	O	ADP	O
preventing	O	VERB	B
hematologic	O	ADJ	B
toxicity	B-Disease	NOUN	B
of	O	ADP	O
zidovudine	B-Chemical	NOUN	B
.	O	PUNCT	O


A	O	DET	O
prospective	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
study	O	NOUN	I
was	O	AUX	O
conducted	O	VERB	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
vitamin	B-Chemical	NOUN	B
B12	I-Chemical	NOUN	I
and	O	CCONJ	O
folinic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
supplementation	O	NOUN	B
in	O	ADP	O
preventing	O	VERB	B
zidovudine	B-Chemical	NOUN	B
(	O	PUNCT	O
ZDV	B-Chemical	NOUN	B
)-	O	ADJ	O
induced	O	VERB	B
bone	B-Disease	NOUN	B
marrow	I-Disease	NOUN	I
suppression	I-Disease	NOUN	B
.	O	PUNCT	O


Seventy	O	NUM	B
-	O	PUNCT	O
five	O	NUM	B
human	B-Disease	ADJ	B
immunodeficiency	I-Disease	NOUN	I
virus	I-Disease	NOUN	I
(HIV)-infected	I-Disease	ADJ	O
patients	O	NOUN	B
with	O	ADP	O
CD4	O	NOUN	B
+	O	CCONJ	O
cell	O	NOUN	B
counts	O	VERB	I
<	O	X	O
500	O	NUM	O
/	O	SYM	O
mm3	O	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
receive	O	VERB	O
either	O	CCONJ	O
ZDV	B-Chemical	NOUN	B
(	O	PUNCT	O
500	O	NUM	O
mg	O	NOUN	O
daily	O	ADV	B
)	O	PUNCT	O
alone	O	ADJ	O
(	O	PUNCT	O
group	O	NOUN	B
I	O	NOUN	I
,	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
38	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
in	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
folinic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
(	O	PUNCT	O
15	O	NUM	O
mg	O	NOUN	O
daily	O	ADV	B
)	O	PUNCT	O
and	O	CCONJ	O
intramascular	O	ADJ	B
vitamin	B-Chemical	NOUN	B
B12	I-Chemical	NOUN	I
(	O	PUNCT	O
1000	O	NUM	O
micrograms	O	NOUN	O
monthly	O	ADJ	B
)(	O	NOUN	O
group	O	NOUN	B
II	O	NUM	I
,	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
37	O	NUM	O
).	O	PUNCT	O
Finally	O	ADV	O
,	O	PUNCT	O
15	O	NUM	O
patients	O	NOUN	B
were	O	AUX	O
excluded	O	VERB	O
from	O	ADP	O
the	O	DET	O
study	O	NOUN	B
(	O	PUNCT	O
noncompliance	O	NOUN	B
14	O	NUM	O
,	O	PUNCT	O
death	B-Disease	NOUN	B
1	O	NUM	O
);	O	ADJ	O
thus	O	ADV	O
,	O	PUNCT	O
60	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
31	O	NUM	O
in	O	ADP	O
group	O	NOUN	B
I	O	NUM	I
and	O	CCONJ	O
29	O	NUM	O
in	O	ADP	O
group	O	NOUN	B
II	O	NUM	I
)	O	PUNCT	O
were	O	AUX	O
eligible	O	ADJ	B
for	O	ADP	O
analysis	O	NOUN	B
.	O	PUNCT	O


No	O	DET	B
significant	O	ADJ	I
differences	O	NOUN	O
between	O	ADP	O
groups	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
at	O	ADP	O
enrollment	O	NOUN	B
.	O	PUNCT	O


During	O	ADP	O
the	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
vitamin	B-Chemical	NOUN	B
B12	I-Chemical	NOUN	I
and	O	CCONJ	O
folate	B-Chemical	NOUN	B
levels	O	NOUN	I
were	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
in	O	ADP	O
group	O	NOUN	B
II	O	NUM	I
patients	O	NOUN	B
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
no	O	DET	O
differences	O	NOUN	O
in	O	ADP	O
hemoglobin	O	NOUN	B
,	O	PUNCT	O
hematocrit	O	NOUN	B
,	O	PUNCT	O
mean	O	ADJ	B
corpuscular	O	ADJ	I
volume	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
white	O	ADJ	B
-	O	PUNCT	O
cell	O	NOUN	B
,	O	PUNCT	O
neutrophil	O	NOUN	B
and	O	CCONJ	O
platelet	O	NOUN	B
counts	O	NOUN	I
were	O	AUX	O
observed	O	VERB	O
between	O	ADP	O
groups	O	NOUN	B
at	O	ADP	O
3	O	NUM	O
,	O	PUNCT	O
6	O	NUM	O
,	O	PUNCT	O
9	O	NUM	O
and	O	CCONJ	O
12	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


Severe	O	ADJ	B
hematologic	O	ADJ	B
toxicity	B-Disease	NOUN	B
(	O	PUNCT	O
neutrophil	O	NOUN	B
count	O	NOUN	O
<	O	X	O
1000	O	NUM	O
/	O	SYM	O
mm3	O	NUM	B
and	O	CCONJ	O
/	O	SYM	B
or	O	CCONJ	O
hemoglobin	O	NOUN	B
<	O	NOUN	O
8	O	NUM	O
g	O	NOUN	B
/	O	SYM	O
dl	O	NOUN	B
)	O	PUNCT	O
occurred	O	VERB	O
in	O	ADP	O
4	O	NUM	O
patients	O	NOUN	B
assigned	O	VERB	O
to	O	PART	O
group	O	NOUN	B
I	O	NUM	I
and	O	CCONJ	O
7	O	NUM	O
assigned	O	VERB	B
to	O	PART	O
group	O	NOUN	B
II	O	NUM	I
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
correlation	O	NOUN	B
between	O	ADP	O
vitamin	B-Chemical	NOUN	B
B12	I-Chemical	NOUN	I
or	O	CCONJ	O
folate	B-Chemical	NOUN	B
levels	O	NOUN	I
and	O	CCONJ	O
development	O	NOUN	B
of	O	ADP	O
myelosuppression	B-Disease	NOUN	B
.	O	PUNCT	O


Vitamin	B-Chemical	NOUN	B
B12	I-Chemical	NOUN	I
and	O	CCONJ	O
folinic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
supplementation	O	NOUN	B
of	O	ADP	O
ZDV	B-Chemical	NOUN	B
therapy	O	NOUN	B
does	O	AUX	O
not	O	PART	O
seem	O	VERB	O
useful	O	ADJ	O
in	O	ADP	O
preventing	O	VERB	B
or	O	CCONJ	O
reducing	O	VERB	B
ZDV	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
myelotoxicity	B-Disease	NOUN	B


Acute	O	ADJ	B
confusion	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
a	O	DET	O
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
infusion	O	NOUN	B
of	O	ADP	O
5-fluorouracil	B-Chemical	NOUN	B
and	O	CCONJ	O
folinic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
.	O	PUNCT	O


A	O	DET	O
61	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
man	O	NOUN	B
was	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
combination	O	NOUN	B
chemotherapy	O	NOUN	I
incorporating	O	VERB	O
cisplatinum	B-Chemical	NOUN	B
,	O	PUNCT	O
etoposide	B-Chemical	NOUN	B
,	O	PUNCT	O
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
5-fluorouracil	B-Chemical	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
,	O	PUNCT	O
250	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2	O	PROPN	B
/	O	SYM	O
24	O	NUM	B
hours	O	NOUN	I
)	O	PUNCT	O
and	O	CCONJ	O
folinic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
for	O	ADP	O
an	O	DET	O
inoperable	O	ADJ	B
gastric	B-Disease	ADJ	I
adenocarcinoma	I-Disease	NOUN	I
.	O	PUNCT	O


He	O	PRON	O
developed	O	VERB	O
acute	O	ADJ	B
neurologic	O	ADJ	O
symptoms	O	NOUN	O
of	O	ADP	O
mental	O	ADJ	B
confusion	B-Disease	NOUN	I
,	O	PUNCT	O
disorientation	B-Disease	NOUN	B
and	O	CCONJ	O
irritability	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
then	O	ADV	O
lapsed	O	VERB	B
into	O	ADP	O
a	O	DET	O
deep	O	ADJ	B
coma	B-Disease	NOUN	I
,	O	PUNCT	O
lasting	O	VERB	O
for	O	ADP	O
approximately	O	ADV	B
40	O	NUM	O
hours	O	NOUN	B
during	O	ADP	O
the	O	DET	O
first	O	ADJ	B
dose	O	NOUN	I
(	O	PUNCT	O
day	O	NOUN	B
2	O	NUM	O
)	O	PUNCT	O
of	O	ADP	O
5-fluorouracil	B-Chemical	NOUN	B
and	O	CCONJ	O
folinic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
infusion	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
complication	O	NOUN	B
reappeared	O	VERB	O
on	O	ADP	O
day	O	NOUN	B
25	O	NUM	O
during	O	ADP	O
the	O	DET	O
second	O	ADJ	O
dose	O	NOUN	B
of	O	ADP	O
5-fluorouracil	B-Chemical	NOUN	B
and	O	CCONJ	O
folinic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
,	O	PUNCT	O
which	O	DET	O
were	O	AUX	O
then	O	ADV	O
the	O	DET	O
only	O	ADJ	O
drugs	O	NOUN	B
given	O	VERB	O
.	O	PUNCT	O


Because	O	SCONJ	O
folinic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
was	O	AUX	O
unlikely	O	ADJ	O
to	O	PART	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
this	O	DET	O
condition	O	NOUN	B
,	O	PUNCT	O
neurotoxicity	B-Disease	NOUN	B
due	O	ADP	O
to	O	PART	O
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
5-fluorouracil	B-Chemical	NOUN	B
was	O	AUX	O
highly	O	ADV	O
suspected	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
pathogenesis	O	NOUN	B
of	O	ADP	O
5-fluorouracil	B-Chemical	NOUN	B
neurotoxicity	B-Disease	NOUN	B
may	O	AUX	O
be	O	AUX	O
due	O	ADJ	O
to	O	PART	O
a	O	DET	O
Krebs	O	NOUN	B
cycle	O	NOUN	I
blockade	O	NOUN	I
by	O	ADP	O
fluoroacetate	B-Chemical	NOUN	B
and	O	CCONJ	O
fluorocitrate	B-Chemical	NOUN	B
,	O	PUNCT	O
thiamine	B-Chemical	NOUN	B
deficiency	O	NOUN	I
,	O	PUNCT	O
or	O	CCONJ	O
dihydrouracil	B-Chemical	NOUN	B
dehydrogenase	O	NOUN	I
deficiency	O	NOUN	I
.	O	PUNCT	O


High	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
5-fluorouracil	B-Chemical	NOUN	B
/	O	PUNCT	O
folinic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
infusion	O	NOUN	B
therapy	O	NOUN	B
has	O	AUX	O
recently	O	ADV	O
become	O	VERB	O
a	O	DET	O
popular	O	ADJ	O
regimen	O	NOUN	B
for	O	ADP	O
various	O	ADJ	O
cancers	B-Disease	NOUN	B


Effect	O	NOUN	B
of	O	ADP	O
switching	O	VERB	B
carbamazepine	B-Chemical	NOUN	B
to	O	ADP	O
oxcarbazepine	B-Chemical	NOUN	B
on	O	ADP	O
the	O	DET	O
plasma	O	NOUN	B
levels	O	NOUN	B
of	O	ADP	O
neuroleptics	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
case	O	NOUN	B
report	O	NOUN	I
.	O	PUNCT	O


Carbamazepine	B-Chemical	PROPN	B
was	O	AUX	O
switched	O	VERB	O
to	O	ADP	O
its	O	PRON	O
10	O	NUM	O
-	O	PUNCT	O
keto	O	NOUN	B
analogue	O	NOUN	B
oxcarbazepine	B-Chemical	NOUN	B
among	O	ADP	O
six	O	NUM	O
difficult	O	ADJ	B
-	O	PUNCT	O
to	O	PART	O
-	O	PUNCT	O
treat	O	VERB	B
schizophrenic	B-Disease	ADJ	B
or	O	CCONJ	O
organic	B-Disease	ADJ	B
psychotic	I-Disease	ADJ	B
patients	O	NOUN	B
using	O	VERB	O
concomitantly	O	ADV	O
haloperidol	B-Chemical	NOUN	B
,	O	PUNCT	O
chlorpromazine	B-Chemical	NOUN	B
or	O	CCONJ	O
clozapine	B-Chemical	NOUN	B
.	O	PUNCT	O


This	O	DET	O
change	O	NOUN	O
resulted	O	VERB	O
within	O	ADP	O
2	O	NUM	O
-	O	SYM	O
4	O	NUM	O
weeks	O	NOUN	B
in	O	ADP	O
the	O	DET	O
50	O	NUM	O
-	O	SYM	O
200	O	NUM	O
%	O	NOUN	O
increase	O	NOUN	B
in	O	ADP	O
the	O	DET	O
plasma	O	NOUN	B
levels	O	NOUN	B
of	O	ADP	O
these	O	DET	O
neuroleptics	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
appearance	O	NOUN	B
of	O	ADP	O
extrapyramidal	B-Disease	ADJ	B
symptoms	I-Disease	NOUN	I
.	O	PUNCT	O


of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
showed	O	VERB	O
any	O	DET	O
clinical	O	ADJ	B
deteriotation	O	NOUN	I
during	O	ADP	O
the	O	DET	O
following	O	VERB	O
3	O	NUM	O
-	O	SYM	O
6	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
of	O	ADP	O
this	O	DET	O
case	O	NOUN	B
report	O	NOUN	I
support	O	VERB	O
the	O	DET	O
idea	O	NOUN	O
that	O	SCONJ	O
in	O	ADP	O
contrast	O	NOUN	O
with	O	ADP	O
carbamazepine	B-Chemical	NOUN	B
oxcarbazepine	B-Chemical	NOUN	B


Erythema	B-Disease	NOUN	B
multiforme	I-Disease	NOUN	I
and	O	CCONJ	O
hypersensitivity	B-Disease	NOUN	B
myocarditis	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
ampicillin	B-Chemical	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
:	O	PUNCT	O
To	O	PART	O
report	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
erythema	B-Disease	NOUN	B
multiforme	I-Disease	NOUN	I
and	O	CCONJ	O
hypersensitivity	B-Disease	NOUN	B
myocarditis	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
ampicillin	B-Chemical	NOUN	B
.	O	PUNCT	O


CASE	O	ADJ	B
SUMMARY	O	NOUN	I
:	O	PUNCT	O
A	O	DET	O
13	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
boy	O	NOUN	B
was	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
ampicillin	B-Chemical	NOUN	B
and	O	CCONJ	O
gentamicin	B-Chemical	NOUN	B
because	O	SCONJ	O
of	O	ADP	O
suspected	O	VERB	B
septicemia	B-Disease	NOUN	B
.	O	PUNCT	O


Medications	O	NOUN	B
were	O	AUX	O
discontinued	O	VERB	B
when	O	SCONJ	O
erythema	B-Disease	NOUN	B
multiforme	I-Disease	NOUN	I
and	O	CCONJ	O
congestive	B-Disease	ADJ	B
heart	I-Disease	NOUN	I
failure	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
myocarditis	B-Disease	NOUN	B
occurred	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
was	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
methylprednisolone	B-Chemical	NOUN	B
and	O	CCONJ	O
gradually	O	ADV	O
improved	O	VERB	B
.	O	PUNCT	O


Macrophage	O	NOUN	B
-	O	PUNCT	O
migration	O	NOUN	B
inhibition	O	NOUN	B
(	O	PUNCT	O
MIF	O	NOUN	B
)	O	PUNCT	O
test	O	NOUN	O
with	O	ADP	O
ampicillin	B-Chemical	NOUN	B
was	O	AUX	O
positive	O	ADJ	B
.	O	PUNCT	O


DISCUSSION	O	NOUN	O
:	O	PUNCT	O
After	O	ADP	O
most	O	ADJ	O
infections	B-Disease	NOUN	B
causing	O	VERB	O
erythema	B-Disease	NOUN	B
multiforme	I-Disease	NOUN	I
and	O	CCONJ	O
myocarditis	B-Disease	NOUN	B
were	O	AUX	O
ruled	O	VERB	O
out	O	ADP	O
,	O	PUNCT	O
a	O	DET	O
drug-induced	B-Disease	ADJ	B
allergic	I-Disease	ADJ	I
reaction	I-Disease	NOUN	I
was	O	AUX	O
suspected	O	VERB	B
.	O	PUNCT	O


Positive	O	ADJ	B
MIF	O	NOUN	O
test	O	NOUN	O
for	O	ADP	O
ampicillin	B-Chemical	NOUN	B
showed	O	VERB	O
sensitization	O	NOUN	B
of	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
'	O	PART	O
s	O	NOUN	O
lymphocytes	O	NOUN	B
to	O	PART	O
ampicillin	B-Chemical	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	B
:	O	PUNCT	O
Hypersensitivity	B-Disease	NOUN	B
myocarditis	I-Disease	NOUN	I
is	O	AUX	O
a	O	DET	O
rare	O	ADJ	B
and	O	CCONJ	O
dangerous	O	ADJ	O
manifestation	O	NOUN	B
of	O	ADP	O
allergy	B-Disease	NOUN	B
to	O	PART	O
penicillins	B-Chemical	NOUN	B


Immediate	O	ADJ	B
allergic	B-Disease	ADJ	I
reactions	I-Disease	NOUN	I
to	O	PART	O
amoxicillin	B-Chemical	NOUN	B
.	O	PUNCT	O


A	O	DET	O
large	O	ADJ	O
group	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
suspected	O	VERB	B
allergic	B-Disease	ADJ	B
reactions	I-Disease	NOUN	I
to	O	PART	O
beta-lactam	B-Chemical	NOUN	B
antibiotics	O	NOUN	I
was	O	AUX	O
evaluated	O	VERB	B
.	O	PUNCT	O


A	O	DET	O
detailed	O	ADJ	O
clinical	O	ADJ	B
history	O	NOUN	I
,	O	PUNCT	O
together	O	ADV	O
with	O	ADP	O
skin	O	NOUN	B
tests	O	NOUN	I
,	O	PUNCT	O
RAST	O	NOUN	B
(	O	PUNCT	O
radioallergosorbent	O	ADJ	B
test	O	NOUN	I
),	O	PUNCT	O
and	O	CCONJ	O
controlled	O	VERB	B
challenge	O	NOUN	I
tests	O	NOUN	I
,	O	PUNCT	O
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
establish	O	VERB	O
whether	O	SCONJ	O
patients	O	NOUN	B
allergic	B-Disease	ADJ	B
to	O	PART	O
beta-lactam	B-Chemical	NOUN	B
antibiotics	O	NOUN	I
had	O	AUX	O
selective	O	ADJ	O
immediate	O	ADJ	B
allergic	B-Disease	ADJ	B
responses	O	NOUN	I
to	O	PART	O
amoxicillin	B-Chemical	NOUN	B
(	O	PUNCT	O
AX	B-Chemical	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
were	O	AUX	O
cross	O	NOUN	B
-	O	PUNCT	O
reacting	O	VERB	B
with	O	ADP	O
other	O	ADJ	O
penicillin	B-Chemical	NOUN	B
derivatives	O	NOUN	O
.	O	PUNCT	O


Skin	O	NOUN	B
tests	O	NOUN	I
were	O	AUX	O
performed	O	VERB	O
with	O	ADP	O
benzylpenicilloyl-poly-L-lysine	B-Chemical	NOUN	B
(	O	PUNCT	O
BPO-PLL	B-Chemical	NOUN	B
),	O	PUNCT	O
benzylpenicilloate	B-Chemical	NOUN	B
,	O	PUNCT	O
benzylpenicillin	B-Chemical	NOUN	B
(	O	PUNCT	O
PG	B-Chemical	NOUN	B
),	O	PUNCT	O
ampicillin	B-Chemical	NOUN	B
(	O	PUNCT	O
AMP	B-Chemical	NOUN	B
),	O	PUNCT	O
and	O	CCONJ	O
AX	B-Chemical	NOUN	B
.	O	PUNCT	O


RAST	O	NOUN	B
for	O	ADP	O
BPO-PLL	B-Chemical	NOUN	B
and	O	CCONJ	O
AX	B-Chemical	PROPN	B
-	O	PUNCT	O
PLL	O	PROPN	B
was	O	AUX	O
done	O	VERB	O
.	O	PUNCT	O


When	O	SCONJ	O
both	O	DET	O
skin	O	NOUN	B
test	O	NOUN	I
and	O	CCONJ	O
RAST	O	NOUN	B
for	O	ADP	O
BPO	B-Chemical	NOUN	B
were	O	AUX	O
negative	O	ADJ	B
,	O	PUNCT	O
single	O	ADJ	B
-	O	PUNCT	O
blind	O	NOUN	B
,	O	PUNCT	O
placebo	O	NOUN	B
-	O	PUNCT	O
controlled	O	VERB	B
challenge	O	NOUN	O
tests	O	NOUN	O
were	O	AUX	O
done	O	VERB	O
to	O	PART	O
ensure	O	VERB	O
tolerance	O	NOUN	B
of	O	ADP	O
PG	B-Chemical	NOUN	B
or	O	CCONJ	O
sensitivity	O	NOUN	B
to	O	PART	O
AX	B-Chemical	NOUN	B
.	O	PUNCT	O


A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
177	O	NUM	O
patients	O	NOUN	B
were	O	AUX	O
diagnosed	O	VERB	B
as	O	ADP	O
allergic	B-Disease	ADJ	B
to	O	PART	O
beta-lactam	B-Chemical	NOUN	B
antibiotics	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
selected	O	VERB	O
the	O	DET	O
54	O	NUM	O
(	O	PUNCT	O
30	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
%)	O	NOUN	O
cases	O	NOUN	B
of	O	ADP	O
immediate	O	ADJ	B
AX	B-Chemical	NOUN	B
allergy	B-Disease	NOUN	I
with	O	ADP	O
good	O	ADJ	O
tolerance	O	NOUN	B
of	O	ADP	O
PG	B-Chemical	NOUN	B
.	O	PUNCT	O


Anaphylaxis	B-Disease	NOUN	B
was	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
37	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
69	O	NUM	O
%),	O	VERB	O
the	O	DET	O
other	O	ADJ	O
17	O	NUM	O
(	O	PUNCT	O
31	O	NUM	O
%)	O	NOUN	O
having	O	VERB	O
urticaria	B-Disease	NOUN	B
and	O	CCONJ	O
/	O	SYM	B
or	O	CCONJ	O
angioedema	B-Disease	NOUN	B
.	O	PUNCT	O


All	O	DET	O
the	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
skin	O	NOUN	B
test	O	NOUN	I
negative	O	ADJ	B
to	O	ADP	O
BPO	B-Chemical	NOUN	B
;	O	PUNCT	O
49	O	NUM	O
of	O	ADP	O
51	O	NUM	O
(	O	PUNCT	O
96	O	NUM	O
%)	O	NOUN	O
were	O	AUX	O
also	O	ADV	O
negative	O	ADJ	B
to	O	PART	O
MDM	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
44	O	NUM	O
of	O	ADP	O
46	O	NUM	O
(	O	PUNCT	O
96	O	NUM	O
%)	O	NOUN	O
to	O	PART	O
PG	B-Chemical	NOUN	B
.	O	PUNCT	O


Skin	O	NOUN	B
tests	O	NOUN	I
with	O	ADP	O
AX	B-Chemical	NOUN	B
were	O	AUX	O
positive	O	ADJ	B
in	O	ADP	O
34	O	NUM	O
(	O	PUNCT	O
63	O	NUM	O
%)	O	NOUN	O
patients	O	NOUN	B
.	O	PUNCT	O


RAST	O	NOUN	B
was	O	AUX	O
positive	O	ADJ	B
for	O	ADP	O
AX	B-Chemical	NOUN	B
in	O	ADP	O
22	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
41	O	NUM	O
%)	O	NOUN	O
and	O	CCONJ	O
to	O	ADP	O
BPO	B-Chemical	PROPN	B
in	O	ADP	O
just	O	ADV	O
5	O	NUM	O
(	O	PUNCT	O
9	O	NUM	O
%).	O	NOUN	O
of	O	ADP	O
the	O	DET	O
sera	O	NOUN	B
with	O	ADP	O
negative	O	ADJ	B
RAST	O	NOUN	B
for	O	ADP	O
AX	B-Chemical	NOUN	B
were	O	AUX	O
positive	O	ADJ	B
to	O	PART	O
BPO	B-Chemical	NOUN	B
.	O	PUNCT	O


Challenge	O	NOUN	B
tests	O	NOUN	I
with	O	ADP	O
AX	B-Chemical	NOUN	B
were	O	AUX	O
performed	O	VERB	O
in	O	ADP	O
23	O	NUM	O
subjects	O	NOUN	B
(	O	PUNCT	O
43	O	NUM	O
%)	O	NOUN	O
to	O	PART	O
establish	O	VERB	O
the	O	DET	O
diagnosis	O	NOUN	B
of	O	ADP	O
immediate	O	ADJ	B
allergic	B-Disease	ADJ	B
reaction	I-Disease	NOUN	I
to	O	ADP	O
AX	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
15	O	NUM	O
cases	O	NOUN	B
(	O	PUNCT	O
28	O	NUM	O
%)	O	NOUN	O
both	O	CCONJ	O
skin	O	NOUN	B
test	O	NOUN	I
and	O	CCONJ	O
RAST	O	NOUN	B
for	O	ADP	O
AX	B-Chemical	NOUN	B
were	O	AUX	O
negative	O	ADJ	B
.	O	PUNCT	O


PG	B-Chemical	NOUN	B
was	O	AUX	O
well	O	ADV	O
tolerated	O	VERB	B
by	O	ADP	O
all	O	DET	O
54	O	NUM	O
patients	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
describe	O	VERB	O
the	O	DET	O
largest	O	ADJ	O
group	O	NOUN	B
of	O	ADP	O
AX	B-Chemical	PROPN	B
-	O	PUNCT	O
allergic	B-Disease	ADJ	B
patients	O	NOUN	B
who	O	PRON	O
have	O	AUX	O
tolerated	O	VERB	B
PG	B-Chemical	NOUN	B
reported	O	VERB	O
so	O	ADV	O
far	O	ADV	O
.	O	PUNCT	O


Diagnosis	O	NOUN	B
of	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
achieved	O	VERB	O
only	O	ADV	O
if	O	SCONJ	O
specific	O	ADJ	O
AX	B-Chemical	NOUN	B


Persistent	O	ADJ	B
paralysis	B-Disease	NOUN	I
after	O	ADP	O
prolonged	O	ADJ	B
use	O	NOUN	O
of	O	ADP	O
atracurium	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
absence	O	NOUN	B
of	O	ADP	O
corticosteroids	O	NOUN	B
.	O	PUNCT	O


Neuromuscular	O	ADJ	B
blocking	O	NOUN	O
agents	O	NOUN	O
(	O	PUNCT	O
NMBAs	O	NOUN	B
)	O	PUNCT	O
are	O	AUX	O
often	O	ADV	O
used	O	VERB	O
for	O	ADP	O
patients	O	NOUN	B
requiring	O	VERB	O
prolonged	O	ADJ	B
mechanical	O	ADJ	B
ventilation	O	NOUN	I
.	O	PUNCT	O


Reports	O	NOUN	B
of	O	ADP	O
persistent	O	ADJ	B
paralysis	B-Disease	NOUN	B
after	O	ADP	O
the	O	DET	O
discontinuance	O	NOUN	B
of	O	ADP	O
these	O	DET	O
drugs	O	NOUN	B
have	O	AUX	O
most	O	ADV	O
often	O	ADV	O
involved	O	VERB	O
aminosteroid	O	NOUN	B
-	O	PUNCT	O
based	O	VERB	B
NMBAs	O	NOUN	B
such	O	ADJ	O
as	O	ADP	O
vecuronium	B-Chemical	NOUN	B
bromide	I-Chemical	NOUN	I
,	O	PUNCT	O
especially	O	ADV	O
when	O	SCONJ	O
used	O	VERB	O
in	O	ADP	O
conjunction	O	NOUN	B
with	O	ADP	O
corticosteroids	O	NOUN	B
.	O	PUNCT	O


Atracurium	B-Chemical	NOUN	B
besylate	I-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
short	O	ADV	B
-	O	PUNCT	O
acting	O	VERB	B
benzylisoquinolinium	B-Chemical	NOUN	B
NMBA	O	PROPN	B
that	O	PRON	O
is	O	AUX	O
eliminated	O	VERB	O
independently	O	ADV	O
of	O	ADP	O
renal	O	ADJ	B
or	O	CCONJ	O
hepatic	O	ADJ	B
function	O	NOUN	I
,	O	PUNCT	O
has	O	AUX	O
also	O	ADV	O
been	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
persistent	O	ADJ	B
paralysis	B-Disease	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
only	O	ADV	O
when	O	SCONJ	O
used	O	VERB	O
with	O	ADP	O
corticosteroids	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
atracurium	B-Chemical	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
paralysis	B-Disease	NOUN	B


Habitual	O	ADJ	B
use	O	NOUN	O
of	O	ADP	O
acetaminophen	B-Chemical	NOUN	B
as	O	ADP	O
a	O	DET	O
risk	O	NOUN	B
factor	O	NOUN	I
for	O	ADP	O
chronic	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
failure	I-Disease	NOUN	I
:	O	PUNCT	O
a	O	DET	O
comparison	O	NOUN	B
with	O	ADP	O
phenacetin	B-Chemical	NOUN	B
.	O	PUNCT	O


Six	O	NUM	O
epidemiologic	O	ADJ	B
studies	O	NOUN	I
in	O	ADP	O
the	O	DET	O
United	O	PROPN	B
States	O	PROPN	I
and	O	CCONJ	O
Europe	O	PROPN	B
indicate	O	VERB	O
that	O	SCONJ	O
habitual	O	ADJ	B
use	O	NOUN	O
of	O	ADP	O
phenacetin	B-Chemical	NOUN	B
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
chronic	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
failure	I-Disease	NOUN	I
and	O	CCONJ	O
end-stage	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
disease	I-Disease	NOUN	I
(	O	PUNCT	O
ESRD	B-Disease	NOUN	B
),	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
relative	O	ADJ	B
risk	O	NOUN	I
in	O	ADP	O
the	O	DET	O
range	O	NOUN	B
of	O	ADP	O
4	O	NUM	O
to	O	PART	O
19	O	NUM	O
.	O	PUNCT	O


As	O	ADP	O
a	O	DET	O
result	O	NOUN	O
of	O	ADP	O
these	O	DET	O
and	O	CCONJ	O
other	O	ADJ	O
studies	O	NOUN	B
,	O	PUNCT	O
phenacetin	B-Chemical	NOUN	B
has	O	AUX	O
now	O	ADV	O
been	O	AUX	O
withdrawn	O	VERB	O
from	O	ADP	O
the	O	DET	O
market	O	NOUN	B
in	O	ADP	O
most	O	ADJ	O
countries	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
three	O	NUM	O
case	O	NOUN	B
control	O	NOUN	I
studies	O	NOUN	I
,	O	PUNCT	O
one	O	NUM	O
each	O	DET	O
in	O	ADP	O
North	O	PROPN	B
Carolina	O	PROPN	I
,	O	PUNCT	O
northern	O	ADJ	B
Maryland	O	PROPN	I
,	O	PUNCT	O
and	O	CCONJ	O
West	O	PROPN	B
Berlin	O	PROPN	I
,	O	PUNCT	O
Germany	O	PROPN	B
,	O	PUNCT	O
showed	O	VERB	O
that	O	SCONJ	O
habitual	O	ADJ	B
use	O	NOUN	O
of	O	ADP	O
acetaminophen	B-Chemical	NOUN	B
is	O	AUX	O
also	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
chronic	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
failure	I-Disease	NOUN	I
and	O	CCONJ	O
ESRD	B-Disease	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
relative	O	ADJ	B
risk	O	NOUN	I
in	O	ADP	O
the	O	DET	O
range	O	NOUN	O
of	O	ADP	O
2	O	NUM	O
to	O	PART	O
4	O	NUM	O
.	O	PUNCT	O


These	O	DET	O
studies	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
both	O	CCONJ	O
phenacetin	B-Chemical	NOUN	B
and	O	CCONJ	O
acetaminophen	B-Chemical	NOUN	B
may	O	AUX	O
contribute	O	VERB	O
to	O	PART	O
the	O	DET	O
burden	O	NOUN	B
of	O	ADP	O
ESRD	B-Disease	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
the	O	DET	O
latter	O	ADJ	O
being	O	AUX	O
somewhat	O	ADV	O
less	O	ADJ	O
than	O	ADP	O
that	O	DET	O
of	O	ADP	O
the	O	DET	O
former	O	NOUN	O
.	O	PUNCT	O


This	O	DET	O
apparent	O	ADJ	B
difference	O	NOUN	O
in	O	ADP	O
risk	O	NOUN	B
may	O	AUX	O
not	O	PART	O
be	O	AUX	O
due	O	ADJ	O
to	O	PART	O
differences	O	NOUN	O
in	O	ADP	O
nephrotoxic	B-Disease	ADJ	B
potential	O	NOUN	B
of	O	ADP	O
the	O	DET	O
drugs	O	NOUN	B
themselves	O	PRON	O
.	O	PUNCT	O


A	O	DET	O
lower	O	ADJ	O
relative	O	ADJ	O
risk	O	NOUN	O
would	O	AUX	O
be	O	AUX	O
expected	O	VERB	O
for	O	ADP	O
acetaminophen	B-Chemical	NOUN	B
if	O	SCONJ	O
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
both	O	DET	O
drugs	O	NOUN	B
in	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
other	O	ADJ	O
analgesics	O	NOUN	B
was	O	AUX	O
higher	O	ADJ	O
than	O	ADP	O
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
either	O	DET	O
agent	O	NOUN	B
alone	O	ADV	O
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
acetaminophen	B-Chemical	NOUN	B
has	O	AUX	O
been	O	AUX	O
used	O	VERB	O
both	O	CCONJ	O
as	O	ADP	O
a	O	DET	O
single	O	ADJ	O
agent	O	NOUN	O
and	O	CCONJ	O
in	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
other	O	ADJ	O
analgesics	O	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
phenacetin	B-Chemical	NOUN	B
was	O	AUX	O
available	O	ADJ	O
only	O	ADV	O
in	O	ADP	O
combinations	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
possibility	O	NOUN	O
that	O	SCONJ	O
habitual	O	ADJ	B
use	O	NOUN	O
of	O	ADP	O
acetaminophen	B-Chemical	NOUN	B
alone	O	ADV	O
increases	O	VERB	B
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
ESRD	B-Disease	NOUN	B


Reduction	O	NOUN	B
of	O	ADP	O
heparan	B-Chemical	NOUN	B
sulphate	I-Chemical	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
anionic	O	ADJ	B
sites	O	NOUN	I
in	O	ADP	O
the	O	DET	O
glomerular	O	ADJ	B
basement	O	NOUN	I
membrane	O	NOUN	I
of	O	ADP	O
rats	O	NOUN	B
with	O	ADP	O
streptozotocin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
diabetic	B-Disease	ADJ	B
nephropathy	I-Disease	NOUN	I
.	O	PUNCT	O


Heparan	B-Chemical	NOUN	B
sulphate	I-Chemical	NOUN	I
-	O	PUNCT	O
associated	O	VERB	B
anionic	O	ADJ	B
sites	O	NOUN	I
in	O	ADP	O
the	O	DET	O
glomerular	O	ADJ	B
basement	O	NOUN	I
membrane	O	NOUN	I
were	O	AUX	O
studied	O	VERB	O
in	O	ADP	O
rats	O	NOUN	B
8	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
induction	O	NOUN	B
of	O	ADP	O
diabetes	B-Disease	NOUN	B
by	O	ADP	O
streptozotocin	B-Chemical	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
age	O	NOUN	B
-	O	PUNCT	O
adn	O	ADJ	B
sex	O	NOUN	B
-	O	PUNCT	O
matched	O	VERB	B
control	O	NOUN	O
rats	O	NOUN	B
,	O	PUNCT	O
employing	O	VERB	O
the	O	DET	O
cationic	O	ADJ	B
dye	O	NOUN	I
cuprolinic	B-Chemical	ADJ	I
blue	I-Chemical	NOUN	I
.	O	PUNCT	O


Morphometric	O	ADJ	B
analysis	O	NOUN	I
at	O	ADP	O
the	O	DET	O
ultrastructural	O	ADJ	B
level	O	NOUN	B
was	O	AUX	O
performed	O	VERB	O
using	O	VERB	O
a	O	DET	O
computerized	O	VERB	B
image	O	NOUN	I
processor	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
heparan	B-Chemical	NOUN	B
sulphate	I-Chemical	NOUN	O
specificity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
cuprolinic	B-Chemical	ADJ	B
blue	I-Chemical	ADJ	I
staining	O	NOUN	I
was	O	AUX	O
demonstrated	O	VERB	O
by	O	ADP	O
glycosaminoglycan	B-Chemical	NOUN	B
-	O	PUNCT	O
degrading	O	VERB	B
enzymes	O	NOUN	B
,	O	PUNCT	O
showing	O	VERB	O
that	O	SCONJ	O
pretreatment	O	NOUN	B
of	O	ADP	O
the	O	DET	O
sections	O	NOUN	B
with	O	ADP	O
heparitinase	O	NOUN	B
abolished	O	VERB	O
all	O	DET	O
staining	O	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
chondroitinase	O	NOUN	B
ABC	O	PROPN	I
had	O	AUX	O
no	O	DET	B
effect	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
majority	O	NOUN	O
of	O	ADP	O
anionic	O	ADJ	B
sites	O	NOUN	I
(	O	PUNCT	O
74	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
diabetic	B-Disease	ADJ	B
and	O	CCONJ	O
81	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
control	O	ADJ	B
rats	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
found	O	VERB	O
within	O	ADP	O
the	O	DET	O
lamina	O	NOUN	B
rara	O	X	O
externa	O	NOUN	O
of	O	ADP	O
the	O	DET	O
glomerular	O	ADJ	B
basement	O	NOUN	I
membrane	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
minority	O	NOUN	B
of	O	ADP	O
anionic	O	ADJ	B
sites	O	NOUN	I
were	O	AUX	O
scattered	O	VERB	O
throughout	O	ADP	O
the	O	DET	O
lamina	O	NOUN	B
densa	O	NOUN	I
and	O	CCONJ	O
lamina	O	NOUN	B
rara	O	X	I
interna	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
were	O	AUX	O
significantly	O	ADV	O
smaller	O	ADJ	O
than	O	ADP	O
those	O	DET	O
in	O	ADP	O
the	O	DET	O
lamina	O	NOUN	B
rara	O	X	I
externa	O	NOUN	I
of	O	ADP	O
the	O	DET	O
glomerular	O	ADJ	B
basement	O	NOUN	I
membrane	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
and	O	CCONJ	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
for	O	ADP	O
diabetic	B-Disease	ADJ	B
and	O	CCONJ	O
control	O	NOUN	B
rats	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
).	O	PUNCT	O
Diabetic	B-Disease	ADJ	B
rats	O	NOUN	B
progressively	O	ADV	O
developed	O	VERB	O
albuminuria	B-Disease	NOUN	B
reaching	O	VERB	O
40	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
(	O	PUNCT	O
32	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
-	O	SYM	O
62	O	NUM	O
.	O	PUNCT	O


0	O	X	O
)	O	PUNCT	O
mg	O	NOUN	O
/	O	SYM	O
24	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
8	O	NUM	O
months	O	NOUN	B
in	O	ADP	O
contrast	O	NOUN	O
to	O	PART	O
the	O	DET	O
control	O	ADJ	B
animals	O	NOUN	I
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
-	O	SYM	O
0	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
)	O	PUNCT	O
mg	O	NOUN	O
/	O	SYM	O
24	O	NUM	O
h	O	NOUN	O
,	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


002	O	NUM	O
).	O	PUNCT	B
At	O	ADP	O
the	O	DET	O
same	O	ADJ	O
time	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
heparan	B-Chemical	NOUN	B
sulphate	I-Chemical	NOUN	B
anionic	O	ADJ	B
sites	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
total	O	ADJ	O
anionic	O	ADJ	B
site	O	NOUN	I
surface	O	NOUN	B
(	O	PUNCT	O
number	O	NOUN	O
of	O	ADP	O
anionic	O	ADJ	B
sites	O	NOUN	I
x	O	NOUN	O
mean	O	ADJ	O
anionic	O	ADJ	B
site	O	NOUN	I
surface	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
lamina	O	NOUN	B
rara	O	X	I
externa	O	NOUN	I
of	O	ADP	O
the	O	DET	O
glomerular	O	ADJ	B
basement	O	NOUN	I
membrane	O	NOUN	I
was	O	AUX	O
reduced	O	VERB	B
by	O	ADP	O
19	O	NUM	O
%(	O	NOUN	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


021	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
by	O	ADP	O
26	O	NUM	O
%(	O	NOUN	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


02	O	NUM	O
),	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Number	O	NOUN	B
and	O	CCONJ	O
total	O	ADJ	O
anionic	O	ADJ	B
site	O	NOUN	I
surface	O	NOUN	B
in	O	ADP	O
the	O	DET	O
remaining	O	VERB	O
part	O	NOUN	O
of	O	ADP	O
the	O	DET	O
glomerular	O	ADJ	B
basement	O	NOUN	I
membrane	O	NOUN	I
(	O	PUNCT	O
lamina	O	NOUN	B
densa	O	NOUN	I
and	O	CCONJ	O
lamina	O	NOUN	B
rara	O	X	I
interna	O	NOUN	I
)	O	PUNCT	O
were	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
changed	O	VERB	B
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
in	O	ADP	O
streptozotocin	B-Chemical	NOUN	B
-	O	PUNCT	O
diabetic	B-Disease	ADJ	B
rats	O	NOUN	B
with	O	ADP	O
an	O	DET	O
increased	O	VERB	B
urinary	O	ADJ	B
albumin	O	NOUN	I
excretion	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
reduced	O	VERB	B
heparan	B-Chemical	NOUN	B
sulphate	I-Chemical	NOUN	O


Effect	O	NOUN	B
of	O	ADP	O
some	O	DET	O
anticancer	O	NOUN	B
drugs	O	NOUN	I
and	O	CCONJ	O
combined	O	ADJ	B
chemotherapy	O	NOUN	I
on	O	ADP	O
renal	B-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
nephrotoxic	B-Disease	ADJ	B
action	O	NOUN	O
of	O	ADP	O
anticancer	O	NOUN	B
drugs	O	NOUN	I
such	O	ADJ	O
as	O	ADP	O
nitrogranulogen	B-Chemical	NOUN	B
(	O	PUNCT	O
NG	B-Chemical	NOUN	B
),	O	PART	O
methotrexate	B-Chemical	NOUN	B
(	O	PUNCT	O
MTX	B-Chemical	NOUN	B
),	O	PUNCT	O
5-fluorouracil	B-Chemical	NOUN	B
(	O	PUNCT	O
5-FU	B-Chemical	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
cyclophosphamide	B-Chemical	NOUN	B
(	O	PUNCT	O
CY	B-Chemical	NOUN	B
)	O	PUNCT	O
administered	O	VERB	B
alone	O	ADV	O
or	O	CCONJ	O
in	O	ADP	O
combination	O	NOUN	B
[	O	PUNCT	O
MTX	B-Chemical	NOUN	B
+	O	CCONJ	O
5-FU	B-Chemical	NOUN	B
+	O	CCONJ	O
CY	B-Chemical	NOUN	B
(	O	PUNCT	O
CMF	O	NOUN	B
)]	O	PUNCT	O
was	O	AUX	O
evaluated	O	VERB	B
in	O	ADP	O
experiments	O	NOUN	B
on	O	ADP	O
Wistar	O	PROPN	B
rats	O	NOUN	I
.	O	PUNCT	O


After	O	ADP	O
drug	O	NOUN	B
administration	O	NOUN	I
,	O	PUNCT	O
creatinine	B-Chemical	NOUN	B
concentrations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
plasma	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
the	O	DET	O
urine	O	NOUN	B
of	O	ADP	O
the	O	DET	O
rats	O	NOUN	B
were	O	AUX	O
determined	O	VERB	O
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
creatinine	B-Chemical	NOUN	B
clearance	O	NOUN	B
.	O	PUNCT	O


Histopathologic	O	ADJ	B
evaluation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
kidneys	O	NOUN	B
was	O	AUX	O
also	O	ADV	O
performed	O	VERB	O
.	O	PUNCT	O


After	O	ADP	O
MTX	B-Chemical	NOUN	B
administration	O	NOUN	B
a	O	DET	O
significant	O	ADJ	O
increase	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


0228	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
plasma	O	NOUN	B
creatinine	B-Chemical	NOUN	O
concentration	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
significant	O	ADJ	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


0001	O	NUM	O
)	O	PUNCT	O
decrease	O	NOUN	B
in	O	ADP	O
creatinine	B-Chemical	NOUN	B
clearance	O	NOUN	B
was	O	AUX	O
noted	O	VERB	O
compared	O	VERB	O
to	O	PART	O
controls	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
the	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
NG	B-Chemical	PROPN	B
,	O	PUNCT	O
5-FU	B-Chemical	NOUN	B
and	O	CCONJ	O
CY	B-Chemical	PROPN	B
neither	O	CCONJ	O
a	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
increase	O	NOUN	B
in	O	ADP	O
creatinine	B-Chemical	NOUN	B
concentration	O	NOUN	B
nor	O	CCONJ	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
creatinine	B-Chemical	NOUN	B
clearance	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
compared	O	VERB	O
to	O	PART	O
the	O	DET	O
group	O	NOUN	B
receiving	O	VERB	O
no	O	DET	O
cytostatics	O	NOUN	B
.	O	PUNCT	O


Following	O	VERB	O
polytherapy	O	NOUN	B
according	O	VERB	O
to	O	ADP	O
the	O	DET	O
CMF	O	NOUN	B
regimen	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
decrease	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


0343	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
creatinine	B-Chemical	NOUN	B
clearance	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
,	O	PUNCT	O
but	O	CCONJ	O
creatinine	B-Chemical	NOUN	B
concentration	O	NOUN	B
did	O	AUX	O
not	O	PART	O
increase	O	VERB	B
significantly	O	ADV	O
compared	O	VERB	O
to	O	PART	O
controls	O	NOUN	B
.	O	PUNCT	O


CY	B-Chemical	PROPN	B
caused	O	VERB	O
hemorrhagic	B-Disease	ADJ	B
cystitis	I-Disease	NOUN	I
in	O	ADP	O
40	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
rats	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
it	O	PRON	O
did	O	AUX	O
not	O	PART	O
cause	O	VERB	O
this	O	DET	O
complication	O	NOUN	B
when	O	SCONJ	O
combined	O	VERB	B
with	O	ADP	O
5-FU	B-Chemical	NOUN	B
and	O	CCONJ	O
MTX	B-Chemical	NOUN	B
.	O	PUNCT	O


Histologic	O	ADJ	B
changes	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
rat	O	NOUN	B
kidneys	O	NOUN	B
after	O	ADP	O
administration	O	NOUN	B
of	O	ADP	O
MTX	B-Chemical	NOUN	B
,	O	PUNCT	O
CY	B-Chemical	NOUN	B
and	O	CCONJ	O
NG	B-Chemical	PROPN	B
,	O	PUNCT	O
while	O	SCONJ	O
no	O	DET	O
such	O	ADJ	O
change	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
after	O	ADP	O
5-FU	B-Chemical	NOUN	B
and	O	CCONJ	O
joint	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
MTX	B-Chemical	NOUN	B
+	O	CCONJ	O
5-FU	B-Chemical	NOUN	B
+	O	CCONJ	O
CY	B-Chemical	NOUN	B
compared	O	VERB	B
to	O	PART	O
controls	O	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
studies	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
nephrotoxicity	B-Disease	NOUN	B
of	O	ADP	O
MTX	B-Chemical	NOUN	B
+	O	CCONJ	O
5-FU	B-Chemical	NOUN	B
+	O	CCONJ	O
CY	B-Chemical	NOUN	B


Lithium	B-Chemical	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
cognitive	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
functional	I-Disease	ADJ	B
deficits	I-Disease	NOUN	I
reduced	O	VERB	B
by	O	ADP	O
a	O	DET	O
switch	O	NOUN	B
to	O	PART	O
divalproex	B-Chemical	NOUN	B
sodium	I-Chemical	NOUN	I
:	O	PUNCT	O
a	O	DET	O
case	O	NOUN	B
series	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Lithium	B-Chemical	NOUN	B
remains	O	VERB	O
a	O	DET	O
first	O	ADJ	B
-	O	PUNCT	O
line	O	NOUN	B
treatment	O	NOUN	B
for	O	ADP	O
the	O	DET	O
acute	O	ADJ	B
and	O	CCONJ	O
maintenance	O	NOUN	B
treatment	O	NOUN	B
of	O	ADP	O
bipolar	B-Disease	ADJ	B
disorder	I-Disease	NOUN	I
.	O	PUNCT	O


Although	O	SCONJ	O
much	O	ADJ	O
has	O	AUX	O
been	O	AUX	O
written	O	VERB	B
about	O	ADP	O
the	O	DET	O
management	O	NOUN	B
of	O	ADP	O
the	O	DET	O
more	O	ADV	O
common	O	ADJ	O
adverse	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
lithium	B-Chemical	NOUN	B
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
polyuria	B-Disease	NOUN	B
and	O	CCONJ	O
tremor	B-Disease	NOUN	B
,	O	PUNCT	O
more	O	ADV	O
subtle	O	ADJ	O
lithium	B-Chemical	NOUN	B
side	O	NOUN	B
effects	O	NOUN	I
such	O	ADJ	O
as	O	ADP	O
cognitive	B-Disease	ADJ	B
deficits	I-Disease	NOUN	I
,	O	PUNCT	O
loss	B-Disease	NOUN	B
of	I-Disease	ADP	O
creativity	I-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
functional	B-Disease	ADJ	B
impairments	I-Disease	NOUN	I
remain	O	VERB	O
understudied	O	ADJ	O
.	O	PUNCT	O


This	O	DET	O
report	O	NOUN	B
summarizes	O	VERB	O
our	O	PRON	O
experience	O	NOUN	O
in	O	ADP	O
switching	O	VERB	B
bipolar	B-Disease	ADJ	B
patients	O	NOUN	B
from	O	ADP	O
lithium	B-Chemical	NOUN	B
to	O	PART	O
divalproex	B-Chemical	NOUN	B
sodium	I-Chemical	NOUN	I
to	O	PART	O
alleviate	O	VERB	O
such	O	ADJ	O
cognitive	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
functional	I-Disease	ADJ	B
impairments	I-Disease	NOUN	I
.	O	PUNCT	O


METHOD	O	NOUN	B
:	O	PUNCT	O
Open	O	ADJ	B
,	O	PUNCT	O
case	O	NOUN	B
series	O	NOUN	I
design	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
We	O	PRON	O
report	O	VERB	O
seven	O	NUM	O
cases	O	NOUN	B
where	O	SCONJ	O
substitution	O	NOUN	B
of	O	ADP	O
lithium	B-Chemical	NOUN	B
,	O	PUNCT	O
either	O	CCONJ	O
fully	O	ADV	O
or	O	CCONJ	O
partially	O	ADV	B
,	O	PUNCT	O
with	O	ADP	O
divalproex	B-Chemical	NOUN	B
sodium	I-Chemical	NOUN	I
was	O	AUX	O
extremely	O	ADV	O
helpful	O	ADJ	O
in	O	ADP	O
reducing	O	VERB	B
the	O	DET	O
cognitive,	B-Disease	PROPN	B
motivational,	I-Disease	NOUN	B
or	I-Disease	CCONJ	O
creative	I-Disease	ADJ	B
deficits	I-Disease	NOUN	I
attributed	O	VERB	O
to	O	PART	O
lithium	B-Chemical	NOUN	B
in	O	ADP	O
our	O	PRON	O
bipolar	B-Disease	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
In	O	ADP	O
this	O	DET	O
preliminary	O	ADJ	O
report	O	NOUN	O
,	O	PUNCT	O
divalproex	B-Chemical	NOUN	B
sodium	I-Chemical	NOUN	I
was	O	AUX	O
a	O	DET	O
superior	O	ADJ	O
alternative	O	NOUN	B
to	O	PART	O
lithium	B-Chemical	NOUN	B
in	O	ADP	O
bipolar	B-Disease	ADJ	B
patients	O	NOUN	B
experiencing	O	VERB	O
cognitive	B-Disease	ADJ	B
deficits	I-Disease	NOUN	I
,	O	PUNCT	O
loss	B-Disease	NOUN	B
of	I-Disease	ADP	O
creativity	I-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
functional	B-Disease	ADJ	B
impairments	I-Disease	NOUN	I


Treatment	O	NOUN	B
of	O	ADP	O
previously	O	ADV	O
treated	O	VERB	B
metastatic	O	ADJ	B
breast	B-Disease	NOUN	I
cancer	I-Disease	NOUN	I
by	O	ADP	O
mitoxantrone	B-Chemical	NOUN	B
and	O	CCONJ	O
48	O	NUM	O
-	O	PUNCT	O
hour	O	NOUN	B
continuous	O	ADJ	B
infusion	O	NOUN	B
of	O	ADP	O
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
5-FU	B-Chemical	NOUN	B
and	O	CCONJ	O
leucovorin	B-Chemical	NOUN	B
(	O	PUNCT	O
MFL	B-Chemical	PROPN	B
):	O	PUNCT	O
low	O	ADJ	B
palliative	O	ADJ	B
benefit	O	NOUN	I
and	O	CCONJ	O
high	O	ADJ	B
treatment	O	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
toxicity	B-Disease	NOUN	B
.	O	PUNCT	O


For	O	ADP	O
previously	O	ADV	O
treated	O	VERB	B
advanced	O	ADJ	O
breast	B-Disease	NOUN	O
cancer	I-Disease	NOUN	O
,	O	PUNCT	O
there	O	PRON	O
is	O	AUX	O
no	O	DET	O
standard	O	ADJ	O
second	O	ADJ	B
-	O	PUNCT	O
line	O	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


Combination	O	NOUN	B
chemotherapy	O	NOUN	I
with	O	ADP	O
mitoxantrone	B-Chemical	NOUN	B
,	O	PUNCT	O
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
5-fluorouracil	B-Chemical	NOUN	B
(	O	PUNCT	O
5-FU	B-Chemical	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
leucovorin	B-Chemical	NOUN	B
(	O	PUNCT	O
MFL	B-Chemical	PROPN	B
regimen	I-Chemical	NOUN	B
)	O	PUNCT	O
had	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
as	O	ADP	O
an	O	DET	O
effective	O	ADJ	B
and	O	CCONJ	O
well	O	ADV	O
tolerated	O	ADJ	B
regimen	O	NOUN	B
.	O	PUNCT	O


From	O	ADP	O
October	O	PROPN	O
1993	O	NUM	O
to	O	ADP	O
November	O	PROPN	O
1995	O	NUM	O
,	O	PUNCT	O
we	O	PRON	O
treated	O	VERB	B
13	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
previously	O	ADV	O
chemotherapy	O	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
metastatic	O	ADJ	B
breast	B-Disease	NOUN	I
cancer	I-Disease	NOUN	I
by	O	ADP	O
mitoxantrone	B-Chemical	NOUN	B
,	O	PUNCT	O
12	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
,	O	PUNCT	O
on	O	ADP	O
day	O	NOUN	B
1	O	NUM	O
and	O	CCONJ	O
continuous	O	ADJ	B
infusion	O	NOUN	B
of	O	ADP	O
5-FU	B-Chemical	NOUN	B
,	O	PUNCT	O
3000	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
,	O	PUNCT	O
together	O	ADV	O
with	O	ADP	O
leucovorin	B-Chemical	NOUN	B
,	O	PUNCT	O
300	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
,	O	PUNCT	O
for	O	ADP	O
48	O	NUM	O
h	O	NOUN	O
from	O	ADP	O
day	O	NOUN	B
1	O	NUM	O
to	O	PART	O
2	O	NUM	O
.	O	PUNCT	O


Each	O	DET	O
course	O	NOUN	B
of	O	ADP	O
chemotherapy	O	NOUN	B
was	O	AUX	O
given	O	VERB	O
every	O	DET	O
4	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


Most	O	ADJ	O
of	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
had	O	AUX	O
more	O	ADJ	O
than	O	ADP	O
two	O	NUM	O
metastatic	O	ADJ	B
sites	O	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
lung	O	NOUN	B
metastasis	O	NOUN	I
predominant	O	ADJ	B
.	O	PUNCT	O


Seven	O	NUM	O
patients	O	NOUN	B
had	O	AUX	O
been	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
anthracycline	B-Chemical	NOUN	B
.	O	PUNCT	O


Seven	O	NUM	O
patients	O	NOUN	B
had	O	AUX	O
previously	O	ADV	O
received	O	VERB	O
radiotherapy	O	NOUN	B
and	O	CCONJ	O
seven	O	NUM	O
had	O	AUX	O
received	O	VERB	O
hormone	O	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


Median	O	ADJ	B
number	O	NOUN	O
of	O	ADP	O
courses	O	NOUN	B
of	O	ADP	O
MFL	B-Chemical	PROPN	B
regimen	I-Chemical	NOUN	B
given	O	VERB	O
was	O	AUX	O
six	O	NUM	O
and	O	CCONJ	O
the	O	DET	O
median	O	ADJ	B
cumulative	O	ADJ	B
dose	O	NOUN	B
of	O	ADP	O
mitoxantrone	B-Chemical	NOUN	B
was	O	AUX	O
68	O	NUM	O
.	O	PUNCT	O


35	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
.	O	PUNCT	O


One	O	NUM	O
patient	O	NOUN	B
had	O	AUX	O
complete	O	ADJ	O
response	O	NOUN	B
,	O	PUNCT	O
seven	O	NUM	O
had	O	AUX	O
stable	O	ADJ	B
disease	O	NOUN	I
,	O	PUNCT	O
none	O	NOUN	O
had	O	AUX	O
partial	O	ADJ	B
response	O	NOUN	O
and	O	CCONJ	O
five	O	NUM	O
had	O	AUX	O
progressive	O	ADJ	B
disease	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
overall	O	ADJ	O
objective	O	ADJ	O
response	O	NOUN	B
rate	O	NOUN	I
was	O	AUX	O
7	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
%.	O	NOUN	B
The	O	DET	O
median	O	ADJ	B
follow	O	NOUN	B
-	O	PUNCT	O
up	O	ADP	O
period	O	NOUN	B
was	O	AUX	O
14	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


Median	O	ADJ	B
survival	O	NOUN	I
was	O	AUX	O
16	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


Median	O	ADJ	B
progression	O	NOUN	B
-	O	PUNCT	O
free	O	ADJ	B
survival	O	NOUN	B
was	O	AUX	O
5	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
complete	O	ADJ	B
responder	O	NOUN	B
had	O	AUX	O
relapse	O	NOUN	B
-	O	PUNCT	O
free	O	ADJ	B
survival	O	NOUN	B
up	O	ADV	O
to	O	PART	O
17	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


Major	O	ADJ	O
toxicities	B-Disease	NOUN	B
were	O	AUX	O
cardiotoxicity	B-Disease	NOUN	B
and	O	CCONJ	O
leukopenia	B-Disease	NOUN	B
.	O	PUNCT	O


Eight	O	NUM	O
patients	O	NOUN	B
were	O	AUX	O
dead	O	ADJ	B
in	O	ADP	O
the	O	DET	O
last	O	ADJ	O
follow	O	NOUN	B
-	O	PUNCT	O
up	O	NOUN	O
;	O	PUNCT	O
two	O	NUM	O
of	O	ADP	O
them	O	PRON	O
died	O	VERB	B
of	O	ADP	O
treatment	O	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
toxicity	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
MFL	B-Chemical	PROPN	B
regimen	I-Chemical	NOUN	B
achieves	O	VERB	O
little	O	ADJ	O
palliative	O	ADJ	B
benefit	O	NOUN	I
and	O	CCONJ	O
induces	O	VERB	O
severe	O	ADJ	B
toxicity	B-Disease	NOUN	B
at	O	ADP	O
a	O	DET	O
fairly	O	ADV	O
high	O	ADJ	O
rate	O	NOUN	B
.	O	PUNCT	O


Administration	O	NOUN	B
of	O	ADP	O
this	O	DET	O
regimen	O	NOUN	B
to	O	PART	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
patients	O	NOUN	B
who	O	PRON	O
have	O	AUX	O
been	O	AUX	O
treated	O	VERB	B
by	O	ADP	O
chemotherapy	O	NOUN	B
and	O	CCONJ	O
those	O	DET	O
with	O	ADP	O
impaired	B-Disease	ADJ	B
heart	I-Disease	NOUN	O
function	I-Disease	NOUN	O


Upregulation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
expression	O	NOUN	B
of	O	ADP	O
vasopressin	B-Chemical	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
the	O	DET	O
paraventricular	O	ADJ	B
and	O	CCONJ	O
supraoptic	O	ADJ	B
nuclei	O	NOUN	I
of	O	ADP	O
the	O	DET	O
lithium	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
diabetes	B-Disease	NOUN	B
insipidus	I-Disease	NOUN	I
rat	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
expression	O	NOUN	B
of	O	ADP	O
arginine	B-Chemical	NOUN	B
vasopressin	I-Chemical	NOUN	I
(	O	PUNCT	I
AVP	B-Chemical	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	O
in	O	ADP	O
the	O	DET	O
paraventricular	O	NOUN	B
(	O	PUNCT	O
PVN	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
supraoptic	O	ADJ	B
nuclei	O	NOUN	I
(	O	PUNCT	O
SON	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
investigated	O	VERB	B
in	O	ADP	O
rats	O	NOUN	B
with	O	ADP	O
lithium	B-Chemical	NOUN	B
(	O	PUNCT	O
Li	B-Chemical	PROPN	B
)-	O	ADJ	O
induced	O	VERB	B
polyuria	B-Disease	NOUN	B
,	O	PUNCT	O
using	O	VERB	O
in	O	X	B
situ	O	X	I
hybridization	O	NOUN	I
histochemistry	O	NOUN	I
and	O	CCONJ	O
radioimmunoassay	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
male	O	NOUN	B
Wistar	O	PROPN	B
rats	O	NOUN	I
consuming	O	VERB	O
a	O	DET	O
diet	O	NOUN	B
that	O	PRON	O
contained	O	VERB	O
LiCl	B-Chemical	NOUN	B
(	O	PUNCT	O
60	O	NUM	O
mmol	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
for	O	ADP	O
4	O	NUM	O
weeks	O	NOUN	B
developed	O	VERB	O
marked	O	ADJ	O
polyuria	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
Li	B-Chemical	PROPN	B
-	O	PUNCT	O
treated	O	VERB	B
rats	O	NOUN	B
produced	O	VERB	O
a	O	DET	O
large	O	ADJ	O
volume	O	NOUN	B
of	O	ADP	O
hypotonic	O	ADJ	B
urine	O	NOUN	B
with	O	ADP	O
low	O	ADJ	B
ionic	O	ADJ	B
concentrations	O	NOUN	I
.	O	PUNCT	O


Plasma	O	NOUN	B
sodium	B-Chemical	NOUN	B
concentrations	O	NOUN	I
were	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
slightly	O	ADV	O
increased	O	VERB	B
in	O	ADP	O
the	O	DET	O
Li	B-Chemical	PROPN	B
-	O	PUNCT	O
treated	O	VERB	B
rats	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
those	O	DET	O
in	O	ADP	O
controls	O	NOUN	B
.	O	PUNCT	O


Plasma	O	NOUN	B
concentration	O	NOUN	B
of	O	ADP	O
AVP	B-Chemical	NOUN	B
and	O	CCONJ	O
transcripts	O	NOUN	B
of	O	ADP	O
AVP	B-Chemical	NOUN	B
gene	O	NOUN	B
in	O	ADP	O
the	O	DET	O
PVN	O	NOUN	B
and	O	CCONJ	O
SON	O	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
increased	O	VERB	B
in	O	ADP	O
the	O	DET	O
Li	B-Chemical	PROPN	B
-	O	PUNCT	O
treated	O	VERB	B
rats	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
controls	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
dehydration	B-Disease	NOUN	B
and	O	CCONJ	O
/	O	PUNCT	O
or	O	CCONJ	O
the	O	DET	O
activation	O	NOUN	B
of	O	ADP	O
visceral	O	ADJ	B
afferent	O	NOUN	B
inputs	O	NOUN	B
may	O	AUX	O
contribute	O	VERB	O
to	O	PART	O
the	O	DET	O
elevation	O	NOUN	B
of	O	ADP	O
plasma	O	NOUN	B
AVP	B-Chemical	NOUN	B
and	O	CCONJ	O
the	O	DET	O
upregulation	O	NOUN	B
of	O	ADP	O
AVP	B-Chemical	NOUN	B
gene	O	NOUN	B
expression	O	NOUN	I
in	O	ADP	O
the	O	DET	O
PVN	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
SON	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Li	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
diabetes	B-Disease	NOUN	B
insipidus	I-Disease	NOUN	I


Suxamethonium	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cardiac	B-Disease	ADJ	B
arrest	I-Disease	NOUN	I
and	O	CCONJ	O
death	B-Disease	NOUN	B
following	O	VERB	O
5	O	NUM	O
days	O	NOUN	B
of	O	ADP	O
immobilization	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
report	O	NOUN	B
describes	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
cardiac	B-Disease	ADJ	B
arrest	I-Disease	NOUN	I
and	O	CCONJ	O
subsequent	O	ADJ	O
death	B-Disease	NOUN	B
as	O	ADP	O
a	O	DET	O
result	O	NOUN	O
of	O	ADP	O
hyperkalaemia	B-Disease	NOUN	B
following	O	VERB	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
suxamethonium	B-Chemical	NOUN	B
in	O	ADP	O
a	O	DET	O
23	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
Malawian	O	ADJ	B
woman	O	NOUN	B
.	O	PUNCT	O


Five	O	NUM	O
days	O	NOUN	B
after	O	ADP	O
the	O	DET	O
onset	O	NOUN	O
of	O	ADP	O
the	O	DET	O
symptoms	O	NOUN	B
of	O	ADP	O
meningitis	B-Disease	NOUN	B
,	O	PUNCT	O
the	O	DET	O
patient	O	NOUN	B
aspirated	O	VERB	B
stomach	O	NOUN	O
contents	O	NOUN	B
and	O	CCONJ	O
needed	O	VERB	O
endotracheal	O	NOUN	B
intubation	O	NOUN	I
.	O	PUNCT	O


Forty	O	NUM	O
seconds	O	NOUN	O
after	O	ADP	O
injection	O	NOUN	B
of	O	ADP	O
suxamethonium	B-Chemical	NOUN	B
,	O	PUNCT	O
bradycardia	B-Disease	NOUN	B
and	O	CCONJ	O
cardiac	B-Disease	ADJ	B
arrest	I-Disease	NOUN	I
occurred	O	VERB	O
.	O	PUNCT	O


Attempts	O	VERB	O
to	O	PART	O
resuscitate	O	VERB	B
the	O	DET	O
patient	O	NOUN	B
were	O	AUX	O
not	O	PART	O
successful	O	ADJ	O
.	O	PUNCT	O


The	O	DET	O
serum	O	NOUN	B
level	O	NOUN	B
of	O	ADP	O
potassium	B-Chemical	NOUN	B
was	O	AUX	O
observed	O	VERB	O
to	O	PART	O
be	O	AUX	O
8	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
mequiv	O	NOUN	O
L	O	PROPN	B
-	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


Apart	O	ADV	O
from	O	ADP	O
the	O	DET	O
reduction	O	NOUN	B
in	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
'	O	PART	O
s	O	NOUN	O
level	O	NOUN	B
of	O	ADP	O
consciousness	O	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
were	O	AUX	O
no	O	DET	O
signs	O	NOUN	O
of	O	ADP	O
motor	O	NOUN	B
neurone	O	NOUN	I
damage	O	NOUN	B
or	O	CCONJ	O
of	O	ADP	O
any	O	DET	O
of	O	ADP	O
the	O	DET	O
other	O	ADJ	O
known	O	ADJ	O
predisposing	O	VERB	B
conditions	O	NOUN	I
for	O	ADP	O
hyperkalaemia	B-Disease	NOUN	B
following	O	VERB	O
the	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
suxamethonium	B-Chemical	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
postulated	O	VERB	O
that	O	SCONJ	O
her	O	PRON	O
death	B-Disease	NOUN	B
was	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
hypersensitivity	B-Disease	NOUN	B
to	O	PART	O
suxamethonium	B-Chemical	NOUN	B


An	O	DET	O
unusual	O	ADJ	B
toxic	O	ADJ	B
reaction	O	NOUN	O
to	O	PART	O
axillary	O	ADJ	B
block	O	NOUN	I
by	O	ADP	O
mepivacaine	B-Chemical	NOUN	B
with	O	ADP	O
adrenaline	B-Chemical	NOUN	B
.	O	PUNCT	O


An	O	DET	O
increase	B-Disease	NOUN	B
in	I-Disease	ADP	O
blood	I-Disease	NOUN	B
pressure	I-Disease	NOUN	I
,	O	PUNCT	O
accompanied	O	VERB	O
by	O	ADP	O
atrial	B-Disease	ADJ	B
fibrillation	I-Disease	NOUN	I
,	O	PUNCT	O
agitation	B-Disease	NOUN	B
,	O	PUNCT	O
incomprehensible	B-Disease	ADJ	B
shouts	I-Disease	NOUN	I
and	O	CCONJ	O
loss	B-Disease	NOUN	B
of	I-Disease	ADP	I
consciousness	I-Disease	NOUN	I
,	O	PUNCT	O
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
an	O	DET	O
elderly	O	ADJ	B
,	O	PUNCT	O
ASA	O	NOUN	B
classification	O	NOUN	O
group	O	NOUN	O
II	O	NUM	O
,	O	PUNCT	O
cardiovascularly	O	ADV	B
medicated	O	VERB	B
male	O	NOUN	B
,	O	PUNCT	O
12	O	NUM	O
min	O	NOUN	O
after	O	ADP	O
performance	O	NOUN	B
of	O	ADP	O
axillary	O	ADJ	B
block	O	NOUN	I
with	O	ADP	O
mepivacaine	B-Chemical	NOUN	B
850	O	NUM	O
mg	O	NOUN	O
containing	O	VERB	O
adrenaline	B-Chemical	NOUN	B
0	O	NUM	O
.	O	PUNCT	O


225	O	NUM	O
mg	O	NOUN	O
,	O	PUNCT	O
for	O	ADP	O
correction	O	NOUN	B
of	O	ADP	O
Dupuytren's	B-Disease	PROPN	B
contracture	I-Disease	NOUN	I
.	O	PUNCT	O


After	O	ADP	O
intravenous	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
labetalol	B-Chemical	NOUN	B
,	O	PUNCT	O
metoprolol	B-Chemical	NOUN	B
and	O	CCONJ	O
midazolam	B-Chemical	NOUN	B
the	O	DET	O
patient	O	NOUN	B
'	O	PART	O
s	O	NOUN	O
condition	O	NOUN	B
improved	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
15	O	NUM	O
min	O	NOUN	O
later	O	ADV	O
he	O	PRON	O
woke	O	VERB	O
up	O	ADP	O
.	O	PUNCT	O


The	O	DET	O
block	O	NOUN	B
was	O	AUX	O
successful	O	ADJ	O
and	O	CCONJ	O
surgery	O	NOUN	B
was	O	AUX	O
conducted	O	VERB	O
as	O	ADP	O
scheduled	O	VERB	B
despite	O	SCONJ	O
persisting	O	VERB	O
atrial	B-Disease	ADJ	B
fibrillation	I-Disease	NOUN	I
.	O	PUNCT	O


Postoperatively	O	ADV	B
,	O	PUNCT	O
the	O	DET	O
patient	O	NOUN	B
refused	O	VERB	O
DC	O	NOUN	B
cardioversion	O	NOUN	I
and	O	CCONJ	O
was	O	AUX	O
treated	O	VERB	B
medically	O	ADV	O
.	O	PUNCT	O


Both	O	CCONJ	O
the	O	DET	O
temporal	O	ADJ	B
relationship	O	NOUN	B
of	O	ADP	O
events	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
response	O	NOUN	B
to	O	PART	O
treatment	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
rapid	O	ADJ	O
systemic	O	ADJ	B
absorption	O	NOUN	B
of	O	ADP	O
mepivacaine	B-Chemical	NOUN	B
with	O	ADP	O
adrenaline	B-Chemical	NOUN	B


Clinical	O	ADJ	B
and	O	CCONJ	O
histopathologic	O	ADJ	B
examination	O	NOUN	I
of	O	ADP	O
renal	O	ADJ	B
allografts	O	NOUN	I
treated	O	VERB	B
with	O	ADP	I
tacrolimus	B-Chemical	NOUN	B
(	O	PUNCT	O
FK506	B-Chemical	NOUN	B
)	O	PUNCT	O
for	O	ADP	O
at	O	ADP	O
least	O	ADV	O
one	O	NUM	O
year	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
We	O	PRON	O
clinically	O	ADV	B
and	O	CCONJ	O
pathologically	O	ADV	B
analyzed	O	VERB	O
renal	O	ADJ	O
allografts	O	NOUN	O
from	O	ADP	O
1	O	NUM	O
9	O	NUM	O
renal	O	ADJ	B
transplant	O	NOUN	I
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
tacrolimus	B-Chemical	NOUN	B
(	O	PUNCT	O
FK506	B-Chemical	NOUN	B
)	O	PUNCT	O
for	O	ADP	O
more	O	ADJ	O
than	O	ADP	O
1	O	NUM	O
year	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
Twenty	O	NUM	B
-	O	PUNCT	O
six	O	NUM	B
renal	O	ADJ	B
allograft	O	NOUN	I
biopsy	O	NOUN	B
specimens	O	NOUN	I
from	O	ADP	O
1	O	NUM	O
9	O	NUM	O
renal	O	ADJ	B
transplant	O	NOUN	I
patients	O	NOUN	B
who	O	PRON	O
underwent	O	VERB	O
transplantations	O	NOUN	B
between	O	ADP	O
1991	O	NUM	O
and	O	CCONJ	O
1993	O	NUM	O
were	O	AUX	O
evaluated	O	VERB	B
.	O	PUNCT	O


Thirteen	O	NUM	O
biopsies	O	NOUN	B
were	O	AUX	O
performed	O	VERB	O
from	O	ADP	O
stable	O	ADJ	B
functioning	O	VERB	O
renal	O	ADJ	B
allografts	O	NOUN	I
with	O	ADP	O
informed	O	ADJ	O
consent	O	NOUN	O
(	O	PUNCT	O
nonepisode	O	NOUN	B
biopsy	O	NOUN	I
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
other	O	ADJ	O
13	O	NUM	O
were	O	AUX	O
from	O	ADP	O
dysfunctional	O	ADJ	B
renal	O	ADJ	I
allografts	O	NOUN	I
with	O	ADP	O
a	O	DET	O
clinical	O	ADJ	B
indication	O	NOUN	B
for	O	ADP	O
biopsy	O	NOUN	B
(	O	PUNCT	O
episode	O	NOUN	B
biopsy	O	NOUN	I
).	O	PUNCT	O
RESULTS	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
main	O	ADJ	O
pathologic	O	ADJ	B
diagnoses	O	NOUN	I
(	O	PUNCT	O
some	O	DET	O
overlap	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
acute	O	ADJ	B
rejection	O	NOUN	I
(	O	PUNCT	O
AR	O	NOUN	B
;	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
4	O	NUM	O
),	O	PUNCT	O
chronic	O	ADJ	B
rejection	O	NOUN	I
(	O	PUNCT	O
CR	O	NOUN	B
;	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
5	O	NUM	O
),	O	PUNCT	O
AR	O	NOUN	B
+	O	CCONJ	O
CR	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
4	O	NUM	O
),	O	PUNCT	O
recurrent	O	ADJ	B
IgA	B-Disease	NOUN	I
nephropathy	I-Disease	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
5	O	NUM	O
),	O	PUNCT	O
normal	O	ADJ	B
findings	O	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
2	O	NUM	O
),	O	PUNCT	O
minimal	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
chronic	O	ADJ	B
FK506	B-Chemical	NOUN	O
nephropathy	B-Disease	NOUN	O
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
9	O	NUM	O
),	O	PUNCT	O
and	O	CCONJ	O
mild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
FK506	B-Chemical	NOUN	B
nephropathy	B-Disease	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
11	O	NUM	O
).	O	PUNCT	O
Of	O	ADP	O
the	O	DET	O
nonepisode	O	NOUN	O
biopsies	O	NOUN	B
,	O	PUNCT	O
7	O	NUM	O
and	O	CCONJ	O
4	O	NUM	O
biopsies	O	NOUN	B
showed	O	VERB	O
minimal	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
and	O	CCONJ	O
mild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
chronic	O	ADJ	B
FK506	B-Chemical	NOUN	O
nephropathy	B-Disease	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Chronic	O	ADJ	B
FK506	B-Chemical	NOUN	I
nephropathy	B-Disease	NOUN	I
consisted	O	VERB	O
of	O	ADP	O
rough	O	ADJ	B
and	O	CCONJ	O
foamy	O	ADJ	B
tubular	O	ADJ	I
vacuolization	O	NOUN	I
(	O	PUNCT	O
5	O	NUM	O
biopsies	O	NOUN	B
),	O	PUNCT	O
arteriolopathy	O	NOUN	B
(	O	PUNCT	O
angiodegeneration	O	NOUN	B
of	O	ADP	O
the	O	DET	O
arteriolar	O	ADJ	B
wall	O	NOUN	I
;	O	PUNCT	O
20	O	NUM	O
biopsies	O	NOUN	B
),	O	PUNCT	O
focal	B-Disease	ADJ	B
segmental	I-Disease	ADJ	I
glomerulosclerosis	I-Disease	NOUN	I
(	O	PUNCT	O
4	O	NUM	O
biopsies	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
striped	O	ADJ	B
form	O	NOUN	I
of	O	ADP	O
interstitial	B-Disease	ADJ	B
fibrosis	I-Disease	NOUN	I
(	O	PUNCT	O
11	O	NUM	O
biopsies	O	NOUN	B
).	O	PUNCT	O
The	O	DET	O
serum	O	NOUN	B
creatinine	B-Chemical	NOUN	I
levels	O	NOUN	I
of	O	ADP	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
mild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
chronic	O	ADJ	B
FK506	B-Chemical	NOUN	O
nephropathy	B-Disease	NOUN	O
group	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
included	O	VERB	O
7	O	NUM	O
episode	O	NOUN	B
biopsies	O	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
statistically	O	ADV	B
higher	O	ADJ	I
than	O	ADP	O
those	O	DET	O
in	O	ADP	O
the	O	DET	O
minimum	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
chronic	O	ADJ	B
FK506	B-Chemical	NOUN	B
-	O	PUNCT	O
nephropathy	B-Disease	NOUN	B
group	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
).	O	PUNCT	O
CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
This	O	DET	O
study	O	NOUN	B
demonstrates	O	VERB	O
that	O	SCONJ	O
chronic	O	ADJ	B
FK506	B-Chemical	NOUN	B
nephropathy	B-Disease	NOUN	I
consists	O	VERB	O
primarily	O	ADV	O
of	O	ADP	O
arteriolopathy	O	NOUN	B
manifesting	O	VERB	O
as	O	ADP	O
insudative	O	ADJ	B
hyalinosis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
arteriolar	O	ADJ	B
wall	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
suggests	O	VERB	O
that	O	SCONJ	O
mild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
chronic	O	ADJ	B
FK506	B-Chemical	NOUN	O
nephropathy	B-Disease	NOUN	O


Memory	O	NOUN	B
facilitation	O	NOUN	I
and	O	CCONJ	O
stimulation	O	NOUN	B
of	O	ADP	O
endogenous	O	ADJ	B
nerve	O	NOUN	B
growth	O	NOUN	I
factor	O	NOUN	I
synthesis	O	NOUN	I
by	O	ADP	O
the	O	DET	O
acetylcholine	B-Chemical	NOUN	B
releaser	O	NOUN	I
PG-9	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
PG-9	B-Chemical	NOUN	B
(	O	PUNCT	O
3alpha-tropyl	B-Chemical	ADJ	O
2-(p-bromophenyl)propionate	I-Chemical	NOUN	B
),	O	PUNCT	O
the	O	DET	O
acetylcholine	B-Chemical	NOUN	B
releaser	O	NOUN	I
,	O	PUNCT	O
on	O	ADP	O
memory	O	NOUN	B
processes	O	NOUN	I
and	O	CCONJ	O
nerve	O	NOUN	B
growth	O	NOUN	I
factor	O	NOUN	I
(	O	PUNCT	O
NGF	O	NOUN	B
)	O	PUNCT	O
synthesis	O	NOUN	B
were	O	AUX	O
evaluated	O	VERB	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
mouse	O	NOUN	B
passive	O	ADJ	B
-	O	PUNCT	O
avoidance	O	NOUN	B
test	O	NOUN	I
,	O	PUNCT	O
PG-9	B-Chemical	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
-	O	SYM	O
30	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


p	O	NOUN	O
.),	O	PUNCT	O
administered	O	VERB	B
20	O	NUM	O
min	O	NOUN	O
before	O	ADP	O
the	O	DET	O
training	O	NOUN	B
session	O	NOUN	B
,	O	PUNCT	O
prevented	O	VERB	B
amnesia	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
both	O	CCONJ	O
the	O	DET	O
non	O	ADJ	B
selective	O	ADJ	O
antimuscarinic	O	ADJ	B
drug	O	NOUN	I
scopolamine	B-Chemical	NOUN	I
and	O	CCONJ	O
the	O	DET	O
M1	O	PROPN	B
-	O	PUNCT	O
selective	O	ADJ	B
antagonist	O	NOUN	I
S-(-)-ET-126	B-Chemical	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
same	O	ADJ	O
experimental	O	ADJ	B
conditions	O	NOUN	I
,	O	PUNCT	O
PG-9	B-Chemical	NOUN	B
(	O	PUNCT	O
5	O	NUM	O
-	O	PUNCT	O
20	O	NUM	O
microg	O	NOUN	B
per	O	ADP	O
mouse	O	NOUN	B
,	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


c	O	X	O
.	O	PUNCT	O


v	O	DET	O
.)	O	NOUN	O
was	O	AUX	O
also	O	ADV	O
able	O	ADJ	O
to	O	PART	O
prevent	O	VERB	O
antimuscarine	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
amnesia	B-Disease	NOUN	B
,	O	PUNCT	O
demonstrating	O	VERB	O
a	O	DET	O
central	O	ADJ	O
localization	O	NOUN	B
of	O	ADP	O
the	O	DET	O
activity	O	NOUN	B
.	O	PUNCT	O


At	O	ADP	O
the	O	DET	O
highest	O	ADJ	O
effective	O	ADJ	B
doses	O	NOUN	B
,	O	PUNCT	O
PG-9	B-Chemical	NOUN	B
did	O	AUX	O
not	O	PART	O
produce	O	VERB	O
any	O	DET	O
collateral	O	ADJ	B
symptoms	O	NOUN	I
as	O	ADP	O
revealed	O	VERB	O
by	O	ADP	O
the	O	DET	O
Irwin	O	PROPN	B
test	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
it	O	PRON	O
did	O	AUX	O
not	O	PART	O
modify	O	VERB	O
spontaneous	O	ADJ	B
motility	O	NOUN	B
and	O	CCONJ	O
inspection	O	NOUN	B
activity	O	NOUN	I
,	O	PUNCT	O
as	O	ADP	O
revealed	O	VERB	O
by	O	ADP	O
the	O	DET	O
hole	O	NOUN	B
-	O	PUNCT	O
board	O	NOUN	B
test	O	NOUN	I
.	O	PUNCT	O


PG-9	B-Chemical	NOUN	B
was	O	AUX	O
also	O	ADV	O
able	O	ADJ	O
to	O	PART	O
increase	O	VERB	B
the	O	DET	O
amount	O	NOUN	B
of	O	ADP	O
NGF	O	NOUN	B
secreted	O	VERB	B
in	O	X	B
vitro	O	X	I
by	O	ADP	O
astrocytes	O	NOUN	B
in	O	ADP	O
a	O	DET	O
dose	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
manner	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
maximal	O	ADJ	B
NGF	O	NOUN	B
contents	O	NOUN	B
obtained	O	VERB	O
by	O	ADP	O
PG-9	B-Chemical	NOUN	B
were	O	AUX	O
17	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
-	O	PUNCT	O
fold	O	NOUN	B
of	O	ADP	O
the	O	DET	O
control	O	NOUN	B
value	O	NOUN	I
.	O	PUNCT	O


During	O	ADP	O
culture	O	NOUN	B
,	O	PUNCT	O
no	O	DET	O
morphological	O	ADJ	B
changes	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
at	O	ADP	O
effective	O	ADJ	B
concentrations	O	NOUN	B
of	O	ADP	O
PG-9	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
current	O	ADJ	O
work	O	NOUN	O
indicates	O	VERB	O
the	O	DET	O
ability	O	NOUN	O
of	O	ADP	O
PG-9	B-Chemical	NOUN	B
to	O	PART	O
induce	O	VERB	B
beneficial	O	ADJ	O
effects	O	NOUN	B
on	O	ADP	O
cognitive	O	ADJ	B
processes	O	NOUN	I
and	O	CCONJ	O
stimulate	O	VERB	B
activity	O	NOUN	B
of	O	ADP	O
NGF	O	NOUN	B
synthesis	O	NOUN	B
in	O	ADP	O
astroglial	O	ADJ	B
cells	O	NOUN	I
.	O	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
PG-9	B-Chemical	NOUN	B


Angioedema	B-Disease	NOUN	B
due	O	ADJ	O
to	O	PART	O
ACE	B-Chemical	NOUN	B
inhibitors	I-Chemical	NOUN	B
:	O	PUNCT	O
common	O	ADJ	O
and	O	CCONJ	O
inadequately	O	ADV	B
diagnosed	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
estimated	O	ADJ	B
incidence	O	NOUN	B
of	O	ADP	O
angioedema	B-Disease	NOUN	B
during	O	ADP	O
angiotensin-converting	B-Chemical	ADJ	B
enzyme	I-Chemical	NOUN	I
(ACE)	I-Chemical	NOUN	I
inhibitor	I-Chemical	NOUN	B


Recurarization	O	NOUN	B
in	O	ADP	O
the	O	DET	O
recovery	O	NOUN	B
room	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
case	O	NOUN	B
of	O	ADP	O
recurarization	O	NOUN	B
in	O	ADP	O
the	O	DET	O
recovery	O	NOUN	B
room	O	NOUN	I
is	O	AUX	O
reported	O	VERB	O
.	O	PUNCT	O


Accumulation	O	NOUN	B
of	O	ADP	O
atracurium	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
intravenous	O	ADJ	B
line	O	NOUN	I
led	O	VERB	O
to	O	PART	O
recurarization	O	NOUN	B
after	O	ADP	O
flushing	O	VERB	B
the	O	DET	O
line	O	NOUN	O
in	O	ADP	O
the	O	DET	O
recovery	O	NOUN	B
room	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
respiratory	B-Disease	ADJ	B
arrest	I-Disease	NOUN	I
with	O	ADP	O
severe	O	ADJ	B
desaturation	B-Disease	NOUN	B
and	O	CCONJ	O
bradycardia	B-Disease	NOUN	B
occurred	O	VERB	O
.	O	PUNCT	O


Circumstances	O	NOUN	B
leading	O	VERB	O
to	O	ADP	O
this	O	DET	O
event	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
mechanisms	O	NOUN	B
enabling	O	VERB	O
a	O	DET	O
neuromuscular	B-Disease	ADJ	B
blockade	I-Disease	NOUN	I


Recurrent	O	ADJ	B
use	O	NOUN	O
of	O	ADP	O
newer	O	ADJ	O
oral	B-Chemical	ADJ	B
contraceptives	I-Chemical	NOUN	I
and	O	CCONJ	O
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
venous	B-Disease	ADJ	B
thromboembolism	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
epidemiological	O	ADJ	B
studies	O	NOUN	I
that	O	PRON	O
assessed	O	VERB	B
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
venous	B-Disease	ADJ	B
thromboembolism	I-Disease	NOUN	I
(	O	PUNCT	O
VTE	B-Disease	NOUN	B
)	O	PUNCT	O
associated	O	VERB	B
with	O	ADP	I
newer	O	ADJ	O
oral	B-Chemical	ADJ	B
contraceptives	I-Chemical	NOUN	I
(	O	PUNCT	O
OC	B-Chemical	NOUN	B
)	O	PUNCT	O
did	O	AUX	O
not	O	PART	O
distinguish	O	VERB	O
between	O	ADP	O
patterns	O	NOUN	B
of	O	ADP	O
OC	B-Chemical	PROPN	B
use	O	NOUN	B
,	O	PUNCT	O
namely	O	ADV	O
first	O	ADJ	B
-	O	PUNCT	O
time	O	NOUN	B
users	O	NOUN	B
,	O	PUNCT	O
repeaters	O	NOUN	B
and	O	CCONJ	O
switchers	O	NOUN	B
.	O	PUNCT	O


Data	O	NOUN	B
from	O	ADP	O
a	O	DET	O
Transnational	O	ADJ	B
case	O	NOUN	I
-	O	PUNCT	O
control	O	NOUN	B
study	O	NOUN	I
were	O	AUX	O
used	O	VERB	O
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
VTE	B-Disease	NOUN	B
for	O	ADP	O
the	O	DET	O
latter	O	ADJ	O
patterns	O	NOUN	B
of	O	ADP	O
use	O	NOUN	O
,	O	PUNCT	O
while	O	SCONJ	O
accounting	O	VERB	O
for	O	ADP	O
duration	O	NOUN	B
of	O	ADP	O
use	O	NOUN	O
.	O	PUNCT	O


Over	O	ADP	O
the	O	DET	O
period	O	NOUN	B
1993	O	NUM	O
-	O	SYM	O
1996	O	NUM	O
,	O	PUNCT	O
551	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
VTE	B-Disease	NOUN	B
were	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
Germany	O	PROPN	B
and	O	CCONJ	O
the	O	DET	O
UK	O	PROPN	B
along	O	ADP	O
with	O	ADP	O
2066	O	NUM	O
controls	O	NOUN	B
.	O	PUNCT	O


Totals	O	NOUN	B
of	O	ADP	O
128	O	NUM	O
cases	O	NOUN	B
and	O	CCONJ	O
650	O	NUM	O
controls	O	NOUN	B
were	O	AUX	O
analysed	O	VERB	B
for	O	ADP	O
repeat	O	NOUN	O
use	O	NOUN	O
and	O	CCONJ	O
135	O	NUM	O
cases	O	NOUN	B
and	O	CCONJ	O
622	O	NUM	O
controls	O	NOUN	B
for	O	ADP	O
switching	O	NOUN	B
patterns	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
adjusted	O	ADJ	O
rate	O	NOUN	B
ratio	O	NOUN	O
of	O	ADP	O
VTE	B-Disease	NOUN	B
for	O	ADP	O
repeat	O	NOUN	O
users	O	NOUN	B
of	O	ADP	O
third	O	ADJ	B
generation	O	NOUN	I
OC	B-Chemical	PROPN	B
was	O	AUX	O
0	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
:	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
-	O	SYM	O
1	O	NUM	O
.	O	PUNCT	O


2	O	X	O
)	O	PUNCT	O
relative	O	ADJ	O
to	O	PART	O
repeat	O	NOUN	O
users	O	NOUN	B
of	O	ADP	O
second	O	ADJ	O
generation	O	NOUN	O
pills	O	NOUN	O
,	O	PUNCT	O
whereas	O	SCONJ	O
it	O	PRON	O
was	O	AUX	O
1	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
:	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
-	O	SYM	O
2	O	NUM	O
.	O	PUNCT	O


4	O	X	O
)	O	PUNCT	O
for	O	ADP	O
switchers	O	NOUN	B
from	O	ADP	O
second	O	ADV	O
to	O	ADP	O
third	O	ADJ	O
generation	O	NOUN	O
pills	O	NOUN	O
relative	O	ADJ	O
to	O	PART	O
switchers	O	NOUN	B
from	O	ADP	O
third	O	ADJ	O
to	O	PART	O
second	O	ADJ	O
generation	O	NOUN	B
pills	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
second	O	ADJ	O
and	O	CCONJ	O
third	O	ADJ	B
generation	O	NOUN	I
agents	O	NOUN	I
are	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
equivalent	O	ADJ	O
risks	O	NOUN	B
of	O	ADP	O
VTE	B-Disease	NOUN	B
when	O	SCONJ	O
the	O	DET	O
same	O	ADJ	O
agent	O	NOUN	B
is	O	AUX	O
used	O	VERB	O
repeatedly	O	ADV	O
after	O	ADP	O
interruption	O	NOUN	B
periods	O	NOUN	B
or	O	CCONJ	O
when	O	SCONJ	O
users	O	NOUN	B
are	O	AUX	O
switched	O	VERB	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
generations	O	NOUN	B
of	O	ADP	O
pills	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
analyses	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
higher	O	ADJ	B
risk	O	NOUN	B
observed	O	VERB	O
for	O	ADP	O
the	O	DET	O
newer	O	ADJ	O
OC	B-Chemical	PROPN	B


Development	O	NOUN	B
of	O	ADP	O
apomorphine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
aggressive	B-Disease	ADJ	B
behavior	I-Disease	NOUN	I
:	O	PUNCT	O
comparison	O	NOUN	B
of	O	ADP	O
adult	O	ADJ	B
male	O	NOUN	B
and	O	CCONJ	O
female	O	ADJ	B
Wistar	O	PROPN	B
rats	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
development	O	NOUN	B
of	O	ADP	O
apomorphine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
(	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
s	O	NOUN	O
.	O	PUNCT	O


c	O	X	O
.	O	PUNCT	O


once	O	ADV	B
daily	O	ADV	I
)	O	PUNCT	O
aggressive	B-Disease	ADJ	B
behavior	I-Disease	NOUN	I
of	O	ADP	O
adult	O	ADJ	B
male	O	NOUN	B
and	O	CCONJ	O
female	O	ADJ	B
Wistar	O	PROPN	B
rats	O	NOUN	I
obtained	O	VERB	O
from	O	ADP	O
the	O	DET	O
same	O	ADJ	O
breeder	O	NOUN	B
was	O	AUX	O
studied	O	VERB	O
in	O	ADP	O
two	O	NUM	O
consecutive	O	ADJ	B
sets	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
male	O	ADJ	B
animals	O	NOUN	I
,	O	PUNCT	O
repeated	O	VERB	O
apomorphine	B-Chemical	NOUN	B
treatment	O	NOUN	O
induced	O	VERB	B
a	O	DET	O
gradual	O	ADJ	O
development	O	NOUN	B
of	O	ADP	O
aggressive	B-Disease	ADJ	B
behavior	I-Disease	NOUN	I
as	O	ADP	O
evidenced	O	VERB	O
by	O	ADP	O
the	O	DET	O
increased	O	VERB	B
intensity	O	NOUN	B
of	O	ADP	O
aggressiveness	B-Disease	NOUN	B
and	O	CCONJ	O
shortened	O	VERB	B
latency	O	NOUN	B
before	O	ADP	O
the	O	DET	O
first	O	ADJ	O
attack	O	NOUN	B
toward	O	ADP	O
the	O	DET	O
opponent	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
female	O	ADJ	B
rats	O	NOUN	B
,	O	PUNCT	O
only	O	ADV	O
a	O	DET	O
weak	O	ADJ	B
tendency	O	NOUN	O
toward	O	ADP	O
aggressiveness	B-Disease	NOUN	B
was	O	AUX	O
found	O	VERB	O
.	O	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
demonstrates	O	VERB	O
gender	O	NOUN	B
differences	O	NOUN	I
in	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
the	O	DET	O
apomorphine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
aggressive	B-Disease	ADJ	B
behavior	I-Disease	NOUN	I


Serotonergic	B-Chemical	ADJ	B
antidepressants	I-Chemical	NOUN	I
and	O	CCONJ	O
urinary	B-Disease	ADJ	B
incontinence	I-Disease	NOUN	I
.	O	PUNCT	O


Many	O	ADJ	O
new	O	ADJ	O
serotonergic	B-Chemical	NOUN	B
antidepressants	I-Chemical	NOUN	B
have	O	AUX	O
been	O	AUX	O
introduced	O	VERB	O
over	O	ADP	O
the	O	DET	O
past	O	ADJ	O
decade	O	NOUN	O
.	O	PUNCT	O


Although	O	SCONJ	O
urinary	B-Disease	ADJ	B
incontinence	I-Disease	NOUN	I
is	O	AUX	O
listed	O	VERB	O
as	O	ADP	O
one	O	NUM	O
side	O	NOUN	B
effect	O	NOUN	I
of	O	ADP	O
these	O	DET	O
drugs	O	NOUN	B
in	O	ADP	O
their	O	PRON	O
package	O	NOUN	B
inserts	O	NOUN	I
there	O	PRON	O
is	O	AUX	O
only	O	ADV	O
one	O	NUM	O
report	O	NOUN	B
in	O	ADP	O
the	O	DET	O
literature	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
concerns	O	NOUN	O
2	O	NUM	O
male	O	NOUN	B
patients	O	NOUN	B
who	O	PRON	O
experienced	O	VERB	O
incontinence	B-Disease	NOUN	B
while	O	SCONJ	O
taking	O	VERB	O
venlafaxine	B-Chemical	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
present	O	ADJ	O
paper	O	NOUN	O
the	O	DET	O
authors	O	NOUN	B
describe	O	VERB	O
2	O	NUM	O
female	O	ADJ	B
patients	O	NOUN	B
who	O	PRON	O
developed	O	VERB	O
incontinence	B-Disease	NOUN	B
secondary	O	ADJ	B
to	O	PART	O
the	O	DET	O
selective	O	ADJ	O
serotonin	B-Chemical	NOUN	B
reuptake	O	NOUN	I
inhibitors	O	NOUN	I
paroxetine	B-Chemical	NOUN	B
and	O	CCONJ	O
sertraline	B-Chemical	NOUN	B
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
a	O	DET	O
third	O	NOUN	O
who	O	PRON	O
developed	O	VERB	O
this	O	DET	O
side	O	NOUN	B
effect	O	NOUN	I
on	O	ADP	O
venlafaxine	B-Chemical	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
2	O	NUM	O
of	O	ADP	O
the	O	DET	O
3	O	NUM	O
cases	O	NOUN	B
the	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
also	O	ADV	O
taking	O	VERB	O
lithium	B-Chemical	NOUN	B
carbonate	I-Chemical	NOUN	I
and	O	CCONJ	O
beta	O	NOUN	B
-	O	PUNCT	O
blockers	O	NOUN	B
,	O	PUNCT	O
both	O	DET	O
of	O	ADP	O
which	O	DET	O
could	O	AUX	O
have	O	AUX	O
contributed	O	VERB	O
to	O	ADP	O
the	O	DET	O
incontinence	B-Disease	NOUN	B
.	O	PUNCT	O


Animal	O	ADJ	B
studies	O	NOUN	I
suggest	O	VERB	O
that	O	SCONJ	O
incontinence	B-Disease	NOUN	B
secondary	O	ADJ	B
to	O	PART	I
serotonergic	B-Chemical	ADJ	B
antidepressants	I-Chemical	NOUN	B


Hypotension	B-Disease	NOUN	B
following	O	VERB	O
the	O	DET	O
initiation	O	NOUN	B
of	O	ADP	O
tizanidine	B-Chemical	NOUN	B
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
an	O	DET	O
angiotensin	B-Chemical	NOUN	B
converting	O	NOUN	O
enzyme	O	NOUN	B
inhibitor	O	NOUN	I
for	O	ADP	O
chronic	O	ADJ	B
hypertension	B-Disease	NOUN	I
.	O	PUNCT	O


Centrally	O	ADV	B
acting	O	VERB	I
alpha	O	NOUN	B
-	O	PUNCT	O
2	O	NUM	B
adrenergic	O	ADJ	B
agonists	O	NOUN	I
are	O	AUX	O
one	O	NUM	O
of	O	ADP	O
several	O	ADJ	O
pharmacologic	O	ADJ	B
agents	O	NOUN	I
used	O	VERB	O
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
spasticity	B-Disease	NOUN	B
related	O	VERB	O
to	O	PART	O
disorders	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
central	I-Disease	ADJ	B
nervous	I-Disease	ADJ	I
system	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
to	O	PART	O
their	O	PRON	O
effects	O	NOUN	B
on	O	ADP	O
spasticity	B-Disease	NOUN	B
,	O	PUNCT	O
certain	O	ADJ	O
adverse	O	ADJ	B
cardiorespiratory	O	ADJ	B
effects	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
.	O	PUNCT	O


Adults	O	NOUN	B
chronically	O	ADV	B
treated	O	VERB	B
with	O	ADP	I
angiotensin	B-Chemical	NOUN	B
converting	O	NOUN	O
enzyme	O	NOUN	B
inhibitors	O	NOUN	I
may	O	AUX	O
have	O	AUX	O
a	O	DET	O
limited	O	ADJ	O
ability	O	NOUN	O
to	O	PART	O
respond	O	VERB	O
to	O	ADP	O
hypotension	B-Disease	NOUN	B
when	O	SCONJ	O
the	O	DET	O
sympathetic	O	ADJ	B
response	O	NOUN	I
is	O	AUX	O
simultaneously	O	ADV	O
blocked	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
authors	O	NOUN	B
present	O	VERB	O
a	O	DET	O
10	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
boy	O	NOUN	B
chronically	O	ADV	B
treated	O	VERB	B
with	O	ADP	I
lisinopril	B-Chemical	NOUN	B
,	O	PUNCT	O
an	O	DET	O
angiotensin	B-Chemical	NOUN	B
converting	O	NOUN	O
enzyme	O	NOUN	B
inhibitor	O	NOUN	I
,	O	PUNCT	O
to	O	PART	O
control	O	VERB	B
hypertension	B-Disease	NOUN	I
who	O	PRON	O
developed	O	VERB	O
hypotension	B-Disease	NOUN	B
following	O	VERB	O
the	O	DET	O
addition	O	NOUN	O
of	O	ADP	O
tizanidine	B-Chemical	NOUN	B
,	O	PUNCT	O
an	O	DET	O
alpha	O	NOUN	B
-	O	PUNCT	O
2	O	NUM	O
agonist	O	NOUN	B
,	O	PUNCT	O
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
spasticity	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
possible	O	ADJ	O
interaction	O	NOUN	B
of	O	ADP	O
tizanidine	B-Chemical	NOUN	B
and	O	CCONJ	O
other	O	ADJ	O
antihypertensive	O	ADJ	B
agents	O	NOUN	I
should	O	AUX	O
be	O	AUX	O
kept	O	VERB	O
in	O	ADP	O
mind	O	NOUN	O
when	O	SCONJ	O
prescribing	O	NOUN	B
therapy	O	NOUN	I
to	O	PART	O
treat	O	VERB	B
either	O	CCONJ	O
hypertension	B-Disease	NOUN	B
or	O	CCONJ	O
spasticity	B-Disease	NOUN	B


Peritubular	O	ADJ	B
capillary	O	ADJ	I
basement	O	NOUN	O
membrane	O	NOUN	O
reduplication	O	NOUN	O
in	O	ADP	O
allografts	O	NOUN	B
and	O	CCONJ	O
native	O	ADJ	B
kidney	B-Disease	NOUN	O
disease	I-Disease	NOUN	O
:	O	PUNCT	O
a	O	DET	O
clinicopathologic	O	ADJ	B
study	O	NOUN	I
of	O	ADP	O
278	O	NUM	O
consecutive	O	ADJ	B
renal	O	ADJ	B
specimens	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
An	O	DET	O
association	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
found	O	VERB	O
between	O	ADP	O
transplant	B-Disease	NOUN	B
glomerulopathy	I-Disease	NOUN	I
(	O	PUNCT	O
TG	B-Disease	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
reduplication	O	NOUN	B
of	O	ADP	O
peritubular	O	ADJ	B
capillary	O	ADJ	I
basement	O	NOUN	O
membranes	O	NOUN	O
(	O	PUNCT	O
PTCR	O	NOUN	B
).	O	PUNCT	O
Although	O	SCONJ	O
such	O	DET	O
an	O	DET	O
association	O	NOUN	B
is	O	AUX	O
of	O	ADP	O
practical	O	ADJ	B
and	O	CCONJ	O
theoretical	O	ADJ	B
importance	O	NOUN	O
,	O	PUNCT	O
only	O	ADV	O
one	O	NUM	O
prospective	O	ADJ	B
study	O	NOUN	I
has	O	AUX	O
tried	O	VERB	O
to	O	PART	O
confirm	O	VERB	O
it	O	PRON	O
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
We	O	PRON	O
examined	O	VERB	O
278	O	NUM	O
consecutive	O	ADJ	B
renal	O	ADJ	B
specimens	O	NOUN	I
(	O	PUNCT	O
from	O	ADP	O
135	O	NUM	O
transplants	O	NOUN	B
and	O	CCONJ	O
143	O	NUM	O
native	O	ADJ	B
kidneys	O	NOUN	B
)	O	PUNCT	O
for	O	ADP	O
ultrastructural	O	ADJ	B
evidence	O	NOUN	B
of	O	ADP	O
PTCR	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
to	O	PART	O
renal	O	ADJ	B
allografts	O	NOUN	I
with	O	ADP	O
TG	B-Disease	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
also	O	ADV	O
examined	O	VERB	O
grafts	O	NOUN	B
with	O	ADP	O
acute	O	ADJ	B
rejection	O	NOUN	I
,	O	PUNCT	O
recurrent	O	ADJ	B
glomerulonephritis	B-Disease	NOUN	I
,	O	PUNCT	O
chronic	B-Disease	ADJ	B
allograft	I-Disease	NOUN	I
nephropathy	I-Disease	NOUN	I
and	O	CCONJ	O
stable	O	ADJ	B
grafts	O	NOUN	I
("	O	NOUN	O
protocol	O	NOUN	B
biopsies	O	NOUN	B
").	O	PUNCT	O
Native	O	ADJ	B
kidney	O	NOUN	I
specimens	O	NOUN	I
included	O	VERB	O
a	O	DET	O
wide	O	ADJ	O
range	O	NOUN	O
of	O	ADP	O
glomerulopathies	B-Disease	NOUN	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
cases	O	NOUN	B
of	O	ADP	O
thrombotic	B-Disease	ADJ	B
microangiopathy	I-Disease	NOUN	I
,	O	PUNCT	O
malignant	B-Disease	ADJ	B
hypertension	I-Disease	NOUN	I
,	O	PUNCT	O
acute	O	ADJ	B
interstitial	B-Disease	ADJ	I
nephritis	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
acute	B-Disease	ADJ	B
tubular	I-Disease	ADJ	O
necrosis	I-Disease	NOUN	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
We	O	PRON	O
found	O	VERB	O
PTCR	O	NOUN	B
in	O	ADP	O
14	O	NUM	O
of	O	ADP	O
15	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
TG	B-Disease	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
7	O	NUM	O
transplant	O	NOUN	B
biopsy	O	NOUN	B
specimens	O	NOUN	I
without	O	ADP	O
TG	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
13	O	NUM	O
of	O	ADP	O
143	O	NUM	O
native	O	ADJ	B
kidney	O	NOUN	O
biopsy	O	NOUN	O
specimens	O	NOUN	O
.	O	PUNCT	O


These	O	DET	O
13	O	NUM	O
included	O	VERB	O
cases	O	NOUN	B
of	O	ADP	O
malignant	B-Disease	ADJ	B
hypertension	I-Disease	NOUN	I
,	O	PUNCT	O
thrombotic	B-Disease	ADJ	B
microangiopathy	I-Disease	NOUN	I
,	O	PUNCT	O
lupus	B-Disease	NOUN	B
nephritis	I-Disease	NOUN	I
,	O	PUNCT	O
Henoch-Schonlein	B-Disease	NOUN	B
nephritis	I-Disease	NOUN	I
,	O	PUNCT	O
crescentic	O	ADJ	B
glomerulonephritis	B-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
acute	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
failure	I-Disease	NOUN	I
.	O	PUNCT	O


Mild	O	ADJ	B
PTCR	O	NOUN	B
in	O	ADP	O
allografts	O	NOUN	B
without	O	ADP	O
TG	B-Disease	NOUN	B
did	O	AUX	O
not	O	PART	O
predict	O	VERB	O
renal	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
or	O	CCONJ	O
significant	O	ADJ	B
proteinuria	B-Disease	NOUN	B
after	O	ADP	O
follow	O	NOUN	B
-	O	PUNCT	O
up	O	ADP	B
periods	O	NOUN	B
of	O	ADP	O
between	O	ADP	O
3	O	NUM	O
months	O	NOUN	B
and	O	CCONJ	O
1	O	NUM	O
year	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
in	O	ADP	O
transplants	O	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
is	O	AUX	O
a	O	DET	O
strong	O	ADJ	O
association	O	NOUN	B
between	O	ADP	O
well	O	ADV	O
-	O	PUNCT	O
developed	O	VERB	B
PTCR	O	NOUN	B
and	O	CCONJ	O
TG	B-Disease	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
the	O	DET	O
significance	O	NOUN	B
of	O	ADP	O
mild	O	ADJ	B
PTCR	O	NOUN	B
and	O	CCONJ	O
its	O	PRON	O
predictive	O	ADJ	B
value	O	NOUN	I
in	O	ADP	O
the	O	DET	O
absence	O	NOUN	B
of	O	ADP	O
TG	B-Disease	NOUN	B
is	O	AUX	O
unclear	O	ADJ	B
.	O	PUNCT	O


PTCR	O	NOUN	B
also	O	ADV	O
occurs	O	VERB	O
in	O	ADP	O
certain	O	ADJ	O
native	O	ADJ	B
kidney	B-Disease	NOUN	B
diseases	I-Disease	NOUN	I
,	O	PUNCT	O
though	O	SCONJ	O
the	O	DET	O
association	O	NOUN	B
is	O	AUX	O
not	O	PART	O
as	O	ADV	O
strong	O	ADJ	O
as	O	ADP	O
that	O	DET	O
for	O	ADP	O
TG	B-Disease	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
suggest	O	VERB	O
that	O	SCONJ	O
repeated	O	VERB	O
endothelial	B-Disease	ADJ	B
injury	I-Disease	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
immunologic	B-Disease	ADJ	B
injury	I-Disease	NOUN	I


Conformationally	O	ADV	B
restricted	O	ADJ	I
analogs	O	NOUN	B
of	O	ADP	O
BD1008	B-Chemical	NOUN	B
and	O	CCONJ	O
an	O	DET	O
antisense	O	ADJ	B
oligodeoxynucleotide	B-Chemical	NOUN	I
targeting	O	NOUN	O
sigma1	O	NOUN	B
receptors	O	NOUN	I
produce	O	VERB	O
anti	O	ADJ	B
-	O	PUNCT	O
cocaine	B-Chemical	NOUN	B
effects	O	NOUN	B
in	O	ADP	O
mice	O	NOUN	B
.	O	PUNCT	O


Cocaine	B-Chemical	NOUN	B
'	O	PART	I
s	O	NOUN	O
ability	O	NOUN	O
to	O	PART	O
interact	O	VERB	B
with	O	ADP	O
sigma	O	NOUN	B
receptors	O	NOUN	I
suggests	O	VERB	O
that	O	SCONJ	O
these	O	DET	O
proteins	O	NOUN	B
mediate	O	VERB	O
some	O	DET	O
of	O	ADP	O
its	O	PRON	O
behavioral	O	ADJ	B
effects	O	NOUN	B
.	O	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
three	O	NUM	O
novel	O	ADJ	B
sigma	O	NOUN	B
receptor	O	NOUN	I
ligands	O	NOUN	B
with	O	ADP	O
antagonist	O	NOUN	B
activity	O	NOUN	B
were	O	AUX	O
evaluated	O	VERB	B
in	O	ADP	O
Swiss	O	ADJ	B
Webster	O	PROPN	I
mice	O	NOUN	I
:	O	PUNCT	O
BD1018	B-Chemical	NOUN	B
(	O	PUNCT	O
3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane	B-Chemical	NOUN	O
),	O	PUNCT	O
BD1063	B-Chemical	NOUN	B
(	O	PUNCT	O
1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine	B-Chemical	NOUN	B
),	O	PUNCT	O
and	O	CCONJ	O
LR132	B-Chemical	NOUN	B
(	O	PUNCT	O
1R	O	NOUN	B
,	O	PUNCT	O
2S	O	NOUN	B
-(+)-	O	NOUN	I
cis	O	NOUN	I
-	O	PUNCT	O
N	O	NOUN	B
-[	O	NOUN	O
2	O	NUM	O
-(	O	NOUN	O
3	O	NUM	O
,	O	PUNCT	O
4	O	NUM	O
-	O	PUNCT	O
dichlorophenyl	O	NOUN	B
)	O	PUNCT	O
ethyl	O	NOUN	B
]-	O	NOUN	I
2	O	NUM	O
-(	O	NOUN	O
1	O	NUM	O
-	O	PUNCT	O
pyrrolidinyl	O	NOUN	B
)	O	PUNCT	O
cyclohexylamine	O	NOUN	B
).	O	PUNCT	B
Competition	O	NOUN	O
binding	O	NOUN	O
assays	O	NOUN	O
demonstrated	O	VERB	O
that	O	SCONJ	O
all	O	DET	O
three	O	NUM	O
compounds	O	NOUN	B
have	O	AUX	O
high	O	ADJ	O
affinities	O	NOUN	B
for	O	ADP	O
sigma1	O	NOUN	B
receptors	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
three	O	NUM	O
compounds	O	NOUN	B
vary	O	VERB	O
in	O	ADP	O
their	O	PRON	O
affinities	O	NOUN	B
for	O	ADP	O
sigma2	O	NOUN	B
receptors	O	NOUN	I
and	O	CCONJ	O
exhibit	O	VERB	O
negligible	O	ADJ	O
affinities	O	NOUN	B
for	O	ADP	O
dopamine	B-Chemical	NOUN	B
,	O	PUNCT	O
opioid	O	NOUN	B
,	O	PUNCT	O
GABA	B-Chemical	NOUN	B
(	O	PUNCT	O
A	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
NMDA	B-Chemical	NOUN	B
receptors	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
behavioral	O	ADJ	B
studies	O	NOUN	I
,	O	PUNCT	O
pre	O	ADJ	B
-	O	PUNCT	O
treatment	O	NOUN	B
of	O	ADP	O
mice	O	NOUN	B
with	O	ADP	O
BD1018	B-Chemical	NOUN	B
,	O	PUNCT	O
BD1063	B-Chemical	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
LR132	B-Chemical	NOUN	B
significantly	O	ADV	O
attenuated	O	VERB	B
cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
convulsions	B-Disease	NOUN	B
and	O	CCONJ	O
lethality	O	NOUN	B
.	O	PUNCT	O


Moreover	O	ADV	O
,	O	PUNCT	O
post	O	NOUN	B
-	O	PUNCT	O
treatment	O	NOUN	B
with	O	ADP	O
LR132	B-Chemical	NOUN	B
prevented	O	VERB	B
cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
lethality	O	NOUN	B
in	O	ADP	O
a	O	DET	O
significant	O	ADJ	O
proportion	O	NOUN	B
of	O	ADP	O
animals	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
to	O	PART	O
the	O	DET	O
protection	O	NOUN	B
provided	O	VERB	O
by	O	ADP	O
the	O	DET	O
putative	O	ADJ	B
antagonists	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
well	O	ADV	B
-	O	PUNCT	O
characterized	O	VERB	B
sigma	O	NOUN	B
receptor	O	NOUN	I
agonist	O	NOUN	B
di-o-tolylguanidine	B-Chemical	NOUN	B
(	O	PUNCT	O
DTG	B-Chemical	PROPN	B
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
novel	O	ADJ	B
sigma	O	NOUN	I
receptor	O	NOUN	I
agonist	O	NOUN	B
BD1031	B-Chemical	NOUN	B
(	O	PUNCT	O
3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane	B-Chemical	NOUN	O
)	O	PUNCT	O
each	O	DET	O
worsened	O	VERB	B
the	O	DET	O
behavioral	O	ADJ	B
toxicity	B-Disease	NOUN	B
of	O	ADP	O
cocaine	B-Chemical	NOUN	B
.	O	PUNCT	O


At	O	ADP	O
doses	O	NOUN	B
where	O	SCONJ	O
alone	O	ADV	O
,	O	PUNCT	O
they	O	PRON	O
produced	O	VERB	O
no	O	DET	O
significant	O	ADJ	O
effects	O	NOUN	B
on	O	ADP	O
locomotion	O	NOUN	B
,	O	PUNCT	O
BD1018	B-Chemical	NOUN	B
,	O	PUNCT	O
BD1063	B-Chemical	NOUN	B
and	O	CCONJ	O
LR132	B-Chemical	NOUN	B
significantly	O	ADV	O
attenuated	O	VERB	B
the	O	DET	O
locomotor	O	NOUN	B
stimulatory	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
cocaine	B-Chemical	NOUN	B
.	O	PUNCT	O


To	O	PART	O
further	O	ADV	O
validate	O	VERB	O
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
the	O	DET	O
anti	O	ADJ	B
-	O	PUNCT	O
cocaine	B-Chemical	NOUN	B
effects	O	NOUN	B
of	O	ADP	O
the	O	DET	O
novel	O	ADJ	B
ligands	O	NOUN	B
involved	O	VERB	O
antagonism	O	NOUN	B
of	O	ADP	O
sigma	O	NOUN	B
receptors	O	NOUN	I
,	O	PUNCT	O
an	O	DET	O
antisense	O	ADJ	B
oligodeoxynucleotide	B-Chemical	NOUN	I
against	O	ADP	O
sigma1	O	NOUN	B
receptors	O	NOUN	I
was	O	AUX	O
also	O	ADV	O
shown	O	VERB	O
to	O	PART	O
significantly	O	ADV	O
attenuate	O	VERB	B
the	O	DET	O
convulsive	B-Disease	ADJ	B
and	O	CCONJ	O
locomotor	O	NOUN	B
stimulatory	O	ADJ	O
effects	O	NOUN	O
of	O	ADP	O
cocaine	B-Chemical	NOUN	B
.	O	PUNCT	O


Together	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
data	O	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
functional	O	ADJ	B
antagonism	O	NOUN	B
of	O	ADP	O
sigma	O	NOUN	B
receptors	O	NOUN	I
is	O	AUX	O
capable	O	ADJ	O
of	O	ADP	O
attenuating	O	VERB	B
a	O	DET	O
number	O	NOUN	O
of	O	ADP	O
cocaine	B-Chemical	NOUN	B


Pharmacokinetic	O	ADJ	B
/	O	PUNCT	O
pharmacodynamic	O	ADJ	B
assessment	O	NOUN	O
of	O	ADP	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
E4031	B-Chemical	NOUN	B
,	O	PUNCT	O
cisapride	B-Chemical	NOUN	B
,	O	PUNCT	O
terfenadine	B-Chemical	NOUN	B
and	O	CCONJ	O
terodiline	B-Chemical	NOUN	B
on	O	ADP	O
monophasic	O	ADJ	B
action	O	NOUN	O
potential	O	ADJ	O
duration	O	NOUN	B
in	O	ADP	O
dog	O	NOUN	B
.	O	PUNCT	O


1	O	X	O
.	O	PUNCT	O


Torsades	B-Disease	NOUN	B
de	I-Disease	X	I
pointes	I-Disease	X	I
(	O	PUNCT	O
TDP	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
potentially	O	ADV	O
fatal	O	ADJ	B
ventricular	B-Disease	ADJ	B
tachycardia	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
increases	O	NOUN	B
in	O	ADP	O
QT	O	NOUN	B
interval	O	NOUN	I
and	O	CCONJ	O
monophasic	O	ADJ	B
action	O	NOUN	O
potential	O	ADJ	O
duration	O	NOUN	O
(	O	PUNCT	O
MAPD	O	NOUN	B
).	O	PUNCT	O
TDP	B-Disease	NOUN	B
is	O	AUX	O
a	O	DET	O
side	O	NOUN	B
-	O	PUNCT	O
effect	O	NOUN	B
that	O	PRON	O
has	O	AUX	O
led	O	VERB	O
to	O	ADP	O
withdrawal	O	NOUN	B
of	O	ADP	I
several	O	ADJ	O
drugs	O	NOUN	B
from	O	ADP	O
the	O	DET	O
market	O	NOUN	B
(	O	PUNCT	O
e	O	X	O
.	O	PUNCT	O


g	O	NOUN	O
.	O	PUNCT	O


terfenadine	B-Chemical	NOUN	B
and	O	CCONJ	O
terodiline	B-Chemical	NOUN	B
).	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
potential	O	NOUN	B
of	O	ADP	O
compounds	O	NOUN	B
to	O	PART	O
cause	O	VERB	O
TDP	B-Disease	NOUN	B
was	O	AUX	O
evaluated	O	VERB	B
by	O	ADP	O
monitoring	O	VERB	B
their	O	PRON	O
effects	O	NOUN	B
on	O	ADP	O
MAPD	O	NOUN	B
in	O	ADP	O
dog	O	NOUN	B
.	O	PUNCT	O


Four	O	NUM	O
compounds	O	NOUN	B
known	O	VERB	O
to	O	PART	O
increase	O	VERB	B
QT	O	NOUN	B
interval	O	NOUN	I
and	O	CCONJ	O
cause	O	VERB	O
TDP	B-Disease	NOUN	B
were	O	AUX	O
investigated	O	VERB	B
:	O	PUNCT	O
terfenadine	B-Chemical	NOUN	B
,	O	PUNCT	O
terodiline	B-Chemical	NOUN	B
,	O	PUNCT	O
cisapride	B-Chemical	NOUN	B
and	O	CCONJ	O
E4031	B-Chemical	NOUN	B
.	O	PUNCT	O


On	O	ADP	O
the	O	DET	O
basis	O	NOUN	O
that	O	SCONJ	O
only	O	ADV	O
free	O	ADJ	B
drug	O	NOUN	I
in	O	ADP	O
the	O	DET	O
systemic	O	ADJ	B
circulation	O	NOUN	I
will	O	AUX	O
elicit	O	VERB	O
a	O	DET	O
pharmacological	O	ADJ	B
response	O	NOUN	I
target	O	NOUN	B
,	O	PUNCT	O
free	O	ADJ	B
concentrations	O	NOUN	B
in	O	ADP	O
plasma	O	NOUN	B
were	O	AUX	O
selected	O	VERB	O
to	O	PART	O
mimic	O	VERB	O
the	O	DET	O
free	O	ADJ	B
drug	O	NOUN	O
exposures	O	NOUN	O
in	O	ADP	O
man	O	NOUN	B
.	O	PUNCT	O


Infusion	O	NOUN	B
regimens	O	NOUN	I
were	O	AUX	O
designed	O	VERB	O
that	O	SCONJ	O
rapidly	O	ADV	O
achieved	O	VERB	O
and	O	CCONJ	O
maintained	O	VERB	B
target	O	NOUN	B
-	O	PUNCT	O
free	O	ADJ	B
concentrations	O	NOUN	B
of	O	ADP	O
these	O	DET	O
drugs	O	NOUN	B
in	O	ADP	O
plasma	O	NOUN	B
and	O	CCONJ	O
data	O	NOUN	B
on	O	ADP	O
the	O	DET	O
relationship	O	NOUN	B
between	O	ADP	O
free	O	ADJ	B
concentration	O	NOUN	B
and	O	CCONJ	O
changes	O	NOUN	B
in	O	ADP	O
MAPD	O	NOUN	B
were	O	AUX	O
obtained	O	VERB	O
for	O	ADP	O
these	O	DET	O
compounds	O	NOUN	B
.	O	PUNCT	O


3	O	X	O
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
free	O	ADJ	B
ED50	O	NOUN	B
in	O	ADP	O
plasma	O	NOUN	B
for	O	ADP	O
terfenadine	B-Chemical	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
nM	O	NOUN	O
),	O	PUNCT	O
terodiline	B-Chemical	NOUN	B
(	O	PUNCT	O
76	O	NUM	O
nM	O	NOUN	O
),	O	PUNCT	O
cisapride	B-Chemical	NOUN	B
(	O	PUNCT	O
11	O	NUM	O
nM	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
E4031	B-Chemical	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
nM	O	NOUN	O
)	O	PUNCT	O
closely	O	ADV	O
correlate	O	VERB	B
with	O	ADP	O
the	O	DET	O
free	O	ADJ	B
concentration	O	NOUN	B
in	O	ADP	O
man	O	NOUN	B
causing	O	VERB	O
QT	O	NOUN	B
effects	O	NOUN	I
.	O	PUNCT	O


For	O	ADP	O
compounds	O	NOUN	B
that	O	PRON	O
have	O	AUX	O
shown	O	VERB	O
TDP	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
clinic	O	NOUN	B
(	O	PUNCT	O
terfenadine	B-Chemical	NOUN	B
,	O	PUNCT	O
terodiline	B-Chemical	NOUN	B
,	O	PUNCT	O
cisapride	B-Chemical	NOUN	B
)	O	PUNCT	O
there	O	PRON	O
is	O	AUX	O
little	O	ADJ	O
differentiation	O	NOUN	B
between	O	ADP	O
the	O	DET	O
dog	O	NOUN	B
ED50	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
efficacious	O	ADJ	B
free	O	ADJ	B
plasma	O	NOUN	B
concentrations	O	NOUN	B
in	O	ADP	O
man	O	NOUN	B
(<	O	NOUN	O
10	O	NUM	O
-	O	PUNCT	O
fold	O	ADJ	B
)	O	PUNCT	O
reflecting	O	VERB	O
their	O	PRON	O
limited	O	ADJ	O
safety	O	NOUN	B
margins	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
underline	O	VERB	O
the	O	DET	O
need	O	NOUN	O
to	O	PART	O
maximize	O	VERB	O
the	O	DET	O
therapeutic	O	ADJ	B
ratio	O	NOUN	I
with	O	ADP	O
respect	O	NOUN	O
to	O	PART	O
TDP	B-Disease	NOUN	B


Fatal	O	ADJ	B
myeloencephalopathy	B-Disease	NOUN	I
due	O	ADP	O
to	O	PART	O
accidental	O	ADJ	B
intrathecal	O	ADJ	I
vincristin	B-Chemical	NOUN	I
administration	O	NOUN	B
:	O	PUNCT	O
a	O	DET	O
report	O	NOUN	B
of	O	ADP	O
two	O	NUM	O
cases	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
on	O	ADP	O
two	O	NUM	O
fatal	O	ADJ	B
cases	O	NOUN	B
of	O	ADP	O
accidental	O	ADJ	B
intrathecal	O	ADJ	I
vincristine	B-Chemical	NOUN	I
instillation	O	NOUN	B
in	O	ADP	O
a	O	DET	O
5	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
old	O	ADJ	B
girl	O	NOUN	I
with	O	ADP	O
recurrent	O	ADJ	B
acute	B-Disease	ADJ	I
lymphoblastic	I-Disease	ADJ	I
leucemia	I-Disease	NOUN	I
and	O	CCONJ	O
a	O	DET	O
57	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
old	O	ADJ	B
man	O	NOUN	I
with	O	ADP	O
lymphoblastic	B-Disease	ADJ	B
lymphoma	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
girl	O	NOUN	B
died	O	VERB	B
seven	O	NUM	O
days	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
man	O	NOUN	B
four	O	NUM	O
weeks	O	NOUN	B
after	O	ADP	O
intrathecal	O	ADJ	B
injection	O	NOUN	I
of	O	ADP	O
vincristine	B-Chemical	NOUN	B
.	O	PUNCT	O


Clinically	O	ADV	B
,	O	PUNCT	O
the	O	DET	O
onset	O	NOUN	O
was	O	AUX	O
characterized	O	VERB	B
by	O	ADP	O
the	O	DET	O
signs	O	NOUN	O
of	O	ADP	O
opistothonus,	B-Disease	ADJ	O
sensory	I-Disease	ADJ	B
and	I-Disease	CCONJ	O
motor	I-Disease	NOUN	B
dysfunction	I-Disease	NOUN	I
and	O	CCONJ	O
ascending	O	VERB	B
paralysis	B-Disease	NOUN	B
.	O	PUNCT	O


Histological	O	ADJ	B
and	O	CCONJ	O
immunohistochemical	O	ADJ	B
investigations	O	NOUN	O
(	O	PUNCT	O
HE	O	NOUN	B
-	O	PUNCT	O
LFB	O	PROPN	B
,	O	PUNCT	O
CD	O	PROPN	B
-	O	PUNCT	O
68	O	NUM	O
,	O	PUNCT	O
Neurofilament	O	ADJ	B
)	O	PUNCT	O
revealed	O	VERB	O
degeneration	B-Disease	NOUN	B
of	I-Disease	ADP	O
myelin	I-Disease	NOUN	B
and	I-Disease	CCONJ	O
axons	I-Disease	NOUN	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
pseudocystic	B-Disease	ADJ	B
transformation	I-Disease	NOUN	I
in	O	ADP	O
areas	O	NOUN	O
exposed	O	VERB	B
to	O	PART	O
vincristine	B-Chemical	NOUN	B
,	O	PUNCT	O
accompanied	O	VERB	O
by	O	ADP	O
secondary	O	ADJ	B
changes	O	NOUN	I
with	O	ADP	O
numerous	O	ADJ	O
prominent	O	ADJ	B
macrophages	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
clinical	O	ADJ	B
course	O	NOUN	I
and	O	CCONJ	O
histopathological	O	ADJ	B
results	O	NOUN	B
of	O	ADP	O
the	O	DET	O
two	O	NUM	O
cases	O	NOUN	B
are	O	AUX	O
presented	O	VERB	O
.	O	PUNCT	O


A	O	DET	O
review	O	NOUN	B
of	O	ADP	O
all	O	DET	O
reported	O	VERB	O
cases	O	NOUN	B
in	O	ADP	O
the	O	DET	O
literature	O	NOUN	B
is	O	AUX	O
given	O	VERB	O
.	O	PUNCT	O


A	O	DET	O
better	O	ADV	O
controlled	O	VERB	B
regimen	O	NOUN	I
for	O	ADP	O
administering	O	VERB	B
vincristine	B-Chemical	NOUN	B


Intravenous	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
prochlorperazine	B-Chemical	NOUN	B
by	O	ADP	O
15	O	NUM	O
-	O	PUNCT	O
minute	O	NOUN	B
infusion	O	NOUN	B
versus	O	CCONJ	O
2	O	NUM	B
-	O	PUNCT	O
minute	O	NOUN	B
bolus	O	NOUN	B
does	O	AUX	O
not	O	PART	O
affect	O	VERB	O
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
akathisia	B-Disease	NOUN	B
:	O	PUNCT	O
a	O	DET	O
prospective	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
controlled	O	VERB	B
trial	O	NOUN	I
.	O	PUNCT	O


STUDY	O	NOUN	O
OBJECTIVE	O	NOUN	O
:	O	PUNCT	O
We	O	PRON	O
sought	O	VERB	O
to	O	PART	O
compare	O	VERB	B
the	O	DET	O
rate	O	NOUN	B
of	O	ADP	O
akathisia	B-Disease	NOUN	B
after	O	ADP	O
administration	O	NOUN	B
of	O	ADP	O
intravenous	O	ADJ	B
prochlorperazine	B-Chemical	NOUN	I
as	O	ADP	O
a	O	DET	O
2	O	NUM	O
-	O	PUNCT	O
minute	O	NOUN	B
bolus	O	NOUN	B
or	O	CCONJ	O
15	O	NUM	O
-	O	PUNCT	O
minute	O	NOUN	B
infusion	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
We	O	PRON	O
conducted	O	VERB	O
a	O	DET	O
prospective	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	ADJ	B
study	O	NOUN	B
in	O	ADP	O
the	O	DET	O
emergency	O	NOUN	B
department	O	NOUN	I
of	O	ADP	O
a	O	DET	O
central	O	ADJ	B
-	O	PUNCT	O
city	O	NOUN	B
teaching	O	NOUN	B
hospital	O	NOUN	I
.	O	PUNCT	O


Patients	O	NOUN	B
aged	O	ADJ	B
18	O	NUM	O
years	O	NOUN	B
or	O	CCONJ	O
older	O	ADJ	B
treated	O	VERB	B
with	O	ADP	I
prochlorperazine	B-Chemical	NOUN	B
for	O	ADP	O
headache	B-Disease	NOUN	B
,	O	PUNCT	O
nausea	B-Disease	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
vomiting	B-Disease	NOUN	B
were	O	AUX	O
eligible	O	ADJ	O
for	O	ADP	O
inclusion	O	NOUN	B
.	O	PUNCT	O


Study	O	NOUN	B
participants	O	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
receive	O	VERB	O
10	O	NUM	O
mg	O	NOUN	O
of	O	ADP	O
prochlorperazine	B-Chemical	NOUN	B
administered	O	VERB	B
intravenously	O	ADV	B
by	O	ADP	O
means	O	NOUN	O
of	O	ADP	O
2	O	NUM	O
-	O	PUNCT	O
minute	O	NOUN	B
push	O	NOUN	O
(	O	PUNCT	O
bolus	O	NOUN	B
group	O	NOUN	I
)	O	PUNCT	O
or	O	CCONJ	O
10	O	NUM	O
mg	O	NOUN	O
diluted	O	VERB	B
in	O	ADP	O
50	O	NUM	O
mL	O	NOUN	O
of	O	ADP	O
normal	O	ADJ	B
saline	O	NOUN	I
solution	O	NOUN	I
administered	O	VERB	B
by	O	ADP	O
means	O	NOUN	O
of	O	ADP	O
intravenous	O	ADJ	B
infusion	O	NOUN	B
during	O	ADP	O
a	O	DET	O
15	O	NUM	O
-	O	PUNCT	O
minute	O	NOUN	B
period	O	NOUN	B
(	O	PUNCT	O
infusion	O	NOUN	B
group	O	NOUN	B
).	O	VERB	O
The	O	DET	O
main	O	ADJ	O
outcome	O	NOUN	B
was	O	AUX	O
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
study	O	NOUN	B
participants	O	NOUN	B
experiencing	O	VERB	O
akathisia	B-Disease	NOUN	B
within	O	ADP	O
60	O	NUM	O
minutes	O	NOUN	O
of	O	ADP	O
administration	O	NOUN	B
.	O	PUNCT	O


Akathisia	O	PROPN	B
was	O	AUX	O
defined	O	VERB	O
as	O	ADP	O
either	O	CCONJ	O
a	O	DET	O
spontaneous	O	ADJ	B
report	O	NOUN	O
of	O	ADP	O
restlessness	O	NOUN	B
or	O	CCONJ	O
agitation	B-Disease	NOUN	B
or	O	CCONJ	O
a	O	DET	O
change	O	NOUN	O
of	O	ADP	O
2	O	NUM	O
or	O	CCONJ	O
more	O	ADJ	O
in	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
-	O	PUNCT	O
reported	O	VERB	B
akathisia	B-Disease	NOUN	B
rating	O	NOUN	O
scale	O	NOUN	O
and	O	CCONJ	O
a	O	DET	O
change	O	NOUN	O
of	O	ADP	O
at	O	ADV	O
least	O	ADJ	O
1	O	NUM	O
in	O	ADP	O
the	O	DET	O
investigator	O	NOUN	B
-	O	PUNCT	O
observed	O	VERB	B
akathisia	B-Disease	NOUN	B
rating	O	NOUN	O
scale	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
intensity	O	NOUN	B
of	O	ADP	O
headache	B-Disease	NOUN	B
and	O	CCONJ	O
nausea	B-Disease	NOUN	B
was	O	AUX	O
measured	O	VERB	B
with	O	ADP	O
a	O	DET	O
100	O	NUM	O
-	O	PUNCT	O
mm	O	NOUN	B
visual	O	ADJ	I
analog	O	NOUN	I
scale	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
One	O	NUM	O
hundred	O	NUM	O
patients	O	NOUN	B
were	O	AUX	O
enrolled	O	VERB	O
.	O	PUNCT	O


One	O	NUM	O
study	O	NOUN	B
participant	O	NOUN	B
was	O	AUX	O
excluded	O	VERB	O
after	O	ADP	O
protocol	O	NOUN	B
violation	O	NOUN	B
.	O	PUNCT	O


Seventy	O	NUM	B
-	O	PUNCT	O
three	O	NUM	O
percent	O	NOUN	O
(	O	PUNCT	O
73	O	NUM	O
/	O	SYM	O
99	O	NUM	O
)	O	PUNCT	O
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
participants	O	NOUN	B
were	O	AUX	O
treated	O	VERB	B
for	O	ADP	O
headache	B-Disease	NOUN	B
and	O	CCONJ	O
70	O	NUM	O
%(	O	NOUN	O
70	O	NUM	O
/	O	SYM	O
99	O	NUM	O
)	O	PUNCT	O
for	O	ADP	O
nausea	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
bolus	O	NOUN	B
group	O	NOUN	I
,	O	PUNCT	O
26	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
%(	O	NOUN	O
13	O	NUM	O
/	O	SYM	O
50	O	NUM	O
)	O	PUNCT	O
had	O	AUX	O
akathisia	B-Disease	NOUN	B
compared	O	VERB	B
with	O	ADP	O
32	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
%(	O	NOUN	O
16	O	NUM	O
/	O	SYM	O
49	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
infusion	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
Delta	O	NOUN	B
=-	O	NOUN	O
6	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
%;	O	NOUN	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
[	O	PUNCT	O
CI	O	PROPN	B
]-	O	NOUN	O
24	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
%	O	NOUN	O
to	O	ADP	O
11	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
%).	O	VERB	O
The	O	DET	O
difference	O	NOUN	O
between	O	ADP	O
the	O	DET	O
bolus	O	NOUN	B
and	O	CCONJ	O
infusion	O	NOUN	B
groups	O	NOUN	B
in	O	ADP	O
the	O	DET	O
percentage	O	NOUN	B
of	O	ADP	O
participants	O	NOUN	B
who	O	PRON	O
saw	O	VERB	O
a	O	DET	O
50	O	NUM	O
%	O	NOUN	O
reduction	O	NOUN	B
in	O	ADP	O
their	O	PRON	O
headache	B-Disease	NOUN	B
intensity	O	NOUN	B
within	O	ADP	O
30	O	NUM	O
minutes	O	NOUN	B
was	O	AUX	O
11	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
%(	O	NOUN	O
95	O	NUM	O
%	O	NOUN	O
CI	O	PROPN	B
-	O	PUNCT	O
9	O	NUM	B
.	O	PUNCT	O


6	O	NUM	O
%	O	NOUN	O
to	O	ADP	O
33	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
%).	O	VERB	O
The	O	DET	O
difference	O	NOUN	O
in	O	ADP	O
the	O	DET	O
percentage	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
a	O	DET	O
50	O	NUM	O
%	O	NOUN	O
reduction	O	NOUN	B
in	O	ADP	O
their	O	PRON	O
nausea	B-Disease	NOUN	B
was	O	AUX	O
12	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
%(	O	NOUN	O
95	O	NUM	O
%	O	NOUN	O
CI	O	PROPN	B
-	O	PUNCT	O
4	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
%	O	NOUN	O
to	O	PART	O
29	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
%).	O	NOUN	O
CONCLUSION	O	NOUN	O
:	O	PUNCT	O
A	O	DET	O
50	O	NUM	O
%	O	NOUN	O
reduction	O	NOUN	B
in	O	ADP	O
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
akathisia	B-Disease	NOUN	B
when	O	SCONJ	O
prochlorperazine	B-Chemical	NOUN	B
was	O	AUX	O
administered	O	VERB	B
by	O	ADP	O
means	O	NOUN	O
of	O	ADP	O
15	O	NUM	O
-	O	PUNCT	O
minute	O	NOUN	B
intravenous	O	ADJ	B
infusion	O	NOUN	O
versus	O	CCONJ	O
a	O	DET	O
2	O	NUM	B
-	O	PUNCT	O
minute	O	NOUN	B
intravenous	O	ADJ	B
push	O	NOUN	O
was	O	AUX	O
not	O	PART	O
detected	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
prochlorperazine	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
headache	B-Disease	NOUN	B
and	O	CCONJ	O
nausea	B-Disease	NOUN	B


Antithymocyte	B-Chemical	NOUN	B
globulin	I-Chemical	NOUN	I
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
D-penicillamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
aplastic	B-Disease	ADJ	B
anemia	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
patient	O	NOUN	B
who	O	PRON	O
received	O	VERB	O
antithymocyte	B-Chemical	NOUN	B
globulin	I-Chemical	NOUN	I
therapy	O	NOUN	I
for	O	ADP	O
aplastic	B-Disease	ADJ	B
anemia	I-Disease	NOUN	I
due	O	ADJ	O
to	O	PART	O
D-penicillamine	B-Chemical	NOUN	B
therapy	O	NOUN	I
is	O	AUX	O
described	O	VERB	O
.	O	PUNCT	O


Bone	O	NOUN	B
marrow	O	NOUN	I
recovery	O	NOUN	B
and	O	CCONJ	O
peripheral	O	ADJ	B
blood	O	NOUN	I
recovery	O	NOUN	I
were	O	AUX	O
complete	O	ADJ	O
1	O	NUM	O
month	O	NOUN	B
and	O	CCONJ	O
3	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
after	O	ADP	O
treatment	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
blood	O	NOUN	B
transfusion	O	NOUN	I
or	O	CCONJ	O
other	O	ADJ	O
therapies	O	NOUN	B
were	O	AUX	O
not	O	PART	O
necessary	O	ADJ	O
in	O	ADP	O
a	O	DET	O
follow	O	NOUN	B
-	O	PUNCT	O
up	O	ADP	O
period	O	NOUN	B
of	O	ADP	O
more	O	ADJ	O
than	O	ADP	O
2	O	NUM	O
years	O	NOUN	B
.	O	PUNCT	O


Use	O	PROPN	O
of	O	ADP	O
antithymocyte	B-Chemical	NOUN	B
globulin	I-Chemical	NOUN	I
may	O	AUX	O
be	O	AUX	O
the	O	DET	O
optimal	O	ADJ	B
treatment	O	NOUN	B
of	O	ADP	O
D-penicillamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
aplastic	B-Disease	ADJ	B
anemia	I-Disease	NOUN	I


The	O	DET	O
relationship	O	NOUN	B
between	O	ADP	O
hippocampal	O	NOUN	B
acetylcholine	B-Chemical	NOUN	B
release	O	NOUN	I
and	O	CCONJ	O
cholinergic	O	ADJ	B
convulsant	O	ADJ	B
sensitivity	O	NOUN	B
in	O	ADP	O
withdrawal	O	NOUN	B
seizure	B-Disease	NOUN	I
-	O	PUNCT	O
prone	O	ADJ	B
and	O	CCONJ	O
withdrawal	O	NOUN	B
seizure	B-Disease	NOUN	B
-	O	PUNCT	O
resistant	O	ADJ	B
selected	O	VERB	O
mouse	O	NOUN	B
lines	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
septo	O	NOUN	B
-	O	PUNCT	O
hippocampal	O	NOUN	B
cholinergic	O	ADJ	B
pathway	O	NOUN	O
has	O	AUX	O
been	O	AUX	O
implicated	O	VERB	O
in	O	ADP	O
epileptogenesis	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
genetic	O	ADJ	B
factors	O	NOUN	I
influence	O	VERB	B
the	O	DET	O
response	O	NOUN	B
to	O	PART	O
cholinergic	O	ADJ	B
agents	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
limited	O	ADJ	O
data	O	NOUN	B
are	O	AUX	O
available	O	ADJ	O
on	O	ADP	O
cholinergic	O	ADJ	B
involvement	O	NOUN	B
in	O	ADP	O
alcohol	B-Chemical	NOUN	B
withdrawal	O	NOUN	I
severity	O	NOUN	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
relationship	O	NOUN	B
between	O	ADP	O
cholinergic	O	ADJ	B
activity	O	NOUN	B
and	O	CCONJ	O
responsiveness	O	NOUN	B
and	O	CCONJ	O
alcohol	B-Chemical	NOUN	B
withdrawal	O	NOUN	I
was	O	AUX	O
investigated	O	VERB	B
in	O	ADP	O
a	O	DET	O
genetic	O	ADJ	B
animal	O	NOUN	I
model	O	NOUN	O
of	O	ADP	O
ethanol	B-Chemical	NOUN	B
withdrawal	O	NOUN	O
severity	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
Cholinergic	O	ADJ	B
convulsant	O	ADJ	B
sensitivity	O	NOUN	B
was	O	AUX	O
examined	O	VERB	O
in	O	ADP	O
alcohol	B-Chemical	NOUN	B
-	O	PUNCT	O
na	O	NOUN	B
ve	O	X	O
Withdrawal	O	PROPN	B
Seizure	B-Disease	PROPN	B
-	O	PUNCT	O
Prone	O	PROPN	B
(	O	PUNCT	O
WSP	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
-	O	PUNCT	O
Resistant	O	NOUN	B
(	O	PUNCT	O
WSR	O	NOUN	B
)	O	PUNCT	O
mice	O	NOUN	B
.	O	PUNCT	O


Animals	O	NOUN	B
were	O	AUX	O
administered	O	VERB	B
nicotine	B-Chemical	NOUN	B
,	O	PUNCT	O
carbachol	B-Chemical	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
neostigmine	B-Chemical	NOUN	B
via	O	ADP	O
timed	O	VERB	B
tail	O	NOUN	I
vein	O	NOUN	I
infusion	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
latencies	O	NOUN	B
to	O	PART	O
onset	O	NOUN	B
of	O	ADP	I
tremor	B-Disease	NOUN	B
and	O	CCONJ	O
clonus	O	NOUN	B
were	O	AUX	O
recorded	O	VERB	O
and	O	CCONJ	O
converted	O	VERB	O
to	O	PART	O
threshold	O	NOUN	B
dose	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
also	O	ADV	O
used	O	VERB	O
microdialysis	O	NOUN	B
to	O	PART	O
measure	O	VERB	B
basal	O	ADJ	B
and	O	CCONJ	O
potassium	B-Chemical	NOUN	B
-	O	PUNCT	O
stimulated	O	VERB	B
acetylcholine	B-Chemical	NOUN	B
(	O	PUNCT	O
ACh	B-Chemical	NOUN	B
)	O	PUNCT	O
release	O	NOUN	B
in	O	ADP	O
the	O	DET	O
CA1	O	NOUN	B
region	O	NOUN	I
of	O	ADP	O
the	O	DET	O
hippocampus	O	NOUN	B
.	O	PUNCT	O


Potassium	B-Chemical	NOUN	B
was	O	AUX	O
applied	O	VERB	O
by	O	ADP	O
reverse	O	ADJ	B
dialysis	O	NOUN	I
twice	O	ADV	O
,	O	PUNCT	O
separated	O	VERB	O
by	O	ADP	O
75	O	NUM	O
min	O	NOUN	O
.	O	PUNCT	O


Hippocampal	O	ADJ	B
ACh	B-Chemical	NOUN	B
also	O	ADV	O
was	O	AUX	O
measured	O	VERB	B
during	O	ADP	O
testing	O	NOUN	B
for	O	ADP	O
handling	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
convulsions	B-Disease	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Sensitivity	O	NOUN	B
to	O	PART	O
several	O	ADJ	O
convulsion	B-Disease	NOUN	B
endpoints	O	NOUN	B
induced	O	VERB	B
by	O	ADP	O
nicotine	B-Chemical	NOUN	B
,	O	PUNCT	O
carbachol	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
neostigmine	B-Chemical	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
greater	O	ADJ	O
in	O	ADP	O
WSR	O	NOUN	B
versus	O	CCONJ	O
WSP	O	NOUN	B
mice	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
microdialysis	O	NOUN	B
experiments	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
lines	O	NOUN	B
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
in	O	ADP	O
basal	O	ADJ	B
release	O	NOUN	I
of	O	ADP	O
ACh	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
50	O	NUM	O
mM	O	ADJ	O
KCl	B-Chemical	NOUN	B
increased	O	VERB	B
ACh	B-Chemical	NOUN	B
output	O	NOUN	B
in	O	ADP	O
both	O	DET	O
lines	O	NOUN	B
of	O	ADP	O
mice	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
release	O	NOUN	B
of	O	ADP	O
ACh	B-Chemical	NOUN	B
produced	O	VERB	O
by	O	ADP	O
the	O	DET	O
first	O	ADJ	O
application	O	NOUN	B
of	O	ADP	O
KCl	B-Chemical	NOUN	B
was	O	AUX	O
2	O	NUM	O
-	O	PUNCT	O
fold	O	NOUN	B
higher	O	ADJ	B
in	O	ADP	O
WSP	O	NOUN	B
versus	O	CCONJ	O
WSR	O	NOUN	B
mice	O	NOUN	I
.	O	PUNCT	O


When	O	SCONJ	O
hippocampal	O	ADJ	B
ACh	B-Chemical	NOUN	B
was	O	AUX	O
measured	O	VERB	O
during	O	ADP	O
testing	O	NOUN	B
for	O	ADP	O
handling	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
convulsions	B-Disease	NOUN	B
,	O	PUNCT	O
extracellular	O	ADJ	B
ACh	B-Chemical	NOUN	I
was	O	AUX	O
significantly	O	ADV	O
elevated	O	ADJ	B
(	O	PUNCT	O
192	O	NUM	O
%)	O	NOUN	O
in	O	ADP	O
WSP	O	NOUN	B
mice	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
was	O	AUX	O
nonsignificantly	O	ADV	O
elevated	O	ADJ	B
(	O	PUNCT	O
59	O	NUM	O
%)	O	NOUN	O
in	O	ADP	O
WSR	O	NOUN	B
mice	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
differences	O	NOUN	B
in	O	ADP	O
cholinergic	O	ADJ	B
activity	O	NOUN	B
and	O	CCONJ	O
postsynaptic	O	ADJ	B
sensitivity	O	NOUN	I
to	O	PART	O
cholinergic	O	ADJ	B
convulsants	B-Disease	NOUN	B
may	O	AUX	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
ethanol	B-Chemical	NOUN	B
withdrawal	O	NOUN	O
severity	O	NOUN	B
and	O	CCONJ	O
implicate	O	VERB	O
cholinergic	O	ADJ	B
mechanisms	O	NOUN	B
in	O	ADP	O
alcohol	B-Chemical	NOUN	B
withdrawal	O	NOUN	I
.	O	PUNCT	O


Specifically	O	ADV	O
,	O	PUNCT	O
WSP	O	NOUN	B
mice	O	NOUN	B
may	O	AUX	O
have	O	AUX	O
lower	O	ADJ	O
sensitivity	O	NOUN	B
to	O	PART	O
cholinergic	O	ADJ	B
convulsants	B-Disease	NOUN	B


Prenatal	O	ADJ	B
dexamethasone	B-Chemical	NOUN	O
programs	O	NOUN	O
hypertension	B-Disease	NOUN	B
and	O	CCONJ	O
renal	B-Disease	ADJ	B
injury	I-Disease	NOUN	I
in	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
.	O	PUNCT	O


Dexamethasone	O	NOUN	B
is	O	AUX	O
frequently	O	ADV	O
administered	O	VERB	B
to	O	ADP	O
the	O	DET	O
developing	O	VERB	O
fetus	O	NOUN	B
to	O	PART	O
accelerate	O	VERB	O
pulmonary	O	ADJ	B
development	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
determine	O	VERB	O
if	O	SCONJ	O
prenatal	O	ADJ	B
dexamethasone	B-Chemical	NOUN	B
programmed	O	VERB	B
a	O	DET	O
progressive	O	ADJ	B
increase	B-Disease	NOUN	B
in	I-Disease	ADP	O
blood	I-Disease	NOUN	B
pressure	I-Disease	NOUN	I
and	O	CCONJ	O
renal	B-Disease	ADJ	B
injury	I-Disease	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


Pregnant	O	ADJ	B
rats	O	NOUN	I
were	O	AUX	O
given	O	VERB	O
either	O	CCONJ	O
vehicle	O	NOUN	B
or	O	CCONJ	O
2	O	NUM	O
daily	O	ADJ	O
intraperitoneal	O	ADJ	B
injections	O	NOUN	O
of	O	ADP	O
dexamethasone	B-Chemical	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
body	O	NOUN	B
weight	O	NOUN	I
)	O	PUNCT	O
on	O	ADP	O
gestational	O	ADJ	B
days	O	NOUN	B
11	O	NUM	O
and	O	CCONJ	O
12	O	NUM	O
,	O	PUNCT	O
13	O	NUM	O
and	O	CCONJ	O
14	O	NUM	O
,	O	PUNCT	O
15	O	NUM	O
and	O	CCONJ	O
16	O	NUM	O
,	O	PUNCT	O
17	O	NUM	O
and	O	CCONJ	O
18	O	NUM	O
,	O	PUNCT	O
or	O	CCONJ	O
19	O	NUM	O
and	O	CCONJ	O
20	O	NUM	O
.	O	PUNCT	O


Offspring	O	NOUN	B
of	O	ADP	O
rats	O	NOUN	B
administered	O	VERB	B
dexamethasone	B-Chemical	NOUN	B
on	O	ADP	O
days	O	NOUN	B
15	O	NUM	O
and	O	CCONJ	O
16	O	NUM	O
gestation	O	NOUN	B
had	O	AUX	O
a	O	DET	O
20	O	NUM	O
%	O	NOUN	O
reduction	B-Disease	NOUN	B
in	I-Disease	ADP	O
glomerular	I-Disease	ADJ	B
number	I-Disease	NOUN	I
compared	O	VERB	B
with	O	ADP	O
control	O	NOUN	B
at	O	ADP	O
6	O	NUM	O
to	O	PART	O
9	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
age	O	NOUN	B
(	O	PUNCT	O
22	O	NUM	O
527	O	NUM	O
+/-	O	CCONJ	O
509	O	NUM	O
versus	O	CCONJ	O
28	O	NUM	O
050	O	NUM	O
+/-	O	CCONJ	O
561	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
),	O	PUNCT	O
which	O	DET	O
was	O	AUX	O
comparable	O	ADJ	O
to	O	ADP	O
the	O	DET	O
percent	O	ADJ	O
reduction	O	NOUN	B
in	O	ADP	O
glomeruli	O	NOUN	B
measured	O	VERB	B
at	O	ADP	O
3	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
age	O	NOUN	B
.	O	PUNCT	O


Six	O	NUM	B
-	O	PUNCT	O
to	O	ADP	O
9	O	NUM	B
-	O	PUNCT	O
month	O	NOUN	B
old	O	ADJ	O
rats	O	NOUN	B
receiving	O	VERB	O
prenatal	O	ADJ	B
dexamethasone	B-Chemical	NOUN	B
on	O	ADP	O
days	O	NOUN	B
17	O	NUM	O
and	O	CCONJ	O
18	O	NUM	O
of	O	ADP	O
gestation	O	NOUN	B
had	O	AUX	O
a	O	DET	O
17	O	NUM	O
%	O	NOUN	O
reduction	O	NOUN	B
in	O	ADP	O
glomeruli	O	NOUN	B
(	O	PUNCT	O
23	O	NUM	O
380	O	NUM	O
+/-	O	CCONJ	O
587	O	NUM	O
)	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
control	O	ADJ	B
rats	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
).	O	PUNCT	O
Male	O	NOUN	B
rats	O	NOUN	B
that	O	PRON	O
received	O	VERB	O
prenatal	O	ADJ	B
dexamethasone	B-Chemical	NOUN	B
on	O	ADP	O
days	O	NOUN	B
15	O	NUM	O
and	O	CCONJ	O
16	O	NUM	O
,	O	PUNCT	O
17	O	NUM	O
and	O	CCONJ	O
18	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
13	O	NUM	O
and	O	CCONJ	O
14	O	NUM	O
of	O	ADP	O
gestation	O	NOUN	B
had	O	AUX	O
elevated	B-Disease	ADJ	B
blood	I-Disease	NOUN	B
pressures	I-Disease	NOUN	I
at	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
age	O	NOUN	B
;	O	PUNCT	O
the	O	DET	O
latter	O	ADJ	O
group	O	NOUN	B
did	O	AUX	O
not	O	PART	O
have	O	AUX	O
a	O	DET	O
reduction	B-Disease	NOUN	B
in	I-Disease	ADP	O
glomerular	I-Disease	ADJ	B
number	I-Disease	NOUN	I
.	O	PUNCT	O


Adult	O	ADJ	B
rats	O	NOUN	B
given	O	VERB	O
dexamethasone	B-Chemical	NOUN	B
on	O	ADP	O
days	O	NOUN	B
15	O	NUM	O
and	O	CCONJ	O
16	O	NUM	O
of	O	ADP	O
gestation	O	NOUN	B
had	O	AUX	O
more	O	ADJ	O
glomeruli	O	NOUN	B
with	O	ADP	O
glomerulosclerosis	B-Disease	NOUN	B
than	O	ADP	O
control	O	NOUN	B
rats	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
shows	O	VERB	O
that	O	SCONJ	O
prenatal	O	ADJ	B
dexamethasone	B-Chemical	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
results	O	VERB	B
in	O	ADP	O
a	O	DET	O
reduction	B-Disease	NOUN	B
in	I-Disease	ADP	O
glomerular	I-Disease	ADJ	B
number	I-Disease	NOUN	I
,	O	PUNCT	O
glomerulosclerosis	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
hypertension	B-Disease	NOUN	B
when	O	SCONJ	O
administered	O	VERB	B
at	O	ADP	O
specific	O	ADJ	O
points	O	NOUN	O
during	O	ADP	O
gestation	O	NOUN	B
.	O	PUNCT	O


Hypertension	B-Disease	NOUN	B
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
animals	O	NOUN	B
that	O	PRON	O
had	O	AUX	O
a	O	DET	O
reduction	O	NOUN	B
in	O	ADP	O
glomeruli	O	NOUN	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
in	O	ADP	O
a	O	DET	O
group	O	NOUN	B
that	O	PRON	O
did	O	AUX	O
not	O	PART	O
have	O	AUX	O
a	O	DET	O
reduction	B-Disease	NOUN	B
in	I-Disease	ADP	O
glomerular	I-Disease	ADJ	B
number	I-Disease	NOUN	I
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
reduction	B-Disease	NOUN	B
in	I-Disease	ADP	O
glomerular	I-Disease	ADJ	B
number	I-Disease	NOUN	I
is	O	AUX	O
not	O	PART	O
the	O	DET	O
sole	O	ADJ	O
cause	O	NOUN	B
for	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
hypertension	B-Disease	NOUN	B


The	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
venous	B-Disease	ADJ	B
thromboembolism	I-Disease	NOUN	I
in	O	ADP	O
women	O	NOUN	B
prescribed	O	VERB	B
cyproterone	B-Chemical	NOUN	B
acetate	I-Chemical	NOUN	B
in	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
ethinyl	B-Chemical	NOUN	B
estradiol	I-Chemical	NOUN	I
:	O	PUNCT	O
a	O	DET	O
nested	O	ADJ	B
cohort	O	NOUN	I
analysis	O	NOUN	I
and	O	CCONJ	O
case	O	NOUN	B
-	O	PUNCT	O
control	O	NOUN	B
study	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Cyproterone	B-Chemical	NOUN	B
acetate	I-Chemical	NOUN	I
combined	O	VERB	O
with	O	ADP	O
ethinyl	B-Chemical	NOUN	B
estradiol	I-Chemical	NOUN	I
(	O	PUNCT	O
CPA	B-Chemical	NOUN	B
/	O	PUNCT	O
EE	B-Chemical	PROPN	B
)	O	PUNCT	O
is	O	AUX	O
licensed	O	VERB	B
in	O	ADP	O
the	O	DET	O
UK	O	PROPN	B
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
women	O	NOUN	B
with	O	ADP	O
acne	B-Disease	NOUN	B
and	O	CCONJ	O
hirsutism	B-Disease	NOUN	B
and	O	CCONJ	O
is	O	AUX	O
also	O	ADV	O
a	O	DET	O
treatment	O	NOUN	B
option	O	NOUN	O
for	O	ADP	O
polycystic	B-Disease	ADJ	B
ovary	I-Disease	ADJ	I
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
PCOS	B-Disease	NOUN	B
).	O	PUNCT	O
Previous	O	ADJ	O
studies	O	NOUN	B
have	O	AUX	O
demonstrated	O	VERB	O
an	O	DET	O
increased	O	VERB	B
risk	O	NOUN	B
of	O	ADP	O
venous	B-Disease	ADJ	B
thromboembolism	I-Disease	NOUN	I
(	O	PUNCT	O
VTE	B-Disease	NOUN	B
)	O	PUNCT	O
associated	O	VERB	B
with	O	ADP	I
CPA	B-Chemical	NOUN	B
/	O	PUNCT	O
EE	B-Chemical	PROPN	B
compared	O	VERB	O
with	O	ADP	O
conventional	O	ADJ	B
combined	O	ADJ	O
oral	B-Chemical	ADJ	O
contraceptives	I-Chemical	NOUN	O
(	O	PUNCT	O
COCs	O	NOUN	B
).	O	PUNCT	O
We	O	PRON	O
believe	O	VERB	O
the	O	DET	O
results	O	NOUN	B
of	O	ADP	O
those	O	DET	O
studies	O	NOUN	B
may	O	AUX	O
have	O	AUX	O
been	O	AUX	O
affected	O	VERB	B
by	O	ADP	O
residual	O	ADJ	B
confounding	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
Using	O	VERB	O
the	O	DET	O
General	O	PROPN	B
Practice	O	PROPN	I
Research	O	PROPN	I
Database	O	PROPN	I
we	O	PRON	O
conducted	O	VERB	O
a	O	DET	O
cohort	O	NOUN	B
analysis	O	NOUN	I
and	O	CCONJ	O
case	O	NOUN	B
-	O	PUNCT	O
control	O	NOUN	B
study	O	NOUN	I
nested	O	VERB	B
within	O	ADP	O
a	O	DET	O
population	O	NOUN	B
of	O	ADP	O
women	O	NOUN	B
aged	O	ADJ	B
between	O	ADP	O
15	O	NUM	O
and	O	CCONJ	O
39	O	NUM	O
years	O	NOUN	B
with	O	ADP	O
acne	B-Disease	NOUN	B
,	O	PUNCT	O
hirsutism	B-Disease	NOUN	B
or	O	CCONJ	O
PCOS	B-Disease	NOUN	B
to	O	PART	O
estimate	O	VERB	B
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
VTE	B-Disease	NOUN	B
associated	O	VERB	B
with	O	ADP	I
CPA	B-Chemical	NOUN	B
/	O	PUNCT	O
EE	B-Chemical	PROPN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
age	O	NOUN	B
-	O	PUNCT	O
adjusted	O	VERB	B
incidence	O	NOUN	B
rate	O	NOUN	O
ratio	O	NOUN	O
for	O	ADP	O
CPA	B-Chemical	NOUN	B
/	O	PUNCT	O
EE	B-Chemical	PROPN	B
versus	O	CCONJ	O
conventional	O	ADJ	B
COCs	O	NOUN	B
was	O	AUX	O
2	O	NUM	O
.	O	PUNCT	O


20	O	NUM	O
[	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
(	O	PUNCT	O
CI	O	NOUN	B
)	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


35	O	NUM	O
-	O	SYM	O
3	O	NUM	O
.	O	PUNCT	O


58	O	NUM	O
].	O	PROPN	O
Using	O	VERB	O
as	O	ADP	O
the	O	DET	O
reference	O	NOUN	B
group	O	NOUN	I
women	O	NOUN	B
who	O	PRON	O
were	O	AUX	O
not	O	PART	O
using	O	VERB	O
oral	O	ADJ	B
contraception	O	NOUN	I
,	O	PUNCT	O
had	O	AUX	O
no	O	DET	O
recent	O	ADJ	O
pregnancy	O	NOUN	B
or	O	CCONJ	O
menopausal	O	ADJ	B
symptoms	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
case	O	NOUN	B
-	O	PUNCT	O
control	O	NOUN	B
analysis	O	NOUN	I
gave	O	VERB	O
an	O	DET	O
adjusted	O	VERB	O
odds	O	NOUN	B
ratio	O	NOUN	I
(	O	PUNCT	O
OR	O	NOUN	B
(	O	PUNCT	O
adj	O	NOUN	O
))	O	PUNCT	O
of	O	ADP	O
7	O	NUM	O
.	O	PUNCT	O


44	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
3	O	NUM	O
.	O	PUNCT	O


67	O	NUM	O
-	O	SYM	O
15	O	NUM	O
.	O	PUNCT	O


08	O	NUM	O
)	O	PUNCT	O
for	O	ADP	O
CPA	B-Chemical	NOUN	B
/	O	PUNCT	O
EE	B-Chemical	PROPN	B
use	O	NOUN	O
compared	O	VERB	B
with	O	ADP	O
an	O	DET	O
OR	O	NOUN	B
(	O	PUNCT	O
adj	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
2	O	NUM	O
.	O	PUNCT	O


58	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
1	O	NUM	O
.	O	PUNCT	O


60	O	NUM	O
-	O	SYM	O
4	O	NUM	O
.	O	PUNCT	O


18	O	NUM	O
)	O	PUNCT	O
for	O	ADP	O
use	O	NOUN	O
of	O	ADP	O
conventional	O	ADJ	B
COCs	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
We	O	PRON	O
have	O	AUX	O
demonstrated	O	VERB	O
an	O	DET	O
increased	O	VERB	B
risk	O	NOUN	B
of	O	ADP	O
VTE	B-Disease	NOUN	B
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
CPA	B-Chemical	PROPN	B
/	O	PUNCT	O
EE	B-Chemical	PROPN	B
in	O	ADP	O
women	O	NOUN	B
with	O	ADP	O
acne	B-Disease	NOUN	B
,	O	PUNCT	O
hirsutism	B-Disease	NOUN	B
or	O	CCONJ	O
PCOS	B-Disease	NOUN	B


Pseudoacromegaly	B-Disease	PROPN	B
induced	O	VERB	B
by	O	ADP	O
the	O	DET	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
use	O	NOUN	O
of	O	ADP	O
minoxidil	B-Chemical	NOUN	B
.	O	PUNCT	O


Acromegaly	B-Disease	NOUN	B
is	O	AUX	O
an	O	DET	O
endocrine	B-Disease	ADJ	B
disorder	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
chronic	O	ADJ	B
excessive	O	ADJ	I
growth	O	NOUN	I
hormone	O	NOUN	I
secretion	O	NOUN	B
from	O	ADP	O
the	O	DET	O
anterior	O	ADJ	B
pituitary	O	ADJ	I
gland	O	NOUN	I
.	O	PUNCT	O


Significant	O	ADJ	O
disfiguring	O	ADJ	B
changes	O	NOUN	B
occur	O	VERB	O
as	O	ADP	O
a	O	DET	O
result	O	NOUN	O
of	O	ADP	O
bone	O	NOUN	B
,	O	PUNCT	O
cartilage	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
soft	O	ADJ	B
tissue	O	NOUN	I
hypertrophy	B-Disease	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
the	O	DET	O
thickening	O	NOUN	B
of	O	ADP	O
the	O	DET	O
skin	O	NOUN	B
,	O	PUNCT	O
coarsening	O	NOUN	B
of	O	ADP	O
facial	O	ADJ	B
features	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
cutis	B-Disease	NOUN	B
verticis	I-Disease	NOUN	I
gyrata	I-Disease	NOUN	I
.	O	PUNCT	O


Pseudoacromegaly	B-Disease	PROPN	B
,	O	PUNCT	O
on	O	ADP	O
the	O	DET	O
other	O	ADJ	O
hand	O	NOUN	B
,	O	PUNCT	O
is	O	AUX	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
similar	O	ADJ	O
acromegaloid	O	ADJ	B
features	O	NOUN	B
in	O	ADP	O
the	O	DET	O
absence	O	NOUN	B
of	O	ADP	O
elevated	O	ADJ	B
growth	O	NOUN	O
hormone	O	NOUN	O
or	O	CCONJ	O
insulin	O	NOUN	B
-	O	PUNCT	O
like	O	ADJ	B
growth	O	NOUN	B
factor	O	NOUN	I
levels	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
present	O	VERB	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
pseudoacromegaly	B-Disease	NOUN	B
that	O	PRON	O
resulted	O	VERB	O
from	O	ADP	O
the	O	DET	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
use	O	NOUN	O
of	O	ADP	O
minoxidil	B-Chemical	NOUN	B
at	O	ADP	O
an	O	DET	O
unusually	O	ADV	O
high	O	ADJ	B
dose	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
case	O	NOUN	B
report	O	NOUN	I
of	O	ADP	O
pseudoacromegaly	B-Disease	NOUN	B
as	O	ADP	O
a	O	DET	O
side	O	NOUN	B
effect	O	NOUN	I
of	O	ADP	O
minoxidil	B-Chemical	NOUN	B


Combined	O	ADJ	B
androgen	O	NOUN	B
blockade	O	NOUN	I
-	O	PUNCT	O
induced	O	VERB	B
anemia	B-Disease	NOUN	B
in	O	ADP	O
prostate	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
patients	O	NOUN	B
without	O	ADP	O
bone	O	NOUN	B
involvement	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
To	O	PART	O
determine	O	VERB	O
the	O	DET	O
onset	O	NOUN	B
and	O	CCONJ	O
extent	O	NOUN	B
of	O	ADP	O
combined	O	ADJ	O
androgen	O	NOUN	O
blockade	O	NOUN	O
(	O	PUNCT	O
CAB	O	NOUN	B
)-	O	ADJ	O
induced	O	VERB	B
anemia	B-Disease	NOUN	B
in	O	ADP	O
prostate	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
patients	O	NOUN	B
without	O	ADP	O
bone	O	NOUN	B
involvement	O	NOUN	B
.	O	PUNCT	O


PATIENTS	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
:	O	PUNCT	O
Forty	O	NUM	B
-	O	PUNCT	O
two	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
biopsy	O	NOUN	B
-	O	PUNCT	O
proven	O	VERB	B
prostatic	B-Disease	ADJ	B
adenocarcinoma	I-Disease	NOUN	I
[	O	PUNCT	O
26	O	NUM	O
with	O	ADP	O
stage	O	NOUN	B
C	O	NOUN	I
(	O	PUNCT	O
T3N0M0	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
16	O	NUM	O
with	O	ADP	O
stage	O	NOUN	B
D1	O	NOUN	I
(	O	PUNCT	O
T3N1M0	O	NOUN	B
)]	O	PUNCT	O
were	O	AUX	O
included	O	VERB	O
in	O	ADP	O
this	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
patients	O	NOUN	B
received	O	VERB	O
CAB	O	PROPN	B
[	O	PUNCT	O
leuprolide	B-Chemical	NOUN	B
acetate	I-Chemical	NOUN	O
(	O	PUNCT	O
LHRH-A	B-Chemical	NOUN	B
)	O	PUNCT	O
3	O	NUM	O
.	O	PUNCT	O


75	O	NUM	O
mg	O	NOUN	O
,	O	PUNCT	O
intramuscularly	O	ADV	B
,	O	PUNCT	O
every	O	DET	O
28	O	NUM	O
days	O	NOUN	B
plus	O	CCONJ	O
250	O	NUM	O
mg	O	NOUN	O
flutamide	B-Chemical	NOUN	B
,	O	PUNCT	O
tid	O	NOUN	B
,	O	PUNCT	O
per	O	ADP	O
Os	O	NOUN	O
]	O	PUNCT	O
and	O	CCONJ	O
were	O	AUX	O
evaluated	O	VERB	B
for	O	ADP	O
anemia	B-Disease	NOUN	B
by	O	ADP	O
physical	O	ADJ	B
examination	O	NOUN	I
and	O	CCONJ	O
laboratory	O	NOUN	B
tests	O	NOUN	I
at	O	ADP	O
baseline	O	NOUN	B
and	O	CCONJ	O
4	O	NUM	O
subsequent	O	ADJ	O
intervals	O	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
,	O	PUNCT	O
2	O	NUM	O
,	O	PUNCT	O
3	O	NUM	O
and	O	CCONJ	O
6	O	NUM	O
months	O	NOUN	B
post	O	NOUN	B
-	O	PUNCT	O
CAB	O	PROPN	B
).	O	PUNCT	B
Hb	O	NOUN	B
,	O	PUNCT	O
PSA	O	NOUN	B
and	O	CCONJ	O
Testosterone	B-Chemical	NOUN	B
measurements	O	NOUN	B
were	O	AUX	O
recorded	O	VERB	O
.	O	PUNCT	O


Patients	O	NOUN	B
with	O	ADP	O
stage	O	NOUN	B
D2	O	NOUN	I
-	O	PUNCT	O
3	O	NUM	O
disease	O	NOUN	B
,	O	PUNCT	O
abnormal	O	ADJ	B
hemoglobin	O	NOUN	O
level	O	NOUN	O
or	O	CCONJ	O
renal	O	ADJ	B
and	O	CCONJ	O
liver	O	NOUN	B
function	O	NOUN	I
tests	O	NOUN	I
that	O	PRON	O
were	O	AUX	O
higher	O	ADJ	O
than	O	ADP	O
the	O	DET	O
upper	O	ADJ	B
limits	O	NOUN	I
were	O	AUX	O
excluded	O	VERB	O
from	O	ADP	O
the	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
duration	O	NOUN	B
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
was	O	AUX	O
six	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
mean	O	ADJ	B
hemoglobin	O	NOUN	I
(	O	PUNCT	O
Hb	O	NOUN	B
)	O	PUNCT	O
levels	O	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
declined	O	VERB	B
in	O	ADP	O
all	O	DET	O
patients	O	NOUN	B
from	O	ADP	O
baseline	O	NOUN	B
of	O	ADP	O
14	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
g	O	NOUN	O
/	O	PUNCT	O
dl	O	NOUN	B
to	O	PART	O
14	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
g	O	NOUN	B
/	O	SYM	O
dl	O	PROPN	B
,	O	PUNCT	O
13	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
g	O	NOUN	B
/	O	SYM	O
dl	O	PROPN	B
,	O	PUNCT	O
13	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
g	O	NOUN	O
/	O	SYM	O
dl	O	PROPN	B
and	O	CCONJ	O
12	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
g	O	NOUN	B
/	O	PUNCT	O
dl	O	NOUN	B
at	O	ADP	O
1	O	NUM	O
,	O	PUNCT	O
2	O	NUM	O
,	O	PUNCT	O
3	O	NUM	O
and	O	CCONJ	O
6	O	NUM	O
months	O	NOUN	B
post	O	NOUN	B
-	O	PUNCT	O
CAB	O	PROPN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Severe	O	ADJ	B
and	O	CCONJ	O
clinically	O	ADV	B
evident	O	ADJ	O
anemia	B-Disease	NOUN	B
of	O	ADP	O
Hb	O	NOUN	B
<	O	NOUN	O
11	O	NUM	O
g	O	NOUN	B
/	O	PUNCT	O
dl	O	NOUN	B
with	O	ADP	O
clinical	O	ADJ	B
symptoms	O	NOUN	I
was	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
6	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
14	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
%).	O	X	O
This	O	DET	O
CAB	O	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
anemia	B-Disease	NOUN	B
was	O	AUX	O
normochromic	O	ADJ	B
and	O	CCONJ	O
normocytic	O	ADJ	B
.	O	PUNCT	O


At	O	ADP	O
six	O	NUM	O
months	O	NOUN	B
post	O	NOUN	B
-	O	PUNCT	O
CAB	O	PROPN	B
,	O	PUNCT	O
patients	O	NOUN	B
with	O	ADP	O
severe	O	ADJ	B
anemia	B-Disease	NOUN	B
had	O	AUX	O
a	O	DET	O
Hb	O	NOUN	B
mean	O	NOUN	B
value	O	NOUN	I
of	O	ADP	O
10	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
g	O	NOUN	B
/	O	SYM	O
dl	O	NOUN	B
(	O	PUNCT	O
X	O	NOUN	O
+/-	O	CCONJ	O
SE	O	NOUN	B
),	O	PUNCT	O
whereas	O	SCONJ	O
the	O	DET	O
other	O	ADJ	O
patients	O	NOUN	B
had	O	AUX	O
mild	O	ADJ	B
anemia	B-Disease	NOUN	B
with	O	ADP	O
Hb	O	NOUN	B
mean	O	NOUN	B
value	O	NOUN	I
of	O	ADP	O
13	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


17	O	NUM	O
(	O	PUNCT	O
X	O	NOUN	O
+/-	O	CCONJ	O
SE	O	NOUN	B
).	O	PUNCT	O
The	O	DET	O
development	O	NOUN	B
of	O	ADP	O
severe	O	ADJ	B
anemia	B-Disease	NOUN	B
at	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
post	O	NOUN	B
-	O	PUNCT	O
CAB	O	PROPN	B
was	O	AUX	O
predictable	O	ADJ	B
by	O	ADP	O
the	O	DET	O
reduction	O	NOUN	B
of	O	ADP	O
Hb	O	NOUN	B
baseline	O	NOUN	B
value	O	NOUN	O
of	O	ADP	O
more	O	ADJ	O
than	O	ADP	O
2	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
g	O	NOUN	B
/	O	PUNCT	O
dl	O	NOUN	B
after	O	ADP	O
3	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
CAB	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
).	O	PUNCT	O
The	O	DET	O
development	O	NOUN	B
of	O	ADP	O
severe	O	ADJ	B
CAB	O	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
anemia	B-Disease	NOUN	B
in	O	ADP	O
prostate	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
patients	O	NOUN	B
did	O	AUX	O
not	O	PART	O
correlate	O	VERB	O
with	O	ADP	O
T	O	NOUN	B
baseline	O	NOUN	I
values	O	NOUN	I
(	O	PUNCT	O
T	O	NOUN	O
<	O	X	O
3	O	NUM	O
ng	O	NOUN	O
/	O	PUNCT	O
ml	O	NOUN	B
versus	O	CCONJ	O
T	O	NOUN	B
>	O	NOUN	O
or	O	CCONJ	O
=	O	ADJ	O
3	O	NUM	O
ng	O	NOUN	O
/	O	PUNCT	O
ml	O	NOUN	O
),	O	PUNCT	O
with	O	ADP	O
age	O	NOUN	B
(<	O	NOUN	O
76	O	NUM	O
yrs	O	NOUN	B
versus	O	CCONJ	O
>	O	X	O
or	O	CCONJ	O
=	O	ADJ	O
76	O	NUM	O
yrs	O	NOUN	B
),	O	PUNCT	O
and	O	CCONJ	O
clinical	O	ADJ	B
stage	O	NOUN	I
(	O	PUNCT	O
stage	O	NOUN	B
C	O	NOUN	I
versus	O	CCONJ	I
stage	O	NOUN	I
D1	O	NOUN	I
).	O	PUNCT	O
Severe	O	ADJ	B
and	O	CCONJ	O
clinically	O	ADV	B
evident	O	ADJ	O
anemia	B-Disease	NOUN	B
was	O	AUX	O
easily	O	ADV	O
corrected	O	VERB	O
by	O	ADP	O
subcutaneous	O	ADJ	B
injections	O	NOUN	I
(	O	PUNCT	O
3	O	NUM	O
times	O	NOUN	B
/	O	PUNCT	O
week	O	NOUN	B
for	O	ADP	O
1	O	NUM	O
month	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
recombinant	O	ADJ	B
erythropoietin	O	NOUN	I
(	O	PUNCT	O
rHuEPO	O	PROPN	B
-	O	PUNCT	O
beta	O	NOUN	B
).	O	PUNCT	O
CONCLUSION	O	NOUN	O
:	O	PUNCT	O
Our	O	PRON	O
data	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
rHuEPO	O	PROPN	B
-	O	PUNCT	O
beta	O	NOUN	B
correctable	O	ADJ	O
CAB	O	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
anemia	B-Disease	NOUN	B
occurs	O	VERB	O
in	O	ADP	O
14	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
prostate	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I


Reversible	O	ADJ	B
dilated	B-Disease	ADJ	I
cardiomyopathy	I-Disease	NOUN	I
related	O	ADJ	O
to	O	PART	O
amphotericin	B-Chemical	NOUN	B
B	I-Chemical	NOUN	I
therapy	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
describe	O	VERB	O
a	O	DET	O
patient	O	NOUN	B
who	O	PRON	O
developed	O	VERB	O
dilated	B-Disease	ADJ	B
cardiomyopathy	I-Disease	NOUN	I
and	O	CCONJ	O
clinical	O	ADJ	B
congestive	O	ADJ	I
heart	B-Disease	NOUN	I
failure	I-Disease	NOUN	I
after	O	ADP	O
2	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
therapy	O	NOUN	B
with	O	ADP	O
amphotericin	B-Chemical	NOUN	B
B	I-Chemical	NOUN	I
(	O	PUNCT	O
AmB	B-Chemical	NOUN	B
)	O	PUNCT	O
for	O	ADP	O
disseminated	O	ADJ	B
coccidioidomycosis	B-Disease	NOUN	I
.	O	PUNCT	O


His	O	PRON	O
echocardiographic	O	ADJ	B
abnormalities	O	NOUN	I
and	O	CCONJ	O
heart	B-Disease	NOUN	B
failure	I-Disease	NOUN	I
resolved	O	VERB	B
after	O	ADP	O
posaconazole	B-Chemical	NOUN	B
was	O	AUX	O
substituted	O	VERB	B
for	O	ADP	O
AmB	B-Chemical	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
important	O	ADJ	O
to	O	PART	O
recognize	O	VERB	O
the	O	DET	O
rare	O	ADJ	B
and	O	CCONJ	O
potentially	O	ADV	O
reversible	O	ADJ	B
toxicity	B-Disease	NOUN	B
of	O	ADP	O
AmB	B-Chemical	NOUN	B


Risks	O	NOUN	B
of	O	ADP	O
the	O	DET	O
consumption	O	NOUN	B
of	O	ADP	O
beverages	O	NOUN	B
containing	O	VERB	O
quinine	B-Chemical	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
the	O	DET	O
United	O	PROPN	B
States	O	PROPN	I
Food	O	PROPN	I
and	O	CCONJ	I
Drug	O	PROPN	I
Administration	O	PROPN	I
banned	O	VERB	O
its	O	PRON	O
use	O	NOUN	O
for	O	ADP	O
nocturnal	B-Disease	ADJ	B
leg	I-Disease	NOUN	I
cramps	I-Disease	NOUN	I
due	O	ADJ	O
to	O	PART	O
lack	O	NOUN	O
of	O	ADP	O
safety	O	NOUN	B
and	O	CCONJ	O
efficacy	O	NOUN	B
,	O	PUNCT	O
quinine	B-Chemical	NOUN	B
is	O	AUX	O
widely	O	ADV	O
available	O	ADJ	O
in	O	ADP	O
beverages	O	NOUN	B
including	O	VERB	O
tonic	O	ADJ	B
water	O	NOUN	I
and	O	CCONJ	O
bitter	O	ADJ	B
lemon	O	NOUN	I
.	O	PUNCT	O


Numerous	O	ADJ	O
anecdotal	O	ADJ	B
reports	O	NOUN	I
suggest	O	VERB	O
that	O	SCONJ	O
products	O	NOUN	B
containing	O	VERB	O
quinine	B-Chemical	NOUN	B
may	O	AUX	O
produce	O	VERB	O
neurological	B-Disease	ADJ	B
complications	I-Disease	NOUN	O
,	O	PUNCT	O
including	O	VERB	O
confusion	B-Disease	NOUN	B
,	O	PUNCT	O
altered	O	ADJ	O
mental	O	ADJ	B
status	O	NOUN	I
,	O	PUNCT	O
seizures	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
coma	B-Disease	NOUN	B
,	O	PUNCT	O
particularly	O	ADV	O
in	O	ADP	O
older	O	ADJ	B
women	O	NOUN	I
.	O	PUNCT	O


Psychologists	O	NOUN	B
need	O	VERB	O
to	O	PART	O
inquire	O	VERB	B
about	O	ADP	O
consumption	O	NOUN	B
of	O	ADP	O
quinine	B-Chemical	NOUN	B


Organophosphate	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
convulsions	B-Disease	NOUN	B
and	O	CCONJ	O
prevention	O	NOUN	B
of	O	ADP	O
neuropathological	B-Disease	ADJ	B
damages	I-Disease	NOUN	B
.	O	PUNCT	O


Such	O	ADJ	O
organophosphorus	B-Chemical	NOUN	B
(	O	PUNCT	O
OP	B-Chemical	NOUN	B
)	O	PUNCT	O
compounds	O	NOUN	O
as	O	ADP	O
diisopropylfluorophosphate	B-Chemical	NOUN	B
(	O	PUNCT	O
DFP	B-Chemical	NOUN	B
),	O	PUNCT	O
sarin	B-Chemical	NOUN	B
and	O	CCONJ	O
soman	B-Chemical	NOUN	B
are	O	AUX	O
potent	O	ADJ	O
inhibitors	O	NOUN	B
of	O	ADP	O
acetylcholinesterases	O	NOUN	B
(	O	PUNCT	O
AChEs	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
butyrylcholinesterases	O	NOUN	B
(	O	PUNCT	O
BChEs	O	NOUN	B
).	O	PUNCT	O
The	O	DET	O
acute	O	ADJ	B
toxicity	B-Disease	NOUN	B
of	O	ADP	O
OPs	B-Chemical	NOUN	B
is	O	AUX	O
the	O	DET	O
result	O	NOUN	O
of	O	ADP	O
their	O	PRON	O
irreversible	O	ADJ	B
binding	O	NOUN	B
with	O	ADP	O
AChEs	O	NOUN	B
in	O	ADP	O
the	O	DET	O
central	O	ADJ	B
nervous	O	ADJ	I
system	O	NOUN	I
(	O	PUNCT	O
CNS	O	NOUN	B
),	O	PUNCT	O
which	O	DET	O
elevates	O	VERB	B
acetylcholine	B-Chemical	NOUN	B
(	O	PUNCT	O
ACh	B-Chemical	NOUN	B
)	O	PUNCT	O
levels	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
protective	O	ADJ	B
action	O	NOUN	I
of	O	ADP	O
subcutaneously	O	ADV	B
(	O	PUNCT	O
SC	O	NOUN	B
)	O	PUNCT	O
administered	O	VERB	B
antidotes	O	NOUN	B
or	O	CCONJ	O
their	O	PRON	O
combinations	O	NOUN	B
in	O	ADP	O
DFP	B-Chemical	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
BW	O	NOUN	B
)	O	PUNCT	O
intoxication	O	NOUN	B
was	O	AUX	O
studied	O	VERB	O
in	O	ADP	O
9	O	NUM	O
-	O	PUNCT	O
10	O	NUM	O
-	O	PUNCT	O
weeks	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
Han	O	PROPN	B
-	O	PUNCT	O
Wistar	O	PROPN	B
male	O	NOUN	O
rats	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
rats	O	NOUN	B
received	O	VERB	O
AChE	O	NOUN	B
reactivator	O	NOUN	I
pralidoxime-2-chloride	B-Chemical	NOUN	B
(	O	PUNCT	O
2PAM	B-Chemical	NOUN	B
)(	O	NOUN	O
30	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
BW	O	NOUN	B
),	O	PUNCT	O
anticonvulsant	O	ADJ	B
diazepam	B-Chemical	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
BW	O	NOUN	B
),	O	PUNCT	O
A	O	NOUN	O
(	O	PUNCT	O
1	O	NUM	O
)-	O	ADJ	O
adenosine	B-Chemical	NOUN	B
receptor	O	NOUN	I
agonist	O	NOUN	B
N(6)-cyclopentyl	B-Chemical	NOUN	B
adenosine	I-Chemical	NOUN	I
(	O	PUNCT	O
CPA	B-Chemical	NOUN	B
)(	O	NOUN	O
2	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
BW	O	NOUN	B
),	O	PUNCT	O
NMDA	B-Chemical	NOUN	B
-	O	PUNCT	O
receptor	O	NOUN	B
antagonist	O	NOUN	B
dizocilpine	B-Chemical	NOUN	B
maleate	I-Chemical	NOUN	I
(+-	O	PUNCT	O
MK801	O	NOUN	B
hydrogen	O	NOUN	B
maleate	O	NOUN	I
)(	O	NOUN	O
2	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
BW	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
their	O	PRON	O
combinations	O	NOUN	B
with	O	ADP	O
cholinolytic	O	ADJ	B
drug	O	NOUN	I
atropine	B-Chemical	NOUN	O
sulfate	I-Chemical	NOUN	O
(	O	PUNCT	O
50	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
BW	O	NOUN	B
)	O	PUNCT	O
immediately	O	ADV	O
or	O	CCONJ	O
30	O	NUM	O
min	O	NOUN	O
after	O	ADP	O
the	O	DET	O
single	O	ADJ	O
SC	O	NOUN	B
injection	O	NOUN	B
of	O	ADP	O
DFP	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
control	O	NOUN	B
rats	O	NOUN	B
received	O	VERB	O
atropine	B-Chemical	NOUN	B
sulfate	I-Chemical	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
also	O	ADV	O
saline	O	NOUN	B
and	O	CCONJ	O
olive	O	NOUN	B
oil	O	NOUN	I
instead	O	ADV	O
of	O	ADP	O
other	O	ADJ	O
antidotes	O	NOUN	B
and	O	CCONJ	O
DFP	B-Chemical	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


All	O	DET	O
rats	O	NOUN	B
were	O	AUX	O
terminated	O	VERB	O
either	O	CCONJ	O
24	O	NUM	O
h	O	NOUN	O
or	O	CCONJ	O
3	O	NUM	O
weeks	O	NOUN	B
after	O	ADP	O
the	O	DET	O
DFP	B-Chemical	NOUN	B
injection	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
rats	O	NOUN	B
treated	O	VERB	B
with	O	ADP	O
DFP	B-Chemical	NOUN	B
-	O	PUNCT	O
atropine	B-Chemical	NOUN	B
showed	O	VERB	O
severe	O	ADJ	B
typical	O	ADJ	O
OP	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
toxicity	B-Disease	NOUN	B
signs	O	NOUN	B
.	O	PUNCT	O


When	O	SCONJ	O
CPA	B-Chemical	NOUN	B
,	O	PUNCT	O
diazepam	B-Chemical	NOUN	B
or	O	CCONJ	O
2PAM	B-Chemical	NOUN	B
was	O	AUX	O
given	O	VERB	O
immediately	O	ADV	O
after	O	ADP	O
DFP	B-Chemical	NOUN	B
-	O	PUNCT	O
atropine	B-Chemical	NOUN	B
,	O	PUNCT	O
these	O	DET	O
treatments	O	NOUN	B
prevented	O	VERB	B
,	O	PUNCT	O
delayed	O	VERB	B
or	O	CCONJ	O
shortened	O	VERB	B
the	O	DET	O
occurrence	O	NOUN	B
of	O	ADP	O
serious	O	ADJ	O
signs	O	NOUN	B
of	O	ADP	O
poisoning	B-Disease	NOUN	B
.	O	PUNCT	O


Atropine	B-Chemical	NOUN	B
-	O	PUNCT	O
MK801	B-Chemical	NOUN	B
did	O	AUX	O
not	O	PART	O
offer	O	VERB	O
any	O	DET	O
additional	O	ADJ	O
protection	O	NOUN	B
against	O	ADP	O
DFP	B-Chemical	NOUN	B
toxicity	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
CPA	B-Chemical	NOUN	B
,	O	PUNCT	O
diazepam	B-Chemical	NOUN	B
and	O	CCONJ	O
2PAM	B-Chemical	NOUN	B
in	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
atropine	B-Chemical	NOUN	B
prevented	O	VERB	B
the	O	DET	O
occurrence	O	NOUN	B
of	O	ADP	O
serious	O	ADJ	O
signs	O	NOUN	B
of	O	ADP	O
poisoning	B-Disease	NOUN	B
and	O	CCONJ	O
thus	O	ADV	O
reduced	O	VERB	B
the	O	DET	O
toxicity	B-Disease	NOUN	B
of	O	ADP	O
DFP	B-Chemical	NOUN	B


Differential	O	ADJ	B
modulation	O	NOUN	I
by	O	ADP	O
estrogen	B-Chemical	NOUN	B
of	O	ADP	O
alpha2	O	NOUN	B
-	O	PUNCT	O
adrenergic	O	ADJ	B
and	O	CCONJ	O
I1	O	NOUN	B
-	O	PUNCT	O
imidazoline	B-Chemical	NOUN	B
receptor	O	NOUN	I
-	O	PUNCT	O
mediated	O	VERB	B
hypotension	B-Disease	NOUN	B
in	O	ADP	O
female	O	ADJ	B
rats	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
recently	O	ADV	O
shown	O	VERB	O
that	O	SCONJ	O
estrogen	B-Chemical	NOUN	B
negatively	O	ADV	O
modulates	O	VERB	B
the	O	DET	O
hypotensive	B-Disease	ADJ	B
effect	O	NOUN	O
of	O	ADP	O
clonidine	B-Chemical	NOUN	B
(	O	PUNCT	O
mixed	O	ADJ	O
alpha2	O	NOUN	B
-/	O	NOUN	O
I1	O	NOUN	B
-	O	PUNCT	O
receptor	O	NOUN	B
agonist	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
female	O	ADJ	B
rats	O	NOUN	B
and	O	CCONJ	O
implicates	O	VERB	O
the	O	DET	O
cardiovascular	O	ADJ	B
autonomic	O	ADJ	B
control	O	NOUN	I
in	O	ADP	O
this	O	DET	O
interaction	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
investigated	O	VERB	B
whether	O	SCONJ	O
this	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
estrogen	B-Chemical	NOUN	B
involves	O	VERB	O
interaction	O	NOUN	B
with	O	ADP	O
alpha2	O	NOUN	B
-	O	PUNCT	O
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
I1	O	NOUN	B
-	O	PUNCT	O
receptors	O	NOUN	B
.	O	PUNCT	O


Changes	O	NOUN	B
evoked	O	VERB	O
by	O	ADP	O
a	O	DET	O
single	O	ADJ	O
intraperitoneal	O	ADJ	B
injection	O	NOUN	B
of	O	ADP	O
rilmenidine	B-Chemical	NOUN	B
(	O	PUNCT	O
600	O	NUM	O
microg	O	NOUN	B
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
alpha-methyldopa	B-Chemical	ADJ	B
(	O	PUNCT	O
100	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
),	O	PUNCT	O
selective	O	ADJ	O
I1	O	NOUN	B
-	O	PUNCT	O
and	O	CCONJ	O
alpha2	O	NUM	B
-	O	PUNCT	O
receptor	O	NOUN	B
agonists	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
in	O	ADP	O
blood	O	NOUN	B
pressure	O	NOUN	I
,	O	PUNCT	O
hemodynamic	O	ADJ	B
variability	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
locomotor	O	NOUN	B
activity	O	NOUN	I
were	O	AUX	O
assessed	O	VERB	B
in	O	ADP	O
radiotelemetered	O	ADJ	B
sham	O	NOUN	B
-	O	PUNCT	O
operated	O	VERB	B
and	O	CCONJ	O
ovariectomized	O	ADJ	B
(	O	PUNCT	O
Ovx	O	PROPN	B
)	O	PUNCT	O
Sprague	O	PROPN	B
-	O	PUNCT	O
Dawley	O	PROPN	B
female	O	NOUN	O
rats	O	NOUN	B
with	O	ADP	O
or	O	CCONJ	O
without	O	ADP	O
12	O	NUM	O
-	O	PUNCT	O
wk	O	NOUN	O
estrogen	B-Chemical	NOUN	B
replacement	O	NOUN	I
.	O	PUNCT	O


Three	O	NUM	O
time	O	NOUN	B
domain	O	NOUN	I
indexes	O	NOUN	B
of	O	ADP	O
hemodynamic	O	ADJ	B
variability	O	NOUN	B
were	O	AUX	O
employed	O	VERB	O
:	O	PUNCT	O
the	O	DET	O
standard	O	ADJ	B
deviation	O	NOUN	I
of	O	ADP	O
mean	O	ADJ	O
arterial	O	ADJ	B
pressure	O	NOUN	I
as	O	ADP	O
a	O	DET	O
measure	O	NOUN	B
of	O	ADP	O
blood	O	NOUN	B
pressure	O	NOUN	I
variability	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
standard	O	ADJ	B
deviation	O	NOUN	I
of	O	ADP	O
beat	O	VERB	B
-	O	PUNCT	O
to	O	PART	O
-	O	PUNCT	O
beat	O	VERB	B
intervals	O	NOUN	B
(	O	PUNCT	O
SDRR	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
root	O	NOUN	B
mean	O	VERB	I
square	O	NOUN	I
of	O	ADP	O
successive	O	ADJ	O
differences	O	NOUN	B
in	O	ADP	O
R	O	NOUN	B
-	O	PUNCT	O
wave	O	NOUN	B
-	O	PUNCT	O
to	O	ADP	O
-	O	PUNCT	O
R	O	PROPN	B
-	O	PUNCT	O
wave	O	NOUN	B
intervals	O	NOUN	B
as	O	ADP	O
measures	O	NOUN	B
of	O	ADP	O
heart	O	NOUN	B
rate	O	NOUN	I
variability	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
sham	O	NOUN	B
-	O	PUNCT	O
operated	O	VERB	B
rats	O	NOUN	B
,	O	PUNCT	O
rilmenidine	B-Chemical	NOUN	B
or	O	CCONJ	O
alpha-methyldopa	B-Chemical	NOUN	B
elicited	O	VERB	O
similar	O	ADJ	O
hypotension	B-Disease	NOUN	B
that	O	PRON	O
lasted	O	VERB	O
at	O	ADP	O
least	O	ADJ	O
5	O	NUM	O
h	O	NOUN	O
and	O	CCONJ	O
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
reductions	O	NOUN	B
in	O	ADP	O
standard	O	ADJ	B
deviation	O	NOUN	I
of	O	ADP	O
mean	O	ADJ	O
arterial	O	ADJ	B
pressure	O	NOUN	I
.	O	PUNCT	O


SDRR	O	NOUN	B
was	O	AUX	O
reduced	O	VERB	B
only	O	ADV	O
by	O	ADP	O
alpha-methyldopa	B-Chemical	NOUN	B
.	O	PUNCT	O


Ovx	O	PROPN	B
significantly	O	ADV	O
enhanced	O	VERB	B
the	O	DET	O
hypotensive	B-Disease	ADJ	B
response	O	NOUN	I
to	O	PART	O
alpha-methyldopa	B-Chemical	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
contrast	O	NOUN	O
to	O	PART	O
no	O	DET	B
effect	O	NOUN	I
on	O	ADP	O
rilmenidine	B-Chemical	NOUN	B
hypotension	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
enhanced	O	VERB	O
alpha-methyldopa	B-Chemical	ADJ	B
hypotension	B-Disease	NOUN	O
in	O	ADP	O
Ovx	O	NOUN	B
rats	O	NOUN	B
was	O	AUX	O
paralleled	O	VERB	O
with	O	ADP	O
further	O	ADJ	O
reduction	O	NOUN	B
in	O	ADP	O
SDRR	O	NOUN	B
and	O	CCONJ	O
a	B-Disease	DET	O
reduced	I-Disease	VERB	B
locomotor	I-Disease	NOUN	B
activity	I-Disease	NOUN	I
.	O	PUNCT	O


Estrogen	O	NOUN	B
replacement	O	NOUN	I
(	O	PUNCT	O
17beta-estradiol	B-Chemical	NOUN	B
subcutaneous	O	ADJ	I
pellet	O	NOUN	I
,	O	PUNCT	O
14	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
microg	O	NOUN	B
/	O	SYM	O
day	O	NOUN	B
,	O	PUNCT	O
12	O	NUM	O
wk	O	NOUN	O
)	O	PUNCT	O
of	O	ADP	O
Ovx	O	NOUN	B
rats	O	NOUN	B
restored	O	VERB	B
the	O	DET	O
hemodynamic	O	ADJ	B
and	O	CCONJ	O
locomotor	O	NOUN	B
effects	O	NOUN	I
of	O	ADP	O
alpha-methyldopa	B-Chemical	NOUN	B
to	O	PART	O
sham	O	NOUN	B
-	O	PUNCT	O
operated	O	VERB	B
levels	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
estrogen	B-Chemical	NOUN	B
downregulates	O	VERB	B
alpha2	O	NOUN	B
-	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
I1	O	NOUN	B
-	O	PUNCT	O
receptor	O	NOUN	B
-	O	PUNCT	O
mediated	O	VERB	B
hypotension	B-Disease	NOUN	B
and	O	CCONJ	O
highlight	O	VERB	O
a	O	DET	O
role	O	NOUN	O
for	O	ADP	O
the	O	DET	O
cardiac	O	ADJ	B
autonomic	O	ADJ	B
control	O	NOUN	I
in	O	ADP	O
alpha-methyldopa	B-Chemical	ADJ	B
-	O	PUNCT	O
estrogen	B-Chemical	NOUN	B


Cardioprotective	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
tincture	B-Chemical	NOUN	B
of	I-Chemical	ADP	O
Crataegus	I-Chemical	NOUN	B
on	O	ADP	O
isoproterenol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
myocardial	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


Tincture	B-Chemical	NOUN	B
of	I-Chemical	ADP	O
Crataegus	I-Chemical	NOUN	B
(	O	PUNCT	O
TCR	B-Chemical	NOUN	B
),	O	PUNCT	O
an	O	DET	O
alcoholic	B-Chemical	ADJ	B
extract	I-Chemical	NOUN	I
of	I-Chemical	ADP	O
the	I-Chemical	DET	O
berries	I-Chemical	NOUN	B
of	I-Chemical	ADP	O
hawthorn	I-Chemical	NOUN	B
(	O	PUNCT	O
Crataegus	B-Chemical	ADJ	B
oxycantha	I-Chemical	NOUN	I
),	O	PUNCT	O
is	O	AUX	O
used	O	VERB	O
in	O	ADP	O
herbal	O	ADJ	B
and	O	CCONJ	O
homeopathic	O	ADJ	B
medicine	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
was	O	AUX	O
done	O	VERB	O
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
protective	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
TCR	B-Chemical	NOUN	B
on	O	ADP	O
experimentally	O	ADV	B
induced	O	VERB	B
myocardial	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


Pretreatment	O	NOUN	B
of	O	ADP	O
TCR	B-Chemical	NOUN	B
,	O	PUNCT	O
at	O	ADP	O
a	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mL	O	NOUN	O
/	O	SYM	O
100	O	NUM	O
g	O	NOUN	B
bodyweight	O	NOUN	I
per	O	ADP	O
day	O	NOUN	B
,	O	PUNCT	O
orally	O	ADV	B
for	O	ADP	O
30	O	NUM	O
days	O	NOUN	B
,	O	PUNCT	O
prevented	O	VERB	B
the	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
lipid	O	NOUN	B
peroxidation	O	NOUN	I
and	O	CCONJ	O
activity	O	NOUN	B
of	O	ADP	O
marker	O	NOUN	B
enzymes	O	NOUN	B
observed	O	VERB	O
in	O	ADP	O
isoproterenol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
rats	O	NOUN	B
(	O	PUNCT	O
85	O	NUM	O
mg	O	NOUN	O
kg	O	NOUN	O
(-	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
s	O	NOUN	O
.	O	PUNCT	O


c	O	X	O
.	O	PUNCT	O


for	O	ADP	O
2	O	NUM	O
days	O	NOUN	B
at	O	ADP	O
an	O	DET	O
interval	O	NOUN	B
of	O	ADP	O
24	O	NUM	O
h	O	NOUN	O
).	O	PUNCT	B
TCR	B-Chemical	NOUN	B
prevented	O	VERB	B
the	O	DET	O
isoproterenol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
decrease	O	NOUN	B
in	O	ADP	O
antioxidant	O	ADJ	B
enzymes	O	NOUN	I
in	O	ADP	O
the	O	DET	O
heart	O	NOUN	B
and	O	CCONJ	O
increased	O	VERB	B
the	O	DET	O
rate	O	NOUN	B
of	O	ADP	O
ADP	B-Chemical	NOUN	B
-	O	PUNCT	O
stimulated	O	VERB	B
oxygen	B-Chemical	NOUN	B
uptake	O	NOUN	I
and	O	CCONJ	O
respiratory	O	ADJ	B
coupling	O	NOUN	I
ratio	O	NOUN	I
.	O	PUNCT	O


TCR	B-Chemical	NOUN	B
protected	O	VERB	O
against	O	ADP	O
pathological	O	ADJ	B
changes	O	NOUN	B
induced	O	VERB	B
by	O	ADP	O
isoproterenol	B-Chemical	NOUN	B
in	O	ADP	O
rat	O	NOUN	B
heart	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
show	O	VERB	O
that	O	SCONJ	O
pretreatment	O	NOUN	B
with	O	ADP	O
TCR	B-Chemical	NOUN	B
may	O	AUX	O
be	O	AUX	O
useful	O	ADJ	O
in	O	ADP	O
preventing	O	VERB	B
the	O	DET	O
damage	O	NOUN	B
induced	O	VERB	B
by	O	ADP	O
isoproterenol	B-Chemical	NOUN	B


Safety	O	NOUN	B
and	O	CCONJ	O
adverse	O	ADJ	B
effects	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
raloxifene	B-Chemical	NOUN	B
:	O	PUNCT	O
multiple	O	ADJ	B
outcomes	O	NOUN	B
of	O	ADP	O
raloxifene	B-Chemical	NOUN	B
evaluation	O	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	B
:	O	PUNCT	O
To	O	PART	O
examine	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
raloxifene	B-Chemical	NOUN	B
on	O	ADP	O
major	O	ADJ	O
adverse	O	ADJ	B
events	O	NOUN	I
that	O	PRON	O
occur	O	VERB	O
with	O	ADP	O
postmenopausal	O	ADJ	B
estrogen	B-Chemical	NOUN	I
therapy	O	NOUN	I
or	O	CCONJ	O
tamoxifen	B-Chemical	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
Multiple	O	ADJ	B
Outcomes	O	NOUN	I
of	O	ADP	O
Raloxifene	B-Chemical	PROPN	B
Evaluation	O	PROPN	B
,	O	PUNCT	O
a	O	DET	O
multicenter	O	NOUN	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	NOUN	B
trial	O	NOUN	B
,	O	PUNCT	O
enrolled	O	VERB	O
7	O	NUM	O
,	O	PUNCT	O
705	O	NUM	O
postmenopausal	O	ADJ	B
women	O	NOUN	B
with	O	ADP	O
osteoporosis	B-Disease	NOUN	B
.	O	PUNCT	O


Women	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
raloxifene	B-Chemical	NOUN	B
60	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
d	O	NOUN	O
or	O	CCONJ	O
120	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
d	O	NOUN	B
or	O	CCONJ	O
placebo	O	NOUN	B
.	O	PUNCT	O


Outcomes	O	NOUN	B
included	O	VERB	O
venous	B-Disease	ADJ	B
thromboembolism	I-Disease	NOUN	I
,	O	PUNCT	O
cataracts	B-Disease	NOUN	B
,	O	PUNCT	O
gallbladder	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
endometrial	B-Disease	ADJ	B
hyperplasia	I-Disease	NOUN	I
or	I-Disease	CCONJ	O
cancer	I-Disease	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
During	O	ADP	O
a	O	DET	O
mean	O	ADJ	O
follow	O	NOUN	B
-	O	PUNCT	O
up	O	NOUN	O
of	O	ADP	O
3	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
years	O	NOUN	B
,	O	PUNCT	O
raloxifene	B-Chemical	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
an	O	DET	O
increased	O	VERB	B
risk	O	NOUN	B
for	O	ADP	O
venous	B-Disease	ADJ	B
thromboembolism	I-Disease	NOUN	I
(	O	PUNCT	O
relative	O	ADJ	B
risk	O	NOUN	I
[	O	PUNCT	O
RR	O	NOUN	B
]	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
[	O	PUNCT	O
CI	O	NOUN	B
]	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
-	O	SYM	O
3	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
).	O	PUNCT	O
The	O	DET	O
excess	O	ADJ	B
event	O	NOUN	B
rate	O	NOUN	B
was	O	AUX	O
1	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
per	O	ADP	O
1	O	NUM	O
,	O	PUNCT	O
000	O	NUM	O
woman	O	NOUN	B
-	O	PUNCT	O
years	O	NOUN	B
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	PROPN	B
-	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
-	O	SYM	O
4	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
),	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
number	O	NOUN	O
needed	O	VERB	O
to	O	PART	O
treat	O	VERB	B
to	O	PART	O
cause	O	VERB	O
1	O	NUM	O
event	O	NOUN	B
was	O	AUX	O
170	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
100	O	NUM	O
-	O	SYM	O
582	O	NUM	O
)	O	PUNCT	O
over	O	ADP	O
3	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
years	O	NOUN	B
.	O	PUNCT	O


Risk	O	NOUN	B
in	O	ADP	O
the	O	DET	O
raloxifene	B-Chemical	NOUN	B
group	O	NOUN	I
was	O	AUX	O
higher	O	ADJ	O
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	B
for	O	ADP	O
the	O	DET	O
first	O	ADJ	O
2	O	NUM	O
years	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
decreased	O	VERB	B
to	O	PART	O
about	O	ADP	O
the	O	DET	O
same	O	ADJ	O
rate	O	NOUN	B
as	O	ADP	O
in	O	ADP	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	B
thereafter	O	ADV	O
.	O	PUNCT	O


Raloxifene	B-Chemical	NOUN	B
did	O	AUX	O
not	O	PART	O
increase	O	VERB	B
risk	O	NOUN	B
for	O	ADP	O
cataracts	B-Disease	NOUN	B
(	O	PUNCT	O
RR	O	NOUN	B
0	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
0	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
-	O	SYM	O
1	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
),	O	PUNCT	O
gallbladder	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
RR	O	NOUN	B
1	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
0	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
-	O	SYM	O
1	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
),	O	PUNCT	O
endometrial	B-Disease	ADJ	B
hyperplasia	I-Disease	NOUN	I
(	O	PUNCT	O
RR	O	NOUN	B
1	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
0	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
-	O	SYM	O
5	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
),	O	PUNCT	O
or	O	CCONJ	O
endometrial	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
(	O	PUNCT	O
RR	O	NOUN	B
0	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
0	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
-	O	SYM	O
2	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
).	O	PUNCT	O
CONCLUSION	O	NOUN	O
:	O	PUNCT	O
Raloxifene	B-Chemical	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
an	O	DET	O
increased	O	VERB	B
risk	O	NOUN	B
for	O	ADP	O
venous	B-Disease	ADJ	B
thromboembolism	I-Disease	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	O
increased	O	VERB	B
risk	O	NOUN	B
for	O	ADP	O
cataracts	B-Disease	NOUN	B
,	O	PUNCT	O
gallbladder	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
,	O	PUNCT	O
endometrial	B-Disease	ADJ	B
hyperplasia	I-Disease	NOUN	I
,	O	PUNCT	O
or	O	CCONJ	O
endometrial	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I


Ceftriaxone	B-Chemical	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
biliary	B-Disease	ADJ	B
pseudolithiasis	I-Disease	NOUN	I
in	O	ADP	O
paediatric	O	ADJ	B
surgical	O	ADJ	I
patients	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
well	O	ADV	O
known	O	VERB	O
that	O	SCONJ	O
ceftriaxone	B-Chemical	NOUN	B
leads	O	VERB	O
to	O	PART	O
pseudolithiasis	B-Disease	NOUN	B
in	O	ADP	O
some	O	DET	O
patients	O	NOUN	B
.	O	PUNCT	O


Clinical	O	ADJ	B
and	O	CCONJ	O
experimental	O	ADJ	B
studies	O	NOUN	I
also	O	ADV	O
suggest	O	VERB	O
that	O	SCONJ	O
situations	O	NOUN	B
causing	O	VERB	O
gallbladder	B-Disease	NOUN	B
dysfunction	I-Disease	NOUN	I
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
fasting	O	NOUN	B
,	O	PUNCT	O
may	O	AUX	O
have	O	AUX	O
a	O	DET	O
role	O	NOUN	O
for	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
pseudolithiasis	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
prospectively	O	ADV	O
evaluated	O	VERB	B
the	O	DET	O
incidence	O	NOUN	B
and	O	CCONJ	O
clinical	O	ADJ	B
importance	O	NOUN	O
of	O	ADP	O
pseudolithiasis	B-Disease	NOUN	B
in	O	ADP	O
paediatric	O	ADJ	B
surgical	O	ADJ	I
patients	O	NOUN	B
receiving	O	VERB	O
ceftriaxone	B-Chemical	NOUN	B
treatment	O	NOUN	B
,	O	PUNCT	O
who	O	PRON	O
often	O	ADV	O
had	O	AUX	O
to	O	PART	O
fast	O	VERB	O
in	O	ADP	O
the	O	DET	O
post	O	NOUN	B
-	O	PUNCT	O
operative	O	ADJ	B
period	O	NOUN	B
.	O	PUNCT	O


Fifty	O	NUM	O
children	O	NOUN	B
who	O	PRON	O
were	O	AUX	O
given	O	VERB	O
ceftriaxone	B-Chemical	NOUN	B
were	O	AUX	O
evaluated	O	VERB	B
by	O	ADP	O
serial	O	ADJ	O
abdominal	O	ADJ	B
sonograms	O	NOUN	I
.	O	PUNCT	O


Of	O	ADP	O
those	O	DET	O
,	O	PUNCT	O
13	O	NUM	O
(	O	PUNCT	O
26	O	NUM	O
%)	O	NOUN	O
developed	O	VERB	O
biliary	O	ADJ	B
pathology	O	NOUN	B
.	O	PUNCT	O


Comparison	O	NOUN	B
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
with	O	ADP	O
or	O	CCONJ	O
without	O	ADP	O
pseudolithiasis	B-Disease	NOUN	B
revealed	O	VERB	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
with	O	ADP	O
respect	O	NOUN	O
to	O	PART	O
age	O	NOUN	B
,	O	PUNCT	O
sex	O	NOUN	B
,	O	PUNCT	O
duration	O	NOUN	B
of	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
and	O	CCONJ	O
starvation	O	NOUN	B
variables	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
cessation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
,	O	PUNCT	O
pseudolithiasis	B-Disease	NOUN	B
resolved	O	VERB	B
spontaneously	O	ADV	B
within	O	ADP	O
a	O	DET	O
short	O	ADJ	O
period	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
pseudolithiasis	B-Disease	NOUN	B


Evaluation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
anticocaine	O	ADJ	B
monoclonal	O	ADJ	I
antibody	O	NOUN	I
GNC92H2	B-Chemical	NOUN	B
as	O	ADP	O
an	O	DET	O
immunotherapy	O	NOUN	B
for	O	ADP	O
cocaine	B-Disease	NOUN	B
overdose	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
illicit	O	NOUN	B
use	O	NOUN	I
of	O	ADP	O
cocaine	B-Chemical	NOUN	B
continues	O	VERB	O
in	O	ADP	O
epidemic	O	ADJ	B
proportions	O	NOUN	B
and	O	CCONJ	O
treatment	O	NOUN	B
for	O	ADP	O
cocaine	B-Disease	NOUN	B
overdose	I-Disease	NOUN	I
remains	O	VERB	O
elusive	O	ADJ	O
.	O	PUNCT	O


Current	O	ADJ	B
protein	O	NOUN	B
-	O	PUNCT	O
based	O	VERB	B
technology	O	NOUN	B
offers	O	VERB	O
a	O	DET	O
new	O	ADJ	O
therapeutic	O	ADJ	B
venue	O	NOUN	O
by	O	ADP	O
which	O	DET	O
antibodies	O	NOUN	B
bind	O	VERB	B
the	O	DET	O
drug	O	NOUN	B
in	O	ADP	O
the	O	DET	O
blood	O	NOUN	B
stream	O	NOUN	I
,	O	PUNCT	O
inactivating	O	VERB	B
its	O	PRON	O
toxic	O	ADJ	B
effects	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
therapeutic	O	ADJ	B
potential	O	NOUN	B
of	O	ADP	O
the	O	DET	O
anticocaine	O	ADJ	B
antibody	O	NOUN	I
GNC92H2	B-Chemical	NOUN	B
was	O	AUX	O
examined	O	VERB	O
using	O	VERB	O
a	O	DET	O
model	O	NOUN	B
of	O	ADP	O
cocaine	B-Disease	NOUN	B
overdose	I-Disease	NOUN	I
.	O	PUNCT	O


Swiss	O	ADJ	B
albino	O	ADJ	B
mice	O	NOUN	I
prepared	O	VERB	O
with	O	ADP	O
intrajugular	O	ADJ	B
catheters	O	NOUN	I
were	O	AUX	O
tested	O	VERB	B
in	O	ADP	O
photocell	O	NOUN	B
cages	O	NOUN	I
after	O	ADP	O
administration	O	NOUN	B
of	O	ADP	O
93	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
kg	O	NOUN	B
(	O	PUNCT	O
LD50	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
cocaine	B-Chemical	NOUN	B
and	O	CCONJ	O
GNC92H2	B-Chemical	NOUN	B
infusions	O	NOUN	B
ranging	O	VERB	O
from	O	ADP	O
30	O	NUM	O
to	O	PART	O
190	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
.	O	PUNCT	O


GNC92H2	B-Chemical	NOUN	B
was	O	AUX	O
delivered	O	VERB	O
30	O	NUM	O
min	O	NOUN	O
before	O	ADV	O
,	O	PUNCT	O
concomitantly	O	ADV	O
or	O	CCONJ	O
3	O	NUM	O
min	O	NOUN	O
after	O	ADP	O
cocaine	B-Chemical	NOUN	B
treatment	O	NOUN	I
.	O	PUNCT	O


Significant	O	ADJ	O
blockade	O	NOUN	B
of	O	ADP	O
cocaine	B-Chemical	NOUN	B
toxicity	B-Disease	NOUN	B
was	O	AUX	O
observed	O	VERB	O
with	O	ADP	O
the	O	DET	O
higher	O	ADJ	B
dose	O	NOUN	B
of	O	ADP	O
GNC92H2	B-Chemical	NOUN	B
(	O	PUNCT	O
190	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
),	O	PUNCT	O
where	O	SCONJ	O
premorbid	O	ADJ	B
behaviors	O	NOUN	I
were	O	AUX	O
reduced	O	VERB	B
up	O	ADP	O
to	O	PART	O
40	O	NUM	O
%,	O	NOUN	B
seizures	B-Disease	NOUN	B
up	O	ADV	O
to	O	PART	O
77	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
death	B-Disease	NOUN	B
by	O	ADP	O
72	O	NUM	O
%.	O	NOUN	B
Importantly	O	ADV	O
,	O	PUNCT	O
GNC92H2	B-Chemical	NOUN	B
prevented	O	VERB	O
death	B-Disease	NOUN	B
even	O	ADV	O
post	O	NOUN	B
-	O	PUNCT	O
cocaine	B-Chemical	NOUN	B
injection	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
support	O	VERB	O
the	O	DET	O
important	O	ADJ	O
potential	O	NOUN	B
of	O	ADP	O
GNC92H2	B-Chemical	NOUN	B
as	O	ADP	O
a	O	DET	O
therapeutic	O	ADJ	B
tool	O	NOUN	I
against	O	ADP	O
cocaine	B-Disease	NOUN	B
overdose	I-Disease	NOUN	B


The	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
short	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
raloxifene	B-Chemical	NOUN	B
therapy	O	NOUN	I
on	O	ADP	O
fibrinolysis	O	NOUN	B
markers	O	NOUN	B
:	O	PUNCT	O
TAFI	O	NOUN	B
,	O	PUNCT	O
tPA	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
PAI	O	PROPN	B
-	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Markers	O	NOUN	B
of	O	ADP	O
fibrinolysis	O	NOUN	B
,	O	PUNCT	O
thrombin	O	NOUN	B
-	O	PUNCT	O
activatable	O	ADJ	B
fibrinolysis	O	NOUN	O
inhibitor	O	NOUN	O
(	O	PUNCT	O
TAFI	O	NOUN	B
),	O	PUNCT	O
tissue	O	NOUN	B
-	O	PUNCT	O
type	O	NOUN	B
plasminogen	O	NOUN	I
activator	O	NOUN	I
(	O	PUNCT	O
tPA	O	NOUN	B
),	O	PUNCT	O
and	O	CCONJ	O
plasminogen	O	NOUN	B
activator	O	NOUN	I
inhibitor	O	NOUN	I
-	O	PUNCT	O
1	O	NUM	B
(	O	PUNCT	O
PAI	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
levels	O	NOUN	B
were	O	AUX	O
studied	O	VERB	O
for	O	ADP	O
the	O	DET	O
evaluation	O	NOUN	B
of	O	ADP	O
short	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
effects	O	NOUN	B
of	O	ADP	O
raloxifene	B-Chemical	NOUN	B
administration	O	NOUN	B
in	O	ADP	O
postmenopausal	O	ADJ	B
women	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
Thirty	O	NUM	B
-	O	PUNCT	O
nine	O	NUM	B
postmenopausal	O	ADJ	B
women	O	NOUN	B
with	O	ADP	O
osteopenia	B-Disease	NOUN	B
or	O	CCONJ	O
osteoporosis	B-Disease	NOUN	B
were	O	AUX	O
included	O	VERB	O
in	O	ADP	O
this	O	DET	O
prospective	O	ADJ	B
,	O	PUNCT	O
controlled	O	VERB	B
clinical	O	ADJ	I
study	O	NOUN	I
.	O	PUNCT	O


Twenty	O	NUM	B
-	O	PUNCT	O
five	O	NUM	B
women	O	NOUN	B
were	O	AUX	O
given	O	VERB	O
raloxifene	B-Chemical	NOUN	B
hydrochloride	I-Chemical	NOUN	I
(	O	PUNCT	O
60	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
day	O	NOUN	B
)	O	PUNCT	O
plus	O	CCONJ	O
calcium	B-Chemical	NOUN	B
(	O	PUNCT	O
500	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
day	O	NOUN	B
).	O	PUNCT	O
Age	O	PROPN	B
-	O	PUNCT	O
matched	O	VERB	B
controls	O	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
14	O	NUM	O
)	O	PUNCT	O
were	O	AUX	O
given	O	VERB	O
only	O	ADV	O
calcium	B-Chemical	NOUN	B
.	O	PUNCT	O


Plasma	O	NOUN	B
TAFI	O	NOUN	B
,	O	PUNCT	O
tPA	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
PAI	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	B
antigen	O	NOUN	I
levels	O	NOUN	B
were	O	AUX	O
measured	O	VERB	B
at	O	ADP	O
baseline	O	NOUN	B
and	O	CCONJ	O
after	O	ADP	O
3	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
by	O	ADP	O
commercially	O	ADV	O
available	O	ADJ	O
ELISA	O	NOUN	B
kits	O	NOUN	I
.	O	PUNCT	O


Variations	O	NOUN	B
of	O	ADP	O
individuals	O	NOUN	B
were	O	AUX	O
assessed	O	VERB	B
by	O	ADP	O
Wilcoxon	O	PROPN	B
'	O	PART	I
s	O	NOUN	I
test	O	NOUN	I
.	O	PUNCT	O


Relationship	O	NOUN	B
between	O	ADP	O
those	O	DET	O
markers	O	NOUN	B
and	O	CCONJ	O
demographic	O	ADJ	B
characteristics	O	NOUN	I
were	O	AUX	O
investigated	O	VERB	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Three	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
raloxifene	B-Chemical	NOUN	B
treatment	O	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
significant	O	ADJ	O
decrease	O	NOUN	B
in	O	ADP	O
the	O	DET	O
plasma	O	NOUN	B
TAFI	O	NOUN	O
antigen	O	NOUN	O
concentrations	O	NOUN	B
(	O	PUNCT	O
16	O	NUM	O
%	O	NOUN	O
change	O	NOUN	B
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
),	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
significant	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
tPA	O	NOUN	B
antigen	O	NOUN	B
concentrations	O	NOUN	B
(	O	PUNCT	O
25	O	NUM	O
%	O	NOUN	O
change	O	NOUN	B
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
).	O	PUNCT	O
A	O	DET	O
significant	O	ADJ	B
correlation	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
between	O	ADP	O
baseline	O	NOUN	B
TAFI	O	NOUN	B
antigen	O	NOUN	B
concentrations	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
duration	O	NOUN	B
of	O	ADP	I
amenorrhea	B-Disease	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
;	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


33	O	NUM	O
).	O	PUNCT	O
CONCLUSION	O	NOUN	O
:	O	PUNCT	O
We	O	PRON	O
suggest	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
increased	O	VERB	B
risk	O	NOUN	B
of	O	ADP	O
venous	B-Disease	ADJ	B
thromboembolism	I-Disease	NOUN	I
due	O	ADJ	O
to	O	PART	O
raloxifene	B-Chemical	NOUN	B


Ketoconazole	B-Chemical	NOUN	B
induced	O	VERB	B
torsades	B-Disease	NOUN	B
de	I-Disease	X	O
pointes	I-Disease	NOUN	B
without	O	ADP	O
concomitant	O	ADJ	B
use	O	NOUN	O
of	O	ADP	O
QT	O	NOUN	B
interval	O	NOUN	I
-	O	PUNCT	O
prolonging	O	VERB	B
drug	O	NOUN	B
.	O	PUNCT	O


Ketoconazole	B-Chemical	NOUN	B
is	O	AUX	O
not	O	PART	O
known	O	VERB	O
to	O	PART	O
be	O	AUX	O
proarrhythmic	O	ADJ	B
without	O	ADP	O
concomitant	O	ADJ	B
use	O	NOUN	O
of	O	ADP	O
QT	O	NOUN	B
interval	O	NOUN	I
-	O	PUNCT	O
prolonging	O	VERB	B
drugs	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
a	O	DET	O
woman	O	NOUN	B
with	O	ADP	O
coronary	B-Disease	ADJ	B
artery	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
who	O	PRON	O
developed	O	VERB	O
a	O	DET	O
markedly	O	ADV	O
prolonged	B-Disease	ADJ	B
QT	I-Disease	NOUN	B
interval	I-Disease	NOUN	I
and	O	CCONJ	O
torsades	B-Disease	NOUN	B
de	I-Disease	X	I
pointes	I-Disease	X	I
(	O	PUNCT	O
TdP	B-Disease	NOUN	B
)	O	PUNCT	O
after	O	ADP	O
taking	O	VERB	O
ketoconazole	B-Chemical	NOUN	B
for	O	ADP	O
treatment	O	NOUN	B
of	O	ADP	O
fungal	B-Disease	ADJ	B
infection	I-Disease	NOUN	I
.	O	PUNCT	O


Her	O	PRON	O
QT	O	NOUN	B
interval	O	NOUN	I
returned	O	VERB	O
to	O	ADP	O
normal	O	ADJ	B
upon	O	SCONJ	O
withdrawal	O	NOUN	B
of	O	ADP	I
ketoconazole	B-Chemical	NOUN	B
.	O	PUNCT	O


Genetic	O	ADJ	B
study	O	NOUN	I
did	O	AUX	O
not	O	PART	O
find	O	VERB	O
any	O	DET	O
mutation	O	NOUN	B
in	O	ADP	O
her	O	PRON	O
genes	O	NOUN	B
that	O	PRON	O
encode	O	VERB	B
cardiac	O	ADJ	B
IKr	O	NOUN	B
channel	O	NOUN	I
proteins	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
postulate	O	VERB	O
that	O	SCONJ	O
by	O	ADP	O
virtue	O	NOUN	O
of	O	ADP	O
its	O	PRON	O
direct	O	ADJ	O
blocking	O	NOUN	B
action	O	NOUN	B
on	O	ADP	O
IKr	O	NOUN	B
,	O	PUNCT	O
ketoconazole	B-Chemical	NOUN	B
alone	O	ADV	O
may	O	AUX	O
prolong	O	VERB	O
QT	O	NOUN	B
interval	O	NOUN	I
and	O	CCONJ	O
induce	O	VERB	B
TdP	B-Disease	NOUN	B
.	O	PUNCT	O


This	O	DET	O
calls	O	VERB	O
for	O	ADP	O
attention	O	NOUN	B
when	O	SCONJ	O
ketoconazole	B-Chemical	NOUN	B
is	O	AUX	O
administered	O	VERB	B
to	O	PART	O
patients	O	NOUN	B
with	O	ADP	O
risk	O	NOUN	B
factors	O	NOUN	I
for	O	ADP	O
acquired	O	VERB	O
long	B-Disease	ADJ	B
QT	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I


Pharmacological	O	ADJ	B
evidence	O	NOUN	B
for	O	ADP	O
the	O	DET	O
potential	O	NOUN	B
of	O	ADP	O
Daucus	O	PROPN	B
carota	O	NOUN	I
in	O	ADP	O
the	O	DET	O
management	O	NOUN	B
of	O	ADP	O
cognitive	B-Disease	ADJ	B
dysfunctions	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
was	O	AUX	O
aimed	O	VERB	O
at	O	ADP	O
investigating	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
Daucus	O	PROPN	B
carota	O	NOUN	I
seeds	O	NOUN	B
on	O	ADP	O
cognitive	O	ADJ	B
functions	O	NOUN	I
,	O	PUNCT	O
total	O	ADJ	O
serum	O	NOUN	O
cholesterol	B-Chemical	NOUN	O
levels	O	NOUN	O
and	O	CCONJ	O
brain	O	NOUN	B
cholinesterase	O	NOUN	I
activity	O	NOUN	B
in	O	ADP	O
mice	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
ethanolic	O	ADJ	B
extract	B-Chemical	NOUN	I
of	I-Chemical	ADP	O
Daucus	I-Chemical	PROPN	B
carota	I-Chemical	NOUN	I
seeds	I-Chemical	NOUN	B
(	O	PUNCT	O
DCE	B-Chemical	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
administered	O	VERB	B
orally	O	ADV	B
in	O	ADP	O
three	O	NUM	O
doses	O	NOUN	B
(	O	PUNCT	O
100	O	NUM	O
,	O	PUNCT	O
200	O	NUM	O
,	O	PUNCT	O
400	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
for	O	ADP	O
seven	O	NUM	O
successive	O	ADJ	O
days	O	NOUN	B
to	O	PART	O
different	O	ADJ	O
groups	O	NOUN	B
of	O	ADP	O
young	O	ADJ	B
and	O	CCONJ	O
aged	O	ADJ	B
mice	O	NOUN	B
.	O	PUNCT	O


Elevated	O	ADJ	B
plus	O	CCONJ	I
maze	O	NOUN	I
and	O	CCONJ	O
passive	O	ADJ	B
avoidance	O	NOUN	I
apparatus	O	NOUN	I
served	O	VERB	O
as	O	ADP	O
the	O	DET	O
exteroceptive	O	ADJ	B
behavioral	O	ADJ	B
models	O	NOUN	O
for	O	ADP	O
testing	O	VERB	B
memory	O	NOUN	I
.	O	PUNCT	O


Diazepam	B-Chemical	NOUN	B
-,	O	NOUN	O
scopolamine	B-Chemical	NOUN	B
-	O	PUNCT	O
and	O	CCONJ	O
ageing	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
amnesia	B-Disease	NOUN	B
served	O	VERB	O
as	O	ADP	O
the	O	DET	O
interoceptive	O	ADJ	B
behavioral	O	ADJ	B
models	O	NOUN	O
.	O	PUNCT	O


DCE	B-Chemical	NOUN	B
(	O	PUNCT	O
200	O	NUM	O
,	O	PUNCT	O
400	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
p	O	NOUN	O
.	O	PUNCT	O


o	O	INTJ	O
.)	O	NOUN	O
showed	O	VERB	O
significant	O	ADJ	O
improvement	O	NOUN	B
in	O	ADP	O
memory	O	NOUN	B
scores	O	NOUN	I
of	O	ADP	O
young	O	ADJ	B
and	O	CCONJ	O
aged	O	ADJ	B
mice	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
extent	O	NOUN	O
of	O	ADP	O
memory	O	NOUN	B
improvement	O	NOUN	B
evoked	O	VERB	B
by	O	ADP	O
DCE	B-Chemical	NOUN	B
was	O	AUX	O
23	O	NUM	O
%	O	NOUN	O
at	O	ADP	O
the	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
200	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
and	O	CCONJ	O
35	O	NUM	O
%	O	NOUN	O
at	O	ADP	O
the	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
400	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
kg	O	NOUN	B
in	O	ADP	O
young	O	ADJ	B
mice	O	NOUN	B
using	O	VERB	O
elevated	O	ADJ	B
plus	O	CCONJ	I
maze	O	NOUN	I
.	O	PUNCT	O


Similarly	O	ADV	O
,	O	PUNCT	O
significant	O	ADJ	O
improvements	O	NOUN	B
in	O	ADP	O
memory	O	NOUN	B
scores	O	NOUN	I
were	O	AUX	O
observed	O	VERB	O
using	O	VERB	O
passive	O	ADJ	B
avoidance	O	NOUN	I
apparatus	O	NOUN	I
and	O	CCONJ	O
aged	O	ADJ	B
mice	O	NOUN	B
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
DCE	B-Chemical	NOUN	B
reversed	O	VERB	B
the	O	DET	O
amnesia	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
scopolamine	B-Chemical	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


p	O	NOUN	O
.)	O	NOUN	O
and	O	CCONJ	O
diazepam	B-Chemical	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


p	O	NOUN	O
.).	O	NOUN	O
Daucus	B-Chemical	PROPN	B
carota	I-Chemical	NOUN	I
extract	I-Chemical	NOUN	I
(	O	PUNCT	O
200	O	NUM	O
,	O	PUNCT	O
400	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
p	O	NOUN	O
.	O	PUNCT	O


o	O	X	O
.)	O	NOUN	O
reduced	O	VERB	B
significantly	O	ADV	O
the	O	DET	O
brain	O	NOUN	B
acetylcholinesterase	O	NOUN	B
activity	O	NOUN	I
and	O	CCONJ	O
cholesterol	B-Chemical	NOUN	B
levels	O	NOUN	O
in	O	ADP	O
young	O	ADJ	B
and	O	CCONJ	O
aged	O	ADJ	B
mice	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
extent	O	NOUN	O
of	O	ADP	O
inhibition	O	NOUN	B
of	O	ADP	O
brain	O	NOUN	B
cholinesterase	O	NOUN	I
activity	O	NOUN	B
evoked	O	VERB	O
by	O	ADP	O
DCE	B-Chemical	NOUN	B
at	O	ADP	O
the	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
400	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
kg	O	NOUN	B
was	O	AUX	O
22	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
young	O	ADJ	B
and	O	CCONJ	O
19	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
aged	O	ADJ	B
mice	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
a	O	DET	O
remarkable	O	ADJ	O
reduction	O	NOUN	B
in	O	ADP	O
total	O	ADJ	B
cholesterol	B-Chemical	NOUN	I
level	O	NOUN	O
as	O	ADV	O
well	O	ADV	O
,	O	PUNCT	O
to	O	PART	O
the	O	DET	O
extent	O	NOUN	O
of	O	ADP	O
23	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
young	O	ADJ	B
and	O	CCONJ	O
21	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
aged	O	ADJ	B
animals	O	NOUN	B
with	O	ADP	O
this	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
DCE	B-Chemical	NOUN	B
.	O	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
DCE	B-Chemical	PROPN	B
may	O	AUX	O
prove	O	VERB	O
to	O	PART	O
be	O	AUX	O
a	O	DET	O
useful	O	ADJ	O
remedy	O	NOUN	O
for	O	ADP	O
the	O	DET	O
management	O	NOUN	B
of	O	ADP	O
cognitive	B-Disease	ADJ	B
dysfunctions	I-Disease	NOUN	I
on	O	ADP	O
account	O	NOUN	O
of	O	ADP	O
its	O	PRON	O
multifarious	O	ADJ	O
beneficial	O	ADJ	O
effects	O	NOUN	B
such	O	ADJ	O
as	O	ADP	O
,	O	PUNCT	O
memory	O	NOUN	B
improving	O	VERB	B
property	O	NOUN	B
,	O	PUNCT	O
cholesterol	B-Chemical	NOUN	B


Cauda	B-Disease	ADJ	B
equina	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
after	O	ADP	O
epidural	O	ADJ	B
steroid	B-Chemical	NOUN	B
injection	O	NOUN	B
:	O	PUNCT	O
a	O	DET	O
case	O	NOUN	B
report	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
:	O	PUNCT	O
Conventional	O	ADJ	B
treatment	O	NOUN	I
methods	O	NOUN	I
of	O	ADP	O
lumbusacral	O	ADJ	B
radiculopathy	B-Disease	NOUN	I
are	O	AUX	O
physical	O	ADJ	B
therapy	O	NOUN	I
,	O	PUNCT	O
epidural	O	ADJ	B
steroid	B-Chemical	NOUN	I
injections	O	NOUN	I
,	O	PUNCT	O
oral	O	ADJ	B
medications	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
spinal	O	ADJ	B
manipulative	O	ADJ	B
therapy	O	NOUN	I
.	O	PUNCT	O


Cauda	B-Disease	ADJ	B
equina	I-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
is	O	AUX	O
a	O	DET	O
rare	O	ADJ	O
complication	O	NOUN	B
of	O	ADP	O
epidural	O	ADJ	B
anesthesia	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
following	O	VERB	O
case	O	NOUN	B
is	O	AUX	O
a	O	DET	O
report	O	NOUN	B
of	O	ADP	O
cauda	B-Disease	ADJ	B
equina	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
possibly	O	ADV	O
caused	O	VERB	O
by	O	ADP	O
epidural	O	ADJ	B
injection	O	NOUN	B
of	O	ADP	O
triamcinolone	B-Chemical	NOUN	B
and	O	CCONJ	O
bupivacaine	B-Chemical	NOUN	B
.	O	PUNCT	O


CLINICAL	O	NOUN	O
FEATURES	O	NOUN	O
:	O	PUNCT	O
A	O	DET	O
50	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
woman	O	NOUN	B
with	O	ADP	O
low	B-Disease	ADJ	B
back	I-Disease	ADV	I
and	I-Disease	CCONJ	O
right	I-Disease	ADJ	B
leg	I-Disease	NOUN	I
pain	I-Disease	NOUN	I
was	O	AUX	O
scheduled	O	VERB	O
for	O	ADP	O
epidural	O	ADJ	B
steroid	B-Chemical	NOUN	B
injection	O	NOUN	B
.	O	PUNCT	O


INTERVENTION	O	PROPN	B
AND	O	CCONJ	O
OUTCOME	O	PROPN	B
:	O	PUNCT	O
An	O	DET	O
18	O	NUM	O
-	O	PUNCT	O
gauge	O	NOUN	B
Touhy	O	PROPN	B
needle	O	NOUN	O
was	O	AUX	O
inserted	O	VERB	O
until	O	ADP	O
loss	O	NOUN	B
of	O	ADP	O
resistance	O	NOUN	B
occurred	O	VERB	O
at	O	ADP	O
the	O	DET	O
L4	O	PROPN	B
-	O	PUNCT	O
5	O	NUM	O
level	O	NOUN	B
.	O	PUNCT	O


Spread	O	VERB	B
of	O	ADP	O
the	O	DET	O
contrast	O	NOUN	B
medium	O	NOUN	I
within	O	ADP	O
the	O	DET	O
epidural	O	ADJ	B
space	O	NOUN	I
was	O	AUX	O
determined	O	VERB	O
by	O	ADP	O
radiographic	O	ADJ	B
imaging	O	NOUN	I
.	O	PUNCT	O


After	O	ADP	O
verifying	O	VERB	O
the	O	DET	O
epidural	O	ADJ	B
space	O	NOUN	I
,	O	PUNCT	O
bupivacaine	B-Chemical	NOUN	B
and	O	CCONJ	O
triamcinolone	B-Chemical	NOUN	B
diacetate	I-Chemical	NOUN	I
were	O	AUX	O
injected	O	VERB	B
.	O	PUNCT	O


After	O	ADP	O
the	O	DET	O
injection	O	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
reduction	O	NOUN	B
in	O	ADP	O
radicular	O	NOUN	B
symptoms	O	NOUN	I
.	O	PUNCT	O


Three	O	NUM	B
hours	O	NOUN	I
later	O	ADV	O
,	O	PUNCT	O
she	O	PRON	O
complained	O	VERB	B
of	O	ADP	O
perineal	O	ADJ	B
numbness	B-Disease	NOUN	I
and	O	CCONJ	O
lower	B-Disease	ADJ	B
extremity	I-Disease	NOUN	I
weakness	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
neurologic	O	ADJ	B
evaluation	O	NOUN	B
revealed	O	VERB	O
loss	B-Disease	NOUN	B
of	I-Disease	ADP	I
sensation	I-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
saddle	O	ADJ	B
area	O	NOUN	I
and	O	CCONJ	O
medial	O	ADJ	B
aspect	O	NOUN	B
of	O	ADP	O
her	O	PRON	O
right	O	ADJ	B
leg	O	NOUN	I
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
a	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
the	O	DET	O
perception	O	NOUN	B
of	O	ADP	O
pinprick	O	ADJ	B
test	O	NOUN	I
.	O	PUNCT	O


Deep	O	PROPN	B
-	O	PUNCT	O
tendon	O	NOUN	B
reflexes	O	NOUN	B
were	O	AUX	O
decreased	O	VERB	B
especially	O	ADV	O
in	O	ADP	O
the	O	DET	O
right	O	ADJ	B
leg	O	NOUN	I
.	O	PUNCT	O


She	O	PRON	O
was	O	AUX	O
unable	O	ADJ	O
to	O	PART	O
urinate	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
'	O	PART	O
s	O	NOUN	O
symptoms	O	NOUN	B
improved	O	VERB	B
slightly	O	ADV	O
over	O	ADP	O
the	O	DET	O
next	O	ADJ	O
few	O	ADJ	O
hours	O	NOUN	O
.	O	PUNCT	O


She	O	PRON	O
had	O	AUX	O
a	O	DET	O
gradual	O	ADJ	O
return	O	NOUN	B
of	O	ADP	I
motor	O	NOUN	I
function	O	NOUN	I
and	O	CCONJ	O
ability	O	NOUN	O
of	O	ADP	O
feeling	O	VERB	O
Foley	O	PROPN	B
catheter	O	NOUN	I
.	O	PUNCT	O


All	O	DET	O
of	O	ADP	O
the	O	DET	O
symptoms	O	NOUN	B
were	O	AUX	O
completely	O	ADV	O
resolved	O	VERB	B
over	O	ADP	O
the	O	DET	O
next	O	ADJ	O
8	O	NUM	O
hours	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
Complications	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
epidural	O	ADJ	B
steroid	B-Chemical	NOUN	I
injections	O	NOUN	I
are	O	AUX	O
rare	O	ADJ	B
.	O	PUNCT	O


Clinical	O	ADJ	B
examination	O	NOUN	I
and	O	CCONJ	O
continued	O	VERB	O
vigilance	O	NOUN	B
for	O	ADP	O
neurologic	B-Disease	ADJ	B
deterioration	I-Disease	NOUN	I
after	O	ADP	O
epidural	O	ADJ	B
steroid	B-Chemical	NOUN	B


High	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
testosterone	B-Chemical	NOUN	B
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
atherosclerosis	B-Disease	NOUN	B
in	O	ADP	O
postmenopausal	O	ADJ	B
women	O	NOUN	B
.	O	PUNCT	O


OBJECTIVES	O	NOUN	O
:	O	PUNCT	O
To	O	PART	O
study	O	VERB	B
the	O	DET	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
effects	O	NOUN	B
of	O	ADP	O
androgen	O	NOUN	B
treatment	O	NOUN	I
on	O	ADP	O
atherosclerosis	B-Disease	NOUN	B
in	O	ADP	O
postmenopausal	O	ADJ	B
women	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
In	O	ADP	O
a	O	DET	O
population	O	NOUN	B
-	O	PUNCT	O
based	O	VERB	B
study	O	NOUN	B
in	O	ADP	O
513	O	NUM	O
naturally	O	ADV	O
postmenopausal	O	ADJ	B
women	O	NOUN	B
aged	O	ADJ	B
54	O	NUM	O
-	O	PUNCT	O
67	O	NUM	O
years	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
studied	O	VERB	O
the	O	DET	O
association	O	NOUN	B
between	O	ADP	O
self	O	NOUN	B
-	O	PUNCT	O
reported	O	VERB	B
intramuscularly	O	ADV	B
administered	O	VERB	B
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
estrogen	B-Chemical	NOUN	B
-	O	PUNCT	O
testosterone	B-Chemical	NOUN	B
therapy	O	NOUN	B
(	O	PUNCT	O
estradiol-	B-Chemical	NOUN	B
and	I-Chemical	CCONJ	O
testosterone	I-Chemical	NOUN	B
esters	I-Chemical	NOUN	I
)	O	PUNCT	O
and	O	CCONJ	O
aortic	O	ADJ	B
atherosclerosis	B-Disease	NOUN	B
.	O	PUNCT	O


Aortic	O	ADJ	B
atherosclerosis	B-Disease	NOUN	I
was	O	AUX	O
diagnosed	O	VERB	B
by	O	ADP	O
radiographic	O	ADJ	B
detection	O	NOUN	B
of	O	ADP	O
calcified	O	VERB	B
deposits	O	NOUN	I
in	O	ADP	O
the	O	DET	O
abdominal	O	ADJ	B
aorta	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
have	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
reflect	O	VERB	O
intima	O	NOUN	B
atherosclerosis	B-Disease	NOUN	I
.	O	PUNCT	O


Hormone	O	NOUN	B
therapy	O	NOUN	I
users	O	NOUN	B
were	O	AUX	O
compared	O	VERB	B
with	O	ADP	O
never	O	ADV	B
users	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Intramuscular	O	ADJ	B
hormone	O	NOUN	I
therapy	O	NOUN	I
use	O	NOUN	O
for	O	ADP	O
1	O	NUM	O
year	O	NOUN	B
or	O	CCONJ	O
longer	O	ADJ	B
was	O	AUX	O
reported	O	VERB	O
by	O	ADP	O
25	O	NUM	O
women	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
almost	O	ADV	O
half	O	NOUN	O
of	O	ADP	O
these	O	DET	O
women	O	NOUN	B
severe	O	ADJ	B
atherosclerosis	B-Disease	NOUN	B
of	O	ADP	O
the	O	DET	O
aorta	O	NOUN	B
was	O	AUX	O
present	O	ADJ	O
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
11	O	NUM	O
),	O	PUNCT	O
while	O	SCONJ	O
in	O	ADP	O
women	O	NOUN	B
without	O	ADP	O
hormone	O	NOUN	B
use	O	VERB	O
severe	O	ADJ	B
atherosclerosis	B-Disease	NOUN	B
of	O	ADP	O
the	O	DET	O
aorta	O	NOUN	B
was	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
less	O	ADJ	O
than	O	ADP	O
20	O	NUM	O
%(	O	NOUN	O
OR	O	CCONJ	B
3	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
-	O	SYM	O
8	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
,	O	PUNCT	O
adjusted	O	VERB	O
for	O	ADP	O
age	O	NOUN	B
,	O	PUNCT	O
years	O	NOUN	B
since	O	SCONJ	O
menopause	O	NOUN	B
,	O	PUNCT	O
smoking	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
body	O	NOUN	B
mass	O	NOUN	I
index	O	NOUN	I
).	O	PUNCT	O
The	O	DET	O
association	O	NOUN	B
remained	O	VERB	O
after	O	ADP	O
additional	O	ADJ	O
adjustment	O	NOUN	B
for	O	ADP	O
diabetes	B-Disease	NOUN	B
,	O	PUNCT	O
cholesterol	B-Chemical	NOUN	B
level	O	NOUN	I
,	O	PUNCT	O
systolic	O	ADJ	B
blood	O	NOUN	I
pressure	O	NOUN	I
,	O	PUNCT	O
or	O	CCONJ	O
alcohol	B-Chemical	NOUN	B
use	O	NOUN	I
.	O	PUNCT	O


No	O	DET	O
association	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
for	O	ADP	O
hormone	O	NOUN	B
use	O	VERB	O
less	O	ADJ	O
than	O	ADP	O
1	O	NUM	O
year	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
Our	O	PRON	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
testosterone	B-Chemical	NOUN	B
therapy	O	NOUN	I
may	O	AUX	O
adversely	O	ADV	O
affect	O	VERB	O
atherosclerosis	B-Disease	NOUN	B


Sirolimus	B-Chemical	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
proteinuria	B-Disease	NOUN	B
and	O	CCONJ	O
renal	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
.	O	PUNCT	O


Sirolimus	B-Chemical	NOUN	B
is	O	AUX	O
a	O	DET	O
novel	O	ADJ	O
immunosuppressant	O	NOUN	B
with	O	ADP	O
potent	O	ADJ	O
antiproliferative	O	ADJ	B
actions	O	NOUN	O
through	O	ADP	O
its	O	PRON	O
ability	O	NOUN	O
to	O	PART	O
inhibit	O	VERB	B
the	O	DET	O
raptor	O	NOUN	B
-	O	PUNCT	O
containing	O	VERB	B
mammalian	O	ADJ	B
target	O	NOUN	B
of	O	ADP	O
rapamycin	B-Chemical	NOUN	B
protein	O	NOUN	I
kinase	O	NOUN	I
.	O	PUNCT	O


Sirolimus	B-Chemical	NOUN	B
represents	O	VERB	O
a	O	DET	O
major	O	ADJ	O
therapeutic	O	ADJ	B
advance	O	NOUN	B
in	O	ADP	O
the	O	DET	O
prevention	O	NOUN	B
of	O	ADP	O
acute	O	ADJ	B
renal	O	ADJ	I
allograft	O	NOUN	I
rejection	O	NOUN	I
and	O	CCONJ	O
chronic	O	ADJ	B
allograft	O	NOUN	I
nephropathy	B-Disease	NOUN	I
.	O	PUNCT	O


Its	O	PRON	O
role	O	NOUN	O
in	O	ADP	O
the	O	DET	O
therapy	O	NOUN	B
of	O	ADP	O
glomerulonephritis	B-Disease	NOUN	B
,	O	PUNCT	O
autoimmunity	B-Disease	NOUN	B
,	O	PUNCT	O
cystic	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
diseases	I-Disease	NOUN	I
and	O	CCONJ	O
renal	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
is	O	AUX	O
under	O	ADP	O
investigation	O	NOUN	B
.	O	PUNCT	O


Because	O	SCONJ	O
sirolimus	B-Chemical	NOUN	B
does	O	AUX	O
not	O	PART	O
share	O	VERB	O
the	O	DET	O
vasomotor	O	NOUN	B
renal	O	ADJ	I
adverse	O	ADJ	B
effects	O	NOUN	I
exhibited	O	VERB	O
by	O	ADP	O
calcineurin	O	NOUN	B
inhibitors	O	NOUN	B
,	O	PUNCT	O
it	O	PRON	O
has	O	AUX	O
been	O	AUX	O
designated	O	VERB	O
a	O	DET	O
'	O	PUNCT	O
non	O	ADJ	B
-	O	PUNCT	O
nephrotoxic	B-Disease	ADJ	B
drug	O	NOUN	B
'.	O	ADJ	I
However	O	ADV	O
,	O	PUNCT	O
clinical	O	ADJ	B
reports	O	NOUN	I
suggest	O	VERB	O
that	O	SCONJ	O
,	O	PUNCT	O
under	O	ADP	O
some	O	DET	O
circumstances	O	NOUN	O
,	O	PUNCT	O
sirolimus	B-Chemical	NOUN	B
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
proteinuria	B-Disease	NOUN	B
and	O	CCONJ	O
acute	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
dysfunction	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
common	O	ADJ	O
risk	O	NOUN	B
factor	O	NOUN	I
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
presence	O	NOUN	B
of	O	ADP	O
pre	O	NOUN	B
-	O	PUNCT	O
existing	O	VERB	B
chronic	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
damage	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
mechanisms	O	NOUN	B
of	O	ADP	O
sirolimus	B-Chemical	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
proteinuria	B-Disease	NOUN	B
are	O	AUX	O
multifactorial	O	ADJ	B
and	O	CCONJ	O
may	O	AUX	O
be	O	AUX	O
due	O	ADJ	O
to	O	PART	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
glomerular	O	ADJ	B
capillary	O	ADJ	I
pressure	O	NOUN	I
following	O	VERB	O
calcineurin	O	NOUN	B
inhibitor	O	NOUN	I
withdrawal	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
has	O	AUX	O
also	O	ADV	O
been	O	AUX	O
suggested	O	VERB	O
that	O	SCONJ	O
sirolimus	B-Chemical	NOUN	B
directly	O	ADV	O
causes	O	VERB	O
increased	O	VERB	B
glomerular	O	ADJ	B
permeability	O	NOUN	I
/	O	PUNCT	O
injury	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
evidence	O	NOUN	B
for	O	ADP	O
this	O	DET	O
mechanism	O	NOUN	B
is	O	AUX	O
currently	O	ADV	O
inconclusive	O	ADJ	B
.	O	PUNCT	O


The	O	DET	O
acute	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
dysfunction	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
sirolimus	B-Chemical	NOUN	B
(	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
in	O	ADP	O
delayed	O	VERB	B
graft	O	NOUN	B
function	O	NOUN	I
)	O	PUNCT	O
may	O	AUX	O
be	O	AUX	O
due	O	ADJ	O
to	O	PART	O
suppression	O	NOUN	B
of	O	ADP	O
compensatory	O	ADJ	B
renal	O	ADJ	I
cell	O	NOUN	I
proliferation	O	NOUN	I
and	O	CCONJ	O
survival	O	NOUN	B
/	O	SYM	O
repair	O	NOUN	B
processes	O	NOUN	I
.	O	PUNCT	O


Although	O	SCONJ	O
these	O	DET	O
adverse	O	ADJ	B
effects	O	NOUN	I
occur	O	VERB	O
in	O	ADP	O
some	O	DET	O
patients	O	NOUN	B
,	O	PUNCT	O
their	O	PRON	O
occurrence	O	NOUN	B
could	O	AUX	O
be	O	AUX	O
minimised	O	VERB	O
by	O	ADP	O
knowledge	O	NOUN	B
of	O	ADP	O
the	O	DET	O
molecular	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
sirolimus	B-Chemical	NOUN	B
on	O	ADP	O
the	O	DET	O
kidney	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
sirolimus	B-Chemical	NOUN	B
in	O	ADP	O
appropriate	O	ADJ	O
patient	O	NOUN	B
populations	O	NOUN	I
,	O	PUNCT	O
close	O	ADJ	O
monitoring	O	NOUN	B
of	O	ADP	O
proteinuria	B-Disease	NOUN	B
and	O	CCONJ	O
renal	O	ADJ	B
function	O	NOUN	I
,	O	PUNCT	O
use	O	NOUN	O
of	O	ADP	O
angiotensin	B-Chemical	NOUN	B
-	O	PUNCT	O
converting	O	VERB	B
enzyme	O	NOUN	B
inhibitors	O	NOUN	I
or	O	CCONJ	O
angiotensin	B-Chemical	NOUN	B
II	I-Chemical	NUM	I
receptor	O	NOUN	I
blockers	O	NOUN	I
if	O	SCONJ	O
proteinuria	B-Disease	NOUN	B
occurs	O	VERB	B
and	O	CCONJ	O
withdrawal	O	NOUN	B
if	O	SCONJ	O
needed	O	VERB	O
.	O	PUNCT	O


Further	O	ADV	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
analysis	O	NOUN	B
of	O	ADP	O
renal	O	ADJ	B
allograft	O	NOUN	I
studies	O	NOUN	B
using	O	VERB	O
sirolimus	B-Chemical	NOUN	B


Progressive	O	ADJ	B
myopathy	B-Disease	NOUN	I
with	O	ADP	O
up	O	ADV	B
-	O	PUNCT	O
regulation	O	NOUN	B
of	O	ADP	O
MHC	O	NOUN	B
-	O	PUNCT	O
I	O	PRON	B
associated	O	VERB	B
with	O	ADP	I
statin	B-Chemical	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


Statins	B-Chemical	NOUN	B
can	O	AUX	O
cause	O	VERB	O
a	O	DET	O
necrotizing	O	NOUN	B
myopathy	B-Disease	NOUN	I
and	O	CCONJ	O
hyperCKaemia	B-Disease	NOUN	B
which	O	DET	O
is	O	AUX	O
reversible	O	ADJ	O
on	O	ADP	O
cessation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
drug	O	NOUN	B
.	O	PUNCT	O


What	O	PRON	O
is	O	AUX	O
less	O	ADV	O
well	O	ADV	O
known	O	VERB	O
is	O	AUX	O
a	O	DET	O
phenomenon	O	NOUN	B
whereby	O	SCONJ	O
statins	B-Chemical	NOUN	B
may	O	AUX	O
induce	O	VERB	B
a	O	DET	O
myopathy	B-Disease	NOUN	B
,	O	PUNCT	O
which	O	DET	O
persists	O	VERB	B
or	O	CCONJ	O
may	O	AUX	O
progress	O	VERB	B
after	O	ADP	O
stopping	O	VERB	B
the	O	DET	O
drug	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
investigated	O	VERB	B
the	O	DET	O
muscle	O	NOUN	B
pathology	O	NOUN	B
in	O	ADP	O
8	O	NUM	O
such	O	ADJ	O
cases	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
had	O	AUX	O
myofibre	O	NOUN	B
necrosis	B-Disease	NOUN	I
but	O	CCONJ	O
only	O	ADV	O
3	O	NUM	O
had	O	AUX	O
an	O	DET	O
inflammatory	O	ADJ	B
infiltrate	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
all	O	DET	O
cases	O	NOUN	B
there	O	PRON	O
was	O	AUX	O
diffuse	O	ADJ	B
or	O	CCONJ	O
multifocal	O	ADJ	B
up	O	NOUN	B
-	O	PUNCT	O
regulation	O	NOUN	B
of	O	ADP	O
MHC	O	NOUN	B
-	O	PUNCT	O
I	O	NOUN	B
expression	O	NOUN	B
even	O	ADV	O
in	O	ADP	O
non	O	ADJ	B
-	O	PUNCT	O
necrotic	B-Disease	ADJ	B
fibres	O	NOUN	O
.	O	PUNCT	O


Progressive	O	ADJ	B
improvement	O	NOUN	B
occurred	O	VERB	O
in	O	ADP	O
7	O	NUM	O
cases	O	NOUN	B
after	O	ADP	O
commencement	O	NOUN	B
of	O	ADP	O
prednisolone	B-Chemical	NOUN	B
and	O	CCONJ	O
methotrexate	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
one	O	NUM	O
case	O	NOUN	B
spontaneously	O	ADV	I
.	O	PUNCT	O


These	O	DET	O
observations	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
statins	B-Chemical	NOUN	B
may	O	AUX	O
initiate	O	VERB	B
an	O	DET	O
immune	O	ADJ	B
-	O	PUNCT	O
mediated	O	VERB	B
myopathy	B-Disease	NOUN	B
that	O	PRON	O
persists	O	VERB	O
after	O	ADP	O
withdrawal	O	NOUN	B
of	O	ADP	I
the	O	DET	I
drug	O	NOUN	B
and	O	CCONJ	O
responds	O	VERB	O
to	O	PART	O
immunosuppressive	O	ADJ	B
therapy	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
mechanism	O	NOUN	B
of	O	ADP	O
this	O	DET	O
myopathy	B-Disease	NOUN	B
is	O	AUX	O
uncertain	O	ADJ	O
but	O	CCONJ	O
may	O	AUX	O
involve	O	VERB	O
the	O	DET	O
induction	O	NOUN	B
by	O	ADP	O
statins	B-Chemical	NOUN	B


Direct	O	ADJ	O
inhibition	O	NOUN	B
of	O	ADP	O
cardiac	O	ADJ	B
hyperpolarization	O	NOUN	B
-	O	PUNCT	O
activated	O	VERB	B
cyclic	B-Chemical	ADJ	B
nucleotide	I-Chemical	NOUN	I
-	O	PUNCT	O
gated	O	VERB	B
pacemaker	O	NOUN	B
channels	O	NOUN	I
by	O	ADP	O
clonidine	B-Chemical	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Inhibition	O	NOUN	B
of	O	ADP	O
cardiac	O	ADJ	B
sympathetic	O	ADJ	I
tone	O	NOUN	I
represents	O	VERB	O
an	O	DET	O
important	O	ADJ	O
strategy	O	NOUN	O
for	O	ADP	O
treatment	O	NOUN	B
of	O	ADP	O
cardiovascular	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
arrhythmia	B-Disease	NOUN	B
,	O	PUNCT	O
coronary	B-Disease	ADJ	B
heart	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
chronic	O	ADJ	B
heart	B-Disease	NOUN	I
failure	I-Disease	NOUN	I
.	O	PUNCT	O


Activation	O	NOUN	B
of	O	ADP	O
presynaptic	O	ADJ	B
alpha2	O	NOUN	B
-	O	PUNCT	O
adrenoceptors	O	NOUN	B
is	O	AUX	O
the	O	DET	O
most	O	ADV	O
widely	O	ADV	O
accepted	O	VERB	O
mechanism	O	NOUN	B
of	O	ADP	O
action	O	NOUN	B
of	O	ADP	O
the	O	DET	O
antisympathetic	O	ADJ	B
drug	O	NOUN	O
clonidine	B-Chemical	NOUN	B
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
other	O	ADJ	O
target	O	NOUN	B
proteins	O	NOUN	O
have	O	AUX	O
been	O	AUX	O
postulated	O	VERB	O
to	O	PART	O
contribute	O	VERB	O
to	O	ADP	O
the	O	DET	O
in	O	X	B
vivo	O	X	I
actions	O	NOUN	B
of	O	ADP	O
clonidine	B-Chemical	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
AND	O	CCONJ	O
RESULTS	O	NOUN	B
:	O	PUNCT	O
To	O	PART	O
test	O	VERB	O
whether	O	SCONJ	O
clonidine	B-Chemical	NOUN	B
elicits	O	VERB	O
pharmacological	O	ADJ	B
effects	O	NOUN	O
independent	O	ADJ	B
of	O	ADP	O
alpha2	O	NOUN	B
-	O	PUNCT	O
adrenoceptors	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
generated	O	VERB	O
mice	O	NOUN	B
with	O	ADP	O
a	O	DET	O
targeted	O	VERB	O
deletion	O	NOUN	B
of	O	ADP	O
all	O	DET	O
3	O	NUM	O
alpha2	O	NOUN	B
-	O	PUNCT	O
adrenoceptor	O	NOUN	B
subtypes	O	NOUN	B
(	O	PUNCT	O
alpha2ABC	O	NOUN	O
-/-).	O	PUNCT	O
Alpha2ABC	O	NOUN	O
-/-	O	ADJ	O
mice	O	NOUN	B
were	O	AUX	O
completely	O	ADV	O
unresponsive	O	ADJ	O
to	O	PART	O
the	O	DET	O
analgesic	O	NOUN	B
and	O	CCONJ	O
hypnotic	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
clonidine	B-Chemical	NOUN	B
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
clonidine	B-Chemical	NOUN	B
significantly	O	ADV	O
lowered	O	VERB	B
heart	O	NOUN	B
rate	O	NOUN	I
in	O	ADP	O
alpha2ABC	O	NOUN	O
-/-	O	ADJ	O
mice	O	NOUN	B
by	O	ADP	O
up	O	ADV	O
to	O	PART	O
150	O	NUM	O
bpm	O	NOUN	O
.	O	PUNCT	O


Clonidine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
bradycardia	B-Disease	NOUN	B
in	O	ADP	O
conscious	O	ADJ	B
alpha2ABC	O	NOUN	O
-/-	O	ADJ	O
mice	O	NOUN	B
was	O	AUX	O
32	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
%(	O	NOUN	O
10	O	NUM	O
microg	O	NOUN	B
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
26	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
%(	O	NOUN	O
100	O	NUM	O
microg	O	NOUN	B
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
the	O	DET	O
effect	O	NOUN	B
in	O	ADP	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
mice	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
similar	O	ADJ	O
bradycardic	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
clonidine	B-Chemical	NOUN	B
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
isolated	O	VERB	B
spontaneously	O	ADV	O
beating	O	VERB	O
right	O	ADJ	O
atria	O	NOUN	O
from	O	ADP	O
alpha2ABC	O	NUM	B
-	O	PUNCT	O
knockout	O	NOUN	B
and	O	CCONJ	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
mice	O	NOUN	B
.	O	PUNCT	O


Clonidine	B-Chemical	NOUN	B
inhibited	O	VERB	B
the	O	DET	O
native	O	ADJ	B
pacemaker	O	NOUN	O
current	O	NOUN	O
(	O	PUNCT	O
I	O	NOUN	B
(	O	PUNCT	O
f	O	X	O
))	O	PUNCT	O
in	O	ADP	O
isolated	O	VERB	B
sinoatrial	O	ADJ	O
node	O	NOUN	O
pacemaker	O	NOUN	O
cells	O	NOUN	O
and	O	CCONJ	O
the	O	DET	O
I	O	NOUN	B
(	O	PUNCT	O
f	O	X	O
)-	O	ADJ	O
generating	O	VERB	O
hyperpolarization	O	NOUN	B
-	O	PUNCT	O
activated	O	VERB	B
cyclic	B-Chemical	ADJ	B
nucleotide	I-Chemical	NOUN	I
-	O	PUNCT	O
gated	O	VERB	B
(	O	PUNCT	O
HCN	O	NOUN	B
)	O	PUNCT	O
2	O	NUM	O
and	O	CCONJ	O
HCN4	O	NOUN	B
channels	O	NOUN	I
in	O	ADP	O
transfected	O	VERB	B
HEK293	O	NOUN	B
cells	O	NOUN	I
.	O	PUNCT	O


As	O	ADP	O
a	O	DET	O
consequence	O	NOUN	B
of	O	ADP	I
blocking	O	VERB	B
I	O	NOUN	I
(	O	PUNCT	O
f	O	X	O
),	O	PUNCT	O
clonidine	B-Chemical	NOUN	B
reduced	O	VERB	B
the	O	DET	O
slope	O	NOUN	O
of	O	ADP	O
the	O	DET	O
diastolic	O	ADJ	B
depolarization	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
frequency	O	NOUN	B
of	O	ADP	O
pacemaker	O	NOUN	B
potentials	O	NOUN	B
in	O	ADP	O
sinoatrial	O	ADJ	B
node	O	NOUN	I
cells	O	NOUN	I
from	O	ADP	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
and	O	CCONJ	O
alpha2ABC	O	NUM	B
-	O	PUNCT	O
knockout	O	NOUN	B
mice	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
Direct	O	ADJ	B
inhibition	O	NOUN	I
of	O	ADP	O
cardiac	O	ADJ	B
HCN	O	NOUN	O
pacemaker	O	NOUN	O
channels	O	NOUN	O
contributes	O	VERB	O
to	O	PART	O
the	O	DET	O
bradycardic	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
clonidine	B-Chemical	NOUN	B
gene	O	NOUN	B
-	O	PUNCT	O
targeted	O	VERB	B
mice	O	NOUN	B
in	O	X	B
vivo	O	X	I
,	O	PUNCT	O
and	O	CCONJ	O
thus	O	ADV	O
,	O	PUNCT	O
clonidine	B-Chemical	NOUN	B


Influence	O	NOUN	B
of	O	ADP	O
smoking	B-Chemical	NOUN	B
on	O	ADP	O
developing	O	VERB	O
cochlea	O	NOUN	B
.	O	PUNCT	O


Does	O	AUX	O
smoking	B-Chemical	VERB	B
during	O	ADP	O
pregnancy	O	NOUN	B
affect	O	VERB	O
the	O	DET	O
amplitudes	O	NOUN	B
of	O	ADP	O
transient	O	ADJ	B
evoked	O	VERB	O
otoacoustic	O	ADJ	O
emissions	O	NOUN	B
in	O	ADP	O
newborns	O	NOUN	B
?	O	PUNCT	O
OBJECTIVE	O	NOUN	O
:	O	PUNCT	O
Maternal	O	ADJ	B
tobacco	O	NOUN	B
smoking	B-Chemical	NOUN	I
has	O	AUX	O
negative	O	ADJ	B
effects	O	NOUN	B
on	O	ADP	O
fetal	O	ADJ	B
growth	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
influence	O	NOUN	B
of	O	ADP	O
smoking	B-Chemical	NOUN	B
during	O	ADP	O
pregnancy	O	NOUN	B
on	O	ADP	O
the	O	DET	O
developing	O	VERB	O
cochlea	O	NOUN	B
has	O	AUX	O
not	O	PART	O
been	O	AUX	O
estimated	O	VERB	B
,	O	PUNCT	O
although	O	SCONJ	O
smoking	B-Chemical	NOUN	B
has	O	AUX	O
been	O	AUX	O
positively	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
hearing	B-Disease	VERB	B
loss	I-Disease	NOUN	I
in	O	ADP	O
adults	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
objective	O	NOUN	B
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
maternal	O	ADJ	B
smoking	B-Chemical	NOUN	I
on	O	ADP	O
transient	O	ADJ	B
evoked	O	VERB	O
otoacoustic	O	ADJ	O
emissions	O	NOUN	O
(	O	PUNCT	O
TEOAEs	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
healthy	O	ADJ	B
neonates	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
This	O	DET	O
study	O	NOUN	B
was	O	AUX	O
undertaken	O	VERB	O
as	O	ADP	O
part	O	NOUN	O
of	O	ADP	O
neonatal	O	ADJ	B
screening	O	NOUN	B
for	O	ADP	O
hearing	B-Disease	VERB	B
impairment	I-Disease	NOUN	I
and	O	CCONJ	O
involved	O	VERB	O
both	O	DET	O
ears	O	NOUN	B
of	O	ADP	O
200	O	NUM	O
newborns	O	NOUN	B
.	O	PUNCT	O


Newborns	O	NOUN	B
whose	O	DET	O
mothers	O	NOUN	B
reported	O	VERB	O
smoking	B-Chemical	NOUN	B
during	O	ADP	O
pregnancy	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
200	O	NUM	O
ears	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
compared	O	VERB	B
to	O	PART	O
a	O	DET	O
control	O	ADJ	B
group	O	NOUN	I
of	O	ADP	O
newborns	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
200	O	NUM	O
ears	O	NOUN	B
),	O	PUNCT	O
whose	O	DET	O
mothers	O	NOUN	B
were	O	AUX	O
non	O	ADJ	B
-	O	PUNCT	O
smokers	O	NOUN	B
.	O	PUNCT	O


Exposure	O	NOUN	B
to	O	PART	I
tobacco	O	NOUN	B
was	O	AUX	O
characterized	O	VERB	B
as	O	ADP	O
low	O	ADJ	B
(<	O	NOUN	O
5	O	NUM	O
cigarettes	O	NOUN	B
per	O	ADP	O
day	O	NOUN	B
,	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
88	O	NUM	O
ears	O	NOUN	B
),	O	PUNCT	O
moderate	O	ADJ	B
(	O	PUNCT	O
5	O	NUM	O
<	O	X	O
or	O	CCONJ	O
=	O	ADJ	O
cigarettes	O	NOUN	B
per	O	ADP	O
day	O	NOUN	B
<	O	X	O
10	O	NUM	O
,	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
76	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
high	O	ADJ	O
(>	O	NOUN	B
or	O	CCONJ	O
=	O	ADJ	O
10	O	NUM	O
cigarettes	O	NOUN	B
per	O	ADP	O
day	O	NOUN	B
,	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
36	O	NUM	O
).	O	PUNCT	O
RESULTS	O	NOUN	B
:	O	PUNCT	O
In	O	ADP	O
exposed	O	VERB	B
neonates	O	NOUN	B
,	O	PUNCT	O
TEOAEs	O	NOUN	B
mean	O	VERB	B
response	O	NOUN	I
(	O	PUNCT	O
across	O	ADP	O
frequency	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
mean	O	VERB	O
amplitude	O	NOUN	B
at	O	ADP	O
4000Hz	O	NOUN	O
was	O	AUX	O
significantly	O	ADV	O
lower	O	ADJ	O
than	O	ADP	O
in	O	ADP	O
non	O	ADJ	B
-	O	PUNCT	O
exposed	O	VERB	B
neonates	O	NOUN	B
.	O	PUNCT	O


Comparisons	O	NOUN	B
between	O	ADP	O
exposed	O	VERB	B
newborns	O	NOUN	B
'	O	PART	O
subgroups	O	NOUN	B
revealed	O	VERB	B
no	O	DET	B
significant	O	ADJ	I
differences	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
by	O	ADP	O
comparing	O	VERB	B
each	O	DET	O
subgroup	O	NOUN	B
to	O	PART	O
control	O	NOUN	B
group	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
found	O	VERB	O
statistically	O	ADV	B
significant	O	ADJ	I
decreases	B-Disease	NOUN	B
of	I-Disease	ADP	O
TEOAEs	I-Disease	NOUN	B
amplitudes	I-Disease	NOUN	B
at	O	ADP	O
4000Hz	O	NOUN	O
for	O	ADP	O
all	O	DET	O
three	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


Mean	O	VERB	B
TEOAEs	O	NOUN	B
responses	O	NOUN	B
of	O	ADP	O
highly	O	ADV	O
exposed	O	VERB	B
newborns	O	NOUN	B
were	O	AUX	O
also	O	ADV	O
significantly	O	ADV	O
lower	O	ADJ	O
in	O	ADP	O
comparison	O	NOUN	B
to	O	PART	O
our	O	PRON	O
control	O	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
In	O	ADP	O
utero	O	NOUN	B
,	O	PUNCT	O
exposure	O	NOUN	B
to	O	PART	I
tobacco	O	NOUN	B
smoking	B-Chemical	NOUN	I
seems	O	VERB	O
to	O	PART	O
have	O	AUX	O
a	O	DET	O
small	O	ADJ	O
impact	O	NOUN	B
on	O	ADP	O
outer	O	ADJ	B
hair	O	NOUN	I
cells	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
effects	O	NOUN	B
seem	O	VERB	O
to	O	PART	O
be	O	AUX	O
equally	O	ADV	O
true	O	ADJ	O
for	O	ADP	O
all	O	DET	O
exposed	O	VERB	B
newborns	O	NOUN	B
,	O	PUNCT	O
regardless	O	ADV	O
of	O	ADP	O
the	O	DET	O
degree	O	NOUN	B
of	O	ADP	O
exposure	O	NOUN	B
.	O	PUNCT	O


Further	O	ADJ	O
studies	O	NOUN	B
are	O	AUX	O
needed	O	VERB	O
in	O	ADP	O
order	O	NOUN	O
to	O	PART	O
establish	O	VERB	O
a	O	DET	O
potential	O	ADJ	O
negative	O	ADJ	B
effect	O	NOUN	B
of	O	ADP	O
maternal	O	ADJ	B
smoking	B-Chemical	NOUN	I


Neuroinflammation	B-Disease	NOUN	B
and	O	CCONJ	O
behavioral	B-Disease	ADJ	B
abnormalities	I-Disease	NOUN	I
after	O	ADP	O
neonatal	O	ADJ	B
terbutaline	B-Chemical	NOUN	B
treatment	O	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
:	O	PUNCT	O
implications	O	NOUN	O
for	O	ADP	O
autism	B-Disease	NOUN	B
.	O	PUNCT	O


Autism	B-Disease	NOUN	B
is	O	AUX	O
a	O	DET	O
neurodevelopmental	B-Disease	ADJ	B
disorder	I-Disease	NOUN	I
presenting	O	VERB	O
before	O	ADP	O
3	O	NUM	O
years	O	NOUN	B
of	O	ADP	O
age	O	NOUN	B
with	O	ADP	O
deficits	B-Disease	NOUN	B
in	I-Disease	ADP	O
communication	I-Disease	NOUN	B
and	I-Disease	CCONJ	O
social	I-Disease	ADJ	B
skills	I-Disease	NOUN	I
and	O	CCONJ	O
repetitive	B-Disease	ADJ	B
behaviors	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
to	O	PART	O
genetic	O	ADJ	B
influences	O	NOUN	B
,	O	PUNCT	O
recent	O	ADJ	O
studies	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
prenatal	O	ADJ	B
drug	O	NOUN	I
or	O	CCONJ	O
chemical	O	NOUN	B
exposures	O	NOUN	I
are	O	AUX	O
risk	O	NOUN	B
factors	O	NOUN	I
for	O	ADP	O
autism	B-Disease	NOUN	B
.	O	PUNCT	O


Terbutaline	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
beta2	O	NOUN	B
-	O	PUNCT	O
adrenoceptor	O	NOUN	B
agonist	O	NOUN	B
used	O	VERB	O
to	O	PART	O
arrest	O	VERB	B
preterm	B-Disease	NOUN	I
labor	I-Disease	NOUN	I
,	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
increased	O	VERB	B
concordance	O	NOUN	B
for	O	ADP	O
autism	B-Disease	NOUN	B
in	O	ADP	O
dizygotic	O	ADJ	B
twins	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
studied	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
terbutaline	B-Chemical	NOUN	B
on	O	ADP	O
microglial	O	ADJ	B
activation	O	NOUN	I
in	O	ADP	O
different	O	ADJ	O
brain	O	NOUN	B
regions	O	NOUN	I
and	O	CCONJ	O
behavioral	O	ADJ	B
outcomes	O	NOUN	B
in	O	ADP	O
developing	O	VERB	O
rats	O	NOUN	B
.	O	PUNCT	O


Newborn	O	ADJ	B
rats	O	NOUN	B
were	O	AUX	O
given	O	VERB	O
terbutaline	B-Chemical	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
daily	O	ADV	B
on	O	ADP	O
postnatal	O	ADJ	B
days	O	NOUN	B
(	O	PUNCT	O
PN	O	NOUN	B
)	O	PUNCT	O
2	O	NUM	O
to	O	PART	O
5	O	NUM	O
or	O	CCONJ	O
PN	O	NOUN	B
11	O	NUM	O
to	O	PART	O
14	O	NUM	O
and	O	CCONJ	O
examined	O	VERB	B
24	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
the	O	DET	O
last	O	ADJ	O
dose	O	NOUN	B
and	O	CCONJ	O
at	O	ADP	O
PN	O	NOUN	B
30	O	NUM	O
.	O	PUNCT	O


Immunohistochemical	O	ADJ	B
studies	O	NOUN	I
showed	O	VERB	O
that	O	SCONJ	O
administration	O	NOUN	B
of	O	ADP	O
terbutaline	B-Chemical	NOUN	B
on	O	ADP	O
PN	O	NOUN	B
2	O	NUM	O
to	O	PART	O
5	O	NUM	O
produced	O	VERB	O
a	O	DET	O
robust	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
microglial	O	ADJ	B
activation	O	NOUN	I
on	O	ADP	O
PN	O	NOUN	B
30	O	NUM	O
in	O	ADP	O
the	O	DET	O
cerebral	O	ADJ	B
cortex	O	NOUN	I
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
in	O	ADP	O
cerebellar	O	ADJ	B
and	O	CCONJ	O
cerebrocortical	O	ADJ	B
white	O	ADJ	O
matter	O	NOUN	O
.	O	PUNCT	O


of	O	ADP	O
these	O	DET	O
effects	O	NOUN	B
occurred	O	VERB	O
in	O	ADP	O
animals	O	NOUN	B
given	O	VERB	O
terbutaline	B-Chemical	NOUN	B
on	O	ADP	O
PN	O	NOUN	B
11	O	NUM	O
to	O	PART	O
14	O	NUM	O
.	O	PUNCT	O


In	O	ADP	O
behavioral	O	ADJ	B
tests	O	NOUN	I
,	O	PUNCT	O
animals	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
terbutaline	B-Chemical	NOUN	B
on	O	ADP	O
PN	O	NOUN	B
2	O	NUM	O
to	O	PART	O
5	O	NUM	O
showed	O	VERB	O
consistent	O	ADJ	O
patterns	O	NOUN	B
of	O	ADP	O
hyper	O	ADJ	B
-	O	PUNCT	O
reactivity	O	NOUN	B
to	O	ADP	O
novelty	O	NOUN	B
and	O	CCONJ	O
aversive	O	ADJ	B
stimuli	O	NOUN	I
when	O	SCONJ	O
assessed	O	VERB	B
in	O	ADP	O
a	O	DET	O
novel	O	ADJ	B
open	O	ADJ	B
field	O	NOUN	I
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
in	O	ADP	O
the	O	DET	O
acoustic	O	ADJ	B
startle	O	NOUN	B
response	O	NOUN	I
test	O	NOUN	I
.	O	PUNCT	O


Our	O	PRON	O
findings	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
beta2	O	NOUN	B
-	O	PUNCT	O
adrenoceptor	O	NOUN	B
overstimulation	O	NOUN	B
during	O	ADP	O
an	O	DET	O
early	O	ADV	B
critical	O	ADJ	O
period	O	NOUN	O
results	O	NOUN	O
in	O	ADP	O
microglial	O	ADJ	B
activation	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
innate	O	ADJ	B
neuroinflammatory	O	ADJ	I
pathways	O	NOUN	I
and	O	CCONJ	O
behavioral	B-Disease	ADJ	B
abnormalities	I-Disease	NOUN	I
,	O	PUNCT	O
similar	O	ADJ	O
to	O	PART	O
those	O	DET	O
described	O	VERB	O
in	O	ADP	O
autism	B-Disease	NOUN	B
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
provides	O	VERB	O
a	O	DET	O
useful	O	ADJ	O
animal	O	NOUN	B
model	O	NOUN	I
for	O	ADP	O
understanding	O	VERB	O
the	O	DET	O
neuropathological	O	ADJ	B
processes	O	NOUN	I
underlying	O	VERB	O
autism	B-Disease	NOUN	B
spectrum	I-Disease	NOUN	I
disorders	I-Disease	NOUN	I


Acute	O	ADJ	B
myocarditis	B-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
clozapine	B-Chemical	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	B
:	O	PUNCT	O
A	O	DET	O
case	O	NOUN	B
of	O	ADP	O
acute	O	ADJ	B
myocarditis	B-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
commencement	O	NOUN	B
of	O	ADP	O
clozapine	B-Chemical	NOUN	B
is	O	AUX	O
described	O	VERB	O
,	O	PUNCT	O
highlighting	O	VERB	O
the	O	DET	O
onset	O	NOUN	B
,	O	PUNCT	O
course	O	NOUN	B
and	O	CCONJ	O
possible	O	ADJ	O
contributing	O	VERB	O
factors	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
is	O	AUX	O
an	O	DET	O
urgent	O	ADJ	O
need	O	NOUN	O
to	O	PART	O
raise	O	VERB	O
awareness	O	NOUN	B
about	O	ADP	O
this	O	DET	O
potentially	O	ADV	O
fatal	O	ADJ	B
complication	O	NOUN	B
of	O	ADP	O
clozapine	B-Chemical	NOUN	B
use	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
A	O	DET	O
20	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
male	O	NOUN	B
with	O	ADP	O
schizophrenia	B-Disease	NOUN	B
developed	O	VERB	O
a	O	DET	O
sudden	O	ADJ	B
onset	O	NOUN	I
of	O	ADP	O
myocarditis	B-Disease	NOUN	B
after	O	ADP	O
commencement	O	NOUN	B
of	O	ADP	O
clozapine	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
recovered	O	VERB	O
with	O	ADP	O
intensive	O	ADJ	B
medical	O	ADJ	I
support	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
symptoms	O	NOUN	B
occurred	O	VERB	O
around	O	ADP	O
2	O	NUM	O
weeks	O	NOUN	B
after	O	ADP	O
starting	O	VERB	O
clozapine	B-Chemical	NOUN	B
in	O	ADP	O
an	O	DET	O
inpatient	O	ADJ	B
setting	O	NOUN	O
.	O	PUNCT	O


Possible	O	ADJ	O
contributing	O	VERB	O
factors	O	NOUN	B
may	O	AUX	O
have	O	AUX	O
been	O	AUX	O
concomitant	O	ADJ	B
antidepressant	B-Chemical	ADJ	B
use	O	NOUN	B
and	O	CCONJ	O
unaccustomed	O	ADJ	B
physical	O	ADJ	B
activity	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	B
:	O	PUNCT	O
Myocarditis	B-Disease	NOUN	B
is	O	AUX	O
an	O	DET	O
increasingly	O	ADV	O
recognized	O	VERB	O
complication	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
clozapine	B-Chemical	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
can	O	AUX	O
be	O	AUX	O
fatal	O	ADJ	B
if	O	SCONJ	O
not	O	PART	O
recognized	O	VERB	O
and	O	CCONJ	O
treated	O	VERB	B
early	O	ADV	B
.	O	PUNCT	O


Considering	O	VERB	O
that	O	SCONJ	O
clozapine	B-Chemical	NOUN	B
remains	O	VERB	O
the	O	DET	O
gold	O	NOUN	B
standard	O	NOUN	O
in	O	ADP	O
treatment	O	NOUN	B
of	O	ADP	O
resistant	O	ADJ	B
psychosis	B-Disease	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
is	O	AUX	O
an	O	DET	O
urgent	O	ADJ	O
need	O	NOUN	O
to	O	PART	O
raise	O	VERB	O
awareness	O	NOUN	B
among	O	ADP	O
medical	O	ADJ	B
and	O	CCONJ	O
paramedical	O	ADJ	B
staff	O	NOUN	I
involved	O	VERB	O
in	O	ADP	O
the	O	DET	O
care	O	NOUN	B
of	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
are	O	AUX	O
also	O	ADV	O
implications	O	NOUN	O
for	O	ADP	O
recommendations	O	NOUN	B
and	O	CCONJ	O
regulations	O	NOUN	B
regarding	O	VERB	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
clozapine	B-Chemical	NOUN	B


Encephalopathy	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
levetiracetam	B-Chemical	NOUN	B
added	O	VERB	O
to	O	PART	O
valproate	B-Chemical	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
We	O	PRON	O
report	O	VERB	O
on	O	ADP	O
the	O	DET	O
manifestation	O	NOUN	B
of	O	ADP	O
a	O	DET	O
levetiracetam	B-Chemical	NOUN	B
(	O	PUNCT	O
LEV	B-Chemical	NOUN	B
)-	O	ADJ	O
induced	O	VERB	B
encephalopathy	B-Disease	NOUN	B
.	O	PUNCT	O


FINDINGS	O	NOUN	B
:	O	PUNCT	O
A	O	DET	O
28	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
man	O	NOUN	B
suffering	O	VERB	B
from	O	ADP	O
idiopathic	B-Disease	ADJ	B
epilepsy	I-Disease	NOUN	I
with	O	ADP	O
generalized	O	ADJ	B
seizures	B-Disease	NOUN	I
was	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
LEV	B-Chemical	NOUN	B
(	O	PUNCT	O
3000	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
added	O	VERB	O
to	O	PART	O
valproate	B-Chemical	NOUN	B
(	O	PUNCT	O
VPA	B-Chemical	NOUN	B
)(	O	NOUN	O
2000	O	NUM	O
mg	O	NOUN	O
).	O	PUNCT	O
Frequency	O	NOUN	B
of	O	ADP	O
generalized	O	VERB	O
tonic-clonic	B-Disease	ADJ	O
seizures	I-Disease	NOUN	O
increased	O	VERB	B
from	O	ADP	O
one	O	NUM	O
per	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
to	O	ADP	O
two	O	NUM	O
per	O	ADP	O
month	O	NOUN	B
.	O	PUNCT	O


Neuropsychological	O	ADJ	B
testing	O	NOUN	I
showed	O	VERB	O
impaired	B-Disease	ADJ	B
word	I-Disease	NOUN	O
fluency,	I-Disease	NOUN	O
psychomotor	I-Disease	NOUN	O
speed	I-Disease	NOUN	B
and	I-Disease	CCONJ	O
working	I-Disease	VERB	B
memory	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
interictal	O	ADJ	B
electroencephalogram	O	NOUN	I
(	O	PUNCT	O
EEG	O	NOUN	B
)	O	PUNCT	O
showed	O	VERB	O
a	O	DET	O
generalized	O	VERB	B
slowing	O	NOUN	I
to	O	ADP	O
5	O	NUM	O
per	O	ADP	O
second	O	ADJ	O
theta	O	NOUN	B
rhythms	O	NOUN	I
with	O	ADP	O
bilateral	O	ADJ	B
generalized	O	VERB	O
high	O	ADJ	B
-	O	PUNCT	O
amplitude	O	NOUN	B
discharges	O	NOUN	O
.	O	PUNCT	O


OUTCOME	O	NOUN	B
:	O	PUNCT	O
Following	O	VERB	O
discontinuation	O	NOUN	B
of	O	ADP	O
LEV	B-Chemical	NOUN	B
,	O	PUNCT	O
EEG	O	PROPN	B
and	O	CCONJ	O
neuropsychological	O	ADJ	B
findings	O	NOUN	I
improved	O	VERB	B
and	O	CCONJ	O
seizure	B-Disease	VERB	B


Norepinephrine	B-Chemical	NOUN	B
signaling	O	NOUN	I
through	O	ADP	O
beta	O	NOUN	B
-	O	PUNCT	O
adrenergic	O	ADJ	B
receptors	O	NOUN	I
is	O	AUX	O
critical	O	ADJ	O
for	O	ADP	O
expression	O	NOUN	B
of	O	ADP	O
cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
anxiety	B-Disease	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Cocaine	B-Chemical	NOUN	B
is	O	AUX	O
a	O	DET	O
widely	O	ADV	O
abused	O	VERB	O
psychostimulant	O	NOUN	B
that	O	PRON	O
has	O	AUX	O
both	O	DET	O
rewarding	O	ADJ	O
and	O	CCONJ	O
aversive	O	ADJ	B
properties	O	NOUN	I
.	O	PUNCT	O


While	O	SCONJ	O
the	O	DET	O
mechanisms	O	NOUN	B
underlying	O	VERB	O
cocaine	B-Chemical	NOUN	B
'	O	PART	O
s	O	NOUN	O
rewarding	O	ADJ	B
effects	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
studied	O	VERB	O
extensively	O	ADV	B
,	O	PUNCT	O
less	O	ADJ	O
attention	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
paid	O	VERB	O
to	O	ADP	O
the	O	DET	O
unpleasant	O	ADJ	B
behavioral	O	ADJ	B
states	O	NOUN	B
induced	O	VERB	B
by	O	ADP	O
cocaine	B-Chemical	NOUN	B
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
anxiety	B-Disease	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
evaluated	O	VERB	B
the	O	DET	O
performance	O	NOUN	B
of	O	ADP	O
dopamine	B-Chemical	NOUN	B
beta	O	NOUN	I
-	O	PUNCT	O
hydroxylase	O	NOUN	B
knockout	O	NOUN	B
(	O	PUNCT	O
Dbh	O	NOUN	B
-/-)	O	NOUN	O
mice	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
lack	O	VERB	O
norepinephrine	B-Chemical	NOUN	B
(	O	PUNCT	O
NE	B-Chemical	NOUN	B
),	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
elevated	O	ADJ	B
plus	O	CCONJ	I
maze	O	NOUN	I
(	O	PUNCT	O
EPM	O	PROPN	B
)	O	PUNCT	O
to	O	PART	O
examine	O	VERB	O
the	O	DET	O
contribution	O	NOUN	B
of	O	ADP	O
noradrenergic	O	ADJ	B
signaling	O	NOUN	B
to	O	PART	O
cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
anxiety	B-Disease	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
We	O	PRON	O
found	O	VERB	O
that	O	SCONJ	O
cocaine	B-Chemical	NOUN	B
dose	O	NOUN	I
-	O	PUNCT	O
dependently	O	ADV	B
increased	O	VERB	B
anxiety	B-Disease	NOUN	B
-	O	PUNCT	O
like	O	ADJ	B
behavior	O	NOUN	B
in	O	ADP	O
control	O	NOUN	B
(	O	PUNCT	O
Dbh	O	NOUN	B
+/-)	O	ADJ	O
mice	O	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
measured	O	VERB	B
by	O	ADP	O
a	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
open	O	ADJ	B
arm	O	NOUN	I
exploration	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
Dbh	O	NOUN	B
-/-	O	ADJ	O
mice	O	NOUN	B
had	O	AUX	O
normal	O	ADJ	O
baseline	O	NOUN	B
performance	O	NOUN	B
in	O	ADP	O
the	O	DET	O
EPM	O	PROPN	B
but	O	CCONJ	O
were	O	AUX	O
completely	O	ADV	O
resistant	O	ADJ	B
to	O	PART	O
the	O	DET	O
anxiogenic	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
cocaine	B-Chemical	NOUN	B
.	O	PUNCT	O


Cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
anxiety	B-Disease	NOUN	B
was	O	AUX	O
also	O	ADV	O
attenuated	O	VERB	B
in	O	ADP	O
Dbh	O	PROPN	B
+/-	O	CCONJ	O
mice	O	NOUN	B
following	O	VERB	O
administration	O	NOUN	B
of	O	ADP	O
disulfiram	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
dopamine	B-Chemical	NOUN	B
beta	O	NOUN	I
-	O	PUNCT	O
hydroxylase	O	NOUN	B
(	O	PUNCT	O
DBH	O	NOUN	B
)	O	PUNCT	O
inhibitor	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
experiments	O	NOUN	B
using	O	VERB	O
specific	O	ADJ	O
adrenergic	O	ADJ	B
antagonists	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
found	O	VERB	O
that	O	SCONJ	O
pretreatment	O	NOUN	B
with	O	ADP	O
the	O	DET	O
beta	O	NOUN	B
-	O	PUNCT	O
adrenergic	O	ADJ	B
receptor	O	NOUN	I
antagonist	O	NOUN	B
propranolol	B-Chemical	NOUN	B
blocked	O	VERB	B
cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
anxiety	B-Disease	NOUN	B
-	O	PUNCT	O
like	O	ADJ	B
behavior	O	NOUN	B
in	O	ADP	O
Dbh	O	PROPN	B
+/-	O	CCONJ	O
and	O	CCONJ	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
C57BL6	O	PROPN	B
/	O	SYM	O
J	O	NOUN	B
mice	O	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
the	O	DET	O
alpha	O	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
antagonist	O	NOUN	B
prazosin	B-Chemical	NOUN	B
and	O	CCONJ	O
the	O	DET	O
alpha	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
antagonist	O	NOUN	B
yohimbine	B-Chemical	NOUN	B
had	O	AUX	O
no	O	DET	B
effect	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
These	O	DET	O
results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
noradrenergic	O	ADJ	B
signaling	O	NOUN	B
via	O	ADP	O
beta	O	NOUN	B
-	O	PUNCT	O
adrenergic	O	ADJ	B
receptors	O	NOUN	I
is	O	AUX	O
required	O	VERB	O
for	O	ADP	O
cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
anxiety	B-Disease	NOUN	B


Clonidine	B-Chemical	NOUN	B
for	O	ADP	O
attention-deficit/hyperactivity	B-Disease	NOUN	B
disorder	I-Disease	NOUN	I
:	O	PUNCT	O
II	O	NUM	B
.	O	PUNCT	O


ECG	O	NOUN	B
changes	O	NOUN	B
and	O	CCONJ	O
adverse	O	ADJ	B
events	O	NOUN	I
analysis	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	B
:	O	PUNCT	O
To	O	PART	O
examine	O	VERB	O
the	O	DET	O
safety	O	NOUN	B
and	O	CCONJ	O
tolerability	O	NOUN	B
of	O	ADP	O
clonidine	B-Chemical	NOUN	B
used	O	VERB	O
alone	O	ADV	O
or	O	CCONJ	O
with	O	ADP	O
methylphenidate	B-Chemical	NOUN	B
in	O	ADP	O
children	O	NOUN	B
with	O	ADP	O
attention-deficit/hyperactivity	B-Disease	NOUN	B
disorder	I-Disease	NOUN	I
(	O	PUNCT	O
ADHD	B-Disease	NOUN	B
).	O	PUNCT	O
METHOD	O	NOUN	O
:	O	PUNCT	O
In	O	ADP	O
a	O	DET	O
16	O	NUM	O
-	O	PUNCT	O
week	O	NOUN	B
multicenter	O	NOUN	B
,	O	PUNCT	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	NOUN	B
trial	O	NOUN	B
,	O	PUNCT	O
122	O	NUM	O
children	O	NOUN	B
with	O	ADP	O
ADHD	B-Disease	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
clonidine	B-Chemical	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
31	O	NUM	O
),	O	PUNCT	O
methylphenidate	B-Chemical	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
29	O	NUM	O
),	O	PUNCT	O
clonidine	B-Chemical	NOUN	B
and	O	CCONJ	O
methylphenidate	B-Chemical	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
32	O	NUM	O
),	O	PUNCT	O
or	O	CCONJ	O
placebo	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
30	O	NUM	O
).	O	PUNCT	O
Doses	O	NOUN	B
were	O	AUX	O
flexibly	O	ADV	O
titrated	O	VERB	B
up	O	ADP	O
to	O	PART	O
0	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
day	O	NOUN	B
for	O	ADP	O
clonidine	B-Chemical	NOUN	B
and	O	CCONJ	O
60	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
day	O	NOUN	B
for	O	ADP	O
methylphenidate	B-Chemical	NOUN	B
(	O	PUNCT	O
both	O	CCONJ	O
with	O	ADP	O
divided	O	ADJ	O
dosing	O	VERB	B
).	O	PUNCT	B
Groups	O	NOUN	B
were	O	AUX	O
compared	O	VERB	O
regarding	O	VERB	O
adverse	O	ADJ	B
events	O	NOUN	I
and	O	CCONJ	O
changes	O	NOUN	B
from	O	ADP	O
baseline	O	NOUN	B
to	O	PART	O
week	O	NOUN	B
16	O	NUM	O
in	O	ADP	O
electrocardiograms	O	NOUN	B
and	O	CCONJ	O
vital	O	ADJ	O
signs	O	NOUN	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
There	O	PRON	O
were	O	AUX	O
more	O	ADJ	O
incidents	O	NOUN	B
of	O	ADP	O
bradycardia	B-Disease	NOUN	B
in	O	ADP	O
subjects	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
clonidine	B-Chemical	NOUN	B
compared	O	VERB	B
with	O	ADP	O
those	O	DET	O
not	O	PART	O
treated	O	VERB	B
with	O	ADP	I
clonidine	B-Chemical	NOUN	B
(	O	PUNCT	O
17	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
%	O	NOUN	O
versus	O	CCONJ	O
3	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
%;	O	NOUN	O
p	O	NOUN	O
=.	O	NOUN	O
02	O	NUM	O
),	O	PUNCT	O
but	O	CCONJ	O
no	O	DET	O
other	O	ADJ	O
significant	O	ADJ	B
group	O	NOUN	B
differences	O	NOUN	O
regarding	O	VERB	O
electrocardiogram	O	NOUN	B
and	O	CCONJ	O
other	O	ADJ	O
cardiovascular	O	ADJ	B
outcomes	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
suggestions	O	NOUN	O
of	O	ADP	O
interactions	O	NOUN	B
between	O	ADP	O
clonidine	B-Chemical	NOUN	B
and	O	CCONJ	O
methylphenidate	B-Chemical	NOUN	B
regarding	O	VERB	O
cardiovascular	O	ADJ	B
outcomes	O	NOUN	B
.	O	PUNCT	O


Moderate	O	ADJ	B
or	O	CCONJ	O
severe	O	ADJ	B
adverse	O	ADJ	B
events	O	NOUN	I
were	O	AUX	O
more	O	ADV	O
common	O	ADJ	O
in	O	ADP	O
subjects	O	NOUN	B
on	O	ADP	O
clonidine	B-Chemical	NOUN	B
(	O	PUNCT	O
79	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
%	O	NOUN	O
versus	O	CCONJ	O
49	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
%;	O	NOUN	O
p	O	NOUN	O
=.	O	NOUN	O
0006	O	NUM	O
)	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
associated	O	VERB	B
with	O	ADP	I
higher	O	ADJ	O
rates	O	NOUN	B
of	O	ADP	O
early	O	ADJ	B
study	O	NOUN	I
withdrawal	O	NOUN	B
.	O	PUNCT	O


Drowsiness	B-Disease	PROPN	B
was	O	AUX	O
common	O	ADJ	O
on	O	ADP	O
clonidine	B-Chemical	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
generally	O	ADV	O
resolved	O	VERB	B
by	O	ADP	O
6	O	NUM	O
to	O	PART	O
8	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
Clonidine	B-Chemical	NOUN	B
,	O	PUNCT	O
used	O	VERB	O
alone	O	ADV	O
or	O	CCONJ	O
with	O	ADP	O
methylphenidate	B-Chemical	NOUN	B
,	O	PUNCT	O
appears	O	VERB	O
safe	O	ADJ	O
and	O	CCONJ	O
well	O	ADV	O
tolerated	O	VERB	B
in	O	ADP	O
childhood	O	NOUN	B
ADHD	B-Disease	NOUN	B
.	O	PUNCT	O


Physicians	O	NOUN	B
prescribing	O	VERB	B
clonidine	B-Chemical	NOUN	B
should	O	AUX	O
monitor	O	VERB	B
for	O	ADP	O
bradycardia	B-Disease	NOUN	B
and	O	CCONJ	O
advise	O	VERB	O
patients	O	NOUN	B
about	O	ADP	O
the	O	DET	O
high	O	ADJ	O
likelihood	O	NOUN	B
of	O	ADP	O
initial	O	ADJ	B
drowsiness	B-Disease	NOUN	B


Thalidomide	B-Chemical	NOUN	B
has	O	AUX	O
limited	O	VERB	O
single	O	ADJ	B
-	O	PUNCT	O
agent	O	NOUN	B
activity	O	NOUN	B
in	O	ADP	O
relapsed	O	ADJ	B
or	O	CCONJ	O
refractory	O	ADJ	B
indolent	O	ADJ	I
non-Hodgkin	B-Disease	ADJ	I
lymphomas	I-Disease	NOUN	I
:	O	PUNCT	O
a	O	DET	O
phase	O	NOUN	B
II	O	NUM	I
trial	O	NOUN	I
of	O	ADP	O
the	O	DET	O
Cancer	B-Disease	PROPN	B
and	O	CCONJ	O
Leukemia	B-Disease	PROPN	B
Group	O	PROPN	B
B	O	NOUN	O
.	O	PUNCT	O


Thalidomide	B-Chemical	NOUN	B
is	O	AUX	O
an	O	DET	O
immunomodulatory	O	ADJ	B
agent	O	NOUN	I
with	O	ADP	O
demonstrated	O	VERB	O
activity	O	NOUN	B
in	O	ADP	O
multiple	B-Disease	ADJ	B
myeloma	I-Disease	NOUN	I
,	O	PUNCT	O
mantle	B-Disease	NOUN	B
cell	I-Disease	NOUN	I
lymphoma	I-Disease	NOUN	I
and	O	CCONJ	O
lymphoplasmacytic	B-Disease	ADJ	B
lymphoma	I-Disease	NOUN	I
.	O	PUNCT	O


Its	O	PRON	O
activity	O	NOUN	B
is	O	AUX	O
believed	O	VERB	O
to	O	PART	O
be	O	AUX	O
due	O	ADJ	O
modulation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
tumour	B-Disease	NOUN	B
milieu	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
downregulation	O	NOUN	B
of	O	ADP	O
angiogenesis	O	NOUN	B
and	O	CCONJ	O
inflammatory	O	ADJ	B
cytokines	O	NOUN	I
.	O	PUNCT	O


Between	O	ADP	O
July	O	PROPN	O
2001	O	NUM	O
and	O	CCONJ	O
April	O	PROPN	O
2004	O	NUM	O
,	O	PUNCT	O
24	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
relapsed	O	ADJ	B
/	O	PUNCT	O
refractory	O	ADJ	B
indolent	O	ADJ	B
lymphomas	B-Disease	NOUN	I
received	O	VERB	O
thalidomide	B-Chemical	NOUN	B
200	O	NUM	O
mg	O	NOUN	O
daily	O	ADV	B
with	O	ADP	O
escalation	O	NOUN	B
by	O	ADP	O
100	O	NUM	O
mg	O	NOUN	O
daily	O	ADV	B
every	O	DET	O
1	O	NUM	O
-	O	SYM	O
2	O	NUM	O
weeks	O	NOUN	B
as	O	ADP	O
tolerated	O	VERB	B
,	O	PUNCT	O
up	O	ADV	O
to	O	ADP	O
a	O	DET	O
maximum	O	NOUN	B
of	O	ADP	O
800	O	NUM	O
mg	O	NOUN	O
daily	O	ADV	B
.	O	PUNCT	O


Patients	O	NOUN	B
had	O	AUX	O
received	O	VERB	O
a	O	DET	O
median	O	NOUN	B
of	O	ADP	O
2	O	NUM	O
(	O	PUNCT	O
range	O	NOUN	B
,	O	PUNCT	O
1	O	NUM	O
-	O	SYM	O
4	O	NUM	O
)	O	PUNCT	O
prior	O	ADJ	O
regimens	O	NOUN	B
.	O	PUNCT	O


Of	O	ADP	O
24	O	NUM	O
evaluable	O	ADJ	O
patients	O	NOUN	B
,	O	PUNCT	O
two	O	NUM	O
achieved	O	VERB	O
a	O	DET	O
complete	O	ADJ	O
remission	O	NOUN	B
and	O	CCONJ	O
one	O	NUM	O
achieved	O	VERB	O
a	O	DET	O
partial	O	ADJ	B
remission	O	NOUN	B
for	O	ADP	O
an	O	DET	O
overall	O	ADJ	B
response	O	NOUN	B
rate	O	NOUN	I
of	O	ADP	O
12	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
%(	O	NOUN	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
:	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
-	O	SYM	O
32	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
%).	O	NOUN	O
Eleven	O	NUM	O
patients	O	NOUN	B
progressed	O	VERB	O
during	O	ADP	O
therapy	O	NOUN	B
.	O	PUNCT	O


Grade	O	NOUN	B
3	O	NUM	I
-	O	SYM	O
4	O	NUM	O
adverse	O	ADJ	B
effects	O	NOUN	I
included	O	VERB	O
myelosuppression	B-Disease	NOUN	B
,	O	PUNCT	O
fatigue	B-Disease	NOUN	B
,	O	PUNCT	O
somnolence	B-Disease	NOUN	B
/	O	SYM	O
depressed	B-Disease	ADJ	B
mood	I-Disease	NOUN	I
,	O	PUNCT	O
neuropathy	B-Disease	NOUN	B
and	O	CCONJ	O
dyspnea	B-Disease	NOUN	B
.	O	PUNCT	O


Of	O	ADP	O
concern	O	NOUN	O
was	O	AUX	O
the	O	DET	O
occurrence	O	NOUN	B
of	O	ADP	O
four	O	NUM	O
thromboembolic	B-Disease	ADJ	B
events	O	NOUN	O
.	O	PUNCT	O


Our	O	PRON	O
results	O	NOUN	O
failed	O	VERB	B
to	O	PART	O
demonstrate	O	VERB	O
an	O	DET	O
important	O	ADJ	O
response	O	NOUN	B
rate	O	NOUN	I
to	O	ADP	O
single	O	ADJ	O
agent	O	NOUN	O
thalidomide	B-Chemical	NOUN	B
in	O	ADP	O
indolent	O	ADJ	B
lymphomas	B-Disease	NOUN	I
and	O	CCONJ	O
contrast	O	NOUN	O
with	O	ADP	O
the	O	DET	O
higher	O	ADJ	O
activity	O	NOUN	B
level	O	NOUN	B
reported	O	VERB	O
with	O	ADP	O
the	O	DET	O
second	O	ADJ	O
generation	O	NOUN	O
immunomodulatory	O	ADJ	B
agent	O	NOUN	I
,	O	PUNCT	O
lenalidomide	B-Chemical	NOUN	B


Intracavernous	O	ADJ	B
epinephrine	B-Chemical	NOUN	I
:	O	PUNCT	O
a	O	DET	O
minimally	O	ADV	B
invasive	O	ADJ	I
treatment	O	NOUN	B
for	O	ADP	O
priapism	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
emergency	O	NOUN	B
department	O	NOUN	I
.	O	PUNCT	O


Priapism	B-Disease	NOUN	B
is	O	AUX	O
the	O	DET	O
prolonged	O	ADJ	B
erection	O	NOUN	B
of	O	ADP	O
the	O	DET	O
penis	O	NOUN	B
in	O	ADP	O
the	O	DET	O
absence	O	NOUN	B
of	O	ADP	O
sexual	O	ADJ	B
arousal	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
45	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
man	O	NOUN	B
,	O	PUNCT	O
an	O	DET	O
admitted	O	VERB	B
frequent	O	ADJ	B
cocaine	B-Chemical	NOUN	B
user	O	NOUN	O
,	O	PUNCT	O
presented	O	VERB	O
to	O	ADP	O
the	O	DET	O
Emergency	O	PROPN	B
Department	O	PROPN	I
(	O	PUNCT	O
ED	O	PROPN	B
)	O	PUNCT	O
on	O	ADP	O
two	O	NUM	O
separate	O	ADJ	O
occasions	O	NOUN	B
with	O	ADP	O
a	O	DET	O
history	O	NOUN	B
of	O	ADP	O
priapism	B-Disease	NOUN	B
after	O	ADP	O
cocaine	B-Chemical	NOUN	B
use	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
management	O	NOUN	B
options	O	NOUN	I
in	O	ADP	O
the	O	DET	O
ED	O	PROPN	B
,	O	PUNCT	O
as	O	ADP	O
exemplified	O	VERB	O
by	O	ADP	O
four	O	NUM	O
individual	O	ADJ	B
case	O	NOUN	B
reports	O	VERB	I
,	O	PUNCT	O
in	O	ADP	O
particular	O	ADJ	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
a	O	DET	O
minimally	O	ADV	B
invasive	O	ADJ	I
method	O	NOUN	I
of	O	ADP	O
intracorporal	O	ADJ	B
epinephrine	B-Chemical	NOUN	I


Effect	O	NOUN	B
of	O	ADP	O
green	B-Chemical	ADJ	B
tea	I-Chemical	NOUN	I
and	O	CCONJ	O
vitamin	B-Chemical	NOUN	B
E	I-Chemical	NOUN	I
combination	O	NOUN	B
in	O	ADP	O
isoproterenol	B-Chemical	NOUN	B
induced	O	VERB	B
myocardial	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
was	O	AUX	O
aimed	O	VERB	O
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
combined	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
green	B-Chemical	ADJ	B
tea	I-Chemical	NOUN	I
and	O	CCONJ	O
vitamin	B-Chemical	NOUN	B
E	I-Chemical	PROPN	I
on	O	ADP	O
heart	O	NOUN	B
weight	O	NOUN	I
,	O	PUNCT	O
body	O	NOUN	B
weight	O	NOUN	I
,	O	PUNCT	O
serum	O	NOUN	B
marker	O	NOUN	I
enzymes	O	NOUN	I
,	O	PUNCT	O
lipid	O	NOUN	B
peroxidation	O	NOUN	I
,	O	PUNCT	O
endogenous	O	ADJ	B
antioxidants	O	NOUN	B
and	O	CCONJ	O
membrane	O	NOUN	B
bound	O	ADJ	O
ATPases	O	NOUN	B
in	O	ADP	O
isoproterenol	B-Chemical	NOUN	B
(	O	PUNCT	O
ISO	B-Chemical	NOUN	B
)-	O	ADJ	O
induced	O	VERB	B
myocardial	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


Adult	O	ADJ	B
male	O	NOUN	B
albino	O	NOUN	B
rats	O	NOUN	I
,	O	PUNCT	O
treated	O	VERB	B
with	O	ADP	I
ISO	B-Chemical	NOUN	B
(	O	PUNCT	O
200	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
s	O	NOUN	O
.	O	PUNCT	O


c	O	X	O
.)	O	NOUN	O
for	O	ADP	O
2	O	NUM	O
days	O	NOUN	B
at	O	ADP	O
an	O	DET	O
interval	O	NOUN	B
of	O	ADP	O
24	O	NUM	O
h	O	NOUN	O
caused	O	VERB	O
a	O	DET	O
significant	O	ADJ	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
)	O	PUNCT	O
elevation	O	NOUN	B
of	O	ADP	O
heart	O	NOUN	B
weight	O	NOUN	I
,	O	PUNCT	O
serum	O	NOUN	B
marker	O	NOUN	I
enzymes	O	NOUN	I
,	O	PUNCT	O
lipid	O	NOUN	B
peroxidation	O	NOUN	I
and	O	CCONJ	O
Ca	B-Chemical	VERB	B
+	O	CCONJ	O
2	O	NUM	O
ATPase	O	NOUN	B
level	O	NOUN	B
whereas	O	SCONJ	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
significant	O	ADJ	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
)	O	PUNCT	O
decrease	O	NOUN	B
in	O	ADP	O
body	O	NOUN	B
weight	O	NOUN	I
,	O	PUNCT	O
endogenous	O	ADJ	B
antioxidants	O	NOUN	B
,	O	PUNCT	O
Na	B-Chemical	NOUN	B
+/	O	VERB	O
K	B-Chemical	NOUN	B
+	O	CCONJ	O
ATPase	O	NOUN	B
and	O	CCONJ	O
Mg	B-Chemical	NOUN	O
+	O	CCONJ	O
2	O	NUM	O
ATPase	O	NOUN	B
levels	O	NOUN	B
.	O	PUNCT	O


Administration	O	NOUN	B
of	O	ADP	O
green	B-Chemical	ADJ	B
tea	I-Chemical	NOUN	I
(	O	PUNCT	O
100	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
/	O	PUNCT	O
day	O	NOUN	B
,	O	PUNCT	O
p	O	NOUN	O
.	O	PUNCT	O


o	O	X	O
.)	O	NOUN	B
and	O	CCONJ	O
vitamin	B-Chemical	NOUN	B
E	I-Chemical	NOUN	I
(	O	PUNCT	O
100	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
/	O	PUNCT	O
day	O	NOUN	B
,	O	PUNCT	O
p	O	NOUN	O
.	O	PUNCT	O


o	O	INTJ	O
.)	O	ADV	O
together	O	ADV	O
for	O	ADP	O
30	O	NUM	O
consecutive	O	ADJ	B
days	O	NOUN	B
and	O	CCONJ	O
challenged	O	VERB	O
with	O	ADP	O
ISO	B-Chemical	NOUN	B
on	O	ADP	O
the	O	DET	O
day	O	NOUN	B
29th	O	NOUN	O
and	O	CCONJ	O
30th	O	NOUN	O
,	O	PUNCT	O
showed	O	VERB	O
a	O	DET	O
significant	O	ADJ	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
)	O	PUNCT	O
decrease	O	NOUN	B
in	O	ADP	O
heart	O	NOUN	B
weight	O	NOUN	I
,	O	PUNCT	O
serum	O	NOUN	B
marker	O	NOUN	I
enzymes	O	NOUN	I
,	O	PUNCT	O
lipid	O	NOUN	B
peroxidation	O	NOUN	I
,	O	PUNCT	O
Ca	B-Chemical	VERB	B
+	O	CCONJ	O
2	O	NUM	O
ATPase	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
significant	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
the	O	DET	O
body	O	NOUN	B
weight	O	NOUN	I
,	O	PUNCT	O
endogenous	O	ADJ	B
antioxidants	O	NOUN	B
,	O	PUNCT	O
Na	B-Chemical	NOUN	B
+/	O	VERB	O
K	B-Chemical	NOUN	B
+	O	CCONJ	O
ATPase	O	NOUN	B
and	O	CCONJ	O
Mg	B-Chemical	NOUN	O
+	O	CCONJ	O
2	O	NUM	O
ATPase	O	NOUN	B
when	O	SCONJ	O
compared	O	VERB	B
with	O	ADP	O
ISO	B-Chemical	NOUN	B
treated	O	ADJ	B
group	O	NOUN	B
and	O	CCONJ	O
green	B-Chemical	ADJ	B
tea	I-Chemical	NOUN	I
or	O	CCONJ	O
vitamin	B-Chemical	NOUN	B
E	I-Chemical	NOUN	I
alone	O	ADV	O
treated	O	VERB	B
groups	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
indicate	O	VERB	O
the	O	DET	O
synergistic	O	ADJ	B
protective	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
green	B-Chemical	ADJ	B
tea	I-Chemical	NOUN	I
and	O	CCONJ	O
vitamin	B-Chemical	NOUN	B
E	I-Chemical	NOUN	I
during	O	ADP	O
ISO	B-Chemical	NOUN	B
induced	O	VERB	B
myocardial	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I


Development	O	NOUN	B
of	O	ADP	O
ocular	B-Disease	ADJ	B
myasthenia	I-Disease	NOUN	I
during	O	ADP	O
pegylated	B-Chemical	ADJ	B
interferon	I-Chemical	NOUN	B
and	O	CCONJ	O
ribavirin	B-Chemical	NOUN	B
treatment	O	NOUN	B
for	O	ADP	O
chronic	B-Disease	ADJ	B
hepatitis	I-Disease	NOUN	I
C	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
63	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
male	O	NOUN	B
experienced	O	VERB	O
sudden	O	ADJ	B
diplopia	B-Disease	NOUN	I
after	O	ADP	O
9	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
administration	O	NOUN	B
of	O	ADP	O
pegylated	B-Chemical	ADJ	B
interferon	I-Chemical	NOUN	I
(IFN)	I-Chemical	ADJ	O
alpha-2b	I-Chemical	NOUN	B
and	O	CCONJ	O
ribavirin	B-Chemical	NOUN	B
for	O	ADP	O
chronic	B-Disease	ADJ	B
hepatitis	I-Disease	NOUN	I
C	I-Disease	NOUN	I
(	O	PUNCT	O
CHC	B-Disease	PROPN	B
).	O	PROPN	O
Ophthalmologic	O	ADJ	B
examinations	O	NOUN	B
showed	O	VERB	O
ptosis	B-Disease	NOUN	B
on	I-Disease	ADP	O
the	I-Disease	DET	O
right	I-Disease	ADJ	B
upper	I-Disease	ADJ	I
lid	I-Disease	NOUN	I
and	O	CCONJ	O
restricted	B-Disease	ADJ	B
right	I-Disease	ADJ	B
eye	I-Disease	NOUN	I
movement	I-Disease	NOUN	I
without	O	ADP	O
any	O	DET	O
other	O	ADJ	O
neurological	O	ADJ	B
signs	O	NOUN	O
.	O	PUNCT	O


A	O	DET	O
brain	O	NOUN	B
imaging	O	NOUN	I
study	O	NOUN	O
and	O	CCONJ	O
repetitive	O	ADJ	B
nerve	O	NOUN	I
stimulation	O	NOUN	I
test	O	NOUN	I
indicated	O	VERB	O
no	O	DET	O
abnormality	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
acetylcholine	B-Chemical	NOUN	B
receptor	O	NOUN	I
antibody	O	NOUN	I
titer	O	NOUN	B
and	O	CCONJ	O
response	O	NOUN	B
to	O	PART	O
acetylcholinesterase	O	NOUN	B
inhibitors	O	NOUN	I
were	O	AUX	O
negative	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
results	O	NOUN	B
of	O	ADP	O
thyroid	O	NOUN	B
function	O	NOUN	I
tests	O	NOUN	I
were	O	AUX	O
normal	O	ADJ	O
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
'	O	PART	O
s	O	NOUN	O
ophthalmological	O	ADJ	B
symptoms	O	NOUN	I
improved	O	VERB	B
rapidly	O	ADV	O
3	O	NUM	O
weeks	O	NOUN	B
after	O	ADP	O
discontinuation	O	NOUN	B
of	O	ADP	O
pegylated	B-Chemical	ADJ	B
IFN	I-Chemical	NOUN	I
alpha-2b	I-Chemical	NOUN	I
and	O	CCONJ	O
ribavirin	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
ocular	B-Disease	ADJ	B
myasthenia	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
combination	O	NOUN	B
therapy	O	NOUN	I
of	O	ADP	O
pegylated	B-Chemical	ADJ	B
IFN	I-Chemical	NOUN	I
alpha-2b	I-Chemical	NOUN	I
and	O	CCONJ	O
ribavirin	B-Chemical	NOUN	B
for	O	ADP	O
CHC	B-Disease	NOUN	B
is	O	AUX	O
very	O	ADV	O
rarely	O	ADV	O
reported	O	VERB	O
;	O	PUNCT	O
therefore	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
present	O	VERB	O
this	O	DET	O
case	O	NOUN	B
with	O	ADP	O
a	O	DET	O
review	O	NOUN	B
of	O	ADP	O
the	O	DET	O
various	O	ADJ	O
eye	O	NOUN	B
complications	O	NOUN	O
of	O	ADP	O
IFN	B-Chemical	NOUN	B


The	O	DET	O
glycine	B-Chemical	NOUN	B
transporter	O	NOUN	I
-	O	PUNCT	O
1	O	NUM	B
inhibitor	O	NOUN	B
SSR103800	B-Chemical	NOUN	B
displays	O	VERB	O
a	O	DET	O
selective	O	ADJ	O
and	O	CCONJ	O
specific	O	ADJ	O
antipsychotic	O	ADJ	B
-	O	PUNCT	O
like	O	ADJ	B
profile	O	NOUN	B
in	O	ADP	O
normal	O	ADJ	B
and	O	CCONJ	O
transgenic	O	ADJ	B
mice	O	NOUN	I
.	O	PUNCT	O


Schizophrenia	B-Disease	NOUN	B
has	O	AUX	O
been	O	AUX	O
initially	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
dysfunction	O	NOUN	B
in	O	ADP	O
dopamine	B-Chemical	NOUN	B
neurotransmission	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
observation	O	NOUN	B
that	O	SCONJ	O
antagonists	O	NOUN	B
of	O	ADP	O
the	O	DET	O
glutamate	B-Chemical	NOUN	B
N-methyl-D-aspartate	B-Chemical	NOUN	I
(	O	PUNCT	O
NMDA	B-Chemical	NOUN	B
)	O	PUNCT	O
receptor	O	NOUN	B
produce	O	VERB	O
schizophrenic	B-Disease	ADJ	B
-	O	PUNCT	O
like	O	ADJ	B
symptoms	O	NOUN	B
in	O	ADP	O
humans	O	NOUN	B
has	O	AUX	O
led	O	VERB	O
to	O	ADP	O
the	O	DET	O
idea	O	NOUN	O
of	O	ADP	O
a	O	DET	O
dysfunctioning	O	NOUN	B
of	O	ADP	O
the	O	DET	O
glutamatergic	O	ADJ	B
system	O	NOUN	I
via	O	ADP	O
its	O	PRON	O
NMDA	B-Chemical	NOUN	B
receptor	O	NOUN	I
.	O	PUNCT	O


As	O	ADP	O
a	O	DET	O
result	O	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
is	O	AUX	O
a	O	DET	O
growing	O	VERB	O
interest	O	NOUN	O
in	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
pharmacological	O	ADJ	B
agents	O	NOUN	I
with	O	ADP	O
potential	O	ADJ	O
antipsychotic	O	ADJ	B
properties	O	NOUN	B
that	O	PRON	O
enhance	O	VERB	B
the	O	DET	O
activity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
glutamatergic	O	ADJ	B
system	O	NOUN	I
via	O	ADP	O
a	O	DET	O
modulation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
NMDA	B-Chemical	NOUN	B
receptor	O	NOUN	I
.	O	PUNCT	O


Among	O	ADP	O
them	O	PRON	O
are	O	AUX	O
glycine	B-Chemical	NOUN	B
transporter	O	NOUN	I
-	O	PUNCT	O
1	O	NUM	O
(	O	PUNCT	O
GlyT1	O	NOUN	B
)	O	PUNCT	O
inhibitors	O	NOUN	B
such	O	ADJ	O
as	O	ADP	O
SSR103800	B-Chemical	NOUN	B
,	O	PUNCT	O
which	O	DET	O
indirectly	O	ADV	O
enhance	O	VERB	O
NMDA	B-Chemical	NOUN	B
receptor	O	NOUN	I
function	O	NOUN	B
by	O	ADP	O
increasing	O	VERB	B
the	O	DET	O
glycine	B-Chemical	NOUN	B
(	O	PUNCT	O
a	O	DET	O
co	O	X	B
-	O	PUNCT	O
agonist	O	NOUN	B
for	O	ADP	O
the	O	DET	O
NMDA	B-Chemical	NOUN	B
receptor	O	NOUN	I
)	O	PUNCT	O
levels	O	NOUN	B
in	O	ADP	O
the	O	DET	O
synapse	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
aimed	O	VERB	O
at	O	ADP	O
investigating	O	VERB	B
the	O	DET	O
potential	O	ADJ	B
antipsychotic	O	ADJ	B
-	O	PUNCT	O
like	O	ADJ	B
properties	O	NOUN	B
of	O	ADP	O
SSR103800	B-Chemical	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
particular	O	ADJ	O
focus	O	NOUN	O
on	O	ADP	O
models	O	NOUN	B
of	O	ADP	O
hyperactivity	B-Disease	NOUN	B
,	O	PUNCT	O
involving	O	VERB	O
either	O	DET	O
drug	O	NOUN	B
challenge	O	NOUN	I
(	O	PUNCT	O
ie	O	X	O
,	O	PUNCT	O
amphetamine	B-Chemical	NOUN	B
and	O	CCONJ	O
MK-801	B-Chemical	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
transgenic	O	ADJ	B
mice	O	NOUN	I
(	O	PUNCT	O
ie	O	X	O
,	O	PUNCT	O
NMDA	B-Chemical	NOUN	B
Nr1	O	NOUN	B
(	O	PUNCT	O
neo	O	NOUN	B
-/-)	O	NOUN	O
and	O	CCONJ	O
DAT	O	NOUN	B
(-/-)).	O	PROPN	O
Results	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
SSR103800	B-Chemical	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
-	O	SYM	O
30	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
p	O	NOUN	O
.	O	PUNCT	O


o	O	INTJ	O
.)	O	NOUN	O
blocked	O	VERB	B
hyperactivity	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
the	O	DET	O
non	O	ADJ	B
-	O	PUNCT	O
competitive	O	ADJ	B
NMDA	B-Chemical	NOUN	B
receptor	O	NOUN	I
antagonist	O	NOUN	B
,	O	PUNCT	O
MK-801	B-Chemical	NOUN	B
and	O	CCONJ	O
partially	O	ADV	O
reversed	O	VERB	O
spontaneous	O	ADJ	B
hyperactivity	B-Disease	NOUN	B
of	O	ADP	O
NMDA	B-Chemical	NOUN	B
Nr1	O	NOUN	B
(	O	PUNCT	O
neo	O	ADJ	B
-/-)	O	NOUN	O
mice	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
SSR103800	B-Chemical	NOUN	B
failed	O	VERB	B
to	O	PART	O
affect	O	VERB	O
hyperactivity	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
amphetamine	B-Chemical	NOUN	B
or	O	CCONJ	O
naturally	O	ADV	O
observed	O	VERB	O
in	O	ADP	O
dopamine	B-Chemical	NOUN	B
transporter	O	NOUN	I
(	O	PUNCT	O
DAT	O	NOUN	B
(-/-))	O	NOUN	O
knockout	O	NOUN	B
mice	O	NOUN	I
(	O	PUNCT	O
10	O	NUM	O
-	O	SYM	O
30	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
p	O	NOUN	O
.	O	PUNCT	O


o	O	INTJ	O
.).	O	NOUN	O
Importantly	O	ADV	O
,	O	PUNCT	O
both	O	CCONJ	O
classical	O	ADJ	O
(	O	PUNCT	O
haloperidol	B-Chemical	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
atypical	O	ADJ	B
(	O	PUNCT	O
olanzapine	B-Chemical	NOUN	B
,	O	PUNCT	O
clozapine	B-Chemical	NOUN	B
and	O	CCONJ	O
aripiprazole	B-Chemical	NOUN	B
)	O	PUNCT	O
antipsychotics	O	NOUN	B
were	O	AUX	O
effective	O	ADJ	B
in	O	ADP	O
all	O	DET	O
these	O	DET	O
models	O	NOUN	B
of	O	ADP	O
hyperactivity	B-Disease	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
unlike	O	ADP	O
these	O	DET	O
latter	O	ADJ	O
,	O	PUNCT	O
SSR103800	B-Chemical	NOUN	B
did	O	AUX	O
not	O	PART	O
produce	O	VERB	O
catalepsy	B-Disease	NOUN	B
(	O	PUNCT	O
retention	O	NOUN	B
on	O	ADP	O
the	O	DET	O
bar	O	NOUN	B
test	O	NOUN	I
)	O	PUNCT	O
up	O	ADV	O
to	O	PART	O
30	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
p	O	NOUN	O
.	O	PUNCT	O


o	O	X	O
.	O	PUNCT	O


Together	O	ADV	O
these	O	DET	O
findings	O	NOUN	B
show	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
GlyT1	O	NOUN	B
inhibitor	O	NOUN	B
,	O	PUNCT	O
SSR103800	B-Chemical	NOUN	B


Phenylephrine	B-Chemical	NOUN	B
but	O	CCONJ	O
not	O	PART	O
ephedrine	B-Chemical	NOUN	B
reduces	B-Disease	VERB	B
frontal	I-Disease	ADJ	B
lobe	I-Disease	ADJ	I
oxygenation	I-Disease	NOUN	I
following	O	VERB	O
anesthesia	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypotension	B-Disease	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Vasopressor	O	NOUN	B
agents	O	NOUN	I
are	O	AUX	O
used	O	VERB	O
to	O	PART	O
correct	O	VERB	B
anesthesia	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypotension	B-Disease	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
describe	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
phenylephrine	B-Chemical	NOUN	B
and	O	CCONJ	O
ephedrine	B-Chemical	NOUN	B
on	O	ADP	O
frontal	O	ADJ	B
lobe	O	ADJ	I
oxygenation	O	NOUN	I
(	O	PUNCT	O
S	O	NOUN	B
(	O	PUNCT	O
c	O	NOUN	O
)	O	PUNCT	O
O	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
))	O	PUNCT	O
following	O	VERB	O
anesthesia	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypotension	B-Disease	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
Following	O	VERB	O
induction	O	NOUN	B
of	O	ADP	O
anesthesia	O	NOUN	B
by	O	ADP	O
fentanyl	B-Chemical	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


15	O	NUM	O
mg	O	NOUN	O
kg	O	NOUN	O
(-	O	PUNCT	O
1	O	NUM	O
))	O	PUNCT	O
and	O	CCONJ	O
propofol	B-Chemical	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
mg	O	NOUN	O
kg	O	NOUN	O
(-	O	PUNCT	O
1	O	NUM	O
)),	O	PUNCT	O
13	O	NUM	O
patients	O	NOUN	B
received	O	VERB	O
phenylephrine	B-Chemical	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
mg	O	NOUN	O
iv	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
12	O	NUM	O
patients	O	NOUN	B
received	O	VERB	O
ephedrine	B-Chemical	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
mg	O	NOUN	O
iv	O	NOUN	O
)	O	PUNCT	O
to	O	PART	O
restore	O	VERB	O
mean	O	ADJ	O
arterial	O	ADJ	B
pressure	O	NOUN	I
(	O	PUNCT	O
MAP	O	NOUN	B
).	O	PROPN	O
Heart	O	PROPN	O
rate	O	NOUN	O
(	O	PUNCT	O
HR	O	NOUN	B
),	O	PUNCT	O
MAP	O	NOUN	B
,	O	PUNCT	O
stroke	B-Disease	NOUN	B
volume	O	NOUN	O
(	O	PUNCT	O
SV	O	NOUN	B
),	O	PUNCT	O
cardiac	O	ADJ	B
output	O	NOUN	I
(	O	PUNCT	O
CO	O	NOUN	B
),	O	PUNCT	O
and	O	CCONJ	O
frontal	O	ADJ	B
lobe	O	ADJ	I
oxygenation	O	NOUN	I
(	O	PUNCT	O
S	O	NOUN	B
(	O	PUNCT	O
c	O	NOUN	O
)	O	PUNCT	O
O	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
))	O	PUNCT	O
were	O	AUX	O
registered	O	VERB	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Induction	O	NOUN	B
of	O	ADP	O
anesthesia	O	NOUN	B
was	O	AUX	O
followed	O	VERB	O
by	O	ADP	O
a	B-Disease	DET	O
decrease	I-Disease	NOUN	B
in	I-Disease	ADP	O
MAP,	I-Disease	PROPN	B
HR,	I-Disease	PROPN	O
SV,	I-Disease	NOUN	B
and	I-Disease	CCONJ	O
CO	I-Disease	NOUN	B
concomitant	O	ADJ	B
with	O	ADP	O
an	O	DET	O
elevation	O	NOUN	B
in	O	ADP	O
S	O	NOUN	B
(	O	PUNCT	I
c	O	NOUN	I
)	O	PUNCT	I
O	O	NOUN	I
(	O	PUNCT	O
2	O	NUM	O
).	O	PUNCT	O
After	O	ADP	O
administration	O	NOUN	B
of	O	ADP	O
phenylephrine	B-Chemical	NOUN	B
,	O	PUNCT	O
MAP	O	NOUN	B
increased	O	VERB	B
(	O	PUNCT	O
51	O	NUM	O
+/-	O	CCONJ	O
12	O	NUM	O
to	O	PART	O
81	O	NUM	O
+/-	O	CCONJ	O
13	O	NUM	O
mmHg	O	NOUN	B
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
;	O	PUNCT	O
mean	O	NOUN	O
+/-	O	CCONJ	O
SD	O	NOUN	B
).	O	PUNCT	O
However	O	ADV	O
,	O	PUNCT	O
a	O	DET	O
14	O	NUM	O
%(	O	NOUN	O
from	O	ADP	O
70	O	NUM	O
+/-	O	CCONJ	O
8	O	NUM	O
%	O	NOUN	O
to	O	PART	O
60	O	NUM	O
+/-	O	CCONJ	O
7	O	NUM	O
%)	O	NOUN	O
reduction	O	NOUN	B
in	O	ADP	O
S	O	NOUN	B
(	O	PUNCT	I
c	O	NOUN	I
)	O	PUNCT	I
O	O	NOUN	I
(	O	PUNCT	O
2	O	NUM	O
)(	O	NOUN	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
)	O	PUNCT	O
followed	O	VERB	B
with	O	ADP	I
no	O	DET	O
change	O	NOUN	O
in	O	ADP	O
CO	O	NOUN	B
(	O	PUNCT	O
3	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
+/-	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
to	O	PART	O
3	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
l	O	NOUN	O
min	O	NOUN	O
(-	O	PUNCT	O
1	O	NUM	O
)).	O	NOUN	O
The	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
ephedrine	B-Chemical	NOUN	B
led	O	VERB	O
to	O	PART	O
a	O	DET	O
similar	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
MAP	O	NOUN	B
(	O	PUNCT	O
53	O	NUM	O
+/-	O	CCONJ	O
9	O	NUM	O
to	O	PART	O
79	O	NUM	O
+/-	O	CCONJ	O
8	O	NUM	O
mmHg	O	NOUN	B
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
),	O	PUNCT	O
restored	O	VERB	B
CO	O	NOUN	B
(	O	PUNCT	O
3	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
+/-	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
to	O	PART	O
5	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
+/-	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
l	O	NOUN	O
min	O	NOUN	O
(-	O	PUNCT	O
1	O	NUM	O
)),	O	PUNCT	O
and	O	CCONJ	O
preserved	O	VERB	B
S	O	NOUN	I
(	O	PUNCT	I
c	O	NOUN	I
)	O	PUNCT	I
O	O	NOUN	I
(	O	PUNCT	O
2	O	NUM	O
).	O	PUNCT	O
CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
utilization	O	NOUN	B
of	O	ADP	O
phenylephrine	B-Chemical	NOUN	B
to	O	PART	O
correct	O	VERB	O
hypotension	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
anesthesia	O	NOUN	B
has	O	AUX	O
a	O	DET	O
negative	O	ADJ	B
impact	O	NOUN	B
on	O	ADP	O
S	O	NOUN	B
(	O	PUNCT	I
c	O	NOUN	I
)	O	PUNCT	I
O	O	NOUN	I
(	O	PUNCT	I
2	O	NUM	I
)	O	PUNCT	O
while	O	SCONJ	O
ephedrine	B-Chemical	NOUN	B


A	O	DET	O
novel	O	ADJ	B
,	O	PUNCT	O
multiple	O	ADJ	B
symptom	O	NOUN	O
model	O	NOUN	O
of	O	ADP	O
obsessive-compulsive-like	B-Disease	ADJ	B
behaviors	I-Disease	NOUN	I
in	O	ADP	O
animals	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Current	O	ADJ	B
animal	O	NOUN	B
models	O	NOUN	I
of	O	ADP	O
obsessive-compulsive	B-Disease	ADJ	B
disorder	I-Disease	NOUN	I
(	O	PUNCT	O
OCD	B-Disease	NOUN	B
)	O	PUNCT	O
typically	O	ADV	O
involve	O	VERB	O
acute	O	ADJ	B
,	O	PUNCT	O
drug	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
symptom	O	NOUN	B
provocation	O	NOUN	I
or	O	CCONJ	O
a	O	DET	O
genetic	O	ADJ	B
association	O	NOUN	B
with	O	ADP	O
stereotypies	O	NOUN	B
or	O	CCONJ	O
anxiety	B-Disease	NOUN	B
.	O	PUNCT	O


of	O	ADP	O
these	O	DET	O
current	O	ADJ	B
models	O	NOUN	B
demonstrate	O	VERB	O
multiple	O	ADJ	B
OCD	B-Disease	PROPN	B
-	O	PUNCT	O
like	O	ADJ	B
behaviors	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
Neonatal	O	ADJ	B
rats	O	NOUN	B
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
the	O	DET	O
tricyclic	O	ADJ	B
antidepressant	B-Chemical	ADJ	B
clomipramine	B-Chemical	NOUN	B
or	O	CCONJ	O
vehicle	O	NOUN	B
between	O	ADP	O
days	O	NOUN	B
9	O	NUM	O
and	O	CCONJ	O
16	O	NUM	O
twice	O	ADV	O
daily	O	ADV	B
and	O	CCONJ	O
behaviorally	O	ADV	B
tested	O	VERB	I
in	O	ADP	B
adulthood	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Clomipramine	B-Chemical	NOUN	B
exposure	O	NOUN	B
in	O	ADP	O
immature	O	ADJ	B
rats	O	NOUN	B
produced	O	VERB	O
significant	O	ADJ	B
behavioral	O	ADJ	B
and	O	CCONJ	O
biochemical	O	ADJ	B
changes	O	NOUN	B
that	O	PRON	O
include	O	VERB	O
enhanced	O	VERB	B
anxiety	B-Disease	NOUN	B
(	O	PUNCT	O
elevated	O	ADJ	B
plus	O	CCONJ	I
maze	O	NOUN	I
and	O	CCONJ	O
marble	O	NOUN	B
burying	O	NOUN	O
),	O	PUNCT	O
behavioral	B-Disease	ADJ	B
inflexibility	I-Disease	NOUN	B
(	O	PUNCT	O
perseveration	O	NOUN	B
in	O	ADP	O
the	O	DET	O
spontaneous	O	ADJ	B
alternation	O	NOUN	B
task	O	NOUN	O
and	O	CCONJ	O
impaired	O	ADJ	B
reversal	O	ADJ	O
learning	O	NOUN	O
),	O	PUNCT	O
working	O	VERB	B
memory	B-Disease	NOUN	I
impairment	I-Disease	NOUN	I
(	O	PUNCT	O
e	O	X	O
.	O	PUNCT	O


g	O	NOUN	O
.,	O	ADV	O
win	O	VERB	O
-	O	PUNCT	O
shift	O	NOUN	B
paradigm	O	NOUN	B
),	O	PUNCT	O
hoarding	B-Disease	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
corticostriatal	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
.	O	PUNCT	O


Dopamine	B-Chemical	NOUN	B
D2	O	NOUN	I
receptors	O	NOUN	I
were	O	AUX	O
elevated	O	ADJ	B
in	O	ADP	O
the	O	DET	O
striatum	O	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
serotonin	B-Chemical	NOUN	B
2C	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
serotonin	B-Chemical	NOUN	B
1A	O	NOUN	I
,	O	PUNCT	O
receptors	O	NOUN	B
were	O	AUX	O
elevated	O	ADJ	B
in	O	ADP	O
the	O	DET	O
orbital	O	ADJ	B
frontal	O	ADJ	I
cortex	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
This	O	DET	O
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
demonstration	O	NOUN	B
of	O	ADP	O
multiple	O	ADJ	B
symptoms	O	NOUN	B
consistent	O	ADJ	B
with	O	ADP	I
an	O	DET	O
OCD	B-Disease	PROPN	B
-	O	PUNCT	O
like	O	ADJ	B
profile	O	NOUN	B
in	O	ADP	O
animals	O	NOUN	B
.	O	PUNCT	O


Moreover	O	ADV	O
,	O	PUNCT	O
these	O	DET	O
behaviors	O	NOUN	B
are	O	AUX	O
accompanied	O	VERB	O
by	O	ADP	O
biochemical	O	ADJ	B
changes	O	NOUN	B
in	O	ADP	O
brain	O	NOUN	B
regions	O	NOUN	I
previously	O	ADV	O
identified	O	VERB	B
as	O	ADP	O
relevant	O	ADJ	O
to	O	ADP	O
OCD	B-Disease	NOUN	B
.	O	PUNCT	O


This	O	DET	O
novel	O	ADJ	O
model	O	NOUN	B
of	O	ADP	O
OCD	B-Disease	PROPN	B
demonstrates	O	VERB	O
that	O	SCONJ	O
drug	O	NOUN	B
exposure	O	NOUN	I
during	O	ADP	O
a	O	DET	O
sensitive	O	ADJ	B
period	O	NOUN	B
can	O	AUX	O
program	O	VERB	B
disease	O	NOUN	I
-	O	PUNCT	O
like	O	ADJ	B
systems	O	NOUN	B
permanently	O	ADV	I
,	O	PUNCT	O
which	O	DET	O
could	O	AUX	O
have	O	AUX	O
implications	O	NOUN	O
for	O	ADP	O
current	O	ADJ	B
and	O	CCONJ	O
future	O	ADJ	O
therapeutic	O	ADJ	B
strategies	O	NOUN	O
for	O	ADP	O
this	O	DET	O
and	O	CCONJ	O
other	O	ADJ	O
psychiatric	B-Disease	ADJ	B
disorders	I-Disease	NOUN	I


Late	O	ADJ	B
recovery	O	NOUN	I
of	O	ADP	O
renal	O	ADJ	B
function	O	NOUN	I
in	O	ADP	O
a	O	DET	O
woman	O	NOUN	B
with	O	ADP	O
the	O	DET	O
hemolytic	B-Disease	ADJ	B
uremic	I-Disease	ADJ	I
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
case	O	NOUN	B
is	O	AUX	O
reported	O	VERB	O
of	O	ADP	O
the	O	DET	O
hemolytic	B-Disease	ADJ	B
uremic	I-Disease	ADJ	I
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
HUS	B-Disease	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
woman	O	NOUN	B
taking	O	VERB	O
oral	B-Chemical	ADJ	B
contraceptives	I-Chemical	NOUN	I
.	O	PUNCT	O


She	O	PRON	O
was	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
heparin	B-Chemical	NOUN	B
,	O	PUNCT	O
dipyridamole	B-Chemical	NOUN	B
and	O	CCONJ	O
hemodialysis	O	NOUN	B
;	O	PUNCT	O
and	O	CCONJ	O
after	O	ADP	O
more	O	ADJ	O
than	O	ADP	O
three	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
her	O	PRON	O
urinary	O	ADJ	B
output	O	NOUN	I
rose	O	VERB	O
above	O	ADP	O
500	O	NUM	O
ml	O	NOUN	O
;	O	PUNCT	O
and	O	CCONJ	O
six	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
the	O	DET	O
onset	O	NOUN	O
of	O	ADP	O
anuria	B-Disease	NOUN	B
,	O	PUNCT	O
dialysis	O	NOUN	B
treatment	O	NOUN	B
was	O	AUX	O
stopped	O	VERB	B
.	O	PUNCT	O


This	O	DET	O
case	O	NOUN	B
emphasizes	O	VERB	O
the	O	DET	O
possibility	O	NOUN	O
that	O	SCONJ	O
HUS	B-Disease	NOUN	B
in	O	ADP	O
adults	O	NOUN	B
is	O	AUX	O
not	O	PART	O
invariably	O	ADV	O
irreversible	O	ADJ	B
and	O	CCONJ	O
that	O	SCONJ	O
,	O	PUNCT	O
despite	O	SCONJ	O
prolonged	O	ADJ	B
oliguria	B-Disease	NOUN	B
,	O	PUNCT	O
recovery	O	NOUN	B
of	O	ADP	O
renal	O	ADJ	B
function	O	NOUN	I
can	O	AUX	O
be	O	AUX	O
obtained	O	VERB	O
.	O	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
in	O	ADP	O
adult	O	ADJ	B
patients	O	NOUN	B
affected	O	VERB	B
by	O	ADP	O
HUS	B-Disease	NOUN	B
,	O	PUNCT	O
dialysis	O	NOUN	B
should	O	AUX	O
not	O	PART	O
be	O	AUX	O
discontinued	O	VERB	B
prematurely	O	ADV	B
;	O	PUNCT	O
moreover	O	ADV	O
,	O	PUNCT	O
bilateral	O	ADJ	B
nephrectomy	O	NOUN	I
,	O	PUNCT	O
for	O	ADP	O
treatment	O	NOUN	B
of	O	ADP	O
severe	O	ADJ	B
hypertension	B-Disease	NOUN	B
and	O	CCONJ	O
microangiopathic	B-Disease	ADJ	B
hemolytic	I-Disease	ADJ	B
anemia	I-Disease	NOUN	I


Effects	O	NOUN	B
of	O	ADP	I
acetylsalicylic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
,	O	PUNCT	O
dipyridamole	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
hydrocortisone	B-Chemical	NOUN	B
on	O	ADP	O
epinephrine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
myocardial	B-Disease	ADJ	B
injury	I-Disease	NOUN	I
in	O	ADP	O
dogs	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
reproducible	O	ADJ	O
model	O	NOUN	O
for	O	ADP	O
producing	O	VERB	O
diffuse	O	ADJ	O
myocardial	B-Disease	ADJ	B
injury	I-Disease	NOUN	I
(	O	PUNCT	O
epinephrine	B-Chemical	NOUN	B
infusion	O	NOUN	B
)	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
developed	O	VERB	O
to	O	PART	O
study	O	VERB	B
the	O	DET	O
cardioprotective	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
agents	O	NOUN	B
or	O	CCONJ	O
maneuvers	O	NOUN	B
which	O	DET	O
might	O	AUX	O
alter	O	VERB	O
the	O	DET	O
evolution	O	NOUN	B
of	O	ADP	O
acute	O	ADJ	B
myocardial	B-Disease	ADJ	I
infarction	I-Disease	NOUN	I
.	O	PUNCT	O


Infusions	O	NOUN	B
of	O	ADP	O
epinephrine	B-Chemical	NOUN	B
(	O	PUNCT	O
4	O	NUM	O
mug	O	NOUN	B
per	O	ADP	O
kilogram	O	NOUN	O
per	O	ADP	O
minute	O	NOUN	O
for	O	ADP	O
6	O	NUM	O
hours	O	NOUN	B
)	O	PUNCT	O
increased	O	VERB	B
radiocalcium	B-Chemical	NOUN	B
uptakes	O	NOUN	B
into	O	ADP	O
intact	O	ADJ	B
myocardium	O	NOUN	B
and	O	CCONJ	O
each	O	DET	O
of	O	ADP	O
its	O	PRON	O
subcellular	O	ADJ	B
components	O	NOUN	I
with	O	ADP	O
the	O	DET	O
mitochondrial	O	ADJ	B
fraction	O	NOUN	O
showing	O	VERB	O
the	O	DET	O
most	O	ADV	O
consistent	O	ADJ	O
changes	O	NOUN	B
when	O	SCONJ	O
compared	O	VERB	B
to	O	PART	O
saline	O	NOUN	B
-	O	PUNCT	O
infused	O	VERB	B
control	O	NOUN	B
animals	O	NOUN	I
(	O	PUNCT	O
4	O	NUM	O
,	O	PUNCT	O
957	O	NUM	O
vs	O	CCONJ	O
.	O	PUNCT	O


827	O	NUM	O
counts	O	NOUN	B
per	O	ADP	O
minute	O	NOUN	O
per	O	ADP	O
gram	O	NOUN	B
of	O	ADP	O
dried	O	VERB	B
tissue	O	NOUN	I
or	O	CCONJ	O
fraction	O	NOUN	B
).	O	PUNCT	O
Myocardial	O	ADJ	B
concentrations	O	NOUN	I
of	O	ADP	O
calcium	B-Chemical	NOUN	B
also	O	ADV	O
increased	O	VERB	B
significantly	O	ADV	O
(	O	PUNCT	O
12	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
vs	O	ADV	O
.	O	PUNCT	O


5	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
mg	O	NOUN	O
.	O	PUNCT	O


per	O	ADP	O
100	O	NUM	O
Gm	O	NOUN	B
.	O	PUNCT	O


of	O	ADP	O
fat	O	ADJ	B
-	O	PUNCT	O
free	O	ADJ	B
dry	O	ADJ	O
weight	O	NOUN	O
).	O	PUNCT	O
Infusions	O	NOUN	B
of	O	ADP	O
calcium	B-Chemical	NOUN	B
chloride	I-Chemical	NOUN	I
sufficient	O	ADJ	O
to	O	PART	O
raise	O	VERB	O
serum	O	NOUN	B
calcium	B-Chemical	NOUN	O
concentrations	O	NOUN	O
2	O	NUM	O
mEq	O	NOUN	O
.	O	PUNCT	O


per	O	ADP	O
liter	O	NOUN	O
failed	O	VERB	B
to	O	PART	O
increase	O	VERB	B
calcium	B-Chemical	NOUN	B
influx	O	NOUN	I
into	O	ADP	O
the	O	DET	O
myocardial	O	ADJ	B
cell	O	NOUN	I
.	O	PUNCT	O


Mitochondrial	O	ADJ	B
radiocalcium	B-Chemical	NOUN	I
uptakes	O	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
decreased	O	VERB	B
in	O	ADP	O
animals	O	NOUN	B
pretreated	O	VERB	B
with	O	ADP	O
acetylsalicylic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
or	O	CCONJ	O
dipyridamole	B-Chemical	NOUN	B
or	O	CCONJ	O
when	O	SCONJ	O
hydrocortisone	B-Chemical	NOUN	B
was	O	AUX	O
added	O	VERB	O
to	O	PART	O
the	O	DET	O
epinephrine	B-Chemical	NOUN	B
infusion	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
,	O	PUNCT	O
682	O	NUM	O
,	O	PUNCT	O
2	O	NUM	O
,	O	PUNCT	O
803	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
3	O	NUM	O
,	O	PUNCT	O
424	O	NUM	O
counts	O	NOUN	B
per	O	ADP	O
minute	O	NOUN	O
per	O	ADP	O
gram	O	NOUN	B
of	O	ADP	O
dried	O	VERB	B
fraction	O	NOUN	I
,	O	PUNCT	O
respectively	O	ADV	O
).	O	PUNCT	O
Myocardial	O	ADJ	B
calcium	B-Chemical	NOUN	I
concentrations	O	NOUN	O
also	O	ADV	O
were	O	AUX	O
decreased	O	VERB	B
(	O	PUNCT	O
11	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
,	O	PUNCT	O
8	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
8	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
mg	O	NOUN	O
.	O	PUNCT	O


per	O	ADP	O
100	O	NUM	O
Gm	O	NOUN	B
.	O	PUNCT	O


of	O	ADP	O
fat	O	ADJ	B
-	O	PUNCT	O
free	O	ADJ	B
dry	O	ADJ	O
weight	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
three	O	NUM	O
treatment	O	NOUN	B
groups	O	NOUN	I
,	O	PUNCT	O
being	O	AUX	O
significantly	O	ADV	O
decreased	O	VERB	B
only	O	ADV	O
in	O	ADP	O
the	O	DET	O
last	O	ADJ	O
two	O	NUM	O
.	O	PUNCT	O


Evidence	O	NOUN	B
of	O	ADP	O
microscopic	O	ADJ	B
damage	O	NOUN	B
was	O	AUX	O
graded	O	VERB	O
as	O	ADP	O
less	O	ADV	O
severe	O	ADJ	B
in	O	ADP	O
the	O	DET	O
three	O	NUM	O
treatment	O	NOUN	B
groups	O	NOUN	I
.	O	PUNCT	O


Acetylsalicylic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
,	O	PUNCT	O
dipyridamole	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
hydrocortisone	B-Chemical	NOUN	B


Changes	O	NOUN	B
in	O	ADP	O
depressive	B-Disease	ADJ	B
status	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
topical	O	ADJ	B
beta	O	NOUN	I
-	O	PUNCT	O
blockers	O	NOUN	B
.	O	PUNCT	O


Depression	B-Disease	NOUN	B
and	O	CCONJ	O
sexual	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
have	O	AUX	O
been	O	AUX	O
related	O	ADJ	O
to	O	PART	O
side	O	NOUN	B
effects	O	NOUN	I
of	O	ADP	O
topical	O	ADJ	B
beta	O	NOUN	I
-	O	PUNCT	O
blockers	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
performed	O	VERB	O
a	O	DET	O
preliminary	O	ADJ	O
study	O	NOUN	B
in	O	ADP	O
order	O	NOUN	O
to	O	PART	O
determine	O	VERB	O
any	O	DET	O
difference	O	NOUN	O
between	O	ADP	O
a	O	DET	O
non	O	ADJ	B
selective	O	ADJ	O
beta	O	NOUN	B
-	O	PUNCT	O
blocker	O	NOUN	B
(	O	PUNCT	O
timolol	B-Chemical	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
selective	O	ADJ	O
beta	O	NOUN	B
-	O	PUNCT	O
blocker	O	NOUN	B
(	O	PUNCT	O
betaxolol	B-Chemical	NOUN	B
)	O	PUNCT	O
regarding	O	VERB	O
CNS	O	NOUN	B
side	O	NOUN	B
effects	O	NOUN	I
.	O	PUNCT	O


Eight	O	NUM	O
glaucomatous	B-Disease	ADJ	B
patients	O	NOUN	B
chronically	O	ADV	B
treated	O	VERB	B
with	O	ADP	I
timolol	B-Chemical	NOUN	B
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
%/	O	NOUN	O
12h	O	NOUN	O
,	O	PUNCT	O
suffering	O	VERB	B
from	O	ADP	O
depression	B-Disease	NOUN	B
diagnosed	O	VERB	B
through	O	ADP	O
DMS	O	NOUN	B
-	O	PUNCT	O
III	O	NUM	B
-	O	PUNCT	O
R	O	NOUN	B
criteria	O	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
included	O	VERB	O
in	O	ADP	O
the	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


During	O	ADP	O
the	O	DET	O
six	O	NUM	B
-	O	PUNCT	O
month	O	NOUN	B
follow	O	VERB	B
up	O	ADP	I
,	O	PUNCT	O
depression	B-Disease	NOUN	B
was	O	AUX	O
quantified	O	VERB	B
through	O	ADP	O
the	O	DET	O
Beck	O	PROPN	B
and	O	CCONJ	O
Zung	O	PROPN	B
-	O	PUNCT	O
Conde	O	PROPN	B
scales	O	NOUN	B
every	O	DET	O
two	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
double	O	ADJ	O
blind	O	ADJ	O
cross	O	NOUN	B
-	O	PUNCT	O
over	O	ADP	B
study	O	NOUN	B
with	O	ADP	O
control	O	ADJ	B
group	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
patients	O	NOUN	B
under	O	ADP	O
timolol	B-Chemical	NOUN	B
treatment	O	NOUN	B
presented	O	VERB	O
higher	O	ADJ	B
depression	B-Disease	NOUN	B
values	O	NOUN	O
measured	O	VERB	B
through	O	ADP	O
the	O	DET	O
Beck	O	PROPN	B
and	O	CCONJ	O
the	O	DET	O
Zung	O	PROPN	B
-	O	PUNCT	O
Conde	O	PROPN	B
scales	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
vs	O	CCONJ	O
control	O	NOUN	B
).	O	PUNCT	O
These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
betaxolol	B-Chemical	NOUN	B
could	O	AUX	O
be	O	AUX	O
less	O	ADJ	O
of	O	ADP	O
a	O	DET	O
depression	B-Disease	NOUN	B
-	O	PUNCT	O
inducer	O	NOUN	B
than	O	ADP	O
timolol	B-Chemical	NOUN	B


Long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
follow	O	VERB	B
-	O	PUNCT	O
up	O	NOUN	O
of	O	ADP	O
ifosfamide	B-Chemical	NOUN	B
renal	B-Disease	ADJ	I
toxicity	I-Disease	NOUN	B
in	O	ADP	O
children	O	NOUN	B
treated	O	VERB	B
for	O	ADP	O
malignant	B-Disease	ADJ	B
mesenchymal	I-Disease	ADJ	B
tumors	I-Disease	NOUN	I
:	O	PUNCT	O
an	O	DET	O
International	O	PROPN	B
Society	O	PROPN	I
of	O	ADP	I
Pediatric	O	PROPN	I
Oncology	O	PROPN	I
report	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
renal	O	ADJ	B
function	O	NOUN	I
of	O	ADP	O
74	O	NUM	O
children	O	NOUN	B
with	O	ADP	O
malignant	B-Disease	ADJ	B
mesenchymal	I-Disease	ADJ	I
tumors	I-Disease	NOUN	I
in	O	ADP	O
complete	O	ADJ	O
remission	O	NOUN	B
and	O	CCONJ	O
who	O	PRON	O
have	O	AUX	O
received	O	VERB	O
the	O	DET	O
same	O	ADJ	O
ifosfamide	B-Chemical	NOUN	B
chemotherapy	O	NOUN	I
protocol	O	NOUN	I
(	O	PUNCT	O
International	O	PROPN	B
Society	O	PROPN	I
of	O	ADP	I
Pediatric	O	PROPN	I
Oncology	O	PROPN	I
Malignant	B-Disease	PROPN	I
Mesenchymal	I-Disease	ADJ	I
Tumor	I-Disease	NOUN	I
Study	O	NOUN	I
84	O	NUM	I
[	O	PUNCT	O
SIOP	O	PROPN	B
MMT	O	PROPN	B
84	O	NUM	O
])	O	PUNCT	O
were	O	AUX	O
studied	O	VERB	O
1	O	NUM	O
year	O	NOUN	B
after	O	ADP	O
the	O	DET	O
completion	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


Total	O	ADJ	O
cumulative	O	ADJ	O
doses	O	NOUN	B
were	O	AUX	O
36	O	NUM	O
or	O	CCONJ	O
60	O	NUM	O
g	O	NOUN	B
/	O	SYM	O
m2	O	NOUN	B
of	O	ADP	O
ifosfamide	B-Chemical	NOUN	B
(	O	PUNCT	O
six	O	NUM	O
or	O	CCONJ	O
10	O	NUM	O
cycles	O	NOUN	O
of	O	ADP	O
ifosfamide,	B-Chemical	X	B
vincristine,	I-Chemical	PROPN	B
and	I-Chemical	CCONJ	O
dactinomycin	I-Chemical	NOUN	B
[	O	PUNCT	O
IVA	B-Chemical	PROPN	B
]).	O	PUNCT	O
of	O	ADP	O
them	O	PRON	O
had	O	AUX	O
received	O	VERB	O
cisplatin	B-Chemical	NOUN	B
chemotherapy	O	NOUN	B
.	O	PUNCT	O


Ages	O	NOUN	B
ranged	O	VERB	O
from	O	ADP	O
4	O	NUM	O
months	O	NOUN	B
to	O	ADP	O
17	O	NUM	O
years	O	NOUN	B
;	O	PUNCT	O
58	O	NUM	O
patients	O	NOUN	B
were	O	AUX	O
males	O	NOUN	B
and	O	CCONJ	O
42	O	NUM	O
females	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
most	O	ADV	O
common	O	ADJ	O
primary	O	ADJ	B
tumor	B-Disease	NOUN	B
site	O	NOUN	I
was	O	AUX	O
the	O	DET	O
head	O	NOUN	B
and	O	CCONJ	I
neck	O	NOUN	B
.	O	PUNCT	O


Renal	O	ADJ	B
function	O	NOUN	I
was	O	AUX	O
investigated	O	VERB	B
by	O	ADP	O
measuring	O	VERB	B
plasma	O	NOUN	B
and	O	CCONJ	O
urinary	O	ADJ	B
electrolytes	O	NOUN	O
,	O	PUNCT	O
glucosuria	B-Disease	NOUN	B
,	O	PUNCT	O
proteinuria	B-Disease	NOUN	B
,	O	PUNCT	O
aminoaciduria	B-Disease	NOUN	B
,	O	PUNCT	O
urinary	O	ADJ	B
pH	O	NOUN	B
,	O	PUNCT	O
osmolarity	O	NOUN	B
,	O	PUNCT	O
creatinine	B-Chemical	NOUN	B
clearance	O	NOUN	B
,	O	PUNCT	O
phosphate	B-Chemical	NOUN	B
tubular	O	ADJ	I
reabsorption	O	NOUN	I
,	O	PUNCT	O
beta	O	NOUN	B
2	O	NUM	I
microglobulinuria	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
lysozymuria	O	NOUN	B
.	O	PUNCT	O


Fifty	O	NUM	B
-	O	PUNCT	O
eight	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
78	O	NUM	O
%)	O	NOUN	O
had	O	AUX	O
normal	O	ADJ	B
renal	O	ADJ	I
tests	O	NOUN	I
,	O	PUNCT	O
whereas	O	SCONJ	O
16	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
22	O	NUM	O
%)	O	NOUN	O
had	O	AUX	O
renal	B-Disease	ADJ	B
abnormalities	I-Disease	NOUN	I
.	O	PUNCT	O


Two	O	NUM	O
subsets	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
were	O	AUX	O
identified	O	VERB	B
from	O	ADP	O
this	O	DET	O
latter	O	ADJ	O
group	O	NOUN	B
:	O	PUNCT	O
the	O	DET	O
first	O	ADJ	O
included	O	VERB	O
four	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
5	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
total	O	ADJ	B
population	O	NOUN	I
)	O	PUNCT	O
who	O	PRON	O
developed	O	VERB	O
major	O	ADJ	O
toxicity	B-Disease	NOUN	B
resulting	O	VERB	O
in	O	ADP	O
Fanconi's	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
TDFS	B-Disease	NOUN	B
);	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
second	O	ADJ	O
group	O	NOUN	B
included	O	VERB	O
five	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
elevated	O	ADJ	B
beta	O	NOUN	O
2	O	NUM	O
microglobulinuria	O	NOUN	B
and	O	CCONJ	O
low	O	ADJ	B
phosphate	B-Chemical	NOUN	I
reabsorption	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
remaining	O	VERB	O
seven	O	NUM	O
patients	O	NOUN	B
had	O	AUX	O
isolated	O	VERB	B
beta	O	NOUN	O
2	O	NUM	O
microglobulinuria	O	NOUN	B
.	O	PUNCT	O


Severe	O	ADJ	B
toxicity	B-Disease	NOUN	B
was	O	AUX	O
correlated	O	VERB	B
with	O	ADP	O
the	O	DET	O
higher	O	ADJ	O
cumulative	O	ADJ	B
dose	O	NOUN	B
of	O	ADP	O
60	O	NUM	O
g	O	NOUN	B
/	O	SYM	O
m2	O	NOUN	B
of	O	ADP	O
ifosfamide	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
younger	O	ADJ	B
age	O	NOUN	I
(	O	PUNCT	O
less	O	ADJ	O
than	O	ADP	O
2	O	NUM	O
1	O	NUM	O
/	O	SYM	O
2	O	NUM	O
years	O	NOUN	B
old	O	ADJ	O
),	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
predominance	O	NOUN	B
of	O	ADP	O
vesicoprostatic	O	ADJ	B
tumor	B-Disease	NOUN	I
involvement	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
low	O	ADJ	B
percentage	O	NOUN	B
(	O	PUNCT	O
5	O	NUM	O
%)	O	NOUN	O
of	O	ADP	O
TDFS	O	NOUN	B
must	O	AUX	O
be	O	AUX	O
evaluated	O	VERB	B
with	O	ADP	O
respect	O	NOUN	O
to	O	PART	O
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
ifosfamide	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
mesenchymal	B-Disease	ADJ	B
tumors	I-Disease	NOUN	I


Evidence	O	NOUN	B
for	O	ADP	O
an	O	DET	O
involvement	O	NOUN	B
of	O	ADP	O
D1	O	NOUN	B
and	O	CCONJ	O
D2	O	NOUN	B
dopamine	B-Chemical	NOUN	I
receptors	O	NOUN	I
in	O	ADP	O
mediating	O	VERB	O
nicotine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hyperactivity	B-Disease	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


Previous	O	ADJ	O
studies	O	NOUN	B
have	O	AUX	O
suggested	O	VERB	O
that	O	SCONJ	O
repeated	O	VERB	O
exposure	O	NOUN	B
of	O	ADP	I
rats	O	NOUN	B
to	O	PART	O
the	O	DET	O
drug	O	NOUN	B
or	O	CCONJ	O
to	O	ADP	O
the	O	DET	O
experimental	O	ADJ	B
environment	O	NOUN	I
is	O	AUX	O
necessary	O	ADJ	O
to	O	PART	O
observe	O	VERB	O
nicotine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
locomotor	O	NOUN	B
stimulation	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
habituation	O	NOUN	B
to	O	ADP	O
the	O	DET	O
experimental	O	ADJ	B
environment	O	NOUN	I
on	O	ADP	O
the	O	DET	O
stimulant	O	ADJ	B
effect	O	NOUN	B
of	O	ADP	O
nicotine	B-Chemical	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
was	O	AUX	O
examined	O	VERB	O
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
dopamine	B-Chemical	NOUN	B
receptors	O	NOUN	I
in	O	ADP	O
mediating	O	VERB	O
nicotine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
locomotor	O	NOUN	B
stimulation	O	NOUN	I
was	O	AUX	O
investigated	O	VERB	B
by	O	ADP	O
examining	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
selective	O	ADJ	B
D1	O	NOUN	I
and	O	CCONJ	O
D2	O	NOUN	B
dopamine	B-Chemical	NOUN	I
receptor	O	NOUN	I
antagonists	O	NOUN	I
on	O	ADP	O
activity	O	NOUN	B
induced	O	VERB	B
by	O	ADP	O
nicotine	B-Chemical	NOUN	B
.	O	PUNCT	O


Locomotor	O	ADJ	B
activity	O	NOUN	I
was	O	AUX	O
assessed	O	VERB	B
in	O	ADP	O
male	O	NOUN	B
Sprague	O	PROPN	B
-	O	PUNCT	O
Dawley	O	NOUN	B
rats	O	NOUN	B
tested	O	VERB	B
in	O	ADP	O
photocell	O	NOUN	B
cages	O	NOUN	I
.	O	PUNCT	O


Nicotine	B-Chemical	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
caused	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
increase	B-Disease	NOUN	B
in	I-Disease	ADP	O
locomotor	I-Disease	NOUN	B
activity	I-Disease	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
that	O	PRON	O
were	O	AUX	O
habituated	O	VERB	B
to	O	ADP	O
the	O	DET	O
test	O	NOUN	B
environment	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
had	O	AUX	O
only	O	ADV	O
a	O	DET	O
weak	O	ADJ	B
and	O	CCONJ	O
delayed	O	VERB	B
stimulant	O	ADJ	O
action	O	NOUN	O
in	O	ADP	O
rats	O	NOUN	B
that	O	PRON	O
were	O	AUX	O
unfamiliar	O	ADJ	O
with	O	ADP	O
the	O	DET	O
test	O	NOUN	B
environment	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
stimulant	O	ADJ	B
action	O	NOUN	B
of	O	ADP	O
nicotine	B-Chemical	NOUN	B
was	O	AUX	O
blocked	O	VERB	B
by	O	ADP	O
the	O	DET	O
central	O	ADJ	B
nicotinic	O	ADJ	I
antagonist	O	NOUN	I
mecamylamine	B-Chemical	NOUN	B
but	O	CCONJ	O
not	O	PART	O
by	O	ADP	O
the	O	DET	O
peripheral	O	ADJ	B
nicotinic	O	ADJ	B
blocker	O	NOUN	I
hexamethonium	B-Chemical	NOUN	B
,	O	PUNCT	O
indicating	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
response	O	NOUN	B
is	O	AUX	O
probably	O	ADV	O
mediated	O	VERB	O
by	O	ADP	O
central	O	ADJ	B
nicotinic	O	ADJ	I
receptors	O	NOUN	I
.	O	PUNCT	O


Nicotine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hyperactivity	B-Disease	NOUN	B
was	O	AUX	O
blocked	O	VERB	B
by	O	ADP	O
the	O	DET	O
selective	O	ADJ	B
D1	O	NOUN	I
antagonist	O	NOUN	I
SCH	B-Chemical	NOUN	B
23390	I-Chemical	NUM	O
,	O	PUNCT	O
the	O	DET	O
selective	O	ADJ	B
D2	O	NOUN	I
antagonist	O	NOUN	I
raclopride	B-Chemical	NOUN	B
and	O	CCONJ	O
the	O	DET	O
D1	O	NOUN	B
/	O	SYM	O
D2	O	NOUN	B
antagonist	O	NOUN	B
fluphenazine	B-Chemical	NOUN	B
.	O	PUNCT	O


Pretreatment	O	NOUN	B
with	O	ADP	O
the	O	DET	O
D2	O	NOUN	B
agonist	O	NOUN	I
PHNO	B-Chemical	NOUN	B
enhanced	O	VERB	O
nicotine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hyperactivity	B-Disease	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
the	O	DET	O
D1	O	NOUN	B
agonist	O	NOUN	B
SKF	B-Chemical	NOUN	B
38393	I-Chemical	NUM	O
had	O	AUX	O
no	O	DET	B
effect	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
acute	O	ADJ	B
nicotine	B-Chemical	NOUN	B
injection	O	NOUN	B
induces	O	VERB	B
a	O	DET	O
pronounced	O	ADJ	O
hyperactivity	B-Disease	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
habituated	O	VERB	B
to	O	PART	O
the	O	DET	O
test	O	NOUN	B
environment	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
mediated	O	VERB	O
by	O	ADP	O
central	O	ADJ	B
nicotine	B-Chemical	NOUN	I
receptors	O	NOUN	I
,	O	PUNCT	O
possibly	O	ADV	O
located	O	ADJ	O
on	O	ADP	O
dopaminergic	O	ADJ	B
neurons	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
also	O	ADV	O
requires	O	VERB	O
the	O	DET	O
activation	O	NOUN	B
of	O	ADP	O
both	O	CCONJ	O
D1	O	NOUN	B
and	O	CCONJ	O
D2	O	NOUN	B
dopamine	B-Chemical	NOUN	I


Neuropsychiatric	O	ADJ	B
side	O	NOUN	I
effects	O	NOUN	I
after	O	ADP	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
mefloquine	B-Chemical	NOUN	B
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
describes	O	VERB	O
neuropsychiatric	O	ADJ	B
side	O	NOUN	I
effects	O	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
after	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
mefloquine	B-Chemical	NOUN	B
.	O	PUNCT	O


Reactions	O	NOUN	B
consisted	O	VERB	O
mainly	O	ADV	O
of	O	ADP	O
seizures	B-Disease	NOUN	B
,	O	PUNCT	O
acute	O	ADJ	B
psychoses	B-Disease	NOUN	I
,	O	PUNCT	O
anxiety	B-Disease	NOUN	B
neurosis	I-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
major	O	ADJ	O
disturbances	B-Disease	NOUN	B
of	I-Disease	ADP	O
sleep-wake	I-Disease	ADJ	B
rhythm	I-Disease	NOUN	I
.	O	PUNCT	O


Side	O	ADJ	B
effects	O	NOUN	I
occurred	O	VERB	O
after	O	ADP	O
both	O	CCONJ	O
therapeutic	O	ADJ	B
and	O	CCONJ	O
prophylactic	O	ADJ	B
intake	O	NOUN	I
and	O	CCONJ	O
were	O	AUX	O
graded	O	VERB	O
from	O	ADP	O
moderate	O	ADJ	B
to	O	ADP	O
severe	O	ADJ	B
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
risk	O	NOUN	B
analysis	O	NOUN	I
of	O	ADP	O
neuropsychiatric	O	ADJ	B
side	O	NOUN	I
effects	O	NOUN	I
in	O	ADP	O
Germany	O	PROPN	B
,	O	PUNCT	O
it	O	PRON	O
is	O	AUX	O
estimated	O	VERB	O
that	O	SCONJ	O
one	O	NUM	O
of	O	ADP	O
8	O	NUM	O
,	O	PUNCT	O
000	O	NUM	O
mefloquine	B-Chemical	NOUN	B
users	O	NOUN	B
suffers	O	VERB	O
from	O	ADP	O
such	O	ADJ	O
reactions	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
incidence	O	NOUN	B
calculation	O	NOUN	O
revealed	O	VERB	B
that	O	SCONJ	O
one	O	NUM	O
of	O	ADP	O
215	O	NUM	O
therapeutic	O	ADJ	B
users	O	NOUN	I
had	O	AUX	O
reactions	O	NOUN	B
,	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
one	O	NUM	O
of	O	ADP	O
13	O	NUM	O
,	O	PUNCT	O
000	O	NUM	O
in	O	ADP	O
the	O	DET	O
prophylaxis	O	NOUN	B
group	O	NOUN	I
,	O	PUNCT	O
making	O	VERB	O
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
neuropsychiatric	O	ADJ	B
reactions	O	NOUN	I
after	O	ADP	O
mefloquine	B-Chemical	NOUN	B
treatment	O	NOUN	B
60	O	NUM	O
times	O	NOUN	O
higher	O	ADJ	B
than	O	ADP	O
after	O	ADP	O
prophylaxis	O	NOUN	B
.	O	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
certain	O	ADJ	O
limitations	O	NOUN	B
for	O	ADP	O
malaria	B-Disease	NOUN	B
prophylaxis	O	NOUN	B
and	O	CCONJ	O
treatment	O	NOUN	B
with	O	ADP	O
mefloquine	B-Chemical	NOUN	B


Reduction	O	NOUN	B
in	O	ADP	O
injection	O	NOUN	B
pain	B-Disease	NOUN	I
using	O	VERB	O
buffered	O	ADJ	B
lidocaine	B-Chemical	NOUN	I
as	O	ADP	O
a	O	DET	O
local	O	ADJ	B
anesthetic	O	NOUN	O
before	O	ADP	O
cardiac	O	ADJ	B
catheterization	O	NOUN	I
.	O	PUNCT	O


Previous	O	ADJ	O
reports	O	NOUN	B
have	O	AUX	O
suggested	O	VERB	O
that	O	SCONJ	O
pain	B-Disease	NOUN	B
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
injection	O	NOUN	B
of	O	ADP	O
lidocaine	B-Chemical	NOUN	B
is	O	AUX	O
related	O	ADJ	O
to	O	PART	O
the	O	DET	O
acidic	O	ADJ	B
pH	O	NOUN	B
of	O	ADP	O
the	O	DET	O
solution	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
determine	O	VERB	O
if	O	SCONJ	O
the	O	DET	O
addition	O	NOUN	O
of	O	ADP	O
a	O	DET	O
buffering	O	NOUN	B
solution	O	NOUN	I
to	O	PART	O
adjust	O	VERB	O
the	O	DET	O
pH	O	NOUN	B
of	O	ADP	O
lidocaine	B-Chemical	NOUN	B
into	O	ADP	O
the	O	DET	O
physiologic	O	ADJ	B
range	O	NOUN	O
would	O	AUX	O
reduce	O	VERB	B
pain	B-Disease	NOUN	B
during	O	ADP	O
injection	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
performed	O	VERB	O
a	O	DET	O
blinded	O	ADJ	O
randomized	O	ADJ	B
study	O	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
undergoing	O	VERB	O
cardiac	O	ADJ	B
catheterization	O	NOUN	I
.	O	PUNCT	O


Twenty	O	NUM	O
patients	O	NOUN	B
were	O	AUX	O
asked	O	VERB	O
to	O	PART	O
quantify	O	VERB	B
the	O	DET	O
severity	O	NOUN	B
of	O	ADP	O
pain	B-Disease	NOUN	B
after	O	ADP	O
receiving	O	VERB	O
standard	O	ADJ	O
lidocaine	B-Chemical	NOUN	B
in	O	ADP	O
one	O	NUM	O
femoral	O	ADJ	B
area	O	NOUN	I
and	O	CCONJ	O
buffered	O	ADJ	B
lidocaine	B-Chemical	NOUN	I
in	O	ADP	O
the	O	DET	O
opposite	O	ADJ	O
femoral	O	ADJ	B
area	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
mean	O	ADJ	B
pain	B-Disease	NOUN	I
score	O	NOUN	I
for	O	ADP	O
buffered	O	ADJ	B
lidocaine	B-Chemical	NOUN	I
was	O	AUX	O
significantly	O	ADV	O
lower	O	ADJ	O
than	O	ADP	O
the	O	DET	O
mean	O	ADJ	B
score	O	NOUN	I
for	O	ADP	O
standard	O	ADJ	B
lidocaine	B-Chemical	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
+/-	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
vs	O	CCONJ	O
.	O	PUNCT	O


3	O	X	O
.	O	PUNCT	O


8	O	NUM	O
+/-	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


03	O	NUM	O
).	O	PUNCT	O
The	O	DET	O
pH	O	ADJ	B
adjustment	O	NOUN	B
of	O	ADP	O
standard	O	ADJ	B
lidocaine	B-Chemical	NOUN	B
can	O	AUX	O
be	O	AUX	O
accomplished	O	VERB	O
easily	O	ADV	O
in	O	ADP	O
the	O	DET	O
catheterization	O	NOUN	B
laboratory	O	NOUN	B
before	O	ADP	O
injection	O	NOUN	B
and	O	CCONJ	O
results	O	VERB	B
in	O	ADP	O
a	O	DET	O
reduction	O	NOUN	B
of	O	ADP	O
the	O	DET	O
pain	B-Disease	NOUN	B


Randomized	O	ADJ	B
,	O	PUNCT	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	NOUN	B
trial	O	NOUN	B
of	O	ADP	O
mazindol	B-Chemical	NOUN	B
in	O	ADP	O
Duchenne	B-Disease	NOUN	B
dystrophy	I-Disease	NOUN	I
.	O	PUNCT	O


There	O	PRON	O
is	O	AUX	O
evidence	O	NOUN	B
that	O	SCONJ	O
growth	O	NOUN	B
hormone	O	NOUN	I
may	O	AUX	O
be	O	AUX	O
related	O	ADJ	O
to	O	PART	O
the	O	DET	O
progression	O	NOUN	B
of	O	ADP	O
weakness	B-Disease	NOUN	B
in	O	ADP	O
Duchenne	B-Disease	NOUN	B
dystrophy	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
conducted	O	VERB	O
a	O	DET	O
12	O	NUM	O
-	O	PUNCT	O
month	O	NOUN	B
controlled	O	VERB	B
trial	O	NOUN	I
of	O	ADP	O
mazindol	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
putative	O	ADJ	B
growth	O	NOUN	I
hormone	O	NOUN	I
secretion	O	NOUN	O
inhibitor	O	NOUN	O
,	O	PUNCT	O
in	O	ADP	O
83	O	NUM	O
boys	O	NOUN	B
with	O	ADP	O
Duchenne	B-Disease	NOUN	B
dystrophy	I-Disease	NOUN	I
.	O	PUNCT	O


Muscle	O	NOUN	B
strength	O	NOUN	I
,	O	PUNCT	O
contractures	O	NOUN	B
,	O	PUNCT	O
functional	O	ADJ	B
ability	O	NOUN	I
and	O	CCONJ	O
pulmonary	O	ADJ	B
function	O	NOUN	I
were	O	AUX	O
tested	O	VERB	B
at	O	ADP	O
baseline	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
6	O	NUM	O
and	O	CCONJ	O
12	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
mazindol	B-Chemical	NOUN	B
(	O	PUNCT	O
3	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
d	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
placebo	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
study	O	NOUN	B
was	O	AUX	O
designed	O	VERB	O
to	O	PART	O
have	O	AUX	O
a	O	DET	O
power	O	NOUN	O
of	O	ADP	O
greater	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


90	O	NUM	O
to	O	PART	O
detect	O	VERB	B
a	O	DET	O
slowing	O	NOUN	O
to	O	ADP	O
25	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
expected	O	ADJ	O
rate	O	NOUN	B
of	O	ADP	O
progression	O	NOUN	B
of	O	ADP	O
weakness	B-Disease	NOUN	B
at	O	ADP	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
.	O	PUNCT	O


Mazindol	B-Chemical	NOUN	B
did	O	AUX	O
not	O	PART	O
benefit	O	VERB	O
strength	O	NOUN	B
at	O	ADP	O
any	O	DET	O
point	O	NOUN	O
in	O	ADP	O
the	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


Side	O	ADJ	B
effects	O	NOUN	I
attributable	O	ADJ	O
to	O	PART	O
mazindol	B-Chemical	NOUN	B
included	O	VERB	O
decreased	B-Disease	VERB	B
appetite	I-Disease	NOUN	I
(	O	PUNCT	O
36	O	NUM	O
%),	O	ADV	O
dry	B-Disease	ADJ	B
mouth	I-Disease	NOUN	I
(	O	PUNCT	O
10	O	NUM	O
%),	O	ADJ	O
behavioral	O	ADJ	B
change	O	NOUN	I
(	O	PUNCT	O
22	O	NUM	O
%),	O	ADJ	O
and	O	CCONJ	O
gastrointestinal	B-Disease	ADJ	B
symptoms	I-Disease	NOUN	I
(	O	PUNCT	O
18	O	NUM	O
%);	O	NUM	O
mazindol	B-Chemical	NOUN	B
dosage	O	NOUN	B
was	O	AUX	O
reduced	O	VERB	B
in	O	ADP	O
43	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
mazindol	B-Chemical	NOUN	B
on	O	ADP	O
GH	O	NOUN	B
secretion	O	NOUN	I
was	O	AUX	O
estimated	O	VERB	O
indirectly	O	ADV	O
by	O	ADP	O
comparing	O	VERB	B
the	O	DET	O
postabsorptive	O	ADJ	B
IGF	O	NOUN	B
-	O	PUNCT	O
I	O	NOUN	B
levels	O	NOUN	B
obtained	O	VERB	O
following	O	VERB	O
3	O	NUM	O
,	O	PUNCT	O
6	O	NUM	O
,	O	PUNCT	O
9	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
12	O	NUM	O
months	O	NOUN	B
in	O	ADP	O
the	O	DET	O
mazindol	B-Chemical	NOUN	B
treated	O	VERB	B
to	O	PART	O
those	O	DET	O
in	O	ADP	O
the	O	DET	O
placebo	O	NOUN	B
groups	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
mazindol	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
patients	O	NOUN	B
gained	O	VERB	O
less	O	ADJ	O
weight	O	NOUN	O
and	O	CCONJ	O
height	O	NOUN	B
than	O	ADP	O
placebo	O	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
patients	O	NOUN	B
,	O	PUNCT	O
no	O	DET	O
significant	O	ADJ	O
effect	O	NOUN	O
on	O	ADP	O
IGF	O	PROPN	B
-	O	PUNCT	O
I	O	NOUN	B
levels	O	NOUN	B
was	O	AUX	O
observed	O	VERB	B
.	O	PUNCT	O


Mazindol	B-Chemical	NOUN	B
doses	O	NOUN	B
not	O	PART	O
slow	O	VERB	O
the	O	DET	O
progression	O	NOUN	B
of	O	ADP	O
weakness	B-Disease	NOUN	B
in	O	ADP	O
Duchenne	B-Disease	NOUN	B
dystrophy	I-Disease	NOUN	I


Pentoxifylline	B-Chemical	NOUN	B
(	O	PUNCT	O
Trental	B-Chemical	NOUN	B
)	O	PUNCT	O
does	O	AUX	O
not	O	PART	O
inhibit	O	VERB	B
dipyridamole	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
coronary	O	ADJ	B
hyperemia	B-Disease	NOUN	I
:	O	PUNCT	O
implications	O	NOUN	O
for	O	ADP	O
dipyridamole	B-Chemical	NOUN	B
-	O	PUNCT	O
thallium	B-Chemical	NOUN	B
-	O	PUNCT	O
201	O	NUM	O
myocardial	O	ADJ	B
imaging	O	NOUN	I
.	O	PUNCT	O


Dipyridamole	B-Chemical	NOUN	B
-	O	PUNCT	O
thallium	B-Chemical	NOUN	B
-	O	PUNCT	O
201	O	NUM	O
imaging	O	NOUN	B
is	O	AUX	O
often	O	ADV	O
performed	O	VERB	O
in	O	ADP	O
patients	O	NOUN	B
unable	O	ADJ	O
to	O	PART	O
exercise	O	VERB	B
because	O	SCONJ	O
of	O	ADP	O
peripheral	B-Disease	ADJ	B
vascular	I-Disease	ADJ	I
disease	I-Disease	NOUN	I
.	O	PUNCT	O


Many	O	ADJ	O
of	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
are	O	AUX	O
taking	O	VERB	O
pentoxifylline	B-Chemical	NOUN	B
(	O	PUNCT	O
Trental	B-Chemical	NOUN	B
),	O	PUNCT	O
a	O	DET	O
methylxanthine	B-Chemical	NOUN	B
derivative	O	NOUN	I
which	O	DET	O
may	O	AUX	O
improve	O	VERB	O
intermittent	B-Disease	ADJ	B
claudication	I-Disease	NOUN	I
.	O	PUNCT	O


Whether	O	SCONJ	O
pentoxifylline	B-Chemical	NOUN	B
inhibits	O	VERB	B
dipyridamole	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
coronary	O	ADJ	B
hyperemia	B-Disease	NOUN	I
like	O	ADP	O
other	O	ADJ	O
methylxanthines	B-Chemical	NOUN	B
such	O	ADJ	O
as	O	ADP	O
theophylline	B-Chemical	NOUN	B
and	O	CCONJ	O
should	O	AUX	O
be	O	AUX	O
stopped	O	VERB	O
prior	O	ADV	O
to	O	PART	O
dipyridamole	B-Chemical	NOUN	B
-	O	PUNCT	O
thallium	B-Chemical	NOUN	B
-	O	PUNCT	O
201	O	NUM	O
imaging	O	NOUN	B
is	O	AUX	O
unknown	O	ADJ	O
.	O	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
studied	O	VERB	O
the	O	DET	O
hyperemic	O	ADJ	B
response	O	NOUN	I
to	O	PART	O
dipyridamole	B-Chemical	NOUN	B
in	O	ADP	O
seven	O	NUM	O
open	O	ADJ	B
-	O	PUNCT	O
chest	O	NOUN	B
anesthetized	O	ADJ	B
dogs	O	NOUN	B
after	O	ADP	O
pretreatment	O	NOUN	B
with	O	ADP	O
either	O	CCONJ	O
pentoxifylline	B-Chemical	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
,	O	PUNCT	O
7	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
,	O	PUNCT	O
or	O	CCONJ	O
15	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
i	O	X	O
.	O	PUNCT	O


v	O	ADP	O
.)	O	NOUN	O
or	O	CCONJ	O
theophylline	B-Chemical	NOUN	B
(	O	PUNCT	O
3	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
i	O	X	O
.	O	PUNCT	O


v	O	ADP	O
.).	O	NOUN	O
Baseline	O	NOUN	B
circumflex	O	NOUN	B
coronary	O	ADJ	B
blood	O	NOUN	I
flows	O	NOUN	I
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
significantly	O	ADV	O
among	O	ADP	O
treatment	O	NOUN	B
groups	O	NOUN	I
.	O	PUNCT	O


Dipyridamole	B-Chemical	NOUN	B
significantly	O	ADV	O
increased	O	VERB	B
coronary	O	ADJ	B
blood	O	NOUN	I
flow	O	NOUN	I
before	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
7	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
or	O	CCONJ	O
15	O	NUM	O
mm	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
i	O	X	O
.	O	PUNCT	O


v	O	NOUN	O
.	O	PUNCT	O


pentoxifylline	B-Chemical	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


002	O	NUM	O
).	O	PUNCT	O
Neither	O	CCONJ	O
dose	O	NOUN	B
of	O	ADP	O
pentoxifylline	B-Chemical	NOUN	B
significantly	O	ADV	O
decreased	O	VERB	B
the	O	DET	O
dipyridamole	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hyperemia	B-Disease	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
peak	O	ADJ	B
coronary	O	ADJ	I
blood	O	NOUN	I
flow	O	NOUN	I
was	O	AUX	O
significantly	O	ADV	O
lower	O	ADJ	O
after	O	ADP	O
theophylline	B-Chemical	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
).	O	PUNCT	O
We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
pentoxyifylline	B-Chemical	NOUN	B
does	O	AUX	O
not	O	PART	O
inhibit	O	VERB	B
dipyridamole	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
coronary	O	ADJ	B
hyperemia	B-Disease	NOUN	I


Cause	O	NOUN	B
of	O	ADP	I
death	B-Disease	NOUN	I
among	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
Parkinson's	B-Disease	ADJ	O
disease	I-Disease	NOUN	O
:	O	PUNCT	O
a	O	DET	O
rare	O	ADJ	B
mortality	O	NOUN	B
due	O	ADJ	O
to	O	ADP	O
cerebral	B-Disease	ADJ	B
haemorrhage	I-Disease	NOUN	I
.	O	PUNCT	O


Causes	O	NOUN	B
of	O	ADP	O
death	B-Disease	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
special	O	ADJ	O
reference	O	NOUN	O
to	O	ADP	O
cerebral	B-Disease	ADJ	B
haemorrhage	I-Disease	NOUN	I
,	O	PUNCT	O
among	O	ADP	O
240	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
pathologically	O	ADV	B
verified	O	VERB	O
Parkinson's	B-Disease	ADJ	O
disease	I-Disease	NOUN	B
were	O	AUX	O
investigated	O	VERB	B
using	O	VERB	O
the	O	DET	O
Annuals	O	PROPN	B
of	O	ADP	O
the	O	DET	O
Pathological	O	ADJ	B
Autopsy	O	PROPN	B
Cases	O	NOUN	B
in	O	ADP	O
Japan	O	PROPN	B
from	O	ADP	O
1981	O	NUM	O
to	O	ADP	O
1985	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
leading	O	NOUN	O
causes	O	NOUN	O
of	O	ADP	O
death	B-Disease	NOUN	B
were	O	AUX	O
pneumonia	B-Disease	NOUN	B
and	O	CCONJ	O
bronchitis	B-Disease	NOUN	B
(	O	PUNCT	O
44	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
%),	O	ADJ	O
malignant	O	ADJ	B
neoplasms	B-Disease	NOUN	I
(	O	PUNCT	O
11	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
%),	O	ADJ	B
heart	B-Disease	NOUN	I
diseases	I-Disease	NOUN	I
(	O	PUNCT	O
4	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
%),	O	ADJ	O
cerebral	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
(	O	PUNCT	O
3	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
%)	O	NOUN	B
and	O	CCONJ	O
septicaemia	B-Disease	NOUN	B
(	O	PUNCT	O
3	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
%).	O	ADJ	O
Cerebral	B-Disease	ADJ	B
haemorrhage	I-Disease	NOUN	I
was	O	AUX	O
the	O	DET	O
11th	O	ADJ	O
most	O	ADV	O
frequent	O	ADJ	B
cause	O	NOUN	B
of	O	ADP	I
death	B-Disease	NOUN	B
,	O	PUNCT	O
accounting	O	VERB	O
for	O	ADP	O
only	O	ADV	O
0	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
deaths	B-Disease	NOUN	B
among	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
it	O	PRON	O
was	O	AUX	O
the	O	DET	O
5th	O	NOUN	O
most	O	ADV	O
common	O	ADJ	O
cause	O	NOUN	B
of	O	ADP	I
death	B-Disease	NOUN	B
among	O	ADP	O
the	O	DET	O
Japanese	O	ADJ	B
general	O	ADJ	B
population	O	NOUN	I
in	O	ADP	O
1985	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
low	O	ADJ	B
incidence	O	NOUN	B
of	O	ADP	O
cerebral	B-Disease	ADJ	B
haemorrhage	I-Disease	NOUN	I
as	O	ADP	O
a	O	DET	O
cause	O	NOUN	O
of	O	ADP	O
death	B-Disease	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
Parkinson's	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
may	O	AUX	O
reflect	O	VERB	O
the	O	DET	O
hypotensive	B-Disease	ADJ	B
effect	O	NOUN	O
of	O	ADP	O
levodopa	B-Chemical	NOUN	B
and	O	CCONJ	O
a	O	DET	O
hypotensive	B-Disease	ADJ	B
mechanism	O	NOUN	B
due	O	ADJ	O
to	O	PART	O
reduced	O	VERB	B
noradrenaline	B-Chemical	NOUN	B
levels	O	NOUN	B
in	O	ADP	O
the	O	DET	O
parkinsonian	B-Disease	ADJ	B


Tolerance	O	NOUN	B
and	O	CCONJ	O
antiviral	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
ribavirin	B-Chemical	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
Argentine	B-Disease	ADJ	B
hemorrhagic	I-Disease	ADJ	I
fever	I-Disease	NOUN	I
.	O	PUNCT	O


Tolerance	O	NOUN	B
and	O	CCONJ	O
antiviral	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
ribavirin	B-Chemical	NOUN	B
was	O	AUX	O
studied	O	VERB	O
in	O	ADP	O
6	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
Argentine	B-Disease	ADJ	B
hemorrhagic	I-Disease	ADJ	I
fever	I-Disease	NOUN	I
(	O	PUNCT	O
AHF	B-Disease	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
more	O	ADJ	O
than	O	ADP	O
8	O	NUM	O
days	O	NOUN	B
of	O	ADP	O
evolution	O	NOUN	B
.	O	PUNCT	O


Administration	O	NOUN	B
of	O	ADP	O
ribavirin	B-Chemical	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
a	O	DET	O
neutralization	O	NOUN	B
of	O	ADP	O
viremia	B-Disease	NOUN	B
and	O	CCONJ	O
a	O	DET	O
drop	O	NOUN	B
of	O	ADP	O
endogenous	O	ADJ	B
interferon	O	NOUN	B
titers	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
average	O	ADJ	B
time	O	NOUN	O
of	O	ADP	O
death	B-Disease	NOUN	B
was	O	AUX	O
delayed	O	VERB	B
.	O	PUNCT	O


A	O	DET	O
reversible	O	ADJ	O
anemia	B-Disease	NOUN	B
was	O	AUX	O
the	O	DET	O
only	O	ADV	O
adverse	O	ADJ	B
effect	O	NOUN	I
observed	O	VERB	B
.	O	PUNCT	O


From	O	ADP	O
these	O	DET	O
results	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
ribavirin	B-Chemical	NOUN	B
has	O	AUX	O
an	O	DET	O
antiviral	O	ADJ	B
effect	O	NOUN	I
in	O	ADP	O
advanced	O	ADJ	O
cases	O	NOUN	B
of	O	ADP	O
AHF	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
that	O	SCONJ	O
anemia	B-Disease	NOUN	B
,	O	PUNCT	O
the	O	DET	O
only	O	ADV	O
secondary	O	ADJ	B
reaction	O	NOUN	O
observed	O	VERB	B
,	O	PUNCT	O
can	O	AUX	O
be	O	AUX	O
easily	O	ADV	O
managed	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
possible	O	ADJ	O
beneficial	O	ADJ	O
effect	O	NOUN	B
of	O	ADP	O
ribavirin	B-Chemical	NOUN	B
during	O	ADP	O
the	O	DET	O
initial	O	ADJ	B
days	O	NOUN	B
of	O	ADP	O
AHF	B-Disease	NOUN	B


Dipyridamole	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
myocardial	B-Disease	ADJ	B
ischemia	I-Disease	NOUN	I
.	O	PUNCT	O


Angina	B-Disease	ADJ	B
and	O	CCONJ	O
ischemic	O	ADJ	B
electrocardiographic	O	ADJ	B
changes	O	NOUN	I
occurred	O	VERB	O
after	O	ADP	O
administration	O	NOUN	B
of	O	ADP	O
oral	O	ADJ	B
dipyridamole	B-Chemical	NOUN	I
in	O	ADP	O
four	O	NUM	O
patients	O	NOUN	B
awaiting	O	VERB	O
urgent	O	ADJ	O
myocardial	O	ADJ	B
revascularization	O	NOUN	I
procedures	O	NOUN	I
.	O	PUNCT	O


To	O	ADP	O
our	O	PRON	O
knowledge	O	NOUN	B
,	O	PUNCT	O
this	O	DET	O
has	O	AUX	O
not	O	PART	O
previously	O	ADV	O
been	O	AUX	O
reported	O	VERB	O
as	O	ADP	O
a	O	DET	O
side	O	NOUN	B
effect	O	NOUN	I
of	O	ADP	O
preoperative	O	ADJ	B
dipyridamole	B-Chemical	NOUN	B
therapy	O	NOUN	I
,	O	PUNCT	O
although	O	SCONJ	O
dipyridamole	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
myocardial	B-Disease	ADJ	B
ischemia	I-Disease	NOUN	I
has	O	AUX	O
been	O	AUX	O
demonstrated	O	VERB	O
to	O	PART	O
occur	O	VERB	O
in	O	ADP	O
animals	O	NOUN	B
and	O	CCONJ	O
humans	O	NOUN	B
with	O	ADP	O
coronary	B-Disease	ADJ	B
artery	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
.	O	PUNCT	O


Epicardial	O	ADJ	B
coronary	O	ADJ	I
collateral	O	ADJ	I
vessels	O	NOUN	I
were	O	AUX	O
demonstrated	O	VERB	O
in	O	ADP	O
all	O	DET	O
four	O	NUM	O
patients	O	NOUN	B
;	O	PUNCT	O
a	O	DET	O
coronary	O	ADJ	B
"	O	PUNCT	O
steal	O	NOUN	B
"	O	PUNCT	O
phenomenon	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
the	O	DET	O
mechanism	O	NOUN	B
of	O	ADP	O
the	O	DET	O
dipyridamole	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
ischemia	B-Disease	NOUN	B


Inhibition	O	NOUN	B
of	O	ADP	O
immunoreactive	O	ADJ	B
corticotropin	O	NOUN	B
-	O	PUNCT	O
releasing	O	VERB	B
factor	O	NOUN	O
secretion	O	NOUN	O
into	O	ADP	O
the	O	DET	O
hypophysial	O	ADJ	B
-	O	PUNCT	O
portal	O	ADJ	B
circulation	O	NOUN	B
by	O	ADP	O
delayed	O	VERB	B
glucocorticoid	O	NOUN	B
feedback	O	NOUN	I
.	O	PUNCT	O


Nitroprusside	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypotension	B-Disease	NOUN	B
evokes	O	VERB	O
ACTH	O	NOUN	B
secretion	O	NOUN	B
which	O	DET	O
is	O	AUX	O
primarily	O	ADV	O
mediated	O	VERB	O
by	O	ADP	O
enhanced	O	VERB	B
secretion	O	NOUN	B
of	O	ADP	O
immunoreactive	O	ADJ	B
corticotropin	O	NOUN	B
-	O	PUNCT	O
releasing	O	VERB	B
factor	O	NOUN	I
(	O	PUNCT	O
irCRF	O	NOUN	B
)	O	PUNCT	O
into	O	ADP	O
the	O	DET	O
hypophysial	O	ADJ	B
-	O	PUNCT	O
portal	O	ADJ	B
circulation	O	NOUN	B
.	O	PUNCT	O


Portal	O	ADJ	B
plasma	O	NOUN	I
concentrations	O	NOUN	B
of	O	ADP	O
neither	O	CCONJ	O
arginine	B-Chemical	NOUN	B
vasopressin	I-Chemical	NOUN	B
nor	O	CCONJ	O
oxytocin	B-Chemical	NOUN	B
are	O	AUX	O
significantly	O	ADV	O
altered	O	VERB	O
in	O	ADP	O
this	O	DET	O
paradigm	O	NOUN	B
.	O	PUNCT	O


Application	O	NOUN	B
of	O	ADP	O
a	O	DET	O
delayed	O	VERB	B
feedback	O	NOUN	I
signal	O	NOUN	I
,	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
form	O	NOUN	O
of	O	ADP	O
a	O	DET	O
2	O	NUM	B
-	O	PUNCT	O
h	O	NOUN	O
systemic	O	ADJ	B
corticosterone	B-Chemical	NOUN	B
infusion	O	NOUN	B
in	O	ADP	O
urethane	B-Chemical	NOUN	B
-	O	PUNCT	O
anesthetized	O	VERB	B
rats	O	NOUN	B
with	O	ADP	O
pharmacological	O	ADJ	B
blockade	O	NOUN	I
of	O	ADP	O
glucocorticoid	O	NOUN	B
synthesis	O	NOUN	I
,	O	PUNCT	O
is	O	AUX	O
without	O	ADP	O
effect	O	NOUN	B
on	O	ADP	O
the	O	DET	O
resting	O	VERB	B
secretion	O	NOUN	I
of	O	ADP	O
arginine	B-Chemical	NOUN	B
vasopressin	I-Chemical	NOUN	I
and	O	CCONJ	O
oxytocin	B-Chemical	NOUN	B
at	O	ADP	O
any	O	DET	O
corticosterone	B-Chemical	NOUN	B
feedback	O	NOUN	B
dose	O	NOUN	I
tested	O	VERB	B
.	O	PUNCT	O


Resting	O	VERB	B
irCRF	O	NOUN	B
levels	O	NOUN	B
are	O	AUX	O
suppressed	O	VERB	B
only	O	ADV	O
at	O	ADP	O
the	O	DET	O
highest	O	ADJ	B
corticosterone	B-Chemical	NOUN	B
infusion	O	NOUN	B
rate	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
resulted	O	VERB	O
in	O	ADP	O
systemic	O	ADJ	B
corticosterone	B-Chemical	NOUN	B
levels	O	NOUN	B
of	O	ADP	O
40	O	NUM	O
micrograms	O	NOUN	B
/	O	SYM	O
dl	O	NOUN	B
.	O	PUNCT	O


Suppression	O	NOUN	B
of	O	ADP	O
irCRF	O	NOUN	B
secretion	O	NOUN	B
in	O	ADP	O
response	O	NOUN	B
to	O	PART	O
nitroprusside	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypotension	B-Disease	NOUN	B
is	O	AUX	O
observed	O	VERB	B
and	O	CCONJ	O
occurs	O	VERB	B
at	O	ADP	O
a	O	DET	O
plasma	O	NOUN	B
corticosterone	B-Chemical	NOUN	B


Noradrenergic	O	ADJ	B
involvement	O	NOUN	B
in	O	ADP	O
catalepsy	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
delta	B-Chemical	NOUN	B
9-tetrahydrocannabinol	I-Chemical	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
order	O	NOUN	O
to	O	PART	O
elucidate	O	VERB	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
the	O	DET	O
catecholaminergic	O	ADJ	B
system	O	NOUN	I
in	O	ADP	O
the	O	DET	O
cataleptogenic	O	ADJ	B
effect	O	NOUN	B
of	O	ADP	O
delta	B-Chemical	NOUN	B
9-tetrahydrocannabinol	I-Chemical	NOUN	I
(	O	PUNCT	O
THC	B-Chemical	NOUN	B
),	O	PUNCT	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
pretreatment	O	NOUN	B
with	O	ADP	O
6-hydroxydopamine	B-Chemical	NOUN	B
(	O	PUNCT	O
6-OHDA	B-Chemical	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
with	O	ADP	O
desipramine	B-Chemical	NOUN	B
and	O	CCONJ	O
6-OHDA	B-Chemical	NOUN	B
and	O	CCONJ	O
lesions	O	NOUN	B
of	O	ADP	O
the	O	DET	O
locus	O	NOUN	B
coeruleus	O	NOUN	I
were	O	AUX	O
investigated	O	VERB	B
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
cataleptogenic	O	ADJ	B
effect	O	NOUN	B
of	O	ADP	O
THC	B-Chemical	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
reduced	O	VERB	B
in	O	ADP	O
rats	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
6-OHDA	B-Chemical	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
rats	O	NOUN	B
with	O	ADP	O
lesions	O	NOUN	B
of	O	ADP	O
the	O	DET	O
locus	O	NOUN	B
coeruleus	O	NOUN	I
but	O	CCONJ	O
not	O	PART	O
in	O	ADP	O
rats	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
desipramine	B-Chemical	NOUN	B
and	O	CCONJ	O
6-OHDA	B-Chemical	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
compared	O	VERB	B
with	O	ADP	O
control	O	ADJ	B
rats	O	NOUN	B
.	O	PUNCT	O


On	O	ADP	O
the	O	DET	O
contrary	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
cataleptogenic	O	ADJ	B
effect	O	NOUN	B
of	O	ADP	O
haloperidol	B-Chemical	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
reduced	O	VERB	B
in	O	ADP	O
rats	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
desipramine	B-Chemical	NOUN	B
and	O	CCONJ	O
6-OHDA	B-Chemical	NOUN	B
but	O	CCONJ	O
not	O	PART	O
in	O	ADP	O
rats	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
6-OHDA	B-Chemical	NOUN	B
or	O	CCONJ	O
in	O	ADP	O
rats	O	NOUN	B
with	O	ADP	O
lesions	O	NOUN	B
of	O	ADP	O
the	O	DET	O
locus	O	NOUN	B
coeruleus	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
noradrenergic	O	ADJ	B
neurons	O	NOUN	B
have	O	AUX	O
an	O	DET	O
important	O	ADJ	O
role	O	NOUN	O
in	O	ADP	O
the	O	DET	O
manifestation	O	NOUN	B
of	O	ADP	O
catalepsy	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
THC	B-Chemical	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
dopaminergic	O	ADJ	B
neurons	O	NOUN	B
are	O	AUX	O
important	O	ADJ	O
in	O	ADP	O
catalepsy	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
haloperidol	B-Chemical	NOUN	B


Intracranial	O	ADJ	B
pressure	O	NOUN	I
increases	O	VERB	B
during	O	ADP	O
alfentanil	B-Chemical	ADJ	B
-	O	PUNCT	O
induced	O	VERB	B
rigidity	B-Disease	NOUN	B
.	O	PUNCT	O


Intracranial	O	ADJ	B
pressure	O	NOUN	I
(	O	PUNCT	O
ICP	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
measured	O	VERB	O
during	O	ADP	O
alfentanil	B-Chemical	ADJ	B
-	O	PUNCT	O
induced	O	VERB	B
rigidity	B-Disease	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


Ten	O	NUM	O
rats	O	NOUN	B
had	O	AUX	O
arterial	O	ADJ	B
,	O	PUNCT	O
central	O	ADJ	B
venous	O	ADJ	I
(	O	PUNCT	I
CVP	O	NOUN	B
),	O	PUNCT	O
and	O	CCONJ	O
subdural	O	ADJ	B
cannulae	O	NOUN	I
inserted	O	VERB	B
under	O	ADP	O
halothane	B-Chemical	NOUN	B
anesthesia	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
animals	O	NOUN	B
were	O	AUX	O
mechanically	O	ADV	B
ventilated	O	VERB	I
to	O	PART	O
achieve	O	VERB	O
normocarbia	O	ADJ	B
(	O	PUNCT	O
PCO2	O	NOUN	B
=	O	ADJ	O
42	O	NUM	O
+/-	O	CCONJ	O
1	O	NUM	O
mmHg	O	NOUN	B
,	O	PUNCT	O
mean	O	NOUN	O
+/-	O	CCONJ	O
SE	O	NOUN	B
).	O	PUNCT	O
Following	O	VERB	O
instrumentation	O	NOUN	B
,	O	PUNCT	O
halothane	B-Chemical	NOUN	B
was	O	AUX	O
discontinued	O	VERB	B
and	O	CCONJ	O
alfentanil	B-Chemical	NOUN	B
(	O	PUNCT	O
125	O	NUM	O
mu	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
administered	O	VERB	B
iv	O	NOUN	O
during	O	ADP	O
emergence	O	NOUN	B
from	O	ADP	O
halothane	B-Chemical	NOUN	B
anesthesia	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
five	O	NUM	O
rats	O	NOUN	B
that	O	PRON	O
developed	O	VERB	O
somatic	B-Disease	ADJ	B
rigidity	I-Disease	NOUN	B
,	O	PUNCT	O
ICP	O	NOUN	B
and	O	CCONJ	O
CVP	O	NOUN	B
increased	O	VERB	B
significantly	O	ADV	O
above	O	ADP	O
baseline	O	NOUN	B
(	O	PUNCT	O
delta	O	NOUN	B
ICP	O	NOUN	I
7	O	NUM	I
.	O	PUNCT	O


5	O	NUM	O
+/-	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
mmHg	O	NOUN	B
,	O	PUNCT	O
delta	O	NOUN	B
CVP	O	NOUN	I
5	O	NUM	I
.	O	PUNCT	O


9	O	NUM	O
+/-	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
mmHg	O	NOUN	B
).	O	PUNCT	O
These	O	DET	O
variables	O	NOUN	B
returned	O	VERB	O
to	O	ADP	O
baseline	O	NOUN	B
when	O	SCONJ	O
rigidity	B-Disease	NOUN	B
was	O	AUX	O
abolished	O	VERB	O
with	O	ADP	O
metocurine	B-Chemical	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
five	O	NUM	O
rats	O	NOUN	B
that	O	PRON	O
did	O	AUX	O
not	O	PART	O
become	O	VERB	O
rigid	O	ADJ	B
,	O	PUNCT	O
ICP	O	NOUN	B
and	O	CCONJ	O
CVP	O	NOUN	B
did	O	AUX	O
not	O	PART	O
change	O	VERB	O
following	O	VERB	O
alfentanil	B-Chemical	NOUN	B
.	O	PUNCT	O


These	O	DET	O
observations	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
rigidity	B-Disease	NOUN	B
should	O	AUX	O
be	O	AUX	O
prevented	O	VERB	B
when	O	SCONJ	O
alfentanil	B-Chemical	ADJ	B


Adverse	O	ADJ	B
cardiac	O	ADJ	I
effects	O	NOUN	I
during	O	ADP	O
induction	O	NOUN	B
chemotherapy	O	NOUN	O
treatment	O	NOUN	B
with	O	ADP	O
cis-platin	B-Chemical	NOUN	B
and	O	CCONJ	O
5-fluorouracil	B-Chemical	NOUN	B
.	O	PUNCT	O


Survival	O	NOUN	B
for	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
advanced	O	ADJ	B
head	B-Disease	NOUN	I
and	I-Disease	CCONJ	O
neck	I-Disease	NOUN	O
carcinoma	I-Disease	NOUN	O
and	O	CCONJ	O
esophageal	B-Disease	NOUN	B
carcinoma	I-Disease	NOUN	I
is	O	AUX	O
poor	O	ADJ	B
with	O	ADP	O
radiotherapy	O	NOUN	B
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
surgery	O	NOUN	B
.	O	PUNCT	O


Obviously	O	ADV	O
,	O	PUNCT	O
there	O	PRON	O
is	O	AUX	O
a	O	DET	O
need	O	NOUN	O
for	O	ADP	O
effective	O	ADJ	B
chemotherapy	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
,	O	PUNCT	O
cis-platin	B-Chemical	NOUN	B
(	O	PUNCT	O
80	O	NUM	O
-	O	SYM	O
120	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2BSA	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
5-FU	B-Chemical	NOUN	B
(	O	PUNCT	O
1000	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2BSA	O	NOUN	B
daily	O	ADV	B
as	O	ADP	O
a	O	DET	O
continuous	O	ADJ	B
infusion	O	NOUN	B
during	O	ADP	O
5	O	NUM	O
days	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
given	O	VERB	O
to	O	PART	O
76	O	NUM	O
patients	O	NOUN	B
before	O	ADP	O
radiotherapy	O	NOUN	B
and	O	CCONJ	O
surgery	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
clarify	O	VERB	O
the	O	DET	O
incidence	O	NOUN	B
and	O	CCONJ	O
severity	O	NOUN	B
of	O	ADP	O
adverse	O	ADJ	B
cardiac	O	ADJ	I
effects	O	NOUN	I
to	O	PART	O
this	O	DET	O
treatment	O	NOUN	B
.	O	PUNCT	O


Before	O	ADP	B
treatment	O	NOUN	B
all	O	DET	O
patients	O	NOUN	B
had	O	AUX	O
a	O	DET	O
cardiac	O	ADJ	B
evaluation	O	NOUN	I
and	O	CCONJ	O
during	O	ADP	O
treatment	O	NOUN	B
serial	O	ADJ	O
ECG	O	PROPN	B
recordings	O	NOUN	I
were	O	AUX	O
performed	O	VERB	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
pre	O	ADJ	B
-	O	PUNCT	O
treatment	O	NOUN	B
evaluation	O	NOUN	B
,	O	PUNCT	O
signs	O	NOUN	O
of	O	ADP	O
cardiovascular	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
33	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
43	O	NUM	O
%).	O	NOUN	O
During	O	ADP	O
treatment	O	NOUN	B
,	O	PUNCT	O
adverse	O	ADJ	B
cardiac	O	ADJ	I
effects	O	NOUN	I
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
14	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
18	O	NUM	O
%).	O	NOUN	O
The	O	DET	O
mean	O	ADJ	O
age	O	NOUN	B
of	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
was	O	AUX	O
the	O	DET	O
same	O	ADJ	O
as	O	ADP	O
for	O	ADP	O
the	O	DET	O
entire	O	ADJ	O
group	O	NOUN	B
,	O	PUNCT	O
64	O	NUM	O
years	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
cardiotoxicity	B-Disease	NOUN	B
was	O	AUX	O
not	O	PART	O
higher	O	ADJ	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
signs	O	NOUN	O
of	O	ADP	O
cardiovascular	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
than	O	ADP	O
in	O	ADP	O
those	O	DET	O
without	O	ADP	O
in	O	ADP	O
the	O	DET	O
pre	O	ADJ	B
-	O	PUNCT	O
treatment	O	NOUN	B
evaluation	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
most	O	ADV	O
common	O	ADJ	O
signs	O	NOUN	B
of	O	ADP	O
cardiotoxicity	B-Disease	NOUN	B
were	O	AUX	O
chest	B-Disease	ADJ	B
pain	I-Disease	NOUN	I
,	O	PUNCT	O
ST	O	ADJ	B
-	O	PUNCT	O
T	O	NOUN	B
wave	O	NOUN	I
changes	O	NOUN	B
and	O	CCONJ	O
atrial	B-Disease	ADJ	B
fibrillation	I-Disease	NOUN	I
.	O	PUNCT	O


This	O	DET	O
was	O	AUX	O
followed	O	VERB	O
by	O	ADP	O
ventricular	B-Disease	ADJ	B
fibrillation	I-Disease	NOUN	I
in	O	ADP	O
one	O	NUM	O
patient	O	NOUN	B
and	O	CCONJ	O
sudden	B-Disease	ADJ	B
death	I-Disease	NOUN	I
in	O	ADP	O
another	O	DET	O
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
concluded	O	VERB	O
that	O	SCONJ	O
patients	O	NOUN	B
on	O	ADP	O
5-FU	B-Chemical	NOUN	B
treatment	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
under	O	ADP	O
close	O	ADJ	O
supervision	O	NOUN	B
and	O	CCONJ	O
that	O	SCONJ	O
the	O	DET	O
treatment	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
discontinued	O	VERB	B
if	O	SCONJ	O
chest	B-Disease	ADJ	B
pain	I-Disease	NOUN	I
or	O	CCONJ	O
tachyarrhythmia	B-Disease	NOUN	B


Verapamil	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
carbamazepine	B-Chemical	NOUN	B
neurotoxicity	B-Disease	NOUN	B
.	O	PUNCT	O


A	O	DET	O
report	O	NOUN	B
of	O	ADP	O
two	O	NUM	O
cases	O	NOUN	B
.	O	PUNCT	O


Two	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
signs	O	NOUN	O
of	O	ADP	O
carbamazepine	B-Chemical	NOUN	B
neurotoxicity	B-Disease	NOUN	B
after	O	ADP	O
combined	O	ADJ	B
treatment	O	NOUN	I
with	O	ADP	O
verapamil	B-Chemical	NOUN	B
showed	O	VERB	O
complete	O	ADJ	O
recovery	O	NOUN	B
after	O	ADP	O
discontinuation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
calcium	B-Chemical	NOUN	B
entry	O	NOUN	O
blocker	O	NOUN	B
.	O	PUNCT	O


Use	O	NOUN	O
of	O	ADP	O
verapamil	B-Chemical	NOUN	B
in	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
carbamazepine	B-Chemical	NOUN	B
should	O	AUX	O
either	O	CCONJ	O
be	O	AUX	O
avoided	O	VERB	O
or	O	CCONJ	O
prescribed	O	VERB	B
only	O	ADV	O
with	O	ADP	O
appropriate	O	ADJ	O
adjustment	O	NOUN	B
of	O	ADP	O
the	O	DET	O
carbamazepine	B-Chemical	NOUN	B
dose	O	NOUN	B
(	O	PUNCT	O
usually	O	ADV	O
reduction	O	NOUN	B
of	O	ADP	O
the	O	DET	O
carbamazepine	B-Chemical	NOUN	B


Serial	O	ADJ	O
studies	O	NOUN	O
of	O	ADP	O
auditory	B-Disease	ADJ	B
neurotoxicity	I-Disease	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
receiving	O	VERB	O
deferoxamine	B-Chemical	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


Visual	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
auditory	I-Disease	ADJ	B
neurotoxicity	I-Disease	NOUN	B
was	O	AUX	O
previously	O	ADV	O
documented	O	VERB	B
in	O	ADP	O
42	O	NUM	O
of	O	ADP	O
89	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
transfusion	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
anemia	B-Disease	NOUN	B
who	O	PRON	O
were	O	AUX	O
receiving	O	VERB	O
iron	B-Chemical	NOUN	B
chelation	O	NOUN	I
therapy	O	NOUN	I
with	O	ADP	O
daily	O	ADJ	B
subcutaneous	O	ADJ	B
deferoxamine	B-Chemical	NOUN	I
.	O	PUNCT	O


Twenty	O	NUM	B
-	O	PUNCT	O
two	O	NUM	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
affected	O	VERB	B
group	O	NOUN	B
had	O	AUX	O
abnormal	B-Disease	ADJ	B
audiograms	I-Disease	NOUN	B
with	I-Disease	ADP	O
deficits	I-Disease	NOUN	B
mostly	I-Disease	ADV	O
in	I-Disease	ADP	O
the	I-Disease	DET	O
high	I-Disease	ADJ	B
frequency	I-Disease	NOUN	I
range	I-Disease	NOUN	O
of	I-Disease	ADP	O
4,000	I-Disease	NUM	O
to	I-Disease	PART	O
8,000	I-Disease	NUM	O
Hz	I-Disease	NOUN	O
and	O	CCONJ	O
in	O	ADP	O
the	O	DET	O
hearing	O	NOUN	B
threshold	O	NOUN	O
levels	O	NOUN	B
of	O	ADP	O
30	O	NUM	O
to	O	PART	O
100	O	NUM	O
decibels	O	NOUN	B
.	O	PUNCT	O


When	O	SCONJ	O
deferoxamine	B-Chemical	NOUN	B
therapy	O	NOUN	I
was	O	AUX	O
discontinued	O	VERB	B
and	O	CCONJ	O
serial	O	ADJ	O
studies	O	NOUN	O
were	O	AUX	O
performed	O	VERB	O
,	O	PUNCT	O
audiograms	O	NOUN	B
in	O	ADP	O
seven	O	NUM	O
cases	O	NOUN	B
reverted	O	VERB	O
to	O	PART	O
normal	O	ADJ	B
or	O	CCONJ	O
near	O	ADP	B
normal	O	ADJ	B
within	O	ADP	O
two	O	NUM	O
to	O	PART	O
three	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
nine	O	NUM	O
of	O	ADP	O
13	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
symptoms	O	NOUN	B
became	O	VERB	O
asymptomatic	O	ADJ	B
.	O	PUNCT	O


Audiograms	O	NOUN	B
from	O	ADP	O
15	O	NUM	O
patients	O	NOUN	B
remained	O	VERB	O
abnormal	O	ADJ	B
and	O	CCONJ	O
four	O	NUM	O
patients	O	NOUN	B
required	O	VERB	O
hearing	O	NOUN	B
aids	O	NOUN	I
because	O	SCONJ	O
of	O	ADP	O
permanent	B-Disease	ADJ	B
disability	I-Disease	NOUN	I
.	O	PUNCT	O


Since	O	SCONJ	O
18	O	NUM	O
of	O	ADP	O
the	O	DET	O
22	O	NUM	O
patients	O	NOUN	B
were	O	AUX	O
initially	O	ADV	O
receiving	O	VERB	O
deferoxamine	B-Chemical	NOUN	B
doses	O	NOUN	B
in	O	ADP	O
excess	O	NOUN	B
of	O	ADP	O
the	O	DET	O
commonly	O	ADV	O
recommended	O	VERB	B
50	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
kg	O	NOUN	B
per	O	ADP	O
dose	O	NOUN	B
,	O	PUNCT	O
therapy	O	NOUN	B
was	O	AUX	O
restarted	O	VERB	O
with	O	ADP	O
lower	O	ADJ	B
doses	O	NOUN	I
,	O	PUNCT	O
usually	O	ADV	O
50	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
per	O	ADP	O
dose	O	NOUN	B
or	O	CCONJ	O
less	O	ADV	O
depending	O	VERB	O
on	O	ADP	O
the	O	DET	O
degree	O	NOUN	B
of	O	ADP	O
auditory	B-Disease	ADJ	B
abnormality	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
with	O	ADP	O
the	O	DET	O
exception	O	NOUN	O
of	O	ADP	O
two	O	NUM	O
cases	O	NOUN	B
no	O	DET	O
further	O	ADJ	O
toxicity	B-Disease	NOUN	B
was	O	AUX	O
demonstrated	O	VERB	O
.	O	PUNCT	O


Auditory	O	ADJ	B
deterioration	O	NOUN	I
and	O	CCONJ	O
improvement	O	NOUN	B
,	O	PUNCT	O
demonstrated	O	VERB	O
serially	O	ADV	O
in	O	ADP	O
individual	O	ADJ	B
patients	O	NOUN	B
receiving	O	VERB	B
and	O	CCONJ	O
not	O	PART	O
receiving	O	VERB	O
deferoxamine	B-Chemical	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
provided	O	VERB	O
convincing	O	ADJ	O
evidence	O	NOUN	B
for	O	ADP	O
a	O	DET	O
cause	O	NOUN	B
-	O	PUNCT	O
and	O	CCONJ	O
-	O	PUNCT	O
effect	O	NOUN	B
relation	O	NOUN	O
between	O	ADP	O
deferoxamine	B-Chemical	NOUN	B
administration	O	NOUN	B
and	O	CCONJ	O
ototoxicity	B-Disease	NOUN	B
.	O	PUNCT	O


Based	O	VERB	O
on	O	ADP	O
these	O	DET	O
data	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
plan	O	NOUN	B
of	O	ADP	O
management	O	NOUN	B
was	O	AUX	O
developed	O	VERB	O
that	O	PRON	O
allows	O	VERB	O
effective	O	ADJ	B
yet	O	ADV	O
safe	O	ADJ	O
administration	O	NOUN	B
of	O	ADP	O
deferoxamine	B-Chemical	NOUN	B
.	O	PUNCT	O


A	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
50	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
kg	O	NOUN	B
is	O	AUX	O
recommended	O	VERB	B
in	O	ADP	O
those	O	DET	O
without	O	ADP	O
audiogram	O	NOUN	B
abnormalities	O	NOUN	I
.	O	PUNCT	O


With	O	ADP	O
mild	O	ADJ	B
toxicity	B-Disease	NOUN	B
,	O	PUNCT	O
a	O	DET	O
reduction	O	NOUN	B
to	O	ADP	O
30	O	NUM	O
or	O	CCONJ	O
40	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
per	O	ADP	O
dose	O	NOUN	B
should	O	AUX	O
result	O	VERB	O
in	O	ADP	O
a	O	DET	O
reversal	O	NOUN	B
of	O	ADP	O
the	O	DET	O
abnormal	O	ADJ	B
results	O	NOUN	O
to	O	PART	O
normal	O	ADJ	B
within	O	ADP	O
four	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


Moderate	O	ADJ	B
abnormalities	O	NOUN	I
require	O	VERB	O
a	O	DET	O
reduction	O	NOUN	B
of	O	ADP	O
deferoxamine	B-Chemical	NOUN	B
to	O	PART	O
25	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
per	O	ADP	O
dose	O	NOUN	B
with	O	ADP	O
careful	O	ADJ	O
monitoring	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
those	O	DET	O
with	O	ADP	O
symptoms	O	NOUN	B
of	O	ADP	O
hearing	B-Disease	VERB	B
loss	I-Disease	NOUN	I
,	O	PUNCT	O
the	O	DET	O
drug	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
stopped	O	VERB	O
for	O	ADP	O
four	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
when	O	SCONJ	O
the	O	DET	O
audiogram	O	NOUN	B
is	O	AUX	O
stable	O	ADJ	B
or	O	CCONJ	O
improved	O	ADJ	B
,	O	PUNCT	O
therapy	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
restarted	O	VERB	B
at	O	ADP	O
10	O	NUM	O
to	O	PART	O
25	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
per	O	ADP	O
dose	O	NOUN	B
.	O	PUNCT	O


Serial	O	ADJ	O
audiograms	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
performed	O	VERB	O
every	O	DET	O
six	O	NUM	O
months	O	NOUN	B
in	O	ADP	O
those	O	DET	O
without	O	ADP	O
problems	O	NOUN	B
and	O	CCONJ	O
more	O	ADV	O
frequently	O	ADV	O
in	O	ADP	O
young	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
normal	O	ADJ	O
serum	O	NOUN	O
ferritin	O	NOUN	O
values	O	NOUN	O
and	O	CCONJ	O
in	O	ADP	O
those	O	DET	O
with	O	ADP	O
auditory	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I


Flurbiprofen	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
juvenile	B-Disease	ADJ	B
rheumatoid	I-Disease	ADJ	I
arthritis	I-Disease	NOUN	I
.	O	PUNCT	O


Thirty	O	NUM	B
-	O	PUNCT	O
four	O	NUM	B
patients	O	NOUN	B
with	O	ADP	O
juvenile	B-Disease	ADJ	B
rheumatoid	I-Disease	ADJ	I
arthritis	I-Disease	NOUN	I
,	O	PUNCT	O
who	O	PRON	O
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
flurbiprofen	B-Chemical	NOUN	B
at	O	ADP	O
a	O	DET	O
maximum	O	ADJ	B
dose	O	NOUN	B
of	O	ADP	O
4	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
/	O	PUNCT	O
day	O	NOUN	B
,	O	PUNCT	O
had	O	AUX	O
statistically	O	ADV	B
significant	O	ADJ	I
decreases	O	NOUN	B
from	O	ADP	O
baseline	O	NOUN	B
in	O	ADP	O
6	O	NUM	O
arthritis	B-Disease	NOUN	B
indices	O	NOUN	I
after	O	ADP	O
12	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


Improvements	O	NOUN	B
were	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
tender	B-Disease	ADJ	B
joints	I-Disease	NOUN	I
,	O	PUNCT	O
the	O	DET	O
severity	O	NOUN	B
of	O	ADP	O
swelling	B-Disease	NOUN	B
and	O	CCONJ	O
tenderness	B-Disease	NOUN	B
,	O	PUNCT	O
the	O	DET	O
time	O	NOUN	B
of	O	ADP	I
walk	O	VERB	I
50	O	NUM	O
feet	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
duration	O	NOUN	B
of	O	ADP	O
morning	B-Disease	NOUN	B
stiffness	I-Disease	NOUN	B
and	O	CCONJ	O
the	O	DET	O
circumference	O	NOUN	B
of	O	ADP	O
the	O	DET	O
left	O	ADJ	B
knee	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
most	O	ADV	O
frequently	O	ADV	O
observed	O	VERB	B
side	O	NOUN	B
effect	O	NOUN	I
was	O	AUX	O
fecal	B-Disease	ADJ	B
occult	I-Disease	ADJ	I
blood	I-Disease	NOUN	I
(	O	PUNCT	O
25	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
);	O	ADJ	O
however	O	ADV	O
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	O
other	O	ADJ	O
evidence	O	NOUN	B
of	O	ADP	O
gastrointestinal	B-Disease	ADJ	B
(GI)	I-Disease	ADJ	I
bleeding	I-Disease	NOUN	B
in	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
.	O	PUNCT	O


One	O	NUM	O
patient	O	NOUN	B
was	O	AUX	O
prematurely	O	ADV	O
discontinued	O	VERB	B
from	O	ADP	O
the	O	DET	O
study	O	NOUN	B
for	O	ADP	O
severe	O	ADJ	B
headache	B-Disease	NOUN	B
and	O	CCONJ	O
abdominal	B-Disease	ADJ	B
pain	I-Disease	NOUN	I


The	O	DET	O
correlation	O	NOUN	B
between	O	ADP	O
neurotoxic	B-Disease	ADJ	B
esterase	O	NOUN	B
inhibition	O	NOUN	B
and	O	CCONJ	O
mipafox	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
neuropathic	B-Disease	ADJ	B
damage	I-Disease	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
correlation	O	NOUN	B
between	O	ADP	O
neuropathic	B-Disease	ADJ	B
damage	I-Disease	NOUN	I
and	O	CCONJ	O
inhibition	O	NOUN	B
of	O	ADP	O
neurotoxic	B-Disease	ADJ	B
esterase	O	NOUN	I
or	O	CCONJ	O
neuropathy	B-Disease	NOUN	B
target	O	NOUN	O
enzyme	O	NOUN	O
(	O	PUNCT	O
NTE	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
examined	O	VERB	O
in	O	ADP	O
rats	O	NOUN	B
acutely	O	ADV	O
exposed	O	VERB	B
to	O	ADP	I
Mipafox	B-Chemical	PROPN	B
(	O	PUNCT	O
N,	B-Chemical	NOUN	O
N'-diisopropylphosphorodiamidofluoridate	I-Chemical	PROPN	B
),	O	PUNCT	O
a	O	DET	O
neurotoxic	B-Disease	ADJ	B
organophosphate	B-Chemical	NOUN	B
.	O	PUNCT	O


Brain	O	PROPN	B
and	O	CCONJ	O
spinal	O	ADJ	B
cord	O	NOUN	I
NTE	O	NOUN	B
activities	O	NOUN	B
were	O	AUX	O
measured	O	VERB	B
in	O	ADP	O
Long	O	PROPN	B
-	O	PUNCT	O
Evans	O	PROPN	B
male	O	NOUN	B
rats	O	NOUN	B
1	O	NUM	O
hr	O	NOUN	O
post	O	NOUN	B
-	O	PUNCT	O
exposure	O	NOUN	B
to	O	PART	O
various	O	ADJ	O
dosages	O	NOUN	B
of	O	ADP	O
Mipafox	B-Chemical	NOUN	B
(	O	PUNCT	O
ip	O	NOUN	B
,	O	PUNCT	O
1	O	NUM	O
-	O	SYM	O
15	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
).	O	PUNCT	O
These	O	DET	O
data	O	NOUN	B
were	O	AUX	O
correlated	O	VERB	B
with	O	ADP	O
histologically	O	ADV	B
scored	O	VERB	O
cervical	O	ADJ	B
cord	B-Disease	NOUN	I
damage	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
separate	O	ADJ	O
group	O	NOUN	B
of	O	ADP	O
similarly	O	ADV	O
dosed	O	VERB	B
rats	O	NOUN	B
sampled	O	VERB	B
14	O	NUM	O
-	O	SYM	O
21	O	NUM	O
days	O	NOUN	B
post	O	NOUN	B
-	O	PUNCT	O
exposure	O	NOUN	B
.	O	PUNCT	O


Those	O	DET	O
dosages	O	NOUN	B
(	O	PUNCT	O
greater	O	ADJ	O
than	O	ADP	O
or	O	CCONJ	O
equal	O	ADJ	O
to	O	PART	O
10	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
that	O	PRON	O
inhibited	O	VERB	B
mean	O	ADJ	O
NTE	O	NOUN	B
activity	O	NOUN	B
in	O	ADP	O
the	O	DET	O
spinal	O	ADJ	B
cord	O	NOUN	I
greater	O	ADJ	O
than	O	ADP	O
or	O	CCONJ	O
equal	O	ADJ	O
to	O	PART	O
73	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
brain	O	NOUN	B
greater	O	ADJ	O
than	O	ADP	O
or	O	CCONJ	O
equal	O	ADJ	O
to	O	PART	O
67	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
control	O	NOUN	B
values	O	NOUN	I
produced	O	VERB	O
severe	O	ADJ	B
(	O	PUNCT	O
greater	O	ADJ	O
than	O	ADP	O
or	O	CCONJ	O
equal	O	ADJ	O
to	O	PART	O
3	O	NUM	O
)	O	PUNCT	O
cervical	O	ADJ	B
cord	O	NOUN	I
pathology	O	NOUN	B
in	O	ADP	O
85	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
rats	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
dosages	O	NOUN	B
of	O	ADP	O
Mipafox	B-Chemical	PROPN	B
(	O	PUNCT	O
less	O	ADJ	O
than	O	ADP	O
or	O	CCONJ	O
equal	O	ADJ	O
to	O	PART	O
5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
which	O	DET	O
inhibited	O	VERB	B
mean	O	ADJ	O
NTE	O	NOUN	B
activity	O	NOUN	B
in	O	ADP	O
spinal	O	ADJ	B
cord	O	NOUN	I
less	O	ADJ	I
than	O	ADP	O
or	O	CCONJ	O
equal	O	ADJ	O
to	O	PART	O
61	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
brain	O	NOUN	B
less	O	ADJ	O
than	O	ADP	O
or	O	CCONJ	O
equal	O	ADJ	O
to	O	PART	O
60	O	NUM	O
%	O	NOUN	O
produced	O	VERB	O
this	O	DET	O
degree	O	NOUN	B
of	O	ADP	O
cord	B-Disease	NOUN	B
damage	I-Disease	NOUN	I
in	O	ADP	O
only	O	ADV	O
9	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
animals	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
critical	O	ADJ	O
percentage	O	NOUN	B
of	O	ADP	O
NTE	O	NOUN	B
inhibition	O	NOUN	B
in	O	ADP	O
brain	O	NOUN	B
and	O	CCONJ	O
spinal	O	ADJ	B
cord	O	NOUN	I
sampled	O	VERB	B
shortly	O	ADV	O
after	O	ADP	O
Mipafox	B-Chemical	NOUN	B
exposure	O	NOUN	B
can	O	AUX	O
predict	O	VERB	O
neuropathic	B-Disease	ADJ	B
damage	I-Disease	NOUN	I


Cerebral	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
with	O	ADP	O
a	O	DET	O
single	O	ADJ	O
oral	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
phenylpropanolamine	B-Chemical	NOUN	B
.	O	PUNCT	O


Phenylpropanolamine	B-Chemical	NOUN	B
(	O	PUNCT	O
PPA	B-Chemical	PROPN	B
),	O	PUNCT	O
a	O	DET	O
synthetic	O	ADJ	B
sympathomimetic	O	NOUN	B
that	O	PRON	O
is	O	AUX	O
structurally	O	ADV	B
similar	O	ADJ	O
to	O	PART	O
amphetamine	B-Chemical	NOUN	B
,	O	PUNCT	O
is	O	AUX	O
available	O	ADJ	O
over	O	ADP	O
the	O	DET	O
counter	O	NOUN	O
in	O	ADP	O
anorectics	O	NOUN	B
,	O	PUNCT	O
nasal	O	ADJ	B
congestants	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
cold	O	ADJ	B
preparations	O	NOUN	I
.	O	PUNCT	O


Its	O	PRON	O
prolonged	O	ADJ	B
use	O	NOUN	O
or	O	CCONJ	O
overuse	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
seizures	B-Disease	NOUN	B
,	O	PUNCT	O
intracerebral	B-Disease	ADJ	B
hemorrhage	I-Disease	NOUN	I
,	O	PUNCT	O
neuropsychiatric	B-Disease	ADJ	B
symptoms	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
nonhemorrhagic	O	ADJ	B
cerebral	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
the	O	DET	O
case	O	NOUN	B
of	O	ADP	O
a	O	DET	O
young	O	ADJ	B
woman	O	NOUN	B
who	O	PRON	O
suffered	O	VERB	O
a	O	DET	O
cerebral	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
after	O	ADP	O
taking	O	VERB	O
a	O	DET	O
single	O	ADJ	O
oral	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
PPA	B-Chemical	PROPN	B


Treatment	O	NOUN	B
of	O	ADP	O
psoriasis	B-Disease	NOUN	B
with	O	ADP	O
azathioprine	B-Chemical	NOUN	B
.	O	PUNCT	O


Azathioprine	B-Chemical	NOUN	B
treatment	O	NOUN	B
benefited	O	VERB	O
19	O	NUM	O
(	O	PUNCT	O
66	O	NUM	O
%)	O	NOUN	O
out	O	ADP	O
of	O	ADP	O
29	O	NUM	O
patients	O	NOUN	B
suffering	O	VERB	B
from	O	ADP	O
severe	O	ADJ	B
psoriasis	B-Disease	NOUN	B
.	O	PUNCT	O


Haematological	O	ADJ	B
complications	O	NOUN	B
were	O	AUX	O
not	O	PART	O
troublesome	O	ADJ	O
and	O	CCONJ	O
results	O	NOUN	B
of	O	ADP	O
biochemical	O	ADJ	B
liver	O	NOUN	B
function	O	NOUN	I
tests	O	NOUN	O
remained	O	VERB	O
normal	O	ADJ	B
.	O	PUNCT	O


Minimal	O	ADJ	B
cholestasis	B-Disease	NOUN	B
was	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
two	O	NUM	O
cases	O	NOUN	B
and	O	CCONJ	O
portal	O	ADJ	B
fibrosis	B-Disease	NOUN	I
of	O	ADP	O
a	O	DET	O
reversible	O	ADJ	O
degree	O	NOUN	B
in	O	ADP	O
eight	O	NUM	O
.	O	PUNCT	O


Liver	O	NOUN	B
biopsies	O	NOUN	I
should	O	AUX	O
be	O	AUX	O
undertaken	O	VERB	O
at	O	ADP	O
regular	O	ADJ	O
intervals	O	NOUN	B
if	O	SCONJ	O
azathioprine	B-Chemical	NOUN	B
therapy	O	NOUN	I
is	O	AUX	O
continued	O	VERB	O
so	O	SCONJ	O
that	O	SCONJ	O
structural	O	ADJ	B
liver	B-Disease	NOUN	O
damage	I-Disease	NOUN	O


Maternal	O	ADJ	B
lithium	B-Chemical	NOUN	B
and	O	CCONJ	O
neonatal	O	ADJ	B
Ebstein's	B-Disease	NOUN	B
anomaly	I-Disease	NOUN	I
:	O	PUNCT	O
evaluation	O	NOUN	B
with	O	ADP	O
cross	O	NOUN	B
-	O	PUNCT	O
sectional	O	ADJ	B
echocardiography	O	NOUN	I
.	O	PUNCT	O


Cross	O	PROPN	B
-	O	PUNCT	O
sectional	O	ADJ	B
echocardiography	O	NOUN	I
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
evaluate	O	VERB	B
two	O	NUM	O
neonates	O	NOUN	B
whose	O	DET	O
mothers	O	NOUN	B
ingested	O	VERB	B
lithium	B-Chemical	NOUN	B
during	O	ADP	O
pregnancy	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
one	O	NUM	O
infant	O	NOUN	B
,	O	PUNCT	O
Ebstein's	B-Disease	NOUN	B
anomaly	I-Disease	NOUN	I
of	O	ADP	O
the	O	DET	O
tricuspid	O	NOUN	B
valve	O	NOUN	I
was	O	AUX	O
identified	O	VERB	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
other	O	ADJ	O
infant	O	NOUN	B
cross	O	NOUN	B
-	O	PUNCT	O
sectional	O	ADJ	B
echocardiography	O	NOUN	I
provided	O	VERB	O
reassurance	O	NOUN	B
that	O	SCONJ	O
the	O	DET	O
infant	O	NOUN	B
did	O	AUX	O
not	O	PART	O
have	O	AUX	O
Ebstein's	B-Disease	NOUN	B
anomaly	I-Disease	NOUN	I
.	O	PUNCT	O


Cross	O	PROPN	B
-	O	PUNCT	O
sectional	O	ADJ	B
echocardiographic	O	ADJ	B
screening	O	NOUN	B
of	O	ADP	O
newborns	O	NOUN	B
exposed	O	VERB	B
to	O	PART	I
lithium	B-Chemical	NOUN	B
during	O	ADP	O
gestation	O	NOUN	B
can	O	AUX	O
provide	O	VERB	O
highly	O	ADV	O
accurate	O	ADJ	B
,	O	PUNCT	O
noninvasive	O	ADJ	B
assessment	O	NOUN	I
of	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
or	O	CCONJ	O
absence	O	NOUN	B
of	O	ADP	O
lithium	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cardiac	B-Disease	ADJ	B
malformations	I-Disease	NOUN	I


Effects	O	NOUN	B
of	O	ADP	I
training	O	NOUN	B
on	O	ADP	O
the	O	DET	O
extent	O	NOUN	O
of	O	ADP	O
experimental	O	ADJ	B
myocardial	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
in	O	ADP	O
aging	O	NOUN	B
rats	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
exercise	O	NOUN	B
on	O	ADP	O
the	O	DET	O
severity	O	NOUN	B
of	O	ADP	O
isoproterenol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
myocardial	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
were	O	AUX	O
studied	O	VERB	O
in	O	ADP	O
female	O	ADJ	B
albino	O	NOUN	B
rats	O	NOUN	B
of	O	ADP	O
20	O	NUM	O
,	O	PUNCT	O
40	O	NUM	O
,	O	PUNCT	O
60	O	NUM	O
and	O	CCONJ	O
80	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
age	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
rats	O	NOUN	B
were	O	AUX	O
trained	O	VERB	O
to	O	PART	O
swim	O	VERB	B
for	O	ADP	O
a	O	DET	O
specific	O	ADJ	O
duration	O	NOUN	B
and	O	CCONJ	O
for	O	ADP	O
a	O	DET	O
particular	O	ADJ	O
period	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
occurrence	O	NOUN	B
of	O	ADP	O
infarcts	B-Disease	NOUN	B
were	O	AUX	O
confirmed	O	VERB	O
by	O	ADP	O
histological	O	ADJ	B
methods	O	NOUN	I
.	O	PUNCT	O


Elevations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
serum	O	NOUN	B
GOT	O	NOUN	B
and	O	CCONJ	O
GPT	O	NOUN	B
were	O	AUX	O
maximum	O	ADJ	B
in	O	ADP	O
the	O	DET	O
sedentary	O	ADJ	B
-	O	PUNCT	O
isoproterenols	B-Chemical	NOUN	B
and	O	CCONJ	O
minimum	O	NOUN	B
in	O	ADP	O
the	O	DET	O
exercise	O	NOUN	B
-	O	PUNCT	O
controls	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
changes	O	NOUN	B
in	O	ADP	O
the	O	DET	O
serum	O	NOUN	B
transaminases	O	NOUN	I
were	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
corresponding	O	ADJ	O
depletions	O	NOUN	B
in	O	ADP	O
the	O	DET	O
cardiac	O	ADJ	B
GOT	O	NOUN	B
and	O	CCONJ	O
GPT	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
age	O	NOUN	B
was	O	AUX	O
seen	O	VERB	O
to	O	PART	O
interfere	O	VERB	B
with	O	ADP	I
the	O	DET	O
responses	O	NOUN	B
exhibited	O	VERB	O
by	O	ADP	O
the	O	DET	O
young	O	ADJ	B
and	O	CCONJ	O
old	O	ADJ	O
rats	O	NOUN	B
.	O	PUNCT	O


Studies	O	NOUN	B
dealing	O	VERB	O
with	O	ADP	O
myocardial	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I


Effect	O	NOUN	B
of	O	ADP	O
polyethylene	B-Chemical	NOUN	B
glycol	I-Chemical	NOUN	I
400	I-Chemical	NUM	I
on	O	ADP	O
adriamycin	B-Chemical	NOUN	B
toxicity	B-Disease	NOUN	B
in	O	ADP	O
mice	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
a	O	DET	O
widely	O	ADV	O
used	O	VERB	O
organic	O	ADJ	B
solvent	O	NOUN	O
,	O	PUNCT	O
polyethylene	B-Chemical	NOUN	B
glycol	I-Chemical	NOUN	I
400	I-Chemical	NUM	I
(	O	PUNCT	O
PEG	B-Chemical	NOUN	B
400	I-Chemical	NUM	O
),	O	PUNCT	O
on	O	ADP	O
the	O	DET	O
toxic	O	ADJ	B
action	O	NOUN	I
of	O	ADP	O
an	O	DET	O
acute	O	ADJ	B
or	O	CCONJ	O
chronic	O	ADJ	B
treatment	O	NOUN	I
with	O	ADP	O
adriamycin	B-Chemical	NOUN	B
(	O	PUNCT	O
ADR	B-Chemical	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
evaluated	O	VERB	B
in	O	ADP	O
mice	O	NOUN	B
.	O	PUNCT	O


PEG	B-Chemical	NOUN	B
400	I-Chemical	NUM	O
impressively	O	ADV	O
decreased	O	VERB	B
both	O	CCONJ	O
acute	O	ADJ	B
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
and	O	CCONJ	O
chronic	O	ADJ	B
low	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
-	O	PUNCT	O
ADR	B-Chemical	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
lethality	O	NOUN	B
.	O	PUNCT	O


Light	O	ADJ	B
microscopic	O	ADJ	I
analysis	O	NOUN	I
showed	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
protection	O	NOUN	B
against	O	ADP	O
ADR	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cardiac	B-Disease	ADJ	B
morphological	I-Disease	ADJ	B
alterations	I-Disease	NOUN	B
.	O	PUNCT	O


Such	O	ADJ	O
treatment	O	NOUN	B
did	O	AUX	O
not	O	PART	O
diminish	O	VERB	O
the	O	DET	O
ADR	B-Chemical	NOUN	B
antitumor	O	NOUN	B
activity	O	NOUN	O
in	O	ADP	O
L1210	B-Disease	ADJ	B
leukemia	I-Disease	NOUN	I
and	O	CCONJ	O
in	O	ADP	O
Ehrlich	B-Disease	NOUN	B
ascites	I-Disease	NOUN	I
tumor	I-Disease	NOUN	I


Intra	O	NOUN	B
-	O	PUNCT	O
arterial	O	ADJ	B
BCNU	B-Chemical	NOUN	B
chemotherapy	O	NOUN	B
for	O	ADP	O
treatment	O	NOUN	B
of	O	ADP	O
malignant	B-Disease	ADJ	B
gliomas	I-Disease	NOUN	I
of	O	ADP	O
the	O	DET	O
central	O	ADJ	B
nervous	O	ADJ	I
system	O	NOUN	I
.	O	PUNCT	O


Because	O	SCONJ	O
of	O	ADP	O
the	O	DET	O
rapid	O	ADJ	B
systemic	O	ADJ	B
clearance	O	NOUN	B
of	O	ADP	O
BCNU	B-Chemical	NOUN	B
(	O	PUNCT	O
1,3-bis-(2-chloroethyl)-1-nitrosourea	B-Chemical	NOUN	O
),	O	PUNCT	O
intra	O	ADJ	B
-	O	PUNCT	O
arterial	O	ADJ	B
administration	O	NOUN	B
should	O	AUX	O
provide	O	VERB	O
a	O	DET	O
substantial	O	ADJ	O
advantage	O	NOUN	O
over	O	ADP	O
intravenous	O	ADJ	B
administration	O	NOUN	I
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
malignant	B-Disease	ADJ	B
gliomas	I-Disease	NOUN	I
.	O	PUNCT	O


Thirty	O	NUM	B
-	O	PUNCT	O
six	O	NUM	B
patients	O	NOUN	B
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
BCNU	B-Chemical	NOUN	B
every	O	DET	O
6	O	NUM	O
to	O	PART	O
8	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
either	O	CCONJ	O
by	O	ADP	O
transfemoral	O	ADJ	B
catheterization	O	NOUN	I
of	O	ADP	O
the	O	DET	O
internal	O	ADJ	B
carotid	O	NOUN	I
or	O	CCONJ	O
vertebral	O	ADJ	B
artery	O	NOUN	I
or	O	CCONJ	O
through	O	ADP	O
a	O	DET	O
fully	O	ADV	O
implantable	O	ADJ	B
intracarotid	O	NOUN	I
drug	O	NOUN	I
delivery	O	NOUN	I
system	O	NOUN	I
,	O	PUNCT	O
beginning	O	VERB	O
with	O	ADP	O
a	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
200	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
sq	O	NOUN	B
m	O	NOUN	O
body	O	NOUN	B
surface	O	NOUN	I
area	O	NOUN	I
.	O	PUNCT	O


Twelve	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
Grade	O	NOUN	B
III	O	NUM	I
or	O	CCONJ	I
IV	O	NUM	B
astrocytomas	B-Disease	NOUN	I
were	O	AUX	O
treated	O	VERB	B
after	O	ADP	O
partial	O	ADJ	B
resection	O	NOUN	B
of	O	ADP	O
the	O	DET	O
tumor	B-Disease	NOUN	B
without	O	ADP	O
prior	O	ADJ	B
radiation	O	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


After	O	ADP	O
two	O	NUM	O
to	O	PART	O
seven	O	NUM	O
cycles	O	NOUN	B
of	O	ADP	O
chemotherapy	O	NOUN	B
,	O	PUNCT	O
nine	O	NUM	O
patients	O	NOUN	B
showed	O	VERB	O
a	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
tumor	B-Disease	NOUN	B
size	O	NOUN	I
and	O	CCONJ	O
surrounding	O	VERB	B
edema	B-Disease	NOUN	B
on	O	ADP	O
contrast	O	NOUN	B
-	O	PUNCT	O
enhanced	O	VERB	B
computerized	O	VERB	B
tomography	O	NOUN	I
scans	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
nine	O	NUM	O
responders	O	NOUN	B
,	O	PUNCT	O
median	O	ADJ	B
duration	O	NOUN	B
of	O	ADP	O
chemotherapy	O	NOUN	B
response	O	NOUN	O
from	O	ADP	O
the	O	DET	O
time	O	NOUN	B
of	O	ADP	I
operation	O	NOUN	B
was	O	AUX	O
25	O	NUM	O
weeks	O	NOUN	B
(	O	PUNCT	O
range	O	NOUN	O
12	O	NUM	O
to	O	PART	O
more	O	ADJ	O
than	O	ADP	O
91	O	NUM	O
weeks	O	NOUN	B
).	O	PUNCT	O
The	O	DET	O
median	O	ADJ	B
duration	O	NOUN	B
of	O	ADP	O
survival	O	NOUN	B
in	O	ADP	O
the	O	DET	O
12	O	NUM	O
patients	O	NOUN	B
was	O	AUX	O
54	O	NUM	O
weeks	O	NOUN	B
(	O	PUNCT	O
range	O	NOUN	O
21	O	NUM	O
to	O	PART	O
more	O	ADJ	O
than	O	ADP	O
156	O	NUM	O
weeks	O	NOUN	B
),	O	PUNCT	O
with	O	ADP	O
an	O	DET	O
18	O	NUM	O
-	O	PUNCT	O
month	O	NOUN	B
survival	O	NOUN	B
rate	O	NOUN	I
of	O	ADP	O
42	O	NUM	O
%.	O	NOUN	B
Twenty	O	NUM	B
-	O	PUNCT	O
four	O	NUM	B
patients	O	NOUN	B
with	O	ADP	O
recurrent	O	ADJ	B
Grade	O	NOUN	I
I	O	NUM	I
to	O	PART	O
IV	O	NUM	B
astrocytomas	B-Disease	NOUN	I
,	O	PUNCT	O
whose	O	DET	O
resection	O	NOUN	B
and	O	CCONJ	O
irradiation	O	NOUN	B
therapy	O	NOUN	I
had	O	AUX	O
failed	O	VERB	B
,	O	PUNCT	O
received	O	VERB	O
two	O	NUM	O
to	O	PART	O
eight	O	NUM	O
courses	O	NOUN	B
of	O	ADP	O
intra	O	ADJ	B
-	O	PUNCT	O
arterial	O	ADJ	B
BCNU	B-Chemical	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


Seventeen	O	NUM	O
of	O	ADP	O
these	O	DET	O
had	O	AUX	O
a	O	DET	O
response	O	NOUN	B
or	O	CCONJ	O
were	O	AUX	O
stable	O	ADJ	B
for	O	ADP	O
a	O	DET	O
median	O	NOUN	B
of	O	ADP	O
20	O	NUM	O
weeks	O	NOUN	B
(	O	PUNCT	O
range	O	NOUN	O
6	O	NUM	O
to	O	PART	O
more	O	ADJ	O
than	O	ADP	O
66	O	NUM	O
weeks	O	NOUN	B
).	O	PUNCT	B
The	O	DET	O
catheterization	O	NOUN	B
procedure	O	NOUN	I
is	O	AUX	O
safe	O	ADJ	O
,	O	PUNCT	O
with	O	ADP	O
no	O	DET	O
immediate	O	ADJ	O
complication	O	NOUN	B
in	O	ADP	O
111	O	NUM	O
infusions	O	NOUN	B
of	O	ADP	O
BCNU	B-Chemical	NOUN	B
.	O	PUNCT	O


A	O	DET	O
delayed	O	VERB	B
complication	O	NOUN	B
in	O	ADP	O
nine	O	NUM	O
patients	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
unilateral	O	ADJ	B
loss	B-Disease	NOUN	O
of	I-Disease	ADP	O
vision	I-Disease	NOUN	O
secondary	O	ADJ	B
to	O	PART	O
a	O	DET	O
retinal	B-Disease	ADJ	B
vasculitis	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
frequency	O	NOUN	B
of	O	ADP	O
visual	B-Disease	ADJ	B
loss	I-Disease	NOUN	I
decreased	O	VERB	B
after	O	ADP	O
the	O	DET	O
concentration	O	NOUN	B
of	O	ADP	O
the	O	DET	O
ethanol	B-Chemical	NOUN	B


Blood	O	NOUN	B
pressure	O	NOUN	I
response	O	NOUN	I
to	O	PART	O
chronic	O	ADJ	B
low	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
intrarenal	O	ADJ	B
noradrenaline	B-Chemical	NOUN	B
infusion	O	NOUN	B
in	O	ADP	O
conscious	O	ADJ	B
rats	O	NOUN	I
.	O	PUNCT	O


Sodium	B-Chemical	NOUN	B
chloride	I-Chemical	NOUN	I
solution	O	NOUN	I
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
%)	O	NOUN	B
or	O	CCONJ	O
noradrenaline	B-Chemical	NOUN	B
in	O	ADP	O
doses	O	NOUN	B
of	O	ADP	O
4	O	NUM	O
,	O	PUNCT	O
12	O	NUM	O
and	O	CCONJ	O
36	O	NUM	O
micrograms	O	NOUN	B
h	O	NOUN	O
-	O	SYM	O
1	O	NUM	O
kg	O	PROPN	O
-	O	PUNCT	O
1	O	NUM	O
was	O	AUX	O
infused	O	VERB	B
for	O	ADP	O
five	O	NUM	O
consecutive	O	ADJ	B
days	O	NOUN	B
,	O	PUNCT	O
either	O	CCONJ	O
intrarenally	O	ADV	B
(	O	PUNCT	O
by	O	ADP	O
a	O	DET	O
new	O	ADJ	O
technique	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
intravenously	O	ADV	B
into	O	ADP	O
rats	O	NOUN	B
with	O	ADP	O
one	O	NUM	O
kidney	O	NOUN	B
removed	O	VERB	B
.	O	PUNCT	O


Intrarenal	O	ADJ	B
infusion	O	NOUN	B
of	O	ADP	O
noradrenaline	B-Chemical	NOUN	B
caused	O	VERB	O
hypertension	B-Disease	NOUN	B
at	O	ADP	O
doses	O	NOUN	B
which	O	DET	O
did	O	AUX	O
not	O	PART	O
do	O	AUX	O
so	O	ADV	O
when	O	SCONJ	O
infused	O	VERB	B
intravenously	O	ADV	B
.	O	PUNCT	O


Intrarenal	O	ADJ	B
compared	O	VERB	B
with	O	ADP	O
intravenous	O	ADJ	B
infusion	O	NOUN	B
of	O	ADP	O
noradrenaline	B-Chemical	NOUN	B
caused	O	VERB	O
higher	O	ADJ	O
plasma	O	NOUN	B
noradrenaline	B-Chemical	NOUN	B
concentrations	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
shift	O	NOUN	B
of	O	ADP	O
the	O	DET	O
plasma	O	NOUN	B
noradrenaline	B-Chemical	NOUN	B
concentration	O	NOUN	B
-	O	PUNCT	O
blood	O	NOUN	B
pressure	O	NOUN	I
effect	O	NOUN	I
curve	O	NOUN	I
towards	O	ADP	O
lower	O	ADJ	O
plasma	O	NOUN	B
noradrenaline	B-Chemical	NOUN	B
levels	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
hypertension	B-Disease	NOUN	B
after	O	ADP	O
chronic	O	ADJ	B
intrarenal	O	ADJ	I
noradrenaline	B-Chemical	NOUN	I
infusion	O	NOUN	B
is	O	AUX	O
produced	O	VERB	O
by	O	ADP	O
relatively	O	ADV	O
higher	O	ADJ	O
levels	O	NOUN	B
of	O	ADP	O
circulating	O	VERB	B
noradrenaline	B-Chemical	NOUN	B


Age	O	NOUN	B
and	O	CCONJ	O
renal	O	ADJ	B
clearance	O	NOUN	I
of	O	ADP	O
cimetidine	B-Chemical	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
35	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
ages	O	NOUN	B
20	O	NUM	O
to	O	PART	O
86	O	NUM	O
yr	O	NOUN	O
)	O	PUNCT	O
receiving	O	VERB	O
cimetidine	B-Chemical	NOUN	B
therapeutically	O	ADV	B
two	O	NUM	O
serum	O	NOUN	B
samples	O	NOUN	I
and	O	CCONJ	O
all	O	DET	O
urine	O	NOUN	B
formed	O	VERB	O
in	O	ADP	O
the	O	DET	O
interim	O	ADJ	B
were	O	AUX	O
collected	O	VERB	B
for	O	ADP	O
analysis	O	NOUN	B
of	O	ADP	O
cimetidine	B-Chemical	NOUN	B
by	O	ADP	O
high	O	ADJ	B
-	O	PUNCT	O
pressure	O	NOUN	B
liquid	O	ADJ	I
chromatography	O	NOUN	I
and	O	CCONJ	O
for	O	ADP	O
creatinine	B-Chemical	NOUN	B
.	O	PUNCT	O


Cimetidine	B-Chemical	NOUN	B
clearance	O	NOUN	B
decreased	O	VERB	B
with	O	ADP	O
age	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
extrapolated	O	VERB	O
6	O	NUM	O
-	O	PUNCT	O
hr	O	NOUN	B
serum	O	NOUN	B
concentration	O	NOUN	B
of	O	ADP	O
cimetidine	B-Chemical	NOUN	B
per	O	ADP	O
unit	O	NOUN	O
dose	O	NOUN	B
,	O	PUNCT	O
after	O	ADP	O
intravenous	O	ADJ	B
cimetidine	B-Chemical	NOUN	B
,	O	PUNCT	O
increased	O	VERB	B
with	O	ADP	O
age	O	NOUN	B
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
ratio	O	NOUN	B
of	O	ADP	O
cimetidine	B-Chemical	NOUN	B
clearance	O	NOUN	B
to	O	PART	O
creatinine	B-Chemical	NOUN	B
clearance	O	NOUN	O
(	O	PUNCT	O
Rc	O	NOUN	B
)	O	PUNCT	O
averaged	O	VERB	O
4	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
+/-	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
,	O	PUNCT	O
indicating	O	VERB	O
net	O	ADJ	O
tubular	O	ADJ	O
secretion	O	NOUN	O
for	O	ADP	O
cimetidine	B-Chemical	NOUN	B
.	O	PUNCT	O


Rc	O	NOUN	B
seemed	O	VERB	O
to	O	PART	O
be	O	AUX	O
independent	O	ADJ	B
of	O	ADP	O
age	O	NOUN	B
and	O	CCONJ	O
decreased	O	VERB	B
with	O	ADP	O
increasing	O	VERB	B
serum	O	NOUN	B
concentration	O	NOUN	B
of	O	ADP	O
cimetidine	B-Chemical	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
secretion	O	NOUN	B
of	O	ADP	O
cimetidine	B-Chemical	NOUN	B
is	O	AUX	O
a	O	DET	O
saturable	O	ADJ	B
process	O	NOUN	I
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
only	O	ADV	O
one	O	NUM	O
case	O	NOUN	B
of	O	ADP	O
dementia	B-Disease	NOUN	B
possibly	O	ADV	O
due	O	ADJ	O
to	O	PART	O
cimetidine	B-Chemical	NOUN	B
(	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
drug	O	NOUN	B
level	O	NOUN	I
of	O	ADP	O
1	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
microgram	O	NOUN	B
/	O	SYM	O
ml	O	NOUN	O
6	O	NUM	O
hr	O	NOUN	O
after	O	ADP	O
a	O	DET	O
dose	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
group	O	NOUN	B
of	O	ADP	O
13	O	NUM	O
patients	O	NOUN	B
without	O	ADP	O
liver	B-Disease	NOUN	B
or	I-Disease	CCONJ	O
kidney	I-Disease	NOUN	B
disease	I-Disease	NOUN	I
who	O	PRON	O
had	O	AUX	O
cimetidine	B-Chemical	NOUN	B
levels	O	NOUN	B
above	O	ADP	O
1	O	NUM	O
.	O	PUNCT	O


25	O	NUM	O
microgram	O	NOUN	B
/	O	SYM	O
ml	O	NOUN	O
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
high	O	ADJ	O
cimetidine	B-Chemical	NOUN	B
levels	O	NOUN	B
alone	O	ADV	O
do	O	AUX	O
not	O	PART	O
always	O	ADV	O
induce	O	VERB	B
dementia	B-Disease	NOUN	B


Development	O	NOUN	B
of	O	ADP	O
clear	B-Disease	ADJ	B
cell	I-Disease	NOUN	I
adenocarcinoma	I-Disease	NOUN	I
in	O	ADP	O
DES	B-Chemical	PROPN	B
-	O	PUNCT	O
exposed	O	VERB	B
offspring	O	NOUN	B
under	O	ADP	O
observation	O	NOUN	B
.	O	PUNCT	O


Two	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
clear	B-Disease	ADJ	B
cell	I-Disease	NOUN	I
adenocarcinoma	I-Disease	NOUN	I
of	I-Disease	ADP	O
the	I-Disease	DET	O
vagina	I-Disease	NOUN	B
detected	O	VERB	B
at	O	ADP	O
follow	O	NOUN	B
-	O	PUNCT	O
up	O	NOUN	O
in	O	ADP	O
young	O	ADJ	B
women	O	NOUN	B
exposed	O	VERB	B
in	O	ADP	O
utero	O	NOUN	B
to	O	PART	O
diethylstilbestrol	B-Chemical	NOUN	B
are	O	AUX	O
reported	O	VERB	O
.	O	PUNCT	O


One	O	NUM	O
patient	O	NOUN	B
,	O	PUNCT	O
aged	O	ADJ	B
23	O	NUM	O
,	O	PUNCT	O
had	O	AUX	O
been	O	AUX	O
followed	O	VERB	O
for	O	ADP	O
2	O	NUM	O
years	O	NOUN	B
before	O	ADP	B
carcinoma	B-Disease	NOUN	B
was	O	AUX	O
diagnosed	O	VERB	B
;	O	PUNCT	O
the	O	DET	O
second	O	ADJ	O
patient	O	NOUN	B
,	O	PUNCT	O
aged	O	ADJ	B
22	O	NUM	O
,	O	PUNCT	O
had	O	AUX	O
been	O	AUX	O
seen	O	VERB	O
on	O	ADP	O
a	O	DET	O
regular	O	ADJ	O
basis	O	NOUN	O
for	O	ADP	O
5	O	NUM	O
years	O	NOUN	B
,	O	PUNCT	O
8	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
both	O	DET	O
instances	O	NOUN	O
,	O	PUNCT	O
suspicion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
carcinoma	B-Disease	NOUN	B


Phenobarbitone	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
enlargement	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
liver	I-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
:	O	PUNCT	O
its	O	PRON	O
relationship	O	NOUN	B
to	O	PART	O
carbon	B-Chemical	NOUN	B
tetrachloride	I-Chemical	NOUN	I
-	O	PUNCT	O
induced	O	VERB	B
cirrhosis	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
yield	O	NOUN	B
of	O	ADP	O
severe	O	ADJ	B
cirrhosis	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
liver	I-Disease	NOUN	B
(	O	PUNCT	O
defined	O	VERB	O
as	O	ADP	O
a	O	DET	O
shrunken	O	ADJ	B
finely	O	ADV	O
nodular	O	ADJ	O
liver	O	NOUN	O
with	O	ADP	O
micronodular	O	ADJ	B
histology	O	NOUN	B
,	O	PUNCT	O
ascites	B-Disease	NOUN	B
greater	O	ADJ	O
than	O	ADP	O
30	O	NUM	O
ml	O	NOUN	O
,	O	PUNCT	O
plasma	O	NOUN	B
albumin	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
2	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
g	O	NOUN	O
/	O	SYM	O
dl	O	NOUN	B
,	O	PUNCT	O
splenomegaly	B-Disease	NOUN	B
2	O	NUM	I
-	O	SYM	O
3	O	NUM	O
times	O	NOUN	O
normal	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
testicular	O	NOUN	B
atrophy	B-Disease	NOUN	I
approximately	O	ADV	O
half	O	ADJ	O
normal	O	ADJ	O
weight	O	NOUN	O
)	O	PUNCT	O
after	O	ADP	O
12	O	NUM	O
doses	O	NOUN	B
of	O	ADP	O
carbon	B-Chemical	NOUN	B
tetrachloride	I-Chemical	NOUN	I
given	O	VERB	O
intragastrically	O	ADV	B
in	O	ADP	O
the	O	DET	O
phenobarbitone	B-Chemical	NOUN	B
-	O	PUNCT	O
primed	O	VERB	B
rat	O	NOUN	B
was	O	AUX	O
increased	O	VERB	B
from	O	ADP	O
25	O	NUM	O
%	O	NOUN	O
to	O	PART	O
56	O	NUM	O
%	O	NOUN	O
by	O	ADP	O
giving	O	VERB	O
the	O	DET	O
initial	O	ADJ	B
"	O	PUNCT	O
calibrating	O	VERB	B
"	O	PUNCT	O
dose	O	NOUN	B
of	O	ADP	O
carbon	B-Chemical	NOUN	B
tetrachloride	I-Chemical	NOUN	I
at	O	ADP	O
the	O	DET	O
peak	O	NOUN	O
of	O	ADP	O
the	O	DET	O
phenobarbitone	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
enlargement	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
liver	I-Disease	NOUN	B
.	O	PUNCT	O


At	O	ADP	O
this	O	DET	O
point	O	NOUN	O
it	O	PRON	O
was	O	AUX	O
assumed	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
cytochrome	O	NOUN	B
P450	O	NOUN	I
/	O	PUNCT	O
CCl4	B-Chemical	NOUN	B
toxic	O	ADJ	B
state	O	NOUN	I
was	O	AUX	O
both	O	CCONJ	O
maximal	O	ADJ	B
and	O	CCONJ	O
stable	O	ADJ	B
.	O	PUNCT	O


The	O	DET	O
optimal	O	ADJ	B
rat	O	NOUN	B
size	O	NOUN	B
to	O	PART	O
begin	O	VERB	O
phenobarbitone	B-Chemical	NOUN	B
was	O	AUX	O
determined	O	VERB	O
as	O	ADP	O
100	O	NUM	O
g	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
this	O	DET	O
size	O	NOUN	B
as	O	ADP	O
a	O	DET	O
group	O	NOUN	B
had	O	AUX	O
a	O	DET	O
mean	O	ADJ	O
maximum	O	ADJ	O
relative	O	ADJ	O
liver	O	NOUN	O
weight	O	NOUN	O
increase	O	VERB	B
47	O	NUM	O
%	O	NOUN	O
greater	O	ADJ	O
than	O	ADP	O
normal	O	ADJ	O
rats	O	NOUN	B
of	O	ADP	O
the	O	DET	O
same	O	ADJ	O
body	O	NOUN	B
weight	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
optimal	O	ADJ	B
time	O	NOUN	O
for	O	ADP	O
the	O	DET	O
initial	O	ADJ	B
dose	O	NOUN	B
of	O	ADP	O
carbon	B-Chemical	NOUN	B
tetrachloride	I-Chemical	NOUN	I
was	O	AUX	O
after	O	ADP	O
14	O	NUM	O
days	O	NOUN	B
on	O	ADP	O
phenobarbitone	B-Chemical	NOUN	B


Attenuation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
lithium	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
diabetes-insipidus-like	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
by	O	ADP	O
amiloride	B-Chemical	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
amiloride	B-Chemical	NOUN	B
on	O	ADP	O
lithium	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
polydipsia	B-Disease	NOUN	B
and	O	CCONJ	O
polyuria	B-Disease	NOUN	B
and	O	CCONJ	O
on	O	ADP	O
the	O	DET	O
lithium	B-Chemical	NOUN	B
concentration	O	NOUN	B
in	O	ADP	O
the	O	DET	O
plasma	O	NOUN	B
,	O	PUNCT	O
brain	O	NOUN	B
,	O	PUNCT	O
kidney	O	NOUN	B
,	O	PUNCT	O
thyroid	O	NOUN	B
and	O	CCONJ	O
red	O	ADJ	B
blood	O	NOUN	I
cells	O	NOUN	I
was	O	AUX	O
investigated	O	VERB	B
in	O	ADP	O
rats	O	NOUN	B
,	O	PUNCT	O
chronically	O	ADV	B
treated	O	VERB	B
with	O	ADP	I
LiCl	B-Chemical	NOUN	B
.	O	PUNCT	O


Amiloride	B-Chemical	NOUN	B
reduced	O	VERB	B
the	O	DET	O
drinking	O	NOUN	B
and	O	CCONJ	O
urine	O	NOUN	B
volume	O	NOUN	I
of	O	ADP	O
rats	O	NOUN	B
in	O	ADP	O
an	O	DET	O
acute	O	ADJ	B
(	O	PUNCT	O
6	O	NUM	O
or	O	CCONJ	O
12	O	NUM	O
h	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
subacute	O	NOUN	B
(	O	PUNCT	O
3	O	NUM	O
days	O	NOUN	B
)	O	PUNCT	O
experiment	O	NOUN	B
.	O	PUNCT	O


6	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
the	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
amiloride	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
reduction	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
the	O	DET	O
lithium	B-Chemical	NOUN	B
content	O	NOUN	B
of	O	ADP	O
the	O	DET	O
renal	O	ADJ	B
medulla	O	NOUN	I
but	O	CCONJ	O
not	O	PART	O
in	O	ADP	O
the	O	DET	O
other	O	ADJ	O
organs	O	NOUN	B
studied	O	VERB	O
.	O	PUNCT	O


At	O	ADP	O
12	O	NUM	O
h	O	NOUN	O
,	O	PUNCT	O
all	O	DET	O
the	O	DET	O
tissues	O	NOUN	B
showed	O	VERB	O
a	O	DET	O
slight	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
lithium	B-Chemical	NOUN	B
levels	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
3	O	NUM	O
days	O	NOUN	B
of	O	ADP	O
combined	O	ADJ	B
treatment	O	NOUN	I
,	O	PUNCT	O
a	O	DET	O
marked	O	ADJ	O
elevation	O	NOUN	B
in	O	ADP	O
plasma	O	NOUN	B
and	O	CCONJ	O
tissue	O	NOUN	B
lithium	B-Chemical	NOUN	O
levels	O	NOUN	O
accompanied	O	VERB	O
a	O	DET	O
reduction	O	NOUN	B
in	O	ADP	O
water	O	NOUN	B
intake	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
all	O	DET	O
the	O	DET	O
experiments	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
attenuation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
lithium	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
diabetes-insipidus-like	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
by	O	ADP	O
amiloride	B-Chemical	NOUN	B
was	O	AUX	O
accompanied	O	VERB	O
by	O	ADP	O
a	O	DET	O
reduction	O	NOUN	B
of	O	ADP	O
the	O	DET	O
ratio	O	NOUN	B
between	O	ADP	O
the	O	DET	O
lithium	B-Chemical	NOUN	B
concentration	O	NOUN	B
in	O	ADP	O
the	O	DET	O
renal	O	ADJ	B
medulla	O	NOUN	I
and	O	CCONJ	O
its	O	PRON	O
levels	O	NOUN	B
in	O	ADP	O
the	O	DET	O
blood	O	NOUN	B
and	O	CCONJ	O
an	O	DET	O
elevation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
plasma	O	NOUN	B
potassium	B-Chemical	NOUN	O
level	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
concluded	O	VERB	O
that	O	SCONJ	O
acute	O	ADJ	B
amiloride	B-Chemical	NOUN	B
administration	O	NOUN	B
to	O	PART	O
lithium	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
patients	O	NOUN	B
suffering	O	VERB	B
from	O	ADP	O
polydipsia	B-Disease	NOUN	B
and	O	CCONJ	O
polyuria	B-Disease	NOUN	B
might	O	AUX	O
relieve	O	VERB	O
these	O	DET	O
patients	O	NOUN	B
but	O	CCONJ	O
prolonged	O	ADJ	B
amiloride	B-Chemical	NOUN	B
supplementation	O	NOUN	B
would	O	AUX	O
result	O	VERB	O
in	O	ADP	O
elevated	O	ADJ	B
lithium	B-Chemical	NOUN	B


Safety	O	NOUN	B
and	O	CCONJ	O
side	O	NOUN	B
-	O	PUNCT	O
effects	O	NOUN	B
of	O	ADP	O
alprazolam	B-Chemical	NOUN	B
.	O	PUNCT	O


Controlled	O	ADJ	B
study	O	NOUN	I
in	O	ADP	O
agoraphobia	B-Disease	NOUN	B
with	O	ADP	O
panic	B-Disease	NOUN	B
disorder	I-Disease	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
widespread	O	ADJ	B
use	O	NOUN	O
of	O	ADP	O
benzodiazepines	B-Chemical	NOUN	B
has	O	AUX	O
led	O	VERB	O
to	O	PART	O
increasing	O	VERB	B
recognition	O	NOUN	B
of	O	ADP	O
their	O	PRON	O
unwanted	O	ADJ	O
effects	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
alprazolam	B-Chemical	NOUN	B
and	O	CCONJ	O
placebo	O	NOUN	B
in	O	ADP	O
panic	B-Disease	NOUN	B
disorder	I-Disease	NOUN	I
with	O	ADP	O
agoraphobia	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
side	O	NOUN	B
-	O	PUNCT	O
effect	O	NOUN	B
and	O	CCONJ	O
adverse	O	ADJ	B
effect	O	NOUN	I
profiles	O	NOUN	O
of	O	ADP	O
both	O	DET	O
drug	O	NOUN	B
groups	O	NOUN	I
were	O	AUX	O
measured	O	VERB	B
.	O	PUNCT	O


METHOD	O	NOUN	B
:	O	PUNCT	O
In	O	ADP	O
London	O	PROPN	B
and	O	CCONJ	O
Toronto	O	PROPN	B
154	O	NUM	O
patients	O	NOUN	B
who	O	PRON	O
met	O	VERB	O
DSM	O	PROPN	B
-	O	PUNCT	O
III	O	NUM	B
criteria	O	NOUN	B
for	O	ADP	O
panic	B-Disease	NOUN	B
disorder	I-Disease	NOUN	I
with	O	ADP	O
agoraphobia	B-Disease	NOUN	B
were	O	AUX	O
randomised	O	VERB	B
to	O	PART	O
alprazolam	B-Chemical	NOUN	B
or	O	CCONJ	O
placebo	O	NOUN	B
.	O	PUNCT	O


Subjects	O	NOUN	B
in	O	ADP	O
each	O	DET	O
drug	O	NOUN	B
group	O	NOUN	I
also	O	ADV	O
received	O	VERB	O
either	O	CCONJ	O
exposure	O	NOUN	B
or	O	CCONJ	O
relaxation	O	NOUN	B
.	O	PUNCT	O


Treatment	O	NOUN	B
was	O	AUX	O
from	O	ADP	O
weeks	O	NOUN	B
0	O	NUM	O
to	O	PART	O
8	O	NUM	O
and	O	CCONJ	O
was	O	AUX	O
then	O	ADV	O
tapered	O	VERB	B
from	O	ADP	O
weeks	O	NOUN	B
8	O	NUM	O
to	O	PART	O
16	O	NUM	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Mean	O	VERB	O
alprazolam	B-Chemical	X	B
dose	O	NOUN	B
was	O	AUX	O
5	O	NUM	O
mg	O	NOUN	O
daily	O	ADV	B
.	O	PUNCT	O


Compared	O	VERB	B
with	O	ADP	O
placebo	O	ADJ	B
subjects	O	NOUN	O
,	O	PUNCT	O
alprazolam	B-Chemical	X	B
patients	O	NOUN	B
developed	O	VERB	O
more	O	ADV	O
adverse	O	ADJ	B
reactions	O	NOUN	I
(	O	PUNCT	O
21	O	NUM	O
%	O	NOUN	O
v	O	NOUN	O
.	O	PUNCT	O


0	O	NUM	O
%)	O	NOUN	O
of	O	ADP	O
depression	B-Disease	NOUN	B
,	O	PUNCT	O
enuresis	B-Disease	NOUN	B
,	O	PUNCT	O
disinhibition	O	NOUN	B
and	O	CCONJ	O
aggression	B-Disease	NOUN	B
;	O	PUNCT	O
and	O	CCONJ	O
more	O	ADJ	O
side	O	NOUN	B
-	O	PUNCT	O
effects	O	NOUN	B
,	O	PUNCT	O
particularly	O	ADV	O
sedation	O	NOUN	B
,	O	PUNCT	O
irritability	B-Disease	NOUN	B
,	O	PUNCT	O
impaired	B-Disease	VERB	B
memory	I-Disease	NOUN	I
,	O	PUNCT	O
weight	B-Disease	NOUN	B
loss	I-Disease	NOUN	I
and	O	CCONJ	O
ataxia	B-Disease	NOUN	B
.	O	PUNCT	O


Side	O	NOUN	B
-	O	PUNCT	O
effects	O	NOUN	B
tended	O	VERB	O
to	O	PART	O
diminish	O	VERB	B
during	O	ADP	O
treatment	O	NOUN	B
but	O	CCONJ	O
remained	O	VERB	O
significant	O	ADJ	B
at	O	ADP	O
week	O	NOUN	B
8	O	NUM	O
.	O	PUNCT	O


Despite	O	SCONJ	O
this	O	DET	O
,	O	PUNCT	O
the	O	DET	O
drop	O	NOUN	B
-	O	PUNCT	O
out	O	ADP	O
rate	O	NOUN	B
was	O	AUX	O
low	O	ADJ	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
Alprazolam	B-Chemical	PROPN	B


Dup	B-Chemical	NOUN	B
753	I-Chemical	NUM	I
prevents	O	VERB	B
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
puromycin	B-Chemical	NOUN	B
aminonucleoside	I-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
nephrosis	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
appearance	O	NOUN	B
of	O	ADP	O
nephrotic	B-Disease	ADJ	B
syndromes	I-Disease	NOUN	I
such	O	ADJ	O
as	O	ADP	O
proteinuria	B-Disease	NOUN	B
,	O	PUNCT	O
hypoalbuminemia	B-Disease	NOUN	B
,	O	PUNCT	O
hypercholesterolemia	B-Disease	NOUN	B
and	O	CCONJ	O
increase	O	NOUN	B
in	O	ADP	O
blood	B-Chemical	NOUN	B
nitrogen	I-Chemical	NOUN	I
urea	I-Chemical	NOUN	I
,	O	PUNCT	O
induced	O	VERB	B
in	O	ADP	O
rats	O	NOUN	B
by	O	ADP	O
injection	O	NOUN	B
of	O	ADP	O
puromycin	B-Chemical	NOUN	B
aminonucleoside	I-Chemical	NOUN	B
was	O	AUX	O
markedly	O	ADV	O
inhibited	O	VERB	B
by	O	ADP	O
oral	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
Dup	B-Chemical	NOUN	B
753	I-Chemical	NUM	I
(	O	PUNCT	O
losartan	B-Chemical	NOUN	B
),	O	PUNCT	O
a	O	DET	O
novel	O	ADJ	O
angiotensin	B-Chemical	NOUN	B
II	I-Chemical	NUM	I
receptor	O	NOUN	I
antagonist	O	NOUN	B
,	O	PUNCT	O
at	O	ADP	O
a	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
1	O	NUM	O
or	O	CCONJ	O
2	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
per	O	ADP	O
day	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
a	O	DET	O
possible	O	ADJ	O
involvement	O	NOUN	B
of	O	ADP	O
the	O	DET	O
renin	O	NOUN	B
-	O	PUNCT	O
angiotensin	B-Chemical	NOUN	B
system	O	NOUN	O
in	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
puromycin	B-Chemical	NOUN	B
aminonucleoside	I-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
nephrosis	B-Disease	NOUN	B


Sodium	B-Chemical	NOUN	B
bicarbonate	I-Chemical	NOUN	I
alleviates	O	VERB	O
penile	B-Disease	ADJ	B
pain	I-Disease	NOUN	I
induced	O	VERB	B
by	O	ADP	O
intracavernous	O	ADJ	B
injections	O	NOUN	I
for	O	ADP	O
erectile	B-Disease	NOUN	B
dysfunction	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
an	O	DET	O
attempt	O	NOUN	O
to	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
penile	B-Disease	ADJ	B
pain	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
intracorporeal	O	NOUN	B
injections	O	NOUN	I
could	O	AUX	O
be	O	AUX	O
due	O	ADJ	O
to	O	PART	O
the	O	DET	O
acidity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
medication	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
performed	O	VERB	O
a	O	DET	O
randomized	O	ADJ	B
study	O	NOUN	I
comparing	O	VERB	B
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
penile	B-Disease	ADJ	B
pain	I-Disease	NOUN	I
following	O	VERB	O
intracorporeal	O	ADJ	B
injections	O	NOUN	I
with	O	ADP	O
or	O	CCONJ	O
without	O	ADP	O
the	O	DET	O
addition	O	NOUN	O
of	O	ADP	O
sodium	B-Chemical	NOUN	B
bicarbonate	I-Chemical	NOUN	I
to	O	ADP	O
the	O	DET	O
intracorporeal	O	NOUN	B
medications	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
38	O	NUM	O
consecutive	O	ADJ	B
patients	O	NOUN	B
who	O	PRON	O
presented	O	VERB	O
to	O	ADP	O
our	O	PRON	O
clinic	O	NOUN	B
with	O	ADP	O
impotence	B-Disease	NOUN	B
received	O	VERB	O
0	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
ml	O	NOUN	O
.	O	PUNCT	O


of	O	ADP	O
a	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
3	O	NUM	O
drugs	O	NOUN	B
:	O	PUNCT	O
6	O	NUM	O
mg	O	NOUN	O
.	O	PUNCT	O


papaverine	B-Chemical	NOUN	B
,	O	PUNCT	O
100	O	NUM	O
micrograms	O	NOUN	B
.	O	PUNCT	O


phentolamine	B-Chemical	NOUN	B
and	O	CCONJ	O
10	O	NUM	O
micrograms	O	NOUN	B
.	O	PUNCT	O


prostaglandin	B-Chemical	NOUN	B
E1	I-Chemical	NOUN	I
with	O	ADP	O
(	O	PUNCT	O
pH	O	NOUN	B
7	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
without	O	ADP	O
(	O	PUNCT	O
pH	O	NOUN	B
4	O	NUM	O
.	O	PUNCT	O


17	O	NUM	O
)	O	PUNCT	O
the	O	DET	O
addition	O	NOUN	O
of	O	ADP	O
sodium	B-Chemical	NOUN	B
bicarbonate	I-Chemical	NOUN	I
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


03	O	NUM	O
mEq	O	NOUN	O
.).	O	NOUN	O
Of	O	ADP	O
the	O	DET	O
19	O	NUM	O
patients	O	NOUN	B
without	O	ADP	O
sodium	B-Chemical	NOUN	B
bicarbonate	I-Chemical	NOUN	I
added	O	VERB	O
to	O	ADP	O
the	O	DET	O
medication	O	NOUN	B
11	O	NUM	I
(	O	PUNCT	O
58	O	NUM	O
%)	O	NOUN	O
complained	O	VERB	B
of	O	ADP	O
penile	B-Disease	ADJ	B
pain	I-Disease	NOUN	I
due	O	ADJ	O
to	O	ADP	O
the	O	DET	O
medication	O	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
only	O	ADV	O
1	O	NUM	O
of	O	ADP	O
the	O	DET	O
19	O	NUM	O
men	O	NOUN	B
(	O	PUNCT	O
5	O	NUM	O
%)	O	NOUN	O
who	O	PRON	O
received	O	VERB	O
sodium	B-Chemical	NOUN	B
bicarbonate	I-Chemical	NOUN	I
complained	O	VERB	O
of	O	ADP	O
penile	B-Disease	ADJ	B
pain	I-Disease	NOUN	I
.	O	PUNCT	O


From	O	ADP	O
these	O	DET	O
data	O	NOUN	B
we	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
penile	B-Disease	ADJ	B
pain	I-Disease	NOUN	I


Prospective	O	ADJ	B
study	O	NOUN	I
of	O	ADP	O
the	O	DET	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
effects	O	NOUN	B
of	O	ADP	I
somatostatin	O	NOUN	B
analog	O	NOUN	O
(	O	PUNCT	O
octreotide	B-Chemical	NOUN	B
)	O	PUNCT	O
on	O	ADP	O
gallbladder	O	NOUN	B
function	O	NOUN	I
and	O	CCONJ	O
gallstone	B-Disease	NOUN	B
formation	O	NOUN	B
in	O	ADP	O
Chinese	O	ADJ	B
acromegalic	B-Disease	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
article	O	NOUN	O
reports	O	VERB	B
the	O	DET	O
changes	O	NOUN	B
in	O	ADP	O
gallbladder	O	NOUN	B
function	O	NOUN	I
examined	O	VERB	O
by	O	ADP	O
ultrasonography	O	NOUN	B
in	O	ADP	O
20	O	NUM	O
Chinese	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
active	O	ADJ	B
acromegaly	B-Disease	NOUN	I
treated	O	VERB	B
with	O	ADP	I
sc	O	ADJ	B
injection	O	NOUN	I
of	O	ADP	O
the	O	DET	O
somatostatin	O	NOUN	B
analog	O	NOUN	O
octreotide	B-Chemical	NOUN	B
in	O	ADP	O
dosages	O	NOUN	B
of	O	ADP	O
300	O	NUM	O
-	O	PUNCT	O
1500	O	NUM	O
micrograms	O	NOUN	B
/	O	PUNCT	O
day	O	NOUN	B
for	O	ADP	O
a	O	DET	O
mean	O	NOUN	O
of	O	ADP	O
24	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
+/-	O	CCONJ	O
13	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


During	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
octreotide	B-Chemical	NOUN	B
,	O	PUNCT	O
17	O	NUM	O
patients	O	NOUN	B
developed	O	VERB	O
sludge	O	NOUN	B
,	O	PUNCT	O
10	O	NUM	O
had	O	AUX	O
gallstones	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
1	O	NUM	O
developed	O	VERB	O
acute	B-Disease	ADJ	B
cholecystitis	I-Disease	NOUN	I
requiring	O	VERB	O
surgery	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
all	O	DET	O
of	O	ADP	O
7	O	NUM	O
patients	O	NOUN	B
examined	O	VERB	O
acutely	O	ADV	B
,	O	PUNCT	O
gallbladder	O	NOUN	B
contractility	O	NOUN	B
was	O	AUX	O
inhibited	O	VERB	B
after	O	ADP	O
a	O	DET	O
single	O	ADJ	O
100	O	NUM	O
-	O	PUNCT	O
micrograms	O	NOUN	B
injection	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
8	O	NUM	O
patients	O	NOUN	B
followed	O	VERB	O
for	O	ADP	O
24	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
gallbladder	O	NOUN	B
contractility	O	NOUN	I
remained	O	VERB	O
depressed	B-Disease	ADJ	B
throughout	O	ADP	O
therapy	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
withdrawal	O	NOUN	B
of	O	ADP	I
octreotide	B-Chemical	NOUN	B
in	O	ADP	O
10	O	NUM	O
patients	O	NOUN	B
without	O	ADP	O
gallstones	B-Disease	NOUN	B
,	O	PUNCT	O
8	O	NUM	O
patients	O	NOUN	B
assessed	O	VERB	B
had	O	AUX	O
return	O	NOUN	B
of	O	ADP	I
normal	O	ADJ	I
gallbladder	O	NOUN	I
contractility	O	NOUN	B
within	O	ADP	O
1	O	NUM	O
month	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
8	O	NUM	O
of	O	ADP	O
the	O	DET	O
remaining	O	VERB	O
10	O	NUM	O
patients	O	NOUN	B
who	O	PRON	O
developed	O	VERB	O
gallstones	B-Disease	NOUN	B
during	O	ADP	O
treatment	O	NOUN	B
,	O	PUNCT	O
gallbladder	O	NOUN	B
contractility	O	NOUN	B
normalized	O	VERB	B
in	O	ADP	O
5	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
3	O	NUM	O
of	O	ADP	O
whom	O	PRON	O
has	O	AUX	O
disappearance	O	NOUN	B
of	O	ADP	O
their	O	PRON	O
stones	O	NOUN	B
within	O	ADP	O
3	O	NUM	O
weeks	O	NOUN	B
),	O	PUNCT	O
and	O	CCONJ	O
remained	O	VERB	O
depressed	B-Disease	ADJ	B
in	O	ADP	O
3	O	NUM	O
(	O	PUNCT	O
2	O	NUM	O
of	O	ADP	O
whom	O	PRON	O
had	O	AUX	O
stones	O	NOUN	B
present	O	ADJ	O
at	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
).	O	PUNCT	O
Our	O	PRON	O
results	O	NOUN	O
suggest	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
suppression	O	NOUN	B
of	O	ADP	O
gallbladder	O	NOUN	B
contractility	O	NOUN	I
is	O	AUX	O
the	O	DET	O
cause	O	NOUN	O
of	O	ADP	O
the	O	DET	O
successive	O	ADJ	O
formation	O	NOUN	B
of	O	ADP	O
bile	O	NOUN	B
sludge	O	NOUN	B
,	O	PUNCT	O
gallstones	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
cholecystitis	B-Disease	NOUN	B
during	O	ADP	O
octreotide	B-Chemical	NOUN	B
therapy	O	NOUN	I
in	O	ADP	O
Chinese	O	ADJ	B
acromegalic	B-Disease	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
therefore	O	ADV	O
very	O	ADV	O
important	O	ADJ	O
to	O	PART	O
follow	O	VERB	O
the	O	DET	O
changes	O	NOUN	B
of	O	ADP	O
gallbladder	O	NOUN	B
function	O	NOUN	I
during	O	ADP	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
octreotide	B-Chemical	NOUN	B
therapy	O	NOUN	I
of	O	ADP	O
acromegalic	B-Disease	ADJ	B


Improvement	O	NOUN	B
of	O	ADP	O
levodopa	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
dyskinesia	B-Disease	NOUN	B
by	O	ADP	O
propranolol	B-Chemical	NOUN	B
in	O	ADP	O
Parkinson's	B-Disease	ADJ	O
disease	I-Disease	NOUN	B
.	O	PUNCT	O


Seven	O	NUM	O
patients	O	NOUN	B
suffering	O	VERB	B
from	O	ADP	O
Parkinson's	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
PD	B-Disease	NOUN	B
)	O	PUNCT	O
with	O	ADP	O
severely	O	ADV	O
disabling	O	VERB	O
dyskinesia	B-Disease	NOUN	B
received	O	VERB	O
low	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
propranolol	B-Chemical	NOUN	B
as	O	ADP	O
an	O	DET	O
adjunct	O	NOUN	B
to	O	ADP	O
the	O	DET	O
currently	O	ADV	O
used	O	VERB	O
medical	O	ADJ	B
treatment	O	NOUN	I
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
a	O	DET	O
significant	O	ADJ	B
40	O	NUM	O
%	O	NOUN	O
improvement	O	NOUN	B
in	O	ADP	O
the	O	DET	O
dyskinesia	B-Disease	NOUN	B
score	O	NOUN	B
without	O	ADP	O
increase	O	NOUN	B
of	O	ADP	O
parkinsonian	B-Disease	ADJ	B
motor	B-Disease	NOUN	B
disability	I-Disease	NOUN	I
.	O	PUNCT	O


Ballistic	O	ADJ	B
and	O	CCONJ	O
choreic	O	ADJ	B
dyskinesia	B-Disease	NOUN	I
were	O	AUX	O
markedly	O	ADV	O
ameliorated	O	VERB	B
,	O	PUNCT	O
whereas	O	SCONJ	O
dystonia	B-Disease	NOUN	B
was	O	AUX	O
not	O	PART	O
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
administration	O	NOUN	B
of	O	ADP	O
low	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
beta	O	NOUN	B
-	O	PUNCT	O
blockers	O	NOUN	B
may	O	AUX	O
improve	O	VERB	O
levodopa	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
ballistic	O	ADJ	B
and	O	CCONJ	O
choreic	O	ADJ	B
dyskinesia	B-Disease	NOUN	I
in	O	ADP	O
PD	B-Disease	NOUN	B


Morphological	O	ADJ	B
features	O	NOUN	B
of	O	ADP	O
encephalopathy	B-Disease	NOUN	B
after	O	ADP	O
chronic	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
the	O	DET	O
antiepileptic	O	ADJ	B
drug	O	NOUN	I
valproate	B-Chemical	NOUN	B
to	O	PART	O
rats	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
transmission	O	NOUN	B
electron	O	NOUN	I
microscopic	O	ADJ	I
study	O	NOUN	O
of	O	ADP	O
capillaries	O	NOUN	B
in	O	ADP	O
the	O	DET	O
cerebellar	O	ADJ	B
cortex	O	NOUN	I
.	O	PUNCT	O


Long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
intragastric	O	ADJ	B
application	O	NOUN	B
of	O	ADP	O
the	O	DET	O
antiepileptic	O	ADJ	B
drug	O	NOUN	I
sodium	B-Chemical	NOUN	I
valproate	I-Chemical	NOUN	I
(	O	PUNCT	O
Vupral	O	PROPN	B
"	O	PUNCT	O
Polfa	O	PROPN	B
")	O	PUNCT	O
at	O	ADP	O
the	O	DET	O
effective	O	ADJ	B
dose	O	NOUN	B
of	O	ADP	O
200	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
b	O	NOUN	O
.	O	PUNCT	O


w	O	X	O
.	O	PUNCT	O


once	O	ADV	B
daily	O	ADV	I
to	O	ADP	O
rats	O	NOUN	B
for	O	ADP	O
1	O	NUM	O
,	O	PUNCT	O
3	O	NUM	O
,	O	PUNCT	O
6	O	NUM	O
,	O	PUNCT	O
9	O	NUM	O
and	O	CCONJ	O
12	O	NUM	O
months	O	NOUN	B
revealed	O	VERB	O
neurological	B-Disease	ADJ	B
disorders	I-Disease	NOUN	I
indicating	O	VERB	O
cerebellum	B-Disease	NOUN	B
damage	I-Disease	NOUN	I
("	O	NOUN	O
valproate	B-Chemical	NOUN	B
encephalopathy	B-Disease	NOUN	I
").	O	VERB	O
The	O	DET	O
first	O	ADJ	O
ultrastructural	O	ADJ	B
changes	O	NOUN	B
in	O	ADP	O
structural	O	ADJ	B
elements	O	NOUN	I
of	O	ADP	O
the	O	DET	O
blood	O	NOUN	B
-	O	PUNCT	O
brain	O	NOUN	B
-	O	PUNCT	O
barrier	O	NOUN	B
(	O	PUNCT	O
BBB	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
cerebellar	O	ADJ	B
cortex	O	NOUN	I
were	O	AUX	O
detectable	O	ADJ	B
after	O	ADP	O
3	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
the	O	DET	O
experiment	O	NOUN	B
.	O	PUNCT	O


They	O	PRON	O
became	O	VERB	O
more	O	ADV	O
severe	O	ADJ	B
in	O	ADP	O
the	O	DET	O
later	O	ADJ	O
months	O	NOUN	B
of	O	ADP	O
the	O	DET	O
experiment	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
were	O	AUX	O
most	O	ADV	O
severe	O	ADJ	B
after	O	ADP	O
12	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
located	O	VERB	O
mainly	O	ADV	O
in	O	ADP	O
the	O	DET	O
molecular	O	ADJ	B
layer	O	NOUN	I
of	O	ADP	O
the	O	DET	O
cerebellar	O	ADJ	B
cortex	O	NOUN	I
.	O	PUNCT	O


Lesions	O	NOUN	B
of	O	ADP	O
the	O	DET	O
capillary	O	NOUN	B
included	O	VERB	O
necrosis	B-Disease	NOUN	B
of	O	ADP	O
endothelial	O	ADJ	B
cells	O	NOUN	I
.	O	PUNCT	O


Organelles	O	NOUN	B
of	O	ADP	O
these	O	DET	O
cells	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
particular	O	ADJ	O
the	O	DET	O
mitochondria	O	NOUN	B
(	O	PUNCT	O
increased	O	VERB	B
number	O	NOUN	O
and	O	CCONJ	O
size	O	NOUN	B
,	O	PUNCT	O
distinct	O	ADJ	O
degeneration	O	NOUN	B
of	O	ADP	O
their	O	PRON	O
matrix	O	NOUN	B
and	O	CCONJ	O
cristae	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
Golgi	O	NOUN	B
apparatus	O	NOUN	I
were	O	AUX	O
altered	O	VERB	O
.	O	PUNCT	O


Reduced	O	VERB	B
size	O	NOUN	O
of	O	ADP	O
capillary	O	ADJ	B
lumen	O	NOUN	I
and	O	CCONJ	O
occlusion	O	NOUN	B
were	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
swollen	O	ADJ	B
endothelial	O	ADJ	B
cells	O	NOUN	I
which	O	DET	O
had	O	AUX	O
luminal	B-Chemical	ADJ	B
protrusions	O	NOUN	I
and	O	CCONJ	O
swollen	O	ADJ	B
microvilli	O	NOUN	B
.	O	PUNCT	O


Pressure	O	NOUN	B
on	O	ADP	O
the	O	DET	O
vessel	O	NOUN	B
wall	O	NOUN	I
was	O	AUX	O
produced	O	VERB	O
by	O	ADP	O
enlarged	O	ADJ	B
perivascular	O	ADJ	B
astrocytic	O	ADJ	B
processes	O	NOUN	I
.	O	PUNCT	O


Fragments	O	NOUN	B
of	O	ADP	O
necrotic	B-Disease	ADJ	B
endothelial	O	ADJ	I
cells	O	NOUN	I
were	O	AUX	O
in	O	ADP	O
the	O	DET	O
vascular	O	ADJ	B
lumens	O	NOUN	I
and	O	CCONJ	O
in	O	ADP	O
these	O	DET	O
there	O	PRON	O
was	O	AUX	O
loosening	O	NOUN	B
and	O	CCONJ	O
breaking	O	NOUN	B
of	O	ADP	O
tight	O	ADJ	O
cellular	O	ADJ	O
junctions	O	NOUN	O
.	O	PUNCT	O


Damage	O	NOUN	B
to	O	PART	O
the	O	DET	O
vascular	O	ADJ	B
basement	O	NOUN	I
lamina	O	NOUN	I
was	O	AUX	O
also	O	ADV	O
observed	O	VERB	O
.	O	PUNCT	O


Damage	O	NOUN	B
to	O	ADP	O
the	O	DET	O
capillary	O	NOUN	B
was	O	AUX	O
accompanied	O	VERB	O
by	O	ADP	O
marked	O	ADJ	O
damage	O	NOUN	B
to	O	PART	O
neuroglial	O	ADJ	B
cells	O	NOUN	I
,	O	PUNCT	O
mainly	O	ADV	O
to	O	PART	O
perivascular	O	ADJ	B
processes	O	NOUN	I
of	O	ADP	O
astrocytes	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
proliferation	O	NOUN	B
of	O	ADP	O
astrocytes	O	NOUN	B
(	O	PUNCT	O
Bergmann	O	PROPN	B
'	O	PART	O
s	O	NOUN	O
in	O	ADP	O
particular	O	ADJ	O
)	O	PUNCT	O
and	O	CCONJ	O
occasionally	O	ADV	O
of	O	ADP	O
oligodendrocytes	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
.	O	PUNCT	O


Alterations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
structural	O	ADJ	B
elements	O	NOUN	I
of	O	ADP	O
the	O	DET	O
BBB	O	NOUN	B
coexisted	O	VERB	O
with	O	ADP	O
marked	O	ADJ	O
lesions	O	NOUN	B
of	O	ADP	O
neurons	O	NOUN	B
of	O	ADP	O
the	O	DET	O
cerebellum	O	NOUN	B
(	O	PUNCT	O
Purkinje	O	NOUN	B
cells	O	NOUN	I
are	O	AUX	O
earliest	O	ADJ	O
).	O	PUNCT	B
In	O	ADP	O
electron	O	NOUN	B
micrographs	O	NOUN	I
both	O	CCONJ	O
luminal	B-Chemical	ADJ	B
and	O	CCONJ	O
antiluminal	O	ADJ	B
sides	O	NOUN	I
of	O	ADP	O
the	O	DET	O
BBB	O	NOUN	B
of	O	ADP	O
the	O	DET	O
cerebellar	O	ADJ	B
cortex	O	NOUN	I
had	O	AUX	O
similar	O	ADJ	O
lesions	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
possible	O	ADJ	O
influence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
hepatic	B-Disease	ADJ	B
damage	I-Disease	NOUN	I
,	O	PUNCT	O
mainly	O	ADV	O
hyperammonemia	B-Disease	NOUN	B
,	O	PUNCT	O
upon	O	SCONJ	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
valproate	B-Chemical	NOUN	B
encephalopathy	B-Disease	NOUN	I


Macula	O	NOUN	B
toxicity	B-Disease	NOUN	B
after	O	ADP	O
intravitreal	O	NOUN	B
amikacin	B-Chemical	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Although	O	SCONJ	O
intravitreal	O	NOUN	B
aminoglycosides	B-Chemical	NOUN	I
have	O	AUX	O
substantially	O	ADV	O
improved	O	VERB	O
visual	O	ADJ	B
prognosis	O	NOUN	I
in	O	ADP	O
endophthalmitis	B-Disease	NOUN	B
,	O	PUNCT	O
macular	O	NOUN	B
infarction	B-Disease	NOUN	I
may	O	AUX	O
impair	O	VERB	B
full	O	ADJ	O
visual	O	ADJ	B
recovery	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
We	O	PRON	O
present	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
presumed	O	VERB	O
amikacin	B-Chemical	NOUN	B
retinal	B-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
following	O	VERB	O
treatment	O	NOUN	B
with	O	ADP	O
amikacin	B-Chemical	NOUN	B
and	O	CCONJ	O
vancomycin	B-Chemical	NOUN	B
for	O	ADP	O
alpha	O	NOUN	B
-	O	PUNCT	O
haemolytic	O	ADJ	B
streptococcal	B-Disease	ADJ	B
endophthalmitis	I-Disease	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Endophthalmitis	B-Disease	NOUN	B
resolved	O	VERB	B
with	O	ADP	O
improvement	O	NOUN	B
in	O	ADP	O
visual	O	ADJ	B
acuity	O	NOUN	I
to	O	ADP	O
6	O	NUM	O
/	O	SYM	O
24	O	NUM	O
at	O	ADP	O
three	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


Fundus	O	NOUN	B
fluorescein	B-Chemical	NOUN	I
angiography	O	NOUN	I
confirmed	O	VERB	O
macular	O	NOUN	B
capillary	O	ADJ	I
closure	O	NOUN	I
and	O	CCONJ	O
telangiectasis	B-Disease	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
Currently	O	ADV	O
accepted	O	VERB	O
intravitreal	O	NOUN	B
antibiotic	O	ADJ	O
regimens	O	NOUN	O
may	O	AUX	O
cause	O	VERB	O
retinal	B-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
and	O	CCONJ	O
macular	O	NOUN	B
ischaemia	B-Disease	NOUN	I
.	O	PUNCT	O


Treatment	O	NOUN	B
strategies	O	NOUN	O
aimed	O	VERB	O
at	O	ADP	O
avoiding	O	VERB	O
retinal	B-Disease	ADJ	B
toxicity	I-Disease	NOUN	B


Iatrogenically	O	ADV	B
induced	O	VERB	B
intractable	O	ADJ	B
atrioventricular	B-Disease	ADJ	B
reentrant	I-Disease	ADJ	I
tachycardia	I-Disease	NOUN	I
after	O	ADP	O
verapamil	B-Chemical	NOUN	B
and	O	CCONJ	O
catheter	O	NOUN	B
ablation	O	NOUN	I
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
Wolff-Parkinson-White	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
and	O	CCONJ	O
idiopathic	B-Disease	ADJ	B
dilated	I-Disease	ADJ	I
cardiomyopathy	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
WPW	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
and	O	CCONJ	O
idiopathic	B-Disease	ADJ	B
dilated	I-Disease	ADJ	I
cardiomyopathy	I-Disease	NOUN	I
,	O	PUNCT	O
intractable	O	ADJ	B
atrioventricular	B-Disease	ADJ	B
reentrant	I-Disease	ADJ	I
tachycardia	I-Disease	NOUN	I
(	O	PUNCT	O
AVRT	B-Disease	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
iatrogenically	O	ADV	B
induced	O	VERB	B
.	O	PUNCT	O


QRS	O	NOUN	B
without	O	ADP	O
preexcitation	O	NOUN	B
,	O	PUNCT	O
caused	O	VERB	O
by	O	ADP	O
junctional	O	ADJ	B
escape	O	NOUN	I
beats	O	NOUN	I
after	O	ADP	O
verapamil	B-Chemical	NOUN	B
or	O	CCONJ	O
unidirectional	O	ADJ	O
antegrade	O	NOUN	B
block	O	NOUN	I
of	O	ADP	O
accessory	O	NOUN	B
pathway	O	NOUN	I
after	O	ADP	O
catheter	O	NOUN	B
ablation	O	NOUN	I
,	O	PUNCT	O
established	O	VERB	O
frequent	O	ADJ	B
AVRT	B-Disease	PROPN	B


Epidemic	O	ADJ	B
of	O	ADP	O
liver	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
hydrochlorofluorocarbons	B-Chemical	NOUN	B
used	O	VERB	O
as	O	ADP	O
ozone	B-Chemical	NOUN	B
-	O	PUNCT	O
sparing	O	NOUN	B
substitutes	O	NOUN	B
of	O	ADP	O
chlorofluorocarbons	B-Chemical	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Hydrochlorofluorocarbons	B-Chemical	NOUN	B
(	O	PUNCT	O
HCFCs	B-Chemical	NOUN	B
)	O	PUNCT	O
are	O	AUX	O
used	O	VERB	O
increasingly	O	ADV	O
in	O	ADP	O
industry	O	NOUN	B
as	O	ADP	O
substitutes	O	VERB	B
for	O	ADP	O
ozone	B-Chemical	NOUN	B
-	O	PUNCT	O
depleting	O	VERB	B
chlorofluorocarbons	B-Chemical	NOUN	B
(	O	PUNCT	O
CFCs	B-Chemical	PROPN	B
).	O	PROPN	O
Limited	O	ADJ	O
studies	O	NOUN	O
in	O	ADP	O
animals	O	NOUN	B
indicate	O	VERB	O
potential	O	ADJ	B
hepatotoxicity	B-Disease	NOUN	B
of	O	ADP	O
some	O	DET	O
of	O	ADP	O
these	O	DET	O
compounds	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
investigated	O	VERB	B
an	O	DET	O
epidemic	O	NOUN	B
of	O	ADP	O
liver	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
in	O	ADP	O
nine	O	NUM	O
industrial	O	ADJ	B
workers	O	NOUN	I
who	O	PRON	O
had	O	AUX	O
had	O	AUX	O
repeated	O	VERB	O
accidental	O	ADJ	B
exposure	O	NOUN	O
to	O	PART	O
a	O	DET	O
mixture	O	NOUN	O
of	O	ADP	O
1,1-dichloro-2,2,2-trifluoroethane	B-Chemical	NOUN	B
(	O	PUNCT	O
HCFC	B-Chemical	NOUN	B
123	I-Chemical	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
1-chloro-1,2,2,2-tetrafluoroethane	B-Chemical	NOUN	B
(	O	PUNCT	O
HCFC	B-Chemical	NOUN	B
124	I-Chemical	NUM	O
).	O	PUNCT	O
All	O	DET	O
nine	O	NUM	O
exposed	O	VERB	B
workers	O	NOUN	I
were	O	AUX	O
affected	O	VERB	B
to	O	ADP	O
various	O	ADJ	O
degrees	O	NOUN	B
.	O	PUNCT	O


Both	O	DET	O
compounds	O	NOUN	B
are	O	AUX	O
metabolised	O	VERB	B
in	O	ADP	O
the	O	DET	O
same	O	ADJ	O
way	O	NOUN	O
as	O	ADP	O
1-bromo-1-chloro-2,2,2-trifluoroethane	B-Chemical	NOUN	B
(	O	PUNCT	O
halothane	B-Chemical	NOUN	B
)	O	PUNCT	O
to	O	PART	O
form	O	VERB	O
reactive	O	ADJ	B
trifluoroacetyl	B-Chemical	NOUN	B
halide	O	NOUN	B
intermediates	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
have	O	AUX	O
been	O	AUX	O
implicated	O	VERB	O
in	O	ADP	O
the	O	DET	O
hepatotoxicity	B-Disease	NOUN	B
of	O	ADP	O
halothane	B-Chemical	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
aimed	O	VERB	O
to	O	PART	O
test	O	VERB	B
whether	O	SCONJ	O
HCFCs	B-Chemical	NOUN	B
123	I-Chemical	NUM	O
and	I-Chemical	CCONJ	O
124	I-Chemical	NUM	O
can	O	AUX	O
result	O	VERB	O
in	O	ADP	O
serious	O	ADJ	O
liver	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
For	O	ADP	O
one	O	NUM	O
severely	O	ADV	O
affected	O	VERB	B
worker	O	NOUN	B
liver	O	NOUN	B
biopsy	O	NOUN	I
and	O	CCONJ	O
immunohistochemical	O	ADJ	B
stainings	O	NOUN	I
for	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
trifluoroacetyl	B-Chemical	ADJ	B
protein	O	NOUN	I
adducts	O	NOUN	B
were	O	AUX	O
done	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
serum	O	NOUN	B
of	O	ADP	O
six	O	NUM	O
affected	O	VERB	B
workers	O	NOUN	B
and	O	CCONJ	O
five	O	NUM	O
controls	O	NOUN	B
was	O	AUX	O
tested	O	VERB	B
for	O	ADP	O
autoantibodies	O	NOUN	B
that	O	PRON	O
react	O	VERB	O
with	O	ADP	O
human	O	ADJ	B
liver	O	NOUN	O
cytochrome	O	NOUN	O
-	O	PUNCT	O
P450	O	NOUN	B
2E1	O	NOUN	I
(	O	PUNCT	O
P450	O	NOUN	B
2E1	O	NOUN	I
)	O	PUNCT	O
and	O	CCONJ	O
P58	O	NOUN	B
protein	O	NOUN	I
disulphide	O	NOUN	B
isomerase	O	NOUN	I
isoform	O	NOUN	I
(	O	PUNCT	O
P58	O	NOUN	O
).	O	PUNCT	O
FINDINGS	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
liver	O	NOUN	B
biopsy	O	NOUN	I
sample	O	NOUN	O
showed	O	VERB	O
hepatocellular	O	NOUN	B
necrosis	B-Disease	NOUN	I
which	O	DET	O
was	O	AUX	O
prominent	O	ADJ	O
in	O	ADP	O
perivenular	O	ADJ	B
zone	O	NOUN	B
three	O	NUM	O
and	O	CCONJ	O
extended	O	VERB	O
focally	O	ADV	B
from	O	ADP	O
portal	O	ADJ	B
tracts	O	NOUN	I
to	O	PART	O
portal	O	ADJ	B
tracts	O	NOUN	I
and	O	CCONJ	O
centrilobular	O	ADJ	B
areas	O	NOUN	O
(	O	PUNCT	O
bridging	O	VERB	B
necrosis	B-Disease	NOUN	I
).	O	PUNCT	O
Trifluoroacetyl	B-Chemical	PROPN	B
-	O	PUNCT	O
adducted	O	VERB	B
proteins	O	NOUN	I
were	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
surviving	O	VERB	O
hepatocytes	O	NOUN	B
.	O	PUNCT	O


Autoantibodies	O	NOUN	B
against	O	ADP	O
P450	O	NOUN	B
2E1	O	NOUN	I
or	O	CCONJ	O
P58	O	NOUN	B
,	O	PUNCT	O
previously	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
halothane	B-Disease	NOUN	B
hepatitis	I-Disease	NOUN	I
,	O	PUNCT	O
were	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
the	O	DET	O
serum	O	NOUN	B
of	O	ADP	O
five	O	NUM	O
affected	O	VERB	B
workers	O	NOUN	B
.	O	PUNCT	O


INTERPRETATION	O	NOUN	B
:	O	PUNCT	O
Repeated	O	VERB	B
exposure	O	NOUN	B
of	O	ADP	O
human	O	ADJ	B
beings	O	NOUN	B
to	O	PART	O
HCFCs	B-Chemical	NOUN	B
123	I-Chemical	NUM	O
and	I-Chemical	CCONJ	O
124	I-Chemical	NUM	O
can	O	AUX	O
result	O	VERB	O
in	O	ADP	O
serious	O	ADJ	O
liver	B-Disease	NOUN	B
injury	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
large	O	ADJ	O
proportion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
exposed	O	VERB	B
population	O	NOUN	I
.	O	PUNCT	O


Although	O	SCONJ	O
the	O	DET	O
exact	O	ADJ	O
mechanism	O	NOUN	B
of	O	ADP	O
hepatotoxicity	B-Disease	NOUN	B
of	O	ADP	O
these	O	DET	O
agents	O	NOUN	B
is	O	AUX	O
not	O	PART	O
known	O	VERB	O
,	O	PUNCT	O
the	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
trifluoroacetyl	B-Chemical	NOUN	B


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
different	O	ADJ	O
anaesthetic	O	ADJ	B
agents	O	NOUN	I
in	O	ADP	O
hearing	B-Disease	VERB	B
loss	I-Disease	NOUN	I
following	O	VERB	O
spinal	O	ADJ	B
anaesthesia	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
cause	O	NOUN	O
of	O	ADP	O
hearing	B-Disease	VERB	B
loss	I-Disease	NOUN	I
after	O	ADP	O
spinal	O	ADJ	B
anaesthesia	O	NOUN	I
is	O	AUX	O
unknown	O	ADJ	O
.	O	PUNCT	O


Up	O	ADP	O
until	O	ADP	O
now	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
only	O	ADJ	O
factor	O	NOUN	B
studied	O	VERB	O
has	O	AUX	O
been	O	AUX	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
the	O	DET	O
diameter	O	NOUN	B
of	O	ADP	O
the	O	DET	O
spinal	O	ADJ	B
needle	O	NOUN	I
on	O	ADP	O
post	O	NOUN	B
-	O	PUNCT	O
operative	O	ADJ	B
sensorineural	B-Disease	ADJ	B
hearing	I-Disease	NOUN	I
loss	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
describe	O	VERB	O
this	O	DET	O
hearing	B-Disease	NOUN	B
loss	I-Disease	NOUN	I
and	O	CCONJ	O
to	O	PART	O
investigate	O	VERB	B
other	O	ADJ	O
factors	O	NOUN	B
influencing	O	VERB	B
the	O	DET	O
degree	O	NOUN	B
of	O	ADP	O
hearing	B-Disease	VERB	B
loss	I-Disease	NOUN	I
.	O	PUNCT	O


Two	O	NUM	O
groups	O	NOUN	B
of	O	ADP	O
22	O	NUM	O
similar	O	ADJ	O
patients	O	NOUN	B
were	O	AUX	O
studied	O	VERB	O
:	O	PUNCT	O
one	O	NUM	O
group	O	NOUN	B
received	O	VERB	O
6	O	NUM	O
mL	O	NOUN	O
prilocaine	B-Chemical	NOUN	B
2	O	NUM	I
%;	O	NOUN	O
and	O	CCONJ	O
the	O	DET	O
other	O	ADJ	O
received	O	VERB	O
3	O	NUM	O
mL	O	NOUN	O
bupivacaine	B-Chemical	NOUN	B
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
%.	O	NOUN	B
Patients	O	NOUN	B
given	O	VERB	O
prilocaine	B-Chemical	NOUN	B
were	O	AUX	O
more	O	ADV	O
likely	O	ADJ	O
to	O	PART	O
develop	O	VERB	O
hearing	B-Disease	VERB	B
loss	I-Disease	NOUN	I
(	O	PUNCT	O
10	O	NUM	O
out	O	ADP	O
of	O	ADP	O
22	O	NUM	O
)	O	PUNCT	O
than	O	ADP	O
those	O	DET	O
given	O	VERB	O
bupivacaine	B-Chemical	NOUN	B
(	O	PUNCT	O
4	O	NUM	O
out	O	ADP	O
of	O	ADP	O
22	O	NUM	O
)(	O	NOUN	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
).	O	PUNCT	O
The	O	DET	O
average	O	ADJ	B
hearing	B-Disease	NOUN	B
loss	I-Disease	NOUN	I
for	O	ADP	O
speech	O	NOUN	B
frequencies	O	NOUN	I
was	O	AUX	O
about	O	ADV	O
10	O	NUM	O
dB	O	NOUN	O
after	O	ADP	O
prilocaine	B-Chemical	NOUN	B
and	O	CCONJ	O
15	O	NUM	O
dB	O	NOUN	O
after	O	ADP	O
bupivacaine	B-Chemical	NOUN	B
.	O	PUNCT	O


of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
complained	O	VERB	B
of	O	ADP	O
subjective	O	ADJ	B
hearing	B-Disease	NOUN	I
loss	I-Disease	NOUN	I


A	O	DET	O
transient	O	ADJ	B
neurological	B-Disease	ADJ	B
deficit	I-Disease	NOUN	I
following	O	VERB	O
intrathecal	O	ADJ	B
injection	O	NOUN	I
of	O	ADP	O
1	O	NUM	O
%	O	NOUN	O
hyperbaric	O	ADJ	B
bupivacaine	B-Chemical	NOUN	I
for	O	ADP	O
unilateral	O	ADJ	B
spinal	O	ADJ	B
anaesthesia	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
describe	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
transient	O	ADJ	B
neurological	B-Disease	ADJ	B
deficit	I-Disease	NOUN	I
that	O	PRON	O
occurred	O	VERB	O
after	O	ADP	O
unilateral	O	ADJ	B
spinal	O	ADJ	B
anaesthesia	O	NOUN	I
with	O	ADP	O
8	O	NUM	O
mg	O	NOUN	O
of	O	ADP	O
1	O	NUM	O
%	O	NOUN	O
hyperbaric	O	ADJ	B
bupivacaine	B-Chemical	NOUN	I
slowly	O	ADV	B
injected	O	VERB	I
through	O	ADP	O
a	O	DET	O
25	O	NUM	O
-	O	PUNCT	O
gauge	O	NOUN	B
pencil	O	NOUN	B
-	O	PUNCT	O
point	O	NOUN	B
spinal	O	ADJ	B
needle	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
surgery	O	NOUN	B
and	O	CCONJ	O
anaesthesia	O	NOUN	B
were	O	AUX	O
uneventful	O	ADJ	B
,	O	PUNCT	O
but	O	CCONJ	O
3	O	NUM	O
days	O	NOUN	B
after	O	ADP	O
surgery	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
patient	O	NOUN	B
reported	O	VERB	O
an	O	DET	O
area	O	NOUN	B
of	O	ADP	O
hypoaesthesia	O	NOUN	B
over	O	ADP	O
L3	O	PROPN	B
-	O	PUNCT	O
L4	O	PROPN	B
dermatomes	O	NOUN	B
of	O	ADP	O
the	O	DET	O
leg	O	NOUN	B
which	O	DET	O
had	O	AUX	O
been	O	AUX	O
operated	O	VERB	O
on	O	ADP	O
(	O	PUNCT	O
loss	B-Disease	NOUN	B
of	I-Disease	ADP	O
pinprick	I-Disease	ADJ	B
sensation	I-Disease	NOUN	I
)	O	PUNCT	O
without	O	ADP	O
reduction	O	NOUN	B
in	O	ADP	O
muscular	O	ADJ	B
strength	O	NOUN	I
.	O	PUNCT	O


Sensation	O	NOUN	B
in	O	ADP	O
this	O	DET	O
area	O	NOUN	B
returned	O	VERB	O
to	O	ADP	O
normal	O	ADJ	B
over	O	ADP	O
the	O	DET	O
following	O	VERB	O
2	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


Prospective	O	ADJ	B
multicentre	O	NOUN	I
studies	O	NOUN	I
with	O	ADP	O
a	O	DET	O
large	O	ADJ	O
population	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
long	O	ADJ	O
follow	O	NOUN	B
-	O	PUNCT	O
up	O	NOUN	O
should	O	AUX	O
be	O	AUX	O
performed	O	VERB	O
in	O	ADP	O
order	O	NOUN	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
this	O	DET	O
unusual	O	ADJ	B
side	O	NOUN	B
effect	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
suggest	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
low	O	ADJ	B
solution	O	NOUN	B
concentration	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
preferred	O	VERB	O
for	O	ADP	O
unilateral	O	ADJ	B
spinal	O	ADJ	B
anaesthesia	O	NOUN	I
with	O	ADP	O
a	O	DET	O
hyperbaric	O	ADJ	B
anaesthetic	O	ADJ	I
solution	O	NOUN	I
(	O	PUNCT	O
if	O	SCONJ	O
pencil	O	NOUN	B
-	O	PUNCT	O
point	O	NOUN	B
needle	O	NOUN	B
and	O	CCONJ	O
slow	O	ADJ	B
injection	O	NOUN	I
rate	O	NOUN	I
are	O	AUX	O
employed	O	VERB	O
),	O	PUNCT	O
in	O	ADP	O
order	O	NOUN	O
to	O	PART	O
minimize	O	VERB	B
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
a	O	DET	O
localized	O	ADJ	B
high	O	ADJ	O
peak	O	NOUN	O
anaesthetic	O	ADJ	O
concentration	O	NOUN	O
,	O	PUNCT	O
which	O	DET	O
might	O	AUX	O
lead	O	VERB	O
to	O	PART	O
a	O	DET	O
transient	O	ADJ	B
neurological	B-Disease	ADJ	B
deficit	I-Disease	NOUN	I


Pethidine	B-Chemical	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
seizure	B-Disease	NOUN	B
in	O	ADP	O
a	O	DET	O
healthy	O	ADJ	B
adolescent	O	ADJ	B
receiving	O	VERB	O
pethidine	B-Chemical	NOUN	B
for	O	ADP	O
postoperative	B-Disease	ADJ	B
pain	I-Disease	NOUN	I
control	O	NOUN	O
.	O	PUNCT	O


A	O	DET	O
healthy	O	ADJ	B
17	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
male	O	NOUN	B
received	O	VERB	O
standard	O	ADJ	B
intermittent	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
pethidine	B-Chemical	NOUN	B
via	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
-	O	PUNCT	O
controlled	O	VERB	B
analgesia	O	NOUN	I
(	O	PUNCT	O
PCA	O	NOUN	B
)	O	PUNCT	O
pump	O	VERB	B
for	O	ADP	O
management	O	NOUN	B
of	O	ADP	O
postoperative	B-Disease	ADJ	B
pain	I-Disease	NOUN	I
control	O	NOUN	O
.	O	PUNCT	O


Twenty	O	NUM	B
-	O	PUNCT	O
three	O	NUM	O
h	O	NOUN	O
postoperatively	O	ADV	B
he	O	PRON	O
developed	O	VERB	O
a	O	DET	O
brief	O	ADJ	O
self	O	NOUN	B
-	O	PUNCT	O
limited	O	ADJ	B
seizure	B-Disease	NOUN	B
.	O	PUNCT	O


Both	O	CCONJ	O
plasma	O	NOUN	B
pethidine	B-Chemical	NOUN	B
and	O	CCONJ	O
norpethidine	B-Chemical	NOUN	B
were	O	AUX	O
elevated	O	ADJ	B
in	O	ADP	O
the	O	DET	O
range	O	NOUN	O
associated	O	VERB	B
with	O	ADP	I
clinical	O	ADJ	B
manifestations	O	NOUN	O
of	O	ADP	O
central	O	ADJ	B
nervous	O	ADJ	I
system	O	NOUN	I
excitation	O	NOUN	I
.	O	PUNCT	O


No	O	DET	O
other	O	ADJ	O
risk	O	NOUN	B
factors	O	NOUN	I
for	O	ADP	O
CNS	O	NOUN	B
toxicity	B-Disease	NOUN	B
were	O	AUX	O
identified	O	VERB	B
.	O	PUNCT	O


This	O	DET	O
method	O	NOUN	B
allowed	O	VERB	O
frequent	O	ADJ	B
self	O	NOUN	B
-	O	PUNCT	O
dosing	O	NOUN	B
of	O	ADP	O
pethidine	B-Chemical	NOUN	B
at	O	ADP	O
short	O	ADJ	B
time	O	NOUN	I
intervals	O	NOUN	I
and	O	CCONJ	O
rapid	O	ADJ	O
accumulation	O	NOUN	B
of	O	ADP	O
pethidine	B-Chemical	NOUN	B
and	O	CCONJ	O
norpethidine	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
routine	O	ADJ	O
use	O	NOUN	O
of	O	ADP	O
pethidine	B-Chemical	NOUN	B


Drug	O	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
acute	O	ADJ	B
-	O	PUNCT	O
onset	O	NOUN	B
vanishing	B-Disease	ADJ	O
bile	I-Disease	NOUN	O
duct	I-Disease	NOUN	O
and	O	CCONJ	O
Stevens-Johnson	B-Disease	NOUN	B
syndromes	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
child	O	NOUN	B
.	O	PUNCT	O


Acute	O	ADJ	B
vanishing	B-Disease	ADJ	I
bile	I-Disease	NOUN	I
duct	I-Disease	NOUN	I
syndrome	O	NOUN	I
is	O	AUX	O
a	O	DET	O
rare	O	ADJ	B
but	O	CCONJ	O
established	O	ADJ	O
cause	O	NOUN	O
of	O	ADP	O
progressive	O	ADJ	B
cholestasis	B-Disease	NOUN	B
in	O	ADP	O
adults	O	NOUN	B
,	O	PUNCT	O
is	O	AUX	O
most	O	ADV	O
often	O	ADV	O
drug	O	NOUN	B
or	O	CCONJ	O
toxin	O	NOUN	B
related	O	ADJ	O
,	O	PUNCT	O
and	O	CCONJ	O
is	O	AUX	O
of	O	ADP	O
unknown	O	ADJ	O
pathogenesis	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
has	O	AUX	O
not	O	PART	O
been	O	AUX	O
reported	O	VERB	O
previously	O	ADV	O
in	O	ADP	O
children	O	NOUN	B
.	O	PUNCT	O


Stevens-Johnson	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
is	O	AUX	O
a	O	DET	O
well	O	ADV	O
-	O	PUNCT	O
recognized	O	VERB	B
immune	O	ADJ	B
complex	O	NOUN	I
-	O	PUNCT	O
mediated	O	VERB	B
hypersensitivity	B-Disease	NOUN	I
reaction	O	NOUN	B
that	O	PRON	O
affects	O	VERB	O
all	O	DET	O
age	O	NOUN	B
groups	O	NOUN	I
,	O	PUNCT	O
is	O	AUX	O
drug	O	NOUN	B
or	O	CCONJ	O
infection	B-Disease	NOUN	B
induced	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
has	O	AUX	O
classic	O	ADJ	O
systemic	O	ADJ	B
,	O	PUNCT	O
mucosal	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
dermatologic	O	ADJ	B
manifestations	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
previously	O	ADV	O
healthy	O	ADJ	B
child	O	NOUN	B
who	O	PRON	O
developed	O	VERB	O
acute	O	ADJ	B
,	O	PUNCT	O
severe	O	ADJ	B
,	O	PUNCT	O
rapidly	O	ADV	O
progressive	O	ADJ	B
vanishing	B-Disease	ADJ	B
bile	I-Disease	NOUN	I
duct	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
shortly	O	ADV	O
after	O	ADP	O
Stevens-Johnson	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
is	O	AUX	O
described	O	VERB	O
;	O	PUNCT	O
this	O	DET	O
was	O	AUX	O
temporally	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
ibuprofen	B-Chemical	NOUN	B
use	O	NOUN	O
.	O	PUNCT	O


Despite	O	SCONJ	O
therapy	O	NOUN	B
with	O	ADP	O
ursodeoxycholic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
,	O	PUNCT	O
prednisone	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
then	O	ADV	O
tacrolimus	B-Chemical	NOUN	B
,	O	PUNCT	O
her	O	PRON	O
cholestatic	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
was	O	AUX	O
unrelenting	O	ADJ	B
,	O	PUNCT	O
with	O	ADP	O
cirrhosis	B-Disease	NOUN	B
shown	O	VERB	O
by	O	ADP	O
biopsy	O	NOUN	B
6	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
presentation	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
case	O	NOUN	B
documents	O	VERB	I
acute	O	ADJ	B
drug	O	NOUN	O
-	O	PUNCT	O
related	O	ADJ	B
vanishing	B-Disease	ADJ	O
bile	I-Disease	NOUN	B
duct	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
in	O	ADP	O
the	O	DET	O
pediatric	O	ADJ	B
age	O	NOUN	B
group	O	NOUN	I
and	O	CCONJ	O
suggests	O	VERB	O
shared	O	VERB	O
immune	O	ADJ	B
mechanisms	O	NOUN	I
in	O	ADP	O
the	O	DET	O
pathogenesis	O	NOUN	B
of	O	ADP	O
both	O	CCONJ	O
Stevens-Johnson	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
and	O	CCONJ	O
vanishing	B-Disease	VERB	B
bile	I-Disease	NOUN	I
duct	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I


High	O	ADJ	B
incidence	O	NOUN	B
of	O	ADP	O
primary	B-Disease	ADJ	B
pulmonary	I-Disease	ADJ	I
hypertension	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
appetite	B-Chemical	ADJ	B
suppressants	I-Chemical	NOUN	I
in	O	ADP	O
Belgium	O	PROPN	B
.	O	PUNCT	O


Primary	B-Disease	ADJ	B
pulmonary	I-Disease	ADJ	I
hypertension	I-Disease	NOUN	I
is	O	AUX	O
a	O	DET	O
rare	O	ADJ	B
,	O	PUNCT	O
progressive	O	ADJ	B
and	O	CCONJ	O
incurable	O	ADJ	B
disease	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
has	O	AUX	O
been	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
intake	O	NOUN	B
of	O	ADP	O
appetite	B-Chemical	ADJ	B
suppressant	I-Chemical	ADJ	I
drugs	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
importance	O	NOUN	O
of	O	ADP	O
this	O	DET	O
association	O	NOUN	B
was	O	AUX	O
evaluated	O	VERB	B
in	O	ADP	O
Belgium	O	PROPN	B
while	O	SCONJ	O
this	O	DET	O
country	O	NOUN	B
still	O	ADV	O
had	O	AUX	O
no	O	DET	O
restriction	O	NOUN	B
on	O	ADP	O
the	O	DET	O
prescription	O	NOUN	B
of	O	ADP	O
appetite	B-Chemical	ADJ	B
suppressants	I-Chemical	NOUN	I
.	O	PUNCT	O


Thirty	O	NUM	B
-	O	PUNCT	O
five	O	NUM	B
patients	O	NOUN	B
with	O	ADP	O
primary	B-Disease	ADJ	B
pulmonary	I-Disease	ADJ	I
hypertension	I-Disease	NOUN	I
and	O	CCONJ	O
85	O	NUM	O
matched	O	VERB	B
controls	O	NOUN	I
were	O	AUX	O
recruited	O	VERB	O
over	O	ADP	O
32	O	NUM	O
months	O	NOUN	B
(	O	PUNCT	O
1992	O	NUM	O
-	O	SYM	O
1994	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
Belgium	O	PROPN	B
.	O	PUNCT	O


Exposure	O	NOUN	B
to	O	PART	I
appetite-suppressants	B-Chemical	NOUN	B
was	O	AUX	O
assessed	O	VERB	B
on	O	ADP	O
the	O	DET	O
basis	O	NOUN	O
of	O	ADP	O
hospital	O	NOUN	B
records	O	NOUN	I
and	O	CCONJ	O
standardized	O	ADJ	B
interview	O	NOUN	I
.	O	PUNCT	O


Twenty	O	NUM	B
-	O	PUNCT	O
three	O	NUM	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
had	O	AUX	O
previously	O	ADV	O
taken	O	VERB	O
appetite	B-Chemical	ADJ	B
suppressants	I-Chemical	NOUN	I
,	O	PUNCT	O
mainly	O	ADV	O
fenfluramines	B-Chemical	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
compared	O	VERB	B
with	O	ADP	O
only	O	ADV	O
5	O	NUM	O
of	O	ADP	O
the	O	DET	O
controls	O	NOUN	B
(	O	PUNCT	O
66	O	NUM	O
versus	O	CCONJ	O
6	O	NUM	O
%,	O	NOUN	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


0001	O	NUM	O
).	O	PUNCT	O
Five	O	NUM	O
patients	O	NOUN	B
died	O	VERB	B
before	O	ADP	O
the	O	DET	O
interview	O	NOUN	B
,	O	PUNCT	O
all	O	DET	O
of	O	ADP	O
them	O	PRON	O
had	O	AUX	O
taken	O	VERB	O
appetite	B-Chemical	ADJ	B
suppressants	I-Chemical	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
8	O	NUM	O
patients	O	NOUN	B
the	O	DET	O
diagnosis	O	NOUN	B
of	O	ADP	O
primary	B-Disease	ADJ	B
pulmonary	I-Disease	ADJ	I
hypertension	I-Disease	NOUN	I
was	O	AUX	O
uncertain	O	ADJ	O
,	O	PUNCT	O
5	O	NUM	O
of	O	ADP	O
them	O	PRON	O
had	O	AUX	O
taken	O	VERB	O
appetite	B-Chemical	ADJ	B
suppressants	I-Chemical	NOUN	I
.	O	PUNCT	O


The	O	DET	O
patients	O	NOUN	B
who	O	PRON	O
had	O	AUX	O
been	O	AUX	O
exposed	O	VERB	B
to	O	PART	I
appetite	B-Chemical	NOUN	B
suppressants	I-Chemical	NOUN	I
tended	O	VERB	O
to	O	PART	O
be	O	AUX	O
on	O	ADP	O
average	O	NOUN	B
more	O	ADV	O
severely	O	ADV	B
ill	O	ADJ	I
,	O	PUNCT	O
and	O	CCONJ	O
to	O	PART	O
have	O	AUX	O
a	O	DET	O
shorter	O	ADJ	B
median	O	ADJ	O
delay	O	NOUN	O
between	O	ADP	O
onset	O	NOUN	B
of	O	ADP	I
symptoms	O	NOUN	B
and	O	CCONJ	O
diagnosis	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
policy	O	NOUN	B
of	O	ADP	O
unrestricted	O	ADJ	O
prescription	O	NOUN	B
of	O	ADP	O
appetite	B-Chemical	ADJ	B
suppressants	I-Chemical	NOUN	I
may	O	AUX	O
lead	O	VERB	O
to	O	PART	O
a	O	DET	O
high	O	ADJ	O
incidence	O	NOUN	B
of	O	ADP	O
associated	O	VERB	O
primary	B-Disease	ADJ	O
pulmonary	I-Disease	ADJ	B
hypertension	I-Disease	NOUN	I
.	O	PUNCT	O


Intake	O	NOUN	B
of	O	ADP	O
appetite	B-Chemical	ADJ	B
suppressants	I-Chemical	NOUN	I


Choreoathetoid	B-Disease	ADJ	B
movements	I-Disease	NOUN	B
associated	O	VERB	B
with	O	ADP	I
rapid	O	ADJ	O
adjustment	O	NOUN	B
to	O	ADP	O
methadone	B-Chemical	NOUN	B
.	O	PUNCT	O


Choreatiform	B-Disease	NOUN	B
hyperkinesias	I-Disease	NOUN	I
are	O	AUX	O
known	O	VERB	O
to	O	PART	O
be	O	AUX	O
occasional	O	ADJ	O
movement	B-Disease	NOUN	B
abnormalities	I-Disease	NOUN	B
during	O	ADP	O
intoxications	O	NOUN	B
with	O	ADP	O
cocaine	B-Chemical	NOUN	B
but	O	CCONJ	O
not	O	PART	O
opiates	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
is	O	AUX	O
a	O	DET	O
case	O	NOUN	B
report	O	NOUN	I
of	O	ADP	O
euphoria	O	NOUN	B
and	O	CCONJ	O
choreoathetoid	B-Disease	ADJ	B
movements	I-Disease	NOUN	B
both	O	CCONJ	O
transiently	O	ADV	B
induced	O	VERB	B
by	O	ADP	O
rapid	O	ADJ	O
adjustment	O	NOUN	B
to	O	PART	O
the	O	DET	O
selective	O	ADJ	O
mu	O	NOUN	B
-	O	PUNCT	O
opioid	O	NOUN	B
receptor	O	NOUN	I
agonist	O	NOUN	B
methadone	B-Chemical	NOUN	B
in	O	ADP	O
an	O	DET	O
inpatient	O	ADJ	B
previously	O	ADV	O
abusing	O	VERB	B
heroine	B-Chemical	NOUN	B
and	O	CCONJ	O
cocaine	B-Chemical	NOUN	B


Cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
mood	B-Disease	NOUN	B
disorder	I-Disease	NOUN	I
:	O	PUNCT	O
prevalence	O	NOUN	B
rates	O	NOUN	I
and	O	CCONJ	O
psychiatric	B-Disease	ADJ	B
symptoms	O	NOUN	I
in	O	ADP	O
an	O	DET	O
outpatient	O	ADJ	B
cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
sample	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
paper	O	NOUN	O
attempts	O	VERB	O
to	O	PART	O
examine	O	VERB	O
and	O	CCONJ	O
compare	O	VERB	B
prevalence	O	NOUN	B
rates	O	NOUN	O
and	O	CCONJ	O
symptom	O	NOUN	B
patterns	O	NOUN	I
of	O	ADP	O
DSM	O	PROPN	B
substance	O	NOUN	I
-	O	PUNCT	O
induced	O	VERB	B
and	O	CCONJ	O
other	O	ADJ	O
mood	B-Disease	NOUN	B
disorders	I-Disease	NOUN	I
.	O	PUNCT	O


243	O	NUM	O
cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
outpatients	O	NOUN	B
with	O	ADP	O
cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
mood	B-Disease	NOUN	B
disorder	I-Disease	NOUN	I
(	O	PUNCT	O
CIMD	B-Disease	NOUN	B
),	O	PUNCT	O
other	O	ADJ	O
mood	B-Disease	NOUN	B
disorders	I-Disease	NOUN	I
,	O	PUNCT	O
or	O	CCONJ	O
no	O	DET	O
mood	B-Disease	NOUN	B
disorder	I-Disease	NOUN	I
were	O	AUX	O
compared	O	VERB	B
on	O	ADP	O
measures	O	NOUN	B
of	O	ADP	O
psychiatric	B-Disease	ADJ	B
symptoms	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
prevalence	O	NOUN	B
rate	O	NOUN	B
for	O	ADP	O
CIMD	B-Disease	NOUN	B
was	O	AUX	O
12	O	NUM	O
%	O	NOUN	O
at	O	ADP	O
baseline	O	NOUN	B
.	O	PUNCT	O


Introduction	O	NOUN	O
of	O	ADP	O
the	O	DET	O
DSM	O	PROPN	B
-	O	PUNCT	O
IV	O	NUM	B
diagnosis	O	NOUN	B
of	O	ADP	O
CIMD	B-Disease	NOUN	B
did	O	AUX	O
not	O	PART	O
substantially	O	ADV	O
affect	O	VERB	O
rates	O	NOUN	B
of	O	ADP	O
the	O	DET	O
other	O	ADJ	O
depressive	B-Disease	ADJ	B
disorders	I-Disease	NOUN	I
.	O	PUNCT	O


Patients	O	NOUN	B
with	O	ADP	O
CIMD	B-Disease	NOUN	B
had	O	AUX	O
symptom	O	NOUN	B
severity	O	NOUN	B
levels	O	NOUN	O
between	O	ADP	O
those	O	DET	O
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
and	O	CCONJ	O
without	O	ADP	O
a	O	DET	O
mood	B-Disease	NOUN	B
disorder	I-Disease	NOUN	I
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
suggest	O	VERB	O
some	O	DET	O
validity	O	NOUN	B
for	O	ADP	O
the	O	DET	O
new	O	ADJ	O
DSM	O	PROPN	B
-	O	PUNCT	O
IV	O	NUM	B
diagnosis	O	NOUN	B
of	O	ADP	O
CIMD	B-Disease	NOUN	B


Hemolysis	B-Disease	NOUN	B
of	O	ADP	O
human	O	ADJ	B
erythrocytes	O	NOUN	B
induced	O	VERB	B
by	O	ADP	O
tamoxifen	B-Chemical	NOUN	B
is	O	AUX	O
related	O	ADJ	O
to	O	PART	O
disruption	O	NOUN	B
of	O	ADP	O
membrane	O	NOUN	B
structure	O	NOUN	I
.	O	PUNCT	O


Tamoxifen	B-Chemical	NOUN	B
(	O	PUNCT	O
TAM	B-Chemical	NOUN	B
),	O	PUNCT	O
the	O	DET	O
antiestrogenic	O	ADJ	B
drug	O	NOUN	I
most	O	ADV	O
widely	O	ADV	O
prescribed	O	VERB	B
in	O	ADP	O
the	O	DET	O
chemotherapy	O	NOUN	B
of	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
,	O	PUNCT	O
induces	O	VERB	O
changes	O	NOUN	B
in	O	ADP	O
normal	O	ADJ	O
discoid	O	ADJ	B
shape	O	NOUN	B
of	O	ADP	O
erythrocytes	O	NOUN	B
and	O	CCONJ	O
hemolytic	B-Disease	ADJ	B
anemia	I-Disease	NOUN	I
.	O	PUNCT	O


This	O	DET	O
work	O	NOUN	O
evaluates	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
TAM	B-Chemical	NOUN	B
on	O	ADP	O
isolated	O	VERB	B
human	O	ADJ	B
erythrocytes	O	NOUN	B
,	O	PUNCT	O
attempting	O	VERB	O
to	O	PART	O
identify	O	VERB	O
the	O	DET	O
underlying	O	ADJ	O
mechanisms	O	NOUN	B
on	O	ADP	O
TAM	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
hemolytic	B-Disease	ADJ	B
anemia	I-Disease	NOUN	B
and	O	CCONJ	O
the	O	DET	O
involvement	O	NOUN	B
of	O	ADP	O
biomembranes	O	NOUN	B
in	O	ADP	O
its	O	PRON	O
cytostatic	O	ADJ	B
action	O	NOUN	I
mechanisms	O	NOUN	B
.	O	PUNCT	O


TAM	B-Chemical	NOUN	B
induces	O	VERB	O
hemolysis	B-Disease	NOUN	B
of	O	ADP	O
erythrocytes	O	NOUN	B
as	O	ADP	O
a	O	DET	O
function	O	NOUN	B
of	O	ADP	O
concentration	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
extension	O	NOUN	B
of	O	ADP	O
hemolysis	B-Disease	NOUN	B
is	O	AUX	O
variable	O	ADJ	B
with	O	ADP	O
erythrocyte	O	NOUN	B
samples	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
12	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
microM	O	NOUN	O
TAM	B-Chemical	NOUN	B
induces	O	VERB	O
total	O	ADJ	O
hemolysis	B-Disease	NOUN	B
of	O	ADP	O
all	O	DET	O
tested	O	VERB	B
suspensions	O	NOUN	B
.	O	PUNCT	O


Despite	O	SCONJ	O
inducing	O	VERB	O
extensive	O	ADJ	O
erythrocyte	O	NOUN	B
lysis	O	NOUN	O
,	O	PUNCT	O
TAM	B-Chemical	NOUN	B
does	O	AUX	O
not	O	PART	O
shift	O	VERB	O
the	O	DET	O
osmotic	O	ADJ	B
fragility	O	NOUN	I
curves	O	NOUN	I
of	O	ADP	O
erythrocytes	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
hemolytic	B-Disease	ADJ	B
effect	O	NOUN	B
of	O	ADP	O
TAM	B-Chemical	NOUN	B
is	O	AUX	O
prevented	O	VERB	B
by	O	ADP	O
low	O	ADJ	B
concentrations	O	NOUN	B
of	O	ADP	O
alpha-tocopherol	B-Chemical	NOUN	B
(	O	PUNCT	O
alpha-T	B-Chemical	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
alpha-tocopherol	B-Chemical	NOUN	B
acetate	I-Chemical	NOUN	I
(	O	PUNCT	O
alpha-TAc	B-Chemical	NOUN	B
)(	O	NOUN	O
inactivated	O	VERB	B
functional	O	ADJ	O
hydroxyl	B-Chemical	NOUN	O
)	O	PUNCT	O
indicating	O	VERB	O
that	O	SCONJ	O
TAM	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
hemolysis	B-Disease	NOUN	B
is	O	AUX	O
not	O	PART	O
related	O	ADJ	O
to	O	PART	O
oxidative	O	ADJ	B
membrane	O	NOUN	I
damage	O	NOUN	O
.	O	PUNCT	O


This	O	DET	O
was	O	AUX	O
further	O	ADV	O
evidenced	O	VERB	O
by	O	ADP	O
absence	O	NOUN	B
of	O	ADP	O
oxygen	B-Chemical	NOUN	B
consumption	O	NOUN	I
and	O	CCONJ	O
hemoglobin	O	NOUN	B
oxidation	O	NOUN	I
both	O	CCONJ	O
determined	O	VERB	O
in	O	ADP	O
parallel	O	NOUN	O
with	O	ADP	O
TAM	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hemolysis	B-Disease	NOUN	B
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
it	O	PRON	O
was	O	AUX	O
observed	O	VERB	O
that	O	SCONJ	O
TAM	B-Chemical	NOUN	B
inhibits	O	VERB	B
the	O	DET	O
peroxidation	O	NOUN	B
of	O	ADP	O
human	O	ADJ	B
erythrocytes	O	NOUN	B
induced	O	VERB	B
by	O	ADP	O
AAPH	B-Chemical	NOUN	B
,	O	PUNCT	O
thus	O	ADV	O
ruling	O	VERB	O
out	O	ADP	O
TAM	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
cell	O	NOUN	B
oxidative	O	ADJ	I
stress	O	NOUN	I
.	O	PUNCT	O


Hemolysis	B-Disease	NOUN	B
caused	O	VERB	O
by	O	ADP	O
TAM	B-Chemical	NOUN	B
was	O	AUX	O
not	O	PART	O
preceded	O	VERB	O
by	O	ADP	O
the	O	DET	O
leakage	O	NOUN	B
of	O	ADP	O
K	B-Chemical	NOUN	B
(+)	O	NOUN	I
from	O	ADP	O
the	O	DET	O
cells	O	NOUN	B
,	O	PUNCT	O
also	O	ADV	O
excluding	O	VERB	O
a	O	DET	O
colloid	O	NOUN	B
-	O	PUNCT	O
osmotic	O	ADJ	B
type	O	NOUN	O
mechanism	O	NOUN	B
of	O	ADP	O
hemolysis	B-Disease	NOUN	B
,	O	PUNCT	O
according	O	VERB	O
to	O	PART	O
the	O	DET	O
effects	O	NOUN	B
on	O	ADP	O
osmotic	O	ADJ	B
fragility	O	NOUN	I
curves	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
TAM	B-Chemical	NOUN	B
induces	O	VERB	O
release	O	NOUN	B
of	O	ADP	O
peripheral	O	ADJ	B
proteins	O	NOUN	I
of	O	ADP	O
membrane	O	NOUN	B
-	O	PUNCT	O
cytoskeleton	O	NOUN	B
and	O	CCONJ	O
cytosol	O	NOUN	B
proteins	O	NOUN	I
essentially	O	ADV	O
bound	O	VERB	O
to	O	PART	O
band	O	NOUN	B
3	O	NUM	I
.	O	PUNCT	O


Either	O	CCONJ	O
alpha-T	B-Chemical	NOUN	B
or	O	CCONJ	O
alpha-TAc	B-Chemical	NOUN	B
increases	O	VERB	B
membrane	O	NOUN	B
packing	O	NOUN	I
and	O	CCONJ	O
prevents	O	VERB	B
TAM	B-Chemical	NOUN	B
partition	O	NOUN	B
into	O	ADP	O
model	O	NOUN	B
membranes	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
effects	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
protection	O	NOUN	B
from	O	ADP	O
hemolysis	B-Disease	NOUN	B
by	O	ADP	O
tocopherols	B-Chemical	NOUN	B
is	O	AUX	O
related	O	ADJ	O
to	O	PART	O
a	O	DET	O
decreased	O	VERB	B
TAM	B-Chemical	NOUN	B
incorporation	O	NOUN	B
in	O	ADP	O
condensed	O	ADJ	B
membranes	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
structural	O	ADJ	B
damage	O	NOUN	I
of	O	ADP	O
the	O	DET	O
erythrocyte	O	NOUN	B
membrane	O	NOUN	I
is	O	AUX	O
consequently	O	ADV	O
avoided	O	VERB	O
.	O	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
TAM	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
hemolysis	B-Disease	NOUN	B
results	O	VERB	B
from	O	ADP	O
a	O	DET	O
structural	O	ADJ	B
perturbation	O	NOUN	B
of	O	ADP	O
red	O	ADJ	B
cell	O	NOUN	I
membrane	O	NOUN	I
,	O	PUNCT	O
leading	O	VERB	O
to	O	PART	O
changes	O	NOUN	B
in	O	ADP	O
the	O	DET	O
framework	O	NOUN	B
of	O	ADP	O
the	O	DET	O
erythrocyte	O	NOUN	B
membrane	O	NOUN	I
and	O	CCONJ	O
its	O	PRON	O
cytoskeleton	O	NOUN	B
caused	O	VERB	O
by	O	ADP	O
its	O	PRON	O
high	O	ADJ	O
partition	O	NOUN	B
in	O	ADP	O
the	O	DET	O
membrane	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
defects	O	NOUN	B
explain	O	VERB	O
the	O	DET	O
abnormal	O	ADJ	B
erythrocyte	O	NOUN	B
shape	O	NOUN	B
and	O	CCONJ	O
decreased	O	VERB	B
mechanical	O	ADJ	B
stability	O	NOUN	I
promoted	O	VERB	O
by	O	ADP	O
TAM	B-Chemical	NOUN	B
,	O	PUNCT	O
resulting	O	VERB	O
in	O	ADP	O
hemolytic	B-Disease	ADJ	B
anemia	I-Disease	NOUN	B
.	O	PUNCT	O


Additionally	O	ADV	O
,	O	PUNCT	O
since	O	SCONJ	O
membrane	O	NOUN	B
leakage	O	NOUN	B
is	O	AUX	O
a	O	DET	O
final	O	ADJ	O
stage	O	NOUN	B
of	O	ADP	O
cytotoxicity	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
disruption	O	NOUN	B
of	O	ADP	O
the	O	DET	O
structural	O	ADJ	B
characteristics	O	NOUN	B
of	O	ADP	O
biomembranes	O	NOUN	B
by	O	ADP	O
TAM	B-Chemical	NOUN	B


Changes	O	NOUN	B
of	O	ADP	O
sodium	B-Chemical	NOUN	B
and	O	CCONJ	O
ATP	B-Chemical	NOUN	B
affinities	O	NOUN	B
of	O	ADP	O
the	O	DET	O
cardiac	O	NOUN	B
(	O	PUNCT	O
Na	B-Chemical	PROPN	B
,	O	PUNCT	O
K	B-Chemical	NOUN	B
)-	O	ADJ	O
ATPase	O	NOUN	B
during	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
nitric	B-Chemical	ADJ	B
oxide	I-Chemical	NOUN	I
deficient	O	ADJ	B
hypertension	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
cardiovascular	O	ADJ	B
system	O	NOUN	I
,	O	PUNCT	O
NO	B-Chemical	NOUN	B
is	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
the	O	DET	O
regulation	O	NOUN	B
of	O	ADP	O
a	O	DET	O
variety	O	NOUN	O
of	O	ADP	O
functions	O	NOUN	B
.	O	PUNCT	O


Inhibition	O	NOUN	B
of	O	ADP	O
NO	B-Chemical	NOUN	B
synthesis	O	NOUN	B
induces	O	VERB	O
sustained	O	ADJ	O
hypertension	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
several	O	ADJ	O
models	O	NOUN	B
of	O	ADP	O
hypertension	B-Disease	NOUN	B
,	O	PUNCT	O
elevation	O	NOUN	B
of	O	ADP	O
intracellular	O	ADJ	B
sodium	B-Chemical	NOUN	O
level	O	NOUN	O
was	O	AUX	O
documented	O	VERB	B
in	O	ADP	O
cardiac	O	ADJ	B
tissue	O	NOUN	I
.	O	PUNCT	O


To	O	PART	O
assess	O	VERB	O
the	O	DET	O
molecular	O	ADJ	B
basis	O	NOUN	I
of	O	ADP	O
disturbances	O	NOUN	B
in	O	ADP	O
transmembraneous	O	ADJ	B
transport	O	NOUN	I
of	O	ADP	O
Na	B-Chemical	NOUN	B
+,	O	NOUN	O
we	O	PRON	O
studied	O	VERB	O
the	O	DET	O
response	O	NOUN	B
of	O	ADP	O
cardiac	O	NOUN	O
(	O	PUNCT	O
Na	B-Chemical	PROPN	B
,	O	PUNCT	O
K	B-Chemical	PROPN	B
)-	O	ADJ	O
ATPase	O	NOUN	B
to	O	PART	O
NO	B-Chemical	NOUN	B
-	O	PUNCT	O
deficient	O	ADJ	B
hypertension	B-Disease	NOUN	B
induced	O	VERB	B
in	O	ADP	O
rats	O	NOUN	B
by	O	ADP	O
NO	B-Chemical	NOUN	B
-	O	PUNCT	O
synthase	O	NOUN	B
inhibition	O	NOUN	B
with	O	ADP	O
40	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
/	O	PUNCT	O
day	O	NOUN	B
N(G)-nitro-L-arginine	B-Chemical	NOUN	B
methyl	I-Chemical	NOUN	I
ester	I-Chemical	NOUN	I
(	O	PUNCT	O
L-NAME	B-Chemical	NOUN	B
)	O	PUNCT	O
for	O	ADP	O
4	O	NUM	O
four	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
4	O	NUM	O
-	O	PUNCT	O
week	O	NOUN	B
administration	O	NOUN	B
of	O	ADP	O
L-NAME	B-Chemical	NOUN	B
,	O	PUNCT	O
the	O	DET	O
systolic	O	NOUN	B
blood	O	NOUN	I
pressure	O	NOUN	I
(	O	PUNCT	O
SBP	O	NOUN	B
)	O	PUNCT	O
increased	O	VERB	B
by	O	ADP	O
36	O	NUM	O
%.	O	NOUN	O
Two	O	NUM	O
weeks	O	NOUN	B
after	O	ADP	O
terminating	O	VERB	O
the	O	DET	O
treatment	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
SBP	O	NOUN	B
recovered	O	VERB	O
to	O	PART	O
control	O	NOUN	B
value	O	NOUN	I
.	O	PUNCT	O


When	O	SCONJ	O
activating	O	VERB	B
the	O	DET	O
(	O	PUNCT	O
Na	B-Chemical	PROPN	B
,	O	PUNCT	O
K	B-Chemical	PROPN	B
)-	O	ADJ	O
ATPase	O	NOUN	B
with	O	ADP	O
its	O	PRON	O
substrate	O	ADJ	B
ATP	B-Chemical	NOUN	B
,	O	PUNCT	O
no	O	DET	O
changes	O	NOUN	O
in	O	ADP	O
Km	O	NOUN	B
and	O	CCONJ	O
Vmax	O	NOUN	B
values	O	NOUN	I
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
NO	B-Chemical	NOUN	B
-	O	PUNCT	O
deficient	O	ADJ	B
rats	O	NOUN	B
.	O	PUNCT	O


During	O	ADP	O
activation	O	NOUN	B
with	O	ADP	O
Na	B-Chemical	NOUN	B
+,	O	NOUN	O
the	O	DET	O
Vmax	O	NOUN	B
remained	O	VERB	O
unchanged	O	ADJ	B
,	O	PUNCT	O
however	O	SCONJ	O
the	O	DET	O
K	B-Chemical	NOUN	B
(	O	PUNCT	I
Na	B-Chemical	NOUN	B
)	O	PUNCT	O
increased	O	VERB	B
by	O	ADP	O
50	O	NUM	O
%,	O	NOUN	O
indicating	O	VERB	O
a	O	DET	O
profound	O	ADJ	O
decrease	O	NOUN	B
in	O	ADP	O
the	O	DET	O
affinity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Na	B-Chemical	NOUN	B
+-	O	NOUN	O
binding	O	NOUN	B
site	O	NOUN	I
in	O	ADP	O
NO	B-Chemical	NOUN	B
-	O	PUNCT	O
deficient	O	ADJ	B
rats	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
recovery	O	NOUN	B
from	O	ADP	O
hypertension	B-Disease	NOUN	B
,	O	PUNCT	O
the	O	DET	O
activity	O	NOUN	B
of	O	ADP	O
(	O	PUNCT	O
Na	B-Chemical	PROPN	B
,	O	PUNCT	O
K	B-Chemical	NOUN	B
)-	O	ADJ	O
ATPase	O	NOUN	B
increased	O	VERB	B
,	O	PUNCT	O
due	O	ADP	O
to	O	PART	O
higher	O	ADJ	B
affinity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
ATP	B-Chemical	NOUN	B
-	O	PUNCT	O
binding	O	VERB	B
site	O	NOUN	I
,	O	PUNCT	O
as	O	ADP	O
revealed	O	VERB	O
from	O	ADP	O
the	O	DET	O
lowered	O	ADJ	B
Km	O	NOUN	B
value	O	NOUN	I
for	O	ADP	O
ATP	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
K	B-Chemical	NOUN	B
(	O	PUNCT	I
Na	B-Chemical	NOUN	B
)	O	PUNCT	O
value	O	NOUN	O
for	O	ADP	O
Na	B-Chemical	NOUN	B
+	O	CCONJ	O
returned	O	VERB	O
to	O	PART	O
control	O	NOUN	B
value	O	NOUN	I
.	O	PUNCT	O


Inhibition	O	NOUN	B
of	O	ADP	O
NO	B-Chemical	PROPN	B
-	O	PUNCT	O
synthase	O	NOUN	B
induced	O	VERB	B
a	O	DET	O
reversible	O	ADJ	B
hypertension	B-Disease	NOUN	B
accompanied	O	VERB	O
by	O	ADP	O
depressed	B-Disease	ADJ	B
Na	B-Chemical	NOUN	O
+-	O	NOUN	O
extrusion	O	NOUN	B
from	O	ADP	O
cardiac	O	ADJ	B
cells	O	NOUN	I
as	O	ADP	O
a	O	DET	O
consequence	O	NOUN	B
of	O	ADP	I
deteriorated	O	VERB	B
Na	B-Chemical	NOUN	B
+-	O	NOUN	O
binding	O	NOUN	B
properties	O	NOUN	B
of	O	ADP	O
the	O	DET	O
(	O	PUNCT	O
Na	B-Chemical	PROPN	B
,	O	PUNCT	O
K	B-Chemical	PROPN	B
)-	O	ADJ	O
ATPase	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
recovery	O	NOUN	B
of	O	ADP	O
blood	O	NOUN	B
pressure	O	NOUN	I
to	O	PART	O
control	O	NOUN	B
values	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
extrusion	O	NOUN	B
of	O	ADP	O
Na	B-Chemical	NOUN	B
+	O	CCONJ	O
from	O	ADP	O
cardiac	O	ADJ	B
cells	O	NOUN	I
was	O	AUX	O
normalized	O	VERB	B
,	O	PUNCT	O
as	O	ADP	O
revealed	O	VERB	O
by	O	ADP	O
restoration	O	NOUN	B
of	O	ADP	O
the	O	DET	O
(	O	PUNCT	O
Na	B-Chemical	PROPN	B
,	O	PUNCT	O
K	B-Chemical	PROPN	B


Effects	O	NOUN	B
of	O	ADP	I
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
pretreatment	O	NOUN	B
with	O	ADP	O
isoproterenol	B-Chemical	NOUN	B
on	O	ADP	O
bromocriptine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
tachycardia	B-Disease	NOUN	B
in	O	ADP	O
conscious	O	ADJ	B
rats	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
that	O	SCONJ	O
bromocriptine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
tachycardia	B-Disease	NOUN	B
,	O	PUNCT	O
which	O	DET	O
persisted	O	VERB	O
after	O	ADP	O
adrenalectomy	O	NOUN	B
,	O	PUNCT	O
is	O	AUX	O
(	O	PUNCT	O
i	O	X	O
)	O	PUNCT	O
mediated	O	VERB	O
by	O	ADP	O
central	O	ADJ	B
dopamine	B-Chemical	NOUN	I
D2	O	NOUN	I
receptor	O	NOUN	I
activation	O	NOUN	I
and	O	CCONJ	O
(	O	PUNCT	O
ii	O	X	O
)	O	PUNCT	O
reduced	O	VERB	B
by	O	ADP	O
5	O	NUM	O
-	O	PUNCT	O
day	O	NOUN	B
isoproterenol	B-Chemical	NOUN	B
pretreatment	O	NOUN	B
,	O	PUNCT	O
supporting	O	VERB	O
therefore	O	ADV	O
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
this	O	DET	O
effect	O	NOUN	B
is	O	AUX	O
dependent	O	ADJ	B
on	O	ADP	O
sympathetic	O	ADJ	B
outflow	O	NOUN	I
to	O	ADP	I
the	O	DET	I
heart	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
was	O	AUX	O
conducted	O	VERB	O
to	O	PART	O
examine	O	VERB	O
whether	O	SCONJ	O
prolonged	O	ADJ	B
pretreatment	O	NOUN	B
with	O	ADP	O
isoproterenol	B-Chemical	NOUN	B
could	O	AUX	O
abolish	O	VERB	B
bromocriptine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
tachycardia	B-Disease	NOUN	B
in	O	ADP	O
conscious	O	ADJ	B
rats	O	NOUN	B
.	O	PUNCT	O


Isoproterenol	B-Chemical	NOUN	B
pretreatment	O	NOUN	B
for	O	ADP	O
15	O	NUM	O
days	O	NOUN	B
caused	O	VERB	O
cardiac	B-Disease	ADJ	B
hypertrophy	I-Disease	NOUN	I
without	O	ADP	O
affecting	O	VERB	B
baseline	O	NOUN	B
blood	O	NOUN	B
pressure	O	NOUN	I
and	O	CCONJ	O
heart	O	NOUN	B
rate	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
control	O	ADJ	B
rats	O	NOUN	B
,	O	PUNCT	O
intravenous	O	ADJ	B
bromocriptine	B-Chemical	NOUN	I
(	O	PUNCT	O
150	O	NUM	O
microg	O	NOUN	B
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
induced	O	VERB	B
significant	O	ADJ	O
hypotension	B-Disease	NOUN	B
and	O	CCONJ	O
tachycardia	B-Disease	NOUN	B
.	O	PUNCT	O


Bromocriptine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypotension	B-Disease	NOUN	B
was	O	AUX	O
unaffected	O	ADJ	O
by	O	ADP	O
isoproterenol	B-Chemical	NOUN	B
pretreatment	O	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
tachycardia	B-Disease	NOUN	B
was	O	AUX	O
reversed	O	VERB	O
to	O	PART	O
significant	O	ADJ	O
bradycardia	B-Disease	NOUN	B
,	O	PUNCT	O
an	O	DET	O
effect	O	NOUN	B
that	O	PRON	O
was	O	AUX	O
partly	O	ADV	O
reduced	O	VERB	B
by	O	ADP	O
i	O	PRON	O
.	O	PUNCT	O


v	O	NOUN	O
.	O	PUNCT	O


domperidone	B-Chemical	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
).	O	PUNCT	O
Neither	O	CCONJ	O
cardiac	O	ADJ	B
vagal	O	NOUN	I
nor	O	CCONJ	O
sympathetic	O	ADJ	B
tone	O	NOUN	I
was	O	AUX	O
altered	O	VERB	O
by	O	ADP	O
isoproterenol	B-Chemical	NOUN	B
pretreatment	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
isolated	O	VERB	B
perfused	O	ADJ	B
heart	O	NOUN	I
preparations	O	NOUN	I
from	O	ADP	O
isoproterenol	B-Chemical	NOUN	B
-	O	PUNCT	O
pretreated	O	VERB	B
rats	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
isoproterenol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
maximal	O	ADJ	B
increase	O	NOUN	B
in	O	ADP	O
left	O	ADJ	B
ventricular	O	ADJ	I
systolic	O	NOUN	I
pressure	O	NOUN	I
was	O	AUX	O
significantly	O	ADV	O
reduced	O	VERB	O
,	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
saline	O	NOUN	B
-	O	PUNCT	O
pretreated	O	VERB	B
rats	O	NOUN	B
(	O	PUNCT	O
the	O	DET	O
EC50	O	NOUN	B
of	O	ADP	O
the	O	DET	O
isoproterenol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
increase	O	NOUN	B
in	O	ADP	O
left	O	ADJ	B
ventricular	O	ADJ	I
systolic	O	NOUN	I
pressure	O	NOUN	I
was	O	AUX	O
enhanced	O	VERB	B
approximately	O	ADV	O
22	O	NUM	O
-	O	PUNCT	O
fold	O	ADJ	B
).	O	PUNCT	B
These	O	DET	O
results	O	NOUN	B
show	O	VERB	O
that	O	SCONJ	O
15	O	NUM	O
-	O	PUNCT	O
day	O	NOUN	B
isoproterenol	B-Chemical	NOUN	B
pretreatment	O	NOUN	B
not	O	PART	O
only	O	ADV	O
abolished	O	VERB	B
but	O	CCONJ	O
reversed	O	VERB	O
bromocriptine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
tachycardia	B-Disease	NOUN	B
to	O	ADP	O
bradycardia	B-Disease	NOUN	B
,	O	PUNCT	O
an	O	DET	O
effect	O	NOUN	B
that	O	PRON	O
is	O	AUX	O
mainly	O	ADV	O
related	O	ADJ	O
to	O	PART	O
further	O	ADJ	O
cardiac	O	ADJ	B
beta	O	NOUN	I
-	O	PUNCT	O
adrenoceptor	O	NOUN	B
desensitization	O	NOUN	B
rather	O	ADV	O
than	O	ADP	O
to	O	PART	O
impairment	O	NOUN	B
of	O	ADP	O
autonomic	O	ADJ	B
regulation	O	NOUN	I
of	O	ADP	O
the	O	DET	O
heart	O	NOUN	B
.	O	PUNCT	O


They	O	PRON	O
suggest	O	VERB	O
that	O	SCONJ	O
,	O	PUNCT	O
in	O	ADP	O
normal	O	ADJ	O
conscious	O	ADJ	O
rats	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
central	O	ADJ	B
tachycardia	B-Disease	NOUN	I
of	O	ADP	O
bromocriptine	B-Chemical	NOUN	B
appears	O	VERB	O
to	O	PART	O
predominate	O	VERB	B
and	O	CCONJ	O
to	O	PART	O
mask	O	VERB	B
the	O	DET	O
bradycardia	B-Disease	NOUN	B
of	O	ADP	O
this	O	DET	O
agonist	O	NOUN	B
at	O	ADP	O
peripheral	O	ADJ	B
dopamine	B-Chemical	NOUN	B


A	O	DET	O
developmental	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
clonidine	B-Chemical	NOUN	B
'	O	PART	O
s	O	NOUN	O
effects	O	NOUN	B
on	O	ADP	O
cardiac	O	ADJ	B
rate	O	NOUN	I
and	O	CCONJ	O
ultrasound	O	NOUN	B
production	O	NOUN	I
in	O	ADP	O
infant	O	NOUN	B
rats	O	NOUN	B
.	O	PUNCT	O


Under	O	ADP	O
controlled	O	ADJ	B
conditions	O	NOUN	I
,	O	PUNCT	O
infant	O	NOUN	B
rats	O	NOUN	B
emit	O	VERB	B
ultrasonic	O	ADJ	B
vocalizations	O	NOUN	B
during	O	ADP	O
extreme	O	ADJ	O
cold	O	ADJ	B
exposure	O	NOUN	I
and	O	CCONJ	O
after	O	ADP	O
administration	O	NOUN	B
of	O	ADP	O
the	O	DET	O
alpha	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
adrenoceptor	O	NOUN	B
agonist	O	NOUN	I
,	O	PUNCT	O
clonidine	B-Chemical	NOUN	B
.	O	PUNCT	O


Previous	O	ADJ	O
investigations	O	NOUN	B
have	O	AUX	O
determined	O	VERB	O
that	O	SCONJ	O
,	O	PUNCT	O
in	O	ADP	O
response	O	NOUN	B
to	O	PART	O
clonidine	B-Chemical	NOUN	B
,	O	PUNCT	O
ultrasound	O	NOUN	B
production	O	NOUN	I
increases	O	VERB	B
through	O	ADP	O
the	O	DET	O
2nd	O	ADJ	B
-	O	PUNCT	O
week	O	NOUN	B
postpartum	O	NOUN	B
and	O	CCONJ	O
decreases	O	VERB	B
thereafter	O	ADV	O
.	O	PUNCT	O


Given	O	VERB	O
that	O	SCONJ	O
sympathetic	O	ADJ	B
neural	O	ADJ	B
dominance	O	NOUN	B
exhibits	O	VERB	O
a	O	DET	O
similar	O	ADJ	O
developmental	O	ADJ	B
pattern	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
given	O	VERB	O
that	O	DET	O
clonidine	B-Chemical	NOUN	B
induces	O	VERB	O
sympathetic	O	ADJ	B
withdrawal	O	NOUN	O
and	O	CCONJ	O
bradycardia	B-Disease	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
hypothesized	O	VERB	O
that	O	SCONJ	O
clonidine	B-Chemical	NOUN	B
'	O	PART	O
s	O	NOUN	O
developmental	O	ADJ	B
effects	O	NOUN	O
on	O	ADP	O
cardiac	O	ADJ	B
rate	O	NOUN	I
and	O	CCONJ	O
ultrasound	O	NOUN	B
production	O	NOUN	I
would	O	AUX	O
mirror	O	VERB	B
each	O	DET	O
other	O	ADJ	O
.	O	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
present	O	ADJ	O
experiment	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
clonidine	B-Chemical	NOUN	B
administration	O	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
on	O	ADP	O
cardiac	O	ADJ	B
rate	O	NOUN	I
and	O	CCONJ	O
ultrasound	O	NOUN	B
production	O	NOUN	I
were	O	AUX	O
examined	O	VERB	O
in	O	ADP	O
2	O	NUM	O
-,	O	NOUN	O
8	O	NUM	O
-,	O	NOUN	O
15	O	NUM	O
-,	O	NOUN	O
and	O	CCONJ	O
20	O	NUM	O
-	O	PUNCT	O
day	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
rats	O	NOUN	B
.	O	PUNCT	O


Age	O	PROPN	B
-	O	PUNCT	O
related	O	VERB	B
changes	O	NOUN	B
in	O	ADP	O
ultrasound	O	NOUN	B
production	O	NOUN	I
corresponded	O	VERB	O
with	O	ADP	O
changes	O	NOUN	B
in	O	ADP	O
cardiovascular	O	ADJ	B
variables	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
baseline	O	NOUN	B
cardiac	O	ADJ	B
rate	O	NOUN	I
and	O	CCONJ	O
clonidine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
bradycardia	B-Disease	NOUN	B
.	O	PUNCT	O


This	O	DET	O
experiment	O	NOUN	B
is	O	AUX	O
discussed	O	VERB	O
with	O	ADP	O
regard	O	NOUN	O
to	O	PART	O
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
ultrasound	O	NOUN	B
production	O	NOUN	I
is	O	AUX	O
the	O	DET	O
acoustic	O	ADJ	B
by	O	ADP	O
-	O	PUNCT	O
product	O	NOUN	B
of	O	ADP	O
a	O	DET	O
physiological	O	ADJ	B
maneuver	O	NOUN	B
that	O	PRON	O
compensates	O	VERB	O
for	O	ADP	O
clonidine	B-Chemical	NOUN	B


Differential	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
systemically	O	ADV	B
administered	O	VERB	B
ketamine	B-Chemical	NOUN	B
and	O	CCONJ	O
lidocaine	B-Chemical	NOUN	B
on	O	ADP	O
dynamic	O	ADJ	B
and	O	CCONJ	O
static	O	ADJ	B
hyperalgesia	B-Disease	NOUN	I
induced	O	VERB	B
by	O	ADP	O
intradermal	O	ADJ	B
capsaicin	B-Chemical	NOUN	B
in	O	ADP	O
humans	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
examined	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
systemic	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
ketamine	B-Chemical	NOUN	B
and	O	CCONJ	O
lidocaine	B-Chemical	NOUN	B
on	O	ADP	O
brush	O	NOUN	B
-	O	PUNCT	O
evoked	O	VERB	B
(	O	PUNCT	O
dynamic	O	ADJ	B
)	O	PUNCT	O
pain	B-Disease	NOUN	O
and	O	CCONJ	O
punctate	O	NOUN	B
-	O	PUNCT	O
evoked	O	VERB	B
(	O	PUNCT	O
static	O	ADJ	B
)	O	PUNCT	O
hyperalgesia	B-Disease	NOUN	O
induced	O	VERB	B
by	O	ADP	O
capsaicin	B-Chemical	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	ADJ	B
,	O	PUNCT	O
placebo	O	NOUN	B
-	O	PUNCT	O
controlled	O	VERB	B
,	O	PUNCT	O
crossover	O	NOUN	B
study	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
studied	O	VERB	O
12	O	NUM	O
volunteers	O	NOUN	B
in	O	ADP	O
three	O	NUM	O
experiments	O	NOUN	B
.	O	PUNCT	O


Capsaicin	B-Chemical	NOUN	B
100	O	NUM	O
micrograms	O	NOUN	B
was	O	AUX	O
injected	O	VERB	B
intradermally	O	ADV	O
on	O	ADP	O
the	O	DET	O
volar	O	ADJ	B
forearm	O	NOUN	I
followed	O	VERB	O
by	O	ADP	O
an	O	DET	O
i	O	NOUN	O
.	O	PUNCT	O


v	O	NOUN	O
.	O	PUNCT	O


infusion	O	NOUN	B
of	O	ADP	O
ketamine	B-Chemical	NOUN	B
(	O	PUNCT	O
bolus	O	NOUN	B
0	O	NUM	I
.	O	PUNCT	O


1	O	NUM	O
mg	O	NOUN	O
kg	O	NOUN	O
-	O	PUNCT	O
1	O	NUM	O
over	O	ADP	O
10	O	NUM	O
min	O	NOUN	O
followed	O	VERB	O
by	O	ADP	O
infusion	O	NOUN	B
of	O	ADP	O
7	O	NUM	O
micrograms	O	NOUN	B
kg	O	NOUN	O
-	O	PUNCT	O
1	O	NUM	O
min	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	O
),	O	PUNCT	O
lidocaine	B-Chemical	NOUN	B
5	O	NUM	O
mg	O	NOUN	O
kg	O	NOUN	O
-	O	PUNCT	O
1	O	NUM	O
or	O	CCONJ	O
saline	O	NOUN	B
for	O	ADP	O
50	O	NUM	O
min	O	NOUN	O
.	O	PUNCT	O


Infusion	O	NOUN	B
started	O	VERB	O
15	O	NUM	O
min	O	NOUN	O
after	O	ADP	O
injection	O	NOUN	B
of	O	ADP	O
capsaicin	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
following	O	NOUN	O
were	O	AUX	O
measured	O	VERB	B
:	O	PUNCT	O
spontaneous	O	ADJ	B
pain	B-Disease	NOUN	I
,	O	PUNCT	O
pain	B-Disease	NOUN	B
evoked	O	VERB	O
by	O	ADP	O
punctate	O	NOUN	B
and	O	CCONJ	O
brush	O	NOUN	B
stimuli	O	NOUN	I
(	O	PUNCT	O
VAS	O	NOUN	B
),	O	PUNCT	O
and	O	CCONJ	O
areas	O	NOUN	B
of	O	ADP	O
brush	O	NOUN	B
-	O	PUNCT	O
evoked	O	VERB	B
and	O	CCONJ	O
punctate	O	NOUN	B
-	O	PUNCT	O
evoked	O	VERB	B
hyperalgesia	B-Disease	NOUN	B
.	O	PUNCT	O


Ketamine	B-Chemical	NOUN	B
reduced	O	VERB	B
both	O	CCONJ	O
the	O	DET	O
area	O	NOUN	B
of	O	ADP	O
brush	O	NOUN	B
-	O	PUNCT	O
evoked	O	VERB	B
and	O	CCONJ	O
punctate	O	NOUN	B
-	O	PUNCT	O
evoked	O	VERB	B
hyperalgesia	B-Disease	NOUN	B
significantly	O	ADV	B
and	O	CCONJ	O
it	O	PRON	O
tended	O	VERB	O
to	O	PART	O
reduce	O	VERB	B
brush	O	NOUN	B
-	O	PUNCT	O
evoked	O	VERB	B
pain	B-Disease	NOUN	I
.	O	PUNCT	O


Lidocaine	B-Chemical	NOUN	B
reduced	O	VERB	B
the	O	DET	O
area	O	NOUN	B
of	O	ADP	O
punctate	O	NOUN	B
-	O	PUNCT	O
evoked	O	VERB	B
hyperalgesia	B-Disease	NOUN	B
significantly	O	ADV	B
.	O	PUNCT	O


It	O	PRON	O
tended	O	VERB	O
to	O	PART	O
reduce	O	VERB	B
VAS	O	NOUN	B
scores	O	NOUN	I
of	O	ADP	O
spontaneous	O	ADJ	B
pain	B-Disease	NOUN	I
but	O	CCONJ	O
had	O	AUX	O
no	O	DET	B
effect	O	NOUN	I
on	O	ADP	O
evoked	O	VERB	B
pain	B-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
differential	O	ADJ	B
effects	O	NOUN	O
of	O	ADP	O
ketamine	B-Chemical	NOUN	B
and	O	CCONJ	O
lidocaine	B-Chemical	NOUN	B
on	O	ADP	O
static	O	ADJ	B
and	O	CCONJ	O
dynamic	O	ADJ	B
hyperalgesia	B-Disease	NOUN	I
suggest	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
two	O	NUM	O
types	O	NOUN	O
of	O	ADP	O
hyperalgesia	B-Disease	NOUN	B


Cyclosporine	B-Chemical	NOUN	B
and	O	CCONJ	O
tacrolimus	B-Chemical	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
thrombotic	B-Disease	ADJ	B
microangiopathy	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
development	O	NOUN	B
of	O	ADP	O
thrombotic	B-Disease	ADJ	B
microangiopathy	I-Disease	NOUN	I
(	O	PUNCT	O
TMA	B-Disease	NOUN	B
)	O	PUNCT	O
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
cyclosporine	B-Chemical	NOUN	B
has	O	AUX	O
been	O	AUX	O
well	O	ADV	O
documented	O	VERB	B
.	O	PUNCT	O


Treatments	O	NOUN	B
have	O	AUX	O
included	O	VERB	O
discontinuation	O	NOUN	B
or	O	CCONJ	O
reduction	O	NOUN	B
of	O	ADP	O
cyclosporine	B-Chemical	NOUN	B
dose	O	NOUN	B
with	O	ADP	O
or	O	CCONJ	O
without	O	ADP	O
concurrent	O	ADJ	B
plasma	O	NOUN	B
exchange	O	NOUN	I
,	O	PUNCT	O
plasma	O	NOUN	B
infusion	O	NOUN	B
,	O	PUNCT	O
anticoagulation	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
intravenous	O	ADJ	B
immunoglobulin	O	NOUN	I
G	O	NOUN	I
infusion	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
for	O	ADP	O
recipients	O	NOUN	B
of	O	ADP	O
organ	O	NOUN	B
transplantation	O	NOUN	I
,	O	PUNCT	O
removing	O	VERB	O
the	O	DET	O
inciting	O	NOUN	B
agent	O	NOUN	I
is	O	AUX	O
not	O	PART	O
without	O	ADP	O
the	O	DET	O
attendant	O	ADJ	O
risk	O	NOUN	B
of	O	ADP	O
precipitating	O	VERB	B
acute	O	ADJ	I
rejection	O	NOUN	I
and	O	CCONJ	O
graft	O	NOUN	B
loss	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
last	O	ADJ	O
decade	O	NOUN	O
has	O	AUX	O
seen	O	VERB	O
the	O	DET	O
emergence	O	NOUN	B
of	O	ADP	O
tacrolimus	B-Chemical	NOUN	B
as	O	ADP	O
a	O	DET	O
potent	O	ADJ	O
immunosuppressive	O	ADJ	B
agent	O	NOUN	I
with	O	ADP	O
mechanisms	O	NOUN	B
of	O	ADP	O
action	O	NOUN	B
virtually	O	ADV	O
identical	O	ADJ	B
to	O	PART	O
those	O	DET	O
of	O	ADP	O
cyclosporine	B-Chemical	NOUN	B
.	O	PUNCT	O


As	O	ADP	O
a	O	DET	O
result	O	NOUN	B
,	O	PUNCT	O
switching	O	NOUN	B
to	O	PART	O
tacrolimus	B-Chemical	NOUN	B
has	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
to	O	PART	O
be	O	AUX	O
a	O	DET	O
viable	O	ADJ	O
therapeutic	O	ADJ	B
option	O	NOUN	O
in	O	ADP	O
the	O	DET	O
setting	O	NOUN	O
of	O	ADP	O
cyclosporine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
TMA	B-Disease	NOUN	B
.	O	PUNCT	O


With	O	ADP	O
the	O	DET	O
more	O	ADV	O
widespread	O	ADJ	O
application	O	NOUN	B
of	O	ADP	O
tacrolimus	B-Chemical	NOUN	B
in	O	ADP	O
organ	O	NOUN	B
transplantation	O	NOUN	I
,	O	PUNCT	O
tacrolimus	B-Chemical	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
TMA	B-Disease	PROPN	B
has	O	AUX	O
also	O	ADV	O
been	O	AUX	O
recognized	O	VERB	O
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
literature	O	NOUN	B
regarding	O	VERB	O
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
recurrence	O	NOUN	B
of	O	ADP	O
TMA	B-Disease	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
exposed	O	VERB	B
sequentially	O	ADV	I
to	O	PART	O
cyclosporine	B-Chemical	NOUN	B
and	O	CCONJ	O
tacrolimus	B-Chemical	NOUN	B
is	O	AUX	O
limited	O	VERB	O
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
a	O	DET	O
living	O	VERB	B
donor	O	NOUN	O
renal	O	ADJ	O
transplant	O	NOUN	O
recipient	O	NOUN	B
who	O	PRON	O
developed	O	VERB	O
cyclosporine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
TMA	B-Disease	NOUN	B
that	O	PRON	O
responded	O	VERB	O
to	O	ADP	O
the	O	DET	O
withdrawal	O	NOUN	B
of	O	ADP	O
cyclosporine	B-Chemical	NOUN	B
in	O	ADP	O
conjunction	O	NOUN	B
with	O	ADP	O
plasmapheresis	O	NOUN	B
and	O	CCONJ	O
fresh	O	ADJ	B
frozen	O	ADJ	B
plasma	O	NOUN	I
replacement	O	NOUN	I
therapy	O	NOUN	I
.	O	PUNCT	O


Introduction	O	NOUN	O
of	O	ADP	O
tacrolimus	B-Chemical	NOUN	B
as	O	ADP	O
an	O	DET	O
alternative	O	ADJ	B
immunosuppressive	O	ADJ	B
agent	O	NOUN	I
resulted	O	VERB	O
in	O	ADP	O
the	O	DET	O
recurrence	O	NOUN	B
of	O	ADP	O
TMA	B-Disease	NOUN	B
and	O	CCONJ	O
the	O	DET	O
subsequent	O	ADJ	O
loss	O	NOUN	B
of	O	ADP	O
the	O	DET	O
renal	O	ADJ	B
allograft	O	NOUN	I
.	O	PUNCT	O


Patients	O	NOUN	B
who	O	PRON	O
are	O	AUX	O
switched	O	VERB	O
from	O	ADP	O
cyclosporine	B-Chemical	NOUN	B
to	O	PART	O
tacrolimus	B-Chemical	NOUN	B
or	O	CCONJ	O
vice	O	ADV	O
versa	O	ADV	O
should	O	AUX	O
be	O	AUX	O
closely	O	ADV	O
monitored	O	VERB	B
for	O	ADP	O
the	O	DET	O
signs	O	NOUN	B
and	O	CCONJ	O
symptoms	O	NOUN	B
of	O	ADP	O
recurrent	O	ADJ	B
TMA	B-Disease	NOUN	B


Repeated	O	VERB	B
transient	O	ADJ	B
anuria	B-Disease	NOUN	I
following	O	VERB	O
losartan	B-Chemical	NOUN	B
administration	O	NOUN	B
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
a	O	DET	O
solitary	O	ADJ	B
kidney	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
the	O	DET	O
case	O	NOUN	B
of	O	ADP	O
a	O	DET	O
70	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
hypertensive	B-Disease	ADJ	B
man	O	NOUN	B
with	O	ADP	O
a	O	DET	O
solitary	O	ADJ	B
kidney	O	NOUN	I
and	O	CCONJ	O
chronic	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
insufficiency	I-Disease	NOUN	I
who	O	PRON	O
developed	O	VERB	O
two	O	NUM	O
episodes	O	NOUN	B
of	O	ADP	O
transient	O	ADJ	B
anuria	B-Disease	NOUN	I
after	O	ADP	O
losartan	B-Chemical	NOUN	B
administration	O	NOUN	B
.	O	PUNCT	O


He	O	PRON	O
was	O	AUX	O
hospitalized	O	VERB	B
for	O	ADP	O
a	O	DET	O
myocardial	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
with	O	ADP	O
pulmonary	B-Disease	ADJ	B
edema	I-Disease	NOUN	I
,	O	PUNCT	O
treated	O	VERB	B
with	O	ADP	I
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
diuretics	O	NOUN	B
.	O	PUNCT	O


Due	O	ADP	O
to	O	ADP	O
severe	O	ADJ	B
systolic	B-Disease	NOUN	B
dysfunction	I-Disease	NOUN	I
losartan	B-Chemical	NOUN	B
was	O	AUX	O
prescribed	O	VERB	B
.	O	PUNCT	O


Surprisingly	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
first	O	ADJ	O
dose	O	NOUN	B
of	O	ADP	O
50	O	NUM	O
mg	O	NOUN	O
of	O	ADP	O
losartan	B-Chemical	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
a	O	DET	O
sudden	O	ADJ	B
anuria	B-Disease	NOUN	I
,	O	PUNCT	O
which	O	DET	O
lasted	O	VERB	O
eight	O	NUM	O
hours	O	NOUN	B
despite	O	SCONJ	O
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
furosemide	B-Chemical	NOUN	B
and	O	CCONJ	O
amine	B-Chemical	NOUN	B
infusion	O	NOUN	I
.	O	PUNCT	O


One	O	NUM	O
week	O	NOUN	B
later	O	ADV	O
,	O	PUNCT	O
by	O	ADP	O
mistake	O	NOUN	O
,	O	PUNCT	O
losartan	B-Chemical	NOUN	B
was	O	AUX	O
prescribed	O	VERB	B
again	O	ADV	O
and	O	CCONJ	O
after	O	ADP	O
the	O	DET	O
second	O	ADJ	O
dose	O	NOUN	B
of	O	ADP	O
50	O	NUM	O
mg	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
patient	O	NOUN	B
developed	O	VERB	O
a	O	DET	O
second	O	ADJ	O
episode	O	NOUN	B
of	O	ADP	O
transient	O	ADJ	B
anuria	B-Disease	NOUN	B
lasting	O	NOUN	O
10	O	NUM	O
hours	O	NOUN	B
.	O	PUNCT	O


During	O	ADP	O
these	O	DET	O
two	O	NUM	O
episodes	O	NOUN	B
,	O	PUNCT	O
his	O	PRON	O
blood	O	NOUN	B
pressure	O	NOUN	I
diminished	O	VERB	B
but	O	CCONJ	O
no	O	DET	O
severe	O	ADJ	B
hypotension	B-Disease	NOUN	B
was	O	AUX	O
noted	O	VERB	O
.	O	PUNCT	O


Ultimately	O	ADV	O
,	O	PUNCT	O
an	O	DET	O
arteriography	O	NOUN	B
showed	O	VERB	O
a	O	DET	O
70	O	NUM	O
-	O	SYM	O
80	O	NUM	O
%	O	NOUN	O
renal	B-Disease	ADJ	B
artery	I-Disease	NOUN	I
stenosis	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
patient	O	NOUN	B
,	O	PUNCT	O
renal	B-Disease	ADJ	B
artery	I-Disease	NOUN	I
stenosis	I-Disease	NOUN	I
combined	O	VERB	O
with	O	ADP	O
heart	B-Disease	NOUN	B
failure	I-Disease	NOUN	I
and	O	CCONJ	O
diuretic	O	ADJ	B
therapy	O	NOUN	I
certainly	O	ADV	O
resulted	O	VERB	O
in	O	ADP	O
a	O	DET	O
strong	O	ADJ	O
activation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
renin	O	NOUN	B
-	O	PUNCT	O
angiotensin	B-Chemical	NOUN	B
system	O	NOUN	I
(	O	PUNCT	O
RAS	O	NOUN	B
).	O	PUNCT	O
Under	O	ADP	O
such	O	ADJ	O
conditions	O	NOUN	B
,	O	PUNCT	O
angiotensin	B-Chemical	NOUN	B
II	I-Chemical	NUM	I
receptor	O	NOUN	I
blockade	O	NOUN	B
by	O	ADP	O
losartan	B-Chemical	NOUN	B
probably	O	ADV	O
induced	O	VERB	B
a	O	DET	O
critical	O	ADJ	O
fall	O	NOUN	B
in	O	ADP	O
glomerular	O	ADJ	B
filtration	O	NOUN	I
pressure	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
case	O	NOUN	B
report	O	NOUN	I
highlights	O	VERB	O
the	O	DET	O
fact	O	NOUN	O
that	O	SCONJ	O
the	O	DET	O
angiotensin	B-Chemical	NOUN	B
II	I-Chemical	NUM	I
receptor	O	NOUN	I
antagonist	O	NOUN	B
losartan	B-Chemical	NOUN	B
can	O	AUX	O
cause	O	VERB	O
serious	O	ADJ	O
unexpected	O	ADJ	O
complications	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
renovascular	B-Disease	ADJ	B
disease	I-Disease	NOUN	I


In	O	X	B
vivo	O	X	I
protection	O	NOUN	B
of	O	ADP	O
dna	O	NOUN	B
damage	O	NOUN	I
associated	O	VERB	O
apoptotic	O	ADJ	B
and	O	CCONJ	O
necrotic	B-Disease	ADJ	B
cell	O	NOUN	I
deaths	O	NOUN	O
during	O	ADP	O
acetaminophen	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
nephrotoxicity	B-Disease	NOUN	B
,	O	PUNCT	O
amiodarone	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
lung	B-Disease	NOUN	B
toxicity	I-Disease	NOUN	B
and	O	CCONJ	O
doxorubicin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cardiotoxicity	B-Disease	NOUN	B
by	O	ADP	O
a	O	DET	O
novel	O	ADJ	O
IH636	B-Chemical	NOUN	B
grape	I-Chemical	NOUN	B
seed	I-Chemical	NOUN	B
proanthocyanidin	I-Chemical	NOUN	I
extract	I-Chemical	NOUN	I
.	O	PUNCT	O


Grape	B-Chemical	NOUN	B
seed	I-Chemical	NOUN	B
extract	I-Chemical	NOUN	I
,	O	PUNCT	O
primarily	O	ADV	O
a	O	DET	O
mixture	O	NOUN	O
of	O	ADP	O
proanthocyanidins	B-Chemical	NOUN	B
,	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
modulate	O	VERB	B
a	O	DET	O
wide	O	ADJ	B
-	O	PUNCT	O
range	O	NOUN	B
of	O	ADP	O
biological	O	ADJ	B
,	O	PUNCT	O
pharmacological	O	ADJ	B
and	O	CCONJ	O
toxicological	O	ADJ	B
effects	O	NOUN	I
which	O	DET	O
are	O	AUX	O
mainly	O	ADV	O
cytoprotective	O	ADJ	B
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
assessed	O	VERB	B
the	O	DET	O
ability	O	NOUN	B
of	O	ADP	O
IH636	B-Chemical	NOUN	B
grape	I-Chemical	NOUN	B
seed	I-Chemical	NOUN	B
proanthocyanidin	I-Chemical	NOUN	I
extract	I-Chemical	NOUN	I
(	O	PUNCT	O
GSPE	B-Chemical	NOUN	B
)	O	PUNCT	O
to	O	PART	O
prevent	O	VERB	B
acetaminophen	B-Chemical	NOUN	B
(	O	PUNCT	O
AAP	B-Chemical	NOUN	B
)-	O	ADJ	O
induced	O	VERB	B
nephrotoxicity	B-Disease	NOUN	B
,	O	PUNCT	O
amiodarone	B-Chemical	NOUN	B
(	O	PUNCT	O
AMI	B-Chemical	NOUN	B
)-	O	ADJ	O
induced	O	VERB	B
lung	B-Disease	NOUN	B
toxicity	I-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
doxorubicin	B-Chemical	NOUN	B
(	O	PUNCT	O
DOX	B-Chemical	NOUN	B
)-	O	ADJ	O
induced	O	VERB	B
cardiotoxicity	B-Disease	NOUN	B
in	O	ADP	O
mice	O	NOUN	B
.	O	PUNCT	O


Experimental	O	ADJ	B
design	O	NOUN	I
consisted	O	VERB	O
of	O	ADP	O
four	O	NUM	O
groups	O	NOUN	B
:	O	PUNCT	O
control	O	NOUN	B
(	O	PUNCT	O
vehicle	O	NOUN	B
alone	O	ADV	O
),	O	PUNCT	O
GSPE	B-Chemical	NOUN	B
alone	O	ADV	O
,	O	PUNCT	O
drug	O	NOUN	B
alone	O	ADV	O
and	O	CCONJ	O
GSPE	B-Chemical	NOUN	B
+	O	CCONJ	O
drug	O	NOUN	B
.	O	PUNCT	O


For	O	ADP	O
the	O	DET	O
cytoprotection	O	NOUN	B
study	O	NOUN	I
,	O	PUNCT	O
animals	O	NOUN	B
were	O	AUX	O
orally	O	ADV	B
gavaged	O	VERB	B
100	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
Kg	O	NOUN	B
GSPE	B-Chemical	NOUN	B
for	O	ADP	O
7	O	NUM	O
-	O	SYM	O
10	O	NUM	O
days	O	NOUN	B
followed	O	VERB	O
by	O	ADP	O
i	O	PRON	O
.	O	PUNCT	O


p	O	NOUN	O
.	O	PUNCT	O


injections	O	NOUN	B
of	O	ADP	O
organ	O	NOUN	B
specific	O	ADJ	O
three	O	NUM	O
drugs	O	NOUN	B
(	O	PUNCT	O
AAP	B-Chemical	PROPN	B
:	O	PUNCT	O
500	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
Kg	O	NOUN	B
for	O	ADP	O
24	O	NUM	O
h	O	NOUN	O
;	O	PUNCT	O
AMI	B-Chemical	NOUN	B
:	O	PUNCT	O
50	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
Kg	O	NOUN	B
/	O	PUNCT	O
day	O	NOUN	B
for	O	ADP	O
four	O	NUM	O
days	O	NOUN	B
;	O	PUNCT	O
DOX	B-Chemical	NOUN	B
:	O	PUNCT	O
20	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
Kg	O	NOUN	B
for	O	ADP	O
48	O	NUM	O
h	O	NOUN	O
).	O	PUNCT	B
Parameters	O	NOUN	B
of	O	ADP	O
study	O	NOUN	B
included	O	VERB	O
analysis	O	NOUN	B
of	O	ADP	O
serum	O	NOUN	B
chemistry	O	NOUN	I
(	O	PUNCT	O
ALT	O	NOUN	B
,	O	PUNCT	O
BUN	O	NOUN	B
and	O	CCONJ	O
CPK	O	NOUN	B
),	O	PUNCT	O
and	O	CCONJ	O
orderly	O	ADJ	O
fragmentation	O	NOUN	B
of	O	ADP	O
genomic	O	ADJ	B
DNA	O	NOUN	I
(	O	PUNCT	O
both	O	DET	O
endonuclease	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
and	O	CCONJ	O
independent	O	ADJ	B
)	O	PUNCT	O
in	O	ADP	O
addition	O	NOUN	O
to	O	PART	O
microscopic	O	ADJ	B
evaluation	O	NOUN	B
of	O	ADP	O
damage	O	NOUN	B
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
protection	O	NOUN	B
in	O	ADP	O
corresponding	O	VERB	O
PAS	O	NOUN	B
stained	O	VERB	B
tissues	O	NOUN	I
.	O	PUNCT	O


Results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
GSPE	B-Chemical	NOUN	B
preexposure	O	NOUN	B
prior	O	ADV	O
to	O	ADP	O
AAP	B-Chemical	PROPN	B
,	O	PUNCT	O
AMI	B-Chemical	NOUN	B
and	O	CCONJ	O
DOX	B-Chemical	NOUN	B
,	O	PUNCT	O
provided	O	VERB	O
near	O	ADP	O
complete	O	ADJ	B
protection	O	NOUN	B
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
serum	O	NOUN	B
chemistry	O	NOUN	I
changes	O	NOUN	I
(	O	PUNCT	O
ALT	O	NOUN	B
,	O	PUNCT	O
BUN	O	NOUN	B
and	O	CCONJ	O
CPK	O	NOUN	B
),	O	PUNCT	O
and	O	CCONJ	O
significantly	O	ADV	O
reduced	O	VERB	O
DNA	O	NOUN	B
fragmentation	O	NOUN	I
.	O	PUNCT	O


Histopathological	O	ADJ	B
examination	O	NOUN	B
of	O	ADP	O
kidney	O	NOUN	B
,	O	PUNCT	O
heart	O	NOUN	B
and	O	CCONJ	O
lung	O	NOUN	B
sections	O	NOUN	I
revealed	O	VERB	O
moderate	O	ADJ	B
to	O	PART	O
massive	O	ADJ	B
tissue	B-Disease	NOUN	B
damage	I-Disease	NOUN	I
with	O	ADP	O
a	O	DET	O
variety	O	NOUN	O
of	O	ADP	O
morphological	O	ADJ	B
aberrations	O	NOUN	B
by	O	ADP	O
all	O	DET	O
the	O	DET	O
three	O	NUM	O
drugs	O	NOUN	B
in	O	ADP	O
the	O	DET	O
absence	O	NOUN	B
of	O	ADP	O
GSPE	B-Chemical	NOUN	B
preexposure	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
its	O	PRON	O
presence	O	NOUN	B
.	O	PUNCT	O


GSPE	B-Chemical	NOUN	B
+	O	CCONJ	O
drug	O	NOUN	B
exposed	O	VERB	O
tissues	O	NOUN	O
exhibited	O	VERB	O
minor	O	ADJ	O
residual	O	ADJ	B
damage	O	NOUN	B
or	O	CCONJ	O
near	O	ADP	O
total	O	ADJ	O
recovery	O	NOUN	B
.	O	PUNCT	O


Additionally	O	ADV	O
,	O	PUNCT	O
histopathological	O	ADJ	B
alterations	O	NOUN	B
mirrored	O	VERB	O
both	O	CCONJ	O
serum	O	NOUN	B
chemistry	O	NOUN	O
changes	O	NOUN	O
and	O	CCONJ	O
the	O	DET	O
pattern	O	NOUN	B
of	O	ADP	O
DNA	O	NOUN	B
fragmentation	O	NOUN	I
.	O	PUNCT	O


Interestingly	O	ADV	O
,	O	PUNCT	O
all	O	DET	O
the	O	DET	O
drugs	O	NOUN	B
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
,	O	PUNCT	O
AAP	B-Chemical	PROPN	B
,	O	PUNCT	O
AMI	B-Chemical	NOUN	B
and	O	CCONJ	O
DOX	B-Chemical	NOUN	B
induced	O	VERB	B
apoptotic	O	ADJ	B
death	O	NOUN	I
in	O	ADP	O
addition	O	NOUN	O
to	O	PART	O
necrosis	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
respective	O	ADJ	O
organs	O	NOUN	B
which	O	DET	O
was	O	AUX	O
very	O	ADV	O
effectively	O	ADV	O
blocked	O	VERB	B
by	O	ADP	O
GSPE	B-Chemical	NOUN	B
.	O	PUNCT	O


Since	O	SCONJ	O
AAP	B-Chemical	PROPN	B
,	O	PUNCT	O
AMI	B-Chemical	NOUN	B
and	O	CCONJ	O
DOX	B-Chemical	NOUN	B
undergo	O	VERB	O
biotransformation	O	NOUN	B
and	O	CCONJ	O
are	O	AUX	O
known	O	VERB	O
to	O	PART	O
produce	O	VERB	O
damaging	O	NOUN	O
radicals	O	NOUN	B
in	O	X	B
vivo	O	X	I
,	O	PUNCT	O
the	O	DET	O
protection	O	NOUN	B
by	O	ADP	O
GSPE	B-Chemical	NOUN	B
may	O	AUX	O
be	O	AUX	O
linked	O	VERB	O
to	O	PART	O
both	O	DET	O
inhibition	O	NOUN	B
of	O	ADP	O
metabolism	O	NOUN	B
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
detoxification	O	NOUN	B
of	O	ADP	O
cytotoxic	O	ADJ	B
radicals	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
its	O	PRON	O
'	O	PUNCT	O
presumed	O	VERB	O
contribution	O	NOUN	B
to	O	PART	O
DNA	O	NOUN	B
repair	O	NOUN	I
may	O	AUX	O
be	O	AUX	O
another	O	DET	O
important	O	ADJ	O
attribute	O	NOUN	O
,	O	PUNCT	O
which	O	DET	O
played	O	VERB	O
a	O	DET	O
role	O	NOUN	O
in	O	ADP	O
the	O	DET	O
chemoprevention	O	NOUN	B
process	O	NOUN	I
.	O	PUNCT	O


Additionally	O	ADV	O
,	O	PUNCT	O
this	O	DET	O
may	O	AUX	O
have	O	AUX	O
been	O	AUX	O
the	O	DET	O
first	O	ADJ	O
report	O	NOUN	O
on	O	ADP	O
AMI	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
apoptotic	O	ADJ	B
death	O	NOUN	I
in	O	ADP	O
the	O	DET	O
lung	O	NOUN	B
tissue	O	NOUN	I
.	O	PUNCT	O


Taken	O	VERB	O
together	O	ADV	O
,	O	PUNCT	O
these	O	DET	O
events	O	NOUN	B
undoubtedly	O	ADV	O
establish	O	VERB	O
GSPE	B-Chemical	NOUN	B


Palpebral	B-Disease	ADJ	B
twitching	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
depressed	B-Disease	ADJ	B
adolescent	O	NOUN	B
on	O	ADP	O
citalopram	B-Chemical	NOUN	B
.	O	PUNCT	O


Current	O	ADJ	B
estimates	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
between	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
8	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
children	O	NOUN	B
and	O	CCONJ	O
adolescents	O	NOUN	B
are	O	AUX	O
affected	O	VERB	B
by	O	ADP	O
major	B-Disease	ADJ	O
depression	I-Disease	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
a	O	DET	O
favorable	O	ADJ	B
response	O	NOUN	I
to	O	PART	O
treatment	O	NOUN	B
with	O	ADP	O
citalopram	B-Chemical	NOUN	B
by	O	ADP	O
a	O	DET	O
15	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
boy	O	NOUN	B
with	O	ADP	O
major	B-Disease	ADJ	O
depression	I-Disease	NOUN	B
who	O	PRON	O
exhibited	O	VERB	O
palpebral	B-Disease	ADJ	B
twitching	I-Disease	NOUN	I
during	O	ADP	O
his	O	PRON	O
first	O	ADJ	O
2	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
may	O	AUX	O
have	O	AUX	O
been	O	AUX	O
a	O	DET	O
side	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
citalopram	B-Chemical	NOUN	B


Metamizol	B-Chemical	PROPN	B
potentiates	O	VERB	B
morphine	B-Chemical	NOUN	B
antinociception	O	NOUN	B
but	O	CCONJ	O
not	O	PART	O
constipation	B-Disease	NOUN	B
after	O	ADP	O
chronic	O	ADJ	B
treatment	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
work	O	NOUN	O
evaluates	O	VERB	O
the	O	DET	O
antinociceptive	O	ADJ	B
and	O	CCONJ	O
constipating	B-Disease	VERB	B
effects	O	NOUN	O
of	O	ADP	O
the	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
3	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
s	O	NOUN	O
.	O	PUNCT	O


c	O	X	O
.	O	PUNCT	O


morphine	B-Chemical	NOUN	B
with	O	ADP	O
177	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
s	O	NOUN	O
.	O	PUNCT	O


c	O	X	O
.	O	PUNCT	O


metamizol	B-Chemical	NOUN	B
in	O	ADP	O
acutely	O	ADV	B
and	O	CCONJ	O
chronically	O	ADV	B
treated	O	VERB	B
(	O	PUNCT	O
once	O	ADV	O
a	O	DET	O
day	O	NOUN	B
for	O	ADP	O
12	O	NUM	O
days	O	NOUN	B
)	O	PUNCT	O
rats	O	NOUN	B
.	O	PUNCT	O


On	O	ADP	O
the	O	DET	O
13th	O	ADJ	O
day	O	NOUN	B
,	O	PUNCT	O
antinociceptive	O	ADJ	B
effects	O	NOUN	I
were	O	AUX	O
assessed	O	VERB	B
using	O	VERB	O
a	O	DET	O
model	O	NOUN	B
of	O	ADP	O
inflammatory	O	ADJ	B
nociception	O	NOUN	I
,	O	PUNCT	O
pain	B-Disease	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
functional	O	ADJ	B
impairment	O	NOUN	I
model	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
charcoal	B-Chemical	NOUN	B
meal	O	NOUN	I
test	O	NOUN	I
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
intestinal	O	ADJ	B
transit	O	NOUN	O
.	O	PUNCT	O


Simultaneous	O	ADJ	B
administration	O	NOUN	B
of	O	ADP	O
morphine	B-Chemical	NOUN	B
with	O	ADP	O
metamizol	B-Chemical	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
a	O	DET	O
markedly	O	ADV	O
antinociceptive	O	ADJ	B
potentiation	O	NOUN	B
and	O	CCONJ	O
an	O	DET	O
increasing	O	NOUN	B
of	O	ADP	O
the	O	DET	O
duration	O	NOUN	B
of	O	ADP	O
action	O	NOUN	O
after	O	ADP	O
a	O	DET	O
single	O	ADJ	O
(	O	PUNCT	O
298	O	NUM	O
+/-	O	CCONJ	O
7	O	NUM	O
vs	O	CCONJ	O
.	O	PUNCT	O


139	O	NUM	O
+/-	O	CCONJ	O
36	O	NUM	O
units	O	NOUN	B
area	O	NOUN	I
(	O	PUNCT	O
ua	O	NOUN	O
);	O	ADJ	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
repeated	O	VERB	O
administration	O	NOUN	B
(	O	PUNCT	O
280	O	NUM	O
+/-	O	CCONJ	O
17	O	NUM	O
vs	O	CCONJ	O
.	O	PUNCT	O


131	O	NUM	O
+/-	O	CCONJ	O
22	O	NUM	O
ua	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
).	O	PUNCT	O
Antinociceptive	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
morphine	B-Chemical	NOUN	B
was	O	AUX	O
reduced	O	VERB	B
in	O	ADP	O
chronically	O	ADV	B
treated	O	VERB	B
rats	O	NOUN	B
(	O	PUNCT	O
39	O	NUM	O
+/-	O	CCONJ	O
10	O	NUM	O
vs	O	ADV	O
.	O	PUNCT	O


18	O	NUM	O
+/-	O	CCONJ	O
5	O	NUM	O
au	O	X	O
)	O	PUNCT	O
while	O	SCONJ	O
the	O	DET	O
combination	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
antinociception	O	NOUN	B
was	O	AUX	O
remained	O	VERB	O
similar	O	ADJ	O
as	O	ADP	O
an	O	DET	O
acute	O	ADJ	B
treatment	O	NOUN	I
(	O	PUNCT	O
298	O	NUM	O
+/-	O	CCONJ	O
7	O	NUM	O
vs	O	CCONJ	O
.	O	PUNCT	O


280	O	NUM	O
+/-	O	CCONJ	O
17	O	NUM	O
au	O	X	O
).	O	PUNCT	O
Acute	O	ADJ	B
antinociceptive	O	ADJ	B
effects	O	NOUN	O
of	O	ADP	O
the	O	DET	O
combination	O	NOUN	B
were	O	AUX	O
partially	O	ADV	O
prevented	O	VERB	B
by	O	ADP	O
3	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
naloxone	B-Chemical	NOUN	B
s	O	NOUN	O
.	O	PUNCT	O


c	O	X	O
.(	O	NUM	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
),	O	PUNCT	O
suggesting	O	VERB	O
the	O	DET	O
partial	O	ADJ	B
involvement	O	NOUN	B
of	O	ADP	O
the	O	DET	O
opioidergic	O	ADJ	B
system	O	NOUN	I
in	O	ADP	O
the	O	DET	O
synergism	O	NOUN	B
observed	O	VERB	B
.	O	PUNCT	O


In	O	ADP	O
independent	O	ADJ	O
groups	O	NOUN	B
,	O	PUNCT	O
morphine	B-Chemical	NOUN	B
inhibited	O	VERB	B
the	O	DET	O
intestinal	O	ADJ	B
transit	O	NOUN	B
in	O	ADP	O
48	O	NUM	O
+/-	O	CCONJ	O
4	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
38	O	NUM	O
+/-	O	CCONJ	O
4	O	NUM	O
%	O	NOUN	O
after	O	ADP	O
acute	O	ADJ	B
and	O	CCONJ	O
chronic	O	ADJ	B
treatment	O	NOUN	I
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
tolerance	O	NOUN	B
did	O	AUX	O
not	O	PART	O
develop	O	VERB	O
to	O	PART	O
the	O	DET	O
constipating	B-Disease	VERB	B
effects	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
combination	O	NOUN	B
inhibited	O	VERB	B
intestinal	O	ADJ	B
transit	O	NOUN	O
similar	O	ADJ	O
to	O	PART	O
that	O	DET	O
produced	O	VERB	O
by	O	ADP	O
morphine	B-Chemical	NOUN	B
regardless	O	ADV	O
of	O	ADP	O
the	O	DET	O
time	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
metamizol	B-Chemical	NOUN	B
did	O	AUX	O
not	O	PART	O
potentiate	O	VERB	O
morphine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
constipation	B-Disease	NOUN	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
show	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
interaction	O	NOUN	B
between	O	ADP	O
morphine	B-Chemical	NOUN	B
and	O	CCONJ	O
metamizol	B-Chemical	NOUN	B
in	O	ADP	O
chronically	O	ADV	B
treated	O	VERB	B
rats	O	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
combination	O	NOUN	B
could	O	AUX	O
be	O	AUX	O
useful	O	ADJ	O
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
chronic	B-Disease	ADJ	B
pain	I-Disease	NOUN	I


Ifosfamide	B-Chemical	NOUN	B
encephalopathy	B-Disease	NOUN	I
presenting	O	VERB	O
with	O	ADP	O
asterixis	B-Disease	NOUN	B
.	O	PUNCT	O


CNS	O	NOUN	B
toxic	O	ADJ	B
effects	O	NOUN	O
of	O	ADP	O
the	O	DET	O
antineoplastic	O	ADJ	B
agent	O	NOUN	I
ifosfamide	B-Chemical	NOUN	I
(	O	PUNCT	O
IFX	B-Chemical	NOUN	B
)	O	PUNCT	O
are	O	AUX	O
frequent	O	ADJ	B
and	O	CCONJ	O
include	O	VERB	O
a	O	DET	O
variety	O	NOUN	O
of	O	ADP	O
neurological	O	ADJ	B
symptoms	O	NOUN	I
that	O	PRON	O
can	O	AUX	O
limit	O	VERB	O
drug	O	NOUN	B
use	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
a	O	DET	O
51	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
man	O	NOUN	B
who	O	PRON	O
developed	O	VERB	O
severe	O	ADV	B
,	O	PUNCT	O
disabling	O	VERB	O
negative	O	ADJ	B
myoclonus	B-Disease	NOUN	B
of	O	ADP	O
the	O	DET	O
upper	O	ADJ	B
and	O	CCONJ	O
lower	O	ADJ	B
extremities	O	NOUN	I
after	O	ADP	O
the	O	DET	O
infusion	O	NOUN	B
of	O	ADP	O
ifosfamide	B-Chemical	NOUN	B
for	O	ADP	O
plasmacytoma	B-Disease	NOUN	B
.	O	PUNCT	O


He	O	PRON	O
was	O	AUX	O
awake	O	ADJ	B
,	O	PUNCT	O
revealed	O	VERB	O
no	O	DET	O
changes	O	NOUN	O
of	O	ADP	O
mental	O	ADJ	B
status	O	NOUN	I
and	O	CCONJ	O
at	O	ADP	O
rest	O	NOUN	B
there	O	PRON	O
were	O	AUX	O
no	O	DET	O
further	O	ADJ	O
motor	O	NOUN	B
symptoms	O	NOUN	I
.	O	PUNCT	O


Cranial	O	ADJ	B
magnetic	O	ADJ	I
resonance	O	NOUN	I
imaging	O	NOUN	I
and	O	CCONJ	O
extensive	O	ADJ	O
laboratory	O	NOUN	B
studies	O	NOUN	I
failed	O	VERB	B
to	O	PART	O
reveal	O	VERB	O
structural	B-Disease	ADJ	B
lesions	I-Disease	NOUN	I
of	I-Disease	ADP	O
the	I-Disease	DET	O
brain	I-Disease	NOUN	B
and	O	CCONJ	O
metabolic	B-Disease	ADJ	B
abnormalities	I-Disease	NOUN	I
.	O	PUNCT	O


An	O	DET	O
electroencephalogram	O	NOUN	B
showed	O	VERB	O
continuous	O	ADJ	B
,	O	PUNCT	O
generalized	O	VERB	B
irregular	O	ADJ	I
slowing	O	NOUN	I
with	O	ADP	O
admixed	O	ADJ	O
periodic	O	ADJ	B
triphasic	O	ADJ	O
waves	O	NOUN	O
indicating	O	VERB	O
symptomatic	O	ADJ	B
encephalopathy	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
ifosfamide	B-Chemical	NOUN	B
was	O	AUX	O
discontinued	O	VERB	B
and	O	CCONJ	O
within	O	ADP	O
12	O	NUM	O
h	O	NOUN	O
the	O	DET	O
asterixis	B-Disease	NOUN	B
resolved	O	VERB	B
completely	O	ADV	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
described	O	VERB	O
,	O	PUNCT	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
asterixis	B-Disease	NOUN	B
during	O	ADP	O
infusion	O	NOUN	B
of	O	ADP	O
ifosfamide	B-Chemical	NOUN	B
,	O	PUNCT	O
normal	O	ADJ	O
laboratory	O	NOUN	O
findings	O	NOUN	O
and	O	CCONJ	O
imaging	O	NOUN	B
studies	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
resolution	O	NOUN	B
of	O	ADP	O
symptoms	O	NOUN	B
following	O	VERB	O
the	O	DET	O
discontinuation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
drug	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
negative	O	ADJ	B
myoclonus	B-Disease	NOUN	B
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
IFX	B-Chemical	NOUN	B


Sub	O	NOUN	B
-	O	PUNCT	O
chronic	O	ADJ	B
low	O	ADJ	O
dose	O	NOUN	O
gamma-vinyl	B-Chemical	NOUN	B
GABA	I-Chemical	NOUN	B
(	O	PUNCT	O
vigabatrin	B-Chemical	NOUN	B
)	O	PUNCT	O
inhibits	O	VERB	B
cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
increases	O	NOUN	B
in	O	ADP	O
nucleus	O	NOUN	B
accumbens	O	NOUN	I
dopamine	B-Chemical	NOUN	B
.	O	PUNCT	O


RATIONALE	O	NOUN	B
:	O	PUNCT	O
gamma-Vinyl	B-Chemical	ADJ	B
GABA	I-Chemical	NOUN	I
(	O	PUNCT	O
GVG	B-Chemical	NOUN	B
)	O	PUNCT	O
irreversibly	O	ADV	O
inhibits	O	VERB	B
GABA	B-Chemical	NOUN	B
-	O	PUNCT	O
transaminase	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
non	O	ADJ	B
-	O	PUNCT	O
receptor	O	NOUN	B
mediated	O	ADJ	O
inhibition	O	NOUN	B
requires	O	VERB	O
de	O	X	O
novo	O	X	O
synthesis	O	NOUN	B
for	O	ADP	O
restoration	O	NOUN	B
of	O	ADP	O
functional	O	ADJ	B
GABA	B-Chemical	NOUN	B
catabolism	O	NOUN	B
.	O	PUNCT	O


OBJECTIVES	O	NOUN	O
:	O	PUNCT	O
Given	O	VERB	O
its	O	PRON	O
preclinical	O	ADJ	B
success	O	NOUN	I
for	O	ADP	O
treating	O	VERB	B
substance	B-Disease	NOUN	B
abuse	I-Disease	NOUN	I
and	O	CCONJ	O
the	O	DET	O
increased	O	VERB	B
risk	O	NOUN	B
of	O	ADP	O
visual	B-Disease	ADJ	B
field	I-Disease	NOUN	I
defects	I-Disease	NOUN	I
(	O	PUNCT	O
VFD	B-Disease	NOUN	B
)	O	PUNCT	O
associated	O	VERB	B
with	O	ADP	I
cumulative	O	ADJ	B
lifetime	O	NOUN	B
exposure	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
explored	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
sub	O	ADV	B
-	O	PUNCT	O
chronic	O	ADJ	B
low	O	ADJ	O
dose	O	NOUN	O
GVG	B-Chemical	NOUN	B
on	O	ADP	O
cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
increases	O	NOUN	B
in	O	ADP	O
nucleus	O	NOUN	B
accumbens	O	NOUN	I
(	O	PUNCT	O
NAcc	O	NOUN	B
)	O	PUNCT	O
dopamine	B-Chemical	NOUN	B
(	O	PUNCT	O
DA	B-Chemical	NOUN	B
).	O	PUNCT	O
METHODS	O	NOUN	O
:	O	PUNCT	O
Using	O	VERB	O
in	O	X	B
vivo	O	X	I
microdialysis	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
compared	O	VERB	O
acute	O	ADJ	B
exposure	O	NOUN	O
(	O	PUNCT	O
450	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
to	O	PART	O
an	O	DET	O
identical	O	ADJ	B
sub	O	NOUN	B
-	O	PUNCT	O
chronic	O	ADJ	B
exposure	O	NOUN	B
(	O	PUNCT	O
150	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
per	O	ADP	O
day	O	NOUN	B
for	O	ADP	O
3	O	NUM	O
days	O	NOUN	B
),	O	PUNCT	O
followed	O	VERB	O
by	O	ADP	O
1	O	NUM	O
-	O	PUNCT	O
or	O	CCONJ	O
3	O	NUM	O
-	O	PUNCT	O
day	O	NOUN	B
washout	O	NOUN	B
.	O	PUNCT	O


Finally	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
examined	O	VERB	O
the	O	DET	O
low	O	ADJ	B
dose	O	NOUN	B
of	O	ADP	O
150	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
(	O	PUNCT	O
50	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
per	O	ADP	O
day	O	NOUN	B
)	O	PUNCT	O
using	O	VERB	O
a	O	DET	O
similar	O	ADJ	O
washout	O	NOUN	O
period	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Sub	O	NOUN	B
-	O	PUNCT	O
chronic	O	ADJ	B
GVG	B-Chemical	NOUN	B
exposure	O	NOUN	B
inhibited	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
cocaine	B-Chemical	NOUN	B
for	O	ADP	O
3	O	NUM	O
days	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
exceeded	O	VERB	O
in	O	ADP	O
magnitude	O	NOUN	B
and	O	CCONJ	O
duration	O	VERB	B
the	O	DET	O
identical	O	ADJ	B
acute	O	ADJ	B
dose	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
Sub	O	NOUN	B
-	O	PUNCT	O
chronic	O	ADJ	B
low	O	ADJ	O
dose	O	NOUN	O
GVG	B-Chemical	NOUN	B
potentiates	O	VERB	B
and	O	CCONJ	O
extends	O	VERB	O
the	O	DET	O
inhibition	O	NOUN	B
of	O	ADP	O
cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
increases	O	NOUN	B
in	O	ADP	O
dopamine	B-Chemical	NOUN	B


Amount	O	NOUN	B
of	O	ADP	O
bleeding	B-Disease	NOUN	B
and	O	CCONJ	O
hematoma	B-Disease	NOUN	B
size	O	NOUN	B
in	O	ADP	O
the	O	DET	O
collagenase	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
intracerebral	B-Disease	ADJ	B
hemorrhage	I-Disease	NOUN	I
rat	O	NOUN	B
model	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
aggravated	O	ADJ	B
risk	O	NOUN	B
on	O	ADP	O
intracerebral	B-Disease	ADJ	B
hemorrhage	I-Disease	NOUN	I
(	O	PUNCT	O
ICH	B-Disease	NOUN	B
)	O	PUNCT	O
with	O	ADP	O
drugs	O	NOUN	B
used	O	VERB	O
for	O	ADP	O
stroke	B-Disease	NOUN	B
patients	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
estimated	O	VERB	B
carefully	O	ADV	O
.	O	PUNCT	O


We	O	PRON	O
therefore	O	ADV	O
established	O	VERB	O
sensitive	O	ADJ	B
quantification	O	NOUN	B
methods	O	NOUN	I
and	O	CCONJ	O
provided	O	VERB	O
a	O	DET	O
rat	O	NOUN	B
ICH	B-Disease	NOUN	B
model	O	NOUN	B
for	O	ADP	O
detection	O	NOUN	B
of	O	ADP	O
ICH	B-Disease	NOUN	B
deterioration	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
ICH	B-Disease	NOUN	B
intrastriatally	O	ADV	B
induced	O	VERB	B
by	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


014	O	NUM	O
-	O	PUNCT	O
unit	O	NOUN	B
,	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


070	O	NUM	O
-	O	PUNCT	O
unit	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


350	O	NUM	O
-	O	PUNCT	O
unit	O	NOUN	B
collagenase	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
amount	O	NOUN	B
of	O	ADP	O
bleeding	B-Disease	NOUN	B
was	O	AUX	O
measured	O	VERB	B
using	O	VERB	O
a	O	DET	O
hemoglobin	O	NOUN	B
assay	O	NOUN	I
developed	O	VERB	O
in	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
and	O	CCONJ	O
was	O	AUX	O
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
morphologically	O	ADV	B
determined	O	ADJ	O
hematoma	B-Disease	NOUN	B
volume	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
blood	O	NOUN	B
amounts	O	NOUN	I
and	O	CCONJ	O
hematoma	B-Disease	NOUN	B
volumes	O	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
correlated	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
hematoma	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


014	O	NUM	O
-	O	PUNCT	O
unit	O	NOUN	B
collagenase	O	NOUN	B
was	O	AUX	O
adequate	O	ADJ	B
to	O	PART	O
detect	O	VERB	B
ICH	B-Disease	NOUN	B
deterioration	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
ICH	B-Disease	NOUN	B
induction	O	NOUN	B
using	O	VERB	O
0	O	NUM	O
.	O	PUNCT	O


014	O	NUM	O
-	O	PUNCT	O
unit	O	NOUN	B
collagenase	O	NOUN	B
,	O	PUNCT	O
heparin	B-Chemical	NOUN	B
enhanced	O	VERB	B
the	O	DET	O
hematoma	B-Disease	NOUN	B
volume	O	NOUN	B
3	O	NUM	I
.	O	PUNCT	O


4	O	NUM	O
-	O	PUNCT	O
fold	O	NOUN	B
over	O	ADP	O
that	O	DET	O
seen	O	VERB	O
in	O	ADP	O
control	O	ADJ	B
ICH	B-Disease	NOUN	B
animals	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
bleeding	B-Disease	ADJ	B
7	O	NUM	I
.	O	PUNCT	O


6	O	NUM	O
-	O	PUNCT	O
fold	O	NOUN	B
.	O	PUNCT	O


Data	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
sensitive	O	ADJ	B
hemoglobin	O	NOUN	B
assay	O	NOUN	I
is	O	AUX	O
useful	O	ADJ	O
for	O	ADP	O
ICH	B-Disease	NOUN	B
detection	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
that	O	SCONJ	O
a	O	DET	O
model	O	NOUN	B
with	O	ADP	O
a	O	DET	O
small	O	ADJ	O
ICH	B-Disease	NOUN	B
induced	O	VERB	B
with	O	ADP	O
a	O	DET	O
low	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
collagenase	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
used	O	VERB	O
for	O	ADP	O
evaluation	O	NOUN	B
of	O	ADP	O
drugs	O	NOUN	B
that	O	PRON	O
may	O	AUX	O
affect	O	VERB	O
ICH	B-Disease	PROPN	B


Estradiol	B-Chemical	NOUN	B
reduces	O	VERB	O
seizure	B-Disease	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hippocampal	B-Disease	NOUN	B
injury	I-Disease	NOUN	O
in	O	ADP	O
ovariectomized	O	ADJ	B
female	O	NOUN	I
but	O	CCONJ	O
not	O	PART	O
in	O	ADP	O
male	O	NOUN	B
rats	O	NOUN	B
.	O	PUNCT	O


Estrogens	O	NOUN	B
protect	O	VERB	O
ovariectomized	O	ADJ	B
rats	O	NOUN	B
from	O	ADP	O
hippocampal	B-Disease	NOUN	B
injury	I-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
kainic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
-	O	PUNCT	O
induced	O	VERB	B
status	B-Disease	NOUN	B
epilepticus	I-Disease	NOUN	I
(	O	PUNCT	O
SE	B-Disease	NOUN	B
).	O	PUNCT	O
We	O	PRON	O
compared	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
17beta-estradiol	B-Chemical	NOUN	B
in	O	ADP	O
adult	O	ADJ	B
male	O	NOUN	B
and	O	CCONJ	O
ovariectomized	O	ADJ	B
female	O	NOUN	O
rats	O	NOUN	B
subjected	O	VERB	O
to	O	PART	O
lithium	B-Chemical	NOUN	B
-	O	PUNCT	O
pilocarpine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
SE	B-Disease	NOUN	B
.	O	PUNCT	O


Rats	O	NOUN	B
received	O	VERB	O
subcutaneous	O	ADJ	B
injections	O	NOUN	I
of	O	ADP	O
17beta-estradiol	B-Chemical	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
microg	O	NOUN	B
/	O	SYM	O
rat	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
oil	O	NOUN	B
once	O	ADV	B
daily	O	ADV	I
for	O	ADP	O
four	O	NUM	O
consecutive	O	ADJ	B
days	O	NOUN	B
.	O	PUNCT	O


SE	B-Disease	NOUN	B
was	O	AUX	O
induced	O	VERB	B
20	O	NUM	O
h	O	NOUN	O
following	O	VERB	O
the	O	DET	O
second	O	ADJ	O
injection	O	NOUN	B
and	O	CCONJ	O
terminated	O	VERB	B
3	O	NUM	O
h	O	NOUN	O
later	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
extent	O	NOUN	O
of	O	ADP	O
silver	B-Chemical	ADV	B
-	O	PUNCT	O
stained	O	VERB	B
CA3	O	NOUN	B
and	O	CCONJ	O
CA1	O	NOUN	B
hippocampal	O	NOUN	B
neurons	O	NOUN	B
was	O	AUX	O
evaluated	O	VERB	B
2	O	NUM	O
days	O	NOUN	B
after	O	ADP	O
SE	B-Disease	NOUN	B
.	O	PUNCT	O


17beta-Estradiol	B-Chemical	NOUN	B
did	O	AUX	O
not	O	PART	O
alter	O	VERB	O
the	O	DET	O
onset	O	NOUN	O
of	O	ADP	O
first	O	ADJ	O
clonus	O	NOUN	B
in	O	ADP	O
ovariectomized	O	ADJ	B
rats	O	NOUN	O
but	O	CCONJ	O
accelerated	O	VERB	B
it	O	PRON	O
in	O	ADP	O
males	O	NOUN	B
.	O	PUNCT	O


17beta-Estradiol	B-Chemical	NOUN	B
reduced	O	VERB	B
the	O	DET	O
argyrophilic	O	ADJ	B
neurons	O	NOUN	B
in	O	ADP	O
the	O	DET	O
CA1	O	NOUN	B
and	O	CCONJ	O
CA3	O	PROPN	B
-	O	PUNCT	O
C	O	NOUN	B
sectors	O	NOUN	B
of	O	ADP	O
ovariectomized	O	ADJ	B
rats	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
males	O	NOUN	B
,	O	PUNCT	O
estradiol	B-Chemical	NOUN	B
increased	O	VERB	B
the	O	DET	O
total	O	ADJ	O
damage	O	NOUN	O
score	O	NOUN	O
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
estradiol	B-Chemical	NOUN	B
on	O	ADP	O
seizure	B-Disease	NOUN	B


Delirium	B-Disease	NOUN	B
during	O	ADP	O
clozapine	B-Chemical	NOUN	B
treatment	O	NOUN	B
:	O	PUNCT	O
incidence	O	NOUN	B
and	O	CCONJ	O
associated	O	VERB	O
risk	O	NOUN	B
factors	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Incidence	O	NOUN	B
and	O	CCONJ	O
risk	O	NOUN	B
factors	O	NOUN	I
for	O	ADP	O
delirium	B-Disease	NOUN	B
during	O	ADP	O
clozapine	B-Chemical	NOUN	B
treatment	O	NOUN	B
require	O	VERB	O
further	O	ADJ	O
clarification	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
We	O	PRON	O
used	O	VERB	O
computerized	O	VERB	B
pharmacy	O	NOUN	I
records	O	NOUN	I
to	O	PART	O
identify	O	VERB	O
all	O	DET	O
adult	O	ADJ	B
psychiatric	B-Disease	ADJ	B
inpatients	O	NOUN	I
treated	O	VERB	B
with	O	ADP	I
clozapine	B-Chemical	NOUN	B
(	O	PUNCT	O
1995	O	NUM	O
-	O	SYM	O
96	O	NUM	O
),	O	PUNCT	O
reviewed	O	VERB	B
their	O	PRON	O
medical	O	ADJ	B
records	O	NOUN	I
to	O	PART	O
score	O	VERB	B
incidence	O	NOUN	B
and	O	CCONJ	O
severity	O	NOUN	B
of	O	ADP	O
delirium	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
tested	O	VERB	B
associations	O	NOUN	B
with	O	ADP	O
potential	O	ADJ	B
risk	O	NOUN	B
factors	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Subjects	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
139	O	NUM	O
)	O	PUNCT	O
were	O	AUX	O
72	O	NUM	O
women	O	NOUN	B
and	O	CCONJ	O
67	O	NUM	O
men	O	NOUN	B
,	O	PUNCT	O
aged	O	ADJ	B
40	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
+/-	O	CCONJ	O
12	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
years	O	NOUN	B
,	O	PUNCT	O
hospitalized	O	VERB	B
for	O	ADP	O
24	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
+/-	O	CCONJ	O
23	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
days	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
given	O	VERB	O
clozapine	B-Chemical	NOUN	B
,	O	PUNCT	O
gradually	O	ADV	O
increased	O	VERB	B
to	O	ADP	O
an	O	DET	O
average	O	ADJ	B
daily	O	ADJ	O
dose	O	NOUN	O
of	O	ADP	O
282	O	NUM	O
+/-	O	CCONJ	O
203	O	NUM	O
mg	O	NOUN	O
(	O	PUNCT	O
3	O	NUM	O
.	O	PUNCT	O


45	O	NUM	O
+/-	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O


45	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
for	O	ADP	O
18	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
+/-	O	CCONJ	O
16	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


Delirium	B-Disease	NOUN	B
was	O	AUX	O
diagnosed	O	VERB	B
in	O	ADP	O
14	O	NUM	O
(	O	PUNCT	O
10	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
%	O	NOUN	O
incidence	O	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


48	O	NUM	O
cases	O	NOUN	B
/	O	SYM	O
person	O	NOUN	B
-	O	PUNCT	O
years	O	NOUN	B
of	O	ADP	O
exposure	O	NOUN	B
);	O	ADJ	O
71	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
cases	O	NOUN	B
were	O	AUX	O
moderate	O	ADJ	B
or	O	CCONJ	O
severe	O	ADJ	B
.	O	PUNCT	O


Associated	O	VERB	B
factors	O	NOUN	I
were	O	AUX	O
co	O	VERB	B
-	O	PUNCT	O
treatment	O	NOUN	B
with	O	ADP	O
other	O	ADJ	O
centrally	O	ADV	O
antimuscarinic	O	ADJ	B
agents	O	NOUN	I
,	O	PUNCT	O
poor	O	ADJ	B
clinical	O	ADJ	I
outcome	O	NOUN	I
,	O	PUNCT	O
older	O	ADJ	B
age	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
longer	O	ADJ	B
hospitalization	O	NOUN	B
(	O	PUNCT	O
by	O	ADP	O
17	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
days	O	NOUN	B
,	O	PUNCT	O
increasing	O	VERB	B
cost	O	NOUN	B
);	O	ADJ	B
sex	O	NOUN	O
,	O	PUNCT	O
diagnosis	O	NOUN	B
or	O	CCONJ	O
medical	O	ADJ	B
co	O	ADJ	I
-	O	PUNCT	O
morbidity	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
daily	O	ADJ	B
clozapine	B-Chemical	NOUN	B
dose	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
fell	O	VERB	O
with	O	ADP	O
age	O	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
unrelated	O	ADJ	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
Delirium	B-Disease	NOUN	B
was	O	AUX	O
found	O	VERB	O
in	O	ADP	O
10	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
clozapine	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
inpatients	O	NOUN	B
,	O	PUNCT	O
particularly	O	ADV	O
in	O	ADP	O
older	O	ADJ	B
patients	O	NOUN	B
exposed	O	VERB	B
to	O	PART	O
other	O	ADJ	O
central	O	ADJ	B
anticholinergics	O	NOUN	I
.	O	PUNCT	O


Delirium	B-Disease	NOUN	B


Ketoconazole	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
neurologic	B-Disease	ADJ	B
sequelae	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
77	O	NUM	O
-	O	PUNCT	O
y	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
patient	O	NOUN	B
developed	O	VERB	O
weakness	B-Disease	NOUN	B
of	I-Disease	ADP	I
extremities	I-Disease	NOUN	I
,	O	PUNCT	O
legs	B-Disease	NOUN	B
paralysis	I-Disease	NOUN	I
,	O	PUNCT	O
dysarthria	B-Disease	NOUN	B
and	O	CCONJ	O
tremor	B-Disease	NOUN	B
1	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
ingestion	O	NOUN	B
of	O	ADP	O
200	O	NUM	O
mg	O	NOUN	O
ketoconazole	B-Chemical	NOUN	B
for	O	ADP	O
the	O	DET	O
first	O	ADJ	O
time	O	NOUN	O
in	O	ADP	O
his	O	PRON	O
life	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
complaints	O	NOUN	B
faded	O	VERB	O
away	O	ADV	O
within	O	ADP	O
24	O	NUM	O
h	O	NOUN	O
.	O	PUNCT	O


Few	O	ADJ	O
days	O	NOUN	B
later	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
patient	O	NOUN	B
used	O	VERB	O
another	O	DET	O
200	O	NUM	O
mg	O	NOUN	O
ketoconazole	B-Chemical	NOUN	B
tablet	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
within	O	ADP	O
an	O	DET	O
hour	O	NOUN	B
experienced	O	VERB	O
a	O	DET	O
similar	O	ADJ	O
clinical	O	ADJ	B
picture	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
resolved	O	VERB	B
again	O	ADV	O
spontaneously	O	ADV	B
within	O	ADP	O
hours	O	NOUN	B
.	O	PUNCT	O


Laboratory	O	NOUN	B
evaluations	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
head	O	NOUN	B
CT	O	NOUN	I
scan	O	NOUN	I
,	O	PUNCT	O
were	O	AUX	O
normal	O	ADJ	B
.	O	PUNCT	O


This	O	DET	O
case	O	NOUN	B
illustrates	O	VERB	O
the	O	DET	O
need	O	NOUN	O
for	O	ADP	O
close	O	ADJ	O
vigilance	O	NOUN	B
in	O	ADP	O
adverse	B-Disease	ADJ	B
drug	I-Disease	NOUN	I
reactions	I-Disease	NOUN	I


Noxious	O	ADJ	B
chemical	O	NOUN	B
stimulation	O	NOUN	I
of	O	ADP	O
rat	O	NOUN	B
facial	O	ADJ	B
mucosa	O	NOUN	I
increases	O	VERB	B
intracranial	O	ADJ	B
blood	O	NOUN	I
flow	O	NOUN	I
through	O	ADP	O
a	O	DET	O
trigemino	O	NOUN	B
-	O	PUNCT	O
parasympathetic	O	ADJ	B
reflex	O	NOUN	B
--	O	PUNCT	O
an	O	DET	O
experimental	O	ADJ	B
model	O	NOUN	I
for	O	ADP	O
vascular	B-Disease	ADJ	B
dysfunctions	I-Disease	NOUN	I
in	O	ADP	O
cluster	B-Disease	NOUN	B
headache	I-Disease	NOUN	I
.	O	PUNCT	O


Cluster	B-Disease	NOUN	B
headache	I-Disease	NOUN	I
is	O	AUX	O
characterized	O	VERB	B
by	O	ADP	O
typical	O	ADJ	O
autonomic	O	ADJ	B
dysfunctions	O	NOUN	I
including	O	VERB	O
facial	O	ADJ	B
and	O	CCONJ	O
intracranial	B-Disease	ADJ	B
vascular	I-Disease	ADJ	O
disturbances	I-Disease	NOUN	O
.	O	PUNCT	O


Both	O	CCONJ	O
the	O	DET	O
trigeminal	O	ADJ	B
and	O	CCONJ	O
the	O	DET	O
cranial	O	ADJ	B
parasympathetic	O	ADJ	I
systems	O	NOUN	I
may	O	AUX	O
be	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
mediating	O	VERB	O
these	O	DET	O
dysfunctions	O	NOUN	B
.	O	PUNCT	O


An	O	DET	O
experimental	O	ADJ	B
model	O	NOUN	I
was	O	AUX	O
developed	O	VERB	O
in	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
to	O	PART	O
measure	O	VERB	B
changes	O	NOUN	B
in	O	ADP	O
lacrimation	O	NOUN	B
and	O	CCONJ	O
intracranial	O	ADJ	B
blood	O	NOUN	I
flow	O	NOUN	I
following	O	VERB	O
noxious	O	ADJ	B
chemical	O	NOUN	I
stimulation	O	NOUN	I
of	O	ADP	O
facial	O	ADJ	B
mucosa	O	NOUN	I
.	O	PUNCT	O


Blood	O	NOUN	B
flow	O	NOUN	I
was	O	AUX	O
monitored	O	VERB	O
in	O	ADP	O
arteries	O	NOUN	B
of	O	ADP	O
the	O	DET	O
exposed	O	VERB	B
cranial	O	ADJ	B
dura	O	NOUN	B
mater	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
parietal	O	ADJ	B
cortex	O	NOUN	I
using	O	VERB	O
laser	O	NOUN	B
Doppler	O	PROPN	I
flowmetry	O	NOUN	I
.	O	PUNCT	O


Capsaicin	B-Chemical	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
-	O	SYM	O
1	O	NUM	O
mm	O	NOUN	O
)	O	PUNCT	O
applied	O	VERB	O
to	O	PART	O
oral	O	ADJ	B
or	O	CCONJ	O
nasal	O	ADJ	B
mucosa	O	NOUN	I
induced	O	VERB	B
increases	B-Disease	NOUN	B
in	I-Disease	ADP	O
dural	I-Disease	ADJ	B
and	I-Disease	CCONJ	O
cortical	I-Disease	ADJ	B
blood	I-Disease	NOUN	I
flow	I-Disease	NOUN	I
and	O	CCONJ	O
provoked	O	VERB	B
lacrimation	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
responses	O	NOUN	B
were	O	AUX	O
blocked	O	VERB	B
by	O	ADP	O
systemic	O	ADJ	B
pre	O	ADJ	B
-	O	PUNCT	O
administration	O	NOUN	B
of	O	ADP	O
hexamethonium	B-Chemical	NOUN	B
chloride	I-Chemical	NOUN	I
(	O	PUNCT	O
20	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
).	O	PUNCT	O
The	O	DET	O
evoked	O	VERB	B
increases	B-Disease	NOUN	B
in	I-Disease	ADP	O
dural	I-Disease	ADJ	B
blood	I-Disease	NOUN	I
flow	I-Disease	NOUN	I
were	O	AUX	O
also	O	ADV	O
abolished	O	VERB	O
by	O	ADP	O
topical	O	ADJ	B
pre	O	NOUN	B
-	O	PUNCT	O
administration	O	NOUN	B
of	O	ADP	O
atropine	B-Chemical	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
mm	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
[	O	PUNCT	O
Lys1	O	PROPN	B
,	O	PUNCT	O
Pro2	O	NOUN	B
,	O	PUNCT	O
5	O	NUM	O
,	O	PUNCT	O
Arg3	O	NOUN	B
,	O	PUNCT	O
4	O	NUM	O
,	O	PUNCT	O
Tyr6	O	NOUN	B
]-	O	NOUN	O
VIP	O	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
mm	O	NOUN	O
),	O	PUNCT	O
a	O	DET	O
vasoactive	O	ADJ	B
intestinal	O	ADJ	I
polypeptide	O	NOUN	I
(	O	PUNCT	O
VIP	O	NOUN	B
)	O	PUNCT	O
antagonist	O	NOUN	B
,	O	PUNCT	O
onto	O	ADP	O
the	O	DET	O
exposed	O	VERB	B
dura	O	NOUN	B
mater	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
noxious	O	ADJ	B
stimulation	O	NOUN	I
of	O	ADP	O
facial	O	ADJ	B
mucosa	O	NOUN	I
increases	O	VERB	B
intracranial	O	ADJ	B
blood	O	NOUN	I
flow	O	NOUN	I
and	O	CCONJ	O
lacrimation	O	NOUN	B
via	O	ADP	O
a	O	DET	O
trigemino	O	NOUN	B
-	O	PUNCT	O
parasympathetic	O	ADJ	B
reflex	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
blood	O	NOUN	B
flow	O	NOUN	I
responses	O	NOUN	B
seem	O	VERB	O
to	O	PART	O
be	O	AUX	O
mediated	O	VERB	O
by	O	ADP	O
the	O	DET	O
release	O	NOUN	B
of	O	ADP	O
acetylcholine	B-Chemical	NOUN	B
and	O	CCONJ	O
VIP	O	NOUN	B
within	O	ADP	O
the	O	DET	O
meninges	O	NOUN	B
.	O	PUNCT	O


Similar	O	ADJ	O
mechanisms	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
the	O	DET	O
pathogenesis	O	NOUN	B
of	O	ADP	O
cluster	B-Disease	NOUN	B
headache	I-Disease	NOUN	I


Recurrent	O	ADJ	B
excitation	O	NOUN	O
in	O	ADP	O
the	O	DET	O
dentate	O	NOUN	B
gyrus	O	NOUN	I
of	O	ADP	O
a	O	DET	O
murine	O	ADJ	B
model	O	NOUN	B
of	O	ADP	O
temporal	B-Disease	ADJ	B
lobe	I-Disease	NOUN	I
epilepsy	I-Disease	NOUN	I
.	O	PUNCT	O


Similar	O	ADJ	O
to	O	PART	O
rats	O	NOUN	B
,	O	PUNCT	O
systemic	O	ADJ	B
pilocarpine	B-Chemical	NOUN	I
injection	O	NOUN	B
causes	O	VERB	O
status	B-Disease	NOUN	B
epilepticus	I-Disease	NOUN	I
(	O	PUNCT	O
SE	B-Disease	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
eventual	O	ADJ	B
development	O	NOUN	B
of	O	ADP	O
spontaneous	O	ADJ	B
seizures	B-Disease	NOUN	B
and	O	CCONJ	O
mossy	O	NOUN	B
fiber	O	NOUN	I
sprouting	O	NOUN	B
in	O	ADP	O
C57BL	O	NOUN	B
/	O	SYM	O
6	O	NUM	B
and	O	CCONJ	O
CD1	O	NOUN	B
mice	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
physiological	O	ADJ	B
correlates	O	NOUN	B
of	O	ADP	O
these	O	DET	O
events	O	NOUN	B
have	O	AUX	O
not	O	PART	O
been	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
mice	O	NOUN	B
.	O	PUNCT	O


Population	O	NOUN	B
responses	O	NOUN	O
in	O	ADP	O
granule	O	NOUN	B
cells	O	NOUN	I
of	O	ADP	O
the	O	DET	O
dentate	O	NOUN	B
gyrus	O	NOUN	I
were	O	AUX	O
examined	O	VERB	O
in	O	ADP	O
transverse	O	ADJ	B
slices	O	NOUN	B
of	O	ADP	O
the	O	DET	O
ventral	O	ADJ	B
hippocampus	O	NOUN	I
from	O	ADP	O
pilocarpine	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
and	O	CCONJ	O
untreated	O	ADJ	B
mice	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
Mg	B-Chemical	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
+)-	O	NOUN	O
free	O	ADJ	B
bathing	O	NOUN	O
medium	O	NOUN	O
containing	O	VERB	O
bicuculline	B-Chemical	NOUN	B
,	O	PUNCT	O
conditions	O	NOUN	B
designed	O	VERB	O
to	O	PART	O
increase	O	VERB	B
excitability	O	NOUN	B
in	O	ADP	O
the	O	DET	O
slices	O	NOUN	B
,	O	PUNCT	O
electrical	O	ADJ	B
stimulation	O	NOUN	I
of	O	ADP	O
the	O	DET	O
hilus	O	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
a	O	DET	O
single	O	ADJ	O
population	O	NOUN	B
spike	O	NOUN	O
in	O	ADP	O
granule	O	NOUN	B
cells	O	NOUN	I
from	O	ADP	O
control	O	NOUN	B
mice	O	NOUN	B
and	O	CCONJ	O
pilocarpine	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
mice	O	NOUN	B
that	O	PRON	O
did	O	AUX	O
not	O	PART	O
experience	O	VERB	O
SE	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
SE	B-Disease	NOUN	B
survivors	O	NOUN	B
,	O	PUNCT	O
similar	O	ADJ	O
stimulation	O	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
a	O	DET	O
population	O	NOUN	B
spike	O	NOUN	O
followed	O	VERB	O
,	O	PUNCT	O
at	O	ADP	O
a	O	DET	O
variable	O	ADJ	B
latency	O	NOUN	I
,	O	PUNCT	O
by	O	ADP	O
negative	O	ADJ	B
DC	O	NOUN	B
shifts	O	NOUN	B
and	O	CCONJ	O
repetitive	O	ADJ	B
afterdischarges	O	NOUN	I
of	O	ADP	O
3	O	NUM	O
-	O	PUNCT	O
60	O	NUM	O
s	O	NOUN	O
duration	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
were	O	AUX	O
blocked	O	VERB	B
by	O	ADP	O
ionotropic	O	ADJ	B
glutamate	B-Chemical	NOUN	I
receptor	O	NOUN	I
antagonists	O	NOUN	I
.	O	PUNCT	O


Focal	O	ADJ	B
glutamate	B-Chemical	NOUN	O
photostimulation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
granule	O	NOUN	B
cell	O	NOUN	I
layer	O	NOUN	I
at	O	ADP	O
sites	O	NOUN	B
distant	O	ADJ	B
from	O	ADP	O
the	O	DET	O
recording	O	NOUN	B
pipette	O	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
population	O	NOUN	B
responses	O	NOUN	I
of	O	ADP	O
1	O	NUM	O
-	O	PUNCT	O
30	O	NUM	O
s	O	NOUN	O
duration	O	NOUN	B
in	O	ADP	O
slices	O	NOUN	B
from	O	ADP	O
SE	B-Disease	NOUN	B
survivors	O	NOUN	B
but	O	CCONJ	O
not	O	PART	O
other	O	ADJ	O
groups	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
support	O	VERB	O
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
SE	B-Disease	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
mossy	O	NOUN	B
fiber	O	NOUN	I
sprouting	O	NOUN	B
and	O	CCONJ	O
synaptic	O	ADJ	B
reorganization	O	NOUN	I
are	O	AUX	O
relevant	O	ADJ	B
characteristics	O	NOUN	B
of	O	ADP	O
seizure	B-Disease	NOUN	B
development	O	NOUN	B
in	O	ADP	O
these	O	DET	O
murine	O	ADJ	B
strains	O	NOUN	B
,	O	PUNCT	O
resembling	O	VERB	O
rat	O	NOUN	B
models	O	NOUN	B
of	O	ADP	O
human	O	ADJ	B
temporal	B-Disease	ADJ	O
lobe	I-Disease	NOUN	O
epilepsy	I-Disease	NOUN	O


The	O	DET	O
alpha3	O	NOUN	B
and	O	CCONJ	O
beta4	O	NOUN	B
nicotinic	O	ADJ	I
acetylcholine	B-Chemical	NOUN	I
receptor	O	NOUN	I
subunits	O	NOUN	I
are	O	AUX	O
necessary	O	ADJ	O
for	O	ADP	O
nicotine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
seizures	B-Disease	NOUN	B
and	O	CCONJ	O
hypolocomotion	B-Disease	NOUN	B
in	O	ADP	O
mice	O	NOUN	B
.	O	PUNCT	O


Binding	O	NOUN	B
of	O	ADP	O
nicotine	B-Chemical	NOUN	B
to	O	PART	O
nicotinic	O	ADJ	B
acetylcholine	B-Chemical	NOUN	I
receptors	O	NOUN	I
(	O	PUNCT	O
nAChRs	O	NOUN	B
)	O	PUNCT	O
elicits	O	VERB	O
a	O	DET	O
series	O	NOUN	B
of	O	ADP	O
dose	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
behaviors	O	NOUN	B
that	O	PRON	O
go	O	VERB	O
from	O	ADP	O
altered	O	ADJ	O
exploration	O	NOUN	B
,	O	PUNCT	O
sedation	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
tremors	B-Disease	NOUN	B
,	O	PUNCT	O
to	O	ADP	O
seizures	B-Disease	NOUN	B
and	O	CCONJ	O
death	B-Disease	NOUN	B
.	O	PUNCT	O


nAChRs	O	NOUN	B
are	O	AUX	O
pentameric	O	ADJ	B
ion	O	NOUN	I
channels	O	NOUN	I
usually	O	ADV	O
composed	O	VERB	O
of	O	ADP	O
alpha	O	NOUN	B
and	O	CCONJ	O
beta	O	NOUN	B
subunits	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
gene	O	NOUN	B
cluster	O	NOUN	I
comprises	O	VERB	O
the	O	DET	O
alpha3	O	NOUN	B
,	O	PUNCT	O
alpha5	O	NOUN	B
and	O	CCONJ	O
beta4	O	NOUN	B
subunits	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
coassemble	O	ADJ	B
to	O	PART	O
form	O	VERB	O
functional	O	ADJ	B
receptors	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
examined	O	VERB	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
the	O	DET	O
beta4	O	NOUN	B
subunits	O	NOUN	I
in	O	ADP	O
nicotine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
seizures	B-Disease	NOUN	B
and	O	CCONJ	O
hypolocomotion	B-Disease	NOUN	B
in	O	ADP	O
beta4	O	NOUN	B
homozygous	O	ADJ	B
null	O	NOUN	O
(	O	PUNCT	O
beta4	O	NOUN	B
-/-)	O	NOUN	O
and	O	CCONJ	O
alpha3	O	NOUN	B
heterozygous	O	ADJ	O
(+/-)	O	NOUN	O
mice	O	NOUN	B
.	O	PUNCT	O


beta4	O	NOUN	B
-/-	O	ADJ	O
mice	O	NOUN	B
were	O	AUX	O
less	O	ADV	O
sensitive	O	ADJ	B
to	O	PART	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
nicotine	B-Chemical	NOUN	B
both	O	CCONJ	O
at	O	ADP	O
low	O	ADJ	B
doses	O	NOUN	I
,	O	PUNCT	O
measured	O	VERB	B
as	O	ADP	O
decreased	O	VERB	B
exploration	O	NOUN	B
in	O	ADP	O
an	O	DET	O
open	O	ADJ	B
field	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
at	O	ADP	O
high	O	ADJ	B
doses	O	NOUN	I
,	O	PUNCT	O
measured	O	VERB	B
as	O	ADP	O
sensitivity	O	NOUN	B
to	O	PART	O
nicotine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
seizures	B-Disease	NOUN	B
.	O	PUNCT	O


Using	O	VERB	O
in	O	X	B
situ	O	X	I
hybridization	O	NOUN	I
probes	O	NOUN	O
for	O	ADP	O
the	O	DET	O
alpha3	O	NOUN	B
and	O	CCONJ	O
alpha5	O	NOUN	B
subunits	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
showed	O	VERB	O
that	O	SCONJ	O
alpha5	O	NOUN	B
mRNA	O	NOUN	B
levels	O	NOUN	O
are	O	AUX	O
unchanged	O	ADJ	B
,	O	PUNCT	O
whereas	O	SCONJ	O
alpha3	O	NOUN	B
mRNA	O	NOUN	B
levels	O	NOUN	O
are	O	AUX	O
selectively	O	ADV	O
decreased	O	VERB	B
in	O	ADP	O
the	O	DET	O
mitral	O	ADJ	B
cell	O	NOUN	I
layer	O	NOUN	I
of	O	ADP	O
the	O	DET	O
olfactory	O	ADJ	B
bulb	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
inferior	O	ADJ	B
and	O	CCONJ	O
the	O	DET	O
superior	O	ADJ	B
colliculus	O	NOUN	B
of	O	ADP	O
beta4	O	NOUN	B
-/-	O	ADJ	O
brains	O	NOUN	B
.	O	PUNCT	O


alpha3	O	NOUN	B
+/-	O	CCONJ	O
mice	O	NOUN	B
were	O	AUX	O
partially	O	ADV	O
resistant	O	ADJ	B
to	O	PART	O
nicotine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
seizures	B-Disease	NOUN	B
when	O	SCONJ	O
compared	O	VERB	B
to	O	ADP	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
littermates	O	NOUN	B
.	O	PUNCT	O


mRNA	O	NOUN	B
levels	O	NOUN	O
for	O	ADP	O
the	O	DET	O
alpha5	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
beta4	O	NOUN	B
subunits	O	NOUN	I
were	O	AUX	O
unchanged	O	ADJ	B
in	O	ADP	O
alpha3	O	NOUN	B
+/-	O	CCONJ	O
brains	O	NOUN	B
.	O	PUNCT	O


Together	O	ADV	O
,	O	PUNCT	O
these	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
beta4	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
alpha3	O	NOUN	B
subunits	O	NOUN	O
are	O	AUX	O
mediators	O	NOUN	B
of	O	ADP	O
nicotine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
seizures	B-Disease	NOUN	B
and	O	CCONJ	O
hypolocomotion	B-Disease	NOUN	B


Recurrent	O	ADJ	B
acute	O	ADJ	I
interstitial	B-Disease	ADJ	I
nephritis	I-Disease	NOUN	I
induced	O	VERB	B
by	O	ADP	O
azithromycin	B-Chemical	NOUN	B
.	O	PUNCT	O


A	O	DET	O
14	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
girl	O	NOUN	I
is	O	AUX	O
reported	O	VERB	O
with	O	ADP	O
recurrent	O	ADJ	B
,	O	PUNCT	O
azithromycin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
,	O	PUNCT	O
acute	O	ADJ	B
interstitial	B-Disease	ADJ	I
nephritis	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
second	O	ADJ	O
episode	O	NOUN	B
was	O	AUX	O
more	O	ADV	O
severe	O	ADJ	B
than	O	ADP	O
the	O	DET	O
first	O	ADJ	O
;	O	PUNCT	O
and	O	CCONJ	O
although	O	SCONJ	O
both	O	DET	O
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
intensive	O	ADJ	B
corticosteroid	O	NOUN	I
therapy	O	NOUN	I
,	O	PUNCT	O
renal	O	ADJ	B
function	O	NOUN	I
remained	O	VERB	O
impaired	O	ADJ	B
.	O	PUNCT	O


Although	O	SCONJ	O
most	O	ADJ	O
cases	O	NOUN	B
of	O	ADP	O
antibiotic	O	ADJ	B
induced	O	VERB	B
acute	O	ADJ	B
interstitial	B-Disease	ADJ	I
nephritis	I-Disease	NOUN	I
are	O	AUX	O
benign	O	ADJ	B
and	O	CCONJ	O
self	O	NOUN	B
-	O	PUNCT	O
limited	O	ADJ	B
,	O	PUNCT	O
some	O	DET	O
patients	O	NOUN	B
are	O	AUX	O
at	O	ADP	O
risk	O	NOUN	B
for	O	ADP	O
permanent	O	ADJ	B
renal	B-Disease	ADJ	I
injury	I-Disease	NOUN	I


Valproate	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
encephalopathy	B-Disease	NOUN	B
.	O	PUNCT	O


Valproate	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
encephalopathy	B-Disease	NOUN	B
is	O	AUX	O
a	O	DET	O
rare	O	ADJ	B
syndrome	O	NOUN	B
that	O	PRON	O
may	O	AUX	O
manifest	O	VERB	B
in	O	ADP	O
otherwise	O	ADV	O
normal	O	ADJ	O
epileptic	B-Disease	ADJ	B
individuals	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
may	O	AUX	O
even	O	ADV	O
present	O	ADJ	O
in	O	ADP	O
patients	O	NOUN	B
who	O	PRON	O
have	O	AUX	O
tolerated	O	VERB	B
this	O	DET	O
medicine	O	NOUN	B
well	O	ADV	O
in	O	ADP	O
the	O	DET	O
past	O	NOUN	O
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
usually	O	ADV	O
but	O	CCONJ	O
not	O	PART	O
necessarily	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
hyperammonemia	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
EEG	O	PROPN	B
shows	O	VERB	O
characteristic	O	ADJ	O
triphasic	O	ADJ	B
waves	O	NOUN	I
in	O	ADP	O
most	O	ADJ	O
patients	O	NOUN	B
with	O	ADP	O
this	O	DET	O
complication	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
case	O	NOUN	B
of	O	ADP	O
valproate	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
encephalopathy	B-Disease	NOUN	B


Nitro-L-arginine	B-Chemical	NOUN	B
methyl	I-Chemical	NOUN	O
ester	I-Chemical	NOUN	O
:	O	PUNCT	O
a	O	DET	O
potential	O	ADJ	B
protector	O	NOUN	B
against	O	ADP	O
gentamicin	B-Chemical	NOUN	B
ototoxicity	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
nitric	B-Chemical	ADJ	B
oxide	I-Chemical	NOUN	I
(	O	PUNCT	O
NO	B-Chemical	NOUN	B
)	O	PUNCT	O
inhibitor	O	NOUN	B
nitro-L-arginine	B-Chemical	NOUN	B
methyl	I-Chemical	NOUN	I
ester	I-Chemical	NOUN	I
(	O	PUNCT	O
L-NAME	B-Chemical	NOUN	B
)	O	PUNCT	O
may	O	AUX	O
act	O	VERB	O
as	O	ADP	O
an	O	DET	O
otoprotectant	O	NOUN	B
against	O	ADP	O
high-frequency	B-Disease	ADJ	B
hearing	I-Disease	NOUN	I
loss	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
gentamicin	B-Chemical	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
further	O	ADJ	O
studies	O	NOUN	B
are	O	AUX	O
needed	O	VERB	O
to	O	PART	O
confirm	O	VERB	B
this	O	DET	O
.	O	PUNCT	O


Aminoglycoside	B-Chemical	NOUN	B
antibiotics	O	NOUN	I
are	O	AUX	O
still	O	ADV	O
widely	O	ADV	O
used	O	VERB	O
by	O	ADP	O
virtue	O	NOUN	O
of	O	ADP	O
their	O	PRON	O
efficacy	O	NOUN	B
and	O	CCONJ	O
low	O	ADJ	B
cost	O	NOUN	B
.	O	PUNCT	O


Their	O	PRON	O
ototoxicity	B-Disease	NOUN	B
is	O	AUX	O
a	O	DET	O
serious	O	ADJ	O
health	O	NOUN	B
problem	O	NOUN	I
and	O	CCONJ	O
,	O	PUNCT	O
as	O	ADP	O
their	O	PRON	O
ototoxic	B-Disease	ADJ	B
mechanism	O	NOUN	O
involves	O	VERB	O
the	O	DET	O
production	O	NOUN	B
of	O	ADP	O
NO	B-Chemical	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
need	O	VERB	O
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
NO	B-Chemical	NOUN	B
inhibitors	O	NOUN	O
for	O	ADP	O
the	O	DET	O
prevention	O	NOUN	B
of	O	ADP	O
aminoglycoside	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
sensorineural	B-Disease	ADJ	B
hearing	I-Disease	NOUN	I
loss	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
experimental	O	ADJ	B
study	O	NOUN	I
we	O	PRON	O
used	O	VERB	O
30	O	NUM	O
Sprague	O	PROPN	B
-	O	PUNCT	O
Dawley	O	PROPN	B
rats	O	NOUN	B
,	O	PUNCT	O
27	O	NUM	O
of	O	ADP	O
which	O	DET	O
had	O	AUX	O
gentamicin	B-Chemical	NOUN	B
instilled	O	VERB	B
into	O	ADP	O
the	O	DET	O
middle	O	ADJ	B
ear	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
otoprotectant	O	ADJ	B
L-NAME	B-Chemical	NOUN	I
was	O	AUX	O
administered	O	VERB	B
topically	O	ADV	B
to	O	PART	O
12	O	NUM	O
/	O	SYM	O
27	O	NUM	O
animals	O	NOUN	B
.	O	PUNCT	O


Its	O	PRON	O
effect	O	NOUN	B
was	O	AUX	O
determined	O	VERB	O
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
attenuation	O	NOUN	B
of	O	ADP	O
hearing	B-Disease	VERB	B
loss	I-Disease	NOUN	I
,	O	PUNCT	O
measured	O	VERB	B
by	O	ADP	O
shifts	O	NOUN	B
in	O	ADP	O
the	O	DET	O
auditory	O	ADJ	B
brainstem	O	NOUN	B
response	O	NOUN	I
threshold	O	NOUN	B
.	O	PUNCT	O


L-NAME	B-Chemical	NOUN	B
reduced	O	VERB	B
gentamicin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hearing	B-Disease	NOUN	B
loss	I-Disease	NOUN	I


Cerebral	B-Disease	ADJ	B
vasculitis	I-Disease	NOUN	I
following	O	VERB	O
oral	O	ADJ	B
methylphenidate	B-Chemical	NOUN	O
intake	O	NOUN	B
in	O	ADP	O
an	O	DET	O
adult	O	NOUN	B
:	O	PUNCT	O
a	O	DET	O
case	O	NOUN	B
report	O	NOUN	I
.	O	PUNCT	O


Methylphenidate	B-Chemical	NOUN	B
is	O	AUX	O
structurally	O	ADV	B
and	O	CCONJ	O
functionally	O	ADV	O
similar	O	ADJ	O
to	O	PART	O
amphetamine	B-Chemical	NOUN	B
.	O	PUNCT	O


Cerebral	B-Disease	ADJ	B
vasculitis	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
amphetamine	B-Disease	NOUN	B
abuse	I-Disease	NOUN	I
is	O	AUX	O
well	O	ADV	O
documented	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
rare	O	ADJ	B
cases	O	NOUN	B
ischaemic	B-Disease	ADJ	B
stroke	I-Disease	NOUN	I
has	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
after	O	ADP	O
methylphenidate	B-Chemical	NOUN	B
intake	O	NOUN	I
in	O	ADP	O
children	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
the	O	DET	O
case	O	NOUN	B
of	O	ADP	O
a	O	DET	O
63	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
female	O	NOUN	B
who	O	PRON	O
was	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
methylphenidate	B-Chemical	NOUN	B
due	O	ADP	O
to	O	ADP	O
hyperactivity	B-Disease	NOUN	B
and	O	CCONJ	O
suffered	O	VERB	O
from	O	ADP	O
multiple	O	ADJ	B
ischaemic	B-Disease	ADJ	B
strokes	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
consider	O	VERB	O
drug	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cerebral	B-Disease	ADJ	B
vasculitis	I-Disease	NOUN	I
as	O	ADP	O
the	O	DET	O
most	O	ADV	O
likely	O	ADJ	O
cause	O	NOUN	O
of	O	ADP	O
recurrent	O	ADJ	B
ischaemic	B-Disease	ADJ	B
strokes	I-Disease	NOUN	I
in	O	ADP	O
the	O	DET	O
absence	O	NOUN	B
of	O	ADP	O
any	O	DET	O
pathological	O	ADJ	B
findings	O	NOUN	B
during	O	ADP	O
the	O	DET	O
diagnostic	O	ADJ	B
work	O	NOUN	O
-	O	PUNCT	O
up	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
methylphenidate	B-Chemical	NOUN	B
mediated	O	ADJ	O
vasculitis	B-Disease	NOUN	B
should	O	AUX	O
be	O	AUX	O
considered	O	VERB	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
neurological	O	ADJ	B
symptoms	O	NOUN	I
and	O	CCONJ	O
a	O	DET	O
history	O	NOUN	B
of	O	ADP	O
methylphenidate	B-Chemical	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
potential	O	ADJ	B
side	O	NOUN	B
-	O	PUNCT	O
effect	O	NOUN	B
,	O	PUNCT	O
though	O	SCONJ	O
very	O	ADV	O
rare	O	ADJ	B
,	O	PUNCT	O
represents	O	VERB	O
one	O	NUM	O
more	O	ADJ	O
reason	O	NOUN	O
to	O	PART	O
be	O	AUX	O
very	O	ADV	O
restrictive	O	ADJ	B
in	O	ADP	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
methylphenidate	B-Chemical	NOUN	B


Cerebral	B-Disease	ADJ	B
haemorrhage	I-Disease	NOUN	I
induced	O	VERB	B
by	O	ADP	O
warfarin	B-Chemical	NOUN	B
-	O	PUNCT	O
the	O	DET	O
influence	O	NOUN	B
of	O	ADP	O
drug	O	NOUN	B
-	O	PUNCT	O
drug	O	NOUN	B
interactions	O	NOUN	B
.	O	PUNCT	O


PURPOSE	O	NOUN	B
:	O	PUNCT	O
To	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
frequency	O	NOUN	B
,	O	PUNCT	O
severity	O	NOUN	B
and	O	CCONJ	O
preventability	O	NOUN	B
of	O	ADP	O
warfarin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cerebral	B-Disease	ADJ	B
haemorrhages	I-Disease	NOUN	I
due	O	ADJ	O
to	O	ADP	O
warfarin	B-Chemical	NOUN	B
and	O	CCONJ	O
warfarin	B-Chemical	NOUN	B
-	O	PUNCT	O
drug	O	NOUN	B
interactions	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
living	O	VERB	B
in	O	ADP	O
the	O	DET	O
county	O	NOUN	B
of	O	ADP	O
Osterg	O	PROPN	B
tland	O	NOUN	I
,	O	PUNCT	O
Sweden	O	PROPN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
All	O	DET	O
patients	O	NOUN	B
with	O	ADP	O
a	O	DET	O
diagnosed	O	ADJ	B
cerebral	B-Disease	ADJ	B
haemorrhage	I-Disease	NOUN	I
at	O	ADP	O
three	O	NUM	O
hospitals	O	NOUN	B
during	O	ADP	O
the	O	DET	O
period	O	NOUN	B
2000	O	NUM	O
-	O	SYM	O
2002	O	NUM	O
were	O	AUX	O
identified	O	VERB	B
.	O	PUNCT	O


Medical	O	ADJ	B
records	O	NOUN	I
were	O	AUX	O
studied	O	VERB	O
retrospectively	O	ADV	B
to	O	PART	O
evaluate	O	VERB	B
whether	O	SCONJ	O
warfarin	B-Chemical	NOUN	B
and	O	CCONJ	O
warfarin	B-Chemical	NOUN	B
-	O	PUNCT	O
drug	O	NOUN	B
interactions	O	NOUN	B
could	O	AUX	O
have	O	AUX	O
caused	O	VERB	O
the	O	DET	O
cerebral	B-Disease	ADJ	B
haemorrhage	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
proportion	O	NOUN	B
of	O	ADP	O
possibly	O	ADV	O
avoidable	O	ADJ	B
cases	O	NOUN	B
due	O	ADJ	O
to	O	PART	O
drug	O	NOUN	B
interactions	O	NOUN	I
was	O	AUX	O
estimated	O	VERB	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Among	O	ADP	O
593	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
cerebral	B-Disease	ADJ	B
haemorrhage	I-Disease	NOUN	I
,	O	PUNCT	O
59	O	NUM	O
(	O	PUNCT	O
10	O	NUM	O
%)	O	NOUN	O
were	O	AUX	O
assessed	O	VERB	B
as	O	ADP	O
related	O	ADJ	O
to	O	PART	O
warfarin	B-Chemical	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
imply	O	VERB	O
an	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
1	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
/	O	SYM	O
100	O	NUM	O
,	O	PUNCT	O
000	O	NUM	O
treatment	O	NOUN	B
years	O	NOUN	O
.	O	PUNCT	O


Of	O	ADP	O
the	O	DET	O
59	O	NUM	O
cases	O	NOUN	B
,	O	PUNCT	O
26	O	NUM	O
(	O	PUNCT	O
44	O	NUM	O
%)	O	NOUN	O
had	O	AUX	O
a	O	DET	O
fatal	O	ADJ	B
outcome	O	NOUN	B
,	O	PUNCT	O
compared	O	VERB	O
to	O	PART	O
136	O	NUM	O
(	O	PUNCT	O
25	O	NUM	O
%)	O	NOUN	O
among	O	ADP	O
the	O	DET	O
non	O	ADJ	B
-	O	PUNCT	O
warfarin	B-Chemical	NOUN	B
patients	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
).	O	PUNCT	O
A	O	NOUN	O
warfarin	B-Chemical	NOUN	B
-	O	PUNCT	O
drug	O	NOUN	B
interaction	O	NOUN	B
could	O	AUX	O
have	O	AUX	O
contributed	O	VERB	O
to	O	ADP	O
the	O	DET	O
haemorrhage	B-Disease	NOUN	B
in	O	ADP	O
24	O	NUM	O
(	O	PUNCT	O
41	O	NUM	O
%)	O	NOUN	O
of	O	ADP	O
the	O	DET	O
warfarin	B-Chemical	NOUN	B
patients	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
7	O	NUM	O
of	O	ADP	O
these	O	DET	O
(	O	PUNCT	O
12	O	NUM	O
%)	O	INTJ	O
the	O	DET	O
bleeding	B-Disease	ADJ	B
complication	O	NOUN	B
was	O	AUX	O
considered	O	VERB	O
being	O	AUX	O
possible	O	ADJ	O
to	O	PART	O
avoid	O	VERB	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
Warfarin	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
cerebral	B-Disease	ADJ	B
haemorrhages	I-Disease	NOUN	I
are	O	AUX	O
a	O	DET	O
major	O	ADJ	O
clinical	O	ADJ	B
problem	O	NOUN	I
with	O	ADP	O
a	O	DET	O
high	O	ADJ	O
fatality	O	NOUN	B
rate	O	NOUN	I
.	O	PUNCT	O


Almost	O	ADV	O
half	O	NOUN	O
of	O	ADP	O
the	O	DET	O
cases	O	NOUN	B
was	O	AUX	O
related	O	ADJ	O
to	O	PART	O
a	O	DET	O
warfarin	B-Chemical	NOUN	B
-	O	PUNCT	O
drug	O	NOUN	B
interaction	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
significant	O	ADJ	O
proportion	O	NOUN	B
of	O	ADP	O
warfarin	B-Chemical	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
cerebral	B-Disease	ADJ	B
haemorrhages	I-Disease	NOUN	I
might	O	AUX	O
have	O	AUX	O
been	O	AUX	O
prevented	O	VERB	B
if	O	SCONJ	O
greater	O	ADJ	O
caution	O	NOUN	O
had	O	AUX	O
been	O	AUX	O
taken	O	VERB	O
when	O	SCONJ	O
prescribing	O	VERB	B
drugs	O	NOUN	B
known	O	VERB	O
to	O	PART	O
interact	O	VERB	B
with	O	ADP	O
warfarin	B-Chemical	NOUN	B


Side	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
postoperative	O	ADJ	B
administration	O	NOUN	B
of	O	ADP	O
methylprednisolone	B-Chemical	NOUN	B
and	O	CCONJ	O
gentamicin	B-Chemical	NOUN	B
into	O	ADP	O
the	O	DET	O
posterior	O	ADJ	B
sub	O	NOUN	I
-	O	PUNCT	O
Tenon	O	PROPN	B
'	O	PART	O
s	O	NOUN	O
space	O	NOUN	B
.	O	PUNCT	O


PURPOSE	O	NOUN	B
:	O	PUNCT	O
To	O	PART	O
assess	O	VERB	O
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
postoperative	O	ADJ	B
emetic	O	ADJ	B
side	O	NOUN	B
effects	O	NOUN	I
after	O	ADP	O
the	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
methylprednisolone	B-Chemical	NOUN	B
and	O	CCONJ	O
gentamicin	B-Chemical	NOUN	B
into	O	ADP	O
the	O	DET	O
posterior	O	ADJ	B
sub	O	NOUN	I
-	O	PUNCT	O
Tenon	O	PROPN	B
'	O	PART	O
s	O	NOUN	O
space	O	NOUN	B
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
routine	O	ADJ	B
cataract	B-Disease	NOUN	B
surgery	O	NOUN	I
.	O	PUNCT	O


SETTING	O	NOUN	B
:	O	PUNCT	O
St	O	PROPN	B
.	O	PUNCT	O


Luke	O	PROPN	B
'	O	PART	I
s	O	PROPN	I
Hospital	O	PROPN	B
,	O	PUNCT	O
Gwardamangia	O	PROPN	B
,	O	PUNCT	O
Malta	O	PROPN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
A	O	DET	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	NOUN	B
double	O	ADV	B
-	O	PUNCT	O
armed	O	ADJ	B
prospective	O	ADJ	B
study	O	NOUN	I
comprised	O	VERB	O
40	O	NUM	O
patients	O	NOUN	B
who	O	PRON	O
had	O	AUX	O
uneventful	O	ADJ	B
sutureless	O	NOUN	B
phacoemulsification	O	NOUN	B
under	O	ADP	O
sub	O	NOUN	B
-	O	PUNCT	O
Tenon	O	PROPN	B
'	O	PART	O
s	O	NOUN	O
local	O	ADJ	B
infiltration	O	NOUN	B
of	O	ADP	O
3	O	NUM	O
mL	O	NOUN	O
of	O	ADP	O
plain	O	ADJ	B
lignocaine	B-Chemical	NOUN	B
.	O	PUNCT	O


At	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
procedure	O	NOUN	B
,	O	PUNCT	O
Group	O	PROPN	B
A	O	PROPN	O
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
20	O	NUM	O
)	O	PUNCT	O
had	O	AUX	O
20	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mL	O	NOUN	O
of	O	ADP	O
methylprednisolone	B-Chemical	NOUN	B
and	O	CCONJ	O
10	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mL	O	NOUN	O
of	O	ADP	O
gentamicin	B-Chemical	NOUN	B
injected	O	VERB	B
into	O	ADP	O
the	O	DET	O
posterior	O	ADJ	B
sub	O	NOUN	I
-	O	PUNCT	O
Tenon	O	PROPN	B
'	O	PART	O
s	O	NOUN	O
space	O	NOUN	B
and	O	CCONJ	O
Group	O	PROPN	B
B	O	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
20	O	NUM	O
)	O	PUNCT	O
had	O	AUX	O
the	O	DET	O
same	O	ADJ	O
combination	O	NOUN	B
injected	O	VERB	B
into	O	ADP	O
the	O	DET	O
anterior	O	ADJ	B
sub	O	NOUN	B
-	O	PUNCT	O
Tenon	O	PROPN	B
'	O	PART	O
s	O	NOUN	O
space	O	NOUN	B
.	O	PUNCT	O


Postoperatively	O	ADV	B
,	O	PUNCT	O
all	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
assessed	O	VERB	B
for	O	ADP	O
symptoms	O	NOUN	B
of	O	ADP	O
nausea,	B-Disease	NOUN	B
vomiting	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
headache	B-Disease	NOUN	B
.	O	PUNCT	O


A	O	DET	O
chi	O	NOUN	B
-	O	PUNCT	O
square	O	ADJ	B
test	O	NOUN	I
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
statistical	O	ADJ	B
significance	O	NOUN	I
of	O	ADP	O
results	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Sixty	O	NUM	O
percent	O	NOUN	O
in	O	ADP	O
Group	O	PROPN	B
A	O	PROPN	O
developed	O	VERB	O
postoperative	B-Disease	ADJ	B
emetic	I-Disease	ADJ	B
symptoms	I-Disease	NOUN	I
,	O	PUNCT	O
headache	B-Disease	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
both	O	DET	O
;	O	PUNCT	O
1	O	NUM	O
patient	O	NOUN	B
in	O	ADP	O
Group	O	PROPN	B
B	O	NOUN	I
developed	O	VERB	O
symptoms	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
methylprednisolone	B-Chemical	NOUN	B
and	O	CCONJ	O
gentamicin	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
posterior	O	ADJ	B
sub	O	NOUN	I
-	O	PUNCT	O
Tenon	O	PROPN	B
'	O	PART	O
s	O	NOUN	O
space	O	NOUN	B
was	O	AUX	O
related	O	ADJ	O
to	O	PART	O
a	O	DET	O
high	O	ADJ	O
incidence	O	NOUN	B
of	O	ADP	O
side	O	NOUN	B
effects	O	NOUN	I
including	O	VERB	O
nausea,	B-Disease	NOUN	B
vomiting	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
headache	B-Disease	NOUN	B


Cardiac	O	PROPN	B
Angiography	O	PROPN	I
in	O	ADP	O
Renally	O	ADV	B
Impaired	O	ADJ	I
Patients	O	NOUN	B
(	O	PUNCT	O
CARE	O	NOUN	B
)	O	PUNCT	O
study	O	NOUN	B
:	O	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
double	O	ADJ	B
-	O	PUNCT	O
blind	O	NOUN	B
trial	O	NOUN	B
of	O	ADP	O
contrast	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
nephropathy	B-Disease	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
chronic	B-Disease	ADJ	B
kidney	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
No	O	DET	O
direct	O	ADJ	O
comparisons	O	NOUN	B
exist	O	VERB	O
of	O	ADP	O
the	O	DET	O
renal	O	ADJ	B
tolerability	O	NOUN	I
of	O	ADP	O
the	O	DET	O
low	O	ADJ	B
-	O	PUNCT	O
osmolality	O	NOUN	B
contrast	B-Chemical	NOUN	B
medium	I-Chemical	NOUN	I
iopamidol	B-Chemical	NOUN	B
with	O	ADP	O
that	O	DET	O
of	O	ADP	O
the	O	DET	O
iso	O	NOUN	B
-	O	PUNCT	O
osmolality	O	NOUN	B
contrast	B-Chemical	NOUN	B
medium	I-Chemical	NOUN	I
iodixanol	B-Chemical	NOUN	B
in	O	ADP	O
high	O	ADJ	B
-	O	PUNCT	O
risk	O	NOUN	B
patients	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
AND	O	CCONJ	O
RESULTS	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
is	O	AUX	O
a	O	DET	O
multicenter	O	NOUN	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	NOUN	B
comparison	O	NOUN	B
of	O	ADP	O
iopamidol	B-Chemical	NOUN	B
and	O	CCONJ	O
iodixanol	B-Chemical	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
chronic	B-Disease	ADJ	B
kidney	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
(	O	PUNCT	O
estimated	O	VERB	B
glomerular	O	ADJ	I
filtration	O	NOUN	I
rate	O	NOUN	I
,	O	PUNCT	O
20	O	NUM	O
to	O	PART	O
59	O	NUM	O
mL	O	NOUN	O
/	O	SYM	O
min	O	NOUN	B
)	O	PUNCT	O
who	O	PRON	O
underwent	O	VERB	O
cardiac	O	ADJ	B
angiography	O	NOUN	I
or	O	CCONJ	O
percutaneous	O	ADJ	B
coronary	O	ADJ	I
interventions	O	NOUN	I
.	O	PUNCT	O


Serum	O	NOUN	B
creatinine	B-Chemical	NOUN	I
(	O	PUNCT	O
SCr	O	NOUN	B
)	O	PUNCT	O
levels	O	NOUN	B
and	O	CCONJ	O
estimated	O	VERB	O
glomerular	O	ADJ	O
filtration	O	NOUN	O
rate	O	NOUN	O
were	O	AUX	O
assessed	O	VERB	B
at	O	ADP	O
baseline	O	NOUN	B
and	O	CCONJ	O
2	O	NUM	O
to	O	PART	O
5	O	NUM	O
days	O	NOUN	B
after	O	ADP	O
receiving	O	VERB	O
medications	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
primary	O	ADJ	B
outcome	O	NOUN	I
was	O	AUX	O
a	O	DET	O
postdose	O	NOUN	B
SCr	O	NOUN	B
increase	O	VERB	B
>	O	NOUN	O
or	O	CCONJ	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
dL	O	NOUN	B
(	O	PUNCT	O
44	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
micromol	O	NOUN	B
/	O	SYM	O
L	O	NOUN	B
)	O	PUNCT	O
over	O	ADP	O
baseline	O	NOUN	B
.	O	PUNCT	O


Secondary	O	ADJ	B
outcomes	O	NOUN	I
were	O	AUX	O
a	O	DET	O
postdose	O	NOUN	B
SCr	O	NOUN	B
increase	O	VERB	B
>	O	NOUN	O
or	O	CCONJ	O
=	O	ADJ	O
25	O	NUM	O
%,	O	NOUN	O
a	O	DET	O
postdose	O	NOUN	B
estimated	O	ADJ	O
glomerular	O	ADJ	O
filtration	O	NOUN	O
rate	O	NOUN	O
decrease	O	NOUN	B
of	O	ADP	O
>	O	NOUN	O
or	O	CCONJ	O
=	O	ADJ	O
25	O	NUM	O
%,	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
mean	O	ADJ	O
peak	O	NOUN	B
change	O	NOUN	I
in	O	ADP	O
SCr	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
414	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
contrast	O	NOUN	B
volume	O	NOUN	I
,	O	PUNCT	O
presence	O	NOUN	B
of	O	ADP	O
diabetes	B-Disease	NOUN	B
mellitus	I-Disease	NOUN	I
,	O	PUNCT	O
use	O	NOUN	O
of	O	ADP	O
N-acetylcysteine	B-Chemical	NOUN	B
,	O	PUNCT	O
mean	O	VERB	O
baseline	O	NOUN	B
SCr	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
estimated	O	VERB	B
glomerular	O	ADJ	I
filtration	O	NOUN	I
rate	O	NOUN	I
were	O	AUX	O
comparable	O	ADJ	O
in	O	ADP	O
the	O	DET	O
2	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


SCr	O	NOUN	B
increases	O	VERB	B
>	O	NOUN	O
or	O	CCONJ	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
dL	O	NOUN	B
occurred	O	VERB	O
in	O	ADP	O
4	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
%(	O	NOUN	O
9	O	NUM	O
of	O	ADP	O
204	O	NUM	O
patients	O	NOUN	B
)	O	PUNCT	O
after	O	ADP	O
iopamidol	B-Chemical	NOUN	B
and	O	CCONJ	O
6	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
%(	O	NOUN	O
14	O	NUM	O
of	O	ADP	O
210	O	NUM	O
patients	O	NOUN	B
)	O	PUNCT	O
after	O	ADP	O
iodixanol	B-Chemical	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


39	O	NUM	O
),	O	PUNCT	O
whereas	O	SCONJ	O
rates	O	NOUN	B
of	O	ADP	O
SCr	O	NOUN	B
increases	O	VERB	B
>	O	NOUN	O
or	O	CCONJ	O
=	O	ADJ	O
25	O	NUM	O
%	O	NOUN	O
were	O	AUX	O
9	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
12	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
%,	O	NOUN	B
respectively	O	ADV	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


44	O	NUM	O
).	O	PUNCT	B
In	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
diabetes	B-Disease	NOUN	B
,	O	PUNCT	O
SCr	O	NOUN	B
increases	O	VERB	B
>	O	NOUN	O
or	O	CCONJ	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
dL	O	NOUN	B
were	O	AUX	O
5	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
%(	O	NOUN	O
4	O	NUM	O
of	O	ADP	O
78	O	NUM	O
patients	O	NOUN	B
)	O	PUNCT	O
with	O	ADP	O
iopamidol	B-Chemical	NOUN	B
and	O	CCONJ	O
13	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
%(	O	NOUN	O
12	O	NUM	O
of	O	ADP	O
92	O	NUM	O
patients	O	NOUN	B
)	O	PUNCT	O
with	O	ADP	O
iodixanol	B-Chemical	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


11	O	NUM	O
),	O	PUNCT	O
whereas	O	SCONJ	O
SCr	O	NOUN	B
increases	O	VERB	B
>	O	NOUN	O
or	O	CCONJ	O
=	O	ADJ	O
25	O	NUM	O
%	O	NOUN	O
were	O	AUX	O
10	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
15	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
%,	O	NOUN	O
respectively	O	ADV	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


37	O	NUM	O
).	O	PUNCT	O
Mean	O	ADJ	O
post	O	NOUN	B
-	O	PUNCT	O
SCr	O	NOUN	B
increases	O	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
less	O	ADJ	O
with	O	ADP	O
iopamidol	B-Chemical	NOUN	B
(	O	PUNCT	O
all	O	DET	O
patients	O	NOUN	B
:	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


07	O	NUM	O
versus	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


12	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
dL	O	NOUN	B
,	O	PUNCT	O
6	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
versus	O	CCONJ	O
10	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
micromol	O	NOUN	B
/	O	SYM	O
L	O	NOUN	B
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


03	O	NUM	O
;	O	PUNCT	O
patients	O	NOUN	B
with	O	ADP	O
diabetes	B-Disease	NOUN	B
:	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


07	O	NUM	O
versus	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


16	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
dL	O	NOUN	B
,	O	PUNCT	O
6	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
versus	O	CCONJ	O
14	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
micromol	O	NOUN	B
/	O	SYM	O
L	O	NOUN	B
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
).	O	PUNCT	O
CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
rate	O	NOUN	B
of	O	ADP	O
contrast	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
nephropathy	B-Disease	NOUN	B
,	O	PUNCT	O
defined	O	VERB	O
by	O	ADP	O
multiple	O	ADJ	O
end	O	NOUN	O
points	O	NOUN	O
,	O	PUNCT	O
is	O	AUX	O
not	O	PART	O
statistically	O	ADV	O
different	O	ADJ	O
after	O	ADP	O
the	O	DET	O
intraarterial	O	ADJ	B
administration	O	NOUN	B
of	O	ADP	O
iopamidol	B-Chemical	NOUN	B
or	O	CCONJ	O
iodixanol	B-Chemical	NOUN	B
to	O	PART	O
high	O	ADJ	B
-	O	PUNCT	O
risk	O	NOUN	B
patients	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
or	O	CCONJ	O
without	O	ADP	O
diabetes	B-Disease	NOUN	B
mellitus	I-Disease	NOUN	I


A	O	DET	O
novel	O	ADJ	O
compound	O	NOUN	O
,	O	PUNCT	O
maltolyl	B-Chemical	ADJ	B
p-coumarate	I-Chemical	NOUN	B
,	O	PUNCT	O
attenuates	O	VERB	B
cognitive	B-Disease	ADJ	B
deficits	I-Disease	NOUN	I
and	O	CCONJ	O
shows	O	VERB	O
neuroprotective	O	ADJ	B
effects	O	NOUN	I
in	O	X	B
vitro	O	X	I
and	O	CCONJ	O
in	O	X	B
vivo	O	X	I
dementia	B-Disease	NOUN	B
models	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
develop	O	VERB	O
a	O	DET	O
novel	O	ADJ	B
and	O	CCONJ	O
effective	O	ADJ	B
drug	O	NOUN	B
that	O	PRON	O
could	O	AUX	O
enhance	O	VERB	O
cognitive	O	ADJ	B
function	O	NOUN	I
and	O	CCONJ	O
neuroprotection	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
newly	O	ADV	O
synthesized	O	VERB	B
maltolyl	B-Chemical	ADJ	B
p-coumarate	I-Chemical	NOUN	B
by	O	ADP	O
the	O	DET	O
esterification	O	NOUN	B
of	O	ADP	O
maltol	B-Chemical	NOUN	B
and	O	CCONJ	O
p-coumaric	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
investigated	O	VERB	B
whether	O	SCONJ	O
maltolyl	B-Chemical	ADJ	B
p-coumarate	I-Chemical	NOUN	B
could	O	AUX	O
improve	O	VERB	B
cognitive	B-Disease	ADJ	B
decline	I-Disease	NOUN	I
in	O	ADP	O
scopolamine	B-Chemical	NOUN	B
-	O	PUNCT	O
injected	O	VERB	B
rats	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
amyloid	B-Chemical	NOUN	B
beta	I-Chemical	NOUN	I
peptide(1-42)	I-Chemical	NUM	B
-	O	PUNCT	O
infused	O	VERB	B
rats	O	NOUN	B
.	O	PUNCT	O


Maltolyl	B-Chemical	PROPN	B
p-coumarate	I-Chemical	NOUN	I
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
attenuate	O	VERB	B
cognitive	B-Disease	ADJ	B
deficits	I-Disease	NOUN	I
in	O	ADP	O
both	O	DET	O
rat	O	NOUN	B
models	O	NOUN	B
using	O	VERB	O
passive	O	ADJ	B
avoidance	O	NOUN	I
test	O	NOUN	I
and	O	CCONJ	O
to	O	PART	O
reduce	O	VERB	B
apoptotic	O	ADJ	B
cell	O	NOUN	I
death	O	NOUN	O
observed	O	VERB	O
in	O	ADP	O
the	O	DET	O
hippocampus	O	NOUN	B
of	O	ADP	O
the	O	DET	O
amyloid	B-Chemical	NOUN	B
beta	I-Chemical	NOUN	I
peptide(1-42)	I-Chemical	NUM	B
-	O	PUNCT	O
infused	O	VERB	B
rats	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
also	O	ADV	O
examined	O	VERB	O
the	O	DET	O
neuroprotective	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
maltolyl	B-Chemical	ADJ	B
p-coumarate	I-Chemical	NOUN	B
in	O	X	B
vitro	O	X	I
using	O	VERB	O
SH	O	NOUN	B
-	O	PUNCT	O
SY5Y	O	NOUN	B
cells	O	NOUN	O
.	O	PUNCT	O


Cells	O	NOUN	B
were	O	AUX	O
pretreated	O	VERB	B
with	O	ADP	O
maltolyl	B-Chemical	ADJ	B
p-coumarate	I-Chemical	NOUN	I
,	O	PUNCT	O
before	O	ADP	O
exposed	O	VERB	O
to	O	PART	O
amyloid	B-Chemical	NOUN	B
beta	I-Chemical	NOUN	I
peptide(1-42)	I-Chemical	NOUN	B
,	O	PUNCT	O
glutamate	B-Chemical	NOUN	B
or	O	CCONJ	O
H2O2	B-Chemical	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
found	O	VERB	O
that	O	SCONJ	O
maltolyl	B-Chemical	ADJ	B
p-coumarate	I-Chemical	NOUN	B
significantly	O	ADV	O
decreased	O	VERB	B
apoptotic	O	ADJ	B
cell	O	NOUN	I
death	O	NOUN	O
and	O	CCONJ	O
reduced	O	VERB	B
reactive	O	ADJ	B
oxygen	O	NOUN	I
species	O	NOUN	I
,	O	PUNCT	O
cytochrome	O	NOUN	B
c	O	NOUN	I
release	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
caspase	O	NOUN	B
3	O	NUM	I
activation	O	NOUN	B
.	O	PUNCT	O


Taking	O	VERB	O
these	O	DET	O
in	O	X	B
vitro	O	X	I
and	O	CCONJ	O
in	O	X	B
vivo	O	X	I
results	O	VERB	B
together	O	ADV	O
,	O	PUNCT	O
our	O	PRON	O
study	O	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
maltolyl	B-Chemical	ADJ	B
p-coumarate	I-Chemical	NOUN	B
is	O	AUX	O
a	O	DET	O
potentially	O	ADV	O
effective	O	ADJ	B
candidate	O	NOUN	O
against	O	ADP	O
Alzheimer's	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
that	O	PRON	O
is	O	AUX	O
characterized	O	VERB	B
by	O	ADP	O
wide	O	ADJ	O
spread	O	NOUN	B
neuronal	B-Disease	ADJ	B
death	I-Disease	NOUN	I
and	O	CCONJ	O
progressive	O	ADJ	B
decline	B-Disease	NOUN	B
of	I-Disease	ADP	O
cognitive	I-Disease	ADJ	B
function	I-Disease	NOUN	I


Interaction	O	NOUN	B
between	O	ADP	O
warfarin	B-Chemical	NOUN	B
and	O	CCONJ	O
levofloxacin	B-Chemical	NOUN	B
:	O	PUNCT	O
case	O	NOUN	B
series	O	NOUN	I
.	O	PUNCT	O


Warfarin	B-Chemical	NOUN	B
is	O	AUX	O
the	O	DET	O
most	O	ADV	O
widely	O	ADV	O
used	O	VERB	O
oral	O	ADJ	B
anticoagulant	O	NOUN	B
and	O	CCONJ	O
is	O	AUX	O
indicated	O	VERB	O
for	O	ADP	O
many	O	ADJ	O
clinical	O	ADJ	B
conditions	O	NOUN	I
.	O	PUNCT	O


Levofloxacin	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
fluoroquinolone	B-Chemical	NOUN	B
,	O	PUNCT	O
is	O	AUX	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
most	O	ADV	O
commonly	O	ADV	O
prescribed	O	VERB	B
antibiotics	O	NOUN	B
in	O	ADP	O
clinical	O	ADJ	B
practice	O	NOUN	I
and	O	CCONJ	O
is	O	AUX	O
effective	O	ADJ	B
against	O	ADP	O
Gram	O	X	B
-	O	PUNCT	O
positive	O	ADJ	B
,	O	PUNCT	O
Gram	O	PROPN	B
-	O	PUNCT	O
negative	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
atypical	O	ADJ	B
bacteria	O	NOUN	B
.	O	PUNCT	O


While	O	SCONJ	O
small	O	ADJ	O
prospective	O	ADJ	B
studies	O	NOUN	I
have	O	AUX	O
not	O	PART	O
revealed	O	VERB	O
any	O	DET	O
significant	O	ADJ	B
drug	O	NOUN	B
-	O	PUNCT	O
drug	O	NOUN	B
interaction	O	NOUN	B
between	O	ADP	O
warfarin	B-Chemical	NOUN	B
and	O	CCONJ	O
levofloxacin	B-Chemical	NOUN	B
,	O	PUNCT	O
several	O	ADJ	O
case	O	NOUN	B
reports	O	NOUN	I
have	O	AUX	O
indicated	O	VERB	O
that	O	SCONJ	O
levofloxacin	B-Chemical	NOUN	B
may	O	AUX	O
significantly	O	ADV	O
potentiate	O	VERB	B
the	O	DET	O
anticoagulation	O	NOUN	B
effect	O	NOUN	I
of	O	ADP	O
warfarin	B-Chemical	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
3	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
serious	O	ADJ	O
bleeding	B-Disease	NOUN	B
complications	O	NOUN	B
that	O	PRON	O
appear	O	VERB	O
to	O	PART	O
be	O	AUX	O
the	O	DET	O
result	O	NOUN	O
of	O	ADP	O
the	O	DET	O
interaction	O	NOUN	B
between	O	ADP	O
warfarin	B-Chemical	NOUN	B
and	O	CCONJ	O
levofloxacin	B-Chemical	NOUN	B
.	O	PUNCT	O


Physicians	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
aware	O	ADJ	O
of	O	ADP	O
this	O	DET	O
potential	O	ADJ	B
interaction	O	NOUN	B
and	O	CCONJ	O
use	O	VERB	O
caution	O	NOUN	O
when	O	SCONJ	O
prescribing	O	VERB	B
levofloxacin	B-Chemical	NOUN	B
to	O	ADP	O
patients	O	NOUN	B
taking	O	VERB	O
warfarin	B-Chemical	NOUN	B


Mutations	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
lamivudine	B-Chemical	NOUN	B
-	O	PUNCT	O
resistance	O	NOUN	B
in	O	ADP	O
therapy	O	NOUN	B
-	O	PUNCT	O
na	B-Chemical	NOUN	B
ve	O	ADP	O
hepatitis	B-Disease	NOUN	B
B	I-Disease	NOUN	I
virus	I-Disease	NOUN	I
(HBV)	I-Disease	ADJ	O
infected	I-Disease	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
and	O	CCONJ	O
without	O	ADP	O
HIV	B-Disease	NOUN	B
co-infection	I-Disease	NOUN	B
:	O	PUNCT	O
implications	O	NOUN	O
for	O	ADP	O
antiretroviral	O	ADJ	B
therapy	O	NOUN	I
in	O	ADP	O
HBV	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
HIV	I-Disease	NOUN	B
co-infected	I-Disease	VERB	B
South	O	ADJ	B
African	O	ADJ	I
patients	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
was	O	AUX	O
an	O	DET	O
exploratory	O	ADJ	B
study	O	NOUN	I
to	O	PART	O
investigate	O	VERB	B
lamivudine	B-Chemical	NOUN	B
-	O	PUNCT	O
resistant	O	ADJ	B
hepatitis	B-Disease	NOUN	B
B	I-Disease	NOUN	I
virus	O	NOUN	I
(	O	PUNCT	O
HBV	O	NOUN	B
)	O	PUNCT	O
strains	O	NOUN	B
in	O	ADP	O
selected	O	VERB	O
lamivudine	B-Chemical	NOUN	B
-	O	PUNCT	O
na	B-Chemical	PART	B
ve	O	ADP	O
HBV	O	NOUN	B
carriers	O	NOUN	B
with	O	ADP	O
and	O	CCONJ	O
without	O	ADP	O
human	B-Disease	ADJ	B
immunodeficiency	I-Disease	NOUN	I
virus	I-Disease	NOUN	I
(HIV)	I-Disease	NOUN	O
co-infection	I-Disease	NOUN	B
in	O	ADP	O
South	O	ADJ	B
African	O	ADJ	I
patients	O	NOUN	B
.	O	PUNCT	O


Thirty	O	NUM	B
-	O	PUNCT	O
five	O	NUM	B
lamivudine	B-Chemical	NOUN	B
-	O	PUNCT	O
na	B-Chemical	NOUN	B
ve	O	X	O
HBV	B-Disease	NOUN	B
infected	I-Disease	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
or	O	CCONJ	O
without	O	ADP	O
HIV	B-Disease	NOUN	B
co-infection	I-Disease	NOUN	B
were	O	AUX	O
studied	O	VERB	O
:	O	PUNCT	O
15	O	NUM	O
chronic	O	ADJ	B
HBV	B-Disease	NOUN	B
mono-infected	I-Disease	ADJ	B
patients	O	NOUN	B
and	O	CCONJ	O
20	O	NUM	O
HBV-HIV	B-Disease	NOUN	B
co-infected	I-Disease	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
latter	O	ADJ	O
group	O	NOUN	B
was	O	AUX	O
further	O	ADV	O
sub	O	ADV	B
-	O	PUNCT	O
divided	O	VERB	B
into	O	ADP	O
13	O	NUM	O
occult	O	NOUN	B
HBV	O	NOUN	B
(	O	PUNCT	O
HBsAg	B-Chemical	NOUN	B
-	O	PUNCT	O
negative	O	ADJ	B
)	O	PUNCT	O
and	O	CCONJ	O
7	O	NUM	O
overt	O	ADJ	B
HBV	O	NOUN	B
(	O	PUNCT	O
HBsAg	B-Chemical	NOUN	B
-	O	PUNCT	O
positive	O	ADJ	B
)	O	PUNCT	O
patients	O	NOUN	B
.	O	PUNCT	O


HBsAg	B-Chemical	NOUN	B
,	O	PUNCT	O
anti	O	ADJ	B
-	O	PUNCT	O
HBs	O	NOUN	B
,	O	PUNCT	O
anti	O	ADJ	B
-	O	PUNCT	O
HBc	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
anti	O	ADJ	B
-	O	PUNCT	O
HIV	O	NOUN	B
1	O	NUM	O
/	O	SYM	O
2	O	NUM	B
were	O	AUX	O
determined	O	VERB	O
as	O	ADP	O
part	O	NOUN	O
of	O	ADP	O
routine	O	ADJ	B
diagnosis	O	NOUN	I
using	O	VERB	O
Axsym	O	NOUN	B
assays	O	NOUN	I
(	O	PUNCT	O
Abbott	O	PROPN	B
Laboratories	O	PROPN	I
,	O	PUNCT	O
North	O	PROPN	B
Chicago	O	PROPN	I
,	O	PUNCT	O
IL	O	NOUN	B
).	O	PUNCT	O
Serum	O	NOUN	B
samples	O	NOUN	I
were	O	AUX	O
PCR	O	NOUN	B
amplified	O	VERB	O
with	O	ADP	O
HBV	O	NOUN	B
reverse	O	NOUN	I
transcriptase	O	NOUN	I
(	O	PUNCT	O
RT	O	NOUN	O
)	O	PUNCT	O
primers	O	NOUN	O
,	O	PUNCT	O
followed	O	VERB	O
by	O	ADP	O
direct	O	ADJ	O
sequencing	O	NOUN	O
across	O	ADP	O
the	O	DET	O
tyrosine	B-Chemical	NOUN	B
-	O	PUNCT	O
methionine	B-Chemical	NOUN	B
-	O	PUNCT	O
aspartate	B-Chemical	NOUN	B
-	O	PUNCT	O
aspartate	B-Chemical	NOUN	B
(	O	PUNCT	O
YMDD	O	NOUN	B
)	O	PUNCT	O
motif	O	NOUN	B
of	O	ADP	O
the	O	DET	O
major	O	ADJ	O
catalytic	O	ADJ	B
region	O	NOUN	I
in	O	ADP	O
the	O	DET	O
C	O	NOUN	B
domain	O	NOUN	I
of	O	ADP	O
the	O	DET	O
HBV	O	NOUN	B
RT	O	NOUN	O
enzyme	O	NOUN	O
.	O	PUNCT	O


HBV	O	NOUN	B
viral	O	ADJ	B
load	O	NOUN	I
was	O	AUX	O
performed	O	VERB	O
with	O	ADP	O
Amplicor	O	NOUN	B
HBV	O	NOUN	I
Monitor	O	PROPN	I
test	O	VERB	I
v2	O	NOUN	I
.	O	PUNCT	O


0	O	NUM	O
(	O	PUNCT	O
Roche	O	PROPN	B
Diagnostics	O	PROPN	I
,	O	PUNCT	O
Penzberg	O	PROPN	B
,	O	PUNCT	O
Germany	O	PROPN	B
).	O	PUNCT	O
HBV	O	NOUN	O
lamivudine	B-Chemical	NOUN	B
-	O	PUNCT	O
resistant	O	ADJ	B
strains	O	NOUN	B
were	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
3	O	NUM	O
of	O	ADP	O
15	O	NUM	O
mono	O	NOUN	B
-	O	PUNCT	O
infected	O	ADJ	B
chronic	O	ADJ	B
hepatitis	B-Disease	NOUN	I
B	I-Disease	NOUN	I
patients	O	NOUN	B
and	O	CCONJ	O
10	O	NUM	O
of	O	ADP	O
20	O	NUM	O
HBV-HIV	B-Disease	NOUN	B
co-infected	I-Disease	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O


To	O	ADP	O
the	O	DET	O
best	O	ADJ	O
of	O	ADP	O
our	O	PRON	O
knowledge	O	NOUN	B
,	O	PUNCT	O
this	O	DET	O
constitutes	O	VERB	O
the	O	DET	O
first	O	ADJ	O
report	O	NOUN	O
of	O	ADP	O
HBV	O	NOUN	B
lamivudine	B-Chemical	NOUN	I
-	O	PUNCT	O
resistant	O	ADJ	B
strains	O	NOUN	B
in	O	ADP	O
therapy	O	NOUN	B
-	O	PUNCT	O
na	B-Chemical	NOUN	B
ve	O	X	O
HBV-HIV	B-Disease	NOUN	B
co-infected	I-Disease	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
HBV	O	NOUN	B
viral	O	ADJ	B
loads	O	NOUN	I
for	O	ADP	O
mono	O	NOUN	B
-	O	PUNCT	O
infected	O	ADJ	B
and	O	CCONJ	O
co	O	X	B
-	O	PUNCT	O
infected	O	VERB	B
patients	O	NOUN	B
ranged	O	VERB	O
from	O	ADP	O
3	O	NUM	O
.	O	PUNCT	O


32	O	NUM	O
x	O	CCONJ	O
10	O	NUM	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
to	O	PART	O
3	O	NUM	O
.	O	PUNCT	O


82	O	NUM	O
x	O	NOUN	O
10	O	NUM	O
(	O	PUNCT	O
7	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
<	O	X	O
200	O	NUM	O
to	O	PART	O
4	O	NUM	O
.	O	PUNCT	O


40	O	NUM	O
x	O	NOUN	O
10	O	NUM	O
(	O	PUNCT	O
3	O	NUM	O
)	O	PUNCT	O
copies	O	NOUN	B
/	O	SYM	O
ml	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


It	O	PRON	O
remains	O	VERB	O
to	O	PART	O
be	O	AUX	O
seen	O	VERB	O
whether	O	SCONJ	O
such	O	ADJ	O
pre	O	NOUN	B
-	O	PUNCT	O
existing	O	VERB	B
antiviral	O	ADJ	B
mutations	O	NOUN	I
could	O	AUX	O
result	O	VERB	O
in	O	ADP	O
widespread	O	ADJ	B
emergence	O	NOUN	B
of	O	ADP	O
HBV	O	NOUN	B
resistant	O	ADJ	B
strains	O	NOUN	O
when	O	SCONJ	O
lamivudine	B-Chemical	NOUN	B
-	O	PUNCT	O
containing	O	VERB	B
highly	O	ADV	O
active	O	ADJ	O
antiretroviral	O	ADJ	B
(	O	PUNCT	O
ARV	O	NOUN	B
)	O	PUNCT	O
treatment	O	NOUN	B
(	O	PUNCT	O
HAART	O	NOUN	B
)	O	PUNCT	O
regimens	O	NOUN	B
become	O	VERB	O
widely	O	ADV	O
applied	O	VERB	O
in	O	ADP	O
South	O	PROPN	B
Africa	O	PROPN	I
,	O	PUNCT	O
as	O	ADP	O
this	O	DET	O
is	O	AUX	O
likely	O	ADJ	O
to	O	PART	O
have	O	AUX	O
potential	O	ADJ	O
implications	O	NOUN	O
in	O	ADP	O
the	O	DET	O
management	O	NOUN	B
of	O	ADP	O
HBV-HIV	B-Disease	NOUN	B
co-infected	I-Disease	VERB	B


Sex	O	NOUN	B
differences	O	NOUN	B
in	O	ADP	O
NMDA	B-Chemical	NOUN	B
antagonist	O	NOUN	B
enhancement	O	NOUN	B
of	O	ADP	O
morphine	B-Chemical	NOUN	B
antihyperalgesia	O	NOUN	B
in	O	ADP	O
a	O	DET	O
capsaicin	B-Chemical	NOUN	B
model	O	NOUN	B
of	O	ADP	O
persistent	O	ADJ	B
pain	B-Disease	NOUN	I
:	O	PUNCT	O
comparisons	O	NOUN	B
to	O	PART	O
two	O	NUM	O
models	O	NOUN	B
of	O	ADP	O
acute	B-Disease	ADJ	B
pain	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
acute	B-Disease	ADJ	B
pain	I-Disease	NOUN	I
models	O	NOUN	I
,	O	PUNCT	O
N-methyl-D-aspartate	B-Chemical	NOUN	B
(	O	PUNCT	O
NMDA	B-Chemical	NOUN	B
)	O	PUNCT	O
antagonists	O	NOUN	B
enhance	O	VERB	O
the	O	DET	O
antinociceptive	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
morphine	B-Chemical	NOUN	B
to	O	PART	O
a	O	DET	O
greater	O	ADJ	O
extent	O	NOUN	O
in	O	ADP	O
males	O	NOUN	B
than	O	ADP	O
females	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
this	O	DET	O
investigation	O	NOUN	B
was	O	AUX	O
to	O	PART	O
extend	O	VERB	O
these	O	DET	O
findings	O	NOUN	B
to	O	PART	O
a	O	DET	O
persistent	O	ADJ	B
pain	B-Disease	NOUN	I
model	O	NOUN	O
which	O	DET	O
could	O	AUX	O
be	O	AUX	O
distinguished	O	VERB	O
from	O	ADP	O
acute	B-Disease	ADJ	B
pain	I-Disease	NOUN	I
models	O	NOUN	I
on	O	ADP	O
the	O	DET	O
basis	O	NOUN	O
of	O	ADP	O
the	O	DET	O
nociceptive	O	ADJ	B
fibers	O	NOUN	I
activated	O	VERB	B
,	O	PUNCT	O
neurochemical	O	ADJ	B
substrates	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
duration	O	NOUN	B
of	O	ADP	O
the	O	DET	O
nociceptive	O	ADJ	B
stimulus	O	NOUN	B
.	O	PUNCT	O


To	O	ADP	O
this	O	DET	O
end	O	NOUN	O
,	O	PUNCT	O
persistent	O	ADJ	B
hyperalgesia	B-Disease	NOUN	B
was	O	AUX	O
induced	O	VERB	B
by	O	ADP	O
administration	O	NOUN	B
of	O	ADP	O
capsaicin	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
tail	O	NOUN	B
of	O	ADP	O
gonadally	O	ADV	B
intact	O	ADJ	O
F344	O	NOUN	B
rats	O	NOUN	B
,	O	PUNCT	O
following	O	VERB	O
which	O	DET	O
the	O	DET	O
tail	O	NOUN	B
was	O	AUX	O
immersed	O	VERB	O
in	O	ADP	O
a	O	DET	O
mildly	O	ADV	B
noxious	O	ADJ	B
thermal	O	ADJ	B
stimulus	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
tail	O	NOUN	B
-	O	PUNCT	O
withdrawal	O	NOUN	B
latencies	O	NOUN	B
measured	O	VERB	B
.	O	PUNCT	O


For	O	ADP	O
comparison	O	NOUN	B
,	O	PUNCT	O
tests	O	NOUN	B
were	O	AUX	O
conducted	O	VERB	O
in	O	ADP	O
two	O	NUM	O
acute	B-Disease	ADJ	B
pain	I-Disease	NOUN	I
models	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
hotplate	O	NOUN	B
and	O	CCONJ	O
warm	O	ADJ	B
water	O	NOUN	I
tail	O	NOUN	B
-	O	PUNCT	O
withdrawal	O	NOUN	B
procedures	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
males	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
non	O	ADJ	B
-	O	PUNCT	O
competitive	O	ADJ	B
NMDA	B-Chemical	NOUN	B
antagonist	O	NOUN	B
dextromethorphan	B-Chemical	NOUN	B
enhanced	O	VERB	B
the	O	DET	O
antihyperalgesic	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
low	O	ADJ	O
to	O	PART	O
moderate	O	ADJ	B
doses	O	NOUN	B
of	O	ADP	O
morphine	B-Chemical	NOUN	B
in	O	ADP	O
a	O	DET	O
dose	O	NOUN	B
-	O	PUNCT	O
and	O	CCONJ	O
time	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
manner	O	NOUN	O
.	O	PUNCT	O


Across	O	ADP	O
the	O	DET	O
doses	O	NOUN	B
and	O	CCONJ	O
pretreatment	O	NOUN	B
times	O	NOUN	O
examined	O	VERB	B
,	O	PUNCT	O
enhancement	O	NOUN	B
was	O	AUX	O
not	O	PART	O
observed	O	VERB	O
in	O	ADP	O
females	O	NOUN	B
.	O	PUNCT	O


Enhancement	O	NOUN	B
of	O	ADP	O
morphine	B-Chemical	NOUN	B
antinociception	O	NOUN	B
by	O	ADP	O
dextromethorphan	B-Chemical	NOUN	B
was	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
both	O	DET	O
males	O	NOUN	B
and	O	CCONJ	O
females	O	NOUN	B
in	O	ADP	O
the	O	DET	O
acute	B-Disease	ADJ	B
pain	I-Disease	NOUN	I
models	O	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
the	O	DET	O
magnitude	O	NOUN	B
of	O	ADP	O
this	O	DET	O
effect	O	NOUN	B
being	O	AUX	O
greater	O	ADJ	O
in	O	ADP	O
males	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
demonstrate	O	VERB	O
a	O	DET	O
sexually	O	ADV	B
-	O	PUNCT	O
dimorphic	O	ADJ	B
interaction	O	NOUN	B
between	O	ADP	O
NMDA	B-Chemical	NOUN	B
antagonists	O	NOUN	B
and	O	CCONJ	O
morphine	B-Chemical	NOUN	B
in	O	ADP	O
a	O	DET	O
persistent	O	ADJ	B
pain	B-Disease	NOUN	I
model	O	NOUN	O
that	O	PRON	O
can	O	AUX	O
be	O	AUX	O
distinguished	O	VERB	O
from	O	ADP	O
those	O	DET	O
observed	O	VERB	B
in	O	ADP	O
acute	B-Disease	ADJ	B
pain	I-Disease	NOUN	I


Development	O	NOUN	B
of	O	ADP	O
proteinuria	B-Disease	NOUN	B
after	O	ADP	O
switch	O	NOUN	O
to	O	PART	O
sirolimus	B-Chemical	NOUN	B
-	O	PUNCT	O
based	O	VERB	B
immunosuppression	O	NOUN	B
in	O	ADP	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
cardiac	O	ADJ	B
transplant	O	NOUN	I
patients	O	NOUN	B
.	O	PUNCT	O


Calcineurin	O	NOUN	B
-	O	PUNCT	O
inhibitor	O	NOUN	B
therapy	O	NOUN	B
can	O	AUX	O
lead	O	VERB	O
to	O	PART	O
renal	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
in	O	ADP	O
heart	O	NOUN	B
transplantation	O	NOUN	I
patients	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
novel	O	ADJ	O
immunosuppressive	O	ADJ	B
(	O	PUNCT	O
IS	O	NOUN	B
)	O	PUNCT	O
drug	O	NOUN	B
sirolmus	B-Chemical	NOUN	I
(	O	PUNCT	O
Srl	B-Chemical	PROPN	B
)	O	PUNCT	O
lacks	O	VERB	O
nephrotoxic	B-Disease	ADJ	B
effects	O	NOUN	O
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
proteinuria	B-Disease	NOUN	B
associated	O	VERB	B
with	O	ADP	I
Srl	B-Chemical	PROPN	B
has	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
following	O	VERB	O
renal	O	ADJ	B
transplantation	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
cardiac	O	ADJ	B
transplantation	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
proteinuria	B-Disease	NOUN	B
associated	O	VERB	B
with	O	ADP	I
Srl	B-Chemical	PROPN	B
is	O	AUX	O
unknown	O	ADJ	O
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
cardiac	O	ADJ	B
transplant	O	NOUN	I
patients	O	NOUN	B
were	O	AUX	O
switched	O	VERB	O
from	O	ADP	O
cyclosporine	B-Chemical	NOUN	B
to	O	ADP	O
Srl	B-Chemical	PROPN	B
-	O	PUNCT	O
based	O	VERB	B
IS	O	PROPN	B
.	O	PUNCT	O


Concomitant	O	ADJ	B
IS	O	NOUN	B
consisted	O	VERB	O
of	O	ADP	O
mycophenolate	B-Chemical	NOUN	B
mofetil	I-Chemical	NOUN	I
+/-	O	CCONJ	O
steroids	B-Chemical	NOUN	B
.	O	PUNCT	O


Proteinuria	O	NOUN	B
increased	O	VERB	B
significantly	O	ADV	O
from	O	ADP	O
a	O	DET	O
median	O	NOUN	B
of	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


13	O	NUM	O
g	O	NOUN	B
/	O	PUNCT	O
day	O	NOUN	B
(	O	PUNCT	O
range	O	NOUN	O
0	O	NUM	O
-	O	SYM	O
5	O	NUM	O
.	O	PUNCT	O


7	O	X	O
)	O	PUNCT	O
preswitch	O	VERB	B
to	O	PART	O
0	O	NUM	O
.	O	PUNCT	O


23	O	NUM	O
g	O	NOUN	B
/	O	PUNCT	O
day	O	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
-	O	SYM	O
9	O	NUM	B
.	O	PUNCT	O


88	O	NUM	O
)	O	PUNCT	O
at	O	ADP	O
24	O	NUM	O
months	O	NOUN	B
postswitch	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


0024	O	NUM	O
).	O	PUNCT	O
Before	O	ADP	O
the	O	DET	O
switch	O	NOUN	B
,	O	PUNCT	O
11	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
had	O	AUX	O
high	O	ADJ	B
-	O	PUNCT	O
grade	O	NOUN	B
proteinuria	B-Disease	NOUN	B
(>	O	NOUN	O
1	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
g	O	NOUN	B
/	O	PUNCT	O
day	O	NOUN	B
);	O	NOUN	O
this	O	DET	O
increased	O	VERB	B
to	O	ADP	O
22	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
%	O	NOUN	O
postswitch	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


006	O	NUM	O
).	O	PUNCT	B
ACE	B-Chemical	NOUN	B
inhibitor	I-Chemical	NOUN	I
and	O	CCONJ	O
angiotensin-releasing	B-Chemical	ADJ	O
blocker	I-Chemical	NOUN	B
(	O	PUNCT	O
ARB	B-Chemical	NOUN	B
)	O	PUNCT	O
therapy	O	NOUN	B
reduced	O	VERB	B
proteinuria	B-Disease	NOUN	B
development	O	NOUN	B
.	O	PUNCT	O


Patients	O	NOUN	B
without	O	ADP	O
proteinuria	B-Disease	NOUN	B
had	O	AUX	O
increased	O	VERB	B
renal	O	ADJ	B
function	O	NOUN	I
(	O	PUNCT	O
median	O	NOUN	B
42	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
vs	O	CCONJ	O
.	O	PUNCT	O


64	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


25	O	NUM	O
),	O	PUNCT	O
whereas	O	SCONJ	O
patients	O	NOUN	B
who	O	PRON	O
developed	O	VERB	O
high	O	ADJ	B
-	O	PUNCT	O
grade	O	NOUN	B
proteinuria	B-Disease	NOUN	B
showed	O	VERB	O
decreased	O	VERB	B
renal	O	ADJ	B
function	O	NOUN	I
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
follow	O	NOUN	B
-	O	PUNCT	O
up	O	NOUN	O
(	O	PUNCT	O
median	O	NOUN	B
39	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
vs	O	CCONJ	O
.	O	PUNCT	O


29	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


125	O	NUM	O
).	O	PUNCT	O
Thus	O	ADV	O
,	O	PUNCT	O
proteinuria	B-Disease	NOUN	B
may	O	AUX	O
develop	O	VERB	O
in	O	ADP	O
cardiac	O	ADJ	B
transplant	O	NOUN	I
patients	O	NOUN	B
after	O	ADP	O
switch	O	NOUN	O
to	O	ADP	O
Srl	B-Chemical	PROPN	B
,	O	PUNCT	O
which	O	DET	O
may	O	AUX	O
have	O	AUX	O
an	O	DET	O
adverse	O	ADJ	B
effect	O	NOUN	I
on	O	ADP	O
renal	O	ADJ	B
function	O	NOUN	I
in	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
.	O	PUNCT	O


Srl	B-Chemical	PROPN	B
should	O	AUX	O
be	O	AUX	O
used	O	VERB	O
with	O	ADP	O
ACEi	B-Chemical	NOUN	B
/	O	SYM	O
ARB	B-Chemical	NOUN	B
therapy	O	NOUN	B
and	O	CCONJ	O
patients	O	NOUN	B
monitored	O	VERB	B
for	O	ADP	O
proteinuria	B-Disease	NOUN	B
and	O	CCONJ	O
increased	O	VERB	B
renal	B-Disease	ADJ	O
dysfunction	I-Disease	NOUN	O


Synthesis	O	NOUN	B
of	O	ADP	O
N-pyrimidinyl-2-phenoxyacetamides	B-Chemical	NOUN	B
as	O	ADP	O
adenosine	B-Chemical	NOUN	B
A2A	O	NOUN	I
receptor	O	NOUN	I
antagonists	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
series	O	NOUN	B
of	O	ADP	O
N-pyrimidinyl-2-phenoxyacetamide	B-Chemical	ADJ	B
adenosine	B-Chemical	NOUN	I
A	O	NOUN	I
(	O	PUNCT	O
2A	O	NOUN	B
)	O	PUNCT	O
antagonists	O	NOUN	B
is	O	AUX	O
described	O	VERB	O
.	O	PUNCT	O


SAR	O	NOUN	B
studies	O	NOUN	B
led	O	VERB	O
to	O	PART	O
compound	O	NOUN	B
14	O	NUM	O
with	O	ADP	O
excellent	O	ADJ	B
potency	O	NOUN	O
(	O	PUNCT	O
K	O	NOUN	B
(	O	PUNCT	O
i	O	PRON	O
)=	O	SYM	O
0	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
nM	O	NOUN	O
),	O	PUNCT	O
selectivity	O	NOUN	B
(	O	PUNCT	O
A	O	NOUN	O
(	O	PUNCT	O
1	O	NUM	O
)/	O	NOUN	O
A	O	NOUN	O
(	O	PUNCT	O
2A	O	NOUN	B
)>	O	SYM	O
100	O	NUM	O
),	O	PUNCT	O
and	O	CCONJ	O
efficacy	O	NOUN	B
(	O	PUNCT	O
MED	O	NOUN	B
10	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
p	O	NOUN	O
.	O	PUNCT	O


o	O	INTJ	O
.)	O	NOUN	O
in	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
haloperidol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
catalepsy	B-Disease	NOUN	B
model	O	NOUN	B
for	O	ADP	O
Parkinson's	B-Disease	ADJ	O
disease	I-Disease	NOUN	B


Methamphetamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
neurotoxicity	B-Disease	NOUN	B
and	O	CCONJ	O
microglial	O	ADJ	B
activation	O	NOUN	I
are	O	AUX	O
not	O	PART	O
mediated	O	VERB	O
by	O	ADP	O
fractalkine	O	NOUN	B
receptor	O	NOUN	I
signaling	O	NOUN	B
.	O	PUNCT	O


Methamphetamine	B-Chemical	NOUN	B
(	O	PUNCT	O
METH	B-Chemical	NOUN	B
)	O	PUNCT	O
damages	O	VERB	B
dopamine	B-Chemical	NOUN	B
(	O	PUNCT	O
DA	B-Chemical	NOUN	B
)	O	PUNCT	O
nerve	O	NOUN	O
endings	O	NOUN	B
by	O	ADP	O
a	O	DET	O
process	O	NOUN	B
that	O	PRON	O
has	O	AUX	O
been	O	AUX	O
linked	O	VERB	O
to	O	PART	O
microglial	O	ADJ	B
activation	O	NOUN	I
but	O	CCONJ	O
the	O	DET	O
signaling	O	NOUN	B
pathways	O	NOUN	I
that	O	PRON	O
mediate	O	VERB	O
this	O	DET	O
response	O	NOUN	B
have	O	AUX	O
not	O	PART	O
yet	O	ADV	O
been	O	AUX	O
delineated	O	VERB	B
.	O	PUNCT	O


Cardona	O	PROPN	O
et	O	X	O
al	O	X	O
.[	O	PROPN	O
Nat	O	PROPN	O
.	O	PUNCT	O


Neurosci	O	NOUN	B
.	O	PUNCT	O


9	O	NUM	O
(	O	PUNCT	O
2006	O	NUM	O
),	O	PUNCT	O
917	O	NUM	O
]	O	PUNCT	O
recently	O	ADV	O
identified	O	VERB	B
the	O	DET	O
microglial	O	ADJ	B
-	O	PUNCT	O
specific	O	ADJ	B
fractalkine	O	NOUN	B
receptor	O	NOUN	I
(	O	PUNCT	O
CX3CR1	O	NOUN	B
)	O	PUNCT	O
as	O	ADP	O
an	O	DET	O
important	O	ADJ	O
mediator	O	NOUN	O
of	O	ADP	O
MPTP	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
neurodegeneration	B-Disease	NOUN	B
of	O	ADP	O
DA	B-Chemical	NOUN	B
neurons	O	NOUN	I
.	O	PUNCT	O


Because	O	SCONJ	O
the	O	DET	O
CNS	B-Disease	NOUN	B
damage	I-Disease	NOUN	B
caused	O	VERB	O
by	O	ADP	O
METH	B-Chemical	NOUN	B
and	O	CCONJ	O
MPTP	B-Chemical	NOUN	B
is	O	AUX	O
highly	O	ADV	O
selective	O	ADJ	O
for	O	ADP	O
the	O	DET	O
DA	B-Chemical	NOUN	B
neuronal	O	ADJ	I
system	O	NOUN	I
in	O	ADP	O
mouse	O	NOUN	B
models	O	NOUN	I
of	O	ADP	O
neurotoxicity	B-Disease	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
hypothesized	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
CX3CR1	O	NOUN	B
plays	O	VERB	O
a	O	DET	O
role	O	NOUN	O
in	O	ADP	O
METH	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
neurotoxicity	B-Disease	NOUN	B
and	O	CCONJ	O
microglial	O	ADJ	B
activation	O	NOUN	I
.	O	PUNCT	O


Mice	O	NOUN	B
in	O	ADP	O
which	O	DET	O
the	O	DET	O
CX3CR1	O	NOUN	B
gene	O	NOUN	I
has	O	AUX	O
been	O	AUX	O
deleted	O	VERB	B
and	O	CCONJ	O
replaced	O	VERB	B
with	O	ADP	I
a	O	DET	O
cDNA	O	NOUN	B
encoding	O	NOUN	B
enhanced	O	VERB	B
green	O	ADJ	B
fluorescent	O	ADJ	I
protein	O	NOUN	I
(	O	PUNCT	O
eGFP	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
METH	B-Chemical	NOUN	B
and	O	CCONJ	O
examined	O	VERB	B
for	O	ADP	O
striatal	O	ADJ	B
neurotoxicity	B-Disease	NOUN	B
.	O	PUNCT	O


METH	B-Chemical	NOUN	B
depleted	O	VERB	B
DA	B-Chemical	NOUN	B
,	O	PUNCT	O
caused	O	VERB	O
microglial	O	ADJ	B
activation	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
increased	O	VERB	B
body	O	NOUN	B
temperature	O	NOUN	I
in	O	ADP	O
CX3CR1	O	NOUN	B
knockout	O	NOUN	B
mice	O	NOUN	I
to	O	PART	O
the	O	DET	O
same	O	ADJ	O
extent	O	NOUN	B
and	O	CCONJ	O
over	O	ADP	O
the	O	DET	O
same	O	ADJ	O
time	O	NOUN	B
course	O	NOUN	I
seen	O	VERB	O
in	O	ADP	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
controls	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
METH	B-Chemical	NOUN	B
in	O	ADP	O
CX3CR1	O	NOUN	B
knockout	O	NOUN	B
mice	O	NOUN	I
were	O	AUX	O
not	O	PART	O
gender	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
and	O	CCONJ	O
did	O	AUX	O
not	O	PART	O
extend	O	VERB	O
beyond	O	ADP	O
the	O	DET	O
striatum	O	NOUN	B
.	O	PUNCT	O


Striatal	O	ADJ	B
microglia	O	NOUN	B
expressing	O	VERB	B
eGFP	O	NOUN	B
constitutively	O	ADV	B
show	O	VERB	O
morphological	O	ADJ	B
changes	O	NOUN	B
after	O	ADP	O
METH	B-Chemical	NOUN	B
that	O	PRON	O
are	O	AUX	O
characteristic	O	ADJ	O
of	O	ADP	O
activation	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
response	O	NOUN	B
was	O	AUX	O
restricted	O	ADJ	O
to	O	PART	O
the	O	DET	O
striatum	O	NOUN	B
and	O	CCONJ	O
contrasted	O	VERB	O
sharply	O	ADV	O
with	O	ADP	O
unresponsive	O	ADJ	O
eGFP	O	NOUN	B
-	O	PUNCT	O
microglia	O	NOUN	B
in	O	ADP	O
surrounding	O	VERB	O
brain	O	NOUN	B
areas	O	NOUN	I
that	O	PRON	O
are	O	AUX	O
not	O	PART	O
damaged	O	VERB	B
by	O	ADP	O
METH	B-Chemical	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
from	O	ADP	O
these	O	DET	O
studies	O	NOUN	B
that	O	SCONJ	O
CX3CR1	O	NOUN	B
signaling	O	NOUN	B
does	O	AUX	O
not	O	PART	O
modulate	O	VERB	O
METH	B-Chemical	NOUN	B
neurotoxicity	B-Disease	NOUN	B
or	O	CCONJ	O
microglial	O	ADJ	B
activation	O	NOUN	I
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
it	O	PRON	O
appears	O	VERB	O
that	O	SCONJ	O
striatal	O	ADJ	B
-	O	PUNCT	O
resident	O	ADJ	B
microglia	O	NOUN	B
respond	O	VERB	O
to	O	PART	O
METH	B-Chemical	NOUN	B


Recovery	O	NOUN	B
of	O	ADP	O
tacrolimus	B-Chemical	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
brachial	B-Disease	ADJ	B
neuritis	I-Disease	NOUN	I
after	O	ADP	O
conversion	O	NOUN	B
to	O	PART	O
everolimus	B-Chemical	NOUN	B
in	O	ADP	O
a	O	DET	O
pediatric	O	ADJ	B
renal	O	ADJ	I
transplant	O	NOUN	I
recipient	O	NOUN	B
--	O	PUNCT	O
case	O	NOUN	B
report	O	NOUN	I
and	O	CCONJ	O
review	O	NOUN	B
of	O	ADP	O
the	O	DET	O
literature	O	NOUN	B
.	O	PUNCT	O


TAC	B-Chemical	NOUN	B
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
be	O	AUX	O
a	O	DET	O
potent	O	ADJ	O
immunosuppressive	O	ADJ	B
agent	O	NOUN	I
for	O	ADP	O
solid	O	ADJ	B
organ	O	NOUN	I
transplantation	O	NOUN	I
in	O	ADP	O
pediatrics	O	NOUN	B
.	O	PUNCT	O


Neurotoxicity	B-Disease	NOUN	B
is	O	AUX	O
a	O	DET	O
potentially	O	ADV	O
serious	O	ADJ	O
toxic	O	ADJ	B
effect	O	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
characterized	O	VERB	B
by	O	ADP	O
encephalopathy	B-Disease	NOUN	B
,	O	PUNCT	O
headaches	B-Disease	NOUN	B
,	O	PUNCT	O
seizures	B-Disease	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
neurological	B-Disease	ADJ	B
deficits	I-Disease	NOUN	I
.	O	PUNCT	O


Here	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
describe	O	VERB	O
an	O	DET	O
eight	O	NUM	O
-	O	PUNCT	O
and	O	CCONJ	O
-	O	PUNCT	O
a	O	DET	O
-	O	PUNCT	O
half	O	NOUN	B
-	O	PUNCT	O
yr	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
male	O	NOUN	B
renal	O	ADJ	O
transplant	O	NOUN	O
recipient	O	NOUN	B
with	O	ADP	O
right	O	ADJ	B
BN	O	NOUN	I
.	O	PUNCT	O


MRI	O	NOUN	B
demonstrated	O	VERB	O
hyperintense	O	ADJ	B
T2	O	NOUN	I
signals	O	NOUN	B
in	O	ADP	O
the	O	DET	O
cervical	O	ADJ	B
cord	O	NOUN	I
and	O	CCONJ	O
right	O	ADJ	B
brachial	O	ADJ	I
plexus	O	NOUN	I
roots	O	NOUN	B
indicative	O	ADJ	O
of	O	ADP	O
both	O	CCONJ	O
myelitis	B-Disease	NOUN	B
and	O	CCONJ	O
right	O	ADJ	B
brachial	B-Disease	ADJ	I
plexitis	I-Disease	NOUN	I
.	O	PUNCT	O


Symptoms	O	NOUN	B
persisted	O	VERB	O
for	O	ADP	O
three	O	NUM	O
months	O	NOUN	B
despite	O	SCONJ	O
TAC	B-Chemical	NOUN	B
dose	O	NOUN	B
reduction	O	NOUN	B
,	O	PUNCT	O
administration	O	NOUN	B
of	O	ADP	O
IVIG	O	NOUN	B
and	O	CCONJ	O
four	O	NUM	O
doses	O	NOUN	B
of	O	ADP	O
methylprednisolone	B-Chemical	ADJ	B
pulse	O	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


Improvement	O	NOUN	B
and	O	CCONJ	O
eventually	O	ADV	O
full	O	ADJ	O
recovery	O	NOUN	B
only	O	ADV	O
occurred	O	VERB	O
after	O	ADP	O
TAC	B-Chemical	NOUN	B
was	O	AUX	O
completely	O	ADV	O
discontinued	O	VERB	B
and	O	CCONJ	O
successfully	O	ADV	O
replaced	O	VERB	O
by	O	ADP	O
everolimus	B-Chemical	NOUN	B


Valvular	B-Disease	ADJ	B
heart	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
Parkinson's	B-Disease	ADJ	O
disease	I-Disease	NOUN	B
treated	O	VERB	B
with	O	ADP	I
pergolide	B-Chemical	NOUN	B
.	O	PUNCT	O


Course	O	NOUN	B
following	O	VERB	O
treatment	O	NOUN	B
modifications	O	NOUN	B
.	O	PUNCT	O


Valvular	B-Disease	ADJ	B
heart	I-Disease	NOUN	I
abnormalities	I-Disease	NOUN	I
have	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
Parkinson's	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
PD	B-Disease	NOUN	B
)	O	PUNCT	O
treated	O	VERB	B
with	O	ADP	I
pergolide	B-Chemical	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
incidence	O	NOUN	B
and	O	CCONJ	O
severity	O	NOUN	B
of	O	ADP	O
these	O	DET	O
abnormalities	O	NOUN	B
vary	O	VERB	O
from	O	ADP	O
study	O	NOUN	B
to	O	PART	O
study	O	VERB	B
and	O	CCONJ	O
their	O	PRON	O
course	O	NOUN	B
after	O	ADP	O
drug	O	NOUN	B
withdrawal	O	NOUN	I
has	O	AUX	O
not	O	PART	O
been	O	AUX	O
systematically	O	ADV	B
assessed	O	VERB	B
.	O	PUNCT	O


OBJECTIVES	O	NOUN	O
:	O	PUNCT	O
To	O	PART	O
estimate	O	VERB	B
the	O	DET	O
frequency	O	NOUN	B
and	O	CCONJ	O
severity	O	NOUN	B
of	O	ADP	O
valvular	B-Disease	ADJ	B
heart	I-Disease	NOUN	I
abnormality	I-Disease	NOUN	I
and	O	CCONJ	O
its	O	PRON	O
possible	O	ADJ	O
reversibility	O	NOUN	B
after	O	ADP	O
drug	O	NOUN	B
withdrawal	O	NOUN	I
in	O	ADP	O
a	O	DET	O
case	O	NOUN	B
-	O	PUNCT	O
control	O	NOUN	B
study	O	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
All	O	DET	O
PD	B-Disease	NOUN	B
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
Amiens	O	PROPN	B
area	O	NOUN	I
treated	O	VERB	B
with	O	ADP	I
pergolide	B-Chemical	NOUN	B
were	O	AUX	O
invited	O	VERB	O
to	O	PART	O
attend	O	VERB	B
a	O	DET	O
cardiologic	O	ADJ	B
assessment	O	NOUN	I
including	O	VERB	O
transthoracic	O	NOUN	B
echocardiography	O	NOUN	I
.	O	PUNCT	O


Thirty	O	NUM	B
PD	B-Disease	NOUN	B
patients	O	NOUN	B
participated	O	VERB	O
in	O	ADP	O
the	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
second	O	ADJ	O
echocardiography	O	NOUN	B
was	O	AUX	O
performed	O	VERB	O
(	O	PUNCT	O
median	O	ADJ	B
interval	O	NOUN	I
:	O	PUNCT	O
13	O	NUM	O
months	O	NOUN	B
)	O	PUNCT	O
after	O	ADP	O
pergolide	B-Chemical	NOUN	B
withdrawal	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
10	O	NUM	O
patients	O	NOUN	B
).	O	PUNCT	B
Controls	O	NOUN	I
were	O	AUX	O
age	O	NOUN	B
-	O	PUNCT	O
and	O	CCONJ	O
sex	O	NOUN	B
-	O	PUNCT	O
matched	O	VERB	B
non	O	NOUN	B
-	O	PUNCT	O
PD	B-Disease	NOUN	B
patients	O	NOUN	B
referred	O	VERB	O
to	O	ADP	O
the	O	DET	O
cardiology	O	NOUN	B
department	O	NOUN	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Compared	O	VERB	O
to	O	PART	O
controls	O	NOUN	B
,	O	PUNCT	O
aortic	B-Disease	ADJ	B
regurgitation	I-Disease	NOUN	I
(	O	PUNCT	O
OR	O	NOUN	B
:	O	PUNCT	O
3	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
IC	O	NOUN	O
:	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
-	O	SYM	O
8	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
mitral	B-Disease	ADJ	B
regurgitation	I-Disease	NOUN	I
(	O	PUNCT	O
OR	O	NOUN	B
:	O	PUNCT	O
10	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
IC	O	NOUN	O
:	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
-	O	SYM	O
53	O	NUM	O
)	O	PUNCT	O
were	O	AUX	O
more	O	ADV	O
frequent	O	ADJ	B
in	O	ADP	O
PD	B-Disease	NOUN	B
patients	O	NOUN	B
(	O	PUNCT	O
tricuspid	O	NOUN	B
:	O	PUNCT	O
NS	O	NOUN	B
).	O	PUNCT	O
The	O	DET	O
number	O	NOUN	O
of	O	ADP	O
affected	O	VERB	B
valves	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
2	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
sum	O	NOUN	O
of	O	ADP	O
regurgitation	O	NOUN	B
grades	O	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
2	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
+/-	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


09	O	NUM	O
)	O	PUNCT	O
were	O	AUX	O
higher	O	ADJ	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


008	O	NUM	O
and	O	CCONJ	O
p	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


006	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
pergolide	B-Chemical	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


Severity	O	NOUN	B
of	O	ADP	O
regurgitation	O	NOUN	B
was	O	AUX	O
not	O	PART	O
correlated	O	VERB	B
with	O	ADP	O
pergolide	B-Chemical	NOUN	B
cumulative	O	ADJ	B
dose	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
restrictive	O	ADJ	B
pattern	O	NOUN	B
of	O	ADP	O
valvular	B-Disease	ADJ	B
regurgitation	I-Disease	NOUN	I
,	O	PUNCT	O
suggestive	O	ADJ	O
of	O	ADP	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
pergolide	B-Chemical	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
12	O	NUM	O
/	O	SYM	O
30	O	NUM	O
(	O	PUNCT	O
40	O	NUM	O
%)	O	NOUN	O
patients	O	NOUN	B
including	O	VERB	O
two	O	NUM	O
with	O	ADP	O
heart	B-Disease	NOUN	B
failure	I-Disease	NOUN	I
.	O	PUNCT	O


Pergolide	B-Chemical	NOUN	B
was	O	AUX	O
discontinued	O	VERB	B
in	O	ADP	O
10	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
valvular	B-Disease	ADJ	B
heart	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
,	O	PUNCT	O
resulting	O	VERB	O
in	O	ADP	O
a	O	DET	O
lower	O	ADJ	O
regurgitation	O	NOUN	B
grade	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
)	O	PUNCT	O
at	O	ADP	O
the	O	DET	O
second	O	ADJ	O
transthoracic	O	NOUN	B
echocardiography	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
two	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
heart	B-Disease	NOUN	B
failure	I-Disease	NOUN	I
returned	O	VERB	O
to	O	PART	O
nearly	O	ADV	O
normal	O	ADJ	O
clinical	O	ADJ	O
examination	O	NOUN	O
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
supports	O	VERB	O
the	O	DET	O
high	O	ADJ	O
frequency	O	NOUN	B
of	O	ADP	O
restrictive	O	ADJ	B
valve	B-Disease	NOUN	I
regurgitation	I-Disease	NOUN	I
in	O	ADP	O
PD	B-Disease	NOUN	B
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
pergolide	B-Chemical	NOUN	B
and	O	CCONJ	O
reveals	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
significant	O	ADJ	B
improvement	O	NOUN	B
is	O	AUX	O
usual	O	ADJ	O
when	O	SCONJ	O
the	O	DET	O
treatment	O	NOUN	B
is	O	AUX	O
converted	O	VERB	O
to	O	PART	O
non	O	ADJ	B
-	O	PUNCT	O
ergot	O	NOUN	B
dopamine	B-Chemical	NOUN	B


Adverse	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
topical	O	ADJ	B
papaverine	B-Chemical	NOUN	B
on	O	ADP	O
auditory	O	ADJ	B
nerve	O	NOUN	I
function	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Papaverine	B-Chemical	NOUN	B
hydrochloride	I-Chemical	NOUN	I
is	O	AUX	O
a	O	DET	O
direct	O	ADJ	B
-	O	PUNCT	O
acting	O	VERB	B
vasodilator	O	NOUN	B
used	O	VERB	O
to	O	PART	O
manage	O	VERB	O
vasospasm	B-Disease	NOUN	B
during	O	ADP	O
various	O	ADJ	O
neurosurgical	O	ADJ	B
operations	O	NOUN	I
.	O	PUNCT	O


Transient	O	ADJ	B
cranial	B-Disease	ADJ	B
nerve	I-Disease	NOUN	I
dysfunction	I-Disease	NOUN	O
has	O	AUX	O
been	O	AUX	O
described	O	VERB	O
in	O	ADP	O
a	O	DET	O
few	O	ADJ	O
cases	O	NOUN	B
with	O	ADP	O
topical	O	ADJ	B
papaverine	B-Chemical	NOUN	B
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
supports	O	VERB	O
previous	O	ADJ	O
reports	O	NOUN	B
and	O	CCONJ	O
provides	O	VERB	O
neurophysiological	O	ADJ	B
evidence	O	NOUN	B
of	O	ADP	O
an	O	DET	O
adverse	O	ADJ	B
effect	O	NOUN	I
on	O	ADP	O
the	O	DET	O
auditory	O	ADJ	B
nerve	O	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
We	O	PRON	O
conducted	O	VERB	O
a	O	DET	O
retrospective	O	ADJ	B
review	O	NOUN	I
of	O	ADP	O
70	O	NUM	O
consecutive	O	ADJ	B
microvascular	O	ADJ	B
decompression	O	NOUN	O
operations	O	NOUN	O
and	O	CCONJ	O
studied	O	VERB	O
those	O	DET	O
patients	O	NOUN	B
who	O	PRON	O
received	O	VERB	O
topical	O	ADJ	B
papaverine	B-Chemical	NOUN	B
for	O	ADP	O
vasospasm	B-Disease	NOUN	B
.	O	PUNCT	O


Topical	O	ADJ	B
papaverine	B-Chemical	NOUN	O
was	O	AUX	O
used	O	VERB	O
as	O	ADP	O
a	O	DET	O
direct	O	ADJ	O
therapeutic	O	ADJ	B
action	O	NOUN	I
to	O	PART	O
manage	O	VERB	O
vasospasm	B-Disease	NOUN	B
in	O	ADP	O
a	O	DET	O
total	O	NOUN	O
of	O	ADP	O
11	O	NUM	O
patients	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
timing	O	NOUN	B
of	O	ADP	O
papaverine	B-Chemical	NOUN	B
application	O	NOUN	B
and	O	CCONJ	O
ongoing	O	ADJ	O
operative	O	ADJ	B
events	O	NOUN	I
was	O	AUX	O
reviewed	O	VERB	B
relative	O	ADJ	O
to	O	PART	O
changes	O	NOUN	B
in	O	ADP	O
neurophysiological	O	ADJ	B
recordings	O	NOUN	I
.	O	PUNCT	O


Brainstem	O	NOUN	B
auditory	O	ADJ	O
evoked	O	ADJ	O
potentials	O	NOUN	O
(	O	PUNCT	O
BAEPs	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
routinely	O	ADV	O
used	O	VERB	O
to	O	PART	O
monitor	O	VERB	O
cochlear	O	ADJ	B
nerve	O	NOUN	I
function	O	NOUN	O
during	O	ADP	O
these	O	DET	O
operations	O	NOUN	B
.	O	PUNCT	O


FINDINGS	O	NOUN	B
:	O	PUNCT	O
A	O	DET	O
temporal	O	ADJ	B
relationship	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
between	O	ADP	O
topical	O	ADJ	B
papaverine	B-Chemical	NOUN	B
and	O	CCONJ	O
BAEP	O	NOUN	B
changes	O	NOUN	B
leading	O	VERB	O
to	O	PART	O
complete	O	VERB	O
waveform	O	NOUN	B
loss	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
average	O	ADJ	B
temporal	O	ADJ	B
delay	O	NOUN	I
between	O	ADP	O
papaverine	B-Chemical	NOUN	B
and	O	CCONJ	O
the	O	DET	O
onset	O	NOUN	O
of	O	ADP	O
an	O	DET	O
adverse	O	ADJ	B
BAEP	O	ADJ	B
change	O	NOUN	B
was	O	AUX	O
5	O	NUM	O
min	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
10	O	NUM	O
of	O	ADP	O
11	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
BAEP	O	NOUN	B
waves	O	NOUN	I
II	O	NUM	I
/	O	SYM	O
III	O	NUM	B
-	O	PUNCT	O
V	O	PROPN	B
completely	O	ADV	B
disappeared	O	VERB	O
within	O	ADP	O
2	O	NUM	O
to	O	PART	O
25	O	NUM	O
min	O	NOUN	O
after	O	ADP	O
papaverine	B-Chemical	NOUN	B
.	O	PUNCT	O


Eight	O	NUM	O
of	O	ADP	O
these	O	DET	O
10	O	NUM	O
patients	O	NOUN	B
had	O	AUX	O
complete	O	ADJ	O
loss	O	NOUN	B
of	O	ADP	O
BAEP	O	NOUN	B
waveforms	O	NOUN	B
within	O	ADP	O
10	O	NUM	O
min	O	NOUN	O
.	O	PUNCT	O


One	O	NUM	O
patient	O	NOUN	B
showed	O	VERB	O
no	O	DET	O
recovery	O	NOUN	B
of	O	ADP	O
later	O	ADJ	O
waves	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
delayed	O	VERB	B
profound	O	ADJ	O
sensorineural	B-Disease	ADJ	B
hearing	I-Disease	NOUN	I
loss	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
average	O	ADJ	B
recovery	O	NOUN	B
time	O	NOUN	O
of	O	ADP	O
BAEP	O	NOUN	B
waveforms	O	NOUN	B
to	O	ADP	O
pre	O	NOUN	B
-	O	PUNCT	O
papaverine	B-Chemical	NOUN	B
baseline	O	NOUN	B
values	O	NOUN	B
was	O	AUX	O
39	O	NUM	O
min	O	NOUN	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
Topical	O	ADJ	B
papaverine	B-Chemical	NOUN	I
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
vasospasm	B-Disease	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
onset	O	NOUN	O
of	O	ADP	O
a	O	DET	O
transient	O	ADJ	B
disturbance	O	NOUN	I
in	O	ADP	O
neurophysiological	O	ADJ	B
function	O	NOUN	I
of	O	ADP	O
the	O	DET	O
ascending	O	VERB	B
auditory	O	ADJ	B
brainstem	O	NOUN	O
pathway	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
complete	O	ADJ	O
disappearance	O	NOUN	B
of	O	ADP	O
BAEP	O	NOUN	B
waveforms	O	NOUN	B
with	O	ADP	O
a	O	DET	O
consistent	O	ADJ	O
temporal	O	ADJ	B
delay	O	NOUN	O
suggests	O	VERB	O
a	O	DET	O
possible	O	ADJ	O
adverse	B-Disease	ADJ	B
effect	I-Disease	NOUN	I
on	I-Disease	ADP	O
the	I-Disease	DET	O
proximal	I-Disease	ADJ	B
eighth	I-Disease	ADJ	O
nerve	I-Disease	NOUN	O
.	O	PUNCT	O


Recommendations	O	NOUN	B
to	O	PART	O
avoid	O	VERB	O
potential	O	ADJ	B
cranial	B-Disease	ADJ	B
nerve	I-Disease	NOUN	I
deficits	I-Disease	NOUN	B
from	O	ADP	O
papaverine	B-Chemical	NOUN	B


Massive	O	ADJ	B
proteinuria	B-Disease	NOUN	B
and	O	CCONJ	O
acute	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
failure	I-Disease	NOUN	I
after	O	ADP	O
oral	O	ADJ	B
bisphosphonate	B-Chemical	NOUN	I
(	O	PUNCT	O
alendronate	B-Chemical	NOUN	B
)	O	PUNCT	O
administration	O	NOUN	B
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
focal	B-Disease	ADJ	B
segmental	I-Disease	ADJ	I
glomerulosclerosis	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
61	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
Japanese	O	ADJ	B
man	O	NOUN	B
with	O	ADP	O
nephrotic	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
due	O	ADJ	O
to	O	PART	O
focal	B-Disease	ADJ	B
segmental	I-Disease	ADJ	I
glomerulosclerosis	I-Disease	NOUN	I
was	O	AUX	O
initially	O	ADV	O
responding	O	VERB	B
well	O	ADV	O
to	O	PART	O
steroid	B-Chemical	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
amount	O	NOUN	B
of	O	ADP	O
daily	O	ADJ	B
urinary	O	ADJ	O
protein	O	NOUN	O
decreased	O	VERB	B
from	O	ADP	O
15	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
to	O	PART	O
2	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
g	O	NOUN	O
.	O	PUNCT	O


Within	O	ADP	O
14	O	NUM	O
days	O	NOUN	B
of	O	ADP	O
the	O	DET	O
oral	O	ADJ	B
bisphosphonate	B-Chemical	NOUN	I
(	O	PUNCT	O
alendronate	B-Chemical	NOUN	B
sodium	I-Chemical	NOUN	I
)	O	PUNCT	O
administration	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
amount	O	NOUN	B
of	O	ADP	O
daily	O	ADJ	B
urinary	O	ADJ	O
protein	O	NOUN	O
increased	O	VERB	B
rapidly	O	ADV	O
up	O	ADV	O
to	O	PART	O
12	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
g	O	NOUN	O
with	O	ADP	O
acute	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
failure	I-Disease	NOUN	I
.	O	PUNCT	O


After	O	ADP	O
discontinuing	O	VERB	B
the	O	DET	O
oral	O	ADJ	B
alendronate	B-Chemical	NOUN	I
,	O	PUNCT	O
the	O	DET	O
patient	O	NOUN	B
underwent	O	VERB	O
six	O	NUM	O
cycles	O	NOUN	B
of	O	ADP	O
hemodialysis	O	NOUN	B
and	O	CCONJ	O
four	O	NUM	O
cycles	O	NOUN	B
of	O	ADP	O
LDL	O	NOUN	B
apheresis	O	NOUN	I
.	O	PUNCT	O


Urinary	O	ADJ	B
volume	O	NOUN	I
and	O	CCONJ	O
serum	O	NOUN	B
creatinine	B-Chemical	NOUN	I
levels	O	NOUN	I
recovered	O	VERB	O
to	O	PART	O
the	O	DET	O
normal	O	ADJ	B
range	O	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
urinary	O	ADJ	B
protein	O	NOUN	I
disappearing	O	VERB	O
completely	O	ADV	O
within	O	ADP	O
40	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
report	O	NOUN	O
demonstrates	O	VERB	O
that	O	SCONJ	O
not	O	PART	O
only	O	ADV	O
intravenous	O	ADJ	B
,	O	PUNCT	O
but	O	CCONJ	O
also	O	ADV	O
oral	O	ADJ	B
bisphosphonates	B-Chemical	NOUN	B
can	O	AUX	O
aggravate	O	VERB	B
proteinuria	B-Disease	NOUN	B
and	O	CCONJ	O
acute	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
failure	I-Disease	NOUN	I


Serum	O	NOUN	B
-	O	PUNCT	O
and	O	CCONJ	O
glucocorticoid	O	NOUN	B
-	O	PUNCT	O
inducible	O	ADJ	B
kinase	O	NOUN	O
1	O	NUM	O
in	O	ADP	O
doxorubicin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
nephrotic	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


Doxorubicin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
nephropathy	B-Disease	NOUN	B
leads	O	VERB	O
to	O	PART	O
epithelial	O	ADJ	B
sodium	B-Chemical	NOUN	I
channel	O	NOUN	I
(	O	PUNCT	O
ENaC	O	NOUN	B
)-	O	ADJ	O
dependent	O	ADJ	O
volume	B-Disease	NOUN	O
retention	I-Disease	NOUN	O
and	O	CCONJ	O
renal	O	ADJ	B
fibrosis	B-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
aldosterone	B-Chemical	NOUN	B
-	O	PUNCT	O
sensitive	O	ADJ	B
serum	O	NOUN	B
-	O	PUNCT	O
and	O	CCONJ	O
glucocorticoid	O	NOUN	B
-	O	PUNCT	O
inducible	O	ADJ	B
kinase	O	NOUN	B
SGK1	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
participate	O	VERB	B
in	O	ADP	O
the	O	DET	O
stimulation	O	NOUN	B
of	O	ADP	O
ENaC	O	NOUN	B
and	O	CCONJ	O
to	O	PART	O
mediate	O	VERB	O
renal	O	ADJ	B
fibrosis	B-Disease	NOUN	I
following	O	VERB	O
mineralocorticoid	O	NOUN	B
and	O	CCONJ	O
salt	O	NOUN	B
excess	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
was	O	AUX	O
performed	O	VERB	O
to	O	PART	O
elucidate	O	VERB	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
SGK1	O	NOUN	B
in	O	ADP	O
the	O	DET	O
volume	B-Disease	NOUN	B
retention	I-Disease	NOUN	I
and	O	CCONJ	O
fibrosis	B-Disease	NOUN	B
during	O	ADP	O
nephrotic	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


To	O	ADP	O
this	O	DET	O
end	O	NOUN	O
,	O	PUNCT	O
doxorubicin	B-Chemical	NOUN	B
(	O	PUNCT	O
15	O	NUM	O
mug	O	NOUN	B
/	O	SYM	O
g	O	NOUN	B
body	O	NOUN	I
wt	O	X	O
)	O	PUNCT	O
was	O	AUX	O
injected	O	VERB	B
intravenously	O	ADV	B
into	O	ADP	O
gene	O	NOUN	B
-	O	PUNCT	O
targeted	O	VERB	B
mice	O	NOUN	B
lacking	O	VERB	O
SGK1	O	NOUN	B
(	O	PUNCT	O
sgk1	O	NOUN	B
(-/-))	O	NOUN	O
and	O	CCONJ	O
their	O	PRON	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
littermates	O	NOUN	B
(	O	PUNCT	O
sgk1	O	NOUN	B
(+/+)).	O	VERB	O
Doxorubicin	B-Chemical	NOUN	B
treatment	O	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
heavy	O	ADJ	B
proteinuria	B-Disease	NOUN	I
(>	O	NOUN	O
100	O	NUM	O
mg	O	NOUN	O
protein	O	NOUN	B
/	O	PUNCT	O
mg	O	NOUN	B
crea	O	NOUN	I
)	O	PUNCT	O
in	O	ADP	O
15	O	NUM	O
/	O	SYM	O
44	O	NUM	O
of	O	ADP	O
sgk1	O	NOUN	B
(+/+)	O	NOUN	B
and	O	CCONJ	O
15	O	NUM	O
/	O	SYM	O
44	O	NUM	O
of	O	ADP	O
sgk1	O	NOUN	B
(-/-)	O	NOUN	O
mice	O	NOUN	B
leading	O	VERB	O
to	O	PART	O
severe	O	ADJ	B
nephrotic	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
with	O	ADP	O
ascites	B-Disease	NOUN	B
,	O	PUNCT	O
lipidemia	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
hypoalbuminemia	B-Disease	NOUN	B
in	O	ADP	O
both	O	DET	O
genotypes	O	NOUN	B
.	O	PUNCT	O


Plasma	O	NOUN	B
aldosterone	B-Chemical	NOUN	B
levels	O	NOUN	O
increased	O	VERB	B
in	O	ADP	O
nephrotic	B-Disease	ADJ	B
mice	O	NOUN	I
of	O	ADP	O
both	O	DET	O
genotypes	O	NOUN	B
and	O	CCONJ	O
was	O	AUX	O
followed	O	VERB	O
by	O	ADP	O
increased	O	VERB	B
SGK1	O	NOUN	B
protein	O	NOUN	B
expression	O	NOUN	I
in	O	ADP	O
sgk1	O	NOUN	B
(+/+)	O	NOUN	B
mice	O	NOUN	I
.	O	PUNCT	O


Urinary	O	ADJ	B
sodium	B-Chemical	NOUN	I
excretion	O	NOUN	B
reached	O	VERB	O
signficantly	O	ADV	B
lower	O	ADJ	O
values	O	NOUN	O
in	O	ADP	O
sgk1	O	NOUN	B
(+/+)	O	NOUN	B
mice	O	NOUN	I
(	O	PUNCT	O
15	O	NUM	O
+/-	O	CCONJ	O
5	O	NUM	O
mumol	O	NOUN	B
/	O	SYM	O
mg	O	NOUN	B
crea	O	NOUN	I
)	O	PUNCT	O
than	O	ADP	O
in	O	ADP	O
sgk1	O	NOUN	B
(-/-)	O	NOUN	O
mice	O	NOUN	B
(	O	PUNCT	O
35	O	NUM	O
+/-	O	CCONJ	O
5	O	NUM	O
mumol	O	NOUN	B
/	O	SYM	O
mg	O	NOUN	B
crea	O	NOUN	I
)	O	PUNCT	O
and	O	CCONJ	O
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
significantly	O	ADV	O
higher	O	ADJ	O
body	O	NOUN	B
weight	B-Disease	NOUN	I
gain	I-Disease	NOUN	O
in	O	ADP	O
sgk1	O	NOUN	B
(+/+)	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
sgk1	O	NOUN	B
(-/-)	O	NOUN	O
mice	O	NOUN	B
(+	O	NOUN	O
6	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
vs	O	CCONJ	O
.+	O	NOUN	O
4	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
g	O	NOUN	O
).	O	PUNCT	B
During	O	ADP	O
the	O	DET	O
course	O	NOUN	B
of	O	ADP	O
nephrotic	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
,	O	PUNCT	O
serum	O	NOUN	B
urea	B-Chemical	NOUN	I
concentrations	O	NOUN	I
increased	O	VERB	B
significantly	O	ADV	O
faster	O	ADV	O
in	O	ADP	O
sgk1	O	NOUN	B
(-/-)	O	NOUN	O
mice	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
sgk1	O	NOUN	B
(+/+)	O	NOUN	B
mice	O	NOUN	I
leading	O	VERB	O
to	O	PART	O
uremia	B-Disease	NOUN	B
and	O	CCONJ	O
a	O	DET	O
reduced	O	VERB	B
median	O	ADJ	B
survival	O	NOUN	O
in	O	ADP	O
sgk1	O	NOUN	B
(-/-)	O	NOUN	O
mice	O	NOUN	B
(	O	PUNCT	O
29	O	NUM	O
vs	O	CCONJ	O
.	O	PUNCT	O


40	O	NUM	O
days	O	NOUN	B
in	O	ADP	O
sgk1	O	NOUN	B
(+/+)	O	NOUN	B
mice	O	NOUN	I
).	O	PUNCT	O
In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
gene	O	NOUN	B
-	O	PUNCT	O
targeted	O	VERB	B
mice	O	NOUN	B
lacking	O	VERB	O
SGK1	O	NOUN	B
showed	O	VERB	O
blunted	O	ADJ	B
volume	B-Disease	NOUN	O
retention	I-Disease	NOUN	O
,	O	PUNCT	O
yet	O	CCONJ	O
were	O	AUX	O
not	O	PART	O
protected	O	VERB	O
against	O	ADP	O
renal	O	ADJ	B
fibrosis	B-Disease	NOUN	I
during	O	ADP	O
experimental	O	ADJ	B
nephrotic	B-Disease	ADJ	I
syndrome	I-Disease	NOUN	I


Severe	O	ADJ	B
and	O	CCONJ	O
long	O	ADV	O
lasting	O	ADJ	O
cholestasis	B-Disease	NOUN	B
after	O	ADP	O
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
co-trimoxazole	B-Chemical	NOUN	B
treatment	O	NOUN	B
for	O	ADP	O
Pneumocystis	B-Disease	NOUN	B
pneumonia	I-Disease	NOUN	I
in	O	ADP	O
HIV-infected	B-Disease	ADJ	B
patients	O	NOUN	B
--	O	PUNCT	O
a	O	DET	O
report	O	NOUN	B
of	O	ADP	O
two	O	NUM	O
cases	O	NOUN	B
.	O	PUNCT	O


Pneumocystis	B-Disease	NOUN	B
pneumonia	I-Disease	NOUN	I
(	O	PUNCT	O
PCP	B-Disease	NOUN	B
),	O	PUNCT	O
a	O	DET	O
common	O	ADJ	O
opportunistic	B-Disease	ADJ	B
infection	I-Disease	NOUN	I
in	O	ADP	O
HIV-infected	B-Disease	ADJ	B
individuals	O	NOUN	B
,	O	PUNCT	O
is	O	AUX	O
generally	O	ADV	O
treated	O	VERB	B
with	O	ADP	I
high	O	ADJ	O
doses	O	NOUN	B
of	O	ADP	O
co-trimoxazole	B-Chemical	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
treatment	O	NOUN	B
is	O	AUX	O
often	O	ADV	O
limited	O	VERB	O
by	O	ADP	O
adverse	O	ADJ	B
effects	O	NOUN	I
.	O	PUNCT	O


Here	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
report	O	VERB	O
two	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
severely	O	ADV	B
immunocompromised	O	VERB	O
HIV-infected	B-Disease	ADJ	B
patients	O	NOUN	B
who	O	PRON	O
developed	O	VERB	O
severe	O	ADJ	B
intrahepatic	B-Disease	ADJ	B
cholestasis	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
one	O	NUM	O
patient	O	NOUN	B
lesions	O	NOUN	B
mimicking	O	VERB	O
liver	B-Disease	NOUN	B
abscess	I-Disease	NOUN	I
formation	O	NOUN	B
on	O	ADP	O
radiologic	O	ADJ	B
exams	O	NOUN	I
,	O	PUNCT	O
during	O	ADP	O
co-trimoxazole	B-Chemical	NOUN	B
treatment	O	NOUN	B
for	O	ADP	O
PCP	B-Disease	NOUN	B
.	O	PUNCT	O


Whereas	O	SCONJ	O
patient	O	NOUN	B
1	O	NUM	I
showed	O	VERB	O
lesions	O	NOUN	B
of	O	ADP	O
up	O	ADV	O
to	O	PART	O
1	O	NUM	O
cm	O	NOUN	O
readily	O	ADV	O
detectable	O	ADJ	B
on	O	ADP	O
magnetic	O	ADJ	B
resonance	O	NOUN	I
imaging	O	NOUN	I
under	O	ADP	O
prolonged	O	ADJ	B
co-trimoxazole	B-Chemical	NOUN	B


Clinically	O	ADV	B
significant	O	ADJ	I
proteinuria	B-Disease	NOUN	B
following	O	VERB	O
the	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
sirolimus	B-Chemical	NOUN	B
to	O	PART	O
renal	O	ADJ	B
transplant	O	NOUN	I
recipients	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Sirolimus	B-Chemical	NOUN	B
is	O	AUX	O
the	O	DET	O
latest	O	ADJ	O
immunosuppressive	O	ADJ	B
agent	O	NOUN	I
used	O	VERB	O
to	O	PART	O
prevent	O	VERB	B
rejection	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
may	O	AUX	O
have	O	AUX	O
less	O	ADJ	O
nephrotoxicity	B-Disease	NOUN	B
than	O	ADP	O
calcineurin	O	NOUN	B
inhibitor	O	NOUN	I
(	O	PUNCT	O
CNI	O	NOUN	B
)-	O	ADJ	O
based	O	VERB	O
regimens	O	NOUN	B
.	O	PUNCT	O


To	O	ADP	O
date	O	NOUN	O
there	O	PRON	O
has	O	AUX	O
been	O	AUX	O
little	O	ADJ	O
documentation	O	NOUN	B
of	O	ADP	O
clinically	O	ADV	B
significant	O	ADJ	I
proteinuria	B-Disease	NOUN	B
linked	O	VERB	O
with	O	ADP	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
sirolimus	B-Chemical	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
encountered	O	VERB	O
several	O	ADJ	O
patients	O	NOUN	B
who	O	PRON	O
developed	O	VERB	O
substantial	O	ADJ	O
proteinuria	B-Disease	NOUN	B
associated	O	VERB	B
with	O	ADP	I
sirolimus	B-Chemical	NOUN	B
use	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
each	O	DET	O
patient	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
close	O	ADJ	O
temporal	O	ADJ	B
association	O	NOUN	B
between	O	ADP	O
the	O	DET	O
commencement	O	NOUN	B
of	O	ADP	O
sirolimus	B-Chemical	NOUN	B
therapy	O	NOUN	I
and	O	CCONJ	O
proteinuria	B-Disease	NOUN	B
implicated	O	VERB	O
sirolimus	B-Chemical	NOUN	B
as	O	ADP	O
the	O	DET	O
most	O	ADV	O
likely	O	ADJ	O
etiology	O	NOUN	B
of	O	ADP	O
the	O	DET	O
proteinuria	B-Disease	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
We	O	PRON	O
analyzed	O	VERB	B
the	O	DET	O
clinical	O	ADJ	B
and	O	CCONJ	O
laboratory	O	ADJ	B
information	O	NOUN	I
available	O	ADJ	O
for	O	ADP	O
all	O	DET	O
119	O	NUM	O
patients	O	NOUN	B
transplanted	O	VERB	B
at	O	ADP	O
the	O	DET	O
Washington	O	PROPN	B
Hospital	O	PROPN	I
Center	O	PROPN	I
between	O	ADP	O
1999	O	NUM	O
-	O	SYM	O
2003	O	NUM	O
for	O	ADP	O
whom	O	PRON	O
sirolimus	B-Chemical	NOUN	B
was	O	AUX	O
a	O	DET	O
component	O	NOUN	B
of	O	ADP	O
their	O	PRON	O
immunosuppressant	O	ADJ	B
regimen	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
magnitude	O	NOUN	B
of	O	ADP	O
proteinuria	B-Disease	NOUN	B
was	O	AUX	O
assessed	O	VERB	B
on	O	ADP	O
morning	O	NOUN	B
urine	O	NOUN	B
samples	O	NOUN	I
by	O	ADP	O
turbidometric	O	ADJ	B
measurement	O	NOUN	I
or	O	CCONJ	O
random	O	ADJ	B
urine	O	NOUN	O
protein	O	NOUN	O
:	O	PUNCT	O
creatinine	B-Chemical	NOUN	B
ratios	O	NOUN	I
,	O	PUNCT	O
an	O	DET	O
estimate	O	NOUN	B
of	O	ADP	O
grams	O	NOUN	B
of	O	ADP	O
proteinuria	B-Disease	NOUN	B
/	O	PUNCT	O
day	O	NOUN	B
.	O	PUNCT	O


Laboratory	O	NOUN	B
results	O	NOUN	I
were	O	AUX	O
compared	O	VERB	B
between	O	ADP	O
prior	O	ADJ	B
,	O	PUNCT	O
during	O	ADP	O
and	O	CCONJ	O
following	O	VERB	O
sirolimus	B-Chemical	NOUN	B
use	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Twenty	O	NUM	B
-	O	PUNCT	O
eight	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
24	O	NUM	O
%)	O	NOUN	O
developed	O	VERB	O
increased	O	VERB	B
proteinuria	B-Disease	NOUN	B
from	O	ADP	O
baseline	O	NOUN	B
during	O	ADP	O
their	O	PRON	O
post	O	NOUN	B
-	O	PUNCT	O
transplantation	O	NOUN	B
course	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
21	O	NUM	O
patients	O	NOUN	B
an	O	DET	O
alternative	O	ADJ	B
cause	O	NOUN	B
of	O	ADP	O
proteinuria	B-Disease	NOUN	B
was	O	AUX	O
either	O	CCONJ	O
obvious	O	ADJ	O
or	O	CCONJ	O
insufficient	O	ADJ	B
data	O	NOUN	B
was	O	AUX	O
available	O	ADJ	O
to	O	PART	O
be	O	AUX	O
conclusive	O	ADJ	B
.	O	PUNCT	O


In	O	ADP	O
7	O	NUM	O
of	O	ADP	O
the	O	DET	O
28	O	NUM	O
patients	O	NOUN	B
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
striking	O	ADJ	O
temporal	O	ADJ	B
association	O	NOUN	B
between	O	ADP	O
the	O	DET	O
initiation	O	NOUN	B
of	O	ADP	O
sirolimus	B-Chemical	NOUN	B
and	O	CCONJ	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
nephrotic	B-Disease	ADJ	B
-	O	PUNCT	O
range	O	NOUN	B
proteinuria	B-Disease	NOUN	B
.	O	PUNCT	O


Proteinuria	B-Disease	NOUN	B
correlated	O	VERB	B
most	O	ADV	O
strongly	O	ADV	O
with	O	ADP	O
sirolimus	B-Chemical	NOUN	B
therapy	O	NOUN	I
when	O	SCONJ	O
compared	O	VERB	B
to	O	PART	O
other	O	ADJ	O
demographic	O	ADJ	B
and	O	CCONJ	O
clinical	O	ADJ	B
variables	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
most	O	ADJ	O
patients	O	NOUN	B
,	O	PUNCT	O
discontinuation	O	NOUN	B
of	O	ADP	O
sirolimus	B-Chemical	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
a	O	DET	O
decrease	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
resolution	O	NOUN	B
,	O	PUNCT	O
of	O	ADP	O
proteinuria	B-Disease	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
Sirolimus	B-Chemical	NOUN	B
induces	O	VERB	B
or	O	CCONJ	O
aggravates	O	VERB	B
pre	O	NOUN	B
-	O	PUNCT	O
existing	O	VERB	B
proteinuria	B-Disease	NOUN	B
in	O	ADP	O
an	O	DET	O
unpredictable	O	ADJ	O
subset	O	NOUN	O
of	O	ADP	O
renal	O	ADJ	B
allograft	O	NOUN	I
recipients	O	NOUN	B
.	O	PUNCT	O


Proteinuria	B-Disease	NOUN	B
may	O	AUX	O
improve	O	VERB	B
,	O	PUNCT	O
but	O	CCONJ	O
does	O	AUX	O
not	O	PART	O
resolve	O	VERB	O
,	O	PUNCT	O
when	O	SCONJ	O
sirolimus	B-Chemical	NOUN	B


Comparative	O	ADJ	B
cognitive	O	ADJ	I
and	O	CCONJ	O
subjective	O	ADJ	O
side	O	NOUN	B
effects	O	NOUN	I
of	O	ADP	O
immediate	O	ADJ	B
-	O	PUNCT	O
release	O	NOUN	B
oxycodone	B-Chemical	NOUN	B
in	O	ADP	O
healthy	O	ADJ	B
middle	O	NOUN	B
-	O	PUNCT	O
aged	O	ADJ	B
and	O	CCONJ	O
older	O	ADJ	B
adults	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
measured	O	VERB	B
the	O	DET	O
objective	O	ADJ	B
and	O	CCONJ	O
subjective	O	ADJ	O
neurocognitive	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
a	O	DET	O
single	O	ADJ	O
10	O	NUM	O
-	O	PUNCT	O
mg	O	NOUN	B
dose	O	NOUN	B
of	O	ADP	O
immediate	O	ADJ	B
-	O	PUNCT	O
release	O	NOUN	B
oxycodone	B-Chemical	NOUN	B
in	O	ADP	O
healthy	O	ADJ	B
,	O	PUNCT	O
older	O	ADJ	B
(>	O	NOUN	O
65	O	NUM	O
years	O	NOUN	B
),	O	PUNCT	O
and	O	CCONJ	O
middle	O	NOUN	B
-	O	PUNCT	O
aged	O	ADJ	B
(	O	PUNCT	O
35	O	NUM	O
to	O	PART	O
55	O	NUM	O
years	O	NOUN	B
)	O	PUNCT	O
adults	O	NOUN	B
who	O	PRON	O
were	O	AUX	O
not	O	PART	O
suffering	O	VERB	O
from	O	ADP	O
chronic	O	ADJ	B
or	O	CCONJ	O
significant	O	ADJ	O
daily	O	ADJ	B
pain	B-Disease	NOUN	I
.	O	PUNCT	O


Seventy	O	NUM	B
-	O	PUNCT	O
one	O	NUM	O
participants	O	NOUN	B
completed	O	VERB	O
2	O	NUM	O
separate	O	ADJ	O
study	O	NOUN	B
days	O	NOUN	B
and	O	CCONJ	O
were	O	AUX	O
blind	O	ADJ	B
to	O	ADP	O
medication	O	NOUN	B
condition	O	NOUN	I
(	O	PUNCT	O
placebo	O	NOUN	B
,	O	PUNCT	O
10	O	NUM	O
-	O	PUNCT	O
mg	O	NOUN	O
oxycodone	B-Chemical	NOUN	B
).	O	PUNCT	O
Plasma	O	NOUN	B
oxycodone	B-Chemical	NOUN	B
concentration	O	NOUN	B
peaked	O	VERB	O
between	O	ADP	O
60	O	NUM	O
and	O	CCONJ	O
90	O	NUM	O
minutes	O	NOUN	O
postdose	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<.	O	ADJ	O
01	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
pupil	O	NOUN	B
size	O	NOUN	I
,	O	PUNCT	O
an	O	DET	O
indication	O	NOUN	B
of	O	ADP	O
physiological	O	ADJ	B
effects	O	NOUN	O
of	O	ADP	O
the	O	DET	O
medication	O	NOUN	B
,	O	PUNCT	O
peaked	O	VERB	O
at	O	ADP	O
approximately	O	ADV	O
90	O	NUM	O
to	O	PART	O
120	O	NUM	O
minutes	O	NOUN	O
postdose	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<.	O	ADJ	O
01	O	NUM	O
).	O	PUNCT	O
Significant	O	ADJ	O
declines	B-Disease	NOUN	B
in	I-Disease	ADP	O
simple	I-Disease	ADJ	O
and	I-Disease	CCONJ	O
sustained	I-Disease	ADJ	B
attention,	I-Disease	ADJ	O
working	I-Disease	NOUN	O
memory,	I-Disease	ADJ	B
and	I-Disease	CCONJ	O
verbal	I-Disease	ADJ	B
memory	I-Disease	NOUN	I
were	O	AUX	O
observed	O	VERB	O
at	O	ADP	O
1	O	NUM	O
hour	O	NOUN	B
postdose	O	NOUN	B
compared	O	VERB	O
to	O	PART	O
baseline	O	NOUN	B
for	O	ADP	O
both	O	DET	O
age	O	NOUN	B
groups	O	NOUN	I
with	O	ADP	O
a	O	DET	O
trend	O	NOUN	O
toward	O	ADP	O
return	O	NOUN	B
to	O	ADP	I
baseline	O	NOUN	B
by	O	ADP	O
5	O	NUM	O
hours	O	NOUN	B
postdose	O	NOUN	B
.	O	PUNCT	O


For	O	ADP	O
almost	O	ADV	O
all	O	DET	O
cognitive	O	ADJ	B
measures	O	NOUN	I
,	O	PUNCT	O
there	O	PRON	O
were	O	AUX	O
no	O	DET	O
medication	O	NOUN	B
by	O	ADP	O
age	O	NOUN	B
-	O	PUNCT	O
interaction	O	NOUN	B
effects	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
indicates	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
2	O	NUM	O
age	O	NOUN	B
groups	O	NOUN	I
exhibited	O	VERB	O
similar	O	ADJ	O
responses	O	NOUN	B
to	O	PART	O
the	O	DET	O
medication	O	NOUN	B
challenge	O	NOUN	O
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
for	O	ADP	O
healthy	O	ADJ	B
older	O	ADJ	B
adults	O	NOUN	I
who	O	PRON	O
are	O	AUX	O
not	O	PART	O
suffering	O	VERB	O
from	O	ADP	O
chronic	B-Disease	ADJ	B
pain	I-Disease	NOUN	I
,	O	PUNCT	O
neurocognitive	O	ADJ	B
and	O	CCONJ	O
pharmacodynamic	O	ADJ	B
changes	O	NOUN	O
in	O	ADP	O
response	O	NOUN	B
to	O	PART	O
a	O	DET	O
10	O	NUM	O
-	O	PUNCT	O
mg	O	NOUN	B
dose	O	NOUN	B
of	O	ADP	O
immediate	O	ADJ	B
-	O	PUNCT	O
release	O	NOUN	B
oxycodone	B-Chemical	NOUN	B
are	O	AUX	O
similar	O	ADJ	O
to	O	PART	O
those	O	DET	O
observed	O	VERB	B
for	O	ADP	O
middle	O	ADJ	B
-	O	PUNCT	O
aged	O	ADJ	B
adults	O	NOUN	B
.	O	PUNCT	O


PERSPECTIVE	O	NOUN	B
:	O	PUNCT	O
Study	O	NOUN	B
findings	O	NOUN	I
indicate	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
metabolism	O	NOUN	B
,	O	PUNCT	O
neurocognitive	O	ADJ	B
effects	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
physical	O	ADJ	B
side	O	NOUN	I
effects	O	NOUN	I
of	O	ADP	O
oral	O	ADJ	B
oxycodone	B-Chemical	NOUN	B


Normalizing	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
modafinil	B-Chemical	NOUN	B
on	O	ADP	O
sleep	O	NOUN	B
in	O	ADP	O
chronic	O	ADJ	B
cocaine	B-Chemical	NOUN	I
users	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
morning	O	NOUN	B
-	O	PUNCT	O
dosed	O	VERB	B
modafinil	B-Chemical	NOUN	B
on	O	ADP	O
sleep	O	NOUN	B
and	O	CCONJ	O
daytime	B-Disease	NOUN	B
sleepiness	I-Disease	NOUN	I
in	O	ADP	O
chronic	O	ADJ	B
cocaine	B-Chemical	NOUN	I
users	O	NOUN	I
.	O	PUNCT	O


METHOD	O	NOUN	B
:	O	PUNCT	O
Twenty	O	NUM	O
cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
participants	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
receive	O	VERB	O
modafinil	B-Chemical	NOUN	B
,	O	PUNCT	O
400	O	NUM	O
mg	O	NOUN	O
(	O	PUNCT	O
N	O	NOUN	O
=	O	ADJ	O
10	O	NUM	O
),	O	PUNCT	O
or	O	CCONJ	O
placebo	O	NOUN	B
(	O	PUNCT	O
N	O	NOUN	O
=	O	ADJ	O
10	O	NUM	O
)	O	PUNCT	O
every	O	DET	O
morning	O	NOUN	B
at	O	ADP	O
7	O	NUM	O
:	O	PUNCT	O
30	O	NUM	O
a	O	DET	O
.	O	PUNCT	O


m	O	NOUN	O
.	O	PUNCT	O


for	O	ADP	O
16	O	NUM	O
days	O	NOUN	B
in	O	ADP	O
an	O	DET	O
inpatient	O	ADJ	B
,	O	PUNCT	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	ADJ	B
randomized	O	ADJ	B
trial	O	NOUN	I
.	O	PUNCT	O


Participants	O	NOUN	B
underwent	O	VERB	O
polysomnographic	O	ADJ	B
sleep	O	NOUN	I
recordings	O	NOUN	I
on	O	ADP	O
days	O	NOUN	B
1	O	NUM	O
to	O	PART	O
3	O	NUM	O
,	O	PUNCT	O
7	O	NUM	O
to	O	PART	O
9	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
14	O	NUM	O
to	O	PART	O
16	O	NUM	O
(	O	PUNCT	O
first	O	ADJ	O
,	O	PUNCT	O
second	O	ADJ	O
,	O	PUNCT	O
and	O	CCONJ	O
third	O	ADJ	O
weeks	O	NOUN	B
of	O	ADP	O
abstinence	O	NOUN	B
).	O	PUNCT	O
The	O	DET	O
Multiple	O	ADJ	B
Sleep	O	PROPN	I
Latency	O	PROPN	I
Test	O	PROPN	I
was	O	AUX	O
performed	O	VERB	O
at	O	ADP	O
11	O	NUM	O
:	O	PUNCT	O
30	O	NUM	O
a	O	DET	O
.	O	PUNCT	O


m	O	NOUN	O
.,	O	NOUN	O
2	O	X	O
:	O	PUNCT	O
00	O	NUM	O
p	O	NOUN	O
.	O	PUNCT	O


m	O	NOUN	O
.,	O	NOUN	O
and	O	CCONJ	O
4	O	NUM	O
:	O	PUNCT	O
30	O	NUM	O
p	O	NOUN	O
.	O	PUNCT	O


m	O	NOUN	O
.	O	PUNCT	O


on	O	ADP	O
days	O	NOUN	B
2	O	NUM	O
,	O	PUNCT	O
8	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
15	O	NUM	O
.	O	PUNCT	O


For	O	ADP	O
comparison	O	NOUN	B
of	O	ADP	O
sleep	O	NOUN	B
architecture	O	NOUN	I
variables	O	NOUN	B
,	O	PUNCT	O
12	O	NUM	O
healthy	O	ADJ	B
comparison	O	NOUN	B
participants	O	NOUN	B
underwent	O	VERB	O
a	O	DET	O
single	O	ADJ	O
night	O	NOUN	B
of	O	ADP	O
experimental	O	ADJ	B
polysomnography	O	NOUN	I
that	O	PRON	O
followed	O	VERB	O
1	O	NUM	O
night	O	NOUN	B
of	O	ADP	O
accommodation	O	NOUN	B
polysomnography	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Progressive	O	ADJ	B
abstinence	O	NOUN	B
from	O	ADP	O
cocaine	B-Chemical	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
worsening	O	NOUN	B
of	O	ADP	O
all	O	DET	O
measured	O	VERB	B
polysomnographic	O	ADJ	B
sleep	O	NOUN	O
outcomes	O	NOUN	B
.	O	PUNCT	O


Compared	O	VERB	B
with	O	ADP	O
placebo	O	NOUN	B
,	O	PUNCT	O
modafinil	B-Chemical	NOUN	B
decreased	O	VERB	B
nighttime	O	ADJ	B
sleep	O	NOUN	B
latency	O	NOUN	I
and	O	CCONJ	O
increased	O	VERB	B
slow	O	ADJ	B
-	O	PUNCT	O
wave	O	NOUN	B
sleep	O	NOUN	I
time	O	NOUN	I
in	O	ADP	O
cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
participants	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
modafinil	B-Chemical	NOUN	B
interacted	O	VERB	B
with	O	ADP	O
the	O	DET	O
abstinence	O	NOUN	B
week	O	NOUN	B
and	O	CCONJ	O
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
longer	O	ADJ	O
total	O	ADJ	O
sleep	O	NOUN	O
time	O	NOUN	O
and	O	CCONJ	O
shorter	O	ADJ	B
REM	O	NOUN	B
sleep	O	NOUN	I
latency	O	NOUN	I
in	O	ADP	O
the	O	DET	O
third	O	ADJ	O
week	O	NOUN	B
of	O	ADP	O
abstinence	O	NOUN	B
.	O	PUNCT	O


Comparison	O	NOUN	B
of	O	ADP	O
slow	O	ADJ	B
-	O	PUNCT	O
wave	O	NOUN	B
sleep	O	NOUN	I
time	O	NOUN	I
,	O	PUNCT	O
total	O	ADJ	B
sleep	O	NOUN	I
time	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
sleep	O	ADJ	B
latency	O	NOUN	I
in	O	ADP	O
cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
and	O	CCONJ	O
healthy	O	ADJ	B
participants	O	NOUN	B
revealed	O	VERB	O
a	O	DET	O
normalizing	O	ADJ	B
effect	O	NOUN	B
of	O	ADP	O
modafinil	B-Chemical	NOUN	B
in	O	ADP	O
cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
participants	O	NOUN	B
.	O	PUNCT	O


Modafinil	B-Chemical	PROPN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
increased	O	VERB	B
daytime	O	NOUN	B
sleep	O	NOUN	I
latency	O	NOUN	I
,	O	PUNCT	O
as	O	ADP	O
measured	O	VERB	B
by	O	ADP	O
the	O	DET	O
Multiple	O	ADJ	B
Sleep	O	PROPN	I
Latency	O	PROPN	I
Test	O	PROPN	I
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
nearly	O	ADV	O
significant	O	ADJ	O
decrease	O	NOUN	B
in	O	ADP	O
subjective	O	ADJ	B
daytime	B-Disease	NOUN	I
sleepiness	I-Disease	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
Morning	O	PROPN	B
-	O	PUNCT	O
dosed	O	VERB	B
modafinil	B-Chemical	NOUN	B
promotes	O	VERB	B
nocturnal	O	ADJ	B
sleep	O	NOUN	I
,	O	PUNCT	O
normalizes	O	VERB	B
sleep	O	NOUN	B
architecture	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
decreases	O	VERB	B
daytime	B-Disease	NOUN	B
sleepiness	I-Disease	NOUN	I
in	O	ADP	O
abstinent	O	VERB	B
cocaine	B-Chemical	NOUN	B
users	O	NOUN	O
.	O	PUNCT	O


These	O	DET	O
effects	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
relevant	O	ADJ	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
cocaine	B-Chemical	NOUN	B


Efficacy	O	NOUN	B
and	O	CCONJ	O
safety	O	NOUN	B
of	O	ADP	O
asenapine	B-Chemical	NOUN	B
in	O	ADP	O
a	O	DET	O
placebo	O	NOUN	B
-	O	PUNCT	O
and	O	CCONJ	O
haloperidol	B-Chemical	NOUN	B
-	O	PUNCT	O
controlled	O	VERB	B
trial	O	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
acute	O	ADJ	B
exacerbation	O	NOUN	I
of	O	ADP	O
schizophrenia	B-Disease	NOUN	B
.	O	PUNCT	O


Asenapine	B-Chemical	NOUN	B
is	O	AUX	O
approved	O	VERB	O
by	O	ADP	O
the	O	DET	O
Food	O	PROPN	B
and	O	CCONJ	I
Drugs	O	PROPN	I
Administration	O	PROPN	I
in	O	ADP	O
adults	O	NOUN	B
for	O	ADP	O
acute	O	ADJ	B
treatment	O	NOUN	B
of	O	ADP	O
schizophrenia	B-Disease	NOUN	B
or	O	CCONJ	O
of	O	ADP	O
manic	B-Disease	ADJ	B
or	O	CCONJ	O
mixed	O	ADJ	O
episodes	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
bipolar	B-Disease	ADJ	B
I	I-Disease	NUM	I
disorder	I-Disease	NOUN	I
with	O	ADP	O
or	O	CCONJ	O
without	O	ADP	O
psychotic	B-Disease	ADJ	B
features	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	NOUN	B
6	O	NUM	O
-	O	PUNCT	O
week	O	NOUN	B
trial	O	NOUN	B
,	O	PUNCT	O
458	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
acute	O	ADJ	B
schizophrenia	B-Disease	NOUN	I
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
fixed	O	VERB	B
-	O	PUNCT	O
dose	O	NOUN	B
treatment	O	NOUN	B
with	O	ADP	O
asenapine	B-Chemical	NOUN	B
at	O	ADP	O
5	O	NUM	O
mg	O	NOUN	O
twice	O	ADV	O
daily	O	ADV	O
(	O	PUNCT	O
BID	O	NOUN	B
),	O	PUNCT	O
asenapine	B-Chemical	NOUN	B
at	O	ADP	O
10	O	NUM	O
mg	O	NOUN	O
BID	O	NOUN	B
,	O	PUNCT	O
placebo	O	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
haloperidol	B-Chemical	NOUN	B
at	O	ADP	O
4	O	NUM	O
mg	O	NOUN	O
BID	O	NOUN	B
(	O	PUNCT	O
to	O	PART	O
verify	O	VERB	O
assay	O	NOUN	B
sensitivity	O	NOUN	B
).	O	PUNCT	B
With	O	ADP	O
last	O	ADJ	O
observations	O	NOUN	B
carried	O	VERB	O
forward	O	NOUN	O
(	O	PUNCT	O
LOCF	O	NOUN	B
),	O	PUNCT	O
mean	O	VERB	O
Positive	O	ADJ	B
and	O	CCONJ	I
Negative	O	ADJ	O
Syndrome	O	NOUN	O
Scale	O	NOUN	O
total	O	ADJ	O
score	O	NOUN	O
reductions	O	NOUN	B
from	O	ADP	O
baseline	O	NOUN	B
to	O	PART	O
endpoint	O	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
greater	O	ADJ	O
with	O	ADP	O
asenapine	B-Chemical	NOUN	B
at	O	ADP	O
5	O	NUM	O
mg	O	NOUN	O
BID	O	NOUN	B
(-	O	X	O
16	O	NUM	O
.	O	PUNCT	O


2	O	X	O
)	O	PUNCT	O
and	O	CCONJ	O
haloperidol	B-Chemical	NOUN	B
(-	O	PUNCT	O
15	O	NUM	O
.	O	PUNCT	O


4	O	X	O
)	O	PUNCT	O
than	O	ADP	O
placebo	O	NOUN	B
(-	O	PUNCT	O
10	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
;	O	PUNCT	O
both	O	CCONJ	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
);	O	ADJ	O
using	O	VERB	O
mixed	O	ADJ	B
model	O	NOUN	I
for	O	ADP	O
repeated	O	VERB	O
measures	O	NOUN	B
(	O	PUNCT	O
MMRM	O	NOUN	B
),	O	PUNCT	O
changes	O	NOUN	B
at	O	ADP	O
day	O	NOUN	B
42	O	NUM	O
were	O	AUX	O
significantly	O	ADV	O
greater	O	ADJ	O
with	O	ADP	O
asenapine	B-Chemical	NOUN	B
at	O	ADP	O
5	O	NUM	O
and	O	CCONJ	O
10	O	NUM	O
mg	O	NOUN	O
BID	O	NOUN	B
(-	O	X	O
21	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
and	O	CCONJ	O
-	O	PUNCT	O
19	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
and	O	CCONJ	O
haloperidol	B-Chemical	NOUN	B
(-	O	PUNCT	O
20	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
)	O	PUNCT	O
than	O	ADP	O
placebo	O	NOUN	B
(-	O	PUNCT	O
14	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
;	O	PUNCT	O
all	O	DET	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
).	O	PUNCT	O
On	O	ADP	O
the	O	DET	O
Positive	O	ADJ	B
and	O	CCONJ	I
Negative	O	ADJ	O
Syndrome	O	NOUN	O
Scale	O	NOUN	O
positive	O	ADJ	O
subscale	O	NOUN	O
,	O	PUNCT	O
all	O	DET	O
treatments	O	NOUN	B
were	O	AUX	O
superior	O	ADJ	O
to	O	PART	O
placebo	O	NOUN	B
with	O	ADP	O
LOCF	O	NOUN	B
and	O	CCONJ	O
MMRM	O	NOUN	B
;	O	PUNCT	O
asenapine	B-Chemical	NOUN	B
at	O	ADP	O
5	O	NUM	O
mg	O	NOUN	O
BID	O	NOUN	B
was	O	AUX	O
superior	O	ADJ	O
to	O	PART	O
placebo	O	NOUN	B
on	O	ADP	O
the	O	DET	O
negative	O	ADJ	B
subscale	O	NOUN	O
with	O	ADP	O
MMRM	O	NOUN	B
and	O	CCONJ	O
on	O	ADP	O
the	O	DET	O
general	O	ADJ	O
psychopathology	O	NOUN	B
subscale	O	NOUN	O
with	O	ADP	O
LOCF	O	NOUN	B
and	O	CCONJ	O
MMRM	O	NOUN	B
.	O	PUNCT	O


Treatment	O	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
adverse	O	ADJ	B
events	O	NOUN	I
(	O	PUNCT	O
AEs	O	NOUN	B
)	O	PUNCT	O
occurred	O	VERB	O
in	O	ADP	O
44	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
52	O	NUM	O
%,	O	NOUN	O
57	O	NUM	O
%,	O	ADJ	B
and	O	CCONJ	O
41	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
asenapine	B-Chemical	NOUN	B
at	O	ADP	O
5	O	NUM	O
and	O	CCONJ	O
10	O	NUM	O
mg	O	NOUN	O
BID	O	NOUN	B
,	O	PUNCT	O
haloperidol	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
placebo	O	ADJ	B
groups	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Extrapyramidal	B-Disease	ADJ	B
symptoms	I-Disease	NOUN	O
reported	O	VERB	O
as	O	ADP	O
AEs	O	NOUN	B
occurred	O	VERB	O
in	O	ADP	O
15	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
18	O	NUM	O
%,	O	NOUN	O
34	O	NUM	O
%,	O	ADJ	B
and	O	CCONJ	O
10	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
asenapine	B-Chemical	NOUN	B
at	O	ADP	O
5	O	NUM	O
and	O	CCONJ	O
10	O	NUM	O
mg	O	NOUN	O
BID	O	NOUN	B
,	O	PUNCT	O
haloperidol	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
placebo	O	ADJ	B
groups	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Across	O	ADP	O
all	O	DET	O
groups	O	NOUN	B
,	O	PUNCT	O
no	O	DET	O
more	O	ADJ	O
than	O	ADP	O
5	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
had	O	AUX	O
clinically	O	ADV	B
significant	O	ADJ	I
weight	O	NOUN	B
change	O	NOUN	I
.	O	PUNCT	O


Post	O	NOUN	B
hoc	O	NOUN	I
analyses	O	NOUN	I
indicated	O	VERB	O
that	O	SCONJ	O
efficacy	O	NOUN	B
was	O	AUX	O
similar	O	ADJ	O
with	O	ADP	O
asenapine	B-Chemical	NOUN	B
and	O	CCONJ	O
haloperidol	B-Chemical	NOUN	B
;	O	PUNCT	O
greater	O	ADJ	O
contrasts	O	NOUN	O
were	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
AEs	O	NOUN	B
,	O	PUNCT	O
especially	O	ADV	O
extrapyramidal	B-Disease	ADJ	B
symptoms	I-Disease	NOUN	I


Permeability	O	NOUN	B
,	O	PUNCT	O
ultrastructural	O	ADJ	B
changes	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
distribution	O	NOUN	B
of	O	ADP	O
novel	O	ADJ	B
proteins	O	NOUN	B
in	O	ADP	O
the	O	DET	O
glomerular	O	ADJ	B
barrier	O	NOUN	I
in	O	ADP	O
early	O	ADJ	O
puromycin	B-Chemical	NOUN	B
aminonucleoside	I-Chemical	NOUN	B
nephrosis	B-Disease	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
/	O	SYM	O
AIMS	O	NOUN	B
:	O	PUNCT	O
It	O	PRON	O
is	O	AUX	O
still	O	ADV	O
unclear	O	ADJ	O
what	O	PRON	O
happens	O	VERB	O
in	O	ADP	O
the	O	DET	O
glomerulus	O	NOUN	B
when	O	SCONJ	O
proteinuria	B-Disease	NOUN	B
starts	O	VERB	O
.	O	PUNCT	O


Using	O	VERB	O
puromycin	B-Chemical	NOUN	B
aminonucleoside	I-Chemical	NOUN	B
nephrosis	B-Disease	NOUN	I
(	O	PUNCT	O
PAN	O	NOUN	B
)	O	PUNCT	O
rats	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
studied	O	VERB	O
early	O	ADJ	O
ultrastructural	O	ADJ	B
and	O	CCONJ	O
permeability	O	NOUN	B
changes	O	NOUN	B
in	O	ADP	O
relation	O	NOUN	O
to	O	PART	O
the	O	DET	O
expression	O	NOUN	B
of	O	ADP	O
the	O	DET	O
podocyte	O	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
molecules	O	NOUN	B
nephrin	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
-	O	PUNCT	O
actinin	O	NOUN	B
,	O	PUNCT	O
dendrin	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
plekhh2	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
last	O	ADJ	O
two	O	NUM	O
of	O	ADP	O
which	O	DET	O
were	O	AUX	O
only	O	ADV	O
recently	O	ADV	O
discovered	O	VERB	O
in	O	ADP	O
podocytes	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
Using	O	VERB	O
immune	O	ADJ	B
stainings	O	NOUN	I
,	O	PUNCT	O
semiquantitative	O	ADJ	B
measurement	O	NOUN	I
was	O	AUX	O
performed	O	VERB	O
under	O	ADP	O
the	O	DET	O
electron	O	NOUN	B
microscope	O	NOUN	I
.	O	PUNCT	O


Permeability	O	NOUN	B
was	O	AUX	O
assessed	O	VERB	B
using	O	VERB	O
isolated	O	VERB	B
kidney	O	NOUN	I
perfusion	O	NOUN	I
with	O	ADP	O
tracers	O	NOUN	B
.	O	PUNCT	O


Possible	O	ADJ	O
effects	O	NOUN	B
of	O	ADP	O
ACE	O	NOUN	B
inhibition	O	NOUN	B
were	O	AUX	O
tested	O	VERB	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
By	O	ADP	O
day	O	NOUN	B
2	O	NUM	O
,	O	PUNCT	O
some	O	DET	O
patchy	O	ADJ	B
foot	O	NOUN	B
process	O	NOUN	I
effacement	O	NOUN	O
,	O	PUNCT	O
but	O	CCONJ	O
no	O	DET	O
proteinuria	B-Disease	NOUN	B
,	O	PUNCT	O
appeared	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
amount	O	NOUN	B
of	O	ADP	O
nephrin	O	NOUN	B
was	O	AUX	O
reduced	O	VERB	B
in	O	ADP	O
both	O	CCONJ	O
diseased	O	ADJ	B
and	O	CCONJ	O
normal	O	ADJ	B
areas	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
other	O	ADJ	O
proteins	O	NOUN	B
showed	O	VERB	O
few	O	ADJ	O
changes	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
were	O	AUX	O
limited	O	ADJ	O
to	O	ADP	O
diseased	O	ADJ	B
areas	O	NOUN	I
.	O	PUNCT	O


By	O	ADP	O
day	O	NOUN	B
4	O	NUM	O
,	O	PUNCT	O
foot	O	NOUN	B
process	O	NOUN	I
effacement	O	NOUN	I
was	O	AUX	O
complete	O	ADJ	B
and	O	CCONJ	O
proteinuria	B-Disease	NOUN	B
appeared	O	VERB	O
in	O	ADP	O
parallel	O	NOUN	O
with	O	ADP	O
signs	O	NOUN	O
of	O	ADP	O
size	O	NOUN	B
barrier	O	NOUN	I
damage	O	NOUN	B
.	O	PUNCT	O


Nephrin	O	NOUN	B
decreased	O	VERB	B
further	O	ADV	O
,	O	PUNCT	O
while	O	SCONJ	O
dendrin	O	NOUN	B
and	O	CCONJ	O
plekhh2	O	NOUN	B
also	O	ADV	O
decreased	O	VERB	B
but	O	CCONJ	O
a	O	DET	O
-	O	PUNCT	O
actinin	O	NOUN	B
remained	O	VERB	O
unchanged	O	ADJ	B
.	O	PUNCT	O


ACE	O	NOUN	B
inhibition	O	NOUN	B
had	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
protective	O	ADJ	B
effect	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
PAN	O	NOUN	B
glomeruli	O	NOUN	I
already	O	ADV	O
showed	O	VERB	O
significant	O	ADJ	O
pathology	O	NOUN	B
by	O	ADP	O
day	O	NOUN	B
4	O	NUM	O
,	O	PUNCT	O
despite	O	SCONJ	O
relatively	O	ADV	O
mild	O	ADJ	O
proteinuria	B-Disease	NOUN	B


Twin	O	ADJ	B
preterm	O	NOUN	I
neonates	O	NOUN	I
with	O	ADP	O
cardiac	B-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
related	O	ADJ	O
to	O	PART	O
lopinavir/ritonavir	B-Chemical	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
twin	O	NOUN	B
neonates	O	NOUN	I
who	O	PRON	O
were	O	AUX	O
born	O	VERB	B
prematurely	O	ADV	O
at	O	ADP	O
32	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
gestation	O	NOUN	B
to	O	ADP	O
a	O	DET	O
mother	O	NOUN	B
with	O	ADP	O
human	B-Disease	ADJ	B
immunodeficiency	I-Disease	NOUN	I
virus	I-Disease	NOUN	I
infection	I-Disease	NOUN	I
.	O	PUNCT	O


One	O	NUM	O
of	O	ADP	O
the	O	DET	O
twins	O	NOUN	B
developed	O	VERB	O
complete	O	ADJ	O
heart	B-Disease	NOUN	B
block	I-Disease	NOUN	I
and	O	CCONJ	O
dilated	B-Disease	ADJ	B
cardiomyopathy	I-Disease	NOUN	I
related	O	ADJ	O
to	O	PART	O
lopinavir/ritonavir	B-Chemical	NOUN	B
therapy	O	NOUN	I
,	O	PUNCT	O
a	O	DET	O
boosted	O	VERB	O
protease	O	NOUN	B
-	O	PUNCT	O
inhibitor	O	NOUN	B
agent	O	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
the	O	DET	O
other	O	ADJ	O
twin	O	NOUN	B
developed	O	VERB	O
mild	O	ADJ	O
bradycardia	B-Disease	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
recommend	O	VERB	O
caution	O	NOUN	O
in	O	ADP	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
lopinavir/ritonavir	B-Chemical	NOUN	B


Learning	O	NOUN	B
of	O	ADP	O
rats	O	NOUN	B
under	O	ADP	O
amnesia	B-Disease	NOUN	B
caused	O	VERB	O
by	O	ADP	O
pentobarbital	B-Chemical	NOUN	B
.	O	PUNCT	O


Dissociated	O	ADJ	B
learning	O	NOUN	I
of	O	ADP	O
rats	O	NOUN	B
in	O	ADP	O
the	O	DET	O
normal	O	ADJ	B
state	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
state	O	NOUN	B
of	O	ADP	O
amnesia	B-Disease	NOUN	B
produced	O	VERB	O
by	O	ADP	O
pentobarbital	B-Chemical	NOUN	B
(	O	PUNCT	O
15	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
ip	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
carried	O	VERB	O
out	O	ADP	O
.	O	PUNCT	O


Rats	O	NOUN	B
were	O	AUX	O
trained	O	VERB	B
to	O	PART	O
approach	O	VERB	O
a	O	DET	O
shelf	O	NOUN	B
where	O	SCONJ	O
they	O	PRON	O
received	O	VERB	O
food	O	NOUN	B
reinforcement	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
Group	O	PROPN	B
1	O	NUM	O
the	O	DET	O
rats	O	NOUN	B
were	O	AUX	O
trained	O	VERB	B
under	O	ADP	O
the	O	DET	O
influence	O	NOUN	B
of	O	ADP	O
pentobarbital	B-Chemical	NOUN	B
to	O	PART	O
run	O	VERB	O
to	O	ADP	O
the	O	DET	O
same	O	ADJ	O
shelf	O	NOUN	O
as	O	ADP	O
in	O	ADP	O
the	O	DET	O
normal	O	ADJ	B
state	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
Group	O	PROPN	B
2	O	NUM	O
the	O	DET	O
rats	O	NOUN	B
were	O	AUX	O
trained	O	VERB	B
to	O	PART	O
approach	O	VERB	O
different	O	ADJ	O
shelves	O	NOUN	B
in	O	ADP	O
different	O	ADJ	O
drug	O	NOUN	B
states	O	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
was	O	AUX	O
shown	O	VERB	O
that	O	SCONJ	O
memory	B-Disease	NOUN	B
dissociation	I-Disease	NOUN	I
occurred	O	VERB	O
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


Differences	O	NOUN	B
in	O	ADP	O
the	O	DET	O
parameters	O	NOUN	B
of	O	ADP	O
training	O	NOUN	B
under	O	ADP	O
the	O	DET	O
influence	O	NOUN	B
of	O	ADP	O
pentobarbital	B-Chemical	NOUN	B
between	O	ADP	O
Groups	O	NOUN	B
1	O	NUM	O
and	O	CCONJ	O
2	O	NUM	O
were	O	AUX	O
revealed	O	VERB	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
show	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
brain	O	NOUN	B
-	O	PUNCT	O
dissociated	O	VERB	B
state	O	NOUN	B
induced	O	VERB	B
by	O	ADP	O
pentobarbital	B-Chemical	ADJ	B


Angiosarcoma	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
liver	I-Disease	NOUN	B
associated	O	VERB	B
with	O	ADP	I
diethylstilbestrol	B-Chemical	NOUN	B
.	O	PUNCT	O


Angiosarcoma	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
liver	I-Disease	NOUN	B
occurred	O	VERB	O
in	O	ADP	O
a	O	DET	O
76	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
man	O	NOUN	B
who	O	PRON	O
had	O	AUX	O
been	O	AUX	O
treated	O	VERB	B
for	O	ADP	O
a	O	DET	O
well	O	ADV	B
-	O	PUNCT	O
differentiated	O	VERB	B
adenocarcinoma	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
liver	I-Disease	NOUN	B
with	O	ADP	O
diethylstilbestrol	B-Chemical	NOUN	B
for	O	ADP	O
13	O	NUM	O
years	O	NOUN	B
.	O	PUNCT	O


Angiosarcoma	B-Disease	NOUN	B
was	O	AUX	O
also	O	ADV	O
present	O	ADJ	O
within	O	ADP	O
pulmonary	O	ADJ	B
and	O	CCONJ	O
renal	O	ADJ	B
arteries	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
possibility	O	NOUN	O
that	O	SCONJ	O
the	O	DET	O
intraarterial	B-Disease	ADJ	B
lesions	I-Disease	NOUN	B
might	O	AUX	O
represent	O	VERB	O
independent	O	ADJ	O
primary	O	ADJ	B
tumors	B-Disease	NOUN	I


Role	O	NOUN	O
of	O	ADP	O
xanthine	B-Chemical	NOUN	B
oxidase	O	NOUN	I
in	O	ADP	O
dexamethasone	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypertension	B-Disease	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


1	O	X	O
.	O	PUNCT	O


Glucocorticoid	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypertension	B-Disease	NOUN	B
(	O	PUNCT	O
GC	O	NOUN	B
-	O	PUNCT	O
HT	B-Disease	PROPN	B
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
nitric	B-Chemical	ADJ	B
oxide	I-Chemical	NOUN	I
-	O	PUNCT	O
redox	O	NOUN	B
imbalance	O	NOUN	B
.	O	PUNCT	O


2	O	X	O
.	O	PUNCT	O


We	O	PRON	O
studied	O	VERB	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
xanthine	B-Chemical	NOUN	B
oxidase	O	NOUN	I
(	O	PUNCT	O
XO	O	NOUN	B
),	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
implicated	O	VERB	O
in	O	ADP	O
the	O	DET	O
production	O	NOUN	B
of	O	ADP	O
reactive	O	ADJ	B
oxygen	O	NOUN	I
species	O	NOUN	I
,	O	PUNCT	O
in	O	ADP	O
dexamethasone	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypertension	B-Disease	NOUN	B
(	O	PUNCT	O
dex	B-Chemical	NOUN	B
-	O	PUNCT	O
HT	B-Disease	PROPN	B
).	O	PROPN	O
3	O	NUM	O
.	O	PUNCT	O


Thirty	O	NUM	O
male	O	NOUN	B
Sprague	O	PROPN	B
-	O	PUNCT	O
Dawley	O	NOUN	B
rats	O	NOUN	B
were	O	AUX	O
divided	O	VERB	O
randomly	O	ADV	O
into	O	ADP	O
four	O	NUM	O
treatment	O	NOUN	B
groups	O	NOUN	I
:	O	PUNCT	O
saline	O	NOUN	B
,	O	PUNCT	O
dexamethasone	B-Chemical	NOUN	B
(	O	PUNCT	O
dex	B-Chemical	NOUN	B
),	O	PUNCT	O
allopurinol	B-Chemical	NOUN	B
plus	O	CCONJ	O
saline	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
allopurinol	B-Chemical	NOUN	B
plus	O	CCONJ	O
dex	B-Chemical	NOUN	B
.	O	PUNCT	O


4	O	X	O
.	O	PUNCT	O


Systolic	O	NOUN	B
blood	O	NOUN	I
pressures	O	NOUN	I
(	O	PUNCT	O
SBP	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
bodyweights	O	NOUN	B
were	O	AUX	O
recorded	O	VERB	O
each	O	DET	O
alternate	O	ADJ	B
day	O	NOUN	I
.	O	PUNCT	O


Thymus	O	NOUN	B
weight	O	NOUN	O
was	O	AUX	O
used	O	VERB	O
as	O	ADP	O
a	O	DET	O
marker	O	NOUN	B
of	O	ADP	O
glucocorticoid	O	NOUN	B
activity	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
serum	O	NOUN	B
urate	B-Chemical	NOUN	I
to	O	PART	O
assess	O	VERB	B
XO	O	NOUN	B
inhibition	O	NOUN	B
.	O	PUNCT	O


5	O	NUM	O
.	O	PUNCT	O


Dex	B-Chemical	NOUN	B
increased	B-Disease	VERB	B
SBP	I-Disease	NOUN	B
(	O	PUNCT	O
110	O	NUM	O
+/-	O	CCONJ	O
2	O	NUM	O
-	O	SYM	O
126	O	NUM	O
+/-	O	CCONJ	O
3	O	NUM	O
mmHg	O	NOUN	B
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
decreased	B-Disease	VERB	B
thymus	I-Disease	NOUN	B
(P	I-Disease	PUNCT	O
<	I-Disease	X	O
0.001)	I-Disease	NOUN	O
and	I-Disease	CCONJ	O
bodyweights	I-Disease	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
"<	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
).	O	PUNCT	O
Allopurinol	B-Chemical	NOUN	B
decreased	O	VERB	B
serum	O	NOUN	B
urate	B-Chemical	NOUN	O
from	O	ADP	O
76	O	NUM	O
+/-	O	CCONJ	O
5	O	NUM	O
to	O	PART	O
30	O	NUM	O
+/-	O	CCONJ	O
3	O	NUM	O
micromol	O	NOUN	O
/	O	SYM	O
L	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
saline	O	NOUN	B
and	O	CCONJ	O
from	O	ADP	O
84	O	NUM	O
+/-	O	CCONJ	O
13	O	NUM	O
to	O	PART	O
28	O	NUM	O
+/-	O	CCONJ	O
2	O	NUM	O
micromol	O	NOUN	B
/	O	SYM	O
L	O	NOUN	B
in	O	ADP	O
dex	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
)	O	PUNCT	O
groups	O	NOUN	B
.	O	PUNCT	O


6	O	NUM	O
.	O	PUNCT	O


Allopurinol	B-Chemical	NOUN	B
did	O	AUX	O
not	O	PART	O
prevent	O	VERB	O
dex	B-Chemical	NOUN	B
-	O	PUNCT	O
HT	B-Disease	PROPN	B
.	O	PUNCT	O


This	O	DET	O
,	O	PUNCT	O
together	O	ADV	O
with	O	ADP	O
our	O	PRON	O
previous	O	ADJ	O
findings	O	NOUN	B
that	O	SCONJ	O
allopurinol	B-Chemical	NOUN	B
failed	O	VERB	B
to	O	PART	O
prevent	O	VERB	B
adrenocorticotrophic	O	ADJ	B
hormone	O	NOUN	I
induced	O	VERB	B
hypertension	B-Disease	NOUN	B
,	O	PUNCT	O
suggests	O	VERB	O
that	O	SCONJ	O
XO	O	NOUN	B
activity	O	NOUN	B
is	O	AUX	O
not	O	PART	O
a	O	DET	O
major	O	ADJ	O
determinant	O	NOUN	O
of	O	ADP	O
GC	O	NOUN	B
-	O	PUNCT	O
HT	B-Disease	PROPN	B


Extrapyramidal	O	ADJ	B
side	O	NOUN	O
effects	O	NOUN	O
with	O	ADP	O
risperidone	B-Chemical	NOUN	B
and	O	CCONJ	O
haloperidol	B-Chemical	NOUN	B
at	O	ADP	O
comparable	O	ADJ	O
D2	O	NOUN	B
receptor	O	NOUN	I
occupancy	O	NOUN	B
levels	O	NOUN	O
.	O	PUNCT	O


Risperidone	B-Chemical	NOUN	B
is	O	AUX	O
an	O	DET	O
antipsychotic	O	ADJ	B
drug	O	NOUN	I
with	O	ADP	O
high	O	ADJ	O
affinity	O	NOUN	B
at	O	ADP	O
dopamine	B-Chemical	NOUN	B
D2	O	NOUN	I
and	O	CCONJ	O
serotonin	B-Chemical	NOUN	B
5-HT2	I-Chemical	NOUN	I
receptors	O	NOUN	I
.	O	PUNCT	O


Previous	O	ADJ	O
clinical	O	ADJ	B
studies	O	NOUN	I
have	O	AUX	O
proposed	O	VERB	O
that	O	SCONJ	O
risperidone	B-Chemical	NOUN	B
'	O	PART	O
s	O	NOUN	O
pharmacologic	O	ADJ	B
profile	O	NOUN	I
may	O	AUX	O
produce	O	VERB	O
improved	O	VERB	O
efficacy	O	NOUN	B
for	O	ADP	O
negative	O	ADJ	B
psychotic	B-Disease	ADJ	B
symptoms	I-Disease	NOUN	O
and	O	CCONJ	O
decreased	O	VERB	B
propensity	O	NOUN	B
for	O	ADP	O
extrapyramidal	O	ADJ	B
side	O	NOUN	I
effects	O	NOUN	I
;	O	PUNCT	O
features	O	NOUN	B
shared	O	VERB	O
by	O	ADP	O
so	O	ADV	O
-	O	PUNCT	O
called	O	VERB	O
'	O	PUNCT	O
atypical	O	ADJ	B
'	O	PUNCT	O
neuroleptics	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
determine	O	VERB	O
if	O	SCONJ	O
routine	O	ADJ	O
risperidone	B-Chemical	NOUN	B
treatment	O	NOUN	B
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
unique	O	ADJ	O
degree	O	NOUN	B
of	O	ADP	O
D2	O	NOUN	B
receptor	O	NOUN	I
occupancy	O	NOUN	B
and	O	CCONJ	O
pattern	O	NOUN	B
of	O	ADP	O
clinical	O	ADJ	B
effects	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
used	O	VERB	O
[	O	PUNCT	O
123I	O	NOUN	O
]	O	PUNCT	O
IBZM	O	NOUN	B
SPECT	O	NOUN	B
to	O	PART	O
determine	O	VERB	O
D2	O	NOUN	B
occupancy	O	NOUN	B
in	O	ADP	O
subjects	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
routine	O	ADJ	O
clinical	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
risperidone	B-Chemical	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
12	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
haloperidol	B-Chemical	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
7	O	NUM	O
).	O	PUNCT	O
Both	O	CCONJ	O
risperidone	B-Chemical	NOUN	B
and	O	CCONJ	O
haloperidol	B-Chemical	NOUN	B
produced	O	VERB	O
D2	O	NOUN	B
occupancy	O	NOUN	O
levels	O	NOUN	O
between	O	ADP	O
approximately	O	ADV	B
60	O	NUM	O
and	O	CCONJ	O
90	O	NUM	O
%	O	NOUN	O
at	O	ADP	O
standard	O	ADJ	O
clinical	O	ADJ	B
doses	O	NOUN	I
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
between	O	ADP	O
occupancy	O	NOUN	B
levels	O	NOUN	O
obtained	O	VERB	O
with	O	ADP	O
haloperidol	B-Chemical	NOUN	B
or	O	CCONJ	O
risperidone	B-Chemical	NOUN	B
.	O	PUNCT	O


Drug-induced	B-Disease	ADJ	B
parkinsonism	I-Disease	NOUN	I
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
subjects	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
risperidone	B-Chemical	NOUN	B
(	O	PUNCT	O
42	O	NUM	O
%)	O	NOUN	B
and	O	CCONJ	O
haloperidol	B-Chemical	NOUN	B
(	O	PUNCT	O
29	O	NUM	O
%)	O	NOUN	O
and	O	CCONJ	O
was	O	AUX	O
observed	O	VERB	O
at	O	ADP	O
occupancy	O	NOUN	B
levels	O	NOUN	O
above	O	ADP	O
60	O	NUM	O
%.	O	NOUN	B
Based	O	VERB	O
on	O	ADP	O
these	O	DET	O
observations	O	NOUN	B
,	O	PUNCT	O
it	O	PRON	O
is	O	AUX	O
concluded	O	VERB	O
that	O	SCONJ	O
5	O	NUM	O
-	O	PUNCT	O
HT2	O	NOUN	B
blockade	O	NOUN	B
obtained	O	VERB	O
with	O	ADP	O
risperidone	B-Chemical	NOUN	B


Simvastatin-ezetimibe	B-Chemical	ADJ	B
-	O	PUNCT	O
induced	O	VERB	B
hepatic	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
necessitating	O	VERB	O
liver	O	NOUN	B
transplantation	O	NOUN	I
.	O	PUNCT	O


Abstract	O	NOUN	B
Serum	O	NOUN	B
aminotransferase	O	NOUN	I
elevations	O	NOUN	B
are	O	AUX	O
a	O	DET	O
commonly	O	ADV	O
known	O	VERB	O
adverse	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
3	O	NUM	O
-	O	PUNCT	O
hydroxy	O	NOUN	B
-	O	PUNCT	O
3	O	NUM	B
-	O	PUNCT	O
methylglutaryl	O	NOUN	B
coenzyme	O	NOUN	I
A	O	NOUN	I
reductase	O	NOUN	I
inhibitor	O	NOUN	I
(	O	PUNCT	O
statin	B-Chemical	NOUN	B
)	O	PUNCT	O
therapy	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
hepatotoxic	B-Disease	ADJ	B
events	O	NOUN	O
have	O	AUX	O
not	O	PART	O
been	O	AUX	O
widely	O	ADV	O
published	O	VERB	B
with	O	ADP	O
ezetimibe	B-Chemical	NOUN	B
or	O	CCONJ	O
the	O	DET	O
combination	O	NOUN	B
agent	O	NOUN	I
simvastatin-ezetimibe	B-Chemical	ADJ	B
.	O	PUNCT	O


We	O	PRON	O
describe	O	VERB	O
a	O	DET	O
70	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
Hispanic	O	ADJ	B
woman	O	NOUN	I
who	O	PRON	O
developed	O	VERB	O
fulminant	B-Disease	ADJ	B
hepatic	I-Disease	ADJ	B
failure	I-Disease	NOUN	I
necessitating	O	VERB	O
liver	O	NOUN	B
transplantation	O	NOUN	I
10	O	NUM	O
weeks	O	NOUN	B
after	O	ADP	O
conversion	O	NOUN	B
from	O	ADP	O
simvastatin	B-Chemical	NOUN	B
40	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
day	O	NOUN	B
to	O	PART	O
simvastatin	B-Chemical	NOUN	B
10	I-Chemical	NUM	O
mg-ezetimibe	I-Chemical	ADJ	O
40	I-Chemical	NUM	O
mg	I-Chemical	NOUN	O
/	O	SYM	O
day	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
'	O	PART	O
s	O	NOUN	O
lipid	O	NOUN	B
panel	O	NOUN	I
had	O	AUX	O
been	O	AUX	O
maintained	O	VERB	B
with	O	ADP	O
simvastatin	B-Chemical	NOUN	B
for	O	ADP	O
18	O	NUM	O
months	O	NOUN	B
before	O	ADP	O
the	O	DET	O
conversion	O	NOUN	B
without	O	ADP	O
evidence	O	NOUN	B
of	O	ADP	O
hepatotoxicity	B-Disease	NOUN	B
.	O	PUNCT	O


A	O	DET	O
routine	O	ADJ	O
laboratory	O	NOUN	B
work	O	NOUN	I
-	O	PUNCT	O
up	O	ADP	O
10	O	NUM	O
weeks	O	NOUN	B
after	O	ADP	O
conversion	O	NOUN	B
revealed	O	VERB	O
elevated	O	ADJ	B
serum	O	NOUN	O
aminotransferase	O	NOUN	O
levels	O	NOUN	O
.	O	PUNCT	O


Simvastatinezetimibe	B-Chemical	PROPN	B
and	O	CCONJ	O
escitalopram	B-Chemical	NOUN	B
(	O	PUNCT	O
which	O	DET	O
she	O	PRON	O
was	O	AUX	O
taking	O	VERB	O
for	O	ADP	O
depression	B-Disease	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
discontinued	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
other	O	ADJ	O
potential	O	ADJ	B
causes	O	NOUN	O
of	O	ADP	O
hepatotoxicity	B-Disease	NOUN	B
were	O	AUX	O
excluded	O	VERB	O
.	O	PUNCT	O


A	O	DET	O
repeat	O	NOUN	O
work	O	NOUN	B
-	O	PUNCT	O
up	O	ADP	B
revealed	O	VERB	O
further	O	ADJ	O
elevations	O	NOUN	B
in	O	ADP	O
aminotransferase	O	NOUN	B
levels	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
liver	O	NOUN	B
biopsy	O	NOUN	I
revealed	O	VERB	O
evidence	O	NOUN	B
of	O	ADP	O
moderate	O	ADJ	B
-	O	PUNCT	O
to	O	ADP	O
-	O	PUNCT	O
severe	O	ADJ	B
drug	B-Disease	NOUN	B
toxicity	I-Disease	NOUN	B
.	O	PUNCT	O


She	O	PRON	O
underwent	O	VERB	O
liver	O	NOUN	B
transplantation	O	NOUN	I
with	O	ADP	O
an	O	DET	O
uneventful	O	ADJ	B
postoperative	O	ADJ	B
course	O	NOUN	I
.	O	PUNCT	O


Her	O	PRON	O
aminotransferase	O	NOUN	B
levels	O	NOUN	B
returned	O	VERB	O
to	O	ADP	O
normal	O	ADJ	O
by	O	ADP	O
postoperative	O	ADJ	B
day	O	NOUN	B
23	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
her	O	PRON	O
2	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
follow	O	NOUN	B
-	O	PUNCT	O
up	O	NOUN	B
showed	O	VERB	O
no	O	DET	B
adverse	O	ADJ	I
events	O	NOUN	I
.	O	PUNCT	O


Ezetimibe	B-Chemical	NOUN	B
undergoes	O	VERB	O
extensive	O	ADJ	B
glucuronidation	O	NOUN	B
by	O	ADP	O
uridine	B-Chemical	NOUN	B
diphosphate	I-Chemical	NOUN	I
glucoronosyltransferases	O	NOUN	I
(	O	PUNCT	O
UGT	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
intestine	O	NOUN	B
and	O	CCONJ	O
liver	O	NOUN	B
and	O	CCONJ	O
may	O	AUX	O
have	O	AUX	O
inhibited	O	VERB	B
the	O	DET	O
glucuronidation	O	NOUN	B
of	O	ADP	O
simvastatin	B-Chemical	NOUN	B
hydroxy	I-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
,	O	PUNCT	O
resulting	O	VERB	O
in	O	ADP	O
increased	O	VERB	B
simvastatin	B-Chemical	NOUN	B
exposure	O	NOUN	B
and	O	CCONJ	O
subsequent	O	ADJ	O
hepatotoxicity	B-Disease	NOUN	B
.	O	PUNCT	O


To	O	ADP	O
our	O	PRON	O
knowledge	O	NOUN	B
,	O	PUNCT	O
this	O	DET	O
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
case	O	NOUN	B
report	O	NOUN	I
of	O	ADP	O
simvastatin-ezetimibe	B-Chemical	ADJ	B
-	O	PUNCT	O
induced	O	VERB	B
liver	B-Disease	NOUN	B
failure	I-Disease	NOUN	I
that	O	PRON	O
resulted	O	VERB	O
in	O	ADP	O
liver	O	NOUN	B
transplantation	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
postulate	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
mechanism	O	NOUN	B
of	O	ADP	O
the	O	DET	O
simvastatinezetimibe	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hepatotoxicity	B-Disease	NOUN	B
is	O	AUX	O
the	O	DET	O
increased	O	VERB	B
simvastatin	B-Chemical	NOUN	B
exposure	O	NOUN	B
by	O	ADP	O
ezetimibe	B-Chemical	ADJ	B
inhibition	O	NOUN	B
of	O	ADP	O
UGT	O	NOUN	B
enzymes	O	NOUN	B
.	O	PUNCT	O


Clinicians	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
aware	O	ADJ	O
of	O	ADP	O
potential	O	ADJ	B
hepatotoxicity	B-Disease	NOUN	B
with	O	ADP	O
simvastatin-ezetimibe	B-Chemical	ADJ	B


Oral	O	ADJ	B
manifestations	O	NOUN	B
of	O	ADP	O
"	O	PUNCT	O
meth	B-Disease	NOUN	B
mouth	I-Disease	NOUN	B
":	O	PUNCT	O
a	O	DET	O
case	O	NOUN	B
report	O	NOUN	I
.	O	PUNCT	O


AIM	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
the	O	DET	O
documentation	O	NOUN	B
of	O	ADP	O
this	O	DET	O
clinical	O	ADJ	B
case	O	NOUN	I
is	O	AUX	O
to	O	PART	O
make	O	VERB	O
clinicians	O	NOUN	B
aware	O	ADJ	O
of	O	ADP	O
"	O	PUNCT	O
meth	B-Disease	NOUN	B
mouth	I-Disease	NOUN	B
"	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
medical	O	ADJ	B
risks	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
this	O	DET	O
serious	O	ADJ	O
condition	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Methamphetamine	B-Chemical	NOUN	B
is	O	AUX	O
a	O	DET	O
very	O	ADV	O
addictive	O	ADJ	B
,	O	PUNCT	O
powerful	O	ADJ	O
stimulant	O	NOUN	B
that	O	PRON	O
increases	O	VERB	B
wakefulness	O	NOUN	B
and	O	CCONJ	O
physical	O	ADJ	B
activity	O	NOUN	I
and	O	CCONJ	O
can	O	AUX	O
produce	O	VERB	O
other	O	ADJ	O
effects	O	NOUN	B
such	O	ADJ	O
as	O	ADP	O
cardiac	B-Disease	ADJ	B
dysrhythmias	I-Disease	NOUN	I
,	O	PUNCT	O
hypertension	B-Disease	NOUN	B
,	O	PUNCT	O
hallucinations	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
violent	B-Disease	ADJ	B
behavior	I-Disease	NOUN	I
.	O	PUNCT	O


Dental	O	NOUN	B
patients	O	NOUN	B
abusing	O	VERB	B
methamphetamine	B-Chemical	NOUN	B
can	O	AUX	O
present	O	VERB	O
with	O	ADP	O
poor	O	ADJ	B
oral	O	ADJ	I
hygiene	O	NOUN	I
,	O	PUNCT	O
xerostomia	B-Disease	NOUN	B
,	O	PUNCT	O
rampant	O	ADJ	B
caries	B-Disease	NOUN	B
("	O	X	O
meth	B-Disease	NOUN	B
mouth	I-Disease	NOUN	I
"),	O	NOUN	B
and	O	CCONJ	O
excessive	O	ADJ	B
tooth	B-Disease	NOUN	B
wear	I-Disease	NOUN	I
.	O	PUNCT	O


Oral	O	ADJ	B
rehabilitation	O	NOUN	I
of	O	ADP	O
patients	O	NOUN	B
using	O	VERB	O
methamphetamine	B-Chemical	NOUN	B
can	O	AUX	O
be	O	AUX	O
challenging	O	ADJ	O
.	O	PUNCT	O


CASE	O	ADJ	O
DESCRIPTION	O	PROPN	B
:	O	PUNCT	O
A	O	DET	O
30	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
Caucasian	O	ADJ	B
woman	O	NOUN	B
presented	O	VERB	O
with	O	ADP	O
dental	O	ADJ	B
pain	B-Disease	NOUN	I
,	O	PUNCT	O
bad	B-Disease	ADJ	B
breath	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
self	O	NOUN	B
-	O	PUNCT	O
reported	O	VERB	B
poor	O	ADJ	B
esthetics	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
comprehensive	O	ADJ	B
examination	O	NOUN	B
including	O	VERB	O
her	O	PRON	O
medical	O	ADJ	B
history	O	NOUN	I
,	O	PUNCT	O
panoramic	O	ADJ	B
radiograph	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
intraoral	O	ADJ	B
examination	O	NOUN	I
revealed	O	VERB	O
19	O	NUM	O
carious	B-Disease	ADJ	B
lesions	I-Disease	NOUN	B
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
not	O	PART	O
very	O	ADV	O
common	O	ADJ	O
for	O	ADP	O
a	O	DET	O
healthy	O	ADJ	B
adult	O	NOUN	I
.	O	PUNCT	O


She	O	PRON	O
reported	O	VERB	O
her	O	PRON	O
use	O	NOUN	O
of	O	ADP	O
methamphetamine	B-Chemical	NOUN	B
for	O	ADP	O
five	O	NUM	O
years	O	NOUN	B
and	O	CCONJ	O
had	O	AUX	O
not	O	PART	O
experienced	O	VERB	O
any	O	DET	O
major	O	ADJ	O
carious	B-Disease	ADJ	B
episodes	I-Disease	NOUN	B
before	O	ADP	O
she	O	PRON	O
started	O	VERB	B
using	O	VERB	O
the	O	DET	O
drug	O	NOUN	B
.	O	PUNCT	O


SUMMARY	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
patient	O	NOUN	B
'	O	PART	O
s	O	NOUN	O
medical	O	ADJ	B
and	O	CCONJ	O
dental	O	NOUN	B
histories	O	NOUN	I
along	O	ADP	O
with	O	ADP	O
radiographic	O	ADJ	B
and	O	CCONJ	O
clinical	O	ADJ	B
findings	O	NOUN	I
lead	O	VERB	O
to	O	PART	O
a	O	DET	O
diagnosis	O	NOUN	B
of	O	ADP	O
"	O	PUNCT	O
meth	B-Disease	NOUN	B
mouth	I-Disease	NOUN	B
."	O	PUNCT	O
Although	O	SCONJ	O
three	O	NUM	O
different	O	ADJ	O
dental	O	NOUN	B
treatment	O	NOUN	I
modalities	O	NOUN	B
(	O	PUNCT	O
either	O	CCONJ	O
conventional	O	ADJ	B
or	O	CCONJ	O
implant	O	NOUN	B
-	O	PUNCT	O
supported	O	VERB	B
)	O	PUNCT	O
have	O	AUX	O
been	O	AUX	O
offered	O	VERB	O
to	O	PART	O
the	O	DET	O
patient	O	NOUN	B
since	O	SCONJ	O
August	O	PROPN	O
2007	O	NUM	O
,	O	PUNCT	O
the	O	DET	O
patient	O	NOUN	B
has	O	AUX	O
yet	O	ADV	O
to	O	PART	O
initiate	O	VERB	B
any	O	DET	O
treatment	O	NOUN	B
.	O	PUNCT	O


CLINICAL	O	X	O
SIGNIFICANCE	O	NOUN	O
:	O	PUNCT	O
This	O	DET	O
clinical	O	ADJ	B
case	O	NOUN	I
showing	O	VERB	O
oral	O	ADJ	B
manifestations	O	NOUN	I
of	O	ADP	O
meth	B-Disease	NOUN	B
mouth	I-Disease	NOUN	B
was	O	AUX	O
presented	O	VERB	O
to	O	PART	O
help	O	VERB	O
dental	O	NOUN	B
practitioners	O	NOUN	I
recognize	O	VERB	B
and	O	CCONJ	O
manage	O	VERB	O
patients	O	NOUN	B
who	O	PRON	O
may	O	AUX	O
be	O	AUX	O
abusing	O	VERB	B
methamphetamines	B-Chemical	NOUN	B


Thyroxine	B-Chemical	NOUN	B
abuse	O	NOUN	B
:	O	PUNCT	O
an	O	DET	O
unusual	O	ADJ	B
case	O	NOUN	B
of	O	ADP	O
thyrotoxicosis	B-Disease	NOUN	B
in	O	ADP	O
pregnancy	O	NOUN	B
.	O	PUNCT	O


Eating	B-Disease	VERB	B
disorders	I-Disease	NOUN	I
and	O	CCONJ	O
the	O	DET	O
associated	O	VERB	O
behavioural	O	ADJ	B
problems	O	NOUN	I
and	O	CCONJ	O
drug	B-Disease	NOUN	B
abuse	I-Disease	NOUN	I
are	O	AUX	O
uncommon	O	ADJ	O
in	O	ADP	O
pregnancy	O	NOUN	B
.	O	PUNCT	O


When	O	SCONJ	O
they	O	PRON	O
do	O	AUX	O
occur	O	VERB	O
they	O	PRON	O
are	O	AUX	O
often	O	ADV	O
unrecognized	O	ADJ	B
because	O	SCONJ	O
of	O	ADP	O
denial	O	ADJ	B
but	O	CCONJ	O
when	O	SCONJ	O
significant	O	ADJ	B
may	O	AUX	O
pose	O	VERB	O
a	O	DET	O
risk	O	NOUN	B
to	O	PART	O
both	O	CCONJ	O
the	O	DET	O
mother	O	NOUN	B
and	O	CCONJ	O
her	O	PRON	O
fetus	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
case	O	NOUN	B
illustrates	O	VERB	O
a	O	DET	O
number	O	NOUN	O
of	O	ADP	O
problems	O	NOUN	B
that	O	PRON	O
may	O	AUX	O
be	O	AUX	O
encountered	O	VERB	O
in	O	ADP	O
women	O	NOUN	B
with	O	ADP	O
eating	B-Disease	VERB	B
disorders	I-Disease	NOUN	I
in	O	ADP	O
pregnancy	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
prolonged	O	ADJ	B
and	O	CCONJ	O
recurrent	O	ADJ	B
metabolic	O	ADJ	B
disturbances	O	NOUN	I
and	O	CCONJ	O
diuretic	O	ADJ	B
abuse	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
particular	O	ADJ	O
it	O	PRON	O
illustrates	O	VERB	O
the	O	DET	O
derangements	O	NOUN	B
of	O	ADP	O
thyroid	O	NOUN	B
function	O	NOUN	I
seen	O	VERB	O
in	O	ADP	O
pregnant	O	ADJ	B
women	O	NOUN	I
with	O	ADP	O
eating	B-Disease	VERB	B
disorders	I-Disease	NOUN	I
and	O	CCONJ	O
reminds	O	VERB	O
us	O	PRON	O
that	O	SCONJ	O
when	O	SCONJ	O
a	O	DET	O
cause	O	NOUN	B
for	O	ADP	O
thyrotoxicosis	B-Disease	NOUN	B
remains	O	VERB	O
obscure	O	ADJ	B
,	O	PUNCT	O
thyroxine	B-Chemical	NOUN	B


Attenuation	O	NOUN	B
of	O	ADP	O
methamphetamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
nigrostriatal	O	ADJ	B
dopaminergic	O	ADJ	O
neurotoxicity	B-Disease	NOUN	B
in	O	ADP	O
mice	O	NOUN	B
by	O	ADP	O
lipopolysaccharide	B-Chemical	NOUN	B
pretreatment	O	NOUN	B
.	O	PUNCT	O


Immunological	O	ADJ	B
activation	O	NOUN	O
has	O	AUX	O
been	O	AUX	O
proposed	O	VERB	O
to	O	PART	O
play	O	VERB	O
a	O	DET	O
role	O	NOUN	O
in	O	ADP	O
methamphetamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
dopaminergic	B-Disease	ADJ	B
terminal	I-Disease	ADJ	O
damage	I-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
examined	O	VERB	O
the	O	DET	O
roles	O	NOUN	O
of	O	ADP	O
lipopolysaccharide	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
pro	O	ADJ	B
-	O	PUNCT	O
inflammatory	O	ADJ	B
and	O	CCONJ	O
inflammatory	O	ADJ	B
factor	O	NOUN	I
,	O	PUNCT	O
treatment	O	NOUN	B
in	O	ADP	O
modulating	O	VERB	B
the	O	DET	O
methamphetamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
nigrostriatal	O	ADJ	B
dopamine	B-Chemical	NOUN	B
neurotoxicity	B-Disease	NOUN	B
.	O	PUNCT	O


Lipopolysaccharide	B-Chemical	NOUN	B
pretreatment	O	NOUN	B
did	O	AUX	O
not	O	PART	O
affect	O	VERB	O
the	O	DET	O
basal	O	ADJ	B
body	O	NOUN	I
temperature	O	NOUN	I
or	O	CCONJ	O
methamphetamine	B-Chemical	NOUN	B
-	O	PUNCT	O
elicited	O	VERB	B
hyperthermia	B-Disease	NOUN	B
three	O	NUM	O
days	O	NOUN	B
later	O	ADV	O
.	O	PUNCT	O


Such	O	ADJ	O
systemic	O	ADJ	B
lipopolysaccharide	B-Chemical	NOUN	B
treatment	O	NOUN	B
mitigated	O	VERB	B
methamphetamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
striatal	O	ADJ	B
dopamine	B-Chemical	NOUN	B
and	O	CCONJ	O
3,4-dihydroxyphenylacetic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
depletions	O	NOUN	B
in	O	ADP	O
a	O	DET	O
dose	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
manner	O	NOUN	O
.	O	PUNCT	O


As	O	ADP	O
the	O	DET	O
most	O	ADV	O
potent	O	ADJ	O
dose	O	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
lipopolysaccharide	B-Chemical	NOUN	B
was	O	AUX	O
administered	O	VERB	B
two	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
one	O	NUM	O
day	O	NOUN	B
before	O	ADP	O
or	O	CCONJ	O
after	O	ADP	O
the	O	DET	O
methamphetamine	B-Chemical	NOUN	B
dosing	O	NOUN	B
regimen	O	NOUN	B
,	O	PUNCT	O
methamphetamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
striatal	O	ADJ	B
dopamine	B-Chemical	NOUN	B
and	O	CCONJ	O
3,4-dihydroxyphenylacetic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
depletions	O	NOUN	B
remained	O	VERB	O
unaltered	O	ADJ	B
.	O	PUNCT	O


Moreover	O	ADV	O
,	O	PUNCT	O
systemic	O	ADJ	B
lipopolysaccharide	B-Chemical	NOUN	B
pretreatment	O	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
attenuated	O	VERB	B
local	O	ADJ	O
methamphetamine	B-Chemical	NOUN	B
infusion	O	NOUN	B
-	O	PUNCT	O
produced	O	VERB	B
dopamine	B-Chemical	NOUN	B
and	O	CCONJ	O
3,4-dihydroxyphenylacetic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
depletions	O	NOUN	B
in	O	ADP	O
the	O	DET	O
striatum	O	NOUN	B
,	O	PUNCT	O
indicating	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
protective	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
lipopolysaccharide	B-Chemical	NOUN	B
is	O	AUX	O
less	O	ADV	O
likely	O	ADV	O
due	O	ADJ	O
to	O	PART	O
interrupted	O	ADJ	B
peripheral	O	ADJ	B
distribution	O	NOUN	O
or	O	CCONJ	O
metabolism	O	NOUN	B
of	O	ADP	O
methamphetamine	B-Chemical	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
concluded	O	VERB	O
a	O	DET	O
critical	O	ADJ	O
time	O	NOUN	O
window	O	NOUN	O
for	O	ADP	O
systemic	O	ADJ	B
lipopolysaccharide	B-Chemical	NOUN	B
pretreatment	O	NOUN	B
in	O	ADP	O
exerting	O	VERB	O
effective	O	ADJ	B
protection	O	NOUN	B
against	O	ADP	O
methamphetamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
nigrostriatal	O	ADJ	B
dopamine	B-Chemical	NOUN	B
neurotoxicity	B-Disease	NOUN	B


Effect	O	NOUN	B
of	O	ADP	O
converting	O	VERB	O
enzyme	O	NOUN	B
inhibition	O	NOUN	O
on	O	ADP	O
the	O	DET	O
course	O	NOUN	B
of	O	ADP	O
adriamycin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
nephropathy	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
the	O	DET	O
converting	O	VERB	O
enzyme	O	NOUN	B
inhibitor	O	NOUN	I
(	O	PUNCT	O
CEI	O	NOUN	B
)	O	PUNCT	O
enalapril	B-Chemical	NOUN	B
was	O	AUX	O
assessed	O	VERB	B
in	O	ADP	O
Munich	O	PROPN	B
-	O	PUNCT	O
Wistar	O	PROPN	B
rats	O	NOUN	B
with	O	ADP	O
established	O	ADJ	O
adriamycin	B-Chemical	NOUN	B
nephrosis	B-Disease	NOUN	B
.	O	PUNCT	O


Rats	O	NOUN	B
were	O	AUX	O
given	O	VERB	O
a	O	DET	O
single	O	ADJ	O
dose	O	NOUN	B
of	O	ADP	O
adriamycin	B-Chemical	NOUN	B
and	O	CCONJ	O
one	O	NUM	O
month	O	NOUN	B
later	O	ADV	O
divided	O	VERB	O
into	O	ADP	O
four	O	NUM	O
groups	O	NOUN	B
matched	O	VERB	B
for	O	ADP	O
albuminuria	B-Disease	NOUN	B
,	O	PUNCT	O
blood	O	NOUN	B
pressure	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
plasma	O	NOUN	B
albumin	O	NOUN	O
concentration	O	NOUN	B
.	O	PUNCT	O


Groups	O	NOUN	B
1	O	NUM	O
and	O	CCONJ	O
3	O	NUM	O
remained	O	VERB	O
untreated	O	ADJ	B
while	O	SCONJ	O
groups	O	NOUN	B
2	O	NUM	O
and	O	CCONJ	O
4	O	NUM	O
received	O	VERB	O
enalapril	B-Chemical	NOUN	B
.	O	PUNCT	O


Groups	O	NOUN	B
1	O	NUM	O
and	O	CCONJ	O
2	O	NUM	O
underwent	O	VERB	O
micropuncture	O	NOUN	B
studies	O	NOUN	I
after	O	ADP	O
10	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
short	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
studies	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
enalapril	B-Chemical	NOUN	B
reduced	O	VERB	B
arterial	O	ADJ	B
blood	O	NOUN	I
pressure	O	NOUN	I
(	O	PUNCT	O
101	O	NUM	O
+/-	O	CCONJ	O
2	O	NUM	O
vs	O	CCONJ	O
.	O	PUNCT	O


124	O	NUM	O
+/-	O	CCONJ	O
3	O	NUM	O
mm	O	NOUN	B
Hg	O	NOUN	I
,	O	PUNCT	O
group	O	NOUN	B
2	O	NUM	I
vs	O	CCONJ	O
.	O	PUNCT	O


1	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
glomerular	O	ADJ	B
capillary	O	ADJ	I
pressure	O	NOUN	I
(	O	PUNCT	O
54	O	NUM	O
+/-	O	CCONJ	O
1	O	NUM	O
vs	O	CCONJ	O
.	O	PUNCT	O


61	O	NUM	O
+/-	O	CCONJ	O
2	O	NUM	O
mm	O	NOUN	O
Hg	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
)	O	PUNCT	O
without	O	ADP	O
reducing	O	VERB	B
albuminuria	B-Disease	NOUN	B
(	O	PUNCT	O
617	O	NUM	O
+/-	O	CCONJ	O
50	O	NUM	O
vs	O	CCONJ	O
.	O	PUNCT	O


570	O	NUM	O
+/-	O	CCONJ	O
47	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
day	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
GFR	O	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


03	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


04	O	NUM	O
vs	O	CCONJ	O
.	O	PUNCT	O


1	O	X	O
.	O	PUNCT	O


04	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


11	O	NUM	O
ml	O	NOUN	O
/	O	SYM	O
min	O	NOUN	B
).	O	PUNCT	B
Groups	O	NOUN	I
3	O	NUM	I
and	O	CCONJ	O
4	O	NUM	O
were	O	AUX	O
studied	O	VERB	O
at	O	ADP	O
four	O	NUM	O
and	O	CCONJ	O
at	O	ADP	O
six	O	NUM	O
months	O	NOUN	B
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
enalapril	B-Chemical	NOUN	B
on	O	ADP	O
progression	O	NOUN	B
of	O	ADP	O
renal	B-Disease	ADJ	B
injury	I-Disease	NOUN	I
in	O	ADP	O
adriamycin	B-Chemical	NOUN	B
nephrosis	B-Disease	NOUN	B
.	O	PUNCT	O


Chronic	O	ADJ	B
enalapril	B-Chemical	ADJ	I
treatment	O	NOUN	O
reduced	O	VERB	O
blood	O	NOUN	B
pressure	O	NOUN	I
without	O	ADP	O
reducing	O	VERB	B
albuminuria	B-Disease	NOUN	B
in	O	ADP	O
group	O	NOUN	B
4	O	NUM	I
.	O	PUNCT	O


Untreated	O	ADJ	B
group	O	NOUN	I
3	O	NUM	I
rats	O	NOUN	B
exhibited	O	VERB	O
a	O	DET	O
progressive	O	ADJ	B
reduction	O	NOUN	B
in	O	ADP	O
GFR	O	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


35	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


08	O	NUM	O
ml	O	NOUN	O
/	O	SYM	O
min	O	NOUN	B
at	O	ADP	O
4	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


27	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


07	O	NUM	O
ml	O	NOUN	O
/	O	SYM	O
min	O	NOUN	B
at	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
).	O	PUNCT	O
Enalapril	B-Chemical	NOUN	B
treatment	O	NOUN	I
blunted	O	VERB	B
but	O	CCONJ	O
did	O	AUX	O
not	O	PART	O
prevent	O	VERB	O
reduction	O	NOUN	B
in	O	ADP	O
GFR	O	NOUN	B
in	O	ADP	O
group	O	NOUN	B
4	O	NUM	I
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


86	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


15	O	NUM	O
ml	O	NOUN	O
/	O	SYM	O
min	O	NOUN	B
at	O	ADP	O
4	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


69	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


13	O	NUM	O
ml	O	NOUN	O
/	O	SYM	O
min	O	NOUN	B
at	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
both	O	CCONJ	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
vs	O	CCONJ	O
.	O	PUNCT	O


group	O	NOUN	B
3	O	NUM	O
).	O	PUNCT	O
Reduction	O	NOUN	B
in	O	ADP	O
GFR	O	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
glomerular	B-Disease	ADJ	B
sclerosis	I-Disease	NOUN	I


Butyrylcholinesterase	O	NOUN	B
gene	O	NOUN	B
mutations	O	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
prolonged	O	ADJ	B
apnea	B-Disease	NOUN	B
after	O	ADP	O
succinylcholine	B-Chemical	NOUN	B
for	O	ADP	O
electroconvulsive	O	ADJ	B
therapy	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
patients	O	NOUN	B
undergoing	O	VERB	O
electroconvulsive	O	ADJ	B
therapy	O	NOUN	I
(	O	PUNCT	O
ECT	O	NOUN	B
)	O	PUNCT	O
often	O	ADV	O
receive	O	VERB	O
succinylcholine	B-Chemical	NOUN	B
as	O	ADP	O
part	O	NOUN	O
of	O	ADP	O
the	O	DET	O
anesthetic	O	ADJ	B
procedure	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
duration	O	NOUN	B
of	O	ADP	I
action	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
prolonged	O	ADJ	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
genetic	O	ADJ	B
variants	O	NOUN	I
of	O	ADP	O
the	O	DET	O
butyrylcholinesterase	O	NOUN	B
enzyme	O	NOUN	I
(	O	PUNCT	O
BChE	O	NOUN	B
),	O	PUNCT	O
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
being	O	AUX	O
the	O	DET	O
K	O	PROPN	B
-	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
A	O	PROPN	B
-	O	PUNCT	O
variants	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
clinical	O	ADJ	B
significance	O	NOUN	I
of	O	ADP	O
genetic	O	ADJ	B
variants	O	NOUN	I
in	O	ADP	O
butyrylcholinesterase	O	NOUN	B
gene	O	NOUN	I
(	O	PUNCT	O
BCHE	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
a	O	DET	O
suspected	O	ADJ	B
prolonged	O	ADJ	B
duration	O	NOUN	B
of	O	ADP	I
action	O	NOUN	B
of	O	ADP	O
succinylcholine	B-Chemical	NOUN	B
after	O	ADP	O
ECT	O	PROPN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
a	O	DET	O
total	O	NOUN	O
of	O	ADP	O
13	O	NUM	O
patients	O	NOUN	B
were	O	AUX	O
referred	O	VERB	O
to	O	ADP	O
the	O	DET	O
Danish	O	PROPN	B
Cholinesterase	O	PROPN	I
Research	O	PROPN	I
Unit	O	PROPN	I
after	O	ADP	O
ECT	O	PROPN	B
during	O	ADP	O
38	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
determined	O	VERB	O
the	O	DET	O
BChE	O	NOUN	B
activity	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
BCHE	O	NOUN	B
genotype	O	NOUN	B
using	O	VERB	O
molecular	O	ADJ	B
genetic	O	ADJ	I
methods	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
duration	O	NOUN	B
of	O	ADP	O
apnea	B-Disease	NOUN	B
,	O	PUNCT	O
time	O	NOUN	O
to	O	PART	O
sufficient	O	ADJ	O
spontaneous	O	ADJ	B
ventilation	O	NOUN	O
and	O	CCONJ	O
whether	O	SCONJ	O
neuromuscular	O	ADJ	B
monitoring	O	NOUN	O
was	O	AUX	O
used	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
duration	O	NOUN	B
of	O	ADP	O
apnea	B-Disease	NOUN	B
was	O	AUX	O
compared	O	VERB	B
with	O	ADP	O
published	O	VERB	B
data	O	NOUN	I
on	O	ADP	O
normal	O	ADJ	B
subjects	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
in	O	ADP	O
11	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
mutations	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
the	O	DET	O
BCHE	O	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
K	O	PROPN	B
-	O	PUNCT	O
variant	O	NOUN	B
being	O	AUX	O
the	O	DET	O
most	O	ADV	O
frequent	O	ADJ	B
.	O	PUNCT	O


The	O	DET	O
duration	O	NOUN	B
of	O	ADP	O
apnea	B-Disease	NOUN	B
was	O	AUX	O
5	O	NUM	O
-	O	PUNCT	O
15	O	NUM	O
min	O	NOUN	O
compared	O	VERB	B
with	O	ADP	O
3	O	NUM	O
-	O	SYM	O
5	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
min	O	NOUN	O
from	O	ADP	O
the	O	DET	O
literature	O	NOUN	B
.	O	PUNCT	O


Severe	O	ADJ	B
distress	O	NOUN	O
was	O	AUX	O
noted	O	VERB	O
in	O	ADP	O
the	O	DET	O
recovery	O	NOUN	B
phase	O	NOUN	B
in	O	ADP	O
two	O	NUM	O
patients	O	NOUN	B
.	O	PUNCT	O


Neuromuscular	O	ADJ	B
monitoring	O	NOUN	B
was	O	AUX	O
used	O	VERB	O
in	O	ADP	O
two	O	NUM	O
patients	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
eleven	O	NUM	O
of	O	ADP	O
13	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
a	O	DET	O
prolonged	O	ADJ	B
duration	O	NOUN	B
of	O	ADP	I
action	O	NOUN	B
of	O	ADP	O
succinylcholine	B-Chemical	NOUN	B
had	O	AUX	O
mutations	O	NOUN	B
in	O	ADP	O
BCHE	O	NOUN	B
,	O	PUNCT	O
indicating	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
is	O	AUX	O
the	O	DET	O
possible	O	ADJ	O
reason	O	NOUN	O
for	O	ADP	O
a	O	DET	O
prolonged	O	ADJ	B
period	O	NOUN	B
of	O	ADP	O
apnea	B-Disease	NOUN	B


Ketamine	B-Chemical	NOUN	B
sedation	O	NOUN	B
for	O	ADP	O
the	O	DET	O
reduction	O	NOUN	B
of	O	ADP	O
children	O	NOUN	B
'	O	PART	O
s	O	NOUN	O
fractures	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
emergency	O	NOUN	B
department	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
There	O	PRON	O
recently	O	ADV	O
has	O	AUX	O
been	O	AUX	O
a	O	DET	O
resurgence	O	NOUN	B
in	O	ADP	O
the	O	DET	O
utilization	O	NOUN	B
of	O	ADP	O
ketamine	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
unique	O	ADJ	B
anesthetic	O	NOUN	B
,	O	PUNCT	O
for	O	ADP	O
emergency	O	NOUN	B
-	O	PUNCT	O
department	O	NOUN	B
procedures	O	NOUN	B
requiring	O	VERB	O
sedation	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
examine	O	VERB	O
the	O	DET	O
safety	O	NOUN	B
and	O	CCONJ	O
efficacy	O	NOUN	B
of	O	ADP	O
ketamine	B-Chemical	NOUN	B
for	O	ADP	O
sedation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
children	O	NOUN	B
'	O	PART	O
s	O	NOUN	O
fractures	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
emergency	O	NOUN	B
department	O	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
One	O	NUM	O
hundred	O	NUM	O
and	O	CCONJ	O
fourteen	O	NUM	O
children	O	NOUN	B
(	O	PUNCT	O
average	O	ADJ	B
age	O	NOUN	B
,	O	PUNCT	O
5	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
years	O	NOUN	B
;	O	PUNCT	O
range	O	NOUN	O
,	O	PUNCT	O
twelve	O	NUM	O
months	O	NOUN	B
to	O	ADP	O
ten	O	NUM	O
years	O	NOUN	B
and	O	CCONJ	O
ten	O	NUM	O
months	O	NOUN	B
)	O	PUNCT	O
who	O	PRON	O
underwent	O	VERB	O
closed	O	ADJ	B
reduction	O	NOUN	I
of	O	ADP	O
an	O	DET	O
isolated	O	VERB	B
fracture	B-Disease	NOUN	I
or	O	CCONJ	O
dislocation	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
emergency	O	NOUN	B
department	O	NOUN	I
at	O	ADP	O
a	O	DET	O
level	O	NOUN	B
-	O	PUNCT	O
I	O	NOUN	B
trauma	B-Disease	NOUN	B
center	O	NOUN	I
were	O	AUX	O
prospectively	O	ADV	O
evaluated	O	VERB	B
.	O	PUNCT	O


Ketamine	B-Chemical	NOUN	B
hydrochloride	I-Chemical	NOUN	B
was	O	AUX	O
administered	O	VERB	B
intravenously	O	ADV	B
(	O	PUNCT	O
at	O	ADP	O
a	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
two	O	NUM	O
milligrams	O	NOUN	O
per	O	ADP	O
kilogram	O	NOUN	O
of	O	ADP	O
body	O	NOUN	B
weight	O	NOUN	I
)	O	PUNCT	O
in	O	ADP	O
ninety	O	NUM	B
-	O	PUNCT	O
nine	O	NUM	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
and	O	CCONJ	O
intramuscularly	O	ADJ	B
(	O	PUNCT	O
at	O	ADP	O
a	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
four	O	NUM	O
milligrams	O	NOUN	O
per	O	ADP	O
kilogram	O	NOUN	O
of	O	ADP	O
body	O	NOUN	B
weight	O	NOUN	I
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
other	O	ADJ	O
fifteen	O	NUM	O
.	O	PUNCT	O


A	O	DET	O
board	O	NOUN	B
-	O	PUNCT	O
certified	O	VERB	B
emergency	O	NOUN	B
physician	O	NOUN	B
skilled	O	ADJ	B
in	O	ADP	O
airway	O	NOUN	B
management	O	NOUN	I
supervised	O	ADJ	O
administration	O	NOUN	B
of	O	ADP	O
the	O	DET	O
anesthetic	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
monitored	O	VERB	O
by	O	ADP	O
a	O	DET	O
registered	O	VERB	O
nurse	O	NOUN	B
.	O	PUNCT	O


Any	O	DET	O
pain	B-Disease	NOUN	B
during	O	ADP	O
the	O	DET	O
reduction	O	NOUN	B
was	O	AUX	O
rated	O	VERB	O
by	O	ADP	O
the	O	DET	O
orthopaedic	O	ADJ	B
surgeon	O	NOUN	I
treating	O	VERB	B
the	O	DET	O
patient	O	NOUN	B
according	O	VERB	O
to	O	ADP	O
the	O	DET	O
Children	O	PROPN	B
'	O	PART	O
s	O	PROPN	O
Hospital	O	PROPN	B
of	O	ADP	O
Eastern	O	PROPN	B
Ontario	O	PROPN	I
Pain	B-Disease	PROPN	I
Scale	O	PROPN	I
(	O	PUNCT	O
CHEOPS	O	NOUN	B
).	O	PUNCT	O
RESULTS	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
average	O	ADJ	B
time	O	NOUN	O
from	O	ADP	O
intravenous	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
ketamine	B-Chemical	NOUN	B
to	O	PART	O
manipulation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
fracture	B-Disease	NOUN	B
or	O	CCONJ	O
dislocation	B-Disease	NOUN	B
was	O	AUX	O
one	O	NUM	O
minute	O	NOUN	B
and	O	CCONJ	O
thirty	O	NUM	B
-	O	PUNCT	O
six	O	NUM	B
seconds	O	NOUN	O
(	O	PUNCT	O
range	O	NOUN	B
,	O	PUNCT	O
twenty	O	NUM	O
seconds	O	NOUN	O
to	O	ADP	O
five	O	NUM	O
minutes	O	NOUN	B
),	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
average	O	ADJ	B
time	O	NOUN	O
from	O	ADP	O
intramuscular	O	ADJ	B
administration	O	NOUN	B
to	O	PART	O
manipulation	O	NOUN	B
was	O	AUX	O
four	O	NUM	O
minutes	O	NOUN	B
and	O	CCONJ	O
forty	O	NUM	B
-	O	PUNCT	O
two	O	NUM	O
seconds	O	NOUN	O
(	O	PUNCT	O
range	O	NOUN	B
,	O	PUNCT	O
sixty	O	NUM	O
seconds	O	NOUN	O
to	O	ADP	O
fifteen	O	NUM	O
minutes	O	NOUN	B
).	O	PUNCT	O
The	O	DET	O
average	O	ADJ	B
score	O	NOUN	I
according	O	VERB	O
to	O	ADP	O
the	O	DET	O
Children	O	PROPN	B
'	O	PART	O
s	O	PROPN	O
Hospital	O	PROPN	B
of	O	ADP	O
Eastern	O	PROPN	B
Ontario	O	PROPN	I
Pain	B-Disease	PROPN	I
Scale	O	PROPN	I
was	O	AUX	O
6	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
points	O	NOUN	O
(	O	PUNCT	O
range	O	NOUN	B
,	O	PUNCT	O
5	O	NUM	O
to	O	PART	O
10	O	NUM	O
points	O	NOUN	O
),	O	PUNCT	O
reflecting	O	VERB	O
minimal	O	ADJ	B
or	O	CCONJ	O
no	O	DET	B
pain	B-Disease	NOUN	I
during	O	ADP	O
fracture	B-Disease	NOUN	B
reduction	O	NOUN	I
.	O	PUNCT	O


Adequate	O	ADJ	B
fracture	B-Disease	NOUN	B
reduction	O	NOUN	B
was	O	AUX	O
obtained	O	VERB	O
in	O	ADP	O
111	O	NUM	O
of	O	ADP	O
the	O	DET	O
children	O	NOUN	B
.	O	PUNCT	O


Ninety	O	NUM	B
-	O	PUNCT	O
nine	O	NUM	B
percent	O	NOUN	O
(	O	PUNCT	O
sixty	O	NUM	B
-	O	PUNCT	O
eight	O	NUM	O
)	O	PUNCT	O
of	O	ADP	O
the	O	DET	O
sixty	O	NUM	B
-	O	PUNCT	O
nine	O	NUM	B
parents	O	NOUN	B
present	O	ADJ	O
during	O	ADP	O
the	O	DET	O
reduction	O	NOUN	B
were	O	AUX	O
pleased	O	VERB	O
with	O	ADP	O
the	O	DET	O
sedation	O	NOUN	B
and	O	CCONJ	O
would	O	AUX	O
allow	O	VERB	O
it	O	PRON	O
to	O	PART	O
be	O	AUX	O
used	O	VERB	O
again	O	ADV	O
in	O	ADP	O
a	O	DET	O
similar	O	ADJ	O
situation	O	NOUN	B
.	O	PUNCT	O


Patency	O	NOUN	B
of	O	ADP	O
the	O	DET	O
airway	O	NOUN	B
and	O	CCONJ	O
independent	O	ADJ	B
respiration	O	NOUN	B
were	O	AUX	O
maintained	O	VERB	B
in	O	ADP	O
all	O	DET	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
.	O	PUNCT	O


Blood	O	NOUN	B
pressure	O	NOUN	I
and	O	CCONJ	O
heart	O	NOUN	B
rate	O	NOUN	I
remained	O	VERB	O
stable	O	ADJ	B
.	O	PUNCT	O


Minor	O	ADJ	B
side	O	NOUN	B
effects	O	NOUN	I
included	O	VERB	O
nausea	B-Disease	NOUN	B
(	O	PUNCT	O
thirteen	O	NUM	O
patients	O	NOUN	B
),	O	PUNCT	O
emesis	B-Disease	NOUN	B
(	O	PUNCT	O
eight	O	NUM	O
of	O	ADP	O
the	O	DET	O
thirteen	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
nausea	B-Disease	ADJ	B
),	O	ADJ	O
clumsiness	B-Disease	NOUN	B
(	O	PUNCT	O
evident	O	ADJ	O
as	O	ADP	O
ataxic	B-Disease	ADJ	B
movements	I-Disease	NOUN	O
in	O	ADP	O
ten	O	NUM	O
patients	O	NOUN	B
),	O	PUNCT	O
and	O	CCONJ	O
dysphoric	B-Disease	ADJ	B
reaction	I-Disease	NOUN	I
(	O	PUNCT	O
one	O	NUM	O
patient	O	NOUN	B
).	O	PUNCT	O
No	O	DET	O
long	O	ADJ	O
-	O	PUNCT	O
term	O	NOUN	B
sequelae	O	NOUN	B
were	O	AUX	O
noted	O	VERB	O
,	O	PUNCT	O
and	O	CCONJ	O
no	O	DET	O
patients	O	NOUN	B
had	O	AUX	O
hallucinations	B-Disease	NOUN	B
or	O	CCONJ	O
nightmares	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
Ketamine	B-Chemical	NOUN	B
reliably	O	ADV	B
,	O	PUNCT	O
safely	O	ADV	O
,	O	PUNCT	O
and	O	CCONJ	O
quickly	O	ADV	O
provided	O	VERB	O
adequate	O	ADJ	B
sedation	O	NOUN	B
to	O	PART	O
effectively	O	ADV	O
facilitate	O	VERB	O
the	O	DET	O
reduction	O	NOUN	B
of	O	ADP	O
children	O	NOUN	B
'	O	PART	O
s	O	NOUN	O
fractures	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
emergency	O	NOUN	B
department	O	NOUN	I
at	O	ADP	O
our	O	PRON	O
institution	O	NOUN	B
.	O	PUNCT	O


Ketamine	B-Chemical	NOUN	B


Prophylactic	O	ADJ	B
use	O	NOUN	O
of	O	ADP	O
lamivudine	B-Chemical	NOUN	B
with	O	ADP	O
chronic	O	ADJ	B
immunosuppressive	O	ADJ	I
therapy	O	NOUN	I
for	O	ADP	O
rheumatologic	B-Disease	ADJ	B
disorders	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
objective	O	NOUN	B
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
report	O	VERB	O
our	O	PRON	O
experience	O	NOUN	O
concerning	O	VERB	O
the	O	DET	O
effectiveness	O	NOUN	B
of	O	ADP	O
the	O	DET	O
prophylactic	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
lamivudine	B-Chemical	NOUN	B
in	O	ADP	O
hepatitis	B-Chemical	NOUN	B
B	I-Chemical	NOUN	I
virus	I-Chemical	NOUN	I
surface	I-Chemical	NOUN	I
antigen	I-Chemical	NOUN	I
(	O	PUNCT	O
HBs	B-Chemical	NOUN	B
Ag	I-Chemical	NOUN	B
)	O	PUNCT	O
positive	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
rheumatologic	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


From	O	ADP	O
June	O	PROPN	O
2004	O	NUM	O
to	O	ADP	O
October	O	PROPN	O
2006	O	NUM	O
,	O	PUNCT	O
11	O	NUM	O
HBs	B-Chemical	NOUN	B
Ag	I-Chemical	NOUN	B
positive	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
rheumatologic	B-Disease	ADJ	B
diseases	I-Disease	NOUN	I
,	O	PUNCT	O
who	O	PRON	O
were	O	AUX	O
on	O	ADP	O
both	O	CCONJ	O
immunosuppressive	O	ADJ	B
and	O	CCONJ	O
prophylactic	O	ADJ	B
lamivudine	B-Chemical	NOUN	I
therapies	O	NOUN	I
,	O	PUNCT	O
were	O	AUX	O
retrospectively	O	ADV	B
assessed	O	VERB	B
.	O	PUNCT	O


Liver	O	NOUN	B
function	O	NOUN	I
tests	O	NOUN	I
,	O	PUNCT	O
hepatitis	B-Disease	NOUN	B
B	I-Disease	NOUN	I
virus	O	NOUN	I
(	O	PUNCT	O
HBV	O	NOUN	B
)	O	PUNCT	O
serologic	O	ADJ	B
markers	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
HBV	O	NOUN	B
DNA	O	NOUN	O
levels	O	NOUN	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
during	O	ADP	O
follow	O	NOUN	B
-	O	PUNCT	O
up	O	NOUN	O
were	O	AUX	O
obtained	O	VERB	O
from	O	ADP	O
hospital	O	NOUN	B
file	O	NOUN	I
records	O	NOUN	I
.	O	PUNCT	O


Eleven	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
six	O	NUM	O
male	O	NOUN	B
)	O	PUNCT	O
with	O	ADP	O
median	O	ADJ	B
age	O	NOUN	B
47	O	NUM	O
years	O	NOUN	B
(	O	PUNCT	O
range	O	NOUN	O
27	O	NUM	O
-	O	SYM	O
73	O	NUM	O
),	O	PUNCT	O
median	O	ADJ	B
disease	O	NOUN	O
duration	O	NOUN	B
50	O	NUM	O
months	O	NOUN	B
(	O	PUNCT	O
range	O	NOUN	O
9	O	NUM	O
-	O	SYM	O
178	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
median	O	ADJ	B
follow	O	NOUN	B
-	O	PUNCT	O
up	O	ADP	O
period	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
13	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
months	O	NOUN	B
(	O	PUNCT	O
range	O	NOUN	O
5	O	NUM	O
-	O	SYM	O
27	O	NUM	O
)	O	PUNCT	O
were	O	AUX	O
enrolled	O	VERB	O
in	O	ADP	O
this	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


Lamivudine	B-Chemical	NOUN	B
therapy	O	NOUN	O
was	O	AUX	O
started	O	VERB	O
3	O	NUM	O
-	O	SYM	O
7	O	NUM	O
days	O	NOUN	B
prior	O	ADJ	O
to	O	PART	O
immunosuppressive	O	ADJ	B
therapy	O	NOUN	I
in	O	ADP	O
all	O	DET	O
patients	O	NOUN	B
.	O	PUNCT	O


Baseline	O	NOUN	B
,	O	PUNCT	O
liver	O	NOUN	B
function	O	NOUN	I
tests	O	NOUN	I
were	O	AUX	O
elevated	O	ADJ	B
in	O	ADP	O
two	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
fourth	O	ADJ	O
patient	O	NOUN	B
:	O	PUNCT	O
ALT	O	NOUN	B
:	O	PUNCT	O
122	O	NUM	O
IU	O	NOUN	B
/	O	SYM	O
l	O	NOUN	B
,	O	PUNCT	O
AST	O	NOUN	B
:	O	PUNCT	O
111	O	NUM	O
IU	O	NOUN	B
/	O	SYM	O
l	O	NOUN	O
,	O	PUNCT	O
tenth	O	ADJ	O
patient	O	NOUN	B
:	O	PUNCT	O
ALT	O	NOUN	B
:	O	PUNCT	O
294	O	NUM	O
IU	O	NOUN	B
/	O	SYM	O
l	O	NOUN	B
,	O	PUNCT	O
AST	O	NOUN	B
:	O	PUNCT	O
274	O	NUM	O
IU	O	NOUN	B
/	O	SYM	O
l	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
minimal	O	ADJ	O
changes	O	NOUN	B
in	O	ADP	O
the	O	DET	O
liver	O	NOUN	B
biopsy	O	NOUN	I
in	O	ADP	O
both	O	CCONJ	O
).	O	PUNCT	B
Shortly	O	ADV	O
after	O	ADP	O
treatment	O	NOUN	B
their	O	PRON	O
tests	O	NOUN	B
normalized	O	VERB	B
and	O	CCONJ	O
during	O	ADP	O
follow	O	NOUN	B
-	O	PUNCT	O
up	O	ADP	O
period	O	NOUN	B
none	O	NOUN	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
had	O	AUX	O
abnormal	B-Disease	ADJ	B
liver	I-Disease	NOUN	B
function	I-Disease	NOUN	I
tests	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
four	O	NUM	O
patients	O	NOUN	B
HBV	O	NOUN	B
DNA	O	NOUN	B
levels	O	NOUN	I
were	O	AUX	O
higher	O	ADJ	O
than	O	ADP	O
normal	O	ADJ	B
at	O	ADP	O
baseline	O	NOUN	B
.	O	PUNCT	O


Two	O	NUM	O
of	O	ADP	O
these	O	DET	O
normalized	O	VERB	B
and	O	CCONJ	O
the	O	DET	O
others	O	NOUN	O
increased	O	VERB	B
later	O	ADV	O
.	O	PUNCT	O


In	O	ADP	O
three	O	NUM	O
additional	O	ADJ	O
patients	O	NOUN	B
,	O	PUNCT	O
HBV	O	NOUN	B
DNA	O	NOUN	I
levels	O	NOUN	I
were	O	AUX	O
increased	O	VERB	B
during	O	ADP	O
follow	O	NOUN	B
-	O	PUNCT	O
up	O	NOUN	B
.	O	PUNCT	O


of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
had	O	AUX	O
significant	O	ADJ	O
clinical	O	ADJ	B
sings	O	NOUN	I
of	O	ADP	O
HBV	O	NOUN	B
activation	O	NOUN	B
.	O	PUNCT	O


Lamivudine	B-Chemical	NOUN	B
was	O	AUX	O
well	O	ADV	O
tolerated	O	VERB	B
and	O	CCONJ	O
was	O	AUX	O
continued	O	VERB	O
in	O	ADP	O
all	O	DET	O
patients	O	NOUN	B
.	O	PUNCT	O


Prophylactic	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
lamivudine	B-Chemical	NOUN	B


Safety	O	NOUN	B
of	O	ADP	O
transesophageal	O	NOUN	B
echocardiography	O	NOUN	I
in	O	ADP	O
adults	O	NOUN	B
:	O	PUNCT	O
study	O	NOUN	B
in	O	ADP	O
a	O	DET	O
multidisciplinary	O	ADJ	B
hospital	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
TEE	O	NOUN	B
is	O	AUX	O
a	O	DET	O
semi	O	ADJ	B
-	O	PUNCT	O
invasive	O	ADJ	B
tool	O	NOUN	B
broadly	O	ADV	O
used	O	VERB	O
and	O	CCONJ	O
its	O	PRON	O
utilization	O	NOUN	B
associated	O	VERB	B
to	O	PART	I
sedatives	O	NOUN	B
drugs	O	NOUN	B
might	O	AUX	O
to	O	PART	O
affect	O	VERB	O
the	O	DET	O
procedure	O	NOUN	B
safety	O	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
:	O	PUNCT	O
to	O	PART	O
analyze	O	VERB	B
aspects	O	NOUN	O
of	O	ADP	O
TEE	O	NOUN	B
safety	O	NOUN	B
associated	O	VERB	B
to	O	ADP	I
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
Midazolan	B-Chemical	PROPN	B
(	O	PUNCT	O
MZ	B-Chemical	PROPN	B
)	O	PUNCT	O
and	O	CCONJ	O
Flumazenil	B-Chemical	NOUN	B
(	O	PUNCT	O
FL	B-Chemical	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
influence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
clinical	O	ADJ	B
variables	O	NOUN	I
on	O	ADP	O
the	O	DET	O
event	O	NOUN	B
rate	O	NOUN	B
.	O	PUNCT	O


METHOD	O	NOUN	B
:	O	PUNCT	O
prospective	O	ADJ	B
study	O	NOUN	I
with	O	ADP	O
137	O	NUM	O
patients	O	NOUN	B
that	O	PRON	O
underwent	O	VERB	O
TEE	O	NOUN	B
with	O	ADP	O
MZ	B-Chemical	NOUN	B
associated	O	VERB	B
to	O	PART	I
moderate	O	ADJ	B
sedation	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
analyzed	O	VERB	B
the	O	DET	O
following	O	VERB	O
events	O	NOUN	B
:	O	PUNCT	O
complications	O	NOUN	B
related	O	VERB	O
with	O	ADP	O
the	O	DET	O
topical	O	ADJ	B
anesthesia	O	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
MZ	B-Chemical	ADJ	B
use	O	NOUN	B
and	O	CCONJ	O
with	O	ADP	O
the	O	DET	O
procedure	O	NOUN	B
.	O	PUNCT	O


Uni	O	PROPN	B
-	O	PUNCT	O
and	O	CCONJ	O
multivariate	O	ADJ	B
analyses	O	NOUN	I
were	O	AUX	O
used	O	VERB	O
to	O	PART	O
test	O	VERB	B
the	O	DET	O
influence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
clinical	O	ADJ	B
variables	O	NOUN	I
:	O	PUNCT	O
age	O	NOUN	B
,	O	PUNCT	O
sex	O	NOUN	B
,	O	PUNCT	O
stroke	B-Disease	NOUN	B
,	O	PUNCT	O
myocardiopathy	B-Disease	NOUN	B
(	O	PUNCT	O
MP	B-Disease	NOUN	B
),	O	PUNCT	O
duration	O	NOUN	B
of	O	ADP	O
the	O	DET	O
test	O	NOUN	B
,	O	PUNCT	O
mitral	B-Disease	ADJ	B
regurgitation	I-Disease	NOUN	I
(	O	PUNCT	O
MR	B-Disease	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
MZ	B-Chemical	ADJ	B
dose	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
All	O	DET	O
patients	O	NOUN	B
(	O	PUNCT	O
65	O	NUM	O
+/-	O	CCONJ	O
16	O	NUM	O
yrs	O	NOUN	B
;	O	PUNCT	O
58	O	NUM	O
%	O	NOUN	O
males	O	NOUN	B
)	O	PUNCT	O
finished	O	VERB	O
the	O	DET	O
examination	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
mean	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
MZ	B-Chemical	NOUN	B
and	O	CCONJ	O
FL	B-Chemical	NOUN	B
were	O	AUX	O
4	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
+/-	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
mg	O	NOUN	O
and	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


28	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
mg	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
duration	O	NOUN	B
of	O	ADP	O
the	O	DET	O
examination	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
mean	O	ADJ	B
ejection	O	NOUN	I
fraction	O	NOUN	I
(	O	PUNCT	O
EF	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
16	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
+/-	O	CCONJ	O
6	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
minutes	O	NOUN	B
and	O	CCONJ	O
60	O	NUM	O
+/-	O	CCONJ	O
9	O	NUM	O
%,	O	NOUN	B
respectively	O	ADV	O
.	O	PUNCT	O


Mild	O	ADJ	B
hypoxia	B-Disease	NOUN	I
(	O	PUNCT	O
SO2	O	NOUN	B
<	O	X	O
90	O	NUM	O
%)	O	NOUN	O
was	O	AUX	O
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
event	O	NOUN	B
(	O	PUNCT	O
11	O	NUM	O
patients	O	NOUN	B
);	O	ADJ	O
3	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
%)	O	NOUN	O
presented	O	VERB	O
transient	O	ADJ	B
hypoxia	B-Disease	NOUN	B
due	O	ADP	O
to	O	ADP	O
upper	O	ADJ	B
airway	B-Disease	NOUN	I
obstruction	I-Disease	NOUN	I
by	O	ADP	O
probe	O	NOUN	B
introduction	O	NOUN	B
and	O	CCONJ	O
8	O	NUM	O
(	O	PUNCT	O
5	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
%)	O	NOUN	O
due	O	ADJ	O
to	O	PART	O
hypoxia	B-Disease	NOUN	B
caused	O	VERB	O
by	O	ADP	O
MZ	B-Chemical	NOUN	B
use	O	NOUN	B
.	O	PUNCT	O


Transient	O	ADJ	B
hypotension	B-Disease	NOUN	I
(	O	PUNCT	O
SAP	O	NOUN	B
<	O	X	O
90mmHg	O	NUM	O
)	O	PUNCT	O
occurred	O	VERB	O
in	O	ADP	O
1	O	NUM	O
patient	O	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
%).	O	VERB	O
The	O	DET	O
multivariate	O	ADJ	B
analysis	O	NOUN	I
showed	O	VERB	O
that	O	SCONJ	O
severe	O	ADJ	B
MR	B-Disease	NOUN	B
,	O	PUNCT	O
MP	B-Disease	NOUN	B
(	O	PUNCT	O
EF	O	NOUN	B
<	O	X	O
45	O	NUM	O
%)	O	NOUN	O
and	O	CCONJ	O
high	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
MZ	B-Chemical	NOUN	B
(>	O	NOUN	O
5mg	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
events	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
).	O	PUNCT	O
The	O	DET	O
EF	O	PROPN	B
was	O	AUX	O
40	O	NUM	O
%,	O	NOUN	B
in	O	ADP	O
the	O	DET	O
group	O	NOUN	B
with	O	ADP	O
MP	B-Disease	NOUN	B
and	O	CCONJ	O
44	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
group	O	NOUN	B
with	O	ADP	O
severe	O	ADJ	B
MR	B-Disease	NOUN	B


Effects	O	NOUN	B
of	O	ADP	I
calcium	B-Chemical	NOUN	B
channel	O	NOUN	I
blockers	O	NOUN	I
on	O	ADP	O
bupivacaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
toxicity	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
influence	O	NOUN	B
of	O	ADP	O
calcium	B-Chemical	NOUN	B
channel	O	NOUN	I
blockers	O	NOUN	I
on	O	ADP	O
bupivacaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
acute	O	ADJ	B
toxicity	B-Disease	NOUN	B
.	O	PUNCT	O


For	O	ADP	O
each	O	DET	O
of	O	ADP	O
the	O	DET	O
three	O	NUM	O
tested	O	VERB	B
calcium	B-Chemical	NOUN	B
channel	O	NOUN	I
blockers	O	NOUN	I
(	O	PUNCT	O
diltiazem	B-Chemical	NOUN	B
,	O	PUNCT	O
verapamil	B-Chemical	NOUN	B
and	O	CCONJ	O
bepridil	B-Chemical	NOUN	B
)	O	PUNCT	O
6	O	NUM	O
groups	O	NOUN	B
of	O	ADP	O
mice	O	NOUN	B
were	O	AUX	O
treated	O	VERB	B
by	O	ADP	O
two	O	NUM	O
different	O	ADJ	O
doses	O	NOUN	B
,	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


e	O	X	O
.	O	PUNCT	O


2	O	NUM	O
and	O	CCONJ	O
10	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
/	O	SYM	O
i	O	PROPN	B
.	O	PUNCT	O


p	O	X	O
.,	O	NOUN	O
or	O	CCONJ	O
an	O	DET	O
equal	O	ADJ	O
volume	O	NOUN	B
of	O	ADP	O
saline	O	NOUN	B
for	O	ADP	O
the	O	DET	O
control	O	ADJ	B
group	O	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
20	O	NUM	O
);	O	ADJ	O
15	O	NUM	O
minutes	O	NOUN	B
later	O	ADV	O
,	O	PUNCT	O
all	O	DET	O
the	O	DET	O
animals	O	NOUN	B
were	O	AUX	O
injected	O	VERB	B
with	O	ADP	O
a	O	DET	O
single	O	ADJ	O
50	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
/	O	SYM	O
i	O	PROPN	B
.	O	PUNCT	O


p	O	NOUN	O
.	O	PUNCT	O


dose	O	NOUN	B
of	O	ADP	O
bupivacaine	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
convulsant	O	ADJ	B
activity	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
time	O	NOUN	O
of	O	ADP	O
latency	O	NOUN	B
to	O	ADP	O
convulse	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
mortality	O	NOUN	B
rate	O	NOUN	I
were	O	AUX	O
assessed	O	VERB	B
in	O	ADP	O
each	O	DET	O
group	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
local	O	ADJ	B
anesthetic	O	ADJ	B
-	O	PUNCT	O
induced	O	VERB	B
mortality	O	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
increased	O	VERB	B
by	O	ADP	O
the	O	DET	O
three	O	NUM	O
different	O	ADJ	O
calcium	B-Chemical	NOUN	B
channel	O	NOUN	I
blockers	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
convulsant	O	ADJ	B
activity	O	NOUN	B
of	O	ADP	O
bupivacaine	B-Chemical	NOUN	B
was	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
modified	O	VERB	O
but	O	CCONJ	O
calcium	B-Chemical	NOUN	B
channel	O	NOUN	I
blockers	O	NOUN	I
decreased	O	VERB	B
the	O	DET	O
time	O	NOUN	B
of	O	ADP	O
latency	O	NOUN	B
to	O	PART	O
obtain	O	VERB	O
bupivacaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
convulsions	B-Disease	NOUN	B
;	O	PUNCT	O
this	O	DET	O
effect	O	NOUN	B
was	O	AUX	O
less	O	ADV	O
pronounced	O	ADJ	O
with	O	ADP	O
bepridil	B-Chemical	NOUN	B


Selegiline	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
postural	B-Disease	ADJ	B
hypotension	I-Disease	NOUN	I
in	O	ADP	O
Parkinson's	B-Disease	ADJ	O
disease	I-Disease	NOUN	B
:	O	PUNCT	O
a	O	DET	O
longitudinal	O	ADJ	B
study	O	NOUN	I
on	O	ADP	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
drug	O	NOUN	B
withdrawal	O	NOUN	I
.	O	PUNCT	O


OBJECTIVES	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
United	O	PROPN	B
Kingdom	O	PROPN	I
Parkinson's	B-Disease	PROPN	O
Disease	I-Disease	PROPN	O
Research	O	PROPN	O
Group	O	PROPN	O
(	O	PUNCT	O
UKPDRG	O	PROPN	B
)	O	PUNCT	O
trial	O	NOUN	B
found	O	VERB	O
an	O	DET	O
increased	O	VERB	B
mortality	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
Parkinson's	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
PD	B-Disease	NOUN	B
)	O	PUNCT	O
randomized	O	VERB	B
to	O	PART	O
receive	O	VERB	O
10	O	NUM	O
mg	O	NOUN	O
selegiline	B-Chemical	NOUN	B
per	O	ADP	O
day	O	NOUN	B
and	O	CCONJ	O
L-dopa	B-Chemical	NOUN	B
compared	O	VERB	B
with	O	ADP	O
those	O	DET	O
taking	O	VERB	O
L-dopa	B-Chemical	NOUN	B
alone	O	ADV	O
.	O	PUNCT	O


Recently	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
found	O	VERB	O
that	O	SCONJ	O
therapy	O	NOUN	B
with	O	ADP	O
selegiline	B-Chemical	NOUN	B
and	O	CCONJ	O
L-dopa	B-Chemical	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
selective	O	ADJ	O
systolic	B-Disease	NOUN	O
orthostatic	I-Disease	ADJ	O
hypotension	I-Disease	NOUN	O
which	O	DET	O
was	O	AUX	O
abolished	O	VERB	O
by	O	ADP	O
withdrawal	O	NOUN	B
of	O	ADP	O
selegiline	B-Chemical	NOUN	B
.	O	PUNCT	O


This	O	DET	O
unwanted	O	ADJ	O
effect	O	NOUN	B
on	O	ADP	O
postural	O	ADJ	B
blood	O	NOUN	I
pressure	O	NOUN	I
was	O	AUX	O
not	O	PART	O
the	O	DET	O
result	O	NOUN	O
of	O	ADP	O
underlying	O	VERB	O
autonomic	O	ADJ	B
failure	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
aims	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
were	O	AUX	O
to	O	PART	O
confirm	O	VERB	B
our	O	PRON	O
previous	O	ADJ	O
findings	O	NOUN	B
in	O	ADP	O
a	O	DET	O
separate	O	ADJ	O
cohort	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
and	O	CCONJ	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
time	O	NOUN	B
course	O	NOUN	I
of	O	ADP	O
the	O	DET	O
cardiovascular	O	ADJ	B
consequences	O	NOUN	B
of	O	ADP	O
stopping	O	VERB	O
selegiline	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
expectation	O	NOUN	B
that	O	SCONJ	O
this	O	DET	O
might	O	AUX	O
shed	O	VERB	O
light	O	NOUN	O
on	O	ADP	O
the	O	DET	O
mechanisms	O	NOUN	B
by	O	ADP	O
which	O	DET	O
the	O	DET	O
drug	O	NOUN	B
causes	O	VERB	O
orthostatic	B-Disease	ADJ	B
hypotension	I-Disease	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
cardiovascular	O	ADJ	B
responses	O	NOUN	B
to	O	ADP	O
standing	O	NOUN	B
and	O	CCONJ	O
head	O	NOUN	B
-	O	PUNCT	O
up	O	ADP	B
tilt	O	NOUN	I
were	O	AUX	O
studied	O	VERB	O
repeatedly	O	ADV	O
in	O	ADP	O
PD	B-Disease	NOUN	B
patients	O	NOUN	B
receiving	O	VERB	O
selegiline	B-Chemical	NOUN	B
and	O	CCONJ	O
as	O	ADP	O
the	O	DET	O
drug	O	NOUN	B
was	O	AUX	O
withdrawn	O	VERB	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Head	O	PROPN	B
-	O	PUNCT	O
up	O	ADP	O
tilt	O	NOUN	B
caused	O	VERB	O
systolic	B-Disease	NOUN	B
orthostatic	I-Disease	ADJ	O
hypotension	I-Disease	NOUN	B
which	O	DET	O
was	O	AUX	O
marked	O	ADJ	O
in	O	ADP	O
six	O	NUM	O
of	O	ADP	O
20	O	NUM	O
PD	B-Disease	NOUN	B
patients	O	NOUN	B
on	O	ADP	O
selegiline	B-Chemical	NOUN	B
,	O	PUNCT	O
one	O	NUM	O
of	O	ADP	O
whom	O	PRON	O
lost	O	VERB	B
consciousness	O	NOUN	B
with	O	ADP	O
unrecordable	O	ADJ	B
blood	O	NOUN	I
pressures	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
lesser	O	ADJ	B
degree	O	NOUN	B
of	O	ADP	O
orthostatic	B-Disease	ADJ	B
hypotension	I-Disease	NOUN	B
occurred	O	VERB	O
with	O	ADP	O
standing	O	NOUN	B
.	O	PUNCT	O


Orthostatic	B-Disease	ADJ	B
hypotension	I-Disease	NOUN	O
was	O	AUX	O
ameliorated	O	VERB	B
4	O	NUM	O
days	O	NOUN	B
after	O	ADP	O
withdrawal	O	NOUN	B
of	O	ADP	O
selegiline	B-Chemical	NOUN	B
and	O	CCONJ	O
totally	O	ADV	O
abolished	O	VERB	O
7	O	NUM	O
days	O	NOUN	B
after	O	ADP	O
discontinuation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
drug	O	NOUN	B
.	O	PUNCT	O


Stopping	O	VERB	B
selegiline	B-Chemical	NOUN	B
also	O	ADV	O
significantly	O	ADV	O
reduced	B-Disease	VERB	B
the	I-Disease	DET	O
supine	I-Disease	ADJ	B
systolic	I-Disease	NOUN	O
and	I-Disease	CCONJ	O
diastolic	I-Disease	ADJ	B
blood	I-Disease	NOUN	I
pressures	I-Disease	NOUN	I
consistent	O	ADJ	B
with	O	ADP	I
a	O	DET	O
previously	O	ADV	O
undescribed	O	ADJ	O
supine	O	NOUN	B
pressor	O	NOUN	B
action	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	B
:	O	PUNCT	O
This	O	DET	O
study	O	NOUN	B
confirms	O	VERB	O
our	O	PRON	O
previous	O	ADJ	O
finding	O	NOUN	O
that	O	SCONJ	O
selegiline	B-Chemical	NOUN	B
in	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
L-dopa	B-Chemical	NOUN	B
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
selective	O	ADJ	O
orthostatic	B-Disease	ADJ	B
hypotension	I-Disease	NOUN	O
.	O	PUNCT	O


The	O	DET	O
possibilities	O	NOUN	B
that	O	SCONJ	O
these	O	DET	O
cardiovascular	O	ADJ	B
findings	O	NOUN	B
might	O	AUX	O
be	O	AUX	O
the	O	DET	O
result	O	NOUN	O
of	O	ADP	O
non	O	ADJ	B
-	O	PUNCT	O
selective	O	ADJ	B
inhibition	O	NOUN	B
of	O	ADP	O
monoamine	O	NOUN	B
oxidase	O	NOUN	I
or	O	CCONJ	O
of	O	ADP	O
amphetamine	B-Chemical	NOUN	B
and	O	CCONJ	O
metamphetamine	B-Chemical	NOUN	B


Explicit	O	ADJ	O
episodic	O	ADJ	B
memory	O	NOUN	B
for	O	ADP	O
sensory	O	ADJ	B
-	O	PUNCT	O
discriminative	O	ADJ	B
components	O	NOUN	B
of	O	ADP	O
capsaicin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
pain	B-Disease	NOUN	B
:	O	PUNCT	O
immediate	O	ADJ	B
and	O	CCONJ	O
delayed	O	VERB	B
ratings	O	NOUN	B
.	O	PUNCT	O


Pain	B-Disease	NOUN	B
memory	O	NOUN	I
is	O	AUX	O
thought	O	VERB	O
to	O	PART	O
affect	O	VERB	O
future	O	ADJ	O
pain	B-Disease	NOUN	B
sensitivity	O	NOUN	I
and	O	CCONJ	O
thus	O	ADV	O
contribute	O	VERB	O
to	O	PART	O
clinical	O	ADJ	B
pain	B-Disease	NOUN	I
conditions	O	NOUN	O
.	O	PUNCT	O


Systematic	O	ADJ	B
investigations	O	NOUN	B
of	O	ADP	O
the	O	DET	O
human	O	ADJ	B
capacity	O	NOUN	B
to	O	PART	O
remember	O	VERB	O
sensory	O	ADJ	B
features	O	NOUN	I
of	O	ADP	O
experimental	O	ADJ	B
pain	B-Disease	NOUN	I
are	O	AUX	O
sparse	O	ADJ	O
.	O	PUNCT	O


In	O	ADP	O
order	O	NOUN	O
to	O	PART	O
address	O	VERB	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
pain	B-Disease	NOUN	B
memory	O	NOUN	I
,	O	PUNCT	O
nine	O	NUM	O
healthy	O	ADJ	B
male	O	NOUN	B
volunteers	O	NOUN	O
received	O	VERB	O
intradermal	O	ADJ	B
injections	O	NOUN	I
of	O	ADP	O
three	O	NUM	O
doses	O	NOUN	B
of	O	ADP	O
capsaicin	B-Chemical	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
,	O	PUNCT	O
1	O	NUM	O
and	O	CCONJ	O
20	O	NUM	O
microg	O	NOUN	B
,	O	PUNCT	O
separated	O	VERB	O
by	O	ADP	O
15	O	NUM	O
min	O	NOUN	O
breaks	O	NOUN	B
),	O	PUNCT	O
each	O	DET	O
given	O	VERB	O
three	O	NUM	O
times	O	NOUN	O
in	O	ADP	O
a	O	DET	O
balanced	O	ADJ	O
design	O	NOUN	B
across	O	ADP	O
three	O	NUM	O
sessions	O	NOUN	B
at	O	ADP	O
one	O	NUM	O
week	O	NOUN	B
intervals	O	NOUN	B
.	O	PUNCT	O


Pain	B-Disease	NOUN	B
rating	O	NOUN	I
was	O	AUX	O
performed	O	VERB	O
using	O	VERB	O
a	O	DET	O
computerized	O	VERB	B
visual	O	ADJ	I
analogue	O	NOUN	I
scale	O	NOUN	I
(	O	PUNCT	O
0	O	NUM	O
-	O	SYM	O
100	O	NUM	O
)	O	PUNCT	O
digitized	O	VERB	B
at	O	ADP	O
1	O	NUM	O
/	O	SYM	O
s	O	NOUN	O
,	O	PUNCT	O
either	O	CCONJ	O
immediately	O	ADV	O
online	O	ADV	B
or	O	CCONJ	O
one	O	NUM	O
hour	O	NOUN	B
or	O	CCONJ	O
one	O	NUM	O
day	O	NOUN	B
after	O	ADP	O
injection	O	NOUN	B
.	O	PUNCT	O


Subjects	O	NOUN	B
also	O	ADV	O
recalled	O	VERB	O
their	O	PRON	O
pains	B-Disease	NOUN	B
one	O	NUM	O
week	O	NOUN	B
later	O	ADV	O
.	O	PUNCT	O


Capsaicin	B-Chemical	NOUN	B
injection	O	NOUN	B
reliably	O	ADV	O
induced	O	VERB	B
a	O	DET	O
dose	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
flare	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
)	O	PUNCT	O
without	O	ADP	O
any	O	DET	O
difference	O	NOUN	O
within	O	ADP	O
or	O	CCONJ	O
across	O	ADP	O
sessions	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
strong	O	ADJ	O
burning	O	VERB	B
pain	B-Disease	NOUN	I
decayed	O	VERB	B
exponentially	O	ADV	O
within	O	ADP	O
a	O	DET	O
few	O	ADJ	O
minutes	O	NOUN	B
.	O	PUNCT	O


Subjects	O	NOUN	B
were	O	AUX	O
able	O	ADJ	O
to	O	PART	O
reliably	O	ADV	O
discriminate	O	VERB	O
pain	B-Disease	NOUN	B
magnitude	O	NOUN	B
and	O	CCONJ	O
duration	O	NOUN	B
across	O	ADP	O
capsaicin	B-Chemical	NOUN	B
doses	O	NOUN	B
(	O	PUNCT	O
both	O	CCONJ	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
),	O	PUNCT	O
regardless	O	ADV	O
of	O	ADP	O
whether	O	SCONJ	O
first	O	ADJ	B
-	O	PUNCT	O
time	O	NOUN	B
ratings	O	NOUN	B
were	O	AUX	O
requested	O	VERB	O
immediately	O	ADV	O
,	O	PUNCT	O
after	O	ADP	O
one	O	NUM	O
hour	O	NOUN	B
or	O	CCONJ	O
after	O	ADP	O
one	O	NUM	O
day	O	NOUN	B
.	O	PUNCT	O


Pain	B-Disease	NOUN	B
recall	O	NOUN	I
after	O	ADP	O
one	O	NUM	O
week	O	NOUN	B
was	O	AUX	O
similarly	O	ADV	O
precise	O	ADJ	O
(	O	PUNCT	O
magnitude	O	NOUN	B
:	O	PUNCT	O
p	O	X	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
,	O	PUNCT	O
duration	O	NOUN	B
:	O	PUNCT	O
p	O	X	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
).	O	PUNCT	O
Correlation	O	NOUN	B
with	O	ADP	O
rating	O	NOUN	B
recall	O	NOUN	I
after	O	ADP	O
one	O	NUM	O
week	O	NOUN	B
was	O	AUX	O
best	O	ADJ	O
when	O	SCONJ	O
first	O	ADJ	B
-	O	PUNCT	O
time	O	NOUN	B
ratings	O	NOUN	B
were	O	AUX	O
requested	O	VERB	O
as	O	ADV	O
late	O	ADV	O
as	O	ADP	O
one	O	NUM	O
day	O	NOUN	B
after	O	ADP	O
injection	O	NOUN	B
(	O	PUNCT	O
R	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
)=	O	SYM	O
0	O	NUM	O
.	O	PUNCT	O


79	O	NUM	O
)	O	PUNCT	O
indicating	O	VERB	O
that	O	SCONJ	O
both	O	DET	O
rating	O	NOUN	B
retrievals	O	NOUN	I
utilized	O	VERB	O
similar	O	ADJ	O
memory	O	NOUN	B
traces	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
indicate	O	VERB	O
a	O	DET	O
reliable	O	ADJ	O
memory	O	NOUN	B
for	O	ADP	O
magnitude	O	NOUN	B
and	O	CCONJ	O
duration	O	NOUN	B
of	O	ADP	O
experimentally	O	ADV	B
induced	O	VERB	B
pain	B-Disease	NOUN	B


Reversibility	O	NOUN	B
of	O	ADP	O
captopril	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
renal	B-Disease	ADJ	B
insufficiency	I-Disease	NOUN	I
after	O	ADP	O
prolonged	O	ADJ	B
use	O	NOUN	O
in	O	ADP	O
an	O	DET	O
unusual	O	ADJ	B
case	O	NOUN	B
of	O	ADP	O
renovascular	B-Disease	ADJ	B
hypertension	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
severe	O	ADJ	B
hypertension	B-Disease	NOUN	B
with	O	ADP	O
an	O	DET	O
occluded	O	VERB	B
renal	O	ADJ	B
artery	O	NOUN	I
to	O	PART	O
a	O	DET	O
solitary	O	ADJ	B
kidney	O	NOUN	I
,	O	PUNCT	O
who	O	PRON	O
developed	O	VERB	O
sudden	B-Disease	ADJ	B
deterioration	I-Disease	NOUN	I
of	I-Disease	ADP	O
renal	I-Disease	ADJ	B
function	I-Disease	NOUN	I
following	O	VERB	O
treatment	O	NOUN	B
with	O	ADP	O
captopril	B-Chemical	NOUN	B
.	O	PUNCT	O


His	O	PRON	O
renal	O	ADJ	B
function	O	NOUN	I
remained	O	VERB	O
impaired	O	ADJ	B
but	O	CCONJ	O
stable	O	ADJ	B
during	O	ADP	O
2	O	NUM	O
years	O	NOUN	B
'	O	PART	O
treatment	O	NOUN	B
with	O	ADP	O
captopril	B-Chemical	NOUN	B
but	O	CCONJ	O
returned	O	VERB	O
to	O	ADP	O
pre	O	NOUN	B
-	O	PUNCT	O
treatment	O	NOUN	B
levels	O	NOUN	B
soon	O	ADV	O
after	O	ADP	O
cessation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
drug	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
indicates	O	VERB	O
reversibility	O	NOUN	B
in	O	ADP	O
captopril	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
renal	B-Disease	ADJ	B
failure	I-Disease	NOUN	I


Liver	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
propylthiouracil	B-Chemical	NOUN	B
.	O	PUNCT	O


This	O	DET	O
report	O	NOUN	B
presents	O	VERB	O
the	O	DET	O
clinical	O	ADJ	B
,	O	PUNCT	O
laboratory	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
light	O	ADJ	B
and	O	CCONJ	O
electron	O	NOUN	B
microscopic	O	ADJ	I
observations	O	NOUN	B
on	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
chronic	B-Disease	ADJ	B
active	I-Disease	ADJ	I
(aggressive)	I-Disease	NOUN	I
hepatitis	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
the	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
propylthiouracil	B-Chemical	NOUN	B
.	O	PUNCT	O


This	O	DET	O
is	O	AUX	O
an	O	DET	O
addition	O	NOUN	O
to	O	ADP	O
the	O	DET	O
list	O	NOUN	O
of	O	ADP	O
drugs	O	NOUN	B
that	O	PRON	O
must	O	AUX	O
be	O	AUX	O
considered	O	VERB	O
in	O	ADP	O
the	O	DET	O
evaluation	O	NOUN	B
of	O	ADP	O
chronic	O	ADJ	B
liver	B-Disease	NOUN	I
disease	I-Disease	NOUN	I


Capsaicin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
muscle	B-Disease	NOUN	B
pain	I-Disease	NOUN	I
alters	O	VERB	O
the	O	DET	O
excitability	O	NOUN	B
of	O	ADP	O
the	O	DET	O
human	O	ADJ	B
jaw	O	NOUN	O
-	O	PUNCT	O
stretch	O	NOUN	B
reflex	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
pathophysiology	O	NOUN	B
of	O	ADP	O
painful	O	ADJ	B
temporomandibular	B-Disease	ADJ	B
disorders	I-Disease	NOUN	I
is	O	AUX	O
not	O	PART	O
fully	O	ADV	O
understood	O	VERB	O
,	O	PUNCT	O
but	O	CCONJ	O
evidence	O	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
muscle	B-Disease	NOUN	B
pain	I-Disease	NOUN	I
modulates	O	VERB	B
motor	O	NOUN	B
function	O	NOUN	I
in	O	ADP	O
characteristic	O	ADJ	O
ways	O	NOUN	O
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
tested	O	VERB	B
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
activation	O	NOUN	B
of	O	ADP	O
nociceptive	B-Disease	ADJ	B
muscle	I-Disease	NOUN	I
afferent	O	NOUN	B
fibers	O	NOUN	B
would	O	AUX	O
be	O	AUX	O
linked	O	VERB	O
to	O	PART	O
an	O	DET	O
increased	O	VERB	B
excitability	O	NOUN	B
of	O	ADP	O
the	O	DET	O
human	O	ADJ	B
jaw	O	NOUN	O
-	O	PUNCT	O
stretch	O	NOUN	B
reflex	O	NOUN	I
and	O	CCONJ	O
whether	O	SCONJ	O
this	O	DET	O
process	O	NOUN	B
would	O	AUX	O
be	O	AUX	O
sensitive	O	ADJ	B
to	O	PART	O
length	O	NOUN	B
and	O	CCONJ	O
velocity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
stretch	O	NOUN	B
.	O	PUNCT	O


Capsaicin	B-Chemical	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
micro	O	ADJ	B
g	O	NOUN	I
)	O	PUNCT	O
was	O	AUX	O
injected	O	VERB	B
into	O	ADP	O
the	O	DET	O
masseter	O	NOUN	B
muscle	O	NOUN	I
to	O	PART	O
induce	O	VERB	B
pain	B-Disease	NOUN	B
in	O	ADP	O
11	O	NUM	O
healthy	O	ADJ	B
volunteers	O	NOUN	I
.	O	PUNCT	O


Short	O	ADJ	B
-	O	PUNCT	O
latency	O	NOUN	B
reflex	O	NOUN	O
responses	O	NOUN	B
were	O	AUX	O
evoked	O	VERB	B
in	O	ADP	O
the	O	DET	O
masseter	O	NOUN	B
and	O	CCONJ	O
temporalis	O	ADJ	B
muscles	O	NOUN	I
by	O	ADP	O
a	O	DET	O
stretch	O	NOUN	B
device	O	NOUN	I
with	O	ADP	O
different	O	ADJ	O
velocities	O	NOUN	B
and	O	CCONJ	O
displacements	O	NOUN	B
before	O	ADV	O
,	O	PUNCT	O
during	O	ADP	O
,	O	PUNCT	O
and	O	CCONJ	O
after	O	ADP	O
the	O	DET	O
pain	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
normalized	O	VERB	O
reflex	O	ADJ	B
amplitude	O	NOUN	B
increased	O	VERB	B
with	O	ADP	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
velocity	O	NOUN	B
at	O	ADP	O
a	O	DET	O
given	O	VERB	O
displacement	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
remained	O	VERB	O
constant	O	ADJ	B
with	O	ADP	O
different	O	ADJ	O
displacements	O	NOUN	B
at	O	ADP	O
a	O	DET	O
given	O	VERB	O
velocity	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
normalized	O	VERB	O
reflex	O	ADJ	B
amplitude	O	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
during	O	ADP	O
pain	B-Disease	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
only	O	ADV	O
at	O	ADP	O
faster	O	ADJ	O
stretches	O	NOUN	B
in	O	ADP	O
the	O	DET	O
painful	B-Disease	ADJ	B
muscle	I-Disease	NOUN	I
.	O	PUNCT	O


Increased	O	VERB	B
sensitivity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
fusimotor	O	ADJ	B
system	O	NOUN	I
during	O	ADP	O
acute	O	ADJ	B
muscle	B-Disease	NOUN	I
pain	I-Disease	NOUN	I


Repetitive	O	ADJ	B
transcranial	O	ADJ	I
magnetic	O	ADJ	O
stimulation	O	NOUN	O
for	O	ADP	O
levodopa	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
dyskinesias	B-Disease	NOUN	B
in	O	ADP	O
Parkinson's	B-Disease	ADJ	O
disease	I-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
placebo	O	NOUN	B
-	O	PUNCT	O
controlled	O	VERB	B
,	O	PUNCT	O
single	O	ADJ	B
-	O	PUNCT	O
blinded	O	VERB	B
,	O	PUNCT	O
crossover	O	NOUN	B
study	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
assessed	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
"	O	PUNCT	O
real	O	ADJ	O
"	O	PUNCT	O
repetitive	O	ADJ	B
transcranial	O	ADJ	I
magnetic	O	ADJ	I
stimulation	O	NOUN	I
(	O	PUNCT	O
rTMS	O	NOUN	B
)	O	PUNCT	O
versus	O	CCONJ	O
"	O	PUNCT	O
sham	O	NOUN	B
"	O	PUNCT	O
rTMS	O	NOUN	B
(	O	PUNCT	O
placebo	O	NOUN	B
)	O	PUNCT	O
on	O	ADP	O
peak	O	NOUN	B
dose	O	NOUN	I
dyskinesias	B-Disease	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
Parkinson's	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
PD	B-Disease	NOUN	B
).	O	PUNCT	O
Ten	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
PD	B-Disease	NOUN	B
and	O	CCONJ	O
prominent	O	ADJ	O
dyskinesias	B-Disease	NOUN	B
had	O	AUX	O
rTMS	O	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
,	O	PUNCT	O
800	O	NUM	O
pulses	O	NOUN	B
;	O	PUNCT	O
1	O	NUM	O
Hz	O	NOUN	O
rate	O	NOUN	B
)	O	PUNCT	O
delivered	O	VERB	O
over	O	ADP	O
the	O	DET	O
motor	O	NOUN	B
cortex	O	NOUN	I
for	O	ADP	O
4	O	NUM	O
consecutive	O	ADJ	B
days	O	NOUN	B
twice	O	ADV	O
,	O	PUNCT	O
once	O	SCONJ	O
real	O	ADJ	O
stimuli	O	NOUN	O
and	O	CCONJ	O
once	O	SCONJ	O
sham	O	NOUN	O
stimulation	O	NOUN	B
were	O	AUX	O
used	O	VERB	O
;	O	PUNCT	O
evaluations	O	NOUN	B
were	O	AUX	O
done	O	VERB	O
at	O	ADP	O
the	O	DET	O
baseline	O	NOUN	B
and	O	CCONJ	O
1	O	NUM	O
day	O	NOUN	B
after	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
each	O	DET	O
of	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
series	O	NOUN	O
.	O	PUNCT	O


Direct	O	ADJ	O
comparison	O	NOUN	B
between	O	ADP	O
sham	O	NOUN	B
and	O	CCONJ	O
real	O	ADJ	O
rTMS	O	NOUN	B
effects	O	NOUN	B
showed	O	VERB	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
in	O	ADP	O
clinician	O	NOUN	B
-	O	PUNCT	O
assessed	O	VERB	B
dyskinesia	B-Disease	NOUN	B
severity	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
comparison	O	NOUN	B
with	O	ADP	O
the	O	DET	O
baseline	O	NOUN	B
showed	O	VERB	O
small	O	ADJ	B
but	O	CCONJ	O
significant	O	ADJ	O
reduction	O	NOUN	B
in	O	ADP	O
dyskinesia	B-Disease	NOUN	B
severity	O	NOUN	B
following	O	VERB	O
real	O	ADJ	O
rTMS	O	NOUN	B
but	O	CCONJ	O
not	O	PART	O
placebo	O	ADJ	B
.	O	PUNCT	O


The	O	DET	O
major	O	ADJ	O
effect	O	NOUN	B
was	O	AUX	O
on	O	ADP	O
dystonia	B-Disease	NOUN	B
subscore	O	NOUN	B
.	O	PUNCT	O


Similarly	O	ADV	O
,	O	PUNCT	O
in	O	ADP	O
patient	O	NOUN	B
diaries	O	NOUN	I
,	O	PUNCT	O
although	O	SCONJ	O
both	O	DET	O
treatments	O	NOUN	B
caused	O	VERB	O
reduction	O	NOUN	B
in	O	ADP	O
subjective	O	ADJ	O
dyskinesia	B-Disease	NOUN	B
scores	O	NOUN	O
during	O	ADP	O
the	O	DET	O
days	O	NOUN	B
of	O	ADP	O
intervention	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
effect	O	NOUN	B
was	O	AUX	O
sustained	O	ADJ	B
for	O	ADP	O
3	O	NUM	O
days	O	NOUN	B
after	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
for	O	ADP	O
the	O	DET	O
real	O	ADJ	O
rTMS	O	NOUN	B
only	O	ADV	O
.	O	PUNCT	O


Following	O	VERB	O
rTMS	O	NOUN	B
,	O	PUNCT	O
no	O	DET	O
side	O	NOUN	B
effects	O	NOUN	I
and	O	CCONJ	O
no	O	DET	O
adverse	O	ADJ	B
effects	O	NOUN	I
on	O	ADP	O
motor	O	NOUN	B
function	O	NOUN	I
and	O	CCONJ	O
PD	B-Disease	NOUN	B
symptoms	O	NOUN	B
were	O	AUX	O
noted	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
the	O	DET	O
existence	O	NOUN	O
of	O	ADP	O
residual	O	ADJ	B
beneficial	O	ADJ	O
clinical	O	ADJ	B
aftereffects	O	NOUN	I
of	O	ADP	O
consecutive	O	ADJ	B
daily	O	ADJ	B
applications	O	NOUN	B
of	O	ADP	O
low	O	ADJ	B
-	O	PUNCT	O
frequency	O	NOUN	B
rTMS	O	NOUN	B
on	O	ADP	O
dyskinesias	B-Disease	NOUN	B
in	O	ADP	O
PD	B-Disease	NOUN	B


Disulfiram	B-Chemical	NOUN	B
-	O	PUNCT	O
like	O	ADJ	B
syndrome	O	NOUN	I
after	O	ADP	O
hydrogen	B-Chemical	NOUN	B
cyanamide	I-Chemical	NOUN	I
professional	O	ADJ	B
skin	O	NOUN	I
exposure	O	NOUN	B
:	O	PUNCT	O
two	O	NUM	O
case	O	NOUN	B
reports	O	VERB	I
in	O	ADP	O
France	O	PROPN	B
.	O	PUNCT	O


Hydrogen	B-Chemical	NOUN	B
cyanamide	I-Chemical	NOUN	I
is	O	AUX	O
a	O	DET	O
plant	O	NOUN	B
growth	O	NOUN	I
regulator	O	NOUN	I
used	O	VERB	O
in	O	ADP	O
agriculture	O	NOUN	B
to	O	PART	O
induce	O	VERB	B
bud	O	NOUN	B
break	O	NOUN	O
in	O	ADP	O
fruit	O	NOUN	B
trees	O	NOUN	B
.	O	PUNCT	O


Contact	O	NOUN	B
with	O	ADP	I
the	O	DET	O
skin	O	NOUN	B
can	O	AUX	O
result	O	VERB	O
in	O	ADP	O
percutaneous	O	ADJ	B
absorption	O	NOUN	I
of	O	ADP	O
the	O	DET	O
substance	O	NOUN	B
that	O	PRON	O
inhibits	O	VERB	B
aldehyde	B-Chemical	NOUN	B
dehydrogenase	O	NOUN	I
and	O	CCONJ	O
can	O	AUX	O
induce	O	VERB	B
acetaldehyde	B-Chemical	NOUN	B
syndrome	O	NOUN	I
in	O	ADP	O
case	O	NOUN	B
of	O	ADP	O
alcohol	B-Chemical	NOUN	B
use	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
this	O	DET	O
report	O	NOUN	B
is	O	AUX	O
to	O	PART	O
describe	O	VERB	O
two	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
a	O	DET	O
disulfiram	B-Chemical	NOUN	B
-	O	PUNCT	O
like	O	ADJ	B
syndrome	O	NOUN	I
following	O	VERB	O
occupational	O	ADJ	B
exposure	O	NOUN	I
to	O	PART	O
hydrogen	B-Chemical	NOUN	B
cyanamide	I-Chemical	NOUN	I
.	O	PUNCT	O


The	O	DET	O
first	O	ADJ	O
case	O	NOUN	B
involved	O	VERB	O
a	O	DET	O
59	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
man	O	NOUN	B
who	O	PRON	O
used	O	VERB	O
Dormex	B-Chemical	PROPN	B
,	O	PUNCT	O
which	O	DET	O
contains	O	VERB	O
hydrogen	B-Chemical	NOUN	B
cyanamide	I-Chemical	NOUN	I
,	O	PUNCT	O
without	O	ADP	O
protection	O	NOUN	B
after	O	ADP	O
consuming	O	VERB	O
a	O	DET	O
large	O	ADJ	O
amount	O	NOUN	O
of	O	ADP	O
alcohol	B-Chemical	NOUN	B
during	O	ADP	O
a	O	DET	O
meal	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
less	O	ADJ	O
than	O	ADP	O
1	O	NUM	O
hour	O	NOUN	B
after	O	ADP	O
the	O	DET	O
ingestion	O	NOUN	B
of	O	ADP	O
alcohol	B-Chemical	NOUN	B
,	O	PUNCT	O
he	O	PRON	O
developed	O	VERB	O
malaise	O	NOUN	B
with	O	ADP	O
flushing	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
face	I-Disease	NOUN	B
,	O	PUNCT	O
tachycardia	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
dyspnea	B-Disease	NOUN	B
.	O	PUNCT	O


Manifestations	O	NOUN	B
regressed	O	VERB	O
spontaneously	O	ADV	B
under	O	ADP	O
surveillance	O	NOUN	B
in	O	ADP	O
the	O	DET	O
hospital	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
second	O	ADJ	O
case	O	NOUN	B
occurred	O	VERB	O
in	O	ADP	O
a	O	DET	O
55	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
farmer	O	NOUN	B
following	O	VERB	O
cutaneous	O	ADJ	B
contact	O	NOUN	B
with	O	ADP	I
Dormex	B-Chemical	PROPN	B
.	O	PUNCT	O


Five	O	NUM	O
hours	O	NOUN	O
after	O	ADP	O
exposure	O	NOUN	B
,	O	PUNCT	O
he	O	PRON	O
developed	O	VERB	O
disulfiram	B-Chemical	NOUN	B
-	O	PUNCT	O
like	O	ADJ	B
syndrome	O	NOUN	I
with	O	ADP	O
flushing	B-Disease	NOUN	B
,	O	PUNCT	O
tachycardia	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
arterial	B-Disease	ADJ	B
hypotension	I-Disease	NOUN	I
after	O	ADP	O
consuming	O	VERB	O
three	O	NUM	O
glasses	O	NOUN	B
of	O	ADP	O
wine	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
recovered	O	VERB	O
spontaneously	O	ADV	B
in	O	ADP	O
3	O	NUM	O
hours	O	NOUN	O
under	O	ADP	O
surveillance	O	NOUN	B
in	O	ADP	O
the	O	DET	O
hospital	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
cases	O	NOUN	B
confirm	O	VERB	B
the	O	DET	O
necessity	O	NOUN	O
of	O	ADP	O
avoiding	O	VERB	O
alcohol	B-Chemical	NOUN	B
consumption	O	NOUN	I
as	O	ADP	O
recommended	O	VERB	B
in	O	ADP	O
the	O	DET	O
instructions	O	NOUN	B
for	O	ADP	O
use	O	NOUN	O
of	O	ADP	O
Dormex	B-Chemical	PROPN	B


Repeated	O	VERB	B
trimipramine	B-Chemical	NOUN	B
induces	O	VERB	O
dopamine	B-Chemical	NOUN	B
D2	O	NOUN	I
/	O	PUNCT	O
D3	O	NOUN	B
and	O	CCONJ	O
alpha1	O	NOUN	B
-	O	PUNCT	O
adrenergic	O	ADJ	B
up	O	NOUN	B
-	O	PUNCT	O
regulation	O	NOUN	B
.	O	PUNCT	O


Trimipramine	B-Chemical	NOUN	B
(	O	PUNCT	O
TRI	B-Chemical	PROPN	B
),	O	PUNCT	O
which	O	DET	O
shows	O	VERB	O
a	O	DET	O
clinical	O	ADJ	B
antidepressant	B-Chemical	ADJ	B
activity	O	NOUN	O
,	O	PUNCT	O
is	O	AUX	O
chemically	O	ADV	B
related	O	ADJ	O
to	O	PART	O
imipramine	B-Chemical	NOUN	B
but	O	CCONJ	O
does	O	AUX	O
not	O	PART	O
inhibit	O	VERB	B
the	O	DET	O
reuptake	O	NOUN	B
of	O	ADP	O
noradrenaline	B-Chemical	NOUN	B
and	O	CCONJ	O
5-hydroxytryptamine	B-Chemical	NOUN	B
,	O	PUNCT	O
nor	O	CCONJ	O
does	O	AUX	O
it	O	PRON	O
induce	O	VERB	O
beta	O	NOUN	B
-	O	PUNCT	O
adrenergic	O	ADJ	B
down	O	NOUN	B
-	O	PUNCT	O
regulation	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
mechanism	O	NOUN	B
of	O	ADP	O
its	O	PRON	O
antidepressant	B-Chemical	ADJ	B
activity	O	NOUN	O
is	O	AUX	O
still	O	ADV	O
unknown	O	ADJ	O
.	O	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
find	O	VERB	O
out	O	ADP	O
whether	O	SCONJ	O
TRI	B-Chemical	PROPN	B
given	O	VERB	O
repeatedly	O	ADV	B
was	O	AUX	O
able	O	ADJ	O
to	O	PART	O
induce	O	VERB	B
adaptive	O	ADJ	B
changes	O	NOUN	I
in	O	ADP	O
the	O	DET	O
dopaminergic	O	ADJ	B
and	O	CCONJ	O
alpha1	O	NOUN	B
-	O	PUNCT	O
adrenergic	O	ADJ	B
systems	O	NOUN	O
,	O	PUNCT	O
demonstrated	O	VERB	O
by	O	ADP	O
us	O	PRON	O
previously	O	ADV	O
for	O	ADP	O
various	O	ADJ	O
antidepressants	B-Chemical	NOUN	B
.	O	PUNCT	O


TRI	B-Chemical	PROPN	B
was	O	AUX	O
given	O	VERB	O
to	O	PART	O
male	O	NOUN	B
Wistar	O	NOUN	B
rats	O	NOUN	I
and	O	CCONJ	O
male	O	NOUN	B
Albino	O	PROPN	B
Swiss	O	ADJ	B
mice	O	NOUN	I
perorally	O	ADV	B
twice	O	ADV	O
daily	O	ADV	B
for	O	ADP	O
14	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
acute	O	ADJ	B
experiment	O	NOUN	B
TRI	B-Chemical	PROPN	B
(	O	PUNCT	O
given	O	VERB	O
i	O	PRON	O
.	O	PUNCT	O


p	O	NOUN	O
.)	O	NOUN	O
does	O	AUX	O
not	O	PART	O
antagonize	O	VERB	B
the	O	DET	O
reserpine	B-Chemical	NOUN	B
hypothermia	B-Disease	NOUN	B
in	O	ADP	O
mice	O	NOUN	B
and	O	CCONJ	O
does	O	AUX	O
not	O	PART	O
potentiate	O	VERB	O
the	O	DET	O
5-hydroxytryptophan	B-Chemical	NOUN	B
head	O	NOUN	B
twitches	O	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


TRI	B-Chemical	PROPN	B
given	O	VERB	O
repeatedly	O	ADV	O
to	O	ADP	O
rats	O	NOUN	B
increases	O	VERB	B
the	O	DET	O
locomotor	O	NOUN	B
hyperactivity	B-Disease	NOUN	I
induced	O	VERB	B
by	O	ADP	O
d-amphetamine	B-Chemical	NOUN	B
,	O	PUNCT	O
quinpirole	B-Chemical	NOUN	B
and	O	CCONJ	O
(+)-	O	NOUN	B
7	O	NUM	O
-	O	PUNCT	O
hydroxy	O	NOUN	B
-	O	PUNCT	O
dipropyloaminotetralin	O	NOUN	B
(	O	PUNCT	O
dopamine	B-Chemical	NOUN	B
D2	O	NOUN	I
and	O	CCONJ	O
D3	O	NOUN	B
effects	O	NOUN	O
).	O	PUNCT	O
The	O	DET	O
stereotypies	O	NOUN	B
induced	O	VERB	B
by	O	ADP	O
d-amphetamine	B-Chemical	NOUN	B
or	O	CCONJ	O
apomorphine	B-Chemical	NOUN	B
are	O	AUX	O
not	O	PART	O
potentiated	O	VERB	B
by	O	ADP	O
TRI	B-Chemical	PROPN	B
.	O	PUNCT	O


It	O	PRON	O
increases	O	VERB	B
the	O	DET	O
behaviour	O	NOUN	B
stimulation	O	NOUN	I
evoked	O	VERB	B
by	O	ADP	O
phenylephrine	B-Chemical	NOUN	B
(	O	PUNCT	O
given	O	VERB	O
intraventricularly	O	ADV	B
)	O	PUNCT	O
in	O	ADP	O
rats	O	NOUN	B
,	O	PUNCT	O
evaluated	O	VERB	B
in	O	ADP	O
the	O	DET	O
open	O	ADJ	B
field	O	NOUN	I
test	O	NOUN	I
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
the	O	DET	O
aggressiveness	B-Disease	NOUN	B
evoked	O	VERB	B
by	O	ADP	O
clonidine	B-Chemical	NOUN	B
in	O	ADP	O
mice	O	NOUN	B
,	O	PUNCT	O
both	O	CCONJ	O
these	O	DET	O
effects	O	NOUN	B
being	O	AUX	O
mediated	O	VERB	O
by	O	ADP	O
an	O	DET	O
alpha1	O	NOUN	B
-	O	PUNCT	O
adrenergic	O	ADJ	B
receptor	O	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
may	O	AUX	O
be	O	AUX	O
concluded	O	VERB	O
that	O	SCONJ	O
,	O	PUNCT	O
like	O	ADP	O
other	O	ADJ	O
tricyclic	O	ADJ	B
antidepressants	B-Chemical	NOUN	I
studied	O	VERB	O
previously	O	ADV	O
,	O	PUNCT	O
TRI	B-Chemical	PROPN	B
given	O	VERB	O
repeatedly	O	ADV	O
increases	O	VERB	B
the	O	DET	O
responsiveness	O	NOUN	B
of	O	ADP	O
brain	O	NOUN	B
dopamine	B-Chemical	NOUN	B
D2	O	NOUN	I
and	O	CCONJ	O
D3	O	NOUN	B
(	O	PUNCT	O
locomotor	O	NOUN	B
activity	O	NOUN	I
but	O	CCONJ	O
not	O	PART	O
stereotypy	O	NOUN	B
)	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
alpha1	O	NOUN	B
-	O	PUNCT	O
adrenergic	O	ADJ	B
receptors	O	NOUN	I
to	O	PART	O
their	O	PRON	O
agonists	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
question	O	NOUN	B
arises	O	VERB	O
whether	O	SCONJ	O
the	O	DET	O
reuptake	O	NOUN	B
inhibition	O	NOUN	B
is	O	AUX	O
of	O	ADP	O
any	O	DET	O
importance	O	NOUN	O
to	O	PART	O
the	O	DET	O
adaptive	O	ADJ	B
changes	O	NOUN	I
induced	O	VERB	B
by	O	ADP	O
repeated	O	VERB	O
antidepressants	B-Chemical	NOUN	B
,	O	PUNCT	O
suggested	O	VERB	O
to	O	PART	O
be	O	AUX	O
responsible	O	ADJ	O
for	O	ADP	O
the	O	DET	O
antidepressant	B-Chemical	NOUN	B


Ranitidine	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
acute	O	ADJ	B
interstitial	B-Disease	ADJ	I
nephritis	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
cadaveric	O	ADJ	B
renal	O	ADJ	I
allograft	O	NOUN	I
.	O	PUNCT	O


Ranitidine	B-Chemical	PROPN	B
frequently	O	ADV	B
is	O	AUX	O
used	O	VERB	O
for	O	ADP	O
preventing	O	VERB	B
peptic	O	ADJ	B
ulceration	O	NOUN	I
after	O	ADP	O
renal	O	ADJ	B
transplantation	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
drug	O	NOUN	B
occasionally	O	ADV	O
has	O	AUX	O
been	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
acute	O	ADJ	B
interstitial	B-Disease	ADJ	I
nephritis	I-Disease	NOUN	I
in	O	ADP	O
native	O	ADJ	B
kidneys	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
are	O	AUX	O
no	O	DET	O
similar	O	ADJ	O
reports	O	NOUN	B
with	O	ADP	O
renal	O	ADJ	B
transplantation	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
ranitidine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
acute	O	ADJ	B
interstitial	B-Disease	ADJ	I
nephritis	I-Disease	NOUN	I


Late	O	ADJ	B
,	O	PUNCT	O
late	O	ADJ	O
doxorubicin	B-Chemical	NOUN	B
cardiotoxicity	B-Disease	NOUN	B
.	O	PUNCT	O


Cardiac	B-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
is	O	AUX	O
a	O	DET	O
major	O	ADJ	O
complication	O	NOUN	B
which	O	DET	O
limits	O	VERB	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
adriamycin	B-Chemical	NOUN	B
as	O	ADP	O
a	O	DET	O
chemotherapeutic	O	ADJ	B
agent	O	NOUN	I
.	O	PUNCT	O


Cardiomyopathy	B-Disease	NOUN	B
is	O	AUX	O
frequent	O	ADJ	B
when	O	SCONJ	O
the	O	DET	O
total	O	ADJ	B
dose	O	NOUN	I
exceeds	O	VERB	O
600	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
and	O	CCONJ	O
occurs	O	VERB	O
within	O	ADP	O
one	O	NUM	O
to	O	PART	O
six	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
cessation	O	NOUN	B
of	O	ADP	O
therapy	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
patient	O	NOUN	B
is	O	AUX	O
reported	O	VERB	O
who	O	PRON	O
developed	O	VERB	O
progressive	O	ADJ	B
cardiomyopathy	B-Disease	NOUN	B
two	O	NUM	O
and	O	CCONJ	O
one	O	NUM	B
-	O	PUNCT	O
half	O	NOUN	B
years	O	NOUN	B
after	O	ADP	O
receiving	O	VERB	O
580	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
which	O	DET	O
apparently	O	ADV	O
represents	O	VERB	O
late	O	ADJ	O
,	O	PUNCT	O
late	O	ADJ	O
cardiotoxicity	B-Disease	NOUN	B


Acetazolamide	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
nephrolithiasis	B-Disease	NOUN	B
:	O	PUNCT	O
implications	O	NOUN	O
for	O	ADP	O
treatment	O	NOUN	B
of	O	ADP	O
neuromuscular	B-Disease	ADJ	B
disorders	I-Disease	NOUN	I
.	O	PUNCT	O


Carbonic	O	ADJ	B
anhydrase	O	NOUN	I
inhibitors	O	NOUN	O
can	O	AUX	O
cause	O	VERB	O
nephrolithiasis	B-Disease	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
studied	O	VERB	O
20	O	NUM	O
patients	O	NOUN	B
receiving	O	VERB	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
carbonic	O	ADJ	B
anhydrase	O	NOUN	I
inhibitor	O	NOUN	I
treatment	O	NOUN	B
for	O	ADP	O
periodic	O	ADJ	B
paralysis	B-Disease	NOUN	I
and	O	CCONJ	O
myotonia	B-Disease	NOUN	B
.	O	PUNCT	O


Three	O	NUM	O
patients	O	NOUN	B
on	O	ADP	O
acetazolamide	B-Chemical	NOUN	B
(	O	PUNCT	O
15	O	NUM	O
%)	O	NOUN	O
developed	O	VERB	O
renal	B-Disease	ADJ	B
calculi	I-Disease	NOUN	I
.	O	PUNCT	O


Extracorporeal	O	ADJ	B
lithotripsy	O	NOUN	I
successfully	O	ADV	O
removed	O	VERB	O
a	O	DET	O
renal	B-Disease	ADJ	B
calculus	I-Disease	NOUN	I
in	O	ADP	O
one	O	NUM	O
patient	O	NOUN	B
and	O	CCONJ	O
surgery	O	NOUN	B
removed	O	VERB	O
a	O	DET	O
staghorn	O	ADJ	B
calculus	B-Disease	NOUN	I
in	O	ADP	O
another	O	DET	O
,	O	PUNCT	O
permitting	O	VERB	O
continued	O	VERB	O
treatment	O	NOUN	B
.	O	PUNCT	O


Renal	O	ADJ	B
function	O	NOUN	I
remained	O	VERB	O
normal	O	ADJ	O
in	O	ADP	O
all	O	DET	O
patients	O	NOUN	B
.	O	PUNCT	O


Nephrolithiasis	B-Disease	NOUN	B
is	O	AUX	O
a	O	DET	O
complication	O	NOUN	B
of	O	ADP	O
acetazolamide	B-Chemical	NOUN	B


Is	O	AUX	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
scabies	B-Disease	NOUN	B
hazardous	O	ADJ	B
?	O	PUNCT	O
Treatment	O	NOUN	B
for	O	ADP	O
scabies	B-Disease	NOUN	B
is	O	AUX	O
usually	O	ADV	O
initiated	O	VERB	O
by	O	ADP	O
general	O	ADJ	B
practitioners	O	NOUN	I
;	O	PUNCT	O
most	O	ADV	O
consider	O	VERB	O
lindane	B-Chemical	NOUN	B
(	O	PUNCT	O
gamma	B-Chemical	NOUN	B
benzene	I-Chemical	NOUN	I
hexachloride	I-Chemical	NOUN	I
)	O	PUNCT	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
choice	O	NOUN	B
.	O	PUNCT	O


Lindane	B-Chemical	NOUN	B
is	O	AUX	O
also	O	ADV	O
widely	O	ADV	O
used	O	VERB	O
as	O	ADP	O
an	O	DET	O
agricultural	O	ADJ	B
and	O	CCONJ	O
industrial	O	ADJ	B
pesticide	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
as	O	ADP	O
a	O	DET	O
result	O	NOUN	O
the	O	DET	O
toxic	O	ADJ	B
profile	O	NOUN	I
of	O	ADP	O
this	O	DET	O
insecticide	O	NOUN	B
is	O	AUX	O
well	O	ADV	O
understood	O	VERB	O
.	O	PUNCT	O


Evidence	O	NOUN	B
is	O	AUX	O
accumulating	O	VERB	O
that	O	SCONJ	O
lindane	B-Chemical	NOUN	B
can	O	AUX	O
be	O	AUX	O
toxic	B-Disease	ADJ	B
to	I-Disease	PART	O
the	I-Disease	DET	O
central	I-Disease	ADJ	B
nervous	I-Disease	ADJ	I
system	I-Disease	NOUN	I
and	O	CCONJ	O
may	O	AUX	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
aplastic	B-Disease	ADJ	B
anaemia	I-Disease	NOUN	I
.	O	PUNCT	O


Preparations	O	NOUN	B
containing	O	VERB	O
lindane	B-Chemical	NOUN	B
continue	O	VERB	O
to	O	PART	O
be	O	AUX	O
sold	O	VERB	B
over	O	ADP	O
the	O	DET	O
counter	O	NOUN	B
and	O	CCONJ	O
may	O	AUX	O
represent	O	VERB	O
a	O	DET	O
hazard	O	NOUN	B
to	O	PART	O
poorly	O	ADV	O
informed	O	VERB	O
patients	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
literature	O	NOUN	B
review	O	NOUN	I
suggests	O	VERB	O
that	O	SCONJ	O
general	O	ADJ	B
practitioners	O	NOUN	I
should	O	AUX	O
prescribe	O	VERB	O
scabicides	O	NOUN	B
with	O	ADP	O
increased	O	VERB	B
caution	O	NOUN	O
for	O	ADP	O
certain	O	ADJ	O
at	O	ADP	O
-	O	PUNCT	O
risk	O	NOUN	B
groups	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
give	O	VERB	O
adequate	O	ADJ	B
warnings	O	NOUN	B
regarding	O	VERB	O
potential	O	ADJ	B
toxicity	B-Disease	NOUN	B


Anaesthetists	O	NOUN	B
'	O	PART	O
nightmare	O	NOUN	B
:	O	PUNCT	O
masseter	B-Disease	NOUN	B
spasm	I-Disease	NOUN	I
after	O	ADP	O
induction	O	NOUN	B
in	O	ADP	O
an	O	DET	O
undiagnosed	O	ADJ	B
case	O	NOUN	B
of	O	ADP	O
myotonia	B-Disease	NOUN	B
congenita	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
an	O	DET	O
undiagnosed	O	ADJ	B
case	O	NOUN	B
of	O	ADP	O
myotonia	B-Disease	NOUN	B
congenita	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
24	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
previously	O	ADV	O
healthy	O	ADJ	B
primigravida	O	NOUN	B
,	O	PUNCT	O
who	O	PRON	O
developed	O	VERB	O
life	O	NOUN	O
threatening	O	VERB	O
masseter	B-Disease	NOUN	B
spasm	I-Disease	NOUN	I
following	O	VERB	O
a	O	DET	O
standard	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
intravenous	O	ADJ	B
suxamethonium	B-Chemical	NOUN	B


Toxicity	B-Disease	NOUN	B
in	O	ADP	O
rhesus	O	NOUN	B
monkeys	O	NOUN	I
following	O	VERB	O
administration	O	NOUN	B
of	O	ADP	O
the	O	DET	O
8-aminoquinoline	B-Chemical	NOUN	B
8-[(4-amino-l-methylbutyl)amino]-	B-Chemical	ADJ	O
5-(l-hexyloxy)-6-methoxy-4-methylquinoline	I-Chemical	NUM	O
(	O	PUNCT	O
WR242511	B-Chemical	NOUN	B
).	O	PUNCT	O
INTRODUCTION	O	NOUN	O
:	O	PUNCT	O
Many	O	ADJ	O
substances	O	NOUN	B
that	O	PRON	O
form	O	VERB	O
methemoglobin	O	NOUN	B
(	O	PUNCT	O
MHb	O	NOUN	B
)	O	PUNCT	O
effectively	O	ADV	O
counter	O	VERB	O
cyanide	O	NOUN	B
(	O	PUNCT	O
CN	O	NOUN	B
)	O	PUNCT	O
toxicity	B-Disease	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
MHb	O	NOUN	B
formers	O	NOUN	B
are	O	AUX	O
generally	O	ADV	O
applied	O	VERB	O
as	O	ADP	O
treatments	O	NOUN	B
for	O	ADP	O
CN	O	NOUN	B
poisoning	B-Disease	NOUN	I
,	O	PUNCT	O
it	O	PRON	O
has	O	AUX	O
been	O	AUX	O
proposed	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
stable	O	ADJ	B
,	O	PUNCT	O
long	O	ADV	B
-	O	PUNCT	O
acting	O	VERB	B
MHb	O	NOUN	B
former	O	ADJ	B
could	O	AUX	O
serve	O	VERB	O
as	O	ADP	O
a	O	DET	O
CN	O	NOUN	B
pretreatment	O	NOUN	B
.	O	PUNCT	O


Using	O	VERB	O
this	O	DET	O
rationale	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
8-aminoquinoline	B-Chemical	NOUN	B
WR242511	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
potent	O	ADJ	O
long	O	ADV	B
-	O	PUNCT	O
lasting	O	VERB	B
MHb	O	NOUN	B
former	O	ADJ	O
in	O	ADP	O
rodents	O	NOUN	B
and	O	CCONJ	O
beagle	O	ADJ	B
dogs	O	NOUN	I
,	O	PUNCT	O
was	O	AUX	O
studied	O	VERB	O
in	O	ADP	O
the	O	DET	O
rhesus	O	NOUN	B
monkey	O	NOUN	I
for	O	ADP	O
advanced	O	ADJ	B
development	O	NOUN	I
as	O	ADP	O
a	O	DET	O
potential	O	ADJ	B
CN	O	NOUN	B
pretreatment	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
WR242511	B-Chemical	NOUN	B
was	O	AUX	O
administered	O	VERB	B
intravenously	O	ADV	B
(	O	PUNCT	O
IV	O	NUM	B
)	O	PUNCT	O
in	O	ADP	O
2	O	NUM	O
female	O	NOUN	B
and	O	CCONJ	O
4	O	NUM	O
male	O	NOUN	B
rhesus	O	NOUN	B
monkeys	O	NOUN	I
in	O	ADP	O
doses	O	NOUN	B
of	O	ADP	O
3	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
7	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
;	O	PUNCT	O
a	O	DET	O
single	O	ADJ	O
male	O	NOUN	B
also	O	ADV	O
received	O	VERB	O
WR242511	B-Chemical	NOUN	B
orally	O	ADV	B
(	O	PUNCT	O
PO	O	NOUN	B
)	O	PUNCT	O
at	O	ADP	O
7	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
.	O	PUNCT	O


Health	O	NOUN	B
status	O	NOUN	I
and	O	CCONJ	O
MHb	O	NOUN	B
levels	O	NOUN	B
were	O	AUX	O
monitored	O	VERB	O
following	O	VERB	O
exposure	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
selected	O	VERB	O
doses	O	NOUN	B
of	O	ADP	O
WR242511	B-Chemical	NOUN	B
,	O	PUNCT	O
which	O	DET	O
produced	O	VERB	O
significant	O	ADJ	O
methemoglobinemia	B-Disease	NOUN	B
in	O	ADP	O
beagle	O	ADJ	B
dogs	O	NOUN	I
in	O	ADP	O
earlier	O	ADJ	O
studies	O	NOUN	B
conducted	O	VERB	O
elsewhere	O	ADV	O
,	O	PUNCT	O
produced	O	VERB	O
very	O	ADV	O
little	O	ADJ	O
MHb	O	NOUN	B
(	O	PUNCT	O
mean	O	NOUN	O
<	O	X	O
2	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
%)	O	NOUN	O
in	O	ADP	O
the	O	DET	O
rhesus	O	NOUN	B
monkey	O	NOUN	I
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
transient	O	ADJ	B
hemoglobinuria	B-Disease	NOUN	I
was	O	AUX	O
noted	O	VERB	O
approximately	O	ADV	O
60	O	NUM	O
minutes	O	NOUN	B
postinjection	O	NOUN	B
of	O	ADP	O
WR242511	B-Chemical	NOUN	B
(	O	PUNCT	O
3	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
or	O	CCONJ	O
7	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
),	O	PUNCT	O
and	O	CCONJ	O
2	O	NUM	O
lethalities	O	NOUN	B
occurred	O	VERB	O
(	O	PUNCT	O
one	O	NUM	O
IV	O	NUM	B
and	O	CCONJ	O
one	O	NUM	O
PO	O	NOUN	B
)	O	PUNCT	O
following	O	VERB	O
the	O	DET	O
7	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
dose	O	NOUN	B
.	O	PUNCT	O


Myoglobinuria	B-Disease	NOUN	B
was	O	AUX	O
also	O	ADV	O
observed	O	VERB	O
following	O	VERB	O
the	O	DET	O
7	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
dose	O	NOUN	B
.	O	PUNCT	O


Histopathology	O	NOUN	B
analyses	O	NOUN	O
in	O	ADP	O
the	O	DET	O
2	O	NUM	O
animals	O	NOUN	B
that	O	PRON	O
died	O	VERB	B
revealed	O	VERB	B
liver	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
kidney	I-Disease	NOUN	B
toxicity	I-Disease	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
greater	O	ADJ	O
severity	O	NOUN	B
in	O	ADP	O
the	O	DET	O
orally	O	ADV	B
-	O	PUNCT	O
treated	O	VERB	B
animal	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
These	O	DET	O
data	O	NOUN	B
demonstrate	O	VERB	O
direct	O	ADJ	O
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
indirect	O	ADJ	B
drug	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
toxicity	B-Disease	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
concluded	O	VERB	O
that	O	SCONJ	O
WR242511	B-Chemical	NOUN	B
should	O	AUX	O
not	O	PART	O
be	O	AUX	O
pursued	O	VERB	O
as	O	ADP	O
a	O	DET	O
pretreatment	O	NOUN	B
for	O	ADP	O
CN	O	NOUN	B
poisoning	B-Disease	NOUN	I
unless	O	SCONJ	O
the	O	DET	O
anti	O	ADJ	B
-	O	PUNCT	O
CN	O	NOUN	B
characteristics	O	NOUN	B
of	O	ADP	O
this	O	DET	O
compound	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
successfully	O	ADV	O
dissociated	O	VERB	O
from	O	ADP	O
those	O	DET	O
producing	O	VERB	O
undesirable	O	ADJ	O
toxicity	B-Disease	NOUN	B


Neuroplasticity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
adult	O	ADJ	B
primate	O	ADJ	B
auditory	O	ADJ	B
cortex	O	NOUN	I
following	O	VERB	O
cochlear	O	ADJ	B
hearing	B-Disease	NOUN	I
loss	I-Disease	NOUN	I
.	O	PUNCT	O


Tonotopic	O	ADJ	B
organization	O	NOUN	I
is	O	AUX	O
an	O	DET	O
essential	O	ADJ	O
feature	O	NOUN	O
of	O	ADP	O
the	O	DET	O
primary	O	ADJ	B
auditory	O	ADJ	I
area	O	NOUN	I
(	O	PUNCT	O
A1	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
primate	O	ADJ	B
cortex	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
A1	O	NOUN	O
of	O	ADP	O
macaque	O	ADJ	B
monkeys	O	NOUN	B
,	O	PUNCT	O
low	O	ADJ	B
frequencies	O	NOUN	B
are	O	AUX	O
represented	O	VERB	O
rostrolaterally	O	ADV	B
and	O	CCONJ	O
high	O	ADJ	O
frequencies	O	NOUN	B
are	O	AUX	O
represented	O	VERB	O
caudomedially	O	ADV	B
.	O	PUNCT	O


The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
determine	O	VERB	O
if	O	SCONJ	O
changes	O	NOUN	B
occur	O	VERB	O
in	O	ADP	O
this	O	DET	O
tonotopic	O	ADJ	B
organization	O	NOUN	I
following	O	VERB	O
cochlear	O	ADJ	B
hearing	B-Disease	NOUN	I
loss	I-Disease	NOUN	I
.	O	PUNCT	O


Under	O	ADP	B
anesthesia	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
superior	O	ADJ	B
temporal	O	ADJ	O
gyrus	O	NOUN	O
of	O	ADP	O
adult	O	ADJ	B
macaque	O	ADJ	B
monkeys	O	NOUN	B
was	O	AUX	O
exposed	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
tonotopic	O	ADJ	B
organization	O	NOUN	I
of	O	ADP	O
A1	O	NOUN	B
was	O	AUX	O
mapped	O	VERB	B
using	O	VERB	O
conventional	O	ADJ	B
microelectrode	O	ADJ	B
recording	O	NOUN	I
techniques	O	NOUN	I
.	O	PUNCT	O


Following	O	VERB	O
recovery	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
monkeys	O	NOUN	B
were	O	AUX	O
selectively	O	ADV	O
deafened	O	VERB	B
for	O	ADP	O
high	O	ADJ	O
frequencies	O	NOUN	B
using	O	VERB	O
kanamycin	B-Chemical	NOUN	B
and	O	CCONJ	O
furosemide	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
actual	O	ADJ	O
frequencies	O	NOUN	B
deafened	O	VERB	B
were	O	AUX	O
determined	O	VERB	O
by	O	ADP	O
the	O	DET	O
loss	O	NOUN	B
of	O	ADP	O
tone	O	NOUN	B
-	O	PUNCT	O
burst	O	NOUN	B
elicited	O	VERB	O
auditory	O	ADJ	B
brainstem	O	NOUN	O
responses	O	NOUN	O
.	O	PUNCT	O


Three	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
deafening	O	NOUN	B
,	O	PUNCT	O
A1	O	NOUN	B
was	O	AUX	O
remapped	O	VERB	O
.	O	PUNCT	O


Postmortem	O	ADJ	B
cytoarchitectural	O	ADJ	B
features	O	NOUN	I
identifying	O	VERB	O
A1	O	NOUN	B
were	O	AUX	O
correlated	O	VERB	B
with	O	ADP	O
the	O	DET	O
electrophysiologic	O	ADJ	B
data	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
deprived	O	ADJ	B
area	O	NOUN	O
of	O	ADP	O
A1	O	NOUN	B
undergoes	O	VERB	O
extensive	O	ADJ	B
reorganization	O	NOUN	B
and	O	CCONJ	O
becomes	O	VERB	O
responsive	O	ADJ	B
to	O	PART	O
intact	O	ADJ	B
cochlear	O	ADJ	B
frequencies	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
region	O	NOUN	B
of	O	ADP	O
cortex	O	NOUN	B
that	O	PRON	O
represents	O	VERB	O
the	O	DET	O
low	O	ADJ	B
frequencies	O	NOUN	B
was	O	AUX	O
not	O	PART	O
obviously	O	ADV	O
affected	O	VERB	B
by	O	ADP	O
the	O	DET	O
cochlear	O	ADJ	B
hearing	B-Disease	NOUN	I
loss	I-Disease	NOUN	I


The	O	DET	O
site	O	NOUN	B
of	O	ADP	O
common	O	ADJ	O
side	O	NOUN	B
effects	O	NOUN	I
of	O	ADP	O
sumatriptan	B-Chemical	NOUN	B
.	O	PUNCT	O


Atypical	B-Disease	ADJ	B
sensations	I-Disease	NOUN	O
following	O	VERB	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
subcutaneous	O	ADJ	B
sumatriptan	B-Chemical	NOUN	B
are	O	AUX	O
common	O	ADJ	O
,	O	PUNCT	O
but	O	CCONJ	O
of	O	ADP	O
uncertain	O	ADJ	O
origin	O	NOUN	B
.	O	PUNCT	O


They	O	PRON	O
are	O	AUX	O
almost	O	ADV	O
always	O	ADV	O
benign	O	ADJ	B
,	O	PUNCT	O
but	O	CCONJ	O
can	O	AUX	O
be	O	AUX	O
mistaken	O	VERB	O
for	O	ADP	O
a	O	DET	O
serious	O	ADJ	O
adverse	O	ADJ	B
event	O	NOUN	I
by	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
.	O	PUNCT	O


Two	O	NUM	O
patients	O	NOUN	B
are	O	AUX	O
presented	O	VERB	O
with	O	ADP	O
tingling	B-Disease	NOUN	B
or	I-Disease	CCONJ	O
burning	I-Disease	VERB	B
sensations	I-Disease	NOUN	B
limited	O	VERB	O
to	O	ADP	O
areas	O	NOUN	B
of	O	ADP	O
heat	O	NOUN	B
exposure	O	NOUN	I
or	O	CCONJ	O
sunburn	B-Disease	NOUN	B


Tremor	B-Disease	NOUN	B
side	O	NOUN	B
effects	O	NOUN	I
of	O	ADP	O
salbutamol	B-Chemical	NOUN	B
,	O	PUNCT	O
quantified	O	VERB	B
by	O	ADP	O
a	O	DET	O
laser	O	NOUN	B
pointer	O	NOUN	I
technique	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	B
:	O	PUNCT	O
To	O	PART	O
study	O	VERB	B
tremor	B-Disease	NOUN	B
side	O	NOUN	B
effects	O	NOUN	I
of	O	ADP	O
salbutamol	B-Chemical	NOUN	B
an	O	DET	O
easily	O	ADV	O
applicable	O	ADJ	O
,	O	PUNCT	O
quick	O	ADJ	B
and	O	CCONJ	O
low	O	ADJ	B
-	O	PUNCT	O
priced	O	VERB	B
method	O	NOUN	B
is	O	AUX	O
needed	O	VERB	O
.	O	PUNCT	O


A	O	DET	O
new	O	ADJ	O
method	O	NOUN	B
using	O	VERB	O
a	O	DET	O
commercially	O	ADV	O
available	O	ADJ	O
,	O	PUNCT	O
pen	O	NOUN	B
-	O	PUNCT	O
shaped	O	VERB	B
laser	O	NOUN	B
pointer	O	NOUN	I
was	O	AUX	O
developed	O	VERB	O
.	O	PUNCT	O


Aim	O	VERB	O
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
determine	O	VERB	O
sensitivity	O	NOUN	B
,	O	PUNCT	O
reproducibility	O	NOUN	B
,	O	PUNCT	O
reference	O	NOUN	B
values	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
agreement	O	NOUN	B
with	O	ADP	O
a	O	DET	O
questionnaire	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
Tremor	B-Disease	NOUN	B
was	O	AUX	O
measured	O	VERB	B
using	O	VERB	O
a	O	DET	O
laser	O	NOUN	B
pointer	O	NOUN	I
technique	O	NOUN	I
.	O	PUNCT	O


To	O	PART	O
determine	O	VERB	O
sensitivity	O	NOUN	B
we	O	PRON	O
assessed	O	VERB	B
tremor	B-Disease	NOUN	B
in	O	ADP	O
44	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
obstructive	B-Disease	ADJ	B
lung	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
after	O	ADP	O
administration	O	NOUN	B
of	O	ADP	O
cumulative	O	ADJ	B
doses	O	NOUN	B
of	O	ADP	O
salbutamol	B-Chemical	NOUN	B
.	O	PUNCT	O


Subjects	O	NOUN	B
were	O	AUX	O
asked	O	VERB	O
to	O	PART	O
aim	O	VERB	O
at	O	ADP	O
the	O	DET	O
centre	O	NOUN	B
of	O	ADP	O
a	O	DET	O
target	O	NOUN	B
,	O	PUNCT	O
subdivided	O	VERB	O
in	O	ADP	O
concentric	O	ADJ	B
circles	O	NOUN	I
,	O	PUNCT	O
from	O	ADP	O
5	O	NUM	O
m	O	NOUN	O
distance	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
circle	O	NOUN	B
in	O	ADP	O
which	O	DET	O
the	O	DET	O
participant	O	NOUN	B
succeeded	O	VERB	O
to	O	PART	O
aim	O	VERB	O
was	O	AUX	O
recorded	O	VERB	O
in	O	ADP	O
millimetres	O	NOUN	B
radius	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
another	O	DET	O
series	O	NOUN	O
of	O	ADP	O
measurements	O	NOUN	B
,	O	PUNCT	O
reproducibility	O	NOUN	B
and	O	CCONJ	O
reference	O	NOUN	B
values	O	NOUN	I
of	O	ADP	O
the	O	DET	O
tremor	B-Disease	NOUN	B
was	O	AUX	O
assessed	O	VERB	B
in	O	ADP	O
65	O	NUM	O
healthy	O	ADJ	B
subjects	O	NOUN	I
in	O	ADP	O
three	O	NUM	O
sessions	O	NOUN	B
,	O	PUNCT	O
at	O	ADP	O
9	O	NUM	O
a	O	DET	O
.	O	PUNCT	O


m	O	NOUN	O
.,	O	NOUN	O
4	O	NUM	O
p	O	NOUN	O
.	O	PUNCT	O


m	O	NOUN	O
.	O	PUNCT	O


and	O	CCONJ	O
9	O	NUM	O
a	O	DET	O
.	O	PUNCT	O


m	O	NOUN	O
.,	O	ADV	O
respectively	O	ADV	O
,	O	PUNCT	O
1	O	NUM	O
week	O	NOUN	B
later	O	ADV	O
.	O	PUNCT	O


Postural	O	ADJ	B
tremor	B-Disease	NOUN	I
was	O	AUX	O
measured	O	VERB	B
with	O	ADP	O
the	O	DET	O
arm	O	NOUN	B
horizontally	O	ADV	I
outstretched	O	ADJ	I
rest	O	NOUN	I
tremor	B-Disease	NOUN	O
with	O	ADP	O
the	O	DET	O
arm	O	NOUN	B
supported	O	VERB	O
by	O	ADP	O
an	O	DET	O
armrest	O	NOUN	B
and	O	CCONJ	O
finally	O	ADV	O
tremor	B-Disease	NOUN	B
was	O	AUX	O
measured	O	VERB	O
after	O	ADP	O
holding	O	VERB	O
a	O	DET	O
2	O	NUM	B
-	O	PUNCT	O
kg	O	NOUN	O
weight	O	NOUN	B
until	O	ADP	O
exhaustion	O	NOUN	B
.	O	PUNCT	O


Inter	O	PROPN	B
-	O	PUNCT	O
observer	O	NOUN	B
variability	O	NOUN	B
was	O	AUX	O
measured	O	VERB	B
in	O	ADP	O
a	O	DET	O
series	O	NOUN	O
of	O	ADP	O
10	O	NUM	O
healthy	O	ADJ	B
subjects	O	NOUN	I
.	O	PUNCT	O


Tremor	B-Disease	NOUN	B
was	O	AUX	O
measured	O	VERB	B
simultaneously	O	ADV	B
by	O	ADP	O
two	O	NUM	O
independent	O	ADJ	B
observers	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Salbutamol	B-Chemical	NOUN	B
significantly	O	ADV	O
increased	O	VERB	B
tremor	B-Disease	NOUN	B
severity	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
in	O	ADP	O
a	O	DET	O
dose	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
way	O	NOUN	O
.	O	PUNCT	O


Within	O	ADP	O
healthy	O	ADJ	B
adults	O	NOUN	B
no	O	DET	O
age	O	NOUN	B
-	O	PUNCT	O
dependency	O	NOUN	B
could	O	AUX	O
be	O	AUX	O
found	O	VERB	O
(	O	PUNCT	O
b	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


262	O	NUM	O
mm	O	NOUN	B
/	O	SYM	O
year	O	NOUN	B
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


72	O	NUM	O
).	O	PUNCT	O
There	O	PRON	O
was	O	AUX	O
no	O	DET	O
agreement	O	NOUN	O
between	O	ADP	O
the	O	DET	O
questionnaire	O	NOUN	B
and	O	CCONJ	O
tremor	B-Disease	NOUN	B
severity	O	NOUN	B
(	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


093	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


53	O	NUM	O
).	O	PUNCT	B
Postural	O	ADJ	B
tremor	B-Disease	NOUN	I
showed	O	VERB	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
between	O	ADP	O
the	O	DET	O
first	O	ADJ	O
and	O	CCONJ	O
third	O	ADJ	O
session	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


07	O	NUM	O
).	O	PUNCT	O
Support	O	NOUN	O
of	O	ADP	O
the	O	DET	O
arm	O	NOUN	B
decreased	O	VERB	B
tremor	B-Disease	NOUN	B
severity	O	NOUN	B
,	O	PUNCT	O
exhaustion	O	NOUN	B
increased	O	VERB	B
tremor	B-Disease	NOUN	B
severity	O	NOUN	B
significantly	O	ADV	O
.	O	PUNCT	O


A	O	DET	O
good	O	ADJ	O
agreement	O	NOUN	O
was	O	AUX	O
found	O	VERB	O
between	O	ADP	O
two	O	NUM	O
independent	O	ADJ	B
observers	O	NOUN	B
(	O	PUNCT	O
interclass	O	NOUN	B
correlation	O	NOUN	I
coefficient	O	NOUN	I
0	O	NUM	I
.	O	PUNCT	O


72	O	NUM	O
).	O	NOUN	O
DISCUSSION	O	NOUN	O
:	O	PUNCT	O
Quantifying	O	VERB	B
tremor	B-Disease	NOUN	B


Increased	O	VERB	B
frequency	O	NOUN	B
of	O	ADP	O
venous	B-Disease	ADJ	B
thromboembolism	I-Disease	NOUN	I
with	O	ADP	O
the	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
docetaxel	B-Chemical	NOUN	B
and	O	CCONJ	O
thalidomide	B-Chemical	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
metastatic	O	ADJ	B
androgen	O	NOUN	I
-	O	PUNCT	O
independent	O	ADJ	B
prostate	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


STUDY	O	NOUN	O
OBJECTIVE	O	NOUN	O
:	O	PUNCT	O
To	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
frequency	O	NOUN	B
of	O	ADP	O
venous	B-Disease	ADJ	B
thromboembolism	I-Disease	NOUN	I
(	O	PUNCT	O
VTE	B-Disease	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
advanced	O	ADJ	B
androgen	O	NOUN	B
-	O	PUNCT	O
independent	O	ADJ	B
prostate	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
who	O	PRON	O
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
docetaxel	B-Chemical	NOUN	B
alone	O	ADV	O
or	O	CCONJ	O
in	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
thalidomide	B-Chemical	NOUN	B
.	O	PUNCT	O


DESIGN	O	NOUN	O
:	O	PUNCT	O
Retrospective	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
phase	O	NOUN	I
II	O	NUM	I
trial	O	NOUN	I
.	O	PUNCT	O


SETTING	O	NOUN	B
:	O	PUNCT	O
National	O	PROPN	B
Institutes	O	PROPN	I
of	O	ADP	I
Health	O	PROPN	I
clinical	O	ADJ	I
research	O	NOUN	I
center	O	NOUN	I
.	O	PUNCT	O


PATIENTS	O	NOUN	B
:	O	PUNCT	O
Seventy	O	NUM	O
men	O	NOUN	B
,	O	PUNCT	O
aged	O	ADJ	B
50	O	NUM	O
-	O	SYM	O
80	O	NUM	O
years	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
advanced	O	ADJ	O
androgen	O	NOUN	B
-	O	PUNCT	O
independent	O	ADJ	B
prostate	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


INTERVENTION	O	NOUN	B
:	O	PUNCT	O
Each	O	DET	O
patient	O	NOUN	B
received	O	VERB	O
either	O	CCONJ	O
intravenous	O	ADJ	B
docetaxel	B-Chemical	NOUN	B
30	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
/	O	SYM	O
week	O	NOUN	B
for	O	ADP	O
3	O	NUM	O
consecutive	O	ADJ	B
weeks	O	NOUN	B
,	O	PUNCT	O
followed	O	VERB	O
by	O	ADP	O
1	O	NUM	O
week	O	NOUN	B
off	O	ADV	O
,	O	PUNCT	O
or	O	CCONJ	O
the	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
continuous	O	ADJ	B
oral	O	ADJ	O
thalidomide	B-Chemical	NOUN	B
200	O	NUM	O
mg	O	NOUN	O
every	O	DET	O
evening	O	NOUN	B
plus	O	CCONJ	O
the	O	DET	O
same	O	ADJ	O
docetaxel	B-Chemical	NOUN	B
regimen	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
4	O	NUM	O
-	O	PUNCT	O
week	O	NOUN	B
cycle	O	NOUN	B
was	O	AUX	O
repeated	O	VERB	O
until	O	ADP	O
there	O	PRON	O
was	O	AUX	O
evidence	O	NOUN	B
of	O	ADP	O
excessive	O	ADJ	B
toxicity	B-Disease	NOUN	B
or	O	CCONJ	O
disease	O	NOUN	B
progression	O	NOUN	I
.	O	PUNCT	O


MEASUREMENTS	O	NOUN	O
AND	O	CCONJ	O
MAIN	O	NOUN	O
RESULTS	O	NOUN	O
:	O	PUNCT	O
of	O	ADP	O
23	O	NUM	O
patients	O	NOUN	B
who	O	PRON	O
received	O	VERB	O
docetaxel	B-Chemical	NOUN	B
alone	O	ADV	O
developed	O	VERB	O
VTE	B-Disease	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
9	O	NUM	O
of	O	ADP	O
47	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
19	O	NUM	O
%)	O	NOUN	O
who	O	PRON	O
received	O	VERB	O
docetaxel	B-Chemical	NOUN	B
plus	O	CCONJ	O
thalidomide	B-Chemical	NOUN	B
developed	O	VERB	O
VTE	B-Disease	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


025	O	NUM	O
).	O	PUNCT	O
CONCLUSION	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
addition	O	NOUN	O
of	O	ADP	O
thalidomide	B-Chemical	NOUN	B
to	O	PART	O
docetaxel	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
prostate	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
significantly	O	ADV	O
increases	O	VERB	B
the	O	DET	O
frequency	O	NOUN	B
of	O	ADP	O
VTE	B-Disease	NOUN	B
.	O	PUNCT	O


Clinicians	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
aware	O	ADJ	O
of	O	ADP	O
this	O	DET	O
potential	O	ADJ	B
complication	O	NOUN	B
when	O	SCONJ	O
adding	O	VERB	O
thalidomide	B-Chemical	NOUN	B


Sublingual	O	ADJ	B
absorption	O	NOUN	B
of	O	ADP	O
the	O	DET	O
quaternary	B-Chemical	ADJ	B
ammonium	I-Chemical	NOUN	I
antiarrhythmic	O	ADJ	I
agent	O	NOUN	I
,	O	PUNCT	O
UM-272	B-Chemical	NOUN	B
.	O	PUNCT	O


UM-272	B-Chemical	NOUN	B
(	O	PUNCT	O
N,N-dimethylpropranolol	B-Chemical	PROPN	B
),	O	PUNCT	O
a	O	DET	O
quaternary	O	ADJ	B
antiarrhythmic	O	ADJ	I
agent	O	NOUN	I
,	O	PUNCT	O
was	O	AUX	O
administered	O	VERB	B
sublingually	O	ADV	B
to	O	ADP	O
dogs	O	NOUN	B
with	O	ADP	O
ouabain	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
ventricular	B-Disease	ADJ	B
tachycardias	I-Disease	NOUN	I
.	O	PUNCT	O


Both	O	CCONJ	O
anti	O	X	B
-	O	PUNCT	O
arrhythmic	O	ADJ	B
efficacy	O	NOUN	B
and	O	CCONJ	O
bioavailability	O	NOUN	B
were	O	AUX	O
compared	O	VERB	O
to	O	PART	O
oral	O	ADJ	B
drug	O	NOUN	I
.	O	PUNCT	O


Sublingual	O	ADJ	B
UM-272	B-Chemical	NOUN	B
converted	O	VERB	O
ventricular	B-Disease	ADJ	B
tachycardia	I-Disease	NOUN	I


Severe	O	ADJ	B
thrombocytopenia	B-Disease	NOUN	B
and	O	CCONJ	O
haemolytic	B-Disease	ADJ	B
anaemia	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
ciprofloxacin	B-Chemical	NOUN	B
:	O	PUNCT	O
a	O	DET	O
case	O	NOUN	B
report	O	NOUN	I
with	O	ADP	O
fatal	O	ADJ	B
outcome	O	NOUN	B
.	O	PUNCT	O


Haematological	O	ADJ	B
adverse	O	ADJ	B
reactions	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
fatal	O	ADJ	B
outcome	O	NOUN	B
are	O	AUX	O
rare	O	ADJ	B
during	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
ciprofloxacin	B-Chemical	NOUN	B
.	O	PUNCT	O


A	O	DET	O
30	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
old	O	ADJ	O
Caucasian	O	ADJ	B
man	O	NOUN	B
reported	O	VERB	O
with	O	ADP	O
abdominal	B-Disease	ADJ	B
pain	I-Disease	NOUN	I
and	O	CCONJ	O
jaundice	B-Disease	NOUN	B
after	O	ADP	O
3	O	NUM	B
-	O	PUNCT	O
day	O	NOUN	B
administration	O	NOUN	B
of	O	ADP	O
oral	O	ADJ	B
ciprofloxacin	B-Chemical	NOUN	I
for	O	ADP	O
a	O	DET	O
suspect	O	NOUN	O
of	O	ADP	O
urinary	B-Disease	ADJ	B
tract	I-Disease	NOUN	I
infection	I-Disease	NOUN	I
.	O	PUNCT	O


Clinical	O	ADJ	B
evaluations	O	NOUN	O
suggested	O	VERB	O
an	O	DET	O
initial	O	ADJ	O
diagnosis	O	NOUN	B
of	O	ADP	O
severe	O	ADJ	B
thrombocytopenia	B-Disease	NOUN	B
and	O	CCONJ	O
haemolysis	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
progressively	O	ADV	O
developed	O	VERB	O
petechiae	B-Disease	NOUN	B
and	O	CCONJ	O
purpura	B-Disease	NOUN	B
on	O	ADP	O
thorax	O	NOUN	B
and	O	CCONJ	O
lower	O	ADJ	B
limbs	O	NOUN	I
.	O	PUNCT	O


Despite	O	SCONJ	O
pharmacological	O	ADJ	B
and	O	CCONJ	O
supportive	O	ADJ	O
interventions	O	NOUN	B
,	O	PUNCT	O
laboratory	O	ADJ	B
parameters	O	NOUN	I
worsened	O	VERB	B
and	O	CCONJ	O
the	O	DET	O
patient	O	NOUN	B
died	O	VERB	B
17	O	NUM	O
hours	O	NOUN	B
after	O	ADP	O
admission	O	NOUN	B
.	O	PUNCT	O


An	O	DET	O
accurate	O	ADJ	B
autopsy	O	NOUN	B
revealed	O	VERB	O
most	O	ADJ	O
organs	O	NOUN	B
with	O	ADP	O
diffuse	O	ADJ	O
petechial	O	ADJ	B
haemorrhages	B-Disease	NOUN	O
.	O	PUNCT	O


No	O	DET	O
signs	O	NOUN	O
of	O	ADP	O
bone	B-Disease	NOUN	B
marrow	I-Disease	NOUN	I
depression	I-Disease	NOUN	I
were	O	AUX	O
found	O	VERB	O
.	O	PUNCT	O


No	O	DET	O
thrombi	B-Disease	NOUN	O
or	O	CCONJ	O
signs	O	NOUN	B
of	O	ADP	I
microangiopathies	B-Disease	NOUN	B
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
arterial	O	ADJ	B
vessels	O	NOUN	I
.	O	PUNCT	O


Blood	O	NOUN	B
and	O	CCONJ	O
urine	O	NOUN	B
cultures	O	NOUN	I
did	O	AUX	O
not	O	PART	O
show	O	VERB	O
any	O	DET	O
bacterial	O	ADJ	B
growth	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
case	O	NOUN	B
report	O	NOUN	I
shows	O	VERB	O
that	O	SCONJ	O
ciprofloxacin	B-Chemical	NOUN	B
may	O	AUX	O
precipitate	O	VERB	B
life	O	NOUN	B
-	O	PUNCT	O
threatening	O	VERB	B
thrombocytopenia	B-Disease	NOUN	B
and	O	CCONJ	O
haemolytic	B-Disease	ADJ	B
anaemia	I-Disease	NOUN	B


Simvastatin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
bilateral	O	ADJ	B
leg	O	NOUN	O
compartment	B-Disease	NOUN	O
syndrome	I-Disease	NOUN	O
and	O	CCONJ	O
myonecrosis	B-Disease	NOUN	B
associated	O	VERB	B
with	O	ADP	I
hypothyroidism	B-Disease	NOUN	B
.	O	PUNCT	O


A	O	DET	O
54	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
hypothyroid	B-Disease	ADJ	B
male	O	NOUN	B
taking	O	VERB	O
thyroxine	B-Chemical	NOUN	B
and	O	CCONJ	O
simvastatin	B-Chemical	NOUN	B
presented	O	VERB	O
with	O	ADP	O
bilateral	O	ADJ	B
leg	O	NOUN	I
compartment	B-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
and	O	CCONJ	O
myonecrosis	B-Disease	NOUN	B
.	O	PUNCT	O


Urgent	O	ADJ	B
fasciotomies	O	NOUN	I
were	O	AUX	O
performed	O	VERB	O
and	O	CCONJ	O
the	O	DET	O
patient	O	NOUN	B
made	O	VERB	O
an	O	DET	O
uneventful	O	ADJ	B
recovery	O	NOUN	B
with	O	ADP	O
the	O	DET	O
withdrawal	O	NOUN	B
of	O	ADP	O
simvastatin	B-Chemical	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
likely	O	ADJ	O
that	O	SCONJ	O
this	O	DET	O
complication	O	NOUN	B
will	O	AUX	O
be	O	AUX	O
seen	O	VERB	O
more	O	ADV	O
often	O	ADV	O
with	O	ADP	O
the	O	DET	O
increased	O	VERB	B
worldwide	O	ADJ	O
use	O	NOUN	O
of	O	ADP	O
this	O	DET	O
drug	O	NOUN	B
and	O	CCONJ	O
its	O	PRON	O
approval	O	NOUN	B
for	O	ADP	O
all	O	DET	O
arteriopathic	B-Disease	ADJ	B


Bile	B-Disease	ADJ	B
duct	I-Disease	NOUN	I
hamartoma	I-Disease	NOUN	B
occurring	O	VERB	O
in	O	ADP	O
association	O	NOUN	B
with	O	ADP	I
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
treatment	O	NOUN	B
with	O	ADP	O
danazol	B-Chemical	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
bile	B-Disease	NOUN	B
duct	I-Disease	NOUN	I
hamartoma	I-Disease	NOUN	B
which	O	DET	O
developed	O	VERB	O
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
who	O	PRON	O
had	O	AUX	O
been	O	AUX	O
on	O	ADP	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
danazol	B-Chemical	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


Such	O	ADJ	O
patients	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
under	O	ADP	O
close	O	ADJ	O
follow	O	NOUN	B
-	O	PUNCT	O
up	O	NOUN	O
,	O	PUNCT	O
preferably	O	ADV	O
with	O	ADP	O
periodic	O	ADJ	B
ultrasound	O	NOUN	O
examination	O	NOUN	O
of	O	ADP	O
the	O	DET	O
liver	O	NOUN	B
.	O	PUNCT	O


If	O	SCONJ	O
the	O	DET	O
patient	O	NOUN	B
develops	O	VERB	O
a	O	DET	O
liver	B-Disease	NOUN	B
mass	I-Disease	NOUN	I


Granulomatous	B-Disease	ADJ	B
hepatitis	I-Disease	NOUN	I
due	O	ADP	O
to	O	PART	O
combination	B-Chemical	NOUN	B
of	I-Chemical	ADP	O
amoxicillin	I-Chemical	NOUN	B
and	I-Chemical	CCONJ	O
clavulanic	I-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
the	O	DET	O
case	O	NOUN	B
of	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
amoxicillin-clavulanic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
-	O	PUNCT	O
induced	O	VERB	B
hepatitis	B-Disease	NOUN	B
with	O	ADP	O
histologic	O	ADJ	B
multiple	O	ADJ	O
granulomas	B-Disease	NOUN	B
.	O	PUNCT	O


This	O	DET	O
type	O	NOUN	O
of	O	ADP	O
lesion	O	NOUN	B
broadens	O	VERB	O
the	O	DET	O
spectrum	O	NOUN	B
of	O	ADP	O
liver	B-Disease	NOUN	B
injury	I-Disease	NOUN	I
due	O	ADP	O
to	O	PART	O
this	O	DET	O
drug	O	NOUN	B
combination	O	NOUN	I
,	O	PUNCT	O
mainly	O	ADV	O
represented	O	VERB	O
by	O	ADP	O
a	O	DET	O
benign	O	ADJ	B
cholestatic	B-Disease	ADJ	I
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
association	O	NOUN	B
of	O	ADP	O
granulomas	B-Disease	NOUN	B
and	O	CCONJ	O
eosinophilia	B-Disease	NOUN	B
favor	O	VERB	O
an	O	DET	O
immunoallergic	O	ADJ	B
mechanism	O	NOUN	B
.	O	PUNCT	O


As	O	ADP	O
penicillin	B-Chemical	NOUN	B
derivatives	O	NOUN	I
and	O	CCONJ	O
amoxicillin	B-Chemical	NOUN	B
alone	O	ADV	O
are	O	AUX	O
known	O	VERB	O
to	O	PART	O
induce	O	VERB	B
such	O	ADJ	O
types	O	NOUN	O
of	O	ADP	O
lesions	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
amoxicillin	B-Chemical	NOUN	B
component	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
or	O	CCONJ	O
without	O	ADP	O
a	O	DET	O
potentiating	O	NOUN	O
effect	O	NOUN	B
of	O	ADP	O
clavulanic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I


Intracranial	B-Disease	ADJ	B
aneurysms	I-Disease	NOUN	I
and	O	CCONJ	O
cocaine	B-Disease	NOUN	B
abuse	I-Disease	NOUN	I
:	O	PUNCT	O
analysis	O	NOUN	B
of	O	ADP	O
prognostic	O	ADJ	B
indicators	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
outcome	O	NOUN	B
of	O	ADP	O
subarachnoid	B-Disease	ADJ	B
hemorrhage	I-Disease	NOUN	B
associated	O	VERB	B
with	O	ADP	I
cocaine	B-Disease	NOUN	B
abuse	I-Disease	NOUN	I
is	O	AUX	O
reportedly	O	ADV	O
poor	O	ADJ	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
no	O	DET	O
study	O	NOUN	O
in	O	ADP	O
the	O	DET	O
literature	O	NOUN	B
has	O	AUX	O
reported	O	VERB	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
a	O	DET	O
statistical	O	ADJ	B
model	O	NOUN	I
to	O	PART	O
analyze	O	VERB	B
the	O	DET	O
variables	O	NOUN	B
that	O	PRON	O
influence	O	VERB	B
outcome	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
A	O	DET	O
review	O	NOUN	B
of	O	ADP	I
admissions	O	NOUN	B
during	O	ADP	O
a	O	DET	O
6	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
period	O	NOUN	B
revealed	O	VERB	O
14	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
aneurysms	B-Disease	NOUN	B
.	O	PUNCT	O


This	O	DET	O
group	O	NOUN	B
was	O	AUX	O
compared	O	VERB	B
with	O	ADP	O
a	O	DET	O
control	O	ADJ	B
group	O	NOUN	I
of	O	ADP	O
135	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
ruptured	B-Disease	ADJ	B
aneurysms	I-Disease	NOUN	B
and	O	CCONJ	O
no	O	DET	B
history	O	NOUN	I
of	O	ADP	O
cocaine	B-Disease	NOUN	B
abuse	I-Disease	NOUN	I
.	O	PUNCT	O


Age	O	NOUN	B
at	O	ADP	O
presentation	O	NOUN	B
,	O	PUNCT	O
time	O	NOUN	B
of	O	ADP	I
ictus	O	NOUN	I
after	O	ADP	O
intoxication	O	NOUN	B
,	O	PUNCT	O
Hunt	O	PROPN	B
and	O	CCONJ	O
Hess	O	PROPN	O
grade	O	NOUN	O
of	O	ADP	O
subarachnoid	B-Disease	ADJ	B
hemorrhage	I-Disease	NOUN	B
,	O	PUNCT	O
size	O	NOUN	B
of	O	ADP	O
the	O	DET	O
aneurysm	B-Disease	NOUN	B
,	O	PUNCT	O
location	O	NOUN	B
of	O	ADP	O
the	O	DET	O
aneurysm	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
Glasgow	O	PROPN	B
Outcome	O	PROPN	I
Scale	O	NOUN	I
score	O	NOUN	I
were	O	AUX	O
assessed	O	VERB	B
and	O	CCONJ	O
compared	O	VERB	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
study	O	NOUN	B
group	O	NOUN	I
were	O	AUX	O
significantly	O	ADV	O
younger	O	ADJ	B
than	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


002	O	NUM	O
).	O	PUNCT	O
In	O	ADP	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
study	O	NOUN	B
group	O	NOUN	I
,	O	PUNCT	O
all	O	DET	O
aneurysms	B-Disease	NOUN	B
were	O	AUX	O
located	O	ADJ	O
in	O	ADP	O
the	O	DET	O
anterior	O	ADJ	B
circulation	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
majority	O	NOUN	O
of	O	ADP	O
these	O	DET	O
aneurysms	B-Disease	NOUN	B
were	O	AUX	O
smaller	O	ADJ	O
than	O	ADP	O
those	O	DET	O
of	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
8	O	NUM	O
+/-	O	CCONJ	O
6	O	NUM	O
.	O	PUNCT	O


08	O	NUM	O
mm	O	NOUN	O
versus	O	CCONJ	O
11	O	NUM	O
+/-	O	CCONJ	O
5	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
mm	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
).	O	PUNCT	O
The	O	DET	O
differences	O	NOUN	B
in	O	ADP	O
mortality	O	NOUN	B
and	O	CCONJ	O
morbidity	O	NOUN	B
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
were	O	AUX	O
not	O	PART	O
significant	O	ADJ	O
.	O	PUNCT	O


Hunt	O	PROPN	B
and	O	CCONJ	O
Hess	O	PROPN	O
grade	O	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


005	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
age	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


007	O	NUM	O
)	O	PUNCT	O
were	O	AUX	O
significant	O	ADJ	O
predictors	O	NOUN	B
of	O	ADP	O
outcome	O	NOUN	B
for	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
with	O	ADP	O
cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
aneurysms	B-Disease	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
Cocaine	B-Chemical	NOUN	B
use	O	VERB	O
predisposed	O	VERB	O
aneurysmal	B-Disease	ADJ	B
rupture	I-Disease	NOUN	I
at	O	ADP	O
a	O	DET	O
significantly	O	ADV	O
earlier	O	ADJ	O
age	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
much	O	ADV	O
smaller	O	ADJ	O
aneurysms	B-Disease	NOUN	B


Anti	O	PROPN	B
-	O	PUNCT	O
epileptic	B-Disease	ADJ	B
drugs	O	NOUN	I
-	O	PUNCT	O
induced	O	VERB	B
de	O	X	O
novo	O	X	O
absence	B-Disease	NOUN	B
seizures	I-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
authors	O	NOUN	B
present	O	VERB	O
three	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
de	O	X	O
novo	O	X	O
absence	B-Disease	NOUN	O
epilepsy	I-Disease	NOUN	B
after	O	ADP	O
administration	O	NOUN	B
of	O	ADP	O
carbamazepine	B-Chemical	NOUN	B
and	O	CCONJ	O
vigabatrin	B-Chemical	NOUN	B
.	O	PUNCT	O


Despite	O	SCONJ	O
the	O	DET	O
underlying	O	VERB	O
diseases	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
prognosis	O	NOUN	B
for	O	ADP	O
drug	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
de	O	X	O
novo	O	X	O
absence	B-Disease	NOUN	B
seizure	I-Disease	NOUN	B
is	O	AUX	O
good	O	ADJ	O
because	O	SCONJ	O
it	O	PRON	O
subsides	O	VERB	O
rapidly	O	ADV	O
after	O	ADP	O
discontinuing	O	VERB	B
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
the	O	DET	O
offending	O	NOUN	B
drugs	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
gamma-aminobutyric	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
-	O	PUNCT	O
transmitted	O	VERB	B
thalamocortical	O	ADJ	B
circuitry	O	NOUN	B
accounts	O	NOUN	O
for	O	ADP	O
a	O	DET	O
major	O	ADJ	O
part	O	NOUN	O
of	O	ADP	O
the	O	DET	O
underlying	O	ADJ	O
neurophysiology	O	NOUN	B
of	O	ADP	O
the	O	DET	O
absence	B-Disease	NOUN	B
epilepsy	I-Disease	NOUN	B
.	O	PUNCT	O


Because	O	SCONJ	O
drug	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
de	O	X	O
novo	O	X	O
absence	B-Disease	NOUN	B
seizure	I-Disease	NOUN	B
is	O	AUX	O
rare	O	ADJ	B
,	O	PUNCT	O
pro	O	ADJ	B
-	O	PUNCT	O
absence	O	NOUN	B
drugs	O	NOUN	B
can	O	AUX	O
only	O	ADV	O
be	O	AUX	O
considered	O	VERB	O
a	O	DET	O
promoting	O	VERB	B
factor	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
underlying	O	ADJ	O
epileptogenecity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
or	O	CCONJ	O
the	O	DET	O
synergistic	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
the	O	DET	O
accompanying	O	VERB	O
drugs	O	NOUN	B
is	O	AUX	O
required	O	VERB	O
to	O	PART	O
trigger	O	VERB	B
the	O	DET	O
de	O	X	B
novo	O	X	I
absence	B-Disease	NOUN	B
seizure	I-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
possibility	O	NOUN	O
of	O	ADP	O
drug	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
aggravation	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
considered	O	VERB	O
whenever	O	SCONJ	O
an	O	DET	O
unexpected	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
seizure	B-Disease	NOUN	B
frequency	O	NOUN	O
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
new	O	ADJ	O
seizure	B-Disease	NOUN	B
types	O	NOUN	O
appear	O	VERB	O
following	O	VERB	O
a	O	DET	O
change	O	NOUN	B
in	O	ADP	O
drug	O	NOUN	B
treatment	O	NOUN	I
.	O	PUNCT	O


By	O	ADP	O
understanding	O	VERB	O
the	O	DET	O
underlying	O	ADJ	O
mechanism	O	NOUN	B
of	O	ADP	O
absence	B-Disease	NOUN	O
epilepsy	I-Disease	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
can	O	AUX	O
avoid	O	VERB	O
the	O	DET	O
inappropriate	O	ADJ	O
use	O	NOUN	O
of	O	ADP	O
anticonvulsants	O	NOUN	B
in	O	ADP	O
children	O	NOUN	B
with	O	ADP	O
epilepsy	B-Disease	NOUN	B
and	O	CCONJ	O
prevent	O	VERB	B
drug	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
absence	B-Disease	NOUN	O
seizures	I-Disease	NOUN	B


Procainamide	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
polymorphous	O	ADJ	B
ventricular	B-Disease	ADJ	B
tachycardia	I-Disease	NOUN	I
.	O	PUNCT	O


Seven	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
procainamide	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
polymorphous	O	ADJ	B
ventricular	B-Disease	ADJ	B
tachycardia	I-Disease	NOUN	I
are	O	AUX	O
presented	O	VERB	O
.	O	PUNCT	O


In	O	ADP	O
four	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
polymorphous	O	ADJ	B
ventricular	B-Disease	ADJ	B
tachycardia	I-Disease	NOUN	I
appeared	O	VERB	O
after	O	ADP	O
intravenous	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
200	O	NUM	O
to	O	PART	O
400	O	NUM	O
mg	O	NOUN	O
of	O	ADP	O
procainamide	B-Chemical	NOUN	B
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
sustained	O	ADJ	B
ventricular	B-Disease	ADJ	B
tachycardia	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
remaining	O	VERB	O
three	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
procainamide	B-Chemical	NOUN	B
was	O	AUX	O
administered	O	VERB	B
orally	O	ADV	B
for	O	ADP	O
treatment	O	NOUN	B
of	O	ADP	O
chronic	O	ADJ	B
premature	B-Disease	ADJ	I
ventricular	I-Disease	ADJ	I
contractions	I-Disease	NOUN	I
or	O	CCONJ	O
atrial	B-Disease	ADJ	B
flutter	I-Disease	NOUN	I
.	O	PUNCT	O


These	O	DET	O
patients	O	NOUN	B
had	O	AUX	O
Q-T	B-Disease	NOUN	B
prolongation	I-Disease	NOUN	I
and	O	CCONJ	O
recurrent	O	ADJ	B
syncope	B-Disease	NOUN	I
due	O	ADJ	O
to	O	PART	O
polymorphous	O	ADJ	B
ventricular	B-Disease	ADJ	B
tachycardia	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
four	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
arrhythmia	B-Disease	NOUN	B
was	O	AUX	O
rapidly	O	ADV	O
diagnosed	O	VERB	B
and	O	CCONJ	O
treated	O	VERB	B
with	O	ADP	I
disappearance	O	NOUN	B
of	O	ADP	O
further	O	ADJ	O
episodes	O	NOUN	B
of	O	ADP	O
the	O	DET	O
arrhythmia	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
two	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
arrhythmia	B-Disease	NOUN	B
degenerated	O	VERB	B
into	O	ADP	O
irreversible	O	ADJ	B
ventricular	B-Disease	ADJ	B
fibrillation	I-Disease	NOUN	I
and	O	CCONJ	O
both	O	DET	O
patients	O	NOUN	B
died	O	VERB	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
seventh	O	ADJ	O
patient	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
permanent	O	ADJ	B
ventricular	O	ADJ	I
pacemaker	O	NOUN	I
was	O	AUX	O
inserted	O	VERB	B
and	O	CCONJ	O
,	O	PUNCT	O
despite	O	SCONJ	O
continuation	O	NOUN	B
of	O	ADP	O
procainamide	B-Chemical	NOUN	B
therapy	O	NOUN	I
,	O	PUNCT	O
polymorphous	O	ADJ	B
ventricular	B-Disease	ADJ	B
tachycardia	I-Disease	NOUN	I
did	O	AUX	O
not	O	PART	O
reoccur	O	VERB	B
.	O	PUNCT	O


These	O	DET	O
seven	O	NUM	O
cases	O	NOUN	B
demonstrate	O	VERB	O
that	O	SCONJ	O
procainamide	B-Chemical	NOUN	B
can	O	AUX	O
produce	O	VERB	O
an	O	DET	O
acquired	O	VERB	O
prolonged	B-Disease	ADJ	B
Q-T	I-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
with	O	ADP	O
polymorphous	O	ADJ	B
ventricular	B-Disease	ADJ	O
tachycardia	I-Disease	NOUN	O


Role	O	NOUN	O
of	O	ADP	O
activation	O	NOUN	B
of	O	ADP	O
bradykinin	B-Chemical	NOUN	B
B2	O	NOUN	I
receptors	O	NOUN	I
in	O	ADP	O
disruption	O	NOUN	B
of	O	ADP	O
the	O	DET	O
blood	O	NOUN	B
-	O	PUNCT	O
brain	O	NOUN	B
barrier	O	NOUN	I
during	O	ADP	O
acute	O	ADJ	B
hypertension	B-Disease	NOUN	I
.	O	PUNCT	O


Cellular	O	ADJ	B
mechanisms	O	NOUN	I
which	O	DET	O
account	O	VERB	O
for	O	ADP	O
disruption	O	NOUN	B
the	O	DET	O
blood	O	NOUN	B
-	O	PUNCT	O
brain	O	NOUN	B
barrier	O	NOUN	I
during	O	ADP	O
acute	O	ADJ	B
hypertension	B-Disease	NOUN	I
are	O	AUX	O
not	O	PART	O
clear	O	ADJ	O
.	O	PUNCT	O


The	O	DET	O
goal	O	NOUN	B
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
synthesis	O	NOUN	B
/	O	PUNCT	O
release	O	NOUN	B
of	O	ADP	O
bradykinin	B-Chemical	NOUN	B
to	O	PART	O
activate	O	VERB	B
B2	O	NOUN	B
receptors	O	NOUN	I
in	O	ADP	O
disruption	O	NOUN	B
of	O	ADP	O
the	O	DET	O
blood	O	NOUN	B
-	O	PUNCT	O
brain	O	NOUN	B
barrier	O	NOUN	I
during	O	ADP	O
acute	O	ADJ	B
hypertension	B-Disease	NOUN	I
.	O	PUNCT	O


Permeability	O	NOUN	B
of	O	ADP	O
the	O	DET	O
blood	O	NOUN	B
-	O	PUNCT	O
brain	O	NOUN	B
barrier	O	NOUN	I
was	O	AUX	O
quantitated	O	VERB	B
by	O	ADP	O
clearance	O	NOUN	B
of	O	ADP	O
fluorescent	O	ADJ	B
-	O	PUNCT	O
labeled	O	VERB	B
dextran	B-Chemical	NOUN	B
before	O	ADP	O
and	O	CCONJ	O
during	O	ADP	O
phenylephrine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
acute	O	ADJ	B
hypertension	B-Disease	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
vehicle	O	NOUN	B
and	O	CCONJ	O
Hoe-140	B-Chemical	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
microM	O	NOUN	O
).	O	PUNCT	O
Phenylephrine	B-Chemical	NOUN	B
infusion	O	NOUN	B
increased	O	VERB	B
arterial	O	ADJ	B
pressure	O	NOUN	I
,	O	PUNCT	O
arteriolar	O	ADJ	B
diameter	O	NOUN	B
and	O	CCONJ	O
clearance	O	NOUN	B
of	O	ADP	O
fluorescent	O	ADJ	B
dextran	B-Chemical	NOUN	I
by	O	ADP	O
a	O	DET	O
similar	O	ADJ	O
magnitude	O	NOUN	B
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
disruption	O	NOUN	B
of	O	ADP	O
the	O	DET	O
blood	O	NOUN	B
-	O	PUNCT	O
brain	O	NOUN	B
barrier	O	NOUN	I
during	O	ADP	O
acute	O	ADJ	B
hypertension	B-Disease	NOUN	I
is	O	AUX	O
not	O	PART	O
related	O	ADJ	O
to	O	PART	O
the	O	DET	O
synthesis	O	NOUN	B
/	O	SYM	O
release	O	NOUN	B
of	O	ADP	O
bradykinin	B-Chemical	NOUN	B


5-azacytidine	B-Chemical	NOUN	B
potentiates	O	VERB	B
initiation	B-Disease	NOUN	B
induced	I-Disease	VERB	B
by	I-Disease	ADP	O
carcinogens	I-Disease	NOUN	B
in	O	ADP	O
rat	O	NOUN	B
liver	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
test	O	VERB	O
the	O	DET	O
validity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
hypomethylation	O	NOUN	B
of	O	ADP	O
DNA	O	NOUN	B
plays	O	VERB	O
an	O	DET	O
important	O	ADJ	O
role	O	NOUN	O
in	O	ADP	O
the	O	DET	O
initiation	B-Disease	NOUN	B
of	I-Disease	ADP	O
carcinogenic	I-Disease	ADJ	B
process	I-Disease	NOUN	I
,	O	PUNCT	O
5-azacytidine	B-Chemical	NOUN	B
(	O	PUNCT	O
5-AzC	B-Chemical	ADJ	O
)(	O	NOUN	O
10	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
),	O	PUNCT	O
an	O	DET	O
inhibitor	O	NOUN	B
of	O	ADP	O
DNA	O	NOUN	B
methylation	O	NOUN	I
,	O	PUNCT	O
was	O	AUX	O
given	O	VERB	O
to	O	ADP	O
rats	O	NOUN	B
during	O	ADP	O
the	O	DET	O
phase	O	NOUN	B
of	O	ADP	O
repair	O	NOUN	B
synthesis	O	NOUN	I
induced	O	VERB	B
by	O	ADP	O
the	O	DET	O
three	O	NUM	O
carcinogens	O	NOUN	B
,	O	PUNCT	O
benzo[a]-pyrene	B-Chemical	NOUN	B
(	O	PUNCT	O
200	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
),	O	PUNCT	O
N-methyl-N-nitrosourea	B-Chemical	NOUN	B
(	O	PUNCT	O
60	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
1,2-dimethylhydrazine	B-Chemical	NOUN	B
(	O	PUNCT	O
1,2-DMH	B-Chemical	NOUN	O
)(	O	NOUN	O
100	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
).	O	PUNCT	O
The	O	DET	O
initiated	O	VERB	O
hepatocytes	O	NOUN	B
in	O	ADP	O
the	O	DET	O
liver	O	NOUN	B
were	O	AUX	O
assayed	O	VERB	B
as	O	ADP	O
the	O	DET	O
gamma	O	NOUN	B
-	O	PUNCT	O
glutamyltransferase	O	NOUN	B
(	O	PUNCT	O
gamma	O	NOUN	B
-	O	PUNCT	O
GT	O	NOUN	B
)	O	PUNCT	O
positive	O	ADJ	B
foci	O	NOUN	B
formed	O	VERB	O
following	O	VERB	O
a	O	DET	O
2	O	NUM	B
-	O	PUNCT	O
week	O	NOUN	B
selection	O	NOUN	B
regimen	O	NOUN	I
consisting	O	VERB	O
of	O	ADP	O
dietary	O	ADJ	B
0	O	NUM	O
.	O	PUNCT	O


02	O	NUM	O
%	O	NOUN	O
2-acetylaminofluorene	B-Chemical	NOUN	B
coupled	O	VERB	B
with	O	ADP	O
a	O	DET	O
necrogenic	O	ADJ	B
dose	O	NOUN	B
of	O	ADP	O
CCl4	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
obtained	O	VERB	O
indicate	O	VERB	O
that	O	SCONJ	O
with	O	ADP	O
all	O	DET	O
three	O	NUM	O
carcinogens	O	NOUN	B
,	O	PUNCT	O
administration	O	NOUN	B
of	O	ADP	O
5-AzC	B-Chemical	NOUN	B
during	O	ADP	O
repair	O	NOUN	B
synthesis	O	NOUN	I
increased	O	VERB	B
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
initiated	O	VERB	O
hepatocytes	O	NOUN	B
,	O	PUNCT	O
for	O	ADP	O
example	O	NOUN	O
10	O	NUM	O
-	O	SYM	O
20	O	NUM	O
foci	O	NOUN	B
/	O	SYM	O
cm2	O	NUM	B
in	O	ADP	O
5-AzC	B-Chemical	ADJ	B
and	O	CCONJ	O
carcinogen	O	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
rats	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
3	O	NUM	O
-	O	PUNCT	O
5	O	NUM	O
foci	O	NOUN	B
/	O	SYM	O
cm2	O	NUM	B
in	O	ADP	O
rats	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
carcinogen	O	NOUN	B
only	O	ADV	O
.	O	PUNCT	O


Administration	O	NOUN	B
of	O	ADP	O
[3H]-5-azadeoxycytidine	B-Chemical	X	B
during	O	ADP	O
the	O	DET	O
repair	O	NOUN	B
synthesis	O	NOUN	I
induced	O	VERB	B
by	O	ADP	O
1,2-DMH	B-Chemical	NUM	O
further	O	ADV	O
showed	O	VERB	O
that	O	SCONJ	O
0	O	NUM	O
.	O	PUNCT	O


019	O	NUM	O
mol	O	NOUN	O
%	O	NOUN	O
of	O	ADP	O
cytosine	B-Chemical	NOUN	B
residues	O	NOUN	I
in	O	ADP	O
DNA	O	NOUN	B
were	O	AUX	O
substituted	O	VERB	B
by	O	ADP	O
the	O	DET	O
analogue	O	NOUN	B
,	O	PUNCT	O
indicating	O	VERB	O
that	O	SCONJ	O
incorporation	O	NOUN	B
of	O	ADP	O
5-AzC	B-Chemical	NOUN	B
occurs	O	NOUN	O
during	O	ADP	O
repair	O	NOUN	B
synthesis	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
absence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
carcinogen	O	NOUN	B
,	O	PUNCT	O
5-AzC	B-Chemical	NOUN	O


Withdrawal-emergent	B-Disease	ADJ	B
rabbit	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
during	O	ADP	O
dose	O	NOUN	B
reduction	O	NOUN	B
of	O	ADP	O
risperidone	B-Chemical	NOUN	B
.	O	PUNCT	O


Rabbit	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
RS	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
rare	O	ADJ	O
extrapyramidal	O	ADJ	B
side	O	NOUN	I
effect	O	NOUN	I
caused	O	VERB	O
by	O	ADP	O
prolonged	O	ADJ	B
neuroleptic	O	ADJ	B
medication	O	NOUN	I
.	O	PUNCT	O


Here	O	ADV	O
we	O	PRON	O
present	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
withdrawal-emergent	B-Disease	ADJ	B
RS	I-Disease	NOUN	I
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
of	O	ADP	O
its	O	PRON	O
kind	O	NOUN	O
to	O	PART	O
be	O	AUX	O
reported	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
developed	O	VERB	O
RS	B-Disease	NOUN	B
during	O	ADP	O
dose	O	NOUN	B
reduction	O	NOUN	B
of	O	ADP	O
risperidone	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
symptom	O	NOUN	B
was	O	AUX	O
treated	O	VERB	B
successfully	O	ADV	O
with	O	ADP	O
trihexyphenidyl	B-Chemical	NOUN	B
anticholinergic	O	ADJ	I
therapy	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
underlying	O	ADJ	O
mechanism	O	NOUN	B
of	O	ADP	O
withdrawal-emergent	B-Disease	ADJ	B
RS	I-Disease	NOUN	I
in	O	ADP	O
the	O	DET	O
present	O	ADJ	O
case	O	NOUN	B
may	O	AUX	O
have	O	AUX	O
been	O	AUX	O
related	O	ADJ	O
to	O	PART	O
the	O	DET	O
pharmacological	O	ADJ	B
profile	O	NOUN	I
of	O	ADP	O
risperidone	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
serotonin	B-Chemical	NOUN	B
-	O	PUNCT	O
dopamine	B-Chemical	NOUN	B
antagonist	O	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
the	O	DET	O
pathophysiologic	O	ADJ	B
influence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
serotonin	B-Chemical	NOUN	B
system	O	NOUN	I
in	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
RS	B-Disease	NOUN	B


Verapamil	B-Chemical	NOUN	B
withdrawal	O	NOUN	B
as	O	ADP	O
a	O	DET	O
possible	O	ADJ	O
cause	O	NOUN	O
of	O	ADP	O
myocardial	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
hypertensive	B-Disease	ADJ	B
woman	O	NOUN	B
with	O	ADP	O
a	O	DET	O
normal	O	ADJ	O
coronary	O	ADJ	O
angiogram	O	NOUN	O
.	O	PUNCT	O


Verapamil	B-Chemical	NOUN	B
is	O	AUX	O
an	O	DET	O
effective	O	ADJ	B
and	O	CCONJ	O
relatively	O	ADV	B
-	O	PUNCT	O
safe	O	ADJ	B
antihypertensive	O	ADJ	B
drug	O	NOUN	I
.	O	PUNCT	O


Serious	O	ADJ	B
adverse	O	ADJ	O
effects	O	NOUN	O
are	O	AUX	O
uncommon	O	ADJ	B
and	O	CCONJ	O
mainly	O	ADV	O
have	O	AUX	O
been	O	AUX	O
related	O	ADJ	O
to	O	ADP	O
the	O	DET	O
depression	B-Disease	NOUN	B
of	O	ADP	O
cardiac	O	ADJ	B
contractility	O	NOUN	I
and	O	CCONJ	O
conduction	O	NOUN	B
,	O	PUNCT	O
especially	O	ADV	O
when	O	SCONJ	O
the	O	DET	O
drug	O	NOUN	B
is	O	AUX	O
combined	O	VERB	O
with	O	ADP	O
beta	O	NOUN	B
-	O	PUNCT	O
blocking	O	VERB	B
agents	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
a	O	DET	O
case	O	NOUN	B
in	O	ADP	O
which	O	DET	O
myocardial	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
coincided	O	VERB	O
with	O	ADP	O
the	O	DET	O
introduction	O	NOUN	B
of	O	ADP	O
captopril	B-Chemical	NOUN	B
and	O	CCONJ	O
the	O	DET	O
withdrawal	O	NOUN	B
of	O	ADP	O
verapamil	B-Chemical	NOUN	B
in	O	ADP	O
a	O	DET	O
previously	O	ADV	O
asymptomatic	O	ADJ	B
woman	O	NOUN	B
with	O	ADP	O
severe	O	ADJ	B
hypertension	B-Disease	NOUN	B
.	O	PUNCT	O


Possible	O	ADJ	O
mechanisms	O	NOUN	B
that	O	PRON	O
involve	O	VERB	O
a	O	DET	O
verapamil	B-Chemical	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
increase	O	NOUN	B
in	O	ADP	O
platelet	O	NOUN	B
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
vascular	O	ADJ	B
alpha	O	NOUN	I
2	O	NUM	I
-	O	PUNCT	O
adrenoreceptor	O	NOUN	B
affinity	O	NOUN	B
for	O	ADP	O
catecholamines	B-Chemical	NOUN	B


Remission	O	NOUN	B
induction	O	NOUN	B
of	O	ADP	O
meningeal	B-Disease	ADJ	B
leukemia	I-Disease	NOUN	I
with	O	ADP	O
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
intravenous	O	ADJ	B
methotrexate	B-Chemical	NOUN	B
.	O	PUNCT	O


Twenty	O	NUM	O
children	O	NOUN	B
with	O	ADP	O
acute	B-Disease	ADJ	B
lymphoblastic	I-Disease	ADJ	I
leukemia	I-Disease	NOUN	I
who	O	PRON	O
developed	O	VERB	O
meningeal	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
a	O	DET	O
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
intravenous	O	ADJ	B
methotrexate	B-Chemical	NOUN	B
regimen	O	NOUN	I
that	O	PRON	O
was	O	AUX	O
designed	O	VERB	O
to	O	PART	O
achieve	O	VERB	O
and	O	CCONJ	O
maintain	O	VERB	O
CSF	O	NOUN	B
methotrexate	B-Chemical	NOUN	B
concentrations	O	NOUN	B
of	O	ADP	O
10	O	NUM	O
(-	O	PUNCT	O
5	O	NUM	O
)	O	PUNCT	O
mol	O	NOUN	B
/	O	SYM	O
L	O	NOUN	B
without	O	ADP	O
the	O	DET	O
need	O	NOUN	O
for	O	ADP	O
concomitant	O	ADJ	B
intrathecal	O	ADJ	B
dosing	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
methotrexate	B-Chemical	NOUN	B
was	O	AUX	O
administered	O	VERB	B
as	O	ADP	O
a	O	DET	O
loading	O	NOUN	B
dose	O	NOUN	I
of	O	ADP	O
6	O	NUM	O
,	O	PUNCT	O
000	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
for	O	ADP	O
a	O	DET	O
period	O	NOUN	B
of	O	ADP	O
one	O	NUM	O
hour	O	NOUN	B
followed	O	VERB	O
by	O	ADP	O
an	O	DET	O
infusion	O	NOUN	B
of	O	ADP	O
1	O	NUM	O
,	O	PUNCT	O
200	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
/	O	SYM	O
h	O	NOUN	O
for	O	ADP	O
23	O	NUM	O
hours	O	NOUN	B
.	O	PUNCT	O


Leucovorin	B-Chemical	NOUN	B
rescue	O	NOUN	B
was	O	AUX	O
initiated	O	VERB	O
12	O	NUM	O
hours	O	NOUN	B
after	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
infusion	O	NOUN	B
with	O	ADP	O
a	O	DET	O
loading	O	NOUN	B
dose	O	NOUN	I
of	O	ADP	O
200	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
followed	O	VERB	O
by	O	ADP	O
12	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
every	O	DET	O
three	O	NUM	O
hours	O	NOUN	B
for	O	ADP	O
six	O	NUM	O
doses	O	NOUN	B
and	O	CCONJ	O
then	O	ADV	O
every	O	DET	O
six	O	NUM	O
hours	O	NOUN	B
until	O	ADP	O
the	O	DET	O
plasma	O	NOUN	B
methotrexate	B-Chemical	NOUN	B
level	O	NOUN	B
decreased	O	VERB	B
to	O	PART	O
less	O	ADJ	O
than	O	ADP	O
1	O	NUM	O
X	O	NOUN	O
10	O	NUM	O
(-	O	PUNCT	O
7	O	NUM	O
)	O	PUNCT	O
mol	O	NOUN	B
/	O	SYM	O
L	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
mean	O	ADJ	B
steady	O	ADJ	B
-	O	PUNCT	O
state	O	NOUN	B
plasma	O	NOUN	B
and	O	CCONJ	O
CSF	O	NOUN	B
methotrexate	B-Chemical	NOUN	B
concentrations	O	NOUN	B
achieved	O	VERB	O
were	O	AUX	O
1	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
X	O	NOUN	O
10	O	NUM	O
(-	O	PUNCT	O
3	O	NUM	O
)	O	PUNCT	O
mol	O	NOUN	B
/	O	SYM	O
L	O	NOUN	B
and	O	CCONJ	O
3	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
X	O	NOUN	O
10	O	NUM	O
(-	O	PUNCT	O
5	O	NUM	O
)	O	PUNCT	O
mol	O	NOUN	B
/	O	SYM	O
L	O	PROPN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


All	O	DET	O
20	O	NUM	O
patients	O	NOUN	B
responded	O	VERB	O
to	O	ADP	O
this	O	DET	O
regimen	O	NOUN	B
,	O	PUNCT	O
16	O	NUM	O
/	O	SYM	O
20	O	NUM	O
(	O	PUNCT	O
80	O	NUM	O
%)	O	NOUN	O
achieved	O	VERB	O
a	O	DET	O
complete	O	ADJ	O
remission	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
20	O	NUM	O
%	O	NOUN	O
obtained	O	VERB	O
a	O	DET	O
partial	O	ADJ	B
remission	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
most	O	ADV	O
common	O	ADJ	O
toxicities	B-Disease	NOUN	B
encountered	O	VERB	O
were	O	AUX	O
transient	O	ADJ	B
serum	O	NOUN	O
transaminase	O	NOUN	O
and	O	CCONJ	O
bilirubin	B-Chemical	NOUN	B
elevations	O	NOUN	B
,	O	PUNCT	O
neutropenia	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
mucositis	B-Disease	NOUN	B
.	O	PUNCT	O


One	O	NUM	O
patient	O	NOUN	B
had	O	AUX	O
focal	O	ADJ	B
seizures	B-Disease	NOUN	I
and	O	CCONJ	O
transient	B-Disease	ADJ	B
hemiparesis	I-Disease	NOUN	I
but	O	CCONJ	O
recovered	O	VERB	O
completely	O	ADV	B
.	O	PUNCT	O


High	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
intravenous	O	ADJ	B
methotrexate	B-Chemical	NOUN	B
is	O	AUX	O
an	O	DET	O
effective	O	ADJ	B
treatment	O	NOUN	B
for	O	ADP	O
the	O	DET	O
induction	O	NOUN	B
of	O	ADP	O
remission	O	NOUN	B
after	O	ADP	O
meningeal	O	ADJ	B
relapse	O	NOUN	I
in	O	ADP	O
acute	B-Disease	ADJ	B
lymphoblastic	I-Disease	ADJ	I
leukemia	I-Disease	NOUN	I


Hypersensitivity	B-Disease	NOUN	B
to	O	PART	O
carbamazepine	B-Chemical	NOUN	B
presenting	O	NOUN	O
with	O	ADP	O
a	O	DET	O
leukemoid	B-Disease	ADJ	B
reaction	I-Disease	NOUN	I
,	O	PUNCT	O
eosinophilia	B-Disease	NOUN	B
,	O	PUNCT	O
erythroderma	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
renal	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
a	O	DET	O
patient	O	NOUN	B
in	O	ADP	O
whom	O	PRON	O
hypersensitivity	B-Disease	NOUN	B
to	O	PART	O
carbamazepine	B-Chemical	NOUN	B
presented	O	VERB	O
with	O	ADP	O
generalized	O	VERB	B
erythroderma	B-Disease	NOUN	I
,	O	PUNCT	O
a	O	DET	O
severe	O	ADJ	O
leukemoid	B-Disease	ADJ	B
reaction	I-Disease	NOUN	I
,	O	PUNCT	O
eosinophilia	B-Disease	NOUN	B
,	O	PUNCT	O
hyponatremia	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
renal	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
.	O	PUNCT	O


This	O	DET	O
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
report	O	NOUN	O
of	O	ADP	O
such	O	DET	O
an	O	DET	O
unusual	O	ADJ	B
reaction	O	NOUN	B
to	O	PART	O
carbamazepine	B-Chemical	NOUN	B


The	O	DET	O
interpeduncular	O	ADJ	B
nucleus	O	NOUN	I
regulates	O	VERB	B
nicotine	B-Chemical	NOUN	B
'	O	PART	O
s	O	NOUN	O
effects	O	NOUN	B
on	O	ADP	O
free	O	ADJ	B
-	O	PUNCT	O
field	O	NOUN	B
activity	O	NOUN	I
.	O	PUNCT	O


Partial	O	ADJ	B
lesions	O	NOUN	B
were	O	AUX	O
made	O	VERB	O
with	O	ADP	O
kainic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
in	O	ADP	O
the	O	DET	O
interpeduncular	O	ADJ	B
nucleus	O	NOUN	I
of	O	ADP	I
the	O	DET	O
ventral	O	ADJ	B
midbrain	O	NOUN	I
of	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
.	O	PUNCT	O


Compared	O	VERB	B
with	O	ADP	O
sham	O	NOUN	B
-	O	PUNCT	O
operated	O	VERB	B
controls	O	NOUN	B
,	O	PUNCT	O
lesions	O	NOUN	B
significantly	O	ADV	O
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


25	O	X	O
)	O	PUNCT	O
blunted	O	VERB	B
the	O	DET	O
early	O	ADJ	B
(<	O	NOUN	O
60	O	NUM	O
min	O	NOUN	O
)	O	PUNCT	O
free	O	ADJ	B
-	O	PUNCT	O
field	O	NOUN	B
locomotor	B-Disease	NOUN	B
hypoactivity	I-Disease	NOUN	O
caused	O	VERB	O
by	O	ADP	O
nicotine	B-Chemical	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
kg	O	NOUN	O
(-	O	PUNCT	O
1	O	NUM	O
),	O	PUNCT	O
i	O	NUM	O
.	O	PUNCT	O


m	O	NOUN	O
.),	O	PUNCT	O
enhanced	O	VERB	B
the	O	DET	O
later	O	ADV	O
(	O	PUNCT	O
60	O	NUM	O
-	O	SYM	O
120	O	NUM	O
min	O	NOUN	O
)	O	PUNCT	O
nicotine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hyperactivity	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
raised	O	VERB	B
spontaneous	O	ADJ	B
nocturnal	O	ADJ	B
activity	O	NOUN	I
.	O	PUNCT	O


Lesions	O	NOUN	B
reduced	O	VERB	B
the	O	DET	O
extent	O	NOUN	O
of	O	ADP	O
immunohistological	O	ADJ	B
staining	O	NOUN	I
for	O	ADP	O
choline	B-Chemical	NOUN	B
acetyltransferase	O	NOUN	I
in	O	ADP	O
the	O	DET	O
interpeduncular	O	ADJ	B
nucleus	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


025	O	NUM	O
),	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
for	O	ADP	O
tyrosine	B-Chemical	NOUN	B
hydroxylase	O	NOUN	I
in	O	ADP	O
the	O	DET	O
surrounding	O	VERB	O
catecholaminergic	O	ADJ	B
A10	O	NOUN	I
region	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
interpeduncular	O	ADJ	B
nucleus	O	NOUN	I
mediates	O	VERB	O
nicotinic	O	ADJ	B
depression	B-Disease	NOUN	I


Assessment	O	NOUN	B
of	O	ADP	O
a	O	DET	O
new	O	ADJ	O
non	O	NOUN	B
-	O	PUNCT	O
invasive	O	ADJ	B
index	O	NOUN	B
of	O	ADP	O
cardiac	O	ADJ	B
performance	O	NOUN	I
for	O	ADP	O
detection	O	NOUN	B
of	O	ADP	O
dobutamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
myocardial	B-Disease	ADJ	B
ischemia	I-Disease	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Electrocardiography	O	NOUN	B
has	O	AUX	O
a	O	DET	O
very	O	ADV	O
low	O	ADJ	O
sensitivity	O	NOUN	B
in	O	ADP	O
detecting	O	VERB	O
dobutamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
myocardial	B-Disease	ADJ	B
ischemia	I-Disease	NOUN	I
.	O	PUNCT	O


OBJECTIVES	O	NOUN	O
:	O	PUNCT	O
To	O	PART	O
assess	O	VERB	O
the	O	DET	O
added	O	VERB	O
diagnostic	O	ADJ	B
value	O	NOUN	I
of	O	ADP	O
a	O	DET	O
new	O	ADJ	O
cardiac	O	ADJ	B
performance	O	NOUN	I
index	O	NOUN	I
(	O	PUNCT	O
dP	O	NOUN	B
/	O	SYM	O
dtejc	O	NOUN	B
)	O	PUNCT	O
measurement	O	NOUN	B
,	O	PUNCT	O
based	O	VERB	O
on	O	ADP	O
brachial	O	ADJ	B
artery	O	NOUN	I
flow	O	NOUN	I
changes	O	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
compared	O	VERB	O
to	O	PART	O
standard	O	ADJ	B
12	O	NUM	O
-	O	PUNCT	O
lead	O	VERB	B
ECG	O	PROPN	B
,	O	PUNCT	O
for	O	ADP	O
detecting	O	VERB	B
dobutamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
myocardial	B-Disease	ADJ	B
ischemia	I-Disease	NOUN	I
,	O	PUNCT	O
using	O	VERB	O
Tc99m-Sestamibi	B-Chemical	NOUN	B
single	O	ADJ	B
-	O	PUNCT	O
photon	O	NOUN	B
emission	O	NOUN	O
computed	O	VERB	O
tomography	O	NOUN	O
as	O	ADP	O
the	O	DET	O
gold	O	NOUN	B
standard	O	NOUN	O
of	O	ADP	O
comparison	O	NOUN	B
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
presence	O	NOUN	B
or	O	CCONJ	O
absence	O	NOUN	B
of	O	ADP	O
ischemia	B-Disease	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
study	O	NOUN	B
group	O	NOUN	I
comprised	O	VERB	O
40	O	NUM	O
patients	O	NOUN	B
undergoing	O	VERB	O
Sestamibi	B-Chemical	PROPN	B
-	O	PUNCT	O
SPECT	O	PROPN	B
/	O	SYM	O
dobutamine	B-Chemical	NOUN	B
stress	O	NOUN	B
test	O	NOUN	I
.	O	PUNCT	O


Simultaneous	O	ADJ	B
measurements	O	NOUN	B
of	O	ADP	O
ECG	O	PROPN	B
and	O	CCONJ	O
brachial	O	ADJ	B
artery	O	NOUN	I
dP	O	NOUN	O
/	O	PUNCT	O
dtejc	O	NOUN	B
were	O	AUX	O
performed	O	VERB	O
at	O	ADP	O
each	O	DET	O
dobutamine	B-Chemical	NOUN	B
level	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
19	O	NUM	O
of	O	ADP	O
the	O	DET	O
40	O	NUM	O
patients	O	NOUN	B
perfusion	O	NOUN	B
defects	O	NOUN	B
compatible	O	ADJ	O
with	O	ADP	O
ischemia	B-Disease	NOUN	B
were	O	AUX	O
detected	O	VERB	B
on	O	ADP	O
SPECT	O	PROPN	B
.	O	PUNCT	O


The	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
dP	O	NOUN	B
/	O	SYM	O
dtejc	O	NOUN	B
during	O	ADP	O
infusion	O	NOUN	B
of	O	ADP	O
dobutamine	B-Chemical	NOUN	B
in	O	ADP	O
this	O	DET	O
group	O	NOUN	B
was	O	AUX	O
severely	O	ADV	O
impaired	O	ADJ	B
as	O	ADP	O
compared	O	VERB	O
to	O	PART	O
the	O	DET	O
non	O	ADJ	B
-	O	PUNCT	O
ischemic	O	ADJ	B
group	O	NOUN	B
.	O	PUNCT	O


dP	O	NOUN	B
/	O	SYM	O
dtejc	O	NOUN	B
outcome	O	NOUN	B
was	O	AUX	O
combined	O	VERB	O
with	O	ADP	O
the	O	DET	O
ECG	O	PROPN	B
results	O	NOUN	B
,	O	PUNCT	O
giving	O	VERB	O
an	O	DET	O
ECG	O	PROPN	B
-	O	PUNCT	O
enhanced	O	VERB	B
value	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
compared	O	VERB	B
to	O	ADP	O
ECG	O	PROPN	B
alone	O	ADV	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
sensitivity	O	NOUN	B
improved	O	VERB	B
dramatically	O	ADV	O
from	O	ADP	O
16	O	NUM	O
%	O	NOUN	O
to	O	PART	O
79	O	NUM	O
%,	O	NOUN	O
positive	O	ADJ	B
predictive	O	ADJ	B
value	O	NOUN	I
increased	O	VERB	B
from	O	ADP	O
60	O	NUM	O
%	O	NOUN	O
to	O	PART	O
68	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
negative	O	ADJ	B
predictive	O	ADJ	O
value	O	NOUN	O
from	O	ADP	O
54	O	NUM	O
%	O	NOUN	O
to	O	PART	O
78	O	NUM	O
%,	O	NOUN	B
and	O	CCONJ	O
specificity	O	NOUN	B
decreased	O	VERB	B
from	O	ADP	O
90	O	NUM	O
%	O	NOUN	O
to	O	PART	O
67	O	NUM	O
%.	O	NOUN	B
CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
If	O	SCONJ	O
ECG	O	PROPN	B
alone	O	ADV	O
is	O	AUX	O
used	O	VERB	O
for	O	ADP	O
specificity	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
combination	O	NOUN	B
with	O	ADP	O
dP	O	NOUN	B
/	O	PUNCT	O
dtejc	O	NOUN	B
improved	O	VERB	B
the	O	DET	O
sensitivity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
test	O	NOUN	B
and	O	CCONJ	O
could	O	AUX	O
be	O	AUX	O
a	O	DET	O
cost	O	NOUN	B
-	O	PUNCT	O
savings	O	NOUN	B
alternative	O	NOUN	B
to	O	ADP	O
cardiac	O	ADJ	B
imaging	O	NOUN	I
or	O	CCONJ	O
perfusion	O	NOUN	B
studies	O	NOUN	B
to	O	PART	O
detect	O	VERB	B
myocardial	B-Disease	ADJ	B
ischemia	I-Disease	NOUN	I


Acute	B-Disease	ADJ	B
liver	I-Disease	NOUN	I
failure	I-Disease	NOUN	I
in	O	ADP	O
two	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
regular	O	ADJ	O
alcohol	B-Chemical	NOUN	B
consumption	O	NOUN	I
ingesting	O	VERB	O
paracetamol	B-Chemical	NOUN	B
at	O	ADP	O
therapeutic	O	ADJ	B
dosage	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
possible	O	ADJ	O
role	O	NOUN	O
of	O	ADP	O
alcohol	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
hepatotoxicity	B-Disease	NOUN	B
associated	O	VERB	B
with	O	ADP	I
therapeutic	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
paracetamol	B-Chemical	NOUN	B
(	O	PUNCT	O
acetaminophen	B-Chemical	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
currently	O	ADV	O
debated	O	VERB	O
.	O	PUNCT	O


CASE	O	ADJ	B
REPORT	O	PROPN	I
:	O	PUNCT	O
We	O	PRON	O
describe	O	VERB	O
2	O	NUM	O
patients	O	NOUN	B
who	O	PRON	O
were	O	AUX	O
regular	O	ADJ	O
consumers	O	NOUN	B
of	O	ADP	O
alcohol	B-Chemical	NOUN	B
and	O	CCONJ	O
who	O	PRON	O
developed	O	VERB	O
liver	B-Disease	NOUN	B
failure	I-Disease	NOUN	I
within	O	ADP	O
3	O	NUM	O
-	O	SYM	O
5	O	NUM	O
days	O	NOUN	B
after	O	ADP	O
hospitalization	O	NOUN	B
and	O	CCONJ	O
stopping	O	VERB	B
alcohol	B-Chemical	NOUN	B
consumption	O	NOUN	I
while	O	SCONJ	O
being	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
4	O	NUM	O
g	O	NOUN	O
paracetamol	B-Chemical	NOUN	B
/	O	SYM	O
day	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
paracetamol	B-Chemical	NOUN	B
serum	O	NOUN	O
level	O	NOUN	O
obtained	O	VERB	O
in	O	ADP	O
one	O	NUM	O
of	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
was	O	AUX	O
not	O	PART	O
in	O	ADP	O
the	O	DET	O
toxic	O	ADJ	B
range	O	NOUN	O
.	O	PUNCT	O


Possible	O	ADJ	O
risk	O	NOUN	B
factors	O	NOUN	I
for	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
hepatotoxicity	B-Disease	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
therapeutic	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
paracetamol	B-Chemical	NOUN	B
are	O	AUX	O
discussed	O	VERB	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
In	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
risk	O	NOUN	B
factors	O	NOUN	I
,	O	PUNCT	O
e	O	X	O
.	O	PUNCT	O


g	O	NOUN	O
.	O	PUNCT	O


regular	O	ADJ	B
consumption	O	NOUN	B
of	O	ADP	O
alcohol	B-Chemical	NOUN	B
,	O	PUNCT	O
liver	B-Disease	NOUN	B
failure	I-Disease	NOUN	I
is	O	AUX	O
possible	O	ADJ	O
when	O	SCONJ	O
therapeutic	O	ADJ	B
doses	O	NOUN	I
are	O	AUX	O
ingested	O	VERB	B
.	O	PUNCT	O


We	O	PRON	O
propose	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
paracetamol	B-Chemical	NOUN	B
dose	O	NOUN	I
should	O	AUX	O
not	O	PART	O
exceed	O	VERB	O
2	O	NUM	O
g	O	NOUN	B
/	O	PUNCT	O
day	O	NOUN	B
in	O	ADP	O
such	O	ADJ	O
patients	O	NOUN	B
and	O	CCONJ	O
that	O	SCONJ	O
their	O	PRON	O
liver	O	NOUN	B
function	O	NOUN	I
should	O	AUX	O
be	O	AUX	O
monitored	O	VERB	B
closely	O	ADV	O
while	O	SCONJ	O
being	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
paracetamol	B-Chemical	NOUN	B


Cocaine	B-Chemical	NOUN	B
related	O	VERB	O
chest	B-Disease	ADJ	B
pain	I-Disease	NOUN	I
:	O	PUNCT	O
are	O	AUX	O
we	O	PRON	O
seeing	O	VERB	O
the	O	DET	O
tip	O	NOUN	B
of	O	ADP	O
an	O	DET	O
iceberg	O	NOUN	O
?	O	PUNCT	O
The	O	DET	O
recreational	O	ADJ	B
use	O	NOUN	O
of	O	ADP	O
cocaine	B-Chemical	NOUN	B
is	O	AUX	O
on	O	ADP	O
the	O	DET	O
increase	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
emergency	O	NOUN	B
nurse	O	NOUN	B
ought	O	AUX	O
to	O	PART	O
be	O	AUX	O
familiar	O	ADJ	O
with	O	ADP	O
some	O	DET	O
of	O	ADP	O
the	O	DET	O
cardiovascular	O	ADJ	B
consequences	O	NOUN	B
of	O	ADP	O
cocaine	B-Chemical	NOUN	B
use	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
particular	O	ADJ	O
,	O	PUNCT	O
the	O	DET	O
tendency	O	NOUN	O
of	O	ADP	O
cocaine	B-Chemical	NOUN	B
to	O	PART	O
produce	O	VERB	O
chest	B-Disease	ADJ	B
pain	I-Disease	NOUN	I
ought	O	AUX	O
to	O	PART	O
be	O	AUX	O
in	O	ADP	O
the	O	DET	O
mind	O	NOUN	O
of	O	ADP	O
the	O	DET	O
emergency	O	NOUN	B
nurse	O	NOUN	B
when	O	SCONJ	O
faced	O	VERB	B
with	O	ADP	I
a	O	DET	O
young	O	ADJ	B
victim	O	NOUN	B
of	O	ADP	O
chest	B-Disease	ADJ	B
pain	I-Disease	NOUN	I
who	O	PRON	O
is	O	AUX	O
otherwise	O	ADV	O
at	O	ADP	O
low	O	ADJ	B
risk	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
mechanism	O	NOUN	B
of	O	ADP	O
chest	B-Disease	ADJ	B
pain	I-Disease	NOUN	I
related	O	ADJ	O
to	O	PART	O
cocaine	B-Chemical	NOUN	B
use	O	NOUN	I
is	O	AUX	O
discussed	O	VERB	O
and	O	CCONJ	O
treatment	O	NOUN	B
dilemmas	O	NOUN	O
are	O	AUX	O
discussed	O	VERB	O
.	O	PUNCT	O


Finally	O	ADV	O
,	O	PUNCT	O
moral	O	ADJ	B
issues	O	NOUN	I
relating	O	VERB	O
to	O	ADP	O
the	O	DET	O
testing	O	NOUN	B
of	O	ADP	O
potential	O	ADJ	B
cocaine	B-Chemical	NOUN	B


Severe	O	ADJ	B
rhabdomyolysis	B-Disease	NOUN	B
and	O	CCONJ	O
acute	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
failure	I-Disease	NOUN	I
secondary	O	ADJ	B
to	O	PART	I
concomitant	O	ADJ	B
use	O	NOUN	O
of	O	ADP	O
simvastatin	B-Chemical	NOUN	B
,	O	PUNCT	O
amiodarone	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
atazanavir	B-Chemical	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
:	O	PUNCT	O
To	O	PART	O
report	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
a	O	DET	O
severe	O	ADJ	B
interaction	O	NOUN	B
between	O	ADP	O
simvastatin	B-Chemical	NOUN	B
,	O	PUNCT	O
amiodarone	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
atazanavir	B-Chemical	NOUN	B
resulting	O	VERB	O
in	O	ADP	O
rhabdomyolysis	B-Disease	NOUN	B
and	O	CCONJ	O
acute	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
failure	I-Disease	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
A	O	DET	O
72	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
white	O	ADJ	O
man	O	NOUN	B
with	O	ADP	O
underlying	O	VERB	O
human	B-Disease	ADJ	B
immunodeficiency	I-Disease	NOUN	I
virus	I-Disease	NOUN	I
,	O	PUNCT	O
atrial	B-Disease	ADJ	B
fibrillation	I-Disease	NOUN	I
,	O	PUNCT	O
coronary	B-Disease	ADJ	B
artery	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
hyperlipidemia	B-Disease	NOUN	B
presented	O	VERB	O
with	O	ADP	O
generalized	O	VERB	B
pain	B-Disease	NOUN	I
,	O	PUNCT	O
fatigue	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
dark	O	ADJ	B
orange	O	ADJ	I
urine	O	NOUN	B
for	O	ADP	O
3	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
was	O	AUX	O
taking	O	VERB	O
80	O	NUM	O
mg	O	NOUN	O
simvastatin	B-Chemical	NOUN	B
at	O	ADP	O
bedtime	O	NOUN	B
(	O	PUNCT	O
initiated	O	VERB	O
27	O	NUM	O
days	O	NOUN	B
earlier	O	ADV	O
);	O	ADJ	B
amiodarone	B-Chemical	NOUN	I
at	O	ADP	O
a	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
400	O	NUM	O
mg	O	NOUN	O
daily	O	ADV	B
for	O	ADP	O
7	O	NUM	O
days	O	NOUN	B
,	O	PUNCT	O
then	O	ADV	O
200	O	NUM	O
mg	O	NOUN	O
daily	O	ADV	B
(	O	PUNCT	O
initiated	O	VERB	O
19	O	NUM	O
days	O	NOUN	B
earlier	O	ADV	O
);	O	ADJ	B
and	O	CCONJ	O
400	O	NUM	O
mg	O	NOUN	O
atazanavir	B-Chemical	NOUN	B
daily	O	ADV	B
(	O	PUNCT	O
initiated	O	VERB	B
at	O	ADP	O
least	O	ADV	O
2	O	NUM	O
years	O	NOUN	B
previously	O	ADV	O
).	O	PUNCT	O
Laboratory	O	NOUN	B
evaluation	O	NOUN	I
revealed	O	VERB	O
66	O	NUM	O
,	O	PUNCT	O
680	O	NUM	O
U	O	PROPN	B
/	O	SYM	O
L	O	NOUN	B
creatine	B-Chemical	NOUN	I
kinase	O	NOUN	I
,	O	PUNCT	O
93	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
dL	O	NOUN	B
blood	B-Chemical	NOUN	O
urea	I-Chemical	NOUN	O
nitrogen	I-Chemical	NOUN	B
,	O	PUNCT	O
4	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
dL	O	NOUN	B
creatinine	B-Chemical	NOUN	B
,	O	PUNCT	O
1579	O	NUM	O
U	O	PROPN	B
/	O	SYM	O
L	O	NOUN	B
aspartate	B-Chemical	NOUN	I
aminotransferase	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
738	O	NUM	O
U	O	PROPN	B
/	O	PUNCT	O
L	O	NOUN	B
alanine	B-Chemical	NOUN	I
aminotransferase	O	NOUN	I
.	O	PUNCT	O


Simvastatin	B-Chemical	NOUN	B
,	O	PUNCT	O
amiodarone	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
patient	O	NOUN	B
'	O	PART	O
s	O	NOUN	O
human	B-Disease	ADJ	B
immunodeficiency	I-Disease	NOUN	I
virus	I-Disease	NOUN	I
medications	O	NOUN	B
were	O	AUX	O
all	O	DET	O
temporarily	O	ADV	O
discontinued	O	VERB	B
and	O	CCONJ	O
the	O	DET	O
patient	O	NOUN	B
was	O	AUX	O
given	O	VERB	O
forced	O	ADJ	O
alkaline	O	NOUN	B
diuresis	O	NOUN	B
and	O	CCONJ	O
started	O	VERB	B
on	O	ADP	O
dialysis	O	NOUN	B
.	O	PUNCT	O


Nine	O	NUM	O
days	O	NOUN	B
later	O	ADV	O
the	O	DET	O
patient	O	NOUN	B
'	O	PART	O
s	O	NOUN	O
creatine	B-Chemical	NOUN	B
kinase	O	NOUN	I
had	O	AUX	O
dropped	O	VERB	O
to	O	ADP	O
1695	O	NUM	O
U	O	NOUN	B
/	O	SYM	O
L	O	NOUN	B
and	O	CCONJ	O
creatinine	B-Chemical	NOUN	B
was	O	AUX	O
3	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
dL	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
was	O	AUX	O
discharged	O	VERB	B
and	O	CCONJ	O
continued	O	VERB	O
outpatient	O	ADJ	B
dialysis	O	NOUN	O
for	O	ADP	O
1	O	NUM	O
month	O	NOUN	B
until	O	ADP	O
his	O	PRON	O
renal	O	ADJ	B
function	O	NOUN	I
recovered	O	VERB	O
.	O	PUNCT	O


DISCUSSION	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
rhabdomyolysis	B-Disease	NOUN	B
is	O	AUX	O
increased	O	VERB	B
in	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
concomitant	O	ADJ	B
drugs	O	NOUN	B
that	O	PRON	O
inhibit	O	VERB	B
simvastatin	B-Chemical	NOUN	B
metabolism	O	NOUN	B
.	O	PUNCT	O


Simvastatin	B-Chemical	NOUN	B
is	O	AUX	O
metabolized	O	VERB	B
by	O	ADP	O
CYP3A4	O	NOUN	B
.	O	PUNCT	O


Amiodarone	B-Chemical	NOUN	B
and	O	CCONJ	O
atazanavir	B-Chemical	NOUN	B
are	O	AUX	O
recognized	O	VERB	O
CYP3A4	O	NOUN	B
inhibitors	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
Pharmacokinetic	O	ADJ	B
differences	O	NOUN	O
in	O	ADP	O
statins	B-Chemical	NOUN	B
are	O	AUX	O
an	O	DET	O
important	O	ADJ	O
consideration	O	NOUN	O
for	O	ADP	O
assessing	O	VERB	B
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
potential	O	ADJ	B
drug	O	NOUN	B
interactions	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
patients	O	NOUN	B
requiring	O	VERB	O
the	O	DET	O
concurrent	O	ADJ	B
use	O	NOUN	O
of	O	ADP	O
statins	B-Chemical	NOUN	B
and	O	CCONJ	O
CYP3A4	O	NOUN	B
inhibitors	O	NOUN	I
,	O	PUNCT	O
pravastatin	B-Chemical	NOUN	B
,	O	PUNCT	O
fluvastatin	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
rosuvastatin	B-Chemical	NOUN	B
carry	O	VERB	O
the	O	DET	O
lowest	O	ADJ	B
risk	O	NOUN	B
of	O	ADP	O
drug	O	NOUN	B
interactions	O	NOUN	I
;	O	PUNCT	O
atorvastatin	B-Chemical	NOUN	B
carries	O	VERB	O
moderate	O	ADJ	B
risk	O	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
simvastatin	B-Chemical	NOUN	B
and	O	CCONJ	O
lovastatin	B-Chemical	NOUN	B


Phase	O	NOUN	B
II	O	NUM	I
trial	O	NOUN	I
of	O	ADP	O
vinorelbine	B-Chemical	NOUN	B
in	O	ADP	O
metastatic	O	ADJ	B
squamous	B-Disease	ADJ	I
cell	I-Disease	NOUN	I
esophageal	I-Disease	NOUN	I
carcinoma	I-Disease	NOUN	I
.	O	PUNCT	O


European	O	PROPN	B
Organization	O	PROPN	I
for	O	ADP	I
Research	O	PROPN	B
and	O	CCONJ	O
Treatment	O	NOUN	B
of	O	ADP	O
Cancer	B-Disease	PROPN	B
Gastrointestinal	O	PROPN	I
Treat	O	PROPN	I
Cancer	B-Disease	PROPN	I
Cooperative	O	PROPN	I
Group	O	PROPN	I
.	O	PUNCT	O


PURPOSE	O	NOUN	B
:	O	PUNCT	O
To	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
response	O	NOUN	B
rate	O	NOUN	I
and	O	CCONJ	O
toxic	O	ADJ	B
effects	O	NOUN	O
of	O	ADP	O
vinorelbine	B-Chemical	NOUN	B
(	O	PUNCT	O
VNB	B-Chemical	NOUN	B
)	O	PUNCT	O
administered	O	VERB	B
as	O	ADP	O
a	O	DET	O
single	O	ADJ	O
agent	O	NOUN	O
in	O	ADP	O
metastatic	O	ADJ	B
squamous	B-Disease	ADJ	I
cell	I-Disease	NOUN	I
esophageal	I-Disease	NOUN	I
carcinoma	I-Disease	NOUN	I
.	O	PUNCT	O


PATIENTS	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
:	O	PUNCT	O
Forty	O	NUM	B
-	O	PUNCT	O
six	O	NUM	O
eligible	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
measurable	O	ADJ	O
lesions	O	NOUN	B
were	O	AUX	O
included	O	VERB	O
and	O	CCONJ	O
were	O	AUX	O
stratified	O	VERB	B
according	O	VERB	O
to	O	PART	O
previous	O	ADJ	O
chemotherapy	O	NOUN	B
.	O	PUNCT	O


Thirty	O	NUM	O
patients	O	NOUN	B
without	O	ADP	O
prior	O	ADJ	B
chemotherapy	O	NOUN	B
and	O	CCONJ	O
16	O	NUM	O
pretreated	O	VERB	B
with	O	ADP	O
cisplatin	B-Chemical	NOUN	B
-	O	PUNCT	O
based	O	VERB	B
chemotherapy	O	NOUN	B
were	O	AUX	O
assessable	O	ADJ	O
for	O	ADP	O
toxicity	B-Disease	NOUN	B
and	O	CCONJ	O
response	O	NOUN	B
.	O	PUNCT	O


VNB	B-Chemical	NOUN	B
was	O	AUX	O
administered	O	VERB	B
weekly	O	ADJ	B
as	O	ADP	O
a	O	DET	O
25	O	NUM	O
-	O	PUNCT	O
mg	O	NOUN	B
/	O	SYM	O
m2	O	NOUN	B
short	O	ADJ	I
intravenous	O	ADJ	I
(	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


v	O	ADP	O
.)	O	NUM	O
infusion	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Six	O	NUM	O
of	O	ADP	O
30	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
20	O	NUM	O
%)	O	NOUN	O
without	O	ADP	O
prior	O	ADJ	O
chemotherapy	O	NOUN	B
achieved	O	VERB	O
a	O	DET	O
partial	O	ADJ	B
response	O	NOUN	I
(	O	PUNCT	O
PR	O	NOUN	B
)(	O	NOUN	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
[	O	PUNCT	O
CI	O	PROPN	B
],	O	PUNCT	O
8	O	NUM	O
%	O	NOUN	O
to	O	ADP	O
39	O	NUM	O
%).	O	NOUN	O
The	O	DET	O
median	O	ADJ	B
duration	O	NOUN	B
of	O	ADP	O
response	O	NOUN	B
was	O	AUX	O
21	O	NUM	O
weeks	O	NOUN	B
(	O	PUNCT	O
range	O	NOUN	B
,	O	PUNCT	O
17	O	NUM	O
to	O	PART	O
28	O	NUM	O
).	O	PUNCT	O
One	O	NUM	O
of	O	ADP	O
16	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
6	O	NUM	O
%)	O	NOUN	O
with	O	ADP	O
prior	O	ADJ	O
chemotherapy	O	NOUN	B
had	O	AUX	O
a	O	DET	O
complete	O	ADJ	B
response	O	NOUN	I
(	O	PUNCT	O
CR	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
31	O	NUM	O
weeks	O	NOUN	B
'	O	PART	O
duration	O	NOUN	B
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
0	O	NUM	O
%	O	NOUN	O
to	O	PART	O
30	O	NUM	O
%).	O	NOUN	O
The	O	DET	O
overall	O	ADJ	O
response	O	NOUN	B
rate	O	NOUN	I
(	O	PUNCT	O
World	O	PROPN	B
Health	O	PROPN	I
Organization	O	PROPN	I
[	O	PUNCT	O
WHO	O	PRON	B
]	O	PUNCT	O
criteria	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
15	O	NUM	O
%(	O	NOUN	O
CR	O	NOUN	B
,	O	PUNCT	O
2	O	NUM	O
%;	O	NOUN	O
PR	O	NOUN	B
13	O	NUM	O
%;	O	NOUN	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
6	O	NUM	O
%	O	NOUN	O
to	O	PART	O
29	O	NUM	O
%).	O	NOUN	O
The	O	DET	O
median	O	ADJ	B
dose	O	NOUN	B
-	O	PUNCT	O
intensity	O	NOUN	B
(	O	PUNCT	O
DI	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
20	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
/	O	SYM	O
wk	O	NOUN	B
.	O	PUNCT	O


VNB	B-Chemical	NOUN	B
was	O	AUX	O
well	O	ADV	O
tolerated	O	VERB	B
and	O	CCONJ	O
zero	O	NUM	O
instances	O	NOUN	O
of	O	ADP	O
WHO	O	PRON	B
grade	O	NOUN	O
4	O	NUM	O
nonhematologic	O	ADJ	B
toxicity	B-Disease	NOUN	B
occurred	O	VERB	O
.	O	PUNCT	O


At	O	ADP	O
least	O	ADV	O
one	O	NUM	O
episode	O	NOUN	B
of	O	ADP	O
grade	O	NOUN	B
3	O	NUM	I
or	O	CCONJ	O
4	O	NUM	O
granulocytopenia	B-Disease	NOUN	B
was	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
59	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
grade	O	NOUN	B
2	O	NUM	I
or	O	CCONJ	O
3	O	NUM	O
infection	B-Disease	NOUN	B
occurred	O	VERB	O
in	O	ADP	O
16	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
no	O	DET	O
toxic	O	ADJ	B
deaths	B-Disease	NOUN	I
occurred	O	VERB	O
.	O	PUNCT	O


Other	O	ADJ	O
side	O	NOUN	B
effects	O	NOUN	I
were	O	AUX	O
rare	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
peripheral	B-Disease	ADJ	B
neurotoxicity	I-Disease	NOUN	B
has	O	AUX	O
been	O	AUX	O
minor	O	ADJ	O
(	O	PUNCT	O
26	O	NUM	O
%	O	NOUN	O
grade	O	NOUN	O
1	O	NUM	O
).	O	PUNCT	O
CONCLUSION	O	NOUN	O
:	O	PUNCT	O
These	O	DET	O
data	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
VNB	B-Chemical	NOUN	B
is	O	AUX	O
an	O	DET	O
active	O	ADJ	B
agent	O	NOUN	I
in	O	ADP	O
metastatic	O	ADJ	B
esophageal	B-Disease	NOUN	I
squamous	I-Disease	ADJ	I
cell	I-Disease	NOUN	I
carcinoma	I-Disease	NOUN	I
.	O	PUNCT	O


Given	O	VERB	O
its	O	PRON	O
excellent	O	ADJ	B
tolerance	O	NOUN	B
profile	O	NOUN	I
and	O	CCONJ	O
low	O	ADJ	B
toxicity	B-Disease	NOUN	B
,	O	PUNCT	O
further	O	ADJ	O
evaluation	O	NOUN	B
of	O	ADP	O
VNB	B-Chemical	NOUN	B


Paclitaxel	B-Chemical	NOUN	B
,	O	PUNCT	O
cisplatin	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
gemcitabine	B-Chemical	NOUN	B
combination	O	NOUN	O
chemotherapy	O	NOUN	B
within	O	ADP	O
a	O	DET	O
multidisciplinary	O	ADJ	B
therapeutic	O	ADJ	B
approach	O	NOUN	I
in	O	ADP	O
metastatic	O	ADJ	B
nonsmall	B-Disease	NOUN	I
cell	I-Disease	NOUN	I
lung	I-Disease	NOUN	I
carcinoma	I-Disease	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Cisplatin	B-Chemical	PROPN	B
-	O	PUNCT	O
based	O	VERB	B
chemotherapy	O	NOUN	B
combinations	O	NOUN	B
improve	O	VERB	B
quality	O	NOUN	B
of	O	ADP	I
life	O	NOUN	I
and	O	CCONJ	O
survival	O	NOUN	B
in	O	ADP	O
advanced	O	ADJ	B
nonsmall	B-Disease	NOUN	I
cell	I-Disease	NOUN	I
lung	I-Disease	NOUN	I
carcinoma	I-Disease	NOUN	I
(	O	PUNCT	O
NSCLC	B-Disease	NOUN	B
).	O	PUNCT	O
The	O	DET	O
emergence	O	NOUN	B
of	O	ADP	O
new	O	ADJ	O
active	O	ADJ	B
drugs	O	NOUN	B
might	O	AUX	O
translate	O	VERB	O
into	O	ADP	O
more	O	ADV	O
effective	O	ADJ	B
regimens	O	NOUN	B
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
this	O	DET	O
disease	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
objective	O	NOUN	B
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
feasibility	O	NOUN	B
,	O	PUNCT	O
response	O	NOUN	B
rate	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
toxicity	B-Disease	NOUN	B
of	O	ADP	O
a	O	DET	O
paclitaxel	B-Chemical	NOUN	B
,	O	PUNCT	O
cisplatin	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
gemcitabine	B-Chemical	NOUN	B
combination	O	NOUN	B
to	O	PART	O
treat	O	VERB	B
metastatic	O	ADJ	B
NSCLC	B-Disease	NOUN	B
.	O	PUNCT	O


Thirty	O	NUM	B
-	O	PUNCT	O
five	O	NUM	O
consecutive	O	ADJ	B
chemotherapy	O	NOUN	B
-	O	PUNCT	O
naive	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
Stage	O	NOUN	B
IV	O	NUM	I
NSCLC	B-Disease	NOUN	I
and	O	CCONJ	O
an	O	DET	O
Eastern	O	PROPN	B
Cooperative	O	PROPN	I
Oncology	O	PROPN	I
Group	O	PROPN	I
performance	O	NOUN	O
status	O	NOUN	O
of	O	ADP	O
0	O	NUM	O
-	O	SYM	O
2	O	NUM	O
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
a	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
paclitaxel	B-Chemical	NOUN	B
(	O	PUNCT	O
135	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
given	O	VERB	O
intravenously	O	ADV	B
in	O	ADP	O
3	O	NUM	O
hours	O	NOUN	B
)	O	PUNCT	O
on	O	ADP	O
Day	O	PROPN	B
1	O	NUM	I
,	O	PUNCT	O
cisplatin	B-Chemical	NOUN	B
(	O	PUNCT	O
120	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
given	O	VERB	O
intravenously	O	ADV	B
in	O	ADP	O
6	O	NUM	O
hours	O	NOUN	B
)	O	PUNCT	O
on	O	ADP	O
Day	O	PROPN	B
1	O	NUM	I
,	O	PUNCT	O
and	O	CCONJ	O
gemcitabine	B-Chemical	NOUN	B
(	O	PUNCT	O
800	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
given	O	VERB	O
intravenously	O	ADV	B
in	O	ADP	O
30	O	NUM	O
minutes	O	NOUN	B
)	O	PUNCT	O
on	O	ADP	O
Days	O	NOUN	B
1	O	NUM	I
and	O	CCONJ	O
8	O	NUM	O
,	O	PUNCT	O
every	O	DET	O
4	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
responding	O	VERB	B
patients	O	NOUN	B
were	O	AUX	O
scheduled	O	VERB	O
to	O	PART	O
receive	O	VERB	O
consolidation	O	NOUN	B
radiotherapy	O	NOUN	I
and	O	CCONJ	O
24	O	NUM	O
patients	O	NOUN	B
received	O	VERB	O
preplanned	O	VERB	B
second	O	ADJ	B
-	O	PUNCT	O
line	O	NOUN	B
chemotherapy	O	NOUN	B
after	O	ADP	O
disease	O	NOUN	B
progression	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
response	O	NOUN	B
and	O	CCONJ	O
toxicity	B-Disease	NOUN	B
rates	O	NOUN	B
reported	O	VERB	O
refer	O	VERB	O
only	O	ADV	O
to	O	PART	O
the	O	DET	O
chemotherapy	O	NOUN	B
regimen	O	NOUN	B
given	O	VERB	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
All	O	DET	O
the	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
examined	O	VERB	O
for	O	ADP	O
toxicity	B-Disease	NOUN	B
;	O	PUNCT	O
34	O	NUM	O
were	O	AUX	O
examinable	O	ADJ	B
for	O	ADP	O
response	O	NOUN	B
.	O	PUNCT	O


An	O	DET	O
objective	O	ADJ	B
response	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
73	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
[	O	PUNCT	O
CI	O	PROPN	B
],	O	PUNCT	O
55	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
-	O	SYM	O
87	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
%),	O	NOUN	O
including	O	VERB	O
4	O	NUM	O
complete	O	ADJ	O
responses	O	NOUN	B
(	O	PUNCT	O
11	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
%).	O	NOUN	O
According	O	VERB	O
to	O	ADP	O
intention	O	NOUN	B
-	O	PUNCT	O
to	O	PART	O
-	O	PUNCT	O
treat	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
overall	O	ADJ	O
response	O	NOUN	B
rate	O	NOUN	I
was	O	AUX	O
71	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
%(	O	NOUN	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
53	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
-	O	SYM	O
85	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
%).	O	NOUN	O
After	O	ADP	O
154	O	NUM	O
courses	O	NOUN	B
of	O	ADP	O
therapy	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
median	O	ADJ	B
dose	O	NOUN	I
intensity	O	NOUN	B
was	O	AUX	O
131	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
for	O	ADP	O
paclitaxel	B-Chemical	NOUN	B
(	O	PUNCT	O
97	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
%),	O	ADJ	O
117	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
for	O	ADP	O
cisplatin	B-Chemical	NOUN	B
(	O	PUNCT	O
97	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
%),	O	NOUN	O
and	O	CCONJ	O
1378	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
for	O	ADP	O
gemcitabine	B-Chemical	NOUN	B
(	O	PUNCT	O
86	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
%).	O	ADJ	O
World	O	PROPN	B
Health	O	PROPN	I
Organization	O	PROPN	I
Grade	O	PROPN	I
3	O	NUM	I
-	O	SYM	O
4	O	NUM	O
neutropenia	B-Disease	NOUN	B
and	O	CCONJ	O
thrombocytopenia	B-Disease	NOUN	B
occurred	O	VERB	O
in	O	ADP	O
39	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
11	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
one	O	NUM	O
treatment	O	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
death	B-Disease	NOUN	B
.	O	PUNCT	O


Nonhematologic	O	ADJ	B
toxicities	B-Disease	NOUN	B
were	O	AUX	O
mild	O	ADJ	B
.	O	PUNCT	O


After	O	ADP	O
a	O	DET	O
median	O	ADJ	B
follow	O	NOUN	B
-	O	PUNCT	O
up	O	NOUN	O
of	O	ADP	O
22	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
median	O	ADJ	B
progression	O	NOUN	B
free	O	ADJ	O
survival	O	NOUN	O
rate	O	NOUN	O
was	O	AUX	O
7	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
median	O	ADJ	B
survival	O	NOUN	I
time	O	NOUN	I
was	O	AUX	O
16	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
paclitaxel	B-Chemical	NOUN	B
,	O	PUNCT	O
cisplatin	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
gemcitabine	B-Chemical	NOUN	B
is	O	AUX	O
well	O	ADV	O
tolerated	O	VERB	B
and	O	CCONJ	O
shows	O	VERB	O
high	O	ADJ	O
activity	O	NOUN	B
in	O	ADP	O
metastatic	O	ADJ	B
NSCLC	B-Disease	NOUN	B
.	O	PUNCT	O


This	O	DET	O
treatment	O	NOUN	B
merits	O	VERB	O
further	O	ADJ	O
comparison	O	NOUN	B
with	O	ADP	O
other	O	ADJ	O
cisplatin	B-Chemical	NOUN	B


Evaluation	O	NOUN	B
of	O	ADP	O
adverse	O	ADJ	B
reactions	O	NOUN	I
of	O	ADP	O
aponidine	B-Chemical	NOUN	B
hydrochloride	I-Chemical	NOUN	B
ophthalmic	O	ADJ	I
solution	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
prospectively	O	ADV	O
evaluated	O	VERB	B
the	O	DET	O
adverse	O	ADJ	B
reactions	O	NOUN	I
of	O	ADP	O
apraclonidine	B-Chemical	NOUN	B
in	O	ADP	O
20	O	NUM	O
normal	O	ADJ	B
volunteers	O	NOUN	I
by	O	ADP	O
instilling	O	VERB	B
a	O	DET	O
single	O	ADJ	O
drop	O	NOUN	B
of	O	ADP	O
1	O	NUM	O
%	O	NOUN	O
apraclonidine	B-Chemical	NOUN	B
in	O	ADP	O
their	O	PRON	O
right	O	ADJ	B
eyes	O	NOUN	I
.	O	PUNCT	O


Examinations	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
blood	O	NOUN	B
pressure	O	NOUN	I
,	O	PUNCT	O
pulse	O	NOUN	B
rate	O	NOUN	I
,	O	PUNCT	O
conjunctiva	O	NOUN	B
and	O	CCONJ	O
cornea	O	NOUN	B
,	O	PUNCT	O
intraocular	O	ADJ	B
pressure	O	NOUN	I
(	O	PUNCT	O
IOP	O	NOUN	B
),	O	PUNCT	O
pupil	O	NOUN	B
diameter	O	NOUN	I
,	O	PUNCT	O
basal	O	ADJ	B
tear	O	ADJ	I
secretion	O	NOUN	I
and	O	CCONJ	O
margin	O	NOUN	B
reflex	O	ADJ	O
distance	O	NOUN	B
of	O	ADP	O
both	O	CCONJ	O
upper	O	ADJ	B
and	O	CCONJ	O
lower	O	ADJ	B
eyelids	O	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
performed	O	VERB	O
prior	O	ADV	O
to	O	PART	O
entry	O	NOUN	B
and	O	CCONJ	O
at	O	ADP	O
1	O	NUM	O
,	O	PUNCT	O
3	O	NUM	O
,	O	PUNCT	O
5	O	NUM	O
and	O	CCONJ	O
7	O	NUM	O
hours	O	NOUN	O
after	O	ADP	O
instillation	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
ocular	B-Disease	ADJ	B
hypotensive	I-Disease	ADJ	O
effects	O	NOUN	O
were	O	AUX	O
statistically	O	ADV	B
significant	O	ADJ	I
for	O	ADP	O
apraclonidine	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
eyes	O	NOUN	B
throughout	O	ADP	O
the	O	DET	O
study	O	NOUN	B
and	O	CCONJ	O
also	O	ADV	O
statistically	O	ADV	B
significant	O	ADJ	I
for	O	ADP	O
contralateral	O	ADJ	B
eyes	O	NOUN	B
from	O	ADP	O
three	O	NUM	O
hours	O	NOUN	O
after	O	ADP	O
topical	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
1	O	NUM	O
%	O	NOUN	O
apraclonidine	B-Chemical	NOUN	B
.	O	PUNCT	O


Decreases	B-Disease	NOUN	B
in	I-Disease	ADP	O
systolic	I-Disease	ADJ	B
blood	I-Disease	NOUN	I
pressure	I-Disease	NOUN	I
were	O	AUX	O
statistically	O	ADV	B
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
clinically	O	ADV	B
,	O	PUNCT	O
significant	O	ADJ	B
.	O	PUNCT	O


No	O	DET	B
significant	O	ADJ	I
changes	O	NOUN	B
in	O	ADP	O
diastolic	O	ADJ	B
blood	O	NOUN	I
pressure	O	NOUN	I
,	O	PUNCT	O
pulse	O	NOUN	B
rate	O	NOUN	I
and	O	CCONJ	O
basal	O	ADJ	B
tear	O	ADJ	I
secretion	O	NOUN	I
were	O	AUX	O
noted	O	VERB	O
.	O	PUNCT	O


Conjunctival	B-Disease	NOUN	B
blanching	I-Disease	NOUN	I
and	O	CCONJ	O
mydriasis	B-Disease	NOUN	B
were	O	AUX	O
commonly	O	ADV	O
found	O	VERB	O
.	O	PUNCT	O


Upper	O	ADJ	B
lid	O	ADJ	I
retraction	O	NOUN	I
was	O	AUX	O
frequently	O	ADV	O
noted	O	VERB	O
.	O	PUNCT	O


While	O	SCONJ	O
the	O	DET	O
elevations	O	NOUN	B
of	O	ADP	O
the	O	DET	O
upper	O	ADJ	B
lid	O	ADJ	I
margin	O	NOUN	I
in	O	ADP	O
most	O	ADJ	O
subjects	O	NOUN	B
were	O	AUX	O
not	O	PART	O
more	O	ADJ	O
than	O	ADP	O
2	O	NUM	O
mm	O	NOUN	O
and	O	CCONJ	O
did	O	AUX	O
not	O	PART	O
cause	O	VERB	O
noticeable	O	ADJ	O
change	O	NOUN	O
in	O	ADP	O
appearance	O	NOUN	B
,	O	PUNCT	O
one	O	NUM	O
subject	O	NOUN	B
suffered	O	VERB	O
from	O	ADP	O
mechanical	O	ADJ	B
entropion	B-Disease	NOUN	I
and	O	CCONJ	O
marked	O	ADJ	O
corneal	B-Disease	NOUN	B
abrasion	I-Disease	NOUN	I


Carmofur	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
organic	B-Disease	ADJ	B
mental	I-Disease	ADJ	I
disorders	I-Disease	NOUN	I
.	O	PUNCT	O


Organic	B-Disease	ADJ	B
mental	I-Disease	ADJ	I
disorder	I-Disease	NOUN	I
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
a	O	DET	O
29	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
female	O	NOUN	B
in	O	ADP	O
the	O	DET	O
prognostic	O	ADJ	B
period	O	NOUN	B
after	O	ADP	O
the	O	DET	O
onset	O	NOUN	O
of	O	ADP	O
carmofur	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
leukoencephalopathy	B-Disease	NOUN	B
.	O	PUNCT	O


Symptoms	O	NOUN	B
such	O	ADJ	O
as	O	ADP	O
euphoria	O	NOUN	B
,	O	PUNCT	O
emotional	O	ADJ	B
lability	O	NOUN	B
and	O	CCONJ	O
puerile	O	ADJ	B
attitude	O	NOUN	B
noted	O	VERB	O
in	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
were	O	AUX	O
diagnosed	O	VERB	B
as	O	ADP	O
organic	B-Disease	ADJ	B
personality	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
according	O	VERB	O
to	O	PART	O
the	O	DET	O
criteria	O	NOUN	B
defined	O	VERB	O
in	O	ADP	O
the	O	DET	O
DSM	O	PROPN	B
-	O	PUNCT	O
III	O	NUM	B
-	O	PUNCT	O
R	O	PROPN	B
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
referred	O	VERB	O
to	O	PART	O
as	O	ADP	O
a	O	DET	O
frontal	B-Disease	ADJ	B
lobe	I-Disease	ADJ	I
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


Brain	O	PROPN	B
CT	O	PROPN	I
revealed	O	VERB	O
a	O	DET	O
periventricular	O	ADJ	B
low	O	ADJ	B
density	O	NOUN	I
area	O	NOUN	I
in	O	ADP	O
the	O	DET	O
frontal	O	ADJ	B
white	O	ADJ	I
matter	O	NOUN	I
and	O	CCONJ	O
moderate	O	ADJ	B
dilatation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
lateral	O	ADJ	B
ventricles	O	NOUN	I
especially	O	ADV	O
at	O	ADP	O
the	O	DET	O
bilateral	O	ADJ	B
anterior	O	ADJ	O
horns	O	NOUN	B
.	O	PUNCT	O


Consequently	O	ADV	O
,	O	PUNCT	O
carmofur	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
leukoencephalopathy	B-Disease	NOUN	B
may	O	AUX	O
uncommonly	O	ADV	O
result	O	VERB	O
in	O	ADP	O
organic	B-Disease	ADJ	B
personality	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
in	O	ADP	O
the	O	DET	O
residual	O	ADJ	B
state	O	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
may	O	AUX	O
be	O	AUX	O
attributed	O	VERB	O
to	O	PART	O
the	O	DET	O
structural	B-Disease	ADJ	B
damage	I-Disease	NOUN	I
to	I-Disease	ADP	O
the	I-Disease	DET	O
frontal	I-Disease	ADJ	B
lobe	I-Disease	NOUN	I


International	O	ADJ	B
mexiletine	B-Chemical	NOUN	B
and	O	CCONJ	O
placebo	O	ADJ	B
antiarrhythmic	O	ADJ	O
coronary	O	ADJ	O
trial	O	NOUN	O
:	O	PUNCT	O
I	O	PRON	B
.	O	PUNCT	O


Report	O	NOUN	B
on	O	ADP	O
arrhythmia	B-Disease	NOUN	B
and	O	CCONJ	O
other	O	ADJ	O
findings	O	NOUN	B
.	O	PUNCT	O


Impact	O	PROPN	B
Research	O	PROPN	B
Group	O	PROPN	I
.	O	PUNCT	O


The	O	DET	O
antiarrhythmic	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
the	O	DET	O
sustained	O	ADJ	B
release	O	NOUN	B
form	O	NOUN	O
of	O	ADP	O
mexiletine	B-Chemical	NOUN	B
(	O	PUNCT	O
Mexitil-Perlongets	B-Chemical	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
evaluated	O	VERB	B
in	O	ADP	O
a	O	DET	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	ADJ	B
placebo	O	NOUN	B
trial	O	NOUN	I
in	O	ADP	O
630	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
recent	O	ADJ	O
documented	O	VERB	O
myocardial	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
primary	O	ADJ	B
response	O	NOUN	I
variable	O	NOUN	B
was	O	AUX	O
based	O	VERB	O
on	O	ADP	O
central	O	ADJ	B
reading	O	NOUN	I
of	O	ADP	O
24	O	NUM	O
hour	O	NOUN	B
ambulatory	O	ADJ	B
electrocardiographic	O	ADJ	O
recordings	O	NOUN	O
and	O	CCONJ	O
was	O	AUX	O
defined	O	VERB	O
as	O	ADP	O
the	O	DET	O
occurrence	O	NOUN	B
of	O	ADP	O
30	O	NUM	O
or	O	CCONJ	O
more	O	ADV	O
single	O	ADJ	O
premature	O	ADJ	B
ventricular	O	ADJ	I
complexes	O	NOUN	I
in	O	ADP	O
any	O	DET	O
two	O	NUM	O
consecutive	O	ADJ	B
30	O	NUM	O
minute	O	NOUN	B
blocks	O	NOUN	I
or	O	CCONJ	O
one	O	NUM	O
or	O	CCONJ	O
more	O	ADJ	O
runs	O	NOUN	O
of	O	ADP	O
two	O	NUM	O
or	O	CCONJ	O
more	O	ADV	O
premature	O	ADJ	B
ventricular	O	ADJ	I
complexes	O	NOUN	I
in	O	ADP	O
the	O	DET	O
entire	O	ADJ	O
24	O	NUM	O
hour	O	NOUN	B
electrocardiographic	O	ADJ	B
recording	O	NOUN	I
.	O	PUNCT	O


Large	O	ADJ	O
differences	O	NOUN	B
,	O	PUNCT	O
regarded	O	VERB	O
as	O	ADP	O
statistically	O	ADV	B
significant	O	ADJ	I
,	O	PUNCT	O
between	O	ADP	O
the	O	DET	O
mexiletine	B-Chemical	NOUN	B
and	O	CCONJ	O
placebo	O	NOUN	B
groups	O	NOUN	B
were	O	AUX	O
noted	O	VERB	O
in	O	ADP	O
that	O	DET	O
end	O	NOUN	O
point	O	NOUN	O
at	O	ADP	O
months	O	NOUN	B
1	O	NUM	O
and	O	CCONJ	O
4	O	NUM	O
,	O	PUNCT	O
but	O	CCONJ	O
only	O	ADV	O
trends	O	NOUN	B
were	O	AUX	O
observed	O	VERB	O
at	O	ADP	O
month	O	NOUN	B
12	O	NUM	O
.	O	PUNCT	O


These	O	DET	O
differences	O	NOUN	O
were	O	AUX	O
observed	O	VERB	B
even	O	ADV	O
though	O	SCONJ	O
the	O	DET	O
serum	O	NOUN	B
mexiletine	B-Chemical	NOUN	B
levels	O	NOUN	B
obtained	O	VERB	O
in	O	ADP	O
this	O	DET	O
study	O	NOUN	B
were	O	AUX	O
generally	O	ADV	O
lower	O	ADJ	O
than	O	ADP	O
those	O	DET	O
observed	O	VERB	B
in	O	ADP	O
studies	O	NOUN	B
that	O	PRON	O
have	O	AUX	O
used	O	VERB	O
the	O	DET	O
regular	O	ADJ	O
form	O	NOUN	O
of	O	ADP	O
the	O	DET	O
drug	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
more	O	ADJ	O
deaths	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
mexiletine	B-Chemical	NOUN	B
group	O	NOUN	B
(	O	PUNCT	O
7	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
%)	O	NOUN	O
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	O
(	O	PUNCT	O
4	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
%);	O	NOUN	O
the	O	DET	O
difference	O	NOUN	B
was	O	AUX	O
not	O	PART	O
statistically	O	ADV	B
significant	O	ADJ	I
.	O	PUNCT	O


The	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
coronary	O	ADJ	B
events	O	NOUN	I
was	O	AUX	O
similar	O	ADJ	O
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


Previously	O	ADV	O
recognized	O	VERB	O
side	O	NOUN	B
effects	O	NOUN	I
,	O	PUNCT	O
particularly	O	ADV	O
tremor	B-Disease	NOUN	B
and	O	CCONJ	O
gastrointestinal	B-Disease	ADJ	B
problems	I-Disease	NOUN	I
,	O	PUNCT	O
were	O	AUX	O
more	O	ADV	O
frequent	O	ADJ	B
in	O	ADP	O
the	O	DET	O
mexiletine	B-Chemical	NOUN	B


Regional	O	ADJ	B
localization	O	NOUN	B
of	O	ADP	O
the	O	DET	O
antagonism	O	NOUN	B
of	O	ADP	O
amphetamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hyperactivity	B-Disease	NOUN	B
by	O	ADP	O
intracerebral	O	ADJ	B
calcitonin	B-Chemical	NOUN	I
injections	O	NOUN	I
.	O	PUNCT	O


Calcitonin	B-Chemical	NOUN	B
receptors	O	NOUN	I
are	O	AUX	O
found	O	VERB	O
in	O	ADP	O
the	O	DET	O
brain	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
intracerebral	O	ADJ	B
infusions	O	NOUN	B
of	O	ADP	O
calcitonin	B-Chemical	NOUN	B
can	O	AUX	O
produce	O	VERB	O
behavioral	O	ADJ	B
effects	O	NOUN	B
.	O	PUNCT	O


Among	O	ADP	O
these	O	DET	O
behavioral	O	ADJ	B
effects	O	NOUN	B
are	O	AUX	O
decreases	O	NOUN	B
in	O	ADP	O
food	O	NOUN	B
intake	O	NOUN	I
and	O	CCONJ	O
decreases	O	VERB	B
in	O	ADP	O
amphetamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
locomotor	O	NOUN	B
activity	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
previous	O	ADJ	O
experiments	O	NOUN	B
we	O	PRON	O
found	O	VERB	O
that	O	SCONJ	O
decreases	O	VERB	B
in	O	ADP	O
food	O	NOUN	B
intake	O	NOUN	I
were	O	AUX	O
induced	O	VERB	B
by	O	ADP	O
local	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
calcitonin	B-Chemical	NOUN	B
into	O	ADP	O
several	O	ADJ	O
hypothalamic	O	ADJ	B
sites	O	NOUN	I
and	O	CCONJ	O
into	O	ADP	O
the	O	DET	O
nucleus	O	NOUN	B
accumbens	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
present	O	ADJ	O
experiment	O	NOUN	B
calcitonin	B-Chemical	NOUN	B
decreased	O	VERB	B
locomotor	O	NOUN	B
activity	O	NOUN	I
when	O	SCONJ	O
locally	O	ADV	B
injected	O	VERB	I
into	O	ADP	O
the	O	DET	O
same	O	ADJ	O
sites	O	NOUN	B
where	O	SCONJ	O
it	O	PRON	O
decreases	O	VERB	B
food	O	NOUN	B
intake	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
areas	O	NOUN	B
where	O	SCONJ	O
calcitonin	B-Chemical	NOUN	B
is	O	AUX	O
most	O	ADV	O
effective	O	ADJ	B
in	O	ADP	O
decreasing	O	VERB	B
locomotor	O	NOUN	B
activity	O	NOUN	I
are	O	AUX	O
located	O	ADJ	O
in	O	ADP	O
the	O	DET	O
hypothalamus	O	NOUN	B
and	O	CCONJ	O
nucleus	O	NOUN	B
accumbens	O	NOUN	I
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
these	O	DET	O
areas	O	NOUN	B
are	O	AUX	O
the	O	DET	O
major	O	ADJ	O
sites	O	NOUN	B
of	O	ADP	O
action	O	NOUN	B
of	O	ADP	O
calcitonin	B-Chemical	NOUN	B
in	O	ADP	O
inhibiting	O	VERB	B
amphetamine	B-Chemical	NOUN	B


Fatal	O	ADJ	B
intracranial	B-Disease	ADJ	B
bleeding	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
prehospital	O	ADJ	B
use	O	NOUN	O
of	O	ADP	O
epinephrine	B-Chemical	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
present	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
paramedic	O	NOUN	B
misjudgment	O	NOUN	B
in	O	ADP	O
the	O	DET	O
execution	O	NOUN	B
of	O	ADP	O
a	O	DET	O
protocol	O	NOUN	B
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
allergic	B-Disease	ADJ	B
reaction	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
pulmonary	B-Disease	ADJ	B
edema	I-Disease	NOUN	I
with	O	ADP	O
wheezing	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
sudden	O	ADJ	B
onset	O	NOUN	I
of	O	ADP	I
respiratory	B-Disease	ADJ	B
distress	I-Disease	NOUN	I
,	O	PUNCT	O
rash	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
history	O	NOUN	B
of	O	ADP	O
a	O	DET	O
new	O	ADJ	O
medicine	O	NOUN	B
led	O	VERB	O
the	O	DET	O
two	O	NUM	O
paramedics	O	NOUN	B
on	O	ADP	O
the	O	DET	O
scene	O	NOUN	B
to	O	PART	O
administer	O	VERB	O
subcutaneous	O	ADJ	B
epinephrine	B-Chemical	NOUN	B
.	O	PUNCT	O


Subsequently	O	ADV	O
,	O	PUNCT	O
acute	O	ADJ	B
cardiac	B-Disease	ADJ	I
arrest	I-Disease	NOUN	I
and	O	CCONJ	O
fatal	O	ADJ	B
subarachnoid	B-Disease	ADJ	B
hemorrhage	I-Disease	NOUN	I
occurred	O	VERB	O
.	O	PUNCT	O


Epinephrine	B-Chemical	NOUN	B
has	O	AUX	O
a	O	DET	O
proven	O	VERB	O
role	O	NOUN	O
in	O	ADP	O
cardiac	B-Disease	ADJ	B
arrest	I-Disease	NOUN	I
in	O	ADP	O
prehospital	O	ADJ	B
care	O	NOUN	I
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
use	O	NOUN	O
by	O	ADP	O
paramedics	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
suspected	O	VERB	B
allergic	B-Disease	ADJ	B
reaction	I-Disease	NOUN	I
and	O	CCONJ	O
severe	O	ADJ	B
hypertension	B-Disease	NOUN	B


A	O	DET	O
case	O	NOUN	B
of	O	ADP	O
massive	O	ADJ	B
rhabdomyolysis	B-Disease	NOUN	B
following	O	VERB	O
molindone	B-Chemical	NOUN	B
administration	O	NOUN	B
.	O	PUNCT	O


Rhabdomyolysis	B-Disease	NOUN	B
is	O	AUX	O
a	O	DET	O
potentially	O	ADV	O
lethal	O	ADJ	B
syndrome	O	NOUN	I
that	O	SCONJ	O
psychiatric	B-Disease	ADJ	B
patients	O	NOUN	I
seem	O	VERB	O
predisposed	O	VERB	O
to	O	PART	O
develop	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
clinical	O	ADJ	B
signs	O	NOUN	I
and	O	CCONJ	O
symptoms	O	NOUN	B
,	O	PUNCT	O
typical	O	ADJ	O
laboratory	O	NOUN	B
features	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
complications	O	NOUN	B
of	O	ADP	O
rhabdomyolysis	B-Disease	NOUN	B
are	O	AUX	O
presented	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
case	O	NOUN	B
of	O	ADP	O
a	O	DET	O
schizophrenic	B-Disease	ADJ	B
patient	O	NOUN	B
is	O	AUX	O
reported	O	VERB	O
to	O	PART	O
illustrate	O	VERB	O
massive	O	ADJ	B
rhabdomyolysis	B-Disease	NOUN	B
and	O	CCONJ	O
subsequent	O	ADJ	O
acute	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
failure	I-Disease	NOUN	I
following	O	VERB	O
molindone	B-Chemical	NOUN	B
administration	O	NOUN	B
.	O	PUNCT	O


Physicians	O	NOUN	B
who	O	PRON	O
prescribe	O	VERB	O
molindone	B-Chemical	NOUN	B


Cardiovascular	B-Disease	ADJ	B
alterations	I-Disease	NOUN	B
in	O	ADP	O
rat	O	NOUN	B
fetuses	O	NOUN	B
exposed	O	VERB	B
to	O	PART	I
calcium	B-Chemical	NOUN	B
channel	O	NOUN	I
blockers	O	NOUN	I
.	O	PUNCT	O


Preclinical	O	ADJ	B
toxicologic	O	ADJ	O
investigation	O	NOUN	B
suggested	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
new	O	ADJ	O
calcium	B-Chemical	NOUN	B
channel	O	NOUN	I
blocker	O	NOUN	I
,	O	PUNCT	O
Ro	B-Chemical	NOUN	B
40-5967	I-Chemical	NUM	B
,	O	PUNCT	O
induced	O	VERB	B
cardiovascular	B-Disease	ADJ	B
alterations	I-Disease	NOUN	B
in	O	ADP	O
rat	O	NOUN	B
fetuses	O	NOUN	B
exposed	O	VERB	B
to	O	PART	I
this	O	DET	O
agent	O	NOUN	B
during	O	ADP	O
organogenesis	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
was	O	AUX	O
designed	O	VERB	O
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
calcium	B-Chemical	NOUN	B
channel	O	NOUN	I
blockers	O	NOUN	I
in	O	ADP	O
general	O	ADJ	O
induce	O	VERB	B
cardiovascular	B-Disease	ADJ	B
malformations	I-Disease	NOUN	I
indicating	O	VERB	O
a	O	DET	O
pharmacologic	O	ADJ	B
class	O	NOUN	I
effect	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
studied	O	VERB	O
three	O	NUM	O
calcium	B-Chemical	NOUN	B
channel	O	NOUN	I
blockers	O	NOUN	I
of	O	ADP	O
different	O	ADJ	O
structure	O	NOUN	B
,	O	PUNCT	O
nifedipine	B-Chemical	NOUN	B
,	O	PUNCT	O
diltiazem	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
verapamil	B-Chemical	NOUN	B
,	O	PUNCT	O
along	O	ADP	O
with	O	ADP	O
the	O	DET	O
new	O	ADJ	O
agent	O	NOUN	B
.	O	PUNCT	O


Pregnant	O	ADJ	B
rats	O	NOUN	I
were	O	AUX	O
administered	O	VERB	B
one	O	NUM	O
of	O	ADP	O
these	O	DET	O
calcium	B-Chemical	NOUN	B
channel	O	NOUN	I
blockers	O	NOUN	I
during	O	ADP	O
the	O	DET	O
period	O	NOUN	B
of	O	ADP	O
cardiac	O	ADJ	B
morphogenesis	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
offspring	O	NOUN	B
examined	O	VERB	B
on	O	ADP	O
day	O	NOUN	B
20	O	NUM	O
of	O	ADP	O
gestation	O	NOUN	B
for	O	ADP	O
cardiovascular	B-Disease	ADJ	B
malformations	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
low	O	ADJ	B
incidence	O	NOUN	B
of	O	ADP	O
cardiovascular	B-Disease	ADJ	B
malformations	I-Disease	NOUN	I
was	O	AUX	O
observed	O	VERB	O
after	O	ADP	O
exposure	O	NOUN	B
to	O	ADP	I
each	O	DET	O
of	O	ADP	O
the	O	DET	O
four	O	NUM	O
calcium	B-Chemical	NOUN	B
channel	O	NOUN	I
blockers	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
this	O	DET	O
incidence	O	NOUN	B
was	O	AUX	O
statistically	O	ADV	B
significant	O	ADJ	I
only	O	ADV	O
for	O	ADP	O
verapamil	B-Chemical	NOUN	B
and	O	CCONJ	O
nifedipine	B-Chemical	NOUN	B
.	O	PUNCT	O


All	O	DET	O
four	O	NUM	O
agents	O	NOUN	B
were	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
aortic	O	ADJ	B
arch	O	ADJ	I
branching	O	NOUN	I
variants	O	NOUN	B
,	O	PUNCT	O
although	O	SCONJ	O
significantly	O	ADV	O
increased	O	VERB	B
only	O	ADV	O
for	O	ADP	O
Ro	B-Chemical	NOUN	B
40-5967	I-Chemical	NUM	B
and	O	CCONJ	O
verapamil	B-Chemical	NOUN	B


Differential	O	ADJ	B
impact	O	NOUN	B
of	O	ADP	O
immune	O	ADJ	B
escape	O	NOUN	I
mutations	O	NOUN	I
G145R	O	NOUN	B
and	O	CCONJ	O
P120T	O	NOUN	B
on	O	ADP	O
the	O	DET	O
replication	O	NOUN	B
of	O	ADP	O
lamivudine	B-Chemical	NOUN	B
-	O	PUNCT	O
resistant	O	ADJ	B
hepatitis	B-Chemical	NOUN	B
B	I-Chemical	NOUN	I
virus	I-Chemical	NOUN	I
e	I-Chemical	NOUN	I
antigen	I-Chemical	NOUN	I
-	O	PUNCT	O
positive	O	ADJ	B
and	O	CCONJ	O
-	O	PUNCT	O
negative	O	ADJ	B
strains	O	NOUN	B
.	O	PUNCT	O


Immune	O	ADJ	B
escape	O	NOUN	I
variants	O	NOUN	B
of	O	ADP	O
the	O	DET	O
hepatitis	B-Disease	NOUN	B
B	I-Disease	NOUN	I
virus	O	NOUN	I
(	O	PUNCT	O
HBV	O	NOUN	B
)	O	PUNCT	O
represent	O	VERB	O
an	O	DET	O
emerging	O	VERB	O
clinical	O	ADJ	B
challenge	O	NOUN	I
,	O	PUNCT	O
because	O	SCONJ	O
they	O	PRON	O
can	O	AUX	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
vaccine	O	NOUN	B
escape	O	NOUN	B
,	O	PUNCT	O
HBV	O	NOUN	B
reactivation	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
failure	O	NOUN	B
of	O	ADP	O
diagnostic	O	ADJ	B
tests	O	NOUN	I
.	O	PUNCT	O


Recent	O	ADJ	O
data	O	NOUN	B
suggest	O	VERB	O
a	O	DET	O
preferential	O	ADJ	O
selection	O	NOUN	B
of	O	ADP	O
immune	O	ADJ	B
escape	O	NOUN	I
mutants	O	NOUN	I
in	O	ADP	O
distinct	O	ADJ	O
peripheral	O	ADJ	B
blood	O	NOUN	I
leukocyte	O	NOUN	I
compartments	O	NOUN	I
of	O	ADP	O
infected	O	ADJ	B
individuals	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
therefore	O	ADV	O
systematically	O	ADV	B
analyzed	O	VERB	B
the	O	DET	O
functional	O	ADJ	B
impact	O	NOUN	B
of	O	ADP	O
the	O	DET	O
most	O	ADV	O
prevalent	O	ADJ	O
immune	O	ADJ	B
escape	O	NOUN	O
variants	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
sG145R	O	NOUN	B
and	O	CCONJ	O
sP120T	O	NOUN	B
mutants	O	NOUN	B
,	O	PUNCT	O
on	O	ADP	O
the	O	DET	O
viral	O	ADJ	B
replication	O	NOUN	I
efficacy	O	NOUN	B
and	O	CCONJ	O
antiviral	O	ADJ	B
drug	O	NOUN	I
susceptibility	O	NOUN	I
of	O	ADP	O
common	O	ADJ	O
treatment	O	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
mutants	O	NOUN	B
with	O	ADP	O
resistance	O	NOUN	B
to	O	PART	O
lamivudine	B-Chemical	NOUN	B
(	O	PUNCT	O
LAM	B-Chemical	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
HBeAg	B-Chemical	NOUN	B
negativity	O	NOUN	B
.	O	PUNCT	O


Replication	O	NOUN	B
-	O	PUNCT	O
competent	O	ADJ	B
HBV	O	NOUN	B
strains	O	NOUN	B
with	O	ADP	O
sG145R	O	NOUN	B
or	O	CCONJ	O
sP120T	O	NOUN	B
and	O	CCONJ	O
LAM	B-Chemical	NOUN	B
resistance	O	NOUN	B
(	O	PUNCT	O
rtM204I	O	NOUN	B
or	O	CCONJ	O
rtL180M	O	NOUN	B
/	O	SYM	O
rtM204V	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
generated	O	VERB	O
on	O	ADP	O
an	O	DET	O
HBeAg	B-Chemical	NOUN	B
-	O	PUNCT	O
positive	O	ADJ	B
and	O	CCONJ	O
an	O	DET	O
HBeAg	B-Chemical	NOUN	B
-	O	PUNCT	O
negative	O	ADJ	B
background	O	NOUN	B
with	O	ADP	O
precore	O	NOUN	B
(	O	PUNCT	O
PC	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
basal	O	ADJ	B
core	O	NOUN	I
promoter	O	NOUN	I
(	O	PUNCT	O
BCP	O	NOUN	B
)	O	PUNCT	O
mutants	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
sG145R	O	NOUN	B
mutation	O	NOUN	B
strongly	O	ADV	O
reduced	O	VERB	O
HBsAg	B-Chemical	NOUN	B
levels	O	NOUN	B
and	O	CCONJ	O
was	O	AUX	O
able	O	ADJ	O
to	O	PART	O
fully	O	ADV	O
restore	O	VERB	B
the	O	DET	O
impaired	O	ADJ	B
replication	O	NOUN	B
of	O	ADP	O
LAM	B-Chemical	NOUN	B
-	O	PUNCT	O
resistant	O	ADJ	B
HBV	O	NOUN	B
mutants	O	NOUN	B
to	O	PART	O
the	O	DET	O
levels	O	NOUN	B
of	O	ADP	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
HBV	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
PC	O	NOUN	B
or	O	CCONJ	O
BCP	O	NOUN	B
mutations	O	NOUN	B
further	O	ADV	O
enhanced	O	VERB	O
viral	O	ADJ	B
replication	O	NOUN	I
.	O	PUNCT	O


Although	O	SCONJ	O
the	O	DET	O
sP120T	O	NOUN	B
substitution	O	NOUN	B
also	O	ADV	O
impaired	O	VERB	B
HBsAg	B-Chemical	NOUN	B
secretion	O	NOUN	B
,	O	PUNCT	O
it	O	PRON	O
did	O	AUX	O
not	O	PART	O
enhance	O	VERB	O
the	O	DET	O
replication	O	NOUN	B
of	O	ADP	O
LAM	B-Chemical	NOUN	B
-	O	PUNCT	O
resistant	O	ADJ	B
clones	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
concomitant	O	ADJ	B
occurrence	O	NOUN	B
of	O	ADP	O
HBeAg	B-Chemical	NOUN	B
negativity	O	NOUN	I
(	O	PUNCT	O
PC	O	NOUN	B
/	O	SYM	O
BCP	O	PROPN	B
),	O	PUNCT	O
sP120T	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
LAM	B-Chemical	NOUN	B
resistance	O	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
the	O	DET	O
restoration	O	NOUN	B
of	O	ADP	O
replication	O	NOUN	B
to	O	PART	O
levels	O	NOUN	B
of	O	ADP	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
HBV	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
all	O	DET	O
clones	O	NOUN	B
with	O	ADP	O
combined	O	ADJ	O
immune	O	ADJ	B
escape	O	NOUN	I
and	O	CCONJ	O
LAM	B-Chemical	NOUN	B
resistance	O	NOUN	B
mutations	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
nucleotide	B-Chemical	NOUN	B
analogues	O	NOUN	I
adefovir	B-Chemical	NOUN	B
and	O	CCONJ	O
tenofovir	B-Chemical	NOUN	B


The	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
sevoflurane	B-Chemical	NOUN	B
on	O	ADP	O
lidocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
convulsions	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
influence	O	NOUN	B
of	O	ADP	O
sevoflurane	B-Chemical	NOUN	B
on	O	ADP	O
lidocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
convulsions	B-Disease	NOUN	B
was	O	AUX	O
studied	O	VERB	O
in	O	ADP	O
cats	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
convulsive	B-Disease	ADJ	B
threshold	O	NOUN	I
(	O	PUNCT	O
mean	O	NOUN	O
+/-	O	CCONJ	O
SD	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
41	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
+/-	O	CCONJ	O
6	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
.	O	PUNCT	O


l	O	NOUN	O
(-	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
with	O	ADP	O
lidocaine	B-Chemical	NOUN	B
infusion	O	NOUN	B
(	O	PUNCT	O
6	O	NUM	O
mg	O	NOUN	O
.	O	PUNCT	O


kg	O	NOUN	O
(-	O	PUNCT	O
1	O	NUM	O
).	O	ADJ	O
min	O	NOUN	O
(-	O	PUNCT	O
1	O	NUM	O
)),	O	PUNCT	O
increasing	O	VERB	B
significantly	O	ADV	O
to	O	PART	O
66	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
+/-	O	CCONJ	O
10	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
mg	O	NOUN	O
.	O	PUNCT	O


l	O	NOUN	O
(-	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
when	O	SCONJ	O
the	O	DET	O
end	O	NOUN	B
-	O	PUNCT	O
tidal	O	ADJ	B
concentration	O	NOUN	B
of	O	ADP	O
sevoflurane	B-Chemical	NOUN	B
was	O	AUX	O
0	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
%.	O	NOUN	B
However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
threshold	O	NOUN	B
(	O	PUNCT	O
61	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
+/-	O	CCONJ	O
8	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
mg	O	NOUN	O
.	O	PUNCT	O


l	O	NOUN	O
(-	O	PUNCT	O
1	O	NUM	O
))	O	PUNCT	O
during	O	ADP	O
1	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
%	O	NOUN	O
sevoflurane	B-Chemical	NOUN	B
was	O	AUX	O
not	O	PART	O
significant	O	ADJ	O
from	O	ADP	O
that	O	DET	O
during	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
%	O	NOUN	O
sevoflurane	B-Chemical	NOUN	B
,	O	PUNCT	O
indicating	O	VERB	O
a	O	DET	O
celling	O	ADJ	B
effect	O	NOUN	I
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
in	O	ADP	O
the	O	DET	O
convulsive	B-Disease	ADJ	B
threshold	O	NOUN	I
between	O	ADP	O
sevoflurane	B-Chemical	NOUN	B
and	O	CCONJ	O
enflurane	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
rise	O	NOUN	O
in	O	ADP	O
blood	O	NOUN	B
pressure	O	NOUN	I
became	O	VERB	O
less	O	ADV	O
marked	O	ADJ	O
when	O	SCONJ	O
higher	O	ADJ	B
concentrations	O	NOUN	B
of	O	ADP	O
sevoflurane	B-Chemical	NOUN	B
or	O	CCONJ	O
enflurane	B-Chemical	NOUN	B
were	O	AUX	O
administered	O	VERB	B
and	O	CCONJ	O
the	O	DET	O
blood	O	NOUN	B
pressure	O	NOUN	I
at	O	ADP	O
convulsions	B-Disease	NOUN	B
decreased	O	VERB	B
significantly	O	ADV	O
in	O	ADP	O
1	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
%	O	NOUN	O
sevoflurane	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
%	O	NOUN	O
enflurane	B-Chemical	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
in	O	ADP	O
the	O	DET	O
lidocaine	B-Chemical	NOUN	B
concentrations	O	NOUN	B
measured	O	VERB	B
when	O	SCONJ	O
the	O	DET	O
systolic	O	NOUN	B
blood	O	NOUN	I
pressure	O	NOUN	I
became	O	VERB	O
70	O	NUM	O
mmHg	O	NOUN	B
.	O	PUNCT	O


Apamin	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
selective	O	ADJ	O
blocker	O	NOUN	B
of	O	ADP	O
calcium	B-Chemical	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
potassium	B-Chemical	NOUN	B
channels	O	NOUN	I
,	O	PUNCT	O
was	O	AUX	O
administered	O	VERB	B
intracerebroventricularly	O	ADV	B
in	O	ADP	O
rats	O	NOUN	B
anesthetized	O	VERB	B
with	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
%	O	NOUN	O
sevoflurane	B-Chemical	NOUN	B
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
mechanism	O	NOUN	B
of	O	ADP	O
the	O	DET	O
anticonvulsive	O	ADJ	B
effects	O	NOUN	I
.	O	PUNCT	O


Apamin	B-Chemical	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
ng	O	NOUN	O
)	O	PUNCT	O
had	O	AUX	O
a	O	DET	O
tendency	O	NOUN	O
to	O	PART	O
decrease	O	VERB	B
the	O	DET	O
convulsive	B-Disease	ADJ	B
threshold	O	NOUN	I
(	O	PUNCT	O
21	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
+/-	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
to	O	PART	O
19	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
+/-	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
.	O	PUNCT	O


l	O	NOUN	O
(-	O	PUNCT	O
1	O	NUM	O
))	O	PUNCT	O
but	O	CCONJ	O
this	O	DET	O
was	O	AUX	O
not	O	PART	O
statistically	O	ADV	B
significant	O	ADJ	I
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
suggested	O	VERB	O
that	O	SCONJ	O
sevoflurane	B-Chemical	NOUN	B
reduces	O	VERB	B
the	O	DET	O
convulsive	B-Disease	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
lidocaine	B-Chemical	NOUN	B
toxicity	B-Disease	NOUN	B
but	O	CCONJ	O
carries	O	VERB	O
some	O	DET	O
risk	O	NOUN	B
due	O	ADJ	O
to	O	PART	O
circulatory	O	ADJ	B
depression	B-Disease	NOUN	I


Anti	O	PROPN	B
-	O	PUNCT	O
oxidant	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
atorvastatin	B-Chemical	NOUN	B
in	O	ADP	O
dexamethasone	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypertension	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
.	O	PUNCT	O


1	O	X	O
.	O	PUNCT	O


Dexamethasone	B-Chemical	NOUN	B
(	O	PUNCT	O
Dex	B-Chemical	NOUN	B
)-	O	ADJ	O
induced	O	VERB	B
hypertension	B-Disease	NOUN	B
is	O	AUX	O
characterized	O	VERB	O
by	O	ADP	O
endothelial	O	ADJ	B
dysfunction	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
nitric	B-Chemical	ADJ	B
oxide	I-Chemical	NOUN	I
(	O	PUNCT	O
NO	B-Chemical	NOUN	B
)	O	PUNCT	O
deficiency	O	NOUN	O
and	O	CCONJ	O
increased	O	VERB	B
superoxide	B-Chemical	NOUN	B
(	O	PUNCT	O
O2-	B-Chemical	NOUN	B
)	O	PUNCT	O
production	O	NOUN	B
.	O	PUNCT	O


Atorvastatin	B-Chemical	NOUN	B
(	O	PUNCT	O
Ato	B-Chemical	NOUN	B
)	O	PUNCT	O
possesses	O	VERB	O
pleiotropic	O	ADJ	B
properties	O	NOUN	I
that	O	PRON	O
have	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
to	O	PART	O
improve	O	VERB	B
endothelial	O	ADJ	B
function	O	NOUN	I
through	O	ADP	O
increased	O	VERB	B
availability	O	NOUN	B
of	O	ADP	O
NO	B-Chemical	NOUN	B
and	O	CCONJ	O
reduced	O	VERB	B
O2-	B-Chemical	NOUN	B
production	O	NOUN	B
in	O	ADP	O
various	O	ADJ	O
forms	O	NOUN	O
of	O	ADP	O
hypertension	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
investigated	O	VERB	B
whether	O	SCONJ	O
50	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
per	O	ADP	O
day	O	NOUN	B
,	O	PUNCT	O
p	O	NOUN	O
.	O	PUNCT	O


o	O	X	O
.,	O	NOUN	O
Ato	B-Chemical	NOUN	B
could	O	AUX	O
prevent	O	VERB	O
endothelial	O	ADJ	B
NO	B-Chemical	NOUN	I
synthase	O	NOUN	I
(	O	PUNCT	O
eNOS	O	NOUN	B
)	O	PUNCT	O
downregulation	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
O2-	B-Chemical	NOUN	B
in	O	ADP	O
Sprague	O	PROPN	B
-	O	PUNCT	O
Dawley	O	PROPN	B
(	O	PUNCT	O
SD	O	NOUN	B
)	O	PUNCT	O
rats	O	NOUN	B
,	O	PUNCT	O
thereby	O	ADV	O
reducing	O	VERB	B
blood	O	NOUN	B
pressure	O	NOUN	I
.	O	PUNCT	O


2	O	X	O
.	O	PUNCT	O


Male	O	NOUN	B
SD	O	NOUN	I
rats	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
30	O	NUM	O
)	O	PUNCT	O
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
Ato	B-Chemical	NOUN	B
(	O	PUNCT	O
50	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
per	O	ADP	O
day	O	NOUN	B
in	O	ADP	O
drinking	O	NOUN	B
water	O	NOUN	I
)	O	PUNCT	O
or	O	CCONJ	O
tap	O	NOUN	B
water	O	NOUN	I
for	O	ADP	O
15	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


Dexamethasone	B-Chemical	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
microg	O	NOUN	B
/	O	SYM	O
kg	O	NOUN	B
per	O	ADP	O
day	O	NOUN	B
,	O	PUNCT	O
s	O	NOUN	O
.	O	PUNCT	O


c	O	X	O
.)	O	NOUN	O
or	O	CCONJ	O
saline	O	NOUN	B
was	O	AUX	O
started	O	VERB	O
after	O	ADP	O
4	O	NUM	O
days	O	NOUN	B
in	O	ADP	O
Ato	B-Chemical	PROPN	B
-	O	PUNCT	O
treated	O	VERB	B
and	O	CCONJ	O
non	O	ADJ	B
-	O	PUNCT	O
treated	O	VERB	B
rats	O	NOUN	B
and	O	CCONJ	O
continued	O	VERB	O
for	O	ADP	O
11	O	NUM	O
-	O	SYM	O
13	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


Systolic	O	NOUN	B
blood	O	NOUN	I
pressure	O	NOUN	I
(	O	PUNCT	O
SBP	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
measured	O	VERB	B
on	O	ADP	O
alternate	O	ADJ	B
days	O	NOUN	I
using	O	VERB	O
the	O	DET	O
tail	O	NOUN	B
-	O	PUNCT	O
cuff	O	NOUN	B
method	O	NOUN	B
.	O	PUNCT	O


Endothelial	O	ADJ	B
function	O	NOUN	I
was	O	AUX	O
assessed	O	VERB	B
by	O	ADP	O
acetylcholine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
vasorelaxation	O	NOUN	B
and	O	CCONJ	O
phenylephrine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
vasoconstriction	O	NOUN	B
in	O	ADP	O
aortic	O	ADJ	B
segments	O	NOUN	B
.	O	PUNCT	O


Vascular	O	ADJ	B
eNOS	O	NOUN	B
mRNA	O	NOUN	B
was	O	AUX	O
assessed	O	VERB	B
by	O	ADP	O
semi	O	ADJ	B
-	O	PUNCT	O
quantitative	O	ADJ	B
reverse	O	ADJ	B
transcription	O	NOUN	I
-	O	PUNCT	O
polymerase	O	NOUN	B
chain	O	NOUN	I
reaction	O	NOUN	I
.	O	PUNCT	O


3	O	X	O
.	O	PUNCT	O


In	O	ADP	O
rats	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
Dex	B-Chemical	NOUN	B
alone	O	ADV	O
,	O	PUNCT	O
SBP	O	NOUN	B
was	O	AUX	O
increased	O	VERB	B
from	O	ADP	O
109	O	NUM	O
+/-	O	CCONJ	O
2	O	NUM	O
to	O	PART	O
133	O	NUM	O
+/-	O	CCONJ	O
2	O	NUM	O
mmHg	O	NOUN	B
on	O	ADP	O
Days	O	NOUN	B
4	O	NUM	I
and	O	CCONJ	O
Day	O	PROPN	B
14	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
).	O	PUNCT	O
In	O	ADP	O
the	O	DET	O
Ato	B-Chemical	NOUN	B
+	O	CCONJ	O
Dex	B-Chemical	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
SBP	O	NOUN	B
was	O	AUX	O
increased	O	VERB	B
from	O	ADP	O
113	O	NUM	O
+/-	O	CCONJ	O
2	O	NUM	O
to	O	PART	O
119	O	NUM	O
+/-	O	CCONJ	O
2	O	NUM	O
mmHg	O	NOUN	B
on	O	ADP	O
Days	O	NOUN	O
4	O	NUM	O
to	O	PART	O
14	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
),	O	PUNCT	O
but	O	CCONJ	O
was	O	AUX	O
significantly	O	ADV	O
lower	O	ADJ	O
than	O	ADP	O
SBP	O	NOUN	B
in	O	ADP	O
the	O	DET	O
group	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
Dex	B-Chemical	NOUN	B
alone	O	ADV	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
).	O	PUNCT	O
Endothelial	O	ADJ	B
-	O	PUNCT	O
dependent	O	ADJ	B
relaxation	O	NOUN	B
and	O	CCONJ	O
eNOS	O	NOUN	B
mRNA	O	NOUN	B
expression	O	NOUN	I
were	O	AUX	O
greater	O	ADJ	O
in	O	ADP	O
the	O	DET	O
Dex	B-Chemical	NOUN	B
+	O	CCONJ	O
Ato	B-Chemical	NOUN	B
group	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
Dex	B-Chemical	NOUN	B
only	O	ADV	O
group	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
and	O	CCONJ	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


0001	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
).	O	PUNCT	O
Aortic	O	ADJ	B
superoxide	B-Chemical	NOUN	O
production	O	NOUN	B
was	O	AUX	O
lower	O	ADJ	O
in	O	ADP	O
the	O	DET	O
Dex	B-Chemical	NOUN	B
+	O	CCONJ	O
Ato	B-Chemical	NOUN	B
group	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
group	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
Dex	B-Chemical	NOUN	B
alone	O	ADV	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


0001	O	NUM	O
).	O	PUNCT	O
4	O	NUM	O
.	O	PUNCT	O


Treatment	O	NOUN	B
with	O	ADP	O
Ato	B-Chemical	NOUN	B
improved	O	VERB	O
endothelial	O	ADJ	B
function	O	NOUN	I
,	O	PUNCT	O
reduced	O	VERB	B
superoxide	B-Chemical	NOUN	B
production	O	NOUN	O
and	O	CCONJ	O
reduced	O	VERB	B
SBP	O	NOUN	B
in	O	ADP	O
Dex	B-Chemical	NOUN	B


99mTc-glucarate	B-Chemical	NOUN	O
for	O	ADP	O
detection	O	NOUN	B
of	O	ADP	O
isoproterenol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
myocardial	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


Infarct	B-Disease	NOUN	B
-	O	PUNCT	O
avid	O	ADJ	B
radiopharmaceuticals	O	NOUN	B
are	O	AUX	O
necessary	O	ADJ	O
for	O	ADP	O
rapid	O	ADJ	B
and	O	CCONJ	O
timely	O	ADV	O
diagnosis	O	NOUN	B
of	O	ADP	O
acute	O	ADJ	B
myocardial	B-Disease	ADJ	I
infarction	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
animal	O	NOUN	B
model	O	NOUN	I
used	O	VERB	O
to	O	PART	O
produce	O	VERB	O
infarction	B-Disease	NOUN	B
implies	O	VERB	O
artery	O	NOUN	B
ligation	O	NOUN	I
but	O	CCONJ	O
chemical	O	NOUN	B
induction	O	NOUN	I
can	O	AUX	O
be	O	AUX	O
easily	O	ADV	O
obtained	O	VERB	O
with	O	ADP	O
isoproterenol	B-Chemical	NOUN	B
.	O	PUNCT	O


A	O	DET	O
new	O	ADJ	O
infarct	B-Disease	NOUN	B
-	O	PUNCT	O
avid	O	ADJ	B
radiopharmaceutical	O	NOUN	B
based	O	VERB	O
on	O	ADP	O
glucaric	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
was	O	AUX	O
prepared	O	VERB	O
in	O	ADP	O
the	O	DET	O
hospital	O	NOUN	B
radiopharmacy	O	NOUN	I
of	O	ADP	O
the	O	DET	O
INCMNSZ	O	PROPN	B
.	O	PUNCT	O


99mTc-glucarate	B-Chemical	NOUN	B
was	O	AUX	O
easy	O	ADJ	O
to	O	PART	O
prepare	O	VERB	O
,	O	PUNCT	O
stable	O	ADJ	B
for	O	ADP	O
96	O	NUM	O
h	O	NOUN	O
and	O	CCONJ	O
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
study	O	VERB	B
its	O	PRON	O
biodistribution	O	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
with	O	ADP	O
isoproterenol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
acute	O	ADJ	B
myocardial	B-Disease	ADJ	I
infarction	I-Disease	NOUN	I
.	O	PUNCT	O


Histological	O	ADJ	B
studies	O	NOUN	I
demonstrated	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
rats	O	NOUN	B
developed	O	VERB	O
an	O	DET	O
infarct	B-Disease	NOUN	B
18	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
isoproterenol	B-Chemical	NOUN	B
administration	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
rat	O	NOUN	B
biodistribution	O	NOUN	B
studies	O	NOUN	O
showed	O	VERB	O
a	O	DET	O
rapid	O	ADJ	O
blood	O	NOUN	B
clearance	O	NOUN	I
via	O	ADP	O
the	O	DET	O
kidneys	O	NOUN	B
.	O	PUNCT	O


Thirty	O	NUM	O
minutes	O	NOUN	O
after	O	ADP	O
99mTc-glucarate	B-Chemical	NOUN	B
administration	O	NOUN	I
the	O	DET	O
standardised	O	VERB	B
heart	O	NOUN	I
uptake	O	NOUN	I
value	O	NOUN	I
S	O	NOUN	B
(	O	PUNCT	O
h	O	NOUN	O
)	O	PUNCT	O
UV	O	NOUN	B
was	O	AUX	O
4	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
in	O	ADP	O
infarcted	O	ADJ	B
rat	O	NOUN	I
heart	O	NOUN	B
which	O	DET	O
is	O	AUX	O
six	O	NUM	O
times	O	NOUN	O
more	O	ADJ	O
than	O	ADP	O
in	O	ADP	O
normal	O	ADJ	O
rats	O	NOUN	B
.	O	PUNCT	O


ROIs	O	NOUN	B
drawn	O	VERB	O
over	O	ADP	O
the	O	DET	O
gamma	O	NOUN	B
camera	O	NOUN	I
images	O	NOUN	B
showed	O	VERB	O
a	O	DET	O
ratio	O	NOUN	B
of	O	ADP	O
4	O	NUM	O
.	O	PUNCT	O


4	O	X	O
.	O	PUNCT	O


The	O	DET	O
high	O	ADJ	O
image	O	NOUN	B
quality	O	NOUN	I
suggests	O	VERB	O
that	O	SCONJ	O
high	O	ADJ	O
contrast	O	NOUN	O
images	O	NOUN	O
can	O	AUX	O
be	O	AUX	O
obtained	O	VERB	O
in	O	ADP	O
humans	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
96	O	NUM	O
h	O	NOUN	O
stability	O	NOUN	B
makes	O	VERB	O
it	O	PRON	O
an	O	DET	O
ideal	O	ADJ	B
agent	O	NOUN	I
to	O	PART	O
detect	O	VERB	B
,	O	PUNCT	O
in	O	ADP	O
patients	O	NOUN	B
,	O	PUNCT	O
early	O	ADJ	B
cardiac	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I


A	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
placebo	O	NOUN	B
-	O	PUNCT	O
controlled	O	VERB	B
dose	O	NOUN	B
-	O	PUNCT	O
comparison	O	NOUN	B
trial	O	NOUN	B
of	O	ADP	O
haloperidol	B-Chemical	NOUN	B
for	O	ADP	O
psychosis	B-Disease	NOUN	B
and	O	CCONJ	O
disruptive	B-Disease	ADJ	B
behaviors	I-Disease	NOUN	I
in	O	ADP	O
Alzheimer's	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
goal	O	NOUN	B
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
compare	O	VERB	B
the	O	DET	O
efficacy	O	NOUN	B
and	O	CCONJ	O
side	O	NOUN	B
effects	O	NOUN	I
of	O	ADP	O
two	O	NUM	O
doses	O	NOUN	B
of	O	ADP	O
haloperidol	B-Chemical	NOUN	B
and	O	CCONJ	O
placebo	O	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
psychosis	B-Disease	NOUN	B
and	O	CCONJ	O
disruptive	B-Disease	ADJ	B
behaviors	I-Disease	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
Alzheimer's	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


METHOD	O	NOUN	B
:	O	PUNCT	O
In	O	ADP	O
a	O	DET	O
6	O	NUM	O
-	O	PUNCT	O
week	O	NOUN	B
random	O	ADJ	B
-	O	PUNCT	O
assignment	O	NOUN	B
,	O	PUNCT	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	ADJ	B
,	O	PUNCT	O
placebo	O	NOUN	B
-	O	PUNCT	O
controlled	O	VERB	B
trial	O	NOUN	I
(	O	PUNCT	O
phase	O	NOUN	B
A	O	NOUN	I
),	O	PUNCT	O
haloperidol	B-Chemical	NOUN	B
,	O	PUNCT	O
2	O	NUM	O
-	O	SYM	O
3	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
day	O	NOUN	B
(	O	PUNCT	O
standard	O	ADJ	B
dose	O	NOUN	I
),	O	PUNCT	O
and	O	CCONJ	O
haloperidol	B-Chemical	NOUN	B
,	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


50	O	NUM	O
-	O	SYM	O
0	O	NUM	O
.	O	PUNCT	O


75	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
day	O	NOUN	B
(	O	PUNCT	O
low	O	ADJ	B
dose	O	NOUN	I
),	O	PUNCT	O
were	O	AUX	O
compared	O	VERB	B
in	O	ADP	O
71	O	NUM	O
outpatients	O	NOUN	B
with	O	ADP	O
Alzheimer's	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


For	O	ADP	O
the	O	DET	O
subsequent	O	ADJ	O
6	O	NUM	O
-	O	PUNCT	O
week	O	NOUN	B
double	O	ADJ	B
-	O	PUNCT	O
blind	O	NOUN	B
crossover	O	NOUN	B
phase	O	NOUN	I
(	O	PUNCT	O
phase	O	NOUN	B
B	O	NOUN	I
),	O	PUNCT	O
patients	O	NOUN	B
taking	O	VERB	O
standard	O	ADJ	B
-	O	PUNCT	O
or	O	CCONJ	O
low	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
haloperidol	B-Chemical	NOUN	B
were	O	AUX	O
switched	O	VERB	O
to	O	PART	O
placebo	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
patients	O	NOUN	B
taking	O	VERB	O
placebo	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	ADP	O
standard	O	ADJ	B
-	O	PUNCT	O
or	O	CCONJ	O
low	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
haloperidol	B-Chemical	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
For	O	ADP	O
the	O	DET	O
60	O	NUM	O
patients	O	NOUN	B
who	O	PRON	O
completed	O	VERB	O
phase	O	NOUN	B
A	O	NOUN	I
,	O	PUNCT	O
standard	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
haloperidol	B-Chemical	NOUN	B
was	O	AUX	O
efficacious	O	ADJ	B
and	O	CCONJ	O
superior	O	ADJ	B
to	O	PART	O
both	O	CCONJ	O
low	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
haloperidol	B-Chemical	NOUN	B
and	O	CCONJ	O
placebo	O	NOUN	B
for	O	ADP	O
scores	O	NOUN	B
on	O	ADP	O
the	O	DET	O
Brief	O	PROPN	B
Psychiatric	O	PROPN	I
Rating	O	NOUN	I
Scale	O	NOUN	I
psychosis	B-Disease	NOUN	B
factor	O	NOUN	I
and	O	CCONJ	O
on	O	ADP	O
psychomotor	B-Disease	NOUN	B
agitation	I-Disease	NOUN	I
.	O	PUNCT	O


Response	O	NOUN	B
rates	O	NOUN	I
according	O	VERB	O
to	O	ADP	O
three	O	NUM	O
sets	O	NOUN	B
of	O	ADP	O
criteria	O	NOUN	B
were	O	AUX	O
greater	O	ADJ	O
with	O	ADP	O
the	O	DET	O
standard	O	ADJ	B
dose	O	NOUN	I
(	O	PUNCT	O
55	O	NUM	O
%-	O	NOUN	B
60	O	NUM	O
%)	O	NOUN	O
than	O	ADP	O
the	O	DET	O
low	O	ADJ	B
dose	O	NOUN	I
(	O	PUNCT	O
25	O	NUM	O
%-	O	NOUN	O
35	O	NUM	O
%)	O	NOUN	B
and	O	CCONJ	O
placebo	O	NOUN	B
(	O	PUNCT	O
25	O	NUM	O
%-	O	NOUN	O
30	O	NUM	O
%).	O	NOUN	O
The	O	DET	O
advantage	O	NOUN	O
of	O	ADP	O
standard	O	ADJ	B
dose	O	NOUN	I
over	O	ADP	O
low	O	ADJ	B
dose	O	NOUN	I
was	O	AUX	O
replicated	O	VERB	O
in	O	ADP	O
phase	O	NOUN	B
B	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
phase	O	NOUN	B
A	O	NOUN	I
,	O	PUNCT	O
extrapyramidal	B-Disease	ADJ	B
signs	I-Disease	NOUN	I
tended	O	VERB	O
to	O	PART	O
be	O	AUX	O
greater	O	ADJ	O
with	O	ADP	O
the	O	DET	O
standard	O	ADJ	B
dose	O	NOUN	I
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
other	O	ADJ	O
two	O	NUM	O
conditions	O	NOUN	B
,	O	PUNCT	O
primarily	O	ADV	O
because	O	SCONJ	O
of	O	ADP	O
a	O	DET	O
subgroup	O	NOUN	B
(	O	PUNCT	O
20	O	NUM	O
%)	O	NOUN	O
who	O	PRON	O
developed	O	VERB	O
moderate	O	ADJ	B
to	O	ADP	O
severe	O	ADJ	B
signs	O	NOUN	B
.	O	PUNCT	O


Low	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
haloperidol	B-Chemical	NOUN	B
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
from	O	ADP	O
placebo	O	NOUN	B
on	O	ADP	O
any	O	DET	O
measure	O	NOUN	B
of	O	ADP	O
efficacy	O	NOUN	B
or	O	CCONJ	O
side	O	NOUN	B
effects	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
results	O	NOUN	B
indicated	O	VERB	O
a	O	DET	O
favorable	O	ADJ	O
therapeutic	O	ADJ	B
profile	O	NOUN	I
for	O	ADP	O
haloperidol	B-Chemical	NOUN	B
in	O	ADP	O
doses	O	NOUN	B
of	O	ADP	O
2	O	NUM	O
-	O	SYM	O
3	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
day	O	NOUN	B
,	O	PUNCT	O
although	O	SCONJ	O
a	O	DET	O
subgroup	O	NOUN	B
developed	O	VERB	O
moderate	O	ADJ	B
to	O	PART	O
severe	O	ADJ	B
extrapyramidal	B-Disease	ADJ	B
signs	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
starting	O	NOUN	O
dose	O	NOUN	B
of	O	ADP	O
1	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
day	O	NOUN	B
with	O	ADP	O
gradual	O	ADJ	B
,	O	PUNCT	O
upward	O	ADJ	B
dose	O	NOUN	B
titration	O	NOUN	B
is	O	AUX	O
recommended	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
narrow	O	ADJ	O
therapeutic	O	ADJ	B
window	O	NOUN	I
observed	O	VERB	O
with	O	ADP	O
haloperidol	B-Chemical	NOUN	B
may	O	AUX	O
also	O	ADV	O
apply	O	VERB	O
to	O	ADP	O
other	O	ADJ	O
neuroleptics	O	NOUN	B
used	O	VERB	O
in	O	ADP	O
Alzheimer's	B-Disease	X	O
disease	I-Disease	NOUN	B
patients	O	NOUN	B
with	O	ADP	O
psychosis	B-Disease	NOUN	B
and	O	CCONJ	O
disruptive	B-Disease	ADJ	B
behaviors	I-Disease	NOUN	I


Individual	O	ADJ	O
differences	O	NOUN	O
in	O	ADP	O
renal	O	ADJ	B
ACE	O	NOUN	B
activity	O	NOUN	B
in	O	ADP	O
healthy	O	ADJ	B
rats	O	NOUN	B
predict	O	VERB	O
susceptibility	O	NOUN	B
to	O	PART	O
adriamycin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
renal	B-Disease	ADJ	B
damage	I-Disease	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
In	O	ADP	O
man	O	NOUN	B
,	O	PUNCT	O
differences	O	NOUN	O
in	O	ADP	O
angiotensin	B-Chemical	NOUN	B
-	O	PUNCT	O
converting	O	VERB	B
enzyme	O	NOUN	B
(	O	PUNCT	O
ACE	O	NOUN	B
)	O	PUNCT	O
levels	O	NOUN	B
,	O	PUNCT	O
related	O	VERB	O
to	O	PART	O
ACE	O	NOUN	B
(	O	PUNCT	O
I	O	NUM	B
/	O	SYM	O
D	O	NOUN	B
)	O	PUNCT	O
genotype	O	NOUN	B
,	O	PUNCT	O
are	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
renal	O	ADJ	B
prognosis	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
raises	O	VERB	O
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
individual	O	ADJ	O
differences	O	NOUN	O
in	O	ADP	O
renal	O	ADJ	B
ACE	O	NOUN	B
activity	O	NOUN	B
are	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
renal	O	ADJ	B
susceptibility	O	NOUN	I
to	O	PART	O
inflicted	O	ADJ	B
damage	O	NOUN	B
.	O	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
studied	O	VERB	O
the	O	DET	O
predictive	O	ADJ	B
effect	O	NOUN	B
of	O	ADP	O
renal	O	ADJ	B
ACE	O	NOUN	B
activity	O	NOUN	B
for	O	ADP	O
the	O	DET	O
severity	O	NOUN	B
of	O	ADP	O
renal	B-Disease	ADJ	B
damage	I-Disease	NOUN	I
induced	O	VERB	B
by	O	ADP	O
a	O	DET	O
single	O	ADJ	O
injection	O	NOUN	B
of	O	ADP	O
adriamycin	B-Chemical	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
Renal	O	ADJ	B
ACE	O	NOUN	I
activity	O	NOUN	I
(	O	PUNCT	O
Hip-His-Leu	B-Chemical	NOUN	B
cleavage	O	NOUN	B
by	O	ADP	O
cortical	O	ADJ	B
homogenates	O	NOUN	O
)	O	PUNCT	O
was	O	AUX	O
determined	O	VERB	O
by	O	ADP	O
renal	O	ADJ	B
biopsy	O	NOUN	I
in	O	ADP	O
27	O	NUM	O
adult	O	ADJ	B
male	O	NOUN	B
Wistar	O	NOUN	B
rats	O	NOUN	I
.	O	PUNCT	O


After	O	ADP	O
1	O	NUM	O
week	O	NOUN	B
of	O	ADP	O
recovery	O	NOUN	B
,	O	PUNCT	O
proteinuria	B-Disease	NOUN	B
was	O	AUX	O
induced	O	VERB	B
by	O	ADP	O
adriamycin	B-Chemical	NOUN	B
[	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
kg	O	NOUN	B
intravenously	O	ADV	B
(	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


v	O	DET	O
.)	O	NUM	O
n	O	NOUN	O
=	O	ADJ	O
18	O	NUM	O
;	O	PUNCT	O
controls	O	NOUN	B
,	O	PUNCT	O
saline	O	NOUN	B
i	O	NUM	O
.	O	PUNCT	O


v	O	NOUN	O
.	O	PUNCT	O


n	O	NOUN	O
=	O	ADJ	O
9	O	NUM	O
].	O	X	B
Proteinuria	B-Disease	NOUN	I
was	O	AUX	O
measured	O	VERB	B
every	O	DET	O
2	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
12	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
rats	O	NOUN	B
were	O	AUX	O
sacrificed	O	VERB	B
and	O	CCONJ	O
their	O	PRON	O
kidneys	O	NOUN	B
harvested	O	VERB	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
As	O	ADP	O
anticipated	O	VERB	B
,	O	PUNCT	O
adriamycin	B-Chemical	NOUN	B
elicited	O	VERB	O
nephrotic	B-Disease	ADJ	B
range	O	NOUN	I
proteinuria	B-Disease	NOUN	B
,	O	PUNCT	O
renal	B-Disease	ADJ	B
interstitial	I-Disease	ADJ	I
damage	I-Disease	NOUN	I
and	O	CCONJ	O
mild	O	ADJ	B
focal	B-Disease	ADJ	I
glomerulosclerosis	I-Disease	NOUN	I
.	O	PUNCT	O


Baseline	O	NOUN	B
renal	O	ADJ	B
ACE	O	NOUN	B
positively	O	ADV	B
correlated	O	VERB	B
with	O	ADP	O
the	O	DET	O
relative	O	ADJ	O
rise	O	NOUN	O
in	O	ADP	O
proteinuria	B-Disease	NOUN	B
after	O	ADP	O
adriamycin	B-Chemical	NOUN	B
(	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


62	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
),	O	PUNCT	O
renal	O	ADJ	B
interstitial	O	ADJ	I
alpha	O	NOUN	I
-	O	PUNCT	O
smooth	O	ADJ	B
muscle	O	NOUN	I
actin	O	NOUN	I
(	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


49	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
),	O	PUNCT	O
interstitial	O	ADJ	B
macrophage	O	NOUN	I
influx	O	NOUN	B
(	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


56	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
),	O	PUNCT	O
interstitial	O	ADJ	B
collagen	O	NOUN	O
III	O	NUM	O
(	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


53	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
),	O	PUNCT	O
glomerular	O	ADJ	B
alpha	O	NOUN	I
-	O	PUNCT	O
smooth	O	ADJ	B
muscle	O	NOUN	I
actin	O	NOUN	I
(	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


74	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
glomerular	O	ADJ	B
desmin	O	NOUN	I
(	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


48	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
).	O	PUNCT	B
Baseline	O	NOUN	B
renal	O	ADJ	B
ACE	O	NOUN	B
did	O	AUX	O
not	O	PART	O
correlate	O	VERB	O
with	O	ADP	O
focal	B-Disease	ADJ	B
glomerulosclerosis	I-Disease	NOUN	I
(	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


22	O	NUM	O
,	O	PUNCT	O
NS	O	NOUN	B
).	O	PUNCT	O
In	O	ADP	O
controls	O	NOUN	B
,	O	PUNCT	O
no	O	DET	O
predictive	O	ADJ	O
values	O	NOUN	O
for	O	ADP	O
renal	O	ADJ	B
parameters	O	NOUN	B
were	O	AUX	O
observed	O	VERB	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
Individual	O	ADJ	O
differences	O	NOUN	O
in	O	ADP	O
renal	O	ADJ	B
ACE	O	NOUN	B
activity	O	NOUN	B
predict	O	VERB	O
the	O	DET	O
severity	O	NOUN	B
of	O	ADP	O
adriamycin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
renal	B-Disease	ADJ	B
damage	I-Disease	NOUN	I
in	O	ADP	O
this	O	DET	O
outbred	O	ADJ	B
rat	O	NOUN	I
strain	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
supports	O	VERB	O
the	O	DET	O
assumption	O	NOUN	O
that	O	SCONJ	O
differences	O	NOUN	B
in	O	ADP	O
renal	O	ADJ	B
ACE	O	NOUN	B
activity	O	NOUN	B
predispose	O	VERB	O
to	O	PART	O
a	O	DET	O
less	O	ADV	O
favourable	O	ADJ	O
course	O	NOUN	O
of	O	ADP	O
renal	B-Disease	ADJ	B
damage	I-Disease	NOUN	I


Clinical	O	ADJ	B
nephrotoxicity	B-Disease	NOUN	O
of	O	ADP	O
tobramycin	B-Chemical	NOUN	B
and	O	CCONJ	O
gentamicin	B-Chemical	NOUN	B
.	O	PUNCT	O


A	O	DET	O
prospective	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


Nearly	O	ADV	O
3	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
million	O	NUM	O
people	O	NOUN	B
in	O	ADP	O
this	O	DET	O
country	O	NOUN	B
receive	O	VERB	O
aminoglycoside	B-Chemical	ADJ	B
antibiotics	O	NOUN	I
annually	O	ADV	B
.	O	PUNCT	O


Gentamicin	B-Chemical	NOUN	B
sulfate	I-Chemical	NOUN	B
and	O	CCONJ	O
tobramycin	B-Chemical	NOUN	B
sulfate	I-Chemical	NOUN	I
continue	O	VERB	O
to	O	PART	O
demonstrate	O	VERB	O
ototoxicity	B-Disease	NOUN	B
and	O	CCONJ	O
nephrotoxicity	B-Disease	NOUN	B
in	O	ADP	O
both	O	CCONJ	O
animal	O	NOUN	B
and	O	CCONJ	O
clinical	O	ADJ	B
studies	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
62	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
confirmed	O	VERB	O
initial	O	ADJ	O
normal	O	ADJ	B
renal	O	ADJ	I
function	O	NOUN	I
and	O	CCONJ	O
treated	O	VERB	B
with	O	ADP	I
2	O	NUM	O
to	O	PART	O
5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
/	O	SYM	O
day	O	NOUN	B
of	O	ADP	O
gentamicin	B-Chemical	NOUN	B
sulfate	I-Chemical	NOUN	B
or	O	CCONJ	O
tobramycin	B-Chemical	NOUN	B
sulfate	I-Chemical	NOUN	I
for	O	ADP	O
a	O	DET	O
minimum	O	NOUN	B
of	O	ADP	O
seven	O	NUM	O
days	O	NOUN	B
were	O	AUX	O
followed	O	VERB	O
up	O	ADP	O
prospectively	O	ADV	O
for	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
aminoglycoside	B-Chemical	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
renal	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
,	O	PUNCT	O
defined	O	VERB	O
as	O	ADP	O
at	O	ADP	O
least	O	ADJ	O
a	O	DET	O
one	O	NUM	O
-	O	PUNCT	O
third	O	ADJ	B
reduction	O	NOUN	B
in	O	ADP	O
renal	O	ADJ	B
function	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
these	O	DET	O
62	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
no	O	DET	O
other	O	ADJ	O
causes	O	NOUN	O
for	O	ADP	O
renal	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
could	O	AUX	O
be	O	AUX	O
identified	O	VERB	B
.	O	PUNCT	O


Five	O	NUM	O
of	O	ADP	O
33	O	NUM	O
(	O	PUNCT	O
15	O	NUM	O
%)	O	NOUN	O
of	O	ADP	O
the	O	DET	O
tobramycin	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
patients	O	NOUN	B
and	O	CCONJ	O
16	O	NUM	O
of	O	ADP	O
29	O	NUM	O
(	O	PUNCT	O
55	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
%)	O	NOUN	O
of	O	ADP	O
the	O	DET	O
gentamicin	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
patients	O	NOUN	B
had	O	AUX	O
renal	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
gentamicin	B-Chemical	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
renal	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
more	O	ADJ	O
than	O	ADP	O
three	O	NUM	O
times	O	NOUN	O
as	O	ADV	O
often	O	ADV	O
as	O	ADP	O
was	O	AUX	O
tobramycin	B-Chemical	NOUN	B


Neuroprotective	O	ADJ	B
action	O	NOUN	I
of	O	ADP	O
MPEP	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
selective	O	ADJ	O
mGluR5	O	NOUN	B
antagonist	O	NOUN	I
,	O	PUNCT	O
in	O	ADP	O
methamphetamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
dopaminergic	O	ADJ	B
neurotoxicity	B-Disease	NOUN	B
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
dopamine	B-Chemical	NOUN	B
outflow	O	NOUN	O
and	O	CCONJ	O
inhibition	O	NOUN	B
of	O	ADP	O
hyperthermia	B-Disease	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
examine	O	VERB	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
metabotropic	O	NOUN	B
glutamate	B-Chemical	NOUN	I
receptor	O	NOUN	I
5	O	NUM	I
(	O	PUNCT	O
mGluR5	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
toxic	O	ADJ	B
action	O	NOUN	I
of	O	ADP	O
methamphetamine	B-Chemical	NOUN	B
on	O	ADP	O
dopaminergic	O	ADJ	B
neurones	O	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


Methamphetamine	B-Chemical	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
sc	O	NOUN	B
),	O	PUNCT	O
administered	O	VERB	B
five	O	NUM	O
times	O	NOUN	O
,	O	PUNCT	O
reduced	O	VERB	B
the	O	DET	O
levels	O	NOUN	B
of	O	ADP	O
dopamine	B-Chemical	NOUN	B
and	O	CCONJ	O
its	O	PRON	O
metabolites	O	NOUN	B
in	O	ADP	O
striatal	O	ADJ	B
tissue	O	NOUN	I
when	O	SCONJ	O
measured	O	VERB	B
72	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
the	O	DET	O
last	O	ADJ	O
injection	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
selective	O	ADJ	O
antagonist	O	NOUN	B
of	O	ADP	O
mGluR5	O	NOUN	B
,	O	PUNCT	O
2-methyl-6-(phenylethynyl)pyridine	B-Chemical	NOUN	B
(	O	PUNCT	O
MPEP	B-Chemical	NOUN	B
;	O	PUNCT	O
5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
ip	O	NOUN	B
),	O	PUNCT	O
when	O	SCONJ	O
administered	O	VERB	B
five	O	NUM	O
times	O	NOUN	O
immediately	O	ADV	O
before	O	ADP	O
each	O	DET	O
methamphetamine	B-Chemical	NOUN	B
injection	O	NOUN	B
reversed	O	VERB	B
the	O	DET	O
above	O	ADV	B
-	O	PUNCT	O
mentioned	O	VERB	B
methamphetamine	B-Chemical	NOUN	B
effects	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
single	O	ADJ	O
MPEP	B-Chemical	NOUN	B
(	O	PUNCT	O
5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
ip	O	NOUN	B
)	O	PUNCT	O
injection	O	NOUN	B
reduced	O	VERB	B
the	O	DET	O
basal	O	ADJ	B
extracellular	O	ADJ	O
dopamine	B-Chemical	NOUN	B
level	O	NOUN	B
in	O	ADP	O
the	O	DET	O
striatum	O	NOUN	B
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
dopamine	B-Chemical	NOUN	B
release	O	NOUN	B
stimulated	O	VERB	B
either	O	CCONJ	O
by	O	ADP	O
methamphetamine	B-Chemical	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
sc	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
by	O	ADP	O
intrastriatally	O	ADV	B
administered	O	VERB	B
veratridine	B-Chemical	NOUN	B
(	O	PUNCT	O
100	O	NUM	O
microM	O	NOUN	O
).	O	PUNCT	O
Moreover	O	ADV	O
,	O	PUNCT	O
it	O	PRON	O
transiently	O	ADV	O
diminished	O	VERB	B
the	O	DET	O
methamphetamine	B-Chemical	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
sc	O	ADV	O
)-	O	ADJ	O
induced	O	VERB	B
hyperthermia	B-Disease	NOUN	B
and	O	CCONJ	O
reduced	O	VERB	B
basal	O	ADJ	B
body	O	NOUN	I
temperature	O	NOUN	O
.	O	PUNCT	O


MPEP	B-Chemical	NOUN	B
administered	O	VERB	B
into	O	ADP	O
the	O	DET	O
striatum	O	NOUN	B
at	O	ADP	O
high	O	ADJ	O
concentrations	O	NOUN	B
(	O	PUNCT	O
500	O	NUM	O
microM	O	NOUN	O
)	O	PUNCT	O
increased	O	VERB	B
extracellular	O	ADJ	B
dopamine	B-Chemical	NOUN	B
levels	O	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
lower	O	ADJ	B
concentrations	O	NOUN	B
(	O	PUNCT	O
50	O	NUM	O
-	O	PUNCT	O
100	O	NUM	O
microM	O	NOUN	O
)	O	PUNCT	O
were	O	AUX	O
devoid	O	ADJ	O
of	O	ADP	O
any	O	DET	O
effect	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
blockade	O	NOUN	B
of	O	ADP	O
mGluR5	O	NOUN	B
by	O	ADP	O
MPEP	B-Chemical	NOUN	B
may	O	AUX	O
protect	O	VERB	O
dopaminergic	O	ADJ	B
neurones	O	NOUN	B
against	O	ADP	O
methamphetamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
toxicity	B-Disease	NOUN	B
.	O	PUNCT	O


Neuroprotection	O	NOUN	B
rendered	O	VERB	O
by	O	ADP	O
MPEP	B-Chemical	NOUN	B
may	O	AUX	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
reduction	O	NOUN	B
of	O	ADP	O
the	O	DET	O
methamphetamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
dopamine	B-Chemical	NOUN	B
efflux	O	NOUN	B
in	O	ADP	O
the	O	DET	O
striatum	O	NOUN	B
due	O	ADJ	O
to	O	PART	O
the	O	DET	O
blockade	O	NOUN	B
of	O	ADP	O
extrastriatal	O	ADJ	B
mGluR5	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
with	O	ADP	O
a	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
hyperthermia	B-Disease	NOUN	B


Pharmacokinetics	O	NOUN	B
of	O	ADP	O
desipramine	B-Chemical	NOUN	B
HCl	I-Chemical	NOUN	B
when	O	SCONJ	O
administered	O	VERB	B
with	O	ADP	O
cinacalcet	B-Chemical	NOUN	B
HCl	I-Chemical	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
:	O	PUNCT	O
In	O	X	B
vitro	O	X	I
work	O	NOUN	I
has	O	AUX	O
demonstrated	O	VERB	O
that	O	SCONJ	O
cinacalcet	B-Chemical	NOUN	B
is	O	AUX	O
a	O	DET	O
strong	O	ADJ	O
inhibitor	O	NOUN	B
of	O	ADP	O
cytochrome	O	NOUN	B
P450	O	NOUN	I
isoenzyme	O	NOUN	I
(	O	PUNCT	O
CYP	O	NOUN	B
)	O	PUNCT	O
2D6	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
cinacalcet	B-Chemical	NOUN	B
on	O	ADP	O
CYP2D6	O	NOUN	B
activity	O	NOUN	I
,	O	PUNCT	O
using	O	VERB	O
desipramine	B-Chemical	NOUN	B
as	O	ADP	O
a	O	DET	O
probe	O	NOUN	B
substrate	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
healthy	O	ADJ	B
subjects	O	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
Seventeen	O	NUM	O
subjects	O	NOUN	B
who	O	PRON	O
were	O	AUX	O
genotyped	O	VERB	B
as	O	ADP	O
CYP2D6	O	NOUN	B
extensive	O	ADJ	O
metabolizers	O	NOUN	B
were	O	AUX	O
enrolled	O	VERB	O
in	O	ADP	O
this	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
open	O	ADJ	B
-	O	PUNCT	O
label	O	NOUN	B
,	O	PUNCT	O
crossover	O	NOUN	B
study	O	NOUN	I
to	O	PART	O
receive	O	VERB	O
a	O	DET	O
single	O	ADJ	O
oral	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
desipramine	B-Chemical	NOUN	B
(	O	PUNCT	O
50	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
on	O	ADP	O
two	O	NUM	O
separate	O	ADJ	O
occasions	O	NOUN	B
,	O	PUNCT	O
once	O	ADV	O
alone	O	ADV	O
and	O	CCONJ	O
once	O	ADV	O
after	O	ADP	O
multiple	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
cinacalcet	B-Chemical	NOUN	B
(	O	PUNCT	O
90	O	NUM	O
mg	O	NOUN	O
for	O	ADP	O
7	O	NUM	O
days	O	NOUN	B
).	O	PUNCT	O
Blood	O	NOUN	B
samples	O	NOUN	I
were	O	AUX	O
obtained	O	VERB	O
predose	O	NOUN	B
and	O	CCONJ	O
up	O	ADP	O
to	O	PART	O
72	O	NUM	O
h	O	NOUN	O
postdose	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Fourteen	O	NUM	O
subjects	O	NOUN	B
completed	O	VERB	O
both	O	CCONJ	O
treatment	O	NOUN	B
arms	O	NOUN	I
.	O	PUNCT	O


Relative	O	ADJ	O
to	O	PART	O
desipramine	B-Chemical	NOUN	B
alone	O	ADV	O
,	O	PUNCT	O
mean	O	VERB	O
AUC	O	NOUN	B
and	O	CCONJ	O
C	O	NOUN	B
(	O	PUNCT	O
max	O	NOUN	O
)	O	PUNCT	O
of	O	ADP	O
desipramine	B-Chemical	NOUN	B
increased	O	VERB	B
3	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
-	O	PUNCT	O
and	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
-	O	PUNCT	O
fold	O	NOUN	B
when	O	SCONJ	O
coadministered	O	VERB	B
with	O	ADP	O
cinacalcet	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
t	O	NOUN	O
(	O	PUNCT	O
1	O	NUM	O
/	O	SYM	O
2	O	NUM	B
,	O	PUNCT	O
z	O	X	O
)	O	PUNCT	O
of	O	ADP	O
desipramine	B-Chemical	NOUN	B
was	O	AUX	O
longer	O	ADJ	O
when	O	SCONJ	O
desipramine	B-Chemical	NOUN	B
was	O	AUX	O
coadministered	O	VERB	B
with	O	ADP	O
cinacalcet	B-Chemical	NOUN	B
(	O	PUNCT	O
21	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
versus	O	CCONJ	O
43	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
hs	O	NOUN	O
).	O	PUNCT	O
The	O	DET	O
t	O	NOUN	O
(	O	PUNCT	O
max	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
similar	O	ADJ	O
between	O	ADP	O
the	O	DET	O
regimens	O	NOUN	B
.	O	PUNCT	O


Fewer	O	ADJ	O
subjects	O	NOUN	B
reported	O	VERB	O
adverse	O	ADJ	B
events	O	NOUN	I
following	O	VERB	O
treatment	O	NOUN	B
with	O	ADP	O
desipramine	B-Chemical	NOUN	B
alone	O	ADV	O
than	O	ADP	O
when	O	SCONJ	O
receiving	O	VERB	O
desipramine	B-Chemical	NOUN	B
with	O	ADP	O
cinacalcet	B-Chemical	NOUN	B
(	O	PUNCT	O
33	O	NUM	O
versus	O	CCONJ	O
86	O	NUM	O
%),	O	VERB	O
the	O	DET	O
most	O	ADV	O
frequent	O	ADJ	B
of	O	ADP	O
which	O	DET	O
(	O	PUNCT	O
nausea	B-Disease	NOUN	B
and	O	CCONJ	O
headache	B-Disease	NOUN	B
)	O	PUNCT	O
have	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
for	O	ADP	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
either	O	CCONJ	O
desipramine	B-Chemical	NOUN	B
or	O	CCONJ	O
cinacalcet	B-Chemical	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	B
:	O	PUNCT	O
This	O	DET	O
study	O	NOUN	B
demonstrates	O	VERB	O
that	O	SCONJ	O
cinacalcet	B-Chemical	NOUN	B
is	O	AUX	O
a	O	DET	O
strong	O	ADJ	O
inhibitor	O	NOUN	B
of	O	ADP	O
CYP2D6	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
during	O	ADP	O
concomitant	O	ADJ	B
treatment	O	NOUN	B
with	O	ADP	O
cinacalcet	B-Chemical	NOUN	B


Proteomic	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
striatal	O	ADJ	B
proteins	O	NOUN	I
in	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
model	O	NOUN	B
of	O	ADP	O
L-DOPA	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
dyskinesia	B-Disease	NOUN	B
.	O	PUNCT	O


L-DOPA	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
dyskinesia	B-Disease	NOUN	B
(	O	PUNCT	O
LID	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
among	O	ADP	O
the	O	DET	O
motor	O	NOUN	B
complications	O	NOUN	I
that	O	PRON	O
arise	O	VERB	O
in	O	ADP	O
Parkinson's	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
PD	B-Disease	NOUN	B
)	O	PUNCT	O
patients	O	NOUN	B
after	O	ADP	O
a	O	DET	O
prolonged	O	ADJ	B
treatment	O	NOUN	B
with	O	ADP	O
L-DOPA	B-Chemical	NOUN	B
.	O	PUNCT	O


To	O	ADP	O
this	O	DET	O
day	O	NOUN	B
,	O	PUNCT	O
transcriptome	O	NOUN	B
analysis	O	NOUN	I
has	O	AUX	O
been	O	AUX	O
performed	O	VERB	O
in	O	ADP	O
a	O	DET	O
rat	O	NOUN	B
model	O	NOUN	B
of	O	ADP	O
LID	B-Disease	NOUN	B
[	O	PUNCT	O
Neurobiol	O	PROPN	B
.	O	PUNCT	O


Dis	O	PROPN	O
.,	O	NOUN	O
17	O	NUM	O
(	O	PUNCT	O
2004	O	NUM	O
),	O	PUNCT	O
219	O	NUM	O
]	O	PUNCT	O
but	O	CCONJ	O
information	O	NOUN	B
regarding	O	VERB	O
the	O	DET	O
proteome	O	NOUN	B
is	O	AUX	O
still	O	ADV	O
lacking	O	VERB	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
investigated	O	VERB	B
the	O	DET	O
changes	O	NOUN	B
occurring	O	VERB	B
at	O	ADP	O
the	O	DET	O
protein	O	NOUN	B
level	O	NOUN	B
in	O	ADP	O
striatal	O	ADJ	B
samples	O	NOUN	I
obtained	O	VERB	O
from	O	ADP	O
the	O	DET	O
unilaterally	O	ADV	B
6-hydroxydopamine	B-Chemical	NOUN	B
-	O	PUNCT	O
lesion	O	NOUN	B
rat	O	NOUN	B
model	O	NOUN	B
of	O	ADP	O
PD	B-Disease	NOUN	B
treated	O	VERB	B
with	O	ADP	I
saline	O	NOUN	B
,	O	PUNCT	O
L-DOPA	B-Chemical	NOUN	B
or	O	CCONJ	O
bromocriptine	B-Chemical	NOUN	B
using	O	VERB	O
two	O	NUM	O
-	O	PUNCT	O
dimensional	O	ADJ	B
difference	O	NOUN	O
gel	O	NOUN	O
electrophoresis	O	NOUN	O
and	O	CCONJ	O
mass	O	ADJ	B
spectrometry	O	NOUN	I
(	O	PUNCT	O
MS	O	NOUN	B
).	O	PUNCT	O
Rats	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
L-DOPA	B-Chemical	NOUN	B
were	O	AUX	O
allocated	O	VERB	O
to	O	ADP	O
two	O	NUM	O
groups	O	NOUN	B
based	O	VERB	O
on	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
or	O	CCONJ	O
absence	O	NOUN	B
of	O	ADP	O
LID	B-Disease	NOUN	B
.	O	PUNCT	O


Among	O	ADP	O
the	O	DET	O
2000	O	NUM	O
spots	O	NOUN	B
compared	O	VERB	B
for	O	ADP	O
statistical	O	ADJ	B
difference	O	NOUN	I
,	O	PUNCT	O
67	O	NUM	O
spots	O	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
changed	O	VERB	B
in	O	ADP	O
abundance	O	NOUN	B
and	O	CCONJ	O
identified	O	VERB	B
using	O	VERB	O
matrix	O	NOUN	B
-	O	PUNCT	O
assisted	O	VERB	B
laser	O	NOUN	B
desorption	O	NOUN	I
/	O	SYM	O
ionization	O	NOUN	B
time	O	NOUN	I
-	O	PUNCT	O
of	O	ADP	O
-	O	PUNCT	O
flight	O	NOUN	B
MS	O	NOUN	B
,	O	PUNCT	O
atmospheric	O	ADJ	B
pressure	O	NOUN	I
matrix	O	NOUN	I
-	O	PUNCT	O
assisted	O	VERB	B
laser	O	NOUN	B
desorption	O	NOUN	I
/	O	SYM	O
ionization	O	NOUN	B
and	O	CCONJ	O
HPLC	O	NOUN	B
coupled	O	VERB	I
tandem	O	ADJ	I
MS	O	NOUN	I
(	O	PUNCT	O
LC	O	NOUN	B
/	O	SYM	O
MS	O	PROPN	B
/	O	SYM	O
MS	O	NOUN	B
).	O	PUNCT	O
Out	O	ADP	O
of	O	ADP	O
these	O	DET	O
67	O	NUM	O
proteins	O	NOUN	B
,	O	PUNCT	O
LID	B-Disease	PROPN	B
significantly	O	ADV	O
changed	O	VERB	B
the	O	DET	O
expression	O	NOUN	B
level	O	NOUN	B
of	O	ADP	O
five	O	NUM	O
proteins	O	NOUN	B
:	O	PUNCT	O
alphabeta	O	NOUN	B
-	O	PUNCT	O
crystalin	O	NOUN	B
,	O	PUNCT	O
gamma	O	NOUN	B
-	O	PUNCT	O
enolase	O	NOUN	B
,	O	PUNCT	O
guanidoacetate	O	NOUN	B
methyltransferase	O	NOUN	I
,	O	PUNCT	O
vinculin	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
proteasome	O	NOUN	B
alpha	O	NOUN	I
-	O	PUNCT	O
2	O	NUM	O
subunit	O	NOUN	B
.	O	PUNCT	O


Complementary	O	ADJ	B
techniques	O	NOUN	I
such	O	ADJ	O
as	O	ADP	O
western	O	ADJ	B
immunoblotting	O	NOUN	I
and	O	CCONJ	O
immunohistochemistry	O	NOUN	B
were	O	AUX	O
performed	O	VERB	O
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
validity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
data	O	NOUN	B
obtained	O	VERB	O
using	O	VERB	O
the	O	DET	O
proteomic	O	ADJ	B
approach	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
this	O	DET	O
study	O	NOUN	B
provides	O	VERB	O
new	O	ADJ	O
insights	O	NOUN	O
into	O	ADP	O
the	O	DET	O
protein	O	NOUN	B
changes	O	NOUN	B
occurring	O	VERB	O
in	O	ADP	O
LID	B-Disease	NOUN	B


Pseudo	O	ADJ	B
-	O	PUNCT	O
allergic	B-Disease	ADJ	B
reactions	I-Disease	NOUN	I
to	O	ADP	O
corticosteroids	B-Chemical	NOUN	B
:	O	PUNCT	O
diagnosis	O	NOUN	B
and	O	CCONJ	O
alternatives	O	NOUN	B
.	O	PUNCT	O


Two	O	NUM	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
parenteral	O	ADJ	B
paramethasone	B-Chemical	NOUN	I
(	O	PUNCT	O
Triniol	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
dexamethasone	B-Chemical	NOUN	B
(	O	PUNCT	O
Sedionbel	O	NOUN	B
)	O	PUNCT	O
are	O	AUX	O
described	O	VERB	O
.	O	PUNCT	O


A	O	DET	O
few	O	ADJ	O
minutes	O	NOUN	O
after	O	ADP	O
administration	O	NOUN	B
of	O	ADP	O
the	O	DET	O
drugs	O	NOUN	B
,	O	PUNCT	O
they	O	PRON	O
presented	O	VERB	O
urticaria	B-Disease	NOUN	B
(	O	PUNCT	O
patients	O	NOUN	B
1	O	NUM	O
and	O	CCONJ	O
2	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
conjunctivitis	B-Disease	NOUN	B
(	O	PUNCT	O
patient	O	NOUN	B
1	O	NUM	O
).	O	PUNCT	O
The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
our	O	PRON	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
cause	O	NOUN	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
'	O	PART	O
reactions	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
immunological	O	ADJ	B
mechanisms	O	NOUN	B
involved	O	VERB	O
and	O	CCONJ	O
whether	O	SCONJ	O
these	O	DET	O
patients	O	NOUN	B
would	O	AUX	O
be	O	AUX	O
able	O	ADJ	O
to	O	PART	O
tolerate	O	VERB	O
any	O	DET	O
kind	O	NOUN	O
of	O	ADP	O
corticoid	O	NOUN	B
.	O	PUNCT	O


Clinical	O	ADJ	B
examinations	O	NOUN	I
and	O	CCONJ	O
skin	O	NOUN	B
,	O	PUNCT	O
oral	O	ADJ	B
and	O	CCONJ	O
parenteral	O	ADJ	B
challenges	O	NOUN	B
with	O	ADP	O
different	O	ADJ	O
corticosteroids	B-Chemical	NOUN	B
and	O	CCONJ	O
ELISA	O	NOUN	B
tests	O	NOUN	I
were	O	AUX	O
performed	O	VERB	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
two	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
skin	O	NOUN	B
and	O	CCONJ	O
ELISA	O	NOUN	B
tests	O	NOUN	B
with	O	ADP	O
paramethasone	B-Chemical	NOUN	B
were	O	AUX	O
negative	O	ADJ	B
,	O	PUNCT	O
as	O	ADP	O
was	O	AUX	O
the	O	DET	O
prick	O	NOUN	B
test	O	NOUN	I
with	O	ADP	O
each	O	DET	O
of	O	ADP	O
its	O	PRON	O
excipients	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
single	O	ADJ	B
-	O	PUNCT	O
blind	O	ADJ	B
parenteral	O	ADJ	B
challenge	O	NOUN	O
with	O	ADP	O
Triniol	O	NOUN	B
was	O	AUX	O
positive	O	ADJ	B
in	O	ADP	O
both	O	DET	O
patients	O	NOUN	B
after	O	ADP	O
the	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
1	O	NUM	O
ml	O	NOUN	O
of	O	ADP	O
the	O	DET	O
drug	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
negative	O	ADJ	B
with	O	ADP	O
its	O	PRON	O
excipients	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
also	O	ADV	O
carried	O	VERB	O
out	O	ADP	O
oral	O	ADJ	B
and	O	CCONJ	O
parenteral	O	ADJ	B
challenges	O	NOUN	B
with	O	ADP	O
other	O	ADJ	O
corticosteroids	B-Chemical	NOUN	B
and	O	CCONJ	O
found	O	VERB	O
intolerance	O	NOUN	B
to	O	ADP	O
some	O	DET	O
of	O	ADP	O
them	O	PRON	O
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
paramethasone	B-Chemical	NOUN	B
caused	O	VERB	O
pseudoallergic	O	ADJ	B
reactions	O	NOUN	I
in	O	ADP	O
our	O	PRON	O
patients	O	NOUN	B
.	O	PUNCT	O


Corticosteroids	O	NOUN	B
different	O	ADJ	O
from	O	ADP	O
paramethasone	B-Chemical	NOUN	B
also	O	ADV	O
produced	O	VERB	O
hypersensitivity	B-Disease	NOUN	B
reactions	O	NOUN	I
in	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
a	O	DET	O
few	O	ADJ	O
of	O	ADP	O
them	O	PRON	O
were	O	AUX	O
tolerated	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
basic	O	ADJ	O
mechanisms	O	NOUN	B
of	O	ADP	O
those	O	DET	O
reactions	O	NOUN	B
are	O	AUX	O
not	O	PART	O
yet	O	ADV	O
fully	O	ADV	O
understood	O	VERB	O
.	O	PUNCT	O


To	O	ADP	O
our	O	PRON	O
knowledge	O	NOUN	B
,	O	PUNCT	O
this	O	DET	O
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
report	O	NOUN	O
of	O	ADP	O
a	O	DET	O
pseudo	O	ADJ	B
-	O	PUNCT	O
allergy	B-Disease	NOUN	B
caused	O	VERB	O
by	O	ADP	O
paramethasone	B-Chemical	NOUN	B


Valproic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
induced	O	VERB	B
encephalopathy	B-Disease	NOUN	B
--	O	PUNCT	O
19	O	NUM	O
new	O	ADJ	O
cases	O	NOUN	B
in	O	ADP	O
Germany	O	PROPN	B
from	O	ADP	O
1994	O	NUM	O
to	O	PART	O
2003	O	NUM	O
--	O	PUNCT	O
a	O	DET	O
side	O	NOUN	B
effect	O	NOUN	I
associated	O	VERB	B
to	O	PART	I
VPA	B-Chemical	NOUN	B
-	O	PUNCT	O
therapy	O	NOUN	B
not	O	PART	O
only	O	ADV	O
in	O	ADP	O
young	O	ADJ	B
children	O	NOUN	B
.	O	PUNCT	O


Valproic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
(	O	PUNCT	O
VPA	B-Chemical	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
broad	O	ADJ	B
-	O	PUNCT	O
spectrum	O	NOUN	B
antiepileptic	O	ADJ	B
drug	O	NOUN	I
and	O	CCONJ	O
is	O	AUX	O
usually	O	ADV	O
well	O	ADV	O
-	O	PUNCT	O
tolerated	O	VERB	B
.	O	PUNCT	O


Rare	O	ADJ	B
serious	O	ADJ	O
complications	O	NOUN	B
may	O	AUX	O
occur	O	VERB	O
in	O	ADP	O
some	O	DET	O
patients	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
haemorrhagic	O	ADJ	B
pancreatitis	B-Disease	NOUN	I
,	O	PUNCT	O
bone	B-Disease	NOUN	B
marrow	I-Disease	NOUN	I
suppression	I-Disease	NOUN	I
,	O	PUNCT	O
VPA	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hepatotoxicity	B-Disease	NOUN	B
and	O	CCONJ	O
VPA	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
encephalopathy	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
typical	O	ADJ	O
signs	O	NOUN	O
of	O	ADP	O
VPA	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
encephalopathy	B-Disease	NOUN	B
are	O	AUX	O
impaired	B-Disease	ADJ	B
consciousness	I-Disease	NOUN	B
,	O	PUNCT	O
sometimes	O	ADV	O
marked	O	ADJ	O
EEG	O	NOUN	B
background	O	NOUN	B
slowing	O	NOUN	I
,	O	PUNCT	O
increased	O	VERB	B
seizure	B-Disease	NOUN	B
frequency	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
or	O	CCONJ	O
without	O	ADP	O
hyperammonemia	B-Disease	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
is	O	AUX	O
still	O	ADV	O
no	O	DET	O
proof	O	NOUN	O
of	O	ADP	O
causative	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
VPA	B-Chemical	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
encephalopathy	B-Disease	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
only	O	ADV	O
of	O	ADP	O
an	O	DET	O
association	O	NOUN	B
with	O	ADP	O
an	O	DET	O
assumed	O	ADJ	O
causal	O	ADJ	O
relation	O	NOUN	O
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
19	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
VPA	B-Chemical	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
encephalopathy	B-Disease	NOUN	B


Haemolytic-uraemic	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
after	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
metronidazole	B-Chemical	NOUN	B
.	O	PUNCT	O


This	O	DET	O
paper	O	NOUN	B
describes	O	VERB	O
the	O	DET	O
clinical	O	ADJ	B
features	O	NOUN	I
of	O	ADP	O
six	O	NUM	O
children	O	NOUN	B
who	O	PRON	O
developed	O	VERB	O
the	O	DET	O
haemolytic-uraemic	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
after	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
metronidazole	B-Chemical	NOUN	B
.	O	PUNCT	O


These	O	DET	O
children	O	NOUN	B
were	O	AUX	O
older	O	ADJ	B
and	O	CCONJ	O
were	O	AUX	O
more	O	ADV	O
likely	O	ADJ	O
to	O	PART	O
have	O	AUX	O
undergone	O	VERB	O
recent	O	ADJ	O
bowel	O	NOUN	B
surgery	O	NOUN	I
than	O	ADP	O
are	O	AUX	O
other	O	ADJ	O
children	O	NOUN	B
with	O	ADP	O
this	O	DET	O
condition	O	NOUN	B
.	O	PUNCT	O


While	O	SCONJ	O
the	O	DET	O
involvement	O	NOUN	B
of	O	ADP	O
metronidazole	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
aetiology	O	NOUN	B
of	O	ADP	O
the	O	DET	O
haemolytic-uraemic	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
is	O	AUX	O
not	O	PART	O
established	O	VERB	O
firmly	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
action	O	NOUN	B
of	O	ADP	O
this	O	DET	O
drug	O	NOUN	B
in	O	ADP	O
sensitizing	O	VERB	B
tissues	O	NOUN	I
to	O	PART	O
oxidation	O	NOUN	B
injury	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
reported	O	VERB	O
evidence	O	NOUN	B
of	O	ADP	O
oxidation	O	NOUN	B
changes	O	NOUN	B
in	O	ADP	O
the	O	DET	O
haemolytic-uraemic	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
suggest	O	VERB	O
a	O	DET	O
possible	O	ADJ	O
link	O	NOUN	O
between	O	ADP	O
metronidazole	B-Chemical	NOUN	B
treatment	O	NOUN	B
and	O	CCONJ	O
some	O	DET	O
cases	O	NOUN	B
of	O	ADP	O
the	O	DET	O
haemolytic-uraemic	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I


Risk	O	NOUN	B
factors	O	NOUN	I
of	O	ADP	O
sensorineural	B-Disease	ADJ	B
hearing	I-Disease	NOUN	I
loss	I-Disease	NOUN	I
in	O	ADP	O
preterm	O	NOUN	B
infants	O	NOUN	I
.	O	PUNCT	O


Among	O	ADP	O
547	O	NUM	O
preterm	O	NOUN	B
infants	O	NOUN	I
of	O	ADP	O
<	O	X	O
or	O	CCONJ	O
=	O	ADJ	O
34	O	NUM	O
weeks	O	NOUN	B
gestation	O	NOUN	B
born	O	VERB	B
between	O	ADP	O
1987	O	NUM	O
and	O	CCONJ	O
1991	O	NUM	O
,	O	PUNCT	O
8	O	NUM	O
children	O	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


46	O	NUM	O
%)	O	NOUN	O
developed	O	VERB	O
severe	O	ADJ	B
progressive	O	ADJ	B
and	O	CCONJ	O
bilateral	O	ADJ	B
sensorineural	B-Disease	ADJ	O
hearing	I-Disease	NOUN	O
loss	I-Disease	NOUN	O
.	O	PUNCT	O


Perinatal	O	ADJ	B
risk	O	NOUN	I
factors	O	NOUN	I
of	O	ADP	O
infants	O	NOUN	B
with	O	ADP	O
hearing	B-Disease	VERB	B
loss	I-Disease	NOUN	I
were	O	AUX	O
compared	O	VERB	B
with	O	ADP	O
those	O	DET	O
of	O	ADP	O
two	O	NUM	O
control	O	NOUN	B
groups	O	NOUN	I
matched	O	VERB	O
for	O	ADP	O
gestation	O	NOUN	B
and	O	CCONJ	O
birth	O	NOUN	B
weight	O	NOUN	I
and	O	CCONJ	O
for	O	ADP	O
perinatal	O	ADJ	B
complications	O	NOUN	I
.	O	PUNCT	O


Our	O	PRON	O
observations	O	NOUN	B
demonstrated	O	VERB	O
an	O	DET	O
association	O	NOUN	B
of	O	ADP	O
hearing	B-Disease	VERB	B
loss	I-Disease	NOUN	I
with	O	ADP	O
a	O	DET	O
higher	O	ADJ	O
incidence	O	NOUN	B
of	O	ADP	O
perinatal	O	ADJ	B
complications	O	NOUN	I
.	O	PUNCT	O


Ototoxicity	B-Disease	NOUN	B
appeared	O	VERB	O
closely	O	ADV	O
related	O	ADJ	O
to	O	PART	O
a	O	DET	O
prolonged	O	ADJ	B
administration	O	NOUN	B
and	O	CCONJ	O
higher	O	ADJ	O
total	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
ototoxic	B-Disease	ADJ	B
drugs	O	NOUN	I
,	O	PUNCT	O
particularly	O	ADV	O
aminoglycosides	B-Chemical	NOUN	B
and	O	CCONJ	O
furosemide	B-Chemical	NOUN	B
.	O	PUNCT	O


Finally	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
strongly	O	ADV	O
recommend	O	VERB	O
to	O	PART	O
prospectively	O	ADV	B
and	O	CCONJ	O
regularly	O	ADV	O
perform	O	VERB	O
audiologic	O	ADJ	B
assessment	O	NOUN	I
in	O	ADP	O
sick	O	ADJ	B
preterm	O	NOUN	I
children	O	NOUN	I
as	O	ADP	O
hearing	B-Disease	VERB	B
loss	I-Disease	NOUN	I


Pharmacokinetic	O	ADJ	B
and	O	CCONJ	O
clinical	O	ADJ	B
studies	O	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
cimetidine	B-Chemical	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
mental	O	ADJ	B
confusion	B-Disease	NOUN	I
.	O	PUNCT	O


15	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
cimetidine	B-Chemical	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
mental	O	ADJ	B
confusion	B-Disease	NOUN	I
have	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
.	O	PUNCT	O


In	O	ADP	O
order	O	NOUN	O
that	O	SCONJ	O
this	O	DET	O
syndrome	O	NOUN	B
might	O	AUX	O
be	O	AUX	O
investigated	O	VERB	B
changes	O	NOUN	B
in	O	ADP	O
mental	O	ADJ	B
status	O	NOUN	I
(	O	PUNCT	O
M	O	NOUN	B
.	O	PUNCT	O


S	O	NOUN	B
.)	O	PUNCT	O
were	O	AUX	O
correlated	O	VERB	B
with	O	ADP	O
serum	O	NOUN	B
concentrations	O	NOUN	I
and	O	CCONJ	O
renal	O	ADJ	B
and	O	CCONJ	O
hepatic	O	ADJ	B
function	O	NOUN	I
in	O	ADP	O
36	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
30	O	NUM	O
patients	O	NOUN	B
had	O	AUX	O
no	O	DET	B
M	O	NOUN	I
.	O	PUNCT	O


S	O	NOUN	B
.	O	PUNCT	O


change	O	NOUN	O
on	O	ADP	O
cimetidine	B-Chemical	NOUN	B
and	O	CCONJ	O
6	O	NUM	O
had	O	AUX	O
moderate	O	ADJ	B
to	O	PART	O
severe	O	ADJ	B
changes	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
6	O	NUM	O
patients	O	NOUN	B
had	O	AUX	O
both	O	CCONJ	O
renal	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
liver	I-Disease	NOUN	B
dysfunction	I-Disease	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
),	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
cimetidine	B-Chemical	NOUN	B
trough	O	NOUN	B
-	O	PUNCT	O
concentrations	O	NOUN	B
of	O	ADP	O
more	O	ADJ	O
than	O	ADP	O
1	O	NUM	O
.	O	PUNCT	O


25	O	NUM	O
microgram	O	NOUN	B
/	O	SYM	O
ml	O	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
).	O	PUNCT	O
The	O	DET	O
severity	O	NOUN	B
of	O	ADP	O
M	O	NOUN	B
.	O	PUNCT	O


S	O	NOUN	B
.	O	PUNCT	O


changes	O	NOUN	B
increased	O	VERB	B
as	O	ADP	O
trough	O	NOUN	B
-	O	PUNCT	O
concentrations	O	NOUN	B
rose	O	VERB	B
,	O	PUNCT	O
5	O	NUM	O
patients	O	NOUN	B
had	O	AUX	O
lumbar	O	ADJ	B
puncture	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
cerebrospinal	O	ADJ	B
fluid	O	NOUN	I
:	O	PUNCT	O
serum	O	NOUN	B
ratio	O	NOUN	I
of	O	ADP	O
cimetidine	B-Chemical	NOUN	B
concentrations	O	NOUN	B
was	O	AUX	O
0	O	NUM	O
.	O	PUNCT	O


24	O	NUM	O
:	O	PUNCT	O
1	O	NUM	O
and	O	CCONJ	O
indicates	O	VERB	O
that	O	SCONJ	O
cimetidine	B-Chemical	NOUN	B
passes	O	VERB	O
the	O	DET	O
blood	O	NOUN	B
-	O	PUNCT	O
brain	O	NOUN	B
barrier	O	NOUN	I
;	O	PUNCT	O
it	O	PRON	O
also	O	ADV	O
raises	O	VERB	O
the	O	DET	O
possibility	O	NOUN	O
that	O	SCONJ	O
M	O	NOUN	B
.	O	PUNCT	O


S	O	NOUN	B
.	O	PUNCT	O


changes	O	NOUN	B
are	O	AUX	O
due	O	ADJ	O
to	O	PART	O
blockade	O	NOUN	B
of	O	ADP	O
histamine	B-Chemical	NOUN	B
H2	O	NOUN	I
-	O	PUNCT	O
receptors	O	NOUN	B
in	O	ADP	O
the	O	DET	O
central	O	ADJ	B
nervous	O	ADJ	I
system	O	NOUN	I
.	O	PUNCT	O


Patients	O	NOUN	B
likely	O	ADJ	O
to	O	PART	O
have	O	AUX	O
both	O	DET	O
raised	O	VERB	O
trough	O	NOUN	B
-	O	PUNCT	O
concentrations	O	NOUN	B
and	O	CCONJ	O
mental	O	ADJ	B
confusion	B-Disease	NOUN	I
are	O	AUX	O
those	O	DET	O
with	O	ADP	O
both	O	CCONJ	O
severe	O	ADJ	B
renal	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
hepatic	I-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
.	O	PUNCT	O


They	O	PRON	O
should	O	AUX	O
be	O	AUX	O
closely	O	ADV	O
observed	O	VERB	B
and	O	CCONJ	O
should	O	AUX	O
be	O	AUX	O
given	O	VERB	O
reduced	O	VERB	B
doses	O	NOUN	I
of	O	ADP	O
cimetidine	B-Chemical	NOUN	B


Different	O	ADJ	O
lobular	O	ADJ	B
distributions	O	NOUN	B
of	O	ADP	O
altered	O	ADJ	O
hepatocyte	O	NOUN	B
tight	O	NOUN	B
junctions	O	NOUN	I
in	O	ADP	O
rat	O	NOUN	B
models	O	NOUN	B
of	O	ADP	O
intrahepatic	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
extrahepatic	I-Disease	ADJ	B
cholestasis	I-Disease	NOUN	I
.	O	PUNCT	O


Hepatocyte	O	NOUN	B
tight	O	ADJ	O
junctions	O	NOUN	O
(	O	PUNCT	O
TJs	O	NOUN	B
),	O	PUNCT	O
the	O	DET	O
only	O	ADJ	O
intercellular	O	ADJ	B
barrier	O	NOUN	I
between	O	ADP	O
the	O	DET	O
sinusoidal	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
canalicular	O	ADJ	B
spaces	O	NOUN	B
,	O	PUNCT	O
play	O	VERB	O
a	O	DET	O
key	O	ADJ	O
role	O	NOUN	O
in	O	ADP	O
bile	O	NOUN	B
formation	O	NOUN	I
.	O	PUNCT	O


Although	O	SCONJ	O
hepatocyte	O	NOUN	B
TJs	O	NOUN	B
are	O	AUX	O
impaired	O	ADJ	B
in	O	ADP	O
cholestasis	B-Disease	NOUN	B
,	O	PUNCT	O
attempts	O	VERB	O
to	O	PART	O
localize	O	VERB	B
the	O	DET	O
precise	O	ADJ	O
site	O	NOUN	B
of	O	ADP	O
hepatocyte	O	NOUN	B
TJ	O	NOUN	B
damage	O	NOUN	B
by	O	ADP	O
freeze	O	NOUN	B
-	O	PUNCT	O
fracture	O	NOUN	B
electron	O	NOUN	I
microscopy	O	NOUN	I
have	O	AUX	O
produced	O	VERB	O
limited	O	ADJ	O
information	O	NOUN	B
.	O	PUNCT	O


Recently	O	ADV	O
,	O	PUNCT	O
several	O	ADJ	O
TJ	O	PROPN	B
-	O	PUNCT	O
associated	O	VERB	B
proteins	O	NOUN	B
like	O	ADP	O
ZO	O	PROPN	B
-	O	PUNCT	O
1	O	NUM	B
and	O	CCONJ	O
7H6	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
identified	O	VERB	B
and	O	CCONJ	O
characterized	O	VERB	B
.	O	PUNCT	O


Immunolocalization	O	NOUN	B
of	O	ADP	O
7H6	O	NOUN	B
appears	O	VERB	O
to	O	PART	O
closely	O	ADV	O
correlate	O	VERB	B
with	O	ADP	O
paracellular	O	ADJ	B
permeability	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
used	O	VERB	O
rat	O	NOUN	B
models	O	NOUN	B
of	O	ADP	O
intrahepatic	B-Disease	ADJ	B
cholestasis	I-Disease	NOUN	I
by	O	ADP	O
ethinyl	B-Chemical	NOUN	B
estradiol	I-Chemical	NOUN	I
(	O	PUNCT	O
EE	B-Chemical	NOUN	B
)	O	PUNCT	O
treatment	O	NOUN	B
and	O	CCONJ	O
extrahepatic	B-Disease	ADJ	B
cholestasis	I-Disease	NOUN	I
by	O	ADP	O
bile	O	NOUN	B
duct	O	NOUN	I
ligation	O	NOUN	I
(	O	PUNCT	O
BDL	O	NOUN	B
)	O	PUNCT	O
to	O	PART	O
precisely	O	ADV	O
determine	O	VERB	O
the	O	DET	O
site	O	NOUN	B
of	O	ADP	O
TJ	O	ADJ	B
damage	O	NOUN	B
.	O	PUNCT	O


Alterations	O	NOUN	B
in	O	ADP	O
hepatocyte	O	NOUN	B
TJs	O	NOUN	B
were	O	AUX	O
assessed	O	VERB	B
by	O	ADP	O
double	O	ADJ	B
-	O	PUNCT	O
immunolabeling	O	NOUN	B
for	O	ADP	O
7H6	O	NOUN	B
and	O	CCONJ	O
ZO	O	PROPN	B
-	O	PUNCT	O
1	O	NUM	O
using	O	VERB	O
a	O	DET	O
confocal	O	ADJ	B
laser	O	NOUN	I
scanning	O	NOUN	I
microscope	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
control	O	ADJ	B
rats	O	NOUN	B
,	O	PUNCT	O
immunostaining	O	NOUN	B
for	O	ADP	O
7H6	O	NOUN	B
and	O	CCONJ	O
ZO	O	PROPN	B
-	O	PUNCT	O
1	O	NUM	O
colocalized	O	VERB	B
to	O	PART	O
outline	O	VERB	O
bile	O	NOUN	B
canaliculi	O	NOUN	I
in	O	ADP	O
a	O	DET	O
continuous	O	ADJ	B
fashion	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
7H6	O	NOUN	B
and	O	CCONJ	O
ZO	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	B
immunostaining	O	NOUN	B
was	O	AUX	O
more	O	ADV	O
discontinuous	O	ADJ	B
,	O	PUNCT	O
outlining	O	VERB	O
the	O	DET	O
bile	O	NOUN	B
canaliculi	O	NOUN	I
after	O	ADP	O
BDL	O	NOUN	B
.	O	PUNCT	O


Immunostaining	O	NOUN	B
for	O	ADP	O
7H6	O	NOUN	B
,	O	PUNCT	O
not	O	PART	O
ZO	O	PROPN	B
-	O	PUNCT	O
1	O	NUM	O
,	O	PUNCT	O
decreased	O	VERB	B
and	O	CCONJ	O
predominantly	O	ADV	O
appeared	O	VERB	O
as	O	ADP	O
discrete	O	ADJ	O
signals	O	NOUN	B
in	O	ADP	O
the	O	DET	O
submembranous	O	ADJ	B
cytoplasm	O	NOUN	I
of	O	ADP	O
periportal	O	ADJ	B
hepatocytes	O	NOUN	B
after	O	ADP	O
BDL	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
EE	B-Chemical	ADJ	B
treatment	O	NOUN	B
,	O	PUNCT	O
changes	O	NOUN	B
in	O	ADP	O
immunostaining	O	NOUN	B
for	O	ADP	O
7H6	O	NOUN	B
and	O	CCONJ	O
ZO	O	PROPN	B
-	O	PUNCT	O
1	O	NUM	O
were	O	AUX	O
similar	O	ADJ	O
to	O	PART	O
those	O	DET	O
seen	O	VERB	O
in	O	ADP	O
periportal	O	ADJ	B
hepatocytes	O	NOUN	B
after	O	ADP	O
BDL	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
distributed	O	VERB	O
more	O	ADV	O
diffusely	O	ADV	B
throughout	O	ADP	O
the	O	DET	O
lobule	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
to	O	PART	O
demonstrate	O	VERB	O
that	O	SCONJ	O
impairment	O	NOUN	B
of	O	ADP	O
hepatocyte	O	NOUN	B
TJs	O	NOUN	B
occurs	O	VERB	O
heterogenously	O	ADV	B
in	O	ADP	O
the	O	DET	O
liver	O	NOUN	B
lobule	O	NOUN	I
after	O	ADP	O
BDL	O	NOUN	B
and	O	CCONJ	O
suggests	O	VERB	O
that	O	SCONJ	O
BDL	O	NOUN	B
and	O	CCONJ	O
EE	B-Chemical	NOUN	B


Long	O	ADJ	B
term	O	NOUN	I
audiological	O	ADJ	B
evaluation	O	NOUN	B
of	O	ADP	O
beta-thalassemic	B-Disease	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
objective	O	NOUN	B
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
identify	O	VERB	O
the	O	DET	O
incidence	O	NOUN	B
and	O	CCONJ	O
to	O	PART	O
monitor	O	VERB	B
the	O	DET	O
progression	O	NOUN	B
of	O	ADP	O
hearing	B-Disease	VERB	B
loss	I-Disease	NOUN	I
in	O	ADP	O
children	O	NOUN	B
and	O	CCONJ	O
young	O	ADJ	B
adults	O	NOUN	I
with	O	ADP	O
beta-thalassemia	B-Disease	ADJ	B
major	O	ADJ	O
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
One	O	NUM	O
hundred	O	NUM	O
and	O	CCONJ	O
four	O	NUM	O
(	O	PUNCT	O
104	O	NUM	O
)	O	PUNCT	O
patients	O	NOUN	B
aged	O	ADJ	B
6	O	NUM	O
-	O	SYM	O
35	O	NUM	O
years	O	NOUN	B
(	O	PUNCT	O
mean	O	NOUN	O
17	O	NUM	O
,	O	PUNCT	O
2	O	NUM	O
years	O	NOUN	B
)	O	PUNCT	O
participated	O	VERB	O
in	O	ADP	O
the	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
on	O	ADP	O
a	O	DET	O
regular	O	ADJ	O
transfusion	O	NOUN	B
-	O	PUNCT	O
chelation	O	NOUN	B
program	O	NOUN	I
maintaining	O	VERB	O
a	O	DET	O
mean	O	ADJ	O
hemoglobin	O	NOUN	B
level	O	NOUN	I
of	O	ADP	O
9	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
gr	O	NOUN	O
/	O	SYM	O
dl	O	PROPN	B
.	O	PUNCT	O


Subjects	O	NOUN	B
were	O	AUX	O
receiving	O	VERB	O
desferrioxamine	B-Chemical	NOUN	B
(	O	PUNCT	O
DFO	B-Chemical	NOUN	B
)	O	PUNCT	O
chelation	O	NOUN	B
treatment	O	NOUN	I
with	O	ADP	O
a	O	DET	O
mean	O	ADJ	O
daily	O	ADJ	O
dose	O	NOUN	O
of	O	ADP	O
50	O	NUM	O
-	O	PUNCT	O
60	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
5	O	NUM	O
-	O	SYM	O
6	O	NUM	O
days	O	NOUN	B
a	O	DET	O
week	O	NOUN	B
during	O	ADP	O
the	O	DET	O
first	O	ADJ	O
six	O	NUM	O
years	O	NOUN	B
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
was	O	AUX	O
then	O	ADV	O
reduced	O	VERB	B
to	O	ADP	O
40	O	NUM	O
-	O	SYM	O
50	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
kg	O	NOUN	O
for	O	ADP	O
the	O	DET	O
following	O	VERB	O
eight	O	NUM	O
years	O	NOUN	B
.	O	PUNCT	O


Patients	O	NOUN	B
were	O	AUX	O
followed	O	VERB	O
for	O	ADP	O
8	O	NUM	O
-	O	PUNCT	O
14	O	NUM	O
years	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Overall	O	ADV	O
,	O	PUNCT	O
21	O	NUM	O
out	O	ADP	O
of	O	ADP	O
104	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
20	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
%)	O	NOUN	O
presented	O	VERB	O
with	O	ADP	O
high	O	ADJ	O
frequency	O	NOUN	O
sensorineural	B-Disease	ADJ	O
hearing	I-Disease	NOUN	O
loss	I-Disease	NOUN	O
(	O	PUNCT	O
SNHL	B-Disease	NOUN	B
),	O	PUNCT	O
either	O	CCONJ	O
unilateral	O	ADJ	B
or	O	CCONJ	O
bilateral	O	ADJ	B
.	O	PUNCT	O


No	O	DET	O
ototoxic	B-Disease	ADJ	B
factor	O	NOUN	I
,	O	PUNCT	O
other	O	ADJ	O
than	O	ADP	O
DFO	B-Chemical	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
any	O	DET	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
.	O	PUNCT	O


Patients	O	NOUN	B
with	O	ADP	O
SNHL	B-Disease	NOUN	B
presented	O	VERB	O
with	O	ADP	O
relatively	O	ADV	O
lower	O	ADJ	O
serum	O	NOUN	B
ferritin	O	NOUN	I
levels	O	NOUN	I
than	O	ADP	O
those	O	DET	O
with	O	ADP	O
normal	O	ADJ	B
hearing	O	NOUN	I
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
no	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
difference	O	NOUN	O
was	O	AUX	O
observed	O	VERB	B
.	O	PUNCT	O


Subjects	O	NOUN	B
with	O	ADP	O
SNHL	B-Disease	NOUN	B
were	O	AUX	O
submitted	O	VERB	O
to	O	PART	O
DFO	B-Chemical	NOUN	B
reduction	O	NOUN	B
or	O	CCONJ	O
temporary	O	ADJ	B
withdrawal	O	NOUN	B
.	O	PUNCT	O


Following	O	VERB	O
intervention	O	NOUN	B
,	O	PUNCT	O
7	O	NUM	O
out	O	ADP	O
of	O	ADP	O
21	O	NUM	O
affected	O	VERB	B
patients	O	NOUN	B
recovered	O	VERB	B
,	O	PUNCT	O
10	O	NUM	O
remained	O	VERB	O
stable	O	ADJ	B
and	O	CCONJ	O
4	O	NUM	O
demonstrated	O	VERB	O
aggravation	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
findings	O	NOUN	B
are	O	AUX	O
indicative	O	ADJ	O
of	O	ADP	O
DFO	B-Chemical	NOUN	B
'	O	PART	O
s	O	NOUN	O
contributing	O	VERB	O
role	O	NOUN	O
in	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
hearing	B-Disease	VERB	B
impairment	I-Disease	NOUN	I
.	O	PUNCT	O


Regular	O	ADJ	B
audiologic	O	ADJ	B
evaluation	O	NOUN	B
is	O	AUX	O
imperative	O	ADJ	O
in	O	ADP	O
all	O	DET	O
thalassemic	B-Disease	ADJ	B
patients	O	NOUN	B
so	O	SCONJ	O
that	O	SCONJ	O
early	O	ADJ	B
changes	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
recognized	O	VERB	O
and	O	CCONJ	O
treatment	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
judiciously	O	ADV	O
adjusted	O	VERB	O
in	O	ADP	O
order	O	NOUN	O
to	O	PART	O
prevent	O	VERB	B
or	O	CCONJ	O
reverse	O	ADJ	B
hearing	B-Disease	NOUN	I
impairment	I-Disease	NOUN	I


Design	O	NOUN	B
and	O	CCONJ	O
analysis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
HYPREN	O	ADJ	B
-	O	PUNCT	O
trial	O	NOUN	B
:	O	PUNCT	O
safety	O	NOUN	B
of	O	ADP	O
enalapril	B-Chemical	NOUN	B
and	O	CCONJ	O
prazosin	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
initial	O	ADJ	B
treatment	O	NOUN	B
phase	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
congestive	B-Disease	ADJ	B
heart	I-Disease	NOUN	I
failure	I-Disease	NOUN	I
.	O	PUNCT	O


Since	O	SCONJ	O
the	O	DET	O
introduction	O	NOUN	B
of	O	ADP	O
angiotensin	B-Chemical	NOUN	B
converting	I-Chemical	NOUN	I
enzyme	I-Chemical	NOUN	B
(ACE)	I-Chemical	NOUN	O
inhibitors	I-Chemical	NOUN	B
into	O	ADP	O
the	O	DET	O
adjunctive	O	ADJ	B
treatment	O	NOUN	I
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
congestive	B-Disease	ADJ	B
heart	I-Disease	NOUN	I
failure	I-Disease	NOUN	I
,	O	PUNCT	O
cases	O	NOUN	B
of	O	ADP	O
severe	O	ADJ	B
hypotension	B-Disease	NOUN	B
,	O	PUNCT	O
especially	O	ADV	O
on	O	ADP	O
the	O	DET	O
first	O	ADJ	O
day	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
,	O	PUNCT	O
have	O	AUX	O
occasionally	O	ADV	O
been	O	AUX	O
reported	O	VERB	O
.	O	PUNCT	O


To	O	PART	O
assess	O	VERB	O
the	O	DET	O
safety	O	NOUN	B
of	O	ADP	O
the	O	DET	O
ACE	B-Chemical	NOUN	B
inhibitor	I-Chemical	NOUN	I
enalapril	B-Chemical	NOUN	B
a	O	DET	O
multicenter	O	NOUN	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
prazosin	B-Chemical	NOUN	B
-	O	PUNCT	O
controlled	O	VERB	B
trial	O	NOUN	I
was	O	AUX	O
designed	O	VERB	O
that	O	SCONJ	O
compared	O	VERB	B
the	O	DET	O
incidence	O	NOUN	B
and	O	CCONJ	O
severity	O	NOUN	B
of	O	ADP	O
symptomatic	O	ADJ	B
hypotension	B-Disease	NOUN	B
on	O	ADP	O
the	O	DET	O
first	O	ADJ	O
day	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


Trial	O	ADJ	B
medication	O	NOUN	O
was	O	AUX	O
2	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
enalapril	B-Chemical	NOUN	B
or	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
prazosin	B-Chemical	NOUN	B
.	O	PUNCT	O


Subjects	O	NOUN	B
were	O	AUX	O
1210	O	NUM	O
inpatients	O	NOUN	B
with	O	ADP	O
New	O	PROPN	B
York	O	PROPN	I
Heart	O	PROPN	I
Association	O	PROPN	I
(	O	PUNCT	O
NYHA	O	NOUN	B
)	O	PUNCT	O
functional	O	ADJ	O
class	O	NOUN	O
II	O	NUM	O
and	O	CCONJ	O
III	O	NUM	B
.	O	PUNCT	O


Patients	O	NOUN	B
who	O	PRON	O
received	O	VERB	O
enalapril	B-Chemical	NOUN	B
experienced	O	VERB	O
clinically	O	ADV	B
and	O	CCONJ	O
statistically	O	ADV	B
significantly	O	ADV	O
less	O	ADV	O
symptomatic	O	ADJ	B
hypotension	B-Disease	NOUN	B
(	O	PUNCT	O
5	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
%)	O	NOUN	O
than	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
who	O	PRON	O
received	O	VERB	O
prazosin	B-Chemical	NOUN	B
(	O	PUNCT	O
12	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
%).	O	VERB	O
All	O	DET	O
patients	O	NOUN	B
recovered	O	VERB	B
.	O	PUNCT	O


It	O	PRON	O
was	O	AUX	O
concluded	O	VERB	O
that	O	SCONJ	O
treatment	O	NOUN	B
with	O	ADP	O
enalapril	B-Chemical	NOUN	B
was	O	AUX	O
well	O	ADV	O
tolerated	O	VERB	B
and	O	CCONJ	O
it	O	PRON	O
is	O	AUX	O
,	O	PUNCT	O
therefore	O	ADV	O
,	O	PUNCT	O
unreasonable	O	ADJ	O
to	O	PART	O
restrict	O	VERB	O
the	O	DET	O
initiation	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
enalapril	B-Chemical	NOUN	B


Antagonism	O	NOUN	B
between	O	ADP	O
interleukin	O	NOUN	B
3	O	NUM	I
and	O	CCONJ	O
erythropoietin	O	NOUN	B
in	O	ADP	O
mice	O	NOUN	B
with	O	ADP	O
azidothymidine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
anemia	B-Disease	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
bone	O	NOUN	B
marrow	O	NOUN	I
endothelial	O	ADJ	I
cells	O	NOUN	I
.	O	PUNCT	O


Azidothymidine	B-Chemical	NOUN	B
(	O	PUNCT	O
AZT	B-Chemical	NOUN	B
)-	O	ADJ	O
induced	O	VERB	B
anemia	B-Disease	NOUN	B
in	O	ADP	O
mice	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
reversed	O	VERB	O
by	O	ADP	O
the	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
IGF	O	PROPN	B
-	O	PUNCT	O
IL	O	PROPN	B
-	O	PUNCT	O
3	O	NUM	B
(	O	PUNCT	O
fusion	O	NOUN	B
protein	O	NOUN	I
of	O	ADP	O
insulin	O	NOUN	B
-	O	PUNCT	O
like	O	ADJ	B
growth	O	NOUN	B
factor	O	NOUN	I
II	O	NUM	I
(	O	PUNCT	O
IGF	O	NOUN	B
II	O	NUM	I
)	O	PUNCT	O
and	O	CCONJ	O
interleukin	O	NOUN	B
3	O	NUM	I
).	O	PUNCT	O
Although	O	SCONJ	O
interleukin	O	NOUN	B
3	O	NUM	I
(	O	PUNCT	O
IL	O	NOUN	B
-	O	PUNCT	O
3	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
erythropoietin	O	NOUN	B
(	O	PUNCT	O
EPO	O	NOUN	B
)	O	PUNCT	O
are	O	AUX	O
known	O	VERB	O
to	O	PART	O
act	O	VERB	O
synergistically	O	ADV	B
on	O	ADP	O
hematopoietic	O	ADJ	B
cell	O	NOUN	I
proliferation	O	NOUN	O
in	O	X	B
vitro	O	X	I
,	O	PUNCT	O
injection	O	NOUN	B
of	O	ADP	O
IGF	O	NOUN	B
-	O	PUNCT	O
IL	O	PROPN	B
-	O	PUNCT	O
3	O	NUM	B
and	O	CCONJ	O
EPO	O	NOUN	B
in	O	ADP	O
AZT	B-Chemical	PROPN	B
-	O	PUNCT	O
treated	O	VERB	B
mice	O	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
a	O	DET	O
reduction	O	NOUN	B
of	O	ADP	O
red	O	ADJ	B
cells	O	NOUN	I
and	O	CCONJ	O
an	O	DET	O
increase	O	NOUN	B
of	O	ADP	O
plasma	O	NOUN	B
EPO	O	NOUN	B
levels	O	NOUN	B
as	O	ADP	O
compared	O	VERB	O
to	O	ADP	O
animals	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
IGF	O	NOUN	B
-	O	PUNCT	O
IL	O	PROPN	B
-	O	PUNCT	O
3	O	NUM	B
or	O	CCONJ	O
EPO	O	NOUN	B
alone	O	ADV	O
.	O	PUNCT	O


We	O	PRON	O
tested	O	VERB	B
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
the	O	DET	O
antagonistic	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
IL	O	NOUN	B
-	O	PUNCT	O
3	O	NUM	B
and	O	CCONJ	O
EPO	O	NOUN	B
on	O	ADP	O
erythroid	O	ADJ	B
cells	O	NOUN	I
may	O	AUX	O
be	O	AUX	O
mediated	O	VERB	O
by	O	ADP	O
endothelial	O	ADJ	B
cells	O	NOUN	I
.	O	PUNCT	O


Bovine	O	ADJ	B
liver	O	NOUN	B
erythroid	O	ADJ	I
cells	O	NOUN	I
were	O	AUX	O
cultured	O	VERB	B
on	O	ADP	O
monolayers	O	NOUN	B
of	O	ADP	O
human	O	ADJ	B
bone	O	NOUN	O
marrow	O	NOUN	O
endothelial	O	ADJ	O
cells	O	NOUN	O
previously	O	ADV	O
treated	O	VERB	B
with	O	ADP	I
EPO	O	NOUN	B
and	O	CCONJ	O
IGF	O	NOUN	B
-	O	PUNCT	O
IL	O	PROPN	B
-	O	PUNCT	O
3	O	NUM	B
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
a	O	DET	O
significant	O	ADJ	O
reduction	O	NOUN	B
of	O	ADP	O
thymidine	B-Chemical	NOUN	B
incorporation	O	NOUN	B
into	O	ADP	O
both	O	CCONJ	O
erythroid	O	ADJ	B
and	O	CCONJ	O
endothelial	O	ADJ	B
cells	O	NOUN	I
in	O	ADP	O
cultures	O	NOUN	B
pre	O	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
with	O	ADP	O
IGF	O	NOUN	B
-	O	PUNCT	O
IL	O	PROPN	B
-	O	PUNCT	O
3	O	NUM	B
and	O	CCONJ	O
EPO	O	NOUN	B
.	O	PUNCT	O


Endothelial	O	ADJ	B
cell	O	NOUN	I
culture	O	NOUN	O
supernatants	O	NOUN	B
separated	O	VERB	O
by	O	ADP	O
ultrafiltration	O	NOUN	B
and	O	CCONJ	O
ultracentrifugation	O	NOUN	B
from	O	ADP	O
cells	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
EPO	O	NOUN	B
and	O	CCONJ	O
IL	O	NOUN	B
-	O	PUNCT	O
3	O	NUM	O
significantly	O	ADV	O
reduced	O	VERB	B
thymidine	B-Chemical	NOUN	B


Interactive	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
variations	O	NOUN	B
in	O	ADP	O
[	O	PUNCT	O
Na	B-Chemical	NOUN	B
]	O	PUNCT	O
o	O	NOUN	O
and	O	CCONJ	O
[	O	PUNCT	O
Ca	B-Chemical	PROPN	B
]	O	PUNCT	O
o	O	NOUN	O
on	O	ADP	O
rat	O	NOUN	B
atrial	O	ADJ	B
spontaneous	O	ADJ	O
frequency	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
varying	O	VERB	B
the	O	DET	O
extracellular	O	ADJ	B
concentrations	O	NOUN	B
of	O	ADP	O
Na	B-Chemical	NOUN	B
and	O	CCONJ	O
Ca	B-Chemical	VERB	B
([	O	PUNCT	O
Na	B-Chemical	NOUN	B
]	O	PUNCT	O
o	O	NOUN	O
and	O	CCONJ	O
[	O	PUNCT	O
Ca	B-Chemical	AUX	B
]	O	PUNCT	O
o	O	X	O
)	O	PUNCT	O
on	O	ADP	O
both	O	DET	O
,	O	PUNCT	O
the	O	DET	O
spontaneous	O	ADJ	B
beating	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
negative	O	ADJ	B
chronotropic	O	ADJ	B
action	O	NOUN	I
of	O	ADP	O
verapamil	B-Chemical	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
studied	O	VERB	O
in	O	ADP	O
the	O	DET	O
isolated	O	VERB	B
rat	O	NOUN	B
atria	O	NOUN	B
.	O	PUNCT	O


Basal	O	ADJ	B
frequency	O	NOUN	I
(	O	PUNCT	O
BF	O	NOUN	B
)	O	PUNCT	O
evaluated	O	VERB	B
by	O	ADP	O
surface	O	NOUN	B
electrogram	O	NOUN	B
was	O	AUX	O
223	O	NUM	O
+/-	O	CCONJ	O
4	O	NUM	O
beats	O	NOUN	B
/	O	SYM	O
min	O	NOUN	B
.	O	PUNCT	O


in	O	ADP	O
control	O	ADJ	B
Krebs	O	PROPN	B
-	O	PUNCT	O
Ringer	O	NOUN	B
containing	O	VERB	O
137	O	NUM	O
mM	O	NOUN	O
Na	B-Chemical	NOUN	B
and	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


35	O	NUM	O
mM	O	NOUN	O
Ca	B-Chemical	NOUN	B
(	O	PUNCT	O
N	O	NOUN	O
).	O	PUNCT	O
It	O	PRON	O
decreased	O	VERB	B
by	O	ADP	O
16	O	NUM	O
+/-	O	CCONJ	O
3	O	NUM	O
%	O	NOUN	O
by	O	ADP	O
lowering	O	VERB	B
[	O	PUNCT	O
Na	B-Chemical	NOUN	B
]	O	PUNCT	O
o	O	NOUN	O
to	O	PART	O
78	O	NUM	O
mM	O	NOUN	O
(	O	PUNCT	O
LNa	O	NOUN	B
),	O	PUNCT	O
23	O	NUM	O
+/-	O	CCONJ	O
2	O	NUM	O
%	O	NOUN	O
by	O	ADP	O
lowering	O	VERB	B
simultaneously	O	ADV	B
[	O	PUNCT	O
Na	B-Chemical	NOUN	B
]	O	PUNCT	O
o	O	NOUN	O
to	O	PART	O
78	O	NUM	O
mM	O	NOUN	O
and	O	CCONJ	O
[	O	PUNCT	O
Ca	B-Chemical	PROPN	B
]	O	PUNCT	O
o	O	NOUN	O
to	O	PART	O
0	O	NUM	O
.	O	PUNCT	O


675	O	NUM	O
mM	O	NOUN	O
(	O	PUNCT	O
LNa	O	NOUN	B
+	O	CCONJ	O
LCa	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
31	O	NUM	O
+/-	O	CCONJ	O
5	O	NUM	O
%	O	NOUN	O
by	O	ADP	O
lowering	O	VERB	B
[	O	PUNCT	O
Na	B-Chemical	NOUN	B
]	O	PUNCT	O
o	O	NOUN	O
to	O	PART	O
78	O	NUM	O
mM	O	NOUN	O
plus	O	CCONJ	O
increasing	O	VERB	B
[	O	PUNCT	O
Ca	B-Chemical	NOUN	B
]	O	PUNCT	O
o	O	X	O
to	O	PART	O
3	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
mM	O	NOUN	O
(	O	PUNCT	O
LNa	O	NOUN	B
+	O	CCONJ	O
HCa	O	NOUN	B
).	O	PUNCT	O
At	O	ADP	O
normal	O	ADJ	B
[	O	PUNCT	O
Na	B-Chemical	NOUN	B
]	O	PUNCT	O
o	O	NOUN	O
,	O	PUNCT	O
decrease	O	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


675	O	NUM	O
mM	O	NOUN	O
)	O	PUNCT	O
or	O	CCONJ	O
increase	O	VERB	B
(	O	PUNCT	O
3	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
mM	O	NOUN	O
)	O	PUNCT	O
of	O	ADP	O
[	O	PUNCT	O
Ca	B-Chemical	PROPN	B
]	O	PUNCT	O
o	O	NOUN	O
did	O	AUX	O
not	O	PART	O
modify	O	VERB	B
BF	O	NOUN	B
;	O	PUNCT	O
a	O	DET	O
reduction	O	NOUN	B
of	O	ADP	O
ten	O	NUM	O
times	O	NOUN	O
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


135	O	NUM	O
mM	O	NOUN	O
of	O	ADP	O
normal	O	ADJ	B
[	O	PUNCT	O
Ca	B-Chemical	NOUN	B
]	O	PUNCT	O
o	O	NOUN	O
was	O	AUX	O
effective	O	ADJ	B
to	O	PART	O
reduce	O	VERB	B
BF	O	NOUN	B
by	O	ADP	O
40	O	NUM	O
+/-	O	CCONJ	O
13	O	NUM	O
%.	O	NOUN	O
All	O	DET	O
negative	O	ADJ	B
chronotropic	O	ADJ	B
effects	O	NOUN	I
were	O	AUX	O
BF	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
.	O	PUNCT	O


Dose	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
bradycardia	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
verapamil	B-Chemical	NOUN	B
was	O	AUX	O
potentiated	O	VERB	B
by	O	ADP	O
LNa	O	NOUN	B
,	O	PUNCT	O
LCa	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
HCa	O	NOUN	B
.	O	PUNCT	O


Independent	O	ADJ	B
but	O	CCONJ	O
not	O	PART	O
additive	O	ADJ	O
effects	O	NOUN	O
of	O	ADP	O
Na	B-Chemical	NOUN	B
and	O	CCONJ	O
Ca	B-Chemical	AUX	B
are	O	AUX	O
shown	O	VERB	O
by	O	ADP	O
decreases	O	NOUN	B
in	O	ADP	O
the	O	DET	O
values	O	NOUN	B
of	O	ADP	O
[	O	PUNCT	O
verapamil	B-Chemical	NOUN	B
]	O	PUNCT	O
o	O	NOUN	O
needed	O	VERB	O
to	O	PART	O
reduce	O	VERB	B
BF	O	NOUN	B
by	O	ADP	O
30	O	NUM	O
%(	O	NOUN	O
IC30	O	NOUN	B
)	O	PUNCT	O
with	O	ADP	O
the	O	DET	O
following	O	ADJ	O
order	O	NOUN	O
of	O	ADP	O
inhibitory	O	ADJ	B
potency	O	NOUN	B
:	O	PUNCT	O
LNa	O	X	B
>	O	PUNCT	O
LCa	O	NOUN	B
>	O	X	O
HCa	O	X	B
>	O	X	O
N	O	NOUN	B
,	O	PUNCT	O
resulting	O	VERB	O
LNa	O	NOUN	B
+	O	CCONJ	O
HCa	O	NOUN	B
similar	O	ADJ	O
to	O	PART	O
LNa	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
[	O	PUNCT	O
verapamil	B-Chemical	NOUN	B
]	O	PUNCT	O
o	O	NOUN	O
that	O	PRON	O
arrested	O	VERB	B
atrial	O	ADJ	B
beating	O	NOUN	I
(	O	PUNCT	O
AC	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
also	O	ADV	O
potentiated	O	VERB	B
with	O	ADP	O
the	O	DET	O
order	O	NOUN	O
LNa	O	NOUN	B
=	O	ADJ	O
LNa	O	NOUN	B
+	O	CCONJ	O
LCa	O	NOUN	B
=	O	VERB	O
LNa	O	NOUN	B
+	O	CCONJ	O
HCa	O	NOUN	B
=	O	ADJ	O
LCa	O	NOUN	B
>	O	X	O
HCa	O	NOUN	B
=	O	ADJ	O
N	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
rat	O	NOUN	B
atrial	O	ADJ	B
spontaneous	O	ADJ	B
beating	O	NOUN	O
is	O	AUX	O
more	O	ADV	O
dependent	O	ADJ	B
on	O	ADP	O
[	O	PUNCT	O
Na	B-Chemical	PROPN	B
]	O	PUNCT	O
o	O	NOUN	O
than	O	ADP	O
on	O	ADP	O
[	O	PUNCT	O
Ca	B-Chemical	PROPN	B
]	O	PUNCT	O
o	O	NOUN	O
in	O	ADP	O
a	O	DET	O
range	O	NOUN	O
of	O	ADP	O
+/-	O	CCONJ	O
50	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
their	O	PRON	O
normal	O	ADJ	B
concentration	O	NOUN	I
.	O	PUNCT	O


Also	O	ADV	O
the	O	DET	O
enhancement	O	NOUN	B
of	O	ADP	O
verapamil	B-Chemical	NOUN	B


Sodium	B-Chemical	NOUN	B
status	O	NOUN	I
influences	O	VERB	O
chronic	O	ADJ	B
amphotericin	B-Chemical	NOUN	I
B	I-Chemical	NOUN	I
nephrotoxicity	B-Disease	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
nephrotoxic	B-Disease	ADJ	B
potential	O	NOUN	B
of	O	ADP	O
amphotericin	B-Chemical	NOUN	B
B	I-Chemical	NOUN	I
(	O	PUNCT	O
5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
per	O	ADP	O
day	O	NOUN	B
intraperitoneally	O	ADV	B
for	O	ADP	O
3	O	NUM	O
weeks	O	NOUN	B
)	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
investigated	O	VERB	B
in	O	ADP	O
salt	O	NOUN	B
-	O	PUNCT	O
depleted	O	VERB	B
,	O	PUNCT	O
normal	O	ADJ	B
-	O	PUNCT	O
salt	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
salt	O	NOUN	B
-	O	PUNCT	O
loaded	O	VERB	B
rats	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
salt	O	NOUN	B
-	O	PUNCT	O
depleted	O	VERB	B
rats	O	NOUN	B
,	O	PUNCT	O
amphotericin	B-Chemical	NOUN	B
B	I-Chemical	NOUN	I
decreased	O	VERB	B
creatinine	B-Chemical	NOUN	B
clearance	O	NOUN	B
linearly	O	ADV	O
with	O	ADP	O
time	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
an	O	DET	O
85	O	NUM	O
%	O	NOUN	O
reduction	O	NOUN	B
by	O	ADP	O
week	O	NOUN	B
3	O	NUM	O
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
in	O	ADP	O
normal	O	ADJ	B
-	O	PUNCT	O
salt	O	NOUN	B
rats	O	NOUN	B
creatinine	B-Chemical	NOUN	B
clearance	O	NOUN	B
was	O	AUX	O
decreased	O	VERB	B
but	O	CCONJ	O
to	O	ADP	O
a	O	DET	O
lesser	O	ADJ	B
extent	O	NOUN	B
at	O	ADP	O
week	O	NOUN	B
2	O	NUM	O
and	O	CCONJ	O
3	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
salt	O	NOUN	B
-	O	PUNCT	O
loaded	O	VERB	B
rats	O	NOUN	B
creatinine	B-Chemical	NOUN	B
clearance	O	NOUN	B
did	O	AUX	O
not	O	PART	O
change	O	VERB	O
for	O	ADP	O
2	O	NUM	O
weeks	O	NOUN	B
and	O	CCONJ	O
was	O	AUX	O
decreased	O	VERB	B
by	O	ADP	O
43	O	NUM	O
%	O	NOUN	O
at	O	ADP	O
week	O	NOUN	B
3	O	NUM	O
.	O	PUNCT	O


All	O	DET	O
rats	O	NOUN	B
in	O	ADP	O
the	O	DET	O
sodium	B-Chemical	NOUN	B
-	O	PUNCT	O
depleted	O	VERB	B
group	O	NOUN	B
had	O	AUX	O
histopathological	O	ADJ	B
evidence	O	NOUN	B
of	O	ADP	O
patchy	O	ADJ	B
tubular	O	ADJ	B
cytoplasmic	O	ADJ	I
degeneration	O	NOUN	I
in	O	ADP	O
tubules	O	NOUN	B
that	O	PRON	O
was	O	AUX	O
not	O	PART	O
observed	O	VERB	O
in	O	ADP	O
any	O	DET	O
normal	O	ADJ	B
-	O	PUNCT	O
salt	O	NOUN	B
or	O	CCONJ	O
salt	O	NOUN	B
-	O	PUNCT	O
loaded	O	VERB	B
rat	O	NOUN	B
.	O	PUNCT	O


Concentrations	O	NOUN	B
of	O	ADP	O
amphotericin	B-Chemical	NOUN	B
B	I-Chemical	NOUN	I
in	O	ADP	O
plasma	O	NOUN	B
were	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
different	O	ADJ	O
among	O	ADP	O
the	O	DET	O
three	O	NUM	O
groups	O	NOUN	B
at	O	ADP	O
any	O	DET	O
time	O	NOUN	O
during	O	ADP	O
the	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
3	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
amphotericin	B-Chemical	NOUN	B
B	I-Chemical	NOUN	I
levels	O	NOUN	B
in	O	ADP	O
the	O	DET	O
kidneys	O	NOUN	B
and	O	CCONJ	O
liver	O	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
in	O	ADP	O
salt	O	NOUN	B
-	O	PUNCT	O
depleted	O	VERB	B
and	O	CCONJ	O
normal	O	ADJ	B
-	O	PUNCT	O
salt	O	NOUN	B
rats	O	NOUN	B
than	O	ADP	O
those	O	DET	O
in	O	ADP	O
salt	O	NOUN	B
-	O	PUNCT	O
loaded	O	VERB	B
rats	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
plasma	O	NOUN	B
/	O	SYM	O
kidney	O	NOUN	B
ratios	O	NOUN	B
of	O	ADP	O
21	O	NUM	O
,	O	PUNCT	O
14	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
8	O	NUM	O
in	O	ADP	O
salt	O	NOUN	B
-	O	PUNCT	O
depleted	O	VERB	B
,	O	PUNCT	O
normal	O	ADJ	B
-	O	PUNCT	O
salt	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
salt	O	NOUN	B
-	O	PUNCT	O
loaded	O	VERB	B
rats	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
reductions	O	NOUN	B
in	O	ADP	O
creatinine	B-Chemical	NOUN	B
clearance	O	NOUN	B
and	O	CCONJ	O
renal	O	ADJ	B
amphotericin	B-Chemical	NOUN	I
B	I-Chemical	NOUN	I
accumulation	O	NOUN	B
after	O	ADP	O
chronic	O	ADJ	B
amphotericin	B-Chemical	NOUN	I
B	I-Chemical	NOUN	I
administration	O	NOUN	B
were	O	AUX	O
enhanced	O	VERB	B
by	O	ADP	O
salt	O	NOUN	B
depletion	O	NOUN	I
and	O	CCONJ	O
attenuated	O	VERB	B
by	O	ADP	O
sodium	B-Chemical	NOUN	B


Reversible	O	ADJ	B
inferior	B-Disease	ADJ	B
colliculus	I-Disease	NOUN	I
lesion	I-Disease	NOUN	I
in	O	ADP	O
metronidazole	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
encephalopathy	B-Disease	NOUN	B
:	O	PUNCT	O
magnetic	O	ADJ	B
resonance	O	NOUN	I
findings	O	NOUN	I
on	O	ADP	O
diffusion	O	NOUN	B
-	O	PUNCT	O
weighted	O	VERB	B
and	O	CCONJ	O
fluid	O	NOUN	B
attenuated	O	VERB	B
inversion	O	NOUN	B
recovery	O	NOUN	I
imaging	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
:	O	PUNCT	O
This	O	DET	O
is	O	AUX	O
to	O	PART	O
present	O	VERB	O
reversible	O	ADJ	B
inferior	B-Disease	ADJ	B
colliculus	I-Disease	NOUN	I
lesions	I-Disease	NOUN	I
in	O	ADP	O
metronidazole	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
encephalopathy	B-Disease	NOUN	B
,	O	PUNCT	O
to	O	PART	O
focus	O	VERB	O
on	O	ADP	O
the	O	DET	O
diffusion	O	NOUN	B
-	O	PUNCT	O
weighted	O	VERB	B
imaging	O	NOUN	I
(	O	PUNCT	O
DWI	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
fluid	O	NOUN	B
attenuated	O	VERB	O
inversion	O	NOUN	O
recovery	O	NOUN	O
(	O	PUNCT	O
FLAIR	O	NOUN	B
)	O	PUNCT	O
imaging	O	NOUN	O
.	O	PUNCT	O


MATERIALS	O	NOUN	O
AND	O	CCONJ	O
METHODS	O	NOUN	O
:	O	PUNCT	O
From	O	ADP	O
November	O	PROPN	O
2005	O	NUM	O
to	O	ADP	O
September	O	PROPN	O
2007	O	NUM	O
,	O	PUNCT	O
8	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
5	O	NUM	O
men	O	NOUN	B
and	O	CCONJ	O
3	O	NUM	O
women	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
diagnosed	O	VERB	B
as	O	ADP	O
having	O	VERB	O
metronidazole	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
encephalopathy	B-Disease	NOUN	B
(	O	PUNCT	O
age	O	NOUN	B
range	O	NOUN	O
;	O	PUNCT	O
43	O	NUM	O
-	O	SYM	O
78	O	NUM	O
years	O	NOUN	B
).	O	PUNCT	B
They	O	PRON	O
had	O	AUX	O
been	O	AUX	O
taking	O	VERB	O
metronidazole	B-Chemical	NOUN	B
(	O	PUNCT	O
total	O	ADJ	B
dosage	O	NOUN	I
,	O	PUNCT	O
45	O	NUM	O
-	O	SYM	O
120	O	NUM	O
g	O	NOUN	O
;	O	PUNCT	O
duration	O	NOUN	B
,	O	PUNCT	O
30	O	NUM	O
days	O	NOUN	B
to	O	PART	O
2	O	NUM	O
months	O	NOUN	B
)	O	PUNCT	O
to	O	PART	O
treat	O	VERB	B
the	O	DET	O
infection	B-Disease	NOUN	B
in	O	ADP	O
various	O	ADJ	O
organs	O	NOUN	B
.	O	PUNCT	O


Initial	O	ADJ	O
brain	O	NOUN	B
magnetic	O	ADJ	B
resonance	O	NOUN	I
imaging	O	NOUN	I
(	O	PUNCT	O
MRI	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
obtained	O	VERB	O
after	O	ADP	O
the	O	DET	O
hospitalization	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
DWI	O	PROPN	B
(	O	PUNCT	O
8	O	NUM	O
/	O	SYM	O
8	O	NUM	O
),	O	PUNCT	O
apparent	O	ADJ	B
diffusion	O	NOUN	I
coefficient	O	NOUN	I
(	O	PUNCT	O
ADC	O	NOUN	B
)	O	PUNCT	O
map	O	NOUN	B
(	O	PUNCT	O
4	O	NUM	O
/	O	SYM	O
8	O	NUM	B
),	O	PUNCT	O
FLAIR	O	NOUN	B
(	O	PUNCT	O
7	O	NUM	O
/	O	SYM	O
8	O	NUM	B
),	O	PUNCT	O
and	O	CCONJ	O
T2	O	NOUN	B
-	O	PUNCT	O
weighted	O	VERB	B
image	O	NOUN	B
(	O	PUNCT	O
8	O	NUM	O
/	O	SYM	O
8	O	NUM	B
).	O	PROPN	O
Follow	O	PROPN	B
-	O	PUNCT	O
up	O	ADP	B
MRIs	O	NOUN	B
were	O	AUX	O
performed	O	VERB	O
on	O	ADP	O
5	O	NUM	O
patients	O	NOUN	B
from	O	ADP	O
third	O	ADJ	O
to	O	PART	O
14th	O	ADJ	O
days	O	NOUN	B
after	O	ADP	O
discontinuation	O	NOUN	B
of	O	ADP	O
metronidazole	B-Chemical	ADJ	B
administration	O	NOUN	B
.	O	PUNCT	O


Findings	O	NOUN	B
of	O	ADP	O
initial	O	ADJ	B
and	O	CCONJ	O
follow	O	VERB	B
-	O	PUNCT	O
up	O	ADP	B
MRIs	O	NOUN	B
were	O	AUX	O
retrospectively	O	ADV	B
evaluated	O	VERB	I
by	O	ADP	O
2	O	NUM	O
neuroradiologists	O	NOUN	B
by	O	ADP	O
consensus	O	NOUN	B
,	O	PUNCT	O
to	O	PART	O
analyze	O	VERB	B
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
abnormal	O	ADJ	B
signal	O	NOUN	O
intensities	O	NOUN	O
,	O	PUNCT	O
their	O	PRON	O
locations	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
signal	O	NOUN	B
changes	O	NOUN	B
on	O	ADP	O
follow	O	NOUN	B
-	O	PUNCT	O
up	O	ADP	O
images	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Initial	O	ADJ	O
MRIs	O	NOUN	B
showed	O	VERB	O
abnormal	O	ADJ	B
high	O	ADJ	O
signal	O	NOUN	O
intensities	O	NOUN	O
on	O	ADP	O
DWI	O	NOUN	B
and	O	CCONJ	O
FLAIR	O	PROPN	B
(	O	PUNCT	O
or	O	CCONJ	O
T2	O	NOUN	B
-	O	PUNCT	O
weighted	O	VERB	B
image	O	NOUN	B
)	O	PUNCT	O
at	O	ADP	O
the	O	DET	O
dentate	O	NOUN	B
nucleus	O	NOUN	I
(	O	PUNCT	O
8	O	NUM	O
/	O	SYM	O
8	O	NUM	B
),	O	PUNCT	O
inferior	O	ADJ	B
colliculus	O	NOUN	I
(	O	PUNCT	O
6	O	NUM	O
/	O	SYM	O
8	O	NUM	O
),	O	PUNCT	O
corpus	O	NOUN	B
callosum	O	NOUN	I
(	O	PUNCT	O
2	O	NUM	O
/	O	SYM	O
8	O	NUM	O
),	O	PUNCT	O
pons	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
/	O	SYM	O
8	O	NUM	B
),	O	PUNCT	O
medulla	O	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
/	O	SYM	O
8	O	NUM	B
),	O	PUNCT	O
and	O	CCONJ	O
bilateral	O	ADJ	B
cerebral	O	ADJ	B
white	O	ADJ	I
matter	O	NOUN	I
(	O	PUNCT	O
1	O	NUM	O
/	O	SYM	O
8	O	NUM	B
).	O	PUNCT	O
High	O	ADJ	B
-	O	PUNCT	O
signal	O	NOUN	B
intensity	O	NOUN	O
lesions	O	NOUN	O
on	O	ADP	O
DWI	O	NOUN	B
tended	O	VERB	O
to	O	PART	O
show	O	VERB	O
low	O	ADJ	B
signal	O	NOUN	O
intensity	O	NOUN	O
on	O	ADP	O
ADC	O	NOUN	B
map	O	NOUN	B
(	O	PUNCT	O
3	O	NUM	O
/	O	SYM	O
4	O	NUM	B
),	O	PUNCT	O
but	O	CCONJ	O
in	O	ADP	O
one	O	NUM	O
patient	O	NOUN	B
,	O	PUNCT	O
high	O	ADJ	B
signal	O	NOUN	O
intensity	O	NOUN	O
was	O	AUX	O
shown	O	VERB	O
at	O	ADP	O
bilateral	O	ADJ	B
dentate	O	NOUN	O
nuclei	O	NOUN	O
on	O	ADP	O
not	O	PART	O
only	O	ADV	O
DWI	O	NOUN	B
but	O	CCONJ	O
also	O	ADV	O
ADC	O	NOUN	B
map	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
the	O	DET	O
lesions	O	NOUN	B
in	O	ADP	O
dentate	O	NOUN	B
,	O	PUNCT	O
inferior	O	ADJ	B
colliculus	O	NOUN	I
,	O	PUNCT	O
pons	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
medullas	O	NOUN	B
had	O	AUX	O
been	O	AUX	O
resolved	O	VERB	B
completely	O	ADV	O
on	O	ADP	O
follow	O	NOUN	B
-	O	PUNCT	O
up	O	ADP	B
MRIs	O	NOUN	B
in	O	ADP	O
5	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
in	O	ADP	O
1	O	NUM	O
patient	O	NOUN	B
of	O	ADP	O
them	O	PRON	O
,	O	PUNCT	O
corpus	O	NOUN	B
callosal	B-Disease	ADJ	B
lesion	I-Disease	NOUN	B
persisted	O	VERB	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
Reversible	O	ADJ	B
inferior	B-Disease	ADJ	B
colliculus	I-Disease	NOUN	I
lesions	I-Disease	NOUN	I
could	O	AUX	O
be	O	AUX	O
considered	O	VERB	O
as	O	ADP	O
the	O	DET	O
characteristic	O	NOUN	B
for	O	ADP	O
metronidazole	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
encephalopathy	B-Disease	NOUN	B


Comparison	O	NOUN	B
of	O	ADP	O
the	O	DET	O
respiratory	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
i	O	PRON	O
.	O	PUNCT	O


v	O	NOUN	O
.	O	PUNCT	O


infusions	O	NOUN	B
of	O	ADP	O
morphine	B-Chemical	NOUN	B
and	O	CCONJ	O
regional	O	ADJ	B
analgesia	O	NOUN	I
by	O	ADP	O
extradural	O	ADJ	B
block	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
postoperative	O	ADJ	B
respiratory	O	ADJ	B
apnoea	B-Disease	NOUN	I
was	O	AUX	O
compared	O	VERB	O
between	O	ADP	O
five	O	NUM	O
patients	O	NOUN	B
receiving	O	VERB	O
a	O	DET	O
continuous	O	ADJ	B
i	O	NOUN	O
.	O	PUNCT	O


v	O	NOUN	O
.	O	PUNCT	O


infusion	O	NOUN	B
of	O	ADP	O
morphine	B-Chemical	NOUN	B
(	O	PUNCT	O
mean	O	NOUN	O
73	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
five	O	NUM	O
patients	O	NOUN	B
receiving	O	VERB	O
a	O	DET	O
continuous	O	ADJ	B
extradural	O	ADJ	B
infusion	O	NOUN	B
of	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


25	O	NUM	O
%	O	NOUN	O
bupivacaine	B-Chemical	NOUN	B
(	O	PUNCT	O
mean	O	NOUN	O
192	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
24	O	NUM	O
-	O	PUNCT	O
h	O	NOUN	O
period	O	NOUN	B
following	O	VERB	O
upper	O	ADJ	B
abdominal	O	ADJ	I
surgery	O	NOUN	I
.	O	PUNCT	O


Monitoring	O	NOUN	B
consisted	O	VERB	O
of	O	ADP	O
airflow	O	NOUN	B
detection	O	NOUN	I
by	O	ADP	O
a	O	DET	O
carbon	B-Chemical	NOUN	B
dioxide	I-Chemical	NOUN	I
analyser	O	NOUN	I
,	O	PUNCT	O
chest	O	ADJ	B
wall	O	NOUN	I
movement	O	NOUN	B
detected	O	VERB	B
by	O	ADP	O
pneumatic	O	ADJ	B
capsules	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
continuous	O	ADJ	B
electrocardiograph	O	NOUN	I
recorded	O	VERB	O
with	O	ADP	O
a	O	DET	O
Holter	O	PROPN	B
ambulatory	O	ADJ	I
monitor	O	NOUN	I
.	O	PUNCT	O


Both	O	CCONJ	O
obstructive	B-Disease	ADJ	B
(P	I-Disease	PUNCT	O
less	I-Disease	ADJ	O
than	I-Disease	ADP	O
0.05)	I-Disease	NUM	O
and	I-Disease	CCONJ	O
central	I-Disease	ADJ	B
apnoea	I-Disease	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
)	O	PUNCT	O
occurred	O	VERB	O
more	O	ADV	O
frequently	O	ADV	O
in	O	ADP	O
patients	O	NOUN	B
who	O	PRON	O
had	O	AUX	O
a	O	DET	O
morphine	B-Chemical	NOUN	B
infusion	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
also	O	ADV	O
a	O	DET	O
higher	O	ADJ	O
incidence	O	NOUN	B
of	O	ADP	O
tachyarrhythmias	B-Disease	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
ventricular	B-Disease	ADJ	B
ectopic	I-Disease	ADJ	I
beats	I-Disease	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
morphine	B-Chemical	NOUN	B


Magnetic	O	ADJ	B
resonance	O	NOUN	I
volumetry	O	NOUN	I
of	O	ADP	O
the	O	DET	O
cerebellum	O	NOUN	B
in	O	ADP	O
epileptic	B-Disease	ADJ	B
patients	O	NOUN	I
after	O	ADP	O
phenytoin	B-Chemical	NOUN	B
overdosages	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
relationship	O	NOUN	B
between	O	ADP	O
phenytoin	B-Chemical	NOUN	B
medication	O	NOUN	B
and	O	CCONJ	O
cerebellar	B-Disease	ADJ	B
atrophy	I-Disease	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
who	O	PRON	O
had	O	AUX	O
experienced	O	VERB	O
clinical	O	ADJ	B
intoxication	O	NOUN	O
.	O	PUNCT	O


Five	O	NUM	O
females	O	NOUN	B
and	O	CCONJ	O
6	O	NUM	O
males	O	NOUN	B
,	O	PUNCT	O
21	O	NUM	O
-	O	SYM	O
59	O	NUM	O
years	O	NOUN	B
of	O	ADP	O
age	O	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
examined	O	VERB	O
with	O	ADP	O
a	O	DET	O
1	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
-	O	PUNCT	O
T	O	NOUN	B
whole	O	ADJ	B
-	O	PUNCT	O
body	O	NOUN	B
system	O	NOUN	I
using	O	VERB	O
a	O	DET	O
circular	O	ADJ	B
polarized	O	VERB	I
head	O	NOUN	I
coil	O	NOUN	I
.	O	PUNCT	O


Conventional	O	ADJ	B
spin	O	NOUN	B
echo	O	NOUN	I
images	O	NOUN	I
were	O	AUX	O
acquired	O	VERB	O
in	O	ADP	O
the	O	DET	O
sagittal	O	ADJ	B
and	O	CCONJ	O
transverse	O	ADJ	B
orientation	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
we	O	PRON	O
performed	O	VERB	O
a	O	DET	O
high	O	ADJ	B
-	O	PUNCT	O
resolution	O	NOUN	B
3D	O	NOUN	B
gradient	O	NOUN	B
echo	O	NOUN	B
,	O	PUNCT	O
T1	O	NOUN	B
-	O	PUNCT	O
weighted	O	VERB	B
sequences	O	NOUN	B
at	O	ADP	O
a	O	DET	O
1	O	NUM	O
-	O	PUNCT	O
mm	O	NOUN	B
slice	O	NOUN	I
thickness	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
images	O	NOUN	B
were	O	AUX	O
subsequently	O	ADV	O
processed	O	VERB	O
to	O	PART	O
obtain	O	VERB	O
volumetric	O	ADJ	B
data	O	NOUN	B
for	O	ADP	O
the	O	DET	O
cerebellum	O	NOUN	B
.	O	PUNCT	O


Cerebellar	O	ADJ	B
volume	O	NOUN	B
for	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
group	O	NOUN	I
ranged	O	VERB	O
between	O	ADP	O
67	O	NUM	O
.	O	PUNCT	O


66	O	NUM	O
and	O	CCONJ	O
131	O	NUM	O
.	O	PUNCT	O


08	O	NUM	O
ml	O	NOUN	O
(	O	PUNCT	O
mean	O	NOUN	O
108	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
ml	O	NOUN	O
).	O	PUNCT	O
In	O	ADP	O
addition	O	NOUN	O
3D	O	NOUN	B
gradient	O	NOUN	B
echo	O	ADJ	B
data	O	NOUN	I
sets	O	VERB	I
from	O	ADP	O
10	O	NUM	O
healthy	O	ADJ	B
male	O	NOUN	B
and	O	CCONJ	O
10	O	NUM	O
healthy	O	ADJ	B
female	O	ADJ	B
age	O	NOUN	B
-	O	PUNCT	O
matched	O	VERB	B
volunteers	O	NOUN	B
were	O	AUX	O
used	O	VERB	O
to	O	PART	O
compare	O	VERB	B
cerebellar	O	ADJ	B
volumes	O	NOUN	B
.	O	PUNCT	O


Using	O	VERB	O
linear	O	ADJ	B
regression	O	NOUN	I
we	O	PRON	O
found	O	VERB	O
that	O	SCONJ	O
no	O	DET	O
correlation	O	NOUN	B
exists	O	VERB	O
between	O	ADP	O
seizure	B-Disease	NOUN	B
duration	O	NOUN	B
,	O	PUNCT	O
elevation	O	NOUN	B
of	O	ADP	O
phenytoin	B-Chemical	NOUN	B
serum	O	NOUN	O
levels	O	NOUN	O
and	O	CCONJ	O
cerebellar	O	ADJ	B
volume	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
multiple	O	ADJ	B
regression	O	NOUN	I
for	O	ADP	O
the	O	DET	O
daily	O	ADJ	B
dosage	O	NOUN	I
,	O	PUNCT	O
duration	O	NOUN	B
of	O	ADP	O
phenytoin	B-Chemical	NOUN	B
treatment	O	NOUN	B
and	O	CCONJ	O
cerebellar	O	ADJ	B
volume	O	NOUN	I
revealed	O	VERB	O
a	O	DET	O
correlation	O	NOUN	B
of	O	ADP	O
these	O	DET	O
parameters	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
phenytoin	B-Chemical	NOUN	B
overdosage	B-Disease	NOUN	B
does	O	AUX	O
not	O	PART	O
necessarily	O	ADV	O
result	O	VERB	O
in	O	ADP	O
cerebellar	B-Disease	ADJ	B
atrophy	I-Disease	NOUN	I
and	O	CCONJ	O
it	O	PRON	O
is	O	AUX	O
unlikely	O	ADJ	O
that	O	SCONJ	O
phenytoin	B-Chemical	NOUN	B
medication	O	NOUN	B
was	O	AUX	O
the	O	DET	O
only	O	ADJ	O
cause	O	NOUN	O
of	O	ADP	O
cerebellar	B-Disease	ADJ	B
atrophy	I-Disease	NOUN	I
in	O	ADP	O
the	O	DET	O
remaining	O	VERB	O
patients	O	NOUN	B
.	O	PUNCT	O


Quantitative	O	ADJ	B
morphometric	O	ADJ	I
studies	O	NOUN	I
of	O	ADP	O
the	O	DET	O
cerebellum	O	NOUN	B
provide	O	VERB	O
valuable	O	ADJ	O
insights	O	NOUN	O
into	O	ADP	O
the	O	DET	O
pathogenesis	O	NOUN	B
of	O	ADP	O
cerebellar	B-Disease	ADJ	B
disorders	I-Disease	NOUN	I


Evaluation	O	NOUN	B
of	O	ADP	O
cardiac	O	ADJ	B
troponin	O	NOUN	O
I	O	NUM	O
and	O	CCONJ	O
T	O	NOUN	B
levels	O	NOUN	O
as	O	ADP	O
markers	O	NOUN	B
of	O	ADP	O
myocardial	B-Disease	ADJ	B
damage	I-Disease	NOUN	I
in	O	ADP	O
doxorubicin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cardiomyopathy	B-Disease	NOUN	B
rats	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
their	O	PRON	O
relationship	O	NOUN	B
with	O	ADP	O
echocardiographic	O	ADJ	B
and	O	CCONJ	O
histological	O	ADJ	B
findings	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Cardiac	O	ADJ	B
troponins	O	NOUN	I
I	O	NUM	I
(	O	PUNCT	O
cTnI	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
T	O	NOUN	B
(	O	PUNCT	O
cTnT	O	NOUN	B
)	O	PUNCT	O
have	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
be	O	AUX	O
highly	O	ADV	O
sensitive	O	ADJ	B
and	O	CCONJ	O
specific	O	ADJ	O
markers	O	NOUN	B
of	O	ADP	O
myocardial	B-Disease	ADJ	B
cell	I-Disease	NOUN	I
injury	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
investigated	O	VERB	B
the	O	DET	O
diagnostic	O	ADJ	B
value	O	NOUN	I
of	O	ADP	O
cTnI	O	NOUN	B
and	O	CCONJ	O
cTnT	O	NOUN	B
for	O	ADP	O
the	O	DET	O
diagnosis	O	NOUN	B
of	O	ADP	O
myocardial	B-Disease	ADJ	B
damage	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
rat	O	NOUN	B
model	O	NOUN	B
of	O	ADP	O
doxorubicin	B-Chemical	NOUN	B
(	O	PUNCT	O
DOX	B-Chemical	NOUN	B
)-	O	ADJ	O
induced	O	VERB	B
cardiomyopathy	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
we	O	PRON	O
examined	O	VERB	O
the	O	DET	O
relationship	O	NOUN	B
between	O	ADP	O
serial	O	ADJ	O
cTnI	O	NOUN	B
and	O	CCONJ	O
cTnT	O	NOUN	B
with	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
cardiac	B-Disease	ADJ	B
disorders	I-Disease	NOUN	I
monitored	O	VERB	B
by	O	ADP	O
echocardiography	O	NOUN	B
and	O	CCONJ	O
histological	O	ADJ	B
examinations	O	NOUN	I
in	O	ADP	O
this	O	DET	O
model	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
Thirty	O	NUM	B
-	O	PUNCT	O
five	O	NUM	B
Wistar	O	PROPN	B
rats	O	NOUN	I
were	O	AUX	O
given	O	VERB	O
1	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
DOX	B-Chemical	NOUN	B
,	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


v	O	ADP	O
.,	O	NOUN	O
weekly	O	ADV	B
for	O	ADP	O
up	O	ADV	O
to	O	PART	O
8	O	NUM	O
weeks	O	NOUN	B
for	O	ADP	O
a	O	DET	O
total	O	ADJ	O
cumulative	O	ADJ	B
dose	O	NOUN	B
of	O	ADP	O
12	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
BW	O	NOUN	B
.	O	PUNCT	O


Ten	O	NUM	O
rats	O	NOUN	B
received	O	VERB	O
saline	O	NOUN	B
as	O	ADP	O
a	O	DET	O
control	O	ADJ	B
group	O	NOUN	I
.	O	PUNCT	O


cTnI	O	NOUN	B
was	O	AUX	O
measured	O	VERB	O
with	O	ADP	O
Access	O	NOUN	B
(	O	PUNCT	O
R	O	NOUN	O
)(	O	NOUN	O
ng	O	NOUN	O
/	O	PUNCT	O
ml	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
research	O	NOUN	B
immunoassay	O	NOUN	I
(	O	PUNCT	O
pg	O	NOUN	O
/	O	SYM	O
ml	O	NOUN	O
),	O	PUNCT	O
and	O	CCONJ	O
compared	O	VERB	B
with	O	ADP	O
cTnT	O	NOUN	B
,	O	PUNCT	O
CK	O	NOUN	B
-	O	PUNCT	O
MB	O	PROPN	B
mass	O	NOUN	B
and	O	CCONJ	O
CK	O	NOUN	B
.	O	PUNCT	O


By	O	ADP	O
using	O	VERB	O
transthoracic	O	NOUN	B
echocardiography	O	NOUN	I
,	O	PUNCT	O
anterior	O	ADJ	B
and	O	CCONJ	O
posterior	O	ADJ	B
wall	O	NOUN	I
thickness	O	NOUN	I
,	O	PUNCT	O
LV	O	PROPN	B
diameters	O	NOUN	I
and	O	CCONJ	O
LV	O	PROPN	B
fractional	O	ADJ	I
shortening	O	NOUN	I
(	O	PUNCT	O
FS	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
measured	O	VERB	B
in	O	ADP	O
all	O	DET	O
rats	O	NOUN	B
before	O	ADP	O
DOX	B-Chemical	NOUN	B
or	O	CCONJ	O
saline	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
at	O	ADP	O
weeks	O	NOUN	B
6	O	NUM	O
and	O	CCONJ	O
9	O	NUM	O
after	O	ADP	O
treatment	O	NOUN	B
in	O	ADP	O
all	O	DET	O
surviving	O	VERB	O
rats	O	NOUN	B
.	O	PUNCT	O


Histology	O	NOUN	B
was	O	AUX	O
performed	O	VERB	O
in	O	ADP	O
DOX	B-Chemical	NOUN	B
-	O	PUNCT	O
rats	O	NOUN	B
at	O	ADP	O
6	O	NUM	O
and	O	CCONJ	O
9	O	NUM	O
weeks	O	NOUN	B
after	O	ADP	O
the	O	DET	O
last	O	ADJ	O
DOX	B-Chemical	NOUN	B
dose	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
all	O	DET	O
controls	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Eighteen	O	NUM	O
of	O	ADP	O
the	O	DET	O
DOX	B-Chemical	NOUN	B
rats	O	NOUN	B
died	O	VERB	B
prematurely	O	ADV	B
of	O	ADP	O
general	O	ADJ	O
toxicity	B-Disease	NOUN	B
during	O	ADP	O
the	O	DET	O
9	O	NUM	B
-	O	PUNCT	O
week	O	NOUN	B
period	O	NOUN	B
.	O	PUNCT	O


End	O	NOUN	B
-	O	PUNCT	O
diastolic	O	NOUN	B
(	O	PUNCT	O
ED	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
end	O	VERB	B
-	O	PUNCT	O
systolic	O	NOUN	B
(	O	PUNCT	O
ES	O	NOUN	B
)	O	PUNCT	O
LV	O	PROPN	B
diameters	O	NOUN	I
/	O	PUNCT	O
BW	O	PROPN	B
significantly	O	ADV	O
increased	O	VERB	B
,	O	PUNCT	O
whereas	O	SCONJ	O
LV	O	PROPN	B
FS	O	PROPN	I
was	O	AUX	O
decreased	O	VERB	B
after	O	ADP	O
9	O	NUM	O
weeks	O	NOUN	B
in	O	ADP	O
the	O	DET	O
DOX	B-Chemical	NOUN	B
group	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
).	O	PUNCT	O
These	O	DET	O
parameters	O	NOUN	B
remained	O	VERB	O
unchanged	O	ADJ	B
in	O	ADP	O
controls	O	NOUN	B
.	O	PUNCT	O


Histological	O	ADJ	B
evaluation	O	NOUN	B
of	O	ADP	O
hearts	O	NOUN	B
from	O	ADP	O
all	O	DET	O
rats	O	NOUN	B
given	O	VERB	O
DOX	B-Chemical	NOUN	B
revealed	O	VERB	O
significant	O	ADJ	O
slight	O	ADJ	O
degrees	O	NOUN	B
of	O	ADP	O
perivascular	O	ADJ	B
and	O	CCONJ	O
interstitial	O	ADJ	B
fibrosis	B-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
7	O	NUM	O
of	O	ADP	O
the	O	DET	O
18	O	NUM	O
rats	O	NOUN	B
,	O	PUNCT	O
degeneration	O	NOUN	B
and	O	CCONJ	O
myocyte	O	NOUN	B
vacuolisation	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
.	O	PUNCT	O


Only	O	ADV	O
five	O	NUM	O
of	O	ADP	O
the	O	DET	O
controls	O	NOUN	B
exhibited	O	VERB	O
evidence	O	NOUN	B
of	O	ADP	O
very	O	ADV	O
slight	O	ADJ	O
perivascular	O	ADJ	B
fibrosis	B-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
significant	O	ADJ	O
rise	O	NOUN	O
in	O	ADP	O
cTnT	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
in	O	ADP	O
DOX	B-Chemical	NOUN	B
rats	O	NOUN	B
after	O	ADP	O
cumulative	O	ADJ	B
doses	O	NOUN	B
of	O	ADP	O
7	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
and	O	CCONJ	O
12	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
kg	O	NOUN	O
in	O	ADP	O
comparison	O	NOUN	B
with	O	ADP	O
baseline	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
).	O	PUNCT	O
cTnT	O	NOUN	B
found	O	VERB	O
in	O	ADP	O
rats	O	NOUN	B
after	O	ADP	O
12	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
kg	O	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
greater	O	ADJ	O
than	O	ADP	O
that	O	DET	O
found	O	VERB	O
after	O	ADP	O
7	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
DOX	B-Chemical	NOUN	B
.	O	PUNCT	O


Maximal	O	ADJ	B
cTnI	O	NOUN	B
(	O	PUNCT	O
pg	O	NOUN	O
/	O	SYM	O
ml	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
cTnT	O	NOUN	B
levels	O	NOUN	O
were	O	AUX	O
significantly	O	ADV	O
increased	O	VERB	B
in	O	ADP	O
DOX	B-Chemical	NOUN	B
rats	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
controls	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


006	O	NUM	O
,	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


007	O	NUM	O
).	O	PUNCT	O
cTnI	O	NOUN	B
(	O	PUNCT	O
ng	O	NOUN	O
/	O	PUNCT	O
ml	O	NOUN	O
),	O	PUNCT	O
CK	O	NOUN	B
-	O	PUNCT	O
MB	O	PROPN	B
mass	O	NOUN	B
and	O	CCONJ	O
CK	O	NOUN	B
remained	O	VERB	O
unchanged	O	ADJ	B
in	O	ADP	O
DOX	B-Chemical	NOUN	B
rats	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
controls	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
markers	O	NOUN	B
remained	O	VERB	O
stable	O	ADJ	B
in	O	ADP	O
controls	O	NOUN	B
.	O	PUNCT	O


Analysis	O	NOUN	B
of	O	ADP	O
data	O	NOUN	B
revealed	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
correlation	O	NOUN	B
between	O	ADP	O
maximal	O	ADJ	B
cTnT	O	NOUN	B
and	O	CCONJ	O
ED	O	PROPN	B
and	O	CCONJ	O
ES	O	PROPN	B
LV	O	PROPN	O
diameters	O	NOUN	B
/	O	PUNCT	O
BW	O	NOUN	B
(	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


81	O	NUM	O
and	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


65	O	NUM	O
;	O	PUNCT	O
p	O	NUM	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


0001	O	NUM	O
).	O	PUNCT	O
A	O	DET	O
significant	O	ADJ	O
relationship	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
between	O	ADP	O
maximal	O	ADJ	B
cTnT	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
extent	O	NOUN	O
of	O	ADP	O
myocardial	O	ADJ	B
morphological	O	ADJ	B
changes	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
between	O	ADP	O
LV	O	PROPN	B
diameters	O	NOUN	B
/	O	PUNCT	O
BW	O	NOUN	B
and	O	CCONJ	O
histological	O	ADJ	B
findings	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
Among	O	ADP	O
markers	O	NOUN	B
of	O	ADP	O
ischemic	B-Disease	ADJ	B
injury	I-Disease	NOUN	I
after	O	ADP	O
DOX	B-Chemical	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
,	O	PUNCT	O
cTnT	O	NOUN	B
showed	O	VERB	O
the	O	DET	O
greatest	O	ADJ	O
ability	O	NOUN	O
to	O	PART	O
detect	O	VERB	B
myocardial	B-Disease	ADJ	B
damage	I-Disease	NOUN	I
assessed	O	VERB	B
by	O	ADP	O
echocardiographic	O	ADJ	B
detection	O	NOUN	B
and	O	CCONJ	O
histological	O	ADJ	B
changes	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
discrepancy	O	NOUN	B
between	O	ADP	O
the	O	DET	O
amount	O	NOUN	B
of	O	ADP	O
cTnI	O	NOUN	B
and	O	CCONJ	O
cTnT	O	NOUN	B
after	O	ADP	O
DOX	B-Chemical	NOUN	B
,	O	PUNCT	O
probably	O	ADV	O
due	O	ADP	O
to	O	PART	O
heterogeneity	O	NOUN	B
in	O	ADP	O
cross	O	NOUN	B
-	O	PUNCT	O
reactivities	O	NOUN	B
of	O	ADP	O
mAbs	O	NOUN	B
to	O	PART	O
various	O	ADJ	O
cTnI	O	NOUN	B
and	O	CCONJ	O
cTnT	O	NOUN	B
forms	O	NOUN	O
,	O	PUNCT	O
it	O	PRON	O
is	O	AUX	O
likely	O	ADJ	O
that	O	SCONJ	O
cTnT	O	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
after	O	ADP	O
DOX	B-Chemical	NOUN	B
indicates	O	VERB	O
cell	O	NOUN	B
damage	O	NOUN	I
determined	O	VERB	O
by	O	ADP	O
the	O	DET	O
magnitude	O	NOUN	B
of	O	ADP	O
injury	O	NOUN	B
induced	O	VERB	B
and	O	CCONJ	O
that	O	SCONJ	O
cTnT	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
a	O	DET	O
useful	O	ADJ	O
marker	O	NOUN	B
for	O	ADP	O
the	O	DET	O
prediction	O	NOUN	B
of	O	ADP	O
experimentally	O	ADV	B
induced	O	VERB	B
cardiotoxicity	B-Disease	NOUN	B


Calcineurin	O	NOUN	B
-	O	PUNCT	O
inhibitor	O	NOUN	B
induced	O	VERB	B
pain	B-Disease	NOUN	B
syndrome	O	NOUN	I
(	O	PUNCT	O
CIPS	B-Disease	PROPN	B
):	O	PUNCT	O
a	O	DET	O
severe	O	ADJ	B
disabling	O	ADJ	O
complication	O	NOUN	B
after	O	ADP	O
organ	O	NOUN	B
transplantation	O	NOUN	I
.	O	PUNCT	O


Bone	O	NOUN	B
pain	B-Disease	NOUN	I
after	O	ADP	O
transplantation	O	NOUN	B
is	O	AUX	O
a	O	DET	O
frequent	O	ADJ	O
complication	O	NOUN	B
that	O	PRON	O
can	O	AUX	O
be	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
several	O	ADJ	O
diseases	O	NOUN	B
.	O	PUNCT	O


Treatment	O	NOUN	B
strategies	O	NOUN	O
depend	O	VERB	O
on	O	ADP	O
the	O	DET	O
correct	O	ADJ	O
diagnosis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
pain	B-Disease	NOUN	B
.	O	PUNCT	O


Nine	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
severe	O	ADJ	B
pain	B-Disease	NOUN	B
in	O	ADP	O
their	O	PRON	O
feet	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
was	O	AUX	O
registered	O	VERB	O
after	O	ADP	O
transplantation	O	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
investigated	O	VERB	B
.	O	PUNCT	O


Bone	O	NOUN	B
scans	O	NOUN	I
showed	O	VERB	O
an	O	DET	O
increased	O	VERB	B
tracer	O	NOUN	B
uptake	O	NOUN	B
of	O	ADP	O
the	O	DET	O
foot	O	NOUN	B
bones	O	NOUN	I
.	O	PUNCT	O


Magnetic	O	ADJ	B
resonance	O	NOUN	I
imaging	O	NOUN	I
demonstrated	O	VERB	O
bone	B-Disease	NOUN	B
marrow	I-Disease	NOUN	I
oedema	I-Disease	NOUN	I
in	O	ADP	O
the	O	DET	O
painful	O	ADJ	B
bones	O	NOUN	B
.	O	PUNCT	O


Pain	B-Disease	NOUN	B
was	O	AUX	O
not	O	PART	O
explained	O	VERB	O
by	O	ADP	O
other	O	ADJ	O
diseases	O	NOUN	B
causing	O	VERB	O
foot	O	NOUN	B
pain	B-Disease	NOUN	I
,	O	PUNCT	O
like	O	ADP	O
reflex	B-Disease	ADJ	B
sympathetic	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
,	O	PUNCT	O
polyneuropathy	B-Disease	NOUN	B
,	O	PUNCT	O
Morton's	B-Disease	PROPN	B
neuralgia	I-Disease	NOUN	I
,	O	PUNCT	O
gout	B-Disease	NOUN	B
,	O	PUNCT	O
osteoporosis	B-Disease	NOUN	B
,	O	PUNCT	O
avascular	B-Disease	ADJ	B
necrosis	I-Disease	NOUN	I
,	O	PUNCT	O
intermittent	B-Disease	ADJ	B
claudication	I-Disease	NOUN	I
,	O	PUNCT	O
orthopaedic	O	ADJ	B
foot	B-Disease	NOUN	I
deformities	I-Disease	NOUN	I
,	O	PUNCT	O
stress	B-Disease	NOUN	B
fractures	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
hyperparathyroidism	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
reduction	O	NOUN	B
of	O	ADP	O
cyclosporine	B-Chemical	NOUN	B
-	O	PUNCT	O
or	O	CCONJ	O
tacrolimus	B-Chemical	NOUN	B
trough	O	NOUN	O
levels	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
calcium	B-Chemical	NOUN	B
channel	O	NOUN	I
blockers	O	NOUN	I
led	O	VERB	O
to	O	PART	O
relief	O	NOUN	B
of	O	ADP	I
pain	B-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
Calcineurin	O	PROPN	B
-	O	PUNCT	O
inhibitor	O	NOUN	B
Induced	O	VERB	B
Pain	B-Disease	PROPN	I
Syndrome	O	NOUN	I
(	O	PUNCT	O
CIPS	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
rare	O	ADJ	B
but	O	CCONJ	O
severe	O	ADJ	B
side	O	NOUN	B
effect	O	NOUN	I
of	O	ADP	O
cyclosporine	B-Chemical	NOUN	B
or	O	CCONJ	O
tacrolimus	B-Chemical	NOUN	B
and	O	CCONJ	O
is	O	AUX	O
accurately	O	ADV	O
diagnosed	O	VERB	B
by	O	ADP	O
its	O	PRON	O
typical	O	ADJ	O
presentation	O	NOUN	B
,	O	PUNCT	O
magnetic	O	ADJ	B
resonance	O	NOUN	I
imaging	O	NOUN	I
and	O	CCONJ	O
bone	O	NOUN	B
scans	O	NOUN	I
.	O	PUNCT	O


Incorrect	O	ADJ	B
diagnosis	O	NOUN	I
of	O	ADP	O
the	O	DET	O
syndrome	O	NOUN	B
will	O	AUX	O
lead	O	VERB	O
to	O	PART	O
a	O	DET	O
significant	O	ADJ	O
reduction	O	NOUN	B
of	O	ADP	O
life	O	NOUN	B
quality	O	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
suffering	O	VERB	B
from	O	ADP	O
CIPS	B-Disease	PROPN	B


The	O	DET	O
haemodynamic	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
propofol	B-Chemical	NOUN	B
in	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
ephedrine	B-Chemical	NOUN	B
in	O	ADP	O
elderly	O	ADJ	B
patients	O	NOUN	I
(	O	PUNCT	O
ASA	O	NOUN	B
groups	O	NOUN	O
3	O	NUM	O
and	O	CCONJ	O
4	O	NUM	O
).	O	PUNCT	O
The	O	DET	O
marked	O	ADJ	O
vasodilator	O	NOUN	B
and	O	CCONJ	O
negative	O	ADJ	B
inotropic	O	ADJ	B
effects	O	NOUN	O
of	O	ADP	O
propofol	B-Chemical	NOUN	B
are	O	AUX	O
disadvantages	O	NOUN	O
in	O	ADP	O
frail	O	ADJ	B
elderly	O	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
investigated	O	VERB	B
the	O	DET	O
safety	O	NOUN	B
and	O	CCONJ	O
efficacy	O	NOUN	B
of	O	ADP	O
adding	O	VERB	O
different	O	ADJ	O
doses	O	NOUN	B
of	O	ADP	O
ephedrine	B-Chemical	NOUN	B
to	O	PART	O
propofol	B-Chemical	NOUN	B
in	O	ADP	O
order	O	NOUN	O
to	O	PART	O
obtund	O	VERB	B
the	O	DET	O
hypotensive	B-Disease	ADJ	B
response	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
haemodynamic	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
adding	O	VERB	O
15	O	NUM	O
,	O	PUNCT	O
20	O	NUM	O
or	O	CCONJ	O
25	O	NUM	O
mg	O	NOUN	O
of	O	ADP	O
ephedrine	B-Chemical	NOUN	B
to	O	PART	O
200	O	NUM	O
mg	O	NOUN	O
of	O	ADP	O
propofol	B-Chemical	NOUN	B
were	O	AUX	O
compared	O	VERB	B
to	O	PART	O
control	O	NOUN	B
in	O	ADP	O
40	O	NUM	O
ASA	O	NOUN	B
3	O	NUM	I
/	O	SYM	O
4	O	NUM	B
patients	O	NOUN	B
over	O	ADP	O
60	O	NUM	O
years	O	NOUN	B
presenting	O	VERB	O
for	O	ADP	O
genito	O	NOUN	B
-	O	PUNCT	O
urinary	O	ADJ	B
surgery	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
addition	O	NOUN	O
of	O	ADP	O
ephedrine	B-Chemical	NOUN	B
to	O	PART	O
propofol	B-Chemical	NOUN	B
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
an	O	DET	O
effective	O	ADJ	B
method	O	NOUN	B
of	O	ADP	O
obtunding	O	VERB	B
the	O	DET	O
hypotensive	B-Disease	ADJ	B
response	O	NOUN	I
to	O	PART	O
propofol	B-Chemical	NOUN	B
at	O	ADP	O
all	O	DET	O
doses	O	NOUN	B
used	O	VERB	O
in	O	ADP	O
this	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
marked	O	ADJ	O
tachycardia	B-Disease	NOUN	B
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
ephedrine	B-Chemical	NOUN	B
in	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
propofol	B-Chemical	NOUN	B
occurred	O	VERB	O
in	O	ADP	O
the	O	DET	O
majority	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
,	O	PUNCT	O
occasionally	O	ADV	O
reaching	O	VERB	O
high	O	ADJ	O
levels	O	NOUN	B
in	O	ADP	O
individual	O	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O


Due	O	ADP	O
to	O	ADP	O
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
this	O	DET	O
tachycardia	B-Disease	NOUN	B
inducing	O	VERB	O
myocardial	B-Disease	ADJ	B
ischemia	I-Disease	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
would	O	AUX	O
not	O	PART	O
recommend	O	VERB	O
the	O	DET	O
use	O	NOUN	O
in	O	ADP	O
elderly	O	ADJ	B
patients	O	NOUN	I
of	O	ADP	O
any	O	DET	O
of	O	ADP	O
the	O	DET	O
ephedrine	B-Chemical	NOUN	B
/	O	SYM	O
propofol	B-Chemical	NOUN	B


Neurotoxicity	B-Disease	NOUN	B
of	O	ADP	O
halogenated	B-Chemical	ADJ	B
hydroxyquinolines	I-Chemical	NOUN	I
:	O	PUNCT	O
clinical	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
cases	O	NOUN	B
reported	O	VERB	O
outside	O	ADP	O
Japan	O	PROPN	B
.	O	PUNCT	O


An	O	DET	O
analysis	O	NOUN	B
is	O	AUX	O
presented	O	VERB	O
of	O	ADP	O
220	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
possible	O	ADJ	O
neurotoxic	B-Disease	ADJ	B
reactions	O	NOUN	I
to	O	PART	O
halogenated	B-Chemical	ADJ	B
hydroxyquinolines	I-Chemical	NOUN	I
reported	O	VERB	O
from	O	ADP	O
outside	O	ADP	O
Japan	O	PROPN	B
.	O	PUNCT	O


In	O	ADP	O
80	O	NUM	O
cases	O	NOUN	B
insufficient	O	ADJ	B
information	O	NOUN	B
was	O	AUX	O
available	O	ADJ	O
for	O	ADP	O
adequate	O	ADJ	B
comment	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
29	O	NUM	O
a	O	DET	O
relationship	O	NOUN	B
to	O	ADP	O
the	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
clioquinol	B-Chemical	NOUN	B
could	O	AUX	O
be	O	AUX	O
excluded	O	VERB	B
.	O	PUNCT	O


Of	O	ADP	O
the	O	DET	O
remainder	O	NOUN	O
,	O	PUNCT	O
a	O	DET	O
relationship	O	NOUN	B
to	O	PART	O
clioquinol	B-Chemical	NOUN	B
was	O	AUX	O
considered	O	VERB	O
probable	O	ADJ	O
in	O	ADP	O
42	O	NUM	O
and	O	CCONJ	O
possible	O	ADJ	O
in	O	ADP	O
69	O	NUM	O
cases	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
six	O	NUM	O
of	O	ADP	O
the	O	DET	O
probable	O	ADJ	O
cases	O	NOUN	B
the	O	DET	O
neurological	B-Disease	ADJ	B
disturbance	I-Disease	NOUN	I
consisted	O	VERB	O
of	O	ADP	O
an	O	DET	O
acute	O	ADJ	B
reversible	O	ADJ	O
encephalopathy	B-Disease	NOUN	O
usually	O	ADV	O
related	O	ADJ	O
to	O	PART	O
the	O	DET	O
ingestion	O	NOUN	B
of	O	ADP	O
a	O	DET	O
high	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
clioquinol	B-Chemical	NOUN	B
over	O	ADP	O
a	O	DET	O
short	O	ADJ	O
period	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
most	O	ADV	O
common	O	ADJ	O
manifestation	O	NOUN	B
,	O	PUNCT	O
observed	O	VERB	O
in	O	ADP	O
15	O	NUM	O
further	O	ADJ	O
cases	O	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
isolated	O	VERB	B
optic	B-Disease	ADJ	B
atrophy	I-Disease	NOUN	I
.	O	PUNCT	O


This	O	DET	O
was	O	AUX	O
most	O	ADV	O
frequently	O	ADV	O
found	O	VERB	O
in	O	ADP	O
children	O	NOUN	B
,	O	PUNCT	O
many	O	ADJ	O
of	O	ADP	O
whom	O	PRON	O
had	O	AUX	O
received	O	VERB	O
clioquinol	B-Chemical	NOUN	B
as	O	ADP	O
treatment	O	NOUN	B
for	O	ADP	O
acrodermatitis	B-Disease	NOUN	B
enteropathica	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
remaining	O	VERB	O
cases	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
myelopathy	B-Disease	ADJ	B
,	O	PUNCT	O
visual	B-Disease	ADJ	B
disturbance	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
peripheral	B-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I
was	O	AUX	O
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
manifestation	O	NOUN	B
.	O	PUNCT	O


Isolated	O	VERB	B
myelopathy	B-Disease	ADJ	I
or	O	CCONJ	O
peripheral	B-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I
,	O	PUNCT	O
or	O	CCONJ	O
these	O	DET	O
manifestations	O	NOUN	B
occurring	O	VERB	O
together	O	ADV	O
,	O	PUNCT	O
were	O	AUX	O
infrequent	O	ADJ	B
.	O	PUNCT	O


The	O	DET	O
onset	O	NOUN	O
of	O	ADP	O
all	O	DET	O
manifestations	O	NOUN	B
(	O	PUNCT	O
except	O	SCONJ	O
toxic	O	ADJ	B
encephalopathy	B-Disease	NOUN	I
)	O	PUNCT	O
was	O	AUX	O
usually	O	ADV	O
subacute	O	ADJ	B
,	O	PUNCT	O
with	O	ADP	O
subsequent	O	ADJ	O
partial	O	ADJ	B
recovery	O	NOUN	B
.	O	PUNCT	O


Older	O	ADJ	B
subjects	O	NOUN	I
tended	O	VERB	O
to	O	PART	O
display	O	VERB	B
more	O	ADJ	O
side	O	NOUN	B
effects	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
full	O	ADJ	B
syndrome	O	NOUN	I
of	O	ADP	O
subacute	O	ADJ	B
myelo-optic	B-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I


Epileptic	B-Disease	ADJ	B
seizures	I-Disease	NOUN	I
following	O	VERB	O
cortical	O	ADJ	B
application	O	NOUN	O
of	O	ADP	O
fibrin	O	NOUN	B
sealants	O	NOUN	I
containing	O	VERB	O
tranexamic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Fibrin	O	NOUN	B
sealants	O	NOUN	I
(	O	PUNCT	O
FS	O	NOUN	B
)	O	PUNCT	O
derived	O	VERB	O
from	O	ADP	O
human	O	ADJ	B
plasma	O	NOUN	B
are	O	AUX	O
frequently	O	ADV	O
used	O	VERB	O
in	O	ADP	O
neurosurgery	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
order	O	NOUN	O
to	O	PART	O
increase	O	VERB	B
clot	O	NOUN	B
stability	O	NOUN	I
,	O	PUNCT	O
FS	O	NOUN	B
typically	O	ADV	O
contain	O	VERB	O
aprotinin	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
natural	O	ADJ	B
fibrinolysis	O	NOUN	O
inhibitor	O	NOUN	B
.	O	PUNCT	O


Recently	O	ADV	O
,	O	PUNCT	O
synthetic	O	ADJ	B
fibrinolysis	O	NOUN	O
inhibitors	O	NOUN	B
such	O	ADJ	O
as	O	ADP	O
tranexamic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
(	O	PUNCT	O
tAMCA	B-Chemical	NOUN	B
)	O	PUNCT	O
have	O	AUX	O
been	O	AUX	O
considered	O	VERB	O
as	O	ADP	O
substitutes	O	NOUN	B
for	O	ADP	O
aprotinin	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
tAMCA	B-Chemical	NOUN	B
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
cause	O	VERB	O
epileptic	B-Disease	ADJ	B
seizures	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
wanted	O	VERB	O
to	O	PART	O
study	O	VERB	B
whether	O	SCONJ	O
tAMCA	B-Chemical	NOUN	B
retains	O	VERB	O
its	O	PRON	O
convulsive	B-Disease	ADJ	B
action	O	NOUN	I
if	O	SCONJ	O
incorporated	O	VERB	O
into	O	ADP	O
a	O	DET	O
FS	O	NOUN	B
.	O	PUNCT	O


METHOD	O	NOUN	B
:	O	PUNCT	O
FS	O	NOUN	B
containing	O	VERB	O
aprotinin	O	NOUN	B
or	O	CCONJ	O
different	O	ADJ	O
concentrations	O	NOUN	B
of	O	ADP	O
tAMCA	B-Chemical	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
-	O	SYM	O
47	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
ml	O	NOUN	O
)	O	PUNCT	O
were	O	AUX	O
applied	O	VERB	O
to	O	PART	O
the	O	DET	O
pial	O	ADJ	B
surface	O	NOUN	B
of	O	ADP	O
the	O	DET	O
cortex	O	NOUN	B
of	O	ADP	O
anaesthetized	O	ADJ	B
rats	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
response	O	NOUN	B
of	O	ADP	O
the	O	DET	O
animals	O	NOUN	B
was	O	AUX	O
evaluated	O	VERB	B
using	O	VERB	O
electroencephalography	O	NOUN	B
and	O	CCONJ	O
by	O	ADP	O
monitoring	O	VERB	B
the	O	DET	O
clinical	O	ADJ	B
behaviour	O	NOUN	I
during	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
recovery	O	NOUN	B
from	O	ADP	O
anaesthesia	O	NOUN	B
.	O	PUNCT	O


FINDINGS	O	NOUN	B
:	O	PUNCT	O
FS	O	NOUN	B
containing	O	VERB	O
tAMCA	B-Chemical	NOUN	B
caused	O	VERB	O
paroxysmal	O	ADJ	B
brain	O	NOUN	I
activity	O	NOUN	I
which	O	DET	O
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
distinct	O	ADJ	O
convulsive	B-Disease	ADJ	B
behaviours	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
degree	O	NOUN	B
of	O	ADP	O
these	O	DET	O
seizures	B-Disease	NOUN	B
increased	O	VERB	B
with	O	ADP	O
increasing	O	VERB	B
concentration	O	NOUN	B
of	O	ADP	O
tAMCA	B-Chemical	NOUN	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
FS	O	NOUN	B
containing	O	VERB	O
47	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
ml	O	NOUN	O
tAMCA	B-Chemical	NOUN	B
evoked	O	VERB	O
generalized	B-Disease	ADJ	O
seizures	I-Disease	NOUN	B
in	O	ADP	O
all	O	DET	O
tested	O	VERB	B
rats	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
6	O	NUM	O
)	O	PUNCT	O
while	O	SCONJ	O
the	O	DET	O
lowest	O	ADJ	B
concentration	O	NOUN	B
of	O	ADP	O
tAMCA	B-Chemical	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
ml	O	NOUN	O
)	O	PUNCT	O
only	O	ADV	O
evoked	O	VERB	O
brief	O	ADJ	O
episodes	O	NOUN	B
of	O	ADP	O
jerk	O	NOUN	B
-	O	PUNCT	O
correlated	O	VERB	B
convulsive	B-Disease	ADJ	B
potentials	O	NOUN	I
in	O	ADP	O
1	O	NUM	O
of	O	ADP	O
6	O	NUM	O
rats	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
FS	O	NOUN	B
containing	O	VERB	O
aprotinin	O	NOUN	B
did	O	AUX	O
not	O	PART	O
evoke	O	VERB	O
any	O	DET	O
paroxysmal	O	ADJ	B
activity	O	NOUN	I
.	O	PUNCT	O


INTERPRETATION	O	NOUN	B
:	O	PUNCT	O
Tranexamic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
retains	O	VERB	O
its	O	PRON	O
convulsive	B-Disease	ADJ	B
action	O	NOUN	I
within	O	ADP	O
FS	O	PROPN	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
use	O	NOUN	O
of	O	ADP	O
FS	O	NOUN	B
containing	O	VERB	O
tAMCA	B-Chemical	NOUN	B


A	O	DET	O
diet	O	NOUN	B
promoting	O	VERB	O
sugar	B-Disease	NOUN	B
dependency	I-Disease	NOUN	B
causes	O	VERB	O
behavioral	B-Disease	ADJ	B
cross-sensitization	I-Disease	NOUN	B
to	O	PART	O
a	O	DET	O
low	O	ADJ	B
dose	O	NOUN	B
of	O	ADP	O
amphetamine	B-Chemical	NOUN	B
.	O	PUNCT	O


Previous	O	ADJ	O
research	O	NOUN	B
in	O	ADP	O
this	O	DET	O
laboratory	O	NOUN	B
has	O	AUX	O
shown	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
diet	O	NOUN	B
of	O	ADP	O
intermittent	O	ADJ	B
excessive	O	ADJ	B
sugar	O	NOUN	B
consumption	O	NOUN	B
produces	O	VERB	O
a	O	DET	O
state	O	NOUN	B
with	O	ADP	O
neurochemical	O	ADJ	B
and	O	CCONJ	O
behavioral	O	ADJ	B
similarities	O	NOUN	B
to	O	PART	O
drug	B-Disease	NOUN	B
dependency	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
examined	O	VERB	O
whether	O	SCONJ	O
female	O	ADJ	B
rats	O	NOUN	B
on	O	ADP	O
various	O	ADJ	O
regimens	O	NOUN	B
of	O	ADP	O
sugar	O	NOUN	B
access	O	NOUN	O
would	O	AUX	O
show	O	VERB	O
behavioral	B-Disease	ADJ	B
cross-sensitization	I-Disease	NOUN	B
to	O	PART	O
a	O	DET	O
low	O	ADJ	B
dose	O	NOUN	B
of	O	ADP	O
amphetamine	B-Chemical	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
a	O	DET	O
30	O	NUM	O
-	O	PUNCT	O
min	O	NOUN	B
baseline	O	NOUN	B
measure	O	NOUN	B
of	O	ADP	O
locomotor	O	NOUN	B
activity	O	NOUN	I
(	O	PUNCT	O
day	O	NOUN	B
0	O	NUM	O
),	O	PUNCT	O
animals	O	NOUN	B
were	O	AUX	O
maintained	O	VERB	B
on	O	ADP	O
a	O	DET	O
cyclic	O	ADJ	B
diet	O	NOUN	I
of	O	ADP	O
12	O	NUM	O
-	O	PUNCT	O
h	O	NOUN	B
deprivation	O	NOUN	B
followed	O	VERB	O
by	O	ADP	O
12	O	NUM	O
-	O	PUNCT	O
h	O	NOUN	O
access	O	NOUN	O
to	O	ADP	O
10	O	NUM	O
%	O	NOUN	O
sucrose	B-Chemical	NOUN	B
solution	O	NOUN	I
and	O	CCONJ	O
chow	O	NOUN	B
pellets	O	NOUN	B
(	O	PUNCT	O
12	O	NUM	O
h	O	NOUN	O
access	O	NOUN	O
starting	O	VERB	O
4	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
onset	O	NOUN	O
of	O	ADP	O
the	O	DET	O
dark	O	ADJ	B
period	O	NOUN	B
)	O	PUNCT	O
for	O	ADP	O
21	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


Locomotor	O	ADJ	B
activity	O	NOUN	I
was	O	AUX	O
measured	O	VERB	B
again	O	ADV	O
for	O	ADP	O
30	O	NUM	O
min	O	NOUN	O
at	O	ADP	O
the	O	DET	O
beginning	O	NOUN	O
of	O	ADP	O
days	O	NOUN	B
1	O	NUM	O
and	O	CCONJ	O
21	O	NUM	O
of	O	ADP	O
sugar	O	NOUN	B
access	O	NOUN	B
.	O	PUNCT	O


Beginning	O	VERB	B
on	O	ADP	O
day	O	NOUN	B
22	O	NUM	O
,	O	PUNCT	O
all	O	DET	O
rats	O	NOUN	B
were	O	AUX	O
maintained	O	VERB	B
on	O	ADP	O
ad	O	NOUN	B
libitum	O	NOUN	I
chow	O	NOUN	I
.	O	PUNCT	O


Nine	O	NUM	O
days	O	NOUN	B
later	O	ADV	O
locomotor	O	NOUN	B
activity	O	NOUN	I
was	O	AUX	O
measured	O	VERB	B
in	O	ADP	O
response	O	NOUN	B
to	O	PART	O
a	O	DET	O
single	O	ADJ	O
low	O	ADJ	O
dose	O	NOUN	B
of	O	ADP	O
amphetamine	B-Chemical	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
).	O	PUNCT	O
The	O	DET	O
animals	O	NOUN	B
that	O	PRON	O
had	O	AUX	O
experienced	O	VERB	O
cyclic	O	ADJ	B
sucrose	B-Chemical	NOUN	I
and	O	CCONJ	O
chow	O	NOUN	B
were	O	AUX	O
hyperactive	B-Disease	ADJ	B
in	O	ADP	O
response	O	NOUN	B
to	O	PART	O
amphetamine	B-Chemical	NOUN	B
compared	O	VERB	B
with	O	ADP	O
four	O	NUM	O
control	O	ADJ	B
groups	O	NOUN	I
(	O	PUNCT	O
ad	O	NOUN	B
libitum	O	NOUN	I
10	O	NUM	O
%	O	NOUN	O
sucrose	B-Chemical	NOUN	B
and	O	CCONJ	O
chow	O	NOUN	B
followed	O	VERB	O
by	O	ADP	O
amphetamine	B-Chemical	NOUN	B
injection	O	NOUN	B
,	O	PUNCT	O
cyclic	O	ADJ	B
chow	O	NOUN	I
followed	O	VERB	O
by	O	ADP	O
amphetamine	B-Chemical	NOUN	B
injection	O	NOUN	B
,	O	PUNCT	O
ad	O	NOUN	B
libitum	O	NOUN	I
chow	O	NOUN	I
with	O	ADP	O
amphetamine	B-Chemical	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
cyclic	O	ADJ	B
10	O	NUM	O
%	O	NOUN	O
sucrose	B-Chemical	NOUN	B
and	O	CCONJ	O
chow	O	NOUN	B
with	O	ADP	O
a	O	DET	O
saline	O	NOUN	B
injection	O	NOUN	I
).	O	PUNCT	O
These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
diet	O	NOUN	B
comprised	O	VERB	O
of	O	ADP	O
alternating	O	VERB	B
deprivation	O	NOUN	B
and	O	CCONJ	O
access	O	NOUN	B
to	O	ADP	O
a	O	DET	O
sugar	O	NOUN	B
solution	O	NOUN	B
and	O	CCONJ	O
chow	O	NOUN	B
produces	O	VERB	O
bingeing	O	VERB	B
on	O	ADP	O
sugar	O	NOUN	B
that	O	PRON	O
leads	O	VERB	O
to	O	PART	O
a	O	DET	O
long	O	ADJ	B
lasting	O	VERB	I
state	O	NOUN	I
of	O	ADP	O
increased	O	VERB	B
sensitivity	O	NOUN	B
to	O	PART	O
amphetamine	B-Chemical	NOUN	B
,	O	PUNCT	O
possibly	O	ADV	O
due	O	ADJ	O
to	O	PART	O
a	O	DET	O
lasting	O	ADJ	O
alteration	O	NOUN	B
in	O	ADP	O
the	O	DET	O
dopamine	B-Chemical	NOUN	B


D-penicillamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
angiopathy	B-Disease	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
high	O	ADJ	B
dose	O	NOUN	I
D-penicillamine	B-Chemical	NOUN	B
treatment	O	NOUN	B
on	O	ADP	O
aortic	O	ADJ	B
permeability	O	NOUN	B
to	O	PART	O
albumin	O	NOUN	B
and	O	CCONJ	O
on	O	ADP	O
the	O	DET	O
ultrastructure	O	NOUN	B
of	O	ADP	O
the	O	DET	O
vessel	O	NOUN	B
.	O	PUNCT	O


Male	O	NOUN	B
Sprague	O	PROPN	B
-	O	PUNCT	O
Dawley	O	NOUN	B
rats	O	NOUN	B
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
D-penicillamine	B-Chemical	NOUN	B
(	O	PUNCT	O
D-pen	B-Chemical	NOUN	B
)	O	PUNCT	O
500	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
/	O	SYM	O
day	O	NOUN	B
for	O	ADP	O
10	O	NUM	O
or	O	CCONJ	O
42	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


Pair	O	NOUN	B
fed	O	VERB	I
rats	O	NOUN	B
served	O	VERB	O
as	O	ADP	O
controls	O	NOUN	B
.	O	PUNCT	O


Changes	O	NOUN	B
in	O	ADP	O
aortic	O	ADJ	B
morphology	O	NOUN	B
were	O	AUX	O
examined	O	VERB	O
by	O	ADP	O
light	O	ADJ	B
-	O	PUNCT	O
and	O	CCONJ	O
transmission	O	NOUN	B
-	O	PUNCT	O
electron	O	NOUN	B
microscopy	O	NOUN	I
(	O	PUNCT	O
TEM	O	PROPN	B
).	O	PUNCT	O
In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
endothelial	O	ADJ	B
permeability	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
penetration	O	NOUN	B
through	O	ADP	O
the	O	DET	O
aortic	O	ADJ	B
wall	O	NOUN	I
of	O	ADP	I
albumin	O	NOUN	I
were	O	AUX	O
studied	O	VERB	O
10	O	NUM	O
minutes	O	NOUN	B
,	O	PUNCT	O
24	O	NUM	O
and	O	CCONJ	O
48	O	NUM	O
hours	O	NOUN	B
after	O	ADP	O
i	O	PRON	O
.	O	PUNCT	O


v	O	NOUN	O
.	O	PUNCT	O


injection	O	NOUN	B
of	O	ADP	O
human	O	ADJ	B
serum	O	NOUN	B
131I	O	NOUN	B
-	O	PUNCT	O
albumin	O	NOUN	B
(	O	PUNCT	O
131I	O	NOUN	B
-	O	PUNCT	O
HSA	O	NOUN	B
).	O	PUNCT	O
TEM	O	PROPN	B
revealed	O	VERB	O
extensive	O	ADJ	O
elastolysis	O	NOUN	B
in	O	ADP	O
the	O	DET	O
arterial	O	ADJ	B
wall	O	NOUN	I
of	O	ADP	O
D-pen	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
rats	O	NOUN	B
,	O	PUNCT	O
consistent	O	ADJ	B
with	O	ADP	I
an	O	DET	O
inhibitory	O	ADJ	B
effect	O	NOUN	O
on	O	ADP	O
crosslink	O	NOUN	B
formation	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
experimental	O	ADJ	B
animals	O	NOUN	I
excess	O	ADJ	B
deposition	O	NOUN	B
of	O	ADP	O
collagen	O	NOUN	B
and	O	CCONJ	O
glycoaminoglycans	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
the	O	DET	O
subendothelial	O	ADJ	B
and	O	CCONJ	O
medial	O	ADJ	B
layer	O	NOUN	I
of	O	ADP	O
the	O	DET	O
aortic	O	ADJ	B
wall	O	NOUN	I
,	O	PUNCT	O
together	O	ADV	O
with	O	ADP	O
prominent	O	ADJ	O
basal	O	ADJ	B
membrane	O	NOUN	I
substance	O	NOUN	I
around	O	ADP	O
aortic	O	ADJ	B
smooth	O	ADJ	B
muscle	O	NOUN	I
cells	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
aorta	O	NOUN	B
/	O	SYM	O
serum	O	NOUN	B
-	O	PUNCT	O
ratio	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
radioactive	O	ADJ	B
build	O	NOUN	B
-	O	PUNCT	O
up	O	ADP	O
24	O	NUM	O
and	O	CCONJ	O
48	O	NUM	O
hours	O	NOUN	B
after	O	ADP	O
injection	O	NOUN	B
of	O	ADP	O
131I	O	NOUN	B
-	O	PUNCT	O
HSA	O	NOUN	B
was	O	AUX	O
reduced	O	VERB	B
in	O	ADP	O
animals	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
D-pen	B-Chemical	NOUN	B
for	O	ADP	O
42	O	NUM	O
days	O	NOUN	B
,	O	PUNCT	O
indicating	O	VERB	O
an	O	DET	O
impeded	O	VERB	O
transmural	O	ADJ	B
transport	O	NOUN	B
of	O	ADP	O
tracer	O	NOUN	B
which	O	DET	O
may	O	AUX	O
be	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
a	O	DET	O
steric	O	ADJ	B
exclusion	O	NOUN	I
effect	O	NOUN	I
of	O	ADP	O
abundant	O	ADJ	B
hyaluronate	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
endothelial	O	ADJ	B
ultrastructure	O	NOUN	B
was	O	AUX	O
unaffected	O	ADJ	O
by	O	ADP	O
D-pen	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
no	O	DET	O
differences	O	NOUN	O
in	O	ADP	O
aortic	O	ADJ	B
131I	O	NOUN	B
-	O	PUNCT	O
HSA	O	NOUN	B
radioactivity	O	NOUN	B
or	O	CCONJ	O
aorta	O	NOUN	B
/	O	SYM	O
serum	O	NOUN	B
-	O	PUNCT	O
ratio	O	NOUN	B
were	O	AUX	O
recorded	O	VERB	O
between	O	ADP	O
experimental	O	ADJ	B
and	O	CCONJ	O
control	O	NOUN	B
groups	O	NOUN	I
10	O	NUM	O
minutes	O	NOUN	B
after	O	ADP	O
tracer	O	NOUN	B
injection	O	NOUN	B
,	O	PUNCT	O
indicating	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
permeability	O	NOUN	B
of	O	ADP	O
the	O	DET	O
endothelial	O	ADJ	B
barrier	O	NOUN	I
to	O	PART	O
albumin	O	NOUN	B
remained	O	VERB	O
unaffected	O	ADJ	O
by	O	ADP	O
D-pen	B-Chemical	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
observations	O	NOUN	B
support	O	VERB	O
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
treatment	O	NOUN	B
with	O	ADP	O
high	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
D-pen	B-Chemical	NOUN	B


Brain	O	NOUN	B
natriuretic	O	ADJ	I
peptide	O	NOUN	I
is	O	AUX	O
a	O	DET	O
predictor	O	NOUN	B
of	O	ADP	O
anthracycline	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cardiotoxicity	B-Disease	NOUN	B
.	O	PUNCT	O


Anthracyclines	B-Chemical	NOUN	B
are	O	AUX	O
effective	O	ADJ	B
antineoplastic	O	ADJ	B
drugs	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
they	O	PRON	O
frequently	O	ADV	O
cause	O	VERB	B
dose	O	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
cardiotoxicity	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
cardiotoxicity	B-Disease	NOUN	B
of	O	ADP	O
conventional	O	ADJ	B
anthracycline	B-Chemical	NOUN	B
therapy	O	NOUN	I
highlights	O	VERB	O
a	O	DET	O
need	O	NOUN	O
to	O	PART	O
search	O	VERB	B
for	O	ADP	O
methods	O	NOUN	B
that	O	PRON	O
are	O	AUX	O
highly	O	ADV	O
sensitive	O	ADJ	B
and	O	CCONJ	O
capable	O	ADJ	O
of	O	ADP	O
predicting	O	VERB	B
cardiac	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
measured	O	VERB	B
the	O	DET	O
plasma	O	NOUN	B
level	O	NOUN	B
of	O	ADP	O
brain	O	NOUN	B
natriuretic	O	ADJ	I
peptide	O	NOUN	I
(	O	PUNCT	O
BNP	O	NOUN	B
)	O	PUNCT	O
to	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
BNP	O	NOUN	B
might	O	AUX	O
serve	O	VERB	O
as	O	ADP	O
a	O	DET	O
simple	O	ADJ	O
diagnostic	O	ADJ	B
indicator	O	NOUN	O
of	O	ADP	O
anthracycline	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cardiotoxicity	B-Disease	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
acute	B-Disease	ADJ	B
leukemia	I-Disease	NOUN	I
treated	O	VERB	B
with	O	ADP	I
a	O	DET	O
daunorubicin	B-Chemical	NOUN	B
(	O	PUNCT	O
DNR	B-Chemical	NOUN	B
)-	O	ADJ	O
containing	O	VERB	O
regimen	O	NOUN	B
.	O	PUNCT	O


Thirteen	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
acute	B-Disease	ADJ	B
leukemia	I-Disease	NOUN	I
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
a	O	DET	O
DNR	B-Chemical	PROPN	B
-	O	PUNCT	O
containing	O	VERB	B
regimen	O	NOUN	B
.	O	PUNCT	O


Cardiac	O	ADJ	B
functions	O	NOUN	I
were	O	AUX	O
evaluated	O	VERB	B
with	O	ADP	O
radionuclide	O	NOUN	B
angiography	O	NOUN	I
before	O	ADP	O
chemotherapies	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
plasma	O	NOUN	B
levels	O	NOUN	B
of	O	ADP	O
atrial	O	ADJ	B
natriuretic	O	ADJ	I
peptide	O	NOUN	I
(	O	PUNCT	O
ANP	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
BNP	O	NOUN	B
were	O	AUX	O
measured	O	VERB	B
at	O	ADP	O
the	O	DET	O
time	O	NOUN	B
of	O	ADP	O
radionuclide	O	NOUN	B
angiography	O	NOUN	I
.	O	PUNCT	O


Three	O	NUM	O
patients	O	NOUN	B
developed	O	VERB	O
congestive	B-Disease	ADJ	B
heart	I-Disease	NOUN	I
failure	I-Disease	NOUN	I
after	O	ADP	O
the	O	DET	O
completion	O	NOUN	B
of	O	ADP	O
chemotherapy	O	NOUN	B
.	O	PUNCT	O


Five	O	NUM	O
patients	O	NOUN	B
were	O	AUX	O
diagnosed	O	VERB	B
as	O	ADP	O
having	O	VERB	O
subclinical	O	ADJ	B
heart	B-Disease	NOUN	I
failure	I-Disease	NOUN	I
after	O	ADP	O
the	O	DET	O
completion	O	NOUN	B
of	O	ADP	O
chemotherapy	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
plasma	O	NOUN	B
levels	O	NOUN	B
of	O	ADP	O
BNP	O	NOUN	B
in	O	ADP	O
all	O	DET	O
the	O	DET	O
patients	O	NOUN	B
with	O	ADP	O
clinical	O	ADJ	B
and	O	CCONJ	O
subclinical	O	ADJ	B
heart	B-Disease	NOUN	I
failure	I-Disease	NOUN	I
increased	O	VERB	B
above	O	ADP	O
the	O	DET	O
normal	O	ADJ	B
limit	O	NOUN	I
(	O	PUNCT	O
40	O	NUM	O
pg	O	NOUN	O
/	O	PUNCT	O
ml	O	NOUN	O
)	O	PUNCT	O
before	O	ADP	O
the	O	DET	O
detection	O	NOUN	B
of	O	ADP	O
clinical	O	ADJ	B
or	O	CCONJ	O
subclinical	O	ADJ	B
heart	B-Disease	NOUN	I
failure	I-Disease	NOUN	I
by	O	ADP	O
radionuclide	O	NOUN	B
angiography	O	NOUN	I
.	O	PUNCT	O


On	O	ADP	O
the	O	DET	O
other	O	ADJ	O
hand	O	NOUN	B
,	O	PUNCT	O
BNP	O	PROPN	B
did	O	AUX	O
not	O	PART	O
increase	O	VERB	B
in	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
without	O	ADP	O
heart	B-Disease	NOUN	B
failure	I-Disease	NOUN	I
given	O	VERB	O
DNR	B-Chemical	NOUN	B
,	O	PUNCT	O
even	O	ADV	O
at	O	ADP	O
more	O	ADJ	O
than	O	ADP	O
700	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
).	O	PUNCT	O
The	O	DET	O
plasma	O	NOUN	B
level	O	NOUN	B
of	O	ADP	O
ANP	O	NOUN	B
did	O	AUX	O
not	O	PART	O
always	O	ADV	O
increase	O	VERB	B
in	O	ADP	O
all	O	DET	O
the	O	DET	O
patients	O	NOUN	B
with	O	ADP	O
clinical	O	ADJ	B
and	O	CCONJ	O
subclinical	O	ADJ	B
heart	B-Disease	NOUN	I
failure	I-Disease	NOUN	I
.	O	PUNCT	O


These	O	DET	O
preliminary	O	ADJ	B
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
BNP	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
useful	O	ADJ	O
as	O	ADP	O
an	O	DET	O
early	O	ADJ	B
and	O	CCONJ	O
sensitive	O	ADJ	B
indicator	O	NOUN	B
of	O	ADP	O
anthracycline	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cardiotoxicity	B-Disease	NOUN	B


Antibacterial	O	ADJ	B
medication	O	NOUN	I
use	O	NOUN	O
during	O	ADP	O
pregnancy	O	NOUN	B
and	O	CCONJ	O
risk	O	NOUN	B
of	O	ADP	O
birth	B-Disease	NOUN	B
defects	I-Disease	NOUN	I
:	O	PUNCT	O
National	O	PROPN	B
Birth	B-Disease	PROPN	I
Defects	I-Disease	PROPN	I
Prevention	O	PROPN	I
Study	O	PROPN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	B
:	O	PUNCT	O
To	O	PART	O
estimate	O	VERB	B
the	O	DET	O
association	O	NOUN	B
between	O	ADP	O
antibacterial	O	ADJ	B
medications	O	NOUN	I
and	O	CCONJ	O
selected	O	VERB	O
birth	B-Disease	NOUN	B
defects	I-Disease	NOUN	I
.	O	PUNCT	O


DESIGN	O	NOUN	B
,	O	PUNCT	O
SETTING	O	NOUN	B
,	O	PUNCT	O
AND	O	CCONJ	O
PARTICIPANTS	O	NOUN	B
:	O	PUNCT	O
Population	O	PROPN	B
-	O	PUNCT	O
based	O	VERB	B
,	O	PUNCT	O
multisite	O	ADJ	B
,	O	PUNCT	O
case	O	NOUN	B
-	O	PUNCT	O
control	O	NOUN	B
study	O	NOUN	I
of	O	ADP	O
women	O	NOUN	B
who	O	PRON	O
had	O	AUX	O
pregnancies	O	NOUN	B
affected	O	VERB	B
by	O	ADP	O
1	O	NUM	O
of	O	ADP	O
more	O	ADJ	O
than	O	ADP	O
30	O	NUM	O
eligible	O	ADJ	O
major	O	ADJ	O
birth	B-Disease	NOUN	B
defects	I-Disease	NOUN	I
identified	O	VERB	B
via	O	ADP	O
birth	B-Disease	NOUN	B
defect	I-Disease	NOUN	I
surveillance	O	NOUN	B
programs	O	NOUN	I
in	O	ADP	O
10	O	NUM	O
states	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
13	O	NUM	O
155	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
control	O	NOUN	B
women	O	NOUN	B
randomly	O	ADV	O
selected	O	VERB	O
from	O	ADP	O
the	O	DET	O
same	O	ADJ	O
geographical	O	ADJ	B
regions	O	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
4941	O	NUM	O
).	O	PUNCT	O
MAIN	O	ADJ	O
EXPOSURE	O	NOUN	B
:	O	PUNCT	O
Reported	O	VERB	O
maternal	O	ADJ	B
use	O	NOUN	O
of	O	ADP	O
antibacterials	O	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
month	O	NOUN	B
before	O	ADP	B
pregnancy	O	NOUN	B
through	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
first	O	ADJ	O
trimester	O	NOUN	B
).	O	PUNCT	O
MAIN	O	NOUN	O
OUTCOME	O	NOUN	O
MEASURE	O	NOUN	O
:	O	PUNCT	O
Odds	O	NOUN	B
ratios	O	NOUN	I
(	O	PUNCT	O
ORs	O	NOUN	B
)	O	PUNCT	O
measuring	O	VERB	B
the	O	DET	O
association	O	NOUN	B
between	O	ADP	O
antibacterial	O	ADJ	B
use	O	NOUN	O
and	O	CCONJ	O
selected	O	VERB	O
birth	B-Disease	NOUN	B
defects	I-Disease	NOUN	I
adjusted	O	VERB	O
for	O	ADP	O
potential	O	ADJ	B
confounders	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
reported	O	ADJ	O
use	O	NOUN	O
of	O	ADP	O
antibacterials	O	NOUN	B
increased	O	VERB	B
during	O	ADP	O
pregnancy	O	NOUN	B
,	O	PUNCT	O
peaking	O	VERB	O
during	O	ADP	O
the	O	DET	O
third	O	ADJ	O
month	O	NOUN	B
.	O	PUNCT	O


Sulfonamides	B-Chemical	NOUN	B
were	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
anencephaly	B-Disease	NOUN	B
(	O	PUNCT	O
adjusted	O	VERB	O
OR	O	CCONJ	B
[	O	PUNCT	O
AOR	O	PROPN	B
]=	O	PUNCT	O
3	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
[	O	PUNCT	O
CI	O	PROPN	B
],	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
-	O	SYM	O
8	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
),	O	PUNCT	O
hypoplastic	B-Disease	ADJ	B
left	I-Disease	ADJ	I
heart	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
AOR	O	NOUN	B
=	O	ADJ	O
3	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
-	O	SYM	O
7	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
),	O	PUNCT	O
coarctation	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
aorta	I-Disease	NOUN	B
(	O	PUNCT	O
AOR	O	NOUN	B
=	O	ADJ	O
2	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
-	O	SYM	O
5	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
),	O	PUNCT	O
choanal	B-Disease	ADJ	B
atresia	I-Disease	NOUN	I
(	O	PUNCT	O
AOR	O	NOUN	B
=	O	ADJ	O
8	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
-	O	SYM	O
23	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
),	O	PUNCT	O
transverse	B-Disease	ADJ	B
limb	I-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
(	O	PUNCT	O
AOR	O	NOUN	B
=	O	ADJ	O
2	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
-	O	SYM	O
5	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
),	O	PUNCT	O
and	O	CCONJ	O
diaphragmatic	B-Disease	ADJ	B
hernia	I-Disease	NOUN	I
(	O	PUNCT	O
AOR	O	NOUN	B
=	O	ADJ	O
2	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
-	O	SYM	O
5	O	NUM	O
.	O	PUNCT	O


4	O	X	O
).	O	PUNCT	O
Nitrofurantoins	B-Chemical	NOUN	B
were	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
anophthalmia	B-Disease	NOUN	B
or	O	CCONJ	O
microphthalmos	B-Disease	ADJ	B
(	O	PUNCT	O
AOR	O	NOUN	B
=	O	ADJ	O
3	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
-	O	SYM	O
12	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
),	O	PUNCT	O
hypoplastic	B-Disease	ADJ	B
left	I-Disease	ADJ	I
heart	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
AOR	O	NOUN	B
=	O	ADJ	O
4	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
-	O	SYM	O
9	O	NUM	B
.	O	PUNCT	O


1	O	NUM	O
),	O	PUNCT	O
atrial	B-Disease	ADJ	B
septal	I-Disease	ADJ	I
defects	I-Disease	NOUN	I
(	O	PUNCT	O
AOR	O	NOUN	B
=	O	ADJ	O
1	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
-	O	SYM	O
3	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
),	O	PUNCT	O
and	O	CCONJ	O
cleft	B-Disease	NOUN	B
lip	I-Disease	NOUN	I
with	O	ADP	I
cleft	B-Disease	ADJ	I
palate	I-Disease	NOUN	I
(	O	PUNCT	O
AOR	O	NOUN	B
=	O	ADJ	O
2	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
-	O	SYM	O
3	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
).	O	PUNCT	O
Other	O	ADJ	O
antibacterial	O	ADJ	B
agents	O	NOUN	I
that	O	PRON	O
showed	O	VERB	O
associations	O	NOUN	B
included	O	VERB	O
erythromycins	B-Chemical	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
defects	O	NOUN	B
),	O	PUNCT	O
penicillins	B-Chemical	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
defect	O	NOUN	B
),	O	PUNCT	O
cephalosporins	B-Chemical	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
defect	O	NOUN	B
),	O	PUNCT	O
and	O	CCONJ	O
quinolones	B-Chemical	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
defect	O	NOUN	B
).	O	PUNCT	B
CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
Reassuringly	O	ADV	B
,	O	PUNCT	O
penicillins	B-Chemical	NOUN	B
,	O	PUNCT	O
erythromycins	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
cephalosporins	B-Chemical	NOUN	B
,	O	PUNCT	O
although	O	SCONJ	O
used	O	VERB	O
commonly	O	ADV	O
by	O	ADP	O
pregnant	O	ADJ	B
women	O	NOUN	I
,	O	PUNCT	O
were	O	AUX	O
not	O	PART	O
associated	O	VERB	B
with	O	ADP	I
many	O	ADJ	O
birth	B-Disease	NOUN	B
defects	I-Disease	NOUN	I
.	O	PUNCT	O


Sulfonamides	B-Chemical	NOUN	B
and	O	CCONJ	O
nitrofurantoins	B-Chemical	NOUN	B
were	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
several	O	ADJ	O
birth	B-Disease	NOUN	B
defects	I-Disease	NOUN	I


Incidence	O	NOUN	B
of	O	ADP	O
neoplasms	B-Disease	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
rheumatoid	B-Disease	ADJ	B
arthritis	I-Disease	NOUN	I
exposed	O	VERB	B
to	O	PART	I
different	O	ADJ	O
treatment	O	NOUN	B
regimens	O	NOUN	I
.	O	PUNCT	O


Immunosuppressive	O	ADJ	B
drugs	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
used	O	VERB	O
during	O	ADP	O
the	O	DET	O
last	O	ADJ	O
30	O	NUM	O
years	O	NOUN	B
in	O	ADP	O
treatment	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
severe	O	ADJ	B
rheumatoid	B-Disease	ADJ	B
arthritis	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
drugs	O	NOUN	B
commonly	O	ADV	O
used	O	VERB	O
are	O	AUX	O
cyclophosphamide	B-Chemical	NOUN	B
and	O	CCONJ	O
chlorambucil	B-Chemical	NOUN	B
(	O	PUNCT	O
alkylating	B-Chemical	VERB	B
agents	I-Chemical	NOUN	I
),	O	PUNCT	O
azathioprine	B-Chemical	NOUN	B
(	O	PUNCT	O
purine	B-Chemical	NOUN	B
analogue	O	NOUN	I
),	O	PUNCT	O
and	O	CCONJ	O
methotrexate	B-Chemical	NOUN	B
(	O	PUNCT	O
folic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
analogue	O	NOUN	I
).	O	PUNCT	B
There	O	PRON	O
is	O	AUX	O
evidence	O	NOUN	B
that	O	SCONJ	O
all	O	DET	O
four	O	NUM	O
immunosuppressive	O	ADJ	B
drugs	O	NOUN	I
can	O	AUX	O
reduce	O	VERB	B
synovitis	B-Disease	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
disease	O	NOUN	B
activity	O	NOUN	I
almost	O	ADV	O
always	O	ADV	O
recurs	O	VERB	O
after	O	ADP	O
therapy	O	NOUN	B
is	O	AUX	O
stopped	O	VERB	B
.	O	PUNCT	O


Since	O	SCONJ	O
adverse	O	ADJ	B
reactions	O	NOUN	I
are	O	AUX	O
frequent	O	ADJ	B
,	O	PUNCT	O
less	O	ADJ	O
than	O	ADP	O
50	O	NUM	O
percent	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
are	O	AUX	O
able	O	ADJ	O
to	O	PART	O
continue	O	VERB	O
a	O	DET	O
particular	O	ADJ	O
drug	O	NOUN	B
for	O	ADP	O
more	O	ADJ	O
than	O	ADP	O
one	O	NUM	O
year	O	NOUN	B
.	O	PUNCT	O


Since	O	SCONJ	O
it	O	PRON	O
takes	O	VERB	O
three	O	NUM	O
to	O	PART	O
12	O	NUM	O
months	O	NOUN	B
to	O	PART	O
achieve	O	VERB	O
maximal	O	ADJ	B
effects	O	NOUN	B
,	O	PUNCT	O
those	O	DET	O
patients	O	NOUN	B
who	O	PRON	O
are	O	AUX	O
unable	O	ADJ	O
to	O	PART	O
continue	O	VERB	O
the	O	DET	O
drug	O	NOUN	B
receive	O	VERB	O
little	O	ADJ	O
benefit	O	NOUN	B
from	O	ADP	O
it	O	PRON	O
.	O	PUNCT	O


Patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
alkylating	B-Chemical	NOUN	B
agents	I-Chemical	NOUN	I
have	O	AUX	O
an	O	DET	O
increased	O	VERB	B
risk	O	NOUN	B
of	O	ADP	O
development	O	NOUN	B
of	O	ADP	O
acute	B-Disease	ADJ	B
nonlymphocytic	I-Disease	ADJ	I
leukemia	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
both	O	DET	O
alkylating	B-Chemical	VERB	B
agents	I-Chemical	NOUN	I
and	O	CCONJ	O
azathioprine	B-Chemical	NOUN	B
are	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
non-Hodgkin's	B-Disease	NOUN	B
lymphoma	I-Disease	NOUN	I
.	O	PUNCT	O


Cyclophosphamide	B-Chemical	NOUN	B
therapy	O	NOUN	I
increases	O	VERB	B
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
carcinoma	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
bladder	I-Disease	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
have	O	AUX	O
been	O	AUX	O
several	O	ADJ	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
studies	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
rheumatoid	B-Disease	ADJ	B
arthritis	I-Disease	NOUN	I
treated	O	VERB	B
with	O	ADP	I
azathioprine	B-Chemical	NOUN	B
and	O	CCONJ	O
cyclophosphamide	B-Chemical	NOUN	B
and	O	CCONJ	O
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
most	O	ADJ	O
of	O	ADP	O
the	O	DET	O
common	O	ADJ	O
cancers	B-Disease	NOUN	B
is	O	AUX	O
not	O	PART	O
increased	O	VERB	B
.	O	PUNCT	O


Data	O	NOUN	B
on	O	ADP	O
the	O	DET	O
possible	O	ADJ	O
increased	O	VERB	B
risk	O	NOUN	B
of	O	ADP	O
malignancy	B-Disease	NOUN	B
in	O	ADP	O
rheumatoid	B-Disease	ADJ	B
arthritis	I-Disease	NOUN	I
are	O	AUX	O
still	O	ADV	O
being	O	AUX	O
collected	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
until	O	ADP	O
further	O	ADJ	O
information	O	NOUN	B
is	O	AUX	O
available	O	ADJ	O
,	O	PUNCT	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
immunosuppressive	O	ADJ	B
drugs	O	NOUN	I
,	O	PUNCT	O
particularly	O	ADV	O
alkylating	B-Chemical	VERB	B
agents	I-Chemical	NOUN	I
,	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
rheumatoid	B-Disease	ADJ	B
arthritis	I-Disease	NOUN	I


Patterns	O	NOUN	B
of	O	ADP	O
hepatic	B-Disease	ADJ	B
injury	I-Disease	NOUN	I
induced	O	VERB	B
by	O	ADP	O
methyldopa	B-Chemical	NOUN	B
.	O	PUNCT	O


Twelve	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
liver	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
related	O	ADJ	O
to	O	PART	O
methyldopa	B-Chemical	NOUN	B
were	O	AUX	O
seen	O	VERB	O
between	O	ADP	O
1967	O	NUM	O
and	O	CCONJ	O
1977	O	NUM	O
.	O	PUNCT	O


Illness	O	NOUN	B
occurred	O	VERB	O
within	O	ADP	O
1	O	NUM	O
--	O	PUNCT	O
9	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
commencement	O	NOUN	B
of	O	ADP	O
therapy	O	NOUN	B
in	O	ADP	O
9	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
remaining	O	VERB	O
3	O	NUM	O
patients	O	NOUN	B
having	O	VERB	O
received	O	VERB	O
the	O	DET	O
drug	O	NOUN	B
for	O	ADP	O
13	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
15	O	NUM	O
months	O	NOUN	B
and	O	CCONJ	O
7	O	NUM	O
years	O	NOUN	B
before	O	ADP	O
experiencing	O	VERB	O
symptoms	O	NOUN	B
.	O	PUNCT	O


Jaundice	B-Disease	NOUN	B
with	O	ADP	O
tender	O	ADJ	B
hepatomegaly	B-Disease	NOUN	I
,	O	PUNCT	O
usually	O	ADV	O
preceded	O	VERB	O
by	O	ADP	O
symptoms	O	NOUN	B
of	O	ADP	O
malaise	O	NOUN	B
,	O	PUNCT	O
anorexia	B-Disease	NOUN	B
,	O	PUNCT	O
nausea	B-Disease	NOUN	B
and	O	CCONJ	O
vomiting	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
associated	O	VERB	B
with	O	ADP	I
upper	O	ADJ	B
abdominal	B-Disease	ADJ	I
pain	I-Disease	NOUN	I
,	O	PUNCT	O
was	O	AUX	O
an	O	DET	O
invariable	O	ADJ	O
finding	O	NOUN	O
in	O	ADP	O
all	O	DET	O
patients	O	NOUN	B
.	O	PUNCT	O


Biochemical	O	ADJ	B
liver	O	NOUN	O
function	O	NOUN	O
tests	O	NOUN	O
indicated	O	VERB	O
hepatocellular	O	NOUN	B
necrosis	B-Disease	NOUN	I
and	O	CCONJ	O
correlated	O	VERB	B
with	O	ADP	O
histopathological	O	ADJ	B
evidence	O	NOUN	B
of	O	ADP	O
hepatic	B-Disease	ADJ	B
injury	I-Disease	NOUN	I
,	O	PUNCT	O
the	O	DET	O
spectrum	O	NOUN	B
of	O	ADP	O
which	O	DET	O
ranged	O	VERB	O
from	O	ADP	O
fatty	B-Disease	ADJ	B
change	I-Disease	NOUN	I
and	O	CCONJ	O
focal	O	ADJ	B
hepatocellular	O	NOUN	I
necrosis	B-Disease	NOUN	I
to	O	PART	O
massive	B-Disease	ADJ	O
hepatic	I-Disease	ADJ	B
necrosis	I-Disease	NOUN	I
.	O	PUNCT	O


Most	O	ADJ	O
patients	O	NOUN	B
showed	O	VERB	O
moderate	O	ADJ	B
to	O	PART	O
severe	O	ADJ	O
acute	B-Disease	ADJ	B
hepatitis	I-Disease	NOUN	I
or	O	CCONJ	O
chronic	B-Disease	ADJ	B
active	I-Disease	ADJ	I
hepatitis	I-Disease	NOUN	I
with	O	ADP	O
associated	O	VERB	O
cholestasis	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
drug	O	NOUN	B
was	O	AUX	O
withdrawn	O	VERB	O
on	O	ADP	O
presentation	O	NOUN	B
to	O	ADP	O
hospital	O	NOUN	B
in	O	ADP	O
11	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
rapid	O	ADJ	O
clinical	O	ADJ	B
improvement	O	NOUN	I
in	O	ADP	O
9	O	NUM	O
.	O	PUNCT	O


One	O	NUM	O
patient	O	NOUN	B
died	O	VERB	B
,	O	PUNCT	O
having	O	VERB	O
presented	O	VERB	O
in	O	ADP	O
hepatic	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
another	O	DET	O
,	O	PUNCT	O
who	O	PRON	O
had	O	AUX	O
been	O	AUX	O
taking	O	VERB	O
methyldopa	B-Chemical	NOUN	B
for	O	ADP	O
7	O	NUM	O
years	O	NOUN	B
,	O	PUNCT	O
showed	O	VERB	O
slower	O	ADJ	O
clinical	O	ADJ	B
and	O	CCONJ	O
biochemical	O	ADJ	B
resolution	O	NOUN	B
over	O	ADP	O
a	O	DET	O
period	O	NOUN	B
of	O	ADP	O
several	O	ADJ	O
months	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
remaining	O	VERB	O
patient	O	NOUN	B
in	O	ADP	O
the	O	DET	O
series	O	NOUN	O
developed	O	VERB	O
fulminant	B-Disease	ADJ	B
hepatitis	I-Disease	NOUN	B
when	O	SCONJ	O
the	O	DET	O
drug	O	NOUN	B
was	O	AUX	O
accidentally	O	ADV	O
recommenced	O	VERB	O
1	O	NUM	O
year	O	NOUN	B
after	O	ADP	O
a	O	DET	O
prior	O	ADJ	O
episode	O	NOUN	B
of	O	ADP	O
methyldopa	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hepatitis	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
latter	O	ADJ	O
patient	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
2	O	NUM	O
others	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
causal	O	ADJ	O
relationship	O	NOUN	B
between	O	ADP	O
methyldopa	B-Chemical	NOUN	B
and	O	CCONJ	O
hepatic	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
was	O	AUX	O
proved	O	VERB	O
with	O	ADP	O
the	O	DET	O
recurrence	O	NOUN	B
of	O	ADP	O
hepatitis	B-Disease	NOUN	B


A	O	DET	O
phase	O	NOUN	B
I	O	NUM	I
/	O	SYM	O
II	O	NUM	B
study	O	NOUN	B
of	O	ADP	O
paclitaxel	B-Chemical	NOUN	B
plus	O	CCONJ	O
cisplatin	B-Chemical	NOUN	B
as	O	ADP	O
first	O	ADJ	B
-	O	PUNCT	O
line	O	NOUN	B
therapy	O	NOUN	I
for	O	ADP	O
head	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
neck	I-Disease	NOUN	O
cancers	I-Disease	NOUN	O
:	O	PUNCT	O
preliminary	O	ADJ	B
results	O	NOUN	B
.	O	PUNCT	O


Improved	O	ADJ	O
outcomes	O	NOUN	B
among	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
head	B-Disease	NOUN	B
and	I-Disease	CCONJ	I
neck	I-Disease	NOUN	I
carcinomas	I-Disease	NOUN	I
require	O	VERB	O
investigations	O	NOUN	B
of	O	ADP	O
new	O	ADJ	O
drugs	O	NOUN	B
for	O	ADP	O
induction	O	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


Preliminary	O	ADJ	B
results	O	NOUN	B
of	O	ADP	O
an	O	DET	O
Eastern	O	PROPN	B
Cooperative	O	PROPN	I
Oncology	O	PROPN	I
Group	O	PROPN	I
study	O	NOUN	I
of	O	ADP	O
single	O	ADJ	B
-	O	PUNCT	O
agent	O	NOUN	B
paclitaxel	B-Chemical	NOUN	B
(	O	PUNCT	O
Taxol	B-Chemical	PROPN	B
;	O	PUNCT	O
Bristol	O	PROPN	B
-	O	PUNCT	O
Myers	O	PROPN	B
Squibb	O	PROPN	I
Company	O	PROPN	I
,	O	PUNCT	O
Princeton	O	PROPN	B
,	O	PUNCT	O
NJ	O	PROPN	B
)	O	PUNCT	O
reported	O	VERB	O
a	O	DET	O
37	O	NUM	O
%	O	NOUN	O
response	O	NOUN	B
rate	O	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
head	B-Disease	NOUN	B
and	I-Disease	CCONJ	I
neck	I-Disease	NOUN	I
cancer	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
paclitaxel	B-Chemical	NOUN	B
/	O	SYM	O
cisplatin	B-Chemical	NOUN	B
combination	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
used	O	VERB	O
successfully	O	ADV	O
and	O	CCONJ	O
has	O	AUX	O
significantly	O	ADV	O
improved	O	VERB	O
median	O	ADJ	B
response	O	NOUN	I
duration	O	NOUN	O
in	O	ADP	O
ovarian	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
patients	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
initiated	O	VERB	O
a	O	DET	O
phase	O	NOUN	B
I	O	NUM	I
/	O	SYM	O
II	O	PROPN	B
trial	O	NOUN	B
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
response	O	NOUN	B
and	O	CCONJ	O
toxicity	B-Disease	NOUN	B
of	O	ADP	O
escalating	O	VERB	B
paclitaxel	B-Chemical	NOUN	B
doses	O	NOUN	B
combined	O	VERB	O
with	O	ADP	O
fixed	O	VERB	B
-	O	PUNCT	O
dose	O	NOUN	B
cisplatin	B-Chemical	NOUN	B
with	O	ADP	O
granulocyte	O	NOUN	B
colony	O	NOUN	B
-	O	PUNCT	O
stimulating	O	VERB	B
factor	O	NOUN	B
support	O	NOUN	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
untreated	O	ADJ	B
locally	O	ADV	B
advanced	O	ADJ	I
inoperable	O	ADJ	O
head	B-Disease	NOUN	O
and	I-Disease	CCONJ	O
neck	I-Disease	NOUN	O
carcinoma	I-Disease	NOUN	O
.	O	PUNCT	O


To	O	ADP	O
date	O	NOUN	O
,	O	PUNCT	O
23	O	NUM	O
men	O	NOUN	B
with	O	ADP	O
a	O	DET	O
median	O	ADJ	O
age	O	NOUN	B
of	O	ADP	O
50	O	NUM	O
years	O	NOUN	B
and	O	CCONJ	O
good	O	ADJ	O
performance	O	NOUN	O
status	O	NOUN	O
have	O	AUX	O
entered	O	VERB	O
the	O	DET	O
trial	O	NOUN	B
.	O	PUNCT	O


Primary	O	ADJ	B
tumor	B-Disease	NOUN	I
sites	O	NOUN	I
were	O	AUX	O
oropharynx	O	ADJ	B
,	O	PUNCT	O
10	O	NUM	O
patients	O	NOUN	B
;	O	PUNCT	O
hypopharynx	O	NOUN	B
,	O	PUNCT	O
four	O	NUM	O
;	O	PUNCT	O
larynx	O	NOUN	B
,	O	PUNCT	O
two	O	NUM	O
;	O	PUNCT	O
oral	O	ADJ	B
cavity	O	NOUN	I
,	O	PUNCT	O
three	O	NUM	O
;	O	PUNCT	O
unknown	O	ADJ	O
primary	O	ADJ	B
,	O	PUNCT	O
two	O	NUM	O
;	O	PUNCT	O
and	O	CCONJ	O
nasal	O	ADJ	B
cavity	O	NOUN	I
and	O	CCONJ	O
parotid	O	NOUN	B
gland	O	NOUN	I
,	O	PUNCT	O
one	O	NUM	O
each	O	DET	O
.	O	PUNCT	O


Of	O	ADP	O
20	O	NUM	O
patients	O	NOUN	B
evaluable	O	ADJ	O
for	O	ADP	O
toxicity	B-Disease	NOUN	B
,	O	PUNCT	O
four	O	NUM	O
had	O	AUX	O
stage	O	NOUN	B
III	O	NUM	I
and	O	CCONJ	O
16	O	NUM	O
had	O	AUX	O
stage	O	NOUN	B
IV	O	NUM	I
disease	O	NOUN	I
.	O	PUNCT	O


Treatment	O	NOUN	B
,	O	PUNCT	O
given	O	VERB	O
every	O	DET	O
21	O	NUM	O
days	O	NOUN	B
for	O	ADP	O
a	O	DET	O
maximum	O	NOUN	B
of	O	ADP	O
three	O	NUM	O
cycles	O	NOUN	B
,	O	PUNCT	O
consisted	O	VERB	O
of	O	ADP	O
paclitaxel	B-Chemical	NOUN	B
by	O	ADP	O
3	O	NUM	O
-	O	PUNCT	O
hour	O	NOUN	B
infusion	O	NOUN	B
followed	O	VERB	O
the	O	DET	O
next	O	ADJ	O
day	O	NOUN	B
by	O	ADP	O
a	O	DET	O
fixed	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
cisplatin	B-Chemical	NOUN	B
(	O	PUNCT	O
75	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
).	O	PUNCT	O
The	O	DET	O
dose	O	NOUN	B
levels	O	NOUN	O
incorporate	O	VERB	O
escalating	O	VERB	O
paclitaxel	B-Chemical	NOUN	B
doses	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
intrapatient	O	ADJ	B
escalations	O	NOUN	B
within	O	ADP	O
a	O	DET	O
given	O	VERB	O
dose	O	NOUN	B
level	O	NOUN	B
are	O	AUX	O
permitted	O	VERB	O
if	O	SCONJ	O
toxicity	B-Disease	NOUN	B
permits	O	NOUN	O
.	O	PUNCT	O


At	O	ADP	O
the	O	DET	O
time	O	NOUN	B
of	O	ADP	O
this	O	DET	O
writing	O	NOUN	B
,	O	PUNCT	O
dose	O	NOUN	B
level	O	NOUN	O
4	O	NUM	O
(	O	PUNCT	O
260	O	NUM	O
,	O	PUNCT	O
270	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
280	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
being	O	AUX	O
evaluated	O	VERB	B
;	O	PUNCT	O
three	O	NUM	O
patients	O	NOUN	B
from	O	ADP	O
this	O	DET	O
level	O	NOUN	B
are	O	AUX	O
evaluable	O	ADJ	O
.	O	PUNCT	O


With	O	ADP	O
paclitaxel	B-Chemical	NOUN	B
doses	O	NOUN	B
of	O	ADP	O
200	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
and	O	CCONJ	O
higher	O	ADJ	B
,	O	PUNCT	O
granulocyte	O	NOUN	B
colony	O	NOUN	B
-	O	PUNCT	O
stimulating	O	VERB	B
factor	O	NOUN	B
5	O	NUM	O
micrograms	O	NOUN	B
/	O	SYM	O
kg	O	NOUN	B
/	O	SYM	O
d	O	NOUN	B
is	O	AUX	O
given	O	VERB	O
(	O	PUNCT	O
days	O	NOUN	B
4	O	NUM	O
through	O	ADP	O
12	O	NUM	O
).	O	PUNCT	O
Of	O	ADP	O
18	O	NUM	O
patients	O	NOUN	B
evaluable	O	ADJ	O
for	O	ADP	O
response	O	NOUN	B
,	O	PUNCT	O
seven	O	NUM	O
(	O	PUNCT	O
39	O	NUM	O
%)	O	NOUN	O
achieved	O	VERB	O
a	O	DET	O
complete	O	ADJ	O
response	O	NOUN	B
and	O	CCONJ	O
six	O	NUM	O
(	O	PUNCT	O
33	O	NUM	O
%)	O	NOUN	O
achieved	O	VERB	O
a	O	DET	O
partial	O	ADJ	B
response	O	NOUN	I
.	O	PUNCT	O


Three	O	NUM	O
patients	O	NOUN	B
had	O	AUX	O
no	O	DET	O
change	O	NOUN	O
and	O	CCONJ	O
disease	O	NOUN	B
progressed	O	VERB	O
in	O	ADP	O
two	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
overall	O	ADJ	O
response	O	NOUN	B
rate	O	NOUN	I
is	O	AUX	O
72	O	NUM	O
%.	O	NOUN	O
Eleven	O	NUM	O
responding	O	VERB	B
patients	O	NOUN	B
had	O	AUX	O
subsequent	O	ADJ	O
surgery	O	NOUN	B
/	O	SYM	O
radiotherapy	O	NOUN	B
or	O	CCONJ	O
radical	O	ADJ	B
radiotherapy	O	NOUN	I
.	O	PUNCT	O


Two	O	NUM	O
pathologic	O	ADJ	B
complete	O	ADJ	O
responses	O	NOUN	B
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
patients	O	NOUN	B
who	O	PRON	O
had	O	AUX	O
achieved	O	VERB	O
clinical	O	ADJ	B
complete	O	ADJ	I
responses	O	NOUN	B
.	O	PUNCT	O


Alopecia	B-Disease	NOUN	B
,	O	PUNCT	O
paresthesias	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
arthralgias	B-Disease	NOUN	B
/	O	SYM	O
myalgias	B-Disease	NOUN	B
have	O	AUX	O
occurred	O	VERB	O
frequently	O	ADV	O
,	O	PUNCT	O
but	O	CCONJ	O
with	O	ADP	O
one	O	NUM	O
exception	O	NOUN	O
(	O	PUNCT	O
a	O	DET	O
grade	O	NOUN	B
3	O	NUM	I
myalgia	B-Disease	NOUN	I
)	O	PUNCT	O
they	O	PRON	O
have	O	AUX	O
been	O	AUX	O
grade	O	NOUN	O
1	O	NUM	O
or	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O


No	O	DET	B
dose	O	NOUN	I
-	O	PUNCT	O
limiting	O	VERB	B
hematologic	O	ADJ	B
toxicity	B-Disease	NOUN	B
has	O	AUX	O
been	O	AUX	O
seen	O	VERB	O
.	O	PUNCT	O


Paclitaxel	B-Chemical	NOUN	B
/	O	SYM	O
cisplatin	B-Chemical	NOUN	B
is	O	AUX	O
an	O	DET	O
effective	O	ADJ	B
first	O	ADJ	B
-	O	PUNCT	O
line	O	NOUN	B
regimen	O	NOUN	B
for	O	ADP	O
locoregionally	O	ADV	B
advanced	O	ADJ	I
head	B-Disease	NOUN	O
and	I-Disease	CCONJ	O
neck	I-Disease	NOUN	O
cancer	I-Disease	NOUN	O
and	O	CCONJ	O
continued	O	VERB	O
study	O	NOUN	B
is	O	AUX	O
warranted	O	VERB	O
.	O	PUNCT	O


Results	O	NOUN	B
thus	O	ADV	O
far	O	ADV	O
suggest	O	VERB	O
no	O	DET	O
dose	O	NOUN	B
-	O	PUNCT	O
response	O	NOUN	B
effect	O	NOUN	B
for	O	ADP	O
paclitaxel	B-Chemical	NOUN	B


A	O	DET	O
phase	O	NOUN	B
I	O	NOUN	I
study	O	NOUN	B
of	O	ADP	O
4'-0-tetrahydropyranyladriamycin	B-Chemical	NOUN	B
.	O	PUNCT	O


Clinical	O	ADJ	B
pharmacology	O	NOUN	I
and	O	CCONJ	O
pharmacokinetics	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
Phase	O	NOUN	B
I	O	NUM	I
study	O	NOUN	B
of	O	ADP	O
intravenous	O	ADJ	B
(	O	PUNCT	O
IV	O	NUM	B
)	O	PUNCT	O
bolus	O	NOUN	B
4'-0-tetrahydropyranyladriamycin	B-Chemical	NOUN	O
(	O	PUNCT	O
Pirarubicin	B-Chemical	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
done	O	VERB	O
in	O	ADP	O
55	O	NUM	O
patients	O	NOUN	B
in	O	ADP	O
good	O	ADJ	B
performance	O	NOUN	I
status	O	NOUN	O
with	O	ADP	O
refractory	O	ADJ	B
tumors	B-Disease	NOUN	I
.	O	PUNCT	O


Twenty	O	NUM	B
-	O	PUNCT	O
six	O	NUM	O
had	O	AUX	O
minimal	O	ADJ	B
prior	O	ADJ	O
therapy	O	NOUN	B
(	O	PUNCT	O
good	O	ADJ	B
risk	O	NOUN	I
),	O	PUNCT	O
23	O	NUM	O
had	O	AUX	O
extensive	O	ADJ	O
prior	O	ADJ	O
therapy	O	NOUN	B
(	O	PUNCT	O
poor	O	ADJ	B
risk	O	NOUN	I
),	O	PUNCT	O
and	O	CCONJ	O
six	O	NUM	O
had	O	AUX	O
renal	B-Disease	ADJ	B
and/or	I-Disease	CCONJ	O
hepatic	I-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
167	O	NUM	O
courses	O	NOUN	B
at	O	ADP	O
doses	O	NOUN	B
of	O	ADP	O
15	O	NUM	O
to	O	PART	O
70	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
were	O	AUX	O
evaluable	O	ADJ	O
.	O	PUNCT	O


Maximum	O	ADJ	B
tolerated	O	ADJ	B
dose	O	NOUN	I
in	O	ADP	O
good	O	ADJ	B
-	O	PUNCT	O
risk	O	NOUN	B
patients	O	NOUN	B
was	O	AUX	O
70	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
poor	O	ADJ	B
-	O	PUNCT	O
risk	O	NOUN	B
patients	O	NOUN	B
,	O	PUNCT	O
60	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
dose	O	NOUN	B
-	O	PUNCT	O
limiting	O	VERB	B
toxic	O	ADJ	B
effect	O	NOUN	I
was	O	AUX	O
transient	O	ADJ	B
noncumulative	O	ADJ	O
granulocytopenia	B-Disease	NOUN	O
.	O	PUNCT	O


Granulocyte	O	NOUN	B
nadir	O	NOUN	B
was	O	AUX	O
on	O	ADP	O
day	O	NOUN	B
14	O	NUM	O
(	O	PUNCT	O
range	O	NOUN	B
,	O	PUNCT	O
4	O	NUM	O
-	O	SYM	O
22	O	NUM	O
).	O	PUNCT	O
Less	O	ADV	O
frequent	O	ADJ	B
toxic	O	ADJ	B
effects	O	NOUN	O
included	O	VERB	O
thrombocytopenia	B-Disease	NOUN	B
,	O	PUNCT	O
anemia	B-Disease	NOUN	B
,	O	PUNCT	O
nausea	B-Disease	NOUN	B
,	O	PUNCT	O
mild	O	ADJ	B
alopecia	B-Disease	NOUN	I
,	O	PUNCT	O
phlebitis	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
mucositis	B-Disease	NOUN	B
.	O	PUNCT	O


Myelosuppression	B-Disease	NOUN	B
was	O	AUX	O
more	O	ADJ	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
hepatic	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
.	O	PUNCT	O


Pharmacokinetic	O	ADJ	B
analyses	O	NOUN	I
in	O	ADP	O
21	O	NUM	O
patients	O	NOUN	B
revealed	O	VERB	O
Pirarubicin	B-Chemical	NOUN	B
plasma	O	NOUN	I
T	O	NOUN	I
1	O	NUM	I
/	O	SYM	O
2	O	NUM	B
alpha	O	NOUN	I
(+/-	O	PUNCT	O
SE	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
2	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


85	O	NUM	O
minutes	O	NOUN	B
,	O	PUNCT	O
T	O	NOUN	B
beta	O	NOUN	I
1	O	NUM	I
/	O	SYM	O
2	O	NUM	O
of	O	ADP	O
25	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
+/-	O	CCONJ	O
6	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
minutes	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
T	O	NOUN	B
1	O	NUM	I
/	O	SYM	O
2	O	NUM	B
gamma	O	NOUN	O
of	O	ADP	O
23	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
+/-	O	CCONJ	O
7	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
hours	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
area	O	NOUN	B
under	O	ADP	I
the	O	DET	I
curve	O	NOUN	I
was	O	AUX	O
537	O	NUM	O
+/-	O	CCONJ	O
149	O	NUM	O
ng	O	NOUN	O
/	O	PUNCT	O
ml	O	NOUN	O
x	O	NOUN	O
hours	O	NOUN	B
,	O	PUNCT	O
volume	O	NOUN	B
of	O	ADP	O
distribution	O	NOUN	B
(	O	PUNCT	O
Vd	O	NOUN	B
)	O	PUNCT	O
3504	O	NUM	O
+/-	O	CCONJ	O
644	O	NUM	O
l	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
total	O	ADJ	B
clearance	O	NOUN	I
(	O	PUNCT	O
ClT	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
204	O	NUM	O
+	O	CCONJ	O
39	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
l	O	X	O
/	O	SYM	O
hour	O	NOUN	B
/	O	SYM	O
m2	O	NOUN	B
.	O	PUNCT	O


Adriamycinol	B-Chemical	NOUN	B
,	O	PUNCT	O
doxorubicin	B-Chemical	NOUN	B
,	O	PUNCT	O
adriamycinone	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
tetrahydropyranyladriamycinol	B-Chemical	NOUN	B
were	O	AUX	O
the	O	DET	O
metabolites	O	NOUN	B
detected	O	VERB	B
in	O	ADP	O
plasma	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
amount	O	NOUN	B
of	O	ADP	O
doxorubicin	B-Chemical	NOUN	B
was	O	AUX	O
less	O	ADJ	O
than	O	ADP	O
or	O	CCONJ	O
equal	O	ADJ	O
to	O	PART	O
10	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
total	O	ADJ	O
metabolites	O	NOUN	B
.	O	PUNCT	O


Urinary	O	ADJ	B
excretion	O	NOUN	B
of	O	ADP	O
Pirarubicin	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
first	O	ADJ	O
24	O	NUM	O
hours	O	NOUN	B
was	O	AUX	O
less	O	ADJ	O
than	O	ADP	O
or	O	CCONJ	O
equal	O	ADJ	O
to	O	PART	O
10	O	NUM	O
%.	O	NOUN	O
Activity	O	NOUN	B
was	O	AUX	O
noted	O	VERB	O
in	O	ADP	O
mesothelioma	B-Disease	NOUN	B
,	O	PUNCT	O
leiomyosarcoma	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
basal	B-Disease	ADJ	B
cell	I-Disease	NOUN	I
carcinoma	I-Disease	NOUN	I


Differential	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
gamma-hexachlorocyclohexane	B-Chemical	NOUN	B
(	O	PUNCT	O
lindane	B-Chemical	NOUN	B
)	O	PUNCT	O
on	O	ADP	O
pharmacologically	O	ADV	B
-	O	PUNCT	O
induced	O	VERB	B
seizures	B-Disease	NOUN	B
.	O	PUNCT	O


Gamma-hexachlorocyclohexane	B-Chemical	NOUN	B
(	O	PUNCT	O
gamma-HCH	B-Chemical	NOUN	B
),	O	PUNCT	O
the	O	DET	O
active	O	ADJ	B
ingredient	O	NOUN	I
of	O	ADP	O
the	O	DET	O
insecticide	O	NOUN	B
lindane	B-Chemical	NOUN	B
,	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
decrease	O	VERB	B
seizure	B-Disease	NOUN	B
threshold	O	NOUN	B
to	O	PART	O
pentylenetrazol	O	NOUN	B
(	O	PUNCT	O
PTZ	B-Chemical	NOUN	B
)	O	PUNCT	O
3	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
exposure	O	NOUN	B
to	O	PART	I
gamma-HCH	B-Chemical	NOUN	B
and	O	CCONJ	O
conversely	O	ADV	O
increase	O	VERB	B
threshold	O	NOUN	B
to	O	ADP	O
PTZ	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
seizures	B-Disease	NOUN	B
24	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
exposure	O	NOUN	B
to	O	PART	I
gamma-HCH	B-Chemical	NOUN	B
(	O	PUNCT	O
Vohland	O	PROPN	B
et	O	X	O
al	O	X	O
.	O	PUNCT	O


1981	O	NUM	O
).	O	PUNCT	O
In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
severity	O	NOUN	B
of	O	ADP	O
response	O	NOUN	B
to	O	PART	O
other	O	ADJ	O
seizure	B-Disease	NOUN	B
-	O	PUNCT	O
inducing	O	VERB	B
agents	O	NOUN	B
was	O	AUX	O
tested	O	VERB	B
in	O	ADP	O
mice	O	NOUN	B
1	O	NUM	O
and	O	CCONJ	O
24	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
intraperitoneal	O	ADJ	B
administration	O	NOUN	B
of	O	ADP	O
80	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
gamma-HCH	B-Chemical	NOUN	B
.	O	PUNCT	O


One	O	NUM	O
hour	O	NOUN	B
after	O	ADP	O
the	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
gamma-HCH	B-Chemical	NOUN	B
,	O	PUNCT	O
the	O	DET	O
activity	O	NOUN	B
of	O	ADP	O
seizure	B-Disease	NOUN	B
-	O	PUNCT	O
inducing	O	VERB	B
agents	O	NOUN	B
was	O	AUX	O
increased	O	VERB	B
,	O	PUNCT	O
regardless	O	ADV	O
of	O	ADP	O
their	O	PRON	O
mechanism	O	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
24	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
gamma-HCH	B-Chemical	NOUN	B
a	O	DET	O
differential	O	ADJ	B
response	O	NOUN	I
was	O	AUX	O
observed	O	VERB	B
.	O	PUNCT	O


Seizure	B-Disease	NOUN	B
activity	O	NOUN	B
due	O	ADJ	O
to	O	ADP	O
PTZ	B-Chemical	NOUN	B
and	O	CCONJ	O
picrotoxin	B-Chemical	NOUN	B
(	O	PUNCT	O
PTX	B-Chemical	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
significantly	O	ADV	O
decreased	O	VERB	B
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
seizure	B-Disease	NOUN	B
activity	O	NOUN	B
due	O	ADJ	O
to	O	PART	O
3-mercaptopropionic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
(	O	PUNCT	O
MPA	B-Chemical	NOUN	B
),	O	PUNCT	O
bicuculline	B-Chemical	NOUN	B
(	O	PUNCT	O
BCC	B-Chemical	NOUN	B
),	O	PUNCT	O
methyl	B-Chemical	NOUN	B
6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate	I-Chemical	NUM	I
(	O	PUNCT	O
DMCM	B-Chemical	NOUN	B
),	O	PUNCT	O
or	O	CCONJ	O
strychnine	B-Chemical	NOUN	B
(	O	PUNCT	O
STR	B-Chemical	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
not	O	PART	O
different	O	ADJ	O
from	O	ADP	O
control	O	NOUN	B
.	O	PUNCT	O


In	O	X	B
vitro	O	X	I
,	O	PUNCT	O
gamma-HCH	B-Chemical	NOUN	B
,	O	PUNCT	O
pentylenetetrazol	B-Chemical	NOUN	B
and	O	CCONJ	O
picrotoxin	B-Chemical	NOUN	B
were	O	AUX	O
shown	O	VERB	O
to	O	PART	O
inhibit	O	VERB	B
3H-TBOB	B-Chemical	NOUN	B
binding	O	NOUN	B
in	O	ADP	O
mouse	O	NOUN	B
whole	O	ADJ	O
brain	O	NOUN	O
,	O	PUNCT	O
with	O	ADP	O
IC50	O	NOUN	B
values	O	NOUN	B
of	O	ADP	O
4	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
,	O	PUNCT	O
404	O	NUM	O
and	O	CCONJ	O
9	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
microM	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


MPA	B-Chemical	NOUN	B
,	O	PUNCT	O
BCC	B-Chemical	NOUN	B
,	O	PUNCT	O
DMCM	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
STR	B-Chemical	NOUN	B
showed	O	VERB	O
no	O	DET	O
inhibition	O	NOUN	B
of	O	ADP	O
3H-TBOB	B-Chemical	NOUN	B
(	O	PUNCT	O
t-butyl	B-Chemical	NOUN	B
bicyclo-orthobenzoate	I-Chemical	NOUN	I
)	O	PUNCT	O
binding	O	NOUN	O
at	O	ADP	O
concentrations	O	NOUN	B
of	O	ADP	O
100	O	NUM	O
micron	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
pharmacological	O	ADJ	B
challenge	O	NOUN	O
data	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
tolerance	O	NOUN	B
may	O	AUX	O
occur	O	VERB	O
to	O	PART	O
seizure	B-Disease	NOUN	B
activity	O	NOUN	B
induced	O	VERB	B
by	O	ADP	O
PTZ	B-Chemical	NOUN	B
and	O	CCONJ	O
PTX	B-Chemical	NOUN	B
24	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
gamma-HCH	B-Chemical	NOUN	B
,	O	PUNCT	O
since	O	SCONJ	O
the	O	DET	O
response	O	NOUN	B
to	O	PART	O
only	O	ADV	O
these	O	DET	O
two	O	NUM	O
seizure	B-Disease	NOUN	B
-	O	PUNCT	O
inducing	O	VERB	B
agents	O	NOUN	B
is	O	AUX	O
decreased	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
in	O	X	B
vitro	O	X	I
data	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
site	O	NOUN	B
responsible	O	ADJ	O
for	O	ADP	O
the	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
seizure	B-Disease	NOUN	B
activity	O	NOUN	B
24	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
gamma-HCH	B-Chemical	NOUN	B
may	O	AUX	O
be	O	AUX	O
the	O	DET	O
GABA	B-Chemical	NOUN	B


Severe	O	ADJ	B
ocular	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
orbital	I-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
after	O	ADP	O
intracarotid	O	NOUN	B
injection	O	NOUN	B
of	O	ADP	O
carboplatin	B-Chemical	NOUN	B
for	O	ADP	O
recurrent	O	ADJ	B
glioblastomas	B-Disease	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Glioblastoma	B-Disease	NOUN	B
is	O	AUX	O
a	O	DET	O
malignant	B-Disease	ADJ	B
tumor	I-Disease	NOUN	I
that	O	PRON	O
occurs	O	VERB	O
in	O	ADP	O
the	O	DET	O
cerebrum	O	NOUN	B
during	O	ADP	O
adulthood	O	NOUN	B
.	O	PUNCT	O


With	O	ADP	O
current	O	ADJ	B
treatment	O	NOUN	B
regimens	O	NOUN	I
including	O	VERB	O
combined	O	ADJ	B
surgery	O	NOUN	I
,	O	PUNCT	O
radiation	O	NOUN	B
and	O	CCONJ	O
chemotherapy	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
average	O	ADJ	B
life	O	NOUN	B
expectancy	O	NOUN	I
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
is	O	AUX	O
limited	O	ADJ	O
to	O	PART	O
approximately	O	ADV	O
1	O	NUM	O
year	O	NOUN	B
.	O	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
patients	O	NOUN	B
with	O	ADP	O
glioblastoma	B-Disease	NOUN	B
sometimes	O	ADV	O
have	O	AUX	O
intracarotid	O	NOUN	B
injection	O	NOUN	B
of	O	ADP	O
carcinostatics	O	NOUN	B
added	O	VERB	O
to	O	PART	O
the	O	DET	O
treatment	O	NOUN	B
regimen	O	NOUN	I
.	O	PUNCT	O


Generally	O	ADV	O
,	O	PUNCT	O
carboplatin	B-Chemical	NOUN	B
is	O	AUX	O
said	O	VERB	O
to	O	PART	O
have	O	AUX	O
milder	O	ADJ	B
side	O	NOUN	B
effects	O	NOUN	I
than	O	ADP	O
cisplatin	B-Chemical	NOUN	B
,	O	PUNCT	O
whose	O	DET	O
ocular	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
orbital	I-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
are	O	AUX	O
well	O	ADV	O
known	O	VERB	O
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
experienced	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
severe	O	ADJ	B
ocular	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
orbital	I-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
after	O	ADP	O
intracarotid	O	NOUN	B
injection	O	NOUN	B
of	O	ADP	O
carboplatin	B-Chemical	NOUN	B
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
infrequently	O	ADV	O
reported	O	VERB	O
.	O	PUNCT	O


CASE	O	NOUN	B
:	O	PUNCT	O
A	O	DET	O
58	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
man	O	NOUN	B
received	O	VERB	O
an	O	DET	O
intracarotid	O	NOUN	B
injection	O	NOUN	B
of	O	ADP	O
carboplatin	B-Chemical	NOUN	B
for	O	ADP	O
recurrent	O	ADJ	B
glioblastomas	B-Disease	NOUN	B
in	O	ADP	O
his	O	PRON	O
left	O	ADJ	B
temporal	O	ADJ	I
lobe	O	NOUN	I
.	O	PUNCT	O


He	O	PRON	O
complained	O	VERB	B
of	O	ADP	O
pain	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
visual	I-Disease	ADJ	B
disturbance	I-Disease	NOUN	I
in	I-Disease	ADP	O
the	I-Disease	DET	O
ipsilateral	I-Disease	ADJ	B
eye	I-Disease	NOUN	O
30	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
the	O	DET	O
injection	O	NOUN	B
.	O	PUNCT	O


Various	O	ADJ	O
ocular	O	ADJ	B
symptoms	O	NOUN	I
and	O	CCONJ	O
findings	O	NOUN	B
caused	O	VERB	O
by	O	ADP	O
carboplatin	B-Chemical	NOUN	B
toxicity	B-Disease	NOUN	B
were	O	AUX	O
seen	O	VERB	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
He	O	PRON	O
was	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
intravenous	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
corticosteroids	O	NOUN	B
and	O	CCONJ	O
glycerin	B-Chemical	NOUN	B
for	O	ADP	O
6	O	NUM	O
days	O	NOUN	B
after	O	ADP	O
the	O	DET	O
injection	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
the	O	DET	O
intraocular	O	ADJ	B
pressure	O	NOUN	I
elevation	O	NOUN	I
caused	O	VERB	O
by	O	ADP	O
secondary	O	ADJ	B
acute	O	ADJ	I
angle	O	NOUN	I
-	O	PUNCT	O
closure	O	NOUN	B
glaucoma	B-Disease	NOUN	B
decreased	O	VERB	B
and	O	CCONJ	O
ocular	B-Disease	ADJ	B
pain	I-Disease	NOUN	I
diminished	O	VERB	B
,	O	PUNCT	O
inexorable	O	ADJ	O
papilledema	B-Disease	NOUN	B
and	O	CCONJ	O
exudative	O	ADJ	B
retinal	B-Disease	ADJ	B
detachment	I-Disease	NOUN	B
continued	O	VERB	O
for	O	ADP	O
3	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


Finally	O	ADV	O
,	O	PUNCT	O
6	O	NUM	O
weeks	O	NOUN	B
later	O	ADV	O
,	O	PUNCT	O
diffuse	O	ADJ	B
chorioretinal	B-Disease	ADJ	B
atrophy	I-Disease	NOUN	I
with	O	ADP	O
optic	B-Disease	ADJ	B
atrophy	I-Disease	NOUN	I
occurred	O	VERB	O
and	O	CCONJ	O
the	O	DET	O
vision	O	NOUN	B
in	O	ADP	O
his	O	PRON	O
left	O	ADJ	B
eye	O	NOUN	I
was	O	AUX	O
lost	O	VERB	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
When	O	SCONJ	O
performing	O	VERB	O
intracarotid	O	NOUN	B
injection	O	NOUN	B
of	O	ADP	O
carboplatin	B-Chemical	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
must	O	AUX	O
be	O	AUX	O
aware	O	ADJ	O
of	O	ADP	O
its	O	PRON	O
potentially	O	ADV	O
blinding	O	VERB	B
ocular	B-Disease	ADJ	B
toxicity	I-Disease	NOUN	B


Phase	O	NOUN	B
II	O	NUM	I
study	O	NOUN	B
of	O	ADP	O
the	O	DET	O
amsacrine	B-Chemical	NOUN	B
analogue	O	NOUN	B
CI-921	B-Chemical	NOUN	B
(	O	PUNCT	O
NSC	B-Chemical	NOUN	B
343499	I-Chemical	NUM	O
)	O	PUNCT	O
in	O	ADP	O
non-small	B-Disease	ADJ	B
cell	I-Disease	NOUN	I
lung	I-Disease	NOUN	I
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


CI-921	B-Chemical	NOUN	B
(	O	PUNCT	O
NSC	B-Chemical	PROPN	B
343499	I-Chemical	NUM	O
;	O	PUNCT	O
9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino]	B-Chemical	NOUN	O
-N,5-dimethyl-	I-Chemical	NOUN	O
4-acridinecarboxamide	I-Chemical	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
topoisomerase	O	NOUN	B
II	O	NUM	I
poison	O	NOUN	I
with	O	ADP	O
high	O	ADJ	O
experimental	O	ADJ	B
antitumour	O	ADJ	B
activity	O	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
was	O	AUX	O
administered	O	VERB	B
by	O	ADP	O
15	O	NUM	O
min	O	NOUN	O
infusion	O	NOUN	B
to	O	PART	O
16	O	NUM	O
evaluable	O	ADJ	O
patients	O	NOUN	B
with	O	ADP	O
non-small	B-Disease	ADJ	B
cell	I-Disease	NOUN	I
lung	I-Disease	NOUN	I
cancer	I-Disease	NOUN	I
(	O	PUNCT	O
NSCLC	B-Disease	NOUN	B
)(	O	NOUN	O
7	O	NUM	O
with	O	ADP	O
no	O	DET	O
prior	O	ADJ	O
treatment	O	NOUN	B
,	O	PUNCT	O
9	O	NUM	O
patients	O	NOUN	B
in	O	ADP	O
relapse	O	NOUN	B
following	O	VERB	O
surgery	O	NOUN	B
/	O	SYM	O
radiotherapy	O	NOUN	B
)	O	PUNCT	O
at	O	ADP	O
a	O	DET	O
dose	O	NOUN	B
(	O	PUNCT	O
648	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
divided	O	VERB	B
over	O	ADP	O
3	O	NUM	O
days	O	NOUN	B
,	O	PUNCT	O
repeated	O	VERB	O
every	O	DET	O
3	O	NUM	O
weeks	O	NOUN	B
)	O	PUNCT	O
determined	O	VERB	O
by	O	ADP	O
phase	O	NOUN	B
I	O	NOUN	I
trial	O	NOUN	I
.	O	PUNCT	O


Patients	O	NOUN	B
had	O	AUX	O
a	O	DET	O
median	O	ADJ	B
performance	O	NOUN	O
status	O	NOUN	O
of	O	ADP	O
1	O	NUM	O
(	O	PUNCT	O
WHO	O	PRON	B
),	O	PUNCT	O
and	O	CCONJ	O
median	O	ADJ	B
age	O	NOUN	B
of	O	ADP	O
61	O	NUM	O
years	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
histology	O	NOUN	B
comprised	O	VERB	O
squamous	B-Disease	ADJ	B
carcinoma	I-Disease	NOUN	I
(	O	PUNCT	O
11	O	NUM	O
),	O	PUNCT	O
adenocarcinoma	B-Disease	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
),	O	PUNCT	O
mixed	O	ADJ	O
histology	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
),	O	PUNCT	O
bronchio-alveolar	B-Disease	ADJ	B
carcinoma	I-Disease	NOUN	I
(	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
large	O	ADJ	O
cell	O	NOUN	B
undifferentiated	B-Disease	ADJ	I
carcinoma	I-Disease	NOUN	I
(	O	PUNCT	O
1	O	NUM	O
).	O	PUNCT	O
Neutropenia	B-Disease	NOUN	B
grade	O	NOUN	O
greater	O	ADJ	O
than	O	ADP	O
or	O	CCONJ	O
equal	O	ADJ	O
to	O	PART	O
3	O	NUM	O
was	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
15	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
infections	B-Disease	NOUN	B
with	O	ADP	O
recovery	O	NOUN	B
in	O	ADP	O
3	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
grand	O	ADJ	O
mal	O	ADJ	B
seizures	B-Disease	NOUN	I
in	O	ADP	O
1	O	NUM	O
patient	O	NOUN	B
.	O	PUNCT	O


Grade	O	NOUN	B
less	O	ADJ	O
than	O	ADP	O
or	O	CCONJ	O
equal	O	ADJ	O
to	O	PART	O
2	O	NUM	O
nausea	B-Disease	NOUN	B
and	O	CCONJ	O
vomiting	B-Disease	NOUN	B
occurred	O	VERB	O
in	O	ADP	O
66	O	NUM	O
%	O	NOUN	O
courses	O	NOUN	B
and	O	CCONJ	O
phlebitis	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
infusion	O	NOUN	B
arm	O	NOUN	O
in	O	ADP	O
37	O	NUM	O
%.	O	NOUN	O
1	O	NUM	O
patient	O	NOUN	B
with	O	ADP	O
squamous	B-Disease	ADJ	B
cell	I-Disease	NOUN	I
carcinoma	I-Disease	NOUN	I
achieved	O	VERB	O
a	O	DET	O
partial	O	ADJ	B
response	O	NOUN	O
lasting	O	VERB	O
5	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


Further	O	ADV	O
testing	O	NOUN	B
in	O	ADP	O
this	O	DET	O
and	O	CCONJ	O
other	O	ADJ	O
tumour	B-Disease	NOUN	B


Alpha-lipoic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
prevents	O	VERB	B
mitochondrial	B-Disease	ADJ	B
damage	I-Disease	NOUN	I
and	O	CCONJ	O
neurotoxicity	B-Disease	NOUN	B
in	O	ADP	O
experimental	O	ADJ	B
chemotherapy	O	NOUN	I
neuropathy	B-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
study	O	NOUN	B
investigates	O	VERB	B
if	O	SCONJ	O
alpha-lipoic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
is	O	AUX	O
neuroprotective	O	ADJ	B
against	O	ADP	O
chemotherapy	O	NOUN	B
induced	O	ADJ	B
neurotoxicity	B-Disease	NOUN	B
,	O	PUNCT	O
if	O	SCONJ	O
mitochondrial	B-Disease	ADJ	B
damage	I-Disease	NOUN	I
plays	O	VERB	O
a	O	DET	O
critical	O	ADJ	O
role	O	NOUN	O
in	O	ADP	O
toxic	B-Disease	ADJ	B
neurodegenerative	I-Disease	ADJ	B
cascade	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
if	O	SCONJ	O
neuroprotective	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
alpha-lipoic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
depend	O	VERB	O
on	O	ADP	O
mitochondria	O	NOUN	B
protection	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
used	O	VERB	O
an	O	DET	O
in	O	X	B
vitro	O	X	I
model	O	NOUN	I
of	O	ADP	O
chemotherapy	O	NOUN	B
induced	O	ADJ	B
peripheral	B-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I
that	O	PRON	O
closely	O	ADV	O
mimic	O	VERB	O
the	O	DET	O
in	O	X	B
vivo	O	X	I
condition	O	NOUN	B
by	O	ADP	O
exposing	O	VERB	O
primary	O	ADJ	B
cultures	O	NOUN	I
of	O	ADP	O
dorsal	O	ADJ	B
root	O	NOUN	I
ganglion	O	NOUN	I
(	O	PUNCT	O
DRG	O	NOUN	B
)	O	PUNCT	O
sensory	O	ADJ	B
neurons	O	NOUN	I
to	O	PART	O
paclitaxel	B-Chemical	NOUN	B
and	O	CCONJ	O
cisplatin	B-Chemical	NOUN	B
,	O	PUNCT	O
two	O	NUM	O
widely	O	ADV	O
used	O	VERB	O
and	O	CCONJ	O
highly	O	ADV	O
effective	O	ADJ	B
chemotherapeutic	O	ADJ	B
drugs	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
approach	O	NOUN	O
allowed	O	VERB	O
investigating	O	VERB	B
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
alpha-lipoic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
in	O	ADP	O
preventing	O	VERB	O
axonal	B-Disease	ADJ	B
damage	I-Disease	NOUN	O
and	O	CCONJ	O
apoptosis	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
function	O	NOUN	B
and	O	CCONJ	O
ultrastructural	O	ADJ	B
morphology	O	NOUN	B
of	O	ADP	O
mitochondria	O	NOUN	B
after	O	ADP	O
exposure	O	NOUN	B
to	O	PART	I
toxic	O	ADJ	B
agents	O	NOUN	I
and	O	CCONJ	O
alpha-lipoic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
.	O	PUNCT	O


Our	O	PRON	O
results	O	NOUN	B
demonstrate	O	VERB	O
that	O	SCONJ	O
both	O	CCONJ	O
cisplatin	B-Chemical	NOUN	B
and	O	CCONJ	O
paclitaxel	B-Chemical	NOUN	B
cause	O	VERB	O
early	O	ADJ	O
mitochondrial	B-Disease	ADJ	B
impairment	I-Disease	NOUN	I
with	O	ADP	O
loss	O	NOUN	B
of	O	ADP	I
membrane	O	NOUN	I
potential	O	NOUN	B
and	O	CCONJ	O
induction	O	NOUN	B
of	O	ADP	O
autophagic	O	ADJ	B
vacuoles	O	NOUN	I
in	O	ADP	O
neurons	O	NOUN	B
.	O	PUNCT	O


Alpha-lipoic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
exerts	O	VERB	O
neuroprotective	O	ADJ	B
effects	O	NOUN	I
against	O	ADP	O
chemotherapy	O	NOUN	B
induced	O	ADJ	B
neurotoxicity	B-Disease	NOUN	B
in	O	ADP	O
sensory	O	ADJ	B
neurons	O	NOUN	I
:	O	PUNCT	O
it	O	PRON	O
rescues	O	VERB	B
the	O	DET	O
mitochondrial	B-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
and	O	CCONJ	O
induces	O	VERB	B
the	O	DET	O
expression	O	NOUN	B
of	O	ADP	O
frataxin	O	NOUN	B
,	O	PUNCT	O
an	O	DET	O
essential	O	ADJ	O
mitochondrial	O	ADJ	B
protein	O	NOUN	I
with	O	ADP	O
anti	O	ADJ	B
-	O	PUNCT	O
oxidant	O	NOUN	B
and	O	CCONJ	O
chaperone	O	NOUN	B
properties	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
mitochondrial	B-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
is	O	AUX	O
an	O	DET	O
early	O	ADV	B
common	O	ADJ	O
event	O	NOUN	B
both	O	CCONJ	O
in	O	ADP	O
paclitaxel	B-Chemical	NOUN	B
and	O	CCONJ	O
cisplatin	B-Chemical	NOUN	B
induced	O	VERB	B
neurotoxicity	B-Disease	NOUN	B
.	O	PUNCT	O


Alpha-lipoic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
protects	O	VERB	B
sensory	O	ADJ	B
neurons	O	NOUN	I
through	O	ADP	O
its	O	PRON	O
anti	O	ADJ	B
-	O	PUNCT	O
oxidant	O	ADJ	B
and	O	CCONJ	O
mitochondrial	O	ADJ	B
regulatory	O	ADJ	O
functions	O	NOUN	O
,	O	PUNCT	O
possibly	O	ADV	O
inducing	O	VERB	B
the	O	DET	O
expression	O	NOUN	B
of	O	ADP	O
frataxin	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
alpha-lipoic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
might	O	AUX	O
reduce	O	VERB	B
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
developing	O	VERB	O
peripheral	B-Disease	ADJ	B
nerve	I-Disease	NOUN	I
toxicity	I-Disease	NOUN	B


Optimising	O	VERB	B
stroke	B-Disease	NOUN	B
prevention	O	NOUN	B
in	O	ADP	O
non	O	ADJ	B
-	O	PUNCT	O
valvular	O	ADJ	B
atrial	B-Disease	ADJ	I
fibrillation	I-Disease	NOUN	I
.	O	PUNCT	O


Atrial	B-Disease	ADJ	B
fibrillation	I-Disease	NOUN	I
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
substantial	O	ADJ	O
morbidity	O	NOUN	B
and	O	CCONJ	O
mortality	O	NOUN	B
.	O	PUNCT	O


Pooled	O	ADJ	B
data	O	NOUN	B
from	O	ADP	O
trials	O	NOUN	B
comparing	O	VERB	O
antithrombotic	O	ADJ	B
treatment	O	NOUN	I
with	O	ADP	O
placebo	O	NOUN	B
have	O	AUX	O
shown	O	VERB	O
that	O	SCONJ	O
warfarin	B-Chemical	NOUN	B
reduces	O	VERB	B
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
stroke	B-Disease	NOUN	B
by	O	ADP	O
62	O	NUM	O
%,	O	NOUN	B
and	O	CCONJ	O
that	O	SCONJ	O
aspirin	B-Chemical	NOUN	B
alone	O	ADV	O
reduces	O	VERB	B
the	O	DET	O
risk	O	NOUN	B
by	O	ADP	O
22	O	NUM	O
%.	O	NOUN	B
Overall	O	ADV	O
,	O	PUNCT	O
in	O	ADP	O
high	O	ADJ	B
-	O	PUNCT	O
risk	O	NOUN	B
patients	O	NOUN	B
,	O	PUNCT	O
warfarin	B-Chemical	NOUN	B
is	O	AUX	O
superior	O	ADJ	O
to	O	PART	O
aspirin	B-Chemical	NOUN	B
in	O	ADP	O
preventing	O	VERB	B
strokes	B-Disease	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
relative	O	ADJ	B
risk	O	NOUN	I
reduction	O	NOUN	B
of	O	ADP	O
36	O	NUM	O
%.	O	NOUN	B
Ximelagatran	B-Chemical	NOUN	B
,	O	PUNCT	O
an	O	DET	O
oral	O	ADJ	B
direct	O	ADJ	O
thrombin	O	NOUN	B
inhibitor	O	NOUN	I
,	O	PUNCT	O
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
as	O	ADV	O
efficient	O	ADJ	B
as	O	ADP	O
vitamin	B-Chemical	NOUN	B
K	I-Chemical	NOUN	I
antagonist	O	NOUN	I
drugs	O	NOUN	B
in	O	ADP	O
the	O	DET	O
prevention	O	NOUN	B
of	O	ADP	O
embolic	B-Disease	ADJ	B
events	I-Disease	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
has	O	AUX	O
been	O	AUX	O
recently	O	ADV	O
withdrawn	O	VERB	O
because	O	SCONJ	O
of	O	ADP	O
abnormal	B-Disease	ADJ	B
liver	I-Disease	NOUN	O
function	I-Disease	NOUN	O
tests	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
ACTIVE	O	PROPN	B
-	O	PUNCT	O
W	O	PROPN	B
(	O	PUNCT	O
Atrial	B-Disease	PROPN	B
Fibrillation	I-Disease	PROPN	I
Clopidogrel	B-Chemical	PROPN	I
Trial	O	PROPN	I
with	O	ADP	O
Irbesartan	B-Chemical	NOUN	B
for	O	ADP	O
Prevention	O	PROPN	B
of	O	ADP	O
Vascular	O	PROPN	B
Events	O	NOUN	I
)	O	PUNCT	O
study	O	NOUN	O
has	O	AUX	O
demonstrated	O	VERB	O
that	O	SCONJ	O
warfarin	B-Chemical	NOUN	B
is	O	AUX	O
superior	O	ADJ	O
to	O	PART	O
platelet	O	NOUN	B
therapy	O	NOUN	I
(	O	PUNCT	O
clopidogrel	B-Chemical	NOUN	B
plus	O	CCONJ	O
aspirin	B-Chemical	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
prevention	O	NOUN	B
af	O	ADP	O
embolic	B-Disease	ADJ	B
events	I-Disease	NOUN	I
.	O	PUNCT	O


Idraparinux	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
Factor	O	NOUN	B
Xa	O	NOUN	I
inhibitor	O	NOUN	I
,	O	PUNCT	O
is	O	AUX	O
being	O	AUX	O
evaluated	O	VERB	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
atrial	B-Disease	ADJ	B
fibrillation	I-Disease	NOUN	I
.	O	PUNCT	O


Angiotensin	B-Chemical	NOUN	B
-	O	PUNCT	O
converting	O	VERB	B
enzyme	O	NOUN	B
inhibitors	O	NOUN	I
and	O	CCONJ	O
angiotensin	B-Chemical	NOUN	B
II	I-Chemical	NUM	I
receptor	O	NOUN	I
-	O	PUNCT	O
blocking	O	VERB	B
drugs	O	NOUN	B
hold	O	VERB	O
promise	O	NOUN	O
in	O	ADP	O
atrial	B-Disease	ADJ	B
fibrillation	I-Disease	NOUN	I
through	O	ADP	O
cardiac	B-Disease	ADJ	B
remodelling	I-Disease	NOUN	I
.	O	PUNCT	O


Preliminary	O	ADJ	B
studies	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
statins	B-Chemical	NOUN	B


Interaction	O	NOUN	B
of	O	ADP	O
cyclosporin	B-Chemical	NOUN	B
A	I-Chemical	NOUN	I
with	O	ADP	O
antineoplastic	O	ADJ	B
agents	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
synergistic	O	ADJ	B
effect	O	NOUN	O
of	O	ADP	O
etoposide	B-Chemical	NOUN	B
and	O	CCONJ	O
cyclosporin	B-Chemical	NOUN	B
A	I-Chemical	NOUN	I
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
acute	B-Disease	ADJ	B
T-lymphocytic	I-Disease	ADJ	I
leukemia	I-Disease	NOUN	I
in	O	ADP	O
relapse	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
concomitant	O	ADJ	B
administration	O	NOUN	B
of	O	ADP	O
etoposide	B-Chemical	NOUN	B
and	O	CCONJ	O
cyclosporin	B-Chemical	NOUN	B
A	I-Chemical	NOUN	O
resulted	O	VERB	O
in	O	ADP	O
eradication	O	NOUN	B
of	O	ADP	O
hitherto	O	ADV	O
refractory	O	ADJ	B
leukemic	B-Disease	ADJ	B
infiltration	I-Disease	NOUN	I
of	O	ADP	O
bone	O	NOUN	B
marrow	O	NOUN	I
.	O	PUNCT	O


Severe	O	ADJ	B
side	O	NOUN	B
effects	O	NOUN	I
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
mental	O	ADJ	B
confusion	B-Disease	NOUN	I
and	O	CCONJ	O
progressive	O	ADJ	B
hyperbilirubinemia	B-Disease	NOUN	B
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
point	O	VERB	O
to	O	PART	O
an	O	DET	O
enhancement	O	NOUN	B
not	O	PART	O
only	O	ADV	O
of	O	ADP	O
antineoplastic	O	ADJ	B
effects	O	NOUN	I
but	O	CCONJ	O
also	O	ADV	O
of	O	ADP	O
toxicity	B-Disease	NOUN	B
in	O	ADP	O
normal	O	ADJ	B
tissues	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
report	O	NOUN	B
demonstrates	O	VERB	O
for	O	ADP	O
the	O	DET	O
first	O	ADJ	O
time	O	NOUN	O
that	O	PRON	O
the	O	DET	O
pharmacodynamic	O	ADJ	B
properties	O	NOUN	O
of	O	ADP	O
cyclosporin	B-Chemical	NOUN	B
A	I-Chemical	NOUN	I


The	O	DET	O
hematologic	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
cefonicid	B-Chemical	NOUN	B
and	O	CCONJ	O
cefazedone	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
dog	O	NOUN	B
:	O	PUNCT	O
a	O	DET	O
potential	O	ADJ	B
model	O	NOUN	B
of	O	ADP	O
cephalosporin	B-Chemical	NOUN	B
hematotoxicity	B-Disease	NOUN	B
in	O	ADP	O
man	O	NOUN	B
.	O	PUNCT	O


Cephalosporin	B-Chemical	NOUN	B
antibiotics	O	NOUN	I
cause	O	VERB	O
a	O	DET	O
variety	O	NOUN	O
of	O	ADP	O
hematologic	B-Disease	ADJ	B
disturbances	I-Disease	NOUN	I
in	O	ADP	O
man	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
pathogeneses	O	NOUN	B
and	O	CCONJ	O
hematopathology	O	NOUN	B
of	O	ADP	O
which	O	DET	O
remain	O	VERB	O
poorly	O	ADV	O
characterized	O	VERB	B
.	O	PUNCT	O


There	O	PRON	O
is	O	AUX	O
a	O	DET	O
need	O	NOUN	O
for	O	ADP	O
a	O	DET	O
well	O	ADV	O
-	O	PUNCT	O
defined	O	VERB	B
animal	O	NOUN	B
model	O	NOUN	I
in	O	ADP	O
which	O	DET	O
these	O	DET	O
blood	B-Disease	NOUN	B
dyscrasias	I-Disease	NOUN	I
can	O	AUX	O
be	O	AUX	O
studied	O	VERB	O
.	O	PUNCT	O


In	O	ADP	O
four	O	NUM	O
subacute	O	ADJ	B
toxicity	B-Disease	NOUN	B
studies	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
intravenous	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
cefonicid	B-Chemical	NOUN	B
or	O	CCONJ	O
cefazedone	B-Chemical	NOUN	B
to	O	ADP	O
beagle	O	ADJ	B
dogs	O	NOUN	I
caused	O	VERB	O
a	O	DET	O
dose	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
incidence	O	NOUN	B
of	O	ADP	O
anemia	B-Disease	NOUN	B
,	O	PUNCT	O
neutropenia	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
thrombocytopenia	B-Disease	NOUN	B
after	O	ADP	O
1	O	NUM	O
-	O	SYM	O
3	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
nonregenerative	O	ADJ	B
anemia	B-Disease	NOUN	I
was	O	AUX	O
the	O	DET	O
most	O	ADV	O
compromising	O	NOUN	B
of	O	ADP	O
the	O	DET	O
cytopenias	B-Disease	NOUN	B
and	O	CCONJ	O
occurred	O	VERB	O
in	O	ADP	O
approximately	O	ADV	O
50	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
dogs	O	NOUN	B
receiving	O	VERB	O
400	O	NUM	O
-	O	SYM	O
500	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
cefonicid	B-Chemical	NOUN	B
or	O	CCONJ	O
540	O	NUM	O
-	O	PUNCT	O
840	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
cefazedone	B-Chemical	NOUN	B
.	O	PUNCT	O


All	O	DET	O
three	O	NUM	O
cytopenias	B-Disease	NOUN	B
were	O	AUX	O
completely	O	ADV	O
reversible	O	ADJ	O
following	O	VERB	O
cessation	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
;	O	PUNCT	O
the	O	DET	O
time	O	NOUN	B
required	O	VERB	O
for	O	ADP	O
recovery	O	NOUN	B
of	O	ADP	O
the	O	DET	O
erythron	O	NOUN	B
(	O	PUNCT	O
approximately	O	ADV	O
1	O	NUM	O
month	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
considerably	O	ADV	O
longer	O	ADV	O
than	O	ADP	O
that	O	DET	O
of	O	ADP	O
the	O	DET	O
granulocytes	O	NOUN	B
and	O	CCONJ	O
platelets	O	NOUN	B
(	O	PUNCT	O
hours	O	NOUN	O
to	O	PART	O
a	O	DET	O
few	O	ADJ	O
days	O	NOUN	B
).	O	PUNCT	O
Upon	O	SCONJ	O
rechallenge	O	NOUN	B
with	O	ADP	I
either	O	CCONJ	O
cephalosporin	B-Chemical	NOUN	B
,	O	PUNCT	O
the	O	DET	O
hematologic	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
was	O	AUX	O
reproduced	O	VERB	O
in	O	ADP	O
most	O	ADJ	O
dogs	O	NOUN	B
tested	O	VERB	B
;	O	PUNCT	O
cefonicid	B-Chemical	NOUN	B
(	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
cefazedone	B-Chemical	NOUN	B
)-	O	ADJ	O
treated	O	VERB	B
dogs	O	NOUN	B
showed	O	VERB	O
a	O	DET	O
substantially	O	ADV	O
reduced	O	VERB	O
induction	O	NOUN	B
period	O	NOUN	B
(	O	PUNCT	O
15	O	NUM	O
+/-	O	CCONJ	O
5	O	NUM	O
days	O	NOUN	B
)	O	PUNCT	O
compared	O	VERB	B
to	O	PART	O
that	O	DET	O
of	O	ADP	O
the	O	DET	O
first	O	ADJ	O
exposure	O	NOUN	B
to	O	PART	O
the	O	DET	O
drug	O	NOUN	B
(	O	PUNCT	O
61	O	NUM	O
+/-	O	CCONJ	O
24	O	NUM	O
days	O	NOUN	B
).	O	PUNCT	O
This	O	DET	O
observation	O	NOUN	B
,	O	PUNCT	O
along	O	ADP	O
with	O	ADP	O
the	O	DET	O
rapid	O	ADJ	O
rate	O	NOUN	B
of	O	ADP	O
decline	O	NOUN	B
in	O	ADP	O
red	O	ADJ	B
cell	O	NOUN	I
mass	O	NOUN	O
parameters	O	NOUN	B
of	O	ADP	O
affected	O	VERB	B
dogs	O	NOUN	B
,	O	PUNCT	O
suggests	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
hemolytic	B-Disease	ADJ	B
component	O	NOUN	B
complicated	O	VERB	B
the	O	DET	O
red	O	ADJ	B
cell	O	NOUN	I
production	O	NOUN	O
problem	O	NOUN	B
and	O	CCONJ	O
that	O	SCONJ	O
multiple	O	ADJ	O
toxicologic	O	ADJ	B
mechanisms	O	NOUN	I
contributed	O	VERB	O
to	O	PART	O
the	O	DET	O
cytopenia	B-Disease	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
high	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
cefonicid	B-Chemical	NOUN	B
or	O	CCONJ	O
cefazedone	B-Chemical	NOUN	B
to	O	ADP	O
dogs	O	NOUN	B
can	O	AUX	O
induce	O	VERB	B
hematotoxicity	B-Disease	NOUN	B
similar	O	ADJ	O
to	O	PART	O
the	O	DET	O
cephalosporin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
blood	B-Disease	NOUN	B
dyscrasias	I-Disease	NOUN	I


A	O	DET	O
pyridoxine	B-Chemical	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
behavioral	B-Disease	ADJ	B
disorder	I-Disease	NOUN	I
unmasked	O	VERB	O
by	O	ADP	O
isoniazid	B-Chemical	NOUN	B
.	O	PUNCT	O


A	O	DET	O
3	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
girl	O	NOUN	I
had	O	AUX	O
behavioral	B-Disease	ADJ	B
deterioration	I-Disease	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
hyperkinesis	B-Disease	NOUN	B
,	O	PUNCT	O
irritability	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
sleeping	B-Disease	VERB	B
difficulties	I-Disease	NOUN	I
after	O	ADP	O
the	O	DET	O
therapeutic	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
isoniazid	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
pharmacologic	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
pyridoxine	B-Chemical	NOUN	B
hydrochloride	I-Chemical	NOUN	I
led	O	VERB	O
to	O	PART	O
a	O	DET	O
disappearance	O	NOUN	B
of	O	ADP	O
symptoms	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
discontinuing	O	VERB	B
isoniazid	B-Chemical	NOUN	B
therapy	O	NOUN	I
a	O	DET	O
similar	O	ADJ	O
pattern	O	NOUN	B
of	O	ADP	O
behavior	O	NOUN	B
was	O	AUX	O
noted	O	VERB	O
that	O	PRON	O
was	O	AUX	O
controlled	O	VERB	B
by	O	ADP	O
pyridoxine	B-Chemical	NOUN	B
.	O	PUNCT	O


A	O	DET	O
placebo	O	NOUN	B
had	O	AUX	O
no	O	DET	B
effect	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
niacinamide	B-Chemical	NOUN	B
was	O	AUX	O
as	O	ADV	O
effective	O	ADJ	B
as	O	ADP	O
pyridoxine	B-Chemical	NOUN	B
.	O	PUNCT	O


Periodic	O	ADJ	B
withdrawal	O	NOUN	B
of	O	ADP	O
pyridoxine	B-Chemical	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
return	O	NOUN	B
of	O	ADP	I
the	O	DET	I
hyperkinesis	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
level	O	NOUN	B
of	O	ADP	O
pyridoxal	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
blood	O	NOUN	B
was	O	AUX	O
normal	O	ADJ	O
during	O	ADP	O
the	O	DET	O
periods	O	NOUN	B
of	O	ADP	O
relapse	O	NOUN	B
.	O	PUNCT	O


Metabolic	O	ADJ	B
studies	O	NOUN	I
suggested	O	VERB	O
a	O	DET	O
block	O	NOUN	B
in	O	ADP	O
the	O	DET	O
kynurenine	B-Chemical	NOUN	B
pathway	O	NOUN	O
of	O	ADP	O
tryptophan	B-Chemical	NOUN	B
metabolism	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
followed	O	VERB	O
for	O	ADP	O
six	O	NUM	O
years	O	NOUN	B
and	O	CCONJ	O
has	O	AUX	O
required	O	VERB	O
pharmacologic	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
pyridoxine	B-Chemical	NOUN	B


A	O	DET	O
selective	O	ADJ	O
dopamine	B-Chemical	NOUN	B
D4	O	NOUN	I
receptor	O	NOUN	I
antagonist	O	NOUN	B
,	O	PUNCT	O
NRA0160	B-Chemical	NOUN	B
:	O	PUNCT	O
a	O	DET	O
preclinical	O	ADJ	B
neuropharmacological	O	ADJ	B
profile	O	NOUN	I
.	O	PUNCT	O


NRA0160	B-Chemical	NOUN	B
,	O	PUNCT	O
5	B-Chemical	NUM	O
-	I-Chemical	PUNCT	O
[2-	I-Chemical	ADJ	B
(	I-Chemical	PUNCT	O
4-	I-Chemical	NUM	O
(	I-Chemical	PUNCT	O
3	I-Chemical	NUM	O
-	I-Chemical	PUNCT	O
fluorobenzylidene)	I-Chemical	ADJ	B
piperidin-1-yl)	I-Chemical	NOUN	O
ethyl]	I-Chemical	PROPN	B
-	I-Chemical	PUNCT	O
4	I-Chemical	NUM	B
-(4-fluorophenyl)	I-Chemical	NOUN	O
thiazole-2-carboxamide	I-Chemical	NOUN	B
,	O	PUNCT	O
has	O	AUX	O
a	O	DET	O
high	O	ADJ	O
affinity	O	NOUN	B
for	O	ADP	O
human	O	ADJ	B
cloned	O	VERB	B
dopamine	B-Chemical	NOUN	B
D4	O	NOUN	I
.	O	PUNCT	O


2	O	NUM	O
,	O	PUNCT	O
D4	O	NOUN	B
.	O	PUNCT	O


4	O	NUM	O
and	O	CCONJ	O
D4	O	NOUN	B
.	O	PUNCT	O


7	O	NUM	O
receptors	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
Ki	O	NOUN	B
values	O	NOUN	I
of	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
,	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
and	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
nM	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


NRA0160	B-Chemical	NOUN	B
is	O	AUX	O
over	O	ADV	O
20	O	NUM	O
,	O	PUNCT	O
000fold	O	ADJ	O
more	O	ADV	O
potent	O	ADJ	O
at	O	ADP	O
the	O	DET	O
dopamine	B-Chemical	NOUN	B
D4	O	NOUN	I
.	O	PUNCT	O


2	O	NUM	O
receptor	O	NOUN	O
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
human	O	ADJ	B
cloned	O	VERB	B
dopamine	B-Chemical	NOUN	O
D2L	O	NOUN	O
receptor	O	NOUN	O
.	O	PUNCT	O


NRA0160	B-Chemical	NOUN	B
has	O	AUX	O
negligible	O	ADJ	O
affinity	O	NOUN	B
for	O	ADP	O
the	O	DET	O
human	O	ADJ	B
cloned	O	VERB	B
dopamine	B-Chemical	NOUN	B
D3	O	NOUN	I
receptor	O	NOUN	I
(	O	PUNCT	O
Ki	O	NOUN	O
=	O	ADJ	O
39	O	NUM	O
nM	O	NOUN	O
),	O	PUNCT	O
rat	O	NOUN	B
serotonin	B-Chemical	NOUN	B
(	O	PUNCT	O
5-HT	B-Chemical	NOUN	B
)	O	PUNCT	O
2A	O	NOUN	B
receptors	O	NOUN	I
(	O	PUNCT	O
Ki	O	NOUN	O
=	O	ADJ	O
180	O	NUM	O
nM	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
rat	O	NOUN	B
alpha1	O	NOUN	O
adrenoceptor	O	NOUN	O
(	O	PUNCT	O
Ki	O	NOUN	O
=	O	ADJ	O
237	O	NUM	O
nM	O	NOUN	O
).	O	PUNCT	O
NRA0160	B-Chemical	NOUN	B
and	O	CCONJ	O
clozapine	B-Chemical	NOUN	B
antagonized	O	VERB	B
locomotor	O	NOUN	B
hyperactivity	B-Disease	NOUN	I
induced	O	VERB	B
by	O	ADP	O
methamphetamine	B-Chemical	NOUN	B
(	O	PUNCT	O
MAP	B-Chemical	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
mice	O	NOUN	B
.	O	PUNCT	O


NRA0160	B-Chemical	NOUN	B
and	O	CCONJ	O
clozapine	B-Chemical	NOUN	B
antagonized	O	VERB	B
MAP	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
stereotyped	O	ADJ	B
behavior	O	NOUN	I
in	O	ADP	O
mice	O	NOUN	B
,	O	PUNCT	O
although	O	SCONJ	O
their	O	PRON	O
effects	O	NOUN	B
did	O	AUX	O
not	O	PART	O
exceed	O	VERB	O
50	O	NUM	O
%	O	NOUN	O
inhibition	O	NOUN	B
,	O	PUNCT	O
even	O	ADV	O
at	O	ADP	O
the	O	DET	O
highest	O	ADJ	B
dose	O	NOUN	B
given	O	VERB	O
.	O	PUNCT	O


NRA0160	B-Chemical	NOUN	B
and	O	CCONJ	O
clozapine	B-Chemical	NOUN	B
significantly	O	ADV	O
induced	O	VERB	B
catalepsy	B-Disease	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
,	O	PUNCT	O
although	O	SCONJ	O
their	O	PRON	O
effects	O	NOUN	B
did	O	AUX	O
not	O	PART	O
exceed	O	VERB	O
50	O	NUM	O
%	O	NOUN	O
induction	O	NOUN	B
even	O	ADV	O
at	O	ADP	O
the	O	DET	O
highest	O	ADJ	B
dose	O	NOUN	B
given	O	VERB	O
.	O	PUNCT	O


NRA0160	B-Chemical	NOUN	B
and	O	CCONJ	O
clozapine	B-Chemical	NOUN	B
significantly	O	ADV	O
reversed	O	VERB	O
the	O	DET	O
disruption	O	NOUN	B
of	O	ADP	O
prepulse	O	NOUN	B
inhibition	O	NOUN	I
(	O	PUNCT	O
PPI	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
rats	O	NOUN	B
produced	O	VERB	O
by	O	ADP	O
apomorphine	B-Chemical	NOUN	B
.	O	PUNCT	O


NRA0160	B-Chemical	NOUN	B
and	O	CCONJ	O
clozapine	B-Chemical	NOUN	B
significantly	O	ADV	O
shortened	O	VERB	O
the	O	DET	O
phencyclidine	B-Chemical	NOUN	B
(	O	PUNCT	O
PCP	B-Chemical	NOUN	B
)-	O	ADJ	O
induced	O	VERB	B
prolonged	O	ADJ	B
swimming	O	NOUN	B
latency	O	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
in	O	ADP	O
a	O	DET	O
water	O	NOUN	B
maze	O	NOUN	I
task	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
NRA0160	B-Chemical	NOUN	B


Prolonged	O	ADJ	B
cholestasis	B-Disease	NOUN	B
after	O	ADP	O
troleandomycin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
acute	O	ADJ	B
hepatitis	B-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
the	O	DET	O
case	O	NOUN	B
of	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
in	O	ADP	O
whom	O	PRON	O
troleandomycin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hepatitis	B-Disease	NOUN	B
was	O	AUX	O
followed	O	VERB	O
by	O	ADP	O
prolonged	O	ADJ	B
anicteric	O	ADJ	B
cholestasis	B-Disease	NOUN	B
.	O	PUNCT	O


Jaundice	B-Disease	NOUN	B
occurred	O	VERB	O
after	O	ADP	O
administration	O	NOUN	B
of	O	ADP	O
troleandomycin	B-Chemical	NOUN	B
for	O	ADP	O
7	O	NUM	O
days	O	NOUN	B
and	O	CCONJ	O
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
hypereosinophilia	B-Disease	NOUN	B
.	O	PUNCT	O


Jaundice	B-Disease	NOUN	B
disappeared	O	VERB	O
within	O	ADP	O
3	O	NUM	O
months	O	NOUN	B
but	O	CCONJ	O
was	O	AUX	O
followed	O	VERB	O
by	O	ADP	O
prolonged	O	ADJ	B
anicteric	O	ADJ	B
cholestasis	B-Disease	NOUN	B
marked	O	VERB	O
by	O	ADP	O
pruritus	B-Disease	NOUN	B
and	O	CCONJ	O
high	O	ADJ	O
levels	O	NOUN	B
of	O	ADP	O
alkaline	O	NOUN	B
phosphatase	O	NOUN	I
and	O	CCONJ	O
gammaglutamyltransferase	O	NOUN	B
activities	O	NOUN	I
.	O	PUNCT	O


Finally	O	ADV	O
,	O	PUNCT	O
pruritus	B-Disease	NOUN	B
disappeared	O	VERB	O
within	O	ADP	O
19	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
liver	O	NOUN	B
tests	O	NOUN	I
returned	O	VERB	O
to	O	PART	O
normal	O	ADJ	O
27	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
the	O	DET	O
onset	O	NOUN	O
of	O	ADP	O
hepatitis	B-Disease	NOUN	B
.	O	PUNCT	O


This	O	DET	O
observation	O	NOUN	B
demonstrates	O	VERB	O
that	O	SCONJ	O
prolonged	O	ADJ	B
cholestasis	B-Disease	NOUN	B
can	O	AUX	O
follow	O	VERB	O
troleandomycin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
acute	O	ADJ	B
hepatitis	B-Disease	NOUN	I


HMG	O	NOUN	B
CoA	O	NOUN	I
reductase	O	NOUN	I
inhibitors	O	NOUN	B
.	O	PUNCT	O


Current	O	ADJ	O
clinical	O	ADJ	B
experience	O	NOUN	O
.	O	PUNCT	O


Lovastatin	B-Chemical	NOUN	B
and	O	CCONJ	O
simvastatin	B-Chemical	NOUN	B
are	O	AUX	O
the	O	DET	O
2	O	NUM	O
best	O	ADV	O
-	O	PUNCT	O
known	O	VERB	O
members	O	NOUN	B
of	O	ADP	O
the	O	DET	O
class	O	NOUN	B
of	O	ADP	O
hypolipidaemic	O	ADJ	B
agents	O	NOUN	I
known	O	VERB	O
as	O	ADP	O
HMG	O	NOUN	B
CoA	O	NOUN	I
reductase	O	NOUN	I
inhibitors	O	NOUN	B
.	O	PUNCT	O


Clinical	O	ADJ	B
experience	O	NOUN	O
with	O	ADP	O
lovastatin	B-Chemical	NOUN	B
includes	O	VERB	O
over	O	ADP	O
5000	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
700	O	NUM	O
of	O	ADP	O
whom	O	PRON	O
have	O	AUX	O
been	O	AUX	O
treated	O	VERB	B
for	O	ADP	O
2	O	NUM	O
years	O	NOUN	B
or	O	CCONJ	O
more	O	ADJ	O
,	O	PUNCT	O
and	O	CCONJ	O
experience	O	NOUN	B
with	O	ADP	O
simvastatin	B-Chemical	NOUN	B
includes	O	VERB	O
over	O	ADP	O
3500	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
of	O	ADP	O
whom	O	PRON	O
350	O	NUM	O
have	O	AUX	O
been	O	AUX	O
treated	O	VERB	B
for	O	ADP	O
18	O	NUM	O
months	O	NOUN	B
or	O	CCONJ	O
more	O	ADJ	O
.	O	PUNCT	O


Lovastatin	B-Chemical	NOUN	B
has	O	AUX	O
been	O	AUX	O
marketed	O	VERB	B
in	O	ADP	O
the	O	DET	O
United	O	PROPN	B
States	O	PROPN	I
for	O	ADP	O
over	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


Both	O	DET	O
agents	O	NOUN	B
show	O	VERB	O
substantial	O	ADJ	O
clinical	O	ADJ	O
efficacy	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
reductions	O	NOUN	B
in	O	ADP	O
total	O	ADJ	O
cholesterol	B-Chemical	NOUN	O
of	O	ADP	O
over	O	ADP	O
30	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
in	O	ADP	O
LDL	O	NOUN	B
-	O	PUNCT	O
cholesterol	B-Chemical	NOUN	B
of	O	ADP	O
40	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
clinical	O	ADJ	B
studies	O	NOUN	I
.	O	PUNCT	O


Modest	O	ADJ	O
increases	O	NOUN	B
in	O	ADP	O
HDL	O	NOUN	B
-	O	PUNCT	O
cholesterol	B-Chemical	NOUN	B
levels	O	NOUN	B
of	O	ADP	O
about	O	ADV	O
10	O	NUM	O
%	O	NOUN	O
are	O	AUX	O
also	O	ADV	O
reported	O	VERB	O
.	O	PUNCT	O


Clinical	O	ADJ	B
tolerability	O	NOUN	O
of	O	ADP	O
both	O	DET	O
agents	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
good	O	ADJ	O
,	O	PUNCT	O
with	O	ADP	O
fewer	O	ADJ	O
than	O	ADP	O
3	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
withdrawn	O	VERB	O
from	O	ADP	O
treatment	O	NOUN	B
because	O	SCONJ	O
of	O	ADP	O
clinical	O	ADJ	B
adverse	O	ADJ	O
experiences	O	NOUN	B
.	O	PUNCT	O


Ophthalmological	O	ADJ	B
examinations	O	NOUN	O
in	O	ADP	O
over	O	ADP	O
1100	O	NUM	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
one	O	NUM	O
or	O	CCONJ	O
the	O	DET	O
other	O	ADJ	O
agent	O	NOUN	B
have	O	AUX	O
revealed	O	VERB	O
no	O	DET	O
evidence	O	NOUN	O
of	O	ADP	O
significant	O	ADJ	B
short	O	ADJ	B
term	O	NOUN	I
(	O	PUNCT	O
up	O	ADV	O
to	O	PART	O
2	O	NUM	O
years	O	NOUN	B
)	O	PUNCT	O
cataractogenic	O	ADJ	B
potential	O	NOUN	B
.	O	PUNCT	O


One	O	NUM	O
to	O	PART	O
2	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
have	O	AUX	O
elevations	O	NOUN	B
of	O	ADP	O
serum	O	NOUN	B
transaminases	O	NOUN	O
to	O	PART	O
greater	O	ADJ	O
than	O	ADP	O
3	O	NUM	O
times	O	NOUN	O
the	O	DET	O
upper	O	ADJ	O
limit	O	NOUN	O
of	O	ADP	O
normal	O	ADJ	O
.	O	PUNCT	O


These	O	DET	O
episodes	O	NOUN	B
are	O	AUX	O
asymptomatic	O	ADJ	B
and	O	CCONJ	O
reversible	O	ADJ	B
when	O	SCONJ	O
therapy	O	NOUN	B
is	O	AUX	O
discontinued	O	VERB	B
.	O	PUNCT	O


Minor	O	ADJ	B
elevations	O	NOUN	B
of	O	ADP	O
creatine	B-Chemical	NOUN	B
kinase	O	NOUN	I
levels	O	NOUN	B
are	O	AUX	O
reported	O	VERB	O
in	O	ADP	O
about	O	ADV	O
5	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
.	O	PUNCT	O


Myopathy	B-Disease	NOUN	B
,	O	PUNCT	O
associated	O	VERB	B
in	O	ADP	I
some	O	DET	O
cases	O	NOUN	B
with	O	ADP	O
myoglobinuria	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
2	O	NUM	O
cases	O	NOUN	B
with	O	ADP	O
transient	O	ADJ	B
renal	B-Disease	ADJ	I
failure	I-Disease	NOUN	I
,	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
rarely	O	ADV	O
reported	O	VERB	O
with	O	ADP	O
lovastatin	B-Chemical	NOUN	B
,	O	PUNCT	O
especially	O	ADV	O
in	O	ADP	O
patients	O	NOUN	B
concomitantly	O	ADV	O
treated	O	VERB	B
with	O	ADP	I
cyclosporin	B-Chemical	NOUN	B
,	O	PUNCT	O
gemfibrozil	B-Chemical	NOUN	B
or	O	CCONJ	O
niacin	B-Chemical	NOUN	B
.	O	PUNCT	O


Lovastatin	B-Chemical	NOUN	B
and	O	CCONJ	O
simvastatin	B-Chemical	NOUN	B
are	O	AUX	O
both	O	CCONJ	O
effective	O	ADJ	B
and	O	CCONJ	O
well	O	ADV	B
-	O	PUNCT	O
tolerated	O	VERB	B
agents	O	NOUN	B
for	O	ADP	O
lowering	O	VERB	B
elevated	O	ADJ	B
levels	O	NOUN	B
of	O	ADP	O
serum	O	NOUN	B
cholesterol	B-Chemical	NOUN	I
.	O	PUNCT	O


As	O	ADP	O
wider	O	ADJ	O
use	O	NOUN	O
confirms	O	VERB	O
their	O	PRON	O
safety	O	NOUN	B
profile	O	NOUN	I
,	O	PUNCT	O
they	O	PRON	O
will	O	AUX	O
gain	O	VERB	O
increasing	O	VERB	B
importance	O	NOUN	O
in	O	ADP	O
the	O	DET	O
therapeutic	O	ADJ	B
approach	O	NOUN	I
to	O	PART	O
hypercholesterolaemia	B-Disease	NOUN	B


Sulfasalazine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
lupus	B-Disease	NOUN	B
erythematosus	I-Disease	NOUN	I
.	O	PUNCT	O


Pneumonitis	B-Disease	NOUN	B
,	O	PUNCT	O
bilateral	O	ADJ	B
pleural	B-Disease	ADJ	I
effusions	I-Disease	NOUN	I
,	O	PUNCT	O
echocardiographic	O	ADJ	B
evidence	O	NOUN	B
of	O	ADP	O
cardiac	B-Disease	ADJ	B
tamponade	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
positive	O	ADJ	B
autoantibodies	O	NOUN	I
developed	O	VERB	O
in	O	ADP	O
a	O	DET	O
43	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
man	O	NOUN	B
,	O	PUNCT	O
who	O	PRON	O
was	O	AUX	O
receiving	O	VERB	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
sulfasalazine	B-Chemical	NOUN	B
therapy	O	NOUN	I
for	O	ADP	O
chronic	O	ADJ	B
ulcerative	B-Disease	ADJ	I
colitis	I-Disease	NOUN	I
.	O	PUNCT	O


After	O	ADP	O
cessation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
sulfasalazine	B-Chemical	NOUN	B
and	O	CCONJ	O
completion	O	NOUN	B
of	O	ADP	O
a	O	DET	O
six	O	NUM	B
-	O	PUNCT	O
week	O	NOUN	B
course	O	NOUN	B
of	O	ADP	O
corticosteroids	O	NOUN	B
,	O	PUNCT	O
these	O	DET	O
problems	O	NOUN	B
resolved	O	VERB	B
over	O	ADP	O
a	O	DET	O
period	O	NOUN	B
of	O	ADP	O
four	O	NUM	O
to	O	PART	O
six	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
suggested	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
patient	O	NOUN	B
had	O	AUX	O
sulfasalazine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
lupus	B-Disease	NOUN	B
,	O	PUNCT	O
which	O	DET	O
manifested	O	VERB	O
with	O	ADP	O
serositis	B-Disease	NOUN	B
and	O	CCONJ	O
pulmonary	O	ADJ	B
parenchymal	O	ADJ	I
involvement	O	NOUN	B
in	O	ADP	O
the	O	DET	O
absence	O	NOUN	B
of	O	ADP	O
joint	O	ADJ	B
symptoms	O	NOUN	I
.	O	PUNCT	O


Physicians	O	NOUN	B
who	O	PRON	O
use	O	VERB	O
sulfasalazine	B-Chemical	NOUN	B
to	O	PART	O
treat	O	VERB	B
patients	O	NOUN	B
with	O	ADP	O
inflammatory	B-Disease	ADJ	B
bowel	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
should	O	AUX	O
be	O	AUX	O
aware	O	ADJ	O
of	O	ADP	O
the	O	DET	O
signs	O	NOUN	B
of	O	ADP	O
sulfasalazine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
lupus	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I


Optimization	O	NOUN	B
of	O	ADP	O
levodopa	B-Chemical	NOUN	B
therapy	O	NOUN	O
.	O	PUNCT	O


While	O	SCONJ	O
there	O	PRON	O
is	O	AUX	O
no	O	DET	O
single	O	ADJ	O
correct	O	ADJ	O
starting	O	VERB	O
dose	O	NOUN	B
for	O	ADP	O
levodopa	B-Chemical	NOUN	B
therapy	O	NOUN	B
,	O	PUNCT	O
many	O	ADJ	O
individuals	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
started	O	VERB	O
on	O	ADP	O
either	O	CCONJ	O
the	O	DET	O
25	O	NUM	O
/	O	SYM	O
100	O	NUM	O
or	O	CCONJ	O
controlled	O	VERB	B
-	O	PUNCT	O
release	O	NOUN	B
formula	O	NOUN	B
,	O	PUNCT	O
following	O	VERB	O
the	O	DET	O
general	O	ADJ	O
rule	O	NOUN	O
not	O	PART	O
to	O	PART	O
attempt	O	VERB	O
to	O	PART	O
titrate	O	VERB	O
carbidopa	B-Chemical	NOUN	B
-	O	PUNCT	O
levodopa	B-Chemical	NOUN	B
to	O	ADP	O
the	O	DET	O
point	O	NOUN	O
of	O	ADP	O
"	O	PUNCT	O
normality	O	NOUN	B
,"	O	PUNCT	O
which	O	DET	O
can	O	AUX	O
lead	O	VERB	O
to	O	PART	O
toxicity	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
physician	O	NOUN	B
should	O	AUX	O
also	O	ADV	O
determine	O	VERB	O
the	O	DET	O
proper	O	ADJ	O
use	O	NOUN	O
of	O	ADP	O
any	O	DET	O
adjunctive	O	ADJ	B
medications	O	NOUN	I
;	O	PUNCT	O
such	O	ADJ	O
combined	O	ADJ	B
therapy	O	NOUN	I
has	O	AUX	O
become	O	VERB	O
the	O	DET	O
standard	O	ADJ	B
approach	O	NOUN	I
to	O	PART	O
treatment	O	NOUN	B
.	O	PUNCT	O


Following	O	VERB	O
the	O	DET	O
initial	O	ADJ	O
period	O	NOUN	B
of	O	ADP	O
therapy	O	NOUN	B
,	O	PUNCT	O
emerging	O	VERB	O
difficulties	O	NOUN	B
require	O	VERB	O
a	O	DET	O
reassessment	O	NOUN	B
of	O	ADP	O
therapeutic	O	ADJ	B
approaches	O	NOUN	I
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
dosage	O	NOUN	B
adjustment	O	NOUN	B
or	O	CCONJ	O
introduction	O	NOUN	B
of	O	ADP	O
a	O	DET	O
dopamine	B-Chemical	NOUN	B
agonist	O	NOUN	B
.	O	PUNCT	O


Other	O	ADJ	O
possible	O	ADJ	O
adverse	O	ADJ	B
effects	O	NOUN	I
--	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
gastrointestinal	B-Disease	ADJ	B
disorders	I-Disease	NOUN	I
,	O	PUNCT	O
orthostatic	B-Disease	ADJ	B
hypotension	I-Disease	NOUN	B
,	O	PUNCT	O
levodopa	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
psychosis	B-Disease	NOUN	B
,	O	PUNCT	O
sleep	B-Disease	NOUN	B
disturbances	I-Disease	NOUN	I
or	O	CCONJ	O
parasomnias	B-Disease	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
drug	O	NOUN	B
interactions	O	NOUN	I
--	O	PUNCT	O
also	O	ADV	O
require	O	VERB	O
carefully	O	ADV	O
monitored	O	VERB	O
individual	O	ADJ	B
treatment	O	NOUN	B
.	O	PUNCT	O


Nonpharmacologic	O	ADJ	B
concerns	O	NOUN	B
can	O	AUX	O
help	O	VERB	O
the	O	DET	O
Parkinson's	B-Disease	ADJ	O
disease	I-Disease	NOUN	B


Alpha	O	NOUN	B
and	O	CCONJ	O
beta	O	NOUN	B
coma	B-Disease	NOUN	I
in	O	ADP	O
drug	O	NOUN	B
intoxication	O	NOUN	I
uncomplicated	O	ADJ	O
by	O	ADP	O
cerebral	B-Disease	ADJ	B
hypoxia	I-Disease	NOUN	I
.	O	PUNCT	O


Four	O	NUM	O
patients	O	NOUN	B
who	O	PRON	O
were	O	AUX	O
rendered	O	VERB	O
comatose	B-Disease	ADJ	B
or	O	CCONJ	O
stuporous	B-Disease	ADJ	B
by	O	ADP	O
drug	O	NOUN	B
intoxication	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
who	O	PRON	O
were	O	AUX	O
not	O	PART	O
hypoxic	O	ADJ	B
,	O	PUNCT	O
are	O	AUX	O
described	O	VERB	O
.	O	PUNCT	O


Three	O	NUM	O
patients	O	NOUN	B
received	O	VERB	O
high	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
chlormethiazole	B-Chemical	NOUN	B
for	O	ADP	O
alcohol	B-Chemical	NOUN	B
withdrawal	B-Disease	NOUN	I
symptoms	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
one	O	NUM	O
took	O	VERB	O
a	O	DET	O
suicidal	O	ADJ	B
overdose	B-Disease	NOUN	B
of	O	ADP	O
nitrazepam	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
nitrazepam	B-Chemical	ADJ	B
overdose	B-Disease	NOUN	I
and	O	CCONJ	O
two	O	NUM	O
of	O	ADP	O
those	O	DET	O
with	O	ADP	O
chlormethiazole	B-Chemical	NOUN	B
intoxication	O	NOUN	B
conformed	O	VERB	O
to	O	PART	O
the	O	DET	O
criteria	O	NOUN	B
of	O	ADP	O
'	O	PUNCT	O
alpha	O	NOUN	B
coma	B-Disease	NOUN	I
',	O	AUX	I
showing	O	VERB	O
non	O	ADJ	B
-	O	PUNCT	O
reactive	O	ADJ	B
generalized	O	VERB	I
or	O	CCONJ	O
frontally	O	ADV	B
predominant	O	ADJ	I
alpha	O	NOUN	B
activity	O	NOUN	I
in	O	ADP	O
the	O	DET	O
EEG	O	PROPN	B
.	O	PUNCT	O


The	O	DET	O
fourth	O	ADJ	O
patient	O	NOUN	B
who	O	PRON	O
was	O	AUX	O
unconscious	O	ADJ	B
after	O	ADP	O
chlormethiazole	B-Chemical	NOUN	B
administration	O	NOUN	B
exhibite	O	ADJ	B
generalized	O	VERB	O
non	O	ADJ	B
-	O	PUNCT	O
reactive	O	ADJ	B
activity	O	NOUN	I
in	O	ADP	O
the	O	DET	O
slow	O	ADJ	B
beta	O	NOUN	I
range	O	NOUN	I
.	O	PUNCT	O


All	O	DET	O
four	O	NUM	O
recovered	O	VERB	B
completely	O	ADV	O
without	O	ADP	O
neurological	B-Disease	ADJ	B
sequelae	I-Disease	NOUN	I
following	O	VERB	O
the	O	DET	O
withdrawal	O	NOUN	B
of	O	ADP	O
the	O	DET	O
offending	O	NOUN	B
agents	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
similarities	O	NOUN	B
between	O	ADP	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
structural	O	ADJ	B
lesions	O	NOUN	I
and	O	CCONJ	O
pharmacological	O	ADJ	B
depression	B-Disease	NOUN	I
of	O	ADP	O
the	O	DET	O
brain	O	NOUN	B
stem	O	NOUN	I
reticular	O	ADJ	I
formation	O	NOUN	B
are	O	AUX	O
discussed	O	VERB	O
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
suggested	O	VERB	O
that	O	SCONJ	O
in	O	ADP	O
both	O	DET	O
situations	O	NOUN	B
disturbed	O	VERB	O
reticulo	O	NOUN	B
-	O	PUNCT	O
thalamic	O	ADJ	B
interactions	O	NOUN	B
are	O	AUX	O
important	O	ADJ	O
in	O	ADP	O
the	O	DET	O
pathogenesis	O	NOUN	B
of	O	ADP	O
alpha	O	NOUN	B
coma	B-Disease	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
concluded	O	VERB	O
that	O	SCONJ	O
when	O	SCONJ	O
this	O	DET	O
electroencephalographic	O	ADJ	B
and	O	CCONJ	O
behavioural	O	ADJ	B
picture	O	NOUN	I
is	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
drug	O	NOUN	B
intoxication	O	NOUN	I
,	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
absence	O	NOUN	B
of	O	ADP	O
significant	O	ADJ	O
hypoxaemia	B-Disease	NOUN	B


Omitting	O	VERB	O
fentanyl	B-Chemical	NOUN	B
reduces	O	VERB	B
nausea	B-Disease	ADJ	B
and	O	CCONJ	O
vomiting	B-Disease	NOUN	B
,	O	PUNCT	O
without	O	ADP	O
increasing	O	VERB	B
pain	B-Disease	NOUN	B
,	O	PUNCT	O
after	O	ADP	O
sevoflurane	B-Chemical	NOUN	B
for	O	ADP	O
day	O	NOUN	B
surgery	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
AND	O	CCONJ	O
OBJECTIVE	O	NOUN	O
:	O	PUNCT	O
Despite	O	SCONJ	O
advantages	O	NOUN	O
of	O	ADP	O
induction	O	NOUN	B
and	O	CCONJ	O
maintenance	O	NOUN	B
of	O	ADP	O
anaesthesia	O	NOUN	B
with	O	ADP	O
sevoflurane	B-Chemical	NOUN	B
,	O	PUNCT	O
postoperative	B-Disease	ADJ	B
nausea	I-Disease	NOUN	B
and	I-Disease	CCONJ	O
vomiting	I-Disease	NOUN	B
occurs	O	VERB	O
frequently	O	ADV	O
.	O	PUNCT	O


Fentanyl	B-Chemical	NOUN	B
is	O	AUX	O
a	O	DET	O
commonly	O	ADV	O
used	O	VERB	O
supplement	O	NOUN	B
that	O	PRON	O
may	O	AUX	O
contribute	O	VERB	O
to	O	ADP	O
this	O	DET	O
,	O	PUNCT	O
although	O	SCONJ	O
it	O	PRON	O
may	O	AUX	O
also	O	ADV	O
improve	O	VERB	B
analgesia	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
This	O	DET	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	ADJ	B
study	O	NOUN	B
examined	O	VERB	O
the	O	DET	O
incidence	O	NOUN	B
and	O	CCONJ	O
severity	O	NOUN	B
of	O	ADP	O
postoperative	B-Disease	ADJ	B
nausea	I-Disease	NOUN	B
and	I-Disease	CCONJ	O
vomiting	I-Disease	NOUN	B
and	O	CCONJ	O
pain	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
first	O	ADJ	O
24	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
sevoflurane	B-Chemical	NOUN	B
anaesthesia	O	NOUN	I
in	O	ADP	O
216	O	NUM	O
adult	O	ADJ	B
day	O	NOUN	B
surgery	O	NOUN	B
patients	O	NOUN	B
.	O	PUNCT	O


Patients	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
allocated	O	VERB	O
to	O	PART	O
either	O	CCONJ	O
receive	O	VERB	B
or	O	CCONJ	O
not	O	PART	O
receive	O	VERB	O
1	O	NUM	O
1	O	NUM	O
fentanyl	B-Chemical	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
a	O	DET	O
third	O	ADJ	O
group	O	NOUN	B
received	O	VERB	O
dexamethasone	B-Chemical	NOUN	B
in	O	ADP	O
addition	O	NOUN	O
to	O	PART	O
fentanyl	B-Chemical	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Omission	O	NOUN	B
of	O	ADP	O
fentanyl	B-Chemical	NOUN	B
did	O	AUX	O
not	O	PART	O
reduce	O	VERB	O
the	O	DET	O
overall	O	ADJ	B
incidence	O	NOUN	B
of	O	ADP	O
postoperative	B-Disease	ADJ	B
nausea	I-Disease	NOUN	B
and	I-Disease	CCONJ	O
vomiting	I-Disease	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
did	O	AUX	O
reduce	O	VERB	O
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
vomiting	B-Disease	NOUN	B
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
moderate	O	ADJ	B
to	O	PART	O
severe	O	ADJ	B
nausea	B-Disease	NOUN	B
prior	O	ADV	O
to	O	PART	O
discharge	O	VERB	B
from	O	ADP	O
20	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
17	O	NUM	O
%	O	NOUN	O
with	O	ADP	O
fentanyl	B-Chemical	NOUN	B
and	O	CCONJ	O
fentanyl	B-Chemical	NOUN	B
-	O	PUNCT	O
dexamethasone	B-Chemical	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
to	O	PART	O
5	O	NUM	O
%(	O	NOUN	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


013	O	NUM	O
).	O	PUNCT	B
Antiemetic	O	ADJ	B
requirements	O	NOUN	B
were	O	AUX	O
reduced	O	VERB	B
from	O	ADP	O
24	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
31	O	NUM	O
%	O	NOUN	O
to	O	PART	O
7	O	NUM	O
%(	O	NOUN	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


0012	O	NUM	O
).	O	PUNCT	O
Dexamethasone	B-Chemical	NOUN	B
had	O	AUX	O
no	O	DET	B
significant	O	ADJ	I
effect	O	NOUN	O
on	O	ADP	O
the	O	DET	O
incidence	O	NOUN	B
or	O	CCONJ	O
severity	O	NOUN	B
of	O	ADP	O
postoperative	B-Disease	ADJ	B
nausea	I-Disease	NOUN	O
and	I-Disease	CCONJ	O
vomiting	I-Disease	NOUN	B
.	O	PUNCT	O


Combining	O	VERB	O
the	O	DET	O
two	O	NUM	O
fentanyl	B-Chemical	NOUN	B
groups	O	NOUN	I
revealed	O	VERB	O
further	O	ADJ	O
significant	O	ADJ	O
benefits	O	NOUN	B
from	O	ADP	O
the	O	DET	O
avoidance	O	NOUN	B
of	O	ADP	O
opioids	O	NOUN	B
,	O	PUNCT	O
reducing	O	VERB	B
postoperative	B-Disease	ADJ	B
nausea	I-Disease	NOUN	B
and	I-Disease	CCONJ	O
vomiting	I-Disease	NOUN	B
and	O	CCONJ	O
nausea	B-Disease	NOUN	B
prior	O	ADV	O
to	O	PART	O
discharge	O	VERB	B
from	O	ADP	O
35	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
33	O	NUM	O
%	O	NOUN	O
to	O	PART	O
22	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
19	O	NUM	O
%(	O	NOUN	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


049	O	NUM	O
and	O	CCONJ	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


035	O	NUM	O
),	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
while	O	SCONJ	O
nausea	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
first	O	ADJ	O
24	O	NUM	O
h	O	NOUN	O
was	O	AUX	O
decreased	O	VERB	B
from	O	ADP	O
42	O	NUM	O
%	O	NOUN	O
to	O	PART	O
27	O	NUM	O
%(	O	NOUN	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


034	O	NUM	O
).	O	PUNCT	B
Pain	B-Disease	NOUN	I
severity	O	NOUN	B
and	O	CCONJ	O
analgesic	O	NOUN	B
requirements	O	NOUN	I
were	O	AUX	O
unaffected	O	ADJ	O
by	O	ADP	O
the	O	DET	O
omission	O	NOUN	B
of	O	ADP	O
fentanyl	B-Chemical	NOUN	B
.	O	PUNCT	O


Fentanyl	B-Chemical	PROPN	B
did	O	AUX	O
reduce	O	VERB	O
minor	O	ADJ	O
intraoperative	O	ADJ	B
movement	O	NOUN	B
but	O	CCONJ	O
had	O	AUX	O
no	O	DET	O
sevoflurane	B-Chemical	NOUN	B
-	O	PUNCT	O
sparing	O	VERB	B
effect	O	NOUN	B
and	O	CCONJ	O
increased	O	VERB	B
respiratory	B-Disease	ADJ	B
depression	I-Disease	NOUN	I
,	O	PUNCT	O
hypotension	B-Disease	NOUN	B
and	O	CCONJ	O
bradycardia	B-Disease	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
As	O	ADP	O
fentanyl	B-Chemical	NOUN	B
exacerbated	O	VERB	B
postoperative	B-Disease	ADJ	B
nausea	I-Disease	NOUN	O
and	I-Disease	CCONJ	O
vomiting	I-Disease	NOUN	B
without	O	ADP	O
an	O	DET	O
improvement	O	NOUN	B
in	O	ADP	O
postoperative	B-Disease	ADJ	B
pain	I-Disease	NOUN	I
and	O	CCONJ	O
also	O	ADV	O
had	O	AUX	O
adverse	O	ADJ	B
cardiorespiratory	O	ADJ	B
effects	O	NOUN	I
,	O	PUNCT	O
it	O	PRON	O
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
an	O	DET	O
unnecessary	O	ADJ	O
and	O	CCONJ	O
possibly	O	ADV	O
detrimental	O	ADJ	B
supplement	O	NOUN	I
to	O	PART	O
sevoflurane	B-Chemical	NOUN	B


Renal	B-Disease	ADJ	B
Fanconi	I-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
and	O	CCONJ	O
myopathy	B-Disease	NOUN	B
after	O	ADP	O
liver	O	NOUN	B
transplantation	O	NOUN	I
:	O	PUNCT	O
drug	O	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
mitochondrial	B-Disease	ADJ	B
cytopathy	I-Disease	NOUN	I
?	O	PUNCT	O
Advances	O	NOUN	B
in	O	ADP	O
the	O	DET	O
field	O	NOUN	B
of	O	ADP	O
transplantation	O	NOUN	B
provide	O	VERB	O
a	O	DET	O
better	O	ADJ	O
quality	O	NOUN	B
of	O	ADP	I
life	O	NOUN	I
and	O	CCONJ	O
allow	O	VERB	O
more	O	ADV	O
favorable	O	ADJ	B
conditions	O	NOUN	B
for	O	ADP	O
growth	O	NOUN	B
and	O	CCONJ	O
development	O	NOUN	B
in	O	ADP	O
children	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
combinations	O	NOUN	B
of	O	ADP	O
different	O	ADJ	O
therapeutic	O	ADJ	B
regimens	O	NOUN	I
require	O	VERB	O
consideration	O	NOUN	O
of	O	ADP	O
potential	O	ADJ	B
adverse	O	ADJ	B
reactions	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
describe	O	VERB	O
a	O	DET	O
15	O	NUM	O
-	O	PUNCT	O
yr	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
girl	O	NOUN	I
who	O	PRON	O
had	O	AUX	O
orthotopic	O	ADJ	B
liver	O	NOUN	B
transplantation	O	NOUN	I
because	O	SCONJ	O
of	O	ADP	O
Wilson's	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


Tacrolimus	B-Chemical	NOUN	B
,	O	PUNCT	O
MMF	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
steroids	B-Chemical	NOUN	B
were	O	AUX	O
given	O	VERB	O
as	O	ADP	O
immunosuppressant	O	ADJ	B
.	O	PUNCT	O


Lamivudine	B-Chemical	NOUN	B
was	O	AUX	O
added	O	VERB	O
because	O	SCONJ	O
of	O	ADP	O
de	O	X	B
nova	O	X	I
hepatitis	B-Disease	NOUN	I
B	I-Disease	NOUN	I
infection	I-Disease	NOUN	I
during	O	ADP	O
her	O	PRON	O
follow	O	NOUN	B
-	O	PUNCT	O
up	O	NOUN	B
.	O	PUNCT	O


Three	O	NUM	O
yr	O	NOUN	O
after	O	ADP	O
transplantation	O	NOUN	B
she	O	PRON	O
developed	O	VERB	O
renal	B-Disease	ADJ	B
Fanconi	I-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
with	O	ADP	O
severe	O	ADJ	B
metabolic	B-Disease	ADJ	B
acidosis	I-Disease	NOUN	I
,	O	PUNCT	O
hypophosphatemia	B-Disease	NOUN	B
,	O	PUNCT	O
glycosuria	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
aminoaciduria	B-Disease	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
tacrolimus	B-Chemical	NOUN	B
was	O	AUX	O
suspected	O	VERB	B
to	O	PART	O
be	O	AUX	O
the	O	DET	O
cause	O	NOUN	O
of	O	ADP	O
late	O	ADJ	O
post	O	NOUN	B
-	O	PUNCT	O
transplant	O	NOUN	B
renal	O	ADJ	B
acidosis	B-Disease	NOUN	I
and	O	CCONJ	O
was	O	AUX	O
replaced	O	VERB	O
by	O	ADP	O
sirolimus	B-Chemical	NOUN	B
,	O	PUNCT	O
acidosis	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
electrolyte	O	NOUN	B
imbalance	O	NOUN	B
got	O	VERB	O
worse	O	ADJ	O
.	O	PUNCT	O


Proximal	O	ADJ	B
muscle	B-Disease	NOUN	B
weakness	I-Disease	NOUN	I
has	O	AUX	O
developed	O	VERB	O
during	O	ADP	O
her	O	PRON	O
follow	O	NOUN	B
-	O	PUNCT	O
up	O	NOUN	B
.	O	PUNCT	O


Fanconi	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
myopathy	B-Disease	NOUN	B
,	O	PUNCT	O
is	O	AUX	O
well	O	ADV	O
recognized	O	VERB	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
mitochondrial	B-Disease	ADJ	B
disorders	I-Disease	NOUN	I
and	O	CCONJ	O
caused	O	VERB	O
by	O	ADP	O
depletion	O	NOUN	B
of	O	ADP	O
mtDNA	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
suggest	O	VERB	O
that	O	SCONJ	O
our	O	PRON	O
patient	O	NOUN	B
'	O	PART	O
s	O	NOUN	O
tubular	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
and	O	CCONJ	O
myopathy	B-Disease	NOUN	B
may	O	AUX	O
have	O	AUX	O
resulted	O	VERB	O
from	O	ADP	O
mitochondrial	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
which	O	DET	O
is	O	AUX	O
triggered	O	VERB	O
by	O	ADP	O
tacrolimus	B-Chemical	NOUN	B
and	O	CCONJ	O
augmented	O	VERB	B
by	O	ADP	O
lamivudine	B-Chemical	NOUN	B


Antipsychotic	O	ADJ	B
-	O	PUNCT	O
like	O	ADJ	B
profile	O	NOUN	B
of	O	ADP	O
thioperamide	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
selective	O	ADJ	O
H3	O	NOUN	B
-	O	PUNCT	O
receptor	O	NOUN	B
antagonist	O	NOUN	B
in	O	ADP	O
mice	O	NOUN	B
.	O	PUNCT	O


Experimental	O	ADJ	B
and	O	CCONJ	O
clinical	O	ADJ	B
evidence	O	NOUN	I
points	O	VERB	O
to	O	PART	O
a	O	DET	O
role	O	NOUN	O
of	O	ADP	O
central	O	ADJ	B
histaminergic	O	ADJ	I
system	O	NOUN	I
in	O	ADP	O
the	O	DET	O
pathogenesis	O	NOUN	B
of	O	ADP	O
schizophrenia	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
was	O	AUX	O
designed	O	VERB	O
to	O	PART	O
study	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
histamine	B-Chemical	NOUN	B
H	O	NOUN	I
(	O	PUNCT	O
3	O	NUM	O
)-	O	ADJ	O
receptor	O	NOUN	O
ligands	O	NOUN	B
on	O	ADP	O
neuroleptic	O	ADJ	B
-	O	PUNCT	O
induced	O	VERB	B
catalepsy	B-Disease	NOUN	B
,	O	PUNCT	O
apomorphine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
climbing	O	NOUN	B
behavior	O	NOUN	O
and	O	CCONJ	O
amphetamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
locomotor	O	NOUN	B
activities	O	NOUN	I
in	O	ADP	O
mice	O	NOUN	B
.	O	PUNCT	O


Catalepsy	B-Disease	PROPN	B
was	O	AUX	O
induced	O	VERB	B
by	O	ADP	O
haloperidol	B-Chemical	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
p	O	NOUN	O
.	O	PUNCT	O


o	O	INTJ	O
.),	O	X	O
while	O	SCONJ	O
apomorphine	B-Chemical	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
s	O	NOUN	O
.	O	PUNCT	O


c	O	X	O
.)	O	NOUN	O
and	O	CCONJ	O
amphetamine	B-Chemical	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
s	O	NOUN	O
.	O	PUNCT	O


c	O	X	O
.)	O	NOUN	O
were	O	AUX	O
used	O	VERB	O
for	O	ADP	O
studying	O	VERB	O
climbing	O	NOUN	B
behavior	O	NOUN	O
and	O	CCONJ	O
locomotor	O	NOUN	B
activities	O	NOUN	I
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


(R)-alpha-methylhistamine	B-Chemical	NOUN	B
(	O	PUNCT	O
RAMH	B-Chemical	NOUN	B
)(	O	NOUN	O
5	O	NUM	O
microg	O	NOUN	B
i	O	NUM	O
.	O	PUNCT	O


c	O	X	O
.	O	PUNCT	O


v	O	ADP	O
.)	O	NOUN	B
and	O	CCONJ	O
thioperamide	B-Chemical	NOUN	B
(	O	PUNCT	O
THP	B-Chemical	NOUN	B
)(	O	NOUN	O
15	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
i	O	X	O
.	O	PUNCT	O


p	O	NOUN	O
.),	O	SYM	O
per	O	X	O
se	O	X	O
did	O	AUX	O
not	O	PART	O
cause	O	VERB	O
catalepsy	B-Disease	NOUN	B
.	O	PUNCT	O


Administration	O	NOUN	B
of	O	ADP	O
THP	B-Chemical	NOUN	B
(	O	PUNCT	O
3	O	NUM	O
.	O	PUNCT	O


75	O	NUM	O
,	O	PUNCT	O
7	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
and	O	CCONJ	O
15	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
i	O	X	O
.	O	PUNCT	O


p	O	NOUN	O
.)	O	SYM	O
1	O	NUM	O
h	O	NOUN	O
prior	O	ADJ	O
to	O	PART	O
haloperidol	B-Chemical	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
a	O	DET	O
dose	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
increase	O	NOUN	B
in	O	ADP	O
the	O	DET	O
catalepsy	B-Disease	NOUN	B
times	O	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
).	O	PUNCT	O
However	O	ADV	O
,	O	PUNCT	O
pretreatment	O	NOUN	B
with	O	ADP	O
RAMH	B-Chemical	NOUN	B
significantly	O	ADV	O
reversed	O	VERB	O
such	O	DET	O
an	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
THP	B-Chemical	NOUN	B
(	O	PUNCT	O
15	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
i	O	X	O
.	O	PUNCT	O


p	O	NOUN	O
.).	O	NOUN	O
RAMH	B-Chemical	NOUN	B
per	O	X	O
se	O	X	O
showed	O	VERB	O
significant	O	ADJ	O
reduction	O	NOUN	B
in	O	ADP	O
locomotor	O	NOUN	B
time	O	NOUN	I
,	O	PUNCT	O
distance	O	NOUN	B
traveled	O	VERB	I
and	O	CCONJ	O
average	O	ADJ	B
speed	O	NOUN	B
but	O	CCONJ	O
THP	B-Chemical	NOUN	B
(	O	PUNCT	O
15	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
i	O	X	O
.	O	PUNCT	O


p	O	NOUN	O
.)	O	NUM	O
per	O	X	O
se	O	X	O
had	O	AUX	O
no	O	DET	B
effect	O	NOUN	I
on	O	ADP	O
these	O	DET	O
parameters	O	NOUN	B
.	O	PUNCT	O


On	O	ADP	O
amphetamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hyperactivity	B-Disease	NOUN	B
,	O	PUNCT	O
THP	B-Chemical	NOUN	B
(	O	PUNCT	O
3	O	NUM	O
.	O	PUNCT	O


75	O	NUM	O
and	O	CCONJ	O
7	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
i	O	X	O
.	O	PUNCT	O


p	O	NOUN	O
.)	O	PUNCT	O
reduced	O	VERB	B
locomotor	O	NOUN	B
time	O	NOUN	I
,	O	PUNCT	O
distance	O	NOUN	B
traveled	O	VERB	I
and	O	CCONJ	O
average	O	ADJ	B
speed	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
).	O	PUNCT	B
Pretreatment	O	NOUN	B
with	O	ADP	O
RAMH	B-Chemical	NOUN	B
(	O	PUNCT	O
5	O	NUM	O
microg	O	NOUN	B
i	O	NUM	O
.	O	PUNCT	O


c	O	X	O
.	O	PUNCT	O


v	O	ADP	O
.)	O	NOUN	O
could	O	AUX	O
partially	O	ADV	O
reverse	O	VERB	B
such	O	ADJ	O
effects	O	NOUN	B
of	O	ADP	O
THP	B-Chemical	NOUN	B
(	O	PUNCT	O
3	O	NUM	O
.	O	PUNCT	O


75	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
i	O	X	O
.	O	PUNCT	O


p	O	NOUN	O
.).	O	NOUN	O
Climbing	O	NOUN	B
behavior	O	NOUN	I
induced	O	VERB	B
by	O	ADP	O
apomorphine	B-Chemical	NOUN	B
was	O	AUX	O
reduced	O	VERB	B
in	O	ADP	O
animals	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
THP	B-Chemical	NOUN	B
.	O	PUNCT	O


Such	O	DET	O
an	O	DET	O
effect	O	NOUN	B
was	O	AUX	O
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
reversed	O	VERB	O
in	O	ADP	O
presence	O	NOUN	B
of	O	ADP	O
RAMH	B-Chemical	NOUN	B
.	O	PUNCT	O


THP	B-Chemical	NOUN	B
exhibited	O	VERB	O
an	O	DET	O
antipsychotic	O	ADJ	B
-	O	PUNCT	O
like	O	ADJ	B
profile	O	NOUN	B
by	O	ADP	O
potentiating	O	VERB	O
haloperidol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
catalepsy	B-Disease	NOUN	B
,	O	PUNCT	O
reducing	O	VERB	B
amphetamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hyperactivity	B-Disease	NOUN	B
and	O	CCONJ	O
reducing	O	VERB	B
apomorphine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
climbing	O	NOUN	B
in	O	ADP	O
mice	O	NOUN	B
.	O	PUNCT	O


Such	O	ADJ	O
effects	O	NOUN	B
of	O	ADP	O
THP	B-Chemical	NOUN	B
were	O	AUX	O
reversed	O	VERB	O
by	O	ADP	O
RAMH	B-Chemical	NOUN	B
indicating	O	VERB	O
the	O	DET	O
involvement	O	NOUN	B
of	O	ADP	O
histamine	B-Chemical	NOUN	B
H	O	NOUN	I
(	O	PUNCT	O
3	O	NUM	O
)-	O	ADJ	O
receptors	O	NOUN	O
.	O	PUNCT	O


Findings	O	NOUN	B
suggest	O	VERB	O
a	O	DET	O
potential	O	NOUN	B
for	O	ADP	O
H	O	NOUN	B
(	O	PUNCT	O
3	O	NUM	O
)-	O	ADJ	O
receptor	O	NOUN	O
antagonists	O	NOUN	B
in	O	ADP	O
improving	O	VERB	B
the	O	DET	O
refractory	O	ADJ	B
cases	O	NOUN	B
of	O	ADP	O
schizophrenia	B-Disease	NOUN	B


Transient	O	ADJ	B
platypnea-orthodeoxia-like	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
induced	O	VERB	B
by	O	ADP	O
propafenone	B-Chemical	NOUN	B
overdose	B-Disease	NOUN	B
in	O	ADP	O
a	O	DET	O
young	O	ADJ	B
woman	O	NOUN	B
with	O	ADP	O
Ebstein's	B-Disease	NOUN	B
anomaly	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
report	O	NOUN	O
we	O	PRON	O
describe	O	VERB	O
the	O	DET	O
case	O	NOUN	B
of	O	ADP	O
a	O	DET	O
37	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
white	O	ADJ	B
woman	O	NOUN	I
with	O	ADP	O
Ebstein's	B-Disease	NOUN	B
anomaly	I-Disease	NOUN	I
,	O	PUNCT	O
who	O	PRON	O
developed	O	VERB	O
a	O	DET	O
rare	O	ADJ	B
syndrome	O	NOUN	I
called	O	VERB	O
platypnea-orthodeoxia	B-Disease	NOUN	B
,	O	PUNCT	O
characterized	O	VERB	B
by	O	ADP	O
massive	O	ADJ	B
right	O	ADV	B
-	O	PUNCT	O
to	O	ADP	O
-	O	PUNCT	O
left	O	VERB	B
interatrial	O	NOUN	I
shunting	O	NOUN	I
with	O	ADP	O
transient	O	ADJ	B
profound	O	ADJ	O
hypoxia	B-Disease	NOUN	B
and	O	CCONJ	O
cyanosis	B-Disease	NOUN	B
.	O	PUNCT	O


This	O	DET	O
shunt	O	NOUN	B
of	O	ADP	O
blood	O	NOUN	B
via	O	ADP	O
a	O	DET	O
patent	B-Disease	NOUN	B
foramen	I-Disease	NOUN	B
ovale	I-Disease	NOUN	B
occurred	O	VERB	O
in	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
a	O	DET	O
normal	O	ADJ	O
pulmonary	O	ADJ	B
artery	O	NOUN	I
pressure	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
was	O	AUX	O
probably	O	ADV	O
precipitated	O	VERB	B
by	O	ADP	O
a	O	DET	O
propafenone	B-Chemical	NOUN	B
overdose	B-Disease	NOUN	B
.	O	PUNCT	O


This	O	DET	O
drug	O	NOUN	B
caused	O	VERB	O
biventricular	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
,	O	PUNCT	O
due	O	ADP	O
to	O	PART	O
its	O	PRON	O
negative	O	ADJ	B
inotropic	O	ADJ	B
effect	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
hypotension	B-Disease	NOUN	B


A	O	DET	O
Phase	O	NOUN	B
II	O	NUM	I
trial	O	NOUN	I
of	O	ADP	O
cisplatin	B-Chemical	NOUN	B
plus	O	CCONJ	O
WR-2721	B-Chemical	NOUN	B
(	O	PUNCT	O
amifostine	B-Chemical	NOUN	B
)	O	PUNCT	O
for	O	ADP	O
metastatic	O	ADJ	B
breast	B-Disease	NOUN	I
carcinoma	I-Disease	NOUN	I
:	O	PUNCT	O
an	O	DET	O
Eastern	O	PROPN	B
Cooperative	O	PROPN	I
Oncology	O	PROPN	I
Group	O	PROPN	I
Study	O	PROPN	I
(	O	PUNCT	O
E8188	O	PROPN	B
).	O	PUNCT	O
BACKGROUND	O	NOUN	O
:	O	PUNCT	O
Cisplatin	B-Chemical	NOUN	B
has	O	AUX	O
minimal	O	ADJ	O
antitumor	O	NOUN	B
activity	O	NOUN	O
when	O	SCONJ	O
used	O	VERB	O
as	O	ADP	O
second	O	ADJ	B
-	O	PUNCT	O
or	O	CCONJ	O
third	O	ADJ	B
-	O	PUNCT	O
line	O	NOUN	B
treatment	O	NOUN	B
of	O	ADP	O
metastatic	O	ADJ	B
breast	B-Disease	NOUN	I
carcinoma	I-Disease	NOUN	I
.	O	PUNCT	O


Older	O	ADJ	B
reports	O	NOUN	I
suggest	O	VERB	O
an	O	DET	O
objective	O	ADJ	O
response	O	NOUN	B
rate	O	NOUN	I
of	O	ADP	O
8	O	NUM	O
%	O	NOUN	O
when	O	SCONJ	O
60	O	NUM	O
-	O	SYM	O
120	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
of	O	ADP	O
cisplatin	B-Chemical	NOUN	B
is	O	AUX	O
administered	O	VERB	B
every	O	DET	O
3	O	NUM	O
-	O	SYM	O
4	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
a	O	DET	O
dose	O	NOUN	B
-	O	PUNCT	O
response	O	NOUN	B
effect	O	NOUN	O
has	O	AUX	O
been	O	AUX	O
observed	O	VERB	O
with	O	ADP	O
cisplatin	B-Chemical	NOUN	B
,	O	PUNCT	O
the	O	DET	O
dose	O	NOUN	B
-	O	PUNCT	O
limiting	O	VERB	B
toxicities	B-Disease	NOUN	B
associated	O	VERB	B
with	O	ADP	I
cisplatin	B-Chemical	NOUN	B
(	O	PUNCT	O
e	O	X	O
.	O	PUNCT	O


g	O	NOUN	O
.,	O	PUNCT	O
nephrotoxicity	B-Disease	NOUN	B
,	O	PUNCT	O
ototoxicity	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
neurotoxicity	B-Disease	NOUN	B
)	O	PUNCT	O
have	O	AUX	O
limited	O	VERB	O
its	O	PRON	O
use	O	NOUN	O
as	O	ADP	O
a	O	DET	O
treatment	O	NOUN	B
for	O	ADP	O
breast	B-Disease	NOUN	B
carcinoma	I-Disease	NOUN	I
.	O	PUNCT	O


WR-2721	B-Chemical	NOUN	B
or	O	CCONJ	O
amifostine	B-Chemical	NOUN	B
initially	O	ADV	B
was	O	AUX	O
developed	O	VERB	O
to	O	PART	O
protect	O	VERB	O
military	O	ADJ	B
personnel	O	NOUN	I
in	O	ADP	O
the	O	DET	O
event	O	NOUN	B
of	O	ADP	O
nuclear	O	ADJ	B
war	O	NOUN	I
.	O	PUNCT	O


Amifostine	B-Chemical	NOUN	B
subsequently	O	ADV	O
was	O	AUX	O
shown	O	VERB	O
to	O	PART	O
protect	O	VERB	O
normal	O	ADJ	B
tissues	O	NOUN	I
from	O	ADP	O
the	O	DET	O
toxic	O	ADJ	B
effects	O	NOUN	O
of	O	ADP	O
alkylating	B-Chemical	NOUN	B
agents	I-Chemical	NOUN	I
and	O	CCONJ	O
cisplatin	B-Chemical	NOUN	B
without	O	ADP	O
decreasing	O	VERB	B
the	O	DET	O
antitumor	O	ADJ	B
effect	O	NOUN	B
of	O	ADP	O
the	O	DET	O
chemotherapy	O	NOUN	B
.	O	PUNCT	O


Early	O	ADJ	B
trials	O	NOUN	I
of	O	ADP	O
cisplatin	B-Chemical	NOUN	B
and	O	CCONJ	O
amifostine	B-Chemical	NOUN	B
also	O	ADV	O
suggested	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
incidence	O	NOUN	B
and	O	CCONJ	O
severity	O	NOUN	B
of	O	ADP	O
cisplatin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
nephrotoxicity	B-Disease	NOUN	B
,	O	PUNCT	O
ototoxicity	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
neuropathy	B-Disease	NOUN	B
were	O	AUX	O
reduced	O	VERB	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
A	O	DET	O
Phase	O	NOUN	B
II	O	NUM	I
study	O	NOUN	B
of	O	ADP	O
the	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
cisplatin	B-Chemical	NOUN	B
plus	O	CCONJ	O
amifostine	B-Chemical	NOUN	B
was	O	AUX	O
conducted	O	VERB	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
progressive	O	ADJ	B
metastatic	O	ADJ	B
breast	B-Disease	NOUN	I
carcinoma	I-Disease	NOUN	I
who	O	PRON	O
had	O	AUX	O
received	O	VERB	O
one	O	NUM	O
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
more	O	ADJ	O
than	O	ADP	O
one	O	NUM	O
,	O	PUNCT	O
chemotherapy	O	NOUN	B
regimen	O	NOUN	I
for	O	ADP	O
metastatic	O	ADJ	B
disease	O	NOUN	I
.	O	PUNCT	O


Patients	O	NOUN	B
received	O	VERB	O
amifostine	B-Chemical	NOUN	B
,	O	PUNCT	O
910	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
intravenously	O	ADV	B
over	O	ADP	O
15	O	NUM	O
minutes	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
completion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
amifostine	B-Chemical	NOUN	B
infusion	O	NOUN	B
,	O	PUNCT	O
cisplatin	B-Chemical	NOUN	B
120	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
was	O	AUX	O
administered	O	VERB	B
over	O	ADP	O
30	O	NUM	O
minutes	O	NOUN	B
.	O	PUNCT	O


Intravenous	O	ADJ	B
hydration	O	NOUN	O
and	O	CCONJ	O
mannitol	B-Chemical	NOUN	B
was	O	AUX	O
administered	O	VERB	B
before	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
cisplatin	B-Chemical	NOUN	B
.	O	PUNCT	O


Treatment	O	NOUN	B
was	O	AUX	O
administered	O	VERB	B
every	O	DET	O
3	O	NUM	O
weeks	O	NOUN	B
until	O	ADP	O
disease	O	NOUN	B
progression	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Forty	O	NUM	B
-	O	PUNCT	O
four	O	NUM	B
patients	O	NOUN	B
were	O	AUX	O
enrolled	O	VERB	O
in	O	ADP	O
the	O	DET	O
study	O	NOUN	B
of	O	ADP	O
which	O	DET	O
7	O	NUM	O
(	O	PUNCT	O
16	O	NUM	O
%)	O	NOUN	O
were	O	AUX	O
ineligible	O	ADJ	O
.	O	PUNCT	O


A	O	DET	O
median	O	NOUN	B
of	O	ADP	O
2	O	NUM	O
cycles	O	NOUN	O
of	O	ADP	O
therapy	O	NOUN	B
was	O	AUX	O
administered	O	VERB	B
to	O	PART	O
the	O	DET	O
37	O	NUM	O
eligible	O	ADJ	O
patients	O	NOUN	B
.	O	PUNCT	O


Six	O	NUM	O
partial	O	ADJ	B
responses	O	NOUN	O
were	O	AUX	O
observed	O	VERB	O
for	O	ADP	O
an	O	DET	O
overall	O	ADJ	B
response	O	NOUN	B
rate	O	NOUN	I
of	O	ADP	O
16	O	NUM	O
%.	O	NOUN	B
Most	O	ADJ	O
patients	O	NOUN	B
(	O	PUNCT	O
57	O	NUM	O
%)	O	NOUN	O
stopped	O	VERB	B
treatment	O	NOUN	B
because	O	SCONJ	O
of	O	ADP	O
disease	O	NOUN	B
progression	O	NOUN	I
.	O	PUNCT	O


Neurologic	B-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
was	O	AUX	O
reported	O	VERB	O
in	O	ADP	O
52	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
.	O	PUNCT	O


Seven	O	NUM	O
different	O	ADJ	O
life	O	NOUN	B
-	O	PUNCT	O
threatening	O	VERB	B
toxicities	B-Disease	NOUN	B
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
patients	O	NOUN	B
while	O	SCONJ	O
receiving	O	VERB	B
treatment	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
cisplatin	B-Chemical	NOUN	B
and	O	CCONJ	O
amifostine	B-Chemical	NOUN	B
in	O	ADP	O
this	O	DET	O
study	O	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
an	O	DET	O
overall	O	ADJ	B
response	O	NOUN	B
rate	O	NOUN	I
of	O	ADP	O
16	O	NUM	O
%.	O	NOUN	B
Neither	O	CCONJ	O
a	O	DET	O
tumor	B-Disease	NOUN	B
-	O	PUNCT	O
protective	O	ADJ	B
effect	O	NOUN	I
nor	O	CCONJ	O
reduced	O	VERB	B
toxicity	B-Disease	NOUN	B
to	O	PART	O
normal	O	ADJ	B
tissues	O	NOUN	I
was	O	AUX	O
observed	O	VERB	O
with	O	ADP	O
the	O	DET	O
addition	O	NOUN	O
of	O	ADP	O
amifostine	B-Chemical	NOUN	B
to	O	PART	O
cisplatin	B-Chemical	NOUN	B


Warfarin	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
iliopsoas	O	ADJ	B
hemorrhage	B-Disease	NOUN	I
with	O	ADP	O
subsequent	O	ADJ	O
femoral	B-Disease	ADJ	B
nerve	I-Disease	NOUN	I
palsy	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
present	O	VERB	O
the	O	DET	O
case	O	NOUN	B
of	O	ADP	O
a	O	DET	O
28	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
man	O	NOUN	B
on	O	ADP	O
chronic	O	ADJ	B
warfarin	B-Chemical	NOUN	B
therapy	O	NOUN	I
who	O	PRON	O
sustained	O	VERB	B
a	O	DET	O
minor	O	ADJ	O
muscle	B-Disease	NOUN	B
tear	I-Disease	NOUN	I
and	O	CCONJ	O
developed	O	VERB	O
increasing	O	VERB	B
pain	B-Disease	NOUN	B
and	O	CCONJ	O
a	O	DET	O
flexure	O	NOUN	B
contracture	B-Disease	NOUN	I
of	O	ADP	O
the	O	DET	O
right	O	ADJ	B
hip	O	NOUN	I
.	O	PUNCT	O


Surgical	O	ADJ	B
exploration	O	NOUN	B
revealed	O	VERB	O
an	O	DET	O
iliopsoas	O	ADJ	B
hematoma	B-Disease	NOUN	I
and	O	CCONJ	O
femoral	O	ADJ	B
nerve	B-Disease	NOUN	I
entrapment	I-Disease	NOUN	B
,	O	PUNCT	O
resulting	O	VERB	O
in	O	ADP	O
a	O	DET	O
femoral	B-Disease	ADJ	B
nerve	I-Disease	NOUN	I
palsy	I-Disease	NOUN	I
and	O	CCONJ	O
partial	B-Disease	ADJ	B
loss	I-Disease	NOUN	O
of	I-Disease	ADP	O
quadriceps	I-Disease	NOUN	B
functions	I-Disease	NOUN	I
.	O	PUNCT	O


Anticoagulant	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
femoral	B-Disease	ADJ	B
nerve	I-Disease	NOUN	I
palsy	I-Disease	NOUN	I
represents	O	VERB	O
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
form	O	NOUN	O
of	O	ADP	O
warfarin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
peripheral	B-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I
;	O	PUNCT	O
it	O	PRON	O
is	O	AUX	O
characterized	O	VERB	B
by	O	ADP	O
severe	O	ADJ	B
pain	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
inguinal	O	ADJ	B
region	O	NOUN	I
,	O	PUNCT	O
varying	O	VERB	O
degrees	O	NOUN	B
of	O	ADP	O
motor	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
sensory	I-Disease	ADJ	B
impairment	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
flexure	O	NOUN	B
contracture	B-Disease	NOUN	O


Myasthenia	B-Disease	ADJ	B
gravis	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
penicillamine	B-Chemical	NOUN	B
and	O	CCONJ	O
chloroquine	B-Chemical	NOUN	B
therapy	O	NOUN	I
for	O	ADP	O
rheumatoid	B-Disease	ADJ	B
arthritis	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
described	O	VERB	O
a	O	DET	O
unique	O	ADJ	B
patient	O	NOUN	B
who	O	PRON	O
had	O	AUX	O
reversible	O	ADJ	B
and	O	CCONJ	O
dose	O	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
myasthenia	B-Disease	NOUN	B
gravis	I-Disease	NOUN	I
after	O	ADP	O
penicillamine	B-Chemical	NOUN	B
and	O	CCONJ	O
chloroquine	B-Chemical	NOUN	B
therapy	O	NOUN	I
for	O	ADP	O
rheumatoid	B-Disease	ADJ	B
arthritis	I-Disease	NOUN	I
.	O	PUNCT	O


Although	O	SCONJ	O
acetylcholine	B-Chemical	NOUN	B


Nephrotoxicity	B-Disease	NOUN	B
of	O	ADP	O
combined	O	ADJ	B
cephalothin	B-Chemical	NOUN	B
-	O	PUNCT	O
gentamicin	B-Chemical	NOUN	B
regimen	O	NOUN	B
.	O	PUNCT	O


Two	O	NUM	O
patients	O	NOUN	B
developed	O	VERB	O
acute	B-Disease	ADJ	B
tubular	I-Disease	ADJ	O
necrosis	I-Disease	NOUN	O
,	O	PUNCT	O
characterized	O	VERB	B
clinically	O	ADV	B
by	O	ADP	O
acute	O	ADJ	B
oliguric	B-Disease	ADJ	I
renal	I-Disease	ADJ	I
failure	I-Disease	NOUN	I
,	O	PUNCT	O
while	O	SCONJ	O
they	O	PRON	O
were	O	AUX	O
receiving	O	VERB	O
a	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
cephalothin	B-Chemical	ADJ	B
sodium	I-Chemical	NOUN	I
and	O	CCONJ	O
gentamicin	B-Chemical	NOUN	B
sulfate	I-Chemical	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


Patients	O	NOUN	B
who	O	PRON	O
are	O	AUX	O
given	O	VERB	O
this	O	DET	O
drug	O	NOUN	B
regimen	O	NOUN	I
should	O	AUX	O
be	O	AUX	O
observed	O	VERB	O
very	O	ADV	O
carefully	O	ADV	O
for	O	ADP	O
early	O	ADJ	B
signs	O	NOUN	O
of	O	ADP	O
nephrotoxicity	B-Disease	NOUN	B
.	O	PUNCT	O


High	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
this	O	DET	O
antibiotic	O	ADJ	B
combination	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
avoided	O	VERB	O
especially	O	ADV	O
in	O	ADP	O
elderly	O	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O


Patients	O	NOUN	B
with	O	ADP	O
renal	B-Disease	ADJ	B
insufficiency	I-Disease	NOUN	I


Components	O	NOUN	B
of	O	ADP	O
lemon	O	ADJ	B
essential	O	ADJ	B
oil	O	NOUN	I
attenuate	O	NOUN	B
dementia	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
scopolamine	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
anti	O	ADJ	B
-	O	PUNCT	O
dementia	B-Disease	NOUN	B
effects	O	NOUN	B
of	O	ADP	O
s-limonene	B-Chemical	NOUN	B
and	O	CCONJ	O
s-perillyl	B-Chemical	ADJ	B
alcohol	I-Chemical	NOUN	I
were	O	AUX	O
observed	O	VERB	O
using	O	VERB	O
the	O	DET	O
passive	O	ADJ	B
avoidance	O	NOUN	I
test	O	NOUN	I
(	O	PUNCT	O
PA	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
open	O	ADJ	B
field	O	NOUN	I
habituation	O	NOUN	I
test	O	NOUN	I
(	O	PUNCT	O
OFH	O	NOUN	B
).	O	PUNCT	O
These	O	DET	O
lemon	O	ADJ	B
essential	O	ADJ	B
oils	O	NOUN	I
showed	O	VERB	O
strong	O	ADJ	O
ability	O	NOUN	O
to	O	PART	O
improve	O	VERB	B
memory	B-Disease	NOUN	B
impaired	I-Disease	VERB	B
by	O	ADP	O
scopolamine	B-Chemical	NOUN	B
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
s-perillyl	B-Chemical	ADJ	B
alcohol	I-Chemical	NOUN	I
relieved	O	VERB	O
the	O	DET	O
deficit	B-Disease	NOUN	B
of	I-Disease	ADP	O
associative	I-Disease	ADJ	B
memory	I-Disease	NOUN	I
in	O	ADP	O
PA	O	NOUN	B
only	O	ADV	O
,	O	PUNCT	O
and	O	CCONJ	O
did	O	AUX	O
not	O	PART	O
improve	O	VERB	O
non	O	ADJ	B
-	O	PUNCT	O
associative	O	NOUN	B
memory	O	NOUN	B
significantly	O	ADV	O
in	O	ADP	O
OFH	O	NOUN	B
.	O	PUNCT	O


Analysis	O	NOUN	B
of	O	ADP	O
neurotransmitter	O	NOUN	B
concentration	O	NOUN	B
in	O	ADP	O
some	O	DET	O
brain	O	NOUN	B
regions	O	NOUN	I
on	O	ADP	O
the	O	DET	O
test	O	NOUN	B
day	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
dopamine	B-Chemical	NOUN	B
concentration	O	NOUN	B
of	O	ADP	O
the	O	DET	O
vehicle	O	NOUN	B
/	O	SYM	O
scopolamine	B-Chemical	NOUN	B
group	O	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
lower	O	ADJ	O
than	O	ADP	O
that	O	DET	O
of	O	ADP	O
the	O	DET	O
vehicle	O	NOUN	B
/	O	SYM	O
vehicle	O	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
this	O	DET	O
phenomenon	O	NOUN	B
was	O	AUX	O
reversed	O	VERB	O
when	O	SCONJ	O
s-limonene	B-Chemical	NOUN	B
or	O	CCONJ	O
s-perillyl	B-Chemical	ADJ	B
alcohol	I-Chemical	NOUN	I
were	O	AUX	O
administered	O	VERB	B
before	O	ADP	O
the	O	DET	O
injection	O	NOUN	B
of	O	ADP	O
scopolamine	B-Chemical	NOUN	B


The	O	DET	O
selective	O	ADJ	O
5	O	NUM	O
-	O	PUNCT	O
HT6	O	NOUN	B
receptor	O	NOUN	I
antagonist	O	NOUN	B
Ro4368554	B-Chemical	NOUN	B
restores	O	VERB	B
memory	O	NOUN	B
performance	O	NOUN	B
in	O	ADP	O
cholinergic	O	ADJ	B
and	O	CCONJ	O
serotonergic	O	ADJ	B
models	O	NOUN	B
of	O	ADP	O
memory	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
in	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
.	O	PUNCT	O


Antagonists	O	NOUN	B
at	O	ADP	O
serotonin	B-Chemical	NOUN	B
type	O	NOUN	I
6	O	NUM	I
(	O	PUNCT	O
5-HT	B-Chemical	NOUN	B
(	O	PUNCT	O
6	O	NUM	O
))	O	NOUN	O
receptors	O	NOUN	B
show	O	VERB	O
activity	O	NOUN	B
in	O	ADP	O
models	O	NOUN	B
of	O	ADP	O
learning	O	NOUN	B
and	O	CCONJ	O
memory	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
the	O	DET	O
underlying	O	ADJ	O
mechanism	O	NOUN	B
(	O	PUNCT	O
s	O	NOUN	O
)	O	PUNCT	O
are	O	AUX	O
not	O	PART	O
well	O	ADV	O
understood	O	VERB	O
,	O	PUNCT	O
these	O	DET	O
effects	O	NOUN	B
may	O	AUX	O
involve	O	VERB	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
acetylcholine	B-Chemical	NOUN	B
(	O	PUNCT	O
ACh	B-Chemical	NOUN	B
)	O	PUNCT	O
levels	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
sought	O	VERB	O
to	O	PART	O
characterize	O	VERB	B
the	O	DET	O
cognitive	O	ADJ	B
-	O	PUNCT	O
enhancing	O	VERB	B
effects	O	NOUN	B
of	O	ADP	I
the	O	DET	O
5-HT	B-Chemical	NOUN	B
(	O	PUNCT	O
6	O	NUM	O
)	O	PUNCT	O
antagonist	O	NOUN	B
Ro4368554	B-Chemical	NOUN	B
(	O	PUNCT	O
3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole	B-Chemical	PROPN	O
)	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
rat	O	NOUN	B
object	O	NOUN	B
recognition	O	NOUN	O
task	O	NOUN	O
employing	O	VERB	O
a	O	DET	O
cholinergic	O	NOUN	B
(	O	PUNCT	O
scopolamine	B-Chemical	NOUN	B
pretreatment	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
serotonergic	O	ADJ	B
-(	O	NOUN	O
tryptophan	B-Chemical	NOUN	B
(	O	PUNCT	O
TRP	B-Chemical	NOUN	B
)	O	PUNCT	O
depletion	O	NOUN	B
)	O	PUNCT	O
deficient	O	ADJ	B
model	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
compared	O	VERB	B
its	O	PRON	O
pattern	O	NOUN	B
of	O	ADP	O
action	O	NOUN	B
with	O	ADP	O
that	O	DET	O
of	O	ADP	O
the	O	DET	O
acetylcholinesterase	O	NOUN	B
inhibitor	O	NOUN	I
metrifonate	B-Chemical	NOUN	B
.	O	PUNCT	O


Initial	O	ADJ	O
testing	O	NOUN	B
in	O	ADP	O
a	O	DET	O
time	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
forgetting	O	NOUN	B
task	O	NOUN	B
employing	O	VERB	O
a	O	DET	O
24	O	NUM	O
-	O	PUNCT	O
h	O	NOUN	O
delay	O	NOUN	B
between	O	ADP	O
training	O	NOUN	B
and	O	CCONJ	O
testing	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
metrifonate	B-Chemical	NOUN	B
improved	O	VERB	B
object	O	NOUN	B
recognition	O	NOUN	I
(	O	PUNCT	O
at	O	ADP	O
10	O	NUM	O
and	O	CCONJ	O
30	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
p	O	NOUN	O
.	O	PUNCT	O


o	O	INTJ	O
.),	O	X	O
whereas	O	SCONJ	O
Ro4368554	B-Chemical	NOUN	B
was	O	AUX	O
inactive	O	ADJ	B
.	O	PUNCT	O


Both	O	DET	O
,	O	PUNCT	O
Ro4368554	B-Chemical	NOUN	B
(	O	PUNCT	O
3	O	NUM	O
and	O	CCONJ	O
10	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
intraperitoneally	O	ADV	B
(	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


p	O	NOUN	O
.))	O	NOUN	O
and	O	CCONJ	O
metrifonate	B-Chemical	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
p	O	NOUN	O
.	O	PUNCT	O


o	O	X	O
.,	O	NOUN	O
respectively	O	ADV	O
)	O	PUNCT	O
reversed	O	VERB	B
memory	B-Disease	NOUN	I
deficits	I-Disease	NOUN	O
induced	O	VERB	B
by	O	ADP	O
scopolamine	B-Chemical	NOUN	B
and	O	CCONJ	O
TRP	B-Chemical	NOUN	B
depletion	O	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


p	O	X	O
.,	O	NOUN	O
and	O	CCONJ	O
3	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
p	O	NOUN	O
.	O	PUNCT	O


o	O	X	O
.,	O	NOUN	O
respectively	O	ADV	O
).	O	PUNCT	B
In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
although	O	SCONJ	O
Ro4368554	B-Chemical	NOUN	B
did	O	AUX	O
not	O	PART	O
improve	O	VERB	O
a	O	DET	O
time	O	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
retention	O	NOUN	B
deficit	O	NOUN	I
,	O	PUNCT	O
it	O	PRON	O
reversed	O	VERB	O
a	O	DET	O
cholinergic	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
serotonergic	O	ADJ	B
memory	B-Disease	NOUN	I
deficit	I-Disease	NOUN	I
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
both	O	DET	O
mechanisms	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
the	O	DET	O
facilitation	O	NOUN	B
of	O	ADP	O
object	O	NOUN	B
memory	O	NOUN	I
by	O	ADP	O
Ro4368554	B-Chemical	NOUN	B
and	O	CCONJ	O
,	O	PUNCT	O
possibly	O	ADV	O
,	O	PUNCT	O
other	O	ADJ	O
5-HT	B-Chemical	NOUN	B


Lone	O	NOUN	B
atrial	B-Disease	ADJ	I
fibrillation	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
creatine	B-Chemical	NOUN	B
monohydrate	O	NOUN	I
supplementation	O	NOUN	B
.	O	PUNCT	O


Atrial	B-Disease	ADJ	B
fibrillation	I-Disease	NOUN	I
in	O	ADP	O
young	O	ADJ	B
patients	O	NOUN	B
without	O	ADP	O
structural	O	ADJ	B
heart	B-Disease	NOUN	I
disease	I-Disease	NOUN	I
is	O	AUX	O
rare	O	ADJ	B
.	O	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
when	O	SCONJ	O
the	O	DET	O
arrhythmia	B-Disease	NOUN	B
is	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
this	O	DET	O
population	O	NOUN	B
,	O	PUNCT	O
reversible	O	ADJ	O
causes	O	NOUN	O
must	O	AUX	O
be	O	AUX	O
identified	O	VERB	B
and	O	CCONJ	O
resolved	O	VERB	B
.	O	PUNCT	O


Thyroid	B-Disease	NOUN	B
disorders	I-Disease	NOUN	I
,	O	PUNCT	O
illicit	O	NOUN	B
drug	O	NOUN	I
or	O	CCONJ	O
stimulant	O	ADJ	B
use	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
acute	B-Disease	ADJ	B
alcohol	I-Disease	NOUN	O
intoxication	I-Disease	NOUN	O
are	O	AUX	O
among	O	ADP	O
these	O	DET	O
causes	O	NOUN	O
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
the	O	DET	O
case	O	NOUN	B
of	O	ADP	O
a	O	DET	O
30	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
Caucasian	O	ADJ	B
man	O	NOUN	B
who	O	PRON	O
came	O	VERB	O
to	O	ADP	O
the	O	DET	O
emergency	O	NOUN	B
department	O	NOUN	I
in	O	ADP	O
atrial	B-Disease	ADJ	B
fibrillation	I-Disease	NOUN	I
with	O	ADP	O
rapid	O	ADJ	O
ventricular	O	ADJ	B
response	O	NOUN	I
.	O	PUNCT	O


His	O	PRON	O
medical	O	ADJ	B
history	O	NOUN	I
was	O	AUX	O
unremarkable	O	ADJ	B
,	O	PUNCT	O
except	O	SCONJ	O
for	O	ADP	O
minor	O	ADJ	B
fractures	B-Disease	NOUN	I
of	O	ADP	O
the	O	DET	O
fingers	O	NOUN	B
and	O	CCONJ	O
foot	O	NOUN	B
.	O	PUNCT	O


Thyroid	O	NOUN	B
-	O	PUNCT	O
stimulating	O	VERB	B
hormone	O	NOUN	B
,	O	PUNCT	O
magnesium	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
potassium	B-Chemical	NOUN	B
levels	O	NOUN	I
were	O	AUX	O
within	O	ADP	O
normal	O	ADJ	O
limits	O	NOUN	O
,	O	PUNCT	O
urine	O	NOUN	B
drug	O	NOUN	O
screen	O	NOUN	O
was	O	AUX	O
negative	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
alcohol	B-Chemical	NOUN	B
use	O	NOUN	I
was	O	AUX	O
denied	O	VERB	O
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
when	O	SCONJ	O
the	O	DET	O
patient	O	NOUN	B
was	O	AUX	O
questioned	O	VERB	O
about	O	ADP	O
use	O	NOUN	O
of	O	ADP	O
herbal	O	ADJ	B
products	O	NOUN	I
and	O	CCONJ	O
supplements	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
creatine	B-Chemical	NOUN	B
monohydrate	O	NOUN	I
was	O	AUX	O
revealed	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
was	O	AUX	O
admitted	O	VERB	B
to	O	ADP	O
the	O	DET	O
hospital	O	NOUN	B
,	O	PUNCT	O
anticoagulated	O	VERB	B
with	O	ADP	O
unfractionated	O	ADJ	B
heparin	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
given	O	VERB	O
intravenous	O	ADJ	B
diltiazem	B-Chemical	NOUN	B
for	O	ADP	O
rate	O	NOUN	B
control	O	NOUN	I
and	O	CCONJ	O
intravenous	O	ADJ	B
amiodarone	B-Chemical	NOUN	O
for	O	ADP	O
rate	O	NOUN	B
and	O	CCONJ	O
rhythm	O	NOUN	B
control	O	NOUN	I
.	O	PUNCT	O


When	O	SCONJ	O
discharged	O	VERB	B
less	O	ADJ	O
than	O	ADP	O
24	O	NUM	O
hours	O	NOUN	B
later	O	ADV	O
,	O	PUNCT	O
he	O	PRON	O
was	O	AUX	O
receiving	O	VERB	O
metoprolol	B-Chemical	NOUN	B
and	O	CCONJ	O
aspirin	B-Chemical	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
follow	O	NOUN	B
-	O	PUNCT	O
up	O	ADP	O
plans	O	NOUN	B
for	O	ADP	O
echocardiography	O	NOUN	B
and	O	CCONJ	O
nuclear	O	ADJ	B
imaging	O	NOUN	I
to	O	PART	O
assess	O	VERB	B
perfusion	O	NOUN	B
.	O	PUNCT	O


Exogenous	O	ADJ	B
creatine	B-Chemical	NOUN	B
is	O	AUX	O
used	O	VERB	O
by	O	ADP	O
athletes	O	NOUN	B
to	O	PART	O
theoretically	O	ADV	O
improve	O	VERB	B
exercise	O	NOUN	B
performance	O	NOUN	B
.	O	PUNCT	O


Vegetarians	O	NOUN	B
may	O	AUX	O
also	O	ADV	O
take	O	VERB	O
creatine	B-Chemical	NOUN	B
to	O	PART	O
replace	O	VERB	O
what	O	PRON	O
they	O	PRON	O
are	O	AUX	O
not	O	PART	O
consuming	O	VERB	O
from	O	ADP	O
meat	O	NOUN	B
,	O	PUNCT	O
fish	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
other	O	ADJ	O
animal	O	NOUN	B
products	O	NOUN	I
.	O	PUNCT	O


Previous	O	ADJ	O
anecdotal	O	ADJ	B
reports	O	NOUN	I
have	O	AUX	O
linked	O	VERB	O
creatine	B-Chemical	NOUN	B
to	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
arrhythmia	B-Disease	NOUN	B


Comparison	O	NOUN	B
of	O	ADP	O
developmental	O	ADJ	B
toxicity	B-Disease	NOUN	B
of	O	ADP	O
selective	O	ADJ	O
and	O	CCONJ	O
non	O	ADJ	B
-	O	PUNCT	O
selective	O	ADJ	B
cyclooxygenase	O	NOUN	B
-	O	PUNCT	O
2	O	NUM	B
inhibitors	O	NOUN	B
in	O	ADP	O
CRL	O	PROPN	B
:(	O	PUNCT	O
WI	O	PROPN	O
)	O	PUNCT	O
WUBR	O	PROPN	B
Wistar	O	PROPN	B
rats	O	NOUN	I
--	O	PUNCT	O
DFU	B-Chemical	NOUN	B
and	O	CCONJ	O
piroxicam	B-Chemical	NOUN	B
study	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Cyclooxygenase	O	NOUN	B
(	O	PUNCT	O
COX	O	NOUN	B
)	O	PUNCT	O
inhibitors	O	NOUN	B
are	O	AUX	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
most	O	ADV	O
often	O	ADV	O
ingested	O	VERB	B
drugs	O	NOUN	B
during	O	ADP	O
pregnancy	O	NOUN	B
.	O	PUNCT	O


Unlike	O	ADP	O
general	O	ADJ	O
toxicity	B-Disease	NOUN	B
data	O	NOUN	B
,	O	PUNCT	O
their	O	PRON	O
prenatal	O	ADJ	B
toxic	O	ADJ	I
effects	O	NOUN	I
were	O	AUX	O
not	O	PART	O
extensively	O	ADV	O
studied	O	VERB	O
before	O	ADP	O
.	O	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
the	O	DET	O
experiment	O	NOUN	B
was	O	AUX	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
developmental	O	ADJ	B
toxicity	B-Disease	NOUN	B
of	O	ADP	O
the	O	DET	O
non	O	ADJ	B
-	O	PUNCT	O
selective	O	ADJ	B
(	O	PUNCT	O
piroxicam	B-Chemical	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
selective	O	ADJ	O
(	O	PUNCT	O
DFU	B-Chemical	NOUN	B
;	O	PUNCT	O
5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl)	B-Chemical	NOUN	O
phenyl-2(5H)-furanon	I-Chemical	NOUN	B
)	O	PUNCT	O
COX	O	NOUN	B
-	O	PUNCT	O
2	O	NUM	B
inhibitors	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
Drugs	O	PROPN	B
were	O	AUX	O
separately	O	ADV	O
,	O	PUNCT	O
orally	O	ADV	B
once	O	SCONJ	O
daily	O	ADV	O
dosed	O	VERB	B
to	O	PART	O
pregnant	O	ADJ	B
rats	O	NOUN	I
from	O	ADP	O
day	O	NOUN	B
8	O	NUM	O
to	O	PART	O
21	O	NUM	O
(	O	PUNCT	O
GD1	O	NOUN	B
=	O	ADJ	O
plug	O	NOUN	B
day	O	NOUN	O
).	O	PUNCT	B
Doses	O	NOUN	B
were	O	AUX	O
set	O	VERB	O
at	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
,	O	PUNCT	O
3	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
and	O	CCONJ	O
30	O	NUM	O
.	O	PUNCT	O


0mg	O	ADJ	B
/	O	SYM	O
kg	O	NOUN	O
for	O	ADP	O
piroxicam	B-Chemical	NOUN	B
and	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
,	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
and	O	CCONJ	O
20	O	NUM	O
.	O	PUNCT	O


0mg	O	ADJ	B
/	O	SYM	O
kg	O	NOUN	O
for	O	ADP	O
DFU	B-Chemical	PROPN	B
.	O	PUNCT	O


Fetuses	O	NOUN	B
were	O	AUX	O
delivered	O	VERB	O
on	O	ADP	O
GD	O	NOUN	B
21	O	NUM	O
and	O	CCONJ	O
routinely	O	ADV	O
examined	O	VERB	B
.	O	PUNCT	O


Comprehensive	O	ADJ	B
clinical	O	ADJ	B
and	O	CCONJ	O
developmental	O	ADJ	B
measurements	O	NOUN	I
were	O	AUX	O
done	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
pooled	O	ADJ	B
statistical	O	ADJ	B
analysis	O	NOUN	I
for	O	ADP	O
ventricular	B-Disease	ADJ	B
septal	I-Disease	ADJ	I
(VSD)	I-Disease	NOUN	I
and	I-Disease	CCONJ	O
midline	I-Disease	NOUN	B
(MD)	I-Disease	NOUN	O
defects	I-Disease	NOUN	B
was	O	AUX	O
performed	O	VERB	O
for	O	ADP	O
rat	O	NOUN	B
fetuses	O	NOUN	B
exposed	O	VERB	B
to	O	PART	O
piroxicam	B-Chemical	NOUN	B
,	O	PUNCT	O
selective	O	ADJ	O
and	O	CCONJ	O
non	O	ADJ	B
-	O	PUNCT	O
selective	O	ADJ	B
COX	O	NOUN	B
-	O	PUNCT	O
2	O	NUM	B
inhibitor	O	NOUN	B
based	O	VERB	O
on	O	ADP	O
present	O	ADJ	O
and	O	CCONJ	O
historic	O	ADJ	B
data	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Maternal	O	ADJ	B
toxicity	B-Disease	NOUN	B
,	O	PUNCT	O
intrauterine	B-Disease	ADJ	B
growth	I-Disease	NOUN	I
retardation	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
increase	B-Disease	NOUN	B
of	I-Disease	ADP	O
external	I-Disease	ADJ	B
and	I-Disease	CCONJ	O
skeletal	I-Disease	ADJ	B
variations	I-Disease	NOUN	O
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
rats	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
the	O	DET	O
highest	O	ADJ	B
dose	O	NOUN	B
of	O	ADP	O
piroxicam	B-Chemical	NOUN	B
.	O	PUNCT	O


Decrease	O	NOUN	B
of	O	ADP	O
fetal	O	ADJ	B
length	O	NOUN	B
was	O	AUX	O
the	O	DET	O
only	O	ADJ	O
signs	O	NOUN	O
of	O	ADP	O
the	O	DET	O
DFU	B-Chemical	NOUN	B
developmental	O	ADJ	B
toxicity	B-Disease	NOUN	B
observed	O	VERB	B
in	O	ADP	O
pups	O	NOUN	B
exposed	O	VERB	B
to	O	PART	O
the	O	DET	O
highest	O	ADJ	B
compound	O	NOUN	B
dose	O	NOUN	I
.	O	PUNCT	O


Lack	O	NOUN	B
of	O	ADP	O
teratogenicity	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
in	O	ADP	O
piroxicam	B-Chemical	NOUN	B
and	O	CCONJ	O
DFU	B-Chemical	PROPN	B
-	O	PUNCT	O
exposed	O	VERB	B
groups	O	NOUN	B
.	O	PUNCT	O


Prenatal	O	ADJ	B
exposure	O	NOUN	O
to	O	PART	O
non	O	ADV	B
-	O	PUNCT	O
selective	O	ADJ	B
COX	O	NOUN	B
inhibitors	O	NOUN	O
increases	O	VERB	B
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
VSD	O	PROPN	B
and	O	CCONJ	O
MD	O	PROPN	B
when	O	SCONJ	O
compared	O	VERB	O
to	O	PART	O
historic	O	ADJ	B
control	O	NOUN	I
but	O	CCONJ	O
not	O	PART	O
with	O	ADP	O
selective	O	ADJ	O
COX	O	NOUN	B
-	O	PUNCT	O
2	O	NUM	B
inhibitors	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
Both	O	CCONJ	O
selective	O	ADJ	O
and	O	CCONJ	O
non	O	ADJ	B
-	O	PUNCT	O
selective	O	ADJ	B
COX	O	NOUN	B
-	O	PUNCT	O
2	O	NUM	B
inhibitors	O	NOUN	B
were	O	AUX	O
toxic	O	ADJ	B
for	O	ADP	O
rats	O	NOUN	B
fetuses	O	NOUN	B
when	O	SCONJ	O
administered	O	VERB	B
in	O	ADP	O
the	O	DET	O
highest	O	ADJ	B
dose	O	NOUN	B
.	O	PUNCT	O


Unlike	O	ADP	O
DFU	B-Chemical	PROPN	B
,	O	PUNCT	O
piroxicam	B-Chemical	NOUN	B
was	O	AUX	O
also	O	ADV	O
highly	O	ADV	O
toxic	O	ADJ	B
to	O	PART	O
the	O	DET	O
dams	O	NOUN	B
.	O	PUNCT	O


Prenatal	O	ADJ	B
exposure	O	NOUN	O
to	O	PART	O
selective	O	ADJ	O
COX	O	NOUN	B
-	O	PUNCT	O
2	O	NUM	B
inhibitors	O	NOUN	B
does	O	AUX	O
not	O	PART	O
increase	O	VERB	B
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
ventricular	B-Disease	ADJ	B
septal	I-Disease	ADJ	I
and	I-Disease	CCONJ	O
midline	I-Disease	NOUN	B
defects	I-Disease	NOUN	O


Protective	O	ADJ	B
efficacy	O	NOUN	I
of	O	ADP	O
neuroactive	O	ADJ	B
steroids	B-Chemical	NOUN	I
against	O	ADP	O
cocaine	B-Chemical	NOUN	B
kindled	O	VERB	B
-	O	PUNCT	O
seizures	B-Disease	NOUN	B
in	O	ADP	O
mice	O	NOUN	B
.	O	PUNCT	O


Neuroactive	O	ADJ	B
steroids	B-Chemical	NOUN	I
demonstrate	O	VERB	O
pharmacological	O	ADJ	B
actions	O	NOUN	O
that	O	PRON	O
have	O	AUX	O
relevance	O	NOUN	B
for	O	ADP	O
a	O	DET	O
host	O	NOUN	B
of	O	ADP	O
neurological	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
psychiatric	I-Disease	ADJ	B
disorders	I-Disease	NOUN	I
.	O	PUNCT	O


They	O	PRON	O
offer	O	VERB	O
protection	O	NOUN	B
against	O	ADP	O
seizures	B-Disease	NOUN	B
in	O	ADP	O
a	O	DET	O
range	O	NOUN	O
of	O	ADP	O
models	O	NOUN	B
and	O	CCONJ	O
seem	O	VERB	O
to	O	PART	O
inhibit	O	VERB	B
certain	O	ADJ	O
stages	O	NOUN	B
of	O	ADP	O
drug	B-Disease	NOUN	B
dependence	I-Disease	NOUN	I
in	O	ADP	O
preclinical	O	ADJ	B
assessments	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
was	O	AUX	O
designed	O	VERB	O
to	O	PART	O
evaluate	O	VERB	B
two	O	NUM	O
endogenous	O	ADJ	B
and	O	CCONJ	O
one	O	NUM	O
synthetic	O	ADJ	B
neuroactive	O	ADJ	B
steroid	B-Chemical	NOUN	I
that	O	PRON	O
positively	O	ADV	O
modulate	O	VERB	B
the	O	DET	O
gamma-aminobutyric	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
(	O	PUNCT	O
GABA	B-Chemical	NOUN	B
(	O	PUNCT	O
A	O	NOUN	O
))	O	PUNCT	O
receptor	O	NOUN	O
against	O	ADP	O
the	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
sensitivity	O	NOUN	B
to	O	PART	O
the	O	DET	O
convulsant	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
cocaine	B-Chemical	NOUN	B
engendered	O	VERB	O
by	O	ADP	O
repeated	O	VERB	O
cocaine	B-Chemical	NOUN	B
administration	O	NOUN	I
(	O	PUNCT	O
seizure	B-Disease	NOUN	B
kindling	O	NOUN	O
).	O	PUNCT	B
Allopregnanolone	B-Chemical	NOUN	B
(	O	PUNCT	O
3alpha-hydroxy-5alpha-pregnan-20-one	B-Chemical	NOUN	B
),	O	PUNCT	O
pregnanolone	B-Chemical	NOUN	B
(	O	PUNCT	O
3alpha-hydroxy-5beta-pregnan-20-one	B-Chemical	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
ganaxolone	B-Chemical	NOUN	B
(	O	PUNCT	O
a	O	DET	O
synthetic	O	ADJ	B
derivative	O	NOUN	I
of	O	ADP	O
allopregnanolone	B-Chemical	NOUN	B
3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one	B-Chemical	NUM	O
)	O	PUNCT	O
were	O	AUX	O
tested	O	VERB	B
for	O	ADP	O
their	O	PRON	O
ability	O	NOUN	O
to	O	PART	O
suppress	O	VERB	B
the	O	DET	O
expression	O	NOUN	B
(	O	PUNCT	O
anticonvulsant	O	ADJ	B
effect	O	NOUN	I
)	O	PUNCT	O
and	O	CCONJ	O
development	O	NOUN	B
(	O	PUNCT	O
antiepileptogenic	O	ADJ	B
effect	O	NOUN	I
)	O	PUNCT	O
of	O	ADP	O
cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
kindled	O	VERB	B
seizures	B-Disease	NOUN	B
in	O	ADP	O
male	O	NOUN	B
,	O	PUNCT	O
Swiss	O	ADJ	B
-	O	PUNCT	O
Webster	O	PROPN	B
mice	O	NOUN	I
.	O	PUNCT	O


Kindled	O	ADJ	B
seizures	B-Disease	NOUN	I
were	O	AUX	O
induced	O	VERB	B
by	O	ADP	O
daily	O	ADJ	B
administration	O	NOUN	B
of	O	ADP	O
60	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
cocaine	B-Chemical	NOUN	B
for	O	ADP	O
5	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
of	O	ADP	O
these	O	DET	O
positive	O	ADJ	B
GABA	B-Chemical	NOUN	B
(	O	PUNCT	O
A	O	NOUN	O
)	O	PUNCT	O
modulators	O	NOUN	O
suppressed	O	VERB	B
the	O	DET	O
expression	O	NOUN	B
of	O	ADP	O
kindled	O	VERB	B
seizures	B-Disease	NOUN	I
,	O	PUNCT	O
whereas	O	SCONJ	O
only	O	ADV	O
allopregnanolone	B-Chemical	NOUN	B
and	O	CCONJ	O
ganaxolone	B-Chemical	NOUN	B
inhibited	O	VERB	B
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
kindling	O	NOUN	B
.	O	PUNCT	O


Allopregnanolone	B-Chemical	NOUN	B
and	O	CCONJ	O
pregnanolone	B-Chemical	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
ganaxolone	B-Chemical	NOUN	B
,	O	PUNCT	O
also	O	ADV	O
reduced	O	VERB	B
cumulative	O	ADJ	B
lethality	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
kindling	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
demonstrate	O	VERB	O
that	O	SCONJ	O
some	O	DET	O
neuroactive	O	ADJ	B
steroids	B-Chemical	NOUN	I
attenuate	O	VERB	B
convulsant	O	ADJ	B
and	O	CCONJ	O
sensitizing	O	VERB	B
properties	O	NOUN	B
of	O	ADP	O
cocaine	B-Chemical	NOUN	B


Kidney	O	NOUN	B
function	O	NOUN	I
and	O	CCONJ	O
morphology	O	NOUN	B
after	O	ADP	O
short	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
combination	O	NOUN	B
therapy	O	NOUN	I
with	O	ADP	O
cyclosporine	B-Chemical	NOUN	B
A	I-Chemical	NOUN	I
,	O	PUNCT	O
tacrolimus	B-Chemical	NOUN	B
and	O	CCONJ	O
sirolimus	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Sirolimus	B-Chemical	NOUN	B
(	O	PUNCT	O
SRL	B-Chemical	NOUN	B
)	O	PUNCT	O
may	O	AUX	O
supplement	O	VERB	O
calcineurin	O	NOUN	B
inhibitors	O	NOUN	B
in	O	ADP	O
clinical	O	ADJ	B
organ	O	NOUN	I
transplantation	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
are	O	AUX	O
nephrotoxic	B-Disease	ADJ	B
,	O	PUNCT	O
but	O	CCONJ	O
SRL	B-Chemical	PROPN	B
seems	O	VERB	O
to	O	PART	O
act	O	VERB	O
differently	O	ADV	O
displaying	O	VERB	O
only	O	ADV	O
minor	O	ADJ	O
nephrotoxic	B-Disease	ADJ	B
effects	O	NOUN	B
,	O	PUNCT	O
although	O	SCONJ	O
this	O	DET	O
question	O	NOUN	B
is	O	AUX	O
still	O	ADV	O
open	O	ADJ	O
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
number	O	NOUN	O
of	O	ADP	O
treatment	O	NOUN	B
protocols	O	NOUN	I
where	O	SCONJ	O
SRL	B-Chemical	PROPN	B
was	O	AUX	O
combined	O	VERB	O
with	O	ADP	O
a	O	DET	O
calcineurin	O	NOUN	B
inhibitor	O	NOUN	B
indications	O	NOUN	B
of	O	ADP	O
a	O	DET	O
synergistic	O	ADJ	B
nephrotoxic	B-Disease	ADJ	B
effect	O	NOUN	O
were	O	AUX	O
described	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
examine	O	VERB	O
further	O	ADV	O
the	O	DET	O
renal	O	ADJ	B
function	O	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
morphological	O	ADJ	B
analysis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
kidneys	O	NOUN	B
of	O	ADP	O
male	O	NOUN	B
Sprague	O	PROPN	B
-	O	PUNCT	O
Dawley	O	NOUN	B
rats	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
either	O	CCONJ	O
cyclosporine	B-Chemical	NOUN	B
A	I-Chemical	NOUN	I
(	O	PUNCT	O
CsA	B-Chemical	NOUN	B
),	O	PUNCT	O
tacrolimus	B-Chemical	NOUN	B
(	O	PUNCT	O
FK506	B-Chemical	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
SRL	B-Chemical	NOUN	B
as	O	ADP	O
monotherapies	O	NOUN	B
or	O	CCONJ	O
in	O	ADP	O
different	O	ADJ	O
combinations	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
For	O	ADP	O
a	O	DET	O
period	O	NOUN	B
of	O	ADP	O
2	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
CsA	B-Chemical	NOUN	B
15	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
/	O	PUNCT	O
day	O	NOUN	B
(	O	PUNCT	O
given	O	VERB	O
orally	O	ADV	B
),	O	PUNCT	O
FK506	B-Chemical	NOUN	B
3	O	NUM	I
.	O	PUNCT	O


0	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
/	O	PUNCT	O
day	O	NOUN	B
(	O	PUNCT	O
given	O	VERB	O
orally	O	ADV	B
)	O	PUNCT	O
or	O	CCONJ	O
SRL	B-Chemical	NOUN	B
0	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
/	O	PUNCT	O
day	O	NOUN	B
(	O	PUNCT	O
given	O	VERB	O
intraperitoneally	O	ADV	B
)	O	PUNCT	O
was	O	AUX	O
administered	O	VERB	B
once	O	ADV	O
a	O	DET	O
day	O	NOUN	B
as	O	ADP	O
these	O	DET	O
doses	O	NOUN	B
have	O	AUX	O
earlier	O	ADV	O
been	O	AUX	O
found	O	VERB	O
to	O	PART	O
achieve	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
immunosuppressive	O	ADJ	B
effect	O	NOUN	I
in	O	ADP	O
Sprague	O	PROPN	B
-	O	PUNCT	O
Dawley	O	NOUN	B
rats	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
'	O	PUNCT	O
conscious	O	ADJ	B
catheterized	O	VERB	I
rat	O	NOUN	B
'	O	PART	O
model	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
glomerular	O	ADJ	B
filtration	O	NOUN	I
rate	O	NOUN	I
(	O	PUNCT	O
GFR	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
measured	O	VERB	B
as	O	ADP	O
the	O	DET	O
clearance	O	NOUN	B
of	O	ADP	O
Cr	O	NOUN	B
(	O	PUNCT	O
EDTA	O	NOUN	B
).	O	PUNCT	O
The	O	DET	O
morphological	O	ADJ	B
analysis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
kidneys	O	NOUN	B
included	O	VERB	O
a	O	DET	O
semi	O	ADJ	B
-	O	PUNCT	O
quantitative	O	ADJ	B
scoring	O	NOUN	I
system	O	NOUN	I
analysing	O	VERB	O
the	O	DET	O
degree	O	NOUN	B
of	O	ADP	O
striped	O	ADJ	B
fibrosis	B-Disease	NOUN	I
,	O	PUNCT	O
subcapsular	O	ADJ	B
fibrosis	B-Disease	NOUN	I
and	O	CCONJ	O
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
basophilic	O	ADJ	B
tubules	O	NOUN	I
,	O	PUNCT	O
plus	O	CCONJ	O
an	O	DET	O
additional	O	ADJ	O
stereological	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
the	O	DET	O
total	O	ADJ	O
grade	O	NOUN	O
of	O	ADP	O
fibrosis	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
cortex	O	NOUN	B
stained	O	VERB	O
with	O	ADP	O
Sirius	O	PROPN	B
Red	O	PROPN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
CsA	B-Chemical	NOUN	B
,	O	PUNCT	O
FK506	B-Chemical	NOUN	B
and	O	CCONJ	O
SRL	B-Chemical	PROPN	B
all	O	DET	O
significantly	O	ADV	O
decreased	O	VERB	B
the	O	DET	O
GFR	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
further	O	ADJ	O
deterioration	O	NOUN	B
was	O	AUX	O
seen	O	VERB	O
when	O	SCONJ	O
CsA	B-Chemical	NOUN	B
was	O	AUX	O
combined	O	VERB	O
with	O	ADP	O
either	O	CCONJ	O
FK506	B-Chemical	NOUN	B
or	O	CCONJ	O
SRL	B-Chemical	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
the	O	DET	O
GFR	O	NOUN	B
remained	O	VERB	O
unchanged	O	ADJ	B
in	O	ADP	O
the	O	DET	O
group	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
FK506	B-Chemical	NOUN	B
plus	O	CCONJ	O
SRL	B-Chemical	PROPN	B
when	O	SCONJ	O
compared	O	VERB	B
with	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
any	O	DET	O
of	O	ADP	O
the	O	DET	O
single	O	ADJ	O
substances	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
morphological	O	ADJ	B
changes	O	NOUN	B
presented	O	VERB	O
a	O	DET	O
similar	O	ADJ	O
pattern	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
semi	O	ADJ	B
-	O	PUNCT	O
quantitative	O	ADJ	B
scoring	O	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
worst	O	ADJ	O
in	O	ADP	O
the	O	DET	O
group	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
CsA	B-Chemical	NOUN	B
plus	O	CCONJ	O
SRL	B-Chemical	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
compared	O	VERB	B
with	O	ADP	O
controls	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
analysis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
total	O	ADJ	O
grade	O	NOUN	O
of	O	ADP	O
fibrosis	B-Disease	NOUN	B
also	O	ADV	O
showed	O	VERB	O
the	O	DET	O
highest	O	ADJ	B
proportion	O	NOUN	B
in	O	ADP	O
the	O	DET	O
same	O	ADJ	O
group	O	NOUN	B
and	O	CCONJ	O
was	O	AUX	O
significantly	O	ADV	O
different	O	ADJ	O
from	O	ADP	O
controls	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


02	O	NUM	O
).	O	PUNCT	O
The	O	DET	O
FK506	B-Chemical	NOUN	B
plus	O	CCONJ	O
SRL	B-Chemical	NOUN	B
combination	O	NOUN	B
showed	O	VERB	O
only	O	ADV	O
a	O	DET	O
marginally	O	ADV	O
higher	O	ADJ	O
degree	O	NOUN	B
of	O	ADP	O
fibrosis	B-Disease	NOUN	B
as	O	ADP	O
compared	O	VERB	B
with	O	ADP	O
controls	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
).	O	PUNCT	O
CONCLUSION	O	NOUN	O
:	O	PUNCT	O
This	O	DET	O
rat	O	NOUN	B
study	O	NOUN	B
demonstrated	O	VERB	O
a	O	DET	O
synergistic	O	ADJ	B
nephrotoxic	B-Disease	ADJ	B
effect	O	NOUN	O
of	O	ADP	O
CsA	B-Chemical	NOUN	B
plus	O	CCONJ	O
SRL	B-Chemical	PROPN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
FK506	B-Chemical	NOUN	B
plus	O	CCONJ	O
SRL	B-Chemical	PROPN	B


Effect	O	NOUN	B
of	O	ADP	O
fucoidan	B-Chemical	ADJ	B
treatment	O	NOUN	B
on	O	ADP	O
collagenase	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
intracerebral	B-Disease	ADJ	B
hemorrhage	I-Disease	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


Inflammatory	O	ADJ	B
cells	O	NOUN	I
are	O	AUX	O
postulated	O	VERB	O
to	O	PART	O
mediate	O	VERB	O
some	O	DET	O
of	O	ADP	O
the	O	DET	O
brain	B-Disease	NOUN	B
damage	I-Disease	NOUN	I
following	O	VERB	O
ischemic	B-Disease	ADJ	B
stroke	I-Disease	NOUN	I
.	O	PUNCT	O


Intracerebral	B-Disease	ADJ	B
hemorrhage	I-Disease	NOUN	I
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
more	O	ADJ	O
inflammation	B-Disease	NOUN	B
than	O	ADP	O
ischemic	B-Disease	ADJ	B
stroke	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
tested	O	VERB	B
the	O	DET	O
sulfated	O	VERB	B
polysaccharide	O	NOUN	I
fucoidan	B-Chemical	NOUN	I
,	O	PUNCT	O
which	O	DET	O
has	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
to	O	PART	O
reduce	O	VERB	O
inflammatory	O	ADJ	B
brain	B-Disease	NOUN	O
damage	I-Disease	NOUN	O
,	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
rat	O	NOUN	B
model	O	NOUN	B
of	O	ADP	O
intracerebral	B-Disease	ADJ	B
hemorrhage	I-Disease	NOUN	I
induced	O	VERB	B
by	O	ADP	O
injection	O	NOUN	B
of	O	ADP	O
bacterial	O	ADJ	B
collagenase	O	NOUN	I
into	O	ADP	O
the	O	DET	O
caudate	O	NOUN	B
nucleus	O	NOUN	I
.	O	PUNCT	O


Rats	O	NOUN	B
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
seven	O	NUM	O
day	O	NOUN	B
intravenous	O	ADJ	B
infusion	O	NOUN	B
of	O	ADP	O
fucoidan	B-Chemical	NOUN	B
(	O	PUNCT	O
30	O	NUM	O
micrograms	O	NOUN	O
h	O	NOUN	O
-	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
vehicle	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
hematoma	B-Disease	NOUN	B
was	O	AUX	O
assessed	O	VERB	B
in	O	X	B
vivo	O	X	I
by	O	ADP	O
magnetic	O	ADJ	B
resonance	O	NOUN	I
imaging	O	NOUN	I
.	O	PUNCT	O


Motor	O	NOUN	B
behavior	O	NOUN	I
,	O	PUNCT	O
passive	O	ADJ	B
avoidance	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
skilled	O	ADJ	B
forelimb	O	NOUN	O
function	O	NOUN	O
were	O	AUX	O
tested	O	VERB	B
repeatedly	O	ADV	O
for	O	ADP	O
six	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


Fucoidan	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
rats	O	NOUN	B
exhibited	O	VERB	O
evidence	O	NOUN	B
of	O	ADP	O
impaired	B-Disease	ADJ	B
blood	I-Disease	NOUN	B
clotting	I-Disease	NOUN	I
and	O	CCONJ	O
hemodilution	B-Disease	NOUN	B
,	O	PUNCT	O
had	O	AUX	O
larger	O	ADJ	O
hematomas	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
tended	O	VERB	O
to	O	PART	O
have	O	AUX	O
less	O	ADJ	O
inflammation	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
vicinity	O	NOUN	O
of	O	ADP	O
the	O	DET	O
hematoma	B-Disease	NOUN	B
after	O	ADP	O
three	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


They	O	PRON	O
showed	O	VERB	O
significantly	O	ADV	O
more	O	ADV	O
rapid	O	ADJ	O
improvement	O	NOUN	B
of	O	ADP	O
motor	O	NOUN	B
function	O	NOUN	I
in	O	ADP	O
the	O	DET	O
first	O	ADJ	O
week	O	NOUN	B
following	O	VERB	O
hemorrhage	B-Disease	NOUN	B
and	O	CCONJ	O
better	O	ADJ	O
memory	O	NOUN	B
retention	O	NOUN	I
in	O	ADP	O
the	O	DET	O
passive	O	ADJ	B
avoidance	O	NOUN	I
test	O	NOUN	I
.	O	PUNCT	O


Acute	O	ADJ	B
white	B-Disease	ADJ	I
matter	I-Disease	NOUN	I
edema	I-Disease	NOUN	I
and	O	CCONJ	O
eventual	O	ADJ	B
neuronal	B-Disease	ADJ	B
loss	I-Disease	NOUN	I
in	O	ADP	O
the	O	DET	O
striatum	O	NOUN	B
adjacent	O	ADJ	B
to	O	ADP	O
the	O	DET	O
hematoma	B-Disease	NOUN	B
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


Investigation	O	NOUN	B
of	O	ADP	O
more	O	ADV	O
specific	O	ADJ	O
anti	O	ADJ	B
-	O	PUNCT	O
inflammatory	O	ADJ	B
agents	O	NOUN	I
and	O	CCONJ	O
hemodiluting	O	ADJ	B
agents	O	NOUN	I
are	O	AUX	O
warranted	O	VERB	O
in	O	ADP	O
intracerebral	B-Disease	ADJ	B
hemorrhage	I-Disease	NOUN	I


Paracetamol	B-Chemical	PROPN	B
-	O	PUNCT	O
associated	O	VERB	B
coma	B-Disease	NOUN	B
,	O	PUNCT	O
metabolic	B-Disease	ADJ	B
acidosis	I-Disease	NOUN	I
,	O	PUNCT	O
renal	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
hepatic	I-Disease	ADJ	B
failure	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
case	O	NOUN	B
of	O	ADP	O
metabolic	B-Disease	ADJ	B
acidosis	I-Disease	NOUN	I
,	O	PUNCT	O
acute	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
failure	I-Disease	NOUN	I
and	I-Disease	CCONJ	O
hepatic	I-Disease	ADJ	B
failure	I-Disease	NOUN	I
following	O	VERB	O
paracetamol	B-Chemical	NOUN	B


Hepatic	O	ADJ	B
reactions	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
ketoconazole	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
United	O	PROPN	B
Kingdom	O	PROPN	I
.	O	PUNCT	O


Ketoconazole	B-Chemical	NOUN	B
was	O	AUX	O
introduced	O	VERB	O
in	O	ADP	O
the	O	DET	O
United	O	PROPN	B
Kingdom	O	PROPN	I
in	O	ADP	O
1981	O	NUM	O
.	O	PUNCT	O


By	O	ADP	O
November	O	PROPN	O
1984	O	NUM	O
the	O	DET	O
Committee	O	PROPN	B
on	O	ADP	O
Safety	O	PROPN	O
of	O	ADP	O
Medicines	O	PROPN	B
had	O	AUX	O
received	O	VERB	O
82	O	NUM	O
reports	O	NOUN	B
of	O	ADP	O
possible	O	ADJ	O
hepatotoxicity	B-Disease	NOUN	B
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
drug	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
five	O	NUM	O
deaths	B-Disease	NOUN	B
.	O	PUNCT	O


An	O	DET	O
analysis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
75	O	NUM	O
cases	O	NOUN	B
that	O	PRON	O
had	O	AUX	O
been	O	AUX	O
adequately	O	ADV	O
followed	O	VERB	O
up	O	ADP	O
suggested	O	VERB	O
that	O	SCONJ	O
16	O	NUM	O
,	O	PUNCT	O
including	O	VERB	O
three	O	NUM	O
deaths	B-Disease	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
probably	O	ADV	O
related	O	ADJ	O
to	O	PART	O
treatment	O	NOUN	B
with	O	ADP	O
the	O	DET	O
drug	O	NOUN	B
.	O	PUNCT	O


Of	O	ADP	O
the	O	DET	O
remainder	O	NOUN	O
,	O	PUNCT	O
48	O	NUM	O
were	O	AUX	O
possibly	O	ADV	O
related	O	ADJ	O
to	O	PART	O
treatment	O	NOUN	B
,	O	PUNCT	O
five	O	NUM	O
were	O	AUX	O
unlikely	O	ADJ	O
to	O	PART	O
be	O	AUX	O
so	O	ADV	O
,	O	PUNCT	O
and	O	CCONJ	O
six	O	NUM	O
were	O	AUX	O
unclassifiable	O	ADJ	B
.	O	PUNCT	O


The	O	DET	O
mean	O	ADJ	O
age	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
16	O	NUM	O
probable	O	ADJ	O
cases	O	NOUN	B
was	O	AUX	O
57	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
,	O	PUNCT	O
with	O	ADP	O
hepatotoxicity	B-Disease	NOUN	B
being	O	AUX	O
more	O	ADV	O
common	O	ADJ	O
in	O	ADP	O
women	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
average	O	ADJ	B
duration	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
before	O	ADP	O
the	O	DET	O
onset	O	NOUN	B
of	O	ADP	I
jaundice	B-Disease	NOUN	B
was	O	AUX	O
61	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


of	O	ADP	O
these	O	DET	O
well	O	ADV	O
validated	O	VERB	O
cases	O	NOUN	B
occurred	O	VERB	O
within	O	ADP	O
the	O	DET	O
first	O	ADJ	O
10	O	NUM	O
days	O	NOUN	B
after	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
of	O	ADP	O
serum	O	NOUN	B
liver	O	NOUN	I
function	O	NOUN	I
tests	O	NOUN	I
suggested	O	VERB	O
hepatocellular	B-Disease	NOUN	B
injury	I-Disease	NOUN	I
in	O	ADP	O
10	O	NUM	O
(	O	PUNCT	O
63	O	NUM	O
%);	O	NOUN	O
the	O	DET	O
rest	O	NOUN	B
showed	O	VERB	O
a	O	DET	O
mixed	O	ADJ	O
pattern	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
results	O	NOUN	B
of	O	ADP	O
histological	O	ADJ	B
examination	O	NOUN	O
of	O	ADP	O
the	O	DET	O
liver	O	NOUN	B
often	O	ADV	O
showed	O	VERB	O
evidence	O	NOUN	B
of	O	ADP	O
cholestasis	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
characteristics	O	NOUN	B
of	O	ADP	O
the	O	DET	O
48	O	NUM	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
possible	O	ADJ	O
cases	O	NOUN	B
were	O	AUX	O
similar	O	ADJ	O
.	O	PUNCT	O


Allergic	O	ADJ	B
manifestations	O	NOUN	I
such	O	ADJ	O
as	O	ADP	O
rash	B-Disease	NOUN	B
and	O	CCONJ	O
eosinophilia	B-Disease	NOUN	B
were	O	AUX	O
rare	O	ADJ	B
.	O	PUNCT	O


Hepatitis	B-Disease	NOUN	B
was	O	AUX	O
usually	O	ADV	O
reversible	O	ADJ	B
when	O	SCONJ	O
treatment	O	NOUN	B
was	O	AUX	O
stopped	O	VERB	B
,	O	PUNCT	O
with	O	ADP	O
the	O	DET	O
results	O	NOUN	B
of	O	ADP	O
liver	O	NOUN	B
function	O	NOUN	I
tests	O	NOUN	I
returning	O	VERB	O
to	O	ADP	O
normal	O	ADJ	B
after	O	ADP	O
an	O	DET	O
average	O	NOUN	B
of	O	ADP	O
3	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
two	O	NUM	O
of	O	ADP	O
the	O	DET	O
three	O	NUM	O
deaths	B-Disease	NOUN	B
probably	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
ketoconazole	B-Chemical	NOUN	B
treatment	O	NOUN	B
the	O	DET	O
drug	O	NOUN	B
had	O	AUX	O
been	O	AUX	O
continued	O	VERB	O
after	O	ADP	O
the	O	DET	O
onset	O	NOUN	B
of	O	ADP	I
jaundice	B-Disease	NOUN	B
and	O	CCONJ	O
other	O	ADJ	O
symptoms	O	NOUN	B
of	O	ADP	O
hepatitis	B-Disease	NOUN	B
.	O	PUNCT	O


Clinical	O	ADJ	B
and	O	CCONJ	O
biochemical	O	ADJ	B
monitoring	O	NOUN	B
at	O	ADP	O
regular	O	ADJ	O
intervals	O	NOUN	B
for	O	ADP	O
evidence	O	NOUN	B
of	O	ADP	O
hepatitis	B-Disease	NOUN	B
is	O	AUX	O
advised	O	VERB	O
during	O	ADP	O
long	O	ADJ	B
term	O	NOUN	I
treatment	O	NOUN	B
with	O	ADP	O
ketoconazole	B-Chemical	NOUN	B
to	O	PART	O
prevent	O	VERB	O
possible	O	ADJ	O
serious	O	ADJ	O
hepatic	B-Disease	ADJ	B
injury	I-Disease	NOUN	I


Combined	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
prolonged	O	ADJ	B
prostaglandin	B-Chemical	NOUN	B
E1	I-Chemical	NOUN	I
-	O	PUNCT	O
induced	O	VERB	B
hypotension	B-Disease	NOUN	B
and	O	CCONJ	O
haemodilution	B-Disease	NOUN	B
on	O	ADP	O
human	O	ADJ	B
hepatic	O	ADJ	B
function	O	NOUN	I
.	O	PUNCT	O


Combined	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
prolonged	O	ADJ	B
prostaglandin	B-Chemical	NOUN	B
E1	I-Chemical	NOUN	I
(	O	PUNCT	O
PGE1	B-Chemical	NOUN	B
)-	O	ADJ	O
induced	O	VERB	B
hypotension	B-Disease	NOUN	B
and	O	CCONJ	O
haemodilution	B-Disease	NOUN	B
on	O	ADP	O
hepatic	O	ADJ	B
function	O	NOUN	I
were	O	AUX	O
studied	O	VERB	O
in	O	ADP	O
30	O	NUM	O
patients	O	NOUN	B
undergoing	O	VERB	O
hip	O	NOUN	B
surgery	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
allocated	O	VERB	O
to	O	ADP	O
one	O	NUM	O
of	O	ADP	O
three	O	NUM	O
groups	O	NOUN	B
;	O	PUNCT	O
those	O	DET	O
in	O	ADP	O
group	O	NOUN	B
A	O	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
10	O	NUM	O
)	O	PUNCT	O
were	O	AUX	O
subjected	O	VERB	O
to	O	PART	O
controlled	O	VERB	B
hypotension	B-Disease	NOUN	I
alone	O	ADV	O
,	O	PUNCT	O
those	O	DET	O
in	O	ADP	O
group	O	NOUN	B
B	O	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
10	O	NUM	O
)	O	PUNCT	O
to	O	PART	O
haemodilution	B-Disease	NOUN	B
alone	O	ADV	O
and	O	CCONJ	O
those	O	DET	O
in	O	ADP	O
group	O	NOUN	B
C	O	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
10	O	NUM	O
)	O	PUNCT	O
to	O	PART	O
both	O	DET	O
controlled	O	VERB	B
hypotension	B-Disease	NOUN	I
and	O	CCONJ	O
haemodilution	B-Disease	NOUN	B
.	O	PUNCT	O


Haemodilution	B-Disease	NOUN	B
in	O	ADP	O
groups	O	NOUN	B
B	O	NOUN	I
and	O	CCONJ	O
C	O	NOUN	B
was	O	AUX	O
produced	O	VERB	O
by	O	ADP	O
withdrawing	O	VERB	O
approximately	O	ADV	O
1000	O	NUM	O
mL	O	NOUN	O
of	O	ADP	O
blood	O	NOUN	B
and	O	CCONJ	O
replacing	O	VERB	O
it	O	PRON	O
with	O	ADP	O
the	O	DET	O
same	O	ADJ	O
amount	O	NOUN	O
of	O	ADP	O
dextran	B-Chemical	NOUN	B
solution	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
final	O	ADJ	O
haematocrit	O	NOUN	B
values	O	NOUN	I
were	O	AUX	O
21	O	NUM	O
or	O	CCONJ	O
22	O	NUM	O
%.	O	NOUN	B
Controlled	O	ADJ	B
hypotension	B-Disease	NOUN	I
in	O	ADP	O
groups	O	NOUN	B
A	O	NOUN	O
and	O	CCONJ	O
C	O	NOUN	B
was	O	AUX	O
induced	O	VERB	B
with	O	ADP	O
PGE1	B-Chemical	NOUN	B
to	O	PART	O
maintain	O	VERB	O
mean	O	ADJ	O
arterial	O	ADJ	B
blood	O	NOUN	I
pressure	O	NOUN	I
at	O	ADP	O
55	O	NUM	O
mmHg	O	NOUN	B
for	O	ADP	O
180	O	NUM	O
min	O	NOUN	O
.	O	PUNCT	O


Measurements	O	NOUN	B
included	O	VERB	O
arterial	O	ADJ	B
ketone	O	NOUN	O
body	O	NOUN	O
ratio	O	NOUN	O
(	O	PUNCT	O
AKBR	O	NOUN	B
,	O	PUNCT	O
aceto-acetate	B-Chemical	ADJ	B
/	O	SYM	O
3-hydroxybutyrate	B-Chemical	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
clinical	O	ADJ	B
hepatic	O	ADJ	B
function	O	NOUN	I
parameters	O	NOUN	B
.	O	PUNCT	O


AKBR	O	NOUN	B
and	O	CCONJ	O
biological	O	ADJ	B
hepatic	O	ADJ	B
function	O	NOUN	I
tests	O	NOUN	O
showed	O	VERB	O
no	O	DET	O
change	O	NOUN	O
throughout	O	ADP	O
the	O	DET	O
time	O	NOUN	B
course	O	NOUN	I
in	O	ADP	O
groups	O	NOUN	B
A	O	NOUN	O
and	O	CCONJ	O
B	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
group	O	NOUN	B
C	O	NOUN	I
,	O	PUNCT	O
AKBR	O	NOUN	B
showed	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
decrease	O	NOUN	B
at	O	ADP	O
120	O	NUM	O
min	O	NOUN	O
(-	O	PUNCT	O
40	O	NUM	O
%)	O	NOUN	O
and	O	CCONJ	O
at	O	ADP	O
180	O	NUM	O
min	O	NOUN	O
(-	O	PUNCT	O
49	O	NUM	O
%)	O	NOUN	O
after	O	ADP	O
the	O	DET	O
start	O	NOUN	O
of	O	ADP	O
hypotension	B-Disease	NOUN	B
and	O	CCONJ	O
at	O	ADP	O
60	O	NUM	O
min	O	NOUN	O
(-	O	PUNCT	O
32	O	NUM	O
%)	O	NOUN	O
after	O	ADP	O
recovery	O	NOUN	B
of	O	ADP	O
normotension	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
SGOT	O	NOUN	B
,	O	PUNCT	O
SGPT	O	NOUN	B
,	O	PUNCT	O
LDH	O	NOUN	B
and	O	CCONJ	O
total	O	ADJ	O
bilirubin	B-Chemical	NOUN	B
showed	O	VERB	O
significant	O	ADJ	O
increases	O	NOUN	B
after	O	ADP	O
operation	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
prolonged	O	ADJ	B
combination	O	NOUN	B
of	O	ADP	O
more	O	ADJ	O
than	O	ADP	O
120	O	NUM	O
min	O	NOUN	O
of	O	ADP	O
PGE1	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypotension	B-Disease	NOUN	B
and	O	CCONJ	O
moderate	O	ADJ	B
haemodilution	B-Disease	NOUN	B
would	O	AUX	O
cause	O	VERB	O
impairment	B-Disease	NOUN	B
of	I-Disease	ADP	O
hepatic	I-Disease	ADJ	B
function	I-Disease	NOUN	I


Levodopa	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
dyskinesias	B-Disease	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
Parkinson's	B-Disease	ADJ	O
disease	I-Disease	NOUN	O
:	O	PUNCT	O
filling	O	VERB	B
the	O	DET	O
bench	O	NOUN	B
-	O	PUNCT	O
to	O	ADP	O
-	O	PUNCT	O
bedside	O	NOUN	B
gap	O	NOUN	B
.	O	PUNCT	O


Levodopa	B-Chemical	NOUN	B
is	O	AUX	O
the	O	DET	O
most	O	ADV	O
effective	O	ADJ	B
drug	O	NOUN	B
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
Parkinson's	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
use	O	NOUN	O
of	O	ADP	O
this	O	DET	O
dopamine	B-Chemical	NOUN	B
precursor	O	NOUN	B
is	O	AUX	O
complicated	O	ADJ	O
by	O	ADP	O
highly	O	ADV	O
disabling	O	ADJ	B
fluctuations	O	NOUN	B
and	O	CCONJ	O
dyskinesias	B-Disease	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
preclinical	O	ADJ	B
and	O	CCONJ	O
clinical	O	ADJ	B
findings	O	NOUN	I
suggest	O	VERB	O
pulsatile	O	ADJ	B
stimulation	O	NOUN	I
of	O	ADP	O
striatal	O	ADJ	B
postsynaptic	O	ADJ	I
receptors	O	NOUN	I
as	O	ADP	O
a	O	DET	O
key	O	ADJ	O
mechanism	O	NOUN	B
underlying	O	VERB	O
levodopa	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
dyskinesias	B-Disease	NOUN	B
,	O	PUNCT	O
their	O	PRON	O
pathogenesis	O	NOUN	B
is	O	AUX	O
still	O	ADV	O
unclear	O	ADJ	O
.	O	PUNCT	O


In	O	ADP	O
recent	O	ADJ	O
years	O	NOUN	B
,	O	PUNCT	O
evidence	O	NOUN	B
from	O	ADP	O
animal	O	NOUN	B
models	O	NOUN	I
of	O	ADP	O
Parkinson's	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
has	O	AUX	O
provided	O	VERB	O
important	O	ADJ	O
information	O	NOUN	B
to	O	PART	O
understand	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
specific	O	ADJ	O
receptor	O	NOUN	B
and	O	CCONJ	O
post	O	NOUN	B
-	O	PUNCT	O
receptor	O	NOUN	B
molecular	O	ADJ	B
mechanisms	O	NOUN	I
underlying	O	VERB	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
dyskinetic	B-Disease	ADJ	B
movements	I-Disease	NOUN	B
.	O	PUNCT	O


Recent	O	ADJ	O
preclinical	O	ADJ	B
and	O	CCONJ	O
clinical	O	ADJ	B
data	O	NOUN	I
from	O	ADP	O
promising	O	ADJ	O
lines	O	NOUN	O
of	O	ADP	O
research	O	NOUN	B
focus	O	NOUN	O
on	O	ADP	O
the	O	DET	O
differential	O	ADJ	O
role	O	NOUN	O
of	O	ADP	O
presynaptic	O	ADJ	B
versus	O	CCONJ	O
postsynaptic	O	ADJ	B
mechanisms	O	NOUN	I
,	O	PUNCT	O
dopamine	B-Chemical	NOUN	B
receptor	O	NOUN	I
subtypes	O	NOUN	B
,	O	PUNCT	O
ionotropic	O	ADJ	B
and	O	CCONJ	O
metabotropic	O	ADJ	B
glutamate	B-Chemical	NOUN	I
receptors	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
non	O	ADJ	B
-	O	PUNCT	O
dopaminergic	O	ADJ	B
neurotransmitter	O	NOUN	B
systems	O	NOUN	I
in	O	ADP	O
the	O	DET	O
pathophysiology	O	NOUN	B
of	O	ADP	O
levodopa	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
dyskinesias	B-Disease	NOUN	B


Prevention	O	NOUN	B
of	O	ADP	O
seizures	B-Disease	NOUN	B
and	O	CCONJ	O
reorganization	O	NOUN	B
of	O	ADP	O
hippocampal	O	NOUN	B
functions	O	NOUN	B
by	O	ADP	O
transplantation	O	NOUN	B
of	O	ADP	O
bone	O	NOUN	B
marrow	O	NOUN	I
cells	O	NOUN	I
in	O	ADP	O
the	O	DET	O
acute	O	ADJ	B
phase	O	NOUN	I
of	O	ADP	O
experimental	O	ADJ	B
epilepsy	B-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
investigated	O	VERB	B
the	O	DET	O
therapeutic	O	ADJ	B
potential	O	NOUN	B
of	O	ADP	O
bone	O	NOUN	B
marrow	O	NOUN	I
mononuclear	O	ADJ	I
cells	O	NOUN	I
(	O	PUNCT	O
BMCs	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
model	O	NOUN	B
of	O	ADP	O
epilepsy	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
pilocarpine	B-Chemical	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


BMCs	O	NOUN	B
obtained	O	VERB	O
from	O	ADP	O
green	O	ADJ	B
fluorescent	O	ADJ	I
protein	O	NOUN	I
(	O	PUNCT	O
GFP	O	NOUN	B
)	O	PUNCT	O
transgenic	O	ADJ	B
mice	O	NOUN	I
or	O	CCONJ	O
rats	O	NOUN	B
were	O	AUX	O
transplanted	O	VERB	B
intravenously	O	ADV	B
after	O	ADP	O
induction	O	NOUN	B
of	O	ADP	O
status	B-Disease	NOUN	B
epilepticus	I-Disease	NOUN	I
(	O	PUNCT	O
SE	B-Disease	NOUN	B
).	O	PUNCT	O
Spontaneous	B-Disease	ADJ	B
recurrent	I-Disease	ADJ	I
seizures	I-Disease	NOUN	I
(	O	PUNCT	O
SRS	B-Disease	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
monitored	O	VERB	B
using	O	VERB	O
Racine	O	PROPN	B
'	O	PART	O
s	O	NOUN	O
seizure	B-Disease	VERB	B
severity	O	NOUN	B
scale	O	NOUN	I
.	O	PUNCT	O


All	O	DET	O
of	O	ADP	O
the	O	DET	O
rats	O	NOUN	B
in	O	ADP	O
the	O	DET	O
saline	O	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
epileptic	B-Disease	ADJ	B
control	O	NOUN	I
group	O	NOUN	I
developed	O	VERB	O
SRS	B-Disease	PROPN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
none	O	NOUN	O
of	O	ADP	O
the	O	DET	O
BMC	O	PROPN	B
-	O	PUNCT	O
treated	O	VERB	B
epileptic	B-Disease	ADJ	B
animals	O	NOUN	I
had	O	AUX	O
seizures	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
short	O	ADJ	B
term	O	NOUN	I
(	O	PUNCT	O
15	O	NUM	O
days	O	NOUN	B
after	O	ADP	O
transplantation	O	NOUN	B
),	O	PUNCT	O
regardless	O	ADV	O
of	O	ADP	O
the	O	DET	O
BMC	O	NOUN	B
source	O	NOUN	B
.	O	PUNCT	O


Over	O	ADP	O
the	O	DET	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
chronic	O	ADJ	B
phase	O	NOUN	I
(	O	PUNCT	O
120	O	NUM	O
days	O	NOUN	B
after	O	ADP	O
transplantation	O	NOUN	B
),	O	PUNCT	O
only	O	ADV	O
25	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
BMC	O	PROPN	B
-	O	PUNCT	O
treated	O	VERB	B
epileptic	B-Disease	ADJ	B
animals	O	NOUN	I
had	O	AUX	O
seizures	B-Disease	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
with	O	ADP	O
a	O	DET	O
lower	O	ADJ	O
frequency	O	NOUN	B
and	O	CCONJ	O
duration	O	NOUN	B
compared	O	VERB	B
to	O	PART	O
the	O	DET	O
epileptic	B-Disease	ADJ	B
control	O	NOUN	I
group	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
density	O	NOUN	B
of	O	ADP	O
hippocampal	O	ADJ	B
neurons	O	NOUN	B
in	O	ADP	O
the	O	DET	O
brains	O	NOUN	B
of	O	ADP	O
animals	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
BMCs	O	NOUN	B
was	O	AUX	O
markedly	O	ADV	O
preserved	O	VERB	O
.	O	PUNCT	O


At	O	ADP	O
hippocampal	O	NOUN	B
Schaeffer	O	PROPN	B
collateral	O	NOUN	I
-	O	PUNCT	O
CA1	O	NOUN	B
synapses	O	NOUN	B
,	O	PUNCT	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
potentiation	O	NOUN	B
was	O	AUX	O
preserved	O	VERB	O
in	O	ADP	O
BMC	O	PROPN	B
-	O	PUNCT	O
transplanted	O	VERB	B
rats	O	NOUN	B
compared	O	VERB	O
to	O	PART	O
epileptic	B-Disease	ADJ	B
controls	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
donor	O	NOUN	B
-	O	PUNCT	O
derived	O	VERB	B
GFP	O	NOUN	B
(+)	O	ADJ	B
cells	O	NOUN	I
were	O	AUX	O
rarely	O	ADV	O
found	O	VERB	O
in	O	ADP	O
the	O	DET	O
brains	O	NOUN	B
of	O	ADP	O
transplanted	O	VERB	B
epileptic	B-Disease	ADJ	O
rats	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
treatment	O	NOUN	B
with	O	ADP	O
BMCs	O	NOUN	B
can	O	AUX	O
prevent	O	VERB	B
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
chronic	O	ADJ	B
seizures	B-Disease	NOUN	I
,	O	PUNCT	O
reduce	O	VERB	B
neuronal	B-Disease	ADJ	B
loss	I-Disease	NOUN	O


Cardioprotective	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
salvianolic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
A	I-Chemical	NOUN	I
on	O	ADP	O
isoproterenol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
myocardial	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
was	O	AUX	O
designed	O	VERB	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
cardioprotective	O	ADJ	B
potential	O	NOUN	B
of	O	ADP	O
salvianolic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
A	I-Chemical	NOUN	I
on	O	ADP	O
isoproterenol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
myocardial	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


Hemodynamic	O	ADJ	B
parameters	O	NOUN	B
and	O	CCONJ	O
lead	O	VERB	B
II	O	NUM	I
electrocardiograph	O	NOUN	I
were	O	AUX	O
monitored	O	VERB	B
and	O	CCONJ	O
recorded	O	VERB	O
continuously	O	ADV	O
.	O	PUNCT	O


Cardiac	O	ADJ	B
marker	O	NOUN	I
enzymes	O	NOUN	B
and	O	CCONJ	O
antioxidative	O	ADJ	B
parameters	O	NOUN	B
in	O	ADP	O
serum	O	NOUN	B
and	O	CCONJ	O
heart	O	NOUN	B
tissues	O	NOUN	I
were	O	AUX	O
measured	O	VERB	B
.	O	PUNCT	O


Assay	O	NOUN	B
for	O	ADP	O
mitochondrial	O	ADJ	B
respiratory	O	ADJ	O
function	O	NOUN	O
and	O	CCONJ	O
histopathological	O	ADJ	B
examination	O	NOUN	B
of	O	ADP	O
heart	O	NOUN	B
tissues	O	NOUN	I
were	O	AUX	O
performed	O	VERB	O
.	O	PUNCT	O


Isoproterenol	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
rats	O	NOUN	B
showed	O	VERB	O
significant	O	ADJ	O
increases	O	NOUN	B
in	O	ADP	O
the	O	DET	O
levels	O	NOUN	B
of	O	ADP	O
lactate	B-Chemical	NOUN	B
dehydrogenase	O	NOUN	I
,	O	PUNCT	O
aspartate	B-Chemical	NOUN	B
transaminase	O	NOUN	I
,	O	PUNCT	O
creatine	B-Chemical	NOUN	B
kinase	O	NOUN	I
and	O	CCONJ	O
malondialdehyde	B-Chemical	NOUN	B
and	O	CCONJ	O
significant	O	ADJ	B
decreases	O	NOUN	B
in	O	ADP	O
the	O	DET	O
activities	O	NOUN	B
of	O	ADP	O
superoxide	B-Chemical	NOUN	B
dismutase	O	NOUN	I
,	O	PUNCT	O
catalase	O	NOUN	B
and	O	CCONJ	O
glutathione	B-Chemical	NOUN	B
peroxidase	O	NOUN	I
in	O	ADP	O
serum	O	NOUN	B
and	O	CCONJ	O
heart	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
rats	O	NOUN	B
also	O	ADV	O
showed	O	VERB	O
declines	O	NOUN	B
in	O	ADP	O
left	O	ADJ	B
ventricular	O	ADJ	I
systolic	O	NOUN	I
pressure	O	NOUN	I
,	O	PUNCT	O
maximum	O	NOUN	B
and	O	CCONJ	O
minimum	O	ADJ	O
rate	O	NOUN	B
of	O	ADP	O
developed	O	VERB	O
left	O	VERB	B
ventricular	O	ADJ	I
pressure	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
elevation	O	NOUN	B
of	O	ADP	O
left	O	ADJ	B
ventricular	O	ADJ	I
end	O	NOUN	I
-	O	PUNCT	O
diastolic	O	ADJ	B
pressure	O	NOUN	I
and	O	CCONJ	O
ST	O	ADJ	B
-	O	PUNCT	O
segment	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
mitochondrial	O	ADJ	B
respiratory	B-Disease	ADJ	I
dysfunction	I-Disease	NOUN	I
characterized	O	VERB	B
by	O	ADP	O
decreased	O	VERB	B
respiratory	O	ADJ	B
control	O	NOUN	I
ratio	O	NOUN	I
and	O	CCONJ	O
ADP	B-Chemical	PROPN	B
/	O	SYM	O
O	O	PROPN	B
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
isoproterenol	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
rats	O	NOUN	B
.	O	PUNCT	O


Administration	O	NOUN	B
of	O	ADP	O
salvianolic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
A	I-Chemical	NOUN	I
for	O	ADP	O
a	O	DET	O
period	O	NOUN	B
of	O	ADP	O
8	O	NUM	O
days	O	NOUN	B
significantly	O	ADV	O
attenuated	O	VERB	B
isoproterenol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cardiac	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
and	O	CCONJ	O
myocardial	B-Disease	ADJ	B
injury	I-Disease	NOUN	I
and	O	CCONJ	O
improved	O	VERB	B
mitochondrial	O	ADJ	B
respiratory	O	ADJ	O
function	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
protective	O	ADJ	O
role	O	NOUN	O
of	O	ADP	O
salvianolic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
A	I-Chemical	NOUN	O
against	O	ADP	O
isoproterenol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
myocardial	B-Disease	ADJ	B
damage	I-Disease	NOUN	I
was	O	AUX	O
further	O	ADV	O
confirmed	O	VERB	O
by	O	ADP	O
histopathological	O	ADJ	B
examination	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
of	O	ADP	O
our	O	PRON	O
study	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
salvianolic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
A	I-Chemical	NOUN	I
possessing	O	VERB	O
antioxidant	O	ADJ	B
activity	O	NOUN	I
has	O	AUX	O
a	O	DET	O
significant	O	ADJ	O
protective	O	ADJ	B
effect	O	NOUN	I
against	O	ADP	O
isoproterenol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
myocardial	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I


Acute	O	ADJ	B
effects	O	NOUN	O
of	O	ADP	O
N-(2-propylpentanoyl)urea	B-Chemical	NOUN	B
on	O	ADP	O
hippocampal	O	NOUN	B
amino	B-Chemical	NOUN	B
acid	I-Chemical	NOUN	I
neurotransmitters	O	NOUN	I
in	O	ADP	O
pilocarpine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
seizure	B-Disease	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
aimed	O	VERB	O
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
anticonvulsant	O	ADJ	B
activity	O	NOUN	I
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
the	O	DET	O
effects	O	NOUN	B
on	O	ADP	O
the	O	DET	O
level	O	NOUN	B
of	O	ADP	O
hippocampal	O	NOUN	B
amino	B-Chemical	NOUN	B
acid	I-Chemical	NOUN	I
neurotransmitters	O	NOUN	I
(	O	PUNCT	O
glutamate	B-Chemical	NOUN	B
,	O	PUNCT	O
aspartate	B-Chemical	NOUN	B
,	O	PUNCT	O
glycine	B-Chemical	NOUN	B
and	O	CCONJ	O
GABA	B-Chemical	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
N-(2-propylpentanoyl)urea	B-Chemical	PROPN	B
(	O	PUNCT	O
VPU	B-Chemical	PROPN	B
)	O	PUNCT	O
in	O	ADP	O
comparison	O	NOUN	B
to	O	PART	O
its	O	PRON	O
parent	O	NOUN	B
compound	O	NOUN	I
,	O	PUNCT	O
valproic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
(	O	PUNCT	O
VPA	B-Chemical	NOUN	B
).	O	PUNCT	O
VPU	B-Chemical	PROPN	B
was	O	AUX	O
more	O	ADV	O
potent	O	ADJ	O
than	O	ADP	O
VPA	B-Chemical	NOUN	B
,	O	PUNCT	O
exhibiting	O	VERB	O
the	O	DET	O
median	O	ADJ	B
effective	O	ADJ	O
dose	O	NOUN	B
(	O	PUNCT	O
ED	O	NOUN	B
(	O	PUNCT	O
50	O	NUM	O
))	O	PUNCT	O
of	O	ADP	O
49	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
kg	O	NOUN	B
in	O	ADP	O
protecting	O	VERB	B
rats	O	NOUN	B
against	O	ADP	O
pilocarpine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
seizure	B-Disease	NOUN	B
whereas	O	SCONJ	O
the	O	DET	O
corresponding	O	ADJ	O
value	O	NOUN	O
for	O	ADP	O
VPA	B-Chemical	NOUN	B
was	O	AUX	O
322	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
.	O	PUNCT	O


In	O	X	B
vivo	O	X	I
microdialysis	O	NOUN	B
demonstrated	O	VERB	O
that	O	SCONJ	O
an	O	DET	O
intraperitoneal	O	ADJ	B
administration	O	NOUN	B
of	O	ADP	O
pilocarpine	B-Chemical	NOUN	B
induced	O	VERB	B
a	O	DET	O
pronounced	O	ADJ	O
increment	O	NOUN	B
of	O	ADP	O
hippocampal	O	ADJ	B
glutamate	B-Chemical	NOUN	B
and	O	CCONJ	O
aspartate	B-Chemical	NOUN	B
whereas	O	SCONJ	O
no	O	DET	O
significant	O	ADJ	O
change	O	NOUN	O
was	O	AUX	O
observed	O	VERB	O
on	O	ADP	O
the	O	DET	O
level	O	NOUN	B
of	O	ADP	O
glycine	B-Chemical	NOUN	B
and	O	CCONJ	O
GABA	B-Chemical	NOUN	B
.	O	PUNCT	O


Pretreatment	O	NOUN	B
with	O	ADP	O
either	O	CCONJ	O
VPU	B-Chemical	PROPN	B
(	O	PUNCT	O
50	O	NUM	O
and	O	CCONJ	O
100	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
VPA	B-Chemical	NOUN	B
(	O	PUNCT	O
300	O	NUM	O
and	O	CCONJ	O
600	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
completely	O	ADV	O
abolished	O	VERB	B
pilocarpine	B-Chemical	NOUN	B
-	O	PUNCT	O
evoked	O	VERB	B
increases	O	NOUN	B
in	O	ADP	O
extracellular	O	ADJ	B
glutamate	B-Chemical	NOUN	B
and	O	CCONJ	O
aspartate	B-Chemical	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
a	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
reduction	O	NOUN	B
was	O	AUX	O
also	O	ADV	O
observed	O	VERB	O
on	O	ADP	O
the	O	DET	O
level	O	NOUN	B
of	O	ADP	O
GABA	B-Chemical	NOUN	B
and	O	CCONJ	O
glycine	B-Chemical	NOUN	B
but	O	CCONJ	O
less	O	ADJ	O
than	O	ADP	O
a	O	DET	O
drastic	O	ADJ	B
reduction	O	NOUN	B
of	O	ADP	O
glutamate	B-Chemical	NOUN	B
and	O	CCONJ	O
aspartate	B-Chemical	NOUN	B
level	O	NOUN	I
.	O	PUNCT	O


Based	O	VERB	O
on	O	ADP	O
the	O	DET	O
finding	O	NOUN	B
that	O	SCONJ	O
VPU	B-Chemical	PROPN	B
and	O	CCONJ	O
VPA	B-Chemical	PROPN	B
could	O	AUX	O
protect	O	VERB	O
the	O	DET	O
animals	O	NOUN	B
against	O	ADP	O
pilocarpine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
seizure	B-Disease	NOUN	B
it	O	PRON	O
is	O	AUX	O
suggested	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
reduction	O	NOUN	B
of	O	ADP	O
inhibitory	O	ADJ	B
amino	B-Chemical	NOUN	B
acid	I-Chemical	NOUN	I
neurotransmitters	O	NOUN	B
was	O	AUX	O
comparatively	O	ADV	O
minor	O	ADJ	B
and	O	CCONJ	O
offset	O	VERB	O
by	O	ADP	O
a	O	DET	O
pronounced	O	ADJ	O
reduction	O	NOUN	B
of	O	ADP	O
glutamate	B-Chemical	NOUN	B
and	O	CCONJ	O
aspartate	B-Chemical	NOUN	B
.	O	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
like	O	ADP	O
VPA	B-Chemical	NOUN	B
,	O	PUNCT	O
the	O	DET	O
finding	O	NOUN	B
that	O	SCONJ	O
VPU	B-Chemical	PROPN	B
could	O	AUX	O
drastically	O	ADV	O
reduce	O	VERB	O
pilocarpine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
increases	O	NOUN	B
in	O	ADP	O
glutamate	B-Chemical	NOUN	B
and	O	CCONJ	O
aspartate	B-Chemical	NOUN	B
should	O	AUX	O
account	O	VERB	O
,	O	PUNCT	O
at	O	ADP	O
least	O	ADJ	O
partly	O	ADV	O
,	O	PUNCT	O
for	O	ADP	O
its	O	PRON	O
anticonvulsant	O	ADJ	B
activity	O	NOUN	I
observed	O	VERB	O
in	O	ADP	O
pilocarpine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
seizure	B-Disease	NOUN	B


Acute	O	ADJ	B
hepatitis	B-Disease	NOUN	I
attack	O	NOUN	I
after	O	ADP	O
exposure	O	NOUN	B
to	O	PART	I
telithromycin	B-Chemical	NOUN	B
.	O	PUNCT	O


INTRODUCTION	O	NOUN	O
:	O	PUNCT	O
Antibiotic	O	ADJ	B
-	O	PUNCT	O
associated	O	VERB	B
hepatotoxicity	B-Disease	NOUN	B
is	O	AUX	O
rare	O	ADJ	B
.	O	PUNCT	O


With	O	ADP	O
widespread	O	ADJ	O
use	O	NOUN	O
of	O	ADP	O
antimicrobial	O	ADJ	B
agents	O	NOUN	I
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
hepatic	B-Disease	ADJ	B
injury	I-Disease	NOUN	I
occurs	O	VERB	O
frequently	O	ADV	O
,	O	PUNCT	O
and	O	CCONJ	O
among	O	ADP	O
adverse	B-Disease	ADJ	B
drug	I-Disease	NOUN	I
reactions	I-Disease	NOUN	I
,	O	PUNCT	O
idiosyncratic	O	ADJ	B
reactions	O	NOUN	I
are	O	AUX	O
the	O	DET	O
most	O	ADV	O
serious	O	ADJ	O
.	O	PUNCT	O


CASE	O	ADJ	B
SUMMARY	O	NOUN	I
:	O	PUNCT	O
A	O	DET	O
25	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
male	O	NOUN	B
patient	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
height	O	NOUN	B
of	O	ADP	O
175	O	NUM	O
cm	O	NOUN	O
and	O	CCONJ	O
weight	O	NOUN	B
of	O	ADP	O
72	O	NUM	O
kg	O	NOUN	O
presented	O	VERB	O
to	O	ADP	O
Marmara	O	PROPN	B
University	O	PROPN	I
Hospital	O	PROPN	I
Emergency	O	PROPN	I
Department	O	PROPN	I
,	O	PUNCT	O
Istanbul	O	PROPN	B
,	O	PUNCT	O
Turkey	O	PROPN	B
,	O	PUNCT	O
with	O	ADP	O
5	O	NUM	O
days	O	NOUN	B
'	O	PART	O
history	O	NOUN	B
of	O	ADP	I
jaundice	B-Disease	NOUN	B
,	O	PUNCT	O
malaise	O	NOUN	B
,	O	PUNCT	O
nausea	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
vomiting	B-Disease	NOUN	B
.	O	PUNCT	O


He	O	PRON	O
had	O	AUX	O
been	O	AUX	O
prescribed	O	VERB	B
telithromycin	B-Chemical	NOUN	B
400	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
d	O	X	B
PO	O	NOUN	B
to	O	PART	O
treat	O	VERB	B
an	O	DET	O
upper	B-Disease	ADJ	B
respiratory	I-Disease	ADJ	I
tract	I-Disease	NOUN	I
infection	I-Disease	NOUN	I
7	O	NUM	O
days	O	NOUN	B
prior	O	ADV	O
.	O	PUNCT	O


Admission	O	NOUN	B
laboratory	O	NOUN	O
tests	O	NOUN	O
were	O	AUX	O
as	O	ADP	O
follows	O	VERB	O
:	O	PUNCT	O
alanine	B-Chemical	NOUN	B
aminotransferase	O	NOUN	I
,	O	PUNCT	O
67	O	NUM	O
U	O	PROPN	B
/	O	SYM	O
L	O	PROPN	B
(	O	PUNCT	O
reference	O	NOUN	O
range	O	NOUN	O
,	O	PUNCT	O
10	O	NUM	O
-	O	SYM	O
37	O	NUM	O
U	O	PROPN	B
/	O	SYM	O
L	O	PROPN	B
);	O	ADJ	B
aspartate	B-Chemical	NOUN	I
aminotransferase	O	NOUN	I
,	O	PUNCT	O
98	O	NUM	O
U	O	NOUN	B
/	O	SYM	O
L	O	PROPN	B
(	O	PUNCT	O
10	O	NUM	O
-	O	SYM	O
40	O	NUM	O
U	O	PROPN	B
/	O	PUNCT	O
L	O	PROPN	B
);	O	ADJ	O
alkaline	O	NOUN	B
phosphatase	O	NOUN	I
,	O	PUNCT	O
513	O	NUM	O
U	O	PROPN	B
/	O	SYM	O
L	O	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
-	O	SYM	O
270	O	NUM	O
U	O	PROPN	B
/	O	SYM	O
L	O	PROPN	B
);	O	ADJ	O
gamma	O	NOUN	B
-	O	PUNCT	O
glutamyltransferase	O	PROPN	B
,	O	PUNCT	O
32	O	NUM	O
U	O	NOUN	B
/	O	SYM	O
L	O	PROPN	B
(	O	PUNCT	O
7	O	NUM	O
-	O	PUNCT	O
49	O	NUM	O
U	O	PROPN	B
/	O	PUNCT	O
L	O	PROPN	B
);	O	ADJ	B
amylase	O	NOUN	I
,	O	PUNCT	O
46	O	NUM	O
U	O	PROPN	B
/	O	SYM	O
L	O	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
-	O	SYM	O
220	O	NUM	O
U	O	PROPN	B
/	O	SYM	O
L	O	PROPN	B
);	O	ADJ	O
total	O	ADJ	O
bilirubin	B-Chemical	NOUN	B
,	O	PUNCT	O
20	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
dL	O	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
-	O	SYM	O
1	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
dL	O	NOUN	B
);	O	ADJ	O
direct	O	ADJ	O
bilirubin	B-Chemical	NOUN	B
,	O	PUNCT	O
14	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
dL	O	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
-	O	SYM	O
0	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
dL	O	NOUN	B
);	O	NOUN	B
and	O	CCONJ	O
albumin	O	NOUN	B
,	O	PUNCT	O
4	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
dL	O	NOUN	B
(	O	PUNCT	O
3	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
-	O	SYM	O
5	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
dL	O	NOUN	B
).	O	PUNCT	O
No	O	DET	O
toxin	O	NOUN	B
,	O	PUNCT	O
alcohol	B-Chemical	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
other	O	ADJ	O
drugs	O	NOUN	B
were	O	AUX	O
reported	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
had	O	AUX	O
suffered	O	VERB	O
a	O	DET	O
previous	O	ADJ	O
episode	O	NOUN	B
of	O	ADP	O
"	O	PUNCT	O
acute	O	ADJ	B
hepatitis	B-Disease	NOUN	I
of	O	ADP	O
unknown	O	ADJ	O
origin	O	NOUN	B
,"	O	PUNCT	O
that	O	PRON	O
occurred	O	VERB	O
after	O	ADP	O
telithromycin	B-Chemical	NOUN	B
usage	O	NOUN	B
.	O	PUNCT	O


Both	O	DET	O
incidents	O	NOUN	B
occurred	O	VERB	O
within	O	ADP	O
a	O	DET	O
year	O	NOUN	B
.	O	PUNCT	O


DISCUSSION	O	NOUN	O
:	O	PUNCT	O
Telithromycin	B-Chemical	NOUN	B
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
of	O	ADP	O
the	O	DET	O
ketolide	O	NOUN	B
antibacterials	O	NOUN	I
to	O	PART	O
receive	O	VERB	O
US	O	PROPN	B
Food	O	PROPN	B
and	O	CCONJ	I
Drug	O	PROPN	I
Administration	O	PROPN	I
approval	O	NOUN	O
for	O	ADP	O
clinical	O	ADJ	B
use	O	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
has	O	AUX	O
been	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
infrequent	O	ADJ	B
and	O	CCONJ	O
usually	O	ADV	O
reversible	O	ADJ	O
severe	O	ADJ	O
hepatic	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
.	O	PUNCT	O


Based	O	VERB	O
on	O	ADP	O
a	O	DET	O
score	O	NOUN	B
of	O	ADP	O
8	O	NUM	O
on	O	ADP	O
the	O	DET	O
Naranjo	O	NOUN	B
adverse	B-Disease	ADJ	I
drug	I-Disease	NOUN	I
reaction	I-Disease	NOUN	I
probability	O	NOUN	I
scale	O	NOUN	I
,	O	PUNCT	O
telithromycin	B-Chemical	NOUN	B
was	O	AUX	O
the	O	DET	O
probable	O	ADJ	O
cause	O	NOUN	O
of	O	ADP	O
acute	O	ADJ	B
hepatitis	B-Disease	NOUN	I
in	O	ADP	O
this	O	DET	O
patient	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
pathological	O	ADJ	B
findings	O	NOUN	B
suggested	O	VERB	O
drug	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
toxic	B-Disease	ADJ	B
hepatitis	I-Disease	NOUN	I
.	O	PUNCT	O


Recurrence	O	NOUN	B
of	O	ADP	O
hepatitis	B-Disease	NOUN	B
attack	O	NOUN	I
might	O	AUX	O
have	O	AUX	O
been	O	AUX	O
avoided	O	VERB	O
if	O	SCONJ	O
the	O	DET	O
initial	O	ADJ	B
incident	O	NOUN	B
had	O	AUX	O
been	O	AUX	O
communicated	O	VERB	O
to	O	ADP	O
the	O	DET	O
attending	O	VERB	B
physician	O	NOUN	B
who	O	PRON	O
prescribed	O	VERB	B
telithromycin	B-Chemical	NOUN	B
the	O	DET	O
second	O	ADJ	O
time	O	NOUN	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
Here	O	ADV	O
we	O	PRON	O
report	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
acute	O	ADJ	B
hepatitis	B-Disease	NOUN	I
probably	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
telithromycin	B-Chemical	NOUN	B


Spironolactone	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
renal	B-Disease	ADJ	B
insufficiency	I-Disease	NOUN	I
and	O	CCONJ	O
hyperkalemia	B-Disease	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
heart	B-Disease	NOUN	B
failure	I-Disease	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
A	O	DET	O
previous	O	ADJ	O
randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
evaluating	O	VERB	B
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
spironolactone	B-Chemical	NOUN	B
in	O	ADP	O
heart	B-Disease	NOUN	B
failure	I-Disease	NOUN	I
patients	O	NOUN	B
reported	O	VERB	O
a	O	DET	O
low	O	ADJ	B
risk	O	NOUN	I
of	O	ADP	O
hyperkalemia	B-Disease	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
%)	O	NOUN	O
and	O	CCONJ	O
renal	B-Disease	ADJ	B
insufficiency	I-Disease	NOUN	I
(	O	PUNCT	O
0	O	NUM	O
%).	O	NOUN	O
Because	O	SCONJ	O
treatments	O	NOUN	B
for	O	ADP	O
heart	B-Disease	NOUN	B
failure	I-Disease	NOUN	I
have	O	AUX	O
changed	O	VERB	B
since	O	SCONJ	O
the	O	DET	O
benefits	O	NOUN	B
of	O	ADP	O
spironolactone	B-Chemical	NOUN	B
were	O	AUX	O
reported	O	VERB	O
,	O	PUNCT	O
the	O	DET	O
prevalence	O	NOUN	B
of	O	ADP	O
these	O	DET	O
complications	O	NOUN	B
may	O	AUX	O
differ	O	VERB	O
in	O	ADP	O
current	O	ADJ	O
clinical	O	ADJ	B
practice	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
therefore	O	ADV	O
sought	O	VERB	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
prevalence	O	NOUN	B
and	O	CCONJ	O
clinical	O	ADJ	B
associations	O	NOUN	B
of	O	ADP	O
hyperkalemia	B-Disease	NOUN	B
and	O	CCONJ	O
renal	B-Disease	ADJ	B
insufficiency	I-Disease	NOUN	I
in	O	ADP	O
heart	B-Disease	NOUN	B
failure	I-Disease	NOUN	I
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
spironolactone	B-Chemical	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
We	O	PRON	O
performed	O	VERB	O
a	O	DET	O
case	O	NOUN	B
control	O	NOUN	I
study	O	NOUN	I
of	O	ADP	O
heart	B-Disease	NOUN	B
failure	I-Disease	NOUN	I
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
spironolactone	B-Chemical	NOUN	B
in	O	ADP	O
our	O	PRON	O
clinical	O	ADJ	B
practice	O	NOUN	I
.	O	PUNCT	O


Cases	O	NOUN	B
were	O	AUX	O
patients	O	NOUN	B
who	O	PRON	O
developed	O	VERB	O
hyperkalemia	B-Disease	NOUN	B
(	O	PUNCT	O
K	B-Chemical	NOUN	B
(+)>	O	PROPN	B
5	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
mEq	O	NOUN	B
/	O	SYM	O
L	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
renal	B-Disease	ADJ	B
insufficiency	I-Disease	NOUN	I
(	O	PUNCT	O
Cr	B-Chemical	NOUN	B
>	O	X	O
or	O	CCONJ	O
=	O	ADJ	O
2	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
dL	O	NOUN	B
),	O	PUNCT	O
and	O	CCONJ	O
they	O	PRON	O
were	O	AUX	O
compared	O	VERB	B
to	O	PART	O
2	O	NUM	O
randomly	O	ADV	O
selected	O	VERB	O
controls	O	NOUN	B
per	O	ADP	O
case	O	NOUN	B
.	O	PUNCT	O


Clinical	O	ADJ	B
characteristics	O	NOUN	I
,	O	PUNCT	O
medications	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
serum	O	NOUN	B
chemistries	O	NOUN	I
at	O	ADP	O
baseline	O	NOUN	B
and	O	CCONJ	O
follow	O	VERB	B
-	O	PUNCT	O
up	O	ADP	O
time	O	NOUN	B
periods	O	NOUN	I
were	O	AUX	O
compared	O	VERB	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Sixty	O	NUM	B
-	O	PUNCT	O
seven	O	NUM	O
of	O	ADP	O
926	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
7	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
%)	O	NOUN	O
required	O	VERB	O
discontinuation	O	NOUN	B
of	O	ADP	O
spironolactone	B-Chemical	NOUN	B
due	O	ADP	O
to	O	PART	O
hyperkalemia	B-Disease	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
33	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
renal	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
34	O	NUM	O
).	O	PUNCT	O
Patients	O	NOUN	B
who	O	PRON	O
developed	O	VERB	O
hyperkalemia	B-Disease	NOUN	B
were	O	AUX	O
older	O	ADJ	B
and	O	CCONJ	O
more	O	ADV	O
likely	O	ADJ	O
to	O	PART	O
have	O	AUX	O
diabetes	B-Disease	NOUN	B
,	O	PUNCT	O
had	O	AUX	O
higher	O	ADJ	O
baseline	O	NOUN	B
serum	O	NOUN	B
potassium	B-Chemical	NOUN	O
levels	O	NOUN	O
and	O	CCONJ	O
lower	O	ADJ	O
baseline	O	NOUN	B
potassium	B-Chemical	NOUN	B
supplement	O	NOUN	I
doses	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
were	O	AUX	O
more	O	ADV	O
likely	O	ADJ	O
to	O	PART	O
be	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
beta	O	NOUN	B
-	O	PUNCT	O
blockers	O	NOUN	B
than	O	ADP	O
controls	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
134	O	NUM	O
).	O	PUNCT	O
Patients	O	NOUN	B
who	O	PRON	O
developed	O	VERB	O
renal	B-Disease	ADJ	B
insufficiency	I-Disease	NOUN	I
had	O	AUX	O
lower	O	ADJ	O
baseline	O	NOUN	B
body	O	NOUN	B
weight	O	NOUN	I
and	O	CCONJ	O
higher	O	ADJ	O
baseline	O	NOUN	B
serum	O	NOUN	B
creatinine	B-Chemical	NOUN	I
,	O	PUNCT	O
required	O	VERB	O
higher	O	ADJ	O
doses	O	NOUN	B
of	O	ADP	O
loop	O	NOUN	B
diuretics	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
were	O	AUX	O
more	O	ADV	O
likely	O	ADJ	O
to	O	PART	O
be	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
thiazide	B-Chemical	ADJ	B
diuretics	O	NOUN	I
than	O	ADP	O
controls	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
Spironolactone	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hyperkalemia	B-Disease	NOUN	B
and	O	CCONJ	O
renal	B-Disease	ADJ	B
insufficiency	I-Disease	NOUN	I


End-stage	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
disease	I-Disease	NOUN	I
(	O	PUNCT	O
ESRD	B-Disease	NOUN	B
)	O	PUNCT	O
after	O	ADP	O
orthotopic	O	ADJ	B
liver	O	NOUN	I
transplantation	O	NOUN	I
(	O	PUNCT	O
OLTX	O	NOUN	B
)	O	PUNCT	O
using	O	VERB	O
calcineurin	O	NOUN	B
-	O	PUNCT	O
based	O	VERB	B
immunotherapy	O	NOUN	B
:	O	PUNCT	O
risk	O	NOUN	B
of	O	ADP	O
development	O	NOUN	B
and	O	CCONJ	O
treatment	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
calcineurin	O	NOUN	B
inhibitors	O	NOUN	B
cyclosporine	B-Chemical	NOUN	B
and	O	CCONJ	O
tacrolimus	B-Chemical	NOUN	B
are	O	AUX	O
both	O	DET	O
known	O	VERB	O
to	O	PART	O
be	O	AUX	O
nephrotoxic	B-Disease	ADJ	B
.	O	PUNCT	O


Their	O	PRON	O
use	O	NOUN	O
in	O	ADP	O
orthotopic	O	ADJ	B
liver	O	NOUN	I
transplantation	O	NOUN	I
(	O	PUNCT	O
OLTX	O	NOUN	B
)	O	PUNCT	O
has	O	AUX	O
dramatically	O	ADV	O
improved	O	VERB	O
success	O	NOUN	B
rates	O	NOUN	B
.	O	PUNCT	O


Recently	O	ADV	O
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
had	O	AUX	O
an	O	DET	O
increase	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
who	O	PRON	O
are	O	AUX	O
presenting	O	VERB	O
after	O	ADP	O
OLTX	O	NOUN	B
with	O	ADP	O
end-stage	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
disease	I-Disease	NOUN	I
(	O	PUNCT	O
ESRD	B-Disease	NOUN	B
).	O	PUNCT	O
This	O	DET	O
retrospective	O	ADJ	B
study	O	NOUN	I
examines	O	VERB	O
the	O	DET	O
incidence	O	NOUN	B
and	O	CCONJ	O
treatment	O	NOUN	B
of	O	ADP	O
ESRD	B-Disease	NOUN	B
and	O	CCONJ	O
chronic	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
failure	I-Disease	NOUN	I
(	O	PUNCT	O
CRF	B-Disease	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
OLTX	O	NOUN	B
patients	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
Patients	O	NOUN	B
receiving	O	VERB	O
an	O	DET	O
OLTX	O	NOUN	B
only	O	ADV	O
from	O	ADP	O
June	O	PROPN	O
1985	O	NUM	O
through	O	ADP	O
December	O	PROPN	O
of	O	ADP	O
1994	O	NUM	O
who	O	PRON	O
survived	O	VERB	O
6	O	NUM	O
months	O	NOUN	B
postoperatively	O	ADV	B
were	O	AUX	O
studied	O	VERB	O
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
834	O	NUM	O
).	O	PUNCT	O
Our	O	PRON	O
prospectively	O	ADV	O
collected	O	VERB	O
database	O	NOUN	B
was	O	AUX	O
the	O	DET	O
source	O	NOUN	B
of	O	ADP	O
information	O	NOUN	B
.	O	PUNCT	O


Patients	O	NOUN	B
were	O	AUX	O
divided	O	VERB	O
into	O	ADP	O
three	O	NUM	O
groups	O	NOUN	B
:	O	PUNCT	O
Controls	O	NOUN	B
,	O	PUNCT	O
no	O	DET	O
CRF	B-Disease	NOUN	B
or	O	CCONJ	O
ESRD	B-Disease	NOUN	B
,	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
748	O	NUM	O
;	O	PUNCT	O
CRF	B-Disease	NOUN	B
,	O	PUNCT	O
sustained	O	ADJ	B
serum	O	NOUN	B
creatinine	B-Chemical	NOUN	I
>	O	NOUN	O
2	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
dl	O	NOUN	B
,	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
41	O	NUM	O
;	O	PUNCT	O
and	O	CCONJ	O
ESRD	B-Disease	NOUN	B
,	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
45	O	NUM	O
.	O	PUNCT	O


Groups	O	NOUN	B
were	O	AUX	O
compared	O	VERB	B
for	O	ADP	O
preoperative	O	ADJ	B
laboratory	O	NOUN	B
variables	O	NOUN	I
,	O	PUNCT	O
diagnosis	O	NOUN	B
,	O	PUNCT	O
postoperative	O	ADJ	B
variables	O	NOUN	B
,	O	PUNCT	O
survival	O	NOUN	B
,	O	PUNCT	O
type	O	NOUN	O
of	O	ADP	O
ESRD	B-Disease	NOUN	B
therapy	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
survival	O	NOUN	B
from	O	ADP	O
onset	O	NOUN	O
of	O	ADP	O
ESRD	B-Disease	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
At	O	ADP	O
13	O	NUM	O
years	O	NOUN	B
after	O	ADP	O
OLTX	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
severe	O	ADJ	B
renal	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
was	O	AUX	O
18	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
%(	O	NOUN	O
CRF	B-Disease	NOUN	B
8	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
ESRD	B-Disease	NOUN	B
9	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
%).	O	NOUN	O
Compared	O	VERB	O
with	O	ADP	O
control	O	ADJ	B
patients	O	NOUN	B
,	O	PUNCT	O
CRF	B-Disease	NOUN	B
and	O	CCONJ	O
ESRD	B-Disease	NOUN	B
patients	O	NOUN	B
had	O	AUX	O
higher	O	ADJ	O
preoperative	O	ADJ	B
serum	O	NOUN	B
creatinine	B-Chemical	NOUN	I
levels	O	NOUN	I
,	O	PUNCT	O
a	O	DET	O
greater	O	ADJ	O
percentage	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
hepatorenal	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
,	O	PUNCT	O
higher	O	ADJ	O
percentage	O	NOUN	B
requirement	O	NOUN	O
for	O	ADP	O
dialysis	O	NOUN	B
in	O	ADP	O
the	O	DET	O
first	O	ADJ	O
3	O	NUM	O
months	O	NOUN	B
postoperatively	O	ADV	B
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
higher	O	ADJ	O
1	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
serum	O	NOUN	B
creatinine	B-Chemical	NOUN	I
.	O	PUNCT	O


Multivariate	O	ADJ	B
stepwise	O	ADJ	O
logistic	O	ADJ	B
regression	O	NOUN	I
analysis	O	NOUN	I
using	O	VERB	O
preoperative	O	ADJ	B
and	O	CCONJ	O
postoperative	O	ADJ	B
variables	O	NOUN	B
identified	O	VERB	B
that	O	SCONJ	O
an	O	DET	O
increase	O	NOUN	B
of	O	ADP	O
serum	O	NOUN	B
creatinine	B-Chemical	NOUN	I
compared	O	VERB	O
with	O	ADP	O
average	O	NOUN	B
at	O	ADP	O
1	O	NUM	O
year	O	NOUN	B
,	O	PUNCT	O
3	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
4	O	NUM	O
weeks	O	NOUN	B
postoperatively	O	ADV	B
were	O	AUX	O
independent	O	ADJ	O
risk	O	NOUN	B
factors	O	NOUN	I
for	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
CRF	B-Disease	NOUN	B
or	O	CCONJ	O
ESRD	B-Disease	NOUN	B
with	O	ADP	O
odds	O	NOUN	B
ratios	O	NOUN	I
of	O	ADP	O
2	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
,	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Overall	O	ADJ	B
survival	O	NOUN	I
from	O	ADP	O
the	O	DET	O
time	O	NOUN	B
of	O	ADP	O
OLTX	O	NOUN	B
was	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
different	O	ADJ	O
among	O	ADP	O
groups	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
by	O	ADP	O
year	O	NOUN	B
13	O	NUM	O
,	O	PUNCT	O
the	O	DET	O
survival	O	NOUN	B
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
who	O	PRON	O
had	O	AUX	O
ESRD	B-Disease	NOUN	B
was	O	AUX	O
only	O	ADV	O
28	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
%	O	NOUN	O
compared	O	VERB	B
with	O	ADP	O
54	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


Patients	O	NOUN	B
developing	O	VERB	O
ESRD	B-Disease	NOUN	B
had	O	AUX	O
a	O	DET	O
6	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
survival	O	NOUN	B
after	O	ADP	O
onset	O	NOUN	O
of	O	ADP	O
ESRD	B-Disease	NOUN	B
of	O	ADP	O
27	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
receiving	O	VERB	O
hemodialysis	O	NOUN	B
versus	O	CCONJ	O
71	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
developing	O	VERB	O
ESRD	B-Disease	NOUN	B
who	O	PRON	O
subsequently	O	ADV	O
received	O	VERB	O
kidney	O	NOUN	B
transplants	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
Patients	O	NOUN	B
who	O	PRON	O
are	O	AUX	O
more	O	ADJ	O
than	O	ADP	O
10	O	NUM	O
years	O	NOUN	B
post	O	NOUN	B
-	O	PUNCT	O
OLTX	O	NOUN	B
have	O	AUX	O
CRF	B-Disease	NOUN	B
and	O	CCONJ	O
ESRD	B-Disease	NOUN	B
at	O	ADP	O
a	O	DET	O
high	O	ADJ	O
rate	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
development	O	NOUN	B
of	O	ADP	O
ESRD	B-Disease	NOUN	B
decreases	O	VERB	B
survival	O	NOUN	B
,	O	PUNCT	O
particularly	O	ADV	O
in	O	ADP	O
those	O	DET	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
dialysis	O	NOUN	B
only	O	ADV	O
.	O	PUNCT	O


Patients	O	NOUN	B
who	O	PRON	O
develop	O	VERB	O
ESRD	B-Disease	NOUN	B
have	O	AUX	O
a	O	DET	O
higher	O	ADJ	O
preoperative	O	ADJ	B
and	O	CCONJ	O
1	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
serum	O	NOUN	B
creatinine	B-Chemical	NOUN	I
and	O	CCONJ	O
are	O	AUX	O
more	O	ADV	O
likely	O	ADJ	O
to	O	PART	O
have	O	AUX	O
hepatorenal	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
an	O	DET	O
increase	O	NOUN	B
of	O	ADP	O
serum	O	NOUN	B
creatinine	B-Chemical	NOUN	I
at	O	ADP	O
various	O	ADJ	O
times	O	NOUN	O
postoperatively	O	ADV	B
is	O	AUX	O
more	O	ADV	O
predictive	O	ADJ	B
of	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
CRF	B-Disease	NOUN	B
or	O	CCONJ	O
ESRD	B-Disease	NOUN	B


Effect	O	NOUN	B
of	O	ADP	O
intravenous	O	ADJ	B
nimodipine	B-Chemical	NOUN	B
on	O	ADP	O
blood	O	NOUN	B
pressure	O	NOUN	I
and	O	CCONJ	O
outcome	O	NOUN	B
after	O	ADP	O
acute	B-Disease	ADJ	B
stroke	I-Disease	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
AND	O	CCONJ	O
PURPOSE	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
Intravenous	O	ADJ	B
Nimodipine	B-Chemical	NOUN	O
West	O	PROPN	O
European	O	PROPN	B
Stroke	B-Disease	PROPN	I
Trial	O	PROPN	I
(	O	PUNCT	O
INWEST	O	NOUN	B
)	O	PUNCT	O
found	O	VERB	O
a	O	DET	O
correlation	O	NOUN	B
between	O	ADP	O
nimodipine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
reduction	B-Disease	NOUN	B
in	I-Disease	ADP	O
blood	I-Disease	NOUN	B
pressure	I-Disease	NOUN	I
(	O	PUNCT	O
BP	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
an	O	DET	O
unfavorable	O	ADJ	B
outcome	O	NOUN	I
in	O	ADP	O
acute	B-Disease	ADJ	B
stroke	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
sought	O	VERB	O
to	O	PART	O
confirm	O	VERB	O
this	O	DET	O
correlation	O	NOUN	B
with	O	ADP	O
and	O	CCONJ	O
without	O	ADP	O
adjustment	O	NOUN	B
for	O	ADP	O
prognostic	O	ADJ	B
variables	O	NOUN	B
and	O	CCONJ	O
to	O	PART	O
investigate	O	VERB	B
outcome	O	NOUN	B
in	O	ADP	O
subgroups	O	NOUN	B
with	O	ADP	O
increasing	O	VERB	B
levels	O	NOUN	B
of	O	ADP	O
BP	B-Disease	NOUN	B
reduction	I-Disease	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
Patients	O	NOUN	B
with	O	ADP	O
a	O	DET	O
clinical	O	ADJ	B
diagnosis	O	NOUN	I
of	O	ADP	O
ischemic	B-Disease	ADJ	B
stroke	I-Disease	NOUN	I
(	O	PUNCT	O
within	O	ADP	O
24	O	NUM	O
hours	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
consecutively	O	ADV	O
allocated	O	VERB	O
to	O	PART	O
receive	O	VERB	O
placebo	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
100	O	NUM	O
),	O	PUNCT	O
1	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
h	O	NOUN	B
(	O	PUNCT	O
low	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
)	O	PUNCT	O
nimodipine	B-Chemical	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
101	O	NUM	O
),	O	PUNCT	O
or	O	CCONJ	O
2	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
h	O	NOUN	O
(	O	PUNCT	O
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
)	O	PUNCT	O
nimodipine	B-Chemical	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
94	O	NUM	O
).	O	PUNCT	O
The	O	DET	O
correlation	O	NOUN	B
between	O	ADP	O
average	O	ADJ	B
BP	O	NOUN	B
change	O	NOUN	O
during	O	ADP	O
the	O	DET	O
first	O	ADJ	O
2	O	NUM	O
days	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
outcome	O	NOUN	B
at	O	ADP	O
day	O	NOUN	B
21	O	NUM	O
was	O	AUX	O
analyzed	O	VERB	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Two	O	NUM	O
hundred	O	NUM	O
sixty	O	NUM	B
-	O	PUNCT	O
five	O	NUM	B
patients	O	NOUN	B
were	O	AUX	O
included	O	VERB	O
in	O	ADP	O
this	O	DET	O
analysis	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
92	O	NUM	O
,	O	PUNCT	O
93	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
80	O	NUM	O
for	O	ADP	O
placebo	O	NOUN	B
,	O	PUNCT	O
low	O	ADJ	B
dose	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
high	O	ADJ	B
dose	O	NOUN	I
,	O	PUNCT	O
respectively	O	ADV	O
).	O	PUNCT	O
Nimodipine	B-Chemical	NOUN	B
treatment	O	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
a	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
reduction	B-Disease	NOUN	B
in	I-Disease	ADP	O
systolic	I-Disease	NOUN	B
BP	I-Disease	NOUN	I
(	O	PUNCT	O
SBP	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
diastolic	O	ADJ	B
BP	O	NOUN	I
(	O	PUNCT	O
DBP	O	NOUN	B
)	O	PUNCT	O
from	O	ADP	O
baseline	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
placebo	O	NOUN	B
during	O	ADP	O
the	O	DET	O
first	O	ADJ	O
few	O	ADJ	O
days	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
multivariate	O	ADJ	B
analysis	O	NOUN	I
,	O	PUNCT	O
a	O	DET	O
significant	O	ADJ	O
correlation	O	NOUN	B
between	O	ADP	O
DBP	B-Disease	NOUN	B
reduction	I-Disease	NOUN	B
and	O	CCONJ	O
worsening	O	NOUN	B
of	O	ADP	O
the	O	DET	O
neurological	O	ADJ	B
score	O	NOUN	I
was	O	AUX	O
found	O	VERB	O
for	O	ADP	O
the	O	DET	O
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
group	O	NOUN	B
(	O	PUNCT	O
beta	O	NOUN	B
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


49	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


048	O	NUM	O
).	O	PUNCT	B
Patients	O	NOUN	B
with	O	ADP	O
a	O	DET	O
DBP	B-Disease	NOUN	B
reduction	I-Disease	NOUN	B
of	O	ADP	O
>	O	NOUN	O
or	O	CCONJ	O
=	O	ADJ	O
20	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
group	O	NOUN	B
had	O	AUX	O
a	O	DET	O
significantly	O	ADV	O
increased	O	VERB	B
adjusted	O	ADJ	O
OR	O	CCONJ	B
for	O	ADP	O
the	O	DET	O
compound	O	NOUN	B
outcome	O	NOUN	I
variable	O	ADJ	I
death	B-Disease	NOUN	I
or	O	CCONJ	O
dependency	O	NOUN	B
(	O	PUNCT	O
Barthel	O	PROPN	B
Index	O	PROPN	I
<	O	X	O
60	O	NUM	O
)(	O	NOUN	O
n	O	NOUN	O
/	O	SYM	O
N	O	NOUN	B
=	O	ADJ	O
25	O	NUM	O
/	O	SYM	O
26	O	NUM	O
,	O	PUNCT	O
OR	O	CCONJ	B
10	O	NUM	O
.	O	PUNCT	O


16	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
1	O	NUM	O
.	O	PUNCT	O


02	O	NUM	O
to	O	PART	O
101	O	NUM	O
.	O	PUNCT	O


74	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
death	B-Disease	NOUN	B
alone	O	ADV	O
(	O	PUNCT	O
n	O	NOUN	O
/	O	SYM	O
N	O	NOUN	B
=	O	ADJ	O
9	O	NUM	O
/	O	SYM	O
26	O	NUM	O
,	O	PUNCT	O
OR	O	CCONJ	B
4	O	NUM	O
.	O	PUNCT	O


336	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
1	O	NUM	O
.	O	PUNCT	O


131	O	NUM	O
16	O	NUM	O
.	O	PUNCT	O


619	O	NUM	O
)	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
all	O	DET	O
placebo	O	ADJ	B
patients	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
/	O	SYM	O
N	O	NOUN	B
=	O	ADJ	O
62	O	NUM	O
/	O	SYM	O
92	O	NUM	O
and	O	CCONJ	O
14	O	NUM	B
/	O	SYM	O
92	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
).	O	PUNCT	B
There	O	PRON	O
was	O	AUX	O
no	O	DET	O
correlation	O	NOUN	B
between	O	ADP	O
SBP	O	NOUN	B
change	O	NOUN	B
and	O	CCONJ	O
outcome	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	B
:	O	PUNCT	O
DBP	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
SBP	O	NOUN	B
,	O	PUNCT	O
reduction	O	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
neurological	O	ADJ	B
worsening	O	NOUN	I
after	O	ADP	O
the	O	DET	O
intravenous	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
nimodipine	B-Chemical	NOUN	B
after	O	ADP	O
acute	B-Disease	ADJ	B
stroke	I-Disease	NOUN	I
.	O	PUNCT	O


For	O	ADP	O
low	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
nimodipine	B-Chemical	NOUN	B
,	O	PUNCT	O
the	O	DET	O
results	O	NOUN	B
were	O	AUX	O
not	O	PART	O
conclusive	O	ADJ	O
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
do	O	AUX	O
not	O	PART	O
confirm	O	VERB	O
or	O	CCONJ	O
exclude	O	VERB	O
a	O	DET	O
neuroprotective	O	ADJ	B
property	O	NOUN	I
of	O	ADP	O
nimodipine	B-Chemical	NOUN	B


Transient	B-Disease	ADJ	B
neurologic	I-Disease	ADJ	O
symptoms	I-Disease	NOUN	O
after	O	ADP	O
spinal	O	ADJ	B
anesthesia	O	NOUN	I
:	O	PUNCT	O
a	O	DET	O
lower	O	ADJ	O
incidence	O	NOUN	B
with	O	ADP	O
prilocaine	B-Chemical	NOUN	B
and	O	CCONJ	O
bupivacaine	B-Chemical	NOUN	B
than	O	ADP	O
with	O	ADP	O
lidocaine	B-Chemical	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Recent	O	ADJ	O
evidence	O	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
transient	B-Disease	ADJ	B
neurologic	I-Disease	ADJ	O
symptoms	I-Disease	NOUN	O
(	O	PUNCT	O
TNSs	B-Disease	NOUN	B
)	O	PUNCT	O
frequently	O	ADV	O
follow	O	VERB	O
lidocaine	B-Chemical	NOUN	B
spinal	O	ADJ	B
anesthesia	O	NOUN	I
but	O	CCONJ	O
are	O	AUX	O
infrequent	O	ADJ	B
with	O	ADP	O
bupivacaine	B-Chemical	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
identification	O	NOUN	B
of	O	ADP	O
a	O	DET	O
short	O	ADJ	B
-	O	PUNCT	O
acting	O	VERB	B
local	O	ADJ	B
anesthetic	O	NOUN	I
to	O	PART	O
substitute	O	VERB	O
for	O	ADP	O
lidocaine	B-Chemical	NOUN	B
for	O	ADP	O
brief	O	ADJ	B
surgical	O	ADJ	I
procedures	O	NOUN	I
remains	O	VERB	O
an	O	DET	O
important	O	ADJ	O
goal	O	NOUN	B
.	O	PUNCT	O


Prilocaine	B-Chemical	NOUN	B
is	O	AUX	O
an	O	DET	O
amide	O	ADJ	B
local	O	ADJ	O
anesthetic	O	NOUN	O
with	O	ADP	O
a	O	DET	O
duration	O	NOUN	B
of	O	ADP	O
action	O	NOUN	B
similar	O	ADJ	O
to	O	PART	O
that	O	DET	O
of	O	ADP	O
lidocaine	B-Chemical	NOUN	B
.	O	PUNCT	O


Accordingly	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
present	O	ADJ	O
,	O	PUNCT	O
prospective	O	ADJ	B
double	O	ADJ	B
-	O	PUNCT	O
blind	O	ADJ	B
study	O	NOUN	B
compares	O	VERB	O
prilocaine	B-Chemical	NOUN	B
with	O	ADP	O
lidocaine	B-Chemical	NOUN	B
and	O	CCONJ	O
bupivacaine	B-Chemical	NOUN	B
with	O	ADP	O
respect	O	NOUN	O
to	O	PART	O
duration	O	NOUN	B
of	O	ADP	O
action	O	NOUN	B
and	O	CCONJ	O
relative	O	ADJ	B
risk	O	NOUN	I
of	O	ADP	O
TNSs	B-Disease	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
Ninety	O	NUM	O
patients	O	NOUN	B
classified	O	VERB	O
as	O	ADP	O
American	O	PROPN	B
Society	O	PROPN	I
of	O	ADP	I
Anesthesiologists	O	PROPN	I
physical	O	ADJ	O
status	O	NOUN	O
I	O	NUM	O
or	O	CCONJ	O
II	O	NUM	O
who	O	PRON	O
were	O	AUX	O
scheduled	O	VERB	B
for	O	ADP	O
short	O	ADJ	B
gynecologic	O	ADJ	I
procedures	O	NOUN	I
under	O	ADP	O
spinal	O	ADJ	B
anesthesia	O	NOUN	I
were	O	AUX	O
randomly	O	ADV	O
allocated	O	VERB	O
to	O	PART	O
receive	O	VERB	O
2	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
ml	O	NOUN	O
2	O	NUM	O
%	O	NOUN	O
lidocaine	B-Chemical	NOUN	B
in	O	ADP	O
7	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
%	O	NOUN	O
glucose	B-Chemical	NOUN	B
,	O	PUNCT	O
2	O	NUM	O
%	O	NOUN	O
prilocaine	B-Chemical	NOUN	B
in	O	ADP	O
7	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
%	O	NOUN	O
glucose	B-Chemical	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
%	O	NOUN	O
bupivacaine	B-Chemical	NOUN	B
in	O	ADP	O
7	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
%	O	NOUN	O
glucose	B-Chemical	NOUN	B
.	O	PUNCT	O


All	O	DET	O
solutions	O	NOUN	B
were	O	AUX	O
provided	O	VERB	O
in	O	ADP	O
blinded	O	VERB	B
vials	O	NOUN	B
by	O	ADP	O
the	O	DET	O
hospital	O	NOUN	B
pharmacy	O	NOUN	I
.	O	PUNCT	O


Details	O	NOUN	O
of	O	ADP	O
spinal	O	ADJ	B
puncture	O	NOUN	I
,	O	PUNCT	O
extension	O	NOUN	B
and	O	CCONJ	O
regression	O	NOUN	B
of	O	ADP	O
spinal	O	ADJ	B
block	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
times	O	NOUN	O
to	O	PART	O
reach	O	VERB	O
discharge	O	NOUN	B
criteria	O	NOUN	I
were	O	AUX	O
noted	O	VERB	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
evening	O	NOUN	B
of	O	ADP	O
postoperative	O	ADJ	B
day	O	NOUN	O
1	O	NUM	O
,	O	PUNCT	O
patients	O	NOUN	B
were	O	AUX	O
evaluated	O	VERB	B
for	O	ADP	O
TNSs	B-Disease	NOUN	B
by	O	ADP	O
a	O	DET	O
physician	O	NOUN	B
unaware	O	ADJ	O
of	O	ADP	O
the	O	DET	O
drug	O	NOUN	B
administered	O	VERB	I
and	O	CCONJ	O
the	O	DET	O
details	O	NOUN	O
of	O	ADP	O
the	O	DET	O
anesthetic	O	ADJ	B
procedure	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Nine	O	NUM	O
of	O	ADP	O
30	O	NUM	O
patients	O	NOUN	B
receiving	O	VERB	O
lidocaine	B-Chemical	NOUN	B
experienced	O	VERB	O
TNSs	B-Disease	NOUN	B
,	O	PUNCT	O
1	O	NUM	O
of	O	ADP	O
30	O	NUM	O
patients	O	NOUN	B
receiving	O	VERB	O
prilocaine	B-Chemical	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


03	O	NUM	O
)	O	PUNCT	O
had	O	AUX	O
them	O	PRON	O
,	O	PUNCT	O
and	O	CCONJ	O
none	O	NOUN	O
of	O	ADP	O
30	O	NUM	O
patients	O	NOUN	B
receiving	O	VERB	O
bupivacaine	B-Chemical	NOUN	B
had	O	AUX	O
TNSs	B-Disease	NOUN	B
.	O	PUNCT	O


Times	O	NOUN	B
to	O	PART	O
ambulate	O	VERB	B
and	O	CCONJ	O
to	O	PART	O
void	O	VERB	O
were	O	AUX	O
similar	O	ADJ	O
after	O	ADP	O
lidocaine	B-Chemical	NOUN	B
and	O	CCONJ	O
prilocaine	B-Chemical	NOUN	B
(	O	PUNCT	O
150	O	NUM	O
vs	O	ADV	O
.	O	PUNCT	O


165	O	NUM	O
min	O	NOUN	O
and	O	CCONJ	O
238	O	NUM	O
vs	O	CCONJ	O
.	O	PUNCT	O


253	O	NUM	O
min	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
but	O	CCONJ	O
prolonged	O	ADJ	B
after	O	ADP	O
bupivacaine	B-Chemical	NOUN	B
(	O	PUNCT	O
200	O	NUM	O
and	O	CCONJ	O
299	O	NUM	O
min	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
).	O	PUNCT	O
CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
Prilocaine	B-Chemical	NOUN	B
may	O	AUX	O
be	O	AUX	O
preferable	O	ADJ	O
to	O	PART	O
lidocaine	B-Chemical	VERB	B
for	O	ADP	O
short	O	ADJ	B
surgical	O	ADJ	I
procedures	O	NOUN	I
because	O	SCONJ	O
it	O	PRON	O
has	O	AUX	O
a	O	DET	O
similar	O	ADJ	O
duration	O	NOUN	B
of	O	ADP	O
action	O	NOUN	B
but	O	CCONJ	O
a	O	DET	O
lower	O	ADJ	O
incidence	O	NOUN	B
of	O	ADP	O
TNSs	B-Disease	NOUN	B


The	O	DET	O
role	O	NOUN	O
of	O	ADP	O
nicotine	B-Chemical	NOUN	B
in	O	ADP	O
smoking	O	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
cardiovascular	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


Nicotine	B-Chemical	NOUN	B
activates	O	VERB	B
the	O	DET	O
sympathetic	O	ADJ	B
nervous	O	ADJ	I
system	O	NOUN	I
and	O	CCONJ	O
in	O	ADP	O
this	O	DET	O
way	O	NOUN	O
could	O	AUX	O
contribute	O	VERB	O
to	O	PART	O
cardiovascular	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


Animal	O	ADJ	B
studies	O	NOUN	I
and	O	CCONJ	O
mechanistic	O	ADJ	B
studies	O	NOUN	I
indicate	O	VERB	O
that	O	SCONJ	O
nicotine	B-Chemical	NOUN	B
could	O	AUX	O
play	O	VERB	O
a	O	DET	O
role	O	NOUN	O
in	O	ADP	O
accelerating	O	VERB	B
atherosclerosis	B-Disease	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
evidence	O	NOUN	B
among	O	ADP	O
humans	O	NOUN	B
is	O	AUX	O
too	O	ADV	O
inadequate	O	ADJ	B
to	O	PART	O
be	O	AUX	O
definitive	O	ADJ	B
about	O	ADP	O
such	O	DET	O
an	O	DET	O
effect	O	NOUN	B
.	O	PUNCT	O


Almost	O	ADV	O
certainly	O	ADV	O
,	O	PUNCT	O
nicotine	B-Chemical	NOUN	B
via	O	ADP	O
its	O	PRON	O
hemodynamic	O	ADJ	B
effects	O	NOUN	O
contributes	O	VERB	O
to	O	PART	O
acute	O	ADJ	B
cardiovascular	O	ADJ	O
events	O	NOUN	O
,	O	PUNCT	O
although	O	SCONJ	O
current	O	ADJ	O
evidence	O	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
nicotine	B-Chemical	NOUN	B
are	O	AUX	O
much	O	ADV	O
less	O	ADV	O
important	O	ADJ	O
than	O	ADP	O
are	O	AUX	O
the	O	DET	O
prothrombotic	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
cigarette	O	NOUN	B
smoking	O	NOUN	I
or	O	CCONJ	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
carbon	B-Chemical	NOUN	B
monoxide	I-Chemical	NOUN	I
.	O	PUNCT	O


Nicotine	B-Chemical	NOUN	B
does	O	AUX	O
not	O	PART	O
appear	O	VERB	O
to	O	PART	O
enhance	O	VERB	O
thrombosis	B-Disease	NOUN	B
among	O	ADP	O
humans	O	NOUN	B
.	O	PUNCT	O


Clinical	O	ADJ	B
studies	O	NOUN	I
of	O	ADP	O
pipe	O	NOUN	B
smokers	O	NOUN	I
and	O	CCONJ	O
people	O	NOUN	B
using	O	VERB	O
transdermal	O	ADJ	B
nicotine	B-Chemical	NOUN	I
support	O	VERB	O
the	O	DET	O
idea	O	NOUN	O
that	O	SCONJ	O
toxins	O	NOUN	B
other	O	ADJ	O
than	O	ADP	O
nicotine	B-Chemical	NOUN	B
are	O	AUX	O
the	O	DET	O
most	O	ADV	O
important	O	ADJ	O
causes	O	NOUN	O
of	O	ADP	O
acute	O	ADJ	B
cardiovascular	O	ADJ	O
events	O	NOUN	O
.	O	PUNCT	O


Finally	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
dose	O	NOUN	B
response	O	NOUN	I
for	O	ADP	O
cardiovascular	O	ADJ	B
events	O	NOUN	I
of	O	ADP	O
nicotine	B-Chemical	NOUN	B
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
flat	O	ADJ	B
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
if	O	SCONJ	O
nicotine	B-Chemical	NOUN	B


Seizure	B-Disease	NOUN	B
resulting	O	VERB	O
from	O	ADP	O
a	O	DET	O
venlafaxine	B-Chemical	NOUN	B
overdose	B-Disease	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
:	O	PUNCT	O
To	O	PART	O
report	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
venlafaxine	B-Chemical	NOUN	B
overdose	B-Disease	NOUN	B
.	O	PUNCT	O


CASE	O	ADJ	B
SUMMARY	O	NOUN	I
:	O	PUNCT	O
A	O	DET	O
40	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
woman	O	NOUN	B
with	O	ADP	O
major	B-Disease	ADJ	O
depression	I-Disease	NOUN	B
took	O	VERB	O
an	O	DET	O
overdose	B-Disease	NOUN	B
of	O	ADP	O
venlafaxine	B-Chemical	NOUN	B
in	O	ADP	O
an	O	DET	O
apparent	O	ADJ	B
suicide	O	NOUN	B
attempt	O	NOUN	I
.	O	PUNCT	O


After	O	ADP	O
the	O	DET	O
ingestion	O	NOUN	B
of	O	ADP	O
26	O	NUM	O
venlafaxine	B-Chemical	NOUN	B
50	O	NUM	O
-	O	PUNCT	O
mg	O	NOUN	O
tablets	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
patient	O	NOUN	B
experienced	O	VERB	O
a	O	DET	O
witnessed	O	VERB	O
generalized	O	VERB	B
seizure	B-Disease	NOUN	I
.	O	PUNCT	O


She	O	PRON	O
was	O	AUX	O
admitted	O	VERB	B
to	O	ADP	O
the	O	DET	O
medical	O	ADJ	B
intensive	O	ADJ	I
care	O	NOUN	I
unit	O	NOUN	I
,	O	PUNCT	O
venlafaxine	B-Chemical	NOUN	B
was	O	AUX	O
discontinued	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
no	O	DET	O
further	O	ADJ	O
sequelae	O	NOUN	B
were	O	AUX	O
seen	O	VERB	O
.	O	PUNCT	O


DISCUSSION	O	NOUN	O
:	O	PUNCT	O
To	O	PART	O
our	O	PRON	O
knowledge	O	NOUN	B
,	O	PUNCT	O
this	O	DET	O
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
reported	O	VERB	O
case	O	NOUN	B
of	O	ADP	O
venlafaxine	B-Chemical	NOUN	B
overdose	B-Disease	NOUN	B
that	O	PRON	O
resulted	O	VERB	O
in	O	ADP	O
a	O	DET	O
generalized	O	VERB	B
seizure	B-Disease	NOUN	I
.	O	PUNCT	O


Based	O	VERB	O
on	O	ADP	O
nonoverdose	O	ADJ	B
pharmacokinetics	O	NOUN	B
and	O	CCONJ	O
pharmacodynamics	O	NOUN	B
of	O	ADP	O
venlafaxine	B-Chemical	NOUN	B
and	O	CCONJ	O
the	O	DET	O
potential	O	ADJ	B
risks	O	NOUN	B
of	O	ADP	O
available	O	ADJ	O
interventions	O	NOUN	B
,	O	PUNCT	O
no	O	DET	O
emergent	O	ADJ	O
therapy	O	NOUN	B
was	O	AUX	O
instituted	O	VERB	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
venlafaxine	B-Chemical	NOUN	B
overdose	B-Disease	NOUN	B
in	O	ADP	O
our	O	PRON	O
patient	O	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
a	O	DET	O
single	O	ADJ	O
episode	O	NOUN	B
of	O	ADP	O
generalized	O	VERB	B
seizure	B-Disease	NOUN	I


Effect	O	NOUN	B
of	O	ADP	O
nifedipine	B-Chemical	NOUN	B
on	O	ADP	O
renal	O	ADJ	B
function	O	NOUN	I
in	O	ADP	O
liver	O	NOUN	B
transplant	O	NOUN	I
recipients	O	NOUN	B
receiving	O	VERB	O
tacrolimus	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
nifedipine	B-Chemical	NOUN	B
on	O	ADP	O
renal	O	ADJ	B
function	O	NOUN	I
in	O	ADP	O
liver	O	NOUN	B
transplant	O	NOUN	I
recipients	O	NOUN	B
who	O	PRON	O
were	O	AUX	O
receiving	O	VERB	O
tacrolimus	B-Chemical	NOUN	B
was	O	AUX	O
evaluated	O	VERB	B
between	O	ADP	O
January	O	PROPN	O
1992	O	NUM	O
and	O	CCONJ	O
January	O	PROPN	O
1996	O	NUM	O
.	O	PUNCT	O


Two	O	NUM	O
groups	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
receiving	O	VERB	O
tacrolimus	B-Chemical	NOUN	B
were	O	AUX	O
compared	O	VERB	B
over	O	ADP	O
a	O	DET	O
period	O	NOUN	B
of	O	ADP	O
1	O	NUM	O
year	O	NOUN	B
,	O	PUNCT	O
one	O	NUM	O
group	O	NOUN	B
comprising	O	VERB	O
hypertensive	B-Disease	ADJ	B
patients	O	NOUN	B
who	O	PRON	O
were	O	AUX	O
receiving	O	VERB	O
nifedipine	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
other	O	ADJ	O
comprising	O	VERB	O
nonhypertensive	O	ADJ	B
patients	O	NOUN	B
not	O	PART	O
receiving	O	VERB	O
nifedipine	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
time	O	NOUN	B
from	O	ADP	O
transplant	O	NOUN	B
to	O	PART	O
baseline	O	NOUN	B
was	O	AUX	O
similar	O	ADJ	O
in	O	ADP	O
all	O	DET	O
patients	O	NOUN	B
.	O	PUNCT	O


Nifedipine	B-Chemical	NOUN	B
significantly	O	ADV	O
improved	O	VERB	O
kidney	O	NOUN	B
function	O	NOUN	I
as	O	ADP	O
indicated	O	VERB	O
by	O	ADP	O
a	O	DET	O
significant	O	ADJ	B
lowering	O	NOUN	B
of	O	ADP	O
serum	O	NOUN	B
creatinine	B-Chemical	NOUN	I
levels	O	NOUN	I
at	O	ADP	O
6	O	NUM	O
and	O	CCONJ	O
12	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
observed	O	VERB	O
positive	O	ADJ	B
impact	O	NOUN	B
of	O	ADP	O
nifedipine	B-Chemical	NOUN	B
on	O	ADP	O
reducing	O	VERB	B
the	O	DET	O
nephrotoxicity	B-Disease	NOUN	B
associated	O	VERB	B
with	O	ADP	I
tacrolimus	B-Chemical	NOUN	B
in	O	ADP	O
liver	O	NOUN	B
transplant	O	NOUN	I
recipients	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
an	O	DET	O
important	O	ADJ	O
factor	O	NOUN	B
in	O	ADP	O
selecting	O	VERB	O
an	O	DET	O
agent	O	NOUN	B
to	O	PART	O
treat	O	VERB	B
hypertension	B-Disease	NOUN	B


Sinus	B-Disease	NOUN	B
arrest	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
continuous	O	ADJ	B
-	O	PUNCT	O
infusion	O	NOUN	B
cimetidine	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
intermittent	O	ADJ	B
intravenous	O	ADJ	B
infusions	O	NOUN	B
of	O	ADP	O
cimetidine	B-Chemical	NOUN	B
is	O	AUX	O
infrequently	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
bradyarrhythmias	B-Disease	NOUN	B
.	O	PUNCT	O


A	O	DET	O
40	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
man	O	NOUN	B
with	O	ADP	O
leukemia	B-Disease	NOUN	B
and	O	CCONJ	O
no	O	DET	B
history	O	NOUN	I
of	O	ADP	O
cardiac	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
developed	O	VERB	O
recurrent	O	ADJ	B
,	O	PUNCT	O
brief	O	ADJ	B
episodes	O	NOUN	I
of	O	ADP	O
apparent	O	ADJ	B
sinus	B-Disease	NOUN	B
arrest	I-Disease	NOUN	O
while	O	SCONJ	O
receiving	O	VERB	O
continuous	O	ADJ	B
-	O	PUNCT	O
infusion	O	NOUN	B
cimetidine	B-Chemical	NOUN	B
50	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
hour	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
arrhythmias	B-Disease	NOUN	B
were	O	AUX	O
temporally	O	ADV	O
related	O	ADJ	O
to	O	PART	O
cimetidine	B-Chemical	NOUN	B
administration	O	NOUN	B
,	O	PUNCT	O
disappeared	O	VERB	O
after	O	ADP	O
dechallenge	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
did	O	AUX	O
not	O	PART	O
recur	O	VERB	O
during	O	ADP	O
ranitidine	B-Chemical	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
reported	O	VERB	O
case	O	NOUN	B
of	O	ADP	O
sinus	B-Disease	NOUN	B
arrest	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
continuous	O	ADJ	B
-	O	PUNCT	O
infusion	O	NOUN	B
cimetidine	B-Chemical	NOUN	B


Composition	O	NOUN	B
of	O	ADP	O
gall	B-Disease	NOUN	B
bladder	I-Disease	NOUN	I
stones	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
octreotide	B-Chemical	NOUN	B
:	O	PUNCT	O
response	O	NOUN	B
to	O	PART	O
oral	O	ADJ	B
ursodeoxycholic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
.	O	PUNCT	O


Octreotide	B-Chemical	NOUN	B
,	O	PUNCT	O
an	O	DET	O
effective	O	ADJ	B
treatment	O	NOUN	B
for	O	ADP	O
acromegaly	B-Disease	NOUN	B
,	O	PUNCT	O
induces	O	VERB	B
gall	B-Disease	ADJ	B
bladder	I-Disease	NOUN	B
stones	I-Disease	NOUN	I
in	O	ADP	O
13	O	NUM	O
-	O	SYM	O
60	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
.	O	PUNCT	O


Because	O	SCONJ	O
knowledge	O	NOUN	B
of	O	ADP	O
stone	O	NOUN	B
composition	O	NOUN	B
is	O	AUX	O
essential	O	ADJ	O
for	O	ADP	O
studies	O	NOUN	B
of	O	ADP	O
their	O	PRON	O
pathogenesis	O	NOUN	B
,	O	PUNCT	O
treatment	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
prevention	O	NOUN	B
,	O	PUNCT	O
this	O	DET	O
was	O	AUX	O
investigated	O	VERB	B
by	O	ADP	O
direct	O	ADJ	O
and	O	CCONJ	O
indirect	O	ADJ	B
methods	O	NOUN	B
in	O	ADP	O
14	O	NUM	O
octreotide	B-Chemical	NOUN	B
treated	O	VERB	B
acromegalic	B-Disease	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
gall	B-Disease	NOUN	B
stones	I-Disease	NOUN	I
.	O	PUNCT	O


Chemical	O	NOUN	B
analysis	O	NOUN	I
of	O	ADP	O
gall	B-Disease	NOUN	B
stones	I-Disease	NOUN	I
retrieved	O	VERB	O
at	O	ADP	O
cholecystectomy	O	NOUN	B
from	O	ADP	O
two	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
showed	O	VERB	O
that	O	SCONJ	O
they	O	PRON	O
contained	O	VERB	O
71	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
87	O	NUM	O
%	O	NOUN	O
cholesterol	B-Chemical	NOUN	B
by	O	ADP	O
weight	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
remaining	O	VERB	O
12	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
localised	O	ADJ	B
computed	O	ADJ	I
tomography	O	NOUN	I
of	O	ADP	O
the	O	DET	O
gall	O	NOUN	B
bladder	O	NOUN	I
showed	O	VERB	O
that	O	SCONJ	O
eight	O	NUM	O
had	O	AUX	O
stones	O	NOUN	B
with	O	ADP	O
maximum	O	ADJ	B
attenuation	O	NOUN	B
scores	O	NOUN	I
of	O	ADP	O
<	O	X	O
100	O	NUM	O
Hounsfield	O	NOUN	B
units	O	NOUN	I
(	O	PUNCT	O
values	O	NOUN	B
of	O	ADP	O
<	O	X	O
100	O	NUM	O
HU	O	NOUN	B
predict	O	VERB	O
cholesterol	B-Chemical	NOUN	B
rich	O	ADJ	O
,	O	PUNCT	O
dissolvable	O	ADJ	B
stones	O	NOUN	B
).	O	PUNCT	O
Gall	O	NOUN	B
bladder	O	NOUN	I
bile	O	NOUN	I
was	O	AUX	O
obtained	O	VERB	O
by	O	ADP	O
ultrasound	O	NOUN	B
guided	O	VERB	I
,	O	PUNCT	O
fine	O	ADJ	O
needle	O	NOUN	B
puncture	O	NOUN	I
from	O	ADP	O
six	O	NUM	O
patients	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
six	O	NUM	O
patients	O	NOUN	B
had	O	AUX	O
supersaturated	O	ADJ	B
bile	O	NOUN	I
(	O	PUNCT	O
mean	O	NOUN	O
(	O	PUNCT	O
SEM	O	NOUN	B
)	O	PUNCT	O
cholesterol	B-Chemical	NOUN	B
saturation	O	NOUN	I
index	O	NOUN	I
of	O	ADP	O
1	O	NUM	O
.	O	PUNCT	O


19	O	NUM	O
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


08	O	NUM	O
)(	O	NOUN	O
range	O	NOUN	O
1	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
-	O	SYM	O
1	O	NUM	O
.	O	PUNCT	O


53	O	NUM	O
))	O	PUNCT	O
and	O	CCONJ	O
all	O	DET	O
had	O	AUX	O
abnormally	O	ADV	B
rapid	O	ADJ	O
cholesterol	B-Chemical	NOUN	B
microcrystal	O	ADJ	B
nucleation	O	NOUN	I
times	O	NOUN	I
(<	O	VERB	O
4	O	NUM	O
days	O	NOUN	B
(	O	PUNCT	O
range	O	NOUN	O
1	O	NUM	O
-	O	SYM	O
4	O	NUM	O
)),	O	PUNCT	O
whilst	O	SCONJ	O
in	O	ADP	O
four	O	NUM	O
,	O	PUNCT	O
the	O	DET	O
bile	O	NOUN	B
contained	O	VERB	O
cholesterol	B-Chemical	NOUN	B
microcrystals	O	NOUN	O
immediately	O	ADV	O
after	O	ADP	O
sampling	O	NOUN	B
.	O	PUNCT	O


Of	O	ADP	O
the	O	DET	O
12	O	NUM	O
patients	O	NOUN	B
considered	O	VERB	O
for	O	ADP	O
oral	O	ADJ	B
ursodeoxycholic	B-Chemical	ADJ	I
acid	I-Chemical	NOUN	I
(	O	PUNCT	O
UDCA	B-Chemical	NOUN	B
)	O	PUNCT	O
treatment	O	NOUN	B
,	O	PUNCT	O
two	O	NUM	O
had	O	AUX	O
a	O	DET	O
blocked	O	VERB	B
cystic	O	ADJ	B
duct	O	NOUN	I
and	O	CCONJ	O
were	O	AUX	O
not	O	PART	O
started	O	VERB	O
on	O	ADP	O
UDCA	B-Chemical	NOUN	B
while	O	SCONJ	O
one	O	NUM	O
was	O	AUX	O
lost	O	VERB	B
to	O	PART	O
follow	O	VERB	O
up	O	ADP	O
.	O	PUNCT	O


After	O	ADP	O
one	O	NUM	O
year	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
,	O	PUNCT	O
five	O	NUM	O
of	O	ADP	O
the	O	DET	O
remaining	O	VERB	O
nine	O	NUM	O
patients	O	NOUN	B
showed	O	VERB	O
either	O	CCONJ	O
partial	O	ADJ	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
3	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
complete	O	ADJ	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
2	O	NUM	O
)	O	PUNCT	O
gall	B-Disease	NOUN	B
stone	I-Disease	NOUN	B
dissolution	O	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
their	O	PRON	O
stones	O	NOUN	B
were	O	AUX	O
cholesterol	B-Chemical	NOUN	B
rich	O	ADJ	O
.	O	PUNCT	O


This	O	DET	O
corresponds	O	VERB	O
,	O	PUNCT	O
by	O	ADP	O
actuarial	O	ADJ	B
(	O	PUNCT	O
life	O	NOUN	B
table	O	NOUN	I
)	O	PUNCT	O
analysis	O	NOUN	B
,	O	PUNCT	O
to	O	PART	O
a	O	DET	O
combined	O	ADJ	O
gall	B-Disease	NOUN	O
stone	I-Disease	NOUN	B
dissolution	O	NOUN	B
rate	O	NOUN	B
of	O	ADP	O
58	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
(	O	PUNCT	O
15	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
%).	O	NOUN	B
In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
octreotide	B-Chemical	NOUN	B
induced	O	VERB	B
gall	B-Disease	NOUN	B
stones	I-Disease	NOUN	I
are	O	AUX	O
generally	O	ADV	O
small	O	ADJ	O
,	O	PUNCT	O
multiple	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
cholesterol	B-Chemical	NOUN	B
rich	O	ADJ	O
although	O	SCONJ	O
,	O	PUNCT	O
in	O	ADP	O
common	O	ADJ	O
with	O	ADP	O
spontaneous	O	ADJ	B
gall	B-Disease	NOUN	O
stone	I-Disease	NOUN	O
disease	I-Disease	NOUN	O
,	O	PUNCT	O
at	O	ADP	O
presentation	O	NOUN	B
some	O	DET	O
patients	O	NOUN	B
will	O	AUX	O
have	O	AUX	O
a	O	DET	O
blocked	O	VERB	B
cystic	O	ADJ	B
duct	O	NOUN	I
and	O	CCONJ	O
some	O	DET	O
gall	B-Disease	NOUN	B
stones	I-Disease	NOUN	I
containing	O	VERB	O
calcium	B-Chemical	NOUN	B


Cardiovascular	B-Disease	ADJ	B
complications	I-Disease	NOUN	B
associated	O	VERB	B
with	O	ADP	I
terbutaline	B-Chemical	NOUN	B
treatment	O	NOUN	B
for	O	ADP	O
preterm	B-Disease	NOUN	B
labor	I-Disease	NOUN	I
.	O	PUNCT	O


Severe	O	ADJ	B
cardiovascular	B-Disease	ADJ	B
complications	I-Disease	NOUN	B
occurred	O	VERB	O
in	O	ADP	O
eight	O	NUM	O
of	O	ADP	O
160	O	NUM	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
terbutaline	B-Chemical	NOUN	B
for	O	ADP	O
preterm	B-Disease	NOUN	B
labor	I-Disease	NOUN	I


Neurologic	O	ADJ	B
effects	O	NOUN	O
of	O	ADP	O
subarachnoid	O	ADJ	B
administration	O	NOUN	B
of	O	ADP	O
2-chloroprocaine-CE	B-Chemical	ADJ	B
,	O	PUNCT	O
bupivacaine	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
low	O	ADJ	B
pH	O	NOUN	B
normal	O	ADJ	O
saline	O	NOUN	B
in	O	ADP	O
dogs	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
neurologic	O	ADJ	B
consequences	O	NOUN	B
of	O	ADP	O
deliberate	O	ADJ	B
subarachnoid	O	ADJ	B
injection	O	NOUN	B
of	O	ADP	O
large	O	ADJ	O
volumes	O	NOUN	B
of	O	ADP	O
2-chloroprocaine-CE	B-Chemical	NUM	O
in	O	ADP	O
experimental	O	ADJ	B
animals	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
possible	O	ADJ	O
role	O	NOUN	O
of	O	ADP	O
low	O	ADJ	B
pH	O	NOUN	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
total	O	ADJ	B
volume	O	NOUN	I
as	O	ADP	O
potential	O	ADJ	O
factors	O	NOUN	B
in	O	ADP	O
causing	O	VERB	O
neurotoxicity	B-Disease	NOUN	B
was	O	AUX	O
evaluated	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
65	O	NUM	O
dogs	O	NOUN	B
in	O	ADP	O
the	O	DET	O
study	O	NOUN	B
received	O	VERB	O
injections	O	NOUN	B
in	O	ADP	O
the	O	DET	O
subarachnoid	O	ADJ	B
space	O	NOUN	O
as	O	ADP	O
follows	O	VERB	O
:	O	PUNCT	O
6	O	NUM	O
to	O	PART	O
8	O	NUM	O
ml	O	NOUN	O
of	O	ADP	O
bupivacaine	B-Chemical	NOUN	B
(	O	PUNCT	O
N	O	NOUN	O
=	O	ADJ	O
15	O	NUM	O
),	O	PUNCT	O
2-chloroprocaine-CE	B-Chemical	NUM	O
(	O	PUNCT	O
N	O	NOUN	O
=	O	ADJ	O
20	O	NUM	O
),	O	PUNCT	O
low	O	ADJ	B
pH	O	NOUN	B
normal	O	ADJ	O
saline	O	NOUN	O
(	O	PUNCT	O
pH	O	NOUN	B
3	O	NUM	I
.	O	PUNCT	O


0	O	NUM	O
)(	O	NOUN	O
N	O	NOUN	O
=	O	ADJ	O
20	O	NUM	O
),	O	PUNCT	O
or	O	CCONJ	O
normal	O	ADJ	B
saline	O	NOUN	I
(	O	PUNCT	O
N	O	NOUN	O
=	O	ADJ	O
10	O	NUM	O
).	O	PUNCT	O
Of	O	ADP	O
the	O	DET	O
20	O	NUM	O
animals	O	NOUN	B
that	O	PRON	O
received	O	VERB	O
subarachnoid	O	ADJ	B
injection	O	NOUN	B
of	O	ADP	O
2-chloroprocaine-CE	B-Chemical	NUM	O
seven	O	NUM	O
(	O	PUNCT	O
35	O	NUM	O
%)	O	NOUN	O
developed	O	VERB	O
hind	O	NOUN	B
-	O	PUNCT	O
limb	O	NOUN	B
paralysis	B-Disease	NOUN	B
.	O	PUNCT	O


of	O	ADP	O
the	O	DET	O
animals	O	NOUN	B
that	O	PRON	O
received	O	VERB	O
bupivacaine	B-Chemical	NOUN	B
,	O	PUNCT	O
normal	O	ADJ	B
saline	O	NOUN	I
,	O	PUNCT	O
or	O	CCONJ	O
normal	O	ADJ	B
saline	O	NOUN	I
titrated	O	VERB	B
to	O	PART	O
a	O	DET	O
pH	O	NOUN	B
3	O	NUM	I
.	O	PUNCT	O


0	O	NUM	O
developed	O	VERB	O
hind	O	NOUN	B
-	O	PUNCT	O
limb	O	NOUN	B
paralysis	B-Disease	NOUN	B
.	O	PUNCT	O


Of	O	ADP	O
the	O	DET	O
15	O	NUM	O
spinal	O	ADJ	B
cords	O	NOUN	I
of	O	ADP	O
the	O	DET	O
animals	O	NOUN	B
that	O	PRON	O
received	O	VERB	O
2-chloroprocaine-CE	B-Chemical	NUM	O
,	O	PUNCT	O
13	O	NUM	O
showed	O	VERB	O
subpial	B-Disease	ADJ	B
necrosis	I-Disease	NOUN	I
;	O	PUNCT	O
the	O	DET	O
nerve	O	NOUN	B
roots	O	NOUN	B
and	O	CCONJ	O
subarachnoid	O	ADJ	B
vessels	O	NOUN	I
were	O	AUX	O
normal	O	ADJ	O
.	O	PUNCT	O


The	O	DET	O
spinal	O	ADJ	B
cords	O	NOUN	I
of	O	ADP	O
the	O	DET	O
animals	O	NOUN	B
that	O	PRON	O
received	O	VERB	O
bupivacaine	B-Chemical	NOUN	B


Early	O	ADJ	B
adjuvant	O	ADJ	O
adriamycin	B-Chemical	NOUN	B
in	O	ADP	O
superficial	O	ADJ	B
bladder	B-Disease	NOUN	I
carcinoma	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
multicenter	O	NOUN	B
study	O	NOUN	I
was	O	AUX	O
performed	O	VERB	O
in	O	ADP	O
110	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
superficial	O	ADJ	B
transitional	O	ADJ	I
cell	O	NOUN	I
carcinoma	B-Disease	NOUN	I
of	I-Disease	ADP	O
the	I-Disease	DET	O
bladder	I-Disease	NOUN	B
.	O	PUNCT	O


Adriamycin	B-Chemical	NOUN	B
(	O	PUNCT	O
50	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
50	O	NUM	O
ml	O	NOUN	O
)	O	PUNCT	O
was	O	AUX	O
administered	O	VERB	B
intravesically	O	ADV	B
within	O	ADP	O
24	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
transurethral	O	ADJ	B
resection	O	NOUN	I
of	O	ADP	O
TA	O	NOUN	B
-	O	PUNCT	O
T1	O	NOUN	B
(	O	PUNCT	O
O	O	NOUN	B
-	O	PUNCT	O
A	O	PROPN	B
)	O	PUNCT	O
bladder	B-Disease	NOUN	B
tumors	I-Disease	NOUN	I
.	O	PUNCT	O


Instillation	O	NOUN	B
was	O	AUX	O
repeated	O	VERB	O
twice	O	ADV	O
during	O	ADP	O
the	O	DET	O
first	O	ADJ	O
week	O	NOUN	B
,	O	PUNCT	O
then	O	ADV	O
weekly	O	ADJ	B
during	O	ADP	O
the	O	DET	O
first	O	ADJ	O
month	O	NOUN	B
and	O	CCONJ	O
afterwards	O	ADV	B
monthly	O	ADV	I
for	O	ADP	O
1	O	NUM	O
year	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
tolerance	O	NOUN	B
was	O	AUX	O
evaluated	O	VERB	B
in	O	ADP	O
these	O	DET	O
110	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
29	O	NUM	O
patients	O	NOUN	B
presented	O	VERB	O
with	O	ADP	O
local	O	ADJ	B
side	O	NOUN	B
-	O	PUNCT	O
effects	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
24	O	NUM	O
of	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
chemical	O	NOUN	B
cystitis	B-Disease	NOUN	I
was	O	AUX	O
severe	O	ADJ	B
enough	O	ADJ	O
for	O	ADP	O
them	O	PRON	O
to	O	PART	O
drop	O	VERB	B
out	O	ADP	O
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


No	O	DET	O
systemic	O	ADJ	B
side	O	NOUN	B
-	O	PUNCT	O
effects	O	NOUN	B
were	O	AUX	O
observed	O	VERB	B
.	O	PUNCT	O


Recurrence	O	NOUN	B
was	O	AUX	O
studied	O	VERB	O
in	O	ADP	O
82	O	NUM	O
evaluable	O	ADJ	O
patients	O	NOUN	B
after	O	ADP	O
1	O	NUM	O
year	O	NOUN	B
of	O	ADP	O
follow	O	NOUN	B
-	O	PUNCT	O
up	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
72	O	NUM	O
patients	O	NOUN	B
followed	O	VERB	O
for	O	ADP	O
2	O	NUM	O
-	O	SYM	O
3	O	NUM	O
years	O	NOUN	B
(	O	PUNCT	O
mean	O	NOUN	O
32	O	NUM	O
months	O	NOUN	B
).	O	PUNCT	O
Of	O	ADP	O
the	O	DET	O
82	O	NUM	O
patients	O	NOUN	B
studied	O	VERB	O
after	O	ADP	O
1	O	NUM	O
year	O	NOUN	B
,	O	PUNCT	O
23	O	NUM	O
had	O	AUX	O
primary	O	ADJ	B
and	O	CCONJ	O
59	O	NUM	O
recurrent	O	ADJ	B
disease	O	NOUN	I
.	O	PUNCT	O


Of	O	ADP	O
the	O	DET	O
82	O	NUM	O
evaluable	O	ADJ	O
patients	O	NOUN	B
,	O	PUNCT	O
50	O	NUM	O
did	O	AUX	O
not	O	PART	O
show	O	VERB	O
any	O	DET	O
recurrence	O	NOUN	B
after	O	ADP	O
1	O	NUM	O
year	O	NOUN	B
(	O	PUNCT	O
61	O	NUM	O
%),	O	ADJ	O
while	O	SCONJ	O
32	O	NUM	O
presented	O	VERB	O
with	O	ADP	O
one	O	NUM	O
or	O	CCONJ	O
more	O	ADJ	O
recurrences	O	NOUN	B
(	O	PUNCT	O
39	O	NUM	O
%).	O	NOUN	O
Of	O	ADP	O
these	O	DET	O
recurrences	O	NOUN	B
,	O	PUNCT	O
27	O	NUM	O
were	O	AUX	O
T1	O	NOUN	B
tumors	B-Disease	NOUN	I
while	O	SCONJ	O
five	O	NUM	O
progressed	O	VERB	O
to	O	ADP	O
more	O	ADV	O
highly	O	ADV	O
invasive	O	ADJ	B
lesions	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
patients	O	NOUN	B
that	O	PRON	O
were	O	AUX	O
free	O	ADJ	B
of	O	ADP	O
recurrence	O	NOUN	B
during	O	ADP	O
the	O	DET	O
first	O	ADJ	O
year	O	NOUN	B
,	O	PUNCT	O
80	O	NUM	O
%	O	NOUN	O
remained	O	VERB	O
tumor	B-Disease	NOUN	B
-	O	PUNCT	O
free	O	ADJ	B
during	O	ADP	O
the	O	DET	O
2	O	NUM	O
-	O	PUNCT	O
to	O	PART	O
3	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
follow	O	NOUN	B
-	O	PUNCT	O
up	O	ADP	O
period	O	NOUN	B
.	O	PUNCT	O


Of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
developing	O	VERB	O
one	O	NUM	O
or	O	CCONJ	O
more	O	ADJ	O
recurrences	O	NOUN	B
during	O	ADP	O
the	O	DET	O
first	O	ADJ	O
year	O	NOUN	B
,	O	PUNCT	O
only	O	ADV	O
50	O	NUM	O
%	O	NOUN	O
presented	O	VERB	O
with	O	ADP	O
further	O	ADJ	O
recurrence	O	NOUN	B
once	O	SCONJ	O
the	O	DET	O
instillations	O	NOUN	B
were	O	AUX	O
stopped	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
beneficial	O	ADJ	O
effect	O	NOUN	B
of	O	ADP	O
Adriamycin	B-Chemical	NOUN	B


Hyperkalemia	B-Disease	NOUN	B
associated	O	VERB	B
with	O	ADP	I
sulindac	B-Chemical	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


Hyperkalemia	B-Disease	NOUN	B
has	O	AUX	O
recently	O	ADV	O
been	O	AUX	O
recognized	O	VERB	O
as	O	ADP	O
a	O	DET	O
complication	O	NOUN	B
of	O	ADP	O
nonsteroidal	O	ADJ	B
antiinflammatory	O	ADJ	I
agents	O	NOUN	I
(	O	PUNCT	O
NSAID	O	NOUN	B
)	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
indomethacin	B-Chemical	NOUN	B
.	O	PUNCT	O


Several	O	ADJ	O
recent	O	ADJ	O
studies	O	NOUN	B
have	O	AUX	O
stressed	O	VERB	B
the	O	DET	O
renal	O	ADJ	B
sparing	O	NOUN	I
features	O	NOUN	B
of	O	ADP	O
sulindac	B-Chemical	NOUN	B
,	O	PUNCT	O
owing	O	VERB	O
to	O	ADP	O
its	O	PRON	O
lack	O	NOUN	B
of	O	ADP	O
interference	O	NOUN	B
with	O	ADP	O
renal	O	ADJ	B
prostacyclin	B-Chemical	NOUN	B
synthesis	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
describe	O	VERB	O
4	O	NUM	O
patients	O	NOUN	B
in	O	ADP	O
whom	O	PRON	O
hyperkalemia	B-Disease	NOUN	B
ranging	O	VERB	O
from	O	ADP	O
6	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
to	O	PART	O
6	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
mEq	O	NOUN	B
/	O	SYM	O
l	O	NOUN	O
developed	O	VERB	O
within	O	ADP	O
3	O	NUM	O
to	O	PART	O
8	O	NUM	O
days	O	NOUN	B
of	O	ADP	O
sulindac	B-Chemical	NOUN	B
administration	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
all	O	DET	O
of	O	ADP	O
them	O	PRON	O
normal	O	ADJ	O
serum	O	NOUN	B
potassium	B-Chemical	NOUN	O
levels	O	NOUN	O
reached	O	VERB	O
within	O	ADP	O
2	O	NUM	O
to	O	PART	O
4	O	NUM	O
days	O	NOUN	B
of	O	ADP	O
stopping	O	VERB	B
sulindac	B-Chemical	NOUN	B
.	O	PUNCT	O


As	O	ADP	O
no	O	DET	O
other	O	ADJ	O
medications	O	NOUN	B
known	O	VERB	O
to	O	PART	O
effect	O	VERB	B
serum	O	NOUN	B
potassium	B-Chemical	NOUN	O
had	O	AUX	O
been	O	AUX	O
given	O	VERB	O
concomitantly	O	ADV	O
,	O	PUNCT	O
this	O	DET	O
course	O	NOUN	B
of	O	ADP	O
events	O	NOUN	B
is	O	AUX	O
suggestive	O	ADJ	O
of	O	ADP	O
a	O	DET	O
cause	O	NOUN	B
-	O	PUNCT	O
and	O	CCONJ	O
-	O	PUNCT	O
effect	O	NOUN	B
relationship	O	NOUN	B
between	O	ADP	O
sulindac	B-Chemical	NOUN	B
and	O	CCONJ	O
hyperkalemia	B-Disease	NOUN	B
.	O	PUNCT	O


These	O	DET	O
observations	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
initial	O	ADJ	O
hopes	O	NOUN	O
that	O	SCONJ	O
sulindac	B-Chemical	NOUN	B


Ventricular	B-Disease	ADJ	B
tachyarrhythmias	I-Disease	NOUN	I
during	O	ADP	O
cesarean	O	NOUN	B
section	O	NOUN	I
after	O	ADP	O
ritodrine	B-Chemical	NOUN	B
therapy	O	NOUN	I
:	O	PUNCT	O
interaction	O	NOUN	B
with	O	ADP	O
anesthetics	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
case	O	NOUN	B
illustrates	O	VERB	O
that	O	SCONJ	O
patients	O	NOUN	B
receiving	O	VERB	O
ritodrine	B-Chemical	NOUN	B
for	O	ADP	O
preterm	B-Disease	NOUN	B
labor	I-Disease	NOUN	I
may	O	AUX	O
risk	O	VERB	B
interactions	O	NOUN	I
between	O	ADP	O
the	O	DET	O
residual	O	ADJ	B
betamimetic	O	ADJ	B
effects	O	NOUN	O
of	O	ADP	O
ritodrine	B-Chemical	NOUN	B
and	O	CCONJ	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
anesthetics	O	NOUN	B
during	O	ADP	O
cesarean	O	NOUN	B
section	O	NOUN	I
.	O	PUNCT	O


Such	O	ADJ	O
interactions	O	NOUN	B
may	O	AUX	O
result	O	VERB	O
in	O	ADP	O
serious	O	ADJ	O
cardiovascular	B-Disease	ADJ	B
complications	I-Disease	NOUN	B
even	O	ADV	O
after	O	ADP	O
cessation	O	NOUN	B
of	O	ADP	O
an	O	DET	O
infusion	O	NOUN	B
of	O	ADP	O
ritodrine	B-Chemical	NOUN	B
.	O	PUNCT	O


Preoperative	O	ADJ	B
assessment	O	NOUN	B
should	O	AUX	O
focus	O	VERB	O
on	O	ADP	O
cardiovascular	O	ADJ	B
status	O	NOUN	I
and	O	CCONJ	O
serum	O	NOUN	B
potassium	B-Chemical	NOUN	I
level	O	NOUN	I
.	O	PUNCT	O


Delaying	O	NOUN	B
induction	O	NOUN	B
of	O	ADP	O
anesthesia	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
considered	O	VERB	O
whenever	O	SCONJ	O
possible	O	ADJ	O
.	O	PUNCT	O


Careful	O	ADJ	O
fluid	O	ADJ	B
administration	O	NOUN	B
and	O	CCONJ	O
cautious	O	ADJ	O
use	O	NOUN	O
of	O	ADP	O
titrated	O	VERB	B
doses	O	NOUN	I
of	O	ADP	O
ephedrine	B-Chemical	NOUN	B
are	O	AUX	O
advised	O	VERB	O
.	O	PUNCT	O


After	O	ADP	O
delivery	O	NOUN	B
of	O	ADP	O
the	O	DET	O
infant	O	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
should	O	AUX	O
be	O	AUX	O
no	O	DET	O
contraindication	O	NOUN	O
to	O	PART	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
an	O	DET	O
alpha	O	NOUN	B
-	O	PUNCT	O
adrenergic	O	ADJ	B
vasopressor	O	NOUN	B
such	O	ADJ	O
as	O	ADP	O
phenylephrine	B-Chemical	NOUN	B
to	O	PART	O
treat	O	VERB	B
hypotensive	B-Disease	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
tachycardia	B-Disease	NOUN	B


Immunohistochemical	O	ADJ	B
,	O	PUNCT	O
electron	O	NOUN	B
microscopic	O	ADJ	I
and	O	CCONJ	O
morphometric	O	ADJ	B
studies	O	NOUN	I
of	O	ADP	O
estrogen	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
rat	O	NOUN	B
prolactinomas	B-Disease	NOUN	B
after	O	ADP	O
bromocriptine	B-Chemical	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
clarify	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
bromocriptine	B-Chemical	NOUN	B
on	O	ADP	O
prolactinoma	B-Disease	NOUN	B
cells	O	NOUN	I
in	O	X	B
vivo	O	X	I
,	O	PUNCT	O
immunohistochemical	O	ADJ	B
,	O	PUNCT	O
ultrastructural	O	ADJ	B
and	O	CCONJ	O
morphometrical	O	ADJ	B
analyses	O	NOUN	I
were	O	AUX	O
applied	O	VERB	O
to	O	PART	O
estrogen	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
rat	O	NOUN	B
prolactinoma	B-Disease	NOUN	B
cells	O	NOUN	I
1	O	NUM	O
h	O	NOUN	O
and	O	CCONJ	O
6	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
injection	O	NOUN	B
of	O	ADP	O
bromocriptine	B-Chemical	NOUN	B
(	O	PUNCT	O
3	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
of	O	ADP	O
body	O	NOUN	B
weight	O	NOUN	I
).	O	PUNCT	O
One	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
treatment	O	NOUN	B
,	O	PUNCT	O
serum	O	NOUN	B
prolactin	O	NOUN	I
levels	O	NOUN	I
decreased	O	VERB	B
markedly	O	ADV	B
.	O	PUNCT	O


Electron	O	NOUN	B
microscopy	O	NOUN	I
disclosed	O	VERB	O
many	O	ADJ	O
secretory	O	ADJ	B
granules	O	NOUN	I
,	O	PUNCT	O
slightly	O	ADV	O
distorted	O	VERB	B
rough	O	ADJ	O
endoplasmic	O	ADJ	O
reticulum	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
partially	O	ADV	O
dilated	O	ADJ	B
Golgi	O	NOUN	B
cisternae	O	NOUN	I
in	O	ADP	O
the	O	DET	O
prolactinoma	B-Disease	NOUN	B
cells	O	NOUN	I
.	O	PUNCT	O


Morphometric	O	ADJ	B
analysis	O	NOUN	I
revealed	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
volume	O	NOUN	B
density	O	NOUN	I
of	O	ADP	O
secretory	O	ADJ	B
granules	O	NOUN	I
increased	O	VERB	B
,	O	PUNCT	O
while	O	SCONJ	O
the	O	DET	O
volume	O	NOUN	B
density	O	NOUN	I
of	O	ADP	O
cytoplasmic	O	ADJ	B
microtubules	O	NOUN	B
decreased	O	VERB	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
lowered	O	ADJ	B
serum	O	NOUN	B
prolactin	O	NOUN	O
levels	O	NOUN	O
in	O	ADP	O
the	O	DET	O
early	O	ADJ	B
phase	O	NOUN	B
of	O	ADP	O
bromocriptine	B-Chemical	NOUN	B
treatment	O	NOUN	B
may	O	AUX	O
result	O	VERB	O
from	O	ADP	O
an	O	DET	O
impaired	O	ADJ	B
secretion	O	NOUN	B
of	O	ADP	O
prolactin	O	NOUN	B
due	O	ADJ	O
to	O	PART	O
decreasing	O	VERB	B
numbers	O	NOUN	O
of	O	ADP	O
cytoplasmic	O	ADJ	B
microtubules	O	NOUN	B
.	O	PUNCT	O


At	O	ADP	O
6	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
injection	O	NOUN	B
,	O	PUNCT	O
serum	O	NOUN	B
prolactin	O	NOUN	I
levels	O	NOUN	I
were	O	AUX	O
still	O	ADV	O
considerably	O	ADV	O
lower	O	ADJ	O
than	O	ADP	O
in	O	ADP	O
controls	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
prolactinoma	B-Disease	NOUN	B
cells	O	NOUN	I
at	O	ADP	O
this	O	DET	O
time	O	NOUN	B
were	O	AUX	O
well	O	ADV	O
granulated	O	ADJ	B
,	O	PUNCT	O
with	O	ADP	O
vesiculated	O	ADJ	B
rough	O	ADJ	I
endoplasmic	O	ADJ	I
reticulum	O	NOUN	I
and	O	CCONJ	O
markedly	O	ADV	O
dilated	O	ADJ	B
Golgi	O	NOUN	B
cisternae	O	NOUN	I
.	O	PUNCT	O


Electron	O	NOUN	B
microscopical	O	ADJ	I
immunohistochemistry	O	NOUN	I
revealed	O	VERB	O
positive	O	ADJ	B
reaction	O	NOUN	O
products	O	NOUN	O
noted	O	VERB	O
on	O	ADP	O
the	O	DET	O
secretory	O	ADJ	B
granules	O	NOUN	I
,	O	PUNCT	O
Golgi	O	NOUN	B
cisternae	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
endoplasmic	O	ADJ	B
reticulum	O	NOUN	I
of	O	ADP	I
the	O	DET	O
untreated	O	ADJ	B
rat	O	NOUN	B
prolactinoma	B-Disease	NOUN	B
cells	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
only	O	ADV	O
secretory	O	ADJ	B
granules	O	NOUN	I
showed	O	VERB	O
the	O	DET	O
positive	O	ADJ	B
reaction	O	NOUN	O
products	O	NOUN	O
for	O	ADP	O
prolactin	O	NOUN	B
6	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
bromocriptine	B-Chemical	NOUN	B
treatment	O	NOUN	B
of	O	ADP	O
the	O	DET	O
adenoma	B-Disease	NOUN	B
cells	O	NOUN	I
.	O	PUNCT	O


An	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
the	O	DET	O
volume	O	NOUN	B
density	O	NOUN	I
of	O	ADP	O
secretory	O	ADJ	B
granules	O	NOUN	I
and	O	CCONJ	O
a	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
the	O	DET	O
volume	O	NOUN	B
densities	O	NOUN	B
of	O	ADP	O
rough	O	ADJ	B
endoplasmic	O	ADJ	I
reticulum	O	NOUN	I
and	O	CCONJ	O
microtubules	O	NOUN	B
was	O	AUX	O
determined	O	VERB	O
by	O	ADP	O
morphometric	O	ADJ	B
analysis	O	NOUN	I
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
bromocriptine	B-Chemical	NOUN	B


On	O	ADP	O
two	O	NUM	O
paradoxical	O	ADJ	B
side	O	NOUN	B
-	O	PUNCT	O
effects	O	NOUN	B
of	O	ADP	O
prednisolone	B-Chemical	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
,	O	PUNCT	O
ribosomal	O	ADJ	B
RNA	O	NOUN	I
biosyntheses	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
mechanism	O	NOUN	B
of	O	ADP	O
action	O	NOUN	B
.	O	PUNCT	O


Liver	B-Disease	NOUN	B
enlargement	I-Disease	NOUN	I
and	O	CCONJ	O
muscle	B-Disease	NOUN	B
wastage	I-Disease	NOUN	I
occurred	O	VERB	O
in	O	ADP	O
Wistar	O	PROPN	B
rats	O	NOUN	I
following	O	VERB	O
the	O	DET	O
subcutaneous	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
prednisolone	B-Chemical	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
liver	O	NOUN	B
both	O	CCONJ	O
the	O	DET	O
content	O	NOUN	B
of	O	ADP	O
RNA	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
biosynthesis	O	NOUN	B
of	O	ADP	O
ribosomal	O	ADJ	B
RNA	O	NOUN	I
increased	O	VERB	B
while	O	SCONJ	O
both	O	CCONJ	O
the	O	DET	O
RNA	O	NOUN	B
content	O	NOUN	B
and	O	CCONJ	O
ribosomal	O	ADJ	B
RNA	O	NOUN	I
biosynthesis	O	NOUN	B
were	O	AUX	O
reduced	O	VERB	B
in	O	ADP	O
the	O	DET	O
gastrocnemius	O	NOUN	B
muscle	O	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
suggested	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
drug	O	NOUN	B
acted	O	VERB	B
in	O	ADP	O
a	O	DET	O
selective	O	ADJ	O
and	O	CCONJ	O
tissue	O	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
manner	O	NOUN	O
to	O	PART	O
enhance	O	VERB	O
ribosomal	O	ADJ	B
RNA	O	NOUN	I
synthesis	O	NOUN	O
in	O	ADP	O
the	O	DET	O
liver	O	NOUN	B
and	O	CCONJ	O
depress	O	VERB	B
such	O	ADJ	O
synthesis	O	NOUN	B
in	O	ADP	O
the	O	DET	O
muscle	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
view	O	NOUN	O
supports	O	VERB	O
the	O	DET	O
contention	O	NOUN	O
that	O	SCONJ	O
the	O	DET	O
liver	O	NOUN	B
and	O	CCONJ	O
muscle	O	NOUN	B
are	O	AUX	O
independent	O	ADJ	O
sites	O	NOUN	B
of	O	ADP	O
prednisolone	B-Chemical	NOUN	B


Possible	O	ADJ	O
intramuscular	O	ADJ	B
midazolam	B-Chemical	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
cardiorespiratory	B-Disease	ADJ	B
arrest	I-Disease	NOUN	I
and	O	CCONJ	O
death	B-Disease	NOUN	B
.	O	PUNCT	O


Midazolam	B-Chemical	NOUN	B
hydrochloride	I-Chemical	NOUN	I
is	O	AUX	O
commonly	O	ADV	O
used	O	VERB	O
for	O	ADP	O
dental	O	NOUN	B
or	O	CCONJ	O
endoscopic	O	ADJ	B
procedures	O	NOUN	I
.	O	PUNCT	O


Although	O	SCONJ	O
generally	O	ADV	O
consisted	O	VERB	O
safe	O	ADJ	O
when	O	SCONJ	O
given	O	VERB	O
intramuscularly	O	ADJ	B
,	O	PUNCT	O
intravenous	O	ADJ	B
administration	O	NOUN	I
is	O	AUX	O
known	O	VERB	O
to	O	PART	O
cause	O	VERB	O
respiratory	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
cardiovascular	I-Disease	ADJ	B
depression	I-Disease	NOUN	I
.	O	PUNCT	O


This	O	DET	O
report	O	NOUN	B
describes	O	VERB	O
the	O	DET	O
first	O	ADJ	O
published	O	VERB	B
case	O	NOUN	I
of	O	ADP	O
cardiorespiratory	B-Disease	ADJ	B
arrest	I-Disease	NOUN	I
and	O	CCONJ	O
death	B-Disease	NOUN	B
associated	O	VERB	B
with	O	ADP	I
intramuscular	O	ADJ	B
administration	O	NOUN	B
of	O	ADP	O
midazolam	B-Chemical	NOUN	B
.	O	PUNCT	O


Information	O	NOUN	B
regarding	O	VERB	O
midazolam	B-Chemical	NOUN	B


Serial	O	ADJ	B
epilepsy	B-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
levodopa/carbidopa	B-Chemical	NOUN	B
administration	O	NOUN	B
in	O	ADP	O
two	O	NUM	O
patients	O	NOUN	B
on	O	ADP	O
hemodialysis	O	NOUN	B
.	O	PUNCT	O


Two	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
similar	O	ADJ	O
clinical	O	ADJ	B
features	O	NOUN	I
are	O	AUX	O
presented	O	VERB	O
:	O	PUNCT	O
both	O	DET	O
patients	O	NOUN	B
had	O	AUX	O
chronic	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
failure	I-Disease	NOUN	I
,	O	PUNCT	O
on	O	ADP	O
hemodialysis	O	NOUN	B
for	O	ADP	O
many	O	ADJ	O
years	O	NOUN	B
but	O	CCONJ	O
recently	O	ADV	O
begun	O	VERB	O
on	O	ADP	O
a	O	DET	O
high	O	ADJ	B
-	O	PUNCT	O
flux	O	NOUN	B
dialyzer	O	NOUN	B
;	O	PUNCT	O
both	O	DET	O
had	O	AUX	O
been	O	AUX	O
receiving	O	VERB	O
a	O	DET	O
carbidopa/levodopa	B-Chemical	NOUN	B
preparation	O	NOUN	B
;	O	PUNCT	O
and	O	CCONJ	O
both	O	DET	O
had	O	AUX	O
the	O	DET	O
onset	O	NOUN	O
of	O	ADP	O
hallucinosis	B-Disease	NOUN	B
and	O	CCONJ	O
recurrent	O	ADJ	B
seizures	B-Disease	NOUN	I
,	O	PUNCT	O
which	O	DET	O
were	O	AUX	O
refractory	O	ADJ	B
to	O	ADP	O
anticonvulsants	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
first	O	ADJ	O
patient	O	NOUN	B
died	O	VERB	B
without	O	ADP	O
a	O	DET	O
diagnosis	O	NOUN	B
;	O	PUNCT	O
the	O	DET	O
second	O	ADJ	O
patient	O	NOUN	B
had	O	AUX	O
a	O	DET	O
dramatic	O	ADJ	O
recovery	O	NOUN	B
following	O	VERB	O
the	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
vitamin	B-Chemical	NOUN	B
B6	I-Chemical	NOUN	I


Effect	O	NOUN	B
of	O	ADP	O
L-alpha-glyceryl-phosphorylcholine	B-Chemical	NOUN	B
on	O	ADP	O
amnesia	B-Disease	NOUN	B
caused	O	VERB	O
by	O	ADP	O
scopolamine	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
was	O	AUX	O
carried	O	VERB	O
out	O	ADP	O
to	O	PART	O
test	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
L-alpha-glycerylphosphorylcholine	B-Chemical	NOUN	B
(	O	PUNCT	O
L-alpha-GFC	B-Chemical	ADJ	B
)	O	PUNCT	O
on	O	ADP	O
memory	B-Disease	NOUN	B
impairment	I-Disease	NOUN	I
induced	O	VERB	B
by	O	ADP	O
scopolamine	B-Chemical	NOUN	B
in	O	ADP	O
man	O	NOUN	B
.	O	PUNCT	O


Thirty	O	NUM	B
-	O	PUNCT	O
two	O	NUM	O
healthy	O	ADJ	B
young	O	ADJ	B
volunteers	O	NOUN	I
were	O	AUX	O
randomly	O	ADV	O
allocated	O	VERB	O
to	O	ADP	O
four	O	NUM	O
different	O	ADJ	O
groups	O	NOUN	B
.	O	PUNCT	O


They	O	PRON	O
were	O	AUX	O
given	O	VERB	O
a	O	DET	O
ten	O	NUM	O
day	O	NOUN	B
pretreatment	O	NOUN	B
with	O	ADP	O
either	O	CCONJ	O
L-alpha-GFC	B-Chemical	ADJ	B
or	O	CCONJ	O
placebo	O	NOUN	B
,	O	PUNCT	O
p	O	NOUN	O
.	O	PUNCT	O


o	O	X	O
.,	O	NOUN	O
and	O	CCONJ	O
on	O	ADP	O
the	O	DET	O
eleventh	O	ADJ	O
day	O	NOUN	B
either	O	CCONJ	O
scopolamine	B-Chemical	NOUN	B
or	O	CCONJ	O
placebo	O	NOUN	B
,	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


m	O	NOUN	O
.	O	PUNCT	O


Before	O	ADP	O
and	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
,	O	PUNCT	O
1	O	NUM	O
,	O	PUNCT	O
2	O	NUM	O
,	O	PUNCT	O
3	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
6	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
injection	O	NOUN	B
the	O	DET	O
subjects	O	NOUN	B
were	O	AUX	O
given	O	VERB	O
attention	O	NOUN	B
and	O	CCONJ	O
mnemonic	O	ADJ	B
tests	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
findings	O	NOUN	B
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
drug	O	NOUN	B
is	O	AUX	O
able	O	ADJ	O
to	O	PART	O
antagonize	O	VERB	B
impairment	B-Disease	NOUN	B
of	I-Disease	ADP	O
attention	I-Disease	NOUN	B
and	I-Disease	CCONJ	O
memory	I-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
scopolamine	B-Chemical	NOUN	B


Seizures	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
the	O	DET	O
cocaine	B-Chemical	NOUN	B
metabolite	O	NOUN	B
benzoylecgonine	B-Chemical	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
half	O	ADJ	B
-	O	PUNCT	O
life	O	NOUN	B
(	O	PUNCT	O
t1	O	NOUN	B
/	O	SYM	O
2	O	NUM	O
)	O	PUNCT	O
of	O	ADP	O
cocaine	B-Chemical	NOUN	B
is	O	AUX	O
relatively	O	ADV	O
short	O	ADJ	O
,	O	PUNCT	O
but	O	CCONJ	O
some	O	DET	O
of	O	ADP	O
the	O	DET	O
consequences	O	NOUN	B
of	O	ADP	O
its	O	PRON	O
use	O	NOUN	O
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
seizures	B-Disease	NOUN	B
and	O	CCONJ	O
strokes	B-Disease	NOUN	B
,	O	PUNCT	O
can	O	AUX	O
occur	O	VERB	O
hours	O	NOUN	O
after	O	ADP	O
exposure	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
led	O	VERB	O
us	O	PRON	O
to	O	PART	O
hypothesize	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
metabolite	O	NOUN	B
of	O	ADP	O
cocaine	B-Chemical	NOUN	B
may	O	AUX	O
be	O	AUX	O
responsible	O	ADJ	O
for	O	ADP	O
some	O	DET	O
of	O	ADP	O
those	O	DET	O
delayed	O	VERB	B
sequelae	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
evaluated	O	VERB	B
the	O	DET	O
potential	O	NOUN	B
of	O	ADP	O
the	O	DET	O
major	O	ADJ	O
metabolite	O	NOUN	B
of	O	ADP	O
cocaine	B-Chemical	NOUN	B
,	O	PUNCT	O
benzoylecgonine	B-Chemical	NOUN	B
(	O	PUNCT	O
BE	B-Chemical	NOUN	B
),	O	PUNCT	O
to	O	PART	O
cause	O	VERB	O
seizures	B-Disease	NOUN	B
.	O	PUNCT	O


Two	O	NUM	O
separate	O	ADJ	O
equimolar	O	ADJ	B
doses	O	NOUN	I
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
and	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
mumol	O	NOUN	O
)	O	PUNCT	O
of	O	ADP	O
either	O	CCONJ	O
cocaine	B-Chemical	NOUN	B
or	O	CCONJ	O
BE	B-Chemical	NOUN	B
were	O	AUX	O
injected	O	VERB	O
ventricularly	O	ADV	B
in	O	ADP	O
unanesthetized	O	ADJ	B
juvenile	O	NOUN	I
rats	O	NOUN	B
.	O	PUNCT	O


Treated	O	ADJ	B
rats	O	NOUN	B
were	O	AUX	O
then	O	ADV	O
evaluated	O	VERB	B
for	O	ADP	O
incidence	O	NOUN	B
,	O	PUNCT	O
latency	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
seizure	B-Disease	NOUN	B
pattern	O	NOUN	O
or	O	CCONJ	O
for	O	ADP	O
locomotor	O	NOUN	B
activity	O	NOUN	I
in	O	ADP	O
animals	O	NOUN	B
without	O	ADP	O
seizures	B-Disease	NOUN	B
.	O	PUNCT	O


BE	B-Chemical	NOUN	B
-	O	PUNCT	O
Induced	O	VERB	B
seizures	B-Disease	NOUN	B
occurred	O	VERB	O
more	O	ADV	O
frequently	O	ADV	B
and	O	CCONJ	O
had	O	AUX	O
significantly	O	ADV	O
longer	O	ADJ	O
latencies	O	NOUN	B
than	O	ADP	O
those	O	DET	O
induced	O	VERB	B
by	O	ADP	O
equimolar	O	ADJ	B
amounts	O	NOUN	I
of	O	ADP	O
cocaine	B-Chemical	NOUN	B
.	O	PUNCT	O


Whereas	O	SCONJ	O
cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
seizures	B-Disease	NOUN	B
were	O	AUX	O
best	O	ADV	O
characterized	O	VERB	B
as	O	ADP	O
brief	O	ADJ	B
,	O	PUNCT	O
generalized	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
tonic	O	ADJ	B
and	O	CCONJ	O
resulted	O	VERB	O
in	O	ADP	O
death	B-Disease	NOUN	B
,	O	PUNCT	O
those	O	DET	O
induced	O	VERB	B
by	O	ADP	O
BE	B-Chemical	NOUN	B
were	O	AUX	O
prolonged	O	ADJ	B
,	O	PUNCT	O
often	O	ADV	O
multiple	O	ADJ	B
and	O	CCONJ	O
mixed	O	ADJ	O
in	O	ADP	O
type	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
rarely	O	ADV	O
resulted	O	VERB	O
in	O	ADP	O
death	B-Disease	NOUN	B
.	O	PUNCT	O


Electrical	O	ADJ	B
recordings	O	NOUN	I
from	O	ADP	O
the	O	DET	O
hippocampus	O	NOUN	B
showed	O	VERB	O
a	O	DET	O
rhythmic	O	ADJ	B
progression	O	NOUN	I
in	O	ADP	O
EEG	O	NOUN	B
frequency	O	NOUN	B
and	O	CCONJ	O
voltage	O	NOUN	B
with	O	ADP	O
clinical	O	ADJ	B
seizure	B-Disease	NOUN	I
expression	O	NOUN	B
.	O	PUNCT	O


BE	B-Chemical	NOUN	B
-	O	PUNCT	O
Injected	O	VERB	B
rats	O	NOUN	B
that	O	PRON	O
did	O	AUX	O
not	O	PART	O
have	O	AUX	O
seizures	B-Disease	NOUN	B
had	O	AUX	O
significantly	O	ADV	O
more	O	ADJ	O
locomotor	O	NOUN	B
activity	O	NOUN	I
than	O	ADP	O
cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
injected	O	VERB	B
animals	O	NOUN	B
without	O	ADP	O
seizures	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
finding	O	NOUN	B
that	O	SCONJ	O
cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
and	O	CCONJ	O
BE	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
seizures	B-Disease	NOUN	B
differ	O	VERB	O
in	O	ADP	O
several	O	ADJ	O
respects	O	NOUN	O
suggests	O	VERB	O
more	O	ADJ	O
than	O	ADP	O
one	O	NUM	O
mechanism	O	NOUN	B
for	O	ADP	O
cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
seizures	B-Disease	NOUN	B
and	O	CCONJ	O
emphasizes	O	VERB	O
the	O	DET	O
importance	O	NOUN	O
of	O	ADP	O
a	O	DET	O
cocaine	B-Chemical	NOUN	B
metabolite	O	NOUN	I
,	O	PUNCT	O
BE	B-Chemical	NOUN	B


Protection	O	NOUN	B
against	O	ADP	O
amphetamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
neurotoxicity	B-Disease	NOUN	B
toward	O	ADP	O
striatal	O	ADJ	B
dopamine	B-Chemical	NOUN	B
neurons	O	NOUN	B
in	O	ADP	O
rodents	O	NOUN	B
by	O	ADP	O
LY274614	B-Chemical	NOUN	B
,	O	PUNCT	O
an	O	DET	O
excitatory	O	ADJ	B
amino	B-Chemical	NOUN	B
acid	I-Chemical	NOUN	I
antagonist	O	NOUN	I
.	O	PUNCT	O


LY274614	B-Chemical	NOUN	B
,	O	PUNCT	O
3SR,4aRS,6SR,8aRS-6-[phosphonomethyl]decahydr	B-Chemical	NOUN	O
oisoquinoline-3-	I-Chemical	NOUN	O
carboxylic	I-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
,	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
described	O	VERB	O
as	O	ADP	O
a	O	DET	O
potent	O	ADJ	O
antagonist	O	NOUN	B
of	O	ADP	O
the	O	DET	O
N-methyl-D-aspartate	B-Chemical	NOUN	B
(	O	PUNCT	O
NMDA	B-Chemical	NOUN	B
)	O	PUNCT	O
subtype	O	NOUN	B
of	O	ADP	O
glutamate	B-Chemical	NOUN	B
receptor	O	NOUN	I
.	O	PUNCT	O


Here	O	ADV	O
its	O	PRON	O
ability	O	NOUN	O
to	O	PART	O
antagonize	O	VERB	B
the	O	DET	O
prolonged	O	ADJ	B
depletion	O	NOUN	B
of	O	ADP	O
dopamine	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
striatum	O	NOUN	B
by	O	ADP	O
amphetamine	B-Chemical	NOUN	B
in	O	ADP	O
iprindole	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
rats	O	NOUN	B
is	O	AUX	O
reported	O	VERB	O
.	O	PUNCT	O


A	O	DET	O
single	O	ADJ	O
18	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
(	O	PUNCT	O
i	O	PRON	O
.	O	PUNCT	O


p	O	X	O
.)	O	NUM	O
dose	O	NOUN	B
of	O	ADP	O
(+/-)-	O	NOUN	O
amphetamine	B-Chemical	NOUN	B
hemisulfate	O	NOUN	B
,	O	PUNCT	O
given	O	VERB	O
to	O	ADP	O
rats	O	NOUN	B
pretreated	O	VERB	B
with	O	ADP	O
iprindole	B-Chemical	NOUN	B
,	O	PUNCT	O
resulted	O	VERB	O
in	O	ADP	O
persistent	O	ADJ	B
depletion	O	NOUN	B
of	O	ADP	O
dopamine	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
striatum	O	NOUN	B
1	O	NUM	I
week	O	NOUN	B
later	O	ADV	O
.	O	PUNCT	O


This	O	DET	O
prolonged	O	ADJ	B
depletion	O	NOUN	B
of	O	ADP	O
dopamine	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
striatum	O	NOUN	B
was	O	AUX	O
antagonized	O	VERB	B
by	O	ADP	O
dizocilpine	B-Chemical	NOUN	B
(	O	PUNCT	O
MK-801	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
non	O	ADJ	B
-	O	PUNCT	O
competitive	O	ADJ	B
antagonist	O	NOUN	B
of	O	ADP	O
NMDA	B-Chemical	NOUN	B
receptors	O	NOUN	I
)	O	PUNCT	O
or	O	CCONJ	O
by	O	ADP	O
LY274614	B-Chemical	NOUN	B
(	O	PUNCT	O
a	O	DET	O
competitive	O	ADJ	B
antagonist	O	NOUN	B
of	O	ADP	O
NMDA	B-Chemical	NOUN	B
receptors	O	NOUN	I
).	O	PUNCT	O
The	O	DET	O
protective	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
LY274614	B-Chemical	NOUN	B
was	O	AUX	O
dose	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
,	O	PUNCT	O
being	O	AUX	O
maximum	O	ADJ	B
at	O	ADP	O
10	O	NUM	O
-	O	SYM	O
40	O	NUM	O
mgkg	O	NOUN	B
(	O	PUNCT	O
i	O	PRON	O
.	O	PUNCT	O


p	O	NOUN	O
.).	O	NOUN	O
A	O	NOUN	O
10	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
dose	O	NOUN	B
of	O	ADP	O
LY274614	B-Chemical	NOUN	B
was	O	AUX	O
effective	O	ADJ	B
in	O	ADP	O
antagonizing	O	VERB	B
the	O	DET	O
depletion	O	NOUN	B
of	O	ADP	O
dopamine	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
striatum	O	NOUN	B
,	O	PUNCT	O
when	O	SCONJ	O
given	O	VERB	O
as	O	ADV	O
long	O	ADV	O
as	O	ADP	O
8	O	NUM	O
hr	O	NOUN	O
prior	O	ADJ	O
to	O	PART	O
amphetamine	B-Chemical	NOUN	B
but	O	CCONJ	O
not	O	PART	O
when	O	SCONJ	O
given	O	VERB	O
24	O	NUM	O
hr	O	NOUN	O
prior	O	ADJ	O
to	O	PART	O
amphetamine	B-Chemical	NOUN	B
.	O	PUNCT	O


Depletion	O	NOUN	B
of	O	ADP	O
dopamine	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
striatum	O	NOUN	B
was	O	AUX	O
also	O	ADV	O
antagonized	O	VERB	B
when	O	SCONJ	O
LY274614	B-Chemical	NOUN	B
was	O	AUX	O
given	O	VERB	O
after	O	ADP	O
the	O	DET	O
injection	O	NOUN	B
of	O	ADP	O
amphetamine	B-Chemical	NOUN	B
;	O	PUNCT	O
LY274614	B-Chemical	NOUN	B
protected	O	VERB	O
when	O	SCONJ	O
given	O	VERB	O
up	O	ADP	O
to	O	PART	O
4	O	NUM	O
hr	O	NOUN	O
after	O	ADP	O
but	O	CCONJ	O
not	O	PART	O
when	O	SCONJ	O
given	O	VERB	O
8	O	NUM	O
or	O	CCONJ	O
24	O	NUM	O
hr	O	NOUN	O
after	O	ADP	O
amphetamine	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
prolonged	O	ADJ	B
depletion	O	NOUN	B
of	O	ADP	O
dopamine	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
striatum	O	NOUN	B
in	O	ADP	O
mice	O	NOUN	B
,	O	PUNCT	O
given	O	VERB	O
multiple	O	ADJ	O
injections	O	NOUN	B
of	O	ADP	O
methamphetamine	B-Chemical	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
also	O	ADV	O
antagonized	O	VERB	B
dose	O	NOUN	B
-	O	PUNCT	O
dependently	O	ADV	B
and	O	CCONJ	O
completely	O	ADV	O
by	O	ADP	O
LY274614	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
data	O	NOUN	B
strengthen	O	VERB	O
the	O	DET	O
evidence	O	NOUN	B
that	O	SCONJ	O
the	O	DET	O
neurotoxic	B-Disease	ADJ	B
effect	O	NOUN	O
of	O	ADP	O
amphetamine	B-Chemical	NOUN	B
and	O	CCONJ	O
related	O	ADJ	O
compounds	O	NOUN	B
toward	O	ADP	O
nigrostriatal	O	ADJ	B
dopamine	B-Chemical	NOUN	B
neurons	O	NOUN	B
involves	O	VERB	O
NMDA	B-Chemical	NOUN	B
receptors	O	NOUN	I
and	O	CCONJ	O
that	O	SCONJ	O
LY274614	B-Chemical	NOUN	B
is	O	AUX	O
an	O	DET	O
NMDA	B-Chemical	NOUN	B


Neonatal	O	ADJ	B
pyridoxine	B-Chemical	NOUN	B
responsive	O	ADJ	O
convulsions	B-Disease	NOUN	B
due	O	ADJ	O
to	O	PART	O
isoniazid	B-Chemical	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
17	O	NUM	O
-	O	PUNCT	O
day	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
infant	O	NOUN	B
on	O	ADP	O
isoniazid	B-Chemical	NOUN	B
therapy	O	NOUN	I
13	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
daily	O	ADV	B
from	O	ADP	O
birth	O	NOUN	B
because	O	SCONJ	O
of	O	ADP	O
maternal	O	ADJ	B
tuberculosis	B-Disease	NOUN	I
was	O	AUX	O
admitted	O	VERB	B
after	O	ADP	O
4	O	NUM	O
days	O	NOUN	B
of	O	ADP	O
clonic	B-Disease	ADJ	B
fits	I-Disease	NOUN	O
.	O	PUNCT	O


No	O	DET	O
underlying	O	VERB	O
infective	O	ADJ	B
or	O	CCONJ	O
biochemical	O	ADJ	B
cause	O	NOUN	B
could	O	AUX	O
be	O	AUX	O
found	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
fits	B-Disease	NOUN	O
ceased	O	VERB	O
within	O	ADP	O
4	O	NUM	O
hours	O	NOUN	B
of	O	ADP	O
administering	O	VERB	B
intramuscular	O	ADJ	B
pyridoxine	B-Chemical	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
an	O	DET	O
aetiology	O	NOUN	B
of	O	ADP	O
pyridoxine	B-Chemical	NOUN	B
deficiency	O	NOUN	I
secondary	O	ADJ	B
to	O	PART	I
isoniazid	B-Chemical	NOUN	B


Reversal	O	ADJ	B
by	O	ADP	O
phenylephrine	B-Chemical	NOUN	B
of	O	ADP	O
the	O	DET	O
beneficial	O	ADJ	O
effects	O	NOUN	B
of	O	ADP	O
intravenous	O	ADJ	B
nitroglycerin	B-Chemical	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
acute	B-Disease	ADJ	B
myocardial	I-Disease	ADJ	I
infarction	I-Disease	NOUN	I
.	O	PUNCT	O


Nitroglycerin	B-Chemical	NOUN	B
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
reduce	O	VERB	B
ST	O	PROPN	B
-	O	PUNCT	O
segment	O	NOUN	B
elevation	O	NOUN	B
during	O	ADP	O
acute	B-Disease	ADJ	B
myocardial	I-Disease	ADJ	I
infarction	I-Disease	NOUN	I
,	O	PUNCT	O
an	O	DET	O
effect	O	NOUN	B
potentiated	O	VERB	B
in	O	ADP	O
the	O	DET	O
dog	O	NOUN	B
by	O	ADP	O
agents	O	NOUN	B
that	O	PRON	O
reverse	O	VERB	B
nitroglycerin	B-Chemical	NOUN	I
-	O	PUNCT	O
induced	O	VERB	B
hypotension	B-Disease	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
study	O	NOUN	B
was	O	AUX	O
designed	O	VERB	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
combined	O	ADJ	B
nitroglycerin	B-Chemical	NOUN	B
and	O	CCONJ	O
phenylephrine	B-Chemical	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


Ten	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
acute	O	ADJ	B
transmural	O	ADJ	I
myocardial	B-Disease	ADJ	I
infarctions	I-Disease	NOUN	I
received	O	VERB	O
intravenous	O	ADJ	B
nitroglycerin	B-Chemical	NOUN	I
,	O	PUNCT	O
sufficient	O	ADJ	O
to	O	PART	O
reduce	O	VERB	B
mean	O	ADJ	O
arterial	O	ADJ	B
pressure	O	NOUN	I
from	O	ADP	O
107	O	NUM	O
+/-	O	CCONJ	O
6	O	NUM	O
to	O	PART	O
85	O	NUM	O
+/-	O	CCONJ	O
6	O	NUM	O
mm	O	NOUN	B
Hg	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
),	O	PUNCT	O
for	O	ADP	O
60	O	NUM	O
minutes	O	NOUN	B
.	O	PUNCT	O


Left	O	ADJ	B
ventricular	O	ADJ	I
filling	O	NOUN	I
pressure	O	NOUN	I
decreased	O	VERB	B
from	O	ADP	O
19	O	NUM	O
+/-	O	CCONJ	O
2	O	NUM	O
to	O	PART	O
11	O	NUM	O
+/-	O	CCONJ	O
2	O	NUM	O
mm	O	NOUN	B
Hg	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
).	O	PUNCT	B
SigmaST	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
sum	O	NOUN	O
of	O	ADP	O
ST	O	ADJ	B
-	O	PUNCT	O
segment	O	NOUN	B
elevations	O	NOUN	B
in	O	ADP	O
16	O	NUM	O
precordial	O	ADJ	B
leads	O	NOUN	O
,	O	PUNCT	O
decreased	O	VERB	B
(	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


02	O	NUM	O
)	O	PUNCT	O
with	O	ADP	O
intravenous	O	ADJ	B
nitroglycerin	B-Chemical	NOUN	I
.	O	PUNCT	O


Subsequent	O	ADJ	O
addition	O	NOUN	O
of	O	ADP	O
phenylephrine	B-Chemical	NOUN	B
infusion	O	NOUN	B
,	O	PUNCT	O
sufficient	O	ADJ	O
to	O	PART	O
re	O	VERB	B
-	O	PUNCT	O
elevate	O	NOUN	B
mean	O	ADJ	O
arterial	O	ADJ	B
pressure	O	NOUN	I
to	O	PART	O
106	O	NUM	O
+/-	O	CCONJ	O
4	O	NUM	O
mm	O	NOUN	B
Hg	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
)	O	PUNCT	O
for	O	ADP	O
30	O	NUM	O
minutes	O	NOUN	B
,	O	PUNCT	O
increased	O	VERB	B
left	O	VERB	B
ventricular	O	ADJ	I
filling	O	NOUN	I
pressure	O	NOUN	I
to	O	ADP	O
17	O	NUM	O
+/-	O	CCONJ	O
2	O	NUM	O
mm	O	NOUN	B
Hg	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
also	O	ADV	O
significantly	O	ADV	O
increased	O	VERB	B
sigmaST	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
).	O	PUNCT	O
Our	O	PRON	O
results	O	NOUN	O
suggest	O	VERB	O
that	O	SCONJ	O
addition	O	NOUN	O
of	O	ADP	O
phenylephrine	B-Chemical	NOUN	B
to	O	ADP	O
nitroglycerin	B-Chemical	NOUN	B
is	O	AUX	O
not	O	PART	O
beneficial	O	ADJ	O
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
acute	B-Disease	ADJ	B
myocardial	I-Disease	ADJ	I
infarction	I-Disease	NOUN	I


Elevation	O	NOUN	B
of	O	ADP	O
ADAM10	O	NOUN	B
,	O	PUNCT	O
ADAM17	O	NOUN	B
,	O	PUNCT	O
MMP	O	NOUN	B
-	O	PUNCT	O
2	O	NUM	B
and	O	CCONJ	O
MMP	O	NOUN	B
-	O	PUNCT	O
9	O	NUM	B
expression	O	NOUN	B
with	O	ADP	O
media	O	NOUN	B
degeneration	O	NOUN	I
features	O	NOUN	B
CaCl2	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
thoracic	B-Disease	ADJ	B
aortic	I-Disease	ADJ	I
aneurysm	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
rat	O	NOUN	B
model	O	NOUN	B
.	O	PUNCT	O


PURPOSE	O	NOUN	B
:	O	PUNCT	O
This	O	DET	O
study	O	NOUN	B
was	O	AUX	O
designed	O	VERB	O
to	O	PART	O
establish	O	VERB	O
a	O	DET	O
rat	O	NOUN	B
model	O	NOUN	B
of	O	ADP	O
thoracic	B-Disease	ADJ	B
aortic	I-Disease	ADJ	I
aneurysm	I-Disease	NOUN	I
(	O	PUNCT	O
TAA	B-Disease	NOUN	B
)	O	PUNCT	O
by	O	ADP	O
calcium	B-Chemical	NOUN	B
chloride	I-Chemical	NOUN	I
(	O	PUNCT	O
CaCl(2)	B-Chemical	NOUN	B
)-	O	ADJ	O
induced	O	VERB	B
arterial	B-Disease	ADJ	B
injury	I-Disease	NOUN	I
and	O	CCONJ	O
to	O	PART	O
explore	O	VERB	O
the	O	DET	O
potential	O	ADJ	O
role	O	NOUN	O
of	O	ADP	O
a	O	DET	O
disintegrin	O	NOUN	B
and	O	CCONJ	I
metalloproteinase	O	NOUN	O
(	O	PUNCT	O
ADAM	O	NOUN	B
),	O	PUNCT	O
matrix	O	NOUN	B
metalloproteinases	O	NOUN	I
(	O	PUNCT	O
MMPs	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
their	O	PRON	O
endogenous	O	ADJ	B
inhibitors	O	NOUN	B
(	O	PUNCT	O
TIMPs	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
TAA	B-Disease	NOUN	B
formation	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
Thoracic	O	ADJ	B
aorta	O	NOUN	I
of	O	ADP	O
male	O	NOUN	B
Sprague	O	PROPN	B
-	O	PUNCT	O
Dawley	O	NOUN	B
rats	O	NOUN	B
was	O	AUX	O
exposed	O	VERB	O
to	O	PART	O
0	O	NUM	O
.	O	PUNCT	O


5M	O	NOUN	B
CaCl(2)	B-Chemical	NOUN	I
or	O	CCONJ	O
normal	O	ADJ	B
saline	O	NOUN	I
(	O	PUNCT	O
NaCl	B-Chemical	NOUN	B
).	O	PUNCT	O
After	O	ADP	O
12weeks	O	NOUN	O
,	O	PUNCT	O
animals	O	NOUN	B
were	O	AUX	O
euthanized	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
CaCl(2)	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
,	O	PUNCT	O
CaCl(2)	B-Chemical	NOUN	B
-	O	PUNCT	O
untreated	O	ADJ	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
12	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
NaCl	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
aortic	O	ADJ	B
segments	O	NOUN	O
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
12	O	NUM	O
)	O	PUNCT	O
were	O	AUX	O
collected	O	VERB	O
for	O	ADP	O
histological	O	ADJ	B
and	O	CCONJ	O
molecular	O	ADJ	B
assessments	O	NOUN	I
.	O	PUNCT	O


MMP	O	NOUN	B
-	O	PUNCT	O
TIMP	O	NOUN	B
and	O	CCONJ	O
ADAM	O	NOUN	B
mRNAs	O	NOUN	B
were	O	AUX	O
semi	O	ADV	B
-	O	PUNCT	O
quantitatively	O	ADV	B
analyzed	O	VERB	B
and	O	CCONJ	O
protein	O	NOUN	B
expressions	O	NOUN	I
were	O	AUX	O
determined	O	VERB	O
by	O	ADP	O
immunohistochemistry	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Despite	O	SCONJ	O
similar	O	ADJ	O
external	O	ADJ	B
diameters	O	NOUN	B
among	O	ADP	O
CaCl(2)	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
,	O	PUNCT	O
non	O	ADJ	B
-	O	PUNCT	O
CaCl(2)	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
and	O	CCONJ	O
NaCl	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
segments	O	NOUN	B
,	O	PUNCT	O
aneurymal	O	ADJ	B
alteration	O	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
6	O	NUM	O
,	O	PUNCT	O
50	O	NUM	O
%),	O	ADJ	O
media	O	NOUN	B
degeneration	O	NOUN	I
with	O	ADP	O
regional	O	ADJ	B
disruption	O	NOUN	B
,	O	PUNCT	O
fragmentation	O	NOUN	B
of	O	ADP	O
elastic	O	ADJ	B
fiber	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
increased	O	VERB	B
collagen	O	NOUN	B
deposition	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
12	O	NUM	O
,	O	PUNCT	O
100	O	NUM	O
%)	O	NOUN	O
were	O	AUX	O
demonstrated	O	VERB	O
in	O	ADP	O
CaCl(2)	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
segments	O	NOUN	B
.	O	PUNCT	O


MMP	O	NOUN	B
-	O	PUNCT	O
2	O	NUM	B
,	O	PUNCT	O
MMP	O	PROPN	B
-	O	PUNCT	O
9	O	NUM	B
,	O	PUNCT	O
ADAM	O	PROPN	B
-	O	PUNCT	O
10	O	NUM	O
and	O	CCONJ	O
ADAM	O	PROPN	B
-	O	PUNCT	O
17	O	NUM	O
mRNA	O	NOUN	B
levels	O	NOUN	O
were	O	AUX	O
increased	O	VERB	B
in	O	ADP	O
CaCl(2)	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
segments	O	NOUN	B
(	O	PUNCT	O
all	O	DET	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
),	O	PUNCT	O
with	O	ADP	O
trends	O	NOUN	B
of	O	ADP	O
elevation	O	NOUN	B
in	O	ADP	O
CaCl(2)	B-Chemical	NOUN	B
-	O	PUNCT	O
untreated	O	ADJ	B
segments	O	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
compared	O	VERB	B
with	O	ADP	O
NaCl	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
segments	O	NOUN	B
.	O	PUNCT	O


Immunohistochemistry	O	NOUN	B
displayed	O	VERB	O
significantly	O	ADV	O
increased	O	VERB	B
expressions	O	NOUN	B
of	O	ADP	O
MMP	O	NOUN	B
-	O	PUNCT	O
2	O	NUM	B
,	O	PUNCT	O
MMP	O	PROPN	B
-	O	PUNCT	O
9	O	NUM	B
,	O	PUNCT	O
ADAM	O	PROPN	B
-	O	PUNCT	O
10	O	NUM	O
and	O	CCONJ	O
ADAM	O	PROPN	B
-	O	PUNCT	O
17	O	NUM	O
(	O	PUNCT	O
all	O	DET	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
intima	O	NOUN	B
and	O	CCONJ	O
media	O	NOUN	B
for	O	ADP	O
CaCl(2)	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
segments	O	NOUN	B
.	O	PUNCT	O


TIMP	O	NOUN	B
mRNA	O	NOUN	B
and	O	CCONJ	O
tissue	O	NOUN	B
levels	O	NOUN	O
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
obviously	O	ADV	O
among	O	ADP	O
the	O	DET	O
three	O	NUM	O
aortic	O	ADJ	B
segments	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	B
:	O	PUNCT	O
This	O	DET	O
study	O	NOUN	B
establishes	O	VERB	O
a	O	DET	O
TAA	B-Disease	NOUN	B
model	O	NOUN	B
by	O	ADP	O
periarterial	O	ADJ	B
CaCl(2)	B-Chemical	NOUN	B


When	O	SCONJ	O
drugs	O	NOUN	B
disappear	O	VERB	O
from	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
:	O	PUNCT	O
elimination	O	NOUN	B
of	O	ADP	O
intravenous	O	ADJ	B
medication	O	NOUN	I
by	O	ADP	O
hemodiafiltration	O	NOUN	B
.	O	PUNCT	O


Twenty	O	NUM	B
-	O	PUNCT	O
three	O	NUM	B
hours	O	NOUN	I
after	O	ADP	O
heart	O	NOUN	B
transplantation	O	NOUN	I
,	O	PUNCT	O
life	O	NOUN	B
-	O	PUNCT	O
threatening	O	VERB	B
acute	O	ADJ	B
right	B-Disease	ADJ	I
heart	I-Disease	NOUN	I
failure	I-Disease	NOUN	I
was	O	AUX	O
diagnosed	O	VERB	B
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
requiring	O	VERB	O
continuous	O	ADJ	O
venovenous	O	ADJ	B
hemodiafiltration	O	NOUN	I
(	O	PUNCT	O
CVVHDF	O	NOUN	B
).	O	PUNCT	O
Increasing	O	VERB	B
doses	O	NOUN	B
of	O	ADP	O
catecholamines	B-Chemical	NOUN	B
,	O	PUNCT	O
sedatives	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
muscle	O	NOUN	B
relaxants	O	NOUN	I
administered	O	VERB	B
through	O	ADP	O
a	O	DET	O
central	O	ADJ	B
venous	O	ADJ	I
catheter	O	NOUN	I
were	O	AUX	O
ineffective	O	ADJ	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
a	O	DET	O
bolus	O	NOUN	B
of	O	ADP	O
epinephrine	B-Chemical	NOUN	B
injected	O	VERB	B
through	O	ADP	O
an	O	DET	O
alternative	O	ADJ	B
catheter	O	NOUN	B
provoked	O	VERB	O
a	O	DET	O
hypertensive	B-Disease	ADJ	B
crisis	O	NOUN	I
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
interference	O	NOUN	B
with	O	ADP	O
the	O	DET	O
central	O	ADJ	B
venous	O	ADJ	I
infusion	O	NOUN	I
by	O	ADP	O
the	O	DET	O
dialysis	O	NOUN	B
catheter	O	NOUN	I
was	O	AUX	O
suspected	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
catheters	O	NOUN	B
were	O	AUX	O
changed	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
hemodynamics	O	NOUN	B
stabilized	O	VERB	B
at	O	ADP	O
lower	O	ADJ	O
catecholamine	B-Chemical	NOUN	B


Long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
glutamate	B-Chemical	NOUN	B
supplementation	O	NOUN	B
failed	O	VERB	B
to	O	PART	O
protect	O	VERB	O
against	O	ADP	O
peripheral	B-Disease	ADJ	B
neurotoxicity	I-Disease	NOUN	B
of	O	ADP	O
paclitaxel	B-Chemical	NOUN	B
.	O	PUNCT	O


Toxic	O	ADJ	B
peripheral	B-Disease	ADJ	O
neuropathy	I-Disease	NOUN	O
is	O	AUX	O
still	O	ADV	O
a	O	DET	O
significant	O	ADJ	O
limiting	O	VERB	O
factor	O	NOUN	B
for	O	ADP	O
chemotherapy	O	NOUN	B
with	O	ADP	O
paclitaxel	B-Chemical	NOUN	B
(	O	PUNCT	O
PAC	B-Chemical	NOUN	B
),	O	PUNCT	O
although	O	SCONJ	O
glutamate	B-Chemical	NOUN	B
and	O	CCONJ	O
its	O	PRON	O
closely	O	ADV	O
related	O	ADJ	O
amino	B-Chemical	NOUN	B
acid	I-Chemical	NOUN	I
glutamine	B-Chemical	NOUN	B
were	O	AUX	O
claimed	O	VERB	O
to	O	PART	O
ameliorate	O	VERB	B
PAC	B-Chemical	NOUN	B
neurotoxicity	B-Disease	NOUN	B
.	O	PUNCT	O


This	O	DET	O
pilot	O	NOUN	B
trial	O	NOUN	I
aimed	O	VERB	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
glutamate	B-Chemical	NOUN	B
supplementation	O	NOUN	B
for	O	ADP	O
preventing	O	VERB	B
PAC	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
peripheral	B-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
placebo	O	NOUN	B
-	O	PUNCT	O
controlled	O	VERB	B
,	O	PUNCT	O
double	O	ADV	B
-	O	PUNCT	O
blinded	O	VERB	B
clinical	O	ADJ	B
and	O	CCONJ	O
electro	O	NOUN	B
-	O	PUNCT	O
diagnostic	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


Forty	O	NUM	B
-	O	PUNCT	O
three	O	NUM	B
ovarian	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
patients	O	NOUN	B
were	O	AUX	O
available	O	ADJ	O
for	O	ADP	O
analysis	O	NOUN	B
following	O	VERB	O
six	O	NUM	O
cycles	O	NOUN	B
of	O	ADP	O
the	O	DET	O
same	O	ADJ	O
PAC	B-Chemical	PROPN	B
-	O	PUNCT	O
containing	O	VERB	B
regimen	O	NOUN	B
:	O	PUNCT	O
23	O	NUM	O
had	O	AUX	O
been	O	AUX	O
supplemented	O	VERB	O
by	O	ADP	O
glutamate	B-Chemical	NOUN	B
all	O	ADV	O
along	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
period	O	NOUN	B
,	O	PUNCT	O
at	O	ADP	O
a	O	DET	O
daily	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
three	O	NUM	O
times	O	NOUN	O
500	O	NUM	O
mg	O	NOUN	O
(	O	PUNCT	O
group	O	NOUN	B
G	O	NOUN	I
),	O	PUNCT	O
and	O	CCONJ	O
20	O	NUM	O
had	O	AUX	O
received	O	VERB	O
a	O	DET	O
placebo	O	NOUN	B
(	O	PUNCT	O
group	O	NOUN	B
P	O	NOUN	O
).	O	PUNCT	B
Patients	O	NOUN	B
were	O	AUX	O
evaluated	O	VERB	B
by	O	ADP	O
neurological	O	ADJ	B
examinations	O	NOUN	I
,	O	PUNCT	O
questionnaires	O	NOUN	B
and	O	CCONJ	O
sensory	O	ADJ	B
-	O	PUNCT	O
motor	O	NOUN	B
nerve	O	NOUN	I
conduction	O	NOUN	O
studies	O	NOUN	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
in	O	ADP	O
the	O	DET	O
frequency	O	NOUN	B
of	O	ADP	O
signs	O	NOUN	B
or	O	CCONJ	O
symptoms	O	NOUN	B
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
although	O	SCONJ	O
neurotoxicity	B-Disease	NOUN	B
symptoms	O	NOUN	B
presented	O	VERB	O
mostly	O	ADV	O
with	O	ADP	O
lower	O	ADJ	O
scores	O	NOUN	B
of	O	ADP	O
severity	O	NOUN	B
in	O	ADP	O
group	O	NOUN	B
G	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
this	O	DET	O
difference	O	NOUN	O
reached	O	VERB	O
statistical	O	ADJ	B
significance	O	NOUN	I
only	O	ADV	O
with	O	ADP	O
regard	O	NOUN	O
to	O	ADP	O
reported	O	VERB	O
pain	B-Disease	NOUN	B
sensation	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


011	O	NUM	O
).	O	PUNCT	O
Also	O	ADV	O
the	O	DET	O
frequency	O	NOUN	B
of	O	ADP	O
abnormal	O	ADJ	B
electro	O	NOUN	B
-	O	PUNCT	O
diagnostic	O	ADJ	B
findings	O	NOUN	B
showed	O	VERB	O
similarity	O	NOUN	B
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
(	O	PUNCT	O
G	O	NOUN	B
:	O	PUNCT	O
7	O	NUM	O
/	O	SYM	O
23	O	NUM	O
=	O	ADJ	O
30	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
%;	O	NOUN	O
P	O	NOUN	O
:	O	PUNCT	O
6	O	NUM	O
/	O	SYM	O
20	O	NUM	O
=	O	ADJ	O
30	O	NUM	O
%).	O	NOUN	O
This	O	DET	O
pilot	O	NOUN	B
study	O	NOUN	I
leads	O	VERB	O
to	O	PART	O
the	O	DET	O
conclusion	O	NOUN	O
that	O	SCONJ	O
glutamate	B-Chemical	NOUN	B
supplementation	O	NOUN	B
at	O	ADP	O
the	O	DET	O
chosen	O	VERB	O
regimen	O	NOUN	B
fails	O	VERB	O
to	O	PART	O
protect	O	VERB	O
against	O	ADP	O
peripheral	B-Disease	ADJ	B
neurotoxicity	I-Disease	NOUN	B
of	O	ADP	O
PAC	B-Chemical	NOUN	B


Attentional	O	ADJ	B
modulation	O	NOUN	I
of	O	ADP	O
perceived	O	VERB	B
pain	B-Disease	NOUN	B
intensity	O	NOUN	I
in	O	ADP	O
capsaicin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
secondary	O	ADJ	B
hyperalgesia	B-Disease	NOUN	I
.	O	PUNCT	O


Perceived	O	VERB	B
pain	B-Disease	NOUN	B
intensity	O	NOUN	I
is	O	AUX	O
modulated	O	VERB	B
by	O	ADP	O
attention	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
it	O	PRON	O
is	O	AUX	O
not	O	PART	O
known	O	VERB	O
that	O	SCONJ	O
how	O	SCONJ	O
pain	B-Disease	NOUN	B
intensity	O	NOUN	I
ratings	O	NOUN	B
are	O	AUX	O
affected	O	VERB	B
by	O	ADP	O
attention	O	NOUN	B
in	O	ADP	O
capsaicin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
secondary	O	ADJ	B
hyperalgesia	B-Disease	NOUN	I
.	O	PUNCT	O


Here	O	ADV	O
we	O	PRON	O
show	O	VERB	O
that	O	SCONJ	O
perceived	O	VERB	B
pain	B-Disease	NOUN	B
intensity	O	NOUN	I
in	O	ADP	O
secondary	O	ADJ	B
hyperalgesia	B-Disease	NOUN	I
is	O	AUX	O
decreased	O	VERB	B
when	O	SCONJ	O
attention	O	NOUN	B
is	O	AUX	O
distracted	O	VERB	B
away	O	ADV	O
from	O	ADP	O
the	O	DET	O
painful	O	ADJ	B
pinprick	O	NOUN	B
stimulus	O	NOUN	I
with	O	ADP	O
a	O	DET	O
visual	O	ADJ	B
task	O	NOUN	I
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
it	O	PRON	O
was	O	AUX	O
found	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
magnitude	O	NOUN	B
of	O	ADP	O
attentional	O	ADJ	B
modulation	O	NOUN	I
in	O	ADP	O
secondary	O	ADJ	B
hyperalgesia	B-Disease	NOUN	I
is	O	AUX	O
very	O	ADV	O
similar	O	ADJ	O
to	O	PART	O
that	O	DET	O
of	O	ADP	O
capsaicin	B-Chemical	NOUN	B
-	O	PUNCT	O
untreated	O	ADJ	B
,	O	PUNCT	O
control	O	ADJ	B
condition	O	NOUN	I
.	O	PUNCT	O


Our	O	PRON	O
findings	O	NOUN	B
,	O	PUNCT	O
showing	O	VERB	O
no	O	DET	O
interaction	O	NOUN	B
between	O	ADP	O
capsaicin	B-Chemical	NOUN	B
treatment	O	NOUN	B
and	O	CCONJ	O
attentional	O	ADJ	B
modulation	O	NOUN	I
suggest	O	VERB	O
that	O	SCONJ	O
capsaicin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
secondary	O	ADJ	B
hyperalgesia	B-Disease	NOUN	I
and	O	CCONJ	O
attention	O	NOUN	B
might	O	AUX	O
affect	O	VERB	O
mechanical	O	ADJ	B
pain	B-Disease	NOUN	I


Testosterone	B-Chemical	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
hypertension	B-Disease	NOUN	B
and	O	CCONJ	O
upregulation	O	NOUN	B
of	O	ADP	O
intrarenal	O	ADJ	B
angiotensinogen	O	NOUN	B
in	O	ADP	O
Dahl	O	NOUN	B
salt	B-Chemical	NOUN	I
-	O	PUNCT	O
sensitive	O	ADJ	B
rats	O	NOUN	B
.	O	PUNCT	O


Blood	O	NOUN	B
pressure	O	NOUN	I
(	O	PUNCT	O
BP	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
more	O	ADJ	O
salt	B-Chemical	NOUN	B
sensitive	O	ADJ	B
in	O	ADP	O
men	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
premenopausal	O	ADJ	B
women	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
Dahl	O	NOUN	B
salt	B-Chemical	NOUN	I
-	O	PUNCT	O
sensitive	O	ADJ	B
rats	O	NOUN	B
(	O	PUNCT	O
DS	O	NOUN	B
),	O	PUNCT	O
high	O	ADJ	B
-	O	PUNCT	O
salt	B-Chemical	NOUN	B
(	O	PUNCT	O
HS	O	NOUN	B
)	O	PUNCT	O
diet	O	NOUN	B
increases	O	VERB	B
BP	O	NOUN	B
more	O	ADV	O
in	O	ADP	O
males	O	NOUN	B
than	O	ADP	O
females	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
to	O	PART	O
the	O	DET	O
systemic	O	ADJ	B
renin	O	NOUN	B
-	O	PUNCT	O
angiotensin	B-Chemical	NOUN	B
system	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
suppressed	O	VERB	B
in	O	ADP	O
response	O	NOUN	B
to	O	PART	O
HS	O	NOUN	B
in	O	ADP	O
male	O	NOUN	B
DS	O	NOUN	B
,	O	PUNCT	O
intrarenal	O	ADJ	B
angiotensinogen	O	NOUN	B
expression	O	NOUN	B
is	O	AUX	O
increased	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
intrarenal	O	ADJ	B
levels	O	NOUN	O
of	O	ADP	O
ANG	O	NOUN	B
II	O	NUM	I
are	O	AUX	O
not	O	PART	O
suppressed	O	VERB	B
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
hypothesis	O	NOUN	B
was	O	AUX	O
tested	O	VERB	B
that	O	SCONJ	O
there	O	PRON	O
is	O	AUX	O
a	O	DET	O
sexual	O	ADJ	B
dimorphism	O	NOUN	I
in	O	ADP	O
HS	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
upregulation	O	NOUN	B
of	O	ADP	O
intrarenal	O	ADJ	B
angiotensinogen	O	NOUN	I
mediated	O	VERB	O
by	O	ADP	O
testosterone	B-Chemical	NOUN	B
that	O	PRON	O
also	O	ADV	O
causes	O	VERB	O
increases	O	NOUN	B
in	O	ADP	O
BP	O	NOUN	B
and	O	CCONJ	O
renal	B-Disease	ADJ	B
injury	I-Disease	NOUN	I
.	O	PUNCT	O


On	O	ADP	O
a	O	DET	O
low	O	ADJ	B
-	O	PUNCT	O
salt	B-Chemical	NOUN	B
(	O	PUNCT	O
LS	O	NOUN	B
)	O	PUNCT	O
diet	O	NOUN	B
,	O	PUNCT	O
male	O	ADJ	B
DS	O	NOUN	B
had	O	AUX	O
higher	O	ADJ	O
levels	O	NOUN	B
of	O	ADP	O
intrarenal	O	ADJ	B
angiotensinogen	O	NOUN	B
mRNA	O	NOUN	B
than	O	ADP	O
females	O	NOUN	B
.	O	PUNCT	O


HS	O	NOUN	B
diet	O	NOUN	O
for	O	ADP	O
4	O	NUM	O
wk	O	NOUN	O
increased	O	VERB	B
renal	O	ADJ	B
cortical	O	ADJ	I
angiotensinogen	O	NOUN	B
mRNA	O	NOUN	B
and	O	CCONJ	O
protein	O	NOUN	B
only	O	ADV	O
in	O	ADP	O
male	O	NOUN	B
DS	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
was	O	AUX	O
prevented	O	VERB	B
by	O	ADP	O
castration	O	NOUN	B
.	O	PUNCT	O


Ovariectomy	O	NOUN	B
of	O	ADP	O
female	O	ADJ	B
DS	O	NOUN	B
had	O	AUX	O
no	O	DET	B
effect	O	NOUN	I
on	O	ADP	O
intrarenal	O	ADJ	B
angiotensinogen	O	NOUN	B
expression	O	NOUN	B
on	O	ADP	O
either	O	DET	O
diet	O	NOUN	B
.	O	PUNCT	O


Radiotelemetric	O	ADJ	B
BP	O	NOUN	I
was	O	AUX	O
similar	O	ADJ	O
between	O	ADP	O
males	O	NOUN	B
and	O	CCONJ	O
castrated	O	VERB	B
rats	O	NOUN	B
on	O	ADP	O
LS	O	NOUN	B
diet	O	NOUN	B
.	O	PUNCT	O


HS	O	NOUN	B
diet	O	NOUN	O
for	O	ADP	O
4	O	NUM	O
wk	O	NOUN	O
caused	O	VERB	O
a	O	DET	O
progressive	O	ADJ	B
increase	O	NOUN	B
in	O	ADP	O
BP	O	NOUN	B
,	O	PUNCT	O
protein	O	NOUN	B
and	O	CCONJ	O
albumin	O	NOUN	B
excretion	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
glomerular	B-Disease	ADJ	B
sclerosis	I-Disease	NOUN	I
in	O	ADP	O
male	O	ADJ	B
DS	O	NOUN	B
rats	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
were	O	AUX	O
attenuated	O	VERB	B
by	O	ADP	O
castration	O	NOUN	B
.	O	PUNCT	O


Testosterone	B-Chemical	NOUN	B
replacement	O	NOUN	B
in	O	ADP	O
castrated	O	VERB	B
DS	O	NOUN	O
rats	O	NOUN	B
increased	O	VERB	B
BP	O	NOUN	B
,	O	PUNCT	O
renal	B-Disease	ADJ	B
injury	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
upregulation	O	NOUN	B
of	O	ADP	O
renal	O	ADJ	B
angiotensinogen	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
HS	O	NOUN	B
diet	O	NOUN	O
.	O	PUNCT	O


Testosterone	B-Chemical	NOUN	B
contributes	O	VERB	O
to	O	PART	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
hypertension	B-Disease	NOUN	B
and	O	CCONJ	O
renal	B-Disease	ADJ	B
injury	I-Disease	NOUN	I
in	O	ADP	O
male	O	ADJ	B
DS	O	NOUN	B
rats	O	NOUN	B
on	O	ADP	O
HS	O	NOUN	B
diet	O	NOUN	O
possibly	O	ADV	O
through	O	ADP	O
upregulation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
intrarenal	O	ADJ	B
renin	O	NOUN	B
-	O	PUNCT	O
angiotensin	B-Chemical	NOUN	B


Prenatal	O	ADJ	B
protein	O	NOUN	I
deprivation	O	NOUN	O
alters	O	VERB	O
dopamine	B-Chemical	NOUN	B
-	O	PUNCT	O
mediated	O	VERB	B
behaviors	O	NOUN	B
and	O	CCONJ	O
dopaminergic	O	ADJ	B
and	O	CCONJ	O
glutamatergic	O	ADJ	B
receptor	O	NOUN	I
binding	O	NOUN	I
.	O	PUNCT	O


Epidemiological	O	ADJ	B
evidence	O	NOUN	B
indicates	O	VERB	O
that	O	SCONJ	O
prenatal	O	ADJ	B
nutritional	O	ADJ	O
deprivation	O	NOUN	O
may	O	AUX	O
increase	O	VERB	B
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
schizophrenia	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
goal	O	NOUN	B
of	O	ADP	O
these	O	DET	O
studies	O	NOUN	B
was	O	AUX	O
to	O	PART	O
use	O	VERB	O
an	O	DET	O
animal	O	NOUN	B
model	O	NOUN	I
to	O	PART	O
examine	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
prenatal	O	ADJ	B
protein	O	NOUN	I
deprivation	O	NOUN	O
on	O	ADP	O
behaviors	O	NOUN	B
and	O	CCONJ	O
receptor	O	NOUN	B
binding	O	NOUN	I
with	O	ADP	O
relevance	O	NOUN	B
to	O	PART	O
schizophrenia	B-Disease	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
that	O	SCONJ	O
prenatally	O	ADV	B
protein	O	NOUN	I
deprived	O	VERB	O
(	O	PUNCT	O
PD	O	NOUN	B
)	O	PUNCT	O
female	O	NOUN	B
rats	O	NOUN	B
showed	O	VERB	O
an	O	DET	O
increased	O	VERB	B
stereotypic	O	ADJ	B
response	O	NOUN	I
to	O	PART	O
apomorphine	B-Chemical	NOUN	B
and	O	CCONJ	O
an	O	DET	O
increased	O	VERB	B
locomotor	O	NOUN	B
response	O	NOUN	I
to	O	PART	O
amphetamine	B-Chemical	NOUN	B
in	O	ADP	B
adulthood	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
differences	O	NOUN	O
were	O	AUX	O
not	O	PART	O
observed	O	VERB	O
during	O	ADP	O
puberty	O	NOUN	B
.	O	PUNCT	O


No	O	DET	O
changes	O	NOUN	O
in	O	ADP	O
haloperidol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
catalepsy	B-Disease	NOUN	B
or	O	CCONJ	O
MK-801	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
locomotion	O	NOUN	B
were	O	AUX	O
seen	O	VERB	O
following	O	VERB	O
PD	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
PD	O	NOUN	B
female	O	NOUN	B
rats	O	NOUN	B
showed	O	VERB	O
increased	O	VERB	B
(	O	PUNCT	O
3	O	X	O
)	O	PUNCT	O
H	B-Chemical	NOUN	B
-	O	PUNCT	O
MK-801	B-Chemical	NOUN	B
binding	O	NOUN	B
in	O	ADP	O
the	O	DET	O
striatum	O	NOUN	B
and	O	CCONJ	O
hippocampus	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
in	O	ADP	O
the	O	DET	O
cortex	O	NOUN	B
.	O	PUNCT	O


PD	O	NOUN	B
female	O	NOUN	B
rats	O	NOUN	B
also	O	ADV	O
showed	O	VERB	O
increased	O	VERB	B
(	O	PUNCT	O
3	O	X	O
)	O	PUNCT	O
H	B-Chemical	NOUN	B
-	O	PUNCT	O
haloperidol	B-Chemical	NOUN	B
binding	O	NOUN	B
and	O	CCONJ	O
decreased	O	VERB	B
dopamine	B-Chemical	NOUN	B
transporter	O	NOUN	I
binding	O	NOUN	O
in	O	ADP	O
striatum	O	NOUN	B
.	O	PUNCT	O


No	O	DET	O
statistically	O	ADV	O
significant	O	ADJ	O
changes	O	NOUN	B
in	O	ADP	O
behavior	O	NOUN	B
or	O	CCONJ	O
receptor	O	NOUN	B
binding	O	NOUN	I
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
PD	O	NOUN	B
males	O	NOUN	B
with	O	ADP	O
the	O	DET	O
exception	O	NOUN	O
of	O	ADP	O
increased	O	VERB	B
(	O	PUNCT	O
3	O	X	O
)	O	PUNCT	O
H	B-Chemical	NOUN	B
-	O	PUNCT	O
MK-801	B-Chemical	NOUN	B
binding	O	NOUN	B
in	O	ADP	O
cortex	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
animal	O	NOUN	B
model	O	NOUN	I
may	O	AUX	O
be	O	AUX	O
useful	O	ADJ	O
to	O	PART	O
explore	O	VERB	O
the	O	DET	O
mechanisms	O	NOUN	B
by	O	ADP	O
which	O	DET	O
prenatal	O	ADJ	B
nutritional	B-Disease	ADJ	I
deficiency	I-Disease	NOUN	I
enhances	O	VERB	O
risk	O	NOUN	B
for	O	ADP	O
schizophrenia	B-Disease	NOUN	B


mToR	O	NOUN	B
inhibitors	O	NOUN	I
-	O	PUNCT	O
induced	O	VERB	B
proteinuria	B-Disease	NOUN	B
:	O	PUNCT	O
mechanisms	O	NOUN	B
,	O	PUNCT	O
significance	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
management	O	NOUN	B
.	O	PUNCT	O


Massive	O	ADJ	B
urinary	O	ADJ	B
protein	O	NOUN	I
excretion	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
observed	O	VERB	O
after	O	ADP	O
conversion	O	NOUN	B
from	O	ADP	O
calcineurin	O	NOUN	B
inhibitors	O	NOUN	B
to	O	PART	O
mammalian	O	ADJ	B
target	O	NOUN	B
of	O	ADP	O
rapamycin	B-Chemical	NOUN	B
(	O	PUNCT	O
mToR	O	NOUN	B
)	O	PUNCT	O
inhibitors	O	NOUN	B
,	O	PUNCT	O
especially	O	ADV	O
sirolimus	B-Chemical	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
renal	O	ADJ	B
transplant	O	NOUN	I
recipients	O	NOUN	B
with	O	ADP	O
chronic	B-Disease	ADJ	B
allograft	I-Disease	NOUN	I
nephropathy	I-Disease	NOUN	I
.	O	PUNCT	O


Because	O	SCONJ	O
proteinuria	B-Disease	NOUN	B
is	O	AUX	O
a	O	DET	O
major	O	ADJ	O
predictive	O	ADJ	B
factor	O	NOUN	I
of	O	ADP	O
poor	O	ADJ	B
transplantation	O	NOUN	I
outcome	O	NOUN	B
,	O	PUNCT	O
many	O	ADJ	O
studies	O	NOUN	B
focused	O	VERB	O
on	O	ADP	O
this	O	DET	O
adverse	O	ADJ	B
event	O	NOUN	I
during	O	ADP	O
the	O	DET	O
past	O	ADJ	O
years	O	NOUN	B
.	O	PUNCT	O


Whether	O	SCONJ	O
proteinuria	B-Disease	NOUN	B
was	O	AUX	O
due	O	ADJ	O
to	O	PART	O
sirolimus	B-Chemical	NOUN	B
or	O	CCONJ	O
only	O	ADV	O
a	O	DET	O
consequence	O	NOUN	O
of	O	ADP	O
calcineurin	O	NOUN	B
inhibitors	O	NOUN	B
withdrawal	O	NOUN	B
remained	O	VERB	O
unsolved	O	ADJ	O
until	O	ADP	O
high	O	ADJ	O
range	O	NOUN	O
proteinuria	B-Disease	NOUN	B
has	O	AUX	O
been	O	AUX	O
observed	O	VERB	O
during	O	ADP	O
sirolimus	B-Chemical	NOUN	B
therapy	O	NOUN	I
in	O	ADP	O
islet	O	NOUN	B
transplantation	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
patients	O	NOUN	B
who	O	PRON	O
received	O	VERB	O
sirolimus	B-Chemical	NOUN	B
de	O	X	O
novo	O	X	O
.	O	PUNCT	O


Podocyte	O	NOUN	B
injury	O	NOUN	O
and	O	CCONJ	O
focal	O	ADJ	B
segmental	O	ADJ	I
glomerulosclerosis	B-Disease	NOUN	I
have	O	AUX	O
been	O	AUX	O
related	O	ADJ	O
to	O	PART	O
mToR	O	NOUN	B
inhibition	O	NOUN	B
in	O	ADP	O
some	O	DET	O
patients	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
pathways	O	NOUN	B
underlying	O	VERB	O
these	O	DET	O
lesions	O	NOUN	B
remain	O	VERB	O
hypothetic	O	ADJ	B
.	O	PUNCT	O


We	O	PRON	O
discuss	O	VERB	O
herein	O	ADV	O
the	O	DET	O
possible	O	ADJ	O
mechanisms	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
significance	O	NOUN	B
of	O	ADP	O
mToR	O	NOUN	B
blockade	O	NOUN	I
-	O	PUNCT	O
induced	O	VERB	B
proteinuria	B-Disease	NOUN	B


Hypothalamic	O	ADJ	B
prolactin	O	NOUN	I
receptor	O	NOUN	I
messenger	O	NOUN	I
ribonucleic	B-Chemical	ADJ	I
acid	I-Chemical	NOUN	I
levels	O	NOUN	I
,	O	PUNCT	O
prolactin	O	NOUN	B
signaling	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
hyperprolactinemic	B-Disease	ADJ	B
inhibition	O	NOUN	B
of	O	ADP	O
pulsatile	O	ADJ	B
luteinizing	O	NOUN	I
hormone	O	NOUN	I
secretion	O	NOUN	B
are	O	AUX	O
dependent	O	ADJ	O
on	O	ADP	O
estradiol	B-Chemical	NOUN	B
.	O	PUNCT	O


Hyperprolactinemia	B-Disease	PROPN	B
can	O	AUX	O
reduce	O	VERB	B
fertility	O	NOUN	B
and	O	CCONJ	O
libido	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
central	O	ADJ	B
prolactin	O	NOUN	I
actions	O	NOUN	I
are	O	AUX	O
thought	O	VERB	O
to	O	PART	O
contribute	O	VERB	O
to	O	ADP	O
this	O	DET	O
,	O	PUNCT	O
the	O	DET	O
mechanisms	O	NOUN	B
are	O	AUX	O
poorly	O	ADV	O
understood	O	VERB	O
.	O	PUNCT	O


We	O	PRON	O
first	O	ADV	O
tested	O	VERB	B
whether	O	SCONJ	O
chronic	O	ADJ	B
hyperprolactinemia	B-Disease	NOUN	B
inhibited	O	VERB	B
two	O	NUM	O
neuroendocrine	O	ADJ	B
parameters	O	NOUN	B
necessary	O	ADJ	O
for	O	ADP	O
female	O	ADJ	B
fertility	O	NOUN	B
:	O	PUNCT	O
pulsatile	O	ADJ	B
LH	O	NOUN	B
secretion	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
estrogen	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
LH	O	NOUN	B
surge	O	NOUN	B
.	O	PUNCT	O


Chronic	O	ADJ	B
hyperprolactinemia	B-Disease	NOUN	I
induced	O	VERB	B
by	O	ADP	O
the	O	DET	O
dopamine	B-Chemical	NOUN	B
antagonist	O	NOUN	B
sulpiride	B-Chemical	NOUN	B
caused	O	VERB	O
a	O	DET	O
40	O	NUM	O
%	O	NOUN	O
reduction	O	NOUN	B
LH	O	NOUN	B
pulse	O	NOUN	B
frequency	O	NOUN	I
in	O	ADP	O
ovariectomized	O	ADJ	B
rats	O	NOUN	O
,	O	PUNCT	O
but	O	CCONJ	O
only	O	ADV	O
in	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
chronic	O	ADJ	B
low	O	ADJ	I
levels	O	NOUN	I
of	O	ADP	O
estradiol	B-Chemical	NOUN	B
.	O	PUNCT	O


Sulpiride	B-Chemical	NOUN	B
did	O	AUX	O
not	O	PART	O
affect	O	VERB	O
the	O	DET	O
magnitude	O	NOUN	B
of	O	ADP	O
a	O	DET	O
steroid	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
LH	O	NOUN	B
surge	O	NOUN	B
or	O	CCONJ	O
the	O	DET	O
percentage	O	NOUN	B
of	O	ADP	O
GnRH	O	NOUN	B
neurons	O	NOUN	B
activated	O	VERB	B
during	O	ADP	O
the	O	DET	O
surge	O	NOUN	B
.	O	PUNCT	O


Estradiol	B-Chemical	NOUN	B
is	O	AUX	O
known	O	VERB	O
to	O	PART	O
influence	O	VERB	B
expression	O	NOUN	B
of	O	ADP	O
the	O	DET	O
long	O	ADJ	B
form	O	NOUN	I
of	O	ADP	O
prolactin	O	NOUN	B
receptors	O	NOUN	I
(	O	PUNCT	O
PRL	O	NOUN	B
-	O	PUNCT	O
R	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
components	O	NOUN	B
of	O	ADP	O
prolactin	O	NOUN	B
'	O	PART	O
s	O	NOUN	O
signaling	O	NOUN	B
pathway	O	NOUN	I
.	O	PUNCT	O


To	O	PART	O
test	O	VERB	O
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
estrogen	B-Chemical	NOUN	B
increases	O	VERB	O
PRL	O	NOUN	B
-	O	PUNCT	O
R	O	NOUN	B
expression	O	NOUN	B
and	O	CCONJ	O
sensitivity	O	NOUN	B
to	O	PART	O
prolactin	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
next	O	ADV	O
demonstrated	O	VERB	O
that	O	SCONJ	O
estradiol	B-Chemical	NOUN	B
greatly	O	ADV	O
augments	O	VERB	O
prolactin	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
STAT5	O	NOUN	B
activation	O	NOUN	B
.	O	PUNCT	O


Lastly	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
measured	O	VERB	O
PRL	O	NOUN	B
-	O	PUNCT	O
R	O	NOUN	B
and	O	CCONJ	O
suppressor	O	NOUN	B
of	O	ADP	O
cytokine	O	NOUN	B
signaling	O	NOUN	I
(	O	PUNCT	O
SOCS	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	B
and	O	CCONJ	O
-	O	PUNCT	O
3	O	NUM	O
and	O	CCONJ	O
CIS	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
reflect	O	VERB	O
the	O	DET	O
level	O	NOUN	B
of	O	ADP	O
prolactin	O	NOUN	B
signaling	O	NOUN	I
)	O	PUNCT	O
mRNAs	O	NOUN	B
in	O	ADP	O
response	O	NOUN	B
to	O	PART	O
sulpiride	B-Chemical	NOUN	B
and	O	CCONJ	O
estradiol	B-Chemical	NOUN	B
.	O	PUNCT	O


Sulpiride	B-Chemical	NOUN	B
induced	O	VERB	B
only	O	ADV	O
SOCS	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	O
in	O	ADP	O
the	O	DET	O
medial	O	ADJ	B
preoptic	O	ADJ	I
area	O	NOUN	I
,	O	PUNCT	O
where	O	SCONJ	O
GnRH	O	NOUN	B
neurons	O	NOUN	B
are	O	AUX	O
regulated	O	VERB	B
,	O	PUNCT	O
but	O	CCONJ	O
in	O	ADP	O
the	O	DET	O
arcuate	O	ADJ	B
nucleus	O	NOUN	I
and	O	CCONJ	O
choroid	O	NOUN	B
plexus	O	NOUN	I
,	O	PUNCT	O
PRL	O	NOUN	B
-	O	PUNCT	O
R	O	PROPN	B
,	O	PUNCT	O
SOCS	O	PROPN	B
-	O	PUNCT	O
3	O	NUM	B
,	O	PUNCT	O
and	O	CCONJ	O
CIS	O	NOUN	B
mRNA	O	NOUN	B
levels	O	NOUN	I
were	O	AUX	O
also	O	ADV	O
induced	O	VERB	B
.	O	PUNCT	O


Estradiol	B-Chemical	NOUN	B
enhanced	O	VERB	B
these	O	DET	O
effects	O	NOUN	B
on	O	ADP	O
SOCS	O	NOUN	B
-	O	PUNCT	O
3	O	NUM	B
and	O	CCONJ	O
CIS	O	NOUN	B
.	O	PUNCT	O


Interestingly	O	ADV	O
,	O	PUNCT	O
estradiol	B-Chemical	NOUN	B
also	O	ADV	O
induced	O	VERB	B
PRL	O	NOUN	B
-	O	PUNCT	O
R	O	PROPN	B
,	O	PUNCT	O
SOCS	O	PROPN	B
-	O	PUNCT	O
3	O	NUM	B
,	O	PUNCT	O
and	O	CCONJ	O
CIS	O	NOUN	B
mRNA	O	NOUN	B
levels	O	NOUN	O
independently	O	ADV	O
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
show	O	VERB	O
that	O	SCONJ	O
GnRH	O	NOUN	B
pulse	O	NOUN	B
frequency	O	NOUN	I
is	O	AUX	O
inhibited	O	VERB	B
by	O	ADP	O
chronic	O	ADJ	B
hyperprolactinemia	B-Disease	NOUN	B
in	O	ADP	O
a	O	DET	O
steroid	B-Chemical	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
manner	O	NOUN	O
.	O	PUNCT	O


They	O	PRON	O
also	O	ADV	O
provide	O	VERB	O
evidence	O	NOUN	B
for	O	ADP	O
estradiol	B-Chemical	NOUN	B


Estrogen	O	NOUN	B
prevents	O	VERB	B
cholesteryl	B-Chemical	NOUN	B
ester	I-Chemical	NOUN	I
accumulation	O	NOUN	B
in	O	ADP	O
macrophages	O	NOUN	B
induced	O	VERB	B
by	O	ADP	O
the	O	DET	O
HIV	O	NOUN	B
protease	O	NOUN	I
inhibitor	O	NOUN	B
ritonavir	B-Chemical	NOUN	B
.	O	PUNCT	O


Individuals	O	NOUN	B
with	O	ADP	O
HIV	O	NOUN	B
can	O	AUX	O
now	O	ADV	O
live	O	VERB	B
long	O	ADJ	O
lives	O	NOUN	O
with	O	ADP	O
drug	O	NOUN	B
therapy	O	NOUN	I
that	O	PRON	O
often	O	ADV	O
includes	O	VERB	O
protease	O	NOUN	B
inhibitors	O	NOUN	I
such	O	ADJ	O
as	O	ADP	O
ritonavir	B-Chemical	NOUN	B
.	O	PUNCT	O


Many	O	ADJ	O
patients	O	NOUN	B
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
develop	O	VERB	O
negative	O	ADJ	B
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
side	O	NOUN	B
effects	O	NOUN	I
such	O	ADJ	O
as	O	ADP	O
premature	B-Disease	ADJ	B
atherosclerosis	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
previously	O	ADV	O
demonstrated	O	VERB	O
that	O	SCONJ	O
ritonavir	B-Chemical	NOUN	B
treatment	O	NOUN	B
increases	O	VERB	B
atherosclerotic	B-Disease	ADJ	B
lesion	I-Disease	NOUN	O
formation	O	NOUN	B
in	O	ADP	O
male	O	NOUN	B
mice	O	NOUN	O
to	O	PART	O
a	O	DET	O
greater	O	ADJ	O
extent	O	NOUN	O
than	O	ADP	O
in	O	ADP	O
female	O	ADJ	B
mice	O	NOUN	O
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
peripheral	O	ADJ	B
blood	O	NOUN	I
monocytes	O	NOUN	I
isolated	O	VERB	B
from	O	ADP	O
ritonavir	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
females	O	NOUN	B
had	O	AUX	O
less	O	ADJ	O
cholesteryl	B-Chemical	NOUN	B
ester	I-Chemical	NOUN	I
accumulation	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
investigated	O	VERB	B
the	O	DET	O
molecular	O	ADJ	B
mechanisms	O	NOUN	I
by	O	ADP	O
which	O	DET	O
female	O	ADJ	B
hormones	O	NOUN	I
influence	O	VERB	B
cholesterol	B-Chemical	NOUN	B
metabolism	O	NOUN	I
in	O	ADP	O
macrophages	O	NOUN	B
in	O	ADP	O
response	O	NOUN	B
to	O	PART	O
the	O	DET	O
HIV	O	NOUN	B
protease	O	NOUN	I
inhibitor	O	NOUN	B
ritonavir	B-Chemical	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
utilized	O	VERB	O
the	O	DET	O
human	O	ADJ	B
monocyte	O	NOUN	O
cell	O	NOUN	O
line	O	NOUN	O
,	O	PUNCT	O
THP	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	O
as	O	ADP	O
a	O	DET	O
model	O	NOUN	B
to	O	PART	O
address	O	VERB	O
this	O	DET	O
question	O	NOUN	B
.	O	PUNCT	O


Briefly	O	ADV	B
,	O	PUNCT	O
cells	O	NOUN	B
were	O	AUX	O
differentiated	O	VERB	O
for	O	ADP	O
72	O	NUM	O
h	O	NOUN	O
with	O	ADP	O
100	O	NUM	O
nM	O	NOUN	O
PMA	O	NOUN	B
to	O	PART	O
obtain	O	VERB	O
a	O	DET	O
macrophage	O	NOUN	B
-	O	PUNCT	O
like	O	ADJ	B
phenotype	O	NOUN	B
in	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
or	O	CCONJ	O
absence	O	NOUN	B
of	O	ADP	O
1	O	NUM	O
nM	O	NOUN	O
17beta-estradiol	B-Chemical	NOUN	B
(	O	PUNCT	O
E2	B-Chemical	NOUN	B
),	O	PUNCT	O
100	O	NUM	O
nM	O	NOUN	O
progesterone	B-Chemical	NOUN	B
or	O	CCONJ	O
vehicle	O	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
%	O	NOUN	O
ethanol	B-Chemical	NOUN	B
).	O	PUNCT	B
Cells	O	NOUN	I
were	O	AUX	O
then	O	ADV	O
treated	O	VERB	B
with	O	ADP	I
30	O	NUM	O
ng	O	NOUN	O
/	O	PUNCT	O
ml	O	NOUN	O
ritonavir	B-Chemical	NOUN	B
or	O	CCONJ	O
vehicle	O	NOUN	B
in	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
aggregated	O	ADJ	B
LDL	O	NOUN	B
for	O	ADP	O
24	O	NUM	O
h	O	NOUN	O
.	O	PUNCT	O


Cell	O	NOUN	B
extracts	O	NOUN	I
were	O	AUX	O
harvested	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
lipid	O	NOUN	B
or	O	CCONJ	O
total	O	ADJ	O
RNA	O	NOUN	B
was	O	AUX	O
isolated	O	VERB	B
.	O	PUNCT	O


E2	B-Chemical	NOUN	B
decreased	O	VERB	B
the	O	DET	O
accumulation	O	NOUN	B
of	O	ADP	O
cholesteryl	B-Chemical	NOUN	B
esters	I-Chemical	NOUN	I
in	O	ADP	O
macrophages	O	NOUN	B
following	O	VERB	O
ritonavir	B-Chemical	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


Ritonavir	B-Chemical	NOUN	B
increased	O	VERB	B
the	O	DET	O
expression	O	NOUN	B
of	O	ADP	O
the	O	DET	O
scavenger	O	NOUN	B
receptor	O	NOUN	I
,	O	PUNCT	O
CD36	O	NOUN	B
mRNA	O	NOUN	B
,	O	PUNCT	O
responsible	O	ADJ	O
for	O	ADP	O
the	O	DET	O
uptake	O	NOUN	B
of	O	ADP	O
LDL	O	NOUN	B
.	O	PUNCT	O


Additionally	O	ADV	O
,	O	PUNCT	O
ritonavir	B-Chemical	NOUN	B
treatment	O	NOUN	B
selectively	O	ADV	O
increased	O	VERB	B
the	O	DET	O
relative	O	ADJ	O
levels	O	NOUN	B
of	O	ADP	O
PPARgamma	O	NOUN	B
mRNA	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
transcription	O	NOUN	B
factor	O	NOUN	I
responsible	O	ADJ	O
for	O	ADP	O
the	O	DET	O
regulation	O	NOUN	B
of	O	ADP	O
CD36	O	NOUN	B
mRNA	O	NOUN	B
expression	O	NOUN	B
.	O	PUNCT	O


Treatment	O	NOUN	B
with	O	ADP	O
E2	B-Chemical	NOUN	B
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
failed	O	VERB	B
to	O	PART	O
prevent	O	VERB	B
these	O	DET	O
increases	O	NOUN	B
at	O	ADP	O
the	O	DET	O
mRNA	O	NOUN	B
level	O	NOUN	B
.	O	PUNCT	O


E2	B-Chemical	NOUN	B
did	O	AUX	O
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
significantly	O	ADV	O
suppress	O	VERB	B
CD36	O	NOUN	B
protein	O	NOUN	I
levels	O	NOUN	B
as	O	ADP	O
measured	O	VERB	B
by	O	ADP	O
fluorescent	O	ADJ	B
immunocytochemistry	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
data	O	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
E2	B-Chemical	NOUN	B
modifies	O	VERB	B
the	O	DET	O
expression	O	NOUN	B
of	O	ADP	O
CD36	O	NOUN	B
at	O	ADP	O
the	O	DET	O
level	O	NOUN	B
of	O	ADP	O
protein	O	NOUN	B
expression	O	NOUN	I
in	O	ADP	O
monocyte	O	NOUN	B
-	O	PUNCT	O
derived	O	VERB	B
macrophages	O	NOUN	B
resulting	O	VERB	O
in	O	ADP	O
reduced	O	VERB	B
cholesteryl	B-Chemical	NOUN	B
ester	I-Chemical	NOUN	I
accumulation	O	NOUN	B
following	O	VERB	O
ritonavir	B-Chemical	NOUN	B


Upregulation	O	NOUN	B
of	O	ADP	O
brain	O	NOUN	B
expression	O	NOUN	I
of	O	ADP	O
P	O	NOUN	B
-	O	PUNCT	O
glycoprotein	O	NOUN	B
in	O	ADP	O
MRP2	O	NOUN	B
-	O	PUNCT	O
deficient	O	ADJ	B
TR	O	NOUN	B
(-)	O	ADJ	I
rats	O	NOUN	B
resembles	O	VERB	O
seizure	B-Disease	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
up	O	ADP	O
-	O	PUNCT	O
regulation	O	NOUN	B
of	O	ADP	O
this	O	DET	O
drug	O	NOUN	B
efflux	O	NOUN	I
transporter	O	NOUN	I
in	O	ADP	O
normal	O	ADJ	O
rats	O	NOUN	B
.	O	PUNCT	O


PURPOSE	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
multidrug	O	ADJ	B
resistance	O	NOUN	I
protein	O	NOUN	I
2	O	NUM	I
(	O	PUNCT	O
MRP2	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
drug	O	NOUN	B
efflux	O	NOUN	I
transporter	O	NOUN	I
that	O	PRON	O
is	O	AUX	O
expressed	O	VERB	B
predominantly	O	ADV	O
at	O	ADP	O
the	O	DET	O
apical	O	ADJ	B
domain	O	NOUN	I
of	O	ADP	O
hepatocytes	O	NOUN	B
but	O	CCONJ	O
seems	O	VERB	O
also	O	ADV	O
to	O	PART	O
be	O	AUX	O
expressed	O	VERB	B
at	O	ADP	O
the	O	DET	O
apical	O	ADJ	B
membrane	O	NOUN	I
of	O	ADP	O
brain	O	NOUN	B
capillary	O	ADJ	I
endothelial	O	ADJ	B
cells	O	NOUN	I
that	O	PRON	O
form	O	VERB	O
the	O	DET	O
blood	O	NOUN	B
-	O	PUNCT	O
brain	O	NOUN	B
barrier	O	NOUN	I
(	O	PUNCT	O
BBB	O	NOUN	B
).	O	PUNCT	O
MRP2	O	NOUN	B
is	O	AUX	O
absent	O	ADJ	B
in	O	ADP	O
the	O	DET	O
transport	O	NOUN	B
-	O	PUNCT	O
deficient	O	ADJ	B
(	O	PUNCT	O
TR	O	NOUN	B
(-))	O	ADJ	O
Wistar	O	PROPN	B
rat	O	NOUN	I
mutant	O	NOUN	I
,	O	PUNCT	O
so	O	SCONJ	O
that	O	SCONJ	O
this	O	DET	O
rat	O	NOUN	B
strain	O	NOUN	B
was	O	AUX	O
very	O	ADV	O
helpful	O	ADJ	O
in	O	ADP	O
defining	O	VERB	O
substrates	O	NOUN	B
of	O	ADP	O
MRP2	O	NOUN	B
by	O	ADP	O
comparing	O	VERB	O
tissue	O	NOUN	B
concentrations	O	NOUN	B
or	O	CCONJ	O
functional	O	ADJ	B
activities	O	NOUN	I
of	O	ADP	O
compounds	O	NOUN	B
in	O	ADP	O
MRP2	O	NOUN	B
-	O	PUNCT	O
deficient	O	ADJ	B
rats	O	NOUN	B
with	O	ADP	O
those	O	DET	O
in	O	ADP	O
transport	O	NOUN	B
-	O	PUNCT	O
competent	O	ADJ	B
Wistar	O	ADJ	B
rats	O	NOUN	I
.	O	PUNCT	O


By	O	ADP	O
using	O	VERB	O
this	O	DET	O
strategy	O	NOUN	O
to	O	PART	O
study	O	VERB	B
the	O	DET	O
involvement	O	NOUN	B
of	O	ADP	O
MRP2	O	NOUN	B
in	O	ADP	O
brain	O	NOUN	B
access	O	NOUN	I
of	O	ADP	O
antiepileptic	O	ADJ	B
drugs	O	NOUN	I
(	O	PUNCT	O
AEDs	O	NOUN	B
),	O	PUNCT	O
we	O	PRON	O
recently	O	ADV	O
reported	O	VERB	O
that	O	SCONJ	O
phenytoin	B-Chemical	NOUN	B
is	O	AUX	O
a	O	DET	O
substrate	O	NOUN	B
for	O	ADP	O
MRP2	O	NOUN	B
in	O	ADP	O
the	O	DET	O
BBB	O	PROPN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
one	O	NUM	O
drawback	O	NOUN	O
of	O	ADP	O
such	O	ADJ	O
studies	O	NOUN	B
in	O	ADP	O
genetically	O	ADV	B
deficient	O	ADJ	I
rats	O	NOUN	B
is	O	AUX	O
the	O	DET	O
fact	O	NOUN	O
that	O	SCONJ	O
compensatory	O	ADJ	B
changes	O	NOUN	B
with	O	ADP	O
upregulation	O	NOUN	B
of	O	ADP	O
other	O	ADJ	O
transporters	O	NOUN	B
can	O	AUX	O
occur	O	VERB	O
.	O	PUNCT	O


This	O	DET	O
prompted	O	VERB	O
us	O	PRON	O
to	O	PART	O
study	O	VERB	B
the	O	DET	O
brain	O	NOUN	B
expression	O	NOUN	I
of	O	ADP	O
P	O	NOUN	B
-	O	PUNCT	O
glycoprotein	O	NOUN	B
(	O	PUNCT	O
Pgp	O	NOUN	B
),	O	PUNCT	O
a	O	DET	O
major	O	ADJ	O
drug	O	NOUN	B
efflux	O	NOUN	I
transporter	O	NOUN	I
in	O	ADP	O
many	O	ADJ	O
tissues	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
the	O	DET	O
BBB	O	PROPN	B
,	O	PUNCT	O
in	O	ADP	O
TR	O	NOUN	B
(-)	O	ADJ	I
rats	O	NOUN	B
compared	O	VERB	O
with	O	ADP	O
nonmutant	O	ADJ	B
(	O	PUNCT	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
)	O	PUNCT	O
Wistar	O	ADJ	B
rats	O	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
expression	O	NOUN	B
of	O	ADP	O
MRP2	O	NOUN	B
and	O	CCONJ	O
Pgp	O	NOUN	B
in	O	ADP	O
brain	O	NOUN	B
and	O	CCONJ	O
liver	O	NOUN	B
sections	O	NOUN	I
of	O	ADP	O
TR	O	NOUN	B
(-)	O	ADJ	I
rats	O	NOUN	B
and	O	CCONJ	O
normal	O	ADJ	O
Wistar	O	ADJ	B
rats	O	NOUN	I
was	O	AUX	O
determined	O	VERB	O
with	O	ADP	O
immunohistochemistry	O	NOUN	B
,	O	PUNCT	O
by	O	ADP	O
using	O	VERB	O
a	O	DET	O
novel	O	ADJ	B
,	O	PUNCT	O
highly	O	ADV	O
selective	O	ADJ	O
monoclonal	O	ADJ	B
MRP2	O	NOUN	B
antibody	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
monoclonal	O	ADJ	B
Pgp	O	NOUN	O
antibody	O	NOUN	O
C219	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Immunofluorescence	O	NOUN	B
staining	O	NOUN	I
with	O	ADP	O
the	O	DET	O
MRP2	O	NOUN	B
antibody	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
label	O	VERB	B
a	O	DET	O
high	O	ADJ	O
number	O	NOUN	O
of	O	ADP	O
microvessels	O	NOUN	B
throughout	O	ADP	O
the	O	DET	O
brain	O	NOUN	B
in	O	ADP	O
normal	O	ADJ	O
Wistar	O	ADJ	B
rats	O	NOUN	I
,	O	PUNCT	O
whereas	O	SCONJ	O
such	O	ADJ	O
labeling	O	NOUN	B
was	O	AUX	O
absent	O	ADJ	B
in	O	ADP	O
TR	O	NOUN	B
(-)	O	ADJ	I
rats	O	NOUN	B
.	O	PUNCT	O


TR	O	NOUN	B
(-)	O	ADJ	I
rats	O	NOUN	B
exhibited	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
up	O	ADV	B
-	O	PUNCT	O
regulation	O	NOUN	B
of	O	ADP	O
Pgp	O	NOUN	B
in	O	ADP	O
brain	O	NOUN	B
capillary	O	ADJ	I
endothelial	O	ADJ	B
cells	O	NOUN	I
compared	O	VERB	B
with	O	ADP	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
controls	O	NOUN	B
.	O	PUNCT	O


No	O	DET	O
such	O	ADJ	O
obvious	O	ADJ	O
upregulation	O	NOUN	B
of	O	ADP	O
Pgp	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
liver	O	NOUN	B
sections	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
comparable	O	ADJ	O
overexpression	O	NOUN	B
of	O	ADP	O
Pgp	O	NOUN	B
in	O	ADP	O
the	O	DET	O
BBB	O	NOUN	B
was	O	AUX	O
obtained	O	VERB	O
after	O	ADP	O
pilocarpine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
seizures	B-Disease	NOUN	B
in	O	ADP	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
Wistar	O	PROPN	B
rats	O	NOUN	I
.	O	PUNCT	O


Experiments	O	NOUN	B
with	O	ADP	O
systemic	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
the	O	DET	O
Pgp	O	NOUN	B
substrate	O	NOUN	B
phenobarbital	B-Chemical	NOUN	B
and	O	CCONJ	O
the	O	DET	O
selective	O	ADJ	O
Pgp	O	NOUN	B
inhibitor	O	NOUN	I
tariquidar	B-Chemical	NOUN	B
in	O	ADP	O
TR	O	NOUN	B
(-)	O	ADJ	I
rats	O	NOUN	B
substantiated	O	VERB	O
that	O	SCONJ	O
Pgp	O	NOUN	B
is	O	AUX	O
functional	O	ADJ	B
and	O	CCONJ	O
compensates	O	VERB	B
for	O	ADP	O
the	O	DET	O
lack	O	NOUN	B
of	O	ADP	O
MRP2	O	NOUN	B
in	O	ADP	O
the	O	DET	O
BBB	O	PROPN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
data	O	NOUN	B
on	O	ADP	O
TR	O	NOUN	B
(-)	O	ADJ	I
rats	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
Pgp	O	NOUN	B
plays	O	VERB	O
an	O	DET	O
important	O	ADJ	O
role	O	NOUN	O
in	O	ADP	O
the	O	DET	O
compensation	O	NOUN	B
of	O	ADP	O
MRP2	O	NOUN	B
deficiency	O	NOUN	B
in	O	ADP	O
the	O	DET	O
BBB	O	PROPN	B
.	O	PUNCT	O


Because	O	SCONJ	O
such	O	DET	O
a	O	DET	O
compensatory	O	ADJ	B
mechanism	O	NOUN	B
most	O	ADV	O
likely	O	ADV	O
occurs	O	VERB	O
to	O	PART	O
reduce	O	VERB	B
injury	B-Disease	NOUN	B
to	I-Disease	ADP	O
the	I-Disease	DET	O
brain	I-Disease	NOUN	B
from	O	ADP	O
cytotoxic	O	ADJ	B
compounds	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
present	O	ADJ	O
data	O	NOUN	B
substantiate	O	VERB	O
the	O	DET	O
concept	O	NOUN	B
that	O	SCONJ	O
MRP2	O	NOUN	B
performs	O	VERB	O
a	O	DET	O
protective	O	ADJ	O
role	O	NOUN	O
in	O	ADP	O
the	O	DET	O
BBB	O	PROPN	B
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
our	O	PRON	O
data	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
TR	O	NOUN	B
(-)	O	ADJ	I
rats	O	NOUN	B
are	O	AUX	O
an	O	DET	O
interesting	O	ADJ	O
tool	O	NOUN	O
to	O	PART	O
study	O	VERB	B
consequences	O	NOUN	B
of	O	ADP	I
overexpression	O	NOUN	B
of	O	ADP	O
Pgp	O	NOUN	B
in	O	ADP	O
the	O	DET	O
BBB	O	PROPN	B
on	O	ADP	O
access	O	NOUN	O
of	O	ADP	O
drugs	O	NOUN	B
in	O	ADP	O
the	O	DET	O
brain	O	NOUN	B
,	O	PUNCT	O
without	O	ADP	O
the	O	DET	O
need	O	NOUN	O
of	O	ADP	O
inducing	O	VERB	B
seizures	B-Disease	NOUN	B


Use	O	NOUN	B
of	O	ADP	I
chromosome	O	NOUN	I
substitution	O	NOUN	I
strains	O	NOUN	I
to	O	PART	O
identify	O	VERB	O
seizure	B-Disease	NOUN	B
susceptibility	O	NOUN	B
loci	O	NOUN	I
in	O	ADP	O
mice	O	NOUN	B
.	O	PUNCT	O


Seizure	B-Disease	NOUN	B
susceptibility	O	NOUN	B
varies	O	VERB	O
among	O	ADP	O
inbred	O	ADJ	B
mouse	O	NOUN	I
strains	O	NOUN	I
.	O	PUNCT	O


Chromosome	O	NOUN	B
substitution	O	NOUN	I
strains	O	NOUN	I
(	O	PUNCT	O
CSS	O	NOUN	B
),	O	PUNCT	O
in	O	ADP	O
which	O	DET	O
a	O	DET	O
single	O	ADJ	B
chromosome	O	NOUN	I
from	O	ADP	O
one	O	NUM	O
inbred	O	ADJ	B
strain	O	NOUN	I
(	O	PUNCT	O
donor	O	NOUN	B
)	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
transferred	O	VERB	B
onto	O	ADP	O
a	O	DET	O
second	O	ADJ	O
strain	O	NOUN	B
(	O	PUNCT	O
host	O	NOUN	B
)	O	PUNCT	O
by	O	ADP	O
repeated	O	VERB	O
backcrossing	O	NOUN	B
,	O	PUNCT	O
may	O	AUX	O
be	O	AUX	O
used	O	VERB	O
to	O	PART	O
identify	O	VERB	O
quantitative	O	ADJ	B
trait	O	NOUN	I
loci	O	NOUN	I
(	O	PUNCT	O
QTLs	O	NOUN	B
)	O	PUNCT	O
that	O	PRON	O
contribute	O	VERB	O
to	O	PART	O
seizure	B-Disease	NOUN	B
susceptibility	O	NOUN	B
.	O	PUNCT	O


QTLs	O	NOUN	B
for	O	ADP	O
susceptibility	O	NOUN	B
to	O	PART	O
pilocarpine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
seizures	B-Disease	NOUN	B
,	O	PUNCT	O
a	O	DET	O
model	O	NOUN	B
of	O	ADP	O
temporal	B-Disease	ADJ	B
lobe	I-Disease	NOUN	I
epilepsy	I-Disease	NOUN	I
,	O	PUNCT	O
have	O	AUX	O
not	O	PART	O
been	O	AUX	O
reported	O	VERB	O
,	O	PUNCT	O
and	O	CCONJ	O
CSS	O	NOUN	B
have	O	AUX	O
not	O	PART	O
previously	O	ADV	O
been	O	AUX	O
used	O	VERB	O
to	O	PART	O
localize	O	VERB	B
seizure	B-Disease	NOUN	B
susceptibility	O	NOUN	B
genes	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
QTLs	O	NOUN	B
identified	O	VERB	B
using	O	VERB	O
a	O	DET	O
B6	O	NOUN	B
(	O	PUNCT	O
host	O	NOUN	B
)	O	PUNCT	O
x	O	NOUN	O
A	O	PROPN	B
/	O	SYM	O
J	O	NOUN	B
(	O	PUNCT	O
donor	O	NOUN	B
)	O	PUNCT	O
CSS	O	NOUN	B
panel	O	NOUN	O
to	O	PART	O
localize	O	VERB	B
genes	O	NOUN	B
involved	O	VERB	O
in	O	ADP	O
susceptibility	O	NOUN	B
to	O	PART	O
pilocarpine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
seizures	B-Disease	NOUN	B
.	O	PUNCT	O


Three	O	NUM	O
hundred	O	NUM	O
fifty	O	NUM	O
-	O	PUNCT	O
five	O	NUM	O
adult	O	ADJ	B
male	O	NOUN	B
CSS	O	NOUN	B
mice	O	NOUN	B
,	O	PUNCT	O
58	O	NUM	O
B6	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
39	O	NUM	O
A	O	PROPN	B
/	O	SYM	O
J	O	PROPN	B
were	O	AUX	O
tested	O	VERB	B
for	O	ADP	O
susceptibility	O	NOUN	B
to	O	PART	O
pilocarpine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
seizures	B-Disease	NOUN	B
.	O	PUNCT	O


Highest	O	ADJ	B
stage	O	NOUN	I
reached	O	VERB	O
and	O	CCONJ	O
latency	O	NOUN	B
to	O	ADP	O
each	O	DET	O
stage	O	NOUN	B
were	O	AUX	O
recorded	O	VERB	O
for	O	ADP	O
all	O	DET	O
mice	O	NOUN	B
.	O	PUNCT	O


B6	O	NOUN	B
mice	O	NOUN	I
were	O	AUX	O
resistant	O	ADJ	B
to	O	ADP	O
seizures	B-Disease	NOUN	B
and	O	CCONJ	O
slower	O	ADJ	B
to	O	PART	O
reach	O	VERB	O
stages	O	NOUN	B
compared	O	VERB	O
to	O	PART	O
A	O	DET	B
/	O	SYM	O
J	O	NOUN	B
mice	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
CSS	O	NOUN	B
for	O	ADP	O
Chromosomes	O	NOUN	B
10	O	NUM	I
and	O	CCONJ	O
18	O	NUM	O
progressed	O	VERB	O
to	O	ADP	O
the	O	DET	O
most	O	ADV	O
severe	O	ADJ	B
stages	O	NOUN	B
,	O	PUNCT	O
diverging	O	VERB	O
dramatically	O	ADV	O
from	O	ADP	O
the	O	DET	O
B6	O	NOUN	B
phenotype	O	NOUN	B
.	O	PUNCT	O


Latencies	O	NOUN	B
to	O	ADP	O
stages	O	NOUN	B
were	O	AUX	O
also	O	ADV	O
significantly	O	ADV	O
shorter	O	ADJ	B
for	O	ADP	O
CSS10	O	NOUN	B
and	O	CCONJ	O
CSS18	O	NOUN	B
mice	O	NOUN	O
.	O	PUNCT	O


CSS	O	NOUN	B
mapping	O	NOUN	B
suggests	O	VERB	O
seizure	B-Disease	NOUN	B
susceptibility	O	NOUN	B
loci	O	NOUN	I
on	O	ADP	O
mouse	O	NOUN	B
Chromosomes	O	NOUN	O
10	O	NUM	O
and	O	CCONJ	O
18	O	NUM	O
.	O	PUNCT	O


This	O	DET	O
approach	O	NOUN	O
provides	O	VERB	O
a	O	DET	O
framework	O	NOUN	B
for	O	ADP	O
identifying	O	VERB	O
potentially	O	ADV	O
novel	O	ADJ	O
homologous	O	ADJ	O
candidate	O	NOUN	O
genes	O	NOUN	O
for	O	ADP	O
human	O	ADJ	B
temporal	B-Disease	ADJ	O
lobe	I-Disease	NOUN	O
epilepsy	I-Disease	NOUN	O


Investigation	O	NOUN	B
of	O	ADP	O
mitochondrial	O	ADJ	B
involvement	O	NOUN	B
in	O	ADP	O
the	O	DET	O
experimental	O	ADJ	B
model	O	NOUN	I
of	O	ADP	O
epilepsy	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
pilocarpine	B-Chemical	NOUN	B
.	O	PUNCT	O


Mitochondrial	B-Disease	ADJ	B
abnormalities	I-Disease	NOUN	I
have	O	AUX	O
been	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
several	O	ADJ	O
aspects	O	NOUN	O
of	O	ADP	O
epileptogenesis	O	NOUN	B
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
energy	O	NOUN	B
generation	O	NOUN	I
,	O	PUNCT	O
control	O	NOUN	B
of	O	ADP	I
cell	O	NOUN	I
death	B-Disease	NOUN	I
,	O	PUNCT	O
neurotransmitter	O	NOUN	B
synthesis	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
free	O	ADJ	B
radical	O	NOUN	I
(	O	PUNCT	O
FR	O	NOUN	B
)	O	PUNCT	O
production	O	NOUN	B
.	O	PUNCT	O


Increased	O	VERB	B
production	O	NOUN	B
of	O	ADP	O
FRs	O	NOUN	B
may	O	AUX	O
cause	O	VERB	O
mtDNA	O	NOUN	B
damage	O	NOUN	B
leading	O	VERB	O
to	O	PART	O
decreased	O	VERB	B
activities	O	NOUN	B
of	O	ADP	O
oxidative	O	ADJ	B
phosphorylation	O	NOUN	O
complexes	O	NOUN	O
containing	O	VERB	O
mtDNA	O	NOUN	B
-	O	PUNCT	O
encoded	O	VERB	B
subunits	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
investigated	O	VERB	B
whether	O	SCONJ	O
increased	O	VERB	B
generation	O	NOUN	B
of	O	ADP	O
FR	O	NOUN	B
during	O	ADP	O
status	B-Disease	NOUN	B
epilepticus	I-Disease	NOUN	I
would	O	AUX	O
be	O	AUX	O
sufficient	O	ADJ	O
to	O	PART	O
provoke	O	VERB	O
abnormalities	O	NOUN	B
in	O	ADP	O
mtDNA	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
the	O	DET	O
expression	O	NOUN	B
and	O	CCONJ	O
activity	O	NOUN	B
of	O	ADP	O
cytochrome	O	NOUN	B
c	O	NOUN	I
oxidase	O	NOUN	I
(	O	PUNCT	O
CCO	O	NOUN	B
),	O	PUNCT	O
complex	O	NOUN	B
IV	O	NUM	I
of	O	ADP	O
the	O	DET	O
respiratory	O	ADJ	B
chain	O	NOUN	I
,	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
chronic	O	ADJ	B
phase	O	NOUN	I
of	O	ADP	O
the	O	DET	O
pilocarpine	B-Chemical	NOUN	B
model	O	NOUN	B
of	O	ADP	O
temporal	B-Disease	ADJ	B
lobe	I-Disease	NOUN	I
epilepsy	I-Disease	NOUN	I
.	O	PUNCT	O


DNA	O	NOUN	B
analysis	O	NOUN	I
revealed	O	VERB	O
low	O	ADJ	B
amounts	O	NOUN	I
of	O	ADP	O
a	O	DET	O
4	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
kb	O	NOUN	O
mtDNA	O	NOUN	B
deletion	O	NOUN	B
but	O	CCONJ	O
with	O	ADP	O
no	O	DET	O
differences	O	NOUN	O
in	O	ADP	O
frequency	O	NOUN	B
or	O	CCONJ	O
quantity	O	NOUN	B
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
and	O	CCONJ	O
experimental	O	ADJ	B
groups	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
did	O	AUX	O
not	O	PART	O
find	O	VERB	O
abnormalities	O	NOUN	B
in	O	ADP	O
the	O	DET	O
expression	O	NOUN	B
and	O	CCONJ	O
distribution	O	NOUN	B
of	O	ADP	O
an	O	DET	O
mtDNA	O	NOUN	B
-	O	PUNCT	O
encoded	O	VERB	B
subunit	O	NOUN	B
of	O	ADP	O
CCO	O	PROPN	O
(	O	PUNCT	O
CCO	O	PROPN	B
-	O	PUNCT	O
I	O	PROPN	B
)	O	PUNCT	O
or	O	CCONJ	O
a	O	DET	O
relative	O	ADJ	O
decrease	O	NOUN	B
in	O	ADP	O
CCO	O	PROPN	B
-	O	PUNCT	O
I	O	PROPN	B
when	O	SCONJ	O
compared	O	VERB	B
with	O	ADP	O
nuclear	O	ADJ	B
-	O	PUNCT	O
encoded	O	VERB	B
subunits	O	NOUN	B
(	O	PUNCT	O
CCO	O	PROPN	B
-	O	PUNCT	O
IV	O	NUM	B
and	O	CCONJ	O
SDH	O	NOUN	B
-	O	PUNCT	O
fp	O	X	O
).	O	PUNCT	O
No	O	DET	O
abnormality	O	NOUN	O
in	O	ADP	O
CCO	O	NOUN	B
activity	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
through	O	ADP	O
histochemistry	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
evidences	O	NOUN	O
of	O	ADP	O
mitochondrial	B-Disease	ADJ	B
abnormalities	I-Disease	NOUN	I


Causes	O	NOUN	B
of	O	ADP	O
acute	O	ADJ	B
thrombotic	B-Disease	ADJ	I
microangiopathy	I-Disease	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
receiving	O	VERB	O
kidney	O	NOUN	B
transplantation	O	NOUN	I
.	O	PUNCT	O


OBJECTIVES	O	NOUN	O
:	O	PUNCT	O
Thrombotic	B-Disease	ADJ	B
microangiopathy	I-Disease	NOUN	I
is	O	AUX	O
a	O	DET	O
well	O	ADV	O
-	O	PUNCT	O
known	O	VERB	O
problem	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
following	O	VERB	O
renal	O	ADJ	B
transplantation	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
postrenal	O	ADJ	B
transplantation	O	NOUN	I
,	O	PUNCT	O
thrombotic	B-Disease	ADJ	B
microangiopathy	I-Disease	NOUN	I
is	O	AUX	O
often	O	ADV	O
a	O	DET	O
reflection	O	NOUN	B
of	O	ADP	O
hemolytic	B-Disease	ADJ	B
uremic	I-Disease	ADJ	I
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
aimed	O	VERB	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
causes	O	NOUN	O
of	O	ADP	O
thrombotic	B-Disease	ADJ	B
microangiopathy	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
population	O	NOUN	B
of	O	ADP	O
renal	O	ADJ	B
transplantation	O	NOUN	I
recipients	O	NOUN	B
and	O	CCONJ	O
discuss	O	VERB	O
the	O	DET	O
literature	O	NOUN	B
.	O	PUNCT	O


MATERIALS	O	NOUN	O
AND	O	CCONJ	O
METHODS	O	NOUN	O
:	O	PUNCT	O
We	O	PRON	O
investigated	O	VERB	B
the	O	DET	O
causes	O	NOUN	O
of	O	ADP	O
thrombotic	B-Disease	ADJ	B
microangiopathy	I-Disease	NOUN	I
during	O	ADP	O
a	O	DET	O
1	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
period	O	NOUN	B
,	O	PUNCT	O
from	O	ADP	O
June	O	PROPN	O
2003	O	NUM	O
to	O	ADP	O
June	O	PROPN	O
2004	O	NUM	O
,	O	PUNCT	O
at	O	ADP	O
the	O	DET	O
King	O	PROPN	B
Fahad	O	PROPN	I
National	O	PROPN	I
Guard	O	PROPN	I
Hospital	O	PROPN	I
in	O	ADP	O
Riyadh	O	PROPN	B
,	O	PUNCT	O
Saudi	O	PROPN	B
Arabia	O	PROPN	I
,	O	PUNCT	O
by	O	ADP	O
reviewing	O	VERB	B
the	O	DET	O
slides	O	NOUN	B
of	O	ADP	O
all	O	DET	O
transplant	O	NOUN	B
biopsies	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
25	O	NUM	O
)	O	PUNCT	O
performed	O	VERB	O
during	O	ADP	O
this	O	DET	O
interval	O	NOUN	B
.	O	PUNCT	O


Pre	O	PROPN	B
-	O	PUNCT	O
and	O	CCONJ	O
posttransplant	O	ADJ	B
crossmatching	O	NOUN	O
was	O	AUX	O
done	O	VERB	O
when	O	SCONJ	O
possible	O	ADJ	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Five	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
thrombotic	B-Disease	ADJ	B
microangiopathy	I-Disease	NOUN	I
were	O	AUX	O
found	O	VERB	O
.	O	PUNCT	O


Three	O	NUM	O
of	O	ADP	O
these	O	DET	O
cases	O	NOUN	B
were	O	AUX	O
from	O	ADP	O
the	O	DET	O
25	O	NUM	O
transplantations	O	NOUN	B
performed	O	VERB	B
at	O	ADP	O
King	O	PROPN	B
Fahad	O	PROPN	I
National	O	PROPN	I
Guard	O	PROPN	I
Hospital	O	PROPN	I
,	O	PUNCT	O
while	O	SCONJ	O
the	O	DET	O
other	O	ADJ	O
2	O	NUM	O
transplantations	O	NOUN	B
had	O	AUX	O
been	O	AUX	O
performed	O	VERB	O
abroad	O	ADV	B
and	O	CCONJ	O
were	O	AUX	O
referred	O	VERB	O
to	O	ADP	O
us	O	PRON	O
for	O	ADP	O
follow	O	NOUN	B
-	O	PUNCT	O
up	O	NOUN	B
.	O	PUNCT	O


Three	O	NUM	O
cases	O	NOUN	B
were	O	AUX	O
related	O	ADJ	O
to	O	PART	O
cyclosporine	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
1	O	NUM	O
case	O	NOUN	B
was	O	AUX	O
secondary	O	ADJ	O
to	O	PART	O
both	O	CCONJ	O
cyclosporine	B-Chemical	NOUN	B
and	O	CCONJ	O
tacrolimus	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
fifth	O	ADJ	O
case	O	NOUN	B
had	O	AUX	O
features	O	NOUN	B
of	O	ADP	O
thrombotic	B-Disease	ADJ	B
microangiopathy	I-Disease	NOUN	I
related	O	ADJ	O
to	O	PART	O
an	O	DET	O
antiphospholipid	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
systemic	B-Disease	ADJ	B
lupus	I-Disease	NOUN	I
erythematosus	I-Disease	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
In	O	ADP	O
the	O	DET	O
literature	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
most	O	ADV	B
-	O	PUNCT	O
frequent	O	ADJ	B
cause	O	NOUN	B
of	O	ADP	O
hemolytic	B-Disease	ADJ	B
uremic	I-Disease	ADJ	I
syndrome	I-Disease	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
following	O	VERB	O
renal	O	ADJ	B
transplantation	O	NOUN	I
is	O	AUX	O
recurrence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
hemolytic	B-Disease	ADJ	B
uremic	I-Disease	ADJ	I
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


Other	O	ADJ	O
causes	O	NOUN	O
include	O	VERB	O
drug	O	NOUN	B
-	O	PUNCT	O
related	O	ADJ	B
(	O	PUNCT	O
cyclosporine	B-Chemical	NOUN	B
,	O	PUNCT	O
tacrolimus	B-Chemical	NOUN	B
)	O	PUNCT	O
toxicity	B-Disease	NOUN	B
,	O	PUNCT	O
procoagulant	O	ADJ	B
status	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
antibody	O	NOUN	B
-	O	PUNCT	O
mediated	O	VERB	B
rejection	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
found	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
most	O	ADV	B
-	O	PUNCT	O
frequent	O	ADJ	B
cause	O	NOUN	B
of	O	ADP	O
thrombotic	B-Disease	ADJ	B
microangiopathy	I-Disease	NOUN	I
was	O	AUX	O
drug	O	NOUN	B
related	O	ADJ	O
,	O	PUNCT	O
secondary	O	ADJ	B
mainly	O	ADV	O
to	O	PART	O
cyclosporine	B-Chemical	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
current	O	ADJ	O
study	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
frequency	O	NOUN	B
of	O	ADP	O
thrombotic	B-Disease	ADJ	B
microangiopathy	I-Disease	NOUN	I


Severe	O	ADJ	B
reversible	O	ADJ	B
left	B-Disease	ADJ	I
ventricular	I-Disease	ADJ	I
systolic	I-Disease	NOUN	I
and	I-Disease	CCONJ	O
diastolic	I-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
due	O	ADJ	O
to	O	ADP	O
accidental	O	ADJ	B
iatrogenic	O	ADJ	B
epinephrine	B-Chemical	NOUN	B
overdose	B-Disease	NOUN	B
.	O	PUNCT	O


Catecholamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cardiomyopathy	B-Disease	NOUN	B
due	O	ADJ	O
to	O	PART	O
chronic	O	ADJ	B
excess	O	NOUN	B
of	O	ADP	O
endogenous	O	ADJ	B
catecholamines	B-Chemical	NOUN	B
has	O	AUX	O
been	O	AUX	O
recognized	O	VERB	O
for	O	ADP	O
decades	O	NOUN	B
as	O	ADP	O
a	O	DET	O
clinical	O	ADJ	B
phenomenon	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
reports	O	NOUN	B
of	O	ADP	O
myocardial	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
due	O	ADJ	O
to	O	PART	O
acute	O	ADJ	B
iatrogenic	O	ADJ	B
overdose	B-Disease	NOUN	B
are	O	AUX	O
rare	O	ADJ	B
.	O	PUNCT	O


A	O	DET	O
35	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
woman	O	NOUN	B
whose	O	DET	O
cervix	O	NOUN	B
uteri	O	NOUN	I
was	O	AUX	O
inadvertently	O	ADV	O
injected	O	VERB	B
with	O	ADP	O
8	O	NUM	O
mg	O	NOUN	O
of	O	ADP	O
epinephrine	B-Chemical	NOUN	B
developed	O	VERB	O
myocardial	B-Disease	ADJ	B
stunning	I-Disease	NOUN	I
that	O	PRON	O
was	O	AUX	O
characterized	O	VERB	B
by	O	ADP	O
severe	O	ADJ	B
hemodynamic	O	ADJ	B
compromise	O	NOUN	B
,	O	PUNCT	O
profound	O	ADJ	O
,	O	PUNCT	O
albeit	O	SCONJ	O
transient	O	ADJ	B
,	O	PUNCT	O
left	B-Disease	VERB	B
ventricular	I-Disease	ADJ	I
systolic	I-Disease	NOUN	I
and	I-Disease	CCONJ	O
diastolic	I-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
only	O	ADV	O
modestly	O	ADV	O
elevated	O	ADJ	B
biochemical	O	ADJ	B
markers	O	NOUN	B
of	O	ADP	O
myocardial	B-Disease	ADJ	B
necrosis	I-Disease	NOUN	I


Urinary	B-Disease	ADJ	B
bladder	I-Disease	NOUN	I
cancer	I-Disease	NOUN	I
in	O	ADP	O
Wegener's	B-Disease	NOUN	B
granulomatosis	I-Disease	NOUN	I
:	O	PUNCT	O
risks	O	NOUN	B
and	O	CCONJ	O
relation	O	NOUN	O
to	O	PART	O
cyclophosphamide	B-Chemical	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	B
:	O	PUNCT	O
To	O	PART	O
assess	O	VERB	B
and	O	CCONJ	O
characterise	O	VERB	B
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
bladder	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
its	O	PRON	O
relation	O	NOUN	O
to	O	PART	O
cyclophosphamide	B-Chemical	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
Wegener's	B-Disease	NOUN	B
granulomatosis	I-Disease	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
In	O	ADP	O
the	O	DET	O
population	O	NOUN	B
based	O	VERB	O
,	O	PUNCT	O
nationwide	O	ADJ	B
Swedish	O	ADJ	I
Inpatient	O	PROPN	I
Register	O	PROPN	I
a	O	DET	I
cohort	O	NOUN	B
of	O	ADP	O
1065	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
Wegener's	B-Disease	NOUN	B
granulomatosis	I-Disease	NOUN	I
,	O	PUNCT	O
1969	O	NUM	O
-	O	SYM	O
95	O	NUM	O
,	O	PUNCT	O
was	O	AUX	O
identified	O	VERB	B
.	O	PUNCT	O


Through	O	ADP	O
linkage	O	NOUN	B
with	O	ADP	O
the	O	DET	O
Swedish	O	PROPN	B
Cancer	B-Disease	PROPN	I
Register	O	PROPN	I
,	O	PUNCT	O
all	O	DET	O
subjects	O	NOUN	B
in	O	ADP	O
this	O	DET	O
cohort	O	NOUN	B
diagnosed	O	VERB	O
with	O	ADP	O
bladder	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
were	O	AUX	O
identified	O	VERB	B
.	O	PUNCT	O


Nested	O	VERB	B
within	O	ADP	O
the	O	DET	O
cohort	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
matched	O	ADJ	O
case	O	NOUN	B
-	O	PUNCT	O
control	O	NOUN	B
study	O	NOUN	I
was	O	AUX	O
performed	O	VERB	O
to	O	PART	O
estimate	O	VERB	B
the	O	DET	O
association	O	NOUN	B
between	O	ADP	O
cyclophosphamide	B-Chemical	NOUN	B
and	O	CCONJ	O
bladder	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
using	O	VERB	O
odds	O	NOUN	B
ratios	O	NOUN	I
(	O	PUNCT	O
ORs	O	NOUN	B
)	O	PUNCT	O
as	O	ADP	O
relative	O	ADJ	B
risk	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
cohort	O	NOUN	B
the	O	DET	O
cumulative	O	ADJ	B
risk	O	NOUN	B
of	O	ADP	O
bladder	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
after	O	ADP	O
Wegener's	B-Disease	NOUN	B
granulomatosis	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
relative	O	ADJ	B
prevalence	O	NOUN	I
of	O	ADP	O
a	O	DET	O
history	O	NOUN	B
of	O	ADP	O
bladder	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
at	O	ADP	O
the	O	DET	O
time	O	NOUN	B
of	O	ADP	O
diagnosis	O	NOUN	B
of	O	ADP	O
Wegener's	B-Disease	NOUN	B
granulomatosis	I-Disease	NOUN	I
,	O	PUNCT	O
were	O	AUX	O
also	O	ADV	O
estimated	O	VERB	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
median	O	ADJ	B
cumulative	O	ADJ	B
doses	O	NOUN	B
of	O	ADP	O
cyclophosphamide	B-Chemical	NOUN	B
among	O	ADP	O
cases	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
11	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
controls	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
25	O	NUM	O
)	O	PUNCT	O
were	O	AUX	O
113	O	NUM	O
g	O	NOUN	O
and	O	CCONJ	O
25	O	NUM	O
g	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
bladder	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
doubled	O	VERB	B
for	O	ADP	O
every	O	DET	O
10	O	NUM	O
g	O	NOUN	O
increment	O	NOUN	B
in	O	ADP	O
cyclophosphamide	B-Chemical	NOUN	B
(	O	PUNCT	O
OR	O	NOUN	B
=	O	ADJ	O
2	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
(	O	PUNCT	O
CI	O	NOUN	B
)	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
to	O	PART	O
4	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
).	O	PUNCT	B
Treatment	O	NOUN	B
duration	O	NOUN	O
longer	O	ADV	O
than	O	ADP	O
1	O	NUM	O
year	O	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
an	O	DET	O
eightfold	O	ADV	O
increased	O	VERB	B
risk	O	NOUN	B
(	O	PUNCT	O
OR	O	NOUN	B
=	O	ADJ	O
7	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
0	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
to	O	PART	O
69	O	NUM	O
).	O	PUNCT	O
The	O	DET	O
absolute	O	ADJ	B
risk	O	NOUN	I
for	O	ADP	O
bladder	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
in	O	ADP	O
the	O	DET	O
cohort	O	NOUN	B
reached	O	VERB	O
10	O	NUM	O
%	O	NOUN	O
16	O	NUM	O
years	O	NOUN	B
after	O	ADP	O
diagnosis	O	NOUN	B
of	O	ADP	O
Wegener's	B-Disease	NOUN	B
granulomatosis	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
history	O	NOUN	B
of	O	ADP	O
bladder	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
was	O	AUX	O
(	O	PUNCT	O
non	O	ADJ	B
-	O	PUNCT	O
significantly	O	ADV	B
)	O	PUNCT	O
twice	O	ADV	O
as	O	ADV	O
common	O	ADJ	O
as	O	ADP	O
expected	O	VERB	O
at	O	ADP	O
the	O	DET	O
time	O	NOUN	B
of	O	ADP	O
diagnosis	O	NOUN	B
of	O	ADP	O
Wegener's	B-Disease	NOUN	B
granulomatosis	I-Disease	NOUN	I
.	O	PUNCT	O


CONCLUSION	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
results	O	NOUN	B
indicate	O	VERB	O
a	O	DET	O
dose	O	NOUN	B
-	O	PUNCT	O
response	O	NOUN	B
relationship	O	NOUN	B
between	O	ADP	O
cyclophosphamide	B-Chemical	NOUN	B
and	O	CCONJ	O
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
bladder	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
,	O	PUNCT	O
high	O	ADJ	O
cumulative	O	ADJ	B
risks	O	NOUN	B
in	O	ADP	O
the	O	DET	O
entire	O	ADJ	O
cohort	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
also	O	ADV	O
the	O	DET	O
possibility	O	NOUN	O
of	O	ADP	O
risk	O	NOUN	B
factors	O	NOUN	I
operating	O	VERB	B
even	O	ADV	O
before	O	ADP	O
Wegener's	B-Disease	NOUN	B
granulomatosis	I-Disease	NOUN	I


L-arginine	B-Chemical	NOUN	B
transport	O	NOUN	B
in	O	ADP	O
humans	O	NOUN	B
with	O	ADP	O
cortisol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypertension	B-Disease	NOUN	B
.	O	PUNCT	O


A	O	DET	O
deficient	O	ADJ	B
L-arginine	B-Chemical	NOUN	B
-	O	PUNCT	O
nitric	B-Chemical	ADJ	B
oxide	I-Chemical	NOUN	I
system	O	NOUN	I
is	O	AUX	O
implicated	O	VERB	O
in	O	ADP	O
cortisol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypertension	B-Disease	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
investigate	O	VERB	B
whether	O	SCONJ	O
abnormalities	O	NOUN	B
in	O	ADP	O
L-arginine	B-Chemical	NOUN	B
uptake	O	NOUN	B
contribute	O	VERB	O
to	O	PART	O
this	O	DET	O
deficiency	O	NOUN	B
.	O	PUNCT	O


Eight	O	NUM	O
healthy	O	ADJ	B
men	O	NOUN	B
were	O	AUX	O
recruited	O	VERB	O
.	O	PUNCT	O


Hydrocortisone	B-Chemical	NOUN	B
acetate	I-Chemical	NOUN	B
(	O	PUNCT	O
50	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
was	O	AUX	O
given	O	VERB	O
orally	O	ADV	B
every	O	DET	O
6	O	NUM	O
hours	O	NOUN	B
for	O	ADP	O
24	O	NUM	O
hours	O	NOUN	B
after	O	ADP	O
a	O	DET	O
5	O	NUM	O
-	O	PUNCT	O
day	O	NOUN	B
fixed	O	VERB	B
-	O	PUNCT	O
salt	O	NOUN	B
diet	O	NOUN	I
(	O	PUNCT	O
150	O	NUM	O
mmol	O	NOUN	O
/	O	SYM	O
d	O	X	B
).	O	PUNCT	B
Crossover	O	NOUN	B
studies	O	NOUN	I
were	O	AUX	O
performed	O	VERB	O
2	O	NUM	O
weeks	O	NOUN	B
apart	O	ADV	O
.	O	PUNCT	O


Thirty	O	NUM	O
milliliters	O	NOUN	B
of	O	ADP	O
blood	O	NOUN	B
was	O	AUX	O
obtained	O	VERB	O
for	O	ADP	O
isolation	O	NOUN	B
of	O	ADP	O
peripheral	O	ADJ	B
blood	O	NOUN	I
mononuclear	O	ADJ	I
cells	O	NOUN	I
after	O	ADP	O
each	O	DET	O
treatment	O	NOUN	B
period	O	NOUN	B
.	O	PUNCT	O


L-arginine	B-Chemical	NOUN	B
uptake	O	NOUN	B
was	O	AUX	O
assessed	O	VERB	B
in	O	ADP	O
mononuclear	O	ADJ	B
cells	O	NOUN	I
incubated	O	VERB	B
with	O	ADP	O
L-arginine	B-Chemical	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
to	O	PART	O
300	O	NUM	O
micromol	O	NOUN	B
/	O	PUNCT	O
L	O	PROPN	B
),	O	PUNCT	O
incorporating	O	VERB	B
100	O	NUM	O
nmol	O	NOUN	B
/	O	SYM	O
L	O	NOUN	B
[3H]-l-arginine	B-Chemical	X	B
for	O	ADP	O
a	O	DET	O
period	O	NOUN	B
of	O	ADP	O
5	O	NUM	O
minutes	O	NOUN	B
at	O	ADP	O
37	O	NUM	O
degrees	O	NOUN	B
C	O	NOUN	I
.	O	PUNCT	O


Forearm	O	NOUN	B
[3H]-L-arginine	B-Chemical	PUNCT	B
extraction	O	NOUN	O
was	O	AUX	O
calculated	O	VERB	O
after	O	ADP	O
infusion	O	NOUN	B
of	O	ADP	O
[3H]-L-arginine	B-Chemical	X	B
into	O	ADP	O
the	O	DET	O
brachial	O	ADJ	B
artery	O	NOUN	I
at	O	ADP	O
a	O	DET	O
rate	O	NOUN	B
of	O	ADP	O
100	O	NUM	O
nCi	O	NOUN	B
/	O	SYM	O
min	O	NOUN	B
for	O	ADP	O
80	O	NUM	O
minutes	O	NOUN	B
.	O	PUNCT	O


Deep	O	ADJ	B
forearm	O	NOUN	I
venous	O	ADJ	B
samples	O	NOUN	I
were	O	AUX	O
collected	O	VERB	O
for	O	ADP	O
determination	O	NOUN	B
of	O	ADP	O
L-arginine	B-Chemical	NOUN	B
extraction	O	NOUN	B
.	O	PUNCT	O


Plasma	O	NOUN	B
cortisol	B-Chemical	NOUN	B
concentrations	O	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
raised	O	VERB	O
during	O	ADP	O
the	O	DET	O
active	O	ADJ	B
phase	O	NOUN	I
(	O	PUNCT	O
323	O	NUM	O
+/-	O	CCONJ	O
43	O	NUM	O
to	O	PART	O
1082	O	NUM	O
+/-	O	CCONJ	O
245	O	NUM	O
mmol	O	NOUN	B
/	O	SYM	O
L	O	NOUN	B
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
).	O	PUNCT	O
Systolic	O	NOUN	B
blood	O	NOUN	I
pressure	O	NOUN	I
was	O	AUX	O
elevated	O	VERB	B
by	O	ADP	O
an	O	DET	O
average	O	NOUN	B
of	O	ADP	O
7	O	NUM	O
mm	O	NOUN	B
Hg	O	NOUN	I
.	O	PUNCT	O


Neither	O	CCONJ	O
L-arginine	B-Chemical	NOUN	B
transport	O	NOUN	B
into	O	ADP	O
mononuclear	O	ADJ	B
cells	O	NOUN	I
(	O	PUNCT	O
placebo	O	NOUN	B
vs	O	CCONJ	O
active	O	ADJ	B
,	O	PUNCT	O
26	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
+/-	O	CCONJ	O
3	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
vs	O	CCONJ	O
29	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
+/-	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
pmol	O	NOUN	B
/	O	SYM	O
10	O	NUM	O
000	O	NUM	O
cells	O	NOUN	B
per	O	ADP	O
5	O	NUM	O
minutes	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
at	O	ADP	O
an	O	DET	O
l-arginine	B-Chemical	NOUN	B
concentration	O	NOUN	B
of	O	ADP	O
300	O	NUM	O
micromol	O	NOUN	B
/	O	SYM	O
L	O	NOUN	B
)	O	PUNCT	O
nor	O	CCONJ	O
L-arginine	B-Chemical	NOUN	B
extraction	O	NOUN	O
in	O	ADP	O
the	O	DET	O
forearm	O	NOUN	B
(	O	PUNCT	O
at	O	ADP	O
80	O	NUM	O
minutes	O	NOUN	B
,	O	PUNCT	O
placebo	O	NOUN	B
vs	O	CCONJ	O
active	O	ADJ	B
,	O	PUNCT	O
1	O	NUM	O
868	O	NUM	O
904	O	NUM	O
+/-	O	CCONJ	O
434	O	NUM	O
962	O	NUM	O
vs	O	CCONJ	O
2	O	NUM	O
013	O	NUM	O
910	O	NUM	O
+/-	O	CCONJ	O
770	O	NUM	O
619	O	NUM	O
disintegrations	O	NOUN	B
per	O	ADP	I
minute	O	NOUN	I
)	O	PUNCT	O
was	O	AUX	O
affected	O	VERB	B
by	O	ADP	O
cortisol	B-Chemical	NOUN	B
treatment	O	NOUN	I
;	O	PUNCT	O
ie	O	X	O
,	O	PUNCT	O
that	O	SCONJ	O
L-arginine	B-Chemical	NOUN	B
uptake	O	NOUN	B
is	O	AUX	O
not	O	PART	O
affected	O	VERB	O
by	O	ADP	O
short	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
cortisol	B-Chemical	NOUN	B
treatment	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
cortisol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
increases	B-Disease	NOUN	B
in	I-Disease	ADP	O
blood	I-Disease	NOUN	B
pressure	I-Disease	NOUN	I
are	O	AUX	O
not	O	PART	O
associated	O	VERB	B
with	O	ADP	I
abnormalities	O	NOUN	B
in	O	ADP	O
the	O	DET	O
l-arginine	B-Chemical	NOUN	B


MR	O	NOUN	B
imaging	O	VERB	I
with	O	ADP	O
quantitative	O	ADJ	B
diffusion	O	NOUN	I
mapping	O	NOUN	I
of	O	ADP	O
tacrolimus	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
neurotoxicity	B-Disease	NOUN	B
in	O	ADP	O
organ	O	NOUN	B
transplant	O	NOUN	I
patients	O	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
objective	O	NOUN	B
was	O	AUX	O
to	O	PART	O
investigate	O	VERB	B
brain	O	NOUN	B
MR	O	NOUN	I
imaging	O	NOUN	I
findings	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
utility	O	NOUN	O
of	O	ADP	O
diffusion	O	NOUN	B
-	O	PUNCT	O
weighted	O	VERB	B
(	O	PUNCT	O
DW	O	NOUN	B
)	O	PUNCT	O
imaging	O	NOUN	B
in	O	ADP	O
organ	O	NOUN	B
transplant	O	NOUN	I
patients	O	NOUN	B
who	O	PRON	O
developed	O	VERB	O
neurologic	O	ADJ	B
symptoms	O	NOUN	I
during	O	ADP	O
tacrolimus	B-Chemical	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


Brain	O	PROPN	B
MR	O	PROPN	I
studies	O	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
DW	O	PROPN	B
imaging	O	NOUN	I
,	O	PUNCT	O
were	O	AUX	O
prospectively	O	ADV	O
performed	O	VERB	O
in	O	ADP	O
14	O	NUM	O
organ	O	NOUN	B
transplant	O	NOUN	I
patients	O	NOUN	B
receiving	O	VERB	O
tacrolimus	B-Chemical	NOUN	B
who	O	PRON	O
developed	O	VERB	O
neurologic	B-Disease	ADJ	B
complications	I-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
each	O	DET	O
patient	O	NOUN	B
who	O	PRON	O
had	O	AUX	O
abnormalities	O	NOUN	B
on	O	ADP	O
the	O	DET	O
initial	O	ADJ	B
MR	O	NOUN	B
study	O	NOUN	O
,	O	PUNCT	O
a	O	DET	O
follow	O	NOUN	B
-	O	PUNCT	O
up	O	ADP	B
MR	O	NOUN	B
study	O	NOUN	O
was	O	AUX	O
performed	O	VERB	O
1	O	NUM	O
month	O	NOUN	B
later	O	ADV	O
.	O	PUNCT	O


Apparent	O	ADJ	B
diffusion	O	NOUN	I
coefficient	O	NOUN	I
(	O	PUNCT	O
ADC	O	NOUN	B
)	O	PUNCT	O
values	O	NOUN	B
on	O	ADP	O
the	O	DET	O
initial	O	ADJ	B
MR	O	NOUN	B
study	O	NOUN	I
were	O	AUX	O
correlated	O	VERB	B
with	O	ADP	O
reversibility	O	NOUN	B
of	O	ADP	O
the	O	DET	O
lesions	O	NOUN	B
.	O	PUNCT	O


Of	O	ADP	O
the	O	DET	O
14	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
5	O	NUM	O
(	O	PUNCT	O
35	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
%)	O	NOUN	O
had	O	AUX	O
white	B-Disease	ADJ	B
matter	I-Disease	NOUN	I
abnormalities	I-Disease	NOUN	B
,	O	PUNCT	O
1	O	NUM	O
(	O	PUNCT	O
7	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
%)	O	NOUN	O
had	O	AUX	O
putaminal	B-Disease	ADJ	B
hemorrhage	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
8	O	NUM	O
(	O	PUNCT	O
57	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
%)	O	NOUN	O
had	O	AUX	O
normal	O	ADJ	O
findings	O	NOUN	B
on	O	ADP	O
initial	O	ADJ	O
MR	O	NOUN	B
images	O	NOUN	B
.	O	PUNCT	O


Among	O	ADP	O
the	O	DET	O
5	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
white	B-Disease	ADJ	B
matter	I-Disease	NOUN	I
abnormalities	I-Disease	NOUN	I
,	O	PUNCT	O
4	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
80	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
%)	O	NOUN	O
showed	O	VERB	O
higher	O	ADJ	O
than	O	ADP	O
normal	O	ADJ	O
ADC	O	NOUN	B
values	O	NOUN	B
on	O	ADP	O
initial	O	ADJ	O
MR	O	NOUN	B
images	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
all	O	DET	O
showed	O	VERB	O
complete	O	ADJ	B
resolution	O	NOUN	B
on	O	ADP	O
follow	O	NOUN	B
-	O	PUNCT	O
up	O	ADP	O
images	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
remaining	O	VERB	O
1	O	NUM	O
patient	O	NOUN	B
(	O	PUNCT	O
20	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
%)	O	NOUN	O
showed	O	VERB	O
lower	O	ADJ	O
than	O	ADP	O
normal	O	ADJ	O
ADC	O	NOUN	B
value	O	NOUN	B
and	O	CCONJ	O
showed	O	VERB	O
incomplete	O	ADJ	B
resolution	O	NOUN	B
with	O	ADP	O
cortical	B-Disease	ADJ	B
laminar	I-Disease	ADJ	O
necrosis	I-Disease	NOUN	O
.	O	PUNCT	O


Diffusion	O	NOUN	B
-	O	PUNCT	O
weighted	O	VERB	B
imaging	O	NOUN	O
may	O	AUX	O
be	O	AUX	O
useful	O	ADJ	O
in	O	ADP	O
predicting	O	VERB	B
the	O	DET	O
outcomes	O	NOUN	B
of	O	ADP	O
the	O	DET	O
lesions	O	NOUN	B
of	O	ADP	O
tacrolimus	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
neurotoxicity	B-Disease	NOUN	B


Octreotide	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypoxemia	B-Disease	NOUN	B
and	O	CCONJ	O
pulmonary	B-Disease	ADJ	B
hypertension	I-Disease	NOUN	I
in	O	ADP	O
premature	O	ADJ	B
neonates	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
authors	O	NOUN	B
report	O	VERB	O
2	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
premature	O	ADJ	B
neonates	O	NOUN	I
who	O	PRON	O
had	O	AUX	O
enterocutaneous	O	ADJ	B
fistula	B-Disease	NOUN	I
complicating	O	VERB	O
necrotizing	B-Disease	NOUN	B
enterocolitis	I-Disease	NOUN	I
.	O	PUNCT	O


Pulmonary	B-Disease	ADJ	B
hypertension	I-Disease	NOUN	I
developed	O	VERB	O
after	O	ADP	O
administration	O	NOUN	B
of	O	ADP	O
a	O	DET	O
somatostatin	O	NOUN	B
analogue	O	NOUN	B
,	O	PUNCT	O
octreotide	B-Chemical	NOUN	B
,	O	PUNCT	O
to	O	PART	O
enhance	O	VERB	O
resolution	O	NOUN	B
of	O	ADP	O
the	O	DET	O
fistula	B-Disease	NOUN	B


Sequential	O	ADJ	B
observations	O	NOUN	B
of	O	ADP	O
exencephaly	B-Disease	NOUN	B
and	O	CCONJ	O
subsequent	O	ADJ	O
morphological	O	ADJ	B
changes	O	NOUN	B
by	O	ADP	O
mouse	O	NOUN	B
exo	O	NOUN	B
utero	O	NOUN	I
development	O	NOUN	O
system	O	NOUN	O
:	O	PUNCT	O
analysis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mechanism	O	NOUN	B
of	O	ADP	O
transformation	O	NOUN	B
from	O	ADP	O
exencephaly	B-Disease	NOUN	B
to	O	PART	O
anencephaly	B-Disease	NOUN	B
.	O	PUNCT	O


Anencephaly	B-Disease	PROPN	B
has	O	AUX	O
been	O	AUX	O
suggested	O	VERB	O
to	O	PART	O
develop	O	VERB	O
from	O	ADP	O
exencephaly	B-Disease	NOUN	B
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
there	O	PRON	O
is	O	AUX	O
little	O	ADJ	O
direct	O	ADJ	O
experimental	O	ADJ	B
evidence	O	NOUN	B
to	O	PART	O
support	O	VERB	O
this	O	DET	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
mechanism	O	NOUN	B
of	O	ADP	O
transformation	O	NOUN	B
remains	O	VERB	O
unclear	O	ADJ	B
.	O	PUNCT	O


We	O	PRON	O
examined	O	VERB	O
this	O	DET	O
theory	O	NOUN	B
using	O	VERB	O
the	O	DET	O
exo	O	NOUN	B
utero	O	NOUN	I
development	O	NOUN	I
system	O	NOUN	O
that	O	PRON	O
allows	O	VERB	O
direct	O	ADJ	O
and	O	CCONJ	O
sequential	O	ADJ	B
observations	O	NOUN	B
of	O	ADP	O
mid	O	ADJ	B
-	O	PUNCT	O
to	O	PART	O
late	O	ADJ	B
-	O	PUNCT	O
gestation	O	NOUN	B
mouse	O	NOUN	B
embryos	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
observed	O	VERB	O
the	O	DET	O
exencephaly	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
5-azacytidine	B-Chemical	NOUN	B
at	O	ADP	O
embryonic	O	ADJ	B
day	O	NOUN	O
13	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
(	O	PUNCT	O
E13	O	NOUN	B
.	O	PUNCT	O


5	O	NUM	O
),	O	PUNCT	O
let	O	VERB	O
the	O	DET	O
embryos	O	NOUN	B
develop	O	VERB	O
exo	O	NOUN	B
utero	O	NOUN	I
until	O	ADP	O
E18	O	NOUN	B
.	O	PUNCT	O


5	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
re	O	ADP	B
-	O	PUNCT	O
observed	O	VERB	B
the	O	DET	O
same	O	ADJ	O
embryos	O	NOUN	B
at	O	ADP	O
E18	O	NOUN	B
.	O	PUNCT	O


5	O	NUM	O
.	O	PUNCT	O


We	O	PRON	O
confirmed	O	VERB	O
several	O	ADJ	O
cases	O	NOUN	B
of	O	ADP	O
transformation	O	NOUN	B
from	O	ADP	O
exencephaly	B-Disease	NOUN	B
to	O	PART	O
anencephaly	B-Disease	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
in	O	ADP	O
many	O	ADJ	O
cases	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
exencephalic	B-Disease	ADJ	B
brain	O	NOUN	O
tissue	O	NOUN	O
was	O	AUX	O
preserved	O	VERB	O
with	O	ADP	O
more	O	ADJ	O
or	O	CCONJ	O
less	O	ADJ	O
reduction	O	NOUN	B
during	O	ADP	O
this	O	DET	O
period	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
analyze	O	VERB	O
the	O	DET	O
transformation	O	NOUN	B
patterns	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
classified	O	VERB	O
the	O	DET	O
exencephaly	B-Disease	NOUN	B
by	O	ADP	O
size	O	NOUN	B
and	O	CCONJ	O
shape	O	NOUN	B
of	O	ADP	O
the	O	DET	O
exencephalic	B-Disease	ADJ	B
tissue	O	NOUN	I
into	O	ADP	O
several	O	ADJ	O
types	O	NOUN	O
at	O	ADP	O
E13	O	NOUN	B
.	O	PUNCT	O


5	O	NUM	O
and	O	CCONJ	O
E18	O	NOUN	B
.	O	PUNCT	O


5	O	NUM	O
.	O	PUNCT	O


It	O	PRON	O
was	O	AUX	O
found	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
transformation	O	NOUN	B
of	O	ADP	O
exencephalic	B-Disease	ADJ	B
tissue	O	NOUN	I
was	O	AUX	O
not	O	PART	O
simply	O	ADV	O
size	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
all	O	DET	O
cases	O	NOUN	B
of	O	ADP	O
anencephaly	B-Disease	NOUN	B
at	O	ADP	O
E18	O	NOUN	B
.	O	PUNCT	O


5	O	NUM	O
resulted	O	VERB	O
from	O	ADP	O
embryos	O	NOUN	B
with	O	ADP	O
a	O	DET	O
large	O	ADJ	O
amount	O	NOUN	O
of	O	ADP	O
exencephalic	B-Disease	ADJ	B
tissue	O	NOUN	I
at	O	ADP	O
E13	O	NOUN	B
.	O	PUNCT	O


5	O	NUM	O
.	O	PUNCT	O


Microscopic	O	ADJ	B
observation	O	NOUN	B
showed	O	VERB	O
the	O	DET	O
configuration	O	NOUN	B
of	O	ADP	O
exencephaly	B-Disease	NOUN	B
at	O	ADP	O
E13	O	NOUN	B
.	O	PUNCT	O


5	O	NUM	O
,	O	PUNCT	O
frequent	O	ADJ	O
hemorrhaging	B-Disease	NOUN	B
and	O	CCONJ	O
detachment	O	NOUN	B
of	O	ADP	O
the	O	DET	O
neural	O	ADJ	B
plate	O	NOUN	I
from	O	ADP	O
surface	O	NOUN	B
ectoderm	O	NOUN	O
in	O	ADP	O
the	O	DET	O
exencephalic	B-Disease	ADJ	B
head	O	NOUN	I
at	O	ADP	O
E15	O	NOUN	B
.	O	PUNCT	O


5	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
multiple	O	ADJ	B
modes	O	NOUN	B
of	O	ADP	O
reduction	O	NOUN	B
in	O	ADP	O
the	O	DET	O
exencephalic	B-Disease	ADJ	B
tissue	O	NOUN	I
at	O	ADP	O
E18	O	NOUN	B
.	O	PUNCT	O


5	O	NUM	O
.	O	PUNCT	O


From	O	ADP	O
observations	O	NOUN	B
of	O	ADP	O
the	O	DET	O
vasculature	O	NOUN	B
,	O	PUNCT	O
altered	O	ADJ	O
distribution	O	NOUN	B
patterns	O	NOUN	O
of	O	ADP	O
vessels	O	NOUN	B
were	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
the	O	DET	O
exencephalic	B-Disease	ADJ	B
head	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
overgrowth	O	NOUN	B
of	O	ADP	O
the	O	DET	O
exencephalic	B-Disease	ADJ	B
neural	O	ADJ	B
tissue	O	NOUN	I
causes	O	VERB	O
the	O	DET	O
altered	O	ADJ	O
distribution	O	NOUN	B
patterns	O	NOUN	O
of	O	ADP	O
vessels	O	NOUN	B
,	O	PUNCT	O
subsequent	O	ADJ	O
peripheral	O	ADJ	B
circulatory	B-Disease	ADJ	I
failure	I-Disease	NOUN	O
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
hemorrhaging	B-Disease	NOUN	B
in	O	ADP	O
various	O	ADJ	O
parts	O	NOUN	B
of	O	ADP	O
the	O	DET	O
exencephalic	B-Disease	ADJ	B
head	O	NOUN	I
,	O	PUNCT	O
leading	O	VERB	O
to	O	PART	O
the	O	DET	O
multiple	O	ADJ	B
modes	O	NOUN	B
of	O	ADP	O
tissue	O	NOUN	B
reduction	O	NOUN	B
during	O	ADP	O
transformation	O	NOUN	B
from	O	ADP	O
exencephaly	B-Disease	NOUN	B
to	O	PART	O
anencephaly	B-Disease	NOUN	B


Acute	O	ADJ	B
cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
seizures	B-Disease	NOUN	B
:	O	PUNCT	O
differential	O	ADJ	B
sensitivity	O	NOUN	I
of	O	ADP	O
six	O	NUM	O
inbred	O	ADJ	B
mouse	O	NOUN	O
strains	O	NOUN	O
.	O	PUNCT	O


Mature	O	ADJ	B
male	O	NOUN	B
and	O	CCONJ	O
female	O	ADJ	B
mice	O	NOUN	I
from	O	ADP	O
six	O	NUM	O
inbred	O	ADJ	B
stains	O	NOUN	I
were	O	AUX	O
tested	O	VERB	B
for	O	ADP	O
susceptibility	O	NOUN	B
to	O	PART	O
behavioral	O	ADJ	B
seizures	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
a	O	DET	O
single	O	ADJ	O
injection	O	NOUN	B
of	O	ADP	O
cocaine	B-Chemical	NOUN	B
.	O	PUNCT	O


Cocaine	B-Chemical	NOUN	B
was	O	AUX	O
injected	O	VERB	B
ip	O	NOUN	B
over	O	ADP	O
a	O	DET	O
range	O	NOUN	O
of	O	ADP	O
doses	O	NOUN	B
(	O	PUNCT	O
50	O	NUM	O
-	O	SYM	O
100	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
behavior	O	NOUN	B
was	O	AUX	O
monitored	O	VERB	B
for	O	ADP	O
20	O	NUM	O
minutes	O	NOUN	B
.	O	PUNCT	O


Seizure	B-Disease	NOUN	B
end	O	NOUN	O
points	O	NOUN	O
included	O	VERB	O
latency	O	NOUN	B
to	O	PART	O
forelimb	O	NOUN	B
or	O	CCONJ	O
hindlimb	O	ADJ	B
clonus	O	NOUN	B
,	O	PUNCT	O
latency	O	NOUN	B
to	O	PART	O
clonic	O	ADJ	B
running	O	NOUN	I
seizure	B-Disease	NOUN	I
and	O	CCONJ	O
latency	O	NOUN	B
to	O	ADP	O
jumping	O	VERB	B
bouncing	O	ADJ	B
seizure	B-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
range	O	NOUN	O
of	O	ADP	O
strain	O	NOUN	B
specific	O	ADJ	O
sensitivities	O	NOUN	B
was	O	AUX	O
documented	O	VERB	B
with	O	ADP	O
A	O	DET	B
/	O	SYM	O
J	O	PROPN	B
and	O	CCONJ	O
SJL	O	NOUN	B
mice	O	NOUN	I
being	O	AUX	O
most	O	ADV	O
sensitive	O	ADJ	B
and	O	CCONJ	O
C57BL	O	NOUN	B
/	O	SYM	O
6J	O	NOUN	B
most	O	ADV	O
resistant	O	ADJ	B
.	O	PUNCT	O


DBA	O	PROPN	B
/	O	SYM	O
2J	O	PROPN	B
,	O	PUNCT	O
BALB	O	PROPN	B
/	O	SYM	O
cByJ	O	PROPN	B
and	O	CCONJ	O
NZW	O	NOUN	B
/	O	SYM	O
LacJ	O	NOUN	B
strains	O	NOUN	B
exhibited	O	VERB	O
intermediate	O	ADJ	B
sensitivity	O	NOUN	I
.	O	PUNCT	O


EEG	O	NOUN	B
recordings	O	NOUN	B
were	O	AUX	O
made	O	VERB	O
in	O	ADP	O
SJL	O	NOUN	B
,	O	PUNCT	O
A	O	DET	B
/	O	SYM	O
J	O	PROPN	B
and	O	CCONJ	O
C57BL	O	NOUN	B
/	O	SYM	O
6J	O	NOUN	B
mice	O	NOUN	B
revealing	O	VERB	O
a	O	DET	O
close	O	ADJ	O
correspondence	O	NOUN	B
between	O	ADP	O
electrical	O	ADJ	B
activity	O	NOUN	I
and	O	CCONJ	O
behavior	O	NOUN	B
.	O	PUNCT	O


Additionally	O	ADV	O
,	O	PUNCT	O
levels	O	NOUN	B
of	O	ADP	O
cocaine	B-Chemical	NOUN	B
determined	O	VERB	O
in	O	ADP	O
hippocampus	O	NOUN	B
and	O	CCONJ	O
cortex	O	NOUN	B
were	O	AUX	O
not	O	PART	O
different	O	ADJ	O
between	O	ADP	O
sensitive	O	ADJ	B
and	O	CCONJ	O
resistant	O	ADJ	B
strains	O	NOUN	B
.	O	PUNCT	O


Additional	O	ADJ	O
studies	O	NOUN	B
of	O	ADP	O
these	O	DET	O
murine	O	ADJ	B
strains	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
useful	O	ADJ	O
for	O	ADP	O
investigating	O	VERB	B
genetic	O	ADJ	B
influences	O	NOUN	B
on	O	ADP	O
cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
seizures	B-Disease	NOUN	B


Microangiopathic	B-Disease	ADJ	B
hemolytic	I-Disease	ADJ	I
anemia	I-Disease	NOUN	I
complicating	O	VERB	O
FK506	B-Chemical	NOUN	B
(	O	PUNCT	O
tacrolimus	B-Chemical	NOUN	B
)	O	PUNCT	O
therapy	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
describe	O	VERB	O
3	O	NUM	O
episodes	O	NOUN	B
of	O	ADP	O
microangiopathic	B-Disease	ADJ	B
hemolytic	I-Disease	ADJ	O
anemia	I-Disease	NOUN	O
(	O	PUNCT	O
MAHA	B-Disease	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
2	O	NUM	O
solid	O	ADJ	B
organ	O	NOUN	I
recipients	O	NOUN	I
under	O	ADP	O
FK506	B-Chemical	NOUN	B
(	O	PUNCT	O
tacrolimus	B-Chemical	NOUN	B
)	O	PUNCT	O
therapy	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
both	O	DET	O
cases	O	NOUN	B
,	O	PUNCT	O
discontinuation	O	NOUN	B
of	O	ADP	O
FK506	B-Chemical	NOUN	B
and	O	CCONJ	O
treatment	O	NOUN	B
with	O	ADP	O
plasma	O	NOUN	B
exchange	O	NOUN	I
,	O	PUNCT	O
fresh	O	ADJ	B
frozen	O	ADJ	B
plasma	O	NOUN	I
replacement	O	NOUN	I
,	O	PUNCT	O
corticosteroids	B-Chemical	NOUN	B
,	O	PUNCT	O
aspirin	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
dipyridamole	B-Chemical	NOUN	B
led	O	VERB	O
to	O	PART	O
resolution	O	NOUN	B
of	O	ADP	O
MAHA	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
one	O	NUM	O
patient	O	NOUN	B
,	O	PUNCT	O
reintroduction	O	NOUN	B
of	O	ADP	O
FK506	B-Chemical	NOUN	B
led	O	VERB	O
to	O	PART	O
rapid	O	ADJ	O
recurrence	O	NOUN	B
of	O	ADP	O
MAHA	B-Disease	NOUN	B
.	O	PUNCT	O


FK506	B-Chemical	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
MAHA	B-Disease	NOUN	B
is	O	AUX	O
probably	O	ADV	O
rare	O	ADJ	B
but	O	CCONJ	O
physicians	O	NOUN	B
must	O	AUX	O
be	O	AUX	O
aware	O	ADJ	O
of	O	ADP	O
this	O	DET	O
severe	O	ADJ	B
complication	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
our	O	PRON	O
experience	O	NOUN	B
and	O	CCONJ	O
according	O	VERB	O
to	O	ADP	O
the	O	DET	O
literature	O	NOUN	B
,	O	PUNCT	O
FK506	B-Chemical	NOUN	B
does	O	AUX	O
not	O	PART	O
seem	O	VERB	O
to	O	PART	O
cross	O	VERB	B
-	O	PUNCT	O
react	O	VERB	B
with	O	ADP	O
cyclosporin	B-Chemical	NOUN	B
A	I-Chemical	NOUN	I
(	O	PUNCT	O
CyA	B-Chemical	NOUN	B
),	O	PUNCT	O
an	O	DET	O
immuno	O	NOUN	B
-	O	PUNCT	O
suppressive	O	ADJ	B
drug	O	NOUN	B
already	O	ADV	O
known	O	VERB	O
to	O	PART	O
induce	O	VERB	B
MAHA	B-Disease	NOUN	B


Variant	O	ADJ	B
ventricular	B-Disease	ADJ	B
tachycardia	I-Disease	NOUN	I
in	O	ADP	O
desipramine	B-Chemical	NOUN	B
toxicity	B-Disease	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
variant	O	ADJ	B
ventricular	B-Disease	ADJ	B
tachycardia	I-Disease	NOUN	I
induced	O	VERB	B
by	O	ADP	O
desipramine	B-Chemical	NOUN	B
toxicity	B-Disease	NOUN	B
.	O	PUNCT	O


Unusual	O	ADJ	B
features	O	NOUN	B
of	O	ADP	O
the	O	DET	O
arrhythmia	B-Disease	NOUN	B
are	O	AUX	O
repetitive	O	ADJ	B
group	O	NOUN	I
beating	O	NOUN	I
,	O	PUNCT	O
progressive	O	ADJ	B
shortening	O	NOUN	B
of	O	ADP	O
the	O	DET	O
R	O	PROPN	B
-	O	PUNCT	O
R	O	PROPN	B
interval	O	NOUN	B
,	O	PUNCT	O
progressive	O	ADJ	B
widening	O	NOUN	B
of	O	ADP	O
the	O	DET	O
QRS	O	NOUN	B
complex	O	NOUN	I
with	O	ADP	O
eventual	O	ADJ	O
failure	O	NOUN	B
of	O	ADP	O
intraventricular	O	ADJ	B
conduction	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
changes	O	NOUN	B
in	O	ADP	O
direction	O	NOUN	B
of	O	ADP	O
the	O	DET	O
QRS	O	NOUN	B
axis	O	NOUN	I
.	O	PUNCT	O


Recognition	O	NOUN	B
of	O	ADP	O
variant	O	ADJ	B
ventricular	B-Disease	ADJ	B
tachycardia	I-Disease	NOUN	I
is	O	AUX	O
important	O	ADJ	O
because	O	SCONJ	O
therapy	O	NOUN	B
differs	O	VERB	O
from	O	ADP	O
that	O	DET	O
of	O	ADP	O
classic	O	ADJ	B
ventricular	B-Disease	ADJ	B
tachycardia	I-Disease	NOUN	I


Desipramine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
delirium	B-Disease	NOUN	B
at	O	ADP	O
"	O	PUNCT	O
subtherapeutic	O	ADJ	B
"	O	PUNCT	O
concentrations	O	NOUN	B
:	O	PUNCT	O
a	O	DET	O
case	O	NOUN	B
report	O	NOUN	I
.	O	PUNCT	O


An	O	DET	O
elderly	O	ADJ	B
patient	O	NOUN	O
treated	O	VERB	B
with	O	ADP	I
low	O	ADJ	B
dose	O	NOUN	I
Desipramine	B-Chemical	NOUN	B
developed	O	VERB	O
a	O	DET	O
delirium	B-Disease	NOUN	B
while	O	SCONJ	O
her	O	PRON	O
plasma	O	NOUN	B
level	O	NOUN	B
was	O	AUX	O
in	O	ADP	O
the	O	DET	O
"	O	PUNCT	O
subtherapeutic	O	ADJ	B
"	O	PUNCT	O
range	O	NOUN	B
.	O	PUNCT	O


Delirium	B-Disease	NOUN	B
,	O	PUNCT	O
which	O	DET	O
may	O	AUX	O
be	O	AUX	O
induced	O	VERB	B
by	O	ADP	O
tricyclic	O	ADJ	B
drug	O	NOUN	I
therapy	O	NOUN	I
in	O	ADP	O
the	O	DET	O
elderly	O	ADJ	B
,	O	PUNCT	O
can	O	AUX	O
be	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
tricyclics	O	NOUN	B
with	O	ADP	O
low	O	ADJ	O
anticholinergic	O	ADJ	B
potency	O	NOUN	B
.	O	PUNCT	O


Therapeutic	O	ADJ	B
ranges	O	NOUN	I
for	O	ADP	O
antidepressants	B-Chemical	NOUN	B


Mouse	O	NOUN	B
strain	O	NOUN	I
-	O	PUNCT	O
dependent	O	ADJ	B
effect	O	NOUN	B
of	O	ADP	O
amantadine	B-Chemical	NOUN	B
on	O	ADP	O
motility	O	NOUN	B
and	O	CCONJ	O
brain	O	NOUN	B
biogenic	O	ADJ	B
amines	B-Chemical	NOUN	I
.	O	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
amantadine	B-Chemical	NOUN	B
hydrochloride	I-Chemical	NOUN	B
,	O	PUNCT	O
injected	O	VERB	B
i	O	X	O
.	O	PUNCT	O


p	O	NOUN	O
.	O	PUNCT	O


in	O	ADP	O
6	O	NUM	O
increments	O	NOUN	B
of	O	ADP	O
100	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
kg	O	NOUN	O
each	O	DET	O
over	O	ADP	O
30	O	NUM	O
hr	O	NOUN	O
,	O	PUNCT	O
on	O	ADP	O
mouse	O	NOUN	B
motility	O	NOUN	I
and	O	CCONJ	O
whole	O	ADJ	O
brain	O	NOUN	B
content	O	NOUN	B
of	O	ADP	O
selected	O	VERB	O
biogenic	O	ADJ	B
amines	B-Chemical	NOUN	I
and	O	CCONJ	O
major	O	ADJ	O
metabolites	O	NOUN	B
was	O	AUX	O
studied	O	VERB	O
in	O	ADP	O
4	O	NUM	O
strains	O	NOUN	B
of	O	ADP	O
mice	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
were	O	AUX	O
the	O	DET	O
albino	O	ADJ	B
Sprague	O	PROPN	B
-	O	PUNCT	O
Dawley	O	PROPN	B
ICR	O	PROPN	B
and	O	CCONJ	O
BALB	O	NOUN	B
/	O	SYM	O
C	O	PROPN	B
,	O	PUNCT	O
the	O	DET	O
black	O	ADJ	B
C57BL	O	NOUN	B
/	O	SYM	O
6	O	NUM	B
and	O	CCONJ	O
the	O	DET	O
brown	O	ADJ	B
CDF	O	PROPN	I
-	O	PUNCT	O
I	O	NOUN	B
mouse	O	NOUN	B
strains	O	NOUN	O
.	O	PUNCT	O


Amantadine	B-Chemical	NOUN	B
treatment	O	NOUN	B
produced	O	VERB	O
a	O	DET	O
biphasic	O	ADJ	B
effect	O	NOUN	I
on	O	ADP	O
mouse	O	NOUN	B
motility	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
initial	O	ADJ	B
dose	O	NOUN	B
of	O	ADP	O
amantadine	B-Chemical	NOUN	B
depressed	B-Disease	ADJ	O
locomotor	O	NOUN	B
activity	O	NOUN	I
in	O	ADP	O
all	O	DET	O
mouse	O	NOUN	B
strains	O	NOUN	B
studied	O	VERB	O
with	O	ADP	O
the	O	DET	O
BALB	O	PROPN	B
/	O	SYM	O
C	O	NOUN	B
mice	O	NOUN	I
being	O	AUX	O
the	O	DET	O
most	O	ADV	O
sensitive	O	ADJ	B
.	O	PUNCT	O


Subsequent	O	ADJ	O
amantadine	B-Chemical	NOUN	B
treatments	O	NOUN	B
produced	O	VERB	O
enhancement	O	NOUN	B
of	O	ADP	O
motility	O	NOUN	B
from	O	ADP	O
corresponding	O	VERB	O
control	O	NOUN	B
in	O	ADP	O
all	O	DET	O
mouse	O	NOUN	B
strains	O	NOUN	O
with	O	ADP	O
the	O	DET	O
BALB	O	PROPN	B
/	O	SYM	O
C	O	NOUN	B
mice	O	NOUN	I
being	O	AUX	O
the	O	DET	O
least	O	ADV	O
sensitive	O	ADJ	B
.	O	PUNCT	O


The	O	DET	O
locomotor	O	NOUN	B
activity	O	NOUN	I
was	O	AUX	O
decreased	O	VERB	B
from	O	ADP	O
corresponding	O	VERB	O
controls	O	NOUN	B
in	O	ADP	O
all	O	DET	O
strains	O	NOUN	B
studied	O	VERB	O
,	O	PUNCT	O
except	O	SCONJ	O
for	O	ADP	O
the	O	DET	O
ICR	O	NOUN	B
mice	O	NOUN	I
,	O	PUNCT	O
during	O	ADP	O
an	O	DET	O
overnight	O	ADJ	B
drug	O	NOUN	B
-	O	PUNCT	O
free	O	ADJ	B
period	O	NOUN	B
following	O	VERB	O
the	O	DET	O
fourth	O	ADJ	O
amantadine	B-Chemical	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


Readministration	O	NOUN	B
of	O	ADP	O
amantadine	B-Chemical	NOUN	B
,	O	PUNCT	O
after	O	ADP	O
a	O	DET	O
drug	O	NOUN	B
-	O	PUNCT	O
free	O	ADJ	B
overnight	O	NOUN	O
period	O	NOUN	B
,	O	PUNCT	O
increased	O	VERB	B
motility	O	NOUN	B
from	O	ADP	O
respective	O	ADJ	O
saline	O	NOUN	B
control	O	NOUN	I
in	O	ADP	O
all	O	DET	O
strains	O	NOUN	B
with	O	ADP	O
exception	O	NOUN	O
of	O	ADP	O
the	O	DET	O
BALB	O	PROPN	B
/	O	SYM	O
C	O	PROPN	B
mice	O	NOUN	B
where	O	SCONJ	O
suppression	B-Disease	NOUN	B
of	I-Disease	ADP	O
motility	I-Disease	NOUN	B
occurred	O	VERB	O
.	O	PUNCT	O


Treatment	O	NOUN	B
with	O	ADP	O
amantadine	B-Chemical	NOUN	B
did	O	AUX	O
not	O	PART	O
alter	O	VERB	O
whole	O	ADJ	O
brain	O	NOUN	B
dopamine	B-Chemical	NOUN	B
levels	O	NOUN	B
but	O	CCONJ	O
decreased	O	VERB	B
the	O	DET	O
amounts	O	NOUN	O
of	O	ADP	O
3,4-dihydroxyphenylacetic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
in	O	ADP	O
the	O	DET	O
BALB	O	PROPN	B
/	O	SYM	O
C	O	NOUN	B
mice	O	NOUN	I
compared	O	VERB	O
to	O	PART	O
saline	O	NOUN	B
control	O	NOUN	I
.	O	PUNCT	O


Conversely	O	ADV	O
,	O	PUNCT	O
brain	O	NOUN	B
normetanephrine	B-Chemical	NOUN	B
concentration	O	NOUN	B
was	O	AUX	O
increased	O	VERB	B
from	O	ADP	O
saline	O	NOUN	B
control	O	NOUN	I
by	O	ADP	O
amantadine	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
BALB	O	PROPN	B
/	O	SYM	O
C	O	NOUN	B
mice	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
a	O	DET	O
strain	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
effect	O	NOUN	B
of	O	ADP	O
amantadine	B-Chemical	NOUN	B
on	O	ADP	O
motility	O	NOUN	B
and	O	CCONJ	O
indicate	O	VERB	O
a	O	DET	O
differential	O	ADJ	B
response	O	NOUN	I
to	O	PART	O
the	O	DET	O
acute	O	ADJ	B
and	O	CCONJ	O
multiple	O	ADJ	B
dose	O	NOUN	O
regimens	O	NOUN	O
used	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
BALB	O	PROPN	B
/	O	SYM	O
C	O	NOUN	B
mouse	O	NOUN	B
was	O	AUX	O
the	O	DET	O
most	O	ADV	O
sensitive	O	ADJ	B
strain	O	NOUN	B
and	O	CCONJ	O
could	O	AUX	O
serve	O	VERB	O
as	O	ADP	O
the	O	DET	O
strain	O	NOUN	B
of	O	ADP	O
choice	O	NOUN	O
for	O	ADP	O
evaluating	O	VERB	B
the	O	DET	O
side	O	NOUN	B
effects	O	NOUN	I
of	O	ADP	O
amantadine	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
biochemical	O	ADJ	B
results	O	NOUN	B
of	O	ADP	O
brain	O	NOUN	B
biogenic	O	ADJ	B
amines	B-Chemical	NOUN	I
of	O	ADP	O
BALB	O	NOUN	B
/	O	SYM	O
C	O	NOUN	B
mouse	O	NOUN	B
strain	O	NOUN	I
suggest	O	VERB	O
a	O	DET	O
probable	O	ADJ	O
decrease	O	NOUN	B
of	O	ADP	O
catecholamine	B-Chemical	NOUN	B
turnover	O	NOUN	O
rate	O	NOUN	O
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
metabolism	O	NOUN	B
by	O	ADP	O
monoamine	O	NOUN	B
oxidase	O	NOUN	I
and	O	CCONJ	O
a	O	DET	O
resulting	O	VERB	O
increase	O	NOUN	B
in	O	ADP	O
O	O	NOUN	B
-	O	PUNCT	O
methylation	O	NOUN	B
of	O	ADP	O
norepinephrine	B-Chemical	NOUN	B
which	O	DET	O
may	O	AUX	O
account	O	VERB	O
for	O	ADP	O
a	O	DET	O
behavioral	B-Disease	ADJ	B
depression	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
amantadine	B-Chemical	NOUN	B


No	O	DET	B
enhancement	O	NOUN	I
by	O	ADP	O
phenobarbital	B-Chemical	NOUN	B
of	O	ADP	O
the	O	DET	O
hepatocarcinogenicity	O	NOUN	B
of	O	ADP	O
a	O	DET	O
choline	B-Chemical	NOUN	B
-	O	PUNCT	O
devoid	O	ADJ	B
diet	O	NOUN	B
in	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
.	O	PUNCT	O


An	O	DET	O
experiment	O	NOUN	B
was	O	AUX	O
performed	O	VERB	O
to	O	PART	O
test	O	VERB	B
whether	O	SCONJ	O
inclusion	O	NOUN	B
of	O	ADP	O
phenobarbital	B-Chemical	NOUN	B
in	O	ADP	O
a	O	DET	O
choline	B-Chemical	NOUN	B
-	O	PUNCT	O
devoid	O	ADJ	B
diet	O	NOUN	B
would	O	AUX	O
increase	O	VERB	B
the	O	DET	O
hepatocarcinogenicity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
diet	O	NOUN	B
.	O	PUNCT	O


Groups	O	NOUN	B
of	O	ADP	O
5	O	NUM	O
-	O	PUNCT	O
week	O	NOUN	B
old	O	ADJ	O
male	O	NOUN	B
Fischer	O	PROPN	O
-	O	PUNCT	O
344	O	NUM	O
rats	O	NOUN	B
were	O	AUX	O
fed	O	VERB	B
for	O	ADP	O
7	O	NUM	O
-	O	PUNCT	O
25	O	NUM	O
months	O	NOUN	B
semipurified	O	VERB	B
choline	B-Chemical	NOUN	B
-	O	PUNCT	O
devoid	O	ADJ	B
or	O	CCONJ	O
choline	B-Chemical	NOUN	B
-	O	PUNCT	O
supplemented	O	VERB	B
diets	O	NOUN	B
,	O	PUNCT	O
containing	O	VERB	O
or	O	CCONJ	O
not	O	PART	O
0	O	NUM	O
.	O	PUNCT	O


06	O	NUM	O
%	O	NOUN	O
phenobarbital	B-Chemical	NOUN	B
.	O	PUNCT	O


No	O	DET	O
hepatic	O	ADJ	B
preneoplastic	O	ADJ	B
nodules	O	NOUN	I
or	O	CCONJ	O
hepatocellular	B-Disease	NOUN	B
carcinomas	I-Disease	NOUN	I
developed	O	VERB	O
in	O	ADP	O
rats	O	NOUN	B
fed	O	VERB	B
the	O	DET	O
plain	O	ADJ	B
choline	B-Chemical	NOUN	B
-	O	PUNCT	O
supplemented	O	VERB	B
diet	O	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
one	O	NUM	O
preneoplastic	O	ADJ	B
nodule	O	NOUN	O
and	O	CCONJ	O
one	O	NUM	O
hepatocellular	B-Disease	NOUN	B
carcinoma	I-Disease	NOUN	I
developed	O	VERB	O
in	O	ADP	O
two	O	NUM	O
rats	O	NOUN	B
fed	O	VERB	B
the	O	DET	O
same	O	ADJ	O
diet	O	NOUN	B
containing	O	VERB	O
phenobarbital	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
preneoplastic	O	ADJ	B
nodules	O	NOUN	O
and	O	CCONJ	O
of	O	ADP	O
hepatocellular	B-Disease	ADJ	B
carcinomas	I-Disease	NOUN	I
was	O	AUX	O
10	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
37	O	NUM	O
%,	O	ADJ	B
respectively	O	ADV	O
,	O	PUNCT	O
in	O	ADP	O
rats	O	NOUN	B
fed	O	VERB	B
the	O	DET	O
plain	O	ADJ	B
choline	B-Chemical	NOUN	B
-	O	PUNCT	O
devoid	O	ADJ	B
diet	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
17	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
30	O	NUM	O
%,	O	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
fed	O	VERB	B
the	O	DET	O
phenobarbital	B-Chemical	NOUN	B
-	O	PUNCT	O
containing	O	VERB	B
choline	B-Chemical	NOUN	B
-	O	PUNCT	O
devoid	O	ADJ	B
diet	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
evinced	O	VERB	O
no	O	DET	O
enhancement	O	NOUN	O
of	O	ADP	O
the	O	DET	O
hepatocarcinogenicity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
choline	B-Chemical	NOUN	B
-	O	PUNCT	O
devoid	O	ADJ	B
diet	O	NOUN	B
by	O	ADP	O
phenobarbital	B-Chemical	NOUN	B


Effect	O	NOUN	B
of	O	ADP	O
direct	O	ADJ	O
intracoronary	O	ADJ	B
administration	O	NOUN	O
of	O	ADP	O
methylergonovine	B-Chemical	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
and	O	CCONJ	O
without	O	ADP	O
variant	B-Disease	ADJ	B
angina	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
intracoronary	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
methylergonovine	B-Chemical	NOUN	B
were	O	AUX	O
studied	O	VERB	O
in	O	ADP	O
21	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
variant	B-Disease	ADJ	B
angina	I-Disease	ADJ	I
and	O	CCONJ	O
22	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
atypical	O	ADJ	B
chest	B-Disease	ADJ	I
pain	I-Disease	NOUN	I
and	O	CCONJ	O
in	O	ADP	O
others	O	NOUN	O
without	O	ADP	O
angina	B-Disease	ADJ	B
pectoris	I-Disease	NOUN	I
(	O	PUNCT	O
control	O	NOUN	B
group	O	NOUN	I
).	O	PUNCT	B
Methylergonovine	B-Chemical	NOUN	B
was	O	AUX	O
administered	O	VERB	B
continuously	O	ADV	O
at	O	ADP	O
a	O	DET	O
rate	O	NOUN	B
of	O	ADP	O
10	O	NUM	O
micrograms	O	NOUN	B
/	O	PUNCT	O
min	O	NOUN	B
up	O	ADV	O
to	O	PART	O
50	O	NUM	O
micrograms	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
all	O	DET	O
patients	O	NOUN	B
with	O	ADP	O
variant	B-Disease	ADJ	B
angina	I-Disease	ADJ	I
,	O	PUNCT	O
coronary	B-Disease	ADJ	B
spasm	I-Disease	NOUN	I
was	O	AUX	O
provoked	O	VERB	O
at	O	ADP	O
a	O	DET	O
mean	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
28	O	NUM	O
+/-	O	CCONJ	O
13	O	NUM	O
micrograms	O	NOUN	B
(	O	PUNCT	O
mean	O	NOUN	O
+/-	O	CCONJ	O
SD	O	NOUN	B
).	O	PUNCT	B
In	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
neither	O	CCONJ	O
ischemic	O	ADJ	B
ST	O	NOUN	B
change	O	NOUN	O
nor	O	CCONJ	O
localized	O	ADJ	B
spasm	B-Disease	NOUN	B
occurred	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
basal	O	ADJ	B
tone	O	NOUN	I
of	O	ADP	O
the	O	DET	O
right	O	ADJ	B
coronary	O	ADJ	I
artery	O	NOUN	I
was	O	AUX	O
significantly	O	ADV	O
lower	O	ADJ	O
than	O	ADP	O
that	O	DET	O
of	O	ADP	O
the	O	DET	O
left	O	ADJ	B
coronary	O	ADJ	I
artery	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
percentage	O	NOUN	B
of	O	ADP	O
vasoconstriction	O	NOUN	B
of	O	ADP	O
the	O	DET	O
right	O	ADJ	B
coronary	O	ADJ	I
artery	O	NOUN	I
was	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
than	O	ADP	O
that	O	DET	O
of	O	ADP	O
the	O	DET	O
left	O	ADJ	B
coronary	O	ADJ	I
artery	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
spasm	B-Disease	NOUN	B
provocation	O	NOUN	B
tests	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
use	O	VERB	O
an	O	DET	O
intracoronary	O	ADJ	B
injection	O	NOUN	B
of	O	ADP	O
a	O	DET	O
relatively	O	ADV	O
low	O	ADJ	O
dose	O	NOUN	B
of	O	ADP	O
methylergonovine	B-Chemical	NOUN	B
,	O	PUNCT	O
have	O	AUX	O
a	O	DET	O
high	O	ADJ	O
sensitivity	O	NOUN	B
in	O	ADP	O
variant	B-Disease	ADJ	B
angina	I-Disease	ADJ	B


Dobutamine	B-Chemical	NOUN	B
stress	O	NOUN	I
echocardiography	O	NOUN	I
:	O	PUNCT	O
a	O	DET	O
sensitive	O	ADJ	B
indicator	O	NOUN	B
of	O	ADP	O
diminished	O	VERB	B
myocardial	O	ADJ	B
function	O	NOUN	I
in	O	ADP	O
asymptomatic	O	ADJ	B
doxorubicin	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
survivors	O	NOUN	B
of	O	ADP	O
childhood	O	NOUN	B
cancer	B-Disease	NOUN	I
.	O	PUNCT	O


Doxorubicin	B-Chemical	NOUN	B
is	O	AUX	O
an	O	DET	O
effective	O	ADJ	B
anticancer	O	NOUN	B
chemotherapeutic	O	ADJ	I
agent	O	NOUN	I
known	O	VERB	O
to	O	PART	O
cause	O	VERB	O
acute	O	ADJ	B
and	O	CCONJ	O
chronic	O	ADJ	B
cardiomyopathy	B-Disease	NOUN	I
.	O	PUNCT	O


To	O	PART	O
develop	O	VERB	O
a	O	DET	O
more	O	ADV	O
sensitive	O	ADJ	B
echocardiographic	O	ADJ	B
screening	O	NOUN	O
test	O	NOUN	O
for	O	ADP	O
cardiac	B-Disease	ADJ	B
damage	I-Disease	NOUN	I
due	O	ADP	O
to	O	PART	O
doxorubicin	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
cohort	O	NOUN	B
study	O	NOUN	I
was	O	AUX	O
performed	O	VERB	O
using	O	VERB	O
dobutamine	B-Chemical	NOUN	B
infusion	O	NOUN	B
to	O	PART	O
differentiate	O	VERB	B
asymptomatic	O	ADJ	B
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
survivors	O	NOUN	B
of	O	ADP	O
childhood	O	NOUN	B
cancer	B-Disease	NOUN	I
treated	O	VERB	B
with	O	ADP	I
doxorubicin	B-Chemical	NOUN	B
from	O	ADP	O
healthy	O	ADJ	B
control	O	NOUN	I
subjects	O	NOUN	I
.	O	PUNCT	O


Echocardiographic	O	ADJ	B
data	O	NOUN	B
from	O	ADP	O
the	O	DET	O
experimental	O	ADJ	B
group	O	NOUN	I
of	O	ADP	O
21	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
mean	O	ADJ	O
age	O	NOUN	B
16	O	NUM	O
+/-	O	CCONJ	O
5	O	NUM	O
years	O	NOUN	B
)	O	PUNCT	O
treated	O	VERB	B
from	O	ADP	O
1	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
to	O	PART	O
14	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
years	O	NOUN	B
(	O	PUNCT	O
median	O	NOUN	B
5	O	NUM	O
.	O	PUNCT	O


3	O	X	O
)	O	PUNCT	O
before	O	ADP	O
this	O	DET	O
study	O	NOUN	B
with	O	ADP	O
27	O	NUM	O
to	O	PART	O
532	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
of	O	ADP	O
doxorubicin	B-Chemical	NOUN	B
(	O	PUNCT	O
mean	O	NOUN	O
196	O	NUM	O
)	O	PUNCT	O
were	O	AUX	O
compared	O	VERB	B
with	O	ADP	O
echocardiographic	O	ADJ	B
data	O	NOUN	B
from	O	ADP	O
12	O	NUM	O
normal	O	ADJ	O
age	O	NOUN	B
-	O	PUNCT	O
matched	O	VERB	B
control	O	NOUN	B
subjects	O	NOUN	I
.	O	PUNCT	O


Graded	O	VERB	B
dobutamine	B-Chemical	NOUN	B
infusions	O	NOUN	B
of	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
,	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
,	O	PUNCT	O
5	O	NUM	O
and	O	CCONJ	O
10	O	NUM	O
micrograms	O	NOUN	B
/	O	PUNCT	O
kg	O	NOUN	O
per	O	ADP	O
min	O	NOUN	O
were	O	AUX	O
administered	O	VERB	B
.	O	PUNCT	O


Echocardiographic	O	ADJ	B
Doppler	O	PROPN	B
studies	O	NOUN	I
were	O	AUX	O
performed	O	VERB	O
before	O	ADP	O
infusion	O	NOUN	B
and	O	CCONJ	O
after	O	ADP	O
15	O	NUM	O
min	O	NOUN	O
of	O	ADP	O
infusion	O	NOUN	B
at	O	ADP	O
each	O	DET	O
rate	O	NOUN	B
.	O	PUNCT	O


Dobutamine	B-Chemical	NOUN	B
infusion	O	NOUN	B
at	O	ADP	O
10	O	NUM	O
micrograms	O	NOUN	B
/	O	PUNCT	O
kg	O	NOUN	O
per	O	ADP	O
min	O	NOUN	O
was	O	AUX	O
discontinued	O	VERB	B
after	O	ADP	O
six	O	NUM	O
studies	O	NOUN	B
secondary	O	ADJ	B
to	O	PART	O
a	O	DET	O
50	O	NUM	O
%	O	NOUN	O
incidence	O	NOUN	B
rate	O	NOUN	B
of	O	ADP	O
adverse	O	ADJ	B
symptoms	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
most	O	ADV	O
important	O	ADJ	O
findings	O	NOUN	B
were	O	AUX	O
that	O	DET	O
compared	O	VERB	B
with	O	ADP	O
values	O	NOUN	B
in	O	ADP	O
control	O	ADJ	B
subjects	O	NOUN	I
,	O	PUNCT	O
end	O	NOUN	B
-	O	PUNCT	O
systolic	O	NOUN	B
left	O	ADJ	B
ventricular	O	ADJ	I
posterior	O	ADJ	I
wall	O	NOUN	I
dimension	O	NOUN	I
and	O	CCONJ	O
percent	O	NOUN	O
of	O	ADP	O
left	O	ADJ	B
ventricular	O	ADJ	I
posterior	O	ADJ	I
wall	O	NOUN	I
thickening	O	NOUN	I
in	O	ADP	O
doxorubicin	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
patients	O	NOUN	B
were	O	AUX	O
decreased	O	VERB	B
at	O	ADP	O
baseline	O	NOUN	B
study	O	NOUN	I
and	O	CCONJ	O
these	O	DET	O
findings	O	NOUN	B
were	O	AUX	O
more	O	ADV	O
clearly	O	ADV	O
delineated	O	VERB	O
with	O	ADP	O
dobutamine	B-Chemical	NOUN	B
stimulation	O	NOUN	O
.	O	PUNCT	O


End	O	NOUN	B
-	O	PUNCT	O
systolic	O	NOUN	B
left	O	ADJ	B
ventricular	O	ADJ	I
posterior	O	ADJ	I
wall	O	NOUN	I
dimension	O	NOUN	B
at	O	ADP	O
baseline	O	NOUN	B
for	O	ADP	O
the	O	DET	O
doxorubicin	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
group	O	NOUN	B
was	O	AUX	O
11	O	NUM	O
+/-	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
mm	O	NOUN	O
versus	O	CCONJ	O
13	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
+/-	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mm	O	NOUN	O
for	O	ADP	O
control	O	ADJ	B
subjects	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
).	O	PUNCT	O
End	O	NOUN	B
-	O	PUNCT	O
systolic	O	NOUN	B
left	O	ADJ	B
ventricular	O	ADJ	I
posterior	O	ADJ	I
wall	O	NOUN	I
dimension	O	NOUN	B
at	O	ADP	O
the	O	DET	O
5	O	NUM	O
-	O	PUNCT	O
micrograms	O	NOUN	B
/	O	PUNCT	O
kg	O	NOUN	B
per	O	ADP	O
min	O	NOUN	O
dobutamine	B-Chemical	NOUN	B
infusion	O	NOUN	B
for	O	ADP	O
the	O	DET	O
doxorubicin	B-Chemical	NOUN	B


Effects	O	NOUN	B
of	O	ADP	I
aminophylline	B-Chemical	NOUN	B
on	O	ADP	O
the	O	DET	O
threshold	O	NOUN	B
for	O	ADP	O
initiating	O	VERB	O
ventricular	B-Disease	ADJ	B
fibrillation	I-Disease	NOUN	I
during	O	ADP	O
respiratory	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
.	O	PUNCT	O


Cardiac	B-Disease	ADJ	B
arrhythmias	I-Disease	NOUN	I
have	O	AUX	O
frequently	O	ADV	O
been	O	AUX	O
reported	O	VERB	O
in	O	ADP	O
association	O	NOUN	B
with	O	ADP	O
respiratory	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
possible	O	ADJ	O
additive	O	ADJ	O
role	O	NOUN	O
of	O	ADP	O
pharmacologic	O	ADJ	B
agents	O	NOUN	I
in	O	ADP	O
precipitating	O	VERB	B
cardiac	B-Disease	ADJ	I
disturbances	I-Disease	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
respiratory	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
has	O	AUX	O
only	O	ADV	O
recently	O	ADV	O
been	O	AUX	O
emphasized	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
aminophylline	B-Chemical	NOUN	B
on	O	ADP	O
the	O	DET	O
ventricular	B-Disease	ADJ	B
fibrillation	I-Disease	NOUN	I
threshold	O	NOUN	B
during	O	ADP	O
normal	O	ADJ	B
acid	O	NOUN	I
-	O	PUNCT	O
base	O	NOUN	B
conditions	O	NOUN	O
and	O	CCONJ	O
during	O	ADP	O
respiratory	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
were	O	AUX	O
studied	O	VERB	O
in	O	ADP	O
anesthetized	O	VERB	B
open	O	ADJ	B
chest	O	ADJ	I
dogs	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
ventricular	B-Disease	ADJ	B
fibrillation	I-Disease	NOUN	I
threshold	O	NOUN	B
was	O	AUX	O
measured	O	VERB	B
by	O	ADP	O
passing	O	VERB	O
a	O	DET	O
gated	O	VERB	B
train	O	NOUN	B
of	O	ADP	O
12	O	NUM	O
constant	O	ADJ	B
current	O	ADJ	O
pulses	O	NOUN	B
through	O	ADP	O
the	O	DET	O
ventricular	O	ADJ	B
myocardium	O	NOUN	I
during	O	ADP	O
the	O	DET	O
vulnerable	O	ADJ	B
period	O	NOUN	B
of	O	ADP	O
the	O	DET	O
cardiac	O	ADJ	B
cycle	O	NOUN	I
.	O	PUNCT	O


During	O	ADP	O
the	O	DET	O
infusion	O	NOUN	B
of	O	ADP	O
aminophylline	B-Chemical	NOUN	B
,	O	PUNCT	O
the	O	DET	O
ventricular	B-Disease	ADJ	B
fibrillation	I-Disease	NOUN	I
threshold	O	NOUN	B
was	O	AUX	O
reduced	O	VERB	B
by	O	ADP	O
30	O	NUM	O
to	O	PART	O
40	O	NUM	O
percent	O	NOUN	O
of	O	ADP	O
the	O	DET	O
control	O	NOUN	B
when	O	SCONJ	O
pH	O	NOUN	B
and	O	CCONJ	O
partial	O	ADJ	B
pressures	O	NOUN	O
of	O	ADP	O
oxygen	B-Chemical	NOUN	O
(	O	PUNCT	O
PO2	B-Chemical	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
carbon	B-Chemical	NOUN	B
dioxide	I-Chemical	NOUN	I
(	O	PUNCT	O
CO2	B-Chemical	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
kept	O	VERB	O
within	O	ADP	O
normal	O	ADJ	O
limits	O	NOUN	O
.	O	PUNCT	O


When	O	SCONJ	O
respiratory	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
was	O	AUX	O
produced	O	VERB	O
by	O	ADP	O
hypoventilation	B-Disease	NOUN	B
(	O	PUNCT	O
pH	O	NOUN	B
7	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
to	O	PART	O
7	O	NUM	O
.	O	PUNCT	O


25	O	NUM	O
;	O	PUNCT	O
PC02	O	NOUN	B
70	O	NUM	I
to	O	PART	O
100	O	NUM	O
mm	O	NOUN	B
Hg	O	NOUN	I
:	O	PUNCT	O
P02	O	NOUN	O
20	O	NUM	O
to	O	PART	O
40	O	NUM	O
mm	O	NOUN	B
Hg	O	NOUN	I
),	O	PUNCT	O
infusion	O	NOUN	B
of	O	ADP	O
aminophylline	B-Chemical	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
an	O	DET	O
even	O	ADV	O
greater	O	ADJ	O
decrease	O	NOUN	B
in	O	ADP	O
ventricular	B-Disease	ADJ	B
fibrillation	I-Disease	NOUN	I
threshold	O	NOUN	B
to	O	ADP	O
60	O	NUM	O
percent	O	NOUN	O
of	O	ADP	O
the	O	DET	O
control	O	NOUN	B
level	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
experiments	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
although	O	SCONJ	O
many	O	ADJ	O
factors	O	NOUN	B
may	O	AUX	O
contribute	O	VERB	O
to	O	PART	O
the	O	DET	O
increased	O	VERB	B
incidence	O	NOUN	B
of	O	ADP	O
ventricular	B-Disease	ADJ	B
arrhythmias	I-Disease	NOUN	I
in	O	ADP	O
respiratory	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
,	O	PUNCT	O
pharmacologic	O	ADJ	B
agents	O	NOUN	I
,	O	PUNCT	O
particularly	O	ADV	O
aminophylline	B-Chemical	NOUN	B


Case	O	NOUN	B
report	O	NOUN	I
:	O	PUNCT	O
acute	O	ADJ	B
unintentional	O	ADJ	O
carbachol	B-Chemical	NOUN	O
intoxication	O	NOUN	B
.	O	PUNCT	O


INTRODUCTION	O	NOUN	O
:	O	PUNCT	O
Intoxications	O	NOUN	B
with	O	ADP	O
carbachol	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
muscarinic	O	ADJ	B
cholinergic	O	ADJ	I
receptor	O	NOUN	I
agonist	O	NOUN	B
are	O	AUX	O
rare	O	ADJ	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
an	O	DET	O
interesting	O	ADJ	O
case	O	NOUN	B
investigating	O	VERB	B
a	O	DET	O
(	O	PUNCT	O
near	O	ADJ	B
)	O	PUNCT	O
fatal	O	ADJ	B
poisoning	B-Disease	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
son	O	NOUN	O
of	O	ADP	O
an	O	DET	O
84	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
male	O	NOUN	B
discovered	O	VERB	O
a	O	DET	O
newspaper	O	NOUN	B
report	O	NOUN	I
stating	O	VERB	O
clinical	O	ADJ	B
success	O	NOUN	I
with	O	ADP	O
plant	O	NOUN	B
extracts	O	NOUN	I
in	O	ADP	O
Alzheimer's	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
mode	O	NOUN	B
of	O	ADP	I
action	O	NOUN	B
was	O	AUX	O
said	O	VERB	O
to	O	PART	O
be	O	AUX	O
comparable	O	ADJ	O
to	O	PART	O
that	O	DET	O
of	O	ADP	O
the	O	DET	O
synthetic	O	ADJ	B
compound	O	NOUN	I
'	O	PUNCT	O
carbamylcholin	B-Chemical	NOUN	B
';	O	NOUN	I
that	O	PRON	O
is	O	ADV	O
,	O	PUNCT	O
carbachol	B-Chemical	NOUN	B
.	O	PUNCT	O


He	O	PRON	O
bought	O	VERB	O
25	O	NUM	O
g	O	NOUN	O
of	O	ADP	O
carbachol	B-Chemical	NOUN	B
as	O	ADP	O
pure	O	ADJ	O
substance	O	NOUN	B
in	O	ADP	O
a	O	DET	O
pharmacy	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
father	O	NOUN	B
was	O	AUX	O
administered	O	VERB	B
400	O	NUM	O
to	O	PART	O
500	O	NUM	O
mg	O	NOUN	O
.	O	PUNCT	O


Carbachol	B-Chemical	NOUN	B
concentrations	O	NOUN	B
in	O	ADP	O
serum	O	NOUN	B
and	O	CCONJ	O
urine	O	NOUN	B
on	O	ADP	O
day	O	NOUN	B
1	O	NUM	O
and	O	CCONJ	O
2	O	NUM	O
of	O	ADP	O
hospital	O	NOUN	B
admission	O	NOUN	I
were	O	AUX	O
analysed	O	VERB	B
by	O	ADP	O
HPLC	O	NOUN	B
-	O	PUNCT	O
mass	O	ADJ	B
spectrometry	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Minutes	O	NOUN	B
after	O	ADP	O
oral	O	ADJ	B
administration	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
patient	O	NOUN	B
developed	O	VERB	O
nausea	B-Disease	NOUN	B
,	O	PUNCT	O
sweating	O	NOUN	B
and	O	CCONJ	O
hypotension	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
finally	O	ADV	O
collapsed	O	VERB	B
.	O	PUNCT	O


Bradycardia	B-Disease	NOUN	B
,	O	PUNCT	O
cholinergic	O	ADJ	B
symptoms	O	NOUN	B
and	O	CCONJ	O
asystole	B-Disease	NOUN	B
occurred	O	VERB	O
.	O	PUNCT	O


Initial	O	ADJ	B
cardiopulmonary	O	ADJ	B
resuscitation	O	NOUN	I
and	O	CCONJ	O
immediate	O	ADJ	B
treatment	O	NOUN	B
with	O	ADP	O
adrenaline	B-Chemical	NOUN	B
(	O	PUNCT	O
epinephrine	B-Chemical	NOUN	B
),	O	PUNCT	O
atropine	B-Chemical	NOUN	B
and	O	CCONJ	O
furosemide	B-Chemical	NOUN	B
was	O	AUX	O
successful	O	ADJ	O
.	O	PUNCT	O


On	O	ADP	O
hospital	O	NOUN	B
admission	O	NOUN	I
,	O	PUNCT	O
blood	O	NOUN	B
pressure	O	NOUN	I
of	O	ADP	O
the	O	DET	O
intubated	O	ADJ	B
,	O	PUNCT	O
bradyarrhythmic	O	ADJ	B
patient	O	NOUN	I
was	O	AUX	O
100	O	NUM	O
/	O	SYM	O
65	O	NUM	O
mmHg	O	NOUN	B
.	O	PUNCT	O


Further	O	ADJ	O
signs	O	NOUN	O
were	O	AUX	O
hyperhidrosis	B-Disease	NOUN	B
,	O	PUNCT	O
hypersalivation	B-Disease	NOUN	B
,	O	PUNCT	O
bronchorrhoea	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
severe	O	ADJ	B
miosis	B-Disease	NOUN	B
;	O	PUNCT	O
the	O	DET	O
electrocardiographic	O	ADJ	B
finding	O	NOUN	I
was	O	AUX	O
atrio-ventricular	B-Disease	ADJ	B
dissociation	I-Disease	NOUN	I
.	O	PUNCT	O


High	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
atropine	B-Chemical	NOUN	B
(	O	PUNCT	O
up	O	ADV	O
to	O	PART	O
50	O	NUM	O
mg	O	NOUN	O
per	O	ADP	O
24	O	NUM	O
hours	O	NOUN	B
),	O	PUNCT	O
adrenaline	B-Chemical	NOUN	B
and	O	CCONJ	O
dopamine	B-Chemical	NOUN	B
were	O	AUX	O
necessary	O	ADJ	O
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
was	O	AUX	O
extubated	O	VERB	B
1	O	NUM	O
week	O	NOUN	B
later	O	ADV	O
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
increased	O	VERB	B
dyspnoea	B-Disease	NOUN	B
and	O	CCONJ	O
bronchospasm	B-Disease	NOUN	B
necessitated	O	VERB	O
reintubation	O	NOUN	B
.	O	PUNCT	O


Respiratory	B-Disease	ADJ	B
insufficiency	I-Disease	NOUN	I
was	O	AUX	O
further	O	ADV	O
worsened	O	VERB	B
by	O	ADP	O
Proteus	B-Disease	X	B
mirabilis	I-Disease	X	I
infection	I-Disease	NOUN	I
and	O	CCONJ	O
severe	O	ADJ	B
bronchoconstriction	O	NOUN	B
.	O	PUNCT	O


One	O	NUM	O
week	O	NOUN	B
later	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
patient	O	NOUN	B
was	O	AUX	O
again	O	ADV	O
extubated	O	VERB	B
and	O	CCONJ	O
3	O	NUM	O
days	O	NOUN	B
later	O	ADV	O
was	O	AUX	O
transferred	O	VERB	B
to	O	PART	O
a	O	DET	O
peripheral	O	ADJ	B
ward	O	NOUN	I
.	O	PUNCT	O


On	O	ADP	O
the	O	DET	O
next	O	ADJ	O
day	O	NOUN	B
he	O	PRON	O
died	O	VERB	B
,	O	PUNCT	O
probably	O	ADV	O
as	O	ADP	O
a	O	DET	O
result	O	NOUN	O
of	O	ADP	O
heart	B-Disease	NOUN	B
failure	I-Disease	NOUN	I
.	O	PUNCT	O


Serum	O	NOUN	B
samples	O	NOUN	I
from	O	ADP	O
the	O	DET	O
first	O	ADJ	O
and	O	CCONJ	O
second	O	ADJ	O
days	O	NOUN	B
contained	O	VERB	O
3	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
and	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
l	O	NOUN	O
carbachol	B-Chemical	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
corresponding	O	ADJ	O
urine	O	NOUN	B
concentrations	O	NOUN	I
amounted	O	VERB	O
to	O	ADP	O
374	O	NUM	O
and	O	CCONJ	O
554	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
l	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	B
:	O	PUNCT	O
This	O	DET	O
case	O	NOUN	B
started	O	VERB	B
with	O	ADP	I
a	O	DET	O
media	O	NOUN	O
report	O	NOUN	O
in	O	ADP	O
a	O	DET	O
popular	O	ADJ	O
newspaper	O	NOUN	B
,	O	PUNCT	O
initiated	O	VERB	O
by	O	ADP	O
published	O	VERB	B
,	O	PUNCT	O
peer	O	NOUN	B
-	O	PUNCT	O
reviewed	O	VERB	B
research	O	NOUN	B
on	O	ADP	O
herbals	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
involved	O	VERB	O
human	O	ADJ	B
failure	O	NOUN	B
in	O	ADP	O
a	O	DET	O
case	O	NOUN	B
history	O	NOUN	I
,	O	PUNCT	O
medical	O	ADJ	B
examination	O	NOUN	I
and	O	CCONJ	O
clinical	O	ADJ	B
treatment	O	NOUN	I
.	O	PUNCT	O


For	O	ADP	O
the	O	DET	O
first	O	ADJ	O
time	O	NOUN	O
,	O	PUNCT	O
an	O	DET	O
analytical	O	ADJ	B
method	O	NOUN	I
for	O	ADP	O
the	O	DET	O
determination	O	NOUN	B
of	O	ADP	O
carbachol	B-Chemical	NOUN	B
in	O	ADP	O
plasma	O	NOUN	B
and	O	CCONJ	O
urine	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
developed	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
analysed	O	VERB	B
carbachol	B-Chemical	NOUN	B
concentration	O	NOUN	B
exceeded	O	VERB	O
the	O	DET	O
supposed	O	VERB	O
serum	O	NOUN	B
level	O	NOUN	B
resulting	O	VERB	O
from	O	ADP	O
a	O	DET	O
therapeutic	O	ADJ	B
dose	O	NOUN	I
by	O	ADP	O
a	O	DET	O
factor	O	NOUN	B
of	O	ADP	O
130	O	NUM	O
to	O	PART	O
260	O	NUM	O
.	O	PUNCT	O


Especially	O	ADV	O
in	O	ADP	O
old	O	ADJ	O
patients	O	NOUN	B
,	O	PUNCT	O
intensivists	O	NOUN	B
should	O	AUX	O
consider	O	VERB	O
intoxications	O	NOUN	B
(	O	PUNCT	O
with	O	ADP	O
cholinergics	O	NOUN	B
)	O	PUNCT	O
as	O	ADP	O
a	O	DET	O
cause	O	NOUN	O
of	O	ADP	O
acute	B-Disease	ADJ	B
cardiovascular	I-Disease	ADJ	B
failure	I-Disease	NOUN	I


Crossover	O	NOUN	B
comparison	O	NOUN	B
of	O	ADP	O
efficacy	O	NOUN	B
and	O	CCONJ	O
preference	O	NOUN	B
for	O	ADP	O
rizatriptan	B-Chemical	NOUN	B
10	O	NUM	O
mg	O	NOUN	O
versus	O	CCONJ	O
ergotamine	B-Chemical	NOUN	B
/	O	PUNCT	O
caffeine	B-Chemical	NOUN	B
in	O	ADP	O
migraine	B-Disease	NOUN	B
.	O	PUNCT	O


Rizatriptan	B-Chemical	PROPN	B
is	O	AUX	O
a	O	DET	O
selective	O	ADJ	O
5-HT	B-Chemical	NOUN	O
(	O	PUNCT	O
1B	O	PROPN	B
/	O	PUNCT	O
1D	O	NOUN	B
)	O	PUNCT	O
receptor	O	NOUN	O
agonist	O	NOUN	B
with	O	ADP	O
rapid	O	ADJ	O
oral	O	ADJ	B
absorption	O	NOUN	B
and	O	CCONJ	O
early	O	ADJ	B
onset	O	NOUN	B
of	O	ADP	I
action	O	NOUN	I
in	O	ADP	O
the	O	DET	O
acute	O	ADJ	B
treatment	O	NOUN	B
of	O	ADP	O
migraine	B-Disease	NOUN	B
.	O	PUNCT	O


This	O	DET	O
randomized	O	ADJ	B
double	O	ADJ	B
-	O	PUNCT	O
blind	O	NOUN	B
crossover	O	NOUN	B
outpatient	O	ADJ	I
study	O	NOUN	I
assessed	O	VERB	B
the	O	DET	O
preference	O	NOUN	B
for	O	ADP	O
1	O	NUM	O
rizatriptan	B-Chemical	NOUN	B
10	O	NUM	O
mg	O	NOUN	O
tablet	O	NOUN	B
to	O	PART	O
2	O	NUM	O
ergotamine	B-Chemical	NOUN	B
1	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
caffeine	B-Chemical	NOUN	B
100	O	NUM	O
mg	O	NOUN	O
tablets	O	NOUN	B
in	O	ADP	O
439	O	NUM	O
patients	O	NOUN	B
treating	O	VERB	B
a	O	DET	O
single	O	ADJ	O
migraine	B-Disease	NOUN	B
attack	O	NOUN	B
with	O	ADP	O
each	O	DET	O
therapy	O	NOUN	B
.	O	PUNCT	O


Of	O	ADP	O
patients	O	NOUN	B
expressing	O	VERB	B
a	O	DET	O
preference	O	NOUN	B
(	O	PUNCT	O
89	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
%),	O	VERB	O
more	O	ADV	O
than	O	ADV	O
twice	O	ADV	O
as	O	ADV	O
many	O	ADJ	O
preferred	O	ADJ	O
rizatriptan	B-Chemical	NOUN	B
to	O	PART	O
ergotamine	B-Chemical	NOUN	B
/	O	PUNCT	O
caffeine	B-Chemical	NOUN	B
(	O	PUNCT	O
69	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
vs	O	CCONJ	O
.	O	PUNCT	O


30	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
%,	O	NOUN	O
p	O	NOUN	O
<	O	X	O
or	O	CCONJ	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
).	O	PUNCT	O
Faster	O	PROPN	O
relief	O	NOUN	B
of	O	ADP	O
headache	B-Disease	NOUN	B
was	O	AUX	O
the	O	DET	O
most	O	ADV	O
important	O	ADJ	O
reason	O	NOUN	O
for	O	ADP	O
preference	O	NOUN	B
,	O	PUNCT	O
cited	O	VERB	O
by	O	ADP	O
67	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
preferring	O	VERB	O
rizatriptan	B-Chemical	NOUN	B
and	O	CCONJ	O
54	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
who	O	PRON	O
preferred	O	VERB	O
ergotamine	B-Chemical	NOUN	B
/	O	SYM	O
caffeine	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
co	O	ADJ	B
-	O	PUNCT	O
primary	O	ADJ	B
endpoint	O	NOUN	B
of	O	ADP	O
being	O	AUX	O
pain	B-Disease	NOUN	B
free	O	ADJ	I
at	O	ADP	O
2	O	NUM	O
h	O	NOUN	O
was	O	AUX	O
also	O	ADV	O
in	O	ADP	O
favor	O	NOUN	O
of	O	ADP	O
rizatriptan	B-Chemical	NOUN	B
.	O	PUNCT	O


Forty	O	NUM	B
-	O	PUNCT	O
nine	O	NUM	O
percent	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
were	O	AUX	O
pain	B-Disease	NOUN	B
free	O	ADJ	I
2	O	NUM	I
h	O	NOUN	O
after	O	ADP	O
rizatriptan	B-Chemical	NOUN	B
,	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
24	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
%	O	NOUN	O
treated	O	VERB	B
with	O	ADP	I
ergotamine	B-Chemical	NOUN	B
/	O	PUNCT	O
caffeine	B-Chemical	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
or	O	CCONJ	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
),	O	PUNCT	O
rizatriptan	B-Chemical	NOUN	B
being	O	AUX	O
superior	O	ADJ	O
within	O	ADP	O
1	O	NUM	O
h	O	NOUN	O
of	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


Headache	B-Disease	NOUN	B
relief	O	NOUN	B
at	O	ADP	O
2	O	NUM	O
h	O	NOUN	O
was	O	AUX	O
75	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
rizatriptan	B-Chemical	NOUN	B
and	O	CCONJ	O
47	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
ergotamine	B-Chemical	NOUN	B
/	O	PUNCT	O
caffeine	B-Chemical	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
or	O	CCONJ	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
),	O	PUNCT	O
with	O	ADP	O
rizatriptan	B-Chemical	NOUN	B
being	O	AUX	O
superior	O	ADJ	O
to	O	PART	O
ergotamine	B-Chemical	NOUN	B
/	O	PUNCT	O
caffeine	B-Chemical	NOUN	B
within	O	ADP	O
30	O	NUM	O
min	O	NOUN	O
of	O	ADP	O
dosing	O	NOUN	B
.	O	PUNCT	O


Almost	O	ADV	O
36	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
taking	O	VERB	O
rizatriptan	B-Chemical	NOUN	B
were	O	AUX	O
pain	B-Disease	NOUN	B
free	O	ADJ	I
at	O	ADP	O
2	O	NUM	O
h	O	NOUN	O
and	O	CCONJ	O
had	O	AUX	O
no	O	DET	O
recurrence	O	NOUN	B
or	O	CCONJ	O
need	O	VERB	O
for	O	ADP	O
additional	O	ADJ	O
medication	O	NOUN	B
within	O	ADP	O
24	O	NUM	O
h	O	NOUN	O
,	O	PUNCT	O
compared	O	VERB	O
to	O	PART	O
20	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
on	O	ADP	O
ergotamine	B-Chemical	NOUN	B
/	O	PUNCT	O
caffeine	B-Chemical	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
or	O	CCONJ	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
).	O	PUNCT	O
Rizatriptan	B-Chemical	PROPN	B
was	O	AUX	O
also	O	ADV	O
superior	O	ADJ	O
to	O	PART	O
ergotamine	B-Chemical	NOUN	B
/	O	PUNCT	O
caffeine	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
proportions	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
no	O	DET	O
nausea	B-Disease	NOUN	O
,	O	PUNCT	O
vomiting	B-Disease	NOUN	B
,	O	PUNCT	O
phonophobia	B-Disease	NOUN	B
or	O	CCONJ	O
photophobia	B-Disease	NOUN	B
and	O	CCONJ	O
for	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
normal	O	ADJ	B
function	O	NOUN	I
2	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
drug	O	NOUN	B
intake	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
or	O	CCONJ	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
).	O	PUNCT	O
More	O	ADJ	O
patients	O	NOUN	B
were	O	AUX	O
(	O	PUNCT	O
completely	O	ADV	B
,	O	PUNCT	O
very	O	ADV	O
or	O	CCONJ	O
somewhat	O	ADV	O
)	O	PUNCT	O
satisfied	O	ADJ	O
2	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
rizatriptan	B-Chemical	NOUN	B
(	O	PUNCT	O
69	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
%)	O	NOUN	O
than	O	ADP	O
at	O	ADP	O
2	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
ergotamine	B-Chemical	NOUN	B
/	O	PUNCT	O
caffeine	B-Chemical	NOUN	B
(	O	PUNCT	O
38	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
%,	O	NOUN	O
p	O	NOUN	O
<	O	X	O
or	O	CCONJ	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
).	O	PUNCT	O
Recurrence	O	NOUN	B
rates	O	NOUN	I
were	O	AUX	O
31	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
%	O	NOUN	O
with	O	ADP	O
rizatriptan	B-Chemical	NOUN	B
and	O	CCONJ	O
15	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
%	O	NOUN	O
with	O	ADP	O
ergotamine	B-Chemical	NOUN	B
/	O	PUNCT	O
caffeine	B-Chemical	NOUN	B
.	O	PUNCT	O


Both	O	CCONJ	O
active	O	ADJ	B
treatments	O	NOUN	I
were	O	AUX	O
well	O	ADV	O
tolerated	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
most	O	ADV	O
common	O	ADJ	O
adverse	O	ADJ	B
events	O	NOUN	I
(	O	PUNCT	O
incidence	O	NOUN	B
>	O	NOUN	O
or	O	CCONJ	O
=	O	ADJ	O
5	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
one	O	NUM	O
group	O	NOUN	B
)	O	PUNCT	O
after	O	ADP	O
rizatriptan	B-Chemical	NOUN	B
and	O	CCONJ	O
ergotamine	B-Chemical	NOUN	B
/	O	SYM	O
caffeine	B-Chemical	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
were	O	AUX	O
dizziness	B-Disease	ADJ	B
(	O	PUNCT	O
6	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
and	O	CCONJ	O
5	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
%),	O	ADJ	O
nausea	B-Disease	ADJ	B
(	O	PUNCT	O
4	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
and	O	CCONJ	O
8	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
%)	O	NOUN	O
and	O	CCONJ	O
somnolence	B-Disease	NOUN	B


Thrombotic	B-Disease	ADJ	B
microangiopathy	I-Disease	NOUN	I
and	O	CCONJ	O
renal	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
antineoplastic	O	ADJ	B
chemotherapy	O	NOUN	I
.	O	PUNCT	O


Five	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
carcinoma	B-Disease	NOUN	B
developed	O	VERB	O
thrombotic	B-Disease	ADJ	B
microangiopathy	I-Disease	NOUN	I
(	O	PUNCT	O
characterized	O	VERB	B
by	O	ADP	O
renal	B-Disease	ADJ	B
insufficiency	I-Disease	NOUN	I
,	O	PUNCT	O
microangiopathic	B-Disease	ADJ	B
hemolytic	I-Disease	ADJ	O
anemia	I-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
usually	O	ADV	O
thrombocytopenia	B-Disease	NOUN	B
)	O	PUNCT	O
after	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
cisplatin	B-Chemical	NOUN	B
,	O	PUNCT	O
bleomycin	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
vinca	B-Chemical	NOUN	B
alkaloid	I-Chemical	NOUN	I
.	O	PUNCT	O


One	O	NUM	O
patient	O	NOUN	B
had	O	AUX	O
thrombotic	B-Disease	ADJ	B
thrombocytopenic	I-Disease	ADJ	I
purpura	I-Disease	NOUN	I
,	O	PUNCT	O
three	O	NUM	O
the	O	DET	O
hemolytic-uremic	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
one	O	NUM	O
an	O	DET	O
apparent	O	ADJ	B
forme	O	ADJ	B
fruste	O	NOUN	I
of	O	ADP	O
one	O	NUM	O
of	O	ADP	O
these	O	DET	O
disorders	O	NOUN	B
.	O	PUNCT	O


Histologic	O	ADJ	B
examination	O	NOUN	I
of	O	ADP	O
the	O	DET	O
renal	O	ADJ	B
tissue	O	NOUN	I
showed	O	VERB	O
evidence	O	NOUN	B
of	O	ADP	O
intravascular	B-Disease	ADJ	B
coagulation	I-Disease	NOUN	I
,	O	PUNCT	O
primarily	O	ADV	O
affecting	O	VERB	B
the	O	DET	O
small	O	ADJ	B
arteries	O	NOUN	I
,	O	PUNCT	O
arterioles	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
glomeruli	O	NOUN	B
.	O	PUNCT	O


Because	O	SCONJ	O
each	O	DET	O
patient	O	NOUN	B
was	O	AUX	O
tumor	B-Disease	NOUN	B
-	O	PUNCT	O
free	O	ADJ	B
or	O	CCONJ	O
had	O	AUX	O
only	O	ADV	O
a	O	DET	O
small	O	ADJ	O
tumor	B-Disease	NOUN	B
at	O	ADP	O
the	O	DET	O
onset	O	NOUN	O
of	O	ADP	O
this	O	DET	O
syndrome	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
thrombotic	B-Disease	ADJ	B
microangiopathy	I-Disease	NOUN	I
may	O	AUX	O
have	O	AUX	O
been	O	AUX	O
induced	O	VERB	B
by	O	ADP	O
chemotherapy	O	NOUN	B
.	O	PUNCT	O


Diagnosis	O	NOUN	B
of	O	ADP	O
this	O	DET	O
potentially	O	ADV	O
fatal	O	ADJ	B
complication	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
delayed	O	VERB	B
or	O	CCONJ	O
missed	O	VERB	O
if	O	SCONJ	O
renal	O	ADJ	B
tissue	O	NOUN	I
or	O	CCONJ	O
the	O	DET	O
peripheral	O	ADJ	B
blood	O	NOUN	I
smear	O	NOUN	I
is	O	AUX	O
not	O	PART	O
examined	O	VERB	O
,	O	PUNCT	O
because	O	SCONJ	O
renal	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
may	O	AUX	O
be	O	AUX	O
ascribed	O	VERB	O
to	O	PART	O
cisplatin	B-Chemical	NOUN	B
nephrotoxicity	B-Disease	NOUN	B
and	O	CCONJ	O
the	O	DET	O
anemia	B-Disease	NOUN	B
and	O	CCONJ	O
thrombocytopenia	B-Disease	NOUN	B
to	O	PART	O
drug	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
bone	B-Disease	NOUN	B
marrow	I-Disease	NOUN	I
suppression	I-Disease	NOUN	B


Salvage	O	NOUN	B
therapy	O	NOUN	I
with	O	ADP	O
nelarabine	B-Chemical	NOUN	B
,	O	PUNCT	O
etoposide	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
cyclophosphamide	B-Chemical	NOUN	B
in	O	ADP	O
relapsed	O	ADJ	B
/	O	PUNCT	O
refractory	O	ADJ	B
paediatric	O	ADJ	B
T-cell	B-Disease	NOUN	I
lymphoblastic	I-Disease	ADJ	I
leukaemia	I-Disease	NOUN	I
and	I-Disease	CCONJ	O
lymphoma	I-Disease	NOUN	B
.	O	PUNCT	O


A	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
5	O	NUM	O
d	O	NOUN	O
of	O	ADP	O
nelarabine	B-Chemical	NOUN	B
(	O	PUNCT	O
AraG	B-Chemical	NOUN	B
)	O	PUNCT	O
with	O	ADP	O
5	O	NUM	O
d	O	NOUN	O
of	O	ADP	O
etoposide	B-Chemical	NOUN	B
(	O	PUNCT	O
VP	B-Chemical	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
cyclophosphamide	B-Chemical	NOUN	B
(	O	PUNCT	O
CPM	B-Chemical	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
prophylactic	O	ADJ	B
intrathecal	O	ADJ	I
chemotherapy	O	NOUN	I
was	O	AUX	O
used	O	VERB	O
as	O	ADP	O
salvage	O	NOUN	B
therapy	O	NOUN	I
in	O	ADP	O
seven	O	NUM	O
children	O	NOUN	B
with	O	ADP	O
refractory	O	ADJ	B
or	O	CCONJ	O
relapsed	O	ADJ	B
T-cell	B-Disease	NOUN	B
leukaemia	I-Disease	NOUN	I
or	I-Disease	CCONJ	O
lymphoma	I-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
most	O	ADV	O
common	O	ADJ	O
side	O	NOUN	B
effects	O	NOUN	I
attributable	O	ADJ	O
to	O	PART	O
the	O	DET	O
AraG	B-Chemical	NOUN	B
included	O	VERB	O
Grade	O	PROPN	B
2	O	NUM	I
and	O	CCONJ	O
3	O	NUM	O
sensory	O	ADJ	B
and	O	CCONJ	O
motor	O	NOUN	B
neuropathy	B-Disease	NOUN	I
and	O	CCONJ	O
musculoskeletal	B-Disease	ADJ	B
pain	I-Disease	NOUN	I
.	O	PUNCT	O


Haematological	B-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
was	O	AUX	O
greater	O	ADJ	O
for	O	ADP	O
the	O	DET	O
combination	O	NOUN	B
than	O	ADP	O
AraG	B-Chemical	NOUN	B
alone	O	ADV	O
,	O	PUNCT	O
although	O	SCONJ	O
median	O	ADJ	B
time	O	NOUN	O
to	O	PART	O
neutrophil	O	NOUN	B
and	O	CCONJ	O
platelet	O	NOUN	B
recovery	O	NOUN	I
was	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
other	O	ADJ	O
salvage	O	NOUN	B
therapies	O	NOUN	I
.	O	PUNCT	O


All	O	DET	O
patients	O	NOUN	B
had	O	AUX	O
some	O	DET	O
response	O	NOUN	B
to	O	PART	O
the	O	DET	O
combined	O	ADJ	B
therapy	O	NOUN	I
and	O	CCONJ	O
five	O	NUM	O
of	O	ADP	O
the	O	DET	O
seven	O	NUM	O
went	O	VERB	O
into	O	ADP	O
complete	O	ADJ	B
remission	O	NOUN	B
after	O	ADP	O
one	O	NUM	O
or	O	CCONJ	O
two	O	NUM	O
courses	O	NOUN	B
of	O	ADP	O
AraG	B-Chemical	NOUN	B
/	O	SYM	O
VP	B-Chemical	PROPN	B
/	O	SYM	O
CPM	B-Chemical	PROPN	B
.	O	PUNCT	O


Our	O	PRON	O
experience	O	NOUN	O
supports	O	VERB	O
the	O	DET	O
safety	O	NOUN	B
of	O	ADP	O
giving	O	VERB	O
AraG	B-Chemical	NOUN	B
as	O	ADP	O
salvage	O	NOUN	B
therapy	O	NOUN	I
in	O	ADP	O
synchrony	O	NOUN	B
with	O	ADP	O
etoposide	B-Chemical	NOUN	B
and	O	CCONJ	O
cyclophosphamide	B-Chemical	NOUN	B
,	O	PUNCT	O
although	O	SCONJ	O
neurological	B-Disease	ADJ	B
toxicity	I-Disease	NOUN	B


The	O	DET	O
3	O	NUM	O
-	O	PUNCT	O
week	O	NOUN	B
sulphasalazine	B-Chemical	NOUN	B
syndrome	O	NOUN	I
strikes	O	VERB	O
again	O	ADV	O
.	O	PUNCT	O


A	O	DET	O
34	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
lady	O	NOUN	I
developed	O	VERB	O
a	O	DET	O
constellation	O	NOUN	B
of	O	ADP	O
dermatitis	B-Disease	NOUN	B
,	O	PUNCT	O
fever	B-Disease	NOUN	B
,	O	PUNCT	O
lymphadenopathy	B-Disease	NOUN	B
and	O	CCONJ	O
hepatitis	B-Disease	NOUN	B
,	O	PUNCT	O
beginning	O	VERB	O
on	O	ADP	O
the	O	DET	O
17th	O	ADJ	O
day	O	NOUN	B
of	O	ADP	O
a	O	DET	O
course	O	NOUN	B
of	O	ADP	O
oral	O	ADJ	B
sulphasalazine	B-Chemical	NOUN	I
for	O	ADP	O
sero	O	NOUN	B
-	O	PUNCT	O
negative	O	ADJ	B
rheumatoid	B-Disease	ADJ	B
arthritis	I-Disease	NOUN	I
.	O	PUNCT	O


Cervical	O	ADJ	B
and	O	CCONJ	O
inguinal	O	ADJ	B
lymph	O	NOUN	I
node	O	NOUN	I
biopsies	O	NOUN	I
showed	O	VERB	O
the	O	DET	O
features	O	NOUN	B
of	O	ADP	O
severe	O	ADJ	B
necrotising	O	NOUN	B
lymphadenitis	B-Disease	NOUN	I
,	O	PUNCT	O
associated	O	VERB	B
with	O	ADP	I
erythrophagocytosis	O	NOUN	B
and	O	CCONJ	O
prominent	O	ADJ	B
eosinophilic	O	ADJ	B
infiltrates	O	NOUN	I
,	O	PUNCT	O
without	O	ADP	O
viral	O	ADJ	B
inclusion	O	NOUN	I
bodies	O	NOUN	I
,	O	PUNCT	O
suggestive	O	ADJ	O
of	O	ADP	O
an	O	DET	O
adverse	B-Disease	ADJ	B
drug	I-Disease	NOUN	I
reaction	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
week	O	NOUN	B
later	O	ADV	O
,	O	PUNCT	O
fulminant	O	ADJ	B
drug-induced	B-Disease	ADJ	O
hepatitis	I-Disease	NOUN	O
,	O	PUNCT	O
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
anti	O	ADJ	B
-	O	PUNCT	O
nuclear	O	ADJ	B
autoantibodies	O	NOUN	I
(	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
with	O	ADP	O
other	O	ADJ	O
markers	O	NOUN	B
of	O	ADP	O
autoimmunity	B-Disease	NOUN	B
),	O	PUNCT	O
and	O	CCONJ	O
accompanied	O	VERB	O
by	O	ADP	O
multi-organ	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
and	O	CCONJ	O
sepsis	B-Disease	NOUN	B
,	O	PUNCT	O
supervened	O	VERB	B
.	O	PUNCT	O


She	O	PRON	O
subsequently	O	ADV	O
died	O	VERB	B
some	O	DET	O
5	O	NUM	O
weeks	O	NOUN	B
after	O	ADP	O
the	O	DET	O
commencement	O	NOUN	B
of	O	ADP	O
her	O	PRON	O
drug	O	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


Post	O	NOUN	B
-	O	PUNCT	O
mortem	O	X	B
examination	O	NOUN	B
showed	O	VERB	O
evidence	O	NOUN	B
of	O	ADP	O
massive	B-Disease	ADJ	B
hepatocellular	I-Disease	NOUN	B
necrosis	I-Disease	NOUN	I
,	O	PUNCT	O
acute	O	ADJ	B
hypersensitivity	O	NOUN	I
myocarditis	B-Disease	NOUN	I
,	O	PUNCT	O
focal	O	ADJ	B
acute	O	ADJ	I
tubulo	O	NOUN	I
-	O	PUNCT	O
interstitial	O	ADJ	B
nephritis	B-Disease	NOUN	I
and	O	CCONJ	O
extensive	O	ADJ	B
bone	B-Disease	NOUN	B
marrow	I-Disease	NOUN	I
necrosis	I-Disease	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
no	O	DET	O
evidence	O	NOUN	O
of	O	ADP	O
malignancy	B-Disease	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
thought	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
clinico	O	NOUN	B
-	O	PUNCT	O
pathological	O	ADJ	B
features	O	NOUN	B
and	O	CCONJ	O
chronology	O	NOUN	B
of	O	ADP	O
this	O	DET	O
case	O	NOUN	B
bore	O	VERB	O
the	O	DET	O
hallmarks	O	NOUN	B
of	O	ADP	O
the	O	DET	O
so	O	ADV	O
-	O	PUNCT	O
called	O	VERB	O
"	O	PUNCT	O
3	O	NUM	O
-	O	PUNCT	O
week	O	NOUN	B
sulphasalazine	B-Chemical	NOUN	B
syndrome	O	NOUN	I
",	O	VERB	O
a	O	DET	O
rare	O	ADJ	B
,	O	PUNCT	O
but	O	CCONJ	O
often	O	ADV	O
fatal	O	ADJ	B
,	O	PUNCT	O
immunoallergic	O	ADJ	B
reaction	O	NOUN	I
to	O	PART	O
sulphasalazine	B-Chemical	NOUN	B


Bupropion	B-Chemical	NOUN	B
(	O	PUNCT	O
Zyban	B-Chemical	PROPN	B
)	O	PUNCT	O
toxicity	B-Disease	NOUN	B
.	O	PUNCT	O


Bupropion	B-Chemical	NOUN	B
is	O	AUX	O
a	O	DET	O
monocyclic	O	ADJ	B
antidepressant	B-Chemical	NOUN	B
structurally	O	ADV	B
related	O	ADJ	O
to	O	PART	O
amphetamine	B-Chemical	NOUN	B
.	O	PUNCT	O


Zyban	B-Chemical	PROPN	B
,	O	PUNCT	O
a	O	DET	O
sustained	O	ADJ	B
-	O	PUNCT	O
release	O	NOUN	B
formulation	O	NOUN	B
of	O	ADP	O
bupropion	B-Chemical	NOUN	B
hydrochloride	I-Chemical	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
recently	O	ADV	O
released	O	VERB	B
in	O	ADP	O
Ireland	O	PROPN	B
,	O	PUNCT	O
as	O	ADP	O
a	O	DET	O
smoking	O	NOUN	B
cessation	O	NOUN	B
aid	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
initial	O	ADJ	O
6	O	NUM	O
months	O	NOUN	B
since	O	SCONJ	O
it	O	PRON	O
'	O	PART	O
s	O	NOUN	O
introduction	O	NOUN	B
,	O	PUNCT	O
12	O	NUM	O
overdose	B-Disease	NOUN	B
cases	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
to	O	ADP	O
The	O	DET	O
National	O	PROPN	B
Poisons	O	PROPN	I
Information	O	PROPN	I
Centre	O	PROPN	I
.	O	PUNCT	O


8	O	NUM	O
patients	O	NOUN	B
developed	O	VERB	O
symptoms	O	NOUN	B
of	O	ADP	O
toxicity	B-Disease	NOUN	B
.	O	PUNCT	O


Common	O	ADJ	O
features	O	NOUN	B
included	O	VERB	O
tachycardia	B-Disease	NOUN	B
,	O	PUNCT	O
drowsiness	O	NOUN	B
,	O	PUNCT	O
hallucinations	B-Disease	NOUN	B
and	O	CCONJ	O
convulsions	B-Disease	NOUN	B
.	O	PUNCT	O


Two	O	NUM	O
patients	O	NOUN	B
developed	O	VERB	O
severe	O	ADJ	B
cardiac	B-Disease	ADJ	B
arrhythmias	I-Disease	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
one	O	NUM	O
patient	O	NOUN	B
who	O	PRON	O
was	O	AUX	O
resuscitated	O	VERB	B
following	O	VERB	O
a	O	DET	O
cardiac	B-Disease	ADJ	B
arrest	I-Disease	NOUN	I
.	O	PUNCT	O


All	O	DET	O
patients	O	NOUN	B
recovered	O	VERB	B
without	O	ADP	O
sequelae	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
a	O	DET	O
31	O	NUM	O
year	O	NOUN	B
old	O	ADJ	O
female	O	NOUN	B
who	O	PRON	O
required	O	VERB	O
admission	O	NOUN	B
to	O	ADP	O
the	O	DET	O
Intensive	O	PROPN	B
Care	O	PROPN	I
Unit	O	PROPN	I
for	O	ADP	O
ventilation	O	NOUN	B
and	O	CCONJ	O
full	O	ADJ	O
supportive	O	ADJ	B
therapy	O	NOUN	I
,	O	PUNCT	O
following	O	VERB	O
ingestion	O	NOUN	B
of	O	ADP	O
13	O	NUM	O
.	O	PUNCT	O


5g	O	NOUN	O
bupropion	B-Chemical	NOUN	B
.	O	PUNCT	O


Recurrent	O	ADJ	B
seizures	B-Disease	NOUN	I
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
diazepam	B-Chemical	NOUN	B
and	O	CCONJ	O
broad	O	ADJ	O
complex	O	ADJ	O
tachycardia	B-Disease	NOUN	O
was	O	AUX	O
successfully	O	ADV	O
treated	O	VERB	B
with	O	ADP	I
adenosine	B-Chemical	NOUN	B
.	O	PUNCT	O


Zyban	B-Chemical	PROPN	B
caused	O	VERB	O
significant	O	ADJ	O
neurological	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
cardiovascular	I-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
in	O	ADP	O
overdose	B-Disease	NOUN	B


Survey	O	NOUN	B
of	O	ADP	O
complications	O	NOUN	B
of	O	ADP	O
indocyanine	B-Chemical	NOUN	B
green	I-Chemical	ADJ	I
angiography	O	NOUN	I
in	O	ADP	O
Japan	O	PROPN	B
.	O	PUNCT	O


PURPOSE	O	NOUN	B
:	O	PUNCT	O
We	O	PRON	O
evaluated	O	VERB	B
the	O	DET	O
safety	O	NOUN	B
of	O	ADP	O
indocyanine	B-Chemical	NOUN	B
green	I-Chemical	NOUN	I
for	O	ADP	O
use	O	NOUN	O
in	O	ADP	O
fundus	O	NOUN	B
angiography	O	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
We	O	PRON	O
sent	O	VERB	O
a	O	DET	O
questionnaire	O	NOUN	B
concerning	O	VERB	O
complications	O	NOUN	B
of	O	ADP	O
indocyanine	B-Chemical	NOUN	B
green	I-Chemical	NOUN	I
to	O	ADP	O
32	O	NUM	O
institutions	O	NOUN	B
in	O	ADP	O
Japan	O	PROPN	B
,	O	PUNCT	O
which	O	DET	O
were	O	AUX	O
selected	O	VERB	O
on	O	ADP	O
the	O	DET	O
basis	O	NOUN	O
of	O	ADP	O
the	O	DET	O
client	O	NOUN	B
list	O	NOUN	O
from	O	ADP	O
the	O	DET	O
Topcon	O	PROPN	B
Company	O	PROPN	I
,	O	PUNCT	O
which	O	DET	O
manufactures	O	VERB	B
the	O	DET	O
indocyanine	B-Chemical	NOUN	B
green	I-Chemical	ADJ	I
fundus	O	NOUN	I
camera	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Ophthalmologists	O	NOUN	B
at	O	ADP	O
15	O	NUM	O
institutions	O	NOUN	B
responded	O	VERB	O
,	O	PUNCT	O
reporting	O	VERB	O
a	O	DET	O
total	O	NOUN	O
of	O	ADP	O
3	O	NUM	O
,	O	PUNCT	O
774	O	NUM	O
indocyanine	B-Chemical	NOUN	B
green	I-Chemical	NOUN	I
angiograms	O	NOUN	B
performed	O	VERB	O
on	O	ADP	O
2	O	NUM	O
,	O	PUNCT	O
820	O	NUM	O
patients	O	NOUN	B
between	O	ADP	O
June	O	PROPN	O
1984	O	NUM	O
and	O	CCONJ	O
September	O	PROPN	O
1992	O	NUM	O
.	O	PUNCT	O


Before	O	ADP	O
angiography	O	NOUN	B
,	O	PUNCT	O
intradermal	O	ADJ	B
or	O	CCONJ	O
intravenous	O	ADJ	B
indocyanine	B-Chemical	NOUN	I
green	I-Chemical	ADJ	I
testing	O	NOUN	I
,	O	PUNCT	O
or	O	CCONJ	O
both	O	DET	O
was	O	AUX	O
performed	O	VERB	O
at	O	ADP	O
13	O	NUM	O
of	O	ADP	O
15	O	NUM	O
institutions	O	NOUN	B
.	O	PUNCT	O


For	O	ADP	O
three	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
decision	O	NOUN	B
was	O	AUX	O
made	O	VERB	O
not	O	PART	O
to	O	PART	O
proceed	O	VERB	O
with	O	ADP	O
angiography	O	NOUN	B
after	O	ADP	O
positive	O	ADJ	B
preangiographic	O	ADJ	B
testing	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
dosage	O	NOUN	B
of	O	ADP	O
indocyanine	B-Chemical	NOUN	B
green	I-Chemical	NOUN	I
used	O	VERB	O
for	O	ADP	O
angiography	O	NOUN	B
varied	O	VERB	O
from	O	ADP	O
25	O	NUM	O
to	O	PART	O
75	O	NUM	O
mg	O	NOUN	O
,	O	PUNCT	O
depending	O	VERB	O
upon	O	SCONJ	O
the	O	DET	O
institution	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
13	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
adverse	O	ADJ	B
reactions	O	NOUN	I
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


34	O	NUM	O
%),	O	VERB	O
ten	O	NUM	O
of	O	ADP	O
which	O	DET	O
were	O	AUX	O
mild	O	ADJ	B
reactions	O	NOUN	I
such	O	ADJ	O
as	O	ADP	O
nausea	B-Disease	ADJ	B
,	O	PUNCT	O
exanthema	B-Disease	NOUN	B
,	O	PUNCT	O
urtication	B-Disease	NOUN	B
,	O	PUNCT	O
itchiness	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
urgency	O	NOUN	B
to	O	PART	O
defecate	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
did	O	AUX	O
not	O	PART	O
require	O	VERB	O
treatment	O	NOUN	B
.	O	PUNCT	O


Also	O	ADV	O
recorded	O	VERB	O
were	O	AUX	O
one	O	NUM	O
case	O	NOUN	B
of	O	ADP	O
pain	B-Disease	NOUN	B
of	O	ADP	O
the	O	DET	O
vein	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
required	O	VERB	O
treatment	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
two	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
hypotension	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
two	O	NUM	O
hypotensive	B-Disease	ADJ	B
patients	O	NOUN	B
required	O	VERB	O
treatment	O	NOUN	B
for	O	ADP	O
shock	B-Disease	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
A	O	DET	O
comparison	O	NOUN	B
of	O	ADP	O
frequency	O	NOUN	B
of	O	ADP	O
adverse	O	ADJ	B
reactions	O	NOUN	I
to	O	ADP	O
indocyanine	B-Chemical	NOUN	B
green	I-Chemical	NOUN	I
with	O	ADP	O
the	O	DET	O
previously	O	ADV	O
reported	O	VERB	O
frequency	O	NOUN	B
of	O	ADP	O
such	O	ADJ	O
reactions	O	NOUN	B
to	O	PART	O
fluorescein	B-Chemical	NOUN	B
sodium	I-Chemical	NOUN	I
indicated	O	VERB	O
that	O	SCONJ	O
indocyanine	B-Chemical	NOUN	B
green	I-Chemical	NOUN	I
is	O	AUX	O
a	O	DET	O
safe	O	ADJ	O
as	O	ADP	O
fluorescein	B-Chemical	NOUN	B


Bradykinin	B-Chemical	NOUN	B
receptors	O	NOUN	I
antagonists	O	NOUN	B
and	O	CCONJ	O
nitric	B-Chemical	ADJ	B
oxide	I-Chemical	NOUN	I
synthase	O	NOUN	I
inhibitors	O	NOUN	I
in	O	ADP	O
vincristine	B-Chemical	NOUN	B
and	O	CCONJ	O
streptozotocin	B-Chemical	NOUN	B
induced	O	VERB	B
hyperalgesia	B-Disease	NOUN	B
in	O	ADP	O
chemotherapy	O	NOUN	B
and	O	CCONJ	O
diabetic	B-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I
rat	O	NOUN	B
model	O	NOUN	B
.	O	PUNCT	O


PURPOSE	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
influence	O	NOUN	B
of	O	ADP	O
an	O	DET	O
irreversible	O	ADJ	B
inhibitor	O	NOUN	B
of	O	ADP	O
constitutive	O	ADJ	B
NO	B-Chemical	NOUN	O
synthase	O	NOUN	O
(	O	PUNCT	O
L	O	PROPN	B
-	O	PUNCT	O
NOArg	O	NOUN	B
;	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
ip	O	NOUN	B
),	O	PUNCT	O
a	O	DET	O
relatively	O	ADV	O
selective	O	ADJ	O
inhibitor	O	NOUN	B
of	O	ADP	O
inducible	O	ADJ	B
NO	B-Chemical	NOUN	O
synthase	O	NOUN	O
(	O	PUNCT	O
L	O	NOUN	B
-	O	PUNCT	O
NIL	O	PROPN	B
;	O	PUNCT	O
1	O	X	O
.	O	PUNCT	O


0	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
ip	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
relatively	O	ADV	O
specific	O	ADJ	O
inhibitor	O	NOUN	B
of	O	ADP	O
neuronal	O	ADJ	B
NO	B-Chemical	NOUN	O
synthase	O	NOUN	O
(	O	PUNCT	O
7	O	NUM	O
-	O	PUNCT	O
NI	O	PROPN	B
;	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
ip	O	NOUN	B
),	O	PUNCT	O
on	O	ADP	O
antihyperalgesic	O	ADJ	B
action	O	NOUN	I
of	O	ADP	O
selective	O	ADJ	O
antagonists	O	NOUN	B
of	O	ADP	O
B2	O	NOUN	B
and	O	CCONJ	O
B1	O	NOUN	B
receptors	O	NOUN	I
:	O	PUNCT	O
D	O	NOUN	B
-	O	PUNCT	O
Arg	O	NOUN	B
-[	O	NUM	O
Hyp3	O	NOUN	B
,	O	PUNCT	O
Thi5	O	NOUN	B
,	O	PUNCT	O
D	O	NOUN	B
-	O	PUNCT	O
Tic7	O	NOUN	B
,	O	PUNCT	O
Oic8	O	NUM	O
]	O	PUNCT	O
bradykinin	B-Chemical	NOUN	B
(	O	PUNCT	O
HOE	B-Chemical	NOUN	B
140	I-Chemical	NUM	O
;	O	PUNCT	O
70	O	NUM	O
nmol	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
ip	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
des	B-Chemical	X	O
Arg10	I-Chemical	NOUN	B
HOE	I-Chemical	NOUN	B
140	I-Chemical	NUM	O
(	O	PUNCT	O
70	O	NUM	O
nmol	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
ip	O	NOUN	B
)	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
in	O	ADP	O
model	O	NOUN	B
of	O	ADP	O
diabetic	B-Disease	ADJ	B
(streptozotocin-induced)	I-Disease	NOUN	I
and	I-Disease	CCONJ	O
toxic	I-Disease	ADJ	B
(vincristine-induced)	I-Disease	NOUN	O
neuropathy	I-Disease	NOUN	B
was	O	AUX	O
investigated	O	VERB	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
changes	O	NOUN	B
in	O	ADP	O
pain	B-Disease	NOUN	B
thresholds	O	NOUN	I
were	O	AUX	O
determined	O	VERB	O
using	O	VERB	O
mechanical	O	ADJ	B
stimuli	O	NOUN	I
--	O	PUNCT	O
the	O	DET	O
modification	O	NOUN	B
of	O	ADP	O
the	O	DET	O
classic	O	ADJ	B
paw	O	NOUN	O
withdrawal	O	NOUN	O
test	O	NOUN	O
described	O	VERB	O
by	O	ADP	O
Randall	O	PROPN	B
-	O	PUNCT	O
Selitto	O	PROPN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
results	O	NOUN	B
of	O	ADP	O
this	O	DET	O
paper	O	NOUN	O
confirm	O	VERB	O
that	O	SCONJ	O
inhibition	O	NOUN	B
of	O	ADP	O
bradykinin	B-Chemical	NOUN	B
receptors	O	NOUN	I
and	O	CCONJ	O
inducible	O	ADJ	B
NO	B-Chemical	NOUN	B
synthase	O	NOUN	I
but	O	CCONJ	O
not	O	PART	O
neuronal	O	ADJ	B
NO	B-Chemical	NOUN	O
synthase	O	NOUN	O
activity	O	NOUN	O
reduces	O	VERB	O
diabetic	B-Disease	ADJ	B
hyperalgesia	I-Disease	NOUN	I
.	O	PUNCT	O


Pretreatment	O	NOUN	B
with	O	ADP	O
L	O	NOUN	B
-	O	PUNCT	O
NOArg	O	PROPN	B
and	O	CCONJ	O
L	O	PROPN	B
-	O	PUNCT	O
NIL	O	PROPN	B
but	O	CCONJ	O
not	O	PART	O
7	O	NUM	O
-	O	PUNCT	O
NI	O	PROPN	B
,	O	PUNCT	O
significantly	O	ADV	O
increases	O	VERB	O
antihyperalgesic	O	ADJ	B
activity	O	NOUN	I
both	O	CCONJ	O
HOE	B-Chemical	NOUN	B
140	I-Chemical	NUM	O
and	O	CCONJ	O
des	B-Chemical	X	O
Arg10	I-Chemical	NOUN	B
HOE	I-Chemical	NOUN	B
140	I-Chemical	NUM	O
.	O	PUNCT	O


It	O	PRON	O
was	O	AUX	O
also	O	ADV	O
shown	O	VERB	O
that	O	SCONJ	O
both	O	DET	O
products	O	NOUN	B
of	O	ADP	O
inducible	O	ADJ	B
NO	B-Chemical	NOUN	B
synthase	O	NOUN	I
and	O	CCONJ	O
neuronal	O	ADJ	B
NO	B-Chemical	NOUN	O
synthase	O	NOUN	O
activation	O	NOUN	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
bradykinin	B-Chemical	NOUN	B
are	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
hyperalgesia	B-Disease	NOUN	B
produced	O	VERB	O
by	O	ADP	O
vincristine	B-Chemical	NOUN	B
.	O	PUNCT	O


Moreover	O	ADV	O
,	O	PUNCT	O
L	O	PROPN	B
-	O	PUNCT	O
NOArg	O	PROPN	B
and	O	CCONJ	O
7	O	NUM	B
-	O	PUNCT	O
NI	O	NOUN	B
but	O	CCONJ	O
not	O	PART	O
L	O	NOUN	B
-	O	PUNCT	O
NIL	O	PROPN	B
intensify	O	VERB	O
antihyperalgesic	O	ADJ	B
activity	O	NOUN	I
of	O	ADP	O
HOE	B-Chemical	NOUN	B
140	I-Chemical	NUM	O
or	O	CCONJ	O
des-Arg10HOE	B-Chemical	NOUN	O
140	I-Chemical	NUM	O
in	O	ADP	O
toxic	B-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
Results	O	NOUN	B
of	O	ADP	O
these	O	DET	O
studies	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
B1	O	NOUN	B
and	O	CCONJ	O
B2	O	NOUN	B
receptors	O	NOUN	I
are	O	AUX	O
engaged	O	VERB	O
in	O	ADP	O
transmission	O	NOUN	B
of	O	ADP	O
nociceptive	O	ADJ	B
stimuli	O	NOUN	I
in	O	ADP	O
both	O	CCONJ	O
diabetic	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
toxic	I-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
streptozotocin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hyperalgesia	B-Disease	NOUN	B
,	O	PUNCT	O
inducible	O	ADJ	B
NO	B-Chemical	NOUN	B
synthase	O	NOUN	I
participates	O	VERB	O
in	O	ADP	O
pronociceptive	O	ADJ	B
activity	O	NOUN	B
of	O	ADP	O
bradykinin	B-Chemical	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
in	O	ADP	O
vincristine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hyperalgesia	B-Disease	NOUN	B
bradykinin	B-Chemical	NOUN	B
seemed	O	VERB	O
to	O	PART	O
activate	O	VERB	B
neuronal	O	ADJ	B
NO	B-Chemical	NOUN	O
synthase	O	NOUN	O
pathway	O	NOUN	O
.	O	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
concomitant	O	ADJ	B
administration	O	NOUN	B
of	O	ADP	O
small	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
bradykinin	B-Chemical	NOUN	B
receptor	O	NOUN	I
antagonists	O	NOUN	B
and	O	CCONJ	O
NO	B-Chemical	NOUN	B
synthase	O	NOUN	I
inhibitors	O	NOUN	I
can	O	AUX	O
be	O	AUX	O
effective	O	ADJ	B
in	O	ADP	O
alleviation	O	NOUN	B
of	O	ADP	O
neuropathic	B-Disease	ADJ	B
pain	I-Disease	NOUN	I


Cardiac	B-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
observed	O	VERB	O
in	O	ADP	O
association	O	NOUN	B
with	O	ADP	O
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
cyclophosphamide	B-Chemical	NOUN	B
-	O	PUNCT	O
based	O	VERB	B
chemotherapy	O	NOUN	B
for	O	ADP	O
metastatic	O	ADJ	B
breast	B-Disease	NOUN	I
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


INTRODUCTION	O	NOUN	O
:	O	PUNCT	O
Cyclophosphamide	B-Chemical	NOUN	B
is	O	AUX	O
an	O	DET	O
alkylating	O	NOUN	B
agent	O	NOUN	I
given	O	VERB	O
frequently	O	ADV	O
as	O	ADP	O
a	O	DET	O
component	O	NOUN	B
of	O	ADP	O
many	O	ADJ	O
conditioning	O	NOUN	B
regimens	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
high	O	ADJ	B
doses	O	NOUN	I
,	O	PUNCT	O
its	O	PRON	O
nonhematological	O	ADJ	B
dose	O	NOUN	B
-	O	PUNCT	O
limiting	O	VERB	B
toxicity	B-Disease	NOUN	B
is	O	AUX	O
cardiomyopathy	B-Disease	NOUN	B
.	O	PUNCT	O


STUDY	O	NOUN	O
DESIGN	O	NOUN	O
:	O	PUNCT	O
We	O	PRON	O
combined	O	VERB	O
paclitaxel	B-Chemical	NOUN	B
,	O	PUNCT	O
melphalan	B-Chemical	NOUN	B
and	O	CCONJ	O
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
cyclophosphamide	B-Chemical	NOUN	B
,	O	PUNCT	O
thiotepa	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
carboplatin	B-Chemical	NOUN	B
in	O	ADP	O
a	O	DET	O
triple	O	ADJ	B
sequential	O	ADJ	B
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
regimen	O	NOUN	B
for	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
metastatic	O	ADJ	B
breast	B-Disease	NOUN	I
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


Analysis	O	NOUN	B
was	O	AUX	O
performed	O	VERB	O
on	O	ADP	O
61	O	NUM	O
women	O	NOUN	B
with	O	ADP	O
chemotherapy	O	NOUN	B
-	O	PUNCT	O
responsive	O	ADJ	B
metastatic	O	ADJ	B
breast	B-Disease	NOUN	O
cancer	I-Disease	NOUN	O
receiving	O	VERB	B
96	O	NUM	O
-	O	PUNCT	O
h	O	NOUN	B
infusional	O	ADJ	B
cyclophosphamide	B-Chemical	NOUN	I
as	O	ADP	O
part	O	NOUN	O
of	O	ADP	O
a	O	DET	O
triple	O	ADJ	B
sequential	O	ADJ	B
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
regimen	O	NOUN	B
to	O	PART	O
assess	O	VERB	O
association	O	NOUN	B
between	O	ADP	O
presence	O	NOUN	B
of	O	ADP	O
peritransplant	O	ADJ	B
congestive	B-Disease	ADJ	B
heart	I-Disease	NOUN	I
failure	I-Disease	NOUN	I
(	O	PUNCT	O
CHF	B-Disease	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
following	O	VERB	O
pretreatment	O	NOUN	B
characteristics	O	NOUN	B
:	O	PUNCT	O
presence	O	NOUN	B
of	O	ADP	O
electrocardiogram	O	NOUN	B
(	O	PUNCT	O
EKG	O	NOUN	B
)	O	PUNCT	O
abnormalities	O	NOUN	B
,	O	PUNCT	O
age	O	NOUN	B
,	O	PUNCT	O
hypertension	B-Disease	NOUN	B
,	O	PUNCT	O
prior	O	ADJ	O
cardiac	O	ADJ	B
history	O	NOUN	I
,	O	PUNCT	O
smoking	O	NOUN	B
,	O	PUNCT	O
diabetes	B-Disease	NOUN	B
mellitus	I-Disease	NOUN	I
,	O	PUNCT	O
prior	O	ADJ	O
use	O	NOUN	O
of	O	ADP	O
anthracyclines	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
left	O	VERB	B
-	O	PUNCT	O
sided	O	ADJ	B
chest	O	ADJ	B
irradiation	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Six	O	NUM	O
of	O	ADP	O
61	O	NUM	O
women	O	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
%)	O	NOUN	O
developed	O	VERB	O
clinically	O	ADV	O
reversible	O	ADJ	O
grade	O	NOUN	O
3	O	NUM	O
CHF	B-Disease	NOUN	B
following	O	VERB	O
infusional	O	ADJ	B
cyclophosphamide	B-Chemical	NOUN	I
with	O	ADP	O
a	O	DET	O
median	O	ADJ	B
percent	O	NOUN	O
decline	O	NOUN	O
in	O	ADP	O
ejection	O	NOUN	B
fraction	O	NOUN	I
of	O	ADP	O
31	O	NUM	O
%.	O	NOUN	B
Incidence	O	NOUN	B
of	O	ADP	O
transient	O	ADJ	B
cyclophosphamide	B-Chemical	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
cardiac	B-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
%)	O	NOUN	O
is	O	AUX	O
comparable	O	ADJ	O
to	O	PART	O
previous	O	ADJ	O
recorded	O	ADJ	O
literature	O	NOUN	B
.	O	PUNCT	O


Older	O	ADJ	B
age	O	NOUN	I
was	O	AUX	O
significantly	O	ADV	O
correlated	O	VERB	B
with	O	ADP	O
the	O	DET	O
CHF	B-Disease	NOUN	B
development	O	NOUN	B
;	O	PUNCT	O
with	O	ADP	O
median	O	ADJ	B
ages	O	NOUN	B
for	O	ADP	O
the	O	DET	O
entire	O	ADJ	O
group	O	NOUN	B
and	O	CCONJ	O
for	O	ADP	O
patients	O	NOUN	B
developing	O	VERB	O
CHF	B-Disease	NOUN	B
of	O	ADP	O
45	O	NUM	O
and	O	CCONJ	O
59	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


No	O	DET	O
association	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
with	O	ADP	O
other	O	ADJ	O
pretreatment	O	NOUN	B
characteristics	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
As	O	ADP	O
a	O	DET	O
result	O	NOUN	O
of	O	ADP	O
these	O	DET	O
findings	O	NOUN	B
,	O	PUNCT	O
oncologists	O	NOUN	B
should	O	AUX	O
carefully	O	ADV	O
monitor	O	VERB	B
fluid	O	ADJ	B
balance	O	NOUN	B
in	O	ADP	O
older	O	ADJ	B
patients	O	NOUN	I
.	O	PUNCT	O


Routine	O	ADJ	B
EKG	O	NOUN	B
monitoring	O	VERB	B
during	O	ADP	O
infusional	O	ADJ	B
cyclophosphamide	B-Chemical	NOUN	I
did	O	AUX	O
not	O	PART	O
predict	O	VERB	O
CHF	B-Disease	NOUN	B


Inappropriate	O	ADJ	B
use	O	NOUN	I
of	O	ADP	O
carbamazepine	B-Chemical	NOUN	B
and	O	CCONJ	O
vigabatrin	B-Chemical	NOUN	B
in	O	ADP	O
typical	O	ADJ	O
absence	B-Disease	NOUN	O
seizures	I-Disease	NOUN	B
.	O	PUNCT	O


Carbamazepine	B-Chemical	NOUN	B
and	O	CCONJ	O
vigabatrin	B-Chemical	NOUN	B
are	O	AUX	O
contraindicated	O	VERB	B
in	O	ADP	O
typical	O	ADJ	O
absence	B-Disease	NOUN	O
seizures	I-Disease	NOUN	B
.	O	PUNCT	O


Of	O	ADP	O
18	O	NUM	O
consecutive	O	ADJ	B
referrals	O	NOUN	B
of	O	ADP	O
children	O	NOUN	B
with	O	ADP	O
resistant	O	ADJ	B
typical	O	ADJ	B
absences	O	NOUN	I
only	O	ADV	O
,	O	PUNCT	O
eight	O	NUM	O
were	O	AUX	O
erroneously	O	ADV	O
treated	O	VERB	B
with	O	ADP	I
carbamazepine	B-Chemical	NOUN	B
either	O	CCONJ	O
as	O	ADP	O
monotherapy	O	NOUN	B
or	O	CCONJ	O
as	O	ADP	O
an	O	DET	O
add	O	VERB	O
-	O	PUNCT	O
on	O	NOUN	O
.	O	PUNCT	O


Vigabatrin	B-Chemical	NOUN	B
was	O	AUX	O
also	O	ADV	O
used	O	VERB	O
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
two	O	NUM	O
children	O	NOUN	B
.	O	PUNCT	O


Frequency	O	NOUN	B
of	O	ADP	O
absences	O	NOUN	B
increased	O	VERB	B
in	O	ADP	O
four	O	NUM	O
children	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
carbamazepine	B-Chemical	NOUN	B
and	O	CCONJ	O
two	O	NUM	O
of	O	ADP	O
these	O	DET	O
developed	O	VERB	O
myoclonic	B-Disease	ADJ	B
jerks	I-Disease	NOUN	I
,	O	PUNCT	O
which	O	DET	O
resolved	O	VERB	B
on	O	ADP	O
withdrawal	O	NOUN	B
of	O	ADP	I
carbamazepine	B-Chemical	NOUN	B
.	O	PUNCT	O


Absences	O	NOUN	B
were	O	AUX	O
aggravated	O	VERB	B
in	O	ADP	O
both	O	DET	O
cases	O	NOUN	B
where	O	SCONJ	O
vigabatrin	B-Chemical	NOUN	B
was	O	AUX	O
added	O	VERB	O
on	O	ADP	O
to	O	PART	O
concurrent	O	ADJ	B
treatment	O	NOUN	B
.	O	PUNCT	O


Optimal	O	ADJ	B
control	O	NOUN	B
of	O	ADP	O
the	O	DET	O
absences	O	NOUN	B
was	O	AUX	O
achieved	O	VERB	O
with	O	ADP	O
sodium	B-Chemical	NOUN	B
valproate	I-Chemical	NOUN	I
,	O	PUNCT	O
lamotrigine	B-Chemical	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
ethosuximide	B-Chemical	NOUN	B


Hemolytic	B-Disease	ADJ	B
anemia	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
omeprazole	B-Chemical	NOUN	B
.	O	PUNCT	O


Omeprazole	B-Chemical	NOUN	B
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
drug	O	NOUN	B
designed	O	VERB	O
to	O	PART	O
block	O	VERB	B
the	O	DET	O
final	O	ADJ	O
step	O	NOUN	O
in	O	ADP	O
the	O	DET	O
acid	O	NOUN	B
secretory	O	ADJ	I
process	O	NOUN	I
within	O	ADP	O
the	O	DET	O
parietal	O	ADJ	B
cell	O	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
be	O	AUX	O
extremely	O	ADV	O
effective	O	ADJ	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
peptic	B-Disease	ADJ	B
ulcer	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
,	O	PUNCT	O
reflux	B-Disease	NOUN	B
esophagitis	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
Zollinger-Ellison	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


Although	O	SCONJ	O
clinical	O	ADJ	B
experience	O	NOUN	O
with	O	ADP	O
omeprazole	B-Chemical	NOUN	B
is	O	AUX	O
still	O	ADV	O
limited	O	ADJ	O
,	O	PUNCT	O
many	O	ADJ	O
controlled	O	VERB	B
studies	O	NOUN	I
have	O	AUX	O
established	O	VERB	O
the	O	DET	O
short	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
safety	O	NOUN	B
of	O	ADP	O
this	O	DET	O
drug	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
the	O	DET	O
first	O	ADJ	O
case	O	NOUN	B
of	O	ADP	O
a	O	DET	O
serious	O	ADJ	O
short	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
adverse	O	ADJ	B
reaction	O	NOUN	I
with	O	ADP	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
omeprazole	B-Chemical	NOUN	B
:	O	PUNCT	O
hemolytic	B-Disease	ADJ	B
anemia	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
developed	O	VERB	O
weakness	O	NOUN	B
,	O	PUNCT	O
lethargy	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
shortness	B-Disease	NOUN	B
of	I-Disease	ADP	O
breath	I-Disease	NOUN	O
2	O	NUM	O
days	O	NOUN	B
after	O	ADP	O
starting	O	VERB	O
therapy	O	NOUN	B
with	O	ADP	O
omeprazole	B-Chemical	NOUN	B
.	O	PUNCT	O


Two	O	NUM	O
weeks	O	NOUN	B
after	O	ADP	O
the	O	DET	O
initiation	O	NOUN	B
of	O	ADP	O
therapy	O	NOUN	B
,	O	PUNCT	O
her	O	PRON	O
hematocrit	O	NOUN	B
had	O	AUX	O
decreased	O	VERB	B
from	O	ADP	O
44	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
%	O	NOUN	O
to	O	PART	O
20	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
%,	O	INTJ	B
and	O	CCONJ	O
she	O	PRON	O
had	O	AUX	O
a	O	DET	O
positive	O	ADJ	B
direct	O	ADJ	O
Coombs	O	NOUN	B
antiglobulin	O	NOUN	I
test	O	NOUN	I
and	O	CCONJ	O
an	O	DET	O
elevated	O	ADJ	B
indirect	O	ADJ	B
bilirubin	B-Chemical	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
she	O	PRON	O
discontinued	O	VERB	B
the	O	DET	O
omeprazole	B-Chemical	NOUN	B
,	O	PUNCT	O
her	O	PRON	O
hemoglobin	O	NOUN	B
and	O	CCONJ	O
hematocrit	O	NOUN	B
gradually	O	ADV	O
returned	O	VERB	O
to	O	ADP	O
normal	O	ADJ	B
.	O	PUNCT	O


The	O	DET	O
mechanism	O	NOUN	B
by	O	ADP	O
which	O	DET	O
omeprazole	B-Chemical	NOUN	B
caused	O	VERB	O
the	O	DET	O
patient	O	NOUN	B
'	O	PART	O
s	O	NOUN	O
hemolytic	B-Disease	ADJ	B
anemia	I-Disease	NOUN	B


The	O	DET	O
use	O	NOUN	O
and	O	CCONJ	O
toxicity	B-Disease	NOUN	B
of	O	ADP	O
didanosine	B-Chemical	NOUN	B
(	O	PUNCT	O
ddI	B-Chemical	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
HIV	B-Disease	NOUN	B
antibody-positive	I-Disease	ADJ	B
individuals	O	NOUN	B
intolerant	O	ADJ	B
to	O	PART	O
zidovudine	B-Chemical	NOUN	B
(	O	PUNCT	O
AZT	B-Chemical	NOUN	B
)	O	PUNCT	O
One	O	NUM	O
hundred	O	NUM	O
and	O	CCONJ	O
fifty	O	NUM	B
-	O	PUNCT	O
one	O	NUM	O
patients	O	NOUN	B
intolerant	O	ADJ	B
to	O	PART	O
zidovudine	B-Chemical	NOUN	B
(	O	PUNCT	O
AZT	B-Chemical	NOUN	B
)	O	PUNCT	O
received	O	VERB	O
didanosine	B-Chemical	NOUN	B
(	O	PUNCT	O
ddI	B-Chemical	NOUN	B
)	O	PUNCT	O
to	O	PART	O
a	O	DET	O
maximum	O	ADJ	B
dose	O	NOUN	B
of	O	ADP	O
12	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
/	O	SYM	O
day	O	NOUN	B
.	O	PUNCT	O


Patient	O	ADJ	B
response	O	NOUN	I
was	O	AUX	O
assessed	O	VERB	B
using	O	VERB	O
changes	O	NOUN	B
in	O	ADP	O
CD4	O	NOUN	B
+	O	CCONJ	O
lymphocyte	O	NOUN	B
subset	O	NOUN	O
count	O	NOUN	O
,	O	PUNCT	O
HIV	O	NOUN	B
p24	O	NOUN	I
antigen	O	NOUN	I
,	O	PUNCT	O
weight	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
quality	O	NOUN	B
of	O	ADP	I
life	O	NOUN	I
.	O	PUNCT	O


Seventy	O	NUM	O
patients	O	NOUN	B
developed	O	VERB	O
major	O	ADJ	O
opportunistic	B-Disease	ADJ	B
infections	I-Disease	NOUN	I
whilst	O	SCONJ	O
on	O	ADP	O
therapy	O	NOUN	B
;	O	PUNCT	O
this	O	DET	O
was	O	AUX	O
the	O	DET	O
first	O	ADJ	O
AIDS	B-Disease	NOUN	B
diagnosis	O	NOUN	B
in	O	ADP	O
17	O	NUM	O
.	O	PUNCT	O


Only	O	ADV	O
minor	O	ADJ	O
changes	O	NOUN	B
in	O	ADP	O
CD4	O	NOUN	B
+	O	CCONJ	O
lymphocyte	O	NOUN	B
subset	O	NOUN	O
count	O	NOUN	O
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
AIDS	B-Disease	NOUN	B
patients	O	NOUN	B
,	O	PUNCT	O
although	O	SCONJ	O
a	O	DET	O
more	O	ADV	O
significant	O	ADJ	B
rise	O	NOUN	O
occurred	O	VERB	O
in	O	ADP	O
those	O	DET	O
with	O	ADP	O
earlier	O	ADJ	O
stages	O	NOUN	B
of	O	ADP	O
disease	O	NOUN	B
.	O	PUNCT	O


Of	O	ADP	O
those	O	DET	O
positive	O	ADJ	B
for	O	ADP	O
p24	O	NOUN	B
antigen	O	NOUN	I
at	O	ADP	O
the	O	DET	O
commencement	O	NOUN	B
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
67	O	NUM	O
%	O	NOUN	O
showed	O	VERB	O
a	O	DET	O
positive	O	ADJ	B
response	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
this	O	DET	O
was	O	AUX	O
most	O	ADV	O
likely	O	ADJ	O
in	O	ADP	O
those	O	DET	O
with	O	ADP	O
CD4	O	NOUN	B
+	O	CCONJ	O
lymphocyte	O	NOUN	B
subset	O	NOUN	O
counts	O	VERB	O
above	O	ADP	O
100	O	NUM	O
mm3	O	NOUN	O
.	O	PUNCT	O


A	O	DET	O
positive	O	ADJ	B
weight	O	NOUN	B
response	O	NOUN	I
was	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
16	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
.	O	PUNCT	O


Most	O	ADJ	O
patients	O	NOUN	B
showed	O	VERB	O
improvement	O	NOUN	B
in	O	ADP	O
individual	O	ADJ	B
parameters	O	NOUN	B
and	O	CCONJ	O
global	O	ADJ	B
score	O	NOUN	I
of	O	ADP	O
quality	O	NOUN	B
of	O	ADP	I
life	O	NOUN	I
.	O	PUNCT	O


Adverse	O	ADJ	B
reactions	O	NOUN	I
possibly	O	ADV	O
attributable	O	ADJ	O
to	O	PART	O
didanosine	B-Chemical	NOUN	B
were	O	AUX	O
common	O	ADJ	O
.	O	PUNCT	O


The	O	DET	O
most	O	ADV	O
common	O	ADJ	O
side	O	NOUN	B
-	O	PUNCT	O
effect	O	NOUN	B
was	O	AUX	O
diarrhoea	B-Disease	ADJ	B
,	O	PUNCT	O
which	O	DET	O
resulted	O	VERB	O
in	O	ADP	O
cessation	O	NOUN	B
of	O	ADP	O
therapy	O	NOUN	B
in	O	ADP	O
19	O	NUM	O
individuals	O	NOUN	B
.	O	PUNCT	O


Peripheral	B-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I
occurred	O	VERB	O
in	O	ADP	O
12	O	NUM	O
patients	O	NOUN	B
and	O	CCONJ	O
pancreatitis	B-Disease	NOUN	B
in	O	ADP	O
six	O	NUM	O
.	O	PUNCT	O


Thirteen	O	NUM	O
patients	O	NOUN	B
developed	O	VERB	O
a	O	DET	O
raised	O	VERB	O
serum	O	NOUN	B
amylase	O	NOUN	I
without	O	ADP	O
abdominal	B-Disease	ADJ	B
pain	I-Disease	NOUN	I
.	O	PUNCT	O


Seven	O	NUM	O
patients	O	NOUN	B
developed	O	VERB	O
glucose	B-Disease	NOUN	B
tolerance	I-Disease	NOUN	I
curves	I-Disease	VERB	I
characteristic	O	ADJ	O
of	O	ADP	O
diabetes	B-Disease	NOUN	B
but	O	CCONJ	O
these	O	DET	O
were	O	AUX	O
mild	O	ADJ	B
,	O	PUNCT	O
did	O	AUX	O
not	O	PART	O
require	O	VERB	O
treatment	O	NOUN	B
and	O	CCONJ	O
returned	O	VERB	O
to	O	ADP	O
normal	O	ADJ	B
on	O	ADP	O
ceasing	O	VERB	B
didanosine	B-Chemical	NOUN	B


Can	O	AUX	O
angiogenesis	O	NOUN	B
be	O	AUX	O
a	O	DET	O
target	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
for	O	ADP	O
ribavirin	B-Chemical	NOUN	B
associated	O	ADJ	O
hemolytic	B-Disease	ADJ	B
anemia	I-Disease	NOUN	B
?	O	PUNCT	O
BACKGROUND	O	NOUN	B
/	O	SYM	O
AIMS	O	NOUN	B
:	O	PUNCT	O
Recently	O	ADV	O
ribavirin	B-Chemical	NOUN	B
has	O	AUX	O
been	O	AUX	O
found	O	VERB	O
to	O	PART	O
inhibit	O	VERB	B
angiogenesis	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
number	O	NOUN	O
of	O	ADP	O
angiogenesis	O	NOUN	B
inhibitors	O	NOUN	B
such	O	ADJ	O
as	O	ADP	O
sunitinib	B-Chemical	NOUN	B
and	O	CCONJ	O
sorafenib	B-Chemical	NOUN	B
have	O	AUX	O
been	O	AUX	O
found	O	VERB	O
to	O	PART	O
cause	O	VERB	O
acute	O	ADJ	B
hemolysis	B-Disease	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
aimed	O	VERB	O
to	O	PART	O
investigate	O	VERB	B
whether	O	SCONJ	O
there	O	PRON	O
is	O	AUX	O
a	O	DET	O
relation	O	NOUN	O
between	O	ADP	O
hemoglobin	O	NOUN	B
,	O	PUNCT	O
haptoglobin	O	NOUN	B
and	O	CCONJ	O
angiogenesis	O	NOUN	B
soluble	O	ADJ	B
markers	O	NOUN	B
which	O	DET	O
are	O	AUX	O
modifiable	O	ADJ	B
and	O	CCONJ	O
can	O	AUX	O
help	O	VERB	O
in	O	ADP	O
developing	O	VERB	O
strategies	O	NOUN	O
against	O	ADP	O
anemia	B-Disease	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
Fourteen	O	NUM	O
patients	O	NOUN	B
chronically	B-Disease	ADV	B
infected	I-Disease	VERB	B
with	I-Disease	ADP	O
hepatitis	I-Disease	NOUN	B
C	I-Disease	NOUN	I
virus	I-Disease	NOUN	I
were	O	AUX	O
treated	O	VERB	B
by	O	ADP	O
pegylated	B-Chemical	ADJ	B
interferon	I-Chemical	NOUN	I
alpha	I-Chemical	NOUN	I
2a	I-Chemical	NOUN	I
and	O	CCONJ	O
ribavirin	B-Chemical	NOUN	B
.	O	PUNCT	O


Serum	O	NOUN	B
hemoglobin	O	NOUN	I
,	O	PUNCT	O
haptoglobin	O	NOUN	B
and	O	CCONJ	O
angiogenesis	O	NOUN	B
markers	O	NOUN	B
of	O	ADP	O
vascular	O	ADJ	B
endothelial	O	ADJ	I
growth	O	NOUN	I
factor	O	NOUN	I
and	O	CCONJ	O
angiopoetin	O	NOUN	B
-	O	PUNCT	O
2	O	NUM	B
were	O	AUX	O
investigated	O	VERB	B
before	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
therapy	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
We	O	PRON	O
observed	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
decrease	O	NOUN	B
in	O	ADP	O
haptoglobin	O	NOUN	B
levels	O	NOUN	B
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
period	O	NOUN	B
.	O	PUNCT	O


Hemoglobin	O	NOUN	B
levels	O	NOUN	I
also	O	ADV	O
decreased	O	VERB	B
but	O	CCONJ	O
insignificantly	O	ADV	O
by	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
with	O	ADP	O
the	O	DET	O
literature	O	NOUN	B
,	O	PUNCT	O
serum	O	NOUN	B
levels	O	NOUN	O
of	O	ADP	O
angiogenesis	O	NOUN	B
factors	O	NOUN	O
did	O	AUX	O
not	O	PART	O
change	O	VERB	O
significantly	O	ADV	O
by	O	ADP	O
pegylated	B-Chemical	ADJ	B
interferon	I-Chemical	NOUN	B
and	O	CCONJ	O
ribavirin	B-Chemical	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
found	O	VERB	O
no	O	DET	O
correlation	O	NOUN	B
of	O	ADP	O
angiogenesis	O	NOUN	B
soluble	O	ADJ	B
markers	O	NOUN	B
with	O	ADP	O
either	O	CCONJ	O
hemoglobin	O	NOUN	B
or	O	CCONJ	O
haptoglobin	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
This	O	DET	O
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
study	O	NOUN	B
in	O	ADP	O
the	O	DET	O
literature	O	NOUN	B
investigating	O	VERB	B
a	O	DET	O
link	O	NOUN	O
between	O	ADP	O
angiogenesis	O	NOUN	B
soluble	O	ADJ	B
markers	O	NOUN	B
and	O	CCONJ	O
ribavirin	B-Chemical	NOUN	B
induced	O	VERB	O
anemia	B-Disease	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
hepatitis	B-Disease	NOUN	B
C	I-Disease	NOUN	I
and	O	CCONJ	O
we	O	PRON	O
could	O	AUX	O
not	O	PART	O
find	O	VERB	O
any	O	DET	O
relation	O	NOUN	O
.	O	PUNCT	O


Future	O	ADJ	O
research	O	NOUN	B
with	O	ADP	O
larger	O	ADJ	O
number	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
is	O	AUX	O
needed	O	VERB	O
to	O	PART	O
find	O	VERB	O
out	O	ADP	O
modifiable	O	ADJ	B
factors	O	NOUN	B
that	O	PRON	O
will	O	AUX	O
improve	O	VERB	O
the	O	DET	O
safety	O	NOUN	B
of	O	ADP	O
ribavirin	B-Chemical	NOUN	B


Cocaine	B-Chemical	NOUN	B
causes	O	VERB	O
memory	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
learning	I-Disease	NOUN	B
impairments	I-Disease	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
:	O	PUNCT	O
involvement	O	NOUN	B
of	O	ADP	O
nuclear	O	ADJ	B
factor	O	NOUN	I
kappa	O	NOUN	I
B	O	NOUN	I
and	O	CCONJ	O
oxidative	O	ADJ	B
stress	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
prevention	O	NOUN	B
by	O	ADP	O
topiramate	B-Chemical	NOUN	B
.	O	PUNCT	O


Different	O	ADJ	O
mechanisms	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
suggested	O	VERB	O
for	O	ADP	O
cocaine	B-Chemical	NOUN	B
toxicity	B-Disease	NOUN	B
including	O	VERB	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
oxidative	O	ADJ	B
stress	O	NOUN	I
but	O	CCONJ	O
the	O	DET	O
association	O	NOUN	B
between	O	ADP	O
oxidative	O	ADJ	B
status	O	NOUN	I
in	O	ADP	O
the	O	DET	O
brain	O	NOUN	B
and	O	CCONJ	O
cocaine	B-Chemical	NOUN	B
induced	O	VERB	B
-	O	PUNCT	O
behaviour	O	NOUN	B
is	O	AUX	O
poorly	O	ADV	O
understood	O	VERB	O
.	O	PUNCT	O


Nuclear	O	ADJ	B
factor	O	NOUN	I
kappa	O	NOUN	I
B	O	NOUN	I
(	O	PUNCT	O
NFkappaB	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
sensor	O	NOUN	B
of	O	ADP	O
oxidative	O	ADJ	B
stress	O	NOUN	I
and	O	CCONJ	O
participates	O	VERB	B
in	O	ADP	O
memory	O	NOUN	B
formation	O	NOUN	I
that	O	PRON	O
could	O	AUX	O
be	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
drug	O	NOUN	B
toxicity	B-Disease	NOUN	B
and	O	CCONJ	O
addiction	O	NOUN	B
mechanisms	O	NOUN	I
.	O	PUNCT	O


Therefore	O	ADV	O
NFkappaB	O	NOUN	B
activity	O	NOUN	I
,	O	PUNCT	O
oxidative	O	ADJ	B
stress	O	NOUN	I
,	O	PUNCT	O
neuronal	O	ADJ	B
nitric	B-Chemical	ADJ	I
oxide	I-Chemical	NOUN	I
synthase	O	NOUN	I
(	O	PUNCT	O
nNOS	O	NOUN	B
)	O	PUNCT	O
activity	O	NOUN	B
,	O	PUNCT	O
spatial	O	ADJ	B
learning	O	NOUN	I
and	O	CCONJ	O
memory	O	NOUN	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
topiramate	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
previously	O	ADV	O
proposed	O	VERB	O
therapy	O	NOUN	B
for	O	ADP	O
cocaine	B-Disease	NOUN	B
addiction	I-Disease	NOUN	I
,	O	PUNCT	O
were	O	AUX	O
evaluated	O	VERB	B
in	O	ADP	O
an	O	DET	O
experimental	O	ADJ	B
model	O	NOUN	I
of	O	ADP	O
cocaine	B-Chemical	NOUN	B
administration	O	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


NFkappaB	O	NOUN	B
activity	O	NOUN	O
was	O	AUX	O
decreased	O	VERB	B
in	O	ADP	O
the	O	DET	O
frontal	O	ADJ	B
cortex	O	NOUN	I
of	O	ADP	O
cocaine	B-Chemical	NOUN	B
treated	O	ADJ	B
rats	O	NOUN	B
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
GSH	B-Chemical	NOUN	B
concentration	O	NOUN	B
and	O	CCONJ	O
glutathione	B-Chemical	NOUN	B
peroxidase	O	NOUN	I
activity	O	NOUN	B
in	O	ADP	O
the	O	DET	O
hippocampus	O	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
nNOS	O	NOUN	B
activity	O	NOUN	B
in	O	ADP	O
the	O	DET	O
hippocampus	O	NOUN	B
was	O	AUX	O
increased	O	VERB	B
.	O	PUNCT	O


Memory	O	NOUN	B
retrieval	O	NOUN	O
of	O	ADP	O
experiences	O	NOUN	B
acquired	O	VERB	O
prior	O	ADV	O
to	O	PART	O
cocaine	B-Chemical	NOUN	B
administration	O	NOUN	I
was	O	AUX	O
impaired	O	ADJ	B
and	O	CCONJ	O
negatively	O	ADV	B
correlated	O	VERB	B
with	O	ADP	O
NFkappaB	O	NOUN	B
activity	O	NOUN	I
in	O	ADP	O
the	O	DET	O
frontal	O	ADJ	B
cortex	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
learning	O	NOUN	B
of	O	ADP	O
new	O	ADJ	O
tasks	O	NOUN	B
was	O	AUX	O
enhanced	O	VERB	B
and	O	CCONJ	O
correlated	O	VERB	B
with	O	ADP	O
the	O	DET	O
increase	O	NOUN	B
of	O	ADP	O
nNOS	O	NOUN	B
activity	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
decrease	O	NOUN	B
of	O	ADP	O
glutathione	B-Chemical	NOUN	B
peroxidase	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
provide	O	VERB	O
evidence	O	NOUN	B
for	O	ADP	O
a	O	DET	O
possible	O	ADJ	O
mechanistic	O	ADJ	O
role	O	NOUN	O
of	O	ADP	O
oxidative	O	ADJ	B
and	O	CCONJ	O
nitrosative	O	ADJ	B
stress	O	NOUN	I
and	O	CCONJ	O
NFkappaB	O	NOUN	B
in	O	ADP	O
the	O	DET	O
alterations	O	NOUN	B
induced	O	VERB	B
by	O	ADP	O
cocaine	B-Chemical	NOUN	B
.	O	PUNCT	O


Topiramate	B-Chemical	NOUN	B


Antinociceptive	O	ADJ	B
and	O	CCONJ	O
antiamnesic	O	ADJ	B
properties	O	NOUN	B
of	O	ADP	O
the	O	DET	O
presynaptic	O	ADJ	B
cholinergic	O	ADJ	I
amplifier	O	NOUN	I
PG-9	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
antinociceptive	O	ADJ	B
effect	O	NOUN	B
of	O	ADP	O
3	B-Chemical	NUM	O
alpha-tropyl	I-Chemical	ADJ	B
2-(p-bromophenyl)propionate	I-Chemical	NOUN	O
[(+/-)-	O	X	O
PG-9	B-Chemical	NOUN	B
](	O	NOUN	O
10	O	NUM	O
-	O	SYM	O
40	O	NUM	O
mg	O	NOUN	O
kg	O	NOUN	O
-	O	PUNCT	O
1	O	NUM	O
s	O	NOUN	O
.	O	PUNCT	O


c	O	X	O
.;	O	NUM	O
30	O	NUM	O
-	O	PUNCT	O
60	O	NUM	O
mg	O	NOUN	O
kg	O	NOUN	O
-	O	PUNCT	O
1	O	NUM	O
p	O	NOUN	O
.	O	PUNCT	O


o	O	NOUN	O
.;	O	NUM	O
10	O	NUM	O
-	O	SYM	O
30	O	NUM	O
mg	O	NOUN	O
kg	O	NOUN	O
-	O	PUNCT	O
1	O	NUM	O
i	O	NUM	O
.	O	PUNCT	O


v	O	DET	O
.;	O	SYM	B
10	O	NUM	O
-	O	SYM	O
30	O	NUM	O
micrograms	O	NOUN	B
/	O	PUNCT	O
mouse	O	NOUN	B
i	O	NUM	O
.	O	PUNCT	O


c	O	X	O
.	O	PUNCT	O


v	O	X	O
.)	O	NOUN	O
was	O	AUX	O
examined	O	VERB	O
in	O	ADP	O
mice	O	NOUN	B
,	O	PUNCT	O
rats	O	NOUN	B
and	O	CCONJ	O
guinea	O	NOUN	B
pigs	O	NOUN	B
by	O	ADP	O
use	O	NOUN	O
of	O	ADP	O
the	O	DET	O
hot	O	ADJ	B
-	O	PUNCT	O
plate	O	NOUN	B
,	O	PUNCT	O
abdominal	O	ADJ	B
-	O	PUNCT	O
constriction	O	NOUN	B
,	O	PUNCT	O
tail	O	NOUN	B
-	O	PUNCT	O
flick	O	NOUN	B
and	O	CCONJ	O
paw	O	NOUN	B
-	O	PUNCT	O
pressure	O	NOUN	B
tests	O	NOUN	I
.(+/-)-	O	PUNCT	O
PG-9	B-Chemical	NOUN	B
antinociception	O	NOUN	B
peaked	O	VERB	O
15	O	NUM	O
min	O	NOUN	O
after	O	ADP	O
injection	O	NOUN	B
and	O	CCONJ	O
then	O	ADV	O
slowly	O	ADV	O
diminished	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
antinociception	O	NOUN	B
produced	O	VERB	O
by	O	ADP	O
(+/-)-	O	NOUN	O
PG-9	B-Chemical	NOUN	B
was	O	AUX	O
prevented	O	VERB	B
by	O	ADP	O
the	O	DET	O
unselective	O	ADJ	O
muscarinic	O	ADJ	B
antagonist	O	NOUN	I
atropine	B-Chemical	NOUN	B
,	O	PUNCT	O
the	O	DET	O
M1	O	PROPN	B
-	O	PUNCT	O
selective	O	ADJ	B
antagonists	O	NOUN	B
pirenzepine	B-Chemical	NOUN	B
and	O	CCONJ	O
dicyclomine	B-Chemical	NOUN	B
and	O	CCONJ	O
the	O	DET	O
acetylcholine	B-Chemical	NOUN	B
depletor	O	NOUN	I
hemicholinium-3	B-Chemical	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
by	O	ADP	O
the	O	DET	O
opioid	O	NOUN	B
antagonist	O	NOUN	B
naloxone	B-Chemical	NOUN	B
,	O	PUNCT	O
the	O	DET	O
gamma-aminobutyric	B-Chemical	ADJ	B
acidB	I-Chemical	NOUN	I
antagonist	O	NOUN	O
3-aminopropyl-diethoxy-methyl-phosphinic	B-Chemical	ADJ	O
acid	I-Chemical	NOUN	B
,	O	PUNCT	O
the	O	DET	O
H3	O	NOUN	B
agonist	O	NOUN	I
R-(alpha)-methylhistamine	B-Chemical	NOUN	B
,	O	PUNCT	O
the	O	DET	O
D2	O	NOUN	B
antagonist	O	NOUN	I
quinpirole	B-Chemical	NOUN	I
,	O	PUNCT	O
the	O	DET	O
5-hydroxytryptamine4	B-Chemical	NOUN	B
antagonist	O	NOUN	B
2-methoxy-4-amino-5-chlorobenzoic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
2-(diethylamino)ethyl	I-Chemical	NUM	O
ester	I-Chemical	NOUN	B
hydrochloride	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
5-hydroxytryptamin1A	B-Chemical	ADJ	O
antagonist	O	NOUN	B
1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine	B-Chemical	NOUN	O
hydrobromide	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
polyamines	O	NOUN	B
depletor	O	NOUN	B
reserpine	B-Chemical	NOUN	B
.	O	PUNCT	O


Based	O	VERB	O
on	O	ADP	O
these	O	DET	O
data	O	NOUN	B
,	O	PUNCT	O
it	O	PRON	O
can	O	AUX	O
be	O	AUX	O
postulated	O	VERB	O
that	O	SCONJ	O
(+/-)-	O	NOUN	O
PG-9	B-Chemical	NOUN	B
exerted	O	VERB	O
an	O	DET	O
antinociceptive	O	ADJ	B
effect	O	NOUN	I
mediated	O	VERB	O
by	O	ADP	O
a	O	DET	O
central	O	ADJ	B
potentiation	O	NOUN	I
of	O	ADP	O
cholinergic	O	ADJ	B
transmission	O	NOUN	B
.(+/-)-	O	NOUN	O
PG-9	B-Chemical	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
-	O	SYM	O
40	O	NUM	O
mg	O	NOUN	O
kg	O	NOUN	O
-	O	PUNCT	O
1	O	NUM	O
i	O	NUM	O
.	O	PUNCT	O


p	O	NOUN	O
.)	O	PUNCT	O
was	O	AUX	O
able	O	ADJ	O
to	O	PART	O
prevent	O	VERB	B
amnesia	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
scopolamine	B-Chemical	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
mg	O	NOUN	O
kg	O	NOUN	O
-	O	PUNCT	O
1	O	NUM	O
i	O	NUM	O
.	O	PUNCT	O


p	O	NOUN	O
.)	O	NOUN	O
and	O	CCONJ	O
dicyclomine	B-Chemical	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
mg	O	NOUN	O
kg	O	NOUN	O
-	O	PUNCT	O
1	O	NUM	O
i	O	NUM	O
.	O	PUNCT	O


p	O	NOUN	O
.)	O	NOUN	O
in	O	ADP	O
the	O	DET	O
mouse	O	NOUN	B
passive	O	ADJ	B
-	O	PUNCT	O
avoidance	O	NOUN	B
test	O	NOUN	I
.	O	PUNCT	O


Affinity	O	NOUN	B
profiles	O	NOUN	I
of	O	ADP	O
(+/-)-	O	ADJ	B
PG-9	B-Chemical	NOUN	B
for	O	ADP	O
muscarinic	O	ADJ	B
receptor	O	NOUN	I
subtypes	O	NOUN	B
,	O	PUNCT	O
determined	O	VERB	O
by	O	ADP	O
functional	O	ADJ	B
studies	O	NOUN	I
(	O	PUNCT	O
rabbit	O	NOUN	B
vas	O	NOUN	O
deferens	O	NOUN	O
for	O	ADP	O
M1	O	NOUN	B
,	O	PUNCT	O
guinea	O	NOUN	B
pig	O	NOUN	B
atrium	O	NOUN	B
for	O	ADP	O
M2	O	NOUN	B
,	O	PUNCT	O
guinea	O	NOUN	B
pig	O	NOUN	B
ileum	O	NOUN	B
for	O	ADP	O
M3	O	NOUN	B
and	O	CCONJ	O
immature	O	ADJ	B
guinea	O	NOUN	B
pig	O	NOUN	I
uterus	O	NOUN	B
for	O	ADP	O
putative	O	ADJ	B
M4	O	NOUN	I
),	O	PUNCT	O
have	O	AUX	O
shown	O	VERB	O
an	O	DET	O
M4	O	NOUN	B
/	O	SYM	O
M1	O	NOUN	B
selectivity	O	NOUN	B
ratio	O	NOUN	I
of	O	ADP	O
10	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
that	O	PRON	O
might	O	AUX	O
be	O	AUX	O
responsible	O	ADJ	O
for	O	ADP	O
the	O	DET	O
antinociception	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
anti	O	ADJ	B
-	O	PUNCT	O
amnesic	B-Disease	ADJ	B
effect	O	NOUN	B
induced	O	VERB	B
by	O	ADP	O
(+/-)-	O	NOUN	O
PG-9	B-Chemical	NOUN	B
through	O	ADP	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
acetylcholine	B-Chemical	NOUN	B
extracellular	O	ADJ	I
levels	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
antinociceptive	O	ADJ	B
and	O	CCONJ	O
antiamnesic	O	ADJ	B
dose	O	NOUN	O
range	O	NOUN	O
,(+/-)-	O	NOUN	B
PG-9	B-Chemical	NOUN	B


Hyperbaric	O	NOUN	B
oxygen	B-Chemical	NOUN	I
therapy	O	NOUN	I
for	O	ADP	O
control	O	NOUN	B
of	O	ADP	O
intractable	O	ADJ	B
cyclophosphamide	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hemorrhagic	B-Disease	ADJ	B
cystitis	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
intractable	O	ADJ	B
hemorrhagic	B-Disease	ADJ	B
cystitis	I-Disease	NOUN	I
due	O	ADP	O
to	O	PART	O
cyclophosphamide	B-Chemical	NOUN	B
therapy	O	NOUN	I
for	O	ADP	O
Wegener's	B-Disease	NOUN	B
granulomatosis	I-Disease	NOUN	I
.	O	PUNCT	O


Conservative	O	ADJ	B
treatment	O	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
bladder	O	ADJ	B
irrigation	O	NOUN	B
with	O	ADP	O
physiological	O	ADJ	B
saline	O	NOUN	I
and	O	CCONJ	O
instillation	O	NOUN	B
of	O	ADP	O
prostaglandin	B-Chemical	NOUN	B
F2	I-Chemical	PROPN	I
alpha	I-Chemical	NOUN	I
,	O	PUNCT	O
failed	O	VERB	O
to	O	PART	O
totally	O	ADV	O
control	O	VERB	O
hemorrhage	B-Disease	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
then	O	ADV	O
used	O	VERB	O
hyperbaric	O	ADJ	B
oxygen	B-Chemical	NOUN	I
at	O	ADP	O
an	O	DET	O
absolute	O	ADJ	B
pressure	O	NOUN	B
of	O	ADP	O
2	O	NUM	O
atm	O	NOUN	O
,	O	PUNCT	O
5	O	NUM	O
days	O	NOUN	B
a	O	DET	O
week	O	NOUN	B
for	O	ADP	O
8	O	NUM	O
consecutive	O	ADJ	B
weeks	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
bleeding	B-Disease	NOUN	B
ceased	O	VERB	B
completely	O	ADV	O
by	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
treatment	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
patient	O	NOUN	B
remained	O	VERB	O
free	O	ADJ	B
of	O	ADP	O
hematuria	B-Disease	NOUN	B
thereafter	O	ADV	O
.	O	PUNCT	O


No	O	DET	B
side	O	NOUN	B
effect	O	NOUN	I
was	O	AUX	O
noted	O	VERB	O
during	O	ADP	O
the	O	DET	O
course	O	NOUN	B
of	O	ADP	O
therapy	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
future	O	NOUN	O
,	O	PUNCT	O
this	O	DET	O
form	O	NOUN	O
of	O	ADP	O
therapy	O	NOUN	B
can	O	AUX	O
offer	O	VERB	O
a	O	DET	O
safe	O	ADJ	O
alternative	O	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
cyclophosphamide	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hemorrhagic	B-Disease	ADJ	B
cystitis	I-Disease	NOUN	I


Further	O	ADJ	O
studies	O	NOUN	B
on	O	ADP	O
effects	O	NOUN	B
of	O	ADP	I
irrigation	O	NOUN	B
solutions	O	NOUN	B
on	O	ADP	O
rat	O	NOUN	B
bladders	O	NOUN	B
.	O	PUNCT	O


Further	O	ADJ	O
studies	O	NOUN	B
on	O	ADP	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
certain	O	ADJ	O
irrigating	O	NOUN	B
fluids	O	NOUN	I
on	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
bladder	O	NOUN	B
for	O	ADP	O
18	O	NUM	O
hours	O	NOUN	B
are	O	AUX	O
reported	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
have	O	AUX	O
shown	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
degradation	O	NOUN	B
product	O	NOUN	O
p-choloroaniline	B-Chemical	NOUN	B
is	O	AUX	O
not	O	PART	O
a	O	DET	O
significant	O	ADJ	O
factor	O	NOUN	B
in	O	ADP	O
chlorhexidine-digluconate	B-Chemical	ADJ	B
associated	O	VERB	O
erosive	O	ADJ	B
cystitis	B-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
high	O	ADJ	O
percentage	O	NOUN	B
of	O	ADP	O
kanamycin	B-Chemical	NOUN	B
-	O	PUNCT	O
colistin	B-Chemical	NOUN	B
and	O	CCONJ	O
povidone-iodine	B-Chemical	ADJ	B
irrigations	O	NOUN	I
were	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
erosive	O	ADJ	B
cystitis	B-Disease	NOUN	I
and	O	CCONJ	O
suggested	O	VERB	O
a	O	DET	O
possible	O	ADJ	O
complication	O	NOUN	B
with	O	ADP	O
human	O	ADJ	B
usage	O	NOUN	B
.	O	PUNCT	O


Picloxydine	B-Chemical	ADJ	B
irrigations	O	NOUN	I
appeared	O	VERB	O
to	O	PART	O
have	O	AUX	O
a	O	DET	O
lower	O	ADJ	O
incidence	O	NOUN	B
of	O	ADP	O
erosive	O	ADJ	B
cystitis	B-Disease	NOUN	I


Clinical	O	ADJ	B
experiences	O	NOUN	B
in	O	ADP	O
an	O	DET	O
open	O	ADJ	B
and	O	CCONJ	O
a	O	DET	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	NOUN	B
trial	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
sixty	O	NUM	O
patients	O	NOUN	B
were	O	AUX	O
trated	O	VERB	B
with	O	ADP	O
bromperidol	B-Chemical	NOUN	B
first	O	ADV	O
in	O	ADP	O
open	O	ADJ	O
conditions	O	NOUN	O
(	O	PUNCT	O
20	O	NUM	O
patients	O	NOUN	B
),	O	PUNCT	O
then	O	ADV	O
on	O	ADP	O
a	O	DET	O
double	O	ADJ	O
blind	O	ADJ	O
basis	O	NOUN	O
(	O	PUNCT	O
40	O	NUM	O
patients	O	NOUN	B
)	O	PUNCT	O
with	O	ADP	O
haloperidol	B-Chemical	NOUN	B
as	O	ADP	O
the	O	DET	O
reference	O	NOUN	B
substance	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
open	O	ADJ	O
study	O	NOUN	B
lasted	O	VERB	O
for	O	ADP	O
four	O	NUM	O
weeks	O	NOUN	B
;	O	PUNCT	O
the	O	DET	O
drug	O	NOUN	B
was	O	AUX	O
administrated	O	VERB	B
in	O	ADP	O
the	O	DET	O
form	O	NOUN	O
of	O	ADP	O
1	O	NUM	O
mg	O	NOUN	O
tablets	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
daily	O	ADJ	B
dose	O	NOUN	I
(	O	PUNCT	O
initial	O	ADJ	B
dose	O	NOUN	B
:	O	PUNCT	O
1	O	NUM	O
mg	O	NOUN	O
;	O	PUNCT	O
mean	O	ADJ	B
dose	O	NOUN	I
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
trial	O	NOUN	B
:	O	PUNCT	O
4	O	NUM	O
.	O	PUNCT	O


47	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
was	O	AUX	O
always	O	ADV	O
administered	O	VERB	B
in	O	ADP	O
one	O	NUM	O
single	O	ADJ	B
dose	O	NOUN	I
.	O	PUNCT	O


Nineteen	O	NUM	O
patients	O	NOUN	B
finished	O	VERB	O
the	O	DET	O
trial	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
18	O	NUM	O
cases	O	NOUN	B
the	O	DET	O
therapeutic	O	ADJ	B
result	O	NOUN	O
was	O	AUX	O
considered	O	VERB	O
very	O	ADV	O
good	O	ADJ	O
to	O	ADP	O
good	O	ADJ	O
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
were	O	AUX	O
confirmed	O	VERB	O
by	O	ADP	O
statistical	O	ADJ	B
analysis	O	NOUN	I
.	O	PUNCT	O


Nine	O	NUM	O
patients	O	NOUN	B
exhibited	O	VERB	O
mild	O	ADJ	B
to	O	PART	O
moderate	O	ADJ	B
extrapyramidal	B-Disease	ADJ	B
concomitant	I-Disease	ADJ	I
symptoms	I-Disease	NOUN	B
;	O	PUNCT	O
no	O	DET	O
other	O	ADJ	O
side	O	NOUN	B
effects	O	NOUN	I
were	O	AUX	O
observed	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
of	O	ADP	O
detailed	O	ADJ	O
laboratory	O	NOUN	B
tests	O	NOUN	I
and	O	CCONJ	O
evaluations	O	NOUN	B
of	O	ADP	O
various	O	ADJ	O
quantitative	O	ADJ	B
and	O	CCONJ	O
qualitative	O	ADJ	B
tolerability	O	NOUN	B
parameters	O	NOUN	B
were	O	AUX	O
not	O	PART	O
indicative	O	ADJ	O
of	O	ADP	O
toxic	O	ADJ	B
effects	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
double	O	ADJ	O
blind	O	ADJ	O
study	O	NOUN	O
with	O	ADP	O
haloperidol	B-Chemical	NOUN	B
,	O	PUNCT	O
both	O	DET	O
substances	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
highly	O	ADV	O
effective	O	ADJ	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
psychotic	B-Disease	ADJ	B
syndromes	I-Disease	NOUN	I
belonging	I-Disease	VERB	O
predominantly	I-Disease	ADV	O
to	I-Disease	PART	O
the	I-Disease	DET	O
schizophrenia	I-Disease	NOUN	B
group	I-Disease	NOUN	B
.	O	PUNCT	O


Certain	O	ADJ	O
clues	O	NOUN	O
,	O	PUNCT	O
including	O	VERB	O
the	O	DET	O
onset	O	NOUN	B
of	O	ADP	I
action	O	NOUN	I
,	O	PUNCT	O
seem	O	VERB	O
to	O	PART	O
be	O	AUX	O
indicative	O	ADJ	B
of	O	ADP	O
the	O	DET	O
superiority	O	NOUN	B
of	O	ADP	O
bromperidol	B-Chemical	NOUN	B


Curcumin	B-Chemical	NOUN	B
ameliorates	O	VERB	B
cognitive	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
and	O	CCONJ	O
oxidative	O	ADJ	B
damage	O	NOUN	I
in	O	ADP	O
phenobarbitone	B-Chemical	NOUN	B
and	O	CCONJ	O
carbamazepine	B-Chemical	NOUN	B
administered	O	ADJ	B
rats	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
antiepileptic	O	ADJ	B
drugs	O	NOUN	I
,	O	PUNCT	O
phenobarbitone	B-Chemical	NOUN	B
and	O	CCONJ	O
carbamazepine	B-Chemical	NOUN	B
are	O	AUX	O
well	O	ADV	O
known	O	VERB	O
to	O	PART	O
cause	O	VERB	O
cognitive	B-Disease	ADJ	B
impairment	I-Disease	NOUN	I
on	O	ADP	O
chronic	O	ADJ	B
use	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
free	O	ADJ	B
radical	O	ADJ	I
generation	O	NOUN	I
has	O	AUX	O
been	O	AUX	O
implicated	O	VERB	O
as	O	ADP	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
important	O	ADJ	O
mechanisms	O	NOUN	B
of	O	ADP	O
cognitive	B-Disease	ADJ	B
impairment	I-Disease	NOUN	I
by	O	ADP	O
antiepileptic	O	ADJ	B
drugs	O	NOUN	I
.	O	PUNCT	O


Curcumin	B-Chemical	NOUN	B
has	O	AUX	O
shown	O	VERB	O
antioxidant	O	ADJ	B
,	O	PUNCT	O
anti	O	ADJ	B
-	O	PUNCT	O
inflammatory	O	ADJ	B
and	O	CCONJ	O
neuro	O	NOUN	B
-	O	PUNCT	O
protective	O	ADJ	B
properties	O	NOUN	B
.	O	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
was	O	AUX	O
carried	O	VERB	O
out	O	ADP	O
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
chronic	O	ADJ	B
curcumin	B-Chemical	NOUN	I
administration	O	NOUN	B
on	O	ADP	O
phenobarbitone	B-Chemical	NOUN	B
-	O	PUNCT	O
and	O	CCONJ	O
carbamazepine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cognitive	B-Disease	ADJ	B
impairment	I-Disease	NOUN	I
and	O	CCONJ	O
oxidative	O	ADJ	B
stress	O	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


Pharmacokinetic	O	ADJ	B
interactions	O	NOUN	I
of	O	ADP	O
curcumin	B-Chemical	NOUN	B
with	O	ADP	O
phenobarbitone	B-Chemical	NOUN	B
and	O	CCONJ	O
carbamazepine	B-Chemical	NOUN	B
were	O	AUX	O
also	O	ADV	O
studied	O	VERB	O
.	O	PUNCT	O


Vehicle	O	NOUN	B
/	O	SYM	O
drugs	O	NOUN	B
were	O	AUX	O
administered	O	VERB	B
daily	O	ADV	B
for	O	ADP	O
21days	O	NOUN	O
to	O	PART	O
male	O	NOUN	B
Wistar	O	NOUN	B
rats	O	NOUN	I
.	O	PUNCT	O


Passive	O	ADJ	B
avoidance	O	NOUN	I
paradigm	O	NOUN	B
and	O	CCONJ	O
elevated	O	ADJ	B
plus	O	CCONJ	I
maze	O	NOUN	I
test	O	NOUN	I
were	O	AUX	O
used	O	VERB	O
to	O	PART	O
assess	O	VERB	B
cognitive	O	ADJ	B
function	O	NOUN	I
.	O	PUNCT	O


At	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
study	O	NOUN	B
period	O	NOUN	B
,	O	PUNCT	O
serum	O	NOUN	B
phenobarbitone	B-Chemical	NOUN	B
and	O	CCONJ	O
carbamazepine	B-Chemical	NOUN	B
,	O	PUNCT	O
whole	O	ADJ	O
brain	O	NOUN	B
malondialdehyde	B-Chemical	NOUN	B
and	O	CCONJ	O
reduced	O	VERB	B
glutathione	B-Chemical	NOUN	B
levels	O	NOUN	O
were	O	AUX	O
estimated	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
phenobarbitone	B-Chemical	NOUN	B
and	O	CCONJ	O
carbamazepine	B-Chemical	NOUN	B
for	O	ADP	O
21days	O	NOUN	O
caused	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
impairment	B-Disease	NOUN	B
of	I-Disease	ADP	O
learning	I-Disease	NOUN	B
and	I-Disease	CCONJ	O
memory	I-Disease	NOUN	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
an	O	DET	O
increased	O	VERB	B
oxidative	O	ADJ	B
stress	O	NOUN	I
.	O	PUNCT	O


Concomitant	O	ADJ	B
curcumin	B-Chemical	NOUN	B
administration	O	NOUN	B
prevented	O	VERB	B
the	O	DET	O
cognitive	B-Disease	ADJ	B
impairment	I-Disease	NOUN	I
and	O	CCONJ	O
decreased	O	VERB	B
the	O	DET	O
increased	O	VERB	B
oxidative	O	ADJ	B
stress	O	NOUN	I
induced	O	VERB	B
by	O	ADP	O
these	O	DET	O
antiepileptic	O	ADJ	B
drugs	O	NOUN	I
.	O	PUNCT	O


Curcumin	B-Chemical	NOUN	B
co	O	X	B
-	O	PUNCT	O
administration	O	NOUN	B
did	O	AUX	O
not	O	PART	O
cause	O	VERB	O
any	O	DET	O
significant	O	ADJ	O
alteration	O	NOUN	B
in	O	ADP	O
the	O	DET	O
serum	O	NOUN	B
concentrations	O	NOUN	B
of	O	ADP	O
both	O	CCONJ	O
phenobarbitone	B-Chemical	NOUN	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
carbamazepine	B-Chemical	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
show	O	VERB	O
that	O	SCONJ	O
curcumin	B-Chemical	NOUN	B
has	O	AUX	O
beneficial	O	ADJ	O
effect	O	NOUN	B
in	O	ADP	O
mitigating	O	VERB	O
the	O	DET	O
deterioration	B-Disease	NOUN	B
of	I-Disease	ADP	O
cognitive	I-Disease	ADJ	B
functions	I-Disease	NOUN	I
and	O	CCONJ	O
oxidative	O	ADJ	B
damage	O	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
treated	O	VERB	B
with	O	ADP	O
phenobarbitone	B-Chemical	NOUN	B
and	O	CCONJ	O
carbamazepine	B-Chemical	NOUN	B
without	O	ADP	O
significantly	O	ADV	O
altering	O	VERB	B
their	O	PRON	O
serum	O	NOUN	B
concentrations	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
findings	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
curcumin	B-Chemical	NOUN	B
can	O	AUX	O
be	O	AUX	O
considered	O	VERB	O
as	O	ADP	O
a	O	DET	O
potential	O	ADJ	B
safe	O	ADJ	O
and	O	CCONJ	O
effective	O	ADJ	B
adjuvant	O	NOUN	B
to	O	PART	O
phenobarbitone	B-Chemical	NOUN	B
and	O	CCONJ	O
carbamazepine	B-Chemical	NOUN	B
therapy	O	NOUN	I
in	O	ADP	O
preventing	O	VERB	B
cognitive	B-Disease	ADJ	B
impairment	I-Disease	NOUN	I


Pyrrolidine	B-Chemical	NOUN	B
dithiocarbamate	I-Chemical	NOUN	I
protects	O	VERB	B
the	O	DET	O
piriform	O	NOUN	B
cortex	O	NOUN	I
in	O	ADP	O
the	O	DET	O
pilocarpine	B-Chemical	NOUN	B
status	B-Disease	NOUN	O
epilepticus	I-Disease	NOUN	O
model	O	NOUN	O
.	O	PUNCT	O


Pyrrolidine	B-Chemical	NOUN	B
dithiocarbamate	I-Chemical	NOUN	I
(	O	PUNCT	O
PDTC	B-Chemical	NOUN	B
)	O	PUNCT	O
has	O	AUX	O
a	O	DET	O
dual	O	ADJ	O
mechanism	O	NOUN	B
of	O	ADP	O
action	O	NOUN	B
as	O	ADP	O
an	O	DET	O
antioxidant	O	NOUN	B
and	O	CCONJ	O
an	O	DET	O
inhibitor	O	NOUN	B
of	O	ADP	O
the	O	DET	O
transcription	O	NOUN	B
factor	O	NOUN	I
kappa	O	NOUN	I
-	O	PUNCT	O
beta	O	NOUN	B
.	O	PUNCT	O


Both	O	DET	O
,	O	PUNCT	O
production	O	NOUN	B
of	O	ADP	O
reactive	O	ADJ	B
oxygen	B-Chemical	NOUN	I
species	O	NOUN	I
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
activation	O	NOUN	B
of	O	ADP	O
NF	O	NOUN	B
-	O	PUNCT	O
kappaB	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
implicated	O	VERB	O
in	O	ADP	O
severe	O	ADJ	B
neuronal	B-Disease	ADJ	B
damage	I-Disease	NOUN	I
in	O	ADP	O
different	O	ADJ	O
sub	O	NOUN	B
-	O	PUNCT	O
regions	O	NOUN	B
of	O	ADP	O
the	O	DET	O
hippocampus	O	NOUN	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
in	O	ADP	O
the	O	DET	O
surrounding	O	VERB	B
cortices	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
PDTC	B-Chemical	NOUN	B
on	O	ADP	O
status	B-Disease	NOUN	B
epilepticus	I-Disease	NOUN	I
-	O	PUNCT	O
associated	O	VERB	B
cell	O	NOUN	B
loss	O	NOUN	I
in	O	ADP	O
the	O	DET	O
hippocampus	O	NOUN	B
and	O	CCONJ	O
piriform	O	NOUN	B
cortex	O	NOUN	I
was	O	AUX	O
evaluated	O	VERB	B
in	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
fractionated	O	VERB	B
pilocarpine	B-Chemical	NOUN	I
model	O	NOUN	I
.	O	PUNCT	O


Treatment	O	NOUN	B
with	O	ADP	O
150	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
PDTC	B-Chemical	NOUN	B
before	O	ADP	O
and	O	CCONJ	O
following	O	VERB	O
status	B-Disease	NOUN	B
epilepticus	I-Disease	NOUN	I
significantly	O	ADV	O
increased	O	VERB	B
the	O	DET	O
mortality	O	NOUN	B
rate	O	NOUN	I
to	O	ADP	O
100	O	NUM	O
%.	O	NOUN	B
Administration	O	NOUN	B
of	O	ADP	O
50	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
PDTC	B-Chemical	NOUN	B
(	O	PUNCT	O
low	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
)	O	PUNCT	O
did	O	AUX	O
not	O	PART	O
exert	O	VERB	O
major	O	ADJ	O
effects	O	NOUN	B
on	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
a	O	DET	O
status	B-Disease	NOUN	B
epilepticus	I-Disease	NOUN	I
or	O	CCONJ	O
the	O	DET	O
mortality	O	NOUN	B
rate	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
vehicle	O	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
rats	O	NOUN	B
,	O	PUNCT	O
status	B-Disease	NOUN	B
epilepticus	I-Disease	NOUN	I
caused	O	VERB	O
pronounced	O	ADJ	O
neuronal	B-Disease	ADJ	B
damage	I-Disease	NOUN	O
in	O	ADP	O
the	O	DET	O
piriform	O	NOUN	B
cortex	O	NOUN	I
comprising	O	VERB	O
both	O	CCONJ	O
pyramidal	O	ADJ	B
cells	O	NOUN	I
and	O	CCONJ	O
interneurons	O	NOUN	B
.	O	PUNCT	O


Low	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
PDTC	B-Chemical	NOUN	B
treatment	O	NOUN	B
almost	O	ADV	O
completely	O	ADV	O
protected	O	VERB	O
from	O	ADP	O
lesions	O	NOUN	B
in	O	ADP	O
the	O	DET	O
piriform	O	NOUN	B
cortex	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
significant	O	ADJ	O
decrease	O	NOUN	B
in	O	ADP	O
neuronal	O	ADJ	B
density	O	NOUN	I
of	O	ADP	O
the	O	DET	O
hippocampal	O	NOUN	B
hilar	O	ADJ	B
formation	O	NOUN	B
was	O	AUX	O
identified	O	VERB	O
in	O	ADP	O
vehicle	O	NOUN	B
-	O	PUNCT	O
and	O	CCONJ	O
PDTC	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
rats	O	NOUN	B
following	O	VERB	O
status	B-Disease	NOUN	B
epilepticus	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
NF	O	NOUN	B
-	O	PUNCT	O
kappaB	O	NOUN	B
inhibitor	O	NOUN	I
and	O	CCONJ	O
antioxidant	O	ADJ	B
PDTC	B-Chemical	NOUN	B
protected	O	VERB	O
the	O	DET	O
piriform	O	NOUN	B
cortex	O	NOUN	I
,	O	PUNCT	O
whereas	O	SCONJ	O
it	O	PRON	O
did	O	AUX	O
not	O	PART	O
affect	O	VERB	O
hilar	O	ADJ	B
neuronal	B-Disease	ADJ	B
loss	I-Disease	NOUN	I
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
might	O	AUX	O
indicate	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
generation	O	NOUN	B
of	O	ADP	O
reactive	O	ADJ	B
oxygen	B-Chemical	NOUN	I
species	O	NOUN	I
and	O	CCONJ	O
activation	O	NOUN	B
of	O	ADP	O
NF	O	NOUN	B
-	O	PUNCT	O
kappaB	O	NOUN	B
plays	O	VERB	O
a	O	DET	O
more	O	ADV	O
central	O	ADJ	O
role	O	NOUN	O
in	O	ADP	O
seizure	B-Disease	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
neuronal	B-Disease	ADJ	B
damage	I-Disease	NOUN	O
in	O	ADP	O
the	O	DET	O
temporal	O	ADJ	B
cortex	O	NOUN	I
as	O	ADP	O
compared	O	VERB	O
to	O	PART	O
the	O	DET	O
hippocampal	O	ADJ	B
hilus	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
future	O	ADJ	O
investigations	O	NOUN	B
are	O	AUX	O
necessary	O	ADJ	O
to	O	PART	O
exactly	O	ADV	O
analyze	O	VERB	B
the	O	DET	O
biochemical	O	ADJ	B
mechanisms	O	NOUN	B
by	O	ADP	O
which	O	DET	O
PDTC	B-Chemical	NOUN	B


Safety	O	NOUN	B
profile	O	NOUN	O
of	O	ADP	O
a	O	DET	O
nicotine	B-Chemical	NOUN	B
lozenge	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
that	O	DET	O
of	O	ADP	O
nicotine	B-Chemical	NOUN	B
gum	O	NOUN	I
in	O	ADP	O
adult	O	ADJ	B
smokers	O	NOUN	B
with	O	ADP	O
underlying	O	VERB	O
medical	O	ADJ	B
conditions	O	NOUN	I
:	O	PUNCT	O
a	O	DET	O
12	O	NUM	O
-	O	PUNCT	O
week	O	NOUN	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
open	O	ADJ	B
-	O	PUNCT	O
label	O	NOUN	B
study	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Nicotine	B-Chemical	NOUN	B
polacrilex	O	NOUN	B
lozenges	O	NOUN	B
deliver	O	VERB	O
25	O	NUM	O
%	O	NOUN	O
to	O	PART	O
27	O	NUM	O
%	O	NOUN	O
more	O	ADJ	O
nicotine	B-Chemical	NOUN	B
compared	O	VERB	B
with	O	ADP	O
equivalent	O	ADJ	O
doses	O	NOUN	B
of	O	ADP	O
nicotine	B-Chemical	NOUN	B
polacrilex	O	NOUN	B
gum	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
increased	O	VERB	B
nicotine	B-Chemical	NOUN	B
exposure	O	NOUN	B
from	O	ADP	O
the	O	DET	O
lozenge	O	NOUN	B
has	O	AUX	O
raised	O	VERB	O
questions	O	NOUN	B
about	O	ADP	O
the	O	DET	O
relative	O	ADJ	O
safety	O	NOUN	B
of	O	ADP	O
the	O	DET	O
lozenge	O	NOUN	B
and	O	CCONJ	O
gum	O	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
objective	O	NOUN	B
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
compare	O	VERB	B
the	O	DET	O
safety	O	NOUN	B
profiles	O	NOUN	I
of	O	ADP	O
the	O	DET	O
4	O	NUM	O
-	O	PUNCT	O
mg	O	NOUN	O
nicotine	B-Chemical	NOUN	B
lozenge	O	NOUN	B
and	O	CCONJ	O
4	O	NUM	O
-	O	PUNCT	O
mg	O	NOUN	O
nicotine	B-Chemical	NOUN	B
gum	O	NOUN	I
in	O	ADP	O
smokers	O	NOUN	B
with	O	ADP	O
selected	O	VERB	O
label	O	NOUN	B
-	O	PUNCT	O
restricted	O	ADJ	B
diseases	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
This	O	DET	O
was	O	AUX	O
a	O	DET	O
multicenter	O	NOUN	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
open	O	ADJ	B
-	O	PUNCT	O
label	O	NOUN	B
study	O	NOUN	B
in	O	ADP	O
adult	O	ADJ	B
smokers	O	NOUN	B
with	O	ADP	O
heart	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
,	O	PUNCT	O
hypertension	B-Disease	NOUN	B
not	O	PART	O
controlled	O	VERB	O
by	O	ADP	O
medication	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
diabetes	B-Disease	NOUN	B
mellitus	I-Disease	NOUN	I
.	O	PUNCT	O


Patients	O	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
in	O	ADP	O
a	O	DET	O
1	O	NUM	O
:	O	PUNCT	O
1	O	NUM	O
ratio	O	NOUN	B
to	O	PART	O
receive	O	VERB	O
the	O	DET	O
4	O	NUM	O
-	O	PUNCT	O
mg	O	NOUN	O
nicotine	B-Chemical	NOUN	B
lozenge	O	NOUN	B
or	O	CCONJ	O
4	O	NUM	O
-	O	PUNCT	O
mg	O	NOUN	O
nicotine	B-Chemical	NOUN	B
gum	O	NOUN	I
.	O	PUNCT	O


Safety	O	NOUN	B
assessments	O	NOUN	B
were	O	AUX	O
made	O	VERB	O
at	O	ADP	O
baseline	O	NOUN	B
and	O	CCONJ	O
at	O	ADP	O
2	O	NUM	O
,	O	PUNCT	O
4	O	NUM	O
,	O	PUNCT	O
6	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
12	O	NUM	O
weeks	O	NOUN	B
after	O	ADP	O
the	O	DET	O
start	O	NOUN	O
of	O	ADP	O
product	O	NOUN	B
use	O	NOUN	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Nine	O	NUM	O
hundred	O	NUM	O
one	O	NUM	O
patients	O	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
treatment	O	NOUN	B
,	O	PUNCT	O
447	O	NUM	O
who	O	PRON	O
received	O	VERB	O
the	O	DET	O
lozenge	O	NOUN	B
and	O	CCONJ	O
454	O	NUM	O
who	O	PRON	O
received	O	VERB	O
the	O	DET	O
gum	O	NOUN	B
(	O	PUNCT	O
safety	O	NOUN	B
population	O	NOUN	I
).	O	PUNCT	O
The	O	DET	O
majority	O	NOUN	O
were	O	AUX	O
women	O	NOUN	B
(	O	PUNCT	O
52	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
%).	O	ADJ	O
Patients	O	NOUN	B
'	O	PART	O
mean	O	ADJ	O
age	O	NOUN	B
was	O	AUX	O
53	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
years	O	NOUN	B
,	O	PUNCT	O
their	O	PRON	O
mean	O	ADJ	O
weight	O	NOUN	O
was	O	AUX	O
193	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
pounds	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
they	O	PRON	O
smoked	O	VERB	B
a	O	DET	O
mean	O	NOUN	O
of	O	ADP	O
25	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
cigarettes	O	NOUN	B
per	O	ADP	O
day	O	NOUN	B
at	O	ADP	O
baseline	O	NOUN	B
.	O	PUNCT	O


Five	O	NUM	O
hundred	O	NUM	O
fifty	O	NUM	O
-	O	PUNCT	O
three	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
264	O	NUM	O
taking	O	VERB	O
the	O	DET	O
lozenge	O	NOUN	B
and	O	CCONJ	O
289	O	NUM	O
taking	O	VERB	O
the	O	DET	O
gum	O	NOUN	B
,	O	PUNCT	O
used	O	VERB	O
the	O	DET	O
study	O	NOUN	B
product	O	NOUN	O
for	O	ADP	O
>	O	NOUN	O
or	O	CCONJ	O
=	O	ADJ	O
4	O	NUM	O
days	O	NOUN	B
per	O	ADP	O
week	O	NOUN	B
during	O	ADP	O
the	O	DET	O
first	O	ADJ	O
2	O	NUM	O
weeks	O	NOUN	B
(	O	PUNCT	O
evaluable	O	ADJ	B
population	O	NOUN	I
).	O	PUNCT	O
The	O	DET	O
nicotine	B-Chemical	NOUN	B
lozenge	O	NOUN	B
and	O	CCONJ	O
nicotine	B-Chemical	NOUN	B
gum	O	NOUN	I
were	O	AUX	O
equally	O	ADV	O
well	O	ADV	O
tolerated	O	ADJ	B
,	O	PUNCT	O
despite	O	SCONJ	O
increased	O	VERB	B
nicotine	B-Chemical	NOUN	B
exposure	O	NOUN	B
from	O	ADP	O
the	O	DET	O
lozenge	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
adverse	O	ADJ	B
events	O	NOUN	I
in	O	ADP	O
the	O	DET	O
2	O	NUM	O
groups	O	NOUN	B
was	O	AUX	O
similar	O	ADJ	O
during	O	ADP	O
the	O	DET	O
first	O	ADJ	O
2	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
product	O	NOUN	B
use	O	NOUN	I
(	O	PUNCT	O
evaluation	O	NOUN	B
population	O	NOUN	I
:	O	PUNCT	O
55	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
%	O	NOUN	O
lozenge	O	NOUN	B
,	O	PUNCT	O
54	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
%	O	NOUN	O
gum	O	NOUN	B
),	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
during	O	ADP	O
the	O	DET	O
entire	O	ADJ	O
study	O	NOUN	B
(	O	PUNCT	O
safety	O	NOUN	B
population	O	NOUN	I
:	O	PUNCT	O
63	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
58	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
%,	O	NOUN	B
respectively	O	ADV	O
).	O	PUNCT	O
Stratification	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
by	O	ADP	O
sex	O	NOUN	B
,	O	PUNCT	O
age	O	NOUN	B
,	O	PUNCT	O
extent	O	NOUN	O
of	O	ADP	O
concurrent	O	ADJ	B
smoking	O	NOUN	B
,	O	PUNCT	O
extent	O	NOUN	O
of	O	ADP	O
product	O	NOUN	B
use	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
severity	O	NOUN	B
of	O	ADP	O
adverse	O	ADJ	B
events	O	NOUN	I
revealed	O	VERB	O
no	O	DET	O
clinically	O	ADV	B
significant	O	ADJ	I
differences	O	NOUN	O
between	O	ADP	O
the	O	DET	O
lozenge	O	NOUN	B
and	O	CCONJ	O
gum	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
most	O	ADV	O
common	O	ADJ	O
adverse	O	ADJ	B
events	O	NOUN	I
were	O	AUX	O
nausea	B-Disease	ADJ	B
(	O	PUNCT	O
17	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
16	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
%;	O	NOUN	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,-	O	PUNCT	O
3	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
to	O	PART	O
6	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
),	O	PUNCT	O
hiccups	B-Disease	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
6	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
%;	O	NOUN	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
to	O	PART	O
7	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
),	O	PUNCT	O
and	O	CCONJ	O
headache	B-Disease	NOUN	B
(	O	PUNCT	O
8	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
9	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
%;	O	NOUN	O
95	O	NUM	O
%	O	NOUN	O
Cl	O	NOUN	B
,-	O	NOUN	I
5	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
to	O	PART	O
2	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
).	O	PUNCT	O
Serious	O	ADJ	B
adverse	O	ADJ	I
events	O	NOUN	I
were	O	AUX	O
reported	O	VERB	O
in	O	ADP	O
11	O	NUM	O
and	O	CCONJ	O
13	O	NUM	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
respective	O	ADJ	O
groups	O	NOUN	B
.	O	PUNCT	O


Fewer	O	ADJ	O
than	O	ADP	O
6	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
in	O	ADP	O
either	O	DET	O
group	O	NOUN	B
were	O	AUX	O
considered	O	VERB	O
by	O	ADP	O
the	O	DET	O
investigator	O	NOUN	B
to	O	PART	O
have	O	AUX	O
a	O	DET	O
worsening	O	NOUN	B
of	O	ADP	O
their	O	PRON	O
overall	O	ADJ	B
disease	O	NOUN	B
condition	O	NOUN	I
during	O	ADP	O
the	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
majority	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
(>	O	NOUN	O
60	O	NUM	O
%)	O	NOUN	O
experienced	O	VERB	O
no	O	DET	O
change	O	NOUN	O
in	O	ADP	O
their	O	PRON	O
disease	O	NOUN	B
status	O	NOUN	I
from	O	ADP	O
baseline	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
4	O	NUM	O
-	O	PUNCT	O
mg	O	NOUN	O
nicotine	B-Chemical	NOUN	B
lozenge	O	NOUN	B
and	O	CCONJ	O
4	O	NUM	O
-	O	PUNCT	O
mg	O	NOUN	O
nicotine	B-Chemical	NOUN	B


Development	O	NOUN	B
of	O	ADP	O
levodopa	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
dyskinesias	B-Disease	NOUN	B
in	O	ADP	O
parkinsonian	B-Disease	ADJ	B
monkeys	O	NOUN	B
may	O	AUX	O
depend	O	VERB	O
upon	O	SCONJ	O
rate	O	NOUN	B
of	O	ADP	O
symptom	O	NOUN	B
onset	O	NOUN	I
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
duration	O	NOUN	B
of	O	ADP	I
symptoms	O	NOUN	B
.	O	PUNCT	O


Levodopa	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
dyskinesias	B-Disease	NOUN	B
(	O	PUNCT	O
LIDs	B-Disease	NOUN	B
)	O	PUNCT	O
present	O	VERB	O
a	O	DET	O
major	O	ADJ	O
problem	O	NOUN	B
for	O	ADP	O
the	O	DET	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
management	O	NOUN	B
of	O	ADP	O
Parkinson's	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
PD	B-Disease	NOUN	B
)	O	PUNCT	O
patients	O	NOUN	B
.	O	PUNCT	O


Due	O	ADP	O
to	O	ADP	O
the	O	DET	O
interdependence	O	NOUN	B
of	O	ADP	O
risk	O	NOUN	B
factors	O	NOUN	I
in	O	ADP	O
clinical	O	ADJ	B
populations	O	NOUN	I
,	O	PUNCT	O
it	O	PRON	O
is	O	AUX	O
difficult	O	ADJ	O
to	O	PART	O
independently	O	ADV	O
examine	O	VERB	O
factors	O	NOUN	B
that	O	PRON	O
may	O	AUX	O
influence	O	VERB	B
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
LIDs	B-Disease	NOUN	B
.	O	PUNCT	O


Using	O	VERB	O
macaque	O	ADJ	B
monkeys	O	NOUN	B
with	O	ADP	O
different	O	ADJ	O
types	O	NOUN	O
of	O	ADP	O
MPTP	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
parkinsonism	B-Disease	NOUN	B
,	O	PUNCT	O
the	O	DET	O
current	O	ADJ	O
study	O	NOUN	B
evaluated	O	VERB	B
the	O	DET	O
degree	O	NOUN	B
to	O	ADP	O
which	O	DET	O
rate	O	NOUN	B
of	O	ADP	O
symptom	O	NOUN	B
progression	O	NOUN	I
,	O	PUNCT	O
symptom	O	NOUN	B
severity	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
response	O	NOUN	B
to	O	PART	O
and	O	CCONJ	O
duration	O	NOUN	B
of	O	ADP	O
levodopa	B-Chemical	NOUN	B
therapy	O	NOUN	O
may	O	AUX	O
be	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
LIDs	B-Disease	NOUN	B
.	O	PUNCT	O


Monkeys	O	NOUN	B
with	O	ADP	O
acute	O	ADJ	B
(	O	PUNCT	O
short	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
)	O	PUNCT	O
MPTP	B-Chemical	NOUN	B
exposure	O	NOUN	B
,	O	PUNCT	O
rapid	O	ADJ	B
symptom	O	NOUN	B
onset	O	NOUN	I
and	O	CCONJ	O
short	O	ADJ	B
symptom	O	NOUN	I
duration	O	NOUN	I
prior	O	ADJ	O
to	O	PART	O
initiation	O	NOUN	B
of	O	ADP	O
levodopa	B-Chemical	NOUN	B
therapy	O	NOUN	O
developed	O	VERB	O
dyskinesia	B-Disease	NOUN	B
between	O	ADP	O
11	O	NUM	O
and	O	CCONJ	O
24	O	NUM	O
days	O	NOUN	B
of	O	ADP	O
daily	O	ADJ	B
levodopa	B-Chemical	NOUN	B
administration	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
monkeys	O	NOUN	B
with	O	ADP	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
MPTP	B-Chemical	NOUN	B
exposure	O	NOUN	B
,	O	PUNCT	O
slow	O	ADJ	B
symptom	O	NOUN	I
progression	O	NOUN	I
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
long	O	ADJ	B
symptom	O	NOUN	I
duration	O	NOUN	I
prior	O	ADJ	O
to	O	PART	O
initiation	O	NOUN	B
of	O	ADP	O
levodopa	B-Chemical	NOUN	B
therapy	O	NOUN	O
were	O	AUX	O
more	O	ADV	O
resistant	O	ADJ	B
to	O	PART	O
developing	O	VERB	O
LIDs	B-Disease	NOUN	B
(	O	PUNCT	O
e	O	X	O
.	O	PUNCT	O


g	O	NOUN	O
.,	O	PUNCT	O
dyskinesia	B-Disease	NOUN	B
developed	O	VERB	O
no	O	DET	O
sooner	O	ADV	O
than	O	ADP	O
146	O	NUM	O
days	O	NOUN	B
of	O	ADP	O
chronic	O	ADJ	B
levodopa	B-Chemical	NOUN	B
administration	O	NOUN	B
).	O	PUNCT	O
All	O	DET	O
animals	O	NOUN	B
were	O	AUX	O
similarly	O	ADV	O
symptomatic	O	ADJ	B
at	O	ADP	O
the	O	DET	O
start	O	NOUN	O
of	O	ADP	O
levodopa	B-Chemical	NOUN	B
treatment	O	NOUN	B
and	O	CCONJ	O
had	O	AUX	O
similar	O	ADJ	O
therapeutic	O	ADJ	B
responses	O	NOUN	I
to	O	PART	O
the	O	DET	O
drug	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
suggest	O	VERB	O
distinct	O	ADJ	O
differences	O	NOUN	B
in	O	ADP	O
the	O	DET	O
propensity	O	NOUN	B
to	O	PART	O
develop	O	VERB	O
LIDs	B-Disease	NOUN	B
in	O	ADP	O
monkeys	O	NOUN	B
with	O	ADP	O
different	O	ADJ	O
rates	O	NOUN	B
of	O	ADP	O
symptom	O	NOUN	B
progression	O	NOUN	I
or	O	CCONJ	O
symptom	O	NOUN	B
durations	O	NOUN	I
prior	O	ADV	O
to	O	PART	O
levodopa	B-Chemical	NOUN	B
and	O	CCONJ	O
demonstrate	O	VERB	O
the	O	DET	O
value	O	NOUN	O
of	O	ADP	O
these	O	DET	O
models	O	NOUN	B
for	O	ADP	O
further	O	ADV	O
studying	O	VERB	O
the	O	DET	O
pathophysiology	O	NOUN	B
of	O	ADP	O
LIDs	B-Disease	NOUN	B


Propylthiouracil	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
perinuclear	O	ADJ	B
-	O	PUNCT	O
staining	O	VERB	B
antineutrophil	O	NOUN	B
cytoplasmic	O	ADJ	I
autoantibody	O	NOUN	I
-	O	PUNCT	O
positive	O	ADJ	B
vasculitis	B-Disease	NOUN	B
in	O	ADP	O
conjunction	O	NOUN	B
with	O	ADP	O
pericarditis	B-Disease	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	B
:	O	PUNCT	O
To	O	PART	O
describe	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
propylthiouracil	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
vasculitis	B-Disease	NOUN	B
manifesting	O	VERB	O
with	O	ADP	O
pericarditis	B-Disease	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
We	O	PRON	O
present	O	VERB	O
the	O	DET	O
first	O	ADJ	O
case	O	NOUN	B
report	O	NOUN	I
of	O	ADP	O
a	O	DET	O
woman	O	NOUN	B
with	O	ADP	O
hyperthyroidism	B-Disease	NOUN	B
treated	O	VERB	B
with	O	ADP	I
propylthiouracil	B-Chemical	NOUN	B
in	O	ADP	O
whom	O	PRON	O
a	O	DET	O
syndrome	O	NOUN	B
of	O	ADP	O
pericarditis	B-Disease	NOUN	B
,	O	PUNCT	O
fever	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
glomerulonephritis	B-Disease	NOUN	B
developed	O	VERB	O
.	O	PUNCT	O


Serologic	O	ADJ	B
testing	O	NOUN	I
and	O	CCONJ	O
immunologic	O	ADJ	B
studies	O	NOUN	I
were	O	AUX	O
done	O	VERB	O
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
pericardial	O	ADJ	B
biopsy	O	NOUN	I
was	O	AUX	O
performed	O	VERB	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
A	O	DET	O
25	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
woman	O	NOUN	B
with	O	ADP	O
Graves'	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
had	O	AUX	O
a	O	DET	O
febrile	B-Disease	ADJ	B
illness	I-Disease	NOUN	I
and	O	CCONJ	O
evidence	O	NOUN	B
of	O	ADP	O
pericarditis	B-Disease	NOUN	B
,	O	PUNCT	O
which	O	DET	O
was	O	AUX	O
confirmed	O	VERB	O
by	O	ADP	O
biopsy	O	NOUN	B
.	O	PUNCT	O


Serologic	O	ADJ	B
evaluation	O	NOUN	B
revealed	O	VERB	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
perinuclear	O	ADJ	B
-	O	PUNCT	O
staining	O	VERB	B
antineutrophil	O	NOUN	B
cytoplasmic	O	ADJ	I
autoantibodies	O	NOUN	I
(	O	PUNCT	O
pANCA	O	NOUN	B
)	O	PUNCT	O
against	O	ADP	O
myeloperoxidase	O	NOUN	B
(	O	PUNCT	O
MPO	O	NOUN	B
).	O	PUNCT	O
Propylthiouracil	B-Chemical	NOUN	B
therapy	O	NOUN	I
was	O	AUX	O
withdrawn	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
she	O	PRON	O
was	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
a	O	DET	O
1	O	NUM	O
-	O	PUNCT	O
month	O	NOUN	B
course	O	NOUN	B
of	O	ADP	O
prednisone	B-Chemical	NOUN	B
,	O	PUNCT	O
which	O	DET	O
alleviated	O	VERB	O
her	O	PRON	O
symptoms	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
literature	O	NOUN	B
review	O	NOUN	I
revealed	O	VERB	B
no	O	DET	O
prior	O	ADJ	O
reports	O	NOUN	B
of	O	ADP	O
pericarditis	B-Disease	NOUN	B
in	O	ADP	O
anti	O	X	B
-	O	PUNCT	O
MPO	O	NOUN	B
pANCA	O	NOUN	B
-	O	PUNCT	O
positive	O	ADJ	B
vasculitis	B-Disease	NOUN	B
associated	O	VERB	B
with	O	ADP	I
propylthio-	B-Chemical	NUM	O
uracil	I-Chemical	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


CONCLUSION	O	NOUN	B
:	O	PUNCT	O
Pericarditis	B-Disease	NOUN	B
may	O	AUX	O
be	O	AUX	O
the	O	DET	O
initial	O	ADJ	O
manifestation	O	NOUN	B
of	O	ADP	O
drug	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
vasculitis	B-Disease	NOUN	B
attributable	O	ADJ	O
to	O	PART	O
propylthio-	B-Chemical	NUM	O
uracil	I-Chemical	NOUN	B


Two	O	NUM	O
mouse	O	NOUN	B
lines	O	NOUN	I
selected	O	VERB	O
for	O	ADP	O
differential	O	ADJ	B
sensitivities	O	NOUN	O
to	O	PART	O
beta-carboline	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
seizures	B-Disease	NOUN	B
are	O	AUX	O
also	O	ADV	O
differentially	O	ADV	O
sensitive	O	ADJ	B
to	O	PART	O
various	O	ADJ	O
pharmacological	O	ADJ	B
effects	O	NOUN	O
of	O	ADP	O
other	O	ADJ	O
GABA	B-Chemical	NOUN	B
(	O	PUNCT	O
A	O	NOUN	O
)	O	PUNCT	O
receptor	O	NOUN	O
ligands	O	NOUN	B
.	O	PUNCT	O


Two	O	NUM	O
mouse	O	NOUN	B
lines	O	NOUN	I
were	O	AUX	O
selectively	O	ADV	O
bred	O	VERB	B
according	O	VERB	O
to	O	ADP	O
their	O	PRON	O
sensitivity	O	NOUN	B
(	O	PUNCT	O
BS	O	NOUN	B
line	O	NOUN	I
)	O	PUNCT	O
or	O	CCONJ	O
resistance	O	NOUN	B
(	O	PUNCT	O
BR	O	NOUN	B
line	O	NOUN	O
)	O	PUNCT	O
to	O	PART	O
seizures	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
a	O	DET	O
single	O	ADJ	O
i	O	NOUN	O
.	O	PUNCT	O


p	O	NOUN	O
.	O	PUNCT	O


injection	O	NOUN	B
of	O	ADP	O
methyl	B-Chemical	NOUN	B
beta-carboline-3-carboxylate	I-Chemical	NOUN	I
(	O	PUNCT	O
beta-CCM	B-Chemical	NOUN	B
),	O	PUNCT	O
an	O	DET	O
inverse	O	ADJ	B
agonist	O	NOUN	B
of	O	ADP	O
the	O	DET	O
GABA	B-Chemical	NOUN	B
(	O	PUNCT	O
A	O	NOUN	O
)	O	PUNCT	O
receptor	O	NOUN	O
benzodiazepine	B-Chemical	NOUN	O
site	O	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
aim	O	NOUN	O
was	O	AUX	O
to	O	PART	O
characterize	O	VERB	O
both	O	DET	O
lines	O	NOUN	B
'	O	PART	O
sensitivities	O	NOUN	B
to	O	PART	O
various	O	ADJ	O
physiological	O	ADJ	B
effects	O	NOUN	O
of	O	ADP	O
other	O	ADJ	O
ligands	O	NOUN	B
of	O	ADP	O
the	O	DET	O
GABA	B-Chemical	NOUN	B
(	O	PUNCT	O
A	O	NOUN	O
)	O	PUNCT	O
receptor	O	NOUN	O
.	O	PUNCT	O


We	O	PRON	O
measured	O	VERB	B
diazepam	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
anxiolysis	O	NOUN	B
with	O	ADP	O
the	O	DET	O
elevated	O	ADJ	B
plus	O	CCONJ	B
-	O	PUNCT	O
maze	O	NOUN	B
test	O	NOUN	O
,	O	PUNCT	O
diazepam	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
sedation	O	NOUN	B
by	O	ADP	O
recording	O	VERB	O
the	O	DET	O
vigilance	O	NOUN	B
states	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
picrotoxin	B-Chemical	NOUN	B
-	O	PUNCT	O
and	O	CCONJ	O
pentylenetetrazol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
seizures	B-Disease	NOUN	B
after	O	ADP	O
i	O	PRON	O
.	O	PUNCT	O


p	O	NOUN	O
.	O	PUNCT	O


injections	O	NOUN	B
.	O	PUNCT	O


Results	O	NOUN	B
presented	O	VERB	O
here	O	ADV	O
show	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
differential	O	ADJ	B
sensitivities	O	NOUN	B
of	O	ADP	O
BS	O	NOUN	B
and	O	CCONJ	O
BR	O	NOUN	B
lines	O	NOUN	O
to	O	PART	O
beta-CCM	B-Chemical	NOUN	B
can	O	AUX	O
be	O	AUX	O
extended	O	VERB	O
to	O	PART	O
diazepam	B-Chemical	NOUN	B
,	O	PUNCT	O
picrotoxin	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
pentylenetetrazol	B-Chemical	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
a	O	DET	O
genetic	O	ADJ	B
selection	O	NOUN	I
of	O	ADP	O
a	O	DET	O
general	O	ADJ	O
sensitivity	O	NOUN	B
and	O	CCONJ	O
resistance	O	NOUN	B
to	O	PART	O
several	O	ADJ	O
ligands	O	NOUN	B
of	O	ADP	O
the	O	DET	O
GABA	B-Chemical	NOUN	B


Analgesic	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
intravenous	O	ADJ	B
ketamine	B-Chemical	NOUN	B
in	O	ADP	O
cancer	B-Disease	NOUN	B
patients	O	NOUN	B
on	O	ADP	O
morphine	B-Chemical	NOUN	B
therapy	O	NOUN	B
:	O	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
controlled	O	VERB	B
,	O	PUNCT	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	NOUN	B
,	O	PUNCT	O
crossover	O	NOUN	B
,	O	PUNCT	O
double	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
study	O	NOUN	B
.	O	PUNCT	O


Pain	B-Disease	NOUN	B
not	O	PART	O
responsive	O	ADJ	O
to	O	PART	O
morphine	B-Chemical	NOUN	B
is	O	AUX	O
often	O	ADV	O
problematic	O	ADJ	O
.	O	PUNCT	O


Animal	O	NOUN	B
and	O	CCONJ	O
clinical	O	ADJ	B
studies	O	NOUN	I
have	O	AUX	O
suggested	O	VERB	O
that	O	SCONJ	O
N-methyl-D-aspartate	B-Chemical	NOUN	B
(	O	PUNCT	O
NMDA	B-Chemical	NOUN	B
)	O	PUNCT	O
antagonists	O	NOUN	B
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
ketamine	B-Chemical	NOUN	B
,	O	PUNCT	O
may	O	AUX	O
be	O	AUX	O
effective	O	ADJ	B
in	O	ADP	O
improving	O	VERB	B
opioid	O	NOUN	B
analgesia	O	NOUN	I
in	O	ADP	O
difficult	O	ADJ	O
pain	B-Disease	NOUN	B
syndromes	O	NOUN	I
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
neuropathic	B-Disease	ADJ	B
pain	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
slow	O	ADJ	B
bolus	O	NOUN	I
of	O	ADP	O
subhypnotic	O	ADJ	B
doses	O	NOUN	B
of	O	ADP	O
ketamine	B-Chemical	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


25	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
or	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


50	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
given	O	VERB	O
to	O	PART	O
10	O	NUM	O
cancer	B-Disease	NOUN	B
patients	O	NOUN	B
whose	O	DET	O
pain	B-Disease	NOUN	B
was	O	AUX	O
unrelieved	O	VERB	O
by	O	ADP	O
morphine	B-Chemical	NOUN	B
in	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	NOUN	B
,	O	PUNCT	O
crossover	O	NOUN	B
,	O	PUNCT	O
double	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
study	O	NOUN	B
.	O	PUNCT	O


Pain	B-Disease	NOUN	B
intensity	O	NOUN	I
on	O	ADP	O
a	O	DET	O
0	O	NUM	O
to	O	PART	O
10	O	NUM	O
numerical	O	ADJ	B
scale	O	NOUN	I
;	O	PUNCT	O
nausea	B-Disease	NOUN	B
and	O	CCONJ	O
vomiting	B-Disease	NOUN	B
,	O	PUNCT	O
drowsiness	O	NOUN	B
,	O	PUNCT	O
confusion	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
dry	B-Disease	ADJ	B
mouth	I-Disease	NOUN	I
,	O	PUNCT	O
using	O	VERB	O
a	O	DET	O
scale	O	NOUN	O
from	O	ADP	O
0	O	NUM	O
to	O	PART	O
3	O	NUM	O
(	O	PUNCT	O
not	O	PART	O
at	O	ADV	O
all	O	ADV	O
,	O	PUNCT	O
slight	O	ADJ	O
,	O	PUNCT	O
a	O	DET	O
lot	O	NOUN	O
,	O	PUNCT	O
awful	O	ADJ	O
);	O	ADJ	B
Mini	O	PROPN	I
-	O	PUNCT	O
Mental	O	PROPN	B
State	O	PROPN	I
Examination	O	PROPN	I
(	O	PUNCT	O
MMSE	O	NOUN	B
)(	O	NOUN	O
0	O	NUM	O
-	O	SYM	O
30	O	NUM	O
);	O	ADJ	B
and	O	CCONJ	O
arterial	O	ADJ	B
pressure	O	NOUN	I
were	O	AUX	O
recorded	O	VERB	O
before	O	ADP	O
administration	O	NOUN	B
of	O	ADP	O
drugs	O	NOUN	B
(	O	PUNCT	O
T0	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
after	O	ADP	O
30	O	NUM	O
minutes	O	NOUN	B
(	O	PUNCT	O
T30	O	NOUN	B
),	O	PUNCT	O
60	O	NUM	O
minutes	O	NOUN	B
(	O	PUNCT	O
T60	O	NOUN	B
),	O	PUNCT	O
120	O	NUM	O
minutes	O	NOUN	B
(	O	PUNCT	O
T120	O	NOUN	B
),	O	PUNCT	O
and	O	CCONJ	O
180	O	NUM	O
minutes	O	NOUN	B
(	O	PUNCT	O
T180	O	NOUN	B
).	O	PUNCT	O
Ketamine	B-Chemical	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
saline	O	NOUN	B
solution	O	NOUN	I
,	O	PUNCT	O
significantly	O	ADV	O
reduced	O	VERB	B
the	O	DET	O
pain	B-Disease	NOUN	B
intensity	O	NOUN	I
in	O	ADP	O
almost	O	ADV	O
all	O	DET	O
the	O	DET	O
patients	O	NOUN	B
at	O	ADP	O
both	O	DET	O
doses	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
effect	O	NOUN	B
was	O	AUX	O
more	O	ADV	O
relevant	O	ADJ	B
in	O	ADP	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
higher	O	ADJ	O
doses	O	NOUN	B
.	O	PUNCT	O


Hallucinations	B-Disease	NOUN	B
occurred	O	VERB	O
in	O	ADP	O
4	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
an	O	DET	O
unpleasant	O	ADJ	B
sensation	O	NOUN	O
("	O	PROPN	O
empty	O	ADJ	B
head	O	NOUN	B
")	O	PUNCT	I
was	O	AUX	O
also	O	ADV	O
reported	O	VERB	O
by	O	ADP	O
2	O	NUM	O
patients	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
episodes	O	NOUN	B
reversed	O	VERB	O
after	O	ADP	O
the	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
diazepam	B-Chemical	NOUN	B
1	O	NUM	I
mg	O	NOUN	I
intravenously	O	ADV	B
.	O	PUNCT	O


Significant	O	ADJ	B
increases	O	NOUN	B
in	O	ADP	O
drowsiness	O	NOUN	B
were	O	AUX	O
reported	O	VERB	O
in	O	ADP	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
ketamine	B-Chemical	NOUN	B
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
and	O	CCONJ	O
were	O	AUX	O
more	O	ADV	O
marked	O	ADJ	O
with	O	ADP	O
ketamine	B-Chemical	NOUN	B
0	O	NUM	O
.	O	PUNCT	O


50	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
significant	O	ADJ	O
difference	O	NOUN	O
in	O	ADP	O
MMSE	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
at	O	ADP	O
T30	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
who	O	PRON	O
received	O	VERB	O
0	O	NUM	O
.	O	PUNCT	O


50	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
kg	O	NOUN	B
of	O	ADP	O
ketamine	B-Chemical	NOUN	B
.	O	PUNCT	O


Ketamine	B-Chemical	NOUN	B
can	O	AUX	O
improve	O	VERB	O
morphine	B-Chemical	NOUN	B
analgesia	O	NOUN	B
in	O	ADP	O
difficult	O	ADJ	O
pain	B-Disease	NOUN	B
syndromes	O	NOUN	I
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
neuropathic	B-Disease	ADJ	B
pain	I-Disease	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
occurrence	O	NOUN	B
of	O	ADP	O
central	O	ADJ	B
adverse	O	ADJ	I
effects	O	NOUN	I
should	O	AUX	O
be	O	AUX	O
taken	O	VERB	O
into	O	ADP	O
account	O	NOUN	O
,	O	PUNCT	O
especially	O	ADV	O
when	O	SCONJ	O
using	O	VERB	O
higher	O	ADJ	O
doses	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
observation	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
tested	O	VERB	B
in	O	ADP	O
studies	O	NOUN	B
of	O	ADP	O
prolonged	O	ADJ	B
ketamine	B-Chemical	NOUN	B


Endocrine	O	ADJ	B
screening	O	NOUN	B
in	O	ADP	O
1	O	NUM	O
,	O	PUNCT	O
022	O	NUM	O
men	O	NOUN	B
with	O	ADP	O
erectile	B-Disease	NOUN	B
dysfunction	I-Disease	NOUN	I
:	O	PUNCT	O
clinical	O	ADJ	B
significance	O	NOUN	I
and	O	CCONJ	O
cost	O	NOUN	B
-	O	PUNCT	O
effective	O	ADJ	B
strategy	O	NOUN	B
.	O	PUNCT	O


PURPOSE	O	NOUN	B
:	O	PUNCT	O
We	O	PRON	O
reviewed	O	VERB	B
the	O	DET	O
results	O	NOUN	B
of	O	ADP	O
serum	O	NOUN	B
testosterone	B-Chemical	NOUN	B
and	O	CCONJ	O
prolactin	O	NOUN	B
determination	O	NOUN	B
in	O	ADP	O
1	O	NUM	O
,	O	PUNCT	O
022	O	NUM	O
patients	O	NOUN	B
referred	O	VERB	O
because	O	SCONJ	O
of	O	ADP	O
erectile	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
and	O	CCONJ	O
compared	O	VERB	B
the	O	DET	O
data	O	NOUN	B
with	O	ADP	O
history	O	NOUN	B
,	O	PUNCT	O
results	O	NOUN	B
of	O	ADP	O
physical	O	ADJ	B
examination	O	NOUN	I
,	O	PUNCT	O
other	O	ADJ	O
etiological	O	ADJ	B
investigations	O	NOUN	B
and	O	CCONJ	O
effects	O	NOUN	B
of	O	ADP	I
endocrine	O	ADJ	B
therapy	O	NOUN	I
to	O	PART	O
refine	O	VERB	O
the	O	DET	O
rules	O	NOUN	B
of	O	ADP	O
cost	O	NOUN	B
-	O	PUNCT	O
effective	O	ADJ	B
endocrine	O	ADJ	B
screening	O	NOUN	O
and	O	CCONJ	O
to	O	PART	O
pinpoint	O	VERB	O
actual	O	ADJ	O
responsibility	O	NOUN	B
for	O	ADP	O
hormonal	O	ADJ	B
abnormalities	O	NOUN	I
.	O	PUNCT	O


MATERIALS	O	NOUN	O
AND	O	CCONJ	O
METHODS	O	NOUN	O
:	O	PUNCT	O
Testosterone	B-Chemical	NOUN	B
and	O	CCONJ	O
prolactin	O	NOUN	B
were	O	AUX	O
determined	O	VERB	O
by	O	ADP	O
radioimmunoassay	O	NOUN	B
.	O	PUNCT	O


Every	O	DET	O
patient	O	NOUN	B
was	O	AUX	O
screened	O	VERB	B
for	O	ADP	O
testosterone	B-Chemical	NOUN	B
and	O	CCONJ	O
451	O	NUM	O
were	O	AUX	O
screened	O	VERB	B
for	O	ADP	O
prolactin	O	NOUN	B
on	O	ADP	O
the	O	DET	O
basis	O	NOUN	O
of	O	ADP	O
low	B-Disease	ADJ	B
sexual	I-Disease	ADJ	B
desire	I-Disease	NOUN	I
,	O	PUNCT	O
gynecomastia	B-Disease	NOUN	B
or	O	CCONJ	O
testosterone	B-Chemical	NOUN	B
less	O	ADJ	O
than	O	ADP	O
4	O	NUM	O
ng	O	NOUN	O
./	O	NOUN	O
ml	O	NOUN	O
.	O	PUNCT	O


Determination	O	NOUN	B
was	O	AUX	O
repeated	O	VERB	O
in	O	ADP	O
case	O	NOUN	B
of	O	ADP	O
abnormal	O	ADJ	B
first	O	ADJ	O
results	O	NOUN	B
.	O	PUNCT	O


Prolactin	O	NOUN	B
results	O	NOUN	B
were	O	AUX	O
compared	O	VERB	B
with	O	ADP	O
those	O	DET	O
of	O	ADP	O
a	O	DET	O
previous	O	ADJ	O
personal	O	ADJ	B
cohort	O	NOUN	I
of	O	ADP	O
1	O	NUM	O
,	O	PUNCT	O
340	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
erectile	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
and	O	CCONJ	O
systematic	O	ADJ	B
prolactin	O	NOUN	I
determination	O	NOUN	B
.	O	PUNCT	O


Main	O	ADJ	O
clinical	O	ADJ	B
criteria	O	NOUN	I
tested	O	VERB	B
regarding	O	VERB	O
efficiency	O	NOUN	B
in	O	ADP	O
hormone	O	NOUN	B
determination	O	NOUN	B
were	O	AUX	O
low	B-Disease	ADJ	B
sexual	I-Disease	ADJ	B
desire	I-Disease	NOUN	I
,	O	PUNCT	O
small	O	ADJ	B
testes	O	NOUN	B
and	O	CCONJ	O
gynecomastia	B-Disease	NOUN	B
.	O	PUNCT	O


Endocrine	O	NOUN	B
therapy	O	NOUN	I
consisted	O	VERB	O
of	O	ADP	O
testosterone	B-Chemical	NOUN	B
heptylate	I-Chemical	NOUN	B
or	O	CCONJ	O
human	O	ADJ	B
chorionic	O	ADJ	O
gonadotropin	O	NOUN	O
for	O	ADP	O
hypogonadism	B-Disease	NOUN	B
and	O	CCONJ	O
bromocriptine	B-Chemical	NOUN	B
for	O	ADP	O
hyperprolactinemia	B-Disease	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Testosterone	B-Chemical	NOUN	B
was	O	AUX	O
less	O	ADJ	O
than	O	ADP	O
3	O	NUM	O
ng	O	NOUN	O
./	O	NOUN	O
ml	O	NOUN	O
.	O	PUNCT	O


in	O	ADP	O
107	O	NUM	O
patients	O	NOUN	B
but	O	CCONJ	O
normal	O	ADJ	B
in	O	ADP	O
40	O	NUM	O
%	O	NOUN	O
at	O	ADP	O
repeat	O	NOUN	O
determination	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
prevalence	O	NOUN	B
of	O	ADP	O
repeatedly	O	ADV	O
low	O	ADJ	B
testosterone	B-Chemical	NOUN	B
increased	O	VERB	B
with	O	ADP	O
age	O	NOUN	B
(	O	PUNCT	O
4	O	NUM	O
%	O	NOUN	O
before	O	ADP	O
age	O	NOUN	B
50	O	NUM	O
years	O	NOUN	B
and	O	CCONJ	O
9	O	NUM	O
%	O	NOUN	O
50	O	NUM	O
years	O	NOUN	B
or	O	CCONJ	O
older	O	ADJ	B
).	O	PUNCT	O
Two	O	NUM	O
pituitary	B-Disease	ADJ	B
tumors	I-Disease	NOUN	I
were	O	AUX	O
discovered	O	VERB	O
after	O	ADP	O
testosterone	B-Chemical	NOUN	B
determination	O	NOUN	B
.	O	PUNCT	O


Most	O	ADJ	O
of	O	ADP	O
the	O	DET	O
other	O	ADJ	O
low	O	ADJ	B
testosterone	B-Chemical	NOUN	B
levels	O	NOUN	B
seemed	O	VERB	O
to	O	PART	O
result	O	VERB	O
from	O	ADP	O
nonorganic	O	ADJ	B
hypothalamic	B-Disease	ADJ	I
dysfunction	I-Disease	NOUN	I
because	O	SCONJ	O
of	O	ADP	O
normal	O	ADJ	O
serum	O	NOUN	O
luteinizing	O	NOUN	O
hormone	O	NOUN	O
and	O	CCONJ	O
prolactin	O	NOUN	B
and	O	CCONJ	O
to	O	PART	O
have	O	AUX	O
only	O	ADV	O
a	O	DET	O
small	O	ADJ	O
role	O	NOUN	O
in	O	ADP	O
erectile	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
(	O	PUNCT	O
definite	O	ADJ	O
improvement	O	NOUN	B
in	O	ADP	O
only	O	ADV	O
16	O	NUM	O
of	O	ADP	O
44	O	NUM	O
[	O	PUNCT	O
36	O	NUM	O
%]	O	NOUN	O
after	O	ADP	O
androgen	O	NOUN	B
therapy	O	NOUN	I
,	O	PUNCT	O
normal	O	ADJ	B
morning	O	NOUN	I
or	O	CCONJ	O
nocturnal	O	ADJ	B
erections	O	NOUN	B
in	O	ADP	O
30	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
definite	O	ADJ	O
vasculogenic	O	ADJ	B
contributions	O	NOUN	B
in	O	ADP	O
42	O	NUM	O
%).	O	NOUN	O
Determining	O	VERB	O
testosterone	B-Chemical	NOUN	B
only	O	ADV	O
in	O	ADP	O
cases	O	NOUN	B
of	O	ADP	O
low	B-Disease	ADJ	B
sexual	I-Disease	ADJ	B
desire	I-Disease	NOUN	I
or	O	CCONJ	O
abnormal	O	ADJ	B
physical	O	ADJ	O
examination	O	NOUN	O
would	O	AUX	O
have	O	AUX	O
missed	O	VERB	O
40	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
cases	O	NOUN	B
with	O	ADP	O
low	O	ADJ	B
testosterone	B-Chemical	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
37	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
those	O	DET	O
subsequently	O	ADV	O
improved	O	VERB	B
by	O	ADP	O
androgen	O	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


Prolactin	O	NOUN	B
exceeded	O	VERB	O
20	O	NUM	O
ng	O	NOUN	O
./	O	NOUN	O
ml	O	NOUN	O
.	O	PUNCT	O


in	O	ADP	O
5	O	NUM	O
men	O	NOUN	B
and	O	CCONJ	O
was	O	AUX	O
normal	O	ADJ	O
in	O	ADP	O
2	O	NUM	O
at	O	ADP	O
repeat	O	NOUN	O
determination	O	NOUN	B
.	O	PUNCT	O


Only	O	ADV	O
1	O	NUM	O
prolactinoma	B-Disease	NOUN	B
was	O	AUX	O
discovered	O	VERB	O
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
are	O	AUX	O
lower	O	ADJ	O
than	O	ADP	O
those	O	DET	O
we	O	PRON	O
found	O	VERB	O
during	O	ADP	O
the	O	DET	O
last	O	ADJ	O
2	O	NUM	O
decades	O	NOUN	B
(	O	PUNCT	O
overall	O	ADJ	O
prolactin	O	NOUN	B
greater	O	ADJ	O
than	O	ADP	O
20	O	NUM	O
ng	O	NOUN	O
./	O	NOUN	O
ml	O	NOUN	O
.	O	PUNCT	O


in	O	ADP	O
1	O	NUM	O
.	O	PUNCT	O


86	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
1	O	NUM	O
,	O	PUNCT	O
821	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
prolactinomas	B-Disease	NOUN	B
in	O	ADP	O
7	O	NUM	O
,	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


38	O	NUM	O
%).	O	ADJ	B
Bromocriptine	B-Chemical	NOUN	B
was	O	AUX	O
definitely	O	ADV	O
effective	O	ADJ	B
in	O	ADP	O
cases	O	NOUN	B
with	O	ADP	O
prolactin	O	NOUN	B
greater	O	ADJ	O
than	O	ADP	O
35	O	NUM	O
ng	O	NOUN	O
./	O	NOUN	O
ml	O	NOUN	O
.(	O	PUNCT	O
8	O	NUM	O
of	O	ADP	O
12	O	NUM	O
compared	O	VERB	B
to	O	PART	O
only	O	ADV	O
9	O	NUM	O
of	O	ADP	O
22	O	NUM	O
cases	O	NOUN	B
with	O	ADP	O
prolactin	O	NOUN	B
between	O	ADP	O
20	O	NUM	O
and	O	CCONJ	O
35	O	NUM	O
ng	O	NOUN	O
./	O	NOUN	O
ml	O	NOUN	O
.).	O	NOUN	O
Testosterone	B-Chemical	NOUN	B
was	O	AUX	O
low	O	ADJ	O
in	O	ADP	O
less	O	ADJ	O
than	O	ADP	O
50	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
cases	O	NOUN	B
with	O	ADP	O
prolactin	O	NOUN	B
greater	O	ADJ	O
than	O	ADP	O
35	O	NUM	O
ng	O	NOUN	O
./	O	NOUN	O
ml	O	NOUN	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
Low	O	ADJ	B
prevalences	O	NOUN	B
and	O	CCONJ	O
effects	O	NOUN	B
of	O	ADP	I
low	O	ADJ	B
testosterone	B-Chemical	NOUN	B
and	O	CCONJ	O
high	O	ADJ	O
prolactin	O	NOUN	B
in	O	ADP	O
erectile	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
cannot	O	PART	O
justify	O	VERB	O
their	O	PRON	O
routine	O	ADJ	B
determination	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
cost	O	NOUN	B
-	O	PUNCT	O
effective	O	ADJ	B
screening	O	NOUN	B
strategies	O	NOUN	O
recommended	O	VERB	B
so	O	ADV	O
far	O	ADV	O
missed	O	VERB	O
40	O	NUM	O
to	O	PART	O
50	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
cases	O	NOUN	B
improved	O	VERB	B
with	O	ADP	O
endocrine	O	ADJ	B
therapy	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
pituitary	B-Disease	ADJ	B
tumors	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
now	O	ADV	O
advocate	O	VERB	O
that	O	SCONJ	O
before	O	ADP	O
age	O	NOUN	B
50	O	NUM	O
years	O	NOUN	B
testosterone	B-Chemical	NOUN	B
be	O	AUX	O
determined	O	VERB	O
only	O	ADV	O
in	O	ADP	O
cases	O	NOUN	B
of	O	ADP	O
low	B-Disease	ADJ	B
sexual	I-Disease	ADJ	B
desire	I-Disease	NOUN	I
and	O	CCONJ	O
abnormal	O	ADJ	B
physical	O	ADJ	O
examination	O	NOUN	O
but	O	CCONJ	O
that	O	SCONJ	O
it	O	PRON	O
be	O	AUX	O
measured	O	VERB	B
in	O	ADP	O
all	O	DET	O
men	O	NOUN	B
older	O	ADJ	B
than	O	ADP	O
50	O	NUM	O
years	O	NOUN	B
.	O	PUNCT	O


Prolactin	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
determined	O	VERB	O
only	O	ADV	O
in	O	ADP	O
cases	O	NOUN	B
of	O	ADP	O
low	B-Disease	ADJ	B
sexual	I-Disease	ADJ	B
desire	I-Disease	NOUN	I
,	O	PUNCT	O
gynecomastia	B-Disease	NOUN	B
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
testosterone	B-Chemical	NOUN	B


Thiopentone	B-Chemical	NOUN	B
pretreatment	O	NOUN	B
for	O	ADP	O
propofol	B-Chemical	NOUN	B
injection	O	NOUN	B
pain	B-Disease	NOUN	I
in	O	ADP	O
ambulatory	O	ADJ	B
patients	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
investigated	O	VERB	B
propofol	B-Chemical	NOUN	B
injection	O	NOUN	B
pain	B-Disease	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
undergoing	O	VERB	O
ambulatory	O	ADJ	B
anaesthesia	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	NOUN	B
trial	O	NOUN	B
,	O	PUNCT	O
90	O	NUM	O
women	O	NOUN	B
were	O	AUX	O
allocated	O	VERB	O
to	O	PART	O
receive	O	VERB	O
one	O	NUM	O
of	O	ADP	O
three	O	NUM	O
treatments	O	NOUN	B
prior	O	ADJ	O
to	O	PART	O
induction	O	NOUN	B
of	O	ADP	O
anaesthesia	O	NOUN	O
with	O	ADP	O
propofol	B-Chemical	NOUN	B
.	O	PUNCT	O


Patients	O	NOUN	B
in	O	ADP	O
Group	O	PROPN	B
C	O	NOUN	O
received	O	VERB	O
2	O	NUM	O
ml	O	NOUN	O
normal	O	ADJ	B
saline	O	NOUN	I
,	O	PUNCT	O
Group	O	PROPN	B
L	O	PROPN	B
,	O	PUNCT	O
2	O	NUM	O
ml	O	NOUN	O
,	O	PUNCT	O
lidocaine	B-Chemical	NOUN	B
2	O	NUM	O
%(	O	NOUN	O
40	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
Group	O	PROPN	B
T	O	NOUN	O
,	O	PUNCT	O
2	O	NUM	O
ml	O	NOUN	O
thiopentone	B-Chemical	NOUN	B
2	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
%(	O	NOUN	O
50	O	NUM	O
mg	O	NOUN	O
).	O	PUNCT	O
Venous	O	ADJ	B
discomfort	O	NOUN	I
was	O	AUX	O
assessed	O	VERB	B
with	O	ADP	O
a	O	DET	O
visual	O	ADJ	B
analogue	O	NOUN	I
scale	O	NOUN	I
(	O	PUNCT	O
VAS	O	NOUN	B
)	O	PUNCT	O
5	O	NUM	O
-	O	SYM	O
15	O	NUM	O
sec	O	NOUN	O
after	O	ADP	O
commencing	O	VERB	O
propofol	B-Chemical	NOUN	B
administration	O	NOUN	B
using	O	VERB	O
an	O	DET	O
infusion	O	NOUN	B
pump	O	NOUN	I
(	O	PUNCT	O
rate	O	NOUN	B
1000	O	NUM	O
micrograms	O	NOUN	B
.	O	PUNCT	O


kg	O	NOUN	O
-	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


min	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	O
).	O	PUNCT	O
Loss	B-Disease	NOUN	B
of	I-Disease	ADP	I
consciousness	I-Disease	NOUN	I
occurred	O	VERB	O
in	O	ADP	O
60	O	NUM	O
-	O	PUNCT	O
90	O	NUM	O
sec	O	NOUN	O
.	O	PUNCT	O


Visual	O	ADJ	B
analogue	O	NOUN	I
scores	O	NOUN	I
(	O	PUNCT	O
mean	O	NOUN	O
+/-	O	CCONJ	O
SD	O	NOUN	B
)	O	PUNCT	O
during	O	ADP	O
induction	O	NOUN	B
were	O	AUX	O
lower	O	ADJ	O
in	O	ADP	O
Groups	O	NOUN	B
L	O	NOUN	O
(	O	PUNCT	O
3	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
+/-	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
T	O	NOUN	B
(	O	PUNCT	O
4	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
+/-	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
)	O	PUNCT	O
than	O	ADP	O
in	O	ADP	O
Group	O	PROPN	B
C	O	NOUN	O
(	O	PUNCT	O
5	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
+/-	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
);	O	ADJ	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


0031	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
venous	O	ADJ	B
discomfort	O	NOUN	I
was	O	AUX	O
lower	O	ADJ	O
in	O	ADP	O
Group	O	PROPN	B
L	O	PROPN	B
(	O	PUNCT	O
76	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
%;	O	NOUN	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
)	O	PUNCT	O
than	O	ADP	O
in	O	ADP	O
Group	O	PROPN	B
C	O	PROPN	O
(	O	PUNCT	O
100	O	NUM	O
%)	O	NOUN	O
but	O	CCONJ	O
not	O	PART	O
different	O	ADJ	O
from	O	ADP	O
Group	O	PROPN	B
T	O	NOUN	O
(	O	PUNCT	O
90	O	NUM	O
%).	O	NOUN	O
The	O	DET	O
VAS	O	PROPN	B
scores	O	NOUN	I
for	O	ADP	O
recall	O	NOUN	B
of	O	ADP	I
pain	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
recovery	O	NOUN	B
room	O	NOUN	I
were	O	AUX	O
correlated	O	VERB	B
with	O	ADP	O
the	O	DET	O
VAS	O	NOUN	B
scores	O	NOUN	I
during	O	ADP	O
induction	O	NOUN	B
(	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


7045	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


0001	O	NUM	O
).	O	PUNCT	B
Recovery	O	NOUN	B
room	O	NOUN	O
discharge	O	NOUN	O
times	O	NOUN	O
were	O	AUX	O
similar	O	ADJ	O
:	O	PUNCT	O
C	O	NOUN	B
(	O	PUNCT	O
75	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
+/-	O	CCONJ	O
19	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
min	O	NOUN	O
);	O	ADJ	B
L	O	NOUN	I
73	O	NUM	I
.	O	PUNCT	O


6	O	NUM	O
+/-	O	CCONJ	O
21	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
min	O	NOUN	O
);	O	ADJ	B
T	O	NOUN	I
(	O	PUNCT	O
77	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
+/-	O	CCONJ	O
18	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
min	O	NOUN	O
).	O	PUNCT	O
Assessing	O	VERB	O
their	O	PRON	O
overall	O	ADJ	B
satisfaction	O	NOUN	B
,	O	PUNCT	O
89	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
%	O	NOUN	O
would	O	AUX	O
choose	O	VERB	O
propofol	B-Chemical	NOUN	B
anaesthesia	O	NOUN	O
again	O	ADV	O
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
lidocaine	B-Chemical	NOUN	B
reduces	O	VERB	B
the	O	DET	O
incidence	O	NOUN	B
and	O	CCONJ	O
severity	O	NOUN	B
of	O	ADP	O
propofol	B-Chemical	NOUN	B
injection	O	NOUN	B
pain	B-Disease	NOUN	I
in	O	ADP	O
ambulatory	O	ADJ	B
patients	O	NOUN	I
whereas	O	SCONJ	O
thiopentone	B-Chemical	NOUN	B


Comparison	O	NOUN	B
of	O	ADP	O
i	O	PRON	O
.	O	PUNCT	O


v	O	NOUN	O
.	O	PUNCT	O


glycopyrrolate	B-Chemical	NOUN	B
and	O	CCONJ	O
atropine	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
prevention	O	NOUN	B
of	O	ADP	O
bradycardia	B-Disease	NOUN	B
and	O	CCONJ	O
arrhythmias	B-Disease	NOUN	B
following	O	VERB	O
repeated	O	VERB	O
doses	O	NOUN	B
of	O	ADP	O
suxamethonium	B-Chemical	NOUN	B
in	O	ADP	O
children	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
effectiveness	O	NOUN	B
of	O	ADP	O
administration	O	NOUN	B
of	O	ADP	O
glycopyrrolate	B-Chemical	NOUN	B
5	O	NUM	I
and	O	CCONJ	O
10	O	NUM	O
micrograms	O	NOUN	O
kg	O	NOUN	O
-	O	PUNCT	O
1	O	NUM	B
and	O	CCONJ	O
atropine	B-Chemical	NOUN	B
10	O	NUM	O
and	O	CCONJ	O
20	O	NUM	O
micrograms	O	NOUN	B
kg	O	NOUN	O
-	O	PUNCT	O
1	O	NUM	O
i	O	NUM	O
.	O	PUNCT	O


v	O	NOUN	O
.	O	PUNCT	O


immediately	O	ADV	O
before	O	ADP	O
the	O	DET	O
induction	O	NOUN	B
of	O	ADP	O
anaesthesia	O	NOUN	O
,	O	PUNCT	O
to	O	PART	O
prevent	O	VERB	B
arrhythmia	B-Disease	NOUN	B
and	O	CCONJ	O
bradycardia	B-Disease	NOUN	B
following	O	VERB	O
repeated	O	VERB	O
doses	O	NOUN	B
of	O	ADP	O
suxamethonium	B-Chemical	NOUN	B
in	O	ADP	O
children	O	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
studied	O	VERB	O
.	O	PUNCT	O


A	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
was	O	AUX	O
included	O	VERB	O
for	O	ADP	O
comparison	O	NOUN	B
with	O	ADP	O
the	O	DET	O
lower	O	ADJ	B
dose	O	NOUN	I
range	O	NOUN	O
of	O	ADP	O
glycopyrrolate	B-Chemical	NOUN	B
and	O	CCONJ	O
atropine	B-Chemical	NOUN	B
.	O	PUNCT	O


A	O	DET	O
frequency	O	NOUN	B
of	O	ADP	O
bradycardia	B-Disease	NOUN	B
of	O	ADP	O
50	O	NUM	O
%	O	NOUN	O
was	O	AUX	O
noted	O	VERB	O
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
this	O	DET	O
was	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
different	O	ADJ	O
from	O	ADP	O
the	O	DET	O
frequency	O	NOUN	B
with	O	ADP	O
the	O	DET	O
active	O	ADJ	B
drugs	O	NOUN	I
.	O	PUNCT	O


Bradycardia	B-Disease	NOUN	B
(	O	PUNCT	O
defined	O	VERB	O
as	O	ADP	O
a	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
heart	O	NOUN	B
rate	O	NOUN	I
to	O	ADP	O
less	O	ADJ	O
than	O	ADP	O
50	O	NUM	O
beat	O	VERB	B
min	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
was	O	AUX	O
prevented	O	VERB	B
when	O	SCONJ	O
the	O	DET	O
larger	O	ADJ	B
dose	O	NOUN	B
of	O	ADP	O
either	O	CCONJ	O
active	O	ADJ	B
drug	O	NOUN	I
was	O	AUX	O
used	O	VERB	O
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
recommended	O	VERB	B
that	O	SCONJ	O
either	O	CCONJ	O
glycopyrrolate	B-Chemical	NOUN	B
10	O	NUM	O
micrograms	O	NOUN	B
kg	O	NOUN	O
-	O	PUNCT	O
1	O	NUM	O
or	O	CCONJ	O
atropine	B-Chemical	NOUN	B
20	O	NUM	O
micrograms	O	NOUN	B
kg	O	NOUN	O
-	O	PUNCT	O
1	O	NUM	O
i	O	NUM	O
.	O	PUNCT	O


v	O	NOUN	O
.	O	PUNCT	O


should	O	AUX	O
immediately	O	ADV	O
precede	O	VERB	O
induction	O	NOUN	B
of	O	ADP	O
anaesthesia	O	NOUN	O
,	O	PUNCT	O
in	O	ADP	O
children	O	NOUN	B
,	O	PUNCT	O
if	O	SCONJ	O
the	O	DET	O
repeated	O	VERB	O
administration	O	NOUN	B
of	O	ADP	O
suxamethonium	B-Chemical	NOUN	B


Reduction	O	NOUN	B
in	O	ADP	O
caffeine	B-Chemical	NOUN	B
toxicity	B-Disease	NOUN	B
by	O	ADP	O
acetaminophen	B-Chemical	NOUN	B
.	O	PUNCT	O


A	O	DET	O
patient	O	NOUN	B
who	O	PRON	O
allegedly	O	ADV	O
consumed	O	VERB	O
100	O	NUM	O
tablets	O	NOUN	B
of	O	ADP	O
an	O	DET	O
over	O	ADV	B
-	O	PUNCT	O
the	O	DET	O
-	O	PUNCT	O
counter	O	NOUN	B
analgesic	O	NOUN	B
containing	O	VERB	O
sodium	B-Chemical	NOUN	B
acetylsalicylate	I-Chemical	NOUN	I
,	O	PUNCT	O
caffeine	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
acetaminophen	B-Chemical	NOUN	B
displayed	O	VERB	O
no	O	DET	O
significant	O	ADJ	O
CNS	O	NOUN	B
stimulation	O	NOUN	O
despite	O	SCONJ	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
175	O	NUM	O
micrograms	O	NOUN	B
of	O	ADP	O
caffeine	B-Chemical	NOUN	B
per	O	ADP	O
mL	O	NOUN	O
of	O	ADP	O
serum	O	NOUN	B
.	O	PUNCT	O


Because	O	SCONJ	O
salicylates	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
to	O	PART	O
augment	O	VERB	B
the	O	DET	O
stimulatory	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
caffeine	B-Chemical	NOUN	B
on	O	ADP	O
the	O	DET	O
CNS	O	NOUN	B
,	O	PUNCT	O
attention	O	NOUN	B
was	O	AUX	O
focused	O	VERB	O
on	O	ADP	O
the	O	DET	O
possibility	O	NOUN	O
that	O	SCONJ	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
acetaminophen	B-Chemical	NOUN	B
(	O	PUNCT	O
52	O	NUM	O
micrograms	O	NOUN	B
/	O	PUNCT	O
mL	O	NOUN	B
)	O	PUNCT	O
reduced	O	VERB	B
the	O	DET	O
CNS	O	NOUN	B
toxicity	B-Disease	NOUN	B
of	O	ADP	O
caffeine	B-Chemical	NOUN	B
.	O	PUNCT	O


Studies	O	NOUN	B
in	O	ADP	O
DBA	O	PROPN	B
/	O	SYM	O
2J	O	NOUN	B
mice	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
:	O	PUNCT	O
1	O	X	O
)	O	PUNCT	O
pretreatment	O	NOUN	B
with	O	ADP	O
acetaminophen	B-Chemical	NOUN	B
(	O	PUNCT	O
100	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
increased	O	VERB	B
the	O	DET	O
interval	O	NOUN	B
between	O	ADP	O
the	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
caffeine	B-Chemical	NOUN	B
(	O	PUNCT	O
300	O	NUM	O
to	O	PART	O
450	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
IP	O	PROPN	B
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
onset	O	NOUN	O
of	O	ADP	O
fatal	O	ADJ	B
convulsions	B-Disease	NOUN	B
by	O	ADP	O
a	O	DET	O
factor	O	NOUN	B
of	O	ADP	O
about	O	ADV	O
two	O	NUM	O
;	O	PUNCT	O
and	O	CCONJ	O
2	O	X	O
)	O	PUNCT	O
pretreatment	O	NOUN	B
with	O	ADP	O
acetaminophen	B-Chemical	NOUN	B
(	O	PUNCT	O
75	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
reduced	O	VERB	B
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
audiogenic	O	ADJ	B
seizures	B-Disease	NOUN	I
produced	O	VERB	O
in	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
caffeine	B-Chemical	NOUN	B
(	O	PUNCT	O
12	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
to	O	PART	O
75	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
IP	O	PROPN	B
).	O	PUNCT	O
The	O	DET	O
frequency	O	NOUN	B
of	O	ADP	O
sound	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
seizures	B-Disease	NOUN	B
after	O	ADP	O
12	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
or	O	CCONJ	O
25	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
caffeine	B-Chemical	NOUN	B
was	O	AUX	O
reduced	O	VERB	B
from	O	ADP	O
50	O	NUM	O
to	O	PART	O
5	O	NUM	O
%	O	NOUN	O
by	O	ADP	O
acetaminophen	B-Chemical	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
absence	O	NOUN	B
of	O	ADP	O
caffeine	B-Chemical	NOUN	B
,	O	PUNCT	O
acetaminophen	B-Chemical	NOUN	B
(	O	PUNCT	O
up	O	ADV	O
to	O	PART	O
300	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
did	O	AUX	O
not	O	PART	O
modify	O	VERB	O
the	O	DET	O
seizures	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
maximal	O	ADJ	B
electroshock	O	NOUN	B
and	O	CCONJ	O
did	O	AUX	O
not	O	PART	O
alter	O	VERB	O
the	O	DET	O
convulsant	O	ADJ	B
dose	O	NOUN	B
of	O	ADP	O
pentylenetetrezol	B-Chemical	NOUN	B
in	O	ADP	O
mice	O	NOUN	B
(	O	PUNCT	O
tests	O	NOUN	B
performed	O	VERB	O
by	O	ADP	O
the	O	DET	O
Anticonvulsant	O	PROPN	B
Screening	O	PROPN	I
Project	O	PROPN	I
of	O	ADP	O
NINCDS	O	PROPN	B
).	O	PUNCT	O
Acetaminophen	B-Chemical	NOUN	B
(	O	PUNCT	O
up	O	ADV	O
to	O	PART	O
150	O	NUM	O
micrograms	O	NOUN	B
/	O	PUNCT	O
mL	O	NOUN	B
)	O	PUNCT	O
did	O	AUX	O
not	O	PART	O
retard	O	VERB	O
the	O	DET	O
incorporation	O	NOUN	B
of	O	ADP	O
radioactive	O	ADJ	B
adenosine	B-Chemical	NOUN	I
into	O	ADP	O
ATP	B-Chemical	NOUN	B
in	O	ADP	O
slices	O	NOUN	B
of	O	ADP	O
rat	O	NOUN	B
cerebral	O	ADJ	B
cortex	O	NOUN	I
.	O	PUNCT	O


Thus	O	ADV	O
the	O	DET	O
mechanism	O	NOUN	B
by	O	ADP	O
which	O	DET	O
acetaminophen	B-Chemical	NOUN	B
antagonizes	O	VERB	B
the	O	DET	O
actions	O	NOUN	B
of	O	ADP	O
caffeine	B-Chemical	NOUN	B


Flestolol	B-Chemical	PROPN	B
:	O	PUNCT	O
an	O	DET	O
ultra	O	ADJ	B
-	O	PUNCT	O
short	O	ADJ	B
-	O	PUNCT	O
acting	O	VERB	B
beta	O	NOUN	B
-	O	PUNCT	O
adrenergic	O	ADJ	B
blocking	O	NOUN	O
agent	O	NOUN	O
.	O	PUNCT	O


Flestolol	B-Chemical	PROPN	B
(	O	PUNCT	O
ACC-9089	B-Chemical	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
nonselective	O	ADJ	B
,	O	PUNCT	O
competitive	O	ADJ	B
,	O	PUNCT	O
ultra	O	ADJ	B
-	O	PUNCT	O
short	O	ADJ	B
-	O	PUNCT	O
acting	O	VERB	B
beta	O	NOUN	B
-	O	PUNCT	O
adrenergic	O	ADJ	B
blocking	O	NOUN	O
agent	O	NOUN	O
,	O	PUNCT	O
without	O	ADP	O
any	O	DET	O
intrinsic	O	ADJ	B
sympathomimetic	O	ADJ	B
activity	O	NOUN	I
.	O	PUNCT	O


Flestolol	B-Chemical	PROPN	B
is	O	AUX	O
metabolized	O	VERB	B
by	O	ADP	O
plasma	O	NOUN	B
esterases	O	NOUN	O
and	O	CCONJ	O
has	O	AUX	O
an	O	DET	O
elimination	O	NOUN	B
half	O	NOUN	B
-	O	PUNCT	O
life	O	NOUN	B
of	O	ADP	O
approximately	O	ADV	B
6	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
minutes	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
agent	O	NOUN	B
was	O	AUX	O
well	O	ADV	O
tolerated	O	VERB	B
in	O	ADP	O
healthy	O	ADJ	B
volunteers	O	NOUN	I
at	O	ADP	O
doses	O	NOUN	B
up	O	ADV	O
to	O	PART	O
100	O	NUM	O
micrograms	O	NOUN	B
/	O	SYM	O
kg	O	NOUN	B
/	O	PUNCT	O
min	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
infusion	O	NOUN	B
studies	O	NOUN	I
,	O	PUNCT	O
flestolol	B-Chemical	NOUN	B
was	O	AUX	O
well	O	ADV	O
tolerated	O	VERB	B
at	O	ADP	O
the	O	DET	O
effective	O	ADJ	B
beta	O	NOUN	B
-	O	PUNCT	O
blocking	O	VERB	B
dose	O	NOUN	B
(	O	PUNCT	O
5	O	NUM	O
micrograms	O	NOUN	B
/	O	SYM	O
kg	O	NOUN	B
/	O	PUNCT	O
min	O	NOUN	B
)	O	PUNCT	O
for	O	ADP	O
up	O	ADV	O
to	O	PART	O
seven	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


Flestolol	B-Chemical	NOUN	B
blood	O	NOUN	B
concentrations	O	NOUN	I
increased	O	VERB	B
linearly	O	ADV	O
with	O	ADP	O
increasing	O	VERB	B
dose	O	NOUN	B
and	O	CCONJ	O
good	O	ADJ	O
correlation	O	NOUN	B
exists	O	VERB	O
between	O	ADP	O
blood	O	NOUN	B
concentrations	O	NOUN	I
of	O	ADP	O
flestolol	B-Chemical	NOUN	B
and	O	CCONJ	O
beta	O	NOUN	B
-	O	PUNCT	O
adrenergic	O	ADJ	B
blockade	O	NOUN	B
.	O	PUNCT	O


Flestolol	B-Chemical	PROPN	B
produced	O	VERB	O
a	O	DET	O
dose	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
attenuation	O	NOUN	B
of	O	ADP	O
isoproterenol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
tachycardia	B-Disease	NOUN	B
.	O	PUNCT	O


Electrophysiologic	O	ADJ	B
and	O	CCONJ	O
hemodynamic	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
flestolol	B-Chemical	NOUN	B
are	O	AUX	O
similar	O	ADJ	O
to	O	PART	O
those	O	DET	O
of	O	ADP	O
other	O	ADJ	O
beta	O	NOUN	B
blockers	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
with	O	ADP	O
other	O	ADJ	O
beta	O	NOUN	B
blockers	O	NOUN	I
,	O	PUNCT	O
flestolol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
effects	O	NOUN	B
reverse	O	VERB	B
rapidly	O	ADV	O
(	O	PUNCT	O
within	O	ADP	O
30	O	NUM	O
minutes	O	NOUN	B
)	O	PUNCT	O
following	O	VERB	O
discontinuation	O	NOUN	B
because	O	SCONJ	O
of	O	ADP	O
its	O	PRON	O
short	O	ADJ	O
half	O	NOUN	B
-	O	PUNCT	O
life	O	NOUN	B
.	O	PUNCT	O


Flestolol	B-Chemical	PROPN	B
effectively	O	ADV	O
reduced	O	VERB	B
heart	O	NOUN	B
rate	O	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
supraventricular	B-Disease	ADJ	B
tachyarrhythmia	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
unstable	B-Disease	ADJ	B
angina	I-Disease	NOUN	I
,	O	PUNCT	O
flestolol	B-Chemical	NOUN	B
infusion	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
safe	O	ADJ	O
and	O	CCONJ	O
effective	O	ADJ	B
in	O	ADP	O
controlling	O	VERB	B
chest	B-Disease	ADJ	B
pain	I-Disease	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
concluded	O	VERB	O
that	O	SCONJ	O
flestolol	B-Chemical	NOUN	B
is	O	AUX	O
a	O	DET	O
potent	O	ADJ	O
,	O	PUNCT	O
well	O	ADV	B
-	O	PUNCT	O
tolerated	O	VERB	B
,	O	PUNCT	O
ultra	O	ADJ	B
-	O	PUNCT	O
short	O	ADJ	B
-	O	PUNCT	O
acting	O	VERB	B
beta	O	NOUN	B
-	O	PUNCT	O
adrenergic	O	ADJ	B
blocking	O	NOUN	O
agent	O	NOUN	O
.	O	PUNCT	O


Use	O	PROPN	B
of	O	ADP	I
flestolol	B-Chemical	NOUN	B


Adverse	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
the	O	DET	O
calcium	B-Chemical	NOUN	B
channel	O	NOUN	I
blocker	O	NOUN	I
nitrendipine	B-Chemical	NOUN	B
on	O	ADP	O
nephrosclerosis	B-Disease	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
with	O	ADP	O
renovascular	B-Disease	ADJ	B
hypertension	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
a	O	DET	O
6	O	NUM	O
-	O	PUNCT	O
week	O	NOUN	B
treatment	O	NOUN	B
with	O	ADP	O
the	O	DET	O
calcium	B-Chemical	NOUN	B
channel	O	NOUN	I
blocker	O	NOUN	I
nitrendipine	B-Chemical	NOUN	B
or	O	CCONJ	O
the	O	DET	O
angiotensin	B-Chemical	NOUN	B
converting	O	NOUN	O
enzyme	O	NOUN	B
inhibitor	O	NOUN	I
enalapril	B-Chemical	NOUN	B
on	O	ADP	O
blood	O	NOUN	B
pressure	O	NOUN	I
,	O	PUNCT	O
albuminuria	B-Disease	NOUN	B
,	O	PUNCT	O
renal	O	ADJ	B
hemodynamics	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
morphology	O	NOUN	B
of	O	ADP	O
the	O	DET	O
nonclipped	O	ADJ	B
kidney	O	NOUN	B
was	O	AUX	O
studied	O	VERB	O
in	O	ADP	O
rats	O	NOUN	B
with	O	ADP	O
two	O	NUM	O
-	O	PUNCT	O
kidney	O	NOUN	B
,	O	PUNCT	O
one	O	NUM	O
clip	O	NOUN	B
renovascular	B-Disease	ADJ	I
hypertension	I-Disease	NOUN	I
.	O	PUNCT	O


Six	O	NUM	B
weeks	O	NOUN	I
after	O	ADP	O
clipping	O	VERB	B
of	O	ADP	O
one	O	NUM	O
renal	O	ADJ	B
artery	O	NOUN	I
,	O	PUNCT	O
hypertensive	B-Disease	ADJ	B
rats	O	NOUN	B
(	O	PUNCT	O
178	O	NUM	O
+/-	O	CCONJ	O
4	O	NUM	O
mm	O	NOUN	B
Hg	O	NOUN	I
)	O	PUNCT	O
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	ADP	O
three	O	NUM	O
groups	O	NOUN	B
:	O	PUNCT	O
untreated	O	ADJ	B
hypertensive	B-Disease	ADJ	I
controls	O	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
8	O	NUM	O
),	O	PUNCT	O
enalapril	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
8	O	NUM	O
),	O	PUNCT	O
or	O	CCONJ	O
nitrendipine	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
10	O	NUM	O
).	O	PUNCT	O
Sham	O	PROPN	B
-	O	PUNCT	O
operated	O	VERB	B
rats	O	NOUN	B
served	O	VERB	O
as	O	ADP	O
normotensive	O	ADJ	B
controls	O	NOUN	O
(	O	PUNCT	O
128	O	NUM	O
+/-	O	CCONJ	O
3	O	NUM	O
mm	O	NOUN	O
Hg	O	NOUN	O
,	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
8	O	NUM	O
).	O	NOUN	O
After	O	ADP	O
6	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
,	O	PUNCT	O
renal	O	ADJ	B
hemodynamics	O	NOUN	I
(	O	PUNCT	O
glomerular	O	ADJ	B
filtration	O	NOUN	I
rate	O	NOUN	I
and	O	CCONJ	O
renal	O	ADJ	B
plasma	O	NOUN	I
flow	O	NOUN	I
)	O	PUNCT	O
were	O	AUX	O
measured	O	VERB	B
in	O	ADP	O
the	O	DET	O
anesthetized	O	VERB	B
rats	O	NOUN	B
.	O	PUNCT	O


Renal	O	ADJ	B
tissue	O	NOUN	I
was	O	AUX	O
obtained	O	VERB	O
for	O	ADP	O
determination	O	NOUN	B
of	O	ADP	O
glomerular	O	ADJ	B
size	O	NOUN	I
and	O	CCONJ	O
sclerosis	O	NOUN	B
.	O	PUNCT	O


Enalapril	B-Chemical	NOUN	B
but	O	CCONJ	O
not	O	PART	O
nitrendipine	B-Chemical	NOUN	B
reduced	O	VERB	B
blood	O	NOUN	B
pressure	O	NOUN	I
significantly	O	ADV	B
.	O	PUNCT	O


After	O	ADP	O
6	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
therapy	O	NOUN	B
,	O	PUNCT	O
glomerular	O	ADJ	B
filtration	O	NOUN	I
rate	O	NOUN	I
was	O	AUX	O
not	O	PART	O
different	O	ADJ	O
among	O	ADP	O
the	O	DET	O
studied	O	VERB	O
groups	O	NOUN	B
.	O	PUNCT	O


Renal	O	ADJ	B
plasma	O	NOUN	I
flow	O	NOUN	I
increased	O	VERB	B
,	O	PUNCT	O
but	O	CCONJ	O
albumin	O	NOUN	B
excretion	O	NOUN	B
and	O	CCONJ	O
glomerulosclerosis	B-Disease	NOUN	B
did	O	AUX	O
not	O	PART	O
change	O	VERB	O
after	O	ADP	O
enalapril	B-Chemical	ADJ	B
treatment	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
nitrendipine	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
group	O	NOUN	B
albuminuria	B-Disease	NOUN	I
increased	O	VERB	B
from	O	ADP	O
12	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
+/-	O	CCONJ	O
2	O	NUM	O
progressively	O	ADV	O
to	O	PART	O
163	O	NUM	O
+/-	O	CCONJ	O
55	O	NUM	O
compared	O	VERB	B
with	O	ADP	O
19	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
+/-	O	CCONJ	O
9	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
24	O	NUM	O
hr	O	NOUN	O
in	O	ADP	O
the	O	DET	O
hypertensive	B-Disease	ADJ	B
controls	O	NOUN	I
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
glomerulosclerosis	B-Disease	NOUN	B
index	O	NOUN	I
was	O	AUX	O
significantly	O	ADV	O
increased	O	VERB	B
in	O	ADP	O
the	O	DET	O
nitrendipine	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
group	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
hypertensive	B-Disease	ADJ	B
controls	O	NOUN	I
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


38	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
versus	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


13	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


04	O	NUM	O
).	O	PUNCT	O
In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
glomerular	O	ADJ	B
size	O	NOUN	I
was	O	AUX	O
higher	O	ADJ	O
in	O	ADP	O
the	O	DET	O
nitrendipine	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
group	O	NOUN	B
(	O	PUNCT	O
14	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


17	O	NUM	O
10	O	NUM	O
(-	O	PUNCT	O
3	O	NUM	O
)	O	PUNCT	O
mm2	O	NUM	O
)	O	PUNCT	O
but	O	CCONJ	O
lower	O	ADJ	O
in	O	ADP	O
the	O	DET	O
enalapril	B-Chemical	ADJ	B
-	O	PUNCT	O
treated	O	VERB	B
group	O	NOUN	B
(	O	PUNCT	O
11	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


15	O	NUM	O
10	O	NUM	O
(-	O	PUNCT	O
3	O	NUM	O
)	O	PUNCT	O
mm2	O	NUM	O
)	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
hypertensive	B-Disease	NOUN	B


Treatment	O	NOUN	B
of	O	ADP	O
tinnitus	B-Disease	NOUN	B
by	O	ADP	O
intratympanic	O	ADJ	B
instillation	O	NOUN	I
of	O	ADP	O
lignocaine	B-Chemical	NOUN	B
(	O	PUNCT	O
lidocaine	B-Chemical	NOUN	B
)	O	PUNCT	O
2	O	NUM	O
per	O	ADP	O
cent	O	NOUN	O
through	O	ADP	O
ventilation	O	NOUN	B
tubes	O	NOUN	I
.	O	PUNCT	O


Idiopathic	B-Disease	ADJ	B
subjective	I-Disease	ADJ	I
tinnitus	I-Disease	NOUN	I
(	O	PUNCT	O
IST	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
most	O	ADV	O
obscure	O	ADJ	O
otological	O	ADJ	B
pathologies	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
paper	O	NOUN	O
presents	O	VERB	O
the	O	DET	O
results	O	NOUN	B
of	O	ADP	O
treating	O	VERB	B
IST	B-Disease	NOUN	B
by	O	ADP	O
intratympanic	O	ADJ	B
instillation	O	NOUN	B
of	O	ADP	O
lignocaine	B-Chemical	NOUN	B
(	O	PUNCT	O
lidocaine	B-Chemical	NOUN	B
)	O	PUNCT	O
2	O	NUM	O
per	O	ADP	O
cent	O	NOUN	O
through	O	ADP	O
a	O	DET	O
grommet	O	NOUN	B
,	O	PUNCT	O
for	O	ADP	O
five	O	NUM	O
weekly	O	ADJ	B
courses	O	NOUN	B
.	O	PUNCT	O


Fifty	O	PROPN	B
-	O	PUNCT	O
two	O	NUM	O
patients	O	NOUN	B
suffering	O	VERB	B
from	O	ADP	O
intractable	O	ADJ	B
tinnitus	B-Disease	NOUN	B
entered	O	VERB	O
this	O	DET	O
therapeutic	O	ADJ	B
trial	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
only	O	ADV	O
nine	O	NUM	O
finished	O	VERB	O
all	O	DET	O
five	O	NUM	O
courses	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
one	O	NUM	O
patient	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
tinnitus	B-Disease	NOUN	B
was	O	AUX	O
almost	O	ADV	O
completely	O	ADV	O
abolished	O	VERB	B
,	O	PUNCT	O
but	O	CCONJ	O
in	O	ADP	O
all	O	DET	O
the	O	DET	O
nine	O	NUM	O
patients	O	NOUN	B
the	O	DET	O
decompensated	O	ADJ	B
tinnitus	B-Disease	NOUN	B
changed	O	VERB	O
to	O	PART	O
a	O	DET	O
compensated	O	VERB	B
one	O	NUM	O
.	O	PUNCT	O


We	O	PRON	O
suggest	O	VERB	O
this	O	DET	O
mode	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
for	O	ADP	O
patients	O	NOUN	B
that	O	PRON	O
were	O	AUX	O
previously	O	ADV	O
treated	O	VERB	B
by	O	ADP	O
drugs	O	NOUN	B
,	O	PUNCT	O
acupuncture	O	NOUN	B
and	O	CCONJ	O
biofeedback	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
disappointing	O	ADJ	O
results	O	NOUN	B
.	O	PUNCT	O


Patients	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
warned	O	VERB	O
about	O	ADP	O
the	O	DET	O
side	O	NOUN	B
effects	O	NOUN	I
of	O	ADP	O
vertigo	B-Disease	ADJ	B
and	O	CCONJ	O
vomiting	B-Disease	NOUN	B
,	O	PUNCT	O
which	O	DET	O
subsides	O	VERB	O
gradually	O	ADV	O
with	O	ADP	O
every	O	DET	O
new	O	ADJ	O
instillation	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
that	O	SCONJ	O
the	O	DET	O
tinnitus	B-Disease	NOUN	B


Perhexiline	B-Chemical	NOUN	B
maleate	I-Chemical	NOUN	B
and	O	CCONJ	O
peripheral	B-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I
.	O	PUNCT	O


Peripheral	B-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I
has	O	AUX	O
been	O	AUX	O
noted	O	VERB	O
as	O	ADP	O
a	O	DET	O
complication	O	NOUN	B
of	O	ADP	O
therapy	O	NOUN	B
with	O	ADP	O
perhexiline	B-Chemical	NOUN	B
maleate	I-Chemical	NOUN	I
,	O	PUNCT	O
a	O	DET	O
drug	O	NOUN	B
widely	O	ADV	O
used	O	VERB	O
in	O	ADP	O
France	O	PROPN	B
(	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
clinical	O	ADJ	B
trials	O	NOUN	I
in	O	ADP	O
the	O	DET	O
United	O	PROPN	B
States	O	PROPN	I
)	O	PUNCT	O
for	O	ADP	O
the	O	DET	O
prophylactic	O	ADJ	B
treatment	O	NOUN	I
of	O	ADP	O
angina	B-Disease	ADJ	B
pectoris	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
24	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
this	O	DET	O
complication	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
marked	O	ADJ	O
slowing	O	NOUN	O
of	O	ADP	O
motor	O	NOUN	B
nerve	O	NOUN	I
conduction	O	NOUN	O
velocity	O	NOUN	O
and	O	CCONJ	O
the	O	DET	O
electromyographic	O	ADJ	B
changes	O	NOUN	B
imply	O	VERB	O
mainly	O	ADV	O
a	O	DET	O
demyelinating	B-Disease	VERB	B
disorder	I-Disease	NOUN	I
.	O	PUNCT	O


Improvement	O	NOUN	B
was	O	AUX	O
noted	O	VERB	O
with	O	ADP	O
cessation	O	NOUN	B
of	O	ADP	O
therapy	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
few	O	ADJ	O
cases	O	NOUN	B
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
active	O	ADJ	B
denervation	O	NOUN	I
signified	O	VERB	O
a	O	DET	O
poor	O	ADJ	B
prognosis	O	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
only	O	ADV	O
slight	O	ADJ	O
improvement	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
underlying	O	ADJ	O
mechanism	O	NOUN	B
causing	O	VERB	O
the	O	DET	O
neuropathy	B-Disease	NOUN	B


Effect	O	NOUN	B
of	O	ADP	O
humoral	O	ADJ	B
modulators	O	NOUN	I
of	O	ADP	O
morphine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
increase	B-Disease	NOUN	B
in	I-Disease	ADP	O
locomotor	I-Disease	NOUN	B
activity	I-Disease	NOUN	I
of	O	ADP	O
mice	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
humoral	O	ADJ	B
modulators	O	NOUN	I
on	O	ADP	O
the	O	DET	O
morphine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
increase	B-Disease	NOUN	B
in	I-Disease	ADP	O
locomotor	I-Disease	NOUN	B
activity	I-Disease	NOUN	I
of	O	ADP	O
mice	O	NOUN	B
was	O	AUX	O
studied	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
subcutaneous	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
10	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
of	O	ADP	O
morphine	B-Chemical	NOUN	B
-	O	PUNCT	O
HC1	O	NOUN	B
produced	O	VERB	O
a	O	DET	O
marked	O	ADJ	O
increase	B-Disease	NOUN	B
in	I-Disease	ADP	O
locomotor	I-Disease	NOUN	B
activity	I-Disease	NOUN	I
in	O	ADP	O
mice	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
morphine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hyperactivity	B-Disease	NOUN	B
was	O	AUX	O
potentiated	O	VERB	B
by	O	ADP	O
scopolamine	B-Chemical	NOUN	B
and	O	CCONJ	O
attenuated	O	VERB	B
by	O	ADP	O
physostigmine	B-Chemical	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
both	O	CCONJ	O
methscopolamine	B-Chemical	NOUN	B
and	O	CCONJ	O
neostigmine	B-Chemical	NOUN	B
,	O	PUNCT	O
which	O	DET	O
do	O	AUX	O
not	O	PART	O
penetrate	O	VERB	B
the	O	DET	O
blood	O	NOUN	B
-	O	PUNCT	O
brain	O	NOUN	B
barrier	O	NOUN	O
,	O	PUNCT	O
had	O	AUX	O
no	O	DET	B
effect	O	NOUN	I
on	O	ADP	O
the	O	DET	O
hyperactivity	B-Disease	NOUN	B
produced	O	VERB	O
by	O	ADP	O
morphine	B-Chemical	NOUN	B
.	O	PUNCT	O


Pretreatment	O	NOUN	B
of	O	ADP	O
mice	O	NOUN	B
with	O	ADP	O
alpha-methyltyrosine	B-Chemical	NOUN	B
(	O	PUNCT	O
20	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
i	O	X	O
.	O	PUNCT	O


p	O	X	O
.,	O	NOUN	O
one	O	NUM	O
hour	O	NOUN	B
),	O	PUNCT	O
an	O	DET	O
inhibitor	O	NOUN	B
of	O	ADP	O
tyrosine	B-Chemical	NOUN	B
hydroxylase	O	NOUN	I
,	O	PUNCT	O
significantly	O	ADV	O
decreased	O	VERB	B
the	O	DET	O
activity	O	NOUN	B
-	O	PUNCT	O
increasing	O	VERB	B
effects	O	NOUN	B
of	O	ADP	O
morphine	B-Chemical	NOUN	B
.	O	PUNCT	O


On	O	ADP	O
the	O	DET	O
other	O	ADJ	O
hand	O	NOUN	B
,	O	PUNCT	O
pretreatment	O	NOUN	B
with	O	ADP	O
p-chlorophenylalamine	B-Chemical	NOUN	B
(	O	PUNCT	O
3	O	NUM	O
X	O	NOUN	O
320	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
i	O	X	O
.	O	PUNCT	O


p	O	X	O
.,	O	NOUN	O
24	O	NUM	O
hr	O	NOUN	O
),	O	PUNCT	O
a	O	DET	O
serotonin	B-Chemical	NOUN	B
depletor	O	NOUN	I
,	O	PUNCT	O
caused	O	VERB	O
no	O	DET	O
significant	O	ADJ	O
change	O	NOUN	O
in	O	ADP	O
the	O	DET	O
hyperactivity	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
study	O	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
activity	O	NOUN	B
-	O	PUNCT	O
increasing	O	VERB	B
effects	O	NOUN	B
of	O	ADP	O
morphine	B-Chemical	NOUN	B
are	O	AUX	O
mediated	O	VERB	O
by	O	ADP	O
the	O	DET	O
release	O	NOUN	B
of	O	ADP	O
catecholamines	B-Chemical	NOUN	B
from	O	ADP	O
adrenergic	O	ADJ	B
neurons	O	NOUN	I
in	O	ADP	O
the	O	DET	O
brain	O	NOUN	B
.	O	PUNCT	O


And	O	CCONJ	O
the	O	DET	O
results	O	NOUN	B
are	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
morphine	B-Chemical	NOUN	B
acts	O	VERB	O
by	O	ADP	O
retarding	O	VERB	B
the	O	DET	O
release	O	NOUN	B
of	O	ADP	O
acetylcholine	B-Chemical	NOUN	B
at	O	ADP	O
some	O	DET	O
central	O	ADJ	B
cholinergic	O	ADJ	I
synapses	O	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
also	O	ADV	O
suggested	O	VERB	O
from	O	ADP	O
collected	O	VERB	O
evidence	O	NOUN	B
that	O	SCONJ	O
the	O	DET	O
activity	O	NOUN	B
-	O	PUNCT	O
increasing	O	VERB	B
effects	O	NOUN	B
of	O	ADP	O
morphine	B-Chemical	NOUN	B
in	O	ADP	O
mice	O	NOUN	B
are	O	AUX	O
mediated	O	VERB	O
by	O	ADP	O
mechanisms	O	NOUN	B
different	O	ADJ	O
from	O	ADP	O
those	O	DET	O
which	O	DET	O
mediate	O	VERB	O
the	O	DET	O
activity	O	NOUN	B
-	O	PUNCT	O
increasing	O	VERB	B
effects	O	NOUN	B
of	O	ADP	O
morphine	B-Chemical	NOUN	B


Mechanisms	O	NOUN	B
of	O	ADP	O
FK	B-Chemical	NOUN	B
506	I-Chemical	NUM	O
-	O	PUNCT	O
induced	O	VERB	B
hypertension	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
.-	O	NUM	O
Tacrolimus	B-Chemical	NOUN	B
(	O	PUNCT	O
FK	B-Chemical	NOUN	B
506	I-Chemical	NUM	O
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
powerful	O	ADJ	O
,	O	PUNCT	O
widely	O	ADV	O
used	O	VERB	O
immunosuppressant	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
clinical	O	ADJ	B
utility	O	NOUN	O
of	O	ADP	O
FK	B-Chemical	NOUN	B
506	I-Chemical	NUM	O
is	O	AUX	O
complicated	O	ADJ	O
by	O	ADP	O
substantial	O	ADJ	O
hypertension	B-Disease	NOUN	B
and	O	CCONJ	O
nephrotoxicity	B-Disease	NOUN	B
.	O	PUNCT	O


To	O	PART	O
clarify	O	VERB	O
the	O	DET	O
mechanisms	O	NOUN	B
of	O	ADP	O
FK	B-Chemical	NOUN	B
506	I-Chemical	NUM	O
-	O	PUNCT	O
induced	O	VERB	B
hypertension	B-Disease	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
studied	O	VERB	O
the	O	DET	O
chronic	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
FK	B-Chemical	NOUN	B
506	I-Chemical	NUM	O
on	O	ADP	O
the	O	DET	O
synthesis	O	NOUN	B
of	O	ADP	O
endothelin	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	B
(	O	PUNCT	O
ET	O	PROPN	B
-	O	PUNCT	O
1	O	NUM	O
),	O	PUNCT	O
the	O	DET	O
expression	O	NOUN	B
of	O	ADP	O
mRNA	O	NOUN	B
of	O	ADP	O
ET	O	PROPN	B
-	O	PUNCT	O
1	O	NUM	B
and	O	CCONJ	O
endothelin	O	NOUN	B
-	O	PUNCT	O
converting	O	VERB	B
enzyme	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	O
(	O	PUNCT	O
ECE	O	PROPN	B
-	O	PUNCT	O
1	O	NUM	O
),	O	PUNCT	O
the	O	DET	O
endothelial	O	ADJ	B
nitric	B-Chemical	ADJ	I
oxide	I-Chemical	NOUN	I
synthase	O	NOUN	I
(	O	PUNCT	O
eNOS	O	NOUN	B
)	O	PUNCT	O
activity	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
expression	O	NOUN	B
of	O	ADP	O
mRNA	O	NOUN	B
of	O	ADP	O
eNOS	O	NOUN	B
and	O	CCONJ	O
C	O	NOUN	B
-	O	PUNCT	O
type	O	NOUN	B
natriuretic	O	ADJ	I
peptide	O	NOUN	I
(	O	PUNCT	O
CNP	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
rat	O	NOUN	B
blood	O	NOUN	B
vessels	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
the	O	DET	O
specific	O	ADJ	O
endothelin	O	NOUN	B
type	O	NOUN	O
A	O	NOUN	O
receptor	O	NOUN	O
antagonist	O	NOUN	B
FR	B-Chemical	NOUN	B
139317	I-Chemical	NUM	O
on	O	ADP	O
FK	B-Chemical	NOUN	B
506	I-Chemical	NUM	O
-	O	PUNCT	O
induced	O	VERB	B
hypertension	B-Disease	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
was	O	AUX	O
studied	O	VERB	O
.	O	PUNCT	O


FK	B-Chemical	NOUN	B
506	I-Chemical	NUM	O
,	O	PUNCT	O
5	O	NUM	O
mg	O	NOUN	O
.	O	PUNCT	O


kg	O	NOUN	O
-	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


d	O	X	O
-	O	SYM	O
1	O	NUM	O
given	O	VERB	O
for	O	ADP	O
4	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
elevated	O	ADJ	B
blood	O	NOUN	I
pressure	O	NOUN	I
from	O	ADP	O
102	O	NUM	O
+/-	O	CCONJ	O
13	O	NUM	O
to	O	PART	O
152	O	NUM	O
+/-	O	CCONJ	O
15	O	NUM	O
mm	O	X	B
Hg	O	NOUN	I
and	O	CCONJ	O
increased	O	VERB	B
the	O	DET	O
synthesis	O	NOUN	B
of	O	ADP	O
ET	O	PROPN	B
-	O	PUNCT	O
1	O	NUM	O
and	O	CCONJ	O
the	O	DET	O
levels	O	NOUN	B
of	O	ADP	O
ET	O	PROPN	B
-	O	PUNCT	O
1	O	NUM	O
mRNA	O	NOUN	B
in	O	ADP	O
the	O	DET	O
mesenteric	O	ADJ	B
artery	O	NOUN	I
(	O	PUNCT	O
240	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
230	O	NUM	O
%,	O	NOUN	O
respectively	O	ADV	O
).	O	PUNCT	O
Little	O	ADJ	O
change	O	NOUN	O
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
the	O	DET	O
expression	O	NOUN	B
of	O	ADP	O
ECE	O	PROPN	B
-	O	PUNCT	O
1	O	NUM	O
mRNA	O	NOUN	B
and	O	CCONJ	O
CNP	O	NOUN	B
mRNA	O	NOUN	B
.	O	PUNCT	O


FK	B-Chemical	NOUN	B
506	I-Chemical	NUM	O
decreased	O	VERB	B
eNOS	O	NOUN	B
activity	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
levels	O	NOUN	B
of	O	ADP	O
eNOS	O	NOUN	B
mRNA	O	NOUN	B
in	O	ADP	O
the	O	DET	O
aorta	O	NOUN	B
(	O	PUNCT	O
48	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
55	O	NUM	O
%,	O	NOUN	B
respectively	O	ADV	O
).	O	PUNCT	O
The	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
FR	B-Chemical	NOUN	B
139317	I-Chemical	NUM	O
(	O	PUNCT	O
10	O	NUM	O
mg	O	NOUN	O
.	O	PUNCT	O


kg	O	NOUN	O
-	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


d	O	X	O
-	O	SYM	O
1	O	NUM	O
)	O	PUNCT	O
prevented	O	VERB	O
FK	B-Chemical	NOUN	B
506	I-Chemical	NUM	O
-	O	PUNCT	O
induced	O	VERB	B
hypertension	B-Disease	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
FK	B-Chemical	NOUN	B
506	I-Chemical	NUM	O
may	O	AUX	O
increase	O	VERB	B
blood	O	NOUN	B
pressure	O	NOUN	I
not	O	PART	O
only	O	ADV	O
by	O	ADP	O
increasing	O	VERB	B
ET	O	PROPN	B
-	O	PUNCT	O
1	O	NUM	O
production	O	NOUN	B
but	O	CCONJ	O
also	O	ADV	O
by	O	ADP	O
decreasing	O	VERB	B
NO	B-Chemical	NOUN	B


Suxamethonium	B-Chemical	NOUN	B
induced	O	VERB	B
prolonged	O	ADJ	B
apnea	B-Disease	NOUN	B
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
receiving	O	VERB	O
electroconvulsive	O	ADJ	B
therapy	O	NOUN	I
.	O	PUNCT	O


Suxamethonium	B-Chemical	NOUN	B
causes	O	VERB	O
prolonged	O	ADJ	B
apnea	B-Disease	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
in	O	ADP	O
whom	O	PRON	O
pseudocholinesterase	O	NOUN	B
enzyme	O	NOUN	B
gets	O	VERB	O
deactivated	O	VERB	O
by	O	ADP	O
organophosphorus	B-Chemical	NOUN	B
(OP)	I-Chemical	NOUN	O
poisons	I-Chemical	NOUN	B
.	O	PUNCT	O


Here	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
present	O	VERB	O
a	O	DET	O
similar	O	ADJ	O
incident	O	NOUN	B
in	O	ADP	O
a	O	DET	O
severely	O	ADV	B
depressed	B-Disease	ADJ	I
patient	O	NOUN	O
who	O	PRON	O
received	O	VERB	O
electroconvulsive	O	ADJ	B
therapy	O	NOUN	I
(	O	PUNCT	O
ECT	O	NOUN	B
).	O	PUNCT	O
Prolonged	O	ADJ	B
apnea	B-Disease	NOUN	B
in	O	ADP	O
our	O	PRON	O
case	O	NOUN	B
ensued	O	VERB	B
because	O	SCONJ	O
the	O	DET	O
information	O	NOUN	B
about	O	ADP	O
suicidal	O	ADJ	B
attempt	O	NOUN	O
by	O	ADP	O
OP	B-Chemical	NOUN	B
compound	I-Chemical	NOUN	I


The	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
the	O	DET	O
adjunctive	O	ADJ	B
bupropion	B-Chemical	NOUN	B
on	O	ADP	O
male	O	ADJ	B
sexual	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
induced	O	VERB	B
by	O	ADP	O
a	O	DET	O
selective	B-Chemical	ADJ	O
serotonin	I-Chemical	NOUN	B
reuptake	I-Chemical	NOUN	I
inhibitor	I-Chemical	NOUN	I
:	O	PUNCT	O
a	O	DET	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	ADJ	B
placebo	O	NOUN	B
-	O	PUNCT	O
controlled	O	VERB	B
and	O	CCONJ	O
randomized	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	B
:	O	PUNCT	O
To	O	PART	O
determine	O	VERB	O
the	O	DET	O
safety	O	NOUN	B
and	O	CCONJ	O
efficacy	O	NOUN	B
of	O	ADP	O
adjunctive	O	ADJ	B
bupropion	B-Chemical	NOUN	B
sustained	O	ADJ	B
-	O	PUNCT	O
release	O	NOUN	B
(	O	PUNCT	O
SR	O	ADJ	B
)	O	PUNCT	O
on	O	ADP	O
male	O	ADJ	B
sexual	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
(	O	PUNCT	O
SD	B-Disease	NOUN	B
)	O	PUNCT	O
induced	O	VERB	B
by	O	ADP	O
a	O	DET	O
selective	B-Chemical	ADJ	O
serotonin	I-Chemical	NOUN	B
reuptake	I-Chemical	NOUN	I
inhibitor	I-Chemical	NOUN	I
(	O	PUNCT	O
SSRI	B-Chemical	NOUN	B
),	O	PUNCT	O
as	O	ADP	O
SD	B-Disease	NOUN	B
is	O	AUX	O
a	O	DET	O
common	O	ADJ	O
side	O	NOUN	B
-	O	PUNCT	O
effect	O	NOUN	B
of	O	ADP	O
SSRIs	B-Chemical	NOUN	B
and	O	CCONJ	O
the	O	DET	O
most	O	ADV	O
effective	O	ADJ	B
treatments	O	NOUN	B
have	O	AUX	O
yet	O	ADV	O
to	O	PART	O
be	O	AUX	O
determined	O	VERB	O
.	O	PUNCT	O


PATIENTS	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
randomized	O	ADJ	B
sample	O	NOUN	I
consisted	O	VERB	O
of	O	ADP	O
234	O	NUM	O
euthymic	O	ADJ	B
men	O	NOUN	B
who	O	PRON	O
were	O	AUX	O
receiving	O	VERB	O
some	O	DET	O
type	O	NOUN	O
of	O	ADP	O
SSRI	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
men	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
bupropion	B-Chemical	NOUN	B
SR	O	NOUN	B
(	O	PUNCT	O
150	O	NUM	O
mg	O	NOUN	O
twice	O	ADV	O
daily	O	ADV	B
,	O	PUNCT	O
117	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
placebo	O	NOUN	B
(	O	PUNCT	O
twice	O	ADV	O
daily	O	ADV	B
,	O	PUNCT	O
117	O	NUM	O
)	O	PUNCT	O
for	O	ADP	O
12	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


Efficacy	O	NOUN	B
was	O	AUX	O
evaluated	O	VERB	B
using	O	VERB	O
the	O	DET	O
Clinical	O	PROPN	B
Global	O	PROPN	I
Impression	O	PROPN	I
-	O	PUNCT	O
Sexual	O	PROPN	B
Function	O	PROPN	I
(	O	PUNCT	O
CGI	O	PROPN	B
-	O	PUNCT	O
SF	O	PROPN	B
;	O	PUNCT	O
the	O	DET	O
primary	O	ADJ	B
outcome	O	NOUN	I
measure	O	NOUN	I
),	O	PUNCT	O
the	O	DET	O
International	O	PROPN	B
Index	O	PROPN	I
of	O	ADP	I
Erectile	O	PROPN	I
Function	O	PROPN	I
(	O	PUNCT	O
IIEF	O	PROPN	B
),	O	PUNCT	O
Arizona	O	PROPN	B
Sexual	O	PROPN	I
Experience	O	PROPN	I
Scale	O	NOUN	I
(	O	PUNCT	O
ASEX	O	NOUN	B
),	O	PUNCT	O
and	O	CCONJ	O
Erectile	B-Disease	NOUN	B
Dysfunction	I-Disease	NOUN	I
Inventory	O	PROPN	I
of	O	ADP	I
Treatment	O	PROPN	I
Satisfaction	O	PROPN	I
(	O	PUNCT	O
EDITS	O	VERB	B
)(	O	NOUN	O
secondary	O	ADJ	O
outcome	O	NOUN	O
measures	O	NOUN	O
).	O	PUNCT	O
Participants	O	NOUN	B
were	O	AUX	O
followed	O	VERB	O
biweekly	O	ADV	B
during	O	ADP	O
study	O	NOUN	B
period	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
After	O	ADP	O
12	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
mean	O	NOUN	B
(	O	PUNCT	O
sd	O	X	O
)	O	PUNCT	O
scores	O	NOUN	B
for	O	ADP	O
CGI	O	PROPN	B
-	O	PUNCT	O
SF	O	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
lower	O	ADJ	O
,	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


e	O	X	O
.	O	PUNCT	O


better	O	ADV	O
,	O	PUNCT	O
in	O	ADP	O
patients	O	NOUN	B
on	O	ADP	O
bupropion	B-Chemical	NOUN	B
SR	O	NOUN	B
,	O	PUNCT	O
at	O	ADP	O
2	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
(	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
),	O	PUNCT	O
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
placebo	O	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
at	O	ADP	O
3	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
(	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
)(	O	NOUN	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
).	O	PUNCT	O
Men	O	NOUN	B
who	O	PRON	O
received	O	VERB	O
bupropion	B-Chemical	NOUN	B
had	O	AUX	O
a	O	DET	O
significant	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
the	O	DET	O
total	O	ADJ	B
IIEF	O	ADJ	I
score	O	NOUN	I
(	O	PUNCT	O
54	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
%	O	NOUN	O
vs	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
%;	O	NOUN	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


003	O	NUM	O
),	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
the	O	DET	O
five	O	NUM	O
different	O	ADJ	O
domains	O	NOUN	B
of	O	ADP	O
the	O	DET	O
IIEF	O	NOUN	B
.	O	PUNCT	O


Total	O	ADJ	B
ASEX	O	NOUN	I
scores	O	NOUN	I
were	O	AUX	O
significantly	O	ADV	O
lower	O	ADJ	O
,	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


e	O	X	O
.	O	PUNCT	O


better	O	ADV	O
,	O	PUNCT	O
among	O	ADP	O
men	O	NOUN	B
who	O	PRON	O
received	O	VERB	O
bupropion	B-Chemical	NOUN	B
than	O	ADP	O
placebo	O	NOUN	B
,	O	PUNCT	O
at	O	ADP	O
15	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
(	O	PUNCT	O
4	O	NUM	O
.	O	PUNCT	O


3	O	X	O
)	O	PUNCT	O
vs	O	CCONJ	O
21	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
(	O	PUNCT	O
4	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
)(	O	NOUN	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


002	O	NUM	O
).	O	PUNCT	O
The	O	DET	O
EDITS	O	PROPN	B
scores	O	NOUN	B
were	O	AUX	O
67	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
(	O	PUNCT	O
10	O	NUM	O
.	O	PUNCT	O


2	O	X	O
)	O	PUNCT	O
for	O	ADP	O
the	O	DET	O
bupropion	B-Chemical	NOUN	B
and	O	CCONJ	O
36	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
(	O	PUNCT	O
11	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
)	O	PUNCT	O
for	O	ADP	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
).	O	PUNCT	O
The	O	DET	O
ASEX	O	NOUN	B
score	O	NOUN	O
and	O	CCONJ	O
CGI	O	PROPN	B
-	O	PUNCT	O
SF	O	NOUN	B
score	O	NOUN	B
were	O	AUX	O
correlated	O	VERB	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


003	O	NUM	O
).	O	PUNCT	O
In	O	ADP	O
linear	O	ADJ	B
regression	O	NOUN	I
analyses	O	VERB	I
the	O	DET	O
CGI	O	PROPN	B
-	O	PUNCT	O
SF	O	NOUN	B
score	O	NOUN	B
was	O	AUX	O
not	O	PART	O
affected	O	VERB	O
significantly	O	ADV	O
by	O	ADP	O
the	O	DET	O
duration	O	NOUN	B
of	O	ADP	O
SD	B-Disease	NOUN	B
,	O	PUNCT	O
type	O	NOUN	O
of	O	ADP	O
SSRI	B-Chemical	NOUN	B
used	O	VERB	O
and	O	CCONJ	O
age	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
Bupropion	B-Chemical	NOUN	B
is	O	AUX	O
an	O	DET	O
effective	O	ADJ	B
treatment	O	NOUN	B
for	O	ADP	O
male	O	NOUN	B
SD	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
SSRIs	B-Chemical	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
provide	O	VERB	O
empirical	O	ADJ	B
support	O	NOUN	O
for	O	ADP	O
conducting	O	VERB	O
a	O	DET	O
further	O	ADJ	O
study	O	NOUN	B
of	O	ADP	O
bupropion	B-Chemical	NOUN	B


Lamivudine	B-Chemical	NOUN	B
for	O	ADP	O
the	O	DET	O
prevention	O	NOUN	B
of	O	ADP	O
hepatitis	B-Disease	NOUN	B
B	I-Disease	NOUN	I
virus	O	NOUN	I
reactivation	O	NOUN	I
in	O	ADP	O
hepatitis-B	B-Chemical	NOUN	B
surface	I-Chemical	NOUN	I
antigen	I-Chemical	NOUN	I
(	O	PUNCT	O
HBSAG	B-Chemical	NOUN	B
)	O	PUNCT	O
seropositive	O	ADJ	B
cancer	B-Disease	NOUN	B
patients	O	NOUN	B
undergoing	O	VERB	O
cytotoxic	O	ADJ	B
chemotherapy	O	NOUN	I
.	O	PUNCT	O


Hepatitis	B-Disease	NOUN	B
B	I-Disease	NOUN	I
virus	O	NOUN	I
(	O	PUNCT	O
HBV	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
major	O	ADJ	O
causes	O	NOUN	O
of	O	ADP	O
chronic	O	ADJ	B
liver	B-Disease	NOUN	I
disease	I-Disease	NOUN	I
worldwide	O	ADV	O
.	O	PUNCT	O


Cancer	B-Disease	NOUN	B
patients	O	NOUN	B
who	O	PRON	O
are	O	AUX	O
chronic	O	ADJ	B
carriers	O	NOUN	I
of	O	ADP	O
HBV	O	NOUN	B
have	O	AUX	O
a	O	DET	O
higher	O	ADJ	O
hepatic	B-Disease	ADJ	B
complication	I-Disease	NOUN	I
rate	O	NOUN	B
while	O	SCONJ	O
receiving	O	VERB	O
cytotoxic	O	ADJ	B
chemotherapy	O	NOUN	I
(	O	PUNCT	O
CT	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
this	O	DET	O
has	O	AUX	O
mainly	O	ADV	O
been	O	AUX	O
attributed	O	VERB	O
to	O	PART	O
HBV	O	NOUN	B
reactivation	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
cancer	B-Disease	NOUN	B
patients	O	NOUN	I
who	O	PRON	O
have	O	AUX	O
solid	O	ADJ	B
and	O	CCONJ	O
hematological	B-Disease	ADJ	B
malignancies	I-Disease	NOUN	I
with	O	ADP	O
chronic	O	ADJ	B
HBV	B-Disease	NOUN	I
infection	I-Disease	NOUN	I
received	O	VERB	O
the	O	DET	O
antiviral	O	ADJ	B
agent	O	NOUN	I
lamivudine	B-Chemical	NOUN	B
prior	O	ADJ	O
and	O	CCONJ	O
during	O	ADP	O
CT	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
historical	O	ADJ	B
control	O	NOUN	I
group	O	NOUN	I
who	O	PRON	O
did	O	AUX	O
not	O	PART	O
receive	O	VERB	O
lamivudine	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
objectives	O	NOUN	B
were	O	AUX	O
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
lamivudine	B-Chemical	NOUN	B
in	O	ADP	O
reducing	O	VERB	B
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
HBV	O	NOUN	B
reactivation	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
diminishing	O	VERB	O
morbidity	O	NOUN	B
and	O	CCONJ	O
mortality	O	NOUN	B
during	O	ADP	O
CT	O	NOUN	B
.	O	PUNCT	O


Two	O	NUM	O
groups	O	NOUN	B
were	O	AUX	O
compared	O	VERB	B
in	O	ADP	O
this	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
prophylactic	O	ADJ	B
lamivudin	B-Chemical	NOUN	O
group	O	NOUN	O
consisted	O	VERB	O
of	O	ADP	O
37	O	NUM	O
patients	O	NOUN	B
who	O	PRON	O
received	O	VERB	O
prophylactic	O	ADJ	B
lamivudine	B-Chemical	NOUN	I
treatment	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
historical	O	ADJ	B
controls	O	NOUN	I
consisted	O	VERB	O
of	O	ADP	O
50	O	NUM	O
consecutive	O	ADJ	B
patients	O	NOUN	B
who	O	PRON	O
underwent	O	VERB	O
CT	O	NOUN	B
without	O	ADP	O
prophylactic	O	ADJ	B
lamivudine	B-Chemical	NOUN	I
.	O	PUNCT	O


They	O	PRON	O
were	O	AUX	O
followed	O	VERB	O
up	O	ADP	O
during	O	ADP	O
and	O	CCONJ	O
for	O	ADP	O
8	O	NUM	O
weeks	O	NOUN	B
after	O	ADP	O
CT	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
outcomes	O	NOUN	B
were	O	AUX	O
compared	O	VERB	B
for	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


Of	O	ADP	O
our	O	PRON	O
control	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
50	O	NUM	O
),	O	SYM	O
21	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
42	O	NUM	O
%)	O	NOUN	O
were	O	AUX	O
established	O	VERB	O
hepatitis	B-Disease	NOUN	B
.	O	PUNCT	O


Twelve	O	NUM	O
(	O	PUNCT	O
24	O	NUM	O
%)	O	NOUN	O
of	O	ADP	O
them	O	PRON	O
were	O	AUX	O
evaluated	O	VERB	B
as	O	ADP	O
severe	O	ADJ	B
hepatitis	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
prophylactic	O	ADJ	B
lamivudine	B-Chemical	NOUN	I
group	O	NOUN	I
severe	O	ADJ	B
hepatitis	B-Disease	NOUN	B
were	O	AUX	O
observed	O	VERB	O
only	O	ADV	O
in	O	ADP	O
1	O	NUM	O
patient	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
%)	O	NOUN	O
of	O	ADP	O
37	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


006	O	NUM	O
).	O	PUNCT	O
Comparison	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mean	O	ADJ	O
ALT	O	NOUN	B
values	O	NOUN	O
revealed	O	VERB	O
significantly	O	ADV	O
higher	O	ADJ	O
mean	O	ADJ	O
alanine	B-Chemical	NOUN	B
aminotransferase	O	NOUN	I
(	O	PUNCT	O
ALT	O	NOUN	B
)	O	PUNCT	O
values	O	NOUN	O
in	O	ADP	O
the	O	DET	O
control	O	ADJ	B
group	O	NOUN	I
than	O	ADP	O
the	O	DET	O
prophylactic	O	ADJ	B
lamivudine	B-Chemical	NOUN	I
group	O	NOUN	I
;	O	PUNCT	O
154	O	NUM	O
:	O	PUNCT	O
64	O	NUM	O
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


32	O	NUM	O
).	O	PUNCT	O
Our	O	PRON	O
study	O	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
prophylactic	O	ADJ	B
lamivudine	B-Chemical	NOUN	I
significantly	O	ADV	O
decreases	O	VERB	B
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
HBV	O	NOUN	B
reactivation	O	NOUN	B
and	O	CCONJ	O
overall	O	ADJ	O
morbidity	O	NOUN	B
in	O	ADP	O
cancer	B-Disease	NOUN	B
patients	O	NOUN	B
during	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
immunosuppressive	O	ADJ	B
therapy	O	NOUN	I
.	O	PUNCT	O


Further	O	ADJ	O
studies	O	NOUN	B
are	O	AUX	O
needed	O	VERB	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
most	O	ADV	O
appropriate	O	ADJ	O
nucleoside	B-Chemical	NOUN	B
or	O	CCONJ	O
nucleotide	B-Chemical	NOUN	B


Ginsenoside	B-Chemical	NOUN	B
Rg1	I-Chemical	NOUN	B
restores	O	VERB	B
the	O	DET	O
impairment	B-Disease	NOUN	B
of	I-Disease	ADP	O
learning	I-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
chronic	O	ADJ	B
morphine	B-Chemical	NOUN	B
administration	O	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


Rg1	B-Chemical	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
a	O	DET	O
ginsenoside	B-Chemical	NOUN	B
extracted	O	VERB	O
from	O	ADP	O
Panax	O	PROPN	B
ginseng	O	NOUN	I
,	O	PUNCT	O
could	O	AUX	O
ameliorate	O	VERB	B
spatial	O	ADJ	B
learning	B-Disease	NOUN	I
impairment	I-Disease	NOUN	O
.	O	PUNCT	O


Previous	O	ADJ	O
studies	O	NOUN	B
have	O	AUX	O
demonstrated	O	VERB	O
that	O	SCONJ	O
Rg1	B-Chemical	NOUN	B
might	O	AUX	O
be	O	AUX	O
a	O	DET	O
useful	O	ADJ	O
agent	O	NOUN	B
for	O	ADP	O
the	O	DET	O
prevention	O	NOUN	B
and	O	CCONJ	O
treatment	O	NOUN	B
of	O	ADP	O
the	O	DET	O
adverse	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
morphine	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
Rg1	B-Chemical	NOUN	B
on	O	ADP	O
learning	B-Disease	NOUN	B
impairment	I-Disease	NOUN	I
by	O	ADP	O
chronic	O	ADJ	B
morphine	B-Chemical	NOUN	B
administration	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
mechanism	O	NOUN	B
responsible	O	ADJ	O
for	O	ADP	O
this	O	DET	O
effect	O	NOUN	B
.	O	PUNCT	O


Male	O	NOUN	B
rats	O	NOUN	B
were	O	AUX	O
subcutaneously	O	ADV	B
injected	O	VERB	I
with	O	ADP	O
morphine	B-Chemical	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
twice	O	DET	O
a	O	DET	O
day	O	NOUN	B
at	O	ADP	O
12	O	NUM	O
hour	O	NOUN	B
intervals	O	NOUN	B
for	O	ADP	O
10	O	NUM	O
days	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
Rg1	B-Chemical	NOUN	B
(	O	PUNCT	O
30	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
intraperitoneally	O	ADV	B
injected	O	VERB	I
2	O	NUM	O
hours	O	NOUN	O
after	O	ADP	O
the	O	DET	O
second	O	ADJ	O
injection	O	NOUN	B
of	O	ADP	O
morphine	B-Chemical	NOUN	B
once	O	ADV	O
a	O	DET	O
day	O	NOUN	B
for	O	ADP	O
10	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


Spatial	O	ADJ	B
learning	O	NOUN	I
capacity	O	NOUN	O
was	O	AUX	O
assessed	O	VERB	B
in	O	ADP	O
the	O	DET	O
Morris	O	PROPN	B
water	O	NOUN	I
maze	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
rats	O	NOUN	B
treated	O	VERB	B
with	O	ADP	O
Morphine	B-Chemical	NOUN	B
/	O	SYM	O
Rg1	B-Chemical	NOUN	B
decreased	O	VERB	B
escape	O	NOUN	B
latency	O	NOUN	I
and	O	CCONJ	O
increased	O	VERB	B
the	O	DET	O
time	O	NOUN	B
spent	O	VERB	O
in	O	ADP	O
platform	O	NOUN	B
quadrant	O	NOUN	I
and	O	CCONJ	O
entering	O	VERB	O
frequency	O	NOUN	B
.	O	PUNCT	O


By	O	ADP	O
implantation	O	NOUN	B
of	O	ADP	O
electrodes	O	NOUN	B
and	O	CCONJ	O
electrophysiological	O	ADJ	B
recording	O	NOUN	I
in	O	X	B
vivo	O	X	I
,	O	PUNCT	O
the	O	DET	O
results	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
Rg1	B-Chemical	NOUN	B
restored	O	VERB	B
the	O	DET	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
potentiation	O	NOUN	B
(	O	PUNCT	O
LTP	O	NOUN	B
)	O	PUNCT	O
impaired	O	VERB	B
by	O	ADP	O
morphine	B-Chemical	NOUN	B
in	O	ADP	O
both	O	CCONJ	O
freely	O	ADV	O
moving	O	VERB	B
and	O	CCONJ	O
anaesthetised	O	ADJ	B
rats	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
electrophysiological	O	ADJ	B
recording	O	NOUN	I
in	O	X	B
vitro	O	X	I
showed	O	VERB	O
that	O	SCONJ	O
Rg1	B-Chemical	NOUN	B
restored	O	VERB	B
the	O	DET	O
LTP	O	NOUN	B
in	O	ADP	O
slices	O	NOUN	B
from	O	ADP	O
the	O	DET	O
rats	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
morphine	B-Chemical	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
changed	O	VERB	O
LTP	O	NOUN	B
in	O	ADP	O
the	O	DET	O
slices	O	NOUN	B
from	O	ADP	O
normal	O	ADJ	O
saline	O	NOUN	B
-	O	PUNCT	O
or	O	CCONJ	O
morphine	B-Chemical	NOUN	B
/	O	SYM	O
Rg1	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
rats	O	NOUN	B
;	O	PUNCT	O
this	O	DET	O
restoration	O	NOUN	B
could	O	AUX	O
be	O	AUX	O
inhibited	O	VERB	B
by	O	ADP	O
N-methyl-D-aspartate	B-Chemical	NOUN	B
(	O	PUNCT	O
NMDA	B-Chemical	NOUN	B
)	O	PUNCT	O
receptor	O	NOUN	O
antagonist	O	NOUN	B
MK801	B-Chemical	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
Rg1	B-Chemical	NOUN	B
may	O	AUX	O
significantly	O	ADV	O
improve	O	VERB	B
the	O	DET	O
spatial	O	ADJ	B
learning	O	NOUN	I
capacity	O	NOUN	O
impaired	O	VERB	B
by	O	ADP	O
chonic	O	ADJ	B
morphine	B-Chemical	NOUN	B
administration	O	NOUN	B
and	O	CCONJ	O
restore	O	VERB	B
the	O	DET	O
morphine	B-Chemical	NOUN	B
-	O	PUNCT	O
inhibited	O	VERB	B
LTP	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
effect	O	NOUN	B
is	O	AUX	O
NMDA	B-Chemical	NOUN	B


A	O	DET	O
study	O	NOUN	B
on	O	ADP	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
the	O	DET	O
duration	O	NOUN	B
of	O	ADP	O
subcutaneous	O	ADJ	B
heparin	B-Chemical	NOUN	I
injection	O	NOUN	B
on	O	ADP	O
bruising	B-Disease	NOUN	B
and	O	CCONJ	O
pain	B-Disease	NOUN	B
.	O	PUNCT	O


AIM	O	NOUN	B
:	O	PUNCT	O
This	O	DET	O
study	O	NOUN	B
was	O	AUX	O
carried	O	VERB	O
out	O	ADP	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
injection	O	NOUN	B
duration	O	NOUN	I
on	O	ADP	O
bruising	B-Disease	NOUN	B
and	O	CCONJ	O
pain	B-Disease	NOUN	B
following	O	VERB	O
the	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
the	O	DET	O
subcutaneous	O	ADJ	B
injection	O	NOUN	I
of	O	ADP	O
heparin	B-Chemical	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Although	O	SCONJ	O
different	O	ADJ	O
methods	O	NOUN	B
to	O	PART	O
prevent	O	VERB	B
bruising	B-Disease	NOUN	B
and	O	CCONJ	O
pain	B-Disease	NOUN	B
following	O	VERB	O
the	O	DET	O
subcutaneous	O	ADJ	B
injection	O	NOUN	I
of	O	ADP	O
heparin	B-Chemical	NOUN	B
have	O	AUX	O
been	O	AUX	O
widely	O	ADV	O
studied	O	VERB	O
and	O	CCONJ	O
described	O	VERB	O
,	O	PUNCT	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
injection	O	NOUN	B
duration	O	NOUN	I
on	O	ADP	O
the	O	DET	O
occurrence	O	NOUN	B
of	O	ADP	O
bruising	B-Disease	NOUN	B
and	O	CCONJ	O
pain	B-Disease	NOUN	B
is	O	AUX	O
little	O	ADV	O
documented	O	VERB	B
.	O	PUNCT	O


DESIGN	O	NOUN	O
:	O	PUNCT	O
This	O	DET	O
study	O	NOUN	B
was	O	AUX	O
designed	O	VERB	O
as	O	ADP	O
within	O	ADP	O
-	O	PUNCT	O
subject	O	NOUN	B
,	O	PUNCT	O
quasi	O	ADV	B
-	O	PUNCT	O
experimental	O	ADJ	B
research	O	NOUN	B
.	O	PUNCT	O


METHOD	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
sample	O	NOUN	B
for	O	ADP	O
the	O	DET	O
study	O	NOUN	B
consisted	O	VERB	O
of	O	ADP	O
50	O	NUM	O
patients	O	NOUN	B
to	O	PART	O
whom	O	PRON	O
subcutaneous	O	ADJ	B
heparin	B-Chemical	NOUN	I
was	O	AUX	O
administered	O	VERB	B
.	O	PUNCT	O


Heparin	B-Chemical	NOUN	B
was	O	AUX	O
injected	O	VERB	B
over	O	ADP	O
10	O	NUM	O
seconds	O	NOUN	O
on	O	ADP	O
the	O	DET	O
right	O	ADJ	B
abdominal	O	ADJ	I
site	O	NOUN	I
and	O	CCONJ	O
30	O	NUM	O
seconds	O	NOUN	O
on	O	ADP	O
the	O	DET	O
left	O	ADJ	B
abdominal	O	ADJ	I
site	O	NOUN	I
.	O	PUNCT	O


Injections	O	NOUN	B
areas	O	NOUN	I
were	O	AUX	O
assessed	O	VERB	B
for	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
bruising	B-Disease	NOUN	B
at	O	ADP	O
48	O	NUM	O
and	O	CCONJ	O
72	O	NUM	O
hours	O	NOUN	B
after	O	ADP	O
each	O	DET	O
injection	O	NOUN	B
.	O	PUNCT	O


Dimensions	O	NOUN	B
of	O	ADP	O
the	O	DET	O
bruising	B-Disease	NOUN	B
on	O	ADP	O
the	O	DET	O
heparin	B-Chemical	NOUN	B
applied	O	ADJ	O
areas	O	NOUN	O
were	O	AUX	O
measured	O	VERB	B
using	O	VERB	O
transparent	O	ADJ	B
millimetric	O	ADJ	B
measuring	O	NOUN	O
paper	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
visual	O	ADJ	B
analog	O	NOUN	I
scale	O	NOUN	I
(	O	PUNCT	O
VAS	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
measure	O	VERB	B
pain	B-Disease	NOUN	B
intensity	O	NOUN	I
and	O	CCONJ	O
a	O	DET	O
stop	O	NOUN	B
-	O	PUNCT	O
watch	O	NOUN	B
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
time	O	VERB	O
the	O	DET	O
pain	B-Disease	NOUN	B
period	O	NOUN	O
.	O	PUNCT	O


Data	O	NOUN	B
were	O	AUX	O
analysed	O	VERB	B
using	O	VERB	O
chi	O	NOUN	B
-	O	PUNCT	O
square	O	ADJ	B
test	O	NOUN	I
,	O	PUNCT	O
Mann	O	PROPN	B
-	O	PUNCT	O
Whitney	O	PROPN	B
U	O	PROPN	I
,	O	PUNCT	O
Wilcoxon	O	PROPN	B
signed	O	VERB	I
ranks	O	NOUN	I
tests	O	NOUN	I
and	O	CCONJ	O
correlation	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
percentage	O	NOUN	B
of	O	ADP	O
bruising	B-Disease	NOUN	B
occurrence	O	NOUN	B
was	O	AUX	O
64	O	NUM	O
%	O	NOUN	O
with	O	ADP	O
the	O	DET	O
injection	O	NOUN	B
of	O	ADP	O
10	O	NUM	O
seconds	O	NOUN	O
duration	O	NOUN	B
and	O	CCONJ	O
42	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
30	O	NUM	O
-	O	PUNCT	O
second	O	ADJ	B
injection	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
was	O	AUX	O
determined	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
size	O	NOUN	B
of	O	ADP	O
the	O	DET	O
bruising	B-Disease	NOUN	B
was	O	AUX	O
smaller	O	ADJ	O
in	O	ADP	O
the	O	DET	O
30	O	NUM	O
-	O	PUNCT	O
second	O	ADJ	B
injection	O	NOUN	B
.	O	PUNCT	O


Pain	B-Disease	NOUN	B
intensity	O	NOUN	I
and	O	CCONJ	O
pain	B-Disease	NOUN	B
period	O	NOUN	I
were	O	AUX	O
statistically	O	ADV	O
significantly	O	ADV	O
lower	O	ADJ	O
for	O	ADP	O
the	O	DET	O
30	O	NUM	O
-	O	PUNCT	O
second	O	ADJ	B
injection	O	NOUN	B
than	O	ADP	O
for	O	ADP	O
the	O	DET	O
10	O	NUM	O
-	O	PUNCT	O
second	O	ADJ	B
injection	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
It	O	PRON	O
was	O	AUX	O
determined	O	VERB	O
that	O	SCONJ	O
injection	O	NOUN	B
duration	O	NOUN	I
had	O	AUX	O
an	O	DET	O
effect	O	NOUN	B
on	O	ADP	O
bruising	B-Disease	NOUN	B
and	O	CCONJ	O
pain	B-Disease	NOUN	B
following	O	VERB	O
the	O	DET	O
subcutaneous	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
heparin	B-Chemical	NOUN	B
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
repeated	O	VERB	O
on	O	ADP	O
a	O	DET	O
larger	O	ADJ	O
sample	O	NOUN	B
.	O	PUNCT	O


RELEVANCE	O	NOUN	B
TO	O	ADP	O
CLINICAL	O	PROPN	O
PRACTICE	O	NOUN	O
:	O	PUNCT	O
When	O	SCONJ	O
administering	O	VERB	B
subcutaneous	O	ADJ	B
heparin	B-Chemical	NOUN	I


Acute	O	ADJ	B
reserpine	B-Chemical	NOUN	B
and	O	CCONJ	O
subchronic	O	ADJ	B
haloperidol	B-Chemical	NOUN	B
treatments	O	NOUN	B
change	O	VERB	O
synaptosomal	O	ADJ	B
brain	O	NOUN	B
glutamate	B-Chemical	NOUN	B
uptake	O	NOUN	B
and	O	CCONJ	O
elicit	O	VERB	O
orofacial	B-Disease	ADJ	B
dyskinesia	I-Disease	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


Reserpine	B-Chemical	NOUN	B
-	O	PUNCT	O
and	O	CCONJ	O
haloperidol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
orofacial	B-Disease	ADJ	B
dyskinesia	I-Disease	NOUN	I
are	O	AUX	O
putative	O	ADJ	O
animal	O	NOUN	B
models	O	NOUN	I
of	O	ADP	O
tardive	B-Disease	ADJ	B
dyskinesia	I-Disease	NOUN	I
(	O	PUNCT	O
TD	B-Disease	NOUN	B
)	O	PUNCT	O
whose	O	DET	O
pathophysiology	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
related	O	ADJ	O
to	O	PART	O
free	O	ADJ	B
radical	O	ADJ	I
generation	O	NOUN	I
and	O	CCONJ	O
oxidative	O	ADJ	B
stress	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
authors	O	NOUN	B
induced	O	VERB	B
orofacial	B-Disease	ADJ	B
dyskinesia	I-Disease	NOUN	I
by	O	ADP	O
acute	O	ADJ	B
reserpine	B-Chemical	NOUN	B
and	O	CCONJ	O
subchronic	O	ADJ	B
haloperidol	B-Chemical	NOUN	B
administration	O	NOUN	B
to	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


Reserpine	B-Chemical	NOUN	B
injection	O	NOUN	B
(	O	PUNCT	O
one	O	NUM	O
dose	O	NOUN	B
of	O	ADP	O
1	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
s	O	NOUN	O
.	O	PUNCT	O


c	O	X	O
.)	O	NOUN	O
every	O	DET	O
other	O	ADJ	O
day	O	NOUN	B
for	O	ADP	O
3	O	NUM	O
days	O	NOUN	B
caused	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
vacuous	O	ADJ	B
chewing	O	NOUN	I
,	O	PUNCT	O
tongue	O	NOUN	B
protrusion	O	NOUN	I
and	O	CCONJ	O
duration	O	NOUN	B
of	O	ADP	O
facial	O	ADJ	B
twitching	O	NOUN	I
,	O	PUNCT	O
compared	O	VERB	B
to	O	PART	O
the	O	DET	O
control	O	NOUN	B
.	O	PUNCT	O


Haloperidol	B-Chemical	NOUN	B
administration	O	NOUN	B
(	O	PUNCT	O
one	O	NUM	O
dose	O	NOUN	B
of	O	ADP	O
12	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
kg	O	NOUN	B
once	O	ADV	O
a	O	DET	O
week	O	NOUN	B
s	O	NOUN	O
.	O	PUNCT	O


c	O	X	O
.)	O	NOUN	O
for	O	ADP	O
4	O	NUM	O
weeks	O	NOUN	B
caused	O	VERB	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
vacuous	O	ADJ	B
chewing	O	NOUN	I
,	O	PUNCT	O
tongue	O	NOUN	B
protrusion	O	NOUN	I
and	O	CCONJ	O
duration	O	NOUN	B
of	O	ADP	O
facial	O	ADJ	B
twitching	O	NOUN	I
observed	O	VERB	B
in	O	ADP	O
four	O	NUM	O
weekly	O	ADJ	B
evaluations	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
the	O	DET	O
treatments	O	NOUN	B
and	O	CCONJ	O
behavioral	O	ADJ	B
observation	O	NOUN	B
,	O	PUNCT	O
glutamate	B-Chemical	NOUN	B
uptake	O	NOUN	B
by	O	ADP	O
segments	O	NOUN	B
of	O	ADP	O
the	O	DET	O
brain	O	NOUN	B
was	O	AUX	O
analyzed	O	VERB	B
.	O	PUNCT	O


A	O	DET	O
decreased	O	VERB	B
glutamate	B-Chemical	NOUN	B
uptake	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
the	O	DET	O
subcortical	O	ADJ	B
parts	O	NOUN	I
of	O	ADP	O
animals	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
reserpine	B-Chemical	NOUN	B
and	O	CCONJ	O
haloperidol	B-Chemical	NOUN	B
,	O	PUNCT	O
compared	O	VERB	O
to	O	PART	O
the	O	DET	O
control	O	NOUN	B
.	O	PUNCT	O


Importantly	O	ADV	O
,	O	PUNCT	O
a	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
glutamate	B-Chemical	NOUN	B
uptake	O	NOUN	B
correlates	O	VERB	B
negatively	O	ADV	O
with	O	ADP	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
orofacial	B-Disease	ADJ	B
diskinesia	I-Disease	NOUN	I
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
early	O	ADJ	O
changes	O	NOUN	B
in	O	ADP	O
glutamate	B-Chemical	NOUN	B


Acute	B-Disease	ADJ	B
psychosis	I-Disease	NOUN	I
due	O	ADP	O
to	O	PART	O
treatment	O	NOUN	B
with	O	ADP	O
phenytoin	B-Chemical	NOUN	B
in	O	ADP	O
a	O	DET	O
nonepileptic	O	ADJ	B
patient	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
development	O	NOUN	B
of	O	ADP	O
psychosis	B-Disease	NOUN	B
related	O	ADJ	O
to	O	PART	O
antiepileptic	O	ADJ	B
drug	O	NOUN	I
treatment	O	NOUN	O
is	O	AUX	O
usually	O	ADV	O
attributed	O	VERB	O
to	O	PART	O
the	O	DET	O
interaction	O	NOUN	B
between	O	ADP	O
the	O	DET	O
epileptic	B-Disease	ADJ	B
brain	O	NOUN	I
substratum	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
antiepileptic	O	ADJ	B
drugs	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
case	O	NOUN	B
of	O	ADP	O
a	O	DET	O
nonepileptic	O	ADJ	B
patient	O	NOUN	I
who	O	PRON	O
developed	O	VERB	O
psychosis	B-Disease	NOUN	B
following	O	VERB	O
phenytoin	B-Chemical	NOUN	B
treatment	O	NOUN	B
for	O	ADP	O
trigeminal	B-Disease	ADJ	B
neuralgia	I-Disease	NOUN	I
is	O	AUX	O
described	O	VERB	O
.	O	PUNCT	O


This	O	DET	O
case	O	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
psychotic	B-Disease	ADJ	B
symptoms	I-Disease	NOUN	O
that	O	PRON	O
occur	O	VERB	O
following	O	VERB	O
phenytoin	B-Chemical	NOUN	B
treatment	O	NOUN	B
in	O	ADP	O
some	O	DET	O
epileptic	B-Disease	ADJ	B
patients	O	NOUN	I
may	O	AUX	O
be	O	AUX	O
the	O	DET	O
direct	O	ADJ	O
result	O	NOUN	O
of	O	ADP	O
medication	O	NOUN	B
,	O	PUNCT	O
unrelated	O	ADJ	O
to	O	ADP	O
seizures	B-Disease	NOUN	B


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
gum	B-Chemical	NOUN	B
Arabic	I-Chemical	ADJ	I
on	O	ADP	O
gentamicin	B-Chemical	NOUN	B
nephrotoxicity	B-Disease	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
:	O	PUNCT	O
a	O	DET	O
preliminary	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
present	O	ADJ	O
work	O	NOUN	O
we	O	PRON	O
assessed	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
of	O	ADP	O
rats	O	NOUN	B
with	O	ADP	O
gum	B-Chemical	NOUN	B
Arabic	I-Chemical	ADJ	I
on	O	ADP	O
acute	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
failure	I-Disease	NOUN	I
induced	O	VERB	B
by	O	ADP	O
gentamicin	B-Chemical	NOUN	B
(	O	PUNCT	O
GM	B-Chemical	NOUN	B
)	O	PUNCT	O
nephrotoxicity	B-Disease	NOUN	B
.	O	PUNCT	O


Rats	O	NOUN	B
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
the	O	DET	O
vehicle	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
mL	O	NOUN	O
/	O	PUNCT	O
kg	O	NOUN	B
of	O	ADP	O
distilled	O	ADJ	B
water	O	NOUN	I
and	O	CCONJ	O
5	O	NUM	O
%	O	NOUN	O
w	O	NOUN	O
/	O	SYM	O
v	O	DET	O
cellulose	O	NOUN	B
,	O	PUNCT	O
10	O	NUM	O
days	O	NOUN	B
),	O	PUNCT	O
gum	B-Chemical	NOUN	B
Arabic	I-Chemical	ADJ	I
(	O	PUNCT	O
2	O	NUM	O
mL	O	NOUN	O
/	O	PUNCT	O
kg	O	NOUN	O
of	O	ADP	O
a	O	DET	O
10	O	NUM	O
%	O	NOUN	O
w	O	NOUN	O
/	O	SYM	O
v	O	NOUN	O
aqueous	O	ADJ	B
suspension	O	NOUN	B
of	O	ADP	O
gum	B-Chemical	NOUN	B
Arabic	I-Chemical	ADJ	I
powder	O	NOUN	I
,	O	PUNCT	O
orally	O	ADV	B
for	O	ADP	O
10	O	NUM	O
days	O	NOUN	B
),	O	PUNCT	O
or	O	CCONJ	O
gum	B-Chemical	NOUN	B
Arabic	I-Chemical	ADJ	I
concomitantly	O	ADV	O
with	O	ADP	O
GM	B-Chemical	PROPN	B
(	O	PUNCT	O
80mg	O	NOUN	B
/	O	SYM	O
kg	O	NOUN	B
/	O	SYM	O
day	O	NOUN	B
intramuscularly	O	ADV	B
,	O	PUNCT	O
during	O	ADP	O
the	O	DET	O
last	O	ADJ	O
six	O	NUM	O
days	O	NOUN	B
of	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
period	O	NOUN	O
).	O	PUNCT	B
Nephrotoxicity	B-Disease	NOUN	B
was	O	AUX	O
assessed	O	VERB	B
by	O	ADP	O
measuring	O	VERB	B
the	O	DET	O
concentrations	O	NOUN	B
of	O	ADP	O
creatinine	B-Chemical	NOUN	B
and	O	CCONJ	O
urea	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
plasma	O	NOUN	B
and	O	CCONJ	O
reduced	O	VERB	B
glutathione	B-Chemical	NOUN	O
(	O	PUNCT	O
GSH	B-Chemical	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
kidney	O	NOUN	B
cortex	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
by	O	ADP	O
light	O	ADJ	O
microscopic	O	ADJ	O
examination	O	NOUN	B
of	O	ADP	O
kidney	O	NOUN	B
sections	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
indicated	O	VERB	O
that	O	SCONJ	O
concomitant	O	ADJ	B
treatment	O	NOUN	B
with	O	ADP	O
gum	B-Chemical	NOUN	B
Arabic	I-Chemical	ADJ	I
and	O	CCONJ	O
GM	B-Chemical	PROPN	B
significantly	O	ADV	O
increased	O	VERB	B
creatinine	B-Chemical	NOUN	B
and	O	CCONJ	O
urea	B-Chemical	NOUN	B
by	O	ADP	O
about	O	ADV	O
183	O	NUM	O
and	O	CCONJ	O
239	O	NUM	O
%,	O	ADJ	B
respectively	O	ADV	O
(	O	PUNCT	O
compared	O	VERB	O
to	O	ADP	O
432	O	NUM	O
and	O	CCONJ	O
346	O	NUM	O
%,	O	NOUN	O
respectively	O	ADV	O
,	O	PUNCT	O
in	O	ADP	O
rats	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
cellulose	O	NOUN	B
and	O	CCONJ	O
GM	B-Chemical	PROPN	B
),	O	PUNCT	O
and	O	CCONJ	O
decreased	O	VERB	B
that	O	DET	O
of	O	ADP	O
cortical	O	ADJ	B
GSH	B-Chemical	NOUN	B
by	O	ADP	O
21	O	NUM	O
%(	O	NOUN	O
compared	O	VERB	B
to	O	ADP	O
27	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
cellulose	O	NOUN	B
plus	O	CCONJ	O
GM	B-Chemical	PROPN	B
group	O	NOUN	B
)	O	PUNCT	O
The	O	DET	O
GM	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
proximal	O	ADJ	B
tubular	B-Disease	ADJ	B
necrosis	I-Disease	NOUN	I
appeared	O	VERB	O
to	O	PART	O
be	O	AUX	O
slightly	O	ADV	O
less	O	ADV	O
severe	O	ADJ	B
in	O	ADP	O
rats	O	NOUN	B
given	O	VERB	O
GM	B-Chemical	PROPN	B
together	O	ADV	O
with	O	ADP	O
gum	B-Chemical	NOUN	B
Arabic	I-Chemical	ADJ	I
than	O	ADP	O
in	O	ADP	O
those	O	DET	O
given	O	VERB	O
GM	B-Chemical	PROPN	B
and	O	CCONJ	O
cellulose	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
could	O	AUX	O
be	O	AUX	O
inferred	O	VERB	O
that	O	DET	O
gum	B-Chemical	NOUN	B
Arabic	I-Chemical	ADJ	I
treatment	O	NOUN	B
has	O	AUX	O
induced	O	VERB	B
a	O	DET	O
modest	O	ADJ	O
amelioration	O	NOUN	B
of	O	ADP	O
some	O	DET	O
of	O	ADP	O
the	O	DET	O
histological	O	ADJ	B
and	O	CCONJ	O
biochemical	O	ADJ	B
indices	O	NOUN	I
of	O	ADP	O
GM	B-Chemical	NOUN	B
nephrotoxicity	B-Disease	NOUN	B
.	O	PUNCT	O


Further	O	ADJ	O
work	O	NOUN	O
is	O	AUX	O
warranted	O	VERB	O
on	O	ADP	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
the	O	DET	O
treatments	O	NOUN	B
on	O	ADP	O
renal	O	ADJ	B
functional	O	ADJ	I
aspects	O	NOUN	I
in	O	ADP	O
models	O	NOUN	B
of	O	ADP	O
chronic	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
failure	I-Disease	NOUN	I


Visual	B-Disease	ADJ	B
hallucinations	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
zonisamide	B-Chemical	NOUN	B
.	O	PUNCT	O


Zonisamide	B-Chemical	NOUN	B
is	O	AUX	O
a	O	DET	O
broad	O	ADJ	B
-	O	PUNCT	O
spectrum	O	NOUN	B
antiepileptic	O	ADJ	B
drug	O	NOUN	I
used	O	VERB	O
to	O	PART	O
treat	O	VERB	B
various	O	ADJ	O
types	O	NOUN	O
of	O	ADP	O
seizures	B-Disease	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
visual	B-Disease	ADJ	B
hallucinations	I-Disease	NOUN	I
have	O	AUX	O
not	O	PART	O
been	O	AUX	O
reported	O	VERB	O
as	O	ADP	O
an	O	DET	O
adverse	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
this	O	DET	O
agent	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
describe	O	VERB	O
three	O	NUM	O
patients	O	NOUN	B
who	O	PRON	O
experienced	O	VERB	O
complex	O	ADJ	B
visual	B-Disease	ADJ	B
hallucinations	I-Disease	NOUN	I
and	O	CCONJ	O
altered	O	ADJ	O
mental	O	ADJ	B
status	O	NOUN	I
after	O	ADP	O
zonisamide	B-Chemical	NOUN	B
treatment	O	NOUN	B
was	O	AUX	O
begun	O	VERB	O
or	O	CCONJ	O
its	O	PRON	O
dosage	O	NOUN	B
increased	O	VERB	B
.	O	PUNCT	O


All	O	DET	O
three	O	NUM	O
had	O	AUX	O
been	O	AUX	O
diagnosed	O	VERB	B
earlier	O	ADV	O
with	O	ADP	O
epilepsy	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
their	O	PRON	O
electroencephalogram	O	NOUN	B
(	O	PUNCT	O
EEG	O	NOUN	B
)	O	PUNCT	O
findings	O	NOUN	B
were	O	AUX	O
abnormal	O	ADJ	B
.	O	PUNCT	O


During	O	ADP	O
monitoring	O	NOUN	B
,	O	PUNCT	O
visual	B-Disease	ADJ	B
hallucinations	I-Disease	NOUN	I
did	O	AUX	O
not	O	PART	O
correlate	O	VERB	O
with	O	ADP	O
EEG	O	NOUN	B
readings	O	NOUN	B
,	O	PUNCT	O
nor	O	CCONJ	O
did	O	AUX	O
video	O	NOUN	B
recording	O	NOUN	O
capture	O	VERB	O
any	O	DET	O
of	O	ADP	O
the	O	DET	O
described	O	VERB	O
events	O	NOUN	B
.	O	PUNCT	O


of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
had	O	AUX	O
experienced	O	VERB	O
visual	B-Disease	ADJ	B
hallucinations	I-Disease	NOUN	I
before	O	ADP	O
this	O	DET	O
event	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
only	O	ADJ	O
recent	O	ADJ	O
change	O	NOUN	O
in	O	ADP	O
their	O	PRON	O
treatment	O	NOUN	B
was	O	AUX	O
the	O	DET	O
introduction	O	NOUN	B
or	O	CCONJ	O
increased	O	VERB	B
dosage	O	NOUN	B
of	O	ADP	O
zonisamide	B-Chemical	NOUN	B
.	O	PUNCT	O


With	O	ADP	O
either	O	CCONJ	O
discontinuation	O	NOUN	B
or	O	CCONJ	O
decreased	O	VERB	B
dosage	O	NOUN	B
of	O	ADP	O
the	O	DET	O
drug	O	NOUN	B
the	O	DET	O
symptoms	O	NOUN	B
disappeared	O	VERB	O
and	O	CCONJ	O
did	O	AUX	O
not	O	PART	O
recur	O	VERB	O
.	O	PUNCT	O


Further	O	ADJ	O
observations	O	NOUN	B
and	O	CCONJ	O
reports	O	NOUN	B
will	O	AUX	O
help	O	VERB	O
clarify	O	VERB	O
this	O	DET	O
adverse	O	ADJ	B
effect	O	NOUN	I
.	O	PUNCT	O


Until	O	ADP	O
then	O	ADV	O
,	O	PUNCT	O
clinicians	O	NOUN	B
need	O	VERB	O
to	O	PART	O
be	O	AUX	O
aware	O	ADJ	O
of	O	ADP	O
this	O	DET	O
possible	O	ADJ	O
complication	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
zonisamide	B-Chemical	NOUN	B


GLEPP1	O	NOUN	B
receptor	O	NOUN	I
tyrosine	B-Chemical	NOUN	I
phosphatase	O	NOUN	I
(	O	PUNCT	O
Ptpro	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
rat	O	NOUN	B
PAN	B-Chemical	NOUN	B
nephrosis	B-Disease	NOUN	B
.	O	PUNCT	O


A	O	DET	O
marker	O	NOUN	B
of	O	ADP	O
acute	O	ADJ	B
podocyte	O	NOUN	O
injury	O	NOUN	O
.	O	PUNCT	O


Glomerular	O	ADJ	B
epithelial	O	ADJ	I
protein	O	NOUN	I
1	O	NUM	I
(	O	PUNCT	O
GLEPP1	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
podocyte	O	NOUN	B
receptor	O	NOUN	I
membrane	O	NOUN	I
protein	O	NOUN	I
tyrosine	B-Chemical	NOUN	I
phosphatase	O	NOUN	I
located	O	ADJ	O
on	O	ADP	O
the	O	DET	O
apical	O	ADJ	B
cell	O	NOUN	I
membrane	O	NOUN	I
of	O	ADP	O
visceral	O	ADJ	B
glomerular	O	ADJ	I
epithelial	O	ADJ	I
cell	O	NOUN	I
and	O	CCONJ	O
foot	O	NOUN	B
processes	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
receptor	O	NOUN	B
plays	O	VERB	O
a	O	DET	O
role	O	NOUN	O
in	O	ADP	O
regulating	O	VERB	B
the	O	DET	O
structure	O	NOUN	B
and	O	CCONJ	O
function	O	NOUN	B
of	O	ADP	O
podocyte	O	NOUN	B
foot	O	NOUN	B
process	O	NOUN	I
.	O	PUNCT	O


To	O	PART	O
better	O	ADV	O
understand	O	VERB	O
the	O	DET	O
utility	O	NOUN	O
of	O	ADP	O
GLEPP1	O	NOUN	B
as	O	ADP	O
a	O	DET	O
marker	O	NOUN	B
of	O	ADP	O
glomerular	B-Disease	ADJ	B
injury	I-Disease	NOUN	I
,	O	PUNCT	O
the	O	DET	O
amount	O	NOUN	B
and	O	CCONJ	O
distribution	O	NOUN	B
of	O	ADP	O
GLEPP1	O	NOUN	B
protein	O	NOUN	I
and	O	CCONJ	O
mRNA	O	NOUN	B
were	O	AUX	O
examined	O	VERB	O
by	O	ADP	O
immunohistochemistry	O	NOUN	B
,	O	PUNCT	O
Western	O	NOUN	B
blot	O	NOUN	I
and	O	CCONJ	O
RNase	O	NOUN	B
protection	O	NOUN	B
assay	O	NOUN	O
in	O	ADP	O
a	O	DET	O
model	O	NOUN	B
of	O	ADP	O
podocyte	O	NOUN	B
injury	O	NOUN	B
in	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
.	O	PUNCT	O


Puromycin	B-Chemical	NOUN	B
aminonucleoside	I-Chemical	NOUN	B
nephrosis	B-Disease	NOUN	I
was	O	AUX	O
induced	O	VERB	B
by	O	ADP	O
single	O	ADJ	O
intraperitoneal	O	ADJ	B
injection	O	NOUN	B
of	O	ADP	O
puromycin	B-Chemical	NOUN	B
aminonucleoside	I-Chemical	NOUN	B
(	O	PUNCT	O
PAN	B-Chemical	NOUN	B
,	O	PUNCT	O
20	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
100g	O	NOUN	B
BW	O	NOUN	I
).	O	PUNCT	O
Tissues	O	PROPN	B
were	O	AUX	O
analyzed	O	VERB	B
at	O	ADP	O
0	O	NUM	O
,	O	PUNCT	O
5	O	NUM	O
,	O	PUNCT	O
7	O	NUM	O
,	O	PUNCT	O
11	O	NUM	O
,	O	PUNCT	O
21	O	NUM	O
,	O	PUNCT	O
45	O	NUM	O
,	O	PUNCT	O
80	O	NUM	O
and	O	CCONJ	O
126	O	NUM	O
days	O	NOUN	B
after	O	ADP	O
PAN	B-Chemical	NOUN	B
injection	O	NOUN	B
so	O	SCONJ	O
as	O	ADP	O
to	O	PART	O
include	O	VERB	O
both	O	CCONJ	O
the	O	DET	O
acute	O	ADJ	B
phase	O	NOUN	O
of	O	ADP	O
proteinuria	B-Disease	NOUN	B
associated	O	VERB	B
with	O	ADP	I
foot	O	NOUN	B
process	O	NOUN	I
effacement	O	NOUN	I
(	O	PUNCT	O
days	O	NOUN	B
5	O	NUM	O
-	O	SYM	O
11	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
chronic	O	ADJ	B
phase	O	NOUN	I
of	O	ADP	O
proteinuria	B-Disease	NOUN	B
associated	O	VERB	B
with	O	ADP	I
glomerulosclerosis	B-Disease	NOUN	B
(	O	PUNCT	O
days	O	NOUN	B
45	O	NUM	O
-	O	SYM	O
126	O	NUM	O
).	O	PUNCT	O
At	O	ADP	O
day	O	NOUN	B
5	O	NUM	O
,	O	PUNCT	O
GLEPP1	O	NOUN	B
protein	O	NOUN	I
and	O	CCONJ	O
mRNA	O	NOUN	B
were	O	AUX	O
reduced	O	VERB	B
from	O	ADP	O
the	O	DET	O
normal	O	ADJ	B
range	O	NOUN	I
(	O	PUNCT	O
265	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
+/-	O	CCONJ	O
79	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
x	O	NOUN	O
10	O	NUM	O
(	O	PUNCT	O
6	O	NUM	O
)	O	PUNCT	O
moles	O	NOUN	B
/	O	PUNCT	O
glomerulus	O	NOUN	B
and	O	CCONJ	O
100	O	NUM	O
%)	O	NOUN	O
to	O	PART	O
15	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
normal	O	ADJ	B
(	O	PUNCT	O
41	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
+/-	O	CCONJ	O
4	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
x	O	CCONJ	O
10	O	NUM	O
(	O	PUNCT	O
6	O	NUM	O
)	O	PUNCT	O
moles	O	NOUN	B
/	O	PUNCT	O
glomerulus	O	NOUN	B
,	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


005	O	NUM	O
).	O	PUNCT	O
This	O	DET	O
occurred	O	VERB	O
in	O	ADP	O
association	O	NOUN	B
with	O	ADP	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
urinary	O	ADJ	B
protein	O	NOUN	I
content	O	NOUN	B
from	O	ADP	O
1	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
+/-	O	CCONJ	O
1	O	NUM	O
to	O	PART	O
99	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
+/-	O	CCONJ	O
61	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
day	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
).	O	PUNCT	O
In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
podocalyxin	O	NOUN	B
did	O	AUX	O
not	O	PART	O
change	O	VERB	O
significantly	O	ADV	O
at	O	ADP	O
this	O	DET	O
time	O	NOUN	B
.	O	PUNCT	O


By	O	ADP	O
day	O	NOUN	B
11	O	NUM	O
,	O	PUNCT	O
GLEPP1	O	NOUN	B
protein	O	NOUN	I
and	O	CCONJ	O
mRNA	O	NOUN	B
had	O	AUX	O
begun	O	VERB	O
to	O	PART	O
return	O	VERB	O
towards	O	ADP	O
baseline	O	NOUN	B
.	O	PUNCT	O


By	O	ADP	O
day	O	NOUN	B
45	O	NUM	O
-	O	SYM	O
126	O	NUM	O
,	O	PUNCT	O
at	O	ADP	O
a	O	DET	O
time	O	NOUN	O
when	O	SCONJ	O
glomerular	O	ADJ	B
scarring	O	NOUN	I
was	O	AUX	O
present	O	ADJ	O
,	O	PUNCT	O
GLEPP1	O	NOUN	B
was	O	AUX	O
absent	O	ADJ	B
from	O	ADP	O
glomerulosclerotic	O	ADJ	B
areas	O	NOUN	I
although	O	SCONJ	O
the	O	DET	O
total	O	ADJ	O
glomerular	O	ADJ	O
content	O	NOUN	B
of	O	ADP	O
GLEPP1	O	NOUN	B
was	O	AUX	O
not	O	PART	O
different	O	ADJ	O
from	O	ADP	O
normal	O	ADJ	B
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
GLEPP1	O	NOUN	B
expression	O	NOUN	B
,	O	PUNCT	O
unlike	O	ADP	O
podocalyxin	O	NOUN	B
,	O	PUNCT	O
reflects	O	VERB	O
podocyte	O	NOUN	B
injury	O	NOUN	B
induced	O	VERB	B
by	O	ADP	O
PAN	B-Chemical	NOUN	B


Ticlopidine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
aplastic	B-Disease	ADJ	B
anemia	I-Disease	NOUN	I
:	O	PUNCT	O
report	O	NOUN	B
of	O	ADP	O
three	O	NUM	O
Chinese	O	ADJ	B
patients	O	NOUN	B
and	O	CCONJ	O
review	O	NOUN	B
of	O	ADP	O
the	O	DET	O
literature	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
three	O	NUM	O
Chinese	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
ticlopidine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
aplastic	B-Disease	ADJ	B
anemia	I-Disease	NOUN	I
were	O	AUX	O
reported	O	VERB	O
and	O	CCONJ	O
another	O	DET	O
13	O	NUM	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
English	O	ADJ	B
literature	O	NOUN	I
were	O	AUX	O
reviewed	O	VERB	B
.	O	PUNCT	O


We	O	PRON	O
attempted	O	VERB	O
to	O	PART	O
find	O	VERB	O
underlying	O	ADJ	O
similarities	O	NOUN	B
,	O	PUNCT	O
evaluate	O	VERB	B
the	O	DET	O
risk	O	NOUN	B
factors	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
identify	O	VERB	O
appropriate	O	ADJ	B
treatment	O	NOUN	B
for	O	ADP	O
this	O	DET	O
complication	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
but	O	CCONJ	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
over	O	ADP	O
60	O	NUM	O
years	O	NOUN	B
old	O	ADJ	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
6	O	NUM	O
who	O	PRON	O
died	O	VERB	B
were	O	AUX	O
all	O	ADV	O
older	O	ADJ	B
than	O	ADP	O
65	O	NUM	O
.	O	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
old	O	ADJ	B
age	O	NOUN	I
may	O	AUX	O
be	O	AUX	O
a	O	DET	O
risk	O	NOUN	B
factor	O	NOUN	I
for	O	ADP	O
developing	O	VERB	O
this	O	DET	O
complication	O	NOUN	B
.	O	PUNCT	O


Agranulocytosis	B-Disease	NOUN	B
occurred	O	VERB	O
3	O	NUM	O
-	O	SYM	O
20	O	NUM	O
weeks	O	NOUN	B
after	O	ADP	O
initiation	O	NOUN	B
of	O	ADP	O
ticlopidine	B-Chemical	NOUN	B
,	O	PUNCT	O
so	O	ADV	O
frequent	O	ADJ	B
examination	O	NOUN	B
of	O	ADP	O
white	O	ADJ	B
cell	O	NOUN	I
count	O	NOUN	O
during	O	ADP	O
treatment	O	NOUN	B
is	O	AUX	O
recommended	O	VERB	B
.	O	PUNCT	O


There	O	PRON	O
seemed	O	VERB	O
to	O	PART	O
be	O	AUX	O
no	O	DET	O
direct	O	ADJ	O
correlation	O	NOUN	B
between	O	ADP	O
the	O	DET	O
dose	O	NOUN	B
or	O	CCONJ	O
duration	O	NOUN	B
used	O	VERB	O
and	O	CCONJ	O
the	O	DET	O
severity	O	NOUN	B
of	O	ADP	O
bone	B-Disease	NOUN	B
marrow	I-Disease	NOUN	I
suppression	I-Disease	NOUN	B
.	O	PUNCT	O


Treatment	O	NOUN	B
for	O	ADP	O
ticlopidine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
aplastic	B-Disease	ADJ	B
anemia	I-Disease	NOUN	I
with	O	ADP	O
colony	O	NOUN	B
-	O	PUNCT	O
stimulating	O	VERB	B
factors	O	NOUN	B
seemed	O	VERB	O
to	O	PART	O
have	O	AUX	O
little	O	ADJ	O
effect	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
fact	O	NOUN	O
that	O	SCONJ	O
5	O	NUM	O
of	O	ADP	O
the	O	DET	O
6	O	NUM	O
patients	O	NOUN	B
who	O	PRON	O
received	O	VERB	O
concurrent	O	ADJ	B
calcium	B-Chemical	NOUN	B


Facilitation	O	NOUN	B
of	O	ADP	O
memory	O	NOUN	B
retrieval	O	NOUN	I
by	O	ADP	O
pre	O	ADJ	B
-	O	PUNCT	O
test	O	NOUN	B
morphine	B-Chemical	NOUN	B
and	O	CCONJ	O
its	O	PRON	O
state	O	NOUN	B
dependency	O	NOUN	I
in	O	ADP	O
the	O	DET	O
step	O	NOUN	B
-	O	PUNCT	O
through	O	ADP	B
type	O	NOUN	O
passive	O	ADJ	O
avoidance	O	NOUN	O
learning	O	NOUN	O
test	O	NOUN	O
in	O	ADP	O
mice	O	NOUN	B
.	O	PUNCT	O


Amnesia	B-Disease	NOUN	B
produced	O	VERB	O
by	O	ADP	O
scopolamine	B-Chemical	NOUN	B
and	O	CCONJ	O
cycloheximide	B-Chemical	NOUN	B
were	O	AUX	O
reversed	O	VERB	O
by	O	ADP	O
morphine	B-Chemical	NOUN	B
given	O	VERB	O
30	O	NUM	O
min	O	NOUN	O
before	O	ADP	O
the	O	DET	O
test	O	NOUN	B
trial	O	NOUN	I
(	O	PUNCT	O
pre	O	ADJ	B
-	O	PUNCT	O
test	O	NOUN	B
),	O	PUNCT	O
and	O	CCONJ	O
pre	O	ADJ	B
-	O	PUNCT	O
test	O	NOUN	B
morphine	B-Chemical	NOUN	B
also	O	ADV	O
facilitated	O	VERB	O
the	O	DET	O
memory	O	NOUN	B
retrieval	O	NOUN	B
in	O	ADP	O
the	O	DET	O
animals	O	NOUN	B
administered	O	VERB	B
naloxone	B-Chemical	NOUN	B
during	O	ADP	O
the	O	DET	O
training	O	NOUN	B
trial	O	NOUN	I
.	O	PUNCT	O


Similarly	O	ADV	O
,	O	PUNCT	O
pre	O	ADJ	B
-	O	PUNCT	O
test	O	NOUN	B
scopolamine	B-Chemical	NOUN	B
partially	O	ADV	O
reversed	O	VERB	O
the	O	DET	O
scopolamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
amnesia	B-Disease	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
significantly	O	ADV	O
;	O	PUNCT	O
and	O	CCONJ	O
pre	O	ADJ	B
-	O	PUNCT	O
test	O	NOUN	B
cycloheximide	B-Chemical	NOUN	B
failed	O	VERB	B
to	O	PART	O
reverse	O	VERB	B
the	O	DET	O
cycloheximide	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
amnesia	B-Disease	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
facilitation	O	NOUN	B
of	O	ADP	O
memory	O	NOUN	B
retrieval	O	NOUN	I
by	O	ADP	O
pre	O	ADJ	B
-	O	PUNCT	O
test	O	NOUN	B
morphine	B-Chemical	NOUN	B
might	O	AUX	O
be	O	AUX	O
the	O	DET	O
direct	O	ADJ	O
action	O	NOUN	B
of	O	ADP	O
morphine	B-Chemical	NOUN	B


Test	O	NOUN	B
conditions	O	NOUN	I
influence	O	VERB	B
the	O	DET	O
response	O	NOUN	B
to	O	PART	O
a	O	DET	O
drug	O	NOUN	B
challenge	O	NOUN	I
in	O	ADP	O
rodents	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
studies	O	NOUN	B
were	O	AUX	O
conducted	O	VERB	O
to	O	PART	O
examine	O	VERB	O
the	O	DET	O
differential	O	ADJ	B
response	O	NOUN	I
to	O	PART	O
a	O	DET	O
drug	O	NOUN	B
challenge	O	NOUN	O
under	O	ADP	O
varied	O	ADJ	O
experimental	O	ADJ	B
test	O	NOUN	I
conditions	O	NOUN	O
routinely	O	ADV	O
employed	O	VERB	O
to	O	PART	O
study	O	VERB	B
drug	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
behavioral	O	ADJ	B
and	O	CCONJ	O
neurophysiological	O	ADJ	B
responses	O	NOUN	I
in	O	ADP	O
rodents	O	NOUN	B
.	O	PUNCT	O


Apomorphine	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
nonselective	O	ADJ	B
dopamine	B-Chemical	NOUN	B
agonist	I-Chemical	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
selected	O	VERB	O
due	O	ADJ	O
to	O	PART	O
its	O	PRON	O
biphasic	O	ADJ	B
behavioral	O	ADJ	B
effects	O	NOUN	O
,	O	PUNCT	O
its	O	PRON	O
ability	O	NOUN	O
to	O	PART	O
induce	O	VERB	B
hypothermia	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
to	O	PART	O
produce	O	VERB	O
distinct	O	ADJ	O
changes	O	NOUN	B
to	O	PART	O
dopamine	B-Chemical	NOUN	B
turnover	O	NOUN	B
in	O	ADP	O
the	O	DET	O
rodent	O	ADJ	B
brain	O	NOUN	B
.	O	PUNCT	O


From	O	ADP	O
such	O	ADJ	O
experiments	O	NOUN	B
there	O	PRON	O
is	O	AUX	O
evidence	O	NOUN	B
that	O	SCONJ	O
characterization	O	NOUN	B
and	O	CCONJ	O
detection	O	NOUN	B
of	O	ADP	O
apomorphine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
activity	O	NOUN	B
in	O	ADP	O
rodents	O	NOUN	B
critically	O	ADV	O
depends	O	VERB	O
upon	O	SCONJ	O
the	O	DET	O
test	O	NOUN	B
conditions	O	NOUN	B
employed	O	VERB	O
.	O	PUNCT	O


In	O	ADP	O
rats	O	NOUN	B
,	O	PUNCT	O
detection	O	NOUN	B
of	O	ADP	O
apomorphine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hyperactivity	B-Disease	NOUN	B
was	O	AUX	O
facilitated	O	VERB	O
by	O	ADP	O
a	O	DET	O
period	O	NOUN	B
of	O	ADP	O
acclimatization	O	NOUN	B
to	O	ADP	O
the	O	DET	O
test	O	NOUN	B
conditions	O	NOUN	I
.	O	PUNCT	O


Moreover	O	ADV	O
,	O	PUNCT	O
test	O	NOUN	B
conditions	O	NOUN	I
can	O	AUX	O
impact	O	VERB	B
upon	O	SCONJ	O
other	O	ADJ	O
physiological	O	ADJ	B
responses	O	NOUN	I
to	O	PART	O
apomorphine	B-Chemical	NOUN	B
such	O	ADJ	O
as	O	ADP	O
drug	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypothermia	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
mice	O	NOUN	B
,	O	PUNCT	O
apomorphine	B-Chemical	NOUN	B
produced	O	VERB	O
qualitatively	O	ADV	B
different	O	ADJ	O
responses	O	NOUN	B
under	O	ADP	O
novel	O	ADJ	B
conditions	O	NOUN	B
when	O	SCONJ	O
compared	O	VERB	B
to	O	PART	O
those	O	DET	O
behaviors	O	NOUN	B
elicited	O	VERB	B
in	O	ADP	O
the	O	DET	O
home	O	NOUN	B
test	O	NOUN	I
cage	O	NOUN	I
.	O	PUNCT	O


Drug	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
gross	O	ADJ	B
activity	O	NOUN	I
counts	O	NOUN	O
were	O	AUX	O
increased	O	VERB	B
in	O	ADP	O
the	O	DET	O
novel	O	ADJ	O
exploratory	O	ADJ	B
box	O	NOUN	I
only	O	ADV	O
,	O	PUNCT	O
while	O	SCONJ	O
measures	O	NOUN	B
of	O	ADP	O
stereotypic	O	ADJ	B
behavior	O	NOUN	I
were	O	AUX	O
similar	O	ADJ	O
in	O	ADP	O
both	O	DET	O
.	O	PUNCT	O


By	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
apomorphine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
locomotion	O	NOUN	B
was	O	AUX	O
more	O	ADV	O
prominent	O	ADJ	B
in	O	ADP	O
the	O	DET	O
novel	O	ADJ	O
exploratory	O	ADJ	O
box	O	NOUN	O
.	O	PUNCT	O


Dopamine	B-Chemical	NOUN	B
turnover	O	NOUN	B
ratios	O	NOUN	I
(	O	PUNCT	O
DOPAC	B-Chemical	NOUN	B
:	O	PUNCT	O
DA	B-Chemical	NOUN	B
and	O	CCONJ	O
HVA	B-Chemical	NOUN	B
:	O	PUNCT	O
DA	B-Chemical	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
lower	O	ADJ	O
in	O	ADP	O
those	O	DET	O
animals	O	NOUN	B
exposed	O	VERB	B
to	O	ADP	O
the	O	DET	O
exploratory	O	ADJ	B
box	O	NOUN	I
when	O	SCONJ	O
compared	O	VERB	B
to	O	ADP	O
their	O	PRON	O
home	O	NOUN	B
cage	O	NOUN	I
counterparts	O	NOUN	O
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
apomorphine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
reductions	O	NOUN	B
in	O	ADP	O
striatal	O	ADJ	B
dopamine	B-Chemical	NOUN	B


